1	A	N	I-MajorClaim
2	combination	N	I-MajorClaim
3	of	N	I-MajorClaim
4	mitoxantrone	N	I-MajorClaim
5	plus	N	I-MajorClaim
6	prednisone	N	I-MajorClaim
7	is	N	I-MajorClaim
8	preferable	N	I-MajorClaim
9	to	N	I-MajorClaim
10	prednisone	N	I-MajorClaim
11	alone	N	I-MajorClaim
12	for	N	I-MajorClaim
13	reduction	N	I-MajorClaim
14	of	N	I-MajorClaim
15	pain	N	I-MajorClaim
16	in	N	I-MajorClaim
17	men	N	I-MajorClaim
18	with	N	I-MajorClaim
19	metastatic	N	I-MajorClaim
20	,	N	I-MajorClaim
21	hormone-resistant	N	I-MajorClaim
22	,	N	I-MajorClaim
23	prostate	N	I-MajorClaim
24	cancer	N	I-MajorClaim
25	.	N	I-MajorClaim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	the	N	O
10	effects	N	O
11	of	N	O
12	these	N	O
13	treatments	N	O
14	on	N	O
15	health-related	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	HQL	N	O
21	)	N	O
22	.	N	O

1	Men	N	O
2	with	N	O
3	metastatic	N	O
4	prostate	N	O
5	cancer	N	O
6	(	N	O
7	n	N	O
8	=	N	O
9	161	N	O
10	)	N	O
11	were	N	O
12	randomized	N	O
13	to	N	O
14	receive	N	O
15	either	N	O
16	daily	N	O
17	prednisone	N	O
18	alone	N	O
19	or	N	O
20	mitoxantrone	N	O
21	(	N	O
22	every	N	O
23	3	N	O
24	weeks	N	O
25	)	N	O
26	plus	N	O
27	prednisone	N	O
28	.	N	O

1	Those	N	O
2	who	N	O
3	received	N	O
4	prednisone	N	O
5	alone	N	O
6	could	N	O
7	have	N	O
8	mitoxantrone	N	O
9	added	N	O
10	after	N	O
11	6	N	O
12	weeks	N	O
13	if	N	O
14	there	N	O
15	was	N	O
16	no	N	O
17	improvement	N	O
18	in	N	O
19	pain	N	O
20	.	N	O

1	HQL	N	O
2	was	N	O
3	assessed	N	O
4	before	N	O
5	treatment	N	O
6	initiation	N	O
7	and	N	O
8	then	N	O
9	every	N	O
10	3	N	O
11	weeks	N	O
12	using	N	O
13	the	N	O
14	European	N	O
15	Organization	N	O
16	for	N	O
17	Research	N	O
18	and	N	O
19	Treatment	N	O
20	of	N	O
21	Cancer	N	O
22	Quality-of-Life	N	O
23	Questionnaire	N	O
24	C30	N	O
25	(	N	O
26	EORTC	N	O
27	QLQ-C30	N	O
28	)	N	O
29	and	N	O
30	the	N	O
31	Quality	N	O
32	of	N	O
33	Life	N	O
34	Module-Prostate	N	O
35	14	N	O
36	(	N	O
37	QOLM-P14	N	O
38	)	N	O
39	,	N	O
40	a	N	O
41	trial-specific	N	O
42	module	N	O
43	developed	N	O
44	for	N	O
45	this	N	O
46	study	N	O
47	.	N	O

1	An	N	O
2	intent-to-treat	N	O
3	analysis	N	O
4	was	N	O
5	used	N	O
6	to	N	O
7	determine	N	O
8	the	N	O
9	mean	N	O
10	duration	N	O
11	of	N	O
12	HQL	N	O
13	improvement	N	O
14	and	N	O
15	differences	N	O
16	in	N	O
17	improvement	N	O
18	duration	N	O
19	between	N	O
20	groups	N	O
21	of	N	O
22	patients	N	O
23	.	N	O

1	At	N	I-Premise
2	6	N	I-Premise
3	weeks	N	I-Premise
4	,	N	I-Premise
5	both	N	I-Premise
6	groups	N	I-Premise
7	showed	N	I-Premise
8	improvement	N	I-Premise
9	in	N	I-Premise
10	several	N	I-Premise
11	HQL	N	I-Premise
12	domains	N	I-Premise
13	,	N	I-Premise
14	and	N	O
15	only	N	I-Premise
16	physical	N	I-Premise
17	functioning	N	I-Premise
18	and	N	I-Premise
19	pain	N	I-Premise
20	were	N	I-Premise
21	better	N	I-Premise
22	in	N	I-Premise
23	the	N	I-Premise
24	mitoxantrone-plus-prednisone	N	I-Premise
25	group	N	I-Premise
26	than	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	prednisone-alone	N	I-Premise
30	group	N	I-Premise
31	.	N	I-Premise

1	After	N	I-Premise
2	6	N	I-Premise
3	weeks	N	I-Premise
4	,	N	I-Premise
5	patients	N	I-Premise
6	taking	N	I-Premise
7	prednisone	N	I-Premise
8	showed	N	I-Premise
9	no	N	I-Premise
10	improvement	N	I-Premise
11	in	N	I-Premise
12	HQL	N	I-Premise
13	scores	N	I-Premise
14	,	N	I-Premise
15	whereas	N	I-Premise
16	those	N	I-Premise
17	taking	N	I-Premise
18	mitoxantrone	N	I-Premise
19	plus	N	I-Premise
20	prednisone	N	I-Premise
21	showed	N	I-Premise
22	significant	N	I-Premise
23	improvements	N	I-Premise
24	in	N	I-Premise
25	global	N	I-Premise
26	quality	N	I-Premise
27	of	N	I-Premise
28	life	N	I-Premise
29	(	N	I-Premise
30	P	N	I-Premise
31	=.009	N	I-Premise
32	)	N	I-Premise
33	,	N	I-Premise
34	four	N	I-Premise
35	functioning	N	I-Premise
36	domains	N	I-Premise
37	,	N	I-Premise
38	and	N	I-Premise
39	nine	N	I-Premise
40	symptoms	N	I-Premise
41	(	N	I-Premise
42	.001	N	I-Premise
43	<	N	I-Premise
44	P	N	I-Premise
45	<	N	I-Premise
46	.	N	I-Premise

1	01	N	I-Premise
2	)	N	I-Premise
3	,	N	I-Premise
4	and	N	O
5	the	N	I-Premise
6	improvement	N	I-Premise
7	(	N	I-Premise
8	>	N	I-Premise
9	10	N	I-Premise
10	units	N	I-Premise
11	on	N	I-Premise
12	a	N	I-Premise
13	scale	N	I-Premise
14	of	N	I-Premise
15	0	N	I-Premise
16	to100	N	I-Premise
17	)	N	I-Premise
18	lasted	N	I-Premise
19	longer	N	I-Premise
20	than	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	prednisone-alone	N	I-Premise
24	group	N	I-Premise
25	(	N	I-Premise
26	.004	N	I-Premise
27	<	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	.05	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	The	N	I-Premise
2	addition	N	I-Premise
3	of	N	I-Premise
4	mitoxantrone	N	I-Premise
5	to	N	I-Premise
6	prednisone	N	I-Premise
7	after	N	I-Premise
8	failure	N	I-Premise
9	of	N	I-Premise
10	prednisone	N	I-Premise
11	alone	N	I-Premise
12	was	N	I-Premise
13	associated	N	I-Premise
14	with	N	I-Premise
15	improvements	N	I-Premise
16	in	N	I-Premise
17	pain	N	I-Premise
18	,	N	I-Premise
19	pain	N	I-Premise
20	impact	N	I-Premise
21	,	N	I-Premise
22	pain	N	I-Premise
23	relief	N	I-Premise
24	,	N	I-Premise
25	insomnia	N	I-Premise
26	,	N	I-Premise
27	and	N	I-Premise
28	global	N	I-Premise
29	quality	N	I-Premise
30	of	N	I-Premise
31	life	N	I-Premise
32	(	N	I-Premise
33	.001	N	I-Premise
34	<	N	I-Premise
35	P	N	I-Premise
36	<	N	I-Premise
37	.003	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	Treatment	N	I-Claim
2	with	N	I-Claim
3	mitoxantrone	N	I-Claim
4	plus	N	I-Claim
5	prednisone	N	I-Claim
6	was	N	I-Claim
7	associated	N	I-Claim
8	with	N	I-Claim
9	greater	N	I-Claim
10	and	N	I-Claim
11	longer-lasting	N	I-Claim
12	improvement	N	I-Claim
13	in	N	I-Claim
14	several	N	I-Claim
15	HQL	N	I-Claim
16	domains	N	I-Claim
17	and	N	I-Claim
18	symptoms	N	I-Claim
19	than	N	I-Claim
20	treatment	N	I-Claim
21	with	N	I-Claim
22	prednisone	N	I-Claim
23	alone	N	I-Claim
24	.	N	I-Claim

1	In	N	I-Claim
2	endocrine	N	I-Claim
3	therapy	N	I-Claim
4	trials	N	I-Claim
5	in	N	I-Claim
6	advanced	N	I-Claim
7	breast	N	I-Claim
8	cancer	N	I-Claim
9	,	N	I-Claim
10	patients	N	I-Claim
11	with	N	I-Claim
12	response	N	I-Claim
13	(	N	I-Claim
14	complete	N	I-Claim
15	response/partial	N	I-Claim
16	response	N	I-Claim
17	[	N	I-Claim
18	CR/PR	N	I-Claim
19	]	N	I-Claim
20	)	N	I-Claim
21	and	N	I-Claim
22	patients	N	I-Claim
23	with	N	I-Claim
24	stable	N	I-Claim
25	disease	N	I-Claim
26	for	N	I-Claim
27	at	N	I-Claim
28	least	N	I-Claim
29	6	N	I-Claim
30	months	N	I-Claim
31	(	N	I-Claim
32	SD	N	I-Claim
33	(	N	I-Claim
34	6m	N	I-Claim
35	)	N	I-Claim
36	)	N	I-Claim
37	have	N	I-Claim
38	shown	N	I-Claim
39	similar	N	I-Claim
40	survival	N	I-Claim
41	and	N	I-Claim
42	therefore	N	I-Claim
43	are	N	I-Claim
44	often	N	I-Claim
45	defined	N	I-Claim
46	as	N	I-Claim
47	a	N	I-Claim
48	population	N	I-Claim
49	with	N	I-Claim
50	clinical	N	I-Claim
51	benefit	N	I-Claim
52	(	N	I-Claim
53	patients	N	I-Claim
54	with	N	I-Claim
55	CR/PR	N	I-Claim
56	or	N	I-Claim
57	SD	N	I-Claim
58	(	N	I-Claim
59	6m	N	I-Claim
60	)	N	I-Claim
61	)	N	I-Claim
62	.	N	I-Claim

1	We	N	O
2	evaluated	N	O
3	the	N	O
4	impact	N	O
5	of	N	O
6	response	N	O
7	and/or	N	O
8	clinical	N	O
9	benefit	N	O
10	on	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	(	N	O
15	QL	N	O
16	)	N	O
17	in	N	O
18	postmenopausal	N	O
19	patients	N	O
20	under	N	O
21	second-line	N	O
22	endocrine	N	O
23	treatment	N	O
24	after	N	O
25	failure	N	O
26	of	N	O
27	tamoxifen	N	O
28	.	N	O

1	One	N	O
2	hundred	N	O
3	twenty-eight	N	O
4	of	N	O
5	177	N	O
6	eligible	N	O
7	patients	N	O
8	of	N	O
9	a	N	O
10	randomized	N	O
11	trial	N	O
12	(	N	O
13	Swiss	N	O
14	Group	N	O
15	for	N	O
16	Clinical	N	O
17	Cancer	N	O
18	Research	N	O
19	20/90	N	O
20	)	N	O
21	receiving	N	O
22	either	N	O
23	formestane	N	O
24	(	N	O
25	250	N	O
26	mg	N	O
27	intramuscularly	N	O
28	biweekly	N	O
29	)	N	O
30	or	N	O
31	megestrol	N	O
32	acetate	N	O
33	(	N	O
34	160	N	O
35	mg	N	O
36	orally	N	O
37	daily	N	O
38	)	N	O
39	were	N	O
40	analyzed	N	O
41	.	N	O

1	The	N	O
2	baseline	N	O
3	characteristics	N	O
4	(	N	O
5	with	N	O
6	the	N	O
7	exception	N	O
8	of	N	O
9	site	N	O
10	of	N	O
11	metastases	N	O
12	)	N	O
13	were	N	O
14	balanced	N	O
15	among	N	O
16	patients	N	O
17	with	N	O
18	CR/PR	N	O
19	,	N	O
20	SD	N	O
21	(	N	O
22	6m	N	O
23	)	N	O
24	,	N	O
25	and	N	O
26	progressive	N	O
27	disease	N	O
28	(	N	O
29	PD	N	O
30	)	N	O
31	.	N	O

1	Patients	N	O
2	completed	N	O
3	QL	N	O
4	indicators	N	O
5	at	N	O
6	baseline	N	O
7	and	N	O
8	at	N	O
9	1	N	O
10	,	N	O
11	3	N	O
12	,	N	O
13	5	N	O
14	,	N	O
15	7	N	O
16	,	N	O
17	9	N	O
18	,	N	O
19	and	N	O
20	11	N	O
21	months	N	O
22	.	N	O

1	Responders	N	O
2	were	N	O
3	separately	N	O
4	compared	N	O
5	with	N	O
6	nonresponders	N	O
7	(	N	O
8	patients	N	O
9	with	N	O
10	SD	N	O
11	(	N	O
12	6m	N	O
13	)	N	O
14	or	N	O
15	PD	N	O
16	)	N	O
17	and	N	O
18	with	N	O
19	patients	N	O
20	with	N	O
21	SD	N	O
22	(	N	O
23	6m	N	O
24	)	N	O
25	,	N	O
26	and	N	O
27	patients	N	O
28	with	N	O
29	clinical	N	O
30	benefit	N	O
31	were	N	O
32	compared	N	O
33	with	N	O
34	patients	N	O
35	with	N	O
36	PD	N	O
37	by	N	O
38	analysis	N	O
39	of	N	O
40	covariance	N	O
41	with	N	O
42	adjustment	N	O
43	for	N	O
44	baseline	N	O
45	scores	N	O
46	.	N	O

1	Overall	N	O
2	,	N	O
3	88	N	O
4	%	N	O
5	(	N	O
6	557	N	O
7	of	N	O
8	634	N	O
9	)	N	O
10	of	N	O
11	expected	N	O
12	QL	N	O
13	forms	N	O
14	were	N	O
15	received	N	O
16	.	N	O

1	In	N	O
2	the	N	O
3	comparison	N	O
4	of	N	O
5	responders	N	O
6	versus	N	O
7	patients	N	O
8	with	N	O
9	both	N	O
10	SD	N	O
11	(	N	O
12	6m	N	O
13	)	N	O
14	and	N	O
15	PD	N	O
16	,	N	O
17	responders	N	I-Premise
18	indicated	N	I-Premise
19	better	N	I-Premise
20	physical	N	I-Premise
21	well-being	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	=	N	I-Premise
25	.	N	I-Premise

1	004	N	I-Premise
2	)	N	I-Premise
3	and	N	I-Premise
4	mood	N	I-Premise
5	(	N	I-Premise
6	P	N	I-Premise
7	=.02	N	I-Premise
8	)	N	I-Premise
9	at	N	I-Premise
10	month	N	I-Premise
11	3	N	I-Premise
12	.	N	I-Premise

1	Compared	N	I-Premise
2	only	N	I-Premise
3	with	N	I-Premise
4	patients	N	I-Premise
5	with	N	I-Premise
6	SD	N	I-Premise
7	(	N	I-Premise
8	6m	N	I-Premise
9	)	N	I-Premise
10	,	N	I-Premise
11	responders	N	I-Premise
12	showed	N	I-Premise
13	no	N	I-Premise
14	significant	N	I-Premise
15	difference	N	I-Premise
16	in	N	I-Premise
17	baseline	N	I-Premise
18	QL	N	I-Premise
19	and	N	I-Premise
20	time	N	I-Premise
21	to	N	I-Premise
22	treatment	N	I-Premise
23	failure	N	I-Premise
24	(	N	I-Premise
25	328.5	N	I-Premise
26	v	N	I-Premise
27	340	N	I-Premise
28	days	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	While	N	I-Premise
2	under	N	I-Premise
3	treatment	N	I-Premise
4	,	N	I-Premise
5	responders	N	I-Premise
6	reported	N	I-Premise
7	significantly	N	I-Premise
8	better	N	I-Premise
9	physical	N	I-Premise
10	well-being	N	I-Premise
11	(	N	I-Premise
12	months	N	I-Premise
13	3	N	I-Premise
14	to	N	I-Premise
15	11	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	mood	N	I-Premise
19	(	N	I-Premise
20	months	N	I-Premise
21	5	N	I-Premise
22	to	N	I-Premise
23	11	N	I-Premise
24	)	N	I-Premise
25	,	N	I-Premise
26	coping	N	I-Premise
27	(	N	I-Premise
28	months	N	I-Premise
29	5	N	I-Premise
30	to	N	I-Premise
31	9	N	I-Premise
32	)	N	I-Premise
33	,	N	I-Premise
34	and	N	I-Premise
35	appetite	N	I-Premise
36	(	N	I-Premise
37	months	N	I-Premise
38	7	N	I-Premise
39	to	N	I-Premise
40	11	N	I-Premise
41	)	N	I-Premise
42	and	N	I-Premise
43	less	N	I-Premise
44	dizziness	N	I-Premise
45	(	N	I-Premise
46	month	N	I-Premise
47	9	N	I-Premise
48	)	N	I-Premise
49	than	N	I-Premise
50	patients	N	I-Premise
51	with	N	I-Premise
52	SD	N	I-Premise
53	(	N	I-Premise
54	6m	N	I-Premise
55	)	N	I-Premise
56	.	N	I-Premise

1	The	N	I-Premise
2	changes	N	I-Premise
3	between	N	I-Premise
4	baseline	N	I-Premise
5	and	N	I-Premise
6	months	N	I-Premise
7	5	N	I-Premise
8	and	N	I-Premise
9	7	N	I-Premise
10	,	N	I-Premise
11	respectively	N	I-Premise
12	,	N	I-Premise
13	indicated	N	I-Premise
14	improvement	N	I-Premise
15	in	N	I-Premise
16	responders	N	I-Premise
17	but	N	I-Premise
18	heterogeneous	N	I-Premise
19	patterns	N	I-Premise
20	in	N	I-Premise
21	patients	N	I-Premise
22	with	N	I-Premise
23	SD	N	I-Premise
24	(	N	I-Premise
25	6m	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	Although	N	I-Premise
2	the	N	I-Premise
3	CR/PR	N	I-Premise
4	and	N	I-Premise
5	SD	N	I-Premise
6	(	N	I-Premise
7	6m	N	I-Premise
8	)	N	I-Premise
9	groups	N	I-Premise
10	had	N	I-Premise
11	similar	N	I-Premise
12	times	N	I-Premise
13	to	N	I-Premise
14	treatment	N	I-Premise
15	failure	N	I-Premise
16	,	N	I-Premise
17	patients	N	I-Claim
18	with	N	I-Claim
19	CR/PR	N	I-Claim
20	reported	N	I-Claim
21	better	N	I-Claim
22	QL	N	I-Claim
23	,	N	I-Claim
24	suggesting	N	I-Claim
25	more	N	I-Claim
26	beneficial	N	I-Claim
27	response	N	I-Claim
28	to	N	I-Claim
29	second-line	N	I-Claim
30	endocrine	N	I-Claim
31	treatment	N	I-Claim
32	.	N	I-Claim

1	Patients	N	O
2	'	N	O
3	subjective	N	O
4	perspective	N	O
5	should	N	O
6	be	N	O
7	taken	N	O
8	into	N	O
9	account	N	O
10	in	N	O
11	this	N	O
12	mainly	N	O
13	palliative	N	O
14	setting	N	O
15	.	N	O

1	Future	N	O
2	trials	N	O
3	should	N	O
4	be	N	O
5	designed	N	O
6	so	N	O
7	that	N	O
8	the	N	O
9	CR/PR	N	O
10	and	N	O
11	SD	N	O
12	(	N	O
13	6m	N	O
14	)	N	O
15	groups	N	O
16	are	N	O
17	investigated	N	O
18	separately	N	O
19	.	N	O

1	Treatment	N	I-Claim
2	with	N	I-Claim
3	cisplatin-based	N	I-Claim
4	chemotherapy	N	I-Claim
5	provides	N	I-Claim
6	a	N	I-Claim
7	modest	N	I-Claim
8	survival	N	I-Claim
9	advantage	N	I-Claim
10	over	N	I-Claim
11	supportive	N	I-Claim
12	care	N	I-Claim
13	alone	N	I-Claim
14	in	N	I-Claim
15	advanced	N	I-Claim
16	non-small-cell	N	I-Claim
17	lung	N	I-Claim
18	cancer	N	I-Claim
19	(	N	I-Claim
20	NSCLC	N	I-Claim
21	)	N	I-Claim
22	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	a	N	O
5	new	N	O
6	agent	N	O
7	,	N	O
8	paclitaxel	N	O
9	,	N	O
10	would	N	O
11	further	N	O
12	improve	N	O
13	survival	N	O
14	in	N	O
15	NSCLC	N	O
16	,	N	O
17	the	N	O
18	Eastern	N	O
19	Cooperative	N	O
20	Oncology	N	O
21	Group	N	O
22	conducted	N	O
23	a	N	O
24	randomized	N	O
25	trial	N	O
26	comparing	N	O
27	paclitaxel	N	O
28	plus	N	O
29	cisplatin	N	O
30	to	N	O
31	a	N	O
32	standard	N	O
33	chemotherapy	N	O
34	regimen	N	O
35	consisting	N	O
36	of	N	O
37	cisplatin	N	O
38	and	N	O
39	etoposide	N	O
40	.	N	O

1	The	N	O
2	study	N	O
3	was	N	O
4	carried	N	O
5	out	N	O
6	by	N	O
7	a	N	O
8	multi-institutional	N	O
9	cooperative	N	O
10	group	N	O
11	in	N	O
12	chemotherapy-naive	N	O
13	stage	N	O
14	IIIB	N	O
15	to	N	O
16	IV	N	O
17	NSCLC	N	O
18	patients	N	O
19	randomized	N	O
20	to	N	O
21	receive	N	O
22	paclitaxel	N	O
23	plus	N	O
24	cisplatin	N	O
25	or	N	O
26	etoposide	N	O
27	plus	N	O
28	cisplatin	N	O
29	.	N	O

1	Paclitaxel	N	O
2	was	N	O
3	administered	N	O
4	at	N	O
5	two	N	O
6	different	N	O
7	dose	N	O
8	levels	N	O
9	(	N	O
10	135	N	O
11	mg/m	N	O
12	(	N	O
13	2	N	O
14	)	N	O
15	and	N	O
16	250	N	O
17	mg/m	N	O
18	(	N	O
19	2	N	O
20	)	N	O
21	)	N	O
22	,	N	O
23	and	N	O
24	etoposide	N	O
25	was	N	O
26	given	N	O
27	at	N	O
28	a	N	O
29	dose	N	O
30	of	N	O
31	100	N	O
32	mg/m	N	O
33	(	N	O
34	2	N	O
35	)	N	O
36	daily	N	O
37	on	N	O
38	days	N	O
39	1	N	O
40	to	N	O
41	3	N	O
42	.	N	O

1	Each	N	O
2	regimen	N	O
3	was	N	O
4	repeated	N	O
5	every	N	O
6	21	N	O
7	days	N	O
8	and	N	O
9	each	N	O
10	included	N	O
11	cisplatin	N	O
12	(	N	O
13	75	N	O
14	mg/m	N	O
15	(	N	O
16	2	N	O
17	)	N	O
18	)	N	O
19	.	N	O

1	The	N	O
2	characteristics	N	O
3	of	N	O
4	the	N	O
5	599	N	O
6	patients	N	O
7	were	N	O
8	well-balanced	N	O
9	across	N	O
10	the	N	O
11	three	N	O
12	treatment	N	O
13	groups	N	O
14	.	N	O

1	Superior	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	observed	N	I-Premise
5	with	N	I-Premise
6	the	N	I-Premise
7	combined	N	I-Premise
8	paclitaxel	N	I-Premise
9	regimens	N	I-Premise
10	(	N	I-Premise
11	median	N	I-Premise
12	survival	N	I-Premise
13	time	N	I-Premise
14	,	N	I-Premise
15	9.9	N	I-Premise
16	months	N	I-Premise
17	;	N	I-Premise
18	1-year	N	I-Premise
19	survival	N	I-Premise
20	rate	N	I-Premise
21	,	N	I-Premise
22	38.9	N	I-Premise
23	%	N	I-Premise
24	)	N	I-Premise
25	compared	N	I-Premise
26	with	N	I-Premise
27	etoposide	N	I-Premise
28	plus	N	I-Premise
29	cisplatin	N	I-Premise
30	(	N	I-Premise
31	median	N	I-Premise
32	survival	N	I-Premise
33	time	N	I-Premise
34	,	N	I-Premise
35	7.6	N	I-Premise
36	months	N	I-Premise
37	;	N	I-Premise
38	1-year	N	I-Premise
39	survival	N	I-Premise
40	rate	N	I-Premise
41	,	N	I-Premise
42	31.8	N	I-Premise
43	%	N	I-Premise
44	;	N	I-Premise
45	P	N	I-Premise
46	=	N	I-Premise
47	.	N	I-Premise

1	048	N	I-Premise
2	)	N	I-Premise
3	.	N	I-Premise

1	Comparing	N	I-Premise
2	survival	N	I-Premise
3	for	N	I-Premise
4	the	N	I-Premise
5	two	N	I-Premise
6	dose	N	I-Premise
7	levels	N	I-Premise
8	of	N	I-Premise
9	paclitaxel	N	I-Premise
10	revealed	N	I-Premise
11	no	N	I-Premise
12	significant	N	I-Premise
13	difference	N	I-Premise
14	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	duration	N	I-Premise
5	for	N	I-Premise
6	the	N	I-Premise
7	stage	N	I-Premise
8	IIIB	N	I-Premise
9	subgroup	N	I-Premise
10	was	N	I-Premise
11	7.9	N	I-Premise
12	months	N	I-Premise
13	for	N	I-Premise
14	etoposide	N	I-Premise
15	plus	N	I-Premise
16	cisplatin	N	I-Premise
17	patients	N	I-Premise
18	versus	N	I-Premise
19	13.1	N	I-Premise
20	months	N	I-Premise
21	for	N	I-Premise
22	all	N	I-Premise
23	paclitaxel	N	I-Premise
24	patients	N	I-Premise
25	(	N	I-Premise
26	P	N	I-Premise
27	=.152	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	For	N	I-Premise
2	the	N	I-Premise
3	stage	N	I-Premise
4	IV	N	I-Premise
5	subgroup	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	median	N	I-Premise
9	survival	N	I-Premise
10	time	N	I-Premise
11	for	N	I-Premise
12	etoposide	N	I-Premise
13	plus	N	I-Premise
14	cisplatin	N	I-Premise
15	was	N	I-Premise
16	7.6	N	I-Premise
17	months	N	I-Premise
18	compared	N	I-Premise
19	with	N	I-Premise
20	8.9	N	I-Premise
21	months	N	I-Premise
22	for	N	I-Premise
23	paclitaxel	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	=.246	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	With	N	I-Premise
2	the	N	I-Premise
3	exceptions	N	I-Premise
4	of	N	I-Premise
5	increased	N	I-Premise
6	granulocytopenia	N	I-Premise
7	on	N	I-Premise
8	the	N	I-Premise
9	low-dose	N	I-Premise
10	paclitaxel	N	I-Premise
11	regimen	N	I-Premise
12	and	N	I-Premise
13	increased	N	I-Premise
14	myalgias	N	I-Premise
15	,	N	I-Premise
16	neurotoxicity	N	I-Premise
17	,	N	I-Premise
18	and	N	I-Premise
19	,	N	I-Premise
20	possibly	N	I-Premise
21	,	N	I-Premise
22	increased	N	I-Premise
23	treatment-related	N	I-Premise
24	cardiac	N	I-Premise
25	events	N	I-Premise
26	with	N	I-Premise
27	high-dose	N	I-Premise
28	paclitaxel	N	I-Premise
29	,	N	I-Premise
30	toxicity	N	I-Premise
31	was	N	I-Premise
32	similar	N	I-Premise
33	across	N	I-Premise
34	all	N	I-Premise
35	three	N	I-Premise
36	arms	N	I-Premise
37	.	N	I-Premise

1	Quality	N	I-Premise
2	of	N	I-Premise
3	life	N	I-Premise
4	(	N	I-Premise
5	QOL	N	I-Premise
6	)	N	I-Premise
7	declined	N	I-Premise
8	significantly	N	I-Premise
9	over	N	I-Premise
10	the	N	I-Premise
11	6	N	I-Premise
12	months	N	I-Premise
13	.	N	I-Premise

1	However	N	O
2	,	N	O
3	QOL	N	I-Claim
4	scores	N	I-Claim
5	were	N	I-Claim
6	not	N	I-Claim
7	significantly	N	I-Claim
8	different	N	I-Claim
9	among	N	I-Claim
10	the	N	I-Claim
11	regimens	N	I-Claim
12	.	N	I-Claim

1	As	N	O
2	a	N	O
3	result	N	O
4	of	N	O
5	these	N	O
6	observations	N	O
7	,	N	O
8	paclitaxel	N	I-Claim
9	(	N	I-Claim
10	135	N	I-Claim
11	mg/m	N	I-Claim
12	(	N	I-Claim
13	2	N	I-Claim
14	)	N	I-Claim
15	)	N	I-Claim
16	combined	N	I-Claim
17	with	N	I-Claim
18	cisplatin	N	I-Claim
19	has	N	I-Claim
20	replaced	N	I-Claim
21	etoposide	N	I-Claim
22	plus	N	I-Claim
23	cisplatin	N	I-Claim
24	as	N	I-Claim
25	the	N	I-Claim
26	reference	N	I-Claim
27	regimen	N	I-Claim
28	in	N	I-Claim
29	our	N	I-Claim
30	recently	N	I-Claim
31	completed	N	I-Claim
32	phase	N	I-Claim
33	III	N	I-Claim
34	trial	N	I-Claim
35	.	N	I-Claim

1	Extracellular	N	O
2	adenosine	N	O
3	5'-triphosphate	N	O
4	(	N	O
5	ATP	N	O
6	)	N	O
7	is	N	O
8	involved	N	O
9	in	N	O
10	the	N	O
11	regulation	N	O
12	of	N	O
13	a	N	O
14	variety	N	O
15	of	N	O
16	biologic	N	O
17	processes	N	O
18	,	N	O
19	including	N	O
20	neurotransmission	N	O
21	,	N	O
22	muscle	N	O
23	contraction	N	O
24	,	N	O
25	and	N	O
26	liver	N	O
27	glucose	N	O
28	metabolism	N	O
29	,	N	O
30	via	N	O
31	purinergic	N	O
32	receptors	N	O
33	.	N	O

1	In	N	I-MajorClaim
2	nonrandomized	N	I-MajorClaim
3	studies	N	I-MajorClaim
4	involving	N	I-MajorClaim
5	patients	N	I-MajorClaim
6	with	N	I-MajorClaim
7	different	N	I-MajorClaim
8	tumor	N	I-MajorClaim
9	types	N	I-MajorClaim
10	including	N	I-MajorClaim
11	non-small-cell	N	I-MajorClaim
12	lung	N	I-MajorClaim
13	cancer	N	I-MajorClaim
14	(	N	I-MajorClaim
15	NSCLC	N	I-MajorClaim
16	)	N	I-MajorClaim
17	,	N	I-MajorClaim
18	ATP	N	I-MajorClaim
19	infusion	N	I-MajorClaim
20	appeared	N	I-MajorClaim
21	to	N	I-MajorClaim
22	inhibit	N	I-MajorClaim
23	loss	N	I-MajorClaim
24	of	N	I-MajorClaim
25	weight	N	I-MajorClaim
26	and	N	I-MajorClaim
27	deterioration	N	I-MajorClaim
28	of	N	I-MajorClaim
29	quality	N	I-MajorClaim
30	of	N	I-MajorClaim
31	life	N	I-MajorClaim
32	(	N	I-MajorClaim
33	QOL	N	I-MajorClaim
34	)	N	I-MajorClaim
35	and	N	I-MajorClaim
36	performance	N	I-MajorClaim
37	status	N	I-MajorClaim
38	.	N	I-MajorClaim

1	We	N	O
2	conducted	N	O
3	a	N	O
4	randomized	N	O
5	clinical	N	O
6	trial	N	O
7	to	N	O
8	evaluate	N	O
9	the	N	O
10	effects	N	O
11	of	N	O
12	ATP	N	O
13	in	N	O
14	patients	N	O
15	with	N	O
16	advanced	N	O
17	NSCLC	N	O
18	(	N	O
19	stage	N	O
20	IIIB	N	O
21	or	N	O
22	IV	N	O
23	)	N	O
24	.	N	O

1	Fifty-eight	N	O
2	patients	N	O
3	were	N	O
4	randomly	N	O
5	assigned	N	O
6	to	N	O
7	receive	N	O
8	either	N	O
9	10	N	O
10	intravenous	N	O
11	30-hour	N	O
12	ATP	N	O
13	infusions	N	O
14	,	N	O
15	with	N	O
16	the	N	O
17	infusions	N	O
18	given	N	O
19	at	N	O
20	2-	N	O
21	to	N	O
22	4-week	N	O
23	intervals	N	O
24	,	N	O
25	or	N	O
26	no	N	O
27	ATP	N	O
28	.	N	O

1	Outcome	N	O
2	parameters	N	O
3	were	N	O
4	assessed	N	O
5	every	N	O
6	4	N	O
7	weeks	N	O
8	until	N	O
9	28	N	O
10	weeks	N	O
11	.	N	O

1	Between-group	N	O
2	differences	N	O
3	were	N	O
4	tested	N	O
5	for	N	O
6	statistical	N	O
7	significance	N	O
8	by	N	O
9	use	N	O
10	of	N	O
11	repeated-measures	N	O
12	analysis	N	O
13	,	N	O
14	and	N	O
15	reported	N	O
16	P	N	O
17	values	N	O
18	are	N	O
19	two-sided	N	O
20	.	N	O

1	Twenty-eight	N	O
2	patients	N	O
3	were	N	O
4	allocated	N	O
5	to	N	O
6	receive	N	O
7	ATP	N	O
8	treatment	N	O
9	and	N	O
10	30	N	O
11	received	N	O
12	no	N	O
13	ATP	N	O
14	.	N	O

1	Mean	N	I-Premise
2	weight	N	I-Premise
3	changes	N	I-Premise
4	per	N	I-Premise
5	4-week	N	I-Premise
6	period	N	I-Premise
7	were	N	I-Premise
8	-1.0	N	I-Premise
9	kg	N	I-Premise
10	(	N	I-Premise
11	95	N	I-Premise
12	%	N	I-Premise
13	confidence	N	I-Premise
14	interval	N	I-Premise
15	[	N	I-Premise
16	CI	N	I-Premise
17	]	N	I-Premise
18	=	N	I-Premise
19	-1.5	N	I-Premise
20	to	N	I-Premise
21	-0.5	N	I-Premise
22	)	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	control	N	I-Premise
26	group	N	I-Premise
27	and	N	I-Premise
28	0.2	N	I-Premise
29	kg	N	I-Premise
30	(	N	I-Premise
31	95	N	I-Premise
32	%	N	I-Premise
33	CI	N	I-Premise
34	=	N	I-Premise
35	-0.2	N	I-Premise
36	to	N	I-Premise
37	+0.6	N	I-Premise
38	)	N	I-Premise
39	in	N	I-Premise
40	the	N	I-Premise
41	ATP	N	I-Premise
42	group	N	I-Premise
43	(	N	I-Premise
44	P	N	I-Premise
45	=.002	N	I-Premise
46	)	N	I-Premise
47	.	N	I-Premise

1	Serum	N	I-Premise
2	albumin	N	I-Premise
3	concentration	N	I-Premise
4	declined	N	I-Premise
5	by	N	I-Premise
6	-1.2	N	I-Premise
7	g/L	N	I-Premise
8	(	N	I-Premise
9	95	N	I-Premise
10	%	N	I-Premise
11	CI=	N	I-Premise
12	-2.0	N	I-Premise
13	to	N	I-Premise
14	-0.4	N	I-Premise
15	)	N	I-Premise
16	per	N	I-Premise
17	4	N	I-Premise
18	weeks	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	control	N	I-Premise
22	group	N	I-Premise
23	but	N	I-Premise
24	remained	N	I-Premise
25	stable	N	I-Premise
26	(	N	I-Premise
27	0.0	N	I-Premise
28	g/L	N	I-Premise
29	;	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	CI	N	I-Premise
33	=	N	I-Premise
34	-0.3	N	I-Premise
35	to	N	I-Premise
36	+0.3	N	I-Premise
37	)	N	I-Premise
38	in	N	I-Premise
39	the	N	I-Premise
40	ATP	N	I-Premise
41	group	N	I-Premise
42	(	N	I-Premise
43	P	N	I-Premise
44	=.006	N	I-Premise
45	)	N	I-Premise
46	.	N	I-Premise

1	Elbow	N	I-Premise
2	flexor	N	I-Premise
3	muscle	N	I-Premise
4	strength	N	I-Premise
5	declined	N	I-Premise
6	by	N	I-Premise
7	-5.5	N	I-Premise
8	%	N	I-Premise
9	(	N	I-Premise
10	95	N	I-Premise
11	%	N	I-Premise
12	CI	N	I-Premise
13	=	N	I-Premise
14	-9.6	N	I-Premise
15	%	N	I-Premise
16	to	N	I-Premise
17	-1	N	I-Premise
18	.	N	I-Premise

1	4	N	I-Premise
2	%	N	I-Premise
3	)	N	I-Premise
4	per	N	I-Premise
5	4	N	I-Premise
6	weeks	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	control	N	I-Premise
10	group	N	I-Premise
11	but	N	I-Premise
12	remained	N	I-Premise
13	stable	N	I-Premise
14	(	N	I-Premise
15	0.0	N	I-Premise
16	%	N	I-Premise
17	;	N	I-Premise
18	95	N	I-Premise
19	%	N	I-Premise
20	CI=	N	I-Premise
21	-1.4	N	I-Premise
22	%	N	I-Premise
23	to	N	I-Premise
24	+1.4	N	I-Premise
25	%	N	I-Premise
26	)	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	ATP	N	I-Premise
30	group	N	I-Premise
31	(	N	I-Premise
32	P	N	I-Premise
33	=.01	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	A	N	I-Premise
2	similar	N	I-Premise
3	pattern	N	I-Premise
4	was	N	I-Premise
5	observed	N	I-Premise
6	for	N	I-Premise
7	knee	N	I-Premise
8	extensor	N	I-Premise
9	muscles	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	=.02	N	I-Premise
13	)	N	I-Premise
14	.	N	I-Premise

1	The	N	I-Premise
2	effects	N	I-Premise
3	of	N	I-Premise
4	ATP	N	I-Premise
5	on	N	I-Premise
6	body	N	I-Premise
7	weight	N	I-Premise
8	,	N	I-Premise
9	muscle	N	I-Premise
10	strength	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	albumin	N	I-Premise
14	concentration	N	I-Premise
15	were	N	I-Premise
16	especially	N	I-Premise
17	marked	N	I-Premise
18	in	N	I-Premise
19	cachectic	N	I-Premise
20	patients	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	=.0002	N	I-Premise
24	,	N	I-Premise
25	P	N	I-Premise
26	=.0001	N	I-Premise
27	,	N	I-Premise
28	and	N	I-Premise
29	P	N	I-Premise
30	=	N	I-Premise
31	.	N	I-Premise

1	0001	N	I-Premise
2	,	N	I-Premise
3	respectively	N	I-Premise
4	,	N	I-Premise
5	for	N	I-Premise
6	ATP	N	I-Premise
7	versus	N	I-Premise
8	no	N	I-Premise
9	ATP	N	I-Premise
10	)	N	I-Premise
11	.	N	I-Premise

1	QOL	N	I-Premise
2	score	N	I-Premise
3	changes	N	I-Premise
4	per	N	I-Premise
5	4-week	N	I-Premise
6	period	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	ATP	N	I-Premise
10	group	N	I-Premise
11	showed	N	I-Premise
12	overall	N	I-Premise
13	less	N	I-Premise
14	deterioration	N	I-Premise
15	than	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	control	N	I-Premise
19	group-physical	N	I-Premise
20	scores	N	I-Premise
21	(	N	I-Premise
22	-0.2	N	I-Premise
23	%	N	I-Premise
24	versus	N	I-Premise
25	-2.4	N	I-Premise
26	%	N	I-Premise
27	;	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	.	N	I-Premise

1	0002	N	I-Premise
2	)	N	I-Premise
3	;	N	I-Premise
4	functional	N	I-Premise
5	scores	N	I-Premise
6	(	N	I-Premise
7	+0.4	N	I-Premise
8	%	N	I-Premise
9	versus	N	I-Premise
10	-5.5	N	I-Premise
11	%	N	I-Premise
12	;	N	I-Premise
13	P	N	I-Premise
14	=.02	N	I-Premise
15	)	N	I-Premise
16	;	N	I-Premise
17	psychologic	N	I-Premise
18	scores	N	I-Premise
19	(	N	I-Premise
20	-0.7	N	I-Premise
21	%	N	I-Premise
22	versus	N	I-Premise
23	-2.4	N	I-Premise
24	%	N	I-Premise
25	;	N	I-Premise
26	P	N	I-Premise
27	=.11	N	I-Premise
28	)	N	I-Premise
29	;	N	I-Premise
30	overall	N	I-Premise
31	QOL	N	I-Premise
32	score	N	I-Premise
33	(	N	I-Premise
34	+0.1	N	I-Premise
35	%	N	I-Premise
36	versus	N	I-Premise
37	-3.5	N	I-Premise
38	%	N	I-Premise
39	;	N	I-Premise
40	P	N	I-Premise
41	=.0001	N	I-Premise
42	)	N	I-Premise
43	.	N	I-Premise

1	This	N	O
2	randomized	N	O
3	trial	N	O
4	demonstrates	N	O
5	that	N	O
6	ATP	N	I-Claim
7	has	N	I-Claim
8	beneficial	N	I-Claim
9	effects	N	I-Claim
10	on	N	I-Claim
11	weight	N	I-Claim
12	,	N	I-Claim
13	muscle	N	I-Claim
14	strength	N	I-Claim
15	,	N	I-Claim
16	and	N	I-Claim
17	QOL	N	I-Claim
18	in	N	I-Claim
19	patients	N	I-Claim
20	with	N	I-Claim
21	advanced	N	I-Claim
22	NSCLC	N	I-Claim
23	.	N	I-Claim

1	This	N	O
2	phase	N	O
3	III	N	O
4	,	N	O
5	double-blind	N	O
6	,	N	O
7	randomized	N	O
8	,	N	O
9	multicenter	N	O
10	study	N	O
11	evaluated	N	O
12	the	N	O
13	efficacy	N	O
14	,	N	O
15	pharmacodynamics	N	O
16	,	N	O
17	and	N	O
18	safety	N	O
19	of	N	O
20	the	N	O
21	oral	N	O
22	aromatase	N	O
23	inactivator	N	O
24	exemestane	N	O
25	(	N	O
26	EXE	N	O
27	)	N	O
28	versus	N	O
29	megestrol	N	O
30	acetate	N	O
31	(	N	O
32	MA	N	O
33	)	N	O
34	in	N	O
35	postmenopausal	N	O
36	women	N	O
37	with	N	O
38	progressive	N	O
39	advanced	N	O
40	breast	N	O
41	cancer	N	O
42	who	N	O
43	experienced	N	O
44	failure	N	O
45	of	N	O
46	tamoxifen	N	O
47	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	769	N	O
5	patients	N	O
6	were	N	O
7	randomized	N	O
8	to	N	O
9	EXE	N	O
10	25	N	O
11	mg/d	N	O
12	(	N	O
13	n	N	O
14	=	N	O
15	366	N	O
16	)	N	O
17	or	N	O
18	MA	N	O
19	(	N	O
20	n	N	O
21	=	N	O
22	403	N	O
23	)	N	O
24	40	N	O
25	mg	N	O
26	four	N	O
27	times	N	O
28	daily	N	O
29	.	N	O

1	Tumor	N	O
2	response	N	O
3	,	N	O
4	duration	N	O
5	of	N	O
6	tumor	N	O
7	control	N	O
8	,	N	O
9	tumor-related	N	O
10	signs	N	O
11	and	N	O
12	symptoms	N	O
13	(	N	O
14	TRSS	N	O
15	)	N	O
16	,	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QOL	N	O
22	)	N	O
23	,	N	O
24	survival	N	O
25	,	N	O
26	and	N	O
27	tolerability	N	O
28	were	N	O
29	evaluated	N	O
30	.	N	O

1	Overall	N	I-Premise
2	objective	N	I-Premise
3	response	N	I-Premise
4	(	N	I-Premise
5	OR	N	I-Premise
6	)	N	I-Premise
7	rates	N	I-Premise
8	were	N	I-Premise
9	higher	N	I-Premise
10	in	N	I-Premise
11	patients	N	I-Premise
12	treated	N	I-Premise
13	with	N	I-Premise
14	EXE	N	I-Premise
15	than	N	I-Premise
16	in	N	I-Premise
17	those	N	I-Premise
18	treated	N	I-Premise
19	with	N	I-Premise
20	MA	N	I-Premise
21	(	N	I-Premise
22	15.0	N	I-Premise
23	%	N	I-Premise
24	v	N	I-Premise
25	12.4	N	I-Premise
26	%	N	I-Premise
27	)	N	I-Premise
28	;	N	I-Premise
29	a	N	I-Premise
30	similar	N	I-Premise
31	trend	N	I-Premise
32	was	N	I-Premise
33	noted	N	I-Premise
34	in	N	I-Premise
35	patients	N	I-Premise
36	with	N	I-Premise
37	visceral	N	I-Premise
38	metastases	N	I-Premise
39	(	N	I-Premise
40	13.5	N	I-Premise
41	%	N	I-Premise
42	v	N	I-Premise
43	10.5	N	I-Premise
44	%	N	I-Premise
45	)	N	I-Premise
46	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	time	N	I-Premise
4	was	N	I-Premise
5	significantly	N	I-Premise
6	longer	N	I-Premise
7	with	N	I-Premise
8	EXE	N	I-Premise
9	(	N	I-Premise
10	median	N	I-Premise
11	not	N	I-Premise
12	reached	N	I-Premise
13	)	N	I-Premise
14	than	N	I-Premise
15	with	N	I-Premise
16	MA	N	I-Premise
17	(	N	I-Premise
18	123.4	N	I-Premise
19	weeks	N	I-Premise
20	;	N	I-Premise
21	P	N	I-Premise
22	=.039	N	I-Premise
23	)	N	I-Premise
24	,	N	I-Premise
25	as	N	I-Premise
26	were	N	I-Premise
27	the	N	I-Premise
28	median	N	I-Premise
29	duration	N	I-Premise
30	of	N	I-Premise
31	overall	N	I-Premise
32	success	N	I-Premise
33	(	N	I-Premise
34	OR	N	I-Premise
35	or	N	I-Premise
36	stable	N	I-Premise
37	disease	N	I-Premise
38	>	N	I-Premise
39	or	N	I-Premise
40	=	N	I-Premise
41	24	N	I-Premise
42	weeks	N	I-Premise
43	;	N	I-Premise
44	60.1	N	I-Premise
45	v	N	I-Premise
46	49.1	N	I-Premise
47	weeks	N	I-Premise
48	;	N	I-Premise
49	P	N	I-Premise
50	=.025	N	I-Premise
51	)	N	I-Premise
52	,	N	I-Premise
53	time	N	I-Premise
54	to	N	I-Premise
55	tumor	N	I-Premise
56	progression	N	I-Premise
57	(	N	I-Premise
58	20.3	N	I-Premise
59	v	N	I-Premise
60	16.6	N	I-Premise
61	weeks	N	I-Premise
62	;	N	I-Premise
63	P	N	I-Premise
64	=.037	N	I-Premise
65	)	N	I-Premise
66	,	N	I-Premise
67	and	N	I-Premise
68	time	N	I-Premise
69	to	N	I-Premise
70	treatment	N	I-Premise
71	failure	N	I-Premise
72	(	N	I-Premise
73	16.3	N	I-Premise
74	v	N	I-Premise
75	15.7	N	I-Premise
76	weeks	N	I-Premise
77	;	N	I-Premise
78	P	N	I-Premise
79	=.042	N	I-Premise
80	)	N	I-Premise
81	.	N	I-Premise

1	Compared	N	I-Premise
2	with	N	I-Premise
3	MA	N	I-Premise
4	,	N	I-Premise
5	there	N	I-Premise
6	were	N	I-Premise
7	similar	N	I-Premise
8	or	N	I-Premise
9	greater	N	I-Premise
10	improvements	N	I-Premise
11	in	N	I-Premise
12	pain	N	I-Premise
13	,	N	I-Premise
14	TRSS	N	I-Premise
15	,	N	I-Premise
16	and	N	I-Premise
17	QOL	N	I-Premise
18	with	N	I-Premise
19	EXE	N	I-Premise
20	.	N	I-Premise

1	Both	N	I-Claim
2	drugs	N	I-Claim
3	were	N	I-Claim
4	well	N	I-Claim
5	tolerated	N	I-Claim
6	.	N	I-Claim

1	Grade	N	I-Premise
2	3	N	I-Premise
3	or	N	I-Premise
4	4	N	I-Premise
5	weight	N	I-Premise
6	changes	N	I-Premise
7	were	N	I-Premise
8	more	N	I-Premise
9	common	N	I-Premise
10	with	N	I-Premise
11	MA	N	I-Premise
12	(	N	I-Premise
13	17.1	N	I-Premise
14	%	N	I-Premise
15	v	N	I-Premise
16	7.6	N	I-Premise
17	%	N	I-Premise
18	;	N	I-Premise
19	P	N	I-Premise
20	=.001	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	EXE	N	I-Claim
2	prolongs	N	I-Claim
3	survival	N	I-Claim
4	time	N	I-Claim
5	,	N	I-Claim
6	time	N	I-Claim
7	to	N	I-Claim
8	tumor	N	I-Claim
9	progression	N	I-Claim
10	,	N	I-Claim
11	and	N	I-Claim
12	time	N	I-Claim
13	to	N	I-Claim
14	treatment	N	I-Claim
15	failure	N	I-Claim
16	compared	N	I-Claim
17	with	N	I-Claim
18	MA	N	I-Claim
19	and	N	I-Claim
20	offers	N	I-Claim
21	a	N	I-Claim
22	well-tolerated	N	I-Claim
23	treatment	N	I-Claim
24	option	N	I-Claim
25	for	N	I-Claim
26	postmenopausal	N	I-Claim
27	women	N	I-Claim
28	with	N	I-Claim
29	progressive	N	I-Claim
30	advanced	N	I-Claim
31	breast	N	I-Claim
32	cancer	N	I-Claim
33	who	N	I-Claim
34	experienced	N	I-Claim
35	failure	N	I-Claim
36	of	N	I-Claim
37	tamoxifen	N	I-Claim
38	.	N	I-Claim

1	This	N	O
2	phase	N	O
3	III	N	O
4	study	N	O
5	was	N	O
6	performed	N	O
7	to	N	O
8	determine	N	O
9	the	N	O
10	superiority	N	O
11	of	N	O
12	doxorubicin	N	O
13	(	N	O
14	DOX	N	O
15	)	N	O
16	and	N	O
17	vinorelbine	N	O
18	(	N	O
19	VNB	N	O
20	)	N	O
21	(	N	O
22	arm	N	O
23	1	N	O
24	)	N	O
25	versus	N	O
26	DOX	N	O
27	alone	N	O
28	(	N	O
29	arm	N	O
30	2	N	O
31	)	N	O
32	in	N	O
33	metastatic	N	O
34	breast	N	O
35	cancer	N	O
36	(	N	O
37	MBC	N	O
38	)	N	O
39	for	N	O
40	overall	N	O
41	survival	N	O
42	(	N	O
43	OS	N	O
44	)	N	O
45	,	N	O
46	time	N	O
47	to	N	O
48	treatment	N	O
49	failure	N	O
50	(	N	O
51	TTF	N	O
52	)	N	O
53	,	N	O
54	toxicity	N	O
55	,	N	O
56	and	N	O
57	quality	N	O
58	of	N	O
59	life	N	O
60	(	N	O
61	QOL	N	O
62	)	N	O
63	.	N	O

1	Three	N	O
2	hundred	N	O
3	three	N	O
4	patients	N	O
5	were	N	O
6	randomized	N	O
7	to	N	O
8	DOX	N	O
9	50	N	O
10	mg/m	N	O
11	(	N	O
12	2	N	O
13	)	N	O
14	intravenously	N	O
15	(	N	O
16	IV	N	O
17	)	N	O
18	on	N	O
19	day	N	O
20	1	N	O
21	and	N	O
22	VNB	N	O
23	25	N	O
24	mg/m	N	O
25	(	N	O
26	2	N	O
27	)	N	O
28	IV	N	O
29	on	N	O
30	days	N	O
31	1	N	O
32	and	N	O
33	8	N	O
34	(	N	O
35	arm	N	O
36	1	N	O
37	)	N	O
38	or	N	O
39	DOX	N	O
40	70	N	O
41	mg/m	N	O
42	(	N	O
43	2	N	O
44	)	N	O
45	IV	N	O
46	on	N	O
47	day	N	O
48	1	N	O
49	(	N	O
50	arm	N	O
51	2	N	O
52	)	N	O
53	.	N	O

1	Both	N	O
2	regimens	N	O
3	were	N	O
4	given	N	O
5	every	N	O
6	3	N	O
7	weeks	N	O
8	until	N	O
9	a	N	O
10	cumulative	N	O
11	DOX	N	O
12	dose	N	O
13	of	N	O
14	450	N	O
15	mg/m	N	O
16	(	N	O
17	2	N	O
18	)	N	O
19	.	N	O

1	After	N	O
2	16	N	O
3	of	N	O
4	the	N	O
5	first	N	O
6	65	N	O
7	randomized	N	O
8	patients	N	O
9	experienced	N	O
10	febrile	N	O
11	neutropenia	N	O
12	(	N	O
13	FN	N	O
14	)	N	O
15	,	N	O
16	the	N	O
17	doses	N	O
18	were	N	O
19	reduced	N	O
20	to	N	O
21	DOX	N	O
22	40	N	O
23	mg/m	N	O
24	(	N	O
25	2	N	O
26	)	N	O
27	on	N	O
28	day	N	O
29	1	N	O
30	and	N	O
31	VNB	N	O
32	20	N	O
33	mg/m	N	O
34	(	N	O
35	2	N	O
36	)	N	O
37	on	N	O
38	days	N	O
39	1	N	O
40	and	N	O
41	8	N	O
42	versus	N	O
43	DOX	N	O
44	60	N	O
45	mg/m	N	O
46	(	N	O
47	2	N	O
48	)	N	O
49	on	N	O
50	day	N	O
51	1	N	O
52	.	N	O

1	Eligible	N	O
2	patients	N	O
3	were	N	O
4	vinca	N	O
5	alkaloid	N	O
6	and	N	O
7	anthracycline	N	O
8	naive	N	O
9	.	N	O

1	Chemotherapy	N	O
2	was	N	O
3	first-line	N	O
4	or	N	O
5	second-line	N	O
6	for	N	O
7	MBC	N	O
8	.	N	O

1	Three	N	O
2	patients	N	O
3	were	N	O
4	ineligible	N	O
5	.	N	O

1	Thus	N	O
2	,	N	O
3	300	N	O
4	patients	N	O
5	were	N	O
6	assessable	N	O
7	for	N	O
8	toxicity	N	O
9	and	N	O
10	to	N	O
11	determine	N	O
12	time	N	O
13	to	N	O
14	disease	N	O
15	progression	N	O
16	(	N	O
17	TTP	N	O
18	)	N	O
19	,	N	O
20	TTF	N	O
21	,	N	O
22	and	N	O
23	OS	N	O
24	.	N	O

1	Two	N	O
2	hundred	N	O
3	eighty-nine	N	O
4	patients	N	O
5	were	N	O
6	assessable	N	O
7	for	N	O
8	response	N	O
9	,	N	O
10	and	N	O
11	99	N	O
12	responders	N	O
13	were	N	O
14	assessable	N	O
15	for	N	O
16	response	N	O
17	duration	N	O
18	(	N	O
19	RD	N	O
20	)	N	O
21	.	N	O

1	The	N	I-Premise
2	response	N	I-Premise
3	rates	N	I-Premise
4	,	N	I-Premise
5	QOL	N	I-Premise
6	,	N	I-Premise
7	and	N	I-Premise
8	median	N	I-Premise
9	RD	N	I-Premise
10	,	N	I-Premise
11	TTP	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	TTF	N	I-Premise
15	were	N	I-Premise
16	not	N	I-Premise
17	significantly	N	I-Premise
18	different	N	I-Premise
19	between	N	I-Premise
20	the	N	I-Premise
21	arms	N	I-Premise
22	.	N	I-Premise

1	Median	N	I-Premise
2	OS	N	I-Premise
3	was	N	I-Premise
4	13.8	N	I-Premise
5	months	N	I-Premise
6	for	N	I-Premise
7	arm	N	I-Premise
8	1	N	I-Premise
9	versus	N	I-Premise
10	14.4	N	I-Premise
11	months	N	I-Premise
12	for	N	I-Premise
13	arm	N	I-Premise
14	2	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	=.4	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	Grade	N	I-Premise
2	3	N	I-Premise
3	or	N	I-Premise
4	4	N	I-Premise
5	granulocytopenia	N	I-Premise
6	was	N	I-Premise
7	equivalent	N	I-Premise
8	in	N	I-Premise
9	both	N	I-Premise
10	arms	N	I-Premise
11	but	N	I-Premise
12	more	N	I-Premise
13	grade	N	I-Premise
14	3/4	N	I-Premise
15	neurotoxicity	N	I-Premise
16	,	N	I-Premise
17	mild	N	I-Premise
18	venous	N	I-Premise
19	toxicity	N	I-Premise
20	,	N	I-Premise
21	and	N	I-Premise
22	FN	N	I-Premise
23	were	N	I-Premise
24	seen	N	I-Premise
25	on	N	I-Premise
26	arm	N	I-Premise
27	1	N	I-Premise
28	.	N	I-Premise

1	The	N	I-Claim
2	survival	N	I-Claim
3	with	N	I-Claim
4	DOX	N	I-Claim
5	and	N	I-Claim
6	VNB	N	I-Claim
7	is	N	I-Claim
8	not	N	I-Claim
9	superior	N	I-Claim
10	to	N	I-Claim
11	DOX	N	I-Claim
12	alone	N	I-Claim
13	in	N	I-Claim
14	MBC	N	I-Claim
15	.	N	I-Claim

1	Menopausal	N	I-MajorClaim
2	symptoms	N	I-MajorClaim
3	(	N	I-MajorClaim
4	e.g.	N	I-MajorClaim
5	,	N	I-MajorClaim
6	hot	N	I-MajorClaim
7	flashes	N	I-MajorClaim
8	,	N	I-MajorClaim
9	vaginal	N	I-MajorClaim
10	dryness	N	I-MajorClaim
11	,	N	I-MajorClaim
12	and	N	I-MajorClaim
13	stress	N	I-MajorClaim
14	urinary	N	I-MajorClaim
15	incontinence	N	I-MajorClaim
16	)	N	I-MajorClaim
17	are	N	I-MajorClaim
18	very	N	I-MajorClaim
19	common	N	I-MajorClaim
20	in	N	I-MajorClaim
21	breast	N	I-MajorClaim
22	cancer	N	I-MajorClaim
23	survivors	N	I-MajorClaim
24	and	N	I-MajorClaim
25	can	N	I-MajorClaim
26	not	N	I-MajorClaim
27	be	N	I-MajorClaim
28	managed	N	I-MajorClaim
29	with	N	I-MajorClaim
30	standard	N	I-MajorClaim
31	estrogen	N	I-MajorClaim
32	replacement	N	I-MajorClaim
33	therapy	N	I-MajorClaim
34	(	N	I-MajorClaim
35	ERT	N	I-MajorClaim
36	)	N	I-MajorClaim
37	in	N	I-MajorClaim
38	these	N	I-MajorClaim
39	patients	N	I-MajorClaim
40	.	N	I-MajorClaim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	test	N	O
9	the	N	O
10	efficacy	N	O
11	of	N	O
12	a	N	O
13	comprehensive	N	O
14	menopausal	N	O
15	assessment	N	O
16	(	N	O
17	CMA	N	O
18	)	N	O
19	intervention	N	O
20	program	N	O
21	in	N	O
22	achieving	N	O
23	relief	N	O
24	of	N	O
25	symptoms	N	O
26	,	N	O
27	the	N	O
28	improvement	N	O
29	in	N	O
30	quality	N	O
31	of	N	O
32	life	N	O
33	(	N	O
34	QOL	N	O
35	)	N	O
36	,	N	O
37	and	N	O
38	sexual	N	O
39	functioning	N	O
40	in	N	O
41	breast	N	O
42	cancer	N	O
43	survivors	N	O
44	.	N	O

1	Using	N	O
2	a	N	O
3	two-group	N	O
4	,	N	O
5	randomized	N	O
6	controlled	N	O
7	design	N	O
8	,	N	O
9	we	N	O
10	assigned	N	O
11	76	N	O
12	postmenopausal	N	O
13	breast	N	O
14	cancer	N	O
15	survivors	N	O
16	with	N	O
17	at	N	O
18	least	N	O
19	one	N	O
20	severe	N	O
21	target	N	O
22	symptom	N	O
23	either	N	O
24	to	N	O
25	the	N	O
26	intervention	N	O
27	group	N	O
28	or	N	O
29	to	N	O
30	a	N	O
31	usual-care	N	O
32	group	N	O
33	.	N	O

1	Seventy-two	N	O
2	women	N	O
3	were	N	O
4	evaluable	N	O
5	at	N	O
6	the	N	O
7	end	N	O
8	of	N	O
9	the	N	O
10	study	N	O
11	period	N	O
12	.	N	O

1	The	N	O
2	CMA	N	O
3	intervention	N	O
4	,	N	O
5	delivered	N	O
6	by	N	O
7	a	N	O
8	nurse	N	O
9	practitioner	N	O
10	,	N	O
11	focused	N	O
12	on	N	O
13	symptom	N	O
14	assessment	N	O
15	,	N	O
16	education	N	O
17	,	N	O
18	counseling	N	O
19	and	N	O
20	,	N	O
21	as	N	O
22	appropriate	N	O
23	,	N	O
24	specific	N	O
25	pharmacologic	N	O
26	and	N	O
27	behavioral	N	O
28	interventions	N	O
29	for	N	O
30	each	N	O
31	of	N	O
32	the	N	O
33	three	N	O
34	target	N	O
35	symptoms	N	O
36	.	N	O

1	Psychosocial	N	O
2	symptoms	N	O
3	were	N	O
4	assessed	N	O
5	with	N	O
6	the	N	O
7	use	N	O
8	of	N	O
9	a	N	O
10	self-report	N	O
11	screening	N	O
12	instrument	N	O
13	,	N	O
14	and	N	O
15	distressed	N	O
16	women	N	O
17	were	N	O
18	referred	N	O
19	for	N	O
20	counseling	N	O
21	if	N	O
22	needed	N	O
23	.	N	O

1	The	N	O
2	intervention	N	O
3	took	N	O
4	place	N	O
5	over	N	O
6	a	N	O
7	4-month	N	O
8	period	N	O
9	.	N	O

1	Outcomes	N	O
2	measured	N	O
3	were	N	O
4	scores	N	O
5	on	N	O
6	a	N	O
7	composite	N	O
8	menopausal	N	O
9	symptom	N	O
10	scale	N	O
11	,	N	O
12	the	N	O
13	RAND	N	O
14	Short	N	O
15	Form	N	O
16	Health	N	O
17	Survey	N	O
18	Vitality	N	O
19	Scale	N	O
20	,	N	O
21	and	N	O
22	the	N	O
23	Cancer	N	O
24	Rehabilitation	N	O
25	Evaluation	N	O
26	System	N	O
27	(	N	O
28	CARES	N	O
29	)	N	O
30	Sexual	N	O
31	Functioning	N	O
32	Scale	N	O
33	at	N	O
34	baseline	N	O
35	and	N	O
36	at	N	O
37	4-month	N	O
38	follow-up	N	O
39	.	N	O

1	All	N	O
2	statistical	N	O
3	tests	N	O
4	were	N	O
5	two-sided	N	O
6	and	N	O
7	were	N	O
8	performed	N	O
9	at	N	O
10	the	N	O
11	alpha	N	O
12	=	N	O
13	.	N	O

1	05	N	O
2	significance	N	O
3	level	N	O
4	.	N	O

1	Patients	N	I-Premise
2	receiving	N	I-Premise
3	the	N	I-Premise
4	intervention	N	I-Premise
5	demonstrated	N	I-Premise
6	statistically	N	I-Premise
7	significant	N	I-Premise
8	improvement	N	I-Premise
9	(	N	I-Premise
10	P	N	I-Premise
11	=.0004	N	I-Premise
12	)	N	I-Premise
13	in	N	I-Premise
14	menopausal	N	I-Premise
15	symptoms	N	I-Premise
16	but	N	I-Premise
17	no	N	I-Premise
18	significant	N	I-Premise
19	change	N	I-Premise
20	in	N	I-Premise
21	vitality	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	=.77	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	Sexual	N	I-Premise
2	functioning	N	I-Premise
3	was	N	I-Premise
4	statistically	N	I-Premise
5	significantly	N	I-Premise
6	improved	N	I-Premise
7	(	N	I-Premise
8	P	N	I-Premise
9	=.04	N	I-Premise
10	)	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	treatment	N	I-Premise
14	group	N	I-Premise
15	compared	N	I-Premise
16	with	N	I-Premise
17	the	N	I-Premise
18	usual-care	N	I-Premise
19	group	N	I-Premise
20	.	N	I-Premise

1	A	N	I-Claim
2	clinical	N	I-Claim
3	assessment	N	I-Claim
4	and	N	I-Claim
5	intervention	N	I-Claim
6	program	N	I-Claim
7	for	N	I-Claim
8	menopausal	N	I-Claim
9	symptom	N	I-Claim
10	management	N	I-Claim
11	in	N	I-Claim
12	breast	N	I-Claim
13	cancer	N	I-Claim
14	survivors	N	I-Claim
15	is	N	I-Claim
16	feasible	N	I-Claim
17	and	N	I-Claim
18	acceptable	N	I-Claim
19	to	N	I-Claim
20	patients	N	I-Claim
21	,	N	I-Claim
22	leading	N	I-Claim
23	to	N	I-Claim
24	reduction	N	I-Claim
25	in	N	I-Claim
26	symptoms	N	I-Claim
27	and	N	I-Claim
28	improvement	N	I-Claim
29	in	N	I-Claim
30	sexual	N	I-Claim
31	functioning	N	I-Claim
32	.	N	I-Claim

1	Measurable	N	I-Claim
2	improvement	N	I-Claim
3	in	N	I-Claim
4	a	N	I-Claim
5	general	N	I-Claim
6	QOL	N	I-Claim
7	measure	N	I-Claim
8	was	N	I-Claim
9	not	N	I-Claim
10	demonstrated	N	I-Claim
11	.	N	I-Claim

1	In	N	I-Claim
2	phase	N	I-Claim
3	II	N	I-Claim
4	trials	N	I-Claim
5	,	N	I-Claim
6	paclitaxel	N	I-Claim
7	has	N	I-Claim
8	been	N	I-Claim
9	shown	N	I-Claim
10	to	N	I-Claim
11	have	N	I-Claim
12	antitumor	N	I-Claim
13	activity	N	I-Claim
14	in	N	I-Claim
15	patients	N	I-Claim
16	with	N	I-Claim
17	advanced	N	I-Claim
18	non-small-cell	N	I-Claim
19	lung	N	I-Claim
20	cancer	N	I-Claim
21	(	N	I-Claim
22	NSCLC	N	I-Claim
23	)	N	I-Claim
24	.	N	I-Claim

1	However	N	O
2	,	N	O
3	the	N	O
4	survival	N	O
5	and	N	O
6	quality-of-life	N	O
7	(	N	O
8	QOL	N	O
9	)	N	O
10	benefits	N	O
11	of	N	O
12	paclitaxel	N	O
13	used	N	O
14	as	N	O
15	a	N	O
16	single	N	O
17	agent	N	O
18	compared	N	O
19	with	N	O
20	supportive	N	O
21	care	N	O
22	alone	N	O
23	have	N	O
24	not	N	O
25	been	N	O
26	assessed	N	O
27	in	N	O
28	a	N	O
29	randomized	N	O
30	clinical	N	O
31	trial	N	O
32	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	157	N	O
5	patients	N	O
6	with	N	O
7	stage	N	O
8	IIIB	N	O
9	or	N	O
10	IV	N	O
11	NSCLC	N	O
12	who	N	O
13	had	N	O
14	received	N	O
15	no	N	O
16	prior	N	O
17	chemotherapy	N	O
18	were	N	O
19	randomly	N	O
20	assigned	N	O
21	to	N	O
22	receive	N	O
23	either	N	O
24	best	N	O
25	supportive	N	O
26	care	N	O
27	alone	N	O
28	(	N	O
29	78	N	O
30	patients	N	O
31	)	N	O
32	or	N	O
33	paclitaxel	N	O
34	plus	N	O
35	supportive	N	O
36	care	N	O
37	(	N	O
38	79	N	O
39	patients	N	O
40	)	N	O
41	.	N	O

1	Paclitaxel	N	O
2	was	N	O
3	administered	N	O
4	as	N	O
5	a	N	O
6	3-hour	N	O
7	intravenous	N	O
8	infusion	N	O
9	every	N	O
10	3	N	O
11	weeks	N	O
12	.	N	O

1	Supportive	N	O
2	care	N	O
3	included	N	O
4	palliative	N	O
5	radiotherapy	N	O
6	and	N	O
7	supportive	N	O
8	therapy	N	O
9	with	N	O
10	corticosteroids	N	O
11	,	N	O
12	antibiotics	N	O
13	,	N	O
14	analgesics	N	O
15	,	N	O
16	antiemetics	N	O
17	,	N	O
18	transfusions	N	O
19	,	N	O
20	and	N	O
21	other	N	O
22	symptomatic	N	O
23	therapy	N	O
24	as	N	O
25	required	N	O
26	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	of	N	O
6	the	N	O
7	study	N	O
8	was	N	O
9	survival	N	O
10	.	N	O

1	Time	N	O
2	to	N	O
3	disease	N	O
4	progression	N	O
5	,	N	O
6	response	N	O
7	rate	N	O
8	,	N	O
9	adverse	N	O
10	events	N	O
11	,	N	O
12	and	N	O
13	QOL	N	O
14	were	N	O
15	secondary	N	O
16	end	N	O
17	points	N	O
18	.	N	O

1	Pretreatment	N	O
2	characteristics	N	O
3	were	N	O
4	evenly	N	O
5	distributed	N	O
6	between	N	O
7	the	N	O
8	two	N	O
9	arms	N	O
10	.	N	O

1	Survival	N	I-Premise
2	was	N	I-Premise
3	statistically	N	I-Premise
4	significantly	N	I-Premise
5	better	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	paclitaxel	N	I-Premise
9	plus	N	I-Premise
10	supportive	N	I-Premise
11	care	N	I-Premise
12	arm	N	I-Premise
13	than	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	supportive	N	I-Premise
17	care	N	I-Premise
18	alone	N	I-Premise
19	arm	N	I-Premise
20	(	N	I-Premise
21	two-sided	N	I-Premise
22	P	N	I-Premise
23	=.037	N	I-Premise
24	)	N	I-Premise
25	(	N	I-Premise
26	median	N	I-Premise
27	survival	N	I-Premise
28	=	N	I-Premise
29	6.8	N	I-Premise
30	months	N	I-Premise
31	versus	N	I-Premise
32	4.8	N	I-Premise
33	months	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	Cox	N	I-Premise
2	multivariate	N	I-Premise
3	analysis	N	I-Premise
4	showed	N	I-Premise
5	paclitaxel	N	I-Premise
6	plus	N	I-Premise
7	supportive	N	I-Premise
8	care	N	I-Premise
9	to	N	I-Premise
10	be	N	I-Premise
11	statistically	N	I-Premise
12	significantly	N	I-Premise
13	associated	N	I-Premise
14	with	N	I-Premise
15	improved	N	I-Premise
16	survival	N	I-Premise
17	(	N	I-Premise
18	two-sided	N	I-Premise
19	P	N	I-Premise
20	=.048	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	QOL	N	I-Premise
2	was	N	I-Premise
3	similar	N	I-Premise
4	for	N	I-Premise
5	both	N	I-Premise
6	treatment	N	I-Premise
7	arms	N	I-Premise
8	,	N	I-Premise
9	except	N	I-Premise
10	for	N	I-Premise
11	the	N	I-Premise
12	functional	N	I-Premise
13	activity	N	I-Premise
14	score	N	I-Premise
15	of	N	I-Premise
16	the	N	I-Premise
17	Rotterdam	N	I-Premise
18	Symptom	N	I-Premise
19	Checklist	N	I-Premise
20	,	N	I-Premise
21	where	N	I-Premise
22	QOL	N	I-Premise
23	data	N	I-Premise
24	statistically	N	I-Premise
25	significantly	N	I-Premise
26	favored	N	I-Premise
27	the	N	I-Premise
28	paclitaxel	N	I-Premise
29	plus	N	I-Premise
30	supportive	N	I-Premise
31	care	N	I-Premise
32	arm	N	I-Premise
33	(	N	I-Premise
34	two-sided	N	I-Premise
35	P	N	I-Premise
36	=.043	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	The	N	I-Claim
2	addition	N	I-Claim
3	of	N	I-Claim
4	paclitaxel	N	I-Claim
5	to	N	I-Claim
6	best	N	I-Claim
7	supportive	N	I-Claim
8	care	N	I-Claim
9	significantly	N	I-Claim
10	improved	N	I-Claim
11	survival	N	I-Claim
12	and	N	I-Claim
13	time	N	I-Claim
14	to	N	I-Claim
15	disease	N	I-Claim
16	progression	N	I-Claim
17	compared	N	I-Claim
18	with	N	I-Claim
19	best	N	I-Claim
20	supportive	N	I-Claim
21	care	N	I-Claim
22	in	N	I-Claim
23	patients	N	I-Claim
24	with	N	I-Claim
25	advanced	N	I-Claim
26	NSCLC	N	I-Claim
27	and	N	I-Claim
28	may	N	I-Claim
29	improve	N	I-Claim
30	some	N	I-Claim
31	aspects	N	I-Claim
32	of	N	I-Claim
33	QOL	N	I-Claim
34	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	project	N	O
6	was	N	O
7	to	N	O
8	identify	N	O
9	clinical	N	O
10	and	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	(	N	O
15	QL	N	O
16	)	N	O
17	factors	N	O
18	that	N	O
19	together	N	O
20	predict	N	O
21	survival	N	O
22	and	N	O
23	response	N	O
24	to	N	O
25	chemotherapy	N	O
26	in	N	O
27	advanced	N	O
28	breast	N	O
29	cancer	N	O
30	.	N	O

1	Potential	N	O
2	prognostic	N	O
3	factors	N	O
4	were	N	O
5	studied	N	O
6	in	N	O
7	187	N	O
8	women	N	O
9	with	N	O
10	baseline	N	O
11	QL	N	O
12	data	N	O
13	from	N	O
14	a	N	O
15	trial	N	O
16	of	N	O
17	paclitaxel	N	O
18	versus	N	O
19	doxorubicin	N	O
20	as	N	O
21	first-line	N	O
22	chemotherapy	N	O
23	.	N	O

1	Demographic	N	O
2	and	N	O
3	clinical	N	O
4	factors	N	O
5	studied	N	O
6	were	N	O
7	age	N	O
8	,	N	O
9	performance	N	O
10	status	N	O
11	,	N	O
12	dominant	N	O
13	site	N	O
14	of	N	O
15	disease	N	O
16	and	N	O
17	preceding	N	O
18	disease-free	N	O
19	interval	N	O
20	(	N	O
21	DFI	N	O
22	)	N	O
23	.	N	O

1	Factors	N	O
2	from	N	O
3	the	N	O
4	EORTC	N	O
5	QLQ-C30	N	O
6	were	N	O
7	all	N	O
8	function	N	O
9	scales	N	O
10	,	N	O
11	fatigue	N	O
12	,	N	O
13	nausea/vomiting	N	O
14	,	N	O
15	pain	N	O
16	,	N	O
17	dyspnoea	N	O
18	,	N	O
19	insomnia	N	O
20	,	N	O
21	loss	N	O
22	of	N	O
23	appetite	N	O
24	and	N	O
25	global	N	O
26	QL	N	O
27	.	N	O

1	The	N	O
2	proportional	N	O
3	hazards	N	O
4	regression	N	O
5	model	N	O
6	with	N	O
7	stratification	N	O
8	for	N	O
9	treatment	N	O
10	,	N	O
11	and	N	O
12	the	N	O
13	logistic	N	O
14	regression	N	O
15	model	N	O
16	adjusting	N	O
17	for	N	O
18	treatment	N	O
19	arm	N	O
20	were	N	O
21	used	N	O
22	for	N	O
23	univariate	N	O
24	and	N	O
25	multivariate	N	O
26	analyses	N	O
27	of	N	O
28	survival	N	O
29	and	N	O
30	response	N	O
31	to	N	O
32	treatment	N	O
33	,	N	O
34	respectively	N	O
35	.	N	O

1	For	N	I-Premise
2	survival	N	I-Premise
3	,	N	I-Premise
4	multiple	N	I-Premise
5	sites	N	I-Premise
6	of	N	I-Premise
7	visceral	N	I-Premise
8	disease	N	I-Premise
9	,	N	I-Premise
10	pain	N	I-Premise
11	,	N	I-Premise
12	global	N	I-Premise
13	QL	N	I-Premise
14	and	N	I-Premise
15	fatigue	N	I-Premise
16	were	N	I-Premise
17	significant	N	I-Premise
18	prognostic	N	I-Premise
19	factors	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	univariate	N	I-Premise
23	analysis	N	I-Premise
24	.	N	I-Premise

1	The	N	I-Premise
2	final	N	I-Premise
3	multivariate	N	I-Premise
4	model	N	I-Premise
5	predicted	N	I-Premise
6	poor	N	I-Premise
7	survival	N	I-Premise
8	with	N	I-Premise
9	multiple	N	I-Premise
10	sites	N	I-Premise
11	of	N	I-Premise
12	visceral	N	I-Premise
13	disease	N	I-Premise
14	(	N	I-Premise
15	P=0.003	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	DFI	N	I-Premise
19	<	N	I-Premise
20	/=2	N	I-Premise
21	years	N	I-Premise
22	(	N	I-Premise
23	P=0.026	N	I-Premise
24	)	N	I-Premise
25	and	N	I-Premise
26	pain	N	I-Premise
27	(	N	I-Premise
28	P=0.003	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	For	N	I-Premise
2	response	N	I-Premise
3	,	N	I-Premise
4	age	N	I-Premise
5	,	N	I-Premise
6	dyspnoea	N	I-Premise
7	,	N	I-Premise
8	fatigue	N	I-Premise
9	and	N	I-Premise
10	global	N	I-Premise
11	QL	N	I-Premise
12	were	N	I-Premise
13	significant	N	I-Premise
14	predictive	N	I-Premise
15	factors	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	univariate	N	I-Premise
19	analysis	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	final	N	I-Premise
3	multivariate	N	I-Premise
4	model	N	I-Premise
5	for	N	I-Premise
6	response	N	I-Premise
7	selected	N	I-Premise
8	DFI	N	I-Premise
9	(	N	I-Premise
10	P=0.009	N	I-Premise
11	)	N	I-Premise
12	,	N	I-Premise
13	multiple	N	I-Premise
14	sites	N	I-Premise
15	of	N	I-Premise
16	visceral	N	I-Premise
17	disease	N	I-Premise
18	(	N	I-Premise
19	P=0.037	N	I-Premise
20	)	N	I-Premise
21	and	N	I-Premise
22	dyspnoea	N	I-Premise
23	(	N	I-Premise
24	P=	N	I-Premise
25	<	N	I-Premise
26	0.001	N	I-Premise
27	)	N	I-Premise
28	using	N	I-Premise
29	forward	N	I-Premise
30	selection	N	I-Premise
31	,	N	I-Premise
32	but	N	I-Premise
33	model	N	I-Premise
34	instability	N	I-Premise
35	was	N	I-Premise
36	indicated	N	I-Premise
37	by	N	I-Premise
38	the	N	I-Premise
39	inclusion	N	I-Premise
40	of	N	I-Premise
41	fatigue	N	I-Premise
42	and	N	I-Premise
43	emotional	N	I-Premise
44	function	N	I-Premise
45	in	N	I-Premise
46	the	N	I-Premise
47	final	N	I-Premise
48	model	N	I-Premise
49	when	N	I-Premise
50	backward	N	I-Premise
51	selection	N	I-Premise
52	was	N	I-Premise
53	used	N	I-Premise
54	.	N	I-Premise

1	In	N	O
2	addition	N	O
3	to	N	O
4	known	N	O
5	clinical	N	O
6	factors	N	O
7	,	N	O
8	patient-assessed	N	I-Claim
9	QL	N	I-Claim
10	variables	N	I-Claim
11	appear	N	I-Claim
12	to	N	I-Claim
13	be	N	I-Claim
14	prognostic	N	I-Claim
15	for	N	I-Claim
16	survival	N	I-Claim
17	and	N	I-Claim
18	response	N	I-Claim
19	to	N	I-Claim
20	chemotherapy	N	I-Claim
21	in	N	I-Claim
22	women	N	I-Claim
23	with	N	I-Claim
24	advanced	N	I-Claim
25	breast	N	I-Claim
26	cancer	N	I-Claim
27	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	identification	N	I-Claim
4	of	N	I-Claim
5	prognostic	N	I-Claim
6	factors	N	I-Claim
7	from	N	I-Claim
8	responses	N	I-Claim
9	to	N	I-Claim
10	questionnaires	N	I-Claim
11	may	N	I-Claim
12	be	N	I-Claim
13	unstable	N	I-Claim
14	,	N	I-Claim
15	and	N	I-Claim
16	their	N	I-Claim
17	reliability	N	I-Claim
18	and	N	I-Claim
19	clinical	N	I-Claim
20	utility	N	I-Claim
21	should	N	I-Claim
22	be	N	I-Claim
23	tested	N	I-Claim
24	prospectively	N	I-Claim
25	.	N	I-Claim

1	In	N	O
2	a	N	O
3	previous	N	O
4	study	N	O
5	of	N	O
6	treatment	N	O
7	for	N	O
8	advanced	N	O
9	colorectal	N	O
10	cancer	N	O
11	,	N	O
12	the	N	O
13	LV5FU2	N	O
14	regimen	N	O
15	,	N	O
16	comprising	N	O
17	leucovorin	N	O
18	(	N	O
19	LV	N	O
20	)	N	O
21	plus	N	O
22	bolus	N	O
23	and	N	O
24	infusional	N	O
25	fluorouracil	N	O
26	(	N	O
27	5FU	N	O
28	)	N	O
29	every	N	O
30	2	N	O
31	weeks	N	O
32	,	N	O
33	was	N	O
34	superior	N	O
35	to	N	O
36	the	N	O
37	standard	N	O
38	North	N	O
39	Central	N	O
40	Cancer	N	O
41	Treatment	N	O
42	Group/Mayo	N	O
43	Clinic	N	O
44	5-day	N	O
45	bolus	N	O
46	5FU/LV	N	O
47	regimen	N	O
48	.	N	O

1	This	N	O
2	phase	N	O
3	III	N	O
4	study	N	O
5	investigated	N	O
6	the	N	O
7	effect	N	O
8	of	N	O
9	combining	N	O
10	oxaliplatin	N	O
11	with	N	O
12	LV5FU2	N	O
13	,	N	O
14	with	N	O
15	progression-free	N	O
16	survival	N	O
17	as	N	O
18	the	N	O
19	primary	N	O
20	end	N	O
21	point	N	O
22	.	N	O

1	Four	N	O
2	hundred	N	O
3	twenty	N	O
4	previously	N	O
5	untreated	N	O
6	patients	N	O
7	with	N	O
8	measurable	N	O
9	disease	N	O
10	were	N	O
11	randomized	N	O
12	to	N	O
13	receive	N	O
14	a	N	O
15	2-hour	N	O
16	infusion	N	O
17	of	N	O
18	LV	N	O
19	(	N	O
20	200	N	O
21	mg/m	N	O
22	(	N	O
23	2	N	O
24	)	N	O
25	/d	N	O
26	)	N	O
27	followed	N	O
28	by	N	O
29	a	N	O
30	5FU	N	O
31	bolus	N	O
32	(	N	O
33	400	N	O
34	mg/m	N	O
35	(	N	O
36	2	N	O
37	)	N	O
38	/d	N	O
39	)	N	O
40	and	N	O
41	22-hour	N	O
42	infusion	N	O
43	(	N	O
44	600	N	O
45	mg/m	N	O
46	(	N	O
47	2	N	O
48	)	N	O
49	/d	N	O
50	)	N	O
51	for	N	O
52	2	N	O
53	consecutive	N	O
54	days	N	O
55	every	N	O
56	2	N	O
57	weeks	N	O
58	,	N	O
59	either	N	O
60	alone	N	O
61	or	N	O
62	together	N	O
63	with	N	O
64	oxaliplatin	N	O
65	85	N	O
66	mg/m	N	O
67	(	N	O
68	2	N	O
69	)	N	O
70	as	N	O
71	a	N	O
72	2-hour	N	O
73	infusion	N	O
74	on	N	O
75	day	N	O
76	1	N	O
77	.	N	O

1	Patients	N	I-Premise
2	allocated	N	I-Premise
3	to	N	I-Premise
4	oxaliplatin	N	I-Premise
5	plus	N	I-Premise
6	LV5FU2	N	I-Premise
7	had	N	I-Premise
8	significantly	N	I-Premise
9	longer	N	I-Premise
10	progression-free	N	I-Premise
11	survival	N	I-Premise
12	(	N	I-Premise
13	median	N	I-Premise
14	,	N	I-Premise
15	9.0	N	I-Premise
16	v	N	I-Premise
17	6.2	N	I-Premise
18	months	N	I-Premise
19	;	N	I-Premise
20	P	N	I-Premise
21	=.0003	N	I-Premise
22	)	N	I-Premise
23	and	N	I-Premise
24	better	N	I-Premise
25	response	N	I-Premise
26	rate	N	I-Premise
27	(	N	I-Premise
28	50.7	N	I-Premise
29	%	N	I-Premise
30	v	N	I-Premise
31	22.3	N	I-Premise
32	%	N	I-Premise
33	;	N	I-Premise
34	P	N	I-Premise
35	=.0001	N	I-Premise
36	)	N	I-Premise
37	when	N	I-Premise
38	compared	N	I-Premise
39	with	N	I-Premise
40	the	N	I-Premise
41	control	N	I-Premise
42	arm	N	I-Premise
43	.	N	I-Premise

1	The	N	I-Premise
2	improvement	N	I-Premise
3	in	N	I-Premise
4	overall	N	I-Premise
5	survival	N	I-Premise
6	did	N	I-Premise
7	not	N	I-Premise
8	reach	N	I-Premise
9	significance	N	I-Premise
10	(	N	I-Premise
11	median	N	I-Premise
12	,	N	I-Premise
13	16.2	N	I-Premise
14	v	N	I-Premise
15	14.7	N	I-Premise
16	months	N	I-Premise
17	;	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	.	N	I-Premise

1	12	N	I-Premise
2	)	N	I-Premise
3	.	N	I-Premise

1	LV5FU2	N	I-Premise
2	plus	N	I-Premise
3	oxaliplatin	N	I-Premise
4	gave	N	I-Premise
5	higher	N	I-Premise
6	frequencies	N	I-Premise
7	of	N	I-Premise
8	National	N	I-Premise
9	Cancer	N	I-Premise
10	Institute	N	I-Premise
11	common	N	I-Premise
12	toxicity	N	I-Premise
13	criteria	N	I-Premise
14	grade	N	I-Premise
15	3/4	N	I-Premise
16	neutropenia	N	I-Premise
17	(	N	I-Premise
18	41	N	I-Premise
19	.	N	I-Premise

1	7	N	I-Premise
2	%	N	I-Premise
3	v	N	I-Premise
4	5.3	N	I-Premise
5	%	N	I-Premise
6	of	N	I-Premise
7	patients	N	I-Premise
8	)	N	I-Premise
9	,	N	I-Premise
10	grade	N	I-Premise
11	3/4	N	I-Premise
12	diarrhea	N	I-Premise
13	(	N	I-Premise
14	11.9	N	I-Premise
15	%	N	I-Premise
16	v	N	I-Premise
17	5.3	N	I-Premise
18	%	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	and	N	I-Premise
22	grade	N	I-Premise
23	3	N	I-Premise
24	neurosensory	N	I-Premise
25	toxicity	N	I-Premise
26	(	N	I-Premise
27	18.2	N	I-Premise
28	%	N	I-Premise
29	v	N	I-Premise
30	0	N	I-Premise
31	%	N	I-Premise
32	)	N	I-Premise
33	,	N	I-Premise
34	but	N	I-Premise
35	this	N	I-Premise
36	did	N	I-Premise
37	not	N	I-Premise
38	result	N	I-Premise
39	in	N	I-Premise
40	impairment	N	I-Premise
41	of	N	I-Premise
42	quality	N	I-Premise
43	of	N	I-Premise
44	life	N	I-Premise
45	(	N	I-Premise
46	QoL	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	Survival	N	I-Premise
2	without	N	I-Premise
3	disease	N	I-Premise
4	progression	N	I-Premise
5	or	N	I-Premise
6	deterioration	N	I-Premise
7	in	N	I-Premise
8	global	N	I-Premise
9	health	N	I-Premise
10	status	N	I-Premise
11	was	N	I-Premise
12	longer	N	I-Premise
13	in	N	I-Premise
14	patients	N	I-Premise
15	allocated	N	I-Premise
16	to	N	I-Premise
17	oxaliplatin	N	I-Premise
18	treatment	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=.004	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	The	N	I-Claim
2	LV5FU2-oxaliplatin	N	I-Claim
3	combination	N	I-Claim
4	seems	N	I-Claim
5	beneficial	N	I-Claim
6	as	N	I-Claim
7	first-line	N	I-Claim
8	therapy	N	I-Claim
9	in	N	I-Claim
10	advanced	N	I-Claim
11	colorectal	N	I-Claim
12	cancer	N	I-Claim
13	,	N	I-Claim
14	demonstrating	N	I-Claim
15	a	N	I-Claim
16	prolonged	N	I-Claim
17	progression-free	N	I-Claim
18	survival	N	I-Claim
19	with	N	I-Claim
20	acceptable	N	I-Claim
21	tolerability	N	I-Claim
22	and	N	I-Claim
23	maintenance	N	I-Claim
24	of	N	I-Claim
25	QoL	N	I-Claim
26	.	N	I-Claim

1	A	N	O
2	randomized	N	O
3	phase	N	O
4	III	N	O
5	trial	N	O
6	was	N	O
7	conducted	N	O
8	to	N	O
9	determine	N	O
10	whether	N	O
11	combination	N	O
12	therapy	N	O
13	with	N	O
14	13-cis-retinoic	N	O
15	acid	N	O
16	(	N	O
17	13-CRA	N	O
18	)	N	O
19	plus	N	O
20	interferon	N	O
21	alfa-2a	N	O
22	(	N	O
23	IFNalpha2a	N	O
24	)	N	O
25	is	N	O
26	superior	N	O
27	to	N	O
28	IFNalpha2a	N	O
29	alone	N	O
30	in	N	O
31	patients	N	O
32	with	N	O
33	advanced	N	O
34	renal	N	O
35	cell	N	O
36	carcinoma	N	O
37	(	N	O
38	RCC	N	O
39	)	N	O
40	.	N	O

1	Two	N	O
2	hundred	N	O
3	eighty-four	N	O
4	patients	N	O
5	were	N	O
6	randomized	N	O
7	to	N	O
8	treatment	N	O
9	with	N	O
10	IFNalpha2a	N	O
11	plus	N	O
12	13-CRA	N	O
13	or	N	O
14	treatment	N	O
15	with	N	O
16	IFNalpha2a	N	O
17	alone	N	O
18	.	N	O

1	IFNalpha2a	N	O
2	was	N	O
3	given	N	O
4	daily	N	O
5	subcutaneously	N	O
6	,	N	O
7	starting	N	O
8	at	N	O
9	a	N	O
10	dose	N	O
11	of	N	O
12	3	N	O
13	million	N	O
14	units	N	O
15	(	N	O
16	MU	N	O
17	)	N	O
18	.	N	O

1	The	N	O
2	dose	N	O
3	was	N	O
4	escalated	N	O
5	every	N	O
6	7	N	O
7	days	N	O
8	from	N	O
9	3	N	O
10	to	N	O
11	9	N	O
12	MU	N	O
13	(	N	O
14	by	N	O
15	increments	N	O
16	of	N	O
17	3	N	O
18	MU	N	O
19	)	N	O
20	,	N	O
21	unless	N	O
22	>	N	O
23	/=	N	O
24	grade	N	O
25	2	N	O
26	toxicity	N	O
27	occurred	N	O
28	,	N	O
29	in	N	O
30	which	N	O
31	case	N	O
32	dose	N	O
33	escalation	N	O
34	was	N	O
35	stopped	N	O
36	.	N	O

1	Patients	N	O
2	randomized	N	O
3	to	N	O
4	combination	N	O
5	therapy	N	O
6	were	N	O
7	given	N	O
8	oral	N	O
9	13-CRA	N	O
10	1	N	O
11	mg/kg/d	N	O
12	plus	N	O
13	IFNalpha2a	N	O
14	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	(	N	O
5	QOL	N	O
6	)	N	O
7	was	N	O
8	assessed	N	O
9	.	N	O

1	Complete	N	I-Premise
2	or	N	I-Premise
3	partial	N	I-Premise
4	responses	N	I-Premise
5	were	N	I-Premise
6	achieved	N	I-Premise
7	by	N	I-Premise
8	12	N	I-Premise
9	%	N	I-Premise
10	of	N	I-Premise
11	patients	N	I-Premise
12	treated	N	I-Premise
13	with	N	I-Premise
14	IFNalpha2a	N	I-Premise
15	plus	N	I-Premise
16	13-CRA	N	I-Premise
17	and	N	I-Premise
18	6	N	I-Premise
19	%	N	I-Premise
20	of	N	I-Premise
21	patients	N	I-Premise
22	treated	N	I-Premise
23	with	N	I-Premise
24	IFNalpha2a	N	I-Premise
25	(	N	I-Premise
26	P	N	I-Premise
27	=.14	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Median	N	I-Premise
2	duration	N	I-Premise
3	of	N	I-Premise
4	response	N	I-Premise
5	(	N	I-Premise
6	complete	N	I-Premise
7	and	N	I-Premise
8	partial	N	I-Premise
9	combined	N	I-Premise
10	)	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	group	N	I-Premise
14	treated	N	I-Premise
15	with	N	I-Premise
16	the	N	I-Premise
17	combination	N	I-Premise
18	was	N	I-Premise
19	33	N	I-Premise
20	months	N	I-Premise
21	(	N	I-Premise
22	range	N	I-Premise
23	,	N	I-Premise
24	9	N	I-Premise
25	to	N	I-Premise
26	50	N	I-Premise
27	months	N	I-Premise
28	)	N	I-Premise
29	,	N	I-Premise
30	versus	N	I-Premise
31	22	N	I-Premise
32	months	N	I-Premise
33	(	N	I-Premise
34	range	N	I-Premise
35	,	N	I-Premise
36	5	N	I-Premise
37	to	N	I-Premise
38	38	N	I-Premise
39	months	N	I-Premise
40	)	N	I-Premise
41	for	N	I-Premise
42	the	N	I-Premise
43	second	N	I-Premise
44	group	N	I-Premise
45	(	N	I-Premise
46	P	N	I-Premise
47	=.03	N	I-Premise
48	)	N	I-Premise
49	.	N	I-Premise

1	Nineteen	N	I-Premise
2	percent	N	I-Premise
3	of	N	I-Premise
4	patients	N	I-Premise
5	treated	N	I-Premise
6	with	N	I-Premise
7	IFNalpha2a	N	I-Premise
8	plus	N	I-Premise
9	13-CRA	N	I-Premise
10	were	N	I-Premise
11	progression-free	N	I-Premise
12	at	N	I-Premise
13	24	N	I-Premise
14	months	N	I-Premise
15	,	N	I-Premise
16	compared	N	I-Premise
17	with	N	I-Premise
18	10	N	I-Premise
19	%	N	I-Premise
20	of	N	I-Premise
21	patients	N	I-Premise
22	treated	N	I-Premise
23	with	N	I-Premise
24	IFNalpha2a	N	I-Premise
25	alone	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	=.05	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	time	N	I-Premise
4	for	N	I-Premise
5	all	N	I-Premise
6	patients	N	I-Premise
7	was	N	I-Premise
8	15	N	I-Premise
9	months	N	I-Premise
10	,	N	I-Premise
11	with	N	I-Premise
12	no	N	I-Premise
13	difference	N	I-Premise
14	in	N	I-Premise
15	survival	N	I-Premise
16	between	N	I-Premise
17	the	N	I-Premise
18	two	N	I-Premise
19	treatment	N	I-Premise
20	arms	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	=.26	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	QOL	N	I-Premise
2	decreased	N	I-Premise
3	during	N	I-Premise
4	the	N	I-Premise
5	first	N	I-Premise
6	8	N	I-Premise
7	weeks	N	I-Premise
8	of	N	I-Premise
9	treatment	N	I-Premise
10	,	N	I-Premise
11	and	N	I-Premise
12	a	N	I-Premise
13	partial	N	I-Premise
14	recovery	N	I-Premise
15	followed	N	I-Premise
16	.	N	I-Premise

1	Lower	N	I-Premise
2	scores	N	I-Premise
3	were	N	I-Premise
4	associated	N	I-Premise
5	with	N	I-Premise
6	the	N	I-Premise
7	combination	N	I-Premise
8	therapy	N	I-Premise
9	.	N	I-Premise

1	Response	N	I-Claim
2	proportion	N	I-Claim
3	and	N	I-Claim
4	survival	N	I-Claim
5	did	N	I-Claim
6	not	N	I-Claim
7	improve	N	I-Claim
8	significantly	N	I-Claim
9	with	N	I-Claim
10	the	N	I-Claim
11	addition	N	I-Claim
12	of	N	I-Claim
13	13-CRA	N	I-Claim
14	to	N	I-Claim
15	IFNalpha2a	N	I-Claim
16	therapy	N	I-Claim
17	in	N	I-Claim
18	patients	N	I-Claim
19	with	N	I-Claim
20	advanced	N	I-Claim
21	RCC	N	I-Claim
22	.	N	I-Claim

1	13-CRA	N	I-Claim
2	may	N	I-Claim
3	lengthen	N	I-Claim
4	response	N	I-Claim
5	to	N	I-Claim
6	IFNalpha2a	N	I-Claim
7	therapy	N	I-Claim
8	in	N	I-Claim
9	patients	N	I-Claim
10	with	N	I-Claim
11	IFNalpha2a-sensitive	N	I-Claim
12	tumors	N	I-Claim
13	.	N	I-Claim

1	Treatment	N	I-Claim
2	,	N	I-Claim
3	particularly	N	I-Claim
4	the	N	I-Claim
5	combination	N	I-Claim
6	therapy	N	I-Claim
7	,	N	I-Claim
8	was	N	I-Claim
9	associated	N	I-Claim
10	with	N	I-Claim
11	a	N	I-Claim
12	decrease	N	I-Claim
13	in	N	I-Claim
14	QOL	N	I-Claim
15	.	N	I-Claim

1	Postoperative	N	I-Claim
2	adjuvant	N	I-Claim
3	chemoradiation	N	I-Claim
4	treatment	N	I-Claim
5	after	N	I-Claim
6	curative	N	I-Claim
7	resection	N	I-Claim
8	for	N	I-Claim
9	rectal	N	I-Claim
10	cancer	N	I-Claim
11	was	N	I-Claim
12	needed	N	I-Claim
13	to	N	I-Claim
14	reduce	N	I-Claim
15	recurrence	N	I-Claim
16	and	N	I-Claim
17	improve	N	I-Claim
18	a	N	I-Claim
19	survival	N	I-Claim
20	rate	N	I-Claim
21	.	N	I-Claim

1	Intravenous	N	I-MajorClaim
2	5-fluorouracil	N	I-MajorClaim
3	(	N	I-MajorClaim
4	5-FU	N	I-MajorClaim
5	)	N	I-MajorClaim
6	and	N	I-MajorClaim
7	leucovorin	N	I-MajorClaim
8	has	N	I-MajorClaim
9	been	N	I-MajorClaim
10	a	N	I-MajorClaim
11	mainstay	N	I-MajorClaim
12	of	N	I-MajorClaim
13	chemotherapy	N	I-MajorClaim
14	,	N	I-MajorClaim
15	but	N	O
16	oral	N	I-MajorClaim
17	5-FU	N	I-MajorClaim
18	derivatives	N	I-MajorClaim
19	have	N	I-MajorClaim
20	been	N	I-MajorClaim
21	shown	N	I-MajorClaim
22	a	N	I-MajorClaim
23	comparable	N	I-MajorClaim
24	antitumor	N	I-MajorClaim
25	activity	N	I-MajorClaim
26	.	N	I-MajorClaim

1	Intravenous	N	O
2	5-FU	N	O
3	and	N	O
4	oral	N	O
5	doxifluridine	N	O
6	were	N	O
7	compared	N	O
8	with	N	O
9	respect	N	O
10	to	N	O
11	therapeutic	N	O
12	efficacy	N	O
13	,	N	O
14	drug	N	O
15	toxicity	N	O
16	,	N	O
17	and	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	166	N	O
5	patients	N	O
6	were	N	O
7	randomized	N	O
8	to	N	O
9	receive	N	O
10	intravenous	N	O
11	5-FU	N	O
12	(	N	O
13	450	N	O
14	mg/m2/day	N	O
15	)	N	O
16	or	N	O
17	oral	N	O
18	doxifluridine	N	O
19	(	N	O
20	900	N	O
21	mg/m2/day	N	O
22	)	N	O
23	in	N	O
24	combination	N	O
25	with	N	O
26	leucovorin	N	O
27	(	N	O
28	20	N	O
29	mg/m2/day	N	O
30	)	N	O
31	for	N	O
32	depth	N	O
33	of	N	O
34	invasion	N	O
35	,	N	O
36	nodal	N	O
37	status	N	O
38	,	N	O
39	metastasis	N	O
40	(	N	O
41	TNM	N	O
42	)	N	O
43	stage	N	O
44	II	N	O
45	and	N	O
46	III	N	O
47	patients	N	O
48	between	N	O
49	October	N	O
50	1997	N	O
51	and	N	O
52	February	N	O
53	1999	N	O
54	.	N	O

1	Consecutive	N	O
2	daily	N	O
3	intravenous	N	O
4	infusion	N	O
5	for	N	O
6	5	N	O
7	days	N	O
8	per	N	O
9	every	N	O
10	month	N	O
11	for	N	O
12	a	N	O
13	total	N	O
14	of	N	O
15	12	N	O
16	cycles	N	O
17	(	N	O
18	IV	N	O
19	arm	N	O
20	,	N	O
21	n	N	O
22	=	N	O
23	74	N	O
24	)	N	O
25	and	N	O
26	oral	N	O
27	doxifluridine	N	O
28	daily	N	O
29	for	N	O
30	3	N	O
31	weeks	N	O
32	and	N	O
33	1	N	O
34	week	N	O
35	rest	N	O
36	for	N	O
37	a	N	O
38	total	N	O
39	of	N	O
40	12	N	O
41	cycles	N	O
42	(	N	O
43	oral	N	O
44	arm	N	O
45	,	N	O
46	n	N	O
47	=	N	O
48	92	N	O
49	)	N	O
50	.	N	O

1	Drug	N	O
2	toxicity	N	O
3	and	N	O
4	quality	N	O
5	of	N	O
6	life	N	O
7	were	N	O
8	observed	N	O
9	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	scored	N	O
6	according	N	O
7	to	N	O
8	22	N	O
9	daily	N	O
10	activity	N	O
11	items	N	O
12	(	N	O
13	good	N	O
14	,	N	O
15	>	N	O
16	or	N	O
17	=71	N	O
18	;	N	O
19	fair	N	O
20	,	N	O
21	<	N	O
22	70	N	O
23	;	N	O
24	poor	N	O
25	,	N	O
26	<	N	O
27	52	N	O
28	)	N	O
29	.	N	O

1	There	N	O
2	was	N	O
3	no	N	O
4	difference	N	O
5	of	N	O
6	sex	N	O
7	between	N	O
8	two	N	O
9	groups	N	O
10	(	N	O
11	IV	N	O
12	arm	N	O
13	:	N	O
14	male/female	N	O
15	=	N	O
16	45/29	N	O
17	,	N	O
18	oral	N	O
19	arm	N	O
20	:	N	O
21	male/female	N	O
22	=	N	O
23	59/33	N	O
24	)	N	O
25	.	N	O

1	The	N	O
2	mean	N	O
3	age	N	O
4	was	N	O
5	52.3	N	O
6	vs.	N	O
7	59.5	N	O
8	,	N	O
9	respectively	N	O
10	.	N	O

1	There	N	O
2	was	N	O
3	also	N	O
4	no	N	O
5	difference	N	O
6	of	N	O
7	TNM	N	O
8	stage	N	O
9	distribution	N	O
10	and	N	O
11	type	N	O
12	of	N	O
13	operation	N	O
14	between	N	O
15	groups	N	O
16	(	N	O
17	P	N	O
18	>	N	O
19	.05	N	O
20	)	N	O
21	.	N	O

1	Mean	N	I-Premise
2	numbers	N	I-Premise
3	of	N	I-Premise
4	chemotherapy	N	I-Premise
5	cycles	N	I-Premise
6	were	N	I-Premise
7	6.5+/-3.7	N	I-Premise
8	(	N	I-Premise
9	IV	N	I-Premise
10	arm	N	I-Premise
11	)	N	I-Premise
12	vs.	N	I-Premise
13	7.2+/-4.3	N	I-Premise
14	(	N	I-Premise
15	oral	N	I-Premise
16	arm	N	I-Premise
17	)	N	I-Premise
18	,	N	I-Premise
19	respectively	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	rate	N	I-Premise
3	of	N	I-Premise
4	recurrence	N	I-Premise
5	was	N	I-Premise
6	9/74	N	I-Premise
7	(	N	I-Premise
8	12.1	N	I-Premise
9	%	N	I-Premise
10	)	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	IV	N	I-Premise
14	arm	N	I-Premise
15	and	N	I-Premise
16	6/92	N	I-Premise
17	(	N	I-Premise
18	6.5	N	I-Premise
19	%	N	I-Premise
20	)	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	oral	N	I-Premise
24	arm	N	I-Premise
25	,	N	I-Premise
26	respectively	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	.937	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Local	N	I-Premise
2	recurrence	N	I-Premise
3	was	N	I-Premise
4	2/74	N	I-Premise
5	(	N	I-Premise
6	stage	N	I-Premise
7	III	N	I-Premise
8	;	N	I-Premise
9	2.7	N	I-Premise
10	%	N	I-Premise
11	)	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	IV	N	I-Premise
15	arm	N	I-Premise
16	and	N	I-Premise
17	1/92	N	I-Premise
18	(	N	I-Premise
19	stage	N	I-Premise
20	II	N	I-Premise
21	;	N	I-Premise
22	1.1	N	I-Premise
23	%	N	I-Premise
24	)	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	oral	N	I-Premise
28	arm	N	I-Premise
29	,	N	I-Premise
30	respectively	N	I-Premise
31	.	N	I-Premise

1	Systemic	N	I-Premise
2	recurrence	N	I-Premise
3	was	N	I-Premise
4	7/74	N	I-Premise
5	(	N	I-Premise
6	stage	N	I-Premise
7	III	N	I-Premise
8	;	N	I-Premise
9	9.4	N	I-Premise
10	%	N	I-Premise
11	)	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	IV	N	I-Premise
15	arm	N	I-Premise
16	and	N	I-Premise
17	5/92	N	I-Premise
18	(	N	I-Premise
19	stage	N	I-Premise
20	III	N	I-Premise
21	;	N	I-Premise
22	5.4	N	I-Premise
23	%	N	I-Premise
24	)	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	oral	N	I-Premise
28	arm	N	I-Premise
29	,	N	I-Premise
30	respectively	N	I-Premise
31	.	N	I-Premise

1	The	N	I-Premise
2	most	N	I-Premise
3	common	N	I-Premise
4	site	N	I-Premise
5	of	N	I-Premise
6	systemic	N	I-Premise
7	recurrence	N	I-Premise
8	was	N	I-Premise
9	the	N	I-Premise
10	liver	N	I-Premise
11	.	N	I-Premise

1	Toxicity	N	I-Premise
2	profile	N	I-Premise
3	was	N	I-Premise
4	as	N	I-Premise
5	follows	N	I-Premise
6	:	N	I-Premise
7	leukopenia	N	I-Premise
8	(	N	I-Premise
9	30/74	N	I-Premise
10	vs.	N	I-Premise
11	17/92	N	I-Premise
12	)	N	I-Premise
13	and	N	I-Premise
14	alopecia	N	I-Premise
15	(	N	I-Premise
16	21/74	N	I-Premise
17	vs.	N	I-Premise
18	13/92	N	I-Premise
19	)	N	I-Premise
20	were	N	I-Premise
21	statistically	N	I-Premise
22	more	N	I-Premise
23	common	N	I-Premise
24	in	N	I-Premise
25	the	N	I-Premise
26	IV	N	I-Premise
27	arm	N	I-Premise
28	.	N	I-Premise

1	Diarrhea	N	I-Premise
2	was	N	I-Premise
3	more	N	I-Premise
4	common	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	oral	N	I-Premise
8	arm	N	I-Premise
9	.	N	I-Premise

1	Poor	N	I-Premise
2	quality	N	I-Premise
3	of	N	I-Premise
4	life	N	I-Premise
5	score	N	I-Premise
6	between	N	I-Premise
7	two	N	I-Premise
8	groups	N	I-Premise
9	was	N	I-Premise
10	observed	N	I-Premise
11	at	N	I-Premise
12	1	N	I-Premise
13	month	N	I-Premise
14	(	N	I-Premise
15	23.9	N	I-Premise
16	%	N	I-Premise
17	vs.	N	I-Premise
18	13	N	I-Premise
19	%	N	I-Premise
20	)	N	I-Premise
21	and	N	I-Premise
22	2	N	I-Premise
23	months	N	I-Premise
24	(	N	I-Premise
25	15.8	N	I-Premise
26	%	N	I-Premise
27	vs.	N	I-Premise
28	3.7	N	I-Premise
29	%	N	I-Premise
30	)	N	I-Premise
31	after	N	I-Premise
32	chemotherapy	N	I-Premise
33	.	N	I-Premise

1	Good	N	I-Premise
2	quality	N	I-Premise
3	of	N	I-Premise
4	life	N	I-Premise
5	score	N	I-Premise
6	was	N	I-Premise
7	observed	N	I-Premise
8	at	N	I-Premise
9	1	N	I-Premise
10	month	N	I-Premise
11	(	N	I-Premise
12	19.5	N	I-Premise
13	%	N	I-Premise
14	vs.	N	I-Premise
15	49	N	I-Premise
16	%	N	I-Premise
17	)	N	I-Premise
18	and	N	I-Premise
19	2	N	I-Premise
20	months	N	I-Premise
21	(	N	I-Premise
22	47	N	I-Premise
23	%	N	I-Premise
24	vs.	N	I-Premise
25	72	N	I-Premise
26	%	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	respectively	N	I-Premise
30	(	N	I-Premise
31	P	N	I-Premise
32	<	N	I-Premise
33	.05	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	Oral	N	I-Claim
2	doxifluridine	N	I-Claim
3	with	N	I-Claim
4	leucovorin	N	I-Claim
5	shows	N	I-Claim
6	a	N	I-Claim
7	comparable	N	I-Claim
8	therapeutic	N	I-Claim
9	efficacy	N	I-Claim
10	to	N	I-Claim
11	intravenous	N	I-Claim
12	5-FU	N	I-Claim
13	regimen	N	I-Claim
14	with	N	I-Claim
15	high	N	I-Claim
16	quality	N	I-Claim
17	of	N	I-Claim
18	life	N	I-Claim
19	as	N	I-Claim
20	postoperative	N	I-Claim
21	adjuvant	N	I-Claim
22	therapy	N	I-Claim
23	.	N	I-Claim

1	The	N	I-Claim
2	oral	N	I-Claim
3	regimen	N	I-Claim
4	also	N	I-Claim
5	can	N	I-Claim
6	be	N	I-Claim
7	safely	N	I-Claim
8	given	N	I-Claim
9	with	N	I-Claim
10	appropriate	N	I-Claim
11	toxicity	N	I-Claim
12	and	N	I-Claim
13	tolerability	N	I-Claim
14	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	randomised	N	O
6	trial	N	O
7	was	N	O
8	to	N	O
9	evaluate	N	O
10	the	N	O
11	activity	N	O
12	and	N	O
13	toxicity	N	O
14	of	N	O
15	a	N	O
16	biweekly	N	O
17	regimen	N	O
18	including	N	O
19	6S-leucovorin-modulated	N	O
20	5-fluorouracil	N	O
21	(	N	O
22	LFA-5-FU	N	O
23	)	N	O
24	,	N	O
25	combined	N	O
26	with	N	O
27	either	N	O
28	irinotecan	N	O
29	(	N	O
30	CPT-11	N	O
31	+	N	O
32	LFA	N	O
33	5-FU	N	O
34	)	N	O
35	or	N	O
36	raltitrexed	N	O
37	(	N	O
38	Tomudex	N	O
39	)	N	O
40	(	N	O
41	TOM	N	O
42	+	N	O
43	LFA-5-FU	N	O
44	)	N	O
45	,	N	O
46	in	N	O
47	advanced	N	O
48	colorectal	N	O
49	cancer	N	O
50	patients	N	O
51	,	N	O
52	and	N	O
53	to	N	O
54	make	N	O
55	a	N	O
56	preliminary	N	O
57	comparison	N	O
58	of	N	O
59	both	N	O
60	these	N	O
61	experimental	N	O
62	regimens	N	O
63	with	N	O
64	a	N	O
65	biweekly	N	O
66	administration	N	O
67	of	N	O
68	LFA-5-FU	N	O
69	modulated	N	O
70	by	N	O
71	methotrexate	N	O
72	(	N	O
73	MTX	N	O
74	+	N	O
75	LFA-5-FU	N	O
76	)	N	O
77	.	N	O

1	One	N	O
2	hundred	N	O
3	fifty-nine	N	O
4	patients	N	O
5	with	N	O
6	advanced	N	O
7	colorectal	N	O
8	carcinoma	N	O
9	previously	N	O
10	untreated	N	O
11	for	N	O
12	the	N	O
13	metastatic	N	O
14	disease	N	O
15	(	N	O
16	34	N	O
17	of	N	O
18	them	N	O
19	previously	N	O
20	exposed	N	O
21	to	N	O
22	adjuvant	N	O
23	5-FU	N	O
24	)	N	O
25	were	N	O
26	randomly	N	O
27	allocated	N	O
28	to	N	O
29	receive	N	O
30	:	N	O
31	CPT-11	N	O
32	,	N	O
33	200	N	O
34	mg/m2	N	O
35	i.v	N	O
36	.	N	O

1	on	N	O
2	day	N	O
3	1	N	O
4	,	N	O
5	followed	N	O
6	on	N	O
7	day	N	O
8	2	N	O
9	by	N	O
10	LFA	N	O
11	,	N	O
12	250	N	O
13	mg/m2	N	O
14	i.v	N	O
15	.	N	O

1	infusion	N	O
2	and	N	O
3	5-FU	N	O
4	,	N	O
5	850	N	O
6	mg/m2	N	O
7	s	N	O
8	i.v	N	O
9	.	N	O

1	bolus	N	O
2	(	N	O
3	arm	N	O
4	A	N	O
5	)	N	O
6	;	N	O
7	TOM	N	O
8	,	N	O
9	3	N	O
10	mg/m2	N	O
11	i.v	N	O
12	.	N	O

1	on	N	O
2	day	N	O
3	1	N	O
4	,	N	O
5	followed	N	O
6	on	N	O
7	day	N	O
8	2	N	O
9	by	N	O
10	LFA	N	O
11	,	N	O
12	250	N	O
13	mg/m2	N	O
14	i.v	N	O
15	.	N	O

1	infusion	N	O
2	and	N	O
3	5-FU	N	O
4	,	N	O
5	1050	N	O
6	mg/m2	N	O
7	i.v	N	O
8	.	N	O

1	bolus	N	O
2	(	N	O
3	arm	N	O
4	B	N	O
5	)	N	O
6	;	N	O
7	or	N	O
8	MTX	N	O
9	,	N	O
10	750	N	O
11	mg/m2	N	O
12	i.v	N	O
13	.	N	O

1	on	N	O
2	day	N	O
3	1	N	O
4	,	N	O
5	followed	N	O
6	on	N	O
7	day	N	O
8	2	N	O
9	by	N	O
10	LFA	N	O
11	,	N	O
12	250	N	O
13	mg/m2	N	O
14	i.v	N	O
15	.	N	O

1	infusion	N	O
2	and	N	O
3	5-FU	N	O
4	,	N	O
5	800	N	O
6	mg/m2	N	O
7	i.v	N	O
8	.	N	O

1	bolus	N	O
2	(	N	O
3	arm	N	O
4	C	N	O
5	)	N	O
6	.	N	O

1	Courses	N	O
2	were	N	O
3	repeated	N	O
4	every	N	O
5	two	N	O
6	weeks	N	O
7	in	N	O
8	all	N	O
9	arms	N	O
10	of	N	O
11	the	N	O
12	trial	N	O
13	.	N	O

1	Response	N	O
2	rate	N	O
3	(	N	O
4	RR	N	O
5	)	N	O
6	was	N	O
7	evaluated	N	O
8	after	N	O
9	every	N	O
10	four	N	O
11	courses	N	O
12	.	N	O

1	The	N	O
2	sample	N	O
3	size	N	O
4	was	N	O
5	defined	N	O
6	to	N	O
7	have	N	O
8	an	N	O
9	80	N	O
10	%	N	O
11	power	N	O
12	to	N	O
13	detect	N	O
14	a	N	O
15	35	N	O
16	%	N	O
17	RR	N	O
18	for	N	O
19	each	N	O
20	experimental	N	O
21	treatment	N	O
22	,	N	O
23	and	N	O
24	to	N	O
25	show	N	O
26	a	N	O
27	difference	N	O
28	of	N	O
29	at	N	O
30	least	N	O
31	4	N	O
32	%	N	O
33	in	N	O
34	RR	N	O
35	with	N	O
36	the	N	O
37	standard	N	O
38	treatment	N	O
39	if	N	O
40	the	N	O
41	true	N	O
42	difference	N	O
43	is	N	O
44	15	N	O
45	%	N	O
46	or	N	O
47	more	N	O
48	.	N	O

1	The	N	O
2	RRs	N	O
3	were	N	O
4	:	N	O
5	34	N	O
6	%	N	O
7	(	N	O
8	95	N	O
9	%	N	O
10	confidence	N	O
11	interval	N	O
12	(	N	O
13	95	N	O
14	%	N	O
15	,	N	O
16	CI	N	O
17	)	N	O
18	:	N	O
19	21	N	O
20	%	N	O
21	-48	N	O
22	%	N	O
23	)	N	O
24	in	N	O
25	arm	N	O
26	A	N	O
27	,	N	O
28	including	N	O
29	3	N	O
30	complete	N	O
31	responses	N	O
32	(	N	O
33	CRs	N	O
34	)	N	O
35	and	N	O
36	15	N	O
37	partial	N	O
38	responses	N	O
39	(	N	O
40	PRs	N	O
41	)	N	O
42	,	N	O
43	24	N	O
44	%	N	O
45	(	N	O
46	95	N	O
47	%	N	O
48	CI	N	O
49	:	N	O
50	14	N	O
51	%	N	O
52	-38	N	O
53	%	N	O
54	)	N	O
55	in	N	O
56	arm	N	O
57	B	N	O
58	,	N	O
59	including	N	O
60	2	N	O
61	CRs	N	O
62	and	N	O
63	11	N	O
64	PRs	N	O
65	,	N	O
66	and	N	O
67	24	N	O
68	%	N	O
69	(	N	O
70	95	N	O
71	%	N	O
72	CI	N	O
73	:	N	O
74	14	N	O
75	%	N	O
76	-38	N	O
77	%	N	O
78	)	N	O
79	,	N	O
80	with	N	O
81	2	N	O
82	CRs	N	O
83	and	N	O
84	11	N	O
85	PRs	N	O
86	,	N	O
87	in	N	O
88	arm	N	O
89	C.	N	O
90	After	N	I-Premise
91	a	N	I-Premise
92	median	N	I-Premise
93	follow-up	N	I-Premise
94	time	N	I-Premise
95	of	N	I-Premise
96	62	N	I-Premise
97	(	N	I-Premise
98	range	N	I-Premise
99	18-108	N	I-Premise
100	)	N	I-Premise
101	weeks	N	I-Premise
102	,	N	I-Premise
103	the	N	I-Premise
104	median	N	I-Premise
105	time	N	I-Premise
106	to	N	I-Premise
107	progression	N	I-Premise
108	was	N	I-Premise
109	38	N	I-Premise
110	,	N	I-Premise
111	25	N	I-Premise
112	,	N	I-Premise
113	and	N	I-Premise
114	27	N	I-Premise
115	weeks	N	I-Premise
116	for	N	I-Premise
117	arm	N	I-Premise
118	A	N	I-Premise
119	,	N	I-Premise
120	B	N	I-Premise
121	,	N	I-Premise
122	and	N	I-Premise
123	C	N	I-Premise
124	,	N	I-Premise
125	respectively	N	I-Premise
126	.	N	I-Premise

1	With	N	I-Premise
2	94	N	I-Premise
3	patients	N	I-Premise
4	still	N	I-Premise
5	alive	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	one-year	N	I-Premise
9	probability	N	I-Premise
10	of	N	I-Premise
11	survival	N	I-Premise
12	was	N	I-Premise
13	61	N	I-Premise
14	%	N	I-Premise
15	,	N	I-Premise
16	54	N	I-Premise
17	%	N	I-Premise
18	,	N	I-Premise
19	and	N	I-Premise
20	59	N	I-Premise
21	%	N	I-Premise
22	,	N	I-Premise
23	respectively	N	I-Premise
24	.	N	I-Premise

1	WHO	N	I-Premise
2	grade	N	I-Premise
3	3	N	I-Premise
4	or	N	I-Premise
5	4	N	I-Premise
6	neutropenia	N	I-Premise
7	and	N	I-Premise
8	diarrhoea	N	I-Premise
9	affected	N	I-Premise
10	46	N	I-Premise
11	%	N	I-Premise
12	and	N	I-Premise
13	16	N	I-Premise
14	%	N	I-Premise
15	,	N	I-Premise
16	respectively	N	I-Premise
17	,	N	I-Premise
18	of	N	I-Premise
19	patients	N	I-Premise
20	treated	N	I-Premise
21	with	N	I-Premise
22	CPT-11	N	I-Premise
23	+	N	I-Premise
24	LFA	N	I-Premise
25	5-FU	N	I-Premise
26	.	N	I-Premise

1	Median	N	I-Premise
2	relative	N	I-Premise
3	dose	N	I-Premise
4	intensity	N	I-Premise
5	over	N	I-Premise
6	eight	N	I-Premise
7	cycles	N	I-Premise
8	(	N	I-Premise
9	DI8	N	I-Premise
10	)	N	I-Premise
11	was	N	I-Premise
12	78	N	I-Premise
13	%	N	I-Premise
14	for	N	I-Premise
15	CPT-11	N	I-Premise
16	and	N	I-Premise
17	82	N	I-Premise
18	%	N	I-Premise
19	for	N	I-Premise
20	5-FU	N	I-Premise
21	.	N	I-Premise

1	Severe	N	I-Premise
2	toxicities	N	I-Premise
3	of	N	I-Premise
4	TOM	N	I-Premise
5	+	N	I-Premise
6	LFA-5-FU	N	I-Premise
7	were	N	I-Premise
8	neutropenia	N	I-Premise
9	(	N	I-Premise
10	16	N	I-Premise
11	%	N	I-Premise
12	)	N	I-Premise
13	and	N	I-Premise
14	diarrhoea	N	I-Premise
15	(	N	I-Premise
16	16	N	I-Premise
17	%	N	I-Premise
18	)	N	I-Premise
19	,	N	I-Premise
20	but	N	I-Premise
21	median	N	I-Premise
22	relative	N	I-Premise
23	DI8	N	I-Premise
24	was	N	I-Premise
25	93	N	I-Premise
26	%	N	I-Premise
27	for	N	I-Premise
28	TOM	N	I-Premise
29	,	N	I-Premise
30	and	N	I-Premise
31	82	N	I-Premise
32	%	N	I-Premise
33	for	N	I-Premise
34	5-FU	N	I-Premise
35	.	N	I-Premise

1	CPT-11	N	I-Premise
2	+	N	I-Premise
3	LFA-5-FU	N	I-Premise
4	compares	N	I-Premise
5	favorably	N	I-Premise
6	in	N	I-Premise
7	term	N	I-Premise
8	of	N	I-Premise
9	activity	N	I-Premise
10	and	N	I-Premise
11	toxicity	N	I-Premise
12	with	N	I-Premise
13	other	N	I-Premise
14	combination	N	I-Premise
15	regimens	N	I-Premise
16	including	N	I-Premise
17	CPT-11	N	I-Premise
18	and	N	I-Premise
19	continuous	N	I-Premise
20	infusional	N	I-Premise
21	5-FU	N	I-Premise
22	.	N	I-Premise

1	The	N	I-Claim
2	hypothesis	N	I-Claim
3	of	N	I-Claim
4	a	N	I-Claim
5	RR	N	I-Claim
6	15	N	I-Claim
7	%	N	I-Claim
8	higher	N	I-Claim
9	than	N	I-Claim
10	the	N	I-Claim
11	MTX	N	I-Claim
12	+	N	I-Claim
13	LFA-5-FU	N	I-Claim
14	treatment	N	I-Claim
15	can	N	I-Claim
16	not	N	I-Claim
17	be	N	I-Claim
18	ruled	N	I-Claim
19	out	N	I-Claim
20	after	N	I-Claim
21	this	N	I-Claim
22	interim	N	I-Claim
23	analysis	N	I-Claim
24	.	N	I-Claim

1	The	N	I-Claim
2	TOM	N	I-Claim
3	+	N	I-Claim
4	LFA	N	I-Claim
5	5-FU	N	I-Claim
6	regimen	N	I-Claim
7	showed	N	I-Claim
8	a	N	I-Claim
9	RR	N	I-Claim
10	and	N	I-Claim
11	a	N	I-Claim
12	toxicity	N	I-Claim
13	profile	N	I-Claim
14	very	N	I-Claim
15	close	N	I-Claim
16	to	N	I-Claim
17	the	N	I-Claim
18	MTX	N	I-Claim
19	+	N	I-Claim
20	LFA	N	I-Claim
21	5-FU	N	I-Claim
22	combination	N	I-Claim
23	,	N	I-Claim
24	and	N	I-Claim
25	does	N	I-Claim
26	not	N	I-Claim
27	deserve	N	I-Claim
28	further	N	I-Claim
29	evaluation	N	I-Claim
30	in	N	I-Claim
31	advanced	N	I-Claim
32	colorectal	N	I-Claim
33	cancer	N	I-Claim
34	patients	N	I-Claim
35	.	N	I-Claim

1	We	N	O
2	have	N	O
3	recently	N	O
4	suggested	N	O
5	that	N	O
6	bolus	N	O
7	5-fluorouracil	N	O
8	(	N	O
9	5-FU	N	O
10	)	N	O
11	may	N	O
12	work	N	O
13	via	N	O
14	a	N	O
15	RNA	N	O
16	directed	N	O
17	mechanism	N	O
18	while	N	O
19	continuous	N	O
20	infusion	N	O
21	5-FU	N	O
22	may	N	O
23	kill	N	O
24	cells	N	O
25	via	N	O
26	a	N	O
27	thymidylate	N	O
28	synthase	N	O
29	related	N	O
30	pathway	N	O
31	.	N	O

1	It	N	O
2	may	N	O
3	thus	N	O
4	be	N	O
5	possible	N	O
6	to	N	O
7	selectively	N	O
8	modulate	N	O
9	each	N	O
10	schedule	N	O
11	biochemically	N	O
12	.	N	O

1	We	N	O
2	have	N	O
3	compared	N	O
4	an	N	O
5	alternating	N	O
6	regimen	N	O
7	of	N	O
8	bolus	N	O
9	and	N	O
10	continuous	N	O
11	infusion	N	O
12	5-FU	N	O
13	,	N	O
14	selectively	N	O
15	modulated	N	O
16	for	N	O
17	the	N	O
18	schedule	N	O
19	of	N	O
20	administration	N	O
21	,	N	O
22	with	N	O
23	modulated	N	O
24	bolus	N	O
25	5-FU	N	O
26	in	N	O
27	advanced	N	O
28	colorectal	N	O
29	cancer	N	O
30	patients	N	O
31	.	N	O

1	Two	N	O
2	hundred	N	O
3	fourteen	N	O
4	patients	N	O
5	from	N	O
6	nineteen	N	O
7	Italian	N	O
8	centers	N	O
9	were	N	O
10	randomized	N	O
11	to	N	O
12	the	N	O
13	control	N	O
14	arm	N	O
15	consisting	N	O
16	of	N	O
17	biweekly	N	O
18	cycles	N	O
19	of	N	O
20	MTX	N	O
21	,	N	O
22	200	N	O
23	mg/m2	N	O
24	on	N	O
25	day	N	O
26	1	N	O
27	,	N	O
28	followed	N	O
29	by	N	O
30	bolus	N	O
31	5-FU	N	O
32	600	N	O
33	mg/m2	N	O
34	on	N	O
35	day	N	O
36	2	N	O
37	and	N	O
38	6-S-leucovorin	N	O
39	rescue	N	O
40	,	N	O
41	or	N	O
42	to	N	O
43	the	N	O
44	experimental	N	O
45	arm	N	O
46	consisting	N	O
47	of	N	O
48	two	N	O
49	biweekly	N	O
50	cycles	N	O
51	of	N	O
52	the	N	O
53	same	N	O
54	regimen	N	O
55	as	N	O
56	in	N	O
57	the	N	O
58	control	N	O
59	arm	N	O
60	alternated	N	O
61	to	N	O
62	three	N	O
63	weeks	N	O
64	of	N	O
65	continuous	N	O
66	infusion	N	O
67	5-FU	N	O
68	(	N	O
69	200	N	O
70	mg/m2	N	O
71	day	N	O
72	)	N	O
73	+	N	O
74	weekly	N	O
75	bolus	N	O
76	6-S-leucovorin	N	O
77	,	N	O
78	20	N	O
79	mg/m2	N	O
80	.	N	O

1	Nine	N	I-Premise
2	CR	N	I-Premise
3	and	N	I-Premise
4	twenty-seven	N	I-Premise
5	PR	N	I-Premise
6	were	N	I-Premise
7	obtained	N	I-Premise
8	on	N	I-Premise
9	one	N	I-Premise
10	hundred	N	I-Premise
11	eleven	N	I-Premise
12	evaluable	N	I-Premise
13	patients	N	I-Premise
14	treated	N	I-Premise
15	in	N	I-Premise
16	experimental	N	I-Premise
17	arm	N	I-Premise
18	(	N	I-Premise
19	RR	N	I-Premise
20	=	N	I-Premise
21	32	N	I-Premise
22	%	N	I-Premise
23	,	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	confidence	N	I-Premise
27	interval	N	I-Premise
28	(	N	I-Premise
29	95	N	I-Premise
30	%	N	I-Premise
31	CI	N	I-Premise
32	)	N	I-Premise
33	:	N	I-Premise
34	24	N	I-Premise
35	%	N	I-Premise
36	-42	N	I-Premise
37	%	N	I-Premise
38	)	N	I-Premise
39	,	N	I-Premise
40	while	N	I-Premise
41	two	N	I-Premise
42	CR	N	I-Premise
43	and	N	I-Premise
44	eleven	N	I-Premise
45	PR	N	I-Premise
46	were	N	I-Premise
47	observed	N	I-Premise
48	among	N	I-Premise
49	one	N	I-Premise
50	hundred	N	I-Premise
51	three	N	I-Premise
52	evaluable	N	I-Premise
53	patients	N	I-Premise
54	in	N	I-Premise
55	control	N	I-Premise
56	arm	N	I-Premise
57	(	N	I-Premise
58	RR	N	I-Premise
59	=	N	I-Premise
60	13	N	I-Premise
61	%	N	I-Premise
62	,	N	I-Premise
63	95	N	I-Premise
64	%	N	I-Premise
65	CI	N	I-Premise
66	:	N	I-Premise
67	7	N	I-Premise
68	%	N	I-Premise
69	-21	N	I-Premise
70	%	N	I-Premise
71	)	N	I-Premise
72	.	N	I-Premise

1	WHO	N	I-Premise
2	grade	N	I-Premise
3	3-4	N	I-Premise
4	toxicity	N	I-Premise
5	occurred	N	I-Premise
6	in	N	I-Premise
7	13	N	I-Premise
8	%	N	I-Premise
9	of	N	I-Premise
10	cycles	N	I-Premise
11	of	N	I-Premise
12	experimental	N	I-Premise
13	arm	N	I-Premise
14	and	N	I-Premise
15	in	N	I-Premise
16	8	N	I-Premise
17	%	N	I-Premise
18	of	N	I-Premise
19	cycles	N	I-Premise
20	in	N	I-Premise
21	control	N	I-Premise
22	arm	N	I-Premise
23	.	N	I-Premise

1	The	N	I-Premise
2	PFS	N	I-Premise
3	was	N	I-Premise
4	significantly	N	I-Premise
5	longer	N	I-Premise
6	in	N	I-Premise
7	experimental	N	I-Premise
8	arm	N	I-Premise
9	(	N	I-Premise
10	6.2	N	I-Premise
11	vs.	N	I-Premise
12	4.3	N	I-Premise
13	months	N	I-Premise
14	,	N	I-Premise
15	odds	N	I-Premise
16	ratio	N	I-Premise
17	0.66	N	I-Premise
18	,	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	0.003	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	while	N	O
25	the	N	I-Premise
26	overall	N	I-Premise
27	survival	N	I-Premise
28	was	N	I-Premise
29	similar	N	I-Premise
30	in	N	I-Premise
31	both	N	I-Premise
32	arms	N	I-Premise
33	(	N	I-Premise
34	14.8	N	I-Premise
35	months	N	I-Premise
36	in	N	I-Premise
37	experimental	N	I-Premise
38	arm	N	I-Premise
39	vs.	N	I-Premise
40	14.1	N	I-Premise
41	months	N	I-Premise
42	in	N	I-Premise
43	control	N	I-Premise
44	arm	N	I-Premise
45	)	N	I-Premise
46	;	N	I-Premise
47	quality	N	I-Claim
48	of	N	I-Claim
49	life	N	I-Claim
50	was	N	I-Claim
51	similar	N	I-Claim
52	as	N	I-Claim
53	well	N	I-Claim
54	.	N	I-Claim

1	Eighty	N	I-Premise
2	percent	N	I-Premise
3	of	N	I-Premise
4	patients	N	I-Premise
5	receiving	N	I-Premise
6	second-line	N	I-Premise
7	chemotherapy	N	I-Premise
8	in	N	I-Premise
9	control	N	I-Premise
10	arm	N	I-Premise
11	were	N	I-Premise
12	treated	N	I-Premise
13	with	N	I-Premise
14	continuous	N	I-Premise
15	infusion	N	I-Premise
16	5-FU	N	I-Premise
17	.	N	I-Premise

1	Alternating	N	O
2	,	N	O
3	schedule-specific	N	I-Claim
4	biochemical	N	I-Claim
5	modulation	N	I-Claim
6	of	N	I-Claim
7	FU	N	I-Claim
8	is	N	I-Claim
9	more	N	I-Claim
10	active	N	I-Claim
11	than	N	I-Claim
12	MTX	N	I-Claim
13	--	N	I-Claim
14	>	N	I-Claim
15	5-FU	N	I-Claim
16	as	N	I-Claim
17	first-line	N	I-Claim
18	treatment	N	I-Claim
19	of	N	I-Claim
20	advanced	N	I-Claim
21	colorectal	N	I-Claim
22	cancer	N	I-Claim
23	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	the	N	I-Claim
4	overall	N	I-Claim
5	survival	N	I-Claim
6	was	N	I-Claim
7	similar	N	I-Claim
8	suggesting	N	I-Claim
9	that	N	I-Claim
10	alternating	N	I-Claim
11	bolus	N	I-Claim
12	and	N	I-Claim
13	infusional	N	I-Claim
14	5-FU	N	I-Claim
15	upfront	N	I-Claim
16	may	N	I-Claim
17	be	N	I-Claim
18	as	N	I-Claim
19	effective	N	I-Claim
20	as	N	I-Claim
21	giving	N	I-Claim
22	them	N	I-Claim
23	in	N	I-Claim
24	sequence	N	I-Claim
25	as	N	I-Claim
26	first-	N	I-Claim
27	and	N	I-Claim
28	second-line	N	I-Claim
29	treatment	N	I-Claim
30	.	N	I-Claim

1	The	N	I-MajorClaim
2	combination	N	I-MajorClaim
3	of	N	I-MajorClaim
4	etoposide	N	I-MajorClaim
5	plus	N	I-MajorClaim
6	cisplatin	N	I-MajorClaim
7	(	N	I-MajorClaim
8	EP	N	I-MajorClaim
9	)	N	I-MajorClaim
10	is	N	I-MajorClaim
11	considered	N	I-MajorClaim
12	to	N	I-MajorClaim
13	be	N	I-MajorClaim
14	standard	N	I-MajorClaim
15	therapy	N	I-MajorClaim
16	for	N	I-MajorClaim
17	small-cell	N	I-MajorClaim
18	lung	N	I-MajorClaim
19	cancer	N	I-MajorClaim
20	(	N	I-MajorClaim
21	SCLC	N	I-MajorClaim
22	)	N	I-MajorClaim
23	.	N	I-MajorClaim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	drug	N	O
5	intensification	N	O
6	improves	N	O
7	survival	N	O
8	of	N	O
9	patients	N	O
10	with	N	O
11	extensive	N	O
12	SCLC	N	O
13	,	N	O
14	we	N	O
15	compared	N	O
16	this	N	O
17	treatment	N	O
18	with	N	O
19	a	N	O
20	four-drug	N	O
21	regimen	N	O
22	containing	N	O
23	EP	N	O
24	plus	N	O
25	cyclophosphamide	N	O
26	and	N	O
27	4'-epidoxorubicin	N	O
28	(	N	O
29	PCDE	N	O
30	)	N	O
31	.	N	O

1	In	N	O
2	a	N	O
3	phase	N	O
4	III	N	O
5	clinical	N	O
6	trial	N	O
7	organized	N	O
8	by	N	O
9	the	N	O
10	French	N	O
11	Federation	N	O
12	of	N	O
13	Cancer	N	O
14	Institutes	N	O
15	,	N	O
16	patients	N	O
17	were	N	O
18	randomly	N	O
19	assigned	N	O
20	to	N	O
21	receive	N	O
22	either	N	O
23	EP	N	O
24	(	N	O
25	n	N	O
26	=	N	O
27	109	N	O
28	;	N	O
29	etoposide	N	O
30	at	N	O
31	a	N	O
32	dose	N	O
33	of	N	O
34	100	N	O
35	mg/m	N	O
36	(	N	O
37	2	N	O
38	)	N	O
39	on	N	O
40	days	N	O
41	1-3	N	O
42	plus	N	O
43	cisplatin	N	O
44	at	N	O
45	100	N	O
46	mg/m	N	O
47	(	N	O
48	2	N	O
49	)	N	O
50	on	N	O
51	day	N	O
52	2	N	O
53	)	N	O
54	or	N	O
55	PCDE	N	O
56	(	N	O
57	n	N	O
58	=	N	O
59	117	N	O
60	;	N	O
61	etoposide	N	O
62	and	N	O
63	cisplatin	N	O
64	given	N	O
65	as	N	O
66	in	N	O
67	EP	N	O
68	plus	N	O
69	cyclophosphamide	N	O
70	at	N	O
71	400	N	O
72	mg/m	N	O
73	(	N	O
74	2	N	O
75	)	N	O
76	on	N	O
77	days	N	O
78	1-3	N	O
79	and	N	O
80	4'-epidoxorubicin	N	O
81	at	N	O
82	40	N	O
83	mg/m	N	O
84	(	N	O
85	2	N	O
86	)	N	O
87	on	N	O
88	day	N	O
89	1	N	O
90	)	N	O
91	every	N	O
92	4	N	O
93	weeks	N	O
94	.	N	O

1	Both	N	O
2	groups	N	O
3	received	N	O
4	a	N	O
5	total	N	O
6	of	N	O
7	six	N	O
8	cycles	N	O
9	.	N	O

1	Survival	N	O
2	differences	N	O
3	were	N	O
4	analyzed	N	O
5	by	N	O
6	Wilcoxon	N	O
7	and	N	O
8	log-rank	N	O
9	tests	N	O
10	.	N	O

1	Associations	N	O
2	of	N	O
3	treatment	N	O
4	group	N	O
5	and	N	O
6	putative	N	O
7	prognostic	N	O
8	variables	N	O
9	with	N	O
10	survival	N	O
11	were	N	O
12	tested	N	O
13	in	N	O
14	the	N	O
15	Cox	N	O
16	proportional	N	O
17	hazards	N	O
18	model	N	O
19	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	assessed	N	O
6	from	N	O
7	the	N	O
8	responses	N	O
9	to	N	O
10	the	N	O
11	European	N	O
12	Organization	N	O
13	for	N	O
14	Research	N	O
15	and	N	O
16	Treatment	N	O
17	of	N	O
18	Cancer	N	O
19	quality-of-life	N	O
20	questionnaire	N	O
21	(	N	O
22	C30	N	O
23	,	N	O
24	health	N	O
25	status	N	O
26	and	N	O
27	lung	N	O
28	cancer	N	O
29	module	N	O
30	13	N	O
31	)	N	O
32	.	N	O

1	All	N	O
2	statistical	N	O
3	tests	N	O
4	were	N	O
5	two-sided	N	O
6	.	N	O

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	PCDE	N	I-Premise
5	arm	N	I-Premise
6	had	N	I-Premise
7	a	N	I-Premise
8	statistically	N	I-Premise
9	significant	N	I-Premise
10	higher	N	I-Premise
11	frequency	N	I-Premise
12	of	N	I-Premise
13	combined	N	I-Premise
14	complete	N	I-Premise
15	plus	N	I-Premise
16	partial	N	I-Premise
17	responses	N	I-Premise
18	compared	N	I-Premise
19	with	N	I-Premise
20	those	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	EP	N	I-Premise
24	arm	N	I-Premise
25	(	N	I-Premise
26	21	N	I-Premise
27	%	N	I-Premise
28	plus	N	I-Premise
29	55	N	I-Premise
30	%	N	I-Premise
31	versus	N	I-Premise
32	13	N	I-Premise
33	%	N	I-Premise
34	plus	N	I-Premise
35	48	N	I-Premise
36	%	N	I-Premise
37	,	N	I-Premise
38	respectively	N	I-Premise
39	;	N	I-Premise
40	P	N	I-Premise
41	=.02	N	I-Premise
42	for	N	I-Premise
43	difference	N	I-Premise
44	in	N	I-Premise
45	combined	N	I-Premise
46	objective	N	I-Premise
47	responses	N	I-Premise
48	)	N	I-Premise
49	.	N	I-Premise

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	PCDE	N	I-Premise
5	arm	N	I-Premise
6	survived	N	I-Premise
7	longer	N	I-Premise
8	than	N	I-Premise
9	those	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	EP	N	I-Premise
13	arm	N	I-Premise
14	(	N	I-Premise
15	1-year	N	I-Premise
16	survival	N	I-Premise
17	rate	N	I-Premise
18	:	N	I-Premise
19	40	N	I-Premise
20	%	N	I-Premise
21	and	N	I-Premise
22	29	N	I-Premise
23	%	N	I-Premise
24	,	N	I-Premise
25	respectively	N	I-Premise
26	;	N	I-Premise
27	median	N	I-Premise
28	survival	N	I-Premise
29	:	N	I-Premise
30	10.5	N	I-Premise
31	and	N	I-Premise
32	9.3	N	I-Premise
33	months	N	I-Premise
34	,	N	I-Premise
35	respectively	N	I-Premise
36	;	N	I-Premise
37	log-rank	N	I-Premise
38	P	N	I-Premise
39	=.0067	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	Cox	N	I-Premise
4	model	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	relative	N	I-Premise
8	risk	N	I-Premise
9	of	N	I-Premise
10	death	N	I-Premise
11	for	N	I-Premise
12	patients	N	I-Premise
13	in	N	I-Premise
14	the	N	I-Premise
15	PCDE	N	I-Premise
16	arm	N	I-Premise
17	compared	N	I-Premise
18	with	N	I-Premise
19	those	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	EP	N	I-Premise
23	arm	N	I-Premise
24	was	N	I-Premise
25	0.70	N	I-Premise
26	(	N	I-Premise
27	95	N	I-Premise
28	%	N	I-Premise
29	confidence	N	I-Premise
30	interval	N	I-Premise
31	=	N	I-Premise
32	0.51	N	I-Premise
33	to	N	I-Premise
34	0.95	N	I-Premise
35	)	N	I-Premise
36	;	N	I-Premise
37	the	N	I-Premise
38	disease	N	I-Premise
39	also	N	I-Premise
40	progressed	N	I-Premise
41	more	N	I-Premise
42	slowly	N	I-Premise
43	in	N	I-Premise
44	patients	N	I-Premise
45	in	N	I-Premise
46	the	N	I-Premise
47	PCDE	N	I-Premise
48	arm	N	I-Premise
49	.	N	I-Premise

1	Hematologic	N	I-Premise
2	toxicity	N	I-Premise
3	was	N	I-Premise
4	higher	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	PCDE	N	I-Premise
8	arm	N	I-Premise
9	(	N	I-Premise
10	22	N	I-Premise
11	%	N	I-Premise
12	with	N	I-Premise
13	documented	N	I-Premise
14	infections	N	I-Premise
15	compared	N	I-Premise
16	with	N	I-Premise
17	8	N	I-Premise
18	%	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	EP	N	I-Premise
22	arm	N	I-Premise
23	;	N	I-Premise
24	P	N	I-Premise
25	=.0038	N	I-Premise
26	)	N	I-Premise
27	,	N	I-Premise
28	and	N	O
29	the	N	I-Premise
30	toxicity-related	N	I-Premise
31	death	N	I-Premise
32	rate	N	I-Premise
33	was	N	I-Premise
34	9	N	I-Premise
35	%	N	I-Premise
36	in	N	I-Premise
37	the	N	I-Premise
38	PCDE	N	I-Premise
39	arm	N	I-Premise
40	versus	N	I-Premise
41	5.5	N	I-Premise
42	%	N	I-Premise
43	in	N	I-Premise
44	the	N	I-Premise
45	EP	N	I-Premise
46	arm	N	I-Premise
47	(	N	I-Premise
48	P	N	I-Premise
49	=.22	N	I-Premise
50	)	N	I-Premise
51	.	N	I-Premise

1	The	N	I-Claim
2	global	N	I-Claim
3	health	N	I-Claim
4	status	N	I-Claim
5	showed	N	I-Claim
6	similar	N	I-Claim
7	improvement	N	I-Claim
8	in	N	I-Claim
9	both	N	I-Claim
10	arms	N	I-Claim
11	during	N	I-Claim
12	treatment	N	I-Claim
13	.	N	I-Claim

1	Compared	N	I-Claim
2	with	N	I-Claim
3	the	N	I-Claim
4	EP	N	I-Claim
5	regimen	N	I-Claim
6	,	N	I-Claim
7	the	N	I-Claim
8	PCDE	N	I-Claim
9	regimen	N	I-Claim
10	yielded	N	I-Claim
11	higher	N	I-Claim
12	response	N	I-Claim
13	rates	N	I-Claim
14	and	N	I-Claim
15	better	N	I-Claim
16	survival	N	I-Claim
17	rates	N	I-Claim
18	in	N	I-Claim
19	patients	N	I-Claim
20	with	N	I-Claim
21	extensive	N	I-Claim
22	SCLC	N	I-Claim
23	without	N	I-Claim
24	affecting	N	I-Claim
25	the	N	I-Claim
26	quality	N	I-Claim
27	of	N	I-Claim
28	life	N	I-Claim
29	of	N	I-Claim
30	the	N	I-Claim
31	patients	N	I-Claim
32	during	N	I-Claim
33	chemotherapy	N	I-Claim
34	.	N	I-Claim

1	To	N	O
2	test	N	O
3	the	N	O
4	equivalence	N	O
5	of	N	O
6	three	N	O
7	versus	N	O
8	four	N	O
9	cycles	N	O
10	of	N	O
11	bleomycin	N	O
12	,	N	O
13	etoposide	N	O
14	,	N	O
15	and	N	O
16	cisplatin	N	O
17	(	N	O
18	BEP	N	O
19	)	N	O
20	and	N	O
21	of	N	O
22	the	N	O
23	5-day	N	O
24	schedule	N	O
25	versus	N	O
26	3	N	O
27	days	N	O
28	per	N	O
29	cycle	N	O
30	in	N	O
31	good-prognosis	N	O
32	germ	N	O
33	cell	N	O
34	cancer	N	O
35	.	N	O

1	The	N	O
2	study	N	O
3	was	N	O
4	designed	N	O
5	as	N	O
6	a	N	O
7	2	N	O
8	x	N	O
9	2	N	O
10	factorial	N	O
11	trial	N	O
12	.	N	O

1	The	N	O
2	aim	N	O
3	was	N	O
4	to	N	O
5	rule	N	O
6	out	N	O
7	a	N	O
8	5	N	O
9	%	N	O
10	decrease	N	O
11	in	N	O
12	the	N	O
13	2-year	N	O
14	progression-free	N	O
15	survival	N	O
16	(	N	O
17	PFS	N	O
18	)	N	O
19	rate	N	O
20	.	N	O

1	The	N	O
2	study	N	O
3	included	N	O
4	the	N	O
5	assessment	N	O
6	of	N	O
7	patient	N	O
8	quality	N	O
9	of	N	O
10	life	N	O
11	.	N	O

1	A	N	O
2	cycle	N	O
3	of	N	O
4	BEP	N	O
5	consisted	N	O
6	of	N	O
7	etoposide	N	O
8	500	N	O
9	mg/m	N	O
10	(	N	O
11	2	N	O
12	)	N	O
13	,	N	O
14	administered	N	O
15	at	N	O
16	either	N	O
17	100	N	O
18	mg/m	N	O
19	(	N	O
20	2	N	O
21	)	N	O
22	days	N	O
23	1	N	O
24	through	N	O
25	5	N	O
26	or	N	O
27	165	N	O
28	mg/m	N	O
29	(	N	O
30	2	N	O
31	)	N	O
32	days	N	O
33	1	N	O
34	through	N	O
35	3	N	O
36	,	N	O
37	cisplatin	N	O
38	100	N	O
39	mg/m	N	O
40	(	N	O
41	2	N	O
42	)	N	O
43	,	N	O
44	administered	N	O
45	at	N	O
46	either	N	O
47	20	N	O
48	mg/m	N	O
49	(	N	O
50	2	N	O
51	)	N	O
52	days	N	O
53	1	N	O
54	through	N	O
55	5	N	O
56	or	N	O
57	50	N	O
58	mg/m	N	O
59	(	N	O
60	2	N	O
61	)	N	O
62	days	N	O
63	1	N	O
64	and	N	O
65	2	N	O
66	.	N	O

1	Bleomycin	N	O
2	30	N	O
3	mg	N	O
4	was	N	O
5	administered	N	O
6	on	N	O
7	days	N	O
8	1	N	O
9	,	N	O
10	8	N	O
11	,	N	O
12	and	N	O
13	15	N	O
14	during	N	O
15	cycles	N	O
16	1	N	O
17	through	N	O
18	3	N	O
19	.	N	O

1	The	N	O
2	randomization	N	O
3	procedure	N	O
4	allowed	N	O
5	some	N	O
6	investigators	N	O
7	to	N	O
8	participate	N	O
9	only	N	O
10	in	N	O
11	the	N	O
12	comparison	N	O
13	of	N	O
14	three	N	O
15	versus	N	O
16	four	N	O
17	cycles	N	O
18	.	N	O

1	From	N	O
2	March	N	O
3	1995	N	O
4	until	N	O
5	April	N	O
6	1998	N	O
7	,	N	O
8	812	N	O
9	patients	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	to	N	O
14	receive	N	O
15	three	N	O
16	or	N	O
17	four	N	O
18	cycles	N	O
19	:	N	O
20	of	N	O
21	these	N	O
22	,	N	O
23	681	N	O
24	were	N	O
25	also	N	O
26	randomly	N	O
27	assigned	N	O
28	to	N	O
29	the	N	O
30	5-day	N	O
31	or	N	O
32	the	N	O
33	3-day	N	O
34	schedule	N	O
35	.	N	O

1	Histology	N	O
2	,	N	O
3	marker	N	O
4	values	N	O
5	,	N	O
6	and	N	O
7	disease	N	O
8	extent	N	O
9	are	N	O
10	well	N	O
11	balanced	N	O
12	in	N	O
13	the	N	O
14	treatment	N	O
15	arms	N	O
16	of	N	O
17	the	N	O
18	two	N	O
19	comparisons	N	O
20	.	N	O

1	The	N	I-Premise
2	projected	N	I-Premise
3	2-year	N	I-Premise
4	PFS	N	I-Premise
5	is	N	I-Premise
6	90.4	N	I-Premise
7	%	N	I-Premise
8	on	N	I-Premise
9	three	N	I-Premise
10	cycles	N	I-Premise
11	and	N	I-Premise
12	89.4	N	I-Premise
13	%	N	I-Premise
14	on	N	I-Premise
15	four	N	I-Premise
16	cycles	N	I-Premise
17	.	N	I-Premise

1	The	N	I-Premise
2	difference	N	I-Premise
3	in	N	I-Premise
4	PFS	N	I-Premise
5	between	N	I-Premise
6	three	N	I-Premise
7	and	N	I-Premise
8	four	N	I-Premise
9	cycles	N	I-Premise
10	is	N	I-Premise
11	-1.0	N	I-Premise
12	%	N	I-Premise
13	(	N	I-Premise
14	80	N	I-Premise
15	%	N	I-Premise
16	confidence	N	I-Premise
17	limit	N	I-Premise
18	[	N	I-Premise
19	CL	N	I-Premise
20	]	N	I-Premise
21	,	N	I-Premise
22	-3.8	N	I-Premise
23	%	N	I-Premise
24	,	N	I-Premise
25	+1.8	N	I-Premise
26	%	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	Equivalence	N	I-Claim
2	for	N	I-Claim
3	three	N	I-Claim
4	versus	N	I-Claim
5	four	N	I-Claim
6	cycles	N	I-Claim
7	is	N	I-Claim
8	claimed	N	I-Claim
9	because	N	I-Claim
10	both	N	I-Claim
11	the	N	I-Claim
12	upper	N	I-Claim
13	and	N	I-Claim
14	lower	N	I-Claim
15	bounds	N	I-Claim
16	of	N	I-Claim
17	the	N	I-Claim
18	80	N	I-Claim
19	%	N	I-Claim
20	CL	N	I-Claim
21	are	N	I-Claim
22	less	N	I-Claim
23	than	N	I-Claim
24	5	N	I-Claim
25	%	N	I-Claim
26	.	N	I-Claim

1	In	N	I-Premise
2	the	N	I-Premise
3	5-	N	I-Premise
4	versus	N	I-Premise
5	3-day	N	I-Premise
6	comparison	N	I-Premise
7	,	N	I-Premise
8	the	N	I-Premise
9	projected	N	I-Premise
10	2-year	N	I-Premise
11	PFS	N	I-Premise
12	is	N	I-Premise
13	88.8	N	I-Premise
14	%	N	I-Premise
15	and	N	I-Premise
16	89.7	N	I-Premise
17	%	N	I-Premise
18	,	N	I-Premise
19	respectively	N	I-Premise
20	(	N	I-Premise
21	difference	N	I-Premise
22	,	N	I-Premise
23	-0.9	N	I-Premise
24	%	N	I-Premise
25	,	N	I-Premise
26	(	N	I-Premise
27	80	N	I-Premise
28	%	N	I-Premise
29	CL	N	I-Premise
30	,	N	I-Premise
31	-4.1	N	I-Premise
32	%	N	I-Premise
33	,	N	I-Premise
34	+2.2	N	I-Premise
35	%	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	Hence	N	O
2	,	N	O
3	equivalence	N	I-Claim
4	is	N	I-Claim
5	claimed	N	I-Claim
6	in	N	I-Claim
7	this	N	I-Claim
8	comparison	N	I-Claim
9	also	N	I-Claim
10	.	N	I-Claim

1	Frequencies	N	I-Premise
2	of	N	I-Premise
3	hematologic	N	I-Premise
4	and	N	I-Premise
5	nonhematologic	N	I-Premise
6	toxicities	N	I-Premise
7	were	N	I-Premise
8	essentially	N	I-Premise
9	similar	N	I-Premise
10	.	N	I-Premise

1	Quality	N	I-Premise
2	of	N	I-Premise
3	life	N	I-Premise
4	was	N	I-Premise
5	maintained	N	I-Premise
6	better	N	I-Premise
7	in	N	I-Premise
8	patients	N	I-Premise
9	receiving	N	I-Premise
10	three	N	I-Premise
11	cycles	N	I-Premise
12	;	N	I-Premise
13	no	N	I-Premise
14	differences	N	I-Premise
15	were	N	I-Premise
16	detected	N	I-Premise
17	between	N	I-Premise
18	3	N	I-Premise
19	and	N	I-Premise
20	5	N	I-Premise
21	days	N	I-Premise
22	of	N	I-Premise
23	treatment	N	I-Premise
24	.	N	I-Premise

1	We	N	O
2	conclude	N	O
3	that	N	O
4	three	N	I-Claim
5	cycles	N	I-Claim
6	of	N	I-Claim
7	BEP	N	I-Claim
8	,	N	I-Claim
9	with	N	I-Claim
10	etoposide	N	I-Claim
11	at	N	I-Claim
12	500	N	I-Claim
13	mg/m	N	I-Claim
14	(	N	I-Claim
15	2	N	I-Claim
16	)	N	I-Claim
17	,	N	I-Claim
18	is	N	I-Claim
19	sufficient	N	I-Claim
20	therapy	N	I-Claim
21	in	N	I-Claim
22	good-prognosis	N	I-Claim
23	germ	N	I-Claim
24	cell	N	I-Claim
25	cancer	N	I-Claim
26	and	N	O
27	that	N	O
28	the	N	I-Claim
29	administration	N	I-Claim
30	of	N	I-Claim
31	the	N	I-Claim
32	chemotherapy	N	I-Claim
33	in	N	I-Claim
34	3	N	I-Claim
35	days	N	I-Claim
36	has	N	I-Claim
37	no	N	I-Claim
38	detrimental	N	I-Claim
39	effect	N	I-Claim
40	on	N	I-Claim
41	the	N	I-Claim
42	effectiveness	N	I-Claim
43	of	N	I-Claim
44	the	N	I-Claim
45	BEP	N	I-Claim
46	regimen	N	I-Claim
47	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	topotecan	N	O
7	in	N	O
8	combination	N	O
9	with	N	O
10	standard	N	O
11	chemotherapy	N	O
12	in	N	O
13	previously	N	O
14	untreated	N	O
15	patients	N	O
16	with	N	O
17	extensive-stage	N	O
18	small-cell	N	O
19	lung	N	O
20	cancer	N	O
21	(	N	O
22	SCLC	N	O
23	)	N	O
24	,	N	O
25	the	N	O
26	Eastern	N	O
27	Cooperative	N	O
28	Oncology	N	O
29	Group	N	O
30	(	N	O
31	ECOG	N	O
32	)	N	O
33	conducted	N	O
34	a	N	O
35	phase	N	O
36	III	N	O
37	trial	N	O
38	.	N	O

1	Eligible	N	O
2	patients	N	O
3	had	N	O
4	measurable	N	O
5	or	N	O
6	assessable	N	O
7	disease	N	O
8	and	N	O
9	an	N	O
10	ECOG	N	O
11	performance	N	O
12	status	N	O
13	of	N	O
14	0	N	O
15	to	N	O
16	2	N	O
17	;	N	O
18	stable	N	O
19	brain	N	O
20	metastases	N	O
21	were	N	O
22	allowed	N	O
23	.	N	O

1	All	N	O
2	patients	N	O
3	received	N	O
4	four	N	O
5	cycles	N	O
6	of	N	O
7	cisplatin	N	O
8	and	N	O
9	etoposide	N	O
10	every	N	O
11	3	N	O
12	weeks	N	O
13	(	N	O
14	step	N	O
15	1	N	O
16	;	N	O
17	PE	N	O
18	)	N	O
19	.	N	O

1	Patients	N	O
2	with	N	O
3	stable	N	O
4	or	N	O
5	responding	N	O
6	disease	N	O
7	were	N	O
8	then	N	O
9	randomized	N	O
10	to	N	O
11	observation	N	O
12	or	N	O
13	four	N	O
14	cycles	N	O
15	of	N	O
16	topotecan	N	O
17	(	N	O
18	1.5	N	O
19	mg/m	N	O
20	(	N	O
21	2	N	O
22	)	N	O
23	/d	N	O
24	for	N	O
25	5	N	O
26	days	N	O
27	,	N	O
28	every	N	O
29	3	N	O
30	weeks	N	O
31	;	N	O
32	step	N	O
33	2	N	O
34	)	N	O
35	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	402	N	O
5	eligible	N	O
6	patients	N	O
7	were	N	O
8	registered	N	O
9	to	N	O
10	step	N	O
11	1	N	O
12	,	N	O
13	and	N	O
14	223	N	O
15	eligible	N	O
16	patients	N	O
17	were	N	O
18	registered	N	O
19	to	N	O
20	step	N	O
21	2	N	O
22	(	N	O
23	observation	N	O
24	,	N	O
25	n	N	O
26	=	N	O
27	111	N	O
28	;	N	O
29	topotecan	N	O
30	,	N	O
31	n	N	O
32	=	N	O
33	112	N	O
34	)	N	O
35	.	N	O

1	Complete	N	I-Premise
2	and	N	I-Premise
3	partial	N	I-Premise
4	response	N	I-Premise
5	rates	N	I-Premise
6	to	N	I-Premise
7	induction	N	I-Premise
8	PE	N	I-Premise
9	were	N	I-Premise
10	3	N	I-Premise
11	%	N	I-Premise
12	and	N	I-Premise
13	32	N	I-Premise
14	%	N	I-Premise
15	,	N	I-Premise
16	respectively	N	I-Premise
17	.	N	I-Premise

1	A	N	I-Premise
2	7	N	I-Premise
3	%	N	I-Premise
4	response	N	I-Premise
5	rate	N	I-Premise
6	was	N	I-Premise
7	observed	N	I-Premise
8	with	N	I-Premise
9	topotecan	N	I-Premise
10	(	N	I-Premise
11	complete	N	I-Premise
12	response	N	I-Premise
13	,	N	I-Premise
14	2	N	I-Premise
15	%	N	I-Premise
16	;	N	I-Premise
17	partial	N	I-Premise
18	response	N	I-Premise
19	,	N	I-Premise
20	5	N	I-Premise
21	%	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	time	N	I-Premise
5	for	N	I-Premise
6	all	N	I-Premise
7	402	N	I-Premise
8	eligible	N	I-Premise
9	patients	N	I-Premise
10	was	N	I-Premise
11	9.6	N	I-Premise
12	months	N	I-Premise
13	.	N	I-Premise

1	Progression-free	N	I-Premise
2	survival	N	I-Premise
3	(	N	I-Premise
4	PFS	N	I-Premise
5	)	N	I-Premise
6	from	N	I-Premise
7	date	N	I-Premise
8	of	N	I-Premise
9	randomization	N	I-Premise
10	on	N	I-Premise
11	step	N	I-Premise
12	2	N	I-Premise
13	was	N	I-Premise
14	significantly	N	I-Premise
15	better	N	I-Premise
16	with	N	I-Premise
17	topotecan	N	I-Premise
18	compared	N	I-Premise
19	with	N	I-Premise
20	observation	N	I-Premise
21	(	N	I-Premise
22	3.6	N	I-Premise
23	months	N	I-Premise
24	v	N	I-Premise
25	2.3	N	I-Premise
26	months	N	I-Premise
27	;	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	.001	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	However	N	O
2	,	N	O
3	overall	N	I-Premise
4	survival	N	I-Premise
5	from	N	I-Premise
6	date	N	I-Premise
7	of	N	I-Premise
8	randomization	N	I-Premise
9	on	N	I-Premise
10	step	N	I-Premise
11	2	N	I-Premise
12	was	N	I-Premise
13	not	N	I-Premise
14	significantly	N	I-Premise
15	different	N	I-Premise
16	between	N	I-Premise
17	the	N	I-Premise
18	observation	N	I-Premise
19	and	N	I-Premise
20	topotecan	N	I-Premise
21	arms	N	I-Premise
22	(	N	I-Premise
23	8.9	N	I-Premise
24	months	N	I-Premise
25	v	N	I-Premise
26	9.3	N	I-Premise
27	months	N	I-Premise
28	;	N	I-Premise
29	P	N	I-Premise
30	=.43	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Grade	N	I-Premise
2	4	N	I-Premise
3	neutropenia	N	I-Premise
4	and	N	I-Premise
5	thrombocytopenia	N	I-Premise
6	occurred	N	I-Premise
7	in	N	I-Premise
8	50	N	I-Premise
9	%	N	I-Premise
10	and	N	I-Premise
11	3	N	I-Premise
12	%	N	I-Premise
13	,	N	I-Premise
14	respectively	N	I-Premise
15	,	N	I-Premise
16	of	N	I-Premise
17	PE	N	I-Premise
18	patients	N	I-Premise
19	in	N	I-Premise
20	step	N	I-Premise
21	1	N	I-Premise
22	and	N	I-Premise
23	60	N	I-Premise
24	%	N	I-Premise
25	and	N	I-Premise
26	13	N	I-Premise
27	%	N	I-Premise
28	of	N	I-Premise
29	topotecan	N	I-Premise
30	patients	N	I-Premise
31	in	N	I-Premise
32	step	N	I-Premise
33	2	N	I-Premise
34	.	N	I-Premise

1	Grade	N	I-Premise
2	4/5	N	I-Premise
3	infection	N	I-Premise
4	was	N	I-Premise
5	observed	N	I-Premise
6	in	N	I-Premise
7	4.6	N	I-Premise
8	%	N	I-Premise
9	of	N	I-Premise
10	PE	N	I-Premise
11	patients	N	I-Premise
12	and	N	I-Premise
13	1.8	N	I-Premise
14	%	N	I-Premise
15	of	N	I-Premise
16	topotecan	N	I-Premise
17	patients	N	I-Premise
18	.	N	I-Premise

1	Grade	N	I-Premise
2	3/4	N	I-Premise
3	anemia	N	I-Premise
4	developed	N	I-Premise
5	in	N	I-Premise
6	22	N	I-Premise
7	%	N	I-Premise
8	of	N	I-Premise
9	patients	N	I-Premise
10	who	N	I-Premise
11	received	N	I-Premise
12	topotecan	N	I-Premise
13	.	N	I-Premise

1	No	N	I-Premise
2	difference	N	I-Premise
3	in	N	I-Premise
4	quality	N	I-Premise
5	of	N	I-Premise
6	life	N	I-Premise
7	between	N	I-Premise
8	topotecan	N	I-Premise
9	and	N	I-Premise
10	observation	N	I-Premise
11	was	N	I-Premise
12	observed	N	I-Premise
13	at	N	I-Premise
14	any	N	I-Premise
15	assessment	N	I-Premise
16	time	N	I-Premise
17	or	N	I-Premise
18	for	N	I-Premise
19	any	N	I-Premise
20	of	N	I-Premise
21	the	N	I-Premise
22	subscale	N	I-Premise
23	scores	N	I-Premise
24	.	N	I-Premise

1	Four	N	I-Claim
2	cycles	N	I-Claim
3	of	N	I-Claim
4	PE	N	I-Claim
5	induction	N	I-Claim
6	therapy	N	I-Claim
7	followed	N	I-Claim
8	by	N	I-Claim
9	four	N	I-Claim
10	cycles	N	I-Claim
11	of	N	I-Claim
12	topotecan	N	I-Claim
13	improved	N	I-Claim
14	PFS	N	I-Claim
15	but	N	I-Claim
16	failed	N	I-Claim
17	to	N	I-Claim
18	improve	N	I-Claim
19	overall	N	I-Claim
20	survival	N	I-Claim
21	or	N	I-Claim
22	quality	N	I-Claim
23	of	N	I-Claim
24	life	N	I-Claim
25	in	N	I-Claim
26	extensive-stage	N	I-Claim
27	SCLC	N	I-Claim
28	.	N	I-Claim

1	Four	N	I-Claim
2	cycles	N	I-Claim
3	of	N	I-Claim
4	standard	N	I-Claim
5	PE	N	I-Claim
6	remains	N	I-Claim
7	an	N	I-Claim
8	appropriate	N	I-Claim
9	first-line	N	I-Claim
10	treatment	N	I-Claim
11	for	N	I-Claim
12	extensive-stage	N	I-Claim
13	SCLC	N	I-Claim
14	patients	N	I-Claim
15	with	N	I-Claim
16	good	N	I-Claim
17	performance	N	I-Claim
18	status	N	I-Claim
19	.	N	I-Claim

1	The	N	I-MajorClaim
2	role	N	I-MajorClaim
3	of	N	I-MajorClaim
4	adjuvant	N	I-MajorClaim
5	chemotherapy	N	I-MajorClaim
6	in	N	I-MajorClaim
7	postmenopausal	N	I-MajorClaim
8	patients	N	I-MajorClaim
9	with	N	I-MajorClaim
10	lymph	N	I-MajorClaim
11	node-negative	N	I-MajorClaim
12	breast	N	I-MajorClaim
13	cancer	N	I-MajorClaim
14	is	N	I-MajorClaim
15	controversial	N	I-MajorClaim
16	.	N	I-MajorClaim

1	After	N	O
2	demonstrating	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	chemotherapy	N	O
7	combined	N	O
8	with	N	O
9	tamoxifen	N	O
10	for	N	O
11	postmenopausal	N	O
12	patients	N	O
13	with	N	O
14	lymph	N	O
15	node-positive	N	O
16	disease	N	O
17	,	N	O
18	the	N	O
19	International	N	O
20	Breast	N	O
21	Cancer	N	O
22	Study	N	O
23	Group	N	O
24	launched	N	O
25	a	N	O
26	randomized	N	O
27	trial	N	O
28	(	N	O
29	Trial	N	O
30	IX	N	O
31	)	N	O
32	to	N	O
33	evaluate	N	O
34	the	N	O
35	role	N	O
36	of	N	O
37	adjuvant	N	O
38	chemotherapy	N	O
39	preceding	N	O
40	treatment	N	O
41	with	N	O
42	tamoxifen	N	O
43	for	N	O
44	patients	N	O
45	with	N	O
46	lymph	N	O
47	node-negative	N	O
48	disease	N	O
49	.	N	O

1	After	N	O
2	stratification	N	O
3	by	N	O
4	estrogen	N	O
5	receptor	N	O
6	(	N	O
7	ER	N	O
8	)	N	O
9	status	N	O
10	,	N	O
11	patients	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	to	N	O
16	receive	N	O
17	three	N	O
18	28-day	N	O
19	courses	N	O
20	of	N	O
21	``	N	O
22	classical	N	O
23	''	N	O
24	adjuvant	N	O
25	CMF	N	O
26	chemotherapy	N	O
27	(	N	O
28	cyclophosphamide	N	O
29	at	N	O
30	100	N	O
31	mg/m	N	O
32	(	N	O
33	2	N	O
34	)	N	O
35	on	N	O
36	days	N	O
37	1-14	N	O
38	,	N	O
39	orally	N	O
40	;	N	O
41	methotrexate	N	O
42	at	N	O
43	40	N	O
44	mg/m	N	O
45	(	N	O
46	2	N	O
47	)	N	O
48	on	N	O
49	days	N	O
50	1	N	O
51	and	N	O
52	8	N	O
53	,	N	O
54	intravenously	N	O
55	;	N	O
56	and	N	O
57	5-fluorouracil	N	O
58	at	N	O
59	600	N	O
60	mg/m	N	O
61	(	N	O
62	2	N	O
63	)	N	O
64	on	N	O
65	days	N	O
66	1	N	O
67	and	N	O
68	8	N	O
69	,	N	O
70	intravenously	N	O
71	)	N	O
72	followed	N	O
73	by	N	O
74	tamoxifen	N	O
75	(	N	O
76	20	N	O
77	mg/day	N	O
78	,	N	O
79	orally	N	O
80	for	N	O
81	57	N	O
82	months	N	O
83	)	N	O
84	(	N	O
85	CMF	N	O
86	--	N	O
87	>	N	O
88	tamoxifen	N	O
89	)	N	O
90	or	N	O
91	to	N	O
92	receive	N	O
93	tamoxifen	N	O
94	alone	N	O
95	(	N	O
96	20	N	O
97	mg/day	N	O
98	,	N	O
99	orally	N	O
100	for	N	O
101	60	N	O
102	months	N	O
103	)	N	O
104	.	N	O

1	We	N	O
2	enrolled	N	O
3	1669	N	O
4	eligible	N	O
5	patients	N	O
6	,	N	O
7	382	N	O
8	(	N	O
9	23	N	O
10	%	N	O
11	)	N	O
12	with	N	O
13	ER-negative	N	O
14	tumors	N	O
15	,	N	O
16	1217	N	O
17	(	N	O
18	73	N	O
19	%	N	O
20	)	N	O
21	with	N	O
22	ER-positive	N	O
23	tumors	N	O
24	,	N	O
25	and	N	O
26	70	N	O
27	(	N	O
28	4	N	O
29	%	N	O
30	)	N	O
31	with	N	O
32	unknown	N	O
33	ER	N	O
34	status	N	O
35	.	N	O

1	The	N	O
2	median	N	O
3	follow-up	N	O
4	was	N	O
5	71	N	O
6	months	N	O
7	.	N	O

1	All	N	O
2	statistical	N	O
3	tests	N	O
4	were	N	O
5	two-sided	N	O
6	.	N	O

1	The	N	I-Premise
2	added	N	I-Premise
3	benefit	N	I-Premise
4	of	N	I-Premise
5	CMF	N	I-Premise
6	followed	N	I-Premise
7	by	N	I-Premise
8	tamoxifen	N	I-Premise
9	over	N	I-Premise
10	tamoxifen	N	I-Premise
11	alone	N	I-Premise
12	was	N	I-Premise
13	statistically	N	I-Premise
14	significantly	N	I-Premise
15	dependent	N	I-Premise
16	on	N	I-Premise
17	ER	N	I-Premise
18	status	N	I-Premise
19	(	N	I-Premise
20	tests	N	I-Premise
21	for	N	I-Premise
22	interaction	N	I-Premise
23	:	N	I-Premise
24	P	N	I-Premise
25	=.01	N	I-Premise
26	for	N	I-Premise
27	disease-free	N	I-Premise
28	survival	N	I-Premise
29	[	N	I-Premise
30	DFS	N	I-Premise
31	]	N	I-Premise
32	and	N	I-Premise
33	P	N	I-Premise
34	=.07	N	I-Premise
35	for	N	I-Premise
36	overall	N	I-Premise
37	survival	N	I-Premise
38	[	N	I-Premise
39	OS	N	I-Premise
40	]	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	For	N	I-Premise
2	patients	N	I-Premise
3	with	N	I-Premise
4	ER-negative	N	I-Premise
5	tumors	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	addition	N	I-Premise
9	of	N	I-Premise
10	CMF	N	I-Premise
11	statistically	N	I-Premise
12	significantly	N	I-Premise
13	improved	N	I-Premise
14	DFS	N	I-Premise
15	(	N	I-Premise
16	5-year	N	I-Premise
17	DFS	N	I-Premise
18	=	N	I-Premise
19	84	N	I-Premise
20	%	N	I-Premise
21	for	N	I-Premise
22	CMF	N	I-Premise
23	--	N	I-Premise
24	>	N	I-Premise
25	tamoxifen	N	I-Premise
26	versus	N	I-Premise
27	69	N	I-Premise
28	%	N	I-Premise
29	for	N	I-Premise
30	tamoxifen	N	I-Premise
31	alone	N	I-Premise
32	;	N	I-Premise
33	difference	N	I-Premise
34	=	N	I-Premise
35	15	N	I-Premise
36	%	N	I-Premise
37	;	N	I-Premise
38	95	N	I-Premise
39	%	N	I-Premise
40	confidence	N	I-Premise
41	interval	N	I-Premise
42	[	N	I-Premise
43	CI	N	I-Premise
44	]	N	I-Premise
45	=	N	I-Premise
46	6	N	I-Premise
47	%	N	I-Premise
48	to	N	I-Premise
49	24	N	I-Premise
50	%	N	I-Premise
51	;	N	I-Premise
52	risk	N	I-Premise
53	ratio	N	I-Premise
54	[	N	I-Premise
55	RR	N	I-Premise
56	]	N	I-Premise
57	=	N	I-Premise
58	0.52	N	I-Premise
59	;	N	I-Premise
60	95	N	I-Premise
61	%	N	I-Premise
62	CI	N	I-Premise
63	=	N	I-Premise
64	0.34	N	I-Premise
65	to	N	I-Premise
66	0.79	N	I-Premise
67	;	N	I-Premise
68	P	N	I-Premise
69	=.003	N	I-Premise
70	)	N	I-Premise
71	and	N	I-Premise
72	OS	N	I-Premise
73	(	N	I-Premise
74	5-year	N	I-Premise
75	OS	N	I-Premise
76	=	N	I-Premise
77	89	N	I-Premise
78	%	N	I-Premise
79	for	N	I-Premise
80	CMF	N	I-Premise
81	--	N	I-Premise
82	>	N	I-Premise
83	tamoxifen	N	I-Premise
84	versus	N	I-Premise
85	81	N	I-Premise
86	%	N	I-Premise
87	for	N	I-Premise
88	tamoxifen	N	I-Premise
89	alone	N	I-Premise
90	;	N	I-Premise
91	difference	N	I-Premise
92	=	N	I-Premise
93	8	N	I-Premise
94	%	N	I-Premise
95	;	N	I-Premise
96	95	N	I-Premise
97	%	N	I-Premise
98	CI	N	I-Premise
99	=	N	I-Premise
100	0	N	I-Premise
101	%	N	I-Premise
102	to	N	I-Premise
103	16	N	I-Premise
104	%	N	I-Premise
105	;	N	I-Premise
106	RR	N	I-Premise
107	=	N	I-Premise
108	0.51	N	I-Premise
109	;	N	I-Premise
110	95	N	I-Premise
111	%	N	I-Premise
112	CI	N	I-Premise
113	=	N	I-Premise
114	0.30	N	I-Premise
115	to	N	I-Premise
116	0.87	N	I-Premise
117	;	N	I-Premise
118	P	N	I-Premise
119	=.01	N	I-Premise
120	)	N	I-Premise
121	.	N	I-Premise

1	By	N	I-Premise
2	contrast	N	I-Premise
3	,	N	I-Premise
4	for	N	I-Premise
5	patients	N	I-Premise
6	with	N	I-Premise
7	ER-positive	N	I-Premise
8	tumors	N	I-Premise
9	,	N	I-Premise
10	addition	N	I-Premise
11	of	N	I-Premise
12	CMF	N	I-Premise
13	provided	N	I-Premise
14	no	N	I-Premise
15	benefit	N	I-Premise
16	in	N	I-Premise
17	terms	N	I-Premise
18	of	N	I-Premise
19	DFS	N	I-Premise
20	(	N	I-Premise
21	5-year	N	I-Premise
22	DFS	N	I-Premise
23	=	N	I-Premise
24	84	N	I-Premise
25	%	N	I-Premise
26	for	N	I-Premise
27	CMF	N	I-Premise
28	--	N	I-Premise
29	>	N	I-Premise
30	tamoxifen	N	I-Premise
31	versus	N	I-Premise
32	85	N	I-Premise
33	%	N	I-Premise
34	for	N	I-Premise
35	tamoxifen	N	I-Premise
36	alone	N	I-Premise
37	;	N	I-Premise
38	difference	N	I-Premise
39	=	N	I-Premise
40	-1	N	I-Premise
41	;	N	I-Premise
42	95	N	I-Premise
43	%	N	I-Premise
44	CI	N	I-Premise
45	=	N	I-Premise
46	-6	N	I-Premise
47	%	N	I-Premise
48	to	N	I-Premise
49	4	N	I-Premise
50	%	N	I-Premise
51	;	N	I-Premise
52	RR	N	I-Premise
53	=	N	I-Premise
54	0.99	N	I-Premise
55	;	N	I-Premise
56	95	N	I-Premise
57	%	N	I-Premise
58	CI	N	I-Premise
59	=	N	I-Premise
60	0.75	N	I-Premise
61	to	N	I-Premise
62	1.30	N	I-Premise
63	;	N	I-Premise
64	P	N	I-Premise
65	=.92	N	I-Premise
66	)	N	I-Premise
67	or	N	I-Premise
68	OS	N	I-Premise
69	(	N	I-Premise
70	5-year	N	I-Premise
71	OS	N	I-Premise
72	=	N	I-Premise
73	95	N	I-Premise
74	%	N	I-Premise
75	for	N	I-Premise
76	CMF	N	I-Premise
77	--	N	I-Premise
78	>	N	I-Premise
79	tamoxifen	N	I-Premise
80	versus	N	I-Premise
81	93	N	I-Premise
82	%	N	I-Premise
83	for	N	I-Premise
84	tamoxifen	N	I-Premise
85	alone	N	I-Premise
86	;	N	I-Premise
87	difference	N	I-Premise
88	=	N	I-Premise
89	2	N	I-Premise
90	%	N	I-Premise
91	;	N	I-Premise
92	95	N	I-Premise
93	%	N	I-Premise
94	CI	N	I-Premise
95	=	N	I-Premise
96	-1	N	I-Premise
97	%	N	I-Premise
98	to	N	I-Premise
99	5	N	I-Premise
100	%	N	I-Premise
101	;	N	I-Premise
102	RR	N	I-Premise
103	=	N	I-Premise
104	0.95	N	I-Premise
105	;	N	I-Premise
106	95	N	I-Premise
107	%	N	I-Premise
108	CI	N	I-Premise
109	=	N	I-Premise
110	0.64	N	I-Premise
111	to	N	I-Premise
112	1.40	N	I-Premise
113	;	N	I-Premise
114	P	N	I-Premise
115	=.80	N	I-Premise
116	)	N	I-Premise
117	.	N	I-Premise

1	Postmenopausal	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	lymph	N	I-Claim
5	node-negative	N	I-Claim
6	breast	N	I-Claim
7	cancer	N	I-Claim
8	benefited	N	I-Claim
9	substantially	N	I-Claim
10	from	N	I-Claim
11	adjuvant	N	I-Claim
12	chemotherapy	N	I-Claim
13	if	N	I-Claim
14	their	N	I-Claim
15	cancer	N	I-Claim
16	was	N	I-Claim
17	ER-negative	N	I-Claim
18	(	N	I-Claim
19	i.e.	N	I-Claim
20	,	N	I-Claim
21	endocrine-nonresponsive	N	I-Claim
22	)	N	I-Claim
23	.	N	I-Claim

1	In	N	I-Claim
2	contrast	N	I-Claim
3	,	N	I-Claim
4	if	N	I-Claim
5	their	N	I-Claim
6	cancer	N	I-Claim
7	was	N	I-Claim
8	ER-positive	N	I-Claim
9	(	N	I-Claim
10	i.e.	N	I-Claim
11	,	N	I-Claim
12	endocrine-responsive	N	I-Claim
13	)	N	I-Claim
14	,	N	I-Claim
15	they	N	I-Claim
16	obtained	N	I-Claim
17	no	N	I-Claim
18	benefit	N	I-Claim
19	from	N	I-Claim
20	the	N	I-Claim
21	combination	N	I-Claim
22	treatment	N	I-Claim
23	compared	N	I-Claim
24	with	N	I-Claim
25	tamoxifen	N	I-Claim
26	alone	N	I-Claim
27	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	a	N	O
7	novel	N	O
8	coloplasty	N	O
9	colonic	N	O
10	pouch	N	O
11	design	N	O
12	in	N	O
13	optimizing	N	O
14	bowel	N	O
15	function	N	O
16	after	N	O
17	ultralow	N	O
18	anterior	N	O
19	resection	N	O
20	.	N	O

1	A	N	I-Claim
2	colonic	N	I-Claim
3	J-pouch	N	I-Claim
4	may	N	I-Claim
5	reduce	N	I-Claim
6	excessive	N	I-Claim
7	stool	N	I-Claim
8	frequency	N	I-Claim
9	and	N	I-Claim
10	incontinence	N	I-Claim
11	after	N	I-Claim
12	anterior	N	I-Claim
13	resection	N	I-Claim
14	,	N	I-Claim
15	but	N	I-Claim
16	at	N	I-Claim
17	the	N	I-Claim
18	risk	N	I-Claim
19	of	N	I-Claim
20	evacuation	N	I-Claim
21	problems	N	I-Claim
22	.	N	I-Claim

1	Experimental	N	I-Claim
2	surgery	N	I-Claim
3	on	N	I-Claim
4	pigs	N	I-Claim
5	has	N	I-Claim
6	suggested	N	I-Claim
7	that	N	I-Claim
8	a	N	I-Claim
9	coloplasty	N	I-Claim
10	pouch	N	I-Claim
11	(	N	I-Claim
12	CP	N	I-Claim
13	)	N	I-Claim
14	may	N	I-Claim
15	be	N	I-Claim
16	a	N	I-Claim
17	useful	N	I-Claim
18	alternative	N	I-Claim
19	.	N	O

1	Although	N	O
2	CP	N	O
3	has	N	O
4	recently	N	O
5	been	N	O
6	shown	N	O
7	to	N	O
8	be	N	O
9	feasible	N	O
10	in	N	O
11	patients	N	O
12	,	N	O
13	there	N	O
14	is	N	O
15	no	N	O
16	randomized	N	O
17	controlled	N	O
18	trial	N	O
19	comparing	N	O
20	bowel	N	O
21	function	N	O
22	with	N	O
23	the	N	O
24	J-pouch	N	O
25	.	N	O

1	After	N	O
2	anterior	N	O
3	resection	N	O
4	for	N	O
5	cancer	N	O
6	,	N	O
7	patients	N	O
8	were	N	O
9	allocated	N	O
10	to	N	O
11	either	N	O
12	J-pouch	N	O
13	or	N	O
14	CP-anal	N	O
15	anastomoses	N	O
16	.	N	O

1	Continence	N	O
2	scoring	N	O
3	,	N	O
4	anorectal	N	O
5	manometry	N	O
6	,	N	O
7	and	N	O
8	endoanal	N	O
9	ultrasound	N	O
10	assessments	N	O
11	were	N	O
12	made	N	O
13	before	N	O
14	surgery	N	O
15	.	N	O

1	All	N	O
2	complications	N	O
3	were	N	O
4	recorded	N	O
5	,	N	O
6	and	N	O
7	these	N	O
8	preoperative	N	O
9	assessments	N	O
10	were	N	O
11	repeated	N	O
12	at	N	O
13	4	N	O
14	months	N	O
15	.	N	O

1	The	N	O
2	assessments	N	O
3	were	N	O
4	repeated	N	O
5	again	N	O
6	at	N	O
7	1	N	O
8	year	N	O
9	,	N	O
10	and	N	O
11	a	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	questionnaire	N	O
16	was	N	O
17	added	N	O
18	.	N	O

1	Eighty-eight	N	O
2	patients	N	O
3	were	N	O
4	recruited	N	O
5	from	N	O
6	October	N	O
7	1998	N	O
8	to	N	O
9	April	N	O
10	2000	N	O
11	.	N	O

1	Both	N	O
2	groups	N	O
3	were	N	O
4	well	N	O
5	matched	N	O
6	for	N	O
7	age	N	O
8	,	N	O
9	gender	N	O
10	,	N	O
11	staging	N	O
12	,	N	O
13	adjuvant	N	O
14	therapy	N	O
15	,	N	O
16	and	N	O
17	mean	N	O
18	follow-up	N	O
19	.	N	O

1	There	N	O
2	were	N	O
3	no	N	O
4	differences	N	O
5	in	N	O
6	the	N	O
7	intraoperative	N	O
8	time	N	O
9	and	N	O
10	hospital	N	O
11	stay	N	O
12	.	N	O

1	CP	N	I-Premise
2	resulted	N	I-Premise
3	in	N	I-Premise
4	more	N	I-Premise
5	anastomotic	N	I-Premise
6	leaks	N	I-Premise
7	.	N	I-Premise

1	At	N	I-Premise
2	4	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	J-pouch	N	I-Premise
6	patients	N	I-Premise
7	had	N	I-Premise
8	10.3	N	I-Premise
9	%	N	I-Premise
10	less	N	I-Premise
11	stool	N	I-Premise
12	fragmentation	N	I-Premise
13	but	N	I-Premise
14	poorer	N	I-Premise
15	stool	N	I-Premise
16	deferment	N	I-Premise
17	and	N	I-Premise
18	more	N	I-Premise
19	nocturnal	N	I-Premise
20	leakage	N	I-Premise
21	.	N	I-Premise

1	However	N	O
2	,	N	O
3	there	N	I-Premise
4	were	N	I-Premise
5	no	N	I-Premise
6	differences	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	bowel	N	I-Premise
10	function	N	I-Premise
11	,	N	I-Premise
12	continence	N	I-Premise
13	score	N	I-Premise
14	,	N	I-Premise
15	and	N	I-Premise
16	quality	N	I-Premise
17	of	N	I-Premise
18	life	N	I-Premise
19	at	N	I-Premise
20	1	N	I-Premise
21	year	N	I-Premise
22	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	differences	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	anorectal	N	I-Premise
8	manometry	N	I-Premise
9	and	N	I-Premise
10	endoanal	N	I-Premise
11	ultrasound	N	I-Premise
12	findings	N	I-Premise
13	.	N	I-Premise

1	Coloplasty	N	I-Claim
2	pouches	N	I-Claim
3	resulted	N	I-Claim
4	in	N	I-Claim
5	more	N	I-Claim
6	anastomotic	N	I-Claim
7	leaks	N	I-Claim
8	and	N	I-Claim
9	minimal	N	I-Claim
10	differences	N	I-Claim
11	in	N	I-Claim
12	bowel	N	I-Claim
13	function	N	I-Claim
14	.	N	I-Claim

1	At	N	O
2	present	N	O
3	,	N	O
4	the	N	I-Claim
5	J-pouch	N	I-Claim
6	remains	N	I-Claim
7	the	N	I-Claim
8	benchmark	N	I-Claim
9	for	N	I-Claim
10	routine	N	I-Claim
11	clinical	N	I-Claim
12	practice	N	I-Claim
13	,	N	I-Claim
14	and	N	O
15	due	N	I-Claim
16	care	N	I-Claim
17	(	N	I-Claim
18	including	N	I-Claim
19	defunctioning	N	I-Claim
20	stoma	N	I-Claim
21	)	N	I-Claim
22	should	N	I-Claim
23	be	N	I-Claim
24	exercised	N	I-Claim
25	in	N	I-Claim
26	situations	N	I-Claim
27	requiring	N	I-Claim
28	CP	N	I-Claim
29	.	N	I-Claim

1	Chemotherapy	N	I-Claim
2	is	N	I-Claim
3	moderately	N	I-Claim
4	efficient	N	I-Claim
5	as	N	I-Claim
6	a	N	I-Claim
7	treatment	N	I-Claim
8	for	N	I-Claim
9	pancreatic	N	I-Claim
10	adenocarcinoma	N	I-Claim
11	,	N	I-Claim
12	but	N	I-Claim
13	patient	N	I-Claim
14	survival	N	I-Claim
15	and	N	I-Claim
16	quality	N	I-Claim
17	of	N	I-Claim
18	life	N	I-Claim
19	has	N	I-Claim
20	improved	N	I-Claim
21	with	N	I-Claim
22	this	N	I-Claim
23	modality	N	I-Claim
24	in	N	I-Claim
25	some	N	I-Claim
26	trials	N	I-Claim
27	.	N	I-Claim

1	In	N	O
2	a	N	O
3	previous	N	O
4	phase	N	O
5	II	N	O
6	trial	N	O
7	,	N	O
8	5-fluorouracil	N	O
9	(	N	O
10	5-FU	N	O
11	)	N	O
12	plus	N	O
13	cisplatin	N	O
14	(	N	O
15	FUP	N	O
16	)	N	O
17	yielded	N	O
18	a	N	O
19	26.5	N	O
20	%	N	O
21	response	N	O
22	rate	N	O
23	and	N	O
24	a	N	O
25	29	N	O
26	%	N	O
27	survival	N	O
28	rate	N	O
29	at	N	O
30	1	N	O
31	year	N	O
32	.	N	O

1	The	N	O
2	present	N	O
3	study	N	O
4	aimed	N	O
5	to	N	O
6	compare	N	O
7	FUP	N	O
8	with	N	O
9	5-FU	N	O
10	alone	N	O
11	,	N	O
12	which	N	O
13	was	N	O
14	the	N	O
15	control	N	O
16	arm	N	O
17	in	N	O
18	former	N	O
19	Mayo	N	O
20	Clinic	N	O
21	trials	N	O
22	.	N	O

1	Patients	N	O
2	with	N	O
3	untreated	N	O
4	cytologically	N	O
5	or	N	O
6	histologically	N	O
7	proven	N	O
8	metastatic	N	O
9	or	N	O
10	locally	N	O
11	advanced	N	O
12	adenocarcinoma	N	O
13	of	N	O
14	the	N	O
15	pancreas	N	O
16	were	N	O
17	deemed	N	O
18	measurable	N	O
19	or	N	O
20	evaluable	N	O
21	.	N	O

1	Chemotherapy	N	O
2	regimens	N	O
3	consisted	N	O
4	of	N	O
5	a	N	O
6	control	N	O
7	FU	N	O
8	arm	N	O
9	(	N	O
10	5-FU	N	O
11	500	N	O
12	mg/m	N	O
13	(	N	O
14	2	N	O
15	)	N	O
16	/day	N	O
17	for	N	O
18	5	N	O
19	days	N	O
20	)	N	O
21	and	N	O
22	the	N	O
23	investigational	N	O
24	FUP	N	O
25	arm	N	O
26	(	N	O
27	continuous	N	O
28	5-FU	N	O
29	1000	N	O
30	mg/m	N	O
31	(	N	O
32	2	N	O
33	)	N	O
34	/day	N	O
35	for	N	O
36	5	N	O
37	days	N	O
38	plus	N	O
39	cisplatin	N	O
40	100	N	O
41	mg/m	N	O
42	(	N	O
43	2	N	O
44	)	N	O
45	on	N	O
46	day	N	O
47	1	N	O
48	or	N	O
49	day	N	O
50	2	N	O
51	)	N	O
52	.	N	O

1	In	N	O
2	both	N	O
3	arms	N	O
4	,	N	O
5	chemotherapy	N	O
6	was	N	O
7	repeated	N	O
8	at	N	O
9	day	N	O
10	29	N	O
11	.	N	O

1	Two-hundred	N	O
2	and	N	O
3	seven	N	O
4	patients	N	O
5	from	N	O
6	18	N	O
7	centres	N	O
8	were	N	O
9	randomised	N	O
10	:	N	O
11	103	N	O
12	in	N	O
13	the	N	O
14	FU	N	O
15	arm	N	O
16	and	N	O
17	104	N	O
18	in	N	O
19	FUP	N	O
20	arm	N	O
21	.	N	O

1	Treatment	N	O
2	arms	N	O
3	were	N	O
4	balanced	N	O
5	with	N	O
6	respect	N	O
7	to	N	O
8	performance	N	O
9	status	N	O
10	grade	N	O
11	0-1	N	O
12	(	N	O
13	83	N	O
14	%	N	O
15	versus	N	O
16	86	N	O
17	%	N	O
18	,	N	O
19	respectively	N	O
20	)	N	O
21	and	N	O
22	the	N	O
23	presence	N	O
24	of	N	O
25	metastases	N	O
26	(	N	O
27	92	N	O
28	%	N	O
29	versus	N	O
30	89	N	O
31	%	N	O
32	,	N	O
33	respectively	N	O
34	)	N	O
35	.	N	O

1	The	N	O
2	median	N	O
3	number	N	O
4	of	N	O
5	cycles	N	O
6	administered	N	O
7	was	N	O
8	two	N	O
9	in	N	O
10	both	N	O
11	arms	N	O
12	(	N	O
13	range	N	O
14	0-14	N	O
15	)	N	O
16	.	N	O

1	Five	N	O
2	patients	N	O
3	did	N	O
4	not	N	O
5	receive	N	O
6	any	N	O
7	chemotherapy	N	O
8	and	N	O
9	45	N	O
10	received	N	O
11	only	N	O
12	one	N	O
13	cycle	N	O
14	.	N	O

1	Toxicity	N	I-Premise
2	(	N	I-Premise
3	WHO	N	I-Premise
4	grade	N	I-Premise
5	3-4	N	I-Premise
6	)	N	I-Premise
7	was	N	I-Premise
8	lower	N	I-Premise
9	with	N	I-Premise
10	FU	N	I-Premise
11	than	N	I-Premise
12	with	N	I-Premise
13	FUP	N	I-Premise
14	(	N	I-Premise
15	20	N	I-Premise
16	%	N	I-Premise
17	versus	N	I-Premise
18	48	N	I-Premise
19	%	N	I-Premise
20	,	N	I-Premise
21	P	N	I-Premise
22	<	N	I-Premise
23	0.001	N	I-Premise
24	)	N	I-Premise
25	,	N	I-Premise
26	as	N	I-Premise
27	was	N	I-Premise
28	neutropenia	N	I-Premise
29	(	N	I-Premise
30	6	N	I-Premise
31	%	N	I-Premise
32	versus	N	I-Premise
33	23	N	I-Premise
34	%	N	I-Premise
35	)	N	I-Premise
36	,	N	I-Premise
37	vomiting	N	I-Premise
38	(	N	I-Premise
39	4	N	I-Premise
40	%	N	I-Premise
41	versus	N	I-Premise
42	17	N	I-Premise
43	%	N	I-Premise
44	)	N	I-Premise
45	and	N	I-Premise
46	toxicity-related	N	I-Premise
47	deaths	N	I-Premise
48	(	N	I-Premise
49	one	N	I-Premise
50	versus	N	I-Premise
51	four	N	I-Premise
52	early	N	I-Premise
53	in	N	I-Premise
54	the	N	I-Premise
55	trial	N	I-Premise
56	)	N	I-Premise
57	.	N	I-Premise

1	The	N	I-Premise
2	response	N	I-Premise
3	rate	N	I-Premise
4	was	N	I-Premise
5	low	N	I-Premise
6	in	N	I-Premise
7	both	N	I-Premise
8	arms	N	I-Premise
9	,	N	I-Premise
10	but	N	I-Premise
11	superior	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	FUP	N	I-Premise
15	arm	N	I-Premise
16	:	N	I-Premise
17	12	N	I-Premise
18	%	N	I-Premise
19	versus	N	I-Premise
20	0	N	I-Premise
21	%	N	I-Premise
22	(	N	I-Premise
23	intention-to-treat	N	I-Premise
24	analysis	N	I-Premise
25	,	N	I-Premise
26	P	N	I-Premise
27	<	N	I-Premise
28	0.01	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Premise
2	survival	N	I-Premise
3	rates	N	I-Premise
4	at	N	I-Premise
5	6	N	I-Premise
6	months	N	I-Premise
7	were	N	I-Premise
8	28	N	I-Premise
9	%	N	I-Premise
10	and	N	I-Premise
11	38	N	I-Premise
12	%	N	I-Premise
13	for	N	I-Premise
14	the	N	I-Premise
15	FU	N	I-Premise
16	and	N	I-Premise
17	FUP	N	I-Premise
18	arms	N	I-Premise
19	,	N	I-Premise
20	respectively	N	I-Premise
21	,	N	I-Premise
22	and	N	I-Premise
23	1-year	N	I-Premise
24	survival	N	I-Premise
25	rates	N	I-Premise
26	were	N	I-Premise
27	9	N	I-Premise
28	%	N	I-Premise
29	and	N	I-Premise
30	17	N	I-Premise
31	%	N	I-Premise
32	(	N	I-Premise
33	log-rank	N	I-Premise
34	test	N	I-Premise
35	,	N	I-Premise
36	P	N	I-Premise
37	=	N	I-Premise
38	0.10	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	One-year	N	I-Premise
2	progression-free	N	I-Premise
3	survival	N	I-Premise
4	was	N	I-Premise
5	0	N	I-Premise
6	%	N	I-Premise
7	with	N	I-Premise
8	FU	N	I-Premise
9	versus	N	I-Premise
10	10	N	I-Premise
11	%	N	I-Premise
12	with	N	I-Premise
13	FUP	N	I-Premise
14	(	N	I-Premise
15	log-rank	N	I-Premise
16	test	N	I-Premise
17	,	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	0.0001	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	In	N	I-Claim
2	advanced	N	I-Claim
3	pancreatic	N	I-Claim
4	carcinomas	N	I-Claim
5	with	N	I-Claim
6	a	N	I-Claim
7	poor	N	I-Claim
8	prognosis	N	I-Claim
9	,	N	I-Claim
10	FUP	N	I-Claim
11	was	N	I-Claim
12	superior	N	I-Claim
13	to	N	I-Claim
14	FU	N	I-Claim
15	in	N	I-Claim
16	terms	N	I-Claim
17	of	N	I-Claim
18	response	N	I-Claim
19	and	N	I-Claim
20	progression-free	N	I-Claim
21	survival	N	I-Claim
22	,	N	I-Claim
23	but	N	I-Claim
24	not	N	I-Claim
25	in	N	I-Claim
26	terms	N	I-Claim
27	of	N	I-Claim
28	overall	N	I-Claim
29	survival	N	I-Claim
30	.	N	I-Claim

1	The	N	O
2	low	N	O
3	response	N	O
4	rate	N	O
5	is	N	O
6	partly	N	O
7	related	N	O
8	to	N	O
9	the	N	O
10	number	N	O
11	of	N	O
12	patients	N	O
13	who	N	O
14	received	N	O
15	only	N	O
16	one	N	O
17	cycle	N	O
18	of	N	O
19	chemotherapy	N	O
20	.	N	O

1	A	N	I-Claim
2	more	N	I-Claim
3	effective	N	I-Claim
4	,	N	I-Claim
5	better	N	I-Claim
6	tolerated	N	I-Claim
7	version	N	I-Claim
8	of	N	I-Claim
9	this	N	I-Claim
10	FUP	N	I-Claim
11	combination	N	I-Claim
12	is	N	I-Claim
13	needed	N	I-Claim
14	.	N	I-Claim

1	Amitriptyline	N	I-Claim
2	is	N	I-Claim
3	the	N	I-Claim
4	most	N	I-Claim
5	common	N	I-Claim
6	analgesic	N	I-Claim
7	adjuvant	N	I-Claim
8	used	N	I-Claim
9	in	N	I-Claim
10	cancer	N	I-Claim
11	patients	N	I-Claim
12	with	N	I-Claim
13	neuropathic	N	I-Claim
14	pain	N	I-Claim
15	,	N	I-Claim
16	even	N	O
17	though	N	O
18	no	N	I-Claim
19	specific	N	I-Claim
20	studies	N	I-Claim
21	have	N	I-Claim
22	demonstrated	N	I-Claim
23	a	N	I-Claim
24	benefit	N	I-Claim
25	.	N	I-Claim

1	A	N	O
2	randomized	N	O
3	placebo-controlled	N	O
4	,	N	O
5	double-blind	N	O
6	crossover	N	O
7	study	N	O
8	was	N	O
9	designed	N	O
10	to	N	O
11	evidence	N	O
12	the	N	O
13	effects	N	O
14	of	N	O
15	amitriptyline	N	O
16	in	N	O
17	patients	N	O
18	with	N	O
19	neuropathic	N	O
20	cancer	N	O
21	pain	N	O
22	.	N	O

1	Sixteen	N	O
2	advanced	N	O
3	cancer	N	O
4	patients	N	O
5	with	N	O
6	neuropathic	N	O
7	pain	N	O
8	on	N	O
9	systemic	N	O
10	morphine	N	O
11	therapy	N	O
12	,	N	O
13	no	N	O
14	longer	N	O
15	receiving	N	O
16	oncologic	N	O
17	treatment	N	O
18	,	N	O
19	presenting	N	O
20	moderate	N	O
21	pain	N	O
22	(	N	O
23	about	N	O
24	4	N	O
25	or	N	O
26	more	N	O
27	,	N	O
28	but	N	O
29	less	N	O
30	than	N	O
31	7	N	O
32	,	N	O
33	on	N	O
34	a	N	O
35	numerical	N	O
36	scale	N	O
37	of	N	O
38	0-10	N	O
39	)	N	O
40	in	N	O
41	the	N	O
42	last	N	O
43	week	N	O
44	,	N	O
45	and	N	O
46	given	N	O
47	a	N	O
48	stable	N	O
49	morphine	N	O
50	dose	N	O
51	in	N	O
52	the	N	O
53	last	N	O
54	2	N	O
55	days	N	O
56	were	N	O
57	admitted	N	O
58	to	N	O
59	the	N	O
60	study	N	O
61	.	N	O

1	During	N	O
2	the	N	O
3	first	N	O
4	week	N	O
5	of	N	O
6	study	N	O
7	,	N	O
8	patients	N	O
9	were	N	O
10	administered	N	O
11	25	N	O
12	mg	N	O
13	of	N	O
14	amitriptyline	N	O
15	or	N	O
16	equivalent	N	O
17	drops	N	O
18	of	N	O
19	placebo	N	O
20	at	N	O
21	night	N	O
22	for	N	O
23	3	N	O
24	days	N	O
25	and	N	O
26	50	N	O
27	mg	N	O
28	for	N	O
29	the	N	O
30	following	N	O
31	4	N	O
32	days	N	O
33	.	N	O

1	Doses	N	O
2	for	N	O
3	patients	N	O
4	aged	N	O
5	more	N	O
6	than	N	O
7	65	N	O
8	years	N	O
9	were	N	O
10	15	N	O
11	mg	N	O
12	(	N	O
13	first	N	O
14	3	N	O
15	days	N	O
16	)	N	O
17	and	N	O
18	30	N	O
19	mg	N	O
20	(	N	O
21	3	N	O
22	days	N	O
23	after	N	O
24	)	N	O
25	.	N	O

1	After	N	O
2	a	N	O
3	week	N	O
4	,	N	O
5	a	N	O
6	crossover	N	O
7	took	N	O
8	place	N	O
9	for	N	O
10	the	N	O
11	second	N	O
12	week	N	O
13	,	N	O
14	with	N	O
15	the	N	O
16	other	N	O
17	treatment	N	O
18	at	N	O
19	an	N	O
20	inverse	N	O
21	sequence	N	O
22	.	N	O

1	Opioid	N	O
2	consumption	N	O
3	,	N	O
4	pain	N	O
5	intensity	N	O
6	,	N	O
7	symptoms	N	O
8	and	N	O
9	adverse	N	O
10	effects	N	O
11	,	N	O
12	mood	N	O
13	,	N	O
14	sleep	N	O
15	,	N	O
16	patient	N	O
17	's	N	O
18	preference	N	O
19	,	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	before	N	O
24	starting	N	O
25	the	N	O
26	study	N	O
27	,	N	O
28	the	N	O
29	first	N	O
30	week	N	O
31	after	N	O
32	and	N	O
33	the	N	O
34	second	N	O
35	week	N	O
36	after	N	O
37	were	N	O
38	recorded	N	O
39	.	N	O

1	No	N	I-Premise
2	significant	N	I-Premise
3	benefits	N	I-Premise
4	in	N	I-Premise
5	analgesia	N	I-Premise
6	were	N	I-Premise
7	found	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	global	N	I-Premise
11	pain	N	I-Premise
12	intensity	N	I-Premise
13	of	N	I-Premise
14	the	N	I-Premise
15	previous	N	I-Premise
16	week	N	I-Premise
17	of	N	I-Premise
18	treatment	N	I-Premise
19	,	N	I-Premise
20	the	N	I-Premise
21	least	N	I-Premise
22	pain	N	I-Premise
23	intensity	N	I-Premise
24	or	N	I-Premise
25	the	N	I-Premise
26	pain	N	I-Premise
27	evaluated	N	I-Premise
28	just	N	I-Premise
29	after	N	I-Premise
30	a	N	I-Premise
31	week	N	I-Premise
32	of	N	I-Premise
33	treatment	N	I-Premise
34	,	N	I-Premise
35	at	N	I-Premise
36	the	N	I-Premise
37	moment	N	I-Premise
38	of	N	I-Premise
39	the	N	I-Premise
40	visit	N	I-Premise
41	,	N	I-Premise
42	when	N	I-Premise
43	amitriptyline	N	I-Premise
44	was	N	I-Premise
45	compared	N	I-Premise
46	with	N	I-Premise
47	placebo	N	I-Premise
48	.	N	I-Premise

1	A	N	I-Premise
2	significant	N	I-Premise
3	difference	N	I-Premise
4	was	N	I-Premise
5	evidenced	N	I-Premise
6	for	N	I-Premise
7	the	N	I-Premise
8	worst	N	I-Premise
9	pain	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	<	N	I-Premise
13	0.035	N	I-Premise
14	)	N	I-Premise
15	.	N	I-Premise

1	No	N	I-Premise
2	differences	N	I-Premise
3	in	N	I-Premise
4	opioid	N	I-Premise
5	doses	N	I-Premise
6	during	N	I-Premise
7	the	N	I-Premise
8	period	N	I-Premise
9	of	N	I-Premise
10	study	N	I-Premise
11	were	N	I-Premise
12	found	N	I-Premise
13	.	N	I-Premise

1	Drowsiness	N	I-Premise
2	,	N	I-Premise
3	confusion	N	I-Premise
4	and	N	I-Premise
5	dry	N	I-Premise
6	mouth	N	I-Premise
7	were	N	I-Premise
8	significantly	N	I-Premise
9	more	N	I-Premise
10	intense	N	I-Premise
11	with	N	I-Premise
12	amitriptyline	N	I-Premise
13	than	N	I-Premise
14	with	N	I-Premise
15	placebo	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	<	N	I-Premise
19	0.036	N	I-Premise
20	,	N	I-Premise
21	0.003	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	0.034	N	I-Premise
25	,	N	I-Premise
26	respectively	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	substantial	N	I-Premise
5	differences	N	I-Premise
6	between	N	I-Premise
7	the	N	I-Premise
8	two	N	I-Premise
9	treatments	N	I-Premise
10	in	N	I-Premise
11	Spitzer	N	I-Premise
12	's	N	I-Premise
13	quality	N	I-Premise
14	of	N	I-Premise
15	life	N	I-Premise
16	score	N	I-Premise
17	and	N	I-Premise
18	for	N	I-Premise
19	each	N	I-Premise
20	item	N	I-Premise
21	.	N	I-Premise

1	No	N	I-Premise
2	differences	N	I-Premise
3	in	N	I-Premise
4	patients	N	I-Premise
5	'	N	I-Premise
6	preference	N	I-Premise
7	for	N	I-Premise
8	the	N	I-Premise
9	two	N	I-Premise
10	treatment	N	I-Premise
11	periods	N	I-Premise
12	were	N	I-Premise
13	found	N	I-Premise
14	.	N	I-Premise

1	The	N	I-Claim
2	analgesic	N	I-Claim
3	effects	N	I-Claim
4	of	N	I-Claim
5	amitriptyline	N	I-Claim
6	were	N	I-Claim
7	slight	N	I-Claim
8	and	N	I-Claim
9	associated	N	I-Claim
10	with	N	I-Claim
11	adverse	N	I-Claim
12	effects	N	I-Claim
13	.	N	I-Claim

1	In	N	O
2	light	N	O
3	of	N	O
4	the	N	O
5	results	N	O
6	obtained	N	O
7	in	N	O
8	the	N	O
9	study	N	O
10	,	N	O
11	the	N	I-Claim
12	extensive	N	I-Claim
13	use	N	I-Claim
14	of	N	I-Claim
15	the	N	I-Claim
16	drug	N	I-Claim
17	for	N	I-Claim
18	cancer	N	I-Claim
19	pain	N	I-Claim
20	should	N	I-Claim
21	be	N	I-Claim
22	questioned	N	I-Claim
23	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	patients	N	O
5	with	N	O
6	locally	N	O
7	advanced	N	O
8	non-small	N	O
9	cell	N	O
10	lung	N	O
11	cancer	N	O
12	unsuitable	N	O
13	for	N	O
14	resection	N	O
15	or	N	O
16	radical	N	O
17	radiotherapy	N	O
18	,	N	O
19	and	N	O
20	with	N	O
21	minimal	N	O
22	thoracic	N	O
23	symptoms	N	O
24	,	N	O
25	should	N	O
26	be	N	O
27	given	N	O
28	palliative	N	O
29	thoracic	N	O
30	radiotherapy	N	O
31	immediately	N	O
32	or	N	O
33	as	N	O
34	needed	N	O
35	to	N	O
36	treat	N	O
37	symptoms	N	O
38	.	N	O

1	Multicentre	N	O
2	randomised	N	O
3	controlled	N	O
4	trial	N	O
5	.	N	O

1	23	N	O
2	centres	N	O
3	in	N	O
4	the	N	O
5	United	N	O
6	Kingdom	N	O
7	,	N	O
8	Ireland	N	O
9	,	N	O
10	and	N	O
11	South	N	O
12	Africa	N	O
13	.	N	O

1	230	N	O
2	patients	N	O
3	with	N	O
4	previously	N	O
5	untreated	N	O
6	,	N	O
7	non-small	N	O
8	cell	N	O
9	lung	N	O
10	cancer	N	O
11	that	N	O
12	is	N	O
13	locally	N	O
14	too	N	O
15	advanced	N	O
16	for	N	O
17	resection	N	O
18	or	N	O
19	radical	N	O
20	radiotherapy	N	O
21	with	N	O
22	curative	N	O
23	intent	N	O
24	,	N	O
25	with	N	O
26	minimal	N	O
27	thoracic	N	O
28	symptoms	N	O
29	,	N	O
30	and	N	O
31	with	N	O
32	no	N	O
33	indication	N	O
34	for	N	O
35	immediate	N	O
36	thoracic	N	O
37	radiotherapy	N	O
38	.	N	O

1	All	N	O
2	patients	N	O
3	were	N	O
4	given	N	O
5	supportive	N	O
6	treatment	N	O
7	and	N	O
8	were	N	O
9	randomised	N	O
10	to	N	O
11	receive	N	O
12	palliative	N	O
13	thoracic	N	O
14	radiotherapy	N	O
15	either	N	O
16	immediately	N	O
17	or	N	O
18	delayed	N	O
19	until	N	O
20	needed	N	O
21	to	N	O
22	treat	N	O
23	symptoms	N	O
24	.	N	O

1	The	N	O
2	recommended	N	O
3	regimens	N	O
4	were	N	O
5	17	N	O
6	Gy	N	O
7	in	N	O
8	two	N	O
9	fractions	N	O
10	one	N	O
11	week	N	O
12	apart	N	O
13	or	N	O
14	10	N	O
15	Gy	N	O
16	as	N	O
17	a	N	O
18	single	N	O
19	dose	N	O
20	.	N	O

1	Primary	N	O
2	--	N	O
3	patients	N	O
4	alive	N	O
5	and	N	O
6	without	N	O
7	moderate	N	O
8	or	N	O
9	severe	N	O
10	cough	N	O
11	,	N	O
12	chest	N	O
13	pain	N	O
14	,	N	O
15	haemoptysis	N	O
16	,	N	O
17	or	N	O
18	dyspnoea	N	O
19	six	N	O
20	months	N	O
21	from	N	O
22	randomisation	N	O
23	,	N	O
24	as	N	O
25	recorded	N	O
26	by	N	O
27	clinicians	N	O
28	.	N	O

1	Secondary	N	O
2	--	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	,	N	O
7	adverse	N	O
8	events	N	O
9	,	N	O
10	survival	N	O
11	.	N	O

1	From	N	O
2	December	N	O
3	1992	N	O
4	to	N	O
5	May	N	O
6	1999	N	O
7	,	N	O
8	230	N	O
9	patients	N	O
10	were	N	O
11	randomised	N	O
12	.	N	O

1	104/115	N	O
2	of	N	O
3	the	N	O
4	patients	N	O
5	in	N	O
6	the	N	O
7	immediate	N	O
8	treatment	N	O
9	group	N	O
10	received	N	O
11	thoracic	N	O
12	radiotherapy	N	O
13	(	N	O
14	90	N	O
15	received	N	O
16	one	N	O
17	of	N	O
18	the	N	O
19	recommended	N	O
20	regimens	N	O
21	)	N	O
22	.	N	O

1	In	N	O
2	the	N	O
3	delayed	N	O
4	treatment	N	O
5	group	N	O
6	,	N	O
7	48/115	N	O
8	(	N	O
9	42	N	O
10	%	N	O
11	)	N	O
12	patients	N	O
13	received	N	O
14	thoracic	N	O
15	radiotherapy	N	O
16	(	N	O
17	29	N	O
18	received	N	O
19	one	N	O
20	of	N	O
21	the	N	O
22	recommended	N	O
23	regimens	N	O
24	)	N	O
25	;	N	O
26	64	N	O
27	(	N	O
28	56	N	O
29	%	N	O
30	)	N	O
31	died	N	O
32	without	N	O
33	receiving	N	O
34	thoracic	N	O
35	radiotherapy	N	O
36	;	N	O
37	the	N	O
38	remaining	N	O
39	three	N	O
40	(	N	O
41	3	N	O
42	%	N	O
43	)	N	O
44	were	N	O
45	alive	N	O
46	at	N	O
47	the	N	O
48	end	N	O
49	of	N	O
50	the	N	O
51	study	N	O
52	without	N	O
53	having	N	O
54	received	N	O
55	the	N	O
56	treatment	N	O
57	.	N	O

1	For	N	O
2	patients	N	O
3	who	N	O
4	received	N	O
5	thoracic	N	O
6	radiotherapy	N	O
7	,	N	O
8	the	N	O
9	median	N	O
10	time	N	O
11	to	N	O
12	start	N	O
13	was	N	O
14	15	N	O
15	days	N	O
16	in	N	O
17	the	N	O
18	immediate	N	O
19	treatment	N	O
20	group	N	O
21	and	N	O
22	125	N	O
23	days	N	O
24	in	N	O
25	the	N	O
26	delayed	N	O
27	treatment	N	O
28	group	N	O
29	.	N	O

1	The	N	I-Premise
2	primary	N	I-Premise
3	outcome	N	I-Premise
4	measure	N	I-Premise
5	was	N	I-Premise
6	achieved	N	I-Premise
7	in	N	I-Premise
8	28	N	I-Premise
9	%	N	I-Premise
10	of	N	I-Premise
11	the	N	I-Premise
12	immediate	N	I-Premise
13	treatment	N	I-Premise
14	group	N	I-Premise
15	and	N	I-Premise
16	26	N	I-Premise
17	%	N	I-Premise
18	of	N	I-Premise
19	patients	N	I-Premise
20	from	N	I-Premise
21	the	N	I-Premise
22	delayed	N	I-Premise
23	treatment	N	I-Premise
24	group	N	I-Premise
25	(	N	I-Premise
26	27/97	N	I-Premise
27	and	N	I-Premise
28	27/103	N	I-Premise
29	,	N	I-Premise
30	respectively	N	I-Premise
31	;	N	I-Premise
32	absolute	N	I-Premise
33	difference	N	I-Premise
34	1.6	N	I-Premise
35	%	N	I-Premise
36	,	N	I-Premise
37	95	N	I-Premise
38	%	N	I-Premise
39	confidence	N	I-Premise
40	interval	N	I-Premise
41	-10.7	N	I-Premise
42	%	N	I-Premise
43	to	N	I-Premise
44	13.9	N	I-Premise
45	%	N	I-Premise
46	)	N	I-Premise
47	.	N	I-Premise

1	No	N	I-Premise
2	evidence	N	I-Premise
3	of	N	I-Premise
4	a	N	I-Premise
5	difference	N	I-Premise
6	was	N	I-Premise
7	observed	N	I-Premise
8	between	N	I-Premise
9	the	N	I-Premise
10	two	N	I-Premise
11	treatment	N	I-Premise
12	groups	N	I-Premise
13	in	N	I-Premise
14	terms	N	I-Premise
15	of	N	I-Premise
16	activity	N	I-Premise
17	level	N	I-Premise
18	,	N	I-Premise
19	anxiety	N	I-Premise
20	,	N	I-Premise
21	depression	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	psychological	N	I-Premise
25	distress	N	I-Premise
26	,	N	I-Premise
27	as	N	I-Premise
28	recorded	N	I-Premise
29	by	N	I-Premise
30	the	N	I-Premise
31	patients	N	I-Premise
32	.	N	I-Premise

1	Adverse	N	I-Premise
2	events	N	I-Premise
3	were	N	I-Premise
4	more	N	I-Premise
5	common	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	immediate	N	I-Premise
9	treatment	N	I-Premise
10	group	N	I-Premise
11	.	N	I-Premise

1	Neither	N	I-Premise
2	group	N	I-Premise
3	had	N	I-Premise
4	a	N	I-Premise
5	survival	N	I-Premise
6	advantage	N	I-Premise
7	(	N	I-Premise
8	hazard	N	I-Premise
9	ratio	N	I-Premise
10	0.95	N	I-Premise
11	,	N	I-Premise
12	0.73	N	I-Premise
13	to	N	I-Premise
14	1.24	N	I-Premise
15	;	N	I-Premise
16	P=0.71	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	8.3	N	I-Premise
5	months	N	I-Premise
6	and	N	I-Premise
7	7.9	N	I-Premise
8	months	N	I-Premise
9	,	N	I-Premise
10	and	N	O
11	the	N	I-Premise
12	survival	N	I-Premise
13	rates	N	I-Premise
14	were	N	I-Premise
15	31	N	I-Premise
16	%	N	I-Premise
17	and	N	I-Premise
18	29	N	I-Premise
19	%	N	I-Premise
20	at	N	I-Premise
21	12	N	I-Premise
22	months	N	I-Premise
23	,	N	I-Premise
24	for	N	I-Premise
25	the	N	I-Premise
26	immediate	N	I-Premise
27	and	N	I-Premise
28	delayed	N	I-Premise
29	treatment	N	I-Premise
30	groups	N	I-Premise
31	,	N	I-Premise
32	respectively	N	I-Premise
33	.	N	I-Premise

1	In	N	I-Claim
2	minimally	N	I-Claim
3	symptomatic	N	I-Claim
4	patients	N	I-Claim
5	with	N	I-Claim
6	locally	N	I-Claim
7	advanced	N	I-Claim
8	non-small	N	I-Claim
9	cell	N	I-Claim
10	lung	N	I-Claim
11	cancer	N	I-Claim
12	,	N	I-Claim
13	no	N	I-Claim
14	persuasive	N	I-Claim
15	evidence	N	I-Claim
16	was	N	I-Claim
17	found	N	I-Claim
18	to	N	I-Claim
19	indicate	N	I-Claim
20	that	N	I-Claim
21	giving	N	I-Claim
22	immediate	N	I-Claim
23	palliative	N	I-Claim
24	thoracic	N	I-Claim
25	radiotherapy	N	I-Claim
26	improves	N	I-Claim
27	symptom	N	I-Claim
28	control	N	I-Claim
29	,	N	I-Claim
30	quality	N	I-Claim
31	of	N	I-Claim
32	life	N	I-Claim
33	,	N	I-Claim
34	or	N	I-Claim
35	survival	N	I-Claim
36	when	N	I-Claim
37	compared	N	I-Claim
38	with	N	I-Claim
39	delaying	N	I-Claim
40	until	N	I-Claim
41	symptoms	N	I-Claim
42	require	N	I-Claim
43	treatment	N	I-Claim
44	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	outcome	N	O
5	of	N	O
6	treatment	N	O
7	of	N	O
8	mediastinoscopy-verified	N	O
9	N2	N	O
10	non-small-cell	N	O
11	lung	N	O
12	cancer	N	O
13	treated	N	O
14	with	N	O
15	induction	N	O
16	chemotherapy	N	O
17	followed	N	O
18	by	N	O
19	either	N	O
20	surgery	N	O
21	or	N	O
22	radiotherapy	N	O
23	(	N	O
24	RT	N	O
25	)	N	O
26	,	N	O
27	with	N	O
28	both	N	O
29	options	N	O
30	followed	N	O
31	by	N	O
32	consolidation	N	O
33	chemotherapy	N	O
34	.	N	O

1	A	N	O
2	randomized	N	O
3	Phase	N	O
4	III	N	O
5	trial	N	O
6	for	N	O
7	Stage	N	O
8	IIIA	N	O
9	(	N	O
10	T1-T3N2M0	N	O
11	)	N	O
12	non-small	N	O
13	cell	N	O
14	lung	N	O
15	cancer	N	O
16	was	N	O
17	conducted	N	O
18	by	N	O
19	the	N	O
20	Radiation	N	O
21	Therapy	N	O
22	Oncology	N	O
23	Group	N	O
24	(	N	O
25	RTOG	N	O
26	)	N	O
27	and	N	O
28	Eastern	N	O
29	Cooperative	N	O
30	Oncology	N	O
31	Group	N	O
32	between	N	O
33	April	N	O
34	1990	N	O
35	and	N	O
36	April	N	O
37	1994	N	O
38	.	N	O

1	After	N	O
2	documentation	N	O
3	of	N	O
4	N2	N	O
5	disease	N	O
6	by	N	O
7	mediastinoscopy	N	O
8	or	N	O
9	anterior	N	O
10	mediastinotomy	N	O
11	,	N	O
12	patients	N	O
13	received	N	O
14	induction	N	O
15	chemotherapy	N	O
16	with	N	O
17	cisplatin	N	O
18	,	N	O
19	vinblastine	N	O
20	,	N	O
21	and	N	O
22	mitomycin-C.	N	O
23	Mitomycin-C	N	O
24	was	N	O
25	later	N	O
26	dropped	N	O
27	from	N	O
28	the	N	O
29	induction	N	O
30	regimen	N	O
31	.	N	O

1	Patients	N	O
2	were	N	O
3	then	N	O
4	randomized	N	O
5	to	N	O
6	surgery	N	O
7	or	N	O
8	RT	N	O
9	(	N	O
10	64	N	O
11	Gy	N	O
12	in	N	O
13	7	N	O
14	weeks	N	O
15	)	N	O
16	followed	N	O
17	by	N	O
18	cisplatin	N	O
19	and	N	O
20	vinblastine	N	O
21	.	N	O

1	RTOG	N	O
2	89-01	N	O
3	accrued	N	O
4	75	N	O
5	patients	N	O
6	,	N	O
7	of	N	O
8	whom	N	O
9	73	N	O
10	were	N	O
11	eligible	N	O
12	and	N	O
13	analyzable	N	O
14	.	N	O

1	Twelve	N	O
2	patients	N	O
3	received	N	O
4	induction	N	O
5	chemotherapy	N	O
6	but	N	O
7	were	N	O
8	not	N	O
9	randomized	N	O
10	to	N	O
11	RT	N	O
12	or	N	O
13	surgery	N	O
14	thereafter	N	O
15	.	N	O

1	Forty-five	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	to	N	O
6	postinduction	N	O
7	RT	N	O
8	or	N	O
9	surgery	N	O
10	.	N	O

1	Of	N	O
2	the	N	O
3	analyzable	N	O
4	patients	N	O
5	,	N	O
6	90	N	O
7	%	N	O
8	had	N	O
9	a	N	O
10	Karnofsky	N	O
11	performance	N	O
12	score	N	O
13	of	N	O
14	90-100	N	O
15	,	N	O
16	18	N	O
17	%	N	O
18	had	N	O
19	weight	N	O
20	loss	N	O
21	>	N	O
22	5	N	O
23	%	N	O
24	,	N	O
25	37	N	O
26	%	N	O
27	had	N	O
28	squamous	N	O
29	cell	N	O
30	histologic	N	O
31	features	N	O
32	,	N	O
33	and	N	O
34	54	N	O
35	%	N	O
36	had	N	O
37	bulky	N	O
38	N2	N	O
39	disease	N	O
40	.	N	O

1	The	N	O
2	distribution	N	O
3	of	N	O
4	bulky	N	O
5	N2	N	O
6	disease	N	O
7	was	N	O
8	uniform	N	O
9	among	N	O
10	the	N	O
11	treatment	N	O
12	arms	N	O
13	.	N	O

1	The	N	I-Premise
2	incidence	N	I-Premise
3	of	N	I-Premise
4	Grade	N	I-Premise
5	4	N	I-Premise
6	toxicity	N	I-Premise
7	was	N	I-Premise
8	56	N	I-Premise
9	%	N	I-Premise
10	in	N	I-Premise
11	patients	N	I-Premise
12	receiving	N	I-Premise
13	mitomycin-C	N	I-Premise
14	and	N	I-Premise
15	29	N	I-Premise
16	%	N	I-Premise
17	in	N	I-Premise
18	those	N	I-Premise
19	who	N	I-Premise
20	did	N	I-Premise
21	not	N	I-Premise
22	.	N	I-Premise

1	Only	N	I-Premise
2	1	N	I-Premise
3	patient	N	I-Premise
4	in	N	I-Premise
5	each	N	I-Premise
6	group	N	I-Premise
7	had	N	I-Premise
8	acute	N	I-Premise
9	nonhematologic	N	I-Premise
10	toxicity	N	I-Premise
11	greater	N	I-Premise
12	than	N	I-Premise
13	Grade	N	I-Premise
14	3	N	I-Premise
15	(	N	I-Premise
16	nausea	N	I-Premise
17	and	N	I-Premise
18	vomiting	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	No	N	I-Premise
2	acute	N	I-Premise
3	Grade	N	I-Premise
4	4	N	I-Premise
5	radiation	N	I-Premise
6	toxicity	N	I-Premise
7	developed	N	I-Premise
8	.	N	I-Premise

1	The	N	I-Premise
2	incidences	N	I-Premise
3	of	N	I-Premise
4	long-term	N	I-Premise
5	toxicity	N	I-Premise
6	were	N	I-Premise
7	equivalent	N	I-Premise
8	across	N	I-Premise
9	the	N	I-Premise
10	arms	N	I-Premise
11	.	N	I-Premise

1	Three	N	I-Premise
2	treatment-related	N	I-Premise
3	deaths	N	I-Premise
4	occurred	N	I-Premise
5	:	N	I-Premise
6	2	N	I-Premise
7	patients	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	surgical	N	I-Premise
11	arms	N	I-Premise
12	(	N	I-Premise
13	one	N	I-Premise
14	late	N	I-Premise
15	pulmonary	N	I-Premise
16	toxicity	N	I-Premise
17	and	N	I-Premise
18	one	N	I-Premise
19	pulmonary	N	I-Premise
20	embolus	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	1	N	I-Premise
25	patient	N	I-Premise
26	in	N	I-Premise
27	the	N	I-Premise
28	radiation	N	I-Premise
29	arm	N	I-Premise
30	(	N	I-Premise
31	radiation	N	I-Premise
32	pneumonitis	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	Induction	N	I-Premise
2	chemotherapy	N	I-Premise
3	was	N	I-Premise
4	completed	N	I-Premise
5	in	N	I-Premise
6	78	N	I-Premise
7	%	N	I-Premise
8	of	N	I-Premise
9	the	N	I-Premise
10	patients	N	I-Premise
11	.	N	I-Premise

1	Complete	N	I-Premise
2	resection	N	I-Premise
3	was	N	I-Premise
4	performed	N	I-Premise
5	in	N	I-Premise
6	73	N	I-Premise
7	%	N	I-Premise
8	of	N	I-Premise
9	26	N	I-Premise
10	patients	N	I-Premise
11	undergoing	N	I-Premise
12	thoracotomy	N	I-Premise
13	.	N	I-Premise

1	Consolidation	N	I-Premise
2	chemotherapy	N	I-Premise
3	was	N	I-Premise
4	completed	N	I-Premise
5	in	N	I-Premise
6	75	N	I-Premise
7	%	N	I-Premise
8	of	N	I-Premise
9	the	N	I-Premise
10	patients	N	I-Premise
11	.	N	I-Premise

1	No	N	I-Premise
2	statistically	N	I-Premise
3	significant	N	I-Premise
4	difference	N	I-Premise
5	was	N	I-Premise
6	found	N	I-Premise
7	among	N	I-Premise
8	the	N	I-Premise
9	treatment	N	I-Premise
10	arms	N	I-Premise
11	.	N	I-Premise

1	The	N	I-Premise
2	overall	N	I-Premise
3	progression-free	N	I-Premise
4	survival	N	I-Premise
5	rate	N	I-Premise
6	was	N	I-Premise
7	53	N	I-Premise
8	%	N	I-Premise
9	at	N	I-Premise
10	1	N	I-Premise
11	year	N	I-Premise
12	and	N	I-Premise
13	17	N	I-Premise
14	%	N	I-Premise
15	at	N	I-Premise
16	3	N	I-Premise
17	years	N	I-Premise
18	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	progression-free	N	I-Premise
4	survival	N	I-Premise
5	was	N	I-Premise
6	14	N	I-Premise
7	months	N	I-Premise
8	.	N	I-Premise

1	No	N	I-Premise
2	difference	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	1-year	N	I-Premise
6	survival	N	I-Premise
7	rate	N	I-Premise
8	(	N	I-Premise
9	70	N	I-Premise
10	%	N	I-Premise
11	vs.	N	I-Premise
12	66	N	I-Premise
13	%	N	I-Premise
14	)	N	I-Premise
15	or	N	I-Premise
16	median	N	I-Premise
17	survival	N	I-Premise
18	time	N	I-Premise
19	(	N	I-Premise
20	19.4	N	I-Premise
21	vs.	N	I-Premise
22	17.4	N	I-Premise
23	months	N	I-Premise
24	)	N	I-Premise
25	between	N	I-Premise
26	the	N	I-Premise
27	surgery	N	I-Premise
28	and	N	I-Premise
29	RT	N	I-Premise
30	arms	N	I-Premise
31	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	patients	N	I-Premise
7	receiving	N	I-Premise
8	induction	N	I-Premise
9	chemotherapy	N	I-Premise
10	only	N	I-Premise
11	was	N	I-Premise
12	8.9	N	I-Premise
13	months	N	I-Premise
14	.	N	I-Premise

1	Mitomycin-C	N	I-Premise
2	had	N	I-Premise
3	no	N	I-Premise
4	impact	N	I-Premise
5	on	N	I-Premise
6	survival	N	I-Premise
7	(	N	I-Premise
8	p	N	I-Premise
9	=	N	I-Premise
10	0.75	N	I-Premise
11	)	N	I-Premise
12	.	N	I-Premise

1	No	N	I-Premise
2	statistically	N	I-Premise
3	significant	N	I-Premise
4	difference	N	I-Premise
5	was	N	I-Premise
6	noted	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	time	N	I-Premise
10	to	N	I-Premise
11	local	N	I-Premise
12	failure	N	I-Premise
13	between	N	I-Premise
14	the	N	I-Premise
15	surgical	N	I-Premise
16	and	N	I-Premise
17	RT	N	I-Premise
18	arms	N	I-Premise
19	.	N	I-Premise

1	The	N	I-Claim
2	patient	N	I-Claim
3	accrual	N	I-Claim
4	to	N	I-Claim
5	this	N	I-Claim
6	trial	N	I-Claim
7	made	N	I-Claim
8	its	N	I-Claim
9	results	N	I-Claim
10	inconclusive	N	I-Claim
11	,	N	I-Claim
12	but	N	O
13	several	N	O
14	observations	N	O
15	are	N	O
16	notable	N	O
17	.	N	O

1	In	N	O
2	this	N	O
3	trial	N	O
4	,	N	O
5	histologic	N	I-Claim
6	confirmation	N	I-Claim
7	of	N	I-Claim
8	N2	N	I-Claim
9	disease	N	I-Claim
10	in	N	I-Claim
11	the	N	I-Claim
12	surgical	N	I-Claim
13	and	N	I-Claim
14	nonsurgical	N	I-Claim
15	arms	N	I-Claim
16	eliminated	N	I-Claim
17	the	N	I-Claim
18	usual	N	I-Claim
19	biases	N	I-Claim
20	from	N	I-Claim
21	clinical	N	I-Claim
22	staging	N	I-Claim
23	.	N	I-Claim

1	In	N	O
2	this	N	O
3	setting	N	O
4	,	N	O
5	local	N	I-Claim
6	control	N	I-Claim
7	and	N	I-Claim
8	survival	N	I-Claim
9	were	N	I-Claim
10	essentially	N	I-Claim
11	equal	N	I-Claim
12	between	N	I-Claim
13	the	N	I-Claim
14	surgical	N	I-Claim
15	and	N	I-Claim
16	RT	N	I-Claim
17	arms	N	I-Claim
18	.	N	I-Claim

1	The	N	I-Claim
2	3-	N	I-Claim
3	and	N	I-Claim
4	5-year	N	I-Claim
5	survival	N	I-Claim
6	rates	N	I-Claim
7	of	N	I-Claim
8	nonsurgical	N	I-Claim
9	therapy	N	I-Claim
10	were	N	I-Claim
11	comparable	N	I-Claim
12	to	N	I-Claim
13	published	N	I-Claim
14	surgical	N	I-Claim
15	trials	N	I-Claim
16	of	N	I-Claim
17	N2	N	I-Claim
18	disease	N	I-Claim
19	.	N	I-Claim

1	Mucositis	N	I-Premise
2	occurs	N	I-Premise
3	in	N	I-Premise
4	almost	N	I-Premise
5	all	N	I-Premise
6	patients	N	I-Premise
7	treated	N	I-Premise
8	with	N	I-Premise
9	radiotherapy	N	I-Premise
10	for	N	I-Premise
11	head	N	I-Premise
12	and	N	I-Premise
13	neck	N	I-Premise
14	cancer	N	I-Premise
15	.	N	I-Premise

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	multicenter	N	O
6	,	N	O
7	double-blind	N	O
8	,	N	O
9	prospective	N	O
10	,	N	O
11	randomized	N	O
12	trial	N	O
13	was	N	O
14	to	N	O
15	evaluate	N	O
16	the	N	O
17	clinical	N	O
18	efficacy	N	O
19	of	N	O
20	an	N	O
21	economically	N	O
22	viable	N	O
23	antimicrobial	N	O
24	lozenge	N	O
25	(	N	O
26	bacitracin	N	O
27	,	N	O
28	clotrimazole	N	O
29	,	N	O
30	and	N	O
31	gentamicin	N	O
32	[	N	O
33	BcoG	N	O
34	]	N	O
35	)	N	O
36	in	N	O
37	the	N	O
38	alleviation	N	O
39	of	N	O
40	radiation-induced	N	O
41	mucositis	N	O
42	in	N	O
43	patients	N	O
44	with	N	O
45	head	N	O
46	and	N	O
47	neck	N	O
48	cancer	N	O
49	.	N	O

1	One	N	O
2	hundred	N	O
3	thirty-seven	N	O
4	eligible	N	O
5	patients	N	O
6	were	N	O
7	randomized	N	O
8	to	N	O
9	treatment	N	O
10	with	N	O
11	either	N	O
12	antimicrobial	N	O
13	lozenge	N	O
14	(	N	O
15	69	N	O
16	patients	N	O
17	)	N	O
18	or	N	O
19	placebo	N	O
20	lozenge	N	O
21	(	N	O
22	68	N	O
23	patients	N	O
24	)	N	O
25	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	of	N	O
6	the	N	O
7	study	N	O
8	was	N	O
9	the	N	O
10	time	N	O
11	to	N	O
12	development	N	O
13	of	N	O
14	severe	N	O
15	mucositis	N	O
16	from	N	O
17	the	N	O
18	start	N	O
19	of	N	O
20	radiotherapy	N	O
21	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	included	N	O
5	severity	N	O
6	and	N	O
7	duration	N	O
8	of	N	O
9	mucositis	N	O
10	,	N	O
11	pain	N	O
12	measurement	N	O
13	,	N	O
14	radiation	N	O
15	therapy	N	O
16	interruption	N	O
17	,	N	O
18	and	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	.	N	O

1	Mucositis	N	O
2	was	N	O
3	scored	N	O
4	using	N	O
5	a	N	O
6	validated	N	O
7	mucositis	N	O
8	scoring	N	O
9	system	N	O
10	.	N	O

1	Toxicity	N	I-Premise
2	profiles	N	I-Premise
3	were	N	I-Premise
4	similar	N	I-Premise
5	between	N	I-Premise
6	the	N	I-Premise
7	two	N	I-Premise
8	arms	N	I-Premise
9	of	N	I-Premise
10	the	N	I-Premise
11	study	N	I-Premise
12	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	time	N	I-Premise
4	to	N	I-Premise
5	development	N	I-Premise
6	of	N	I-Premise
7	severe	N	I-Premise
8	mucositis	N	I-Premise
9	from	N	I-Premise
10	the	N	I-Premise
11	start	N	I-Premise
12	of	N	I-Premise
13	radiotherapy	N	I-Premise
14	was	N	I-Premise
15	3.61	N	I-Premise
16	weeks	N	I-Premise
17	on	N	I-Premise
18	BCoG	N	I-Premise
19	and	N	I-Premise
20	3.96	N	I-Premise
21	weeks	N	I-Premise
22	on	N	I-Premise
23	placebo	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	=.61	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	differences	N	I-Premise
7	between	N	I-Premise
8	the	N	I-Premise
9	arms	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	extent	N	I-Premise
13	of	N	I-Premise
14	severe	N	I-Premise
15	mucositis	N	I-Premise
16	as	N	I-Premise
17	measured	N	I-Premise
18	by	N	I-Premise
19	physician	N	I-Premise
20	,	N	I-Premise
21	in	N	I-Premise
22	oral	N	I-Premise
23	toxicities	N	I-Premise
24	as	N	I-Premise
25	recorded	N	I-Premise
26	by	N	I-Premise
27	patients	N	I-Premise
28	,	N	I-Premise
29	or	N	I-Premise
30	in	N	I-Premise
31	radiotherapy	N	I-Premise
32	delays	N	I-Premise
33	.	N	I-Premise

1	This	N	O
2	study	N	O
3	was	N	O
4	conducted	N	O
5	on	N	O
6	the	N	O
7	basis	N	O
8	of	N	O
9	a	N	O
10	pilot	N	O
11	study	N	O
12	that	N	O
13	demonstrated	N	O
14	the	N	O
15	BCoG	N	O
16	lozenge	N	O
17	to	N	O
18	be	N	O
19	tolerable	N	O
20	and	N	O
21	microbiologically	N	O
22	efficacious	N	O
23	.	N	O

1	A	N	O
2	validated	N	O
3	mucositis	N	O
4	scoring	N	O
5	system	N	O
6	was	N	O
7	used	N	O
8	.	N	O

1	However	N	O
2	,	N	O
3	in	N	I-Claim
4	this	N	I-Claim
5	group	N	I-Claim
6	of	N	I-Claim
7	patients	N	I-Claim
8	treated	N	I-Claim
9	with	N	I-Claim
10	conventional	N	I-Claim
11	radiotherapy	N	I-Claim
12	,	N	I-Claim
13	the	N	I-Claim
14	lozenge	N	I-Claim
15	did	N	I-Claim
16	not	N	I-Claim
17	impact	N	I-Claim
18	significantly	N	I-Claim
19	on	N	I-Claim
20	the	N	I-Claim
21	severity	N	I-Claim
22	of	N	I-Claim
23	mucositis	N	I-Claim
24	.	N	I-Claim

1	Whether	N	I-Claim
2	such	N	I-Claim
3	a	N	I-Claim
4	lozenge	N	I-Claim
5	would	N	I-Claim
6	be	N	I-Claim
7	beneficial	N	I-Claim
8	in	N	I-Claim
9	treatment	N	I-Claim
10	situations	N	I-Claim
11	where	N	I-Claim
12	rate	N	I-Claim
13	of	N	I-Claim
14	severe	N	I-Claim
15	mucositis	N	I-Claim
16	is	N	I-Claim
17	higher	N	I-Claim
18	(	N	I-Claim
19	ie	N	I-Claim
20	,	N	I-Claim
21	in	N	I-Claim
22	patients	N	I-Claim
23	treated	N	I-Claim
24	with	N	I-Claim
25	unconventional	N	I-Claim
26	fractionation	N	I-Claim
27	or	N	I-Claim
28	with	N	I-Claim
29	concomitant	N	I-Claim
30	chemotherapy	N	I-Claim
31	)	N	I-Claim
32	is	N	I-Claim
33	unknown	N	I-Claim
34	.	N	I-Claim

1	Bone	N	I-Claim
2	metastases	N	I-Claim
3	are	N	I-Claim
4	a	N	I-Claim
5	common	N	I-Claim
6	cause	N	I-Claim
7	of	N	I-Claim
8	morbidity	N	I-Claim
9	in	N	I-Claim
10	patients	N	I-Claim
11	with	N	I-Claim
12	prostate	N	I-Claim
13	carcinoma	N	I-Claim
14	.	N	I-Claim

1	We	N	O
2	studied	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	a	N	O
7	new	N	O
8	bisphosphonate	N	O
9	,	N	O
10	zoledronic	N	O
11	acid	N	O
12	,	N	O
13	which	N	O
14	blocks	N	O
15	bone	N	O
16	destruction	N	O
17	,	N	O
18	on	N	O
19	skeletal	N	O
20	complications	N	O
21	in	N	O
22	prostate	N	O
23	cancer	N	O
24	patients	N	O
25	with	N	O
26	bone	N	O
27	metastases	N	O
28	.	N	O

1	Patients	N	O
2	with	N	O
3	hormone-refractory	N	O
4	prostate	N	O
5	cancer	N	O
6	and	N	O
7	a	N	O
8	history	N	O
9	of	N	O
10	bone	N	O
11	metastases	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	to	N	O
16	a	N	O
17	double-blind	N	O
18	treatment	N	O
19	regimen	N	O
20	of	N	O
21	intravenous	N	O
22	zoledronic	N	O
23	acid	N	O
24	at	N	O
25	4	N	O
26	mg	N	O
27	(	N	O
28	N	N	O
29	=	N	O
30	214	N	O
31	)	N	O
32	,	N	O
33	zoledronic	N	O
34	acid	N	O
35	at	N	O
36	8	N	O
37	mg	N	O
38	(	N	O
39	subsequently	N	O
40	reduced	N	O
41	to	N	O
42	4	N	O
43	mg	N	O
44	;	N	O
45	8/4	N	O
46	)	N	O
47	(	N	O
48	N	N	O
49	=	N	O
50	221	N	O
51	)	N	O
52	,	N	O
53	or	N	O
54	placebo	N	O
55	(	N	O
56	N	N	O
57	=	N	O
58	208	N	O
59	)	N	O
60	every	N	O
61	3	N	O
62	weeks	N	O
63	for	N	O
64	15	N	O
65	months	N	O
66	.	N	O

1	Proportions	N	O
2	of	N	O
3	patients	N	O
4	with	N	O
5	skeletal-related	N	O
6	events	N	O
7	,	N	O
8	time	N	O
9	to	N	O
10	the	N	O
11	first	N	O
12	skeletal-related	N	O
13	event	N	O
14	,	N	O
15	skeletal	N	O
16	morbidity	N	O
17	rate	N	O
18	,	N	O
19	pain	N	O
20	and	N	O
21	analgesic	N	O
22	scores	N	O
23	,	N	O
24	disease	N	O
25	progression	N	O
26	,	N	O
27	and	N	O
28	safety	N	O
29	were	N	O
30	assessed	N	O
31	.	N	O

1	All	N	O
2	statistical	N	O
3	tests	N	O
4	were	N	O
5	two-sided	N	O
6	.	N	O

1	Approximately	N	O
2	38	N	O
3	%	N	O
4	of	N	O
5	patients	N	O
6	who	N	O
7	received	N	O
8	zoledronic	N	O
9	acid	N	O
10	at	N	O
11	4	N	O
12	mg	N	O
13	,	N	O
14	28	N	O
15	%	N	O
16	who	N	O
17	received	N	O
18	zoledronic	N	O
19	acid	N	O
20	at	N	O
21	8/4	N	O
22	mg	N	O
23	,	N	O
24	and	N	O
25	31	N	O
26	%	N	O
27	who	N	O
28	received	N	O
29	placebo	N	O
30	completed	N	O
31	the	N	O
32	study	N	O
33	.	N	O

1	A	N	I-Premise
2	greater	N	I-Premise
3	proportion	N	I-Premise
4	of	N	I-Premise
5	patients	N	I-Premise
6	who	N	I-Premise
7	received	N	I-Premise
8	placebo	N	I-Premise
9	had	N	I-Premise
10	skeletal-related	N	I-Premise
11	events	N	I-Premise
12	than	N	I-Premise
13	those	N	I-Premise
14	who	N	I-Premise
15	received	N	I-Premise
16	zoledronic	N	I-Premise
17	acid	N	I-Premise
18	at	N	I-Premise
19	4	N	I-Premise
20	mg	N	I-Premise
21	(	N	I-Premise
22	44.2	N	I-Premise
23	%	N	I-Premise
24	versus	N	I-Premise
25	33.2	N	I-Premise
26	%	N	I-Premise
27	;	N	I-Premise
28	difference	N	I-Premise
29	=	N	I-Premise
30	-11.0	N	I-Premise
31	%	N	I-Premise
32	,	N	I-Premise
33	95	N	I-Premise
34	%	N	I-Premise
35	confidence	N	I-Premise
36	interval	N	I-Premise
37	[	N	I-Premise
38	CI	N	I-Premise
39	]	N	I-Premise
40	=	N	I-Premise
41	-20.3	N	I-Premise
42	%	N	I-Premise
43	to	N	I-Premise
44	-1.8	N	I-Premise
45	%	N	I-Premise
46	;	N	I-Premise
47	P	N	I-Premise
48	=.021	N	I-Premise
49	)	N	I-Premise
50	or	N	I-Premise
51	those	N	I-Premise
52	who	N	I-Premise
53	received	N	I-Premise
54	zoledronic	N	I-Premise
55	acid	N	I-Premise
56	at	N	I-Premise
57	8/4	N	I-Premise
58	mg	N	I-Premise
59	(	N	I-Premise
60	38.5	N	I-Premise
61	%	N	I-Premise
62	;	N	I-Premise
63	difference	N	I-Premise
64	versus	N	I-Premise
65	placebo	N	I-Premise
66	=	N	I-Premise
67	-5.8	N	I-Premise
68	%	N	I-Premise
69	,	N	I-Premise
70	95	N	I-Premise
71	%	N	I-Premise
72	CI	N	I-Premise
73	=	N	I-Premise
74	-15.1	N	I-Premise
75	%	N	I-Premise
76	to	N	I-Premise
77	3.6	N	I-Premise
78	%	N	I-Premise
79	;	N	I-Premise
80	P	N	I-Premise
81	=.222	N	I-Premise
82	)	N	I-Premise
83	.	N	I-Premise

1	Median	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	first	N	I-Premise
5	skeletal-related	N	I-Premise
6	event	N	I-Premise
7	was	N	I-Premise
8	321	N	I-Premise
9	days	N	I-Premise
10	for	N	I-Premise
11	patients	N	I-Premise
12	who	N	I-Premise
13	received	N	I-Premise
14	placebo	N	I-Premise
15	,	N	I-Premise
16	was	N	I-Premise
17	not	N	I-Premise
18	reached	N	I-Premise
19	for	N	I-Premise
20	patients	N	I-Premise
21	who	N	I-Premise
22	received	N	I-Premise
23	zoledronic	N	I-Premise
24	acid	N	I-Premise
25	at	N	I-Premise
26	4	N	I-Premise
27	mg	N	I-Premise
28	(	N	I-Premise
29	P	N	I-Premise
30	=.011	N	I-Premise
31	versus	N	I-Premise
32	placebo	N	I-Premise
33	)	N	I-Premise
34	,	N	I-Premise
35	and	N	I-Premise
36	was	N	I-Premise
37	363	N	I-Premise
38	days	N	I-Premise
39	for	N	I-Premise
40	those	N	I-Premise
41	who	N	I-Premise
42	received	N	I-Premise
43	zoledronic	N	I-Premise
44	acid	N	I-Premise
45	at	N	I-Premise
46	8/4	N	I-Premise
47	mg	N	I-Premise
48	(	N	I-Premise
49	P	N	I-Premise
50	=.491	N	I-Premise
51	versus	N	I-Premise
52	placebo	N	I-Premise
53	)	N	I-Premise
54	.	N	I-Premise

1	Compared	N	I-Premise
2	with	N	I-Premise
3	urinary	N	I-Premise
4	markers	N	I-Premise
5	in	N	I-Premise
6	patients	N	I-Premise
7	who	N	I-Premise
8	received	N	I-Premise
9	placebo	N	I-Premise
10	,	N	I-Premise
11	urinary	N	I-Premise
12	markers	N	I-Premise
13	of	N	I-Premise
14	bone	N	I-Premise
15	resorption	N	I-Premise
16	were	N	I-Premise
17	statistically	N	I-Premise
18	significantly	N	I-Premise
19	decreased	N	I-Premise
20	in	N	I-Premise
21	patients	N	I-Premise
22	who	N	I-Premise
23	received	N	I-Premise
24	zoledronic	N	I-Premise
25	acid	N	I-Premise
26	at	N	I-Premise
27	either	N	I-Premise
28	dose	N	I-Premise
29	(	N	I-Premise
30	P	N	I-Premise
31	=.001	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	Pain	N	I-Premise
2	and	N	I-Premise
3	analgesic	N	I-Premise
4	scores	N	I-Premise
5	increased	N	I-Premise
6	more	N	I-Premise
7	in	N	I-Premise
8	patients	N	I-Premise
9	who	N	I-Premise
10	received	N	I-Premise
11	placebo	N	I-Premise
12	than	N	I-Premise
13	in	N	I-Premise
14	patients	N	I-Premise
15	who	N	I-Premise
16	received	N	I-Premise
17	zoledronic	N	I-Premise
18	acid	N	I-Premise
19	,	N	I-Premise
20	but	N	O
21	there	N	I-Premise
22	were	N	I-Premise
23	no	N	I-Premise
24	differences	N	I-Premise
25	in	N	I-Premise
26	disease	N	I-Premise
27	progression	N	I-Premise
28	,	N	I-Premise
29	performance	N	I-Premise
30	status	N	I-Premise
31	,	N	I-Premise
32	or	N	I-Premise
33	quality-of-life	N	I-Premise
34	scores	N	I-Premise
35	among	N	I-Premise
36	the	N	I-Premise
37	groups	N	I-Premise
38	.	N	I-Premise

1	Zoledronic	N	I-Claim
2	acid	N	I-Claim
3	at	N	I-Claim
4	4	N	I-Claim
5	mg	N	I-Claim
6	given	N	I-Claim
7	as	N	I-Claim
8	a	N	I-Claim
9	15-minute	N	I-Claim
10	infusion	N	I-Claim
11	was	N	I-Claim
12	well	N	I-Claim
13	tolerated	N	I-Claim
14	,	N	I-Claim
15	but	N	O
16	the	N	I-Claim
17	8-mg	N	I-Claim
18	dose	N	I-Claim
19	was	N	I-Claim
20	associated	N	I-Claim
21	with	N	I-Claim
22	renal	N	I-Claim
23	function	N	I-Claim
24	deterioration	N	I-Claim
25	.	N	I-Claim

1	Zoledronic	N	I-Claim
2	acid	N	I-Claim
3	at	N	I-Claim
4	4	N	I-Claim
5	mg	N	I-Claim
6	reduced	N	I-Claim
7	skeletal-related	N	I-Claim
8	events	N	I-Claim
9	in	N	I-Claim
10	prostate	N	I-Claim
11	cancer	N	I-Claim
12	patients	N	I-Claim
13	with	N	I-Claim
14	bone	N	I-Claim
15	metastases	N	I-Claim
16	.	N	I-Claim

1	In	N	O
2	the	N	O
3	Asia-Pacific	N	O
4	region	N	O
5	and	N	O
6	elsewhere	N	O
7	,	N	O
8	almost	N	O
9	85	N	O
10	%	N	O
11	of	N	O
12	patients	N	O
13	with	N	O
14	hepatocellular	N	O
15	carcinoma	N	O
16	(	N	O
17	HCC	N	O
18	)	N	O
19	are	N	O
20	inoperable	N	O
21	at	N	O
22	diagnosis	N	O
23	and	N	O
24	have	N	O
25	a	N	O
26	dismal	N	O
27	prognosis	N	O
28	.	N	O

1	Tamoxifen	N	I-Claim
2	(	N	I-Claim
3	TMX	N	I-Claim
4	)	N	I-Claim
5	is	N	I-Claim
6	believed	N	I-Claim
7	to	N	I-Claim
8	inhibit	N	I-Claim
9	HCC	N	I-Claim
10	positive	N	I-Claim
11	for	N	I-Claim
12	estrogen	N	I-Claim
13	receptor	N	I-Claim
14	(	N	I-Claim
15	ER	N	I-Claim
16	)	N	I-Claim
17	,	N	I-Claim
18	but	N	I-Claim
19	most	N	I-Claim
20	HCCs	N	I-Claim
21	are	N	I-Claim
22	ER	N	I-Claim
23	negative	N	I-Claim
24	.	N	I-Claim

1	Results	N	I-Claim
2	of	N	I-Claim
3	previous	N	I-Claim
4	phase	N	I-Claim
5	3	N	I-Claim
6	trials	N	I-Claim
7	in	N	I-Claim
8	inoperable	N	I-Claim
9	HCC	N	I-Claim
10	have	N	I-Claim
11	been	N	I-Claim
12	conflicting	N	I-Claim
13	and	N	I-Claim
14	inconclusive	N	I-Claim
15	.	N	I-Claim

1	At	N	I-Claim
2	higher	N	I-Claim
3	doses	N	I-Claim
4	,	N	I-Claim
5	however	N	I-Claim
6	,	N	I-Claim
7	TMX	N	I-Claim
8	inhibits	N	I-Claim
9	HCC	N	I-Claim
10	through	N	I-Claim
11	ER-independent	N	I-Claim
12	mechanisms	N	I-Claim
13	.	N	I-Claim

1	A	N	O
2	multicenter	N	O
3	randomized	N	O
4	controlled	N	O
5	trial	N	O
6	was	N	O
7	performed	N	O
8	to	N	O
9	assess	N	O
10	the	N	O
11	role	N	O
12	of	N	O
13	high-dose	N	O
14	TMX	N	O
15	versus	N	O
16	placebo	N	O
17	(	N	O
18	P	N	O
19	)	N	O
20	in	N	O
21	the	N	O
22	treatment	N	O
23	of	N	O
24	patients	N	O
25	with	N	O
26	inoperable	N	O
27	HCC	N	O
28	with	N	O
29	respect	N	O
30	to	N	O
31	survival	N	O
32	and	N	O
33	quality	N	O
34	of	N	O
35	life	N	O
36	(	N	O
37	QoL	N	O
38	)	N	O
39	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	329	N	O
5	patients	N	O
6	from	N	O
7	10	N	O
8	centers	N	O
9	in	N	O
10	9	N	O
11	countries	N	O
12	in	N	O
13	the	N	O
14	Asia-Pacific	N	O
15	region	N	O
16	enrolled	N	O
17	in	N	O
18	a	N	O
19	double-blind	N	O
20	randomized	N	O
21	controlled	N	O
22	trial	N	O
23	of	N	O
24	TMX	N	O
25	120	N	O
26	mg/d	N	O
27	(	N	O
28	TMX120	N	O
29	)	N	O
30	against	N	O
31	P	N	O
32	as	N	O
33	a	N	O
34	control	N	O
35	arm	N	O
36	with	N	O
37	an	N	O
38	intermediate	N	O
39	dosage	N	O
40	of	N	O
41	TMX	N	O
42	60	N	O
43	mg/d	N	O
44	(	N	O
45	TMX60	N	O
46	)	N	O
47	to	N	O
48	assess	N	O
49	possible	N	O
50	dose	N	O
51	response	N	O
52	.	N	O

1	An	N	O
2	independent	N	O
3	data	N	O
4	monitoring	N	O
5	committee	N	O
6	reviewed	N	O
7	all	N	O
8	aspects	N	O
9	of	N	O
10	the	N	O
11	trial	N	O
12	.	N	O

1	QoL	N	O
2	was	N	O
3	assessed	N	O
4	using	N	O
5	the	N	O
6	European	N	O
7	Organization	N	O
8	for	N	O
9	Research	N	O
10	and	N	O
11	Treatment	N	O
12	of	N	O
13	Cancer	N	O
14	QLQ-C30	N	O
15	questionnaire	N	O
16	.	N	O

1	Three-month	N	I-Premise
2	survival	N	I-Premise
3	rates	N	I-Premise
4	for	N	I-Premise
5	the	N	I-Premise
6	P	N	I-Premise
7	,	N	I-Premise
8	TMX60	N	I-Premise
9	,	N	I-Premise
10	and	N	I-Premise
11	TMX120	N	I-Premise
12	groups	N	I-Premise
13	were	N	I-Premise
14	44	N	I-Premise
15	%	N	I-Premise
16	,	N	I-Premise
17	41	N	I-Premise
18	%	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	35	N	I-Premise
22	%	N	I-Premise
23	,	N	I-Premise
24	respectively	N	I-Premise
25	,	N	I-Premise
26	with	N	I-Premise
27	a	N	I-Premise
28	statistically	N	I-Premise
29	significant	N	I-Premise
30	trend	N	I-Premise
31	difference	N	I-Premise
32	in	N	I-Premise
33	survival	N	I-Premise
34	across	N	I-Premise
35	the	N	I-Premise
36	3	N	I-Premise
37	treatment	N	I-Premise
38	regimens	N	I-Premise
39	(	N	I-Premise
40	P	N	I-Premise
41	=.011	N	I-Premise
42	)	N	I-Premise
43	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significantly	N	I-Premise
5	higher	N	I-Premise
6	risk	N	I-Premise
7	of	N	I-Premise
8	death	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	TMX120	N	I-Premise
12	group	N	I-Premise
13	compared	N	I-Premise
14	with	N	I-Premise
15	the	N	I-Premise
16	P	N	I-Premise
17	group	N	I-Premise
18	(	N	I-Premise
19	hazard	N	I-Premise
20	ratio	N	I-Premise
21	,	N	I-Premise
22	1.39	N	I-Premise
23	;	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	confidence	N	I-Premise
27	interval	N	I-Premise
28	,	N	I-Premise
29	1.07-1.81	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	Adverse	N	I-Premise
2	drug	N	I-Premise
3	reactions	N	I-Premise
4	were	N	I-Premise
5	reported	N	I-Premise
6	in	N	I-Premise
7	3	N	I-Premise
8	%	N	I-Premise
9	(	N	I-Premise
10	9	N	I-Premise
11	patients	N	I-Premise
12	)	N	I-Premise
13	,	N	I-Premise
14	and	N	O
15	8	N	I-Premise
16	patients	N	I-Premise
17	were	N	I-Premise
18	lost	N	I-Premise
19	to	N	I-Premise
20	follow-up	N	I-Premise
21	.	N	I-Premise

1	In	N	O
2	conclusion	N	O
3	,	N	O
4	TMX	N	I-Claim
5	does	N	I-Claim
6	not	N	I-Claim
7	prolong	N	I-Claim
8	survival	N	I-Claim
9	in	N	I-Claim
10	patients	N	I-Claim
11	with	N	I-Claim
12	inoperable	N	I-Claim
13	HCC	N	I-Claim
14	and	N	I-Claim
15	has	N	I-Claim
16	an	N	I-Claim
17	increasingly	N	I-Claim
18	negative	N	I-Claim
19	impact	N	I-Claim
20	with	N	I-Claim
21	increasing	N	I-Claim
22	dose	N	I-Claim
23	.	N	I-Claim

1	No	N	I-Claim
2	appreciable	N	I-Claim
3	advantage	N	I-Claim
4	to	N	I-Claim
5	QoL	N	I-Claim
6	with	N	I-Claim
7	TMX	N	I-Claim
8	was	N	I-Claim
9	observed	N	I-Claim
10	.	N	I-Claim

1	Increased	N	I-Claim
2	expression	N	I-Claim
3	of	N	I-Claim
4	metalloproteinases	N	I-Claim
5	is	N	I-Claim
6	associated	N	I-Claim
7	with	N	I-Claim
8	poor	N	I-Claim
9	prognosis	N	I-Claim
10	in	N	I-Claim
11	small-cell	N	I-Claim
12	lung	N	I-Claim
13	cancer	N	I-Claim
14	(	N	I-Claim
15	SCLC	N	I-Claim
16	)	N	I-Claim
17	.	N	I-Claim

1	This	N	O
2	trial	N	O
3	was	N	O
4	undertaken	N	O
5	to	N	O
6	determine	N	O
7	whether	N	O
8	adjuvant	N	O
9	treatment	N	O
10	with	N	O
11	the	N	O
12	metalloproteinase	N	O
13	inhibitor	N	O
14	marimastat	N	O
15	could	N	O
16	prolong	N	O
17	survival	N	O
18	in	N	O
19	responding	N	O
20	patients	N	O
21	with	N	O
22	SCLC	N	O
23	after	N	O
24	chemotherapy	N	O
25	.	N	O

1	SCLC	N	O
2	patients	N	O
3	in	N	O
4	complete	N	O
5	or	N	O
6	partial	N	O
7	remission	N	O
8	were	N	O
9	eligible	N	O
10	.	N	O

1	They	N	O
2	were	N	O
3	stratified	N	O
4	by	N	O
5	radiotherapy	N	O
6	(	N	O
7	early	N	O
8	,	N	O
9	late	N	O
10	,	N	O
11	or	N	O
12	none	N	O
13	)	N	O
14	,	N	O
15	stage	N	O
16	(	N	O
17	extensive	N	O
18	or	N	O
19	limited	N	O
20	)	N	O
21	,	N	O
22	response	N	O
23	(	N	O
24	complete	N	O
25	or	N	O
26	partial	N	O
27	)	N	O
28	,	N	O
29	and	N	O
30	cooperative	N	O
31	group	N	O
32	(	N	O
33	National	N	O
34	Cancer	N	O
35	Institute	N	O
36	of	N	O
37	Canada-Clinical	N	O
38	Trials	N	O
39	Group	N	O
40	or	N	O
41	European	N	O
42	Organization	N	O
43	for	N	O
44	Research	N	O
45	and	N	O
46	Treatment	N	O
47	of	N	O
48	Cancer	N	O
49	)	N	O
50	.	N	O

1	They	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	receive	N	O
6	marimastat	N	O
7	10	N	O
8	mg	N	O
9	or	N	O
10	placebo	N	O
11	orally	N	O
12	bid	N	O
13	for	N	O
14	up	N	O
15	to	N	O
16	2	N	O
17	years	N	O
18	.	N	O

1	There	N	O
2	were	N	O
3	532	N	O
4	eligible	N	O
5	patients	N	O
6	(	N	O
7	266	N	O
8	marimastat	N	O
9	and	N	O
10	266	N	O
11	placebo	N	O
12	)	N	O
13	.	N	O

1	Stage	N	O
2	was	N	O
3	limited	N	O
4	for	N	O
5	279	N	O
6	patients	N	O
7	(	N	O
8	52	N	O
9	%	N	O
10	)	N	O
11	and	N	O
12	extensive	N	O
13	for	N	O
14	253	N	O
15	(	N	O
16	48	N	O
17	%	N	O
18	)	N	O
19	.	N	O

1	Best	N	I-Premise
2	response	N	I-Premise
3	to	N	I-Premise
4	induction	N	I-Premise
5	therapy	N	I-Premise
6	was	N	I-Premise
7	complete	N	I-Premise
8	remission	N	I-Premise
9	for	N	I-Premise
10	176	N	I-Premise
11	patients	N	I-Premise
12	(	N	I-Premise
13	33	N	I-Premise
14	%	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	partial	N	I-Premise
18	remission	N	I-Premise
19	for	N	I-Premise
20	341	N	I-Premise
21	(	N	I-Premise
22	64	N	I-Premise
23	%	N	I-Premise
24	)	N	I-Premise
25	,	N	I-Premise
26	and	N	I-Premise
27	15	N	I-Premise
28	patients	N	I-Premise
29	(	N	I-Premise
30	3	N	I-Premise
31	%	N	I-Premise
32	)	N	I-Premise
33	had	N	I-Premise
34	undergone	N	I-Premise
35	surgical	N	I-Premise
36	resection	N	I-Premise
37	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	time	N	I-Premise
4	to	N	I-Premise
5	progression	N	I-Premise
6	for	N	I-Premise
7	marimastat	N	I-Premise
8	patients	N	I-Premise
9	was	N	I-Premise
10	4.3	N	I-Premise
11	months	N	I-Premise
12	compared	N	I-Premise
13	with	N	I-Premise
14	4.4	N	I-Premise
15	months	N	I-Premise
16	for	N	I-Premise
17	placebo	N	I-Premise
18	patients	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=.81	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	Median	N	I-Premise
2	survivals	N	I-Premise
3	for	N	I-Premise
4	marimastat	N	I-Premise
5	and	N	I-Premise
6	placebo	N	I-Premise
7	patients	N	I-Premise
8	were	N	I-Premise
9	9.3	N	I-Premise
10	months	N	I-Premise
11	and	N	I-Premise
12	9.7	N	I-Premise
13	months	N	I-Premise
14	,	N	I-Premise
15	respectively	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	=.90	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	Toxicity	N	I-Premise
2	was	N	I-Premise
3	generally	N	I-Premise
4	limited	N	I-Premise
5	to	N	I-Premise
6	musculoskeletal	N	I-Premise
7	symptoms	N	I-Premise
8	(	N	I-Premise
9	18	N	I-Premise
10	%	N	I-Premise
11	grade	N	I-Premise
12	3/4	N	I-Premise
13	for	N	I-Premise
14	marimastat	N	I-Premise
15	)	N	I-Premise
16	.	N	I-Premise

1	Dose	N	I-Premise
2	modifications	N	I-Premise
3	for	N	I-Premise
4	musculoskeletal	N	I-Premise
5	toxicity	N	I-Premise
6	were	N	I-Premise
7	required	N	I-Premise
8	in	N	I-Premise
9	90	N	I-Premise
10	patients	N	I-Premise
11	(	N	I-Premise
12	33	N	I-Premise
13	%	N	I-Premise
14	)	N	I-Premise
15	on	N	I-Premise
16	the	N	I-Premise
17	marimastat	N	I-Premise
18	arm	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	87	N	I-Premise
22	(	N	I-Premise
23	32	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	permanently	N	I-Premise
27	stopped	N	I-Premise
28	marimastat	N	I-Premise
29	because	N	I-Premise
30	of	N	I-Premise
31	toxicity	N	I-Premise
32	.	N	I-Premise

1	Patients	N	I-Premise
2	on	N	I-Premise
3	marimastat	N	I-Premise
4	had	N	I-Premise
5	significantly	N	I-Premise
6	poorer	N	I-Premise
7	quality	N	I-Premise
8	of	N	I-Premise
9	life	N	I-Premise
10	at	N	I-Premise
11	3	N	I-Premise
12	and	N	I-Premise
13	6	N	I-Premise
14	months	N	I-Premise
15	.	N	I-Premise

1	Treatment	N	I-Claim
2	with	N	I-Claim
3	marimastat	N	I-Claim
4	after	N	I-Claim
5	induction	N	I-Claim
6	therapy	N	I-Claim
7	for	N	I-Claim
8	SCLC	N	I-Claim
9	did	N	I-Claim
10	not	N	I-Claim
11	result	N	I-Claim
12	in	N	I-Claim
13	improved	N	I-Claim
14	survival	N	I-Claim
15	and	N	I-Claim
16	had	N	I-Claim
17	a	N	I-Claim
18	negative	N	I-Claim
19	impact	N	I-Claim
20	on	N	I-Claim
21	quality	N	I-Claim
22	of	N	I-Claim
23	life	N	I-Claim
24	.	N	I-Claim

1	Morbidity	N	I-Claim
2	associated	N	I-Claim
3	with	N	I-Claim
4	wound	N	I-Claim
5	complications	N	I-Claim
6	may	N	I-Claim
7	translate	N	I-Claim
8	into	N	I-Claim
9	disability	N	I-Claim
10	and	N	I-Claim
11	quality-of-life	N	I-Claim
12	disadvantages	N	I-Claim
13	for	N	I-Claim
14	patients	N	I-Claim
15	treated	N	I-Claim
16	with	N	I-Claim
17	radiotherapy	N	I-Claim
18	(	N	I-Claim
19	RT	N	I-Claim
20	)	N	I-Claim
21	for	N	I-Claim
22	soft	N	I-Claim
23	tissue	N	I-Claim
24	sarcoma	N	I-Claim
25	(	N	I-Claim
26	STS	N	I-Claim
27	)	N	I-Claim
28	of	N	I-Claim
29	the	N	I-Claim
30	extremities	N	I-Claim
31	.	N	I-Claim

1	Functional	N	O
2	outcome	N	O
3	and	N	O
4	health	N	O
5	status	N	O
6	of	N	O
7	extremity	N	O
8	STS	N	O
9	patients	N	O
10	randomized	N	O
11	in	N	O
12	a	N	O
13	phase	N	O
14	III	N	O
15	trial	N	O
16	comparing	N	O
17	preoperative	N	O
18	versus	N	O
19	postoperative	N	O
20	RT	N	O
21	is	N	O
22	described	N	O
23	.	N	O

1	One	N	O
2	hundred	N	O
3	ninety	N	O
4	patients	N	O
5	with	N	O
6	extremity	N	O
7	STS	N	O
8	were	N	O
9	randomized	N	O
10	after	N	O
11	stratification	N	O
12	by	N	O
13	tumor	N	O
14	size	N	O
15	dichotomized	N	O
16	at	N	O
17	10	N	O
18	cm	N	O
19	.	N	O

1	Function	N	O
2	and	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	were	N	O
7	measured	N	O
8	by	N	O
9	the	N	O
10	Musculoskeletal	N	O
11	Tumor	N	O
12	Society	N	O
13	Rating	N	O
14	Scale	N	O
15	(	N	O
16	MSTS	N	O
17	)	N	O
18	,	N	O
19	the	N	O
20	Toronto	N	O
21	Extremity	N	O
22	Salvage	N	O
23	Score	N	O
24	(	N	O
25	TESS	N	O
26	)	N	O
27	,	N	O
28	and	N	O
29	the	N	O
30	Short	N	O
31	Form-36	N	O
32	(	N	O
33	SF-36	N	O
34	)	N	O
35	at	N	O
36	randomization	N	O
37	,	N	O
38	6	N	O
39	weeks	N	O
40	,	N	O
41	and	N	O
42	3	N	O
43	,	N	O
44	6	N	O
45	,	N	O
46	12	N	O
47	,	N	O
48	and	N	O
49	24	N	O
50	months	N	O
51	after	N	O
52	surgery	N	O
53	.	N	O

1	One	N	O
2	hundred	N	O
3	eighty-five	N	O
4	patients	N	O
5	had	N	O
6	function	N	O
7	data	N	O
8	.	N	O

1	Patients	N	I-Premise
2	treated	N	I-Premise
3	with	N	I-Premise
4	postoperative	N	I-Premise
5	RT	N	I-Premise
6	had	N	I-Premise
7	better	N	I-Premise
8	function	N	I-Premise
9	with	N	I-Premise
10	higher	N	I-Premise
11	MSTS	N	I-Premise
12	(	N	I-Premise
13	25.8	N	I-Premise
14	v	N	I-Premise
15	21.3	N	I-Premise
16	,	N	I-Premise
17	P	N	I-Premise
18	<	N	I-Premise
19	.01	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	TESS	N	I-Premise
23	(	N	I-Premise
24	69.8	N	I-Premise
25	v	N	I-Premise
26	60.6	N	I-Premise
27	,	N	I-Premise
28	P	N	I-Premise
29	=.01	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	and	N	I-Premise
33	SF-36	N	I-Premise
34	bodily	N	I-Premise
35	pain	N	I-Premise
36	(	N	I-Premise
37	67.7	N	I-Premise
38	v	N	I-Premise
39	58.5	N	I-Premise
40	,	N	I-Premise
41	P	N	I-Premise
42	=.03	N	I-Premise
43	)	N	I-Premise
44	scores	N	I-Premise
45	at	N	I-Premise
46	6	N	I-Premise
47	weeks	N	I-Premise
48	after	N	I-Premise
49	surgery	N	I-Premise
50	.	N	I-Premise

1	There	N	O
2	were	N	O
3	no	N	O
4	differences	N	O
5	at	N	O
6	later	N	O
7	time	N	O
8	points	N	O
9	.	N	O

1	Scores	N	I-Premise
2	on	N	I-Premise
3	the	N	I-Premise
4	physical	N	I-Premise
5	function	N	I-Premise
6	,	N	I-Premise
7	role-physical	N	I-Premise
8	,	N	I-Premise
9	and	N	I-Premise
10	general	N	I-Premise
11	health	N	I-Premise
12	subscales	N	I-Premise
13	of	N	I-Premise
14	the	N	I-Premise
15	SF-36	N	I-Premise
16	were	N	I-Premise
17	significantly	N	I-Premise
18	lower	N	I-Premise
19	than	N	I-Premise
20	Canadian	N	I-Premise
21	normative	N	I-Premise
22	data	N	I-Premise
23	at	N	I-Premise
24	all	N	I-Premise
25	time	N	I-Premise
26	points	N	I-Premise
27	.	N	I-Premise

1	After	N	O
2	treatment	N	O
3	arm	N	O
4	was	N	O
5	controlled	N	O
6	for	N	O
7	,	N	O
8	MSTS	N	O
9	change	N	O
10	scores	N	O
11	were	N	O
12	predicted	N	O
13	by	N	O
14	a	N	O
15	lower-extremity	N	O
16	tumor	N	O
17	,	N	O
18	a	N	O
19	large	N	O
20	resection	N	O
21	specimen	N	O
22	,	N	O
23	and	N	O
24	motor	N	O
25	nerve	N	O
26	sacrifice	N	O
27	;	N	O
28	TESS	N	O
29	change	N	O
30	scores	N	O
31	were	N	O
32	predicted	N	O
33	by	N	O
34	lower-extremity	N	O
35	tumor	N	O
36	and	N	O
37	prior	N	O
38	incomplete	N	O
39	excision	N	O
40	.	N	O

1	When	N	I-Premise
2	wound	N	I-Premise
3	complication	N	I-Premise
4	was	N	I-Premise
5	included	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	model	N	I-Premise
9	,	N	I-Premise
10	patients	N	I-Premise
11	with	N	I-Premise
12	complications	N	I-Premise
13	had	N	I-Premise
14	lower	N	I-Premise
15	MSTS	N	I-Premise
16	and	N	I-Premise
17	TESS	N	I-Premise
18	scores	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	first	N	I-Premise
22	2	N	I-Premise
23	years	N	I-Premise
24	after	N	I-Premise
25	treatment	N	I-Premise
26	.	N	I-Premise

1	The	N	I-Claim
2	timing	N	I-Claim
3	of	N	I-Claim
4	RT	N	I-Claim
5	has	N	I-Claim
6	minimal	N	I-Claim
7	impact	N	I-Claim
8	on	N	I-Claim
9	the	N	I-Claim
10	function	N	I-Claim
11	of	N	I-Claim
12	STS	N	I-Claim
13	patients	N	I-Claim
14	in	N	I-Claim
15	the	N	I-Claim
16	first	N	I-Claim
17	year	N	I-Claim
18	after	N	I-Claim
19	surgery	N	I-Claim
20	.	N	O

1	Tumor	N	I-Claim
2	characteristics	N	I-Claim
3	and	N	I-Claim
4	wound	N	I-Claim
5	complications	N	I-Claim
6	have	N	I-Claim
7	a	N	I-Claim
8	detrimental	N	I-Claim
9	effect	N	I-Claim
10	on	N	I-Claim
11	patient	N	I-Claim
12	function	N	I-Claim
13	.	N	I-Claim

1	The	N	O
2	standard	N	O
3	doublet	N	O
4	,	N	O
5	vinorelbine-cisplatin	N	O
6	,	N	O
7	was	N	O
8	compared	N	O
9	with	N	O
10	a	N	O
11	triplet	N	O
12	of	N	O
13	vinorelbine-ifosfamide-cisplatin	N	O
14	,	N	O
15	in	N	O
16	terms	N	O
17	of	N	O
18	survival	N	O
19	,	N	O
20	in	N	O
21	patients	N	O
22	with	N	O
23	advanced	N	O
24	non-small-cell	N	O
25	lung	N	O
26	cancer	N	O
27	(	N	O
28	NSCLC	N	O
29	)	N	O
30	.	N	O

1	From	N	O
2	February	N	O
3	1998	N	O
4	to	N	O
5	June	N	O
6	1999	N	O
7	,	N	O
8	259	N	O
9	chemonaïve	N	O
10	patients	N	O
11	entered	N	O
12	the	N	O
13	study	N	O
14	and	N	O
15	were	N	O
16	randomised	N	O
17	to	N	O
18	receive	N	O
19	either	N	O
20	vinorelbine-cisplatin	N	O
21	(	N	O
22	NP	N	O
23	;	N	O
24	vinorelbine	N	O
25	30	N	O
26	mg/m	N	O
27	(	N	O
28	2	N	O
29	)	N	O
30	on	N	O
31	days	N	O
32	1	N	O
33	,	N	O
34	8	N	O
35	and	N	O
36	15	N	O
37	with	N	O
38	cisplatin	N	O
39	80	N	O
40	mg/m	N	O
41	(	N	O
42	2	N	O
43	)	N	O
44	on	N	O
45	day	N	O
46	1	N	O
47	)	N	O
48	or	N	O
49	vinorelbine-ifosfamide-cisplatin	N	O
50	(	N	O
51	NIP	N	O
52	;	N	O
53	vinorelbine	N	O
54	25	N	O
55	mg/m	N	O
56	(	N	O
57	2	N	O
58	)	N	O
59	on	N	O
60	days	N	O
61	1	N	O
62	and	N	O
63	8	N	O
64	,	N	O
65	ifosfamide	N	O
66	3	N	O
67	g/m	N	O
68	(	N	O
69	2	N	O
70	)	N	O
71	on	N	O
72	day	N	O
73	1	N	O
74	and	N	O
75	cisplatin	N	O
76	75	N	O
77	mg/m	N	O
78	(	N	O
79	2	N	O
80	)	N	O
81	on	N	O
82	day	N	O
83	1	N	O
84	)	N	O
85	,	N	O
86	with	N	O
87	both	N	O
88	regimens	N	O
89	being	N	O
90	repeated	N	O
91	every	N	O
92	3	N	O
93	weeks	N	O
94	.	N	O

1	All	N	O
2	patients	N	O
3	had	N	O
4	stage	N	O
5	IV	N	O
6	or	N	O
7	relapsed	N	O
8	disease	N	O
9	and	N	O
10	a	N	O
11	performance	N	O
12	score	N	O
13	of	N	O
14	0	N	O
15	or	N	O
16	1	N	O
17	.	N	O

1	The	N	I-Premise
2	overall	N	I-Premise
3	response	N	I-Premise
4	rate	N	I-Premise
5	was	N	I-Premise
6	34.6	N	I-Premise
7	%	N	I-Premise
8	for	N	I-Premise
9	NP	N	I-Premise
10	and	N	I-Premise
11	35.7	N	I-Premise
12	%	N	I-Premise
13	for	N	I-Premise
14	NIP	N	I-Premise
15	.	N	I-Premise

1	Median	N	I-Premise
2	and	N	I-Premise
3	1-year	N	I-Premise
4	survival	N	I-Premise
5	rates	N	I-Premise
6	were	N	I-Premise
7	10.0	N	I-Premise
8	months	N	I-Premise
9	and	N	I-Premise
10	38.4	N	I-Premise
11	%	N	I-Premise
12	for	N	I-Premise
13	NP	N	I-Premise
14	,	N	I-Premise
15	and	N	I-Premise
16	8.2	N	I-Premise
17	months	N	I-Premise
18	and	N	I-Premise
19	33.7	N	I-Premise
20	%	N	I-Premise
21	for	N	I-Premise
22	NIP	N	I-Premise
23	,	N	I-Premise
24	respectively	N	I-Premise
25	.	N	I-Premise

1	A	N	O
2	median	N	O
3	of	N	O
4	four	N	O
5	cycles	N	O
6	was	N	O
7	administered	N	O
8	in	N	O
9	each	N	O
10	arm	N	O
11	.	N	O

1	The	N	I-Premise
2	major	N	I-Premise
3	World	N	I-Premise
4	Health	N	I-Premise
5	Organization	N	I-Premise
6	grade	N	I-Premise
7	3-4	N	I-Premise
8	toxicities	N	I-Premise
9	for	N	I-Premise
10	NP	N	I-Premise
11	and	N	I-Premise
12	NIP	N	I-Premise
13	,	N	I-Premise
14	respectively	N	I-Premise
15	,	N	I-Premise
16	were	N	I-Premise
17	:	N	I-Premise
18	neutropenia	N	I-Premise
19	(	N	I-Premise
20	20.3	N	I-Premise
21	%	N	I-Premise
22	compared	N	I-Premise
23	with	N	I-Premise
24	9	N	I-Premise
25	%	N	I-Premise
26	of	N	I-Premise
27	cycles	N	I-Premise
28	)	N	I-Premise
29	,	N	I-Premise
30	anaemia	N	I-Premise
31	(	N	I-Premise
32	4.1	N	I-Premise
33	%	N	I-Premise
34	compared	N	I-Premise
35	with	N	I-Premise
36	5	N	I-Premise
37	%	N	I-Premise
38	of	N	I-Premise
39	cycles	N	I-Premise
40	)	N	I-Premise
41	,	N	I-Premise
42	nausea	N	I-Premise
43	and	N	I-Premise
44	vomiting	N	I-Premise
45	(	N	I-Premise
46	22.2	N	I-Premise
47	%	N	I-Premise
48	compared	N	I-Premise
49	with	N	I-Premise
50	19.4	N	I-Premise
51	%	N	I-Premise
52	of	N	I-Premise
53	patients	N	I-Premise
54	)	N	I-Premise
55	and	N	I-Premise
56	alopecia	N	I-Premise
57	(	N	I-Premise
58	5.6	N	I-Premise
59	%	N	I-Premise
60	compared	N	I-Premise
61	with	N	I-Premise
62	29.8	N	I-Premise
63	%	N	I-Premise
64	of	N	I-Premise
65	patients	N	I-Premise
66	)	N	I-Premise
67	.	N	I-Premise

1	Four	N	I-Premise
2	toxic	N	I-Premise
3	deaths	N	I-Premise
4	occurred	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	NP	N	I-Premise
8	arm	N	I-Premise
9	and	N	I-Premise
10	eight	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	NIP	N	I-Premise
14	arm	N	I-Premise
15	.	N	I-Premise

1	The	N	I-Premise
2	different	N	I-Premise
3	schedules	N	I-Premise
4	of	N	I-Premise
5	vinorelbine	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	two	N	I-Premise
9	arms	N	I-Premise
10	led	N	I-Premise
11	to	N	I-Premise
12	a	N	I-Premise
13	greater	N	I-Premise
14	survival	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	NP	N	I-Premise
18	arm	N	I-Premise
19	without	N	I-Premise
20	impairing	N	I-Premise
21	the	N	I-Premise
22	tolerance	N	I-Premise
23	profile	N	I-Premise
24	,	N	I-Premise
25	although	N	I-Premise
26	this	N	I-Premise
27	is	N	I-Premise
28	not	N	I-Premise
29	statistically	N	I-Premise
30	significant	N	I-Premise
31	.	N	I-Premise

1	This	N	I-Claim
2	confirms	N	I-Claim
3	that	N	I-Claim
4	the	N	I-Claim
5	two-drug	N	I-Claim
6	combination	N	I-Claim
7	NP	N	I-Claim
8	is	N	I-Claim
9	a	N	I-Claim
10	reference	N	I-Claim
11	treatment	N	I-Claim
12	for	N	I-Claim
13	metastatic	N	I-Claim
14	NSCLC	N	I-Claim
15	.	N	I-Claim

1	The	N	I-Claim
2	role	N	I-Claim
3	of	N	I-Claim
4	three-drug	N	I-Claim
5	combinations	N	I-Claim
6	remains	N	I-Claim
7	questionable	N	I-Claim
8	in	N	I-Claim
9	this	N	I-Claim
10	subset	N	I-Claim
11	of	N	I-Claim
12	patients	N	I-Claim
13	.	N	I-Claim

1	A	N	O
2	multicenter	N	O
3	trial	N	O
4	was	N	O
5	conducted	N	O
6	to	N	O
7	determine	N	O
8	the	N	O
9	efficacy	N	O
10	and	N	O
11	toxicity	N	O
12	of	N	O
13	escalating	N	O
14	dosages	N	O
15	of	N	O
16	liposomal	N	O
17	tretinoin	N	O
18	(	N	O
19	all-trans-retinoic	N	O
20	acid	N	O
21	)	N	O
22	administered	N	O
23	once	N	O
24	or	N	O
25	three	N	O
26	times	N	O
27	weekly	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	acquired	N	O
32	immunodeficiency	N	O
33	syndrome	N	O
34	(	N	O
35	AIDS	N	O
36	)	N	O
37	-associated	N	O
38	Kaposi	N	O
39	sarcoma	N	O
40	.	N	O

1	Seventy-six	N	O
2	patients	N	O
3	with	N	O
4	acquired	N	O
5	immunodeficiency	N	O
6	syndrome	N	O
7	(	N	O
8	AIDS	N	O
9	)	N	O
10	-associated	N	O
11	Kaposi	N	O
12	sarcoma	N	O
13	were	N	O
14	randomized	N	O
15	to	N	O
16	receive	N	O
17	the	N	O
18	study	N	O
19	drug	N	O
20	either	N	O
21	once	N	O
22	(	N	O
23	n	N	O
24	=	N	O
25	30	N	O
26	)	N	O
27	or	N	O
28	3	N	O
29	times	N	O
30	weekly	N	O
31	(	N	O
32	n	N	O
33	=	N	O
34	46	N	O
35	)	N	O
36	.	N	O

1	The	N	O
2	starting	N	O
3	dosage	N	O
4	was	N	O
5	60	N	O
6	mg/m	N	O
7	(	N	O
8	2	N	O
9	)	N	O
10	,	N	O
11	which	N	O
12	was	N	O
13	escalated	N	O
14	to	N	O
15	90	N	O
16	mg/m	N	O
17	(	N	O
18	2	N	O
19	)	N	O
20	and	N	O
21	then	N	O
22	120	N	O
23	mg/m	N	O
24	(	N	O
25	2	N	O
26	)	N	O
27	if	N	O
28	the	N	O
29	drug	N	O
30	was	N	O
31	well	N	O
32	tolerated	N	O
33	(	N	O
34	<	N	O
35	or=	N	O
36	Grade	N	O
37	2	N	O
38	toxicities	N	O
39	[	N	O
40	according	N	O
41	to	N	O
42	the	N	O
43	Southwest	N	O
44	Oncology	N	O
45	Group	N	O
46	toxicity	N	O
47	scale	N	O
48	]	N	O
49	)	N	O
50	.	N	O

1	Four	N	O
2	weeks	N	O
3	of	N	O
4	therapy	N	O
5	constituted	N	O
6	1	N	O
7	cycle	N	O
8	;	N	O
9	patients	N	O
10	could	N	O
11	receive	N	O
12	up	N	O
13	to	N	O
14	8	N	O
15	cycles	N	O
16	and	N	O
17	those	N	O
18	who	N	O
19	completed	N	O
20	8	N	O
21	cycles	N	O
22	were	N	O
23	given	N	O
24	the	N	O
25	option	N	O
26	of	N	O
27	receiving	N	O
28	extended	N	O
29	therapy	N	O
30	.	N	O

1	Clinical	N	O
2	response	N	O
3	was	N	O
4	defined	N	O
5	as	N	O
6	complete	N	O
7	response	N	O
8	(	N	O
9	CR	N	O
10	)	N	O
11	,	N	O
12	partial	N	O
13	response	N	O
14	(	N	O
15	PR	N	O
16	)	N	O
17	,	N	O
18	or	N	O
19	stable	N	O
20	disease	N	O
21	(	N	O
22	SD	N	O
23	)	N	O
24	.	N	O

1	Efficacy	N	O
2	was	N	O
3	assessed	N	O
4	after	N	O
5	the	N	O
6	completion	N	O
7	of	N	O
8	3	N	O
9	treatment	N	O
10	cycles	N	O
11	;	N	O
12	28.9	N	O
13	%	N	O
14	of	N	O
15	patients	N	O
16	(	N	O
17	22	N	O
18	of	N	O
19	76	N	O
20	patients	N	O
21	)	N	O
22	responded	N	O
23	(	N	O
24	no	N	O
25	CRs	N	O
26	,	N	O
27	1	N	O
28	PR	N	O
29	,	N	O
30	and	N	O
31	21	N	O
32	SDs	N	O
33	)	N	O
34	.	N	O

1	Among	N	I-Premise
2	the	N	I-Premise
3	patients	N	I-Premise
4	receiving	N	I-Premise
5	treatment	N	I-Premise
6	3	N	I-Premise
7	times	N	I-Premise
8	weekly	N	I-Premise
9	,	N	I-Premise
10	16	N	I-Premise
11	of	N	I-Premise
12	49	N	I-Premise
13	patients	N	I-Premise
14	(	N	I-Premise
15	32.7	N	I-Premise
16	%	N	I-Premise
17	)	N	I-Premise
18	achieved	N	I-Premise
19	a	N	I-Premise
20	clinical	N	I-Premise
21	response	N	I-Premise
22	at	N	I-Premise
23	the	N	I-Premise
24	end	N	I-Premise
25	of	N	I-Premise
26	the	N	I-Premise
27	third	N	I-Premise
28	treatment	N	I-Premise
29	cycle	N	I-Premise
30	(	N	I-Premise
31	no	N	I-Premise
32	CRs	N	I-Premise
33	,	N	I-Premise
34	1	N	I-Premise
35	PR	N	I-Premise
36	,	N	I-Premise
37	and	N	I-Premise
38	15	N	I-Premise
39	SDs	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	Concomitant	N	I-Premise
2	or	N	I-Premise
3	prior	N	I-Premise
4	use	N	I-Premise
5	of	N	I-Premise
6	protease	N	I-Premise
7	inhibitors	N	I-Premise
8	did	N	I-Premise
9	not	N	I-Premise
10	appear	N	I-Premise
11	to	N	I-Premise
12	affect	N	I-Premise
13	the	N	I-Premise
14	patient	N	I-Premise
15	's	N	I-Premise
16	response	N	I-Premise
17	to	N	I-Premise
18	treatment	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	0.183	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Liposomal	N	I-Premise
2	tretinoin	N	I-Premise
3	is	N	I-Premise
4	a	N	I-Premise
5	new	N	I-Premise
6	therapeutic	N	I-Premise
7	agent	N	I-Premise
8	that	N	I-Premise
9	has	N	I-Premise
10	been	N	I-Premise
11	reported	N	I-Premise
12	to	N	I-Premise
13	have	N	I-Premise
14	some	N	I-Premise
15	clinical	N	I-Premise
16	activity	N	I-Premise
17	in	N	I-Premise
18	patients	N	I-Premise
19	with	N	I-Premise
20	AIDS-associated	N	I-Premise
21	Kaposi	N	I-Premise
22	sarcoma	N	I-Premise
23	.	N	I-Premise

1	A	N	I-Claim
2	three-times-per-week	N	I-Claim
3	dosing	N	I-Claim
4	schedule	N	I-Claim
5	was	N	I-Claim
6	noted	N	I-Claim
7	to	N	I-Claim
8	be	N	I-Claim
9	more	N	I-Claim
10	effective	N	I-Claim
11	compared	N	I-Claim
12	with	N	I-Claim
13	a	N	I-Claim
14	once-a-week	N	I-Claim
15	schedule	N	I-Claim
16	without	N	I-Claim
17	any	N	I-Claim
18	significant	N	I-Claim
19	difference	N	I-Claim
20	in	N	I-Claim
21	toxicity	N	I-Claim
22	reported	N	I-Claim
23	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	in	N	O
4	a	N	O
5	phase	N	O
6	III	N	O
7	study	N	O
8	the	N	O
9	safety	N	O
10	and	N	O
11	efficacy	N	O
12	of	N	O
13	fludarabine	N	O
14	to	N	O
15	that	N	O
16	of	N	O
17	cyclophosphamide	N	O
18	,	N	O
19	vincristine	N	O
20	,	N	O
21	and	N	O
22	prednisone	N	O
23	(	N	O
24	CVP	N	O
25	)	N	O
26	in	N	O
27	recurrent	N	O
28	,	N	O
29	low-grade	N	O
30	,	N	O
31	non-Hodgkin	N	O
32	's	N	O
33	lymphoma	N	O
34	after	N	O
35	previous	N	O
36	response	N	O
37	to	N	O
38	systemic	N	O
39	treatment	N	O
40	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	fludarabine	N	O
6	(	N	O
7	25	N	O
8	mg/m	N	O
9	(	N	O
10	2	N	O
11	)	N	O
12	intravenously	N	O
13	on	N	O
14	days	N	O
15	1	N	O
16	to	N	O
17	5	N	O
18	,	N	O
19	every	N	O
20	28	N	O
21	days	N	O
22	)	N	O
23	or	N	O
24	CVP	N	O
25	(	N	O
26	cyclophosphamide	N	O
27	750	N	O
28	mg/m	N	O
29	(	N	O
30	2	N	O
31	)	N	O
32	and	N	O
33	vincristine	N	O
34	1.2	N	O
35	mg/m	N	O
36	(	N	O
37	2	N	O
38	)	N	O
39	both	N	O
40	intravenously	N	O
41	on	N	O
42	day	N	O
43	1	N	O
44	and	N	O
45	prednisone	N	O
46	40	N	O
47	mg/m	N	O
48	(	N	O
49	2	N	O
50	)	N	O
51	orally	N	O
52	on	N	O
53	days	N	O
54	1	N	O
55	to	N	O
56	5	N	O
57	,	N	O
58	every	N	O
59	21	N	O
60	days	N	O
61	)	N	O
62	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	assessed	N	O
5	was	N	O
6	progression-free	N	O
7	survival	N	O
8	(	N	O
9	PFS	N	O
10	)	N	O
11	;	N	O
12	secondary	N	O
13	outcomes	N	O
14	included	N	O
15	treatment-free	N	O
16	survival	N	O
17	(	N	O
18	TFS	N	O
19	)	N	O
20	,	N	O
21	overall	N	O
22	survival	N	O
23	(	N	O
24	OS	N	O
25	)	N	O
26	,	N	O
27	treatment-related	N	O
28	toxicity	N	O
29	,	N	O
30	and	N	O
31	quality	N	O
32	of	N	O
33	life	N	O
34	(	N	O
35	QoL	N	O
36	)	N	O
37	according	N	O
38	to	N	O
39	the	N	O
40	European	N	O
41	Organization	N	O
42	for	N	O
43	Research	N	O
44	and	N	O
45	Treatment	N	O
46	of	N	O
47	Cancer	N	O
48	's	N	O
49	Quality	N	O
50	of	N	O
51	Life	N	O
52	Questionnaire	N	O
53	C-30	N	O
54	version	N	O
55	1.0	N	O
56	instrument	N	O
57	.	N	O

1	Ninety-one	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	,	N	O
6	47	N	O
7	to	N	O
8	fludarabine	N	O
9	and	N	O
10	44	N	O
11	to	N	O
12	CVP	N	O
13	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	response	N	I-Premise
7	rates	N	I-Premise
8	,	N	I-Premise
9	with	N	I-Premise
10	64	N	I-Premise
11	%	N	I-Premise
12	(	N	I-Premise
13	complete	N	I-Premise
14	response	N	I-Premise
15	[	N	I-Premise
16	CR	N	I-Premise
17	]	N	I-Premise
18	,	N	I-Premise
19	9	N	I-Premise
20	%	N	I-Premise
21	)	N	I-Premise
22	for	N	I-Premise
23	fludarabine	N	I-Premise
24	versus	N	I-Premise
25	52	N	I-Premise
26	%	N	I-Premise
27	(	N	I-Premise
28	CR	N	I-Premise
29	,	N	I-Premise
30	7	N	I-Premise
31	%	N	I-Premise
32	)	N	I-Premise
33	for	N	I-Premise
34	CVP	N	I-Premise
35	(	N	I-Premise
36	P	N	I-Premise
37	=.72	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	With	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	42	N	I-Premise
7	months	N	I-Premise
8	,	N	I-Premise
9	median	N	I-Premise
10	PFS	N	I-Premise
11	(	N	I-Premise
12	11	N	I-Premise
13	months	N	I-Premise
14	v	N	I-Premise
15	9.1	N	I-Premise
16	months	N	I-Premise
17	;	N	I-Premise
18	P	N	I-Premise
19	=.03	N	I-Premise
20	)	N	I-Premise
21	and	N	I-Premise
22	TFS	N	I-Premise
23	(	N	I-Premise
24	15	N	I-Premise
25	months	N	I-Premise
26	v	N	I-Premise
27	11	N	I-Premise
28	months	N	I-Premise
29	;	N	I-Premise
30	P	N	I-Premise
31	=.02	N	I-Premise
32	)	N	I-Premise
33	were	N	I-Premise
34	superior	N	I-Premise
35	in	N	I-Premise
36	patients	N	I-Premise
37	receiving	N	I-Premise
38	fludarabine	N	I-Premise
39	.	N	I-Premise

1	No	N	I-Premise
2	difference	N	I-Premise
3	in	N	I-Premise
4	median	N	I-Premise
5	overall	N	I-Premise
6	survival	N	I-Premise
7	was	N	I-Premise
8	detected	N	I-Premise
9	(	N	I-Premise
10	57	N	I-Premise
11	months	N	I-Premise
12	for	N	I-Premise
13	fludarabine	N	I-Premise
14	v	N	I-Premise
15	44	N	I-Premise
16	months	N	I-Premise
17	for	N	I-Premise
18	CVP	N	I-Premise
19	;	N	I-Premise
20	P	N	I-Premise
21	=.95	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	Three	N	I-Premise
2	patients	N	I-Premise
3	receiving	N	I-Premise
4	fludarabine	N	I-Premise
5	died	N	I-Premise
6	of	N	I-Premise
7	treatment-related	N	I-Premise
8	toxicity	N	I-Premise
9	compared	N	I-Premise
10	with	N	I-Premise
11	none	N	I-Premise
12	of	N	I-Premise
13	the	N	I-Premise
14	patients	N	I-Premise
15	receiving	N	I-Premise
16	CVP	N	I-Premise
17	.	N	I-Premise

1	Peripheral	N	I-Premise
2	neuropathy	N	I-Premise
3	and	N	I-Premise
4	alopecia	N	I-Premise
5	were	N	I-Premise
6	more	N	I-Premise
7	common	N	I-Premise
8	with	N	I-Premise
9	CVP	N	I-Premise
10	.	N	I-Premise

1	Patients	N	I-Premise
2	receiving	N	I-Premise
3	fludarabine	N	I-Premise
4	had	N	I-Premise
5	higher	N	I-Premise
6	scores	N	I-Premise
7	for	N	I-Premise
8	social	N	I-Premise
9	function	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	=.008	N	I-Premise
13	)	N	I-Premise
14	;	N	I-Premise
15	no	N	I-Premise
16	other	N	I-Premise
17	differences	N	I-Premise
18	in	N	I-Premise
19	QoL	N	I-Premise
20	were	N	I-Premise
21	detected	N	I-Premise
22	.	N	I-Premise

1	In	N	I-Claim
2	recurrent	N	I-Claim
3	low-grade	N	I-Claim
4	lymphoma	N	I-Claim
5	,	N	I-Claim
6	fludarabine	N	I-Claim
7	improves	N	I-Claim
8	PFS	N	I-Claim
9	,	N	I-Claim
10	TFS	N	I-Claim
11	,	N	I-Claim
12	and	N	I-Claim
13	social	N	I-Claim
14	function	N	I-Claim
15	scores	N	I-Claim
16	in	N	I-Claim
17	comparison	N	I-Claim
18	with	N	I-Claim
19	CVP	N	I-Claim
20	but	N	I-Claim
21	does	N	I-Claim
22	not	N	I-Claim
23	improve	N	I-Claim
24	OS	N	I-Claim
25	.	N	I-Claim

1	Anemia	N	I-Claim
2	,	N	I-Claim
3	highly	N	I-Claim
4	common	N	I-Claim
5	among	N	I-Claim
6	cancer	N	I-Claim
7	patients	N	I-Claim
8	,	N	I-Claim
9	is	N	I-Claim
10	often	N	I-Claim
11	an	N	I-Claim
12	underlying	N	I-Claim
13	cause	N	I-Claim
14	of	N	I-Claim
15	cancer-related	N	I-Claim
16	fatigue	N	I-Claim
17	and	N	I-Claim
18	other	N	I-Claim
19	quality-of-life	N	I-Claim
20	(	N	I-Claim
21	QOL	N	I-Claim
22	)	N	I-Claim
23	deficits	N	I-Claim
24	.	N	I-Claim

1	Although	N	O
2	randomized	N	O
3	clinical	N	O
4	trials	N	O
5	have	N	O
6	shown	N	O
7	that	N	O
8	treatment	N	O
9	with	N	O
10	epoetin	N	O
11	alfa	N	O
12	increases	N	O
13	hemoglobin	N	O
14	levels	N	O
15	,	N	O
16	reduces	N	O
17	fatigue	N	O
18	,	N	O
19	lessens	N	O
20	transfusion	N	O
21	requirements	N	O
22	,	N	O
23	and	N	O
24	improves	N	O
25	overall	N	O
26	QOL	N	O
27	,	N	O
28	cancer-related	N	O
29	anemia	N	O
30	and	N	O
31	fatigue	N	O
32	remain	N	O
33	undertreated	N	O
34	.	N	O

1	This	N	O
2	is	N	O
3	,	N	O
4	in	N	O
5	part	N	O
6	,	N	O
7	because	N	O
8	scales	N	O
9	and	N	O
10	measures	N	O
11	of	N	O
12	QOL	N	O
13	are	N	O
14	still	N	O
15	relatively	N	O
16	unfamiliar	N	O
17	to	N	O
18	most	N	O
19	clinicians	N	O
20	and	N	O
21	because	N	O
22	population-based	N	O
23	reference	N	O
24	ranges	N	O
25	are	N	O
26	lacking	N	O
27	,	N	O
28	thus	N	O
29	making	N	O
30	clinical	N	O
31	trial	N	O
32	results	N	O
33	difficult	N	O
34	to	N	O
35	interpret	N	O
36	.	N	O

1	To	N	O
2	aid	N	O
3	in	N	O
4	the	N	O
5	interpretation	N	O
6	of	N	O
7	QOL	N	O
8	results	N	O
9	from	N	O
10	clinical	N	O
11	trials	N	O
12	,	N	O
13	we	N	O
14	administered	N	O
15	the	N	O
16	Functional	N	O
17	Assessment	N	O
18	of	N	O
19	Cancer	N	O
20	Therapy-Anemia	N	O
21	(	N	O
22	FACT-An	N	O
23	)	N	O
24	QOL	N	O
25	instrument	N	O
26	to	N	O
27	a	N	O
28	nationally	N	O
29	representative	N	O
30	sample	N	O
31	of	N	O
32	1,400	N	O
33	people	N	O
34	using	N	O
35	an	N	O
36	Internet	N	O
37	survey	N	O
38	panel	N	O
39	in	N	O
40	the	N	O
41	United	N	O
42	States	N	O
43	.	N	O

1	We	N	O
2	then	N	O
3	compared	N	O
4	the	N	O
5	FACT-An	N	O
6	data	N	O
7	from	N	O
8	the	N	O
9	Internet	N	O
10	survey	N	O
11	with	N	O
12	the	N	O
13	QOL	N	O
14	data	N	O
15	of	N	O
16	a	N	O
17	375-patient	N	O
18	randomized	N	O
19	,	N	O
20	double-blind	N	O
21	clinical	N	O
22	trial	N	O
23	evaluating	N	O
24	epoetin	N	O
25	alfa	N	O
26	versus	N	O
27	placebo	N	O
28	in	N	O
29	anemic	N	O
30	cancer	N	O
31	patients	N	O
32	.	N	O

1	FACT-An	N	O
2	,	N	O
3	as	N	O
4	administered	N	O
5	to	N	O
6	the	N	O
7	survey	N	O
8	population	N	O
9	,	N	O
10	displayed	N	O
11	good	N	O
12	psychometric	N	O
13	properties	N	O
14	and	N	O
15	was	N	O
16	able	N	O
17	to	N	O
18	discriminate	N	O
19	between	N	O
20	respondents	N	O
21	with	N	O
22	histories	N	O
23	of	N	O
24	specified	N	O
25	illnesses	N	O
26	,	N	O
27	including	N	O
28	anemia	N	O
29	and	N	O
30	cancer	N	O
31	,	N	O
32	and	N	O
33	those	N	O
34	without	N	O
35	.	N	O

1	Comparison	N	I-Premise
2	of	N	I-Premise
3	the	N	I-Premise
4	population	N	I-Premise
5	norm	N	I-Premise
6	and	N	I-Premise
7	clinical	N	I-Premise
8	trial	N	I-Premise
9	data	N	I-Premise
10	showed	N	I-Premise
11	that	N	I-Premise
12	treatment	N	I-Premise
13	with	N	I-Premise
14	epoetin	N	I-Premise
15	alfa	N	I-Premise
16	resulted	N	I-Premise
17	in	N	I-Premise
18	clinically	N	I-Premise
19	meaningful	N	I-Premise
20	as	N	I-Premise
21	well	N	I-Premise
22	as	N	I-Premise
23	statistically	N	I-Premise
24	significant	N	I-Premise
25	improvements	N	I-Premise
26	in	N	I-Premise
27	QOL	N	I-Premise
28	(	N	I-Premise
29	P	N	I-Premise
30	<	N	I-Premise
31	.01	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	Reliable	N	O
2	population	N	O
3	norm	N	O
4	data	N	O
5	are	N	O
6	now	N	O
7	available	N	O
8	to	N	O
9	aid	N	O
10	in	N	O
11	the	N	O
12	interpretation	N	O
13	of	N	O
14	clinical	N	O
15	trial	N	O
16	results	N	O
17	where	N	O
18	the	N	O
19	FACT-An	N	O
20	questionnaire	N	O
21	is	N	O
22	administered	N	O
23	.	N	O

1	In	N	I-Claim
2	the	N	I-Claim
3	clinical	N	I-Claim
4	trial	N	I-Claim
5	,	N	I-Claim
6	treatment	N	I-Claim
7	with	N	I-Claim
8	epoetin	N	I-Claim
9	alfa	N	I-Claim
10	overcame	N	I-Claim
11	much	N	I-Claim
12	of	N	I-Claim
13	the	N	I-Claim
14	QOL	N	I-Claim
15	deficit	N	I-Claim
16	seen	N	I-Claim
17	in	N	I-Claim
18	anemic	N	I-Claim
19	cancer	N	I-Claim
20	patients	N	I-Claim
21	compared	N	I-Claim
22	with	N	I-Claim
23	the	N	I-Claim
24	norm	N	I-Claim
25	population	N	I-Claim
26	sample	N	I-Claim
27	.	N	I-Claim

1	To	N	O
2	examine	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	a	N	O
7	progressive	N	O
8	upper-body	N	O
9	exercise	N	O
10	program	N	O
11	on	N	O
12	lymphedema	N	O
13	secondary	N	O
14	to	N	O
15	breast	N	O
16	cancer	N	O
17	treatment	N	O
18	.	N	O

1	Fourteen	N	O
2	breast	N	O
3	cancer	N	O
4	survivors	N	O
5	with	N	O
6	unilateral	N	O
7	upper	N	O
8	extremity	N	O
9	lymphedema	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	to	N	O
14	an	N	O
15	exercise	N	O
16	(	N	O
17	n	N	O
18	=	N	O
19	7	N	O
20	)	N	O
21	or	N	O
22	control	N	O
23	group	N	O
24	(	N	O
25	n	N	O
26	=	N	O
27	7	N	O
28	)	N	O
29	.	N	O

1	The	N	O
2	exercise	N	O
3	group	N	O
4	followed	N	O
5	a	N	O
6	progressive	N	O
7	,	N	O
8	8-week	N	O
9	upper-body	N	O
10	exercise	N	O
11	program	N	O
12	consisting	N	O
13	of	N	O
14	resistance	N	O
15	training	N	O
16	plus	N	O
17	aerobic	N	O
18	exercise	N	O
19	using	N	O
20	a	N	O
21	Monark	N	O
22	Rehab	N	O
23	Trainer	N	O
24	arm	N	O
25	ergometer	N	O
26	.	N	O

1	Lymphedema	N	O
2	was	N	O
3	assessed	N	O
4	by	N	O
5	arm	N	O
6	circumference	N	O
7	and	N	O
8	measurement	N	O
9	of	N	O
10	arm	N	O
11	volume	N	O
12	by	N	O
13	water	N	O
14	displacement	N	O
15	.	N	O

1	Patients	N	O
2	were	N	O
3	evaluated	N	O
4	on	N	O
5	five	N	O
6	occasions	N	O
7	over	N	O
8	the	N	O
9	experimental	N	O
10	period	N	O
11	.	N	O

1	The	N	O
2	Medical	N	O
3	Outcomes	N	O
4	Trust	N	O
5	Short-Form	N	O
6	36	N	O
7	Survey	N	O
8	was	N	O
9	used	N	O
10	to	N	O
11	measure	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	before	N	O
16	and	N	O
17	after	N	O
18	the	N	O
19	intervention	N	O
20	.	N	O

1	Significance	N	O
2	was	N	O
3	set	N	O
4	at	N	O
5	alpha	N	O
6	<	N	O
7	or	N	O
8	=	N	O
9	0.01	N	O
10	.	N	O

1	No	N	I-Premise
2	changes	N	I-Premise
3	were	N	I-Premise
4	found	N	I-Premise
5	in	N	I-Premise
6	arm	N	I-Premise
7	circumference	N	I-Premise
8	or	N	I-Premise
9	arm	N	I-Premise
10	volume	N	I-Premise
11	as	N	I-Premise
12	a	N	I-Premise
13	result	N	I-Premise
14	of	N	I-Premise
15	the	N	I-Premise
16	exercise	N	I-Premise
17	program	N	I-Premise
18	.	N	I-Premise

1	Three	N	I-Premise
2	of	N	I-Premise
3	the	N	I-Premise
4	quality-of-life	N	I-Premise
5	domains	N	I-Premise
6	showed	N	I-Premise
7	trends	N	I-Premise
8	toward	N	I-Premise
9	increases	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	exercise	N	I-Premise
13	group	N	I-Premise
14	:	N	I-Premise
15	physical	N	I-Premise
16	functioning	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	=.050	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	general	N	I-Premise
23	health	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	=.048	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	and	N	I-Premise
30	vitality	N	I-Premise
31	(	N	I-Premise
32	P	N	I-Premise
33	=.023	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	Mental	N	I-Premise
2	health	N	I-Premise
3	increased	N	I-Premise
4	,	N	I-Premise
5	although	N	I-Premise
6	not	N	I-Premise
7	significantly	N	I-Premise
8	,	N	I-Premise
9	for	N	I-Premise
10	all	N	I-Premise
11	subjects	N	I-Premise
12	(	N	I-Premise
13	P	N	I-Premise
14	=.019	N	I-Premise
15	)	N	I-Premise
16	.	N	I-Premise

1	Arm	N	I-Premise
2	volume	N	I-Premise
3	measured	N	I-Premise
4	by	N	I-Premise
5	water	N	I-Premise
6	displacement	N	I-Premise
7	was	N	I-Premise
8	correlated	N	I-Premise
9	with	N	I-Premise
10	calculated	N	I-Premise
11	arm	N	I-Premise
12	volume	N	I-Premise
13	(	N	I-Premise
14	r	N	I-Premise
15	=.973	N	I-Premise
16	,	N	I-Premise
17	P	N	I-Premise
18	<	N	I-Premise
19	.001	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	although	N	I-Premise
23	the	N	I-Premise
24	exercise	N	I-Premise
25	and	N	I-Premise
26	control	N	I-Premise
27	group	N	I-Premise
28	means	N	I-Premise
29	were	N	I-Premise
30	significantly	N	I-Premise
31	different	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	<	N	I-Premise
35	.001	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	Participation	N	I-Claim
2	in	N	I-Claim
3	an	N	I-Claim
4	upper-body	N	I-Claim
5	exercise	N	I-Claim
6	program	N	I-Claim
7	caused	N	I-Claim
8	no	N	I-Claim
9	changes	N	I-Claim
10	in	N	I-Claim
11	arm	N	I-Claim
12	circumference	N	I-Claim
13	or	N	I-Claim
14	arm	N	I-Claim
15	volume	N	I-Claim
16	in	N	I-Claim
17	women	N	I-Claim
18	with	N	I-Claim
19	lymphedema	N	I-Claim
20	after	N	I-Claim
21	breast	N	I-Claim
22	cancer	N	I-Claim
23	,	N	I-Claim
24	and	N	I-Claim
25	they	N	I-Claim
26	may	N	I-Claim
27	have	N	I-Claim
28	experienced	N	I-Claim
29	an	N	I-Claim
30	increase	N	I-Claim
31	in	N	I-Claim
32	quality	N	I-Claim
33	of	N	I-Claim
34	life	N	I-Claim
35	.	N	I-Claim

1	Additional	N	I-Claim
2	studies	N	I-Claim
3	should	N	I-Claim
4	be	N	I-Claim
5	done	N	I-Claim
6	in	N	I-Claim
7	this	N	I-Claim
8	area	N	I-Claim
9	to	N	I-Claim
10	determine	N	I-Claim
11	the	N	I-Claim
12	optimum	N	I-Claim
13	training	N	I-Claim
14	program	N	I-Claim
15	.	N	I-Claim

1	Radiotherapy	N	I-Claim
2	is	N	I-Claim
3	an	N	I-Claim
4	effective	N	I-Claim
5	palliative	N	I-Claim
6	treatment	N	I-Claim
7	for	N	I-Claim
8	cancer	N	I-Claim
9	patients	N	I-Claim
10	with	N	I-Claim
11	painful	N	I-Claim
12	bone	N	I-Claim
13	metastases	N	I-Claim
14	.	N	I-Claim

1	Although	N	O
2	single-	N	O
3	and	N	O
4	multiple-fraction	N	O
5	radiotherapy	N	O
6	are	N	O
7	thought	N	O
8	to	N	O
9	provide	N	O
10	equal	N	O
11	palliation	N	O
12	,	N	O
13	which	N	O
14	treatment	N	O
15	schedule	N	O
16	provides	N	O
17	better	N	O
18	value	N	O
19	for	N	O
20	the	N	O
21	money	N	O
22	is	N	O
23	unknown	N	O
24	.	N	O

1	We	N	O
2	compared	N	O
3	quality-adjusted	N	O
4	life	N	O
5	expectancy	N	O
6	(	N	O
7	the	N	O
8	overall	N	O
9	valuation	N	O
10	of	N	O
11	the	N	O
12	health	N	O
13	of	N	O
14	the	N	O
15	patients	N	O
16	)	N	O
17	and	N	O
18	societal	N	O
19	costs	N	O
20	for	N	O
21	patients	N	O
22	receiving	N	O
23	either	N	O
24	single-	N	O
25	or	N	O
26	multiple-fraction	N	O
27	radiotherapy	N	O
28	.	N	O

1	A	N	O
2	societal	N	O
3	cost-utility	N	O
4	analysis	N	O
5	was	N	O
6	performed	N	O
7	on	N	O
8	a	N	O
9	Dutch	N	O
10	randomized	N	O
11	,	N	O
12	controlled	N	O
13	trial	N	O
14	of	N	O
15	1157	N	O
16	patients	N	O
17	with	N	O
18	painful	N	O
19	bone	N	O
20	metastases	N	O
21	that	N	O
22	compared	N	O
23	pain	N	O
24	responses	N	O
25	and	N	O
26	quality	N	O
27	of	N	O
28	life	N	O
29	from	N	O
30	a	N	O
31	single-fraction	N	O
32	treatment	N	O
33	schedule	N	O
34	of	N	O
35	8	N	O
36	Gy	N	O
37	with	N	O
38	a	N	O
39	treatment	N	O
40	schedule	N	O
41	of	N	O
42	six	N	O
43	fractions	N	O
44	of	N	O
45	4	N	O
46	Gy	N	O
47	each	N	O
48	.	N	O

1	The	N	O
2	societal	N	O
3	values	N	O
4	of	N	O
5	life	N	O
6	expectancies	N	O
7	were	N	O
8	assessed	N	O
9	with	N	O
10	the	N	O
11	EuroQol	N	O
12	classification	N	O
13	system	N	O
14	(	N	O
15	EQ-5D	N	O
16	)	N	O
17	questionnaire	N	O
18	.	N	O

1	A	N	O
2	subset	N	O
3	of	N	O
4	166	N	O
5	patients	N	O
6	also	N	O
7	answered	N	O
8	additional	N	O
9	questionnaires	N	O
10	to	N	O
11	estimate	N	O
12	nonradiotherapy	N	O
13	and	N	O
14	nonmedical	N	O
15	costs	N	O
16	.	N	O

1	Statistical	N	O
2	tests	N	O
3	were	N	O
4	two-sided	N	O
5	.	N	O

1	Comparing	N	I-Premise
2	the	N	I-Premise
3	single-	N	I-Premise
4	and	N	I-Premise
5	multiple-fraction	N	I-Premise
6	radiotherapy	N	I-Premise
7	schedules	N	I-Premise
8	,	N	I-Premise
9	no	N	I-Premise
10	differences	N	I-Premise
11	were	N	I-Premise
12	found	N	I-Premise
13	in	N	I-Premise
14	life	N	I-Premise
15	expectancy	N	I-Premise
16	(	N	I-Premise
17	43.0	N	I-Premise
18	versus	N	I-Premise
19	40.4	N	I-Premise
20	weeks	N	I-Premise
21	,	N	I-Premise
22	P	N	I-Premise
23	=.20	N	I-Premise
24	)	N	I-Premise
25	or	N	I-Premise
26	quality-adjusted	N	I-Premise
27	life	N	I-Premise
28	expectancy	N	I-Premise
29	(	N	I-Premise
30	17.7	N	I-Premise
31	versus	N	I-Premise
32	16.0	N	I-Premise
33	weeks	N	I-Premise
34	,	N	I-Premise
35	P	N	I-Premise
36	=.21	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	The	N	I-Premise
2	estimated	N	I-Premise
3	cost	N	I-Premise
4	of	N	I-Premise
5	radiotherapy	N	I-Premise
6	,	N	I-Premise
7	including	N	I-Premise
8	retreatments	N	I-Premise
9	and	N	I-Premise
10	nonmedical	N	I-Premise
11	costs	N	I-Premise
12	,	N	I-Premise
13	was	N	I-Premise
14	statistically	N	I-Premise
15	significantly	N	I-Premise
16	lower	N	I-Premise
17	for	N	I-Premise
18	the	N	I-Premise
19	single-fraction	N	I-Premise
20	schedule	N	I-Premise
21	than	N	I-Premise
22	for	N	I-Premise
23	the	N	I-Premise
24	multiple-fraction	N	I-Premise
25	schedule	N	I-Premise
26	(	N	I-Premise
27	$	N	I-Premise
28	2438	N	I-Premise
29	versus	N	I-Premise
30	$	N	I-Premise
31	3311	N	I-Premise
32	,	N	I-Premise
33	difference	N	I-Premise
34	=	N	I-Premise
35	$	N	I-Premise
36	873	N	I-Premise
37	,	N	I-Premise
38	95	N	I-Premise
39	%	N	I-Premise
40	confidence	N	I-Premise
41	interval	N	I-Premise
42	[	N	I-Premise
43	CI	N	I-Premise
44	]	N	I-Premise
45	on	N	I-Premise
46	the	N	I-Premise
47	difference	N	I-Premise
48	=	N	I-Premise
49	$	N	I-Premise
50	449	N	I-Premise
51	to	N	I-Premise
52	$	N	I-Premise
53	1297	N	I-Premise
54	;	N	I-Premise
55	P	N	I-Premise
56	<	N	I-Premise
57	.001	N	I-Premise
58	)	N	I-Premise
59	.	N	I-Premise

1	The	N	I-Premise
2	estimated	N	I-Premise
3	difference	N	I-Premise
4	in	N	I-Premise
5	total	N	I-Premise
6	societal	N	I-Premise
7	costs	N	I-Premise
8	was	N	I-Premise
9	larger	N	I-Premise
10	,	N	I-Premise
11	also	N	I-Premise
12	in	N	I-Premise
13	favor	N	I-Premise
14	of	N	I-Premise
15	the	N	I-Premise
16	single-fraction	N	I-Premise
17	schedule	N	I-Premise
18	,	N	I-Premise
19	but	N	I-Premise
20	it	N	I-Premise
21	was	N	I-Premise
22	not	N	I-Premise
23	statistically	N	I-Premise
24	significant	N	I-Premise
25	(	N	I-Premise
26	$	N	I-Premise
27	4700	N	I-Premise
28	versus	N	I-Premise
29	$	N	I-Premise
30	6453	N	I-Premise
31	,	N	I-Premise
32	difference	N	I-Premise
33	=	N	I-Premise
34	$	N	I-Premise
35	1753	N	I-Premise
36	,	N	I-Premise
37	95	N	I-Premise
38	%	N	I-Premise
39	CI	N	I-Premise
40	on	N	I-Premise
41	the	N	I-Premise
42	difference	N	I-Premise
43	=	N	I-Premise
44	-	N	I-Premise
45	$	N	I-Premise
46	99	N	I-Premise
47	to	N	I-Premise
48	$	N	I-Premise
49	3604	N	I-Premise
50	;	N	I-Premise
51	P	N	I-Premise
52	=.06	N	I-Premise
53	)	N	I-Premise
54	.	N	I-Premise

1	For	N	I-Premise
2	willingness-to-pay	N	I-Premise
3	between	N	I-Premise
4	$	N	I-Premise
5	5000	N	I-Premise
6	and	N	I-Premise
7	$	N	I-Premise
8	40	N	I-Premise
9	000	N	I-Premise
10	per	N	I-Premise
11	quality-adjusted	N	I-Premise
12	life	N	I-Premise
13	year	N	I-Premise
14	,	N	I-Premise
15	the	N	I-Premise
16	single-fraction	N	I-Premise
17	schedule	N	I-Premise
18	was	N	I-Premise
19	statistically	N	I-Premise
20	significantly	N	I-Premise
21	more	N	I-Premise
22	cost-effective	N	I-Premise
23	than	N	I-Premise
24	the	N	I-Premise
25	multiple-fraction	N	I-Premise
26	schedule	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	or	N	I-Premise
31	=.05	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	Compared	N	I-Claim
2	with	N	I-Claim
3	multiple-fraction	N	I-Claim
4	radiotherapy	N	I-Claim
5	,	N	I-Claim
6	single-fraction	N	I-Claim
7	radiotherapy	N	I-Claim
8	provides	N	I-Claim
9	equal	N	I-Claim
10	palliation	N	I-Claim
11	and	N	I-Claim
12	quality	N	I-Claim
13	of	N	I-Claim
14	life	N	I-Claim
15	and	N	I-Claim
16	has	N	I-Claim
17	lower	N	I-Claim
18	medical	N	I-Claim
19	and	N	I-Claim
20	societal	N	I-Claim
21	costs	N	I-Claim
22	,	N	I-Claim
23	at	N	I-Claim
24	least	N	I-Claim
25	in	N	I-Claim
26	The	N	I-Claim
27	Netherlands	N	I-Claim
28	.	N	I-Claim

1	Therefore	N	I-Claim
2	,	N	I-Claim
3	single-fraction	N	I-Claim
4	radiotherapy	N	I-Claim
5	should	N	I-Claim
6	be	N	I-Claim
7	considered	N	I-Claim
8	as	N	I-Claim
9	the	N	I-Claim
10	palliative	N	I-Claim
11	treatment	N	I-Claim
12	of	N	I-Claim
13	choice	N	I-Claim
14	for	N	I-Claim
15	cancer	N	I-Claim
16	patients	N	I-Claim
17	with	N	I-Claim
18	painful	N	I-Claim
19	bone	N	I-Claim
20	metastases	N	I-Claim
21	.	N	I-Claim

1	Randomized	N	I-Claim
2	trials	N	I-Claim
3	in	N	I-Claim
4	fluorouracil	N	I-Claim
5	(	N	I-Claim
6	FU	N	I-Claim
7	)	N	I-Claim
8	-refractory	N	I-Claim
9	colorectal	N	I-Claim
10	cancer	N	I-Claim
11	demonstrate	N	I-Claim
12	significant	N	I-Claim
13	survival	N	I-Claim
14	advantages	N	I-Claim
15	for	N	I-Claim
16	patients	N	I-Claim
17	receiving	N	I-Claim
18	irinotecan	N	I-Claim
19	.	N	I-Claim

1	We	N	O
2	prospectively	N	O
3	compared	N	O
4	the	N	O
5	efficacy	N	O
6	and	N	O
7	tolerability	N	O
8	of	N	O
9	two	N	O
10	irinotecan	N	O
11	regimens	N	O
12	(	N	O
13	once	N	O
14	a	N	O
15	week	N	O
16	for	N	O
17	4	N	O
18	weeks	N	O
19	followed	N	O
20	by	N	O
21	a	N	O
22	2-week	N	O
23	rest	N	O
24	period	N	O
25	[	N	O
26	weekly	N	O
27	]	N	O
28	v	N	O
29	once	N	O
30	every	N	O
31	3	N	O
32	weeks	N	O
33	)	N	O
34	in	N	O
35	such	N	O
36	patients	N	O
37	.	N	O

1	This	N	O
2	multicenter	N	O
3	,	N	O
4	open-label	N	O
5	,	N	O
6	phase	N	O
7	III	N	O
8	study	N	O
9	randomly	N	O
10	assigned	N	O
11	patients	N	O
12	in	N	O
13	a	N	O
14	1:2	N	O
15	ratio	N	O
16	to	N	O
17	irinotecan	N	O
18	given	N	O
19	either	N	O
20	weekly	N	O
21	(	N	O
22	125	N	O
23	mg/m	N	O
24	(	N	O
25	2	N	O
26	)	N	O
27	)	N	O
28	or	N	O
29	once	N	O
30	every	N	O
31	3	N	O
32	weeks	N	O
33	(	N	O
34	350	N	O
35	mg/m	N	O
36	(	N	O
37	2	N	O
38	)	N	O
39	,	N	O
40	or	N	O
41	300	N	O
42	mg/m	N	O
43	(	N	O
44	2	N	O
45	)	N	O
46	in	N	O
47	patients	N	O
48	who	N	O
49	were	N	O
50	>	N	O
51	/=	N	O
52	70	N	O
53	years	N	O
54	of	N	O
55	age	N	O
56	,	N	O
57	who	N	O
58	had	N	O
59	Eastern	N	O
60	Cooperative	N	O
61	Oncology	N	O
62	Group	N	O
63	performance	N	O
64	status	N	O
65	equal	N	O
66	to	N	O
67	2	N	O
68	,	N	O
69	or	N	O
70	who	N	O
71	had	N	O
72	prior	N	O
73	pelvic	N	O
74	irradiation	N	O
75	)	N	O
76	.	N	O

1	With	N	I-Premise
2	median	N	I-Premise
3	follow-up	N	I-Premise
4	of	N	I-Premise
5	15.8	N	I-Premise
6	months	N	I-Premise
7	,	N	I-Premise
8	there	N	I-Premise
9	was	N	I-Premise
10	no	N	I-Premise
11	significant	N	I-Premise
12	difference	N	I-Premise
13	in	N	I-Premise
14	1-year	N	I-Premise
15	survival	N	I-Premise
16	(	N	I-Premise
17	46	N	I-Premise
18	%	N	I-Premise
19	v	N	I-Premise
20	41	N	I-Premise
21	%	N	I-Premise
22	,	N	I-Premise
23	respectively	N	I-Premise
24	;	N	I-Premise
25	P	N	I-Premise
26	=.42	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	median	N	I-Premise
30	survival	N	I-Premise
31	(	N	I-Premise
32	9.9	N	I-Premise
33	v	N	I-Premise
34	9.9	N	I-Premise
35	months	N	I-Premise
36	,	N	I-Premise
37	respectively	N	I-Premise
38	;	N	I-Premise
39	P	N	I-Premise
40	=.43	N	I-Premise
41	)	N	I-Premise
42	,	N	I-Premise
43	or	N	I-Premise
44	median	N	I-Premise
45	time	N	I-Premise
46	to	N	I-Premise
47	progression	N	I-Premise
48	(	N	I-Premise
49	4.0	N	I-Premise
50	v	N	I-Premise
51	3.0	N	I-Premise
52	months	N	I-Premise
53	,	N	I-Premise
54	respectively	N	I-Premise
55	;	N	I-Premise
56	P	N	I-Premise
57	=.54	N	I-Premise
58	)	N	I-Premise
59	between	N	I-Premise
60	the	N	I-Premise
61	two	N	I-Premise
62	regimens	N	I-Premise
63	.	N	I-Premise

1	Grade	N	I-Premise
2	3/4	N	I-Premise
3	diarrhea	N	I-Premise
4	occurred	N	I-Premise
5	in	N	I-Premise
6	36	N	I-Premise
7	%	N	I-Premise
8	of	N	I-Premise
9	patients	N	I-Premise
10	treated	N	I-Premise
11	weekly	N	I-Premise
12	and	N	I-Premise
13	in	N	I-Premise
14	19	N	I-Premise
15	%	N	I-Premise
16	of	N	I-Premise
17	those	N	I-Premise
18	treated	N	I-Premise
19	once	N	I-Premise
20	every	N	I-Premise
21	3	N	I-Premise
22	weeks	N	I-Premise
23	(	N	I-Premise
24	P	N	I-Premise
25	=.002	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	Grade	N	I-Premise
2	3/4	N	I-Premise
3	neutropenia	N	I-Premise
4	occurred	N	I-Premise
5	in	N	I-Premise
6	29	N	I-Premise
7	%	N	I-Premise
8	of	N	I-Premise
9	patients	N	I-Premise
10	treated	N	I-Premise
11	weekly	N	I-Premise
12	and	N	I-Premise
13	34	N	I-Premise
14	%	N	I-Premise
15	of	N	I-Premise
16	those	N	I-Premise
17	treated	N	I-Premise
18	once	N	I-Premise
19	every	N	I-Premise
20	3	N	I-Premise
21	weeks	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	=.35	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	Treatment-related	N	I-Premise
2	mortality	N	I-Premise
3	occurred	N	I-Premise
4	in	N	I-Premise
5	five	N	I-Premise
6	patients	N	I-Premise
7	(	N	I-Premise
8	5.3	N	I-Premise
9	%	N	I-Premise
10	)	N	I-Premise
11	receiving	N	I-Premise
12	irinotecan	N	I-Premise
13	weekly	N	I-Premise
14	and	N	I-Premise
15	three	N	I-Premise
16	patients	N	I-Premise
17	(	N	I-Premise
18	1.6	N	I-Premise
19	%	N	I-Premise
20	)	N	I-Premise
21	given	N	I-Premise
22	therapy	N	I-Premise
23	once	N	I-Premise
24	every	N	I-Premise
25	3	N	I-Premise
26	weeks	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=.12	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	Global	N	I-Premise
2	quality	N	I-Premise
3	of	N	I-Premise
4	life	N	I-Premise
5	was	N	I-Premise
6	not	N	I-Premise
7	statistically	N	I-Premise
8	different	N	I-Premise
9	between	N	I-Premise
10	treatment	N	I-Premise
11	groups	N	I-Premise
12	.	N	I-Premise

1	Irinotecan	N	I-Claim
2	schedules	N	I-Claim
3	of	N	I-Claim
4	weekly	N	I-Claim
5	and	N	I-Claim
6	of	N	I-Claim
7	once	N	I-Claim
8	every	N	I-Claim
9	3	N	I-Claim
10	weeks	N	I-Claim
11	demonstrated	N	I-Claim
12	similar	N	I-Claim
13	efficacy	N	I-Claim
14	and	N	I-Claim
15	quality	N	I-Claim
16	of	N	I-Claim
17	life	N	I-Claim
18	in	N	I-Claim
19	patients	N	I-Claim
20	with	N	I-Claim
21	FU-refractory	N	I-Claim
22	,	N	I-Claim
23	metastatic	N	I-Claim
24	colorectal	N	I-Claim
25	cancer	N	I-Claim
26	.	N	I-Claim

1	The	N	I-Claim
2	regimen	N	I-Claim
3	of	N	I-Claim
4	once	N	I-Claim
5	every	N	I-Claim
6	3	N	I-Claim
7	weeks	N	I-Claim
8	was	N	I-Claim
9	associated	N	I-Claim
10	with	N	I-Claim
11	a	N	I-Claim
12	significantly	N	I-Claim
13	lower	N	I-Claim
14	incidence	N	I-Claim
15	of	N	I-Claim
16	severe	N	I-Claim
17	diarrhea	N	I-Claim
18	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	a	N	O
7	standard	N	O
8	anthracycline-based	N	O
9	regimen	N	O
10	to	N	O
11	a	N	O
12	dose-intensified	N	O
13	anthracycline	N	O
14	regimen	N	O
15	in	N	O
16	locally	N	O
17	advanced	N	O
18	breast	N	O
19	cancer	N	O
20	.	N	O

1	Locally	N	O
2	advanced	N	O
3	breast	N	O
4	cancer	N	O
5	patients	N	O
6	were	N	O
7	randomly	N	O
8	assigned	N	O
9	onto	N	O
10	a	N	O
11	study	N	O
12	comparing	N	O
13	cyclophosphamide	N	O
14	(	N	O
15	C	N	O
16	;	N	O
17	75	N	O
18	mg/m	N	O
19	(	N	O
20	2	N	O
21	)	N	O
22	orally	N	O
23	days	N	O
24	1	N	O
25	to	N	O
26	14	N	O
27	)	N	O
28	,	N	O
29	epirubicin	N	O
30	(	N	O
31	E	N	O
32	;	N	O
33	60	N	O
34	mg/m	N	O
35	(	N	O
36	2	N	O
37	)	N	O
38	intravenously	N	O
39	[	N	O
40	IV	N	O
41	]	N	O
42	days	N	O
43	1	N	O
44	,	N	O
45	8	N	O
46	)	N	O
47	,	N	O
48	and	N	O
49	fluorouracil	N	O
50	(	N	O
51	F	N	O
52	;	N	O
53	500	N	O
54	mg/m	N	O
55	(	N	O
56	2	N	O
57	)	N	O
58	IV	N	O
59	days	N	O
60	1	N	O
61	,	N	O
62	8	N	O
63	)	N	O
64	six	N	O
65	cycles	N	O
66	every	N	O
67	28	N	O
68	days	N	O
69	versus	N	O
70	E	N	O
71	(	N	O
72	120	N	O
73	mg/m	N	O
74	(	N	O
75	2	N	O
76	)	N	O
77	IV	N	O
78	day	N	O
79	1	N	O
80	)	N	O
81	,	N	O
82	C	N	O
83	(	N	O
84	830	N	O
85	mg/m	N	O
86	(	N	O
87	2	N	O
88	)	N	O
89	IV	N	O
90	day	N	O
91	1	N	O
92	)	N	O
93	,	N	O
94	and	N	O
95	granulocyte	N	O
96	colony-stimulating	N	O
97	factor	N	O
98	(	N	O
99	filgrastim	N	O
100	;	N	O
101	5	N	O
102	micro	N	O
103	g/kg/d	N	O
104	subcutaneously	N	O
105	days	N	O
106	2	N	O
107	to	N	O
108	13	N	O
109	)	N	O
110	six	N	O
111	cycles	N	O
112	every	N	O
113	14	N	O
114	days	N	O
115	.	N	O

1	The	N	O
2	study	N	O
3	was	N	O
4	designed	N	O
5	to	N	O
6	detect	N	O
7	a	N	O
8	15	N	O
9	%	N	O
10	improvement	N	O
11	;	N	O
12	that	N	O
13	is	N	O
14	,	N	O
15	from	N	O
16	50	N	O
17	%	N	O
18	to	N	O
19	65	N	O
20	%	N	O
21	in	N	O
22	median	N	O
23	progression-free	N	O
24	survival	N	O
25	(	N	O
26	PFS	N	O
27	)	N	O
28	in	N	O
29	favor	N	O
30	of	N	O
31	the	N	O
32	dose-intensified	N	O
33	regimen	N	O
34	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	448	N	O
5	patients	N	O
6	were	N	O
7	enrolled	N	O
8	over	N	O
9	a	N	O
10	period	N	O
11	of	N	O
12	3	N	O
13	years	N	O
14	.	N	O

1	The	N	O
2	median	N	O
3	dose	N	O
4	intensity	N	O
5	delivered	N	O
6	for	N	O
7	C	N	O
8	and	N	O
9	E	N	O
10	reached	N	O
11	,	N	O
12	respectively	N	O
13	,	N	O
14	85	N	O
15	%	N	O
16	and	N	O
17	87	N	O
18	%	N	O
19	of	N	O
20	that	N	O
21	planned	N	O
22	in	N	O
23	the	N	O
24	CEF	N	O
25	arm	N	O
26	and	N	O
27	96	N	O
28	%	N	O
29	and	N	O
30	95	N	O
31	%	N	O
32	of	N	O
33	that	N	O
34	planned	N	O
35	in	N	O
36	the	N	O
37	EC	N	O
38	arm	N	O
39	.	N	O

1	The	N	I-Premise
2	dose-intensified	N	I-Premise
3	arm	N	I-Premise
4	was	N	I-Premise
5	slightly	N	I-Premise
6	more	N	I-Premise
7	emetogenic	N	I-Premise
8	and	N	I-Premise
9	generated	N	I-Premise
10	more	N	I-Premise
11	grade	N	I-Premise
12	3	N	I-Premise
13	to	N	I-Premise
14	4	N	I-Premise
15	anemia	N	I-Premise
16	but	N	I-Premise
17	less	N	I-Premise
18	febrile	N	I-Premise
19	neutropenia	N	I-Premise
20	episodes	N	I-Premise
21	.	N	I-Premise

1	After	N	O
2	a	N	O
3	median	N	O
4	follow-up	N	O
5	of	N	O
6	5.5	N	O
7	years	N	O
8	,	N	O
9	277	N	O
10	events	N	O
11	have	N	O
12	been	N	O
13	reported	N	O
14	.	N	O

1	The	N	I-Premise
2	median	N	I-Premise
3	PFS	N	I-Premise
4	was	N	I-Premise
5	34	N	I-Premise
6	and	N	I-Premise
7	33.7	N	I-Premise
8	months	N	I-Premise
9	for	N	I-Premise
10	CEF	N	I-Premise
11	and	N	I-Premise
12	EC	N	I-Premise
13	,	N	I-Premise
14	respectively	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	=.68	N	I-Premise
18	)	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	the	N	I-Premise
22	5-year	N	I-Premise
23	survival	N	I-Premise
24	rate	N	I-Premise
25	was	N	I-Premise
26	53	N	I-Premise
27	%	N	I-Premise
28	and	N	I-Premise
29	51	N	I-Premise
30	%	N	I-Premise
31	for	N	I-Premise
32	CEF	N	I-Premise
33	and	N	I-Premise
34	EC	N	I-Premise
35	,	N	I-Premise
36	respectively	N	I-Premise
37	(	N	I-Premise
38	P	N	I-Premise
39	=.94	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	Dose-intensified	N	I-Claim
2	EC	N	I-Claim
3	does	N	I-Claim
4	not	N	I-Claim
5	provide	N	I-Claim
6	a	N	I-Claim
7	measurable	N	I-Claim
8	therapeutic	N	I-Claim
9	benefit	N	I-Claim
10	over	N	I-Claim
11	CEF	N	I-Claim
12	as	N	I-Claim
13	neoadjuvant	N	I-Claim
14	chemotherapy	N	I-Claim
15	for	N	I-Claim
16	unselected	N	I-Claim
17	locally	N	I-Claim
18	advanced	N	I-Claim
19	breast	N	I-Claim
20	cancer	N	I-Claim
21	patients	N	I-Claim
22	.	N	I-Claim

1	Several	N	O
2	multicomponent	N	O
3	regimens	N	O
4	have	N	O
5	been	N	O
6	reported	N	O
7	to	N	O
8	be	N	O
9	useful	N	O
10	in	N	O
11	advanced	N	O
12	androgen-independent	N	O
13	prostate	N	O
14	cancer	N	O
15	.	N	O

1	We	N	O
2	used	N	O
3	a	N	O
4	randomized	N	O
5	phase	N	O
6	II	N	O
7	design	N	O
8	to	N	O
9	evaluate	N	O
10	and	N	O
11	compare	N	O
12	two	N	O
13	such	N	O
14	regimens	N	O
15	.	N	O

1	Patients	N	O
2	were	N	O
3	accrued	N	O
4	primarily	N	O
5	in	N	O
6	the	N	O
7	community	N	O
8	setting	N	O
9	.	N	O

1	Patients	N	O
2	with	N	O
3	progressive	N	O
4	,	N	O
5	androgen-independent	N	O
6	prostate	N	O
7	cancer	N	O
8	were	N	O
9	randomly	N	O
10	assigned	N	O
11	to	N	O
12	one	N	O
13	of	N	O
14	two	N	O
15	treatments	N	O
16	:	N	O
17	either	N	O
18	ketoconazole/doxorubicin	N	O
19	alternating	N	O
20	with	N	O
21	vinblastine/estramustine	N	O
22	(	N	O
23	KA/VE	N	O
24	)	N	O
25	or	N	O
26	paclitaxel	N	O
27	,	N	O
28	estramustine	N	O
29	,	N	O
30	and	N	O
31	oral	N	O
32	etoposide	N	O
33	(	N	O
34	TEE	N	O
35	)	N	O
36	.	N	O

1	Patients	N	O
2	were	N	O
3	prospectively	N	O
4	stratified	N	O
5	on	N	O
6	the	N	O
7	basis	N	O
8	of	N	O
9	disease	N	O
10	volume	N	O
11	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	points	N	O
5	were	N	O
6	response	N	O
7	and	N	O
8	overall	N	O
9	survival	N	O
10	time	N	O
11	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	75	N	O
5	patients	N	O
6	were	N	O
7	registered	N	O
8	;	N	O
9	71	N	O
10	are	N	O
11	included	N	O
12	in	N	O
13	the	N	O
14	analysis	N	O
15	.	N	O

1	By	N	O
2	the	N	O
3	criterion	N	O
4	of	N	O
5	an	N	O
6	80	N	O
7	%	N	O
8	prostate-specific	N	O
9	antigen	N	O
10	reduction	N	O
11	maintained	N	O
12	for	N	O
13	at	N	O
14	least	N	O
15	8	N	O
16	weeks	N	O
17	,	N	O
18	11	N	O
19	(	N	O
20	30	N	O
21	%	N	O
22	)	N	O
23	of	N	O
24	37	N	O
25	patients	N	O
26	in	N	O
27	the	N	O
28	TEE	N	O
29	arm	N	O
30	responded	N	O
31	,	N	O
32	whereas	N	O
33	11	N	O
34	(	N	O
35	32	N	O
36	%	N	O
37	)	N	O
38	of	N	O
39	34	N	O
40	assigned	N	O
41	to	N	O
42	KA/VE	N	O
43	responded	N	O
44	.	N	O

1	Median	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	16.9	N	I-Premise
5	months	N	I-Premise
6	(	N	I-Premise
7	95	N	I-Premise
8	%	N	I-Premise
9	confidence	N	I-Premise
10	interval	N	I-Premise
11	[	N	I-Premise
12	CI	N	I-Premise
13	]	N	I-Premise
14	,	N	I-Premise
15	10.5	N	I-Premise
16	to	N	I-Premise
17	21.2	N	I-Premise
18	months	N	I-Premise
19	)	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	TEE	N	I-Premise
23	arm	N	I-Premise
24	and	N	I-Premise
25	23.4	N	I-Premise
26	months	N	I-Premise
27	(	N	I-Premise
28	95	N	I-Premise
29	%	N	I-Premise
30	CI	N	I-Premise
31	,	N	I-Premise
32	12.9	N	I-Premise
33	to	N	I-Premise
34	30.6	N	I-Premise
35	months	N	I-Premise
36	)	N	I-Premise
37	for	N	I-Premise
38	patients	N	I-Premise
39	treated	N	I-Premise
40	with	N	I-Premise
41	KA/VE	N	I-Premise
42	.	N	I-Premise

1	Many	N	I-Premise
2	patients	N	I-Premise
3	(	N	I-Premise
4	24	N	I-Premise
5	%	N	I-Premise
6	)	N	I-Premise
7	failed	N	I-Premise
8	to	N	I-Premise
9	complete	N	I-Premise
10	at	N	I-Premise
11	least	N	I-Premise
12	6	N	I-Premise
13	weeks	N	I-Premise
14	of	N	I-Premise
15	therapy	N	I-Premise
16	,	N	I-Premise
17	including	N	I-Premise
18	five	N	I-Premise
19	(	N	I-Premise
20	8	N	I-Premise
21	%	N	I-Premise
22	)	N	I-Premise
23	treatment-related	N	I-Premise
24	early	N	I-Premise
25	deaths	N	I-Premise
26	.	N	I-Premise

1	Each	N	I-Claim
2	of	N	I-Claim
3	these	N	I-Claim
4	regimens	N	I-Claim
5	produced	N	I-Claim
6	clinically	N	I-Claim
7	significant	N	I-Claim
8	responses	N	I-Claim
9	,	N	I-Claim
10	and	N	O
11	the	N	I-Claim
12	observed	N	I-Claim
13	median	N	I-Claim
14	survival	N	I-Claim
15	(	N	I-Claim
16	18.9	N	I-Claim
17	months	N	I-Claim
18	for	N	I-Claim
19	all	N	I-Claim
20	71	N	I-Claim
21	patients	N	I-Claim
22	)	N	I-Claim
23	compares	N	I-Claim
24	favorably	N	I-Claim
25	with	N	I-Claim
26	previously	N	I-Claim
27	published	N	I-Claim
28	results	N	I-Claim
29	,	N	I-Claim
30	especially	N	I-Claim
31	in	N	I-Claim
32	the	N	I-Claim
33	community	N	I-Claim
34	setting	N	I-Claim
35	.	N	I-Claim

1	Nonetheless	N	I-Claim
2	,	N	I-Claim
3	it	N	I-Claim
4	is	N	I-Claim
5	apparent	N	I-Claim
6	that	N	I-Claim
7	these	N	I-Claim
8	first-generation	N	I-Claim
9	regimens	N	I-Claim
10	must	N	I-Claim
11	be	N	I-Claim
12	applied	N	I-Claim
13	judiciously	N	I-Claim
14	,	N	I-Claim
15	and	N	O
16	thus	N	I-Claim
17	we	N	I-Claim
18	view	N	I-Claim
19	efforts	N	I-Claim
20	at	N	I-Claim
21	better	N	I-Claim
22	patient	N	I-Claim
23	selection	N	I-Claim
24	and	N	I-Claim
25	the	N	I-Claim
26	development	N	I-Claim
27	of	N	I-Claim
28	more	N	I-Claim
29	tolerable	N	I-Claim
30	therapies	N	I-Claim
31	as	N	I-Claim
32	higher	N	I-Claim
33	priorities	N	I-Claim
34	than	N	I-Claim
35	carrying	N	I-Claim
36	either	N	I-Claim
37	of	N	I-Claim
38	these	N	I-Claim
39	regimens	N	I-Claim
40	to	N	I-Claim
41	phase	N	I-Claim
42	III	N	I-Claim
43	evaluation	N	I-Claim
44	in	N	I-Claim
45	the	N	I-Claim
46	cooperative	N	I-Claim
47	group	N	I-Claim
48	setting	N	I-Claim
49	.	N	I-Claim

1	Vinorelbine	N	I-Claim
2	prolongs	N	I-Claim
3	survival	N	I-Claim
4	and	N	I-Claim
5	improves	N	I-Claim
6	quality	N	I-Claim
7	of	N	I-Claim
8	life	N	I-Claim
9	in	N	I-Claim
10	elderly	N	I-Claim
11	patients	N	I-Claim
12	with	N	I-Claim
13	advanced	N	I-Claim
14	non-small-cell	N	I-Claim
15	lung	N	I-Claim
16	cancer	N	I-Claim
17	(	N	I-Claim
18	NSCLC	N	I-Claim
19	)	N	I-Claim
20	.	N	I-Claim

1	Some	N	I-Claim
2	studies	N	I-Claim
3	have	N	I-Claim
4	also	N	I-Claim
5	suggested	N	I-Claim
6	that	N	I-Claim
7	gemcitabine	N	I-Claim
8	is	N	I-Claim
9	well	N	I-Claim
10	tolerated	N	I-Claim
11	and	N	I-Claim
12	effective	N	I-Claim
13	in	N	I-Claim
14	such	N	I-Claim
15	patients	N	I-Claim
16	.	N	I-Claim

1	We	N	O
2	compared	N	O
3	the	N	O
4	effectiveness	N	O
5	and	N	O
6	toxicity	N	O
7	of	N	O
8	the	N	O
9	combination	N	O
10	of	N	O
11	vinorelbine	N	O
12	plus	N	O
13	gemcitabine	N	O
14	with	N	O
15	those	N	O
16	of	N	O
17	each	N	O
18	drug	N	O
19	given	N	O
20	alone	N	O
21	in	N	O
22	an	N	O
23	open-label	N	O
24	,	N	O
25	randomized	N	O
26	phase	N	O
27	III	N	O
28	trial	N	O
29	in	N	O
30	elderly	N	O
31	patients	N	O
32	with	N	O
33	advanced	N	O
34	NSCLC	N	O
35	.	N	O

1	Patients	N	O
2	aged	N	O
3	70	N	O
4	years	N	O
5	and	N	O
6	older	N	O
7	,	N	O
8	enrolled	N	O
9	between	N	O
10	December	N	O
11	1997	N	O
12	and	N	O
13	November	N	O
14	2000	N	O
15	,	N	O
16	were	N	O
17	randomly	N	O
18	assigned	N	O
19	to	N	O
20	receive	N	O
21	intravenous	N	O
22	vinorelbine	N	O
23	(	N	O
24	30	N	O
25	mg/m	N	O
26	(	N	O
27	2	N	O
28	)	N	O
29	of	N	O
30	body	N	O
31	surface	N	O
32	area	N	O
33	)	N	O
34	,	N	O
35	gemcitabine	N	O
36	(	N	O
37	1200	N	O
38	mg/m	N	O
39	(	N	O
40	2	N	O
41	)	N	O
42	)	N	O
43	,	N	O
44	or	N	O
45	vinorelbine	N	O
46	(	N	O
47	25	N	O
48	mg/m	N	O
49	(	N	O
50	2	N	O
51	)	N	O
52	)	N	O
53	plus	N	O
54	gemcitabine	N	O
55	(	N	O
56	1000	N	O
57	mg/m	N	O
58	(	N	O
59	2	N	O
60	)	N	O
61	)	N	O
62	.	N	O

1	All	N	O
2	treatments	N	O
3	were	N	O
4	delivered	N	O
5	on	N	O
6	days	N	O
7	1	N	O
8	and	N	O
9	8	N	O
10	every	N	O
11	3	N	O
12	weeks	N	O
13	for	N	O
14	a	N	O
15	maximum	N	O
16	of	N	O
17	six	N	O
18	cycles	N	O
19	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	survival	N	O
6	.	N	O

1	Survival	N	O
2	curves	N	O
3	were	N	O
4	drawn	N	O
5	using	N	O
6	the	N	O
7	Kaplan-Meier	N	O
8	method	N	O
9	and	N	O
10	analyzed	N	O
11	by	N	O
12	the	N	O
13	Mantel-Haenszel	N	O
14	test	N	O
15	.	N	O

1	Secondary	N	O
2	endpoints	N	O
3	were	N	O
4	quality	N	O
5	of	N	O
6	life	N	O
7	and	N	O
8	toxicity	N	O
9	.	N	O

1	Of	N	O
2	698	N	O
3	patients	N	O
4	available	N	O
5	for	N	O
6	intention-to-treat	N	O
7	analysis	N	O
8	,	N	O
9	233	N	O
10	were	N	O
11	assigned	N	O
12	to	N	O
13	receive	N	O
14	vinorelbine	N	O
15	,	N	O
16	233	N	O
17	to	N	O
18	gemcitabine	N	O
19	,	N	O
20	and	N	O
21	232	N	O
22	to	N	O
23	vinorelbine	N	O
24	plus	N	O
25	gemcitabine	N	O
26	.	N	O

1	Compared	N	I-Premise
2	with	N	I-Premise
3	each	N	I-Premise
4	single	N	I-Premise
5	drug	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	combination	N	I-Premise
9	treatment	N	I-Premise
10	did	N	I-Premise
11	not	N	I-Premise
12	improve	N	I-Premise
13	survival	N	I-Premise
14	.	N	I-Premise

1	The	N	I-Premise
2	hazard	N	I-Premise
3	ratio	N	I-Premise
4	of	N	I-Premise
5	death	N	I-Premise
6	for	N	I-Premise
7	patients	N	I-Premise
8	receiving	N	I-Premise
9	the	N	I-Premise
10	combination	N	I-Premise
11	treatment	N	I-Premise
12	was	N	I-Premise
13	1.17	N	I-Premise
14	(	N	I-Premise
15	95	N	I-Premise
16	%	N	I-Premise
17	confidence	N	I-Premise
18	interval	N	I-Premise
19	[	N	I-Premise
20	CI	N	I-Premise
21	]	N	I-Premise
22	=	N	I-Premise
23	0.95	N	I-Premise
24	to	N	I-Premise
25	1.44	N	I-Premise
26	)	N	I-Premise
27	that	N	I-Premise
28	of	N	I-Premise
29	patients	N	I-Premise
30	receiving	N	I-Premise
31	vinorelbine	N	I-Premise
32	and	N	I-Premise
33	1.06	N	I-Premise
34	(	N	I-Premise
35	95	N	I-Premise
36	%	N	I-Premise
37	CI	N	I-Premise
38	=	N	I-Premise
39	0.86	N	I-Premise
40	to	N	I-Premise
41	1.29	N	I-Premise
42	)	N	I-Premise
43	that	N	I-Premise
44	of	N	I-Premise
45	patients	N	I-Premise
46	receiving	N	I-Premise
47	gemcitabine	N	I-Premise
48	.	N	I-Premise

1	Although	N	I-Premise
2	quality	N	I-Premise
3	of	N	I-Premise
4	life	N	I-Premise
5	was	N	I-Premise
6	similar	N	I-Premise
7	across	N	I-Premise
8	the	N	I-Premise
9	three	N	I-Premise
10	treatment	N	I-Premise
11	arms	N	I-Premise
12	,	N	I-Premise
13	the	N	I-Premise
14	combination	N	I-Premise
15	treatment	N	I-Premise
16	was	N	I-Premise
17	more	N	I-Premise
18	toxic	N	I-Premise
19	than	N	I-Premise
20	the	N	I-Premise
21	two	N	I-Premise
22	drugs	N	I-Premise
23	given	N	I-Premise
24	singly	N	I-Premise
25	.	N	I-Premise

1	The	N	I-Claim
2	combination	N	I-Claim
3	of	N	I-Claim
4	vinorelbine	N	I-Claim
5	plus	N	I-Claim
6	gemcitabine	N	I-Claim
7	is	N	I-Claim
8	not	N	I-Claim
9	more	N	I-Claim
10	effective	N	I-Claim
11	than	N	I-Claim
12	single-agent	N	I-Claim
13	vinorelbine	N	I-Claim
14	or	N	I-Claim
15	gemcitabine	N	I-Claim
16	in	N	I-Claim
17	the	N	I-Claim
18	treatment	N	I-Claim
19	of	N	I-Claim
20	elderly	N	I-Claim
21	patients	N	I-Claim
22	with	N	I-Claim
23	advanced	N	I-Claim
24	NSCLC	N	I-Claim
25	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	,	N	O
4	multicenter	N	O
5	,	N	O
6	phase	N	O
7	III	N	O
8	study	N	O
9	compared	N	O
10	doxorubicin	N	O
11	and	N	O
12	docetaxel	N	O
13	(	N	O
14	AT	N	O
15	)	N	O
16	with	N	O
17	doxorubicin	N	O
18	and	N	O
19	cyclophosphamide	N	O
20	(	N	O
21	AC	N	O
22	)	N	O
23	as	N	O
24	first-line	N	O
25	chemotherapy	N	O
26	(	N	O
27	CT	N	O
28	)	N	O
29	in	N	O
30	metastatic	N	O
31	breast	N	O
32	cancer	N	O
33	(	N	O
34	MBC	N	O
35	)	N	O
36	.	N	O

1	Patients	N	O
2	(	N	O
3	n	N	O
4	=	N	O
5	429	N	O
6	)	N	O
7	were	N	O
8	randomly	N	O
9	assigned	N	O
10	to	N	O
11	receive	N	O
12	doxorubicin	N	O
13	50	N	O
14	mg/m	N	O
15	(	N	O
16	2	N	O
17	)	N	O
18	plus	N	O
19	docetaxel	N	O
20	75	N	O
21	mg/m	N	O
22	(	N	O
23	2	N	O
24	)	N	O
25	(	N	O
26	n	N	O
27	=	N	O
28	214	N	O
29	)	N	O
30	or	N	O
31	doxorubicin	N	O
32	60	N	O
33	mg/m	N	O
34	(	N	O
35	2	N	O
36	)	N	O
37	plus	N	O
38	cyclophosphamide	N	O
39	600	N	O
40	mg/m	N	O
41	(	N	O
42	2	N	O
43	)	N	O
44	(	N	O
45	n	N	O
46	=	N	O
47	215	N	O
48	)	N	O
49	on	N	O
50	day	N	O
51	1	N	O
52	,	N	O
53	every	N	O
54	3	N	O
55	weeks	N	O
56	for	N	O
57	up	N	O
58	to	N	O
59	eight	N	O
60	cycles	N	O
61	.	N	O

1	Time	N	I-Premise
2	to	N	I-Premise
3	progression	N	I-Premise
4	(	N	I-Premise
5	TTP	N	I-Premise
6	;	N	I-Premise
7	primary	N	I-Premise
8	end	N	I-Premise
9	point	N	I-Premise
10	)	N	I-Premise
11	and	N	I-Premise
12	time	N	I-Premise
13	to	N	I-Premise
14	treatment	N	I-Premise
15	failure	N	I-Premise
16	(	N	I-Premise
17	TTF	N	I-Premise
18	)	N	I-Premise
19	were	N	I-Premise
20	significantly	N	I-Premise
21	longer	N	I-Premise
22	with	N	I-Premise
23	AT	N	I-Premise
24	than	N	I-Premise
25	AC	N	I-Premise
26	(	N	I-Premise
27	median	N	I-Premise
28	TTP	N	I-Premise
29	,	N	I-Premise
30	37.3	N	I-Premise
31	v	N	I-Premise
32	31.9	N	I-Premise
33	weeks	N	I-Premise
34	;	N	I-Premise
35	log-rank	N	I-Premise
36	P	N	I-Premise
37	=.014	N	I-Premise
38	;	N	I-Premise
39	median	N	I-Premise
40	TTF	N	I-Premise
41	,	N	I-Premise
42	25.6	N	I-Premise
43	v	N	I-Premise
44	23.7	N	I-Premise
45	weeks	N	I-Premise
46	;	N	I-Premise
47	log-rank	N	I-Premise
48	P	N	I-Premise
49	=.048	N	I-Premise
50	)	N	I-Premise
51	.	N	I-Premise

1	The	N	I-Premise
2	overall	N	I-Premise
3	response	N	I-Premise
4	rate	N	I-Premise
5	(	N	I-Premise
6	ORR	N	I-Premise
7	)	N	I-Premise
8	was	N	I-Premise
9	significantly	N	I-Premise
10	greater	N	I-Premise
11	for	N	I-Premise
12	patients	N	I-Premise
13	taking	N	I-Premise
14	AT	N	I-Premise
15	(	N	I-Premise
16	59	N	I-Premise
17	%	N	I-Premise
18	,	N	I-Premise
19	with	N	I-Premise
20	10	N	I-Premise
21	%	N	I-Premise
22	complete	N	I-Premise
23	response	N	I-Premise
24	[	N	I-Premise
25	CR	N	I-Premise
26	]	N	I-Premise
27	,	N	I-Premise
28	49	N	I-Premise
29	%	N	I-Premise
30	partial	N	I-Premise
31	response	N	I-Premise
32	[	N	I-Premise
33	PR	N	I-Premise
34	]	N	I-Premise
35	)	N	I-Premise
36	than	N	I-Premise
37	for	N	I-Premise
38	those	N	I-Premise
39	taking	N	I-Premise
40	AC	N	I-Premise
41	(	N	I-Premise
42	47	N	I-Premise
43	%	N	I-Premise
44	,	N	I-Premise
45	with	N	I-Premise
46	7	N	I-Premise
47	%	N	I-Premise
48	CR	N	I-Premise
49	,	N	I-Premise
50	39	N	I-Premise
51	%	N	I-Premise
52	PR	N	I-Premise
53	)	N	I-Premise
54	(	N	I-Premise
55	P	N	I-Premise
56	=.009	N	I-Premise
57	)	N	I-Premise
58	.	N	I-Premise

1	The	N	I-Premise
2	ORR	N	I-Premise
3	was	N	I-Premise
4	also	N	I-Premise
5	higher	N	I-Premise
6	with	N	I-Premise
7	AT	N	I-Premise
8	in	N	I-Premise
9	patients	N	I-Premise
10	with	N	I-Premise
11	visceral	N	I-Premise
12	involvement	N	I-Premise
13	(	N	I-Premise
14	58	N	I-Premise
15	%	N	I-Premise
16	v	N	I-Premise
17	41	N	I-Premise
18	%	N	I-Premise
19	;	N	I-Premise
20	liver	N	I-Premise
21	,	N	I-Premise
22	62	N	I-Premise
23	%	N	I-Premise
24	v	N	I-Premise
25	42	N	I-Premise
26	%	N	I-Premise
27	;	N	I-Premise
28	lung	N	I-Premise
29	,	N	I-Premise
30	58	N	I-Premise
31	%	N	I-Premise
32	v	N	I-Premise
33	35	N	I-Premise
34	%	N	I-Premise
35	)	N	I-Premise
36	,	N	I-Premise
37	three	N	I-Premise
38	or	N	I-Premise
39	more	N	I-Premise
40	organs	N	I-Premise
41	involved	N	I-Premise
42	(	N	I-Premise
43	59	N	I-Premise
44	%	N	I-Premise
45	v	N	I-Premise
46	40	N	I-Premise
47	%	N	I-Premise
48	)	N	I-Premise
49	,	N	I-Premise
50	or	N	I-Premise
51	prior	N	I-Premise
52	adjuvant	N	I-Premise
53	CT	N	I-Premise
54	(	N	I-Premise
55	53	N	I-Premise
56	%	N	I-Premise
57	v	N	I-Premise
58	41	N	I-Premise
59	%	N	I-Premise
60	)	N	I-Premise
61	.	N	I-Premise

1	Overall	N	I-Premise
2	survival	N	I-Premise
3	(	N	I-Premise
4	OS	N	I-Premise
5	)	N	I-Premise
6	was	N	I-Premise
7	comparable	N	I-Premise
8	in	N	I-Premise
9	both	N	I-Premise
10	arms	N	I-Premise
11	.	N	I-Premise

1	Grade	N	I-Premise
2	3/4	N	I-Premise
3	neutropenia	N	I-Premise
4	was	N	I-Premise
5	frequent	N	I-Premise
6	in	N	I-Premise
7	both	N	I-Premise
8	groups	N	I-Premise
9	,	N	I-Premise
10	although	N	I-Premise
11	febrile	N	I-Premise
12	neutropenia	N	I-Premise
13	and	N	I-Premise
14	infections	N	I-Premise
15	were	N	I-Premise
16	more	N	I-Premise
17	frequent	N	I-Premise
18	for	N	I-Premise
19	patients	N	I-Premise
20	taking	N	I-Premise
21	AT	N	I-Premise
22	(	N	I-Premise
23	respectively	N	I-Premise
24	,	N	I-Premise
25	33	N	I-Premise
26	%	N	I-Premise
27	v	N	I-Premise
28	10	N	I-Premise
29	%	N	I-Premise
30	,	N	I-Premise
31	P	N	I-Premise
32	<	N	I-Premise
33	.001	N	I-Premise
34	;	N	I-Premise
35	8	N	I-Premise
36	%	N	I-Premise
37	v	N	I-Premise
38	2	N	I-Premise
39	%	N	I-Premise
40	,	N	I-Premise
41	P	N	I-Premise
42	=.01	N	I-Premise
43	)	N	I-Premise
44	.	N	I-Premise

1	Severe	N	I-Premise
2	nonhematologic	N	I-Premise
3	toxicity	N	I-Premise
4	was	N	I-Premise
5	infrequent	N	I-Premise
6	in	N	I-Premise
7	both	N	I-Premise
8	groups	N	I-Premise
9	,	N	I-Premise
10	including	N	I-Premise
11	grade	N	I-Premise
12	3/4	N	I-Premise
13	cardiac	N	I-Premise
14	events	N	I-Premise
15	(	N	I-Premise
16	AT	N	I-Premise
17	,	N	I-Premise
18	3	N	I-Premise
19	%	N	I-Premise
20	;	N	I-Premise
21	AC	N	I-Premise
22	,	N	I-Premise
23	4	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	AT	N	I-Claim
2	significantly	N	I-Claim
3	improves	N	I-Claim
4	TTP	N	I-Claim
5	and	N	I-Claim
6	ORR	N	I-Claim
7	compared	N	I-Claim
8	with	N	I-Claim
9	AC	N	I-Claim
10	in	N	I-Claim
11	patients	N	I-Claim
12	with	N	I-Claim
13	MBC	N	I-Claim
14	,	N	I-Claim
15	but	N	I-Claim
16	there	N	I-Claim
17	is	N	I-Claim
18	no	N	I-Claim
19	difference	N	I-Claim
20	in	N	I-Claim
21	OS	N	I-Claim
22	.	N	I-Claim

1	AT	N	I-Claim
2	represents	N	I-Claim
3	a	N	I-Claim
4	valid	N	I-Claim
5	option	N	I-Claim
6	for	N	I-Claim
7	the	N	I-Claim
8	treatment	N	I-Claim
9	of	N	I-Claim
10	MBC	N	I-Claim
11	.	N	I-Claim

1	Despite	N	I-MajorClaim
2	considerable	N	I-MajorClaim
3	improvement	N	I-MajorClaim
4	in	N	I-MajorClaim
5	the	N	I-MajorClaim
6	treatment	N	I-MajorClaim
7	of	N	I-MajorClaim
8	advanced	N	I-MajorClaim
9	ovarian	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	,	N	I-MajorClaim
12	the	N	I-MajorClaim
13	optimization	N	I-MajorClaim
14	of	N	I-MajorClaim
15	efficacy	N	I-MajorClaim
16	and	N	I-MajorClaim
17	tolerability	N	I-MajorClaim
18	remains	N	I-MajorClaim
19	an	N	I-MajorClaim
20	important	N	I-MajorClaim
21	issue	N	I-MajorClaim
22	.	N	I-MajorClaim

1	Therefore	N	O
2	,	N	O
3	we	N	O
4	performed	N	O
5	a	N	O
6	randomized	N	O
7	,	N	O
8	phase	N	O
9	III	N	O
10	non-inferiority	N	O
11	trial	N	O
12	comparing	N	O
13	paclitaxel	N	O
14	plus	N	O
15	cisplatin	N	O
16	(	N	O
17	PT	N	O
18	)	N	O
19	with	N	O
20	paclitaxel	N	O
21	plus	N	O
22	carboplatin	N	O
23	(	N	O
24	TC	N	O
25	)	N	O
26	in	N	O
27	patients	N	O
28	with	N	O
29	advanced	N	O
30	ovarian	N	O
31	cancer	N	O
32	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	798	N	O
5	patients	N	O
6	with	N	O
7	International	N	O
8	Federation	N	O
9	of	N	O
10	Gynecology	N	O
11	and	N	O
12	Obstetrics	N	O
13	stage	N	O
14	IIB-IV	N	O
15	were	N	O
16	randomly	N	O
17	assigned	N	O
18	to	N	O
19	receive	N	O
20	six	N	O
21	courses	N	O
22	of	N	O
23	either	N	O
24	PT	N	O
25	or	N	O
26	TC	N	O
27	at	N	O
28	3-week	N	O
29	intervals	N	O
30	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	the	N	O
6	proportion	N	O
7	of	N	O
8	patients	N	O
9	without	N	O
10	progression	N	O
11	at	N	O
12	2	N	O
13	years	N	O
14	.	N	O

1	Secondary	N	O
2	endpoints	N	O
3	included	N	O
4	toxicity	N	O
5	,	N	O
6	response	N	O
7	to	N	O
8	treatment	N	O
9	,	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	,	N	O
14	and	N	O
15	overall	N	O
16	and	N	O
17	progression-free	N	O
18	survival	N	O
19	time	N	O
20	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	evaluated	N	O
6	using	N	O
7	the	N	O
8	European	N	O
9	Organization	N	O
10	for	N	O
11	Research	N	O
12	and	N	O
13	Treatment	N	O
14	of	N	O
15	Cancer	N	O
16	quality-of-life	N	O
17	questionnaire	N	O
18	(	N	O
19	QLQ	N	O
20	)	N	O
21	-C30	N	O
22	,	N	O
23	version	N	O
24	2.0	N	O
25	.	N	O

1	Survival	N	O
2	curves	N	O
3	were	N	O
4	calculated	N	O
5	using	N	O
6	the	N	O
7	Kaplan-Meier	N	O
8	method	N	O
9	,	N	O
10	and	N	O
11	hazard	N	O
12	ratios	N	O
13	were	N	O
14	estimated	N	O
15	using	N	O
16	the	N	O
17	Cox	N	O
18	proportional	N	O
19	hazards	N	O
20	model	N	O
21	.	N	O

1	The	N	I-Premise
2	proportion	N	I-Premise
3	of	N	I-Premise
4	patients	N	I-Premise
5	without	N	I-Premise
6	progression	N	I-Premise
7	at	N	I-Premise
8	2	N	I-Premise
9	years	N	I-Premise
10	was	N	I-Premise
11	not	N	I-Premise
12	statistically	N	I-Premise
13	significantly	N	I-Premise
14	different	N	I-Premise
15	between	N	I-Premise
16	the	N	I-Premise
17	two	N	I-Premise
18	treatment	N	I-Premise
19	arms	N	I-Premise
20	(	N	I-Premise
21	40.0	N	I-Premise
22	%	N	I-Premise
23	for	N	I-Premise
24	PT	N	I-Premise
25	versus	N	I-Premise
26	37.5	N	I-Premise
27	%	N	I-Premise
28	for	N	I-Premise
29	TC	N	I-Premise
30	,	N	I-Premise
31	difference	N	I-Premise
32	=	N	I-Premise
33	2.5	N	I-Premise
34	%	N	I-Premise
35	,	N	I-Premise
36	one-sided	N	I-Premise
37	95	N	I-Premise
38	%	N	I-Premise
39	confidence	N	I-Premise
40	interval	N	I-Premise
41	[	N	I-Premise
42	CI	N	I-Premise
43	]	N	I-Premise
44	=	N	I-Premise
45	-	N	I-Premise
46	infinity	N	I-Premise
47	to	N	I-Premise
48	8.2	N	I-Premise
49	%	N	I-Premise
50	)	N	I-Premise
51	.	N	I-Premise

1	Median	N	I-Premise
2	progression-free	N	I-Premise
3	survival	N	I-Premise
4	time	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	TC	N	I-Premise
8	arm	N	I-Premise
9	(	N	I-Premise
10	17.2	N	I-Premise
11	months	N	I-Premise
12	,	N	I-Premise
13	95	N	I-Premise
14	%	N	I-Premise
15	CI	N	I-Premise
16	=	N	I-Premise
17	15.2	N	I-Premise
18	to	N	I-Premise
19	19.3	N	I-Premise
20	months	N	I-Premise
21	)	N	I-Premise
22	and	N	I-Premise
23	the	N	I-Premise
24	PT	N	I-Premise
25	arm	N	I-Premise
26	(	N	I-Premise
27	19.1	N	I-Premise
28	months	N	I-Premise
29	,	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	CI	N	I-Premise
33	=	N	I-Premise
34	16.7	N	I-Premise
35	to	N	I-Premise
36	21.5	N	I-Premise
37	months	N	I-Premise
38	)	N	I-Premise
39	were	N	I-Premise
40	also	N	I-Premise
41	not	N	I-Premise
42	statistically	N	I-Premise
43	significantly	N	I-Premise
44	different	N	I-Premise
45	;	N	I-Premise
46	the	N	I-Premise
47	same	N	I-Premise
48	was	N	I-Premise
49	true	N	I-Premise
50	of	N	I-Premise
51	median	N	I-Premise
52	overall	N	I-Premise
53	survival	N	I-Premise
54	time	N	I-Premise
55	(	N	I-Premise
56	43.3	N	I-Premise
57	months	N	I-Premise
58	,	N	I-Premise
59	95	N	I-Premise
60	%	N	I-Premise
61	CI	N	I-Premise
62	=	N	I-Premise
63	37.2	N	I-Premise
64	to	N	I-Premise
65	47.8	N	I-Premise
66	months	N	I-Premise
67	versus	N	I-Premise
68	44.1	N	I-Premise
69	months	N	I-Premise
70	,	N	I-Premise
71	95	N	I-Premise
72	%	N	I-Premise
73	CI	N	I-Premise
74	=	N	I-Premise
75	40.2	N	I-Premise
76	to	N	I-Premise
77	49.4	N	I-Premise
78	months	N	I-Premise
79	,	N	I-Premise
80	for	N	I-Premise
81	the	N	I-Premise
82	TC	N	I-Premise
83	and	N	I-Premise
84	PT	N	I-Premise
85	arms	N	I-Premise
86	,	N	I-Premise
87	respectively	N	I-Premise
88	)	N	I-Premise
89	.	N	I-Premise

1	The	N	I-Premise
2	TC	N	I-Premise
3	regimen	N	I-Premise
4	was	N	I-Premise
5	associated	N	I-Premise
6	with	N	I-Premise
7	a	N	I-Premise
8	higher	N	I-Premise
9	frequency	N	I-Premise
10	of	N	I-Premise
11	hematologic	N	I-Premise
12	toxicity	N	I-Premise
13	,	N	I-Premise
14	but	N	I-Premise
15	a	N	I-Premise
16	lower	N	I-Premise
17	frequency	N	I-Premise
18	of	N	I-Premise
19	gastrointestinal	N	I-Premise
20	and	N	I-Premise
21	neurologic	N	I-Premise
22	toxicity	N	I-Premise
23	,	N	I-Premise
24	than	N	I-Premise
25	the	N	I-Premise
26	PT	N	I-Premise
27	regimen	N	I-Premise
28	.	N	I-Premise

1	Mean	N	I-Premise
2	global	N	I-Premise
3	quality-of-life	N	I-Premise
4	scores	N	I-Premise
5	at	N	I-Premise
6	the	N	I-Premise
7	end	N	I-Premise
8	of	N	I-Premise
9	treatment	N	I-Premise
10	were	N	I-Premise
11	statistically	N	I-Premise
12	significantly	N	I-Premise
13	better	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	TC	N	I-Premise
17	arm	N	I-Premise
18	than	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	PT	N	I-Premise
22	arm	N	I-Premise
23	(	N	I-Premise
24	65.25	N	I-Premise
25	versus	N	I-Premise
26	51.97	N	I-Premise
27	,	N	I-Premise
28	respectively	N	I-Premise
29	;	N	I-Premise
30	difference	N	I-Premise
31	=	N	I-Premise
32	-13.28	N	I-Premise
33	,	N	I-Premise
34	95	N	I-Premise
35	%	N	I-Premise
36	CI	N	I-Premise
37	=	N	I-Premise
38	-18.88	N	I-Premise
39	to	N	I-Premise
40	-7.68	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	The	N	I-Claim
2	TC	N	I-Claim
3	regimen	N	I-Claim
4	achieved	N	I-Claim
5	comparable	N	I-Claim
6	efficacy	N	I-Claim
7	to	N	I-Claim
8	the	N	I-Claim
9	PT	N	I-Claim
10	regimen	N	I-Claim
11	but	N	I-Claim
12	was	N	I-Claim
13	associated	N	I-Claim
14	with	N	I-Claim
15	better	N	I-Claim
16	tolerability	N	I-Claim
17	and	N	I-Claim
18	quality	N	I-Claim
19	of	N	I-Claim
20	life	N	I-Claim
21	,	N	I-Claim
22	and	N	I-Claim
23	should	N	I-Claim
24	,	N	I-Claim
25	therefore	N	I-Claim
26	,	N	I-Claim
27	be	N	I-Claim
28	considered	N	I-Claim
29	as	N	I-Claim
30	an	N	I-Claim
31	important	N	I-Claim
32	alternative	N	I-Claim
33	for	N	I-Claim
34	standard	N	I-Claim
35	first-line	N	I-Claim
36	chemotherapy	N	I-Claim
37	in	N	I-Claim
38	patients	N	I-Claim
39	with	N	I-Claim
40	advanced	N	I-Claim
41	ovarian	N	I-Claim
42	cancer	N	I-Claim
43	.	N	I-Claim

1	This	N	O
2	trial	N	O
3	was	N	O
4	conducted	N	O
5	to	N	O
6	determine	N	O
7	whether	N	O
8	high-dose	N	O
9	fluorouracil	N	O
10	(	N	O
11	FU	N	O
12	)	N	O
13	given	N	O
14	as	N	O
15	a	N	O
16	weekly	N	O
17	24-hour	N	O
18	infusion	N	O
19	is	N	O
20	more	N	O
21	active	N	O
22	than	N	O
23	bolus	N	O
24	FU	N	O
25	+	N	O
26	leucovorin	N	O
27	(	N	O
28	LV	N	O
29	)	N	O
30	,	N	O
31	and	N	O
32	whether	N	O
33	high-dose	N	O
34	infusional	N	O
35	FU	N	O
36	can	N	O
37	be	N	O
38	modulated	N	O
39	by	N	O
40	LV	N	O
41	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	497	N	O
5	patients	N	O
6	with	N	O
7	previously	N	O
8	untreated	N	O
9	metastatic	N	O
10	colorectal	N	O
11	cancer	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	to	N	O
16	receive	N	O
17	bolus	N	O
18	FU	N	O
19	425	N	O
20	mg/m2	N	O
21	intravenously	N	O
22	+	N	O
23	LV	N	O
24	20	N	O
25	mg/m2	N	O
26	on	N	O
27	days	N	O
28	1	N	O
29	to	N	O
30	5	N	O
31	and	N	O
32	repeated	N	O
33	on	N	O
34	day	N	O
35	28	N	O
36	(	N	O
37	FU	N	O
38	+	N	O
39	LV	N	O
40	)	N	O
41	,	N	O
42	or	N	O
43	FU	N	O
44	2600	N	O
45	mg/m2	N	O
46	as	N	O
47	a	N	O
48	24-hour	N	O
49	infusion	N	O
50	alone	N	O
51	(	N	O
52	FU24h	N	O
53	)	N	O
54	or	N	O
55	in	N	O
56	combination	N	O
57	with	N	O
58	500	N	O
59	mg/m2	N	O
60	LV	N	O
61	(	N	O
62	FU24h	N	O
63	+	N	O
64	LV	N	O
65	)	N	O
66	-all	N	O
67	given	N	O
68	weekly	N	O
69	x6	N	O
70	followed	N	O
71	by	N	O
72	a	N	O
73	2-week	N	O
74	rest	N	O
75	period	N	O
76	.	N	O

1	Survival	N	O
2	was	N	O
3	the	N	O
4	major	N	O
5	study	N	O
6	end	N	O
7	point	N	O
8	.	N	O

1	With	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	more	N	I-Premise
7	than	N	I-Premise
8	3	N	I-Premise
9	years	N	I-Premise
10	,	N	I-Premise
11	survival	N	I-Premise
12	did	N	I-Premise
13	not	N	I-Premise
14	differ	N	I-Premise
15	among	N	I-Premise
16	the	N	I-Premise
17	treatment	N	I-Premise
18	groups	N	I-Premise
19	(	N	I-Premise
20	median	N	I-Premise
21	FU	N	I-Premise
22	+	N	I-Premise
23	LV	N	I-Premise
24	,	N	I-Premise
25	11.1	N	I-Premise
26	months	N	I-Premise
27	[	N	I-Premise
28	95	N	I-Premise
29	%	N	I-Premise
30	CI	N	I-Premise
31	,	N	I-Premise
32	10.2	N	I-Premise
33	to	N	I-Premise
34	15.0	N	I-Premise
35	months	N	I-Premise
36	]	N	I-Premise
37	;	N	I-Premise
38	FU24h	N	I-Premise
39	,	N	I-Premise
40	13.0	N	I-Premise
41	months	N	I-Premise
42	[	N	I-Premise
43	95	N	I-Premise
44	%	N	I-Premise
45	CI	N	I-Premise
46	,	N	I-Premise
47	10.4	N	I-Premise
48	to	N	I-Premise
49	15.4	N	I-Premise
50	months	N	I-Premise
51	]	N	I-Premise
52	;	N	I-Premise
53	FU24h	N	I-Premise
54	+	N	I-Premise
55	LV	N	I-Premise
56	,	N	I-Premise
57	13.7	N	I-Premise
58	months	N	I-Premise
59	[	N	I-Premise
60	95	N	I-Premise
61	%	N	I-Premise
62	CI	N	I-Premise
63	,	N	I-Premise
64	12.0	N	I-Premise
65	to	N	I-Premise
66	16.4	N	I-Premise
67	months	N	I-Premise
68	]	N	I-Premise
69	;	N	I-Premise
70	P	N	I-Premise
71	=.724	N	I-Premise
72	)	N	I-Premise
73	.	N	I-Premise

1	Progression-free	N	I-Premise
2	survival	N	I-Premise
3	(	N	I-Premise
4	PFS	N	I-Premise
5	)	N	I-Premise
6	was	N	I-Premise
7	significantly	N	I-Premise
8	longer	N	I-Premise
9	for	N	I-Premise
10	FU24h	N	I-Premise
11	+	N	I-Premise
12	LV	N	I-Premise
13	(	N	I-Premise
14	median	N	I-Premise
15	FU	N	I-Premise
16	+	N	I-Premise
17	LV	N	I-Premise
18	,	N	I-Premise
19	4.0	N	I-Premise
20	months	N	I-Premise
21	[	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	,	N	I-Premise
26	3.4	N	I-Premise
27	to	N	I-Premise
28	4.9	N	I-Premise
29	]	N	I-Premise
30	;	N	I-Premise
31	FU24h	N	I-Premise
32	,	N	I-Premise
33	4.1	N	I-Premise
34	months	N	I-Premise
35	[	N	I-Premise
36	95	N	I-Premise
37	%	N	I-Premise
38	CI	N	I-Premise
39	,	N	I-Premise
40	3.4	N	I-Premise
41	to	N	I-Premise
42	5.0	N	I-Premise
43	]	N	I-Premise
44	;	N	I-Premise
45	FU24h	N	I-Premise
46	+	N	I-Premise
47	LV	N	I-Premise
48	5.6	N	I-Premise
49	months	N	I-Premise
50	[	N	I-Premise
51	95	N	I-Premise
52	%	N	I-Premise
53	CI	N	I-Premise
54	,	N	I-Premise
55	4.4	N	I-Premise
56	to	N	I-Premise
57	6.7	N	I-Premise
58	]	N	I-Premise
59	;	N	I-Premise
60	P	N	I-Premise
61	=.029	N	I-Premise
62	)	N	I-Premise
63	.	N	I-Premise

1	The	N	I-Premise
2	response	N	I-Premise
3	rates	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	subgroup	N	I-Premise
7	of	N	I-Premise
8	patients	N	I-Premise
9	with	N	I-Premise
10	measurable	N	I-Premise
11	disease	N	I-Premise
12	were	N	I-Premise
13	12	N	I-Premise
14	%	N	I-Premise
15	,	N	I-Premise
16	10	N	I-Premise
17	%	N	I-Premise
18	,	N	I-Premise
19	and	N	I-Premise
20	17	N	I-Premise
21	%	N	I-Premise
22	for	N	I-Premise
23	FU	N	I-Premise
24	+	N	I-Premise
25	LV	N	I-Premise
26	,	N	I-Premise
27	FU24h	N	I-Premise
28	,	N	I-Premise
29	and	N	I-Premise
30	FU24h	N	I-Premise
31	+	N	I-Premise
32	LV	N	I-Premise
33	,	N	I-Premise
34	respectively	N	I-Premise
35	(	N	I-Premise
36	not	N	I-Premise
37	significant	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	Occurrence	N	I-Premise
2	of	N	I-Premise
3	grade	N	I-Premise
4	3	N	I-Premise
5	and	N	I-Premise
6	4	N	I-Premise
7	diarrhea	N	I-Premise
8	was	N	I-Premise
9	higher	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	FU24h	N	I-Premise
13	+	N	I-Premise
14	LV	N	I-Premise
15	arm	N	I-Premise
16	(	N	I-Premise
17	22	N	I-Premise
18	%	N	I-Premise
19	)	N	I-Premise
20	compared	N	I-Premise
21	with	N	I-Premise
22	the	N	I-Premise
23	FU24h	N	I-Premise
24	(	N	I-Premise
25	6	N	I-Premise
26	%	N	I-Premise
27	)	N	I-Premise
28	or	N	I-Premise
29	FU	N	I-Premise
30	+	N	I-Premise
31	LV	N	I-Premise
32	(	N	I-Premise
33	9	N	I-Premise
34	%	N	I-Premise
35	)	N	I-Premise
36	arms	N	I-Premise
37	;	N	I-Premise
38	however	N	I-Premise
39	,	N	I-Premise
40	stomatitis	N	I-Premise
41	(	N	I-Premise
42	11	N	I-Premise
43	%	N	I-Premise
44	in	N	I-Premise
45	FU	N	I-Premise
46	+	N	I-Premise
47	LV	N	I-Premise
48	v	N	I-Premise
49	3	N	I-Premise
50	%	N	I-Premise
51	in	N	I-Premise
52	FU24h	N	I-Premise
53	v	N	I-Premise
54	5	N	I-Premise
55	%	N	I-Premise
56	in	N	I-Premise
57	FU24h	N	I-Premise
58	+	N	I-Premise
59	LV	N	I-Premise
60	arms	N	I-Premise
61	)	N	I-Premise
62	and	N	I-Premise
63	hematologic	N	I-Premise
64	toxicity	N	I-Premise
65	were	N	I-Premise
66	higher	N	I-Premise
67	in	N	I-Premise
68	the	N	I-Premise
69	bolus	N	I-Premise
70	FU	N	I-Premise
71	+	N	I-Premise
72	LV	N	I-Premise
73	arm	N	I-Premise
74	.	N	I-Premise

1	Global	N	I-Claim
2	quality	N	I-Claim
3	of	N	I-Claim
4	life	N	I-Claim
5	did	N	I-Claim
6	not	N	I-Claim
7	differ	N	I-Claim
8	within	N	I-Claim
9	the	N	I-Claim
10	three	N	I-Claim
11	arms	N	I-Claim
12	.	N	I-Claim

1	Neither	N	I-Claim
2	FU24h	N	I-Claim
3	+	N	I-Claim
4	LV	N	I-Claim
5	nor	N	I-Claim
6	FU24h	N	I-Claim
7	prolong	N	I-Claim
8	survival	N	I-Claim
9	,	N	I-Claim
10	relative	N	I-Claim
11	to	N	I-Claim
12	bolus	N	I-Claim
13	FU	N	I-Claim
14	+	N	I-Claim
15	LV	N	I-Claim
16	.	N	I-Claim

1	Leucovorin	N	I-Claim
2	increases	N	I-Claim
3	PFS	N	I-Claim
4	if	N	I-Claim
5	added	N	I-Claim
6	to	N	I-Claim
7	FU24h	N	I-Claim
8	,	N	I-Claim
9	but	N	I-Claim
10	increases	N	I-Claim
11	toxicity	N	I-Claim
12	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	patient-reported	N	O
4	prostate	N	O
5	cancer-specific	N	O
6	quality	N	O
7	of	N	O
8	life	N	O
9	2	N	O
10	and	N	O
11	3	N	O
12	years	N	O
13	after	N	O
14	radiotherapy	N	O
15	to	N	O
16	the	N	O
17	prostate	N	O
18	in	N	O
19	a	N	O
20	randomized	N	O
21	dose-escalation	N	O
22	trial	N	O
23	of	N	O
24	70	N	O
25	versus	N	O
26	78	N	O
27	Gy	N	O
28	conducted	N	O
29	from	N	O
30	1993	N	O
31	to	N	O
32	1998	N	O
33	.	N	O

1	Two	N	O
2	years	N	O
3	after	N	O
4	completing	N	O
5	radiotherapy	N	O
6	,	N	O
7	a	N	O
8	questionnaire	N	O
9	that	N	O
10	assessed	N	O
11	bladder	N	O
12	,	N	O
13	rectal	N	O
14	,	N	O
15	and	N	O
16	sexual	N	O
17	function	N	O
18	was	N	O
19	sent	N	O
20	to	N	O
21	301	N	O
22	patients	N	O
23	in	N	O
24	the	N	O
25	study	N	O
26	.	N	O

1	Three	N	O
2	years	N	O
3	after	N	O
4	treatment	N	O
5	,	N	O
6	a	N	O
7	second	N	O
8	questionnaire	N	O
9	was	N	O
10	sent	N	O
11	to	N	O
12	the	N	O
13	175	N	O
14	patients	N	O
15	with	N	O
16	adequate	N	O
17	follow-up	N	O
18	.	N	O

1	Three	N	I-Premise
2	years	N	I-Premise
3	after	N	I-Premise
4	radiotherapy	N	I-Premise
5	,	N	I-Premise
6	urinary	N	I-Premise
7	incontinence	N	I-Premise
8	was	N	I-Premise
9	reported	N	I-Premise
10	by	N	I-Premise
11	35	N	I-Premise
12	%	N	I-Premise
13	of	N	I-Premise
14	patients	N	I-Premise
15	,	N	I-Premise
16	but	N	I-Premise
17	only	N	I-Premise
18	6	N	I-Premise
19	%	N	I-Premise
20	required	N	I-Premise
21	the	N	I-Premise
22	use	N	I-Premise
23	of	N	I-Premise
24	a	N	I-Premise
25	pad	N	I-Premise
26	or	N	I-Premise
27	other	N	I-Premise
28	protective	N	I-Premise
29	device	N	I-Premise
30	.	N	I-Premise

1	Patients	N	I-Premise
2	reported	N	I-Premise
3	increased	N	I-Premise
4	leakage	N	I-Premise
5	with	N	I-Premise
6	a	N	I-Premise
7	full	N	I-Premise
8	bladder	N	I-Premise
9	(	N	I-Premise
10	urge	N	I-Premise
11	incontinence	N	I-Premise
12	)	N	I-Premise
13	between	N	I-Premise
14	the	N	I-Premise
15	2	N	I-Premise
16	and	N	I-Premise
17	3-year	N	I-Premise
18	questionnaires	N	I-Premise
19	(	N	I-Premise
20	42	N	I-Premise
21	%	N	I-Premise
22	versus	N	I-Premise
23	50	N	I-Premise
24	%	N	I-Premise
25	;	N	I-Premise
26	P	N	I-Premise
27	=	N	I-Premise
28	0.03	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	At	N	I-Premise
2	3	N	I-Premise
3	years	N	I-Premise
4	,	N	I-Premise
5	33	N	I-Premise
6	%	N	I-Premise
7	of	N	I-Premise
8	patients	N	I-Premise
9	reported	N	I-Premise
10	rectal	N	I-Premise
11	bleeding	N	I-Premise
12	compared	N	I-Premise
13	with	N	I-Premise
14	47	N	I-Premise
15	%	N	I-Premise
16	at	N	I-Premise
17	2	N	I-Premise
18	years	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	0.006	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	78-Gy	N	I-Premise
5	arm	N	I-Premise
6	reported	N	I-Premise
7	more	N	I-Premise
8	frequent	N	I-Premise
9	bowel	N	I-Premise
10	movements	N	I-Premise
11	at	N	I-Premise
12	3	N	I-Premise
13	years	N	I-Premise
14	and	N	I-Premise
15	less	N	I-Premise
16	change	N	I-Premise
17	in	N	I-Premise
18	bowel	N	I-Premise
19	function	N	I-Premise
20	at	N	I-Premise
21	2	N	I-Premise
22	years	N	I-Premise
23	than	N	I-Premise
24	patients	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	70-Gy	N	I-Premise
28	arm	N	I-Premise
29	.	N	I-Premise

1	Before	N	I-Premise
2	radiotherapy	N	I-Premise
3	,	N	I-Premise
4	84	N	I-Premise
5	%	N	I-Premise
6	of	N	I-Premise
7	patients	N	I-Premise
8	reported	N	I-Premise
9	erections	N	I-Premise
10	adequate	N	I-Premise
11	for	N	I-Premise
12	intercourse	N	I-Premise
13	at	N	I-Premise
14	least	N	I-Premise
15	a	N	I-Premise
16	few	N	I-Premise
17	times	N	I-Premise
18	during	N	I-Premise
19	the	N	I-Premise
20	previous	N	I-Premise
21	year	N	I-Premise
22	.	N	I-Premise

1	After	N	I-Premise
2	2	N	I-Premise
3	and	N	I-Premise
4	3	N	I-Premise
5	years	N	I-Premise
6	,	N	I-Premise
7	this	N	I-Premise
8	had	N	I-Premise
9	decreased	N	I-Premise
10	to	N	I-Premise
11	49	N	I-Premise
12	%	N	I-Premise
13	and	N	I-Premise
14	41	N	I-Premise
15	%	N	I-Premise
16	,	N	I-Premise
17	respectively	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	0.02	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	By	N	I-Claim
2	patient-reported	N	I-Claim
3	questionnaire	N	I-Claim
4	,	N	I-Claim
5	78	N	I-Claim
6	Gy	N	I-Claim
7	produced	N	I-Claim
8	an	N	I-Claim
9	increase	N	I-Claim
10	in	N	I-Claim
11	bowel	N	I-Claim
12	movement	N	I-Claim
13	frequency	N	I-Claim
14	and	N	I-Claim
15	no	N	I-Claim
16	increase	N	I-Claim
17	in	N	I-Claim
18	bladder	N	I-Claim
19	or	N	I-Claim
20	sexual	N	I-Claim
21	side	N	I-Claim
22	effects	N	I-Claim
23	at	N	I-Claim
24	3	N	I-Claim
25	years	N	I-Claim
26	compared	N	I-Claim
27	with	N	I-Claim
28	70	N	I-Claim
29	Gy	N	I-Claim
30	.	N	I-Claim

1	Comparing	N	I-Claim
2	the	N	I-Claim
3	results	N	I-Claim
4	2	N	I-Claim
5	and	N	I-Claim
6	3	N	I-Claim
7	years	N	I-Claim
8	after	N	I-Claim
9	radiotherapy	N	I-Claim
10	,	N	I-Claim
11	the	N	I-Claim
12	symptoms	N	I-Claim
13	of	N	I-Claim
14	rectal	N	I-Claim
15	bleeding	N	I-Claim
16	had	N	I-Claim
17	improved	N	I-Claim
18	,	N	I-Claim
19	erectile	N	I-Claim
20	function	N	I-Claim
21	had	N	I-Claim
22	decreased	N	I-Claim
23	,	N	I-Claim
24	and	N	I-Claim
25	urinary	N	I-Claim
26	urge	N	I-Claim
27	incontinence	N	I-Claim
28	had	N	I-Claim
29	increased	N	I-Claim
30	.	N	I-Claim

1	In	N	I-Premise
2	a	N	I-Premise
3	multinational	N	I-Premise
4	trial	N	I-Premise
5	of	N	I-Premise
6	anaemic	N	I-Premise
7	patients	N	I-Premise
8	with	N	I-Premise
9	cancer	N	I-Premise
10	receiving	N	I-Premise
11	nonplatinum-containing	N	I-Premise
12	chemotherapy	N	I-Premise
13	,	N	I-Premise
14	epoetin-alfa	N	I-Premise
15	effectively	N	I-Premise
16	increased	N	I-Premise
17	haemoglobin	N	I-Premise
18	levels	N	I-Premise
19	,	N	I-Premise
20	reduced	N	I-Premise
21	red	N	I-Premise
22	blood	N	I-Premise
23	cell	N	I-Premise
24	transfusion	N	I-Premise
25	requirements	N	I-Premise
26	,	N	I-Premise
27	and	N	I-Premise
28	improved	N	I-Premise
29	QOL	N	I-Premise
30	.	N	I-Premise

1	Although	N	O
2	the	N	O
3	study	N	O
4	was	N	O
5	not	N	O
6	designed	N	O
7	or	N	O
8	powered	N	O
9	to	N	O
10	evaluate	N	O
11	survival	N	O
12	,	N	O
13	a	N	I-Premise
14	survival	N	I-Premise
15	trend	N	I-Premise
16	was	N	I-Premise
17	noted	N	I-Premise
18	favouring	N	I-Premise
19	epoetin-alfa	N	I-Premise
20	compared	N	I-Premise
21	with	N	I-Premise
22	placebo	N	I-Premise
23	(	N	I-Premise
24	median	N	I-Premise
25	survival	N	I-Premise
26	17	N	I-Premise
27	vs	N	I-Premise
28	11	N	I-Premise
29	months	N	I-Premise
30	[	N	I-Premise
31	p	N	I-Premise
32	=	N	I-Premise
33	0.126	N	I-Premise
34	]	N	I-Premise
35	)	N	I-Premise
36	.	N	I-Premise

1	To	N	O
2	determine	N	O
3	the	N	O
4	incremental	N	O
5	cost	N	O
6	utility	N	O
7	of	N	O
8	epoetin-alfa	N	O
9	versus	N	O
10	placebo	N	O
11	in	N	O
12	anaemic	N	O
13	patients	N	O
14	with	N	O
15	stage	N	O
16	IV	N	O
17	breast	N	O
18	cancer	N	O
19	from	N	O
20	a	N	O
21	UK	N	O
22	National	N	O
23	Health	N	O
24	Service	N	O
25	perspective	N	O
26	.	N	O

1	Patient	N	O
2	data	N	O
3	regarding	N	O
4	transfusions	N	O
5	,	N	O
6	epoetin-alfa	N	O
7	usage	N	O
8	,	N	O
9	chemotherapy	N	O
10	treatment	N	O
11	cycles	N	O
12	,	N	O
13	and	N	O
14	adverse	N	O
15	events	N	O
16	were	N	O
17	recorded	N	O
18	,	N	O
19	with	N	O
20	survival	N	O
21	follow-up	N	O
22	for	N	O
23	12-36	N	O
24	months	N	O
25	post-study	N	O
26	.	N	O

1	Stage	N	O
2	IV	N	O
3	breast	N	O
4	cancer	N	O
5	therapy	N	O
6	costs	N	O
7	were	N	O
8	collected	N	O
9	by	N	O
10	surveying	N	O
11	UK	N	O
12	oncologists	N	O
13	,	N	O
14	and	N	O
15	utilities	N	O
16	for	N	O
17	associated	N	O
18	health	N	O
19	states	N	O
20	were	N	O
21	from	N	O
22	published	N	O
23	sources	N	O
24	.	N	O

1	Costs	N	O
2	were	N	O
3	in	N	O
4	British	N	O
5	pounds	N	O
6	and	N	O
7	year	N	O
8	2000	N	O
9	values	N	O
10	.	N	O

1	Costs	N	O
2	and	N	O
3	benefits	N	O
4	were	N	O
5	jointly	N	O
6	determined	N	O
7	for	N	O
8	the	N	O
9	stage	N	O
10	IV	N	O
11	breast	N	O
12	cancer	N	O
13	subgroup	N	O
14	(	N	O
15	n	N	O
16	=	N	O
17	55	N	O
18	)	N	O
19	.	N	O

1	Incremental	N	O
2	cost-utility	N	O
3	ratios	N	O
4	(	N	O
5	ICURs	N	O
6	)	N	O
7	were	N	O
8	calculated	N	O
9	assuming	N	O
10	a	N	O
11	6	N	O
12	%	N	O
13	annual	N	O
14	discount	N	O
15	rate	N	O
16	for	N	O
17	costs	N	O
18	and	N	O
19	a	N	O
20	1.5	N	O
21	%	N	O
22	annual	N	O
23	discount	N	O
24	rate	N	O
25	for	N	O
26	benefits	N	O
27	.	N	O

1	Bootstrap	N	O
2	simulations	N	O
3	(	N	O
4	10,000	N	O
5	iterations	N	O
6	)	N	O
7	were	N	O
8	conducted	N	O
9	to	N	O
10	account	N	O
11	for	N	O
12	uncertainty	N	O
13	,	N	O
14	and	N	O
15	sensitivity	N	O
16	analyses	N	O
17	were	N	O
18	conducted	N	O
19	to	N	O
20	establish	N	O
21	robustness	N	O
22	.	N	O

1	The	N	I-Premise
2	ICUR	N	I-Premise
3	for	N	I-Premise
4	epoetin-alfa	N	I-Premise
5	treatment	N	I-Premise
6	was	N	I-Premise
7	pounds	N	I-Premise
8	8,851	N	I-Premise
9	per	N	I-Premise
10	QALY	N	I-Premise
11	,	N	I-Premise
12	with	N	I-Premise
13	a	N	I-Premise
14	99	N	I-Premise
15	%	N	I-Premise
16	probability	N	I-Premise
17	of	N	I-Premise
18	a	N	I-Premise
19	positive	N	I-Premise
20	net	N	I-Premise
21	benefit	N	I-Premise
22	in	N	I-Premise
23	QALYs	N	I-Premise
24	(	N	I-Premise
25	net	N	I-Premise
26	benefit	N	I-Premise
27	=	N	I-Premise
28	0.4805	N	I-Premise
29	years	N	I-Premise
30	of	N	I-Premise
31	perfect	N	I-Premise
32	life	N	I-Premise
33	)	N	I-Premise
34	and	N	I-Premise
35	a	N	I-Premise
36	94	N	I-Premise
37	%	N	I-Premise
38	probability	N	I-Premise
39	of	N	I-Premise
40	being	N	I-Premise
41	acceptable	N	I-Premise
42	using	N	I-Premise
43	a	N	I-Premise
44	threshold	N	I-Premise
45	ICUR	N	I-Premise
46	of	N	I-Premise
47	pounds	N	I-Premise
48	30,000/QALY	N	I-Premise
49	.	N	I-Premise

1	The	N	I-Premise
2	main	N	I-Premise
3	cost	N	I-Premise
4	drivers	N	I-Premise
5	distinguishing	N	I-Premise
6	epoetin-alfa	N	I-Premise
7	from	N	I-Premise
8	placebo	N	I-Premise
9	were	N	I-Premise
10	the	N	I-Premise
11	costs	N	I-Premise
12	of	N	I-Premise
13	drug	N	I-Premise
14	and	N	I-Premise
15	patient	N	I-Premise
16	care	N	I-Premise
17	due	N	I-Premise
18	to	N	I-Premise
19	increased	N	I-Premise
20	survival	N	I-Premise
21	.	N	I-Premise

1	The	N	I-Claim
2	available	N	I-Claim
3	data	N	I-Claim
4	suggest	N	I-Claim
5	a	N	I-Claim
6	high	N	I-Claim
7	probability	N	I-Claim
8	of	N	I-Claim
9	favourable	N	I-Claim
10	cost-utility	N	I-Claim
11	outcomes	N	I-Claim
12	with	N	I-Claim
13	epoetin-alfa	N	I-Claim
14	treatment	N	I-Claim
15	for	N	I-Claim
16	anaemia	N	I-Claim
17	in	N	I-Claim
18	patients	N	I-Claim
19	with	N	I-Claim
20	stage	N	I-Claim
21	IV	N	I-Claim
22	breast	N	I-Claim
23	cancer	N	I-Claim
24	receiving	N	I-Claim
25	nonplatinum-containing	N	I-Claim
26	chemotherapy	N	I-Claim
27	.	N	I-Claim

1	Additional	N	I-Claim
2	studies	N	I-Claim
3	are	N	I-Claim
4	warranted	N	I-Claim
5	.	N	I-Claim

1	In	N	I-Claim
2	advanced	N	I-Claim
3	not	N	I-Claim
4	selected	N	I-Claim
5	NSCLC	N	I-Claim
6	chemotherapy	N	I-Claim
7	achieved	N	I-Claim
8	an	N	I-Claim
9	advantage	N	I-Claim
10	of	N	I-Claim
11	approximately	N	I-Claim
12	1-2	N	I-Claim
13	months	N	I-Claim
14	on	N	I-Claim
15	median	N	I-Claim
16	survival	N	I-Claim
17	versus	N	I-Claim
18	best	N	I-Claim
19	supportive	N	I-Claim
20	care	N	I-Claim
21	.	N	I-Claim

1	Chemotherapy	N	I-Claim
2	seems	N	I-Claim
3	to	N	I-Claim
4	improve	N	I-Claim
5	symptoms	N	I-Claim
6	control	N	I-Claim
7	,	N	I-Claim
8	even	N	O
9	if	N	O
10	randomised	N	O
11	studies	N	O
12	with	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	as	N	O
17	first	N	O
18	endpoint	N	O
19	are	N	O
20	lacking	N	O
21	and	N	O
22	often	N	O
23	chemotherapy	N	O
24	toxicity	N	O
25	compromises	N	O
26	the	N	O
27	frail	N	O
28	cost/benefit	N	O
29	ratio	N	O
30	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	present	N	O
6	study	N	O
7	is	N	O
8	to	N	O
9	evaluate	N	O
10	the	N	O
11	impact	N	O
12	on	N	O
13	QoL	N	O
14	,	N	O
15	substituting	N	O
16	cisplatin	N	O
17	,	N	O
18	a	N	O
19	pivot	N	O
20	drug	N	O
21	in	N	O
22	NSCLC	N	O
23	therapy	N	O
24	,	N	O
25	with	N	O
26	carboplatin	N	O
27	,	N	O
28	an	N	O
29	analogue	N	O
30	with	N	O
31	an	N	O
32	improved	N	O
33	toxicity	N	O
34	profile	N	O
35	.	N	O

1	The	N	O
2	combination	N	O
3	of	N	O
4	cisplatin	N	O
5	with	N	O
6	Mitomycin	N	O
7	and	N	O
8	Vinblastine	N	O
9	was	N	O
10	one	N	O
11	of	N	O
12	the	N	O
13	most	N	O
14	frequently	N	O
15	used	N	O
16	in	N	O
17	the	N	O
18	palliative	N	O
19	setting	N	O
20	at	N	O
21	the	N	O
22	time	N	O
23	of	N	O
24	design	N	O
25	of	N	O
26	our	N	O
27	study	N	O
28	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	receive	N	O
6	MVP	N	O
7	regimen	N	O
8	(	N	O
9	Mitomycin-C	N	O
10	8	N	O
11	mg/m2	N	O
12	d1	N	O
13	,	N	O
14	Vinblastine	N	O
15	4	N	O
16	mg/m2	N	O
17	d	N	O
18	1-8	N	O
19	,	N	O
20	Cisplatin	N	O
21	100	N	O
22	mg/m2	N	O
23	d1	N	O
24	)	N	O
25	or	N	O
26	MVC	N	O
27	regimen	N	O
28	(	N	O
29	Mitomycin-C	N	O
30	8	N	O
31	mg/m2	N	O
32	d1	N	O
33	,	N	O
34	Vinblastine	N	O
35	4	N	O
36	mg/m2	N	O
37	d	N	O
38	1-8	N	O
39	,	N	O
40	Carboplatin	N	O
41	300	N	O
42	mg/m2	N	O
43	d1	N	O
44	)	N	O
45	every	N	O
46	3	N	O
47	weeks	N	O
48	.	N	O

1	The	N	O
2	QoL	N	O
3	was	N	O
4	evaluated	N	O
5	by	N	O
6	the	N	O
7	Spitzer	N	O
8	QL-Index	N	O
9	and	N	O
10	by	N	O
11	the	N	O
12	EORTC	N	O
13	QLQ-C30+LC	N	O
14	13	N	O
15	questionnaires	N	O
16	before	N	O
17	chemotherapy	N	O
18	,	N	O
19	after	N	O
20	one	N	O
21	cycle	N	O
22	,	N	O
23	after	N	O
24	three	N	O
25	cycles	N	O
26	,	N	O
27	and	N	O
28	then	N	O
29	every	N	O
30	6	N	O
31	weeks	N	O
32	in	N	O
33	the	N	O
34	first	N	O
35	6	N	O
36	months	N	O
37	and	N	O
38	every	N	O
39	3	N	O
40	months	N	O
41	thenafter	N	O
42	.	N	O

1	From	N	O
2	September	N	O
3	1994	N	O
4	to	N	O
5	July	N	O
6	1997	N	O
7	,	N	O
8	153	N	O
9	consecutive	N	O
10	patients	N	O
11	were	N	O
12	randomized	N	O
13	to	N	O
14	MVP	N	O
15	(	N	O
16	75	N	O
17	patients	N	O
18	)	N	O
19	or	N	O
20	MVC	N	O
21	arm	N	O
22	(	N	O
23	78	N	O
24	patients	N	O
25	)	N	O
26	.	N	O

1	Despite	N	I-Premise
2	difficulties	N	I-Premise
3	in	N	I-Premise
4	carrying	N	I-Premise
5	out	N	I-Premise
6	and	N	I-Premise
7	analysing	N	I-Premise
8	QoL	N	I-Premise
9	items	N	I-Premise
10	in	N	I-Premise
11	such	N	I-Premise
12	patients	N	I-Premise
13	,	N	I-Premise
14	the	N	I-Premise
15	global	N	I-Premise
16	QoL	N	I-Premise
17	evaluated	N	I-Premise
18	by	N	I-Premise
19	the	N	I-Premise
20	Spitzer	N	I-Premise
21	's	N	I-Premise
22	questionnaire	N	I-Premise
23	suggested	N	I-Premise
24	an	N	I-Premise
25	advantage	N	I-Premise
26	for	N	I-Premise
27	MVC	N	I-Premise
28	regimen	N	I-Premise
29	(	N	I-Premise
30	P=0.05	N	I-Premise
31	)	N	I-Premise
32	and	N	I-Premise
33	a	N	I-Premise
34	significant	N	I-Premise
35	difference	N	I-Premise
36	was	N	I-Premise
37	observed	N	I-Premise
38	in	N	I-Premise
39	global	N	I-Premise
40	health	N	I-Premise
41	subdomain	N	I-Premise
42	(	N	I-Premise
43	P=0.04	N	I-Premise
44	)	N	I-Premise
45	.	N	I-Premise

1	The	N	I-Premise
2	disease-related	N	I-Premise
3	symptoms	N	I-Premise
4	improved	N	I-Premise
5	with	N	I-Premise
6	time	N	I-Premise
7	,	N	I-Premise
8	and	N	O
9	the	N	I-Premise
10	benefits	N	I-Premise
11	lasted	N	I-Premise
12	for	N	I-Premise
13	the	N	I-Premise
14	entire	N	I-Premise
15	treatment	N	I-Premise
16	period	N	I-Premise
17	.	N	I-Premise

1	When	N	I-Premise
2	evaluated	N	I-Premise
3	with	N	I-Premise
4	the	N	I-Premise
5	EORTC	N	I-Premise
6	questionnaire	N	I-Premise
7	there	N	I-Premise
8	was	N	I-Premise
9	significantly	N	I-Premise
10	less	N	I-Premise
11	nausea	N	I-Premise
12	and	N	I-Premise
13	vomiting	N	I-Premise
14	(	N	I-Premise
15	P=0.0001	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	appetite	N	I-Premise
19	loss	N	I-Premise
20	(	N	I-Premise
21	P=0.01	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	insomnia	N	I-Premise
25	(	N	I-Premise
26	P=0.03	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	constipation	N	I-Premise
30	(	N	I-Premise
31	P=0.01	N	I-Premise
32	)	N	I-Premise
33	and	N	I-Premise
34	peripheral	N	I-Premise
35	neuropathy	N	I-Premise
36	(	N	I-Premise
37	P=0.01	N	I-Premise
38	)	N	I-Premise
39	in	N	I-Premise
40	favour	N	I-Premise
41	of	N	I-Premise
42	MVC	N	I-Premise
43	,	N	I-Premise
44	and	N	I-Premise
45	a	N	I-Premise
46	trend	N	I-Premise
47	for	N	I-Premise
48	less	N	I-Premise
49	hair	N	I-Premise
50	loss	N	I-Premise
51	(	N	I-Premise
52	P=0.05	N	I-Premise
53	)	N	I-Premise
54	.	N	I-Premise

1	The	N	I-Premise
2	advantage	N	I-Premise
3	lasted	N	I-Premise
4	for	N	I-Premise
5	all	N	I-Premise
6	the	N	I-Premise
7	duration	N	I-Premise
8	of	N	I-Premise
9	chemotherapy	N	I-Premise
10	.	N	I-Premise

1	No	N	I-Premise
2	differences	N	I-Premise
3	were	N	I-Premise
4	observed	N	I-Premise
5	in	N	I-Premise
6	global	N	I-Premise
7	quality	N	I-Premise
8	of	N	I-Premise
9	life	N	I-Premise
10	subdomain	N	I-Premise
11	(	N	I-Premise
12	P=0.40	N	I-Premise
13	)	N	I-Premise
14	between	N	I-Premise
15	the	N	I-Premise
16	two	N	I-Premise
17	regimen	N	I-Premise
18	.	N	I-Premise

1	QoL	N	O
2	was	N	O
3	the	N	O
4	first	N	O
5	endpoint	N	O
6	and	N	O
7	the	N	O
8	statistical	N	O
9	power	N	O
10	was	N	O
11	inadequate	N	O
12	to	N	O
13	assess	N	O
14	other	N	O
15	parameters	N	O
16	.	N	O

1	However	N	O
2	,	N	O
3	we	N	I-Premise
4	reported	N	I-Premise
5	a	N	I-Premise
6	response	N	I-Premise
7	rate	N	I-Premise
8	of	N	I-Premise
9	43.1	N	I-Premise
10	and	N	I-Premise
11	38.6	N	I-Premise
12	%	N	I-Premise
13	,	N	I-Premise
14	respectively	N	I-Premise
15	,	N	I-Premise
16	in	N	I-Premise
17	MVP	N	I-Premise
18	and	N	I-Premise
19	MVC	N	I-Premise
20	arm	N	I-Premise
21	(	N	I-Premise
22	P=0.59	N	I-Premise
23	)	N	I-Premise
24	and	N	I-Premise
25	a	N	I-Premise
26	median	N	I-Premise
27	survival	N	I-Premise
28	of	N	I-Premise
29	10.2	N	I-Premise
30	and	N	I-Premise
31	7.2	N	I-Premise
32	months	N	I-Premise
33	,	N	I-Premise
34	respectively	N	I-Premise
35	,	N	I-Premise
36	for	N	I-Premise
37	cisplatin	N	I-Premise
38	and	N	I-Premise
39	carboplatin	N	I-Premise
40	arm	N	I-Premise
41	(	N	I-Premise
42	P=0.39	N	I-Premise
43	)	N	I-Premise
44	.	N	I-Premise

1	The	N	I-Premise
2	carboplatin	N	I-Premise
3	containing	N	I-Premise
4	regimen	N	I-Premise
5	(	N	I-Premise
6	MVC	N	I-Premise
7	)	N	I-Premise
8	has	N	I-Premise
9	a	N	I-Premise
10	significant	N	I-Premise
11	better	N	I-Premise
12	toxicity	N	I-Premise
13	profile	N	I-Premise
14	than	N	I-Premise
15	the	N	I-Premise
16	cisplatin	N	I-Premise
17	containing	N	I-Premise
18	(	N	I-Premise
19	MVP	N	I-Premise
20	)	N	I-Premise
21	regimen	N	I-Premise
22	as	N	I-Premise
23	proven	N	I-Premise
24	both	N	I-Premise
25	by	N	I-Premise
26	the	N	I-Premise
27	EORTC	N	I-Premise
28	questionnaires	N	I-Premise
29	and	N	I-Premise
30	by	N	I-Premise
31	the	N	I-Premise
32	WHO	N	I-Premise
33	toxicity	N	I-Premise
34	data	N	I-Premise
35	reported	N	I-Premise
36	by	N	I-Premise
37	physicians	N	I-Premise
38	.	N	I-Premise

1	No	N	I-Claim
2	significant	N	I-Claim
3	differences	N	I-Claim
4	in	N	I-Claim
5	terms	N	I-Claim
6	of	N	I-Claim
7	response	N	I-Claim
8	rate	N	I-Claim
9	,	N	I-Claim
10	time	N	I-Claim
11	to	N	I-Claim
12	progression	N	I-Claim
13	and	N	I-Claim
14	overall	N	I-Claim
15	survival	N	I-Claim
16	were	N	I-Claim
17	observed	N	I-Claim
18	between	N	I-Claim
19	the	N	I-Claim
20	two	N	I-Claim
21	regimen	N	I-Claim
22	.	N	I-Claim

1	The	N	I-Claim
2	two	N	I-Claim
3	chemotherapy	N	I-Claim
4	regimen	N	I-Claim
5	showed	N	I-Claim
6	a	N	I-Claim
7	similar	N	I-Claim
8	effectiveness	N	I-Claim
9	in	N	I-Claim
10	symptom	N	I-Claim
11	palliation	N	I-Claim
12	when	N	I-Claim
13	evaluated	N	I-Claim
14	with	N	I-Claim
15	C30	N	I-Claim
16	addendum	N	I-Claim
17	of	N	I-Claim
18	EORTC	N	I-Claim
19	QOL	N	I-Claim
20	questionnaire	N	I-Claim
21	.	N	I-Claim

1	With	N	I-Premise
2	the	N	I-Premise
3	Spitzer	N	I-Premise
4	's	N	I-Premise
5	questionnaires	N	I-Premise
6	a	N	I-Premise
7	trend	N	I-Premise
8	towards	N	I-Premise
9	an	N	I-Premise
10	improved	N	I-Premise
11	quality	N	I-Premise
12	of	N	I-Premise
13	life	N	I-Premise
14	index	N	I-Premise
15	was	N	I-Premise
16	observed	N	I-Premise
17	during	N	I-Premise
18	treatment	N	I-Premise
19	with	N	I-Premise
20	the	N	I-Premise
21	carboplatin	N	I-Premise
22	combination	N	I-Premise
23	in	N	I-Premise
24	comparison	N	I-Premise
25	to	N	I-Premise
26	the	N	I-Premise
27	cisplatin	N	I-Premise
28	combination	N	I-Premise
29	.	N	I-Premise

1	This	N	I-Premise
2	difference	N	I-Premise
3	,	N	I-Premise
4	however	N	I-Premise
5	,	N	I-Premise
6	was	N	I-Premise
7	not	N	I-Premise
8	observed	N	I-Premise
9	when	N	I-Premise
10	the	N	I-Premise
11	global	N	I-Premise
12	quality	N	I-Premise
13	of	N	I-Premise
14	life	N	I-Premise
15	was	N	I-Premise
16	evaluated	N	I-Premise
17	with	N	I-Premise
18	the	N	I-Premise
19	EORTC	N	I-Premise
20	patients	N	I-Premise
21	compiled	N	I-Premise
22	questionnaires	N	I-Premise
23	.	N	I-Premise

1	A	N	I-Claim
2	carboplatin	N	I-Claim
3	containing	N	I-Claim
4	regimen	N	I-Claim
5	with	N	I-Claim
6	better	N	I-Claim
7	toxicity	N	I-Claim
8	profile	N	I-Claim
9	and	N	I-Claim
10	a	N	I-Claim
11	similar	N	I-Claim
12	potentiality	N	I-Claim
13	for	N	I-Claim
14	symptoms	N	I-Claim
15	control	N	I-Claim
16	offers	N	I-Claim
17	an	N	I-Claim
18	option	N	I-Claim
19	in	N	I-Claim
20	comparison	N	I-Claim
21	to	N	I-Claim
22	similar	N	I-Claim
23	cisplatin	N	I-Claim
24	containing	N	I-Claim
25	combinations	N	I-Claim
26	in	N	I-Claim
27	the	N	I-Claim
28	palliative	N	I-Claim
29	treatment	N	I-Claim
30	of	N	I-Claim
31	advanced	N	I-Claim
32	NSCLC	N	I-Claim
33	.	N	I-Claim

1	N	N	O
2	,	N	O
3	N-diethyl-2-	N	O
4	[	N	O
5	4-	N	O
6	(	N	O
7	phenylmethyl	N	O
8	)	N	O
9	phenoxy	N	O
10	]	N	O
11	ethanamine	N	O
12	(	N	O
13	DPPE	N	O
14	;	N	O
15	tesmilifene	N	O
16	)	N	O
17	is	N	O
18	a	N	O
19	novel	N	O
20	agent	N	O
21	that	N	O
22	augments	N	O
23	chemotherapy	N	O
24	cytotoxicity	N	O
25	in	N	O
26	vitro	N	O
27	and	N	O
28	in	N	O
29	vivo	N	O
30	.	N	O

1	A	N	O
2	phase	N	O
3	II	N	O
4	trial	N	O
5	combining	N	O
6	DPPE	N	O
7	and	N	O
8	doxorubicin	N	O
9	(	N	O
10	DOX	N	O
11	)	N	O
12	in	N	O
13	metastatic	N	O
14	breast	N	O
15	carcinoma	N	O
16	showed	N	O
17	increased	N	O
18	response	N	O
19	over	N	O
20	that	N	O
21	expected	N	O
22	with	N	O
23	DOX	N	O
24	.	N	O

1	We	N	O
2	report	N	O
3	a	N	O
4	phase	N	O
5	III	N	O
6	trial	N	O
7	comparing	N	O
8	DOX	N	O
9	with	N	O
10	DPPE	N	O
11	plus	N	O
12	DOX	N	O
13	in	N	O
14	metastatic	N	O
15	or	N	O
16	recurrent	N	O
17	breast	N	O
18	cancer	N	O
19	.	N	O

1	Anthracycline-naive	N	O
2	women	N	O
3	with	N	O
4	measurable	N	O
5	metastatic	N	O
6	disease	N	O
7	were	N	O
8	randomly	N	O
9	assigned	N	O
10	to	N	O
11	receive	N	O
12	,	N	O
13	every	N	O
14	21	N	O
15	days	N	O
16	,	N	O
17	either	N	O
18	DOX	N	O
19	60	N	O
20	mg/m	N	O
21	(	N	O
22	2	N	O
23	)	N	O
24	intravenously	N	O
25	or	N	O
26	DOX	N	O
27	during	N	O
28	the	N	O
29	last	N	O
30	20	N	O
31	minutes	N	O
32	of	N	O
33	an	N	O
34	80-minute	N	O
35	infusion	N	O
36	of	N	O
37	DPPE	N	O
38	(	N	O
39	5.3	N	O
40	mg/kg	N	O
41	)	N	O
42	,	N	O
43	in	N	O
44	both	N	O
45	cases	N	O
46	to	N	O
47	cumulative	N	O
48	DOX	N	O
49	doses	N	O
50	of	N	O
51	450	N	O
52	mg/m	N	O
53	(	N	O
54	2	N	O
55	)	N	O
56	.	N	O

1	Patients	N	O
2	receiving	N	O
3	DPPE	N	O
4	were	N	O
5	aggressively	N	O
6	premedicated	N	O
7	to	N	O
8	ameliorate	N	O
9	toxicity	N	O
10	.	N	O

1	End	N	O
2	points	N	O
3	included	N	O
4	progression-free	N	O
5	survival	N	O
6	(	N	O
7	PFS	N	O
8	)	N	O
9	,	N	O
10	response	N	O
11	rate	N	O
12	(	N	O
13	RR	N	O
14	)	N	O
15	,	N	O
16	and	N	O
17	response	N	O
18	duration	N	O
19	(	N	O
20	RD	N	O
21	)	N	O
22	,	N	O
23	quality	N	O
24	of	N	O
25	life	N	O
26	(	N	O
27	QOL	N	O
28	)	N	O
29	,	N	O
30	toxicity	N	O
31	,	N	O
32	and	N	O
33	overall	N	O
34	survival	N	O
35	(	N	O
36	OS	N	O
37	)	N	O
38	.	N	O

1	A	N	O
2	planned	N	O
3	interim	N	O
4	analysis	N	O
5	failed	N	O
6	to	N	O
7	detect	N	O
8	an	N	O
9	RR	N	O
10	difference	N	O
11	more	N	O
12	than	N	O
13	5	N	O
14	%	N	O
15	.	N	O

1	The	N	O
2	study	N	O
3	was	N	O
4	closed	N	O
5	to	N	O
6	additional	N	O
7	accrual	N	O
8	and	N	O
9	all	N	O
10	DPPE	N	O
11	was	N	O
12	discontinued	N	O
13	.	N	O

1	The	N	O
2	final	N	O
3	analysis	N	O
4	was	N	O
5	conducted	N	O
6	as	N	O
7	planned	N	O
8	after	N	O
9	256	N	O
10	progression	N	O
11	events	N	O
12	(	N	O
13	median	N	O
14	follow-up	N	O
15	,	N	O
16	20.5	N	O
17	months	N	O
18	)	N	O
19	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	RR	N	I-Premise
8	,	N	I-Premise
9	RD	N	I-Premise
10	,	N	I-Premise
11	or	N	I-Premise
12	PFS	N	I-Premise
13	between	N	I-Premise
14	arms	N	I-Premise
15	.	N	I-Premise

1	DPPE	N	I-Premise
2	plus	N	I-Premise
3	DOX	N	I-Premise
4	was	N	I-Premise
5	statistically	N	I-Premise
6	superior	N	I-Premise
7	to	N	I-Premise
8	DOX	N	I-Premise
9	in	N	I-Premise
10	OS	N	I-Premise
11	(	N	I-Premise
12	hazard	N	I-Premise
13	ratio	N	I-Premise
14	,	N	I-Premise
15	0.66	N	I-Premise
16	;	N	I-Premise
17	95	N	I-Premise
18	%	N	I-Premise
19	CI	N	I-Premise
20	,	N	I-Premise
21	0.48	N	I-Premise
22	to	N	I-Premise
23	0.91	N	I-Premise
24	;	N	I-Premise
25	P	N	I-Premise
26	=.021	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	DPPE	N	I-Premise
2	plus	N	I-Premise
3	DOX	N	I-Premise
4	was	N	I-Premise
5	associated	N	I-Premise
6	with	N	I-Premise
7	more	N	I-Premise
8	gastrointestinal	N	I-Premise
9	and	N	I-Premise
10	CNS	N	I-Premise
11	toxicity	N	I-Premise
12	.	N	I-Premise

1	No	N	I-Premise
2	consistent	N	I-Premise
3	influence	N	I-Premise
4	on	N	I-Premise
5	QOL	N	I-Premise
6	was	N	I-Premise
7	detected	N	I-Premise
8	.	N	I-Premise

1	This	N	I-Claim
2	study	N	I-Claim
3	demonstrated	N	I-Claim
4	no	N	I-Claim
5	advantage	N	I-Claim
6	in	N	I-Claim
7	RR	N	I-Claim
8	,	N	I-Claim
9	RD	N	I-Claim
10	,	N	I-Claim
11	or	N	I-Claim
12	PFS	N	I-Claim
13	but	N	I-Claim
14	significantly	N	I-Claim
15	superior	N	I-Claim
16	OS	N	I-Claim
17	for	N	I-Claim
18	DPPE	N	I-Claim
19	plus	N	I-Claim
20	DOX	N	I-Claim
21	.	N	I-Claim

1	Additional	N	I-Claim
2	studies	N	I-Claim
3	of	N	I-Claim
4	DPPE	N	I-Claim
5	are	N	I-Claim
6	warranted	N	I-Claim
7	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	whether	N	O
4	the	N	O
5	effect	N	O
6	of	N	O
7	hypofractionated	N	O
8	thoracic	N	O
9	radiotherapy	N	O
10	(	N	O
11	TRT	N	O
12	)	N	O
13	is	N	O
14	comparable	N	O
15	to	N	O
16	more	N	O
17	standard	N	O
18	fractionated	N	O
19	radiotherapy	N	O
20	(	N	O
21	RT	N	O
22	)	N	O
23	in	N	O
24	advanced	N	O
25	non-small-cell	N	O
26	lung	N	O
27	cancer	N	O
28	(	N	O
29	NSCLC	N	O
30	)	N	O
31	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	421	N	O
5	patients	N	O
6	with	N	O
7	locally	N	O
8	advanced	N	O
9	stage	N	O
10	III	N	O
11	or	N	O
12	stage	N	O
13	IV	N	O
14	NSCLC	N	O
15	tumors	N	O
16	were	N	O
17	included	N	O
18	.	N	O

1	Inclusion	N	O
2	criteria	N	O
3	were	N	O
4	inoperable	N	O
5	,	N	O
6	disease	N	O
7	too	N	O
8	advanced	N	O
9	for	N	O
10	curative	N	O
11	radiotherapy	N	O
12	,	N	O
13	and	N	O
14	chest	N	O
15	symptoms	N	O
16	or	N	O
17	central	N	O
18	tumor	N	O
19	threatening	N	O
20	the	N	O
21	airways	N	O
22	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	three	N	O
7	arms	N	O
8	:	N	O
9	A	N	O
10	,	N	O
11	17	N	O
12	Gy	N	O
13	per	N	O
14	two	N	O
15	fractions	N	O
16	(	N	O
17	n	N	O
18	=	N	O
19	146	N	O
20	)	N	O
21	;	N	O
22	B	N	O
23	,	N	O
24	42	N	O
25	Gy	N	O
26	per	N	O
27	15	N	O
28	fractions	N	O
29	(	N	O
30	n	N	O
31	=	N	O
32	145	N	O
33	)	N	O
34	;	N	O
35	and	N	O
36	C	N	O
37	,	N	O
38	50	N	O
39	Gy	N	O
40	per	N	O
41	25	N	O
42	fractions	N	O
43	(	N	O
44	n	N	O
45	=	N	O
46	130	N	O
47	)	N	O
48	.	N	O

1	Four	N	O
2	hundred	N	O
3	seven	N	O
4	patients	N	O
5	were	N	O
6	eligible	N	O
7	for	N	O
8	the	N	O
9	study	N	O
10	;	N	O
11	395	N	O
12	patients	N	O
13	(	N	O
14	97	N	O
15	%	N	O
16	)	N	O
17	participated	N	O
18	in	N	O
19	the	N	O
20	health-related	N	O
21	quality-of-life	N	O
22	(	N	O
23	HRQOL	N	O
24	)	N	O
25	study	N	O
26	.	N	O

1	The	N	O
2	European	N	O
3	Organization	N	O
4	for	N	O
5	Research	N	O
6	and	N	O
7	Treatment	N	O
8	of	N	O
9	Cancer	N	O
10	(	N	O
11	EORTC	N	O
12	)	N	O
13	Quality	N	O
14	of	N	O
15	Life	N	O
16	Questionnaire	N	O
17	(	N	O
18	QLQ	N	O
19	)	N	O
20	-C30	N	O
21	and	N	O
22	EORTC	N	O
23	QLQ-lung	N	O
24	cancer-specific	N	O
25	module	N	O
26	(	N	O
27	LC13	N	O
28	)	N	O
29	were	N	O
30	used	N	O
31	to	N	O
32	investigate	N	O
33	airway	N	O
34	symptom	N	O
35	relief	N	O
36	and	N	O
37	changes	N	O
38	in	N	O
39	HRQOL	N	O
40	.	N	O

1	Assessments	N	O
2	were	N	O
3	performed	N	O
4	before	N	O
5	TRT	N	O
6	and	N	O
7	until	N	O
8	week	N	O
9	54	N	O
10	.	N	O

1	Clinicians	N	O
2	'	N	O
3	assessments	N	O
4	of	N	O
5	symptom	N	O
6	improvement	N	O
7	were	N	O
8	at	N	O
9	2	N	O
10	,	N	O
11	6	N	O
12	,	N	O
13	and	N	O
14	14	N	O
15	weeks	N	O
16	after	N	O
17	completion	N	O
18	of	N	O
19	TRT	N	O
20	.	N	O

1	The	N	O
2	patients	N	O
3	were	N	O
4	observed	N	O
5	for	N	O
6	a	N	O
7	minimum	N	O
8	of	N	O
9	3	N	O
10	years	N	O
11	.	N	O

1	Results	N	O
2	Baseline	N	O
3	prognostic	N	O
4	data	N	O
5	were	N	O
6	equally	N	O
7	distributed	N	O
8	in	N	O
9	the	N	O
10	treatment	N	O
11	groups	N	O
12	.	N	O

1	Patient	N	O
2	compliance	N	O
3	with	N	O
4	respect	N	O
5	to	N	O
6	the	N	O
7	HRQOL	N	O
8	investigation	N	O
9	was	N	O
10	minimum	N	O
11	74	N	O
12	%	N	O
13	.	N	O

1	HRQOL	N	I-Premise
2	and	N	I-Premise
3	symptom	N	I-Premise
4	relief	N	I-Premise
5	were	N	I-Premise
6	equivalent	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	treatment	N	I-Premise
10	arms	N	I-Premise
11	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	difference	N	I-Premise
4	in	N	I-Premise
5	survival	N	I-Premise
6	among	N	I-Premise
7	arms	N	I-Premise
8	A	N	I-Premise
9	,	N	I-Premise
10	B	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	C	N	I-Premise
14	was	N	I-Premise
15	found	N	I-Premise
16	,	N	I-Premise
17	with	N	I-Premise
18	median	N	I-Premise
19	survival	N	I-Premise
20	8.2	N	I-Premise
21	,	N	I-Premise
22	7.0	N	I-Premise
23	,	N	I-Premise
24	and	N	I-Premise
25	6.8	N	I-Premise
26	months	N	I-Premise
27	,	N	I-Premise
28	respectively	N	I-Premise
29	.	N	I-Premise

1	Our	N	I-Claim
2	data	N	I-Claim
3	indicate	N	I-Claim
4	that	N	I-Claim
5	protracted	N	I-Claim
6	palliative	N	I-Claim
7	TRT	N	I-Claim
8	renders	N	I-Claim
9	no	N	I-Claim
10	improvement	N	I-Claim
11	in	N	I-Claim
12	symptom	N	I-Claim
13	relief	N	I-Claim
14	,	N	I-Claim
15	HRQOL	N	I-Claim
16	,	N	I-Claim
17	or	N	I-Claim
18	survival	N	I-Claim
19	when	N	I-Claim
20	compared	N	I-Claim
21	with	N	I-Claim
22	short-term	N	I-Claim
23	hypofractionated	N	I-Claim
24	treatment	N	I-Claim
25	in	N	I-Claim
26	advanced	N	I-Claim
27	NSCLC	N	I-Claim
28	.	N	I-Claim

1	During	N	I-Premise
2	the	N	I-Premise
3	last	N	I-Premise
4	decade	N	I-Premise
5	,	N	I-Premise
6	survival	N	I-Premise
7	rates	N	I-Premise
8	for	N	I-Premise
9	breast	N	I-Premise
10	cancer	N	I-Premise
11	have	N	I-Premise
12	increased	N	I-Premise
13	as	N	I-Premise
14	a	N	I-Premise
15	result	N	I-Premise
16	of	N	I-Premise
17	earlier	N	I-Premise
18	detection	N	I-Premise
19	and	N	I-Premise
20	increased	N	I-Premise
21	use	N	I-Premise
22	of	N	I-Premise
23	adjuvant	N	I-Premise
24	therapy	N	I-Premise
25	.	N	I-Premise

1	Limited	N	O
2	data	N	O
3	exist	N	O
4	on	N	O
5	the	N	O
6	psychosocial	N	O
7	aspects	N	O
8	of	N	O
9	the	N	O
10	transitional	N	O
11	period	N	O
12	between	N	O
13	the	N	O
14	end	N	O
15	of	N	O
16	primary	N	O
17	treatment	N	O
18	and	N	O
19	survivorship	N	O
20	.	N	O

1	We	N	O
2	investigated	N	O
3	the	N	O
4	baseline	N	O
5	psychosocial	N	O
6	status	N	O
7	of	N	O
8	women	N	O
9	enrolled	N	O
10	in	N	O
11	a	N	O
12	randomized	N	O
13	trial	N	O
14	testing	N	O
15	two	N	O
16	psychosocial	N	O
17	interventions	N	O
18	for	N	O
19	women	N	O
20	at	N	O
21	the	N	O
22	end	N	O
23	of	N	O
24	primary	N	O
25	treatment	N	O
26	.	N	O

1	Participants	N	O
2	,	N	O
3	identified	N	O
4	within	N	O
5	1	N	O
6	month	N	O
7	after	N	O
8	surgery	N	O
9	(	N	O
10	registration	N	O
11	)	N	O
12	,	N	O
13	provided	N	O
14	demographic	N	O
15	information	N	O
16	and	N	O
17	limited	N	O
18	measures	N	O
19	of	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	.	N	O

1	They	N	O
2	were	N	O
3	followed	N	O
4	until	N	O
5	they	N	O
6	finished	N	O
7	primary	N	O
8	treatment	N	O
9	(	N	O
10	enrollment	N	O
11	)	N	O
12	,	N	O
13	at	N	O
14	which	N	O
15	time	N	O
16	they	N	O
17	completed	N	O
18	a	N	O
19	mailed	N	O
20	baseline	N	O
21	survey	N	O
22	that	N	O
23	included	N	O
24	standardized	N	O
25	measures	N	O
26	of	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	(	N	O
31	including	N	O
32	standardized	N	O
33	scales	N	O
34	of	N	O
35	physical	N	O
36	and	N	O
37	emotional	N	O
38	functioning	N	O
39	)	N	O
40	,	N	O
41	mood	N	O
42	,	N	O
43	symptoms	N	O
44	,	N	O
45	and	N	O
46	sexual	N	O
47	functioning	N	O
48	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	558	N	O
5	patients	N	O
6	(	N	O
7	mean	N	O
8	age	N	O
9	=	N	O
10	56.9	N	O
11	years	N	O
12	)	N	O
13	were	N	O
14	enrolled	N	O
15	in	N	O
16	the	N	O
17	study	N	O
18	between	N	O
19	July	N	O
20	1	N	O
21	,	N	O
22	1999	N	O
23	,	N	O
24	and	N	O
25	June	N	O
26	30	N	O
27	,	N	O
28	2002	N	O
29	.	N	O

1	Health	N	O
2	outcomes	N	O
3	were	N	O
4	examined	N	O
5	according	N	O
6	to	N	O
7	treatment	N	O
8	received	N	O
9	:	N	O
10	mastectomy	N	O
11	with	N	O
12	and	N	O
13	without	N	O
14	chemotherapy	N	O
15	,	N	O
16	and	N	O
17	lumpectomy	N	O
18	with	N	O
19	and	N	O
20	without	N	O
21	chemotherapy	N	O
22	.	N	O

1	All	N	O
2	statistical	N	O
3	tests	N	O
4	were	N	O
5	two-sided	N	O
6	.	N	O

1	Among	N	I-Premise
2	all	N	I-Premise
3	treatment	N	I-Premise
4	groups	N	I-Premise
5	,	N	I-Premise
6	patients	N	I-Premise
7	who	N	I-Premise
8	had	N	I-Premise
9	a	N	I-Premise
10	mastectomy	N	I-Premise
11	had	N	I-Premise
12	the	N	I-Premise
13	poorest	N	I-Premise
14	physical	N	I-Premise
15	functioning	N	I-Premise
16	at	N	I-Premise
17	registration	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	.001	N	I-Premise
22	)	N	I-Premise
23	and	N	I-Premise
24	at	N	I-Premise
25	enrollment	N	I-Premise
26	(	N	I-Premise
27	P=.05	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	At	N	I-Premise
2	enrollment	N	I-Premise
3	,	N	I-Premise
4	mood	N	I-Premise
5	and	N	I-Premise
6	emotional	N	I-Premise
7	functioning	N	I-Premise
8	were	N	I-Premise
9	similar	N	I-Premise
10	among	N	I-Premise
11	all	N	I-Premise
12	patients	N	I-Premise
13	,	N	I-Premise
14	with	N	I-Premise
15	no	N	I-Premise
16	differences	N	I-Premise
17	by	N	I-Premise
18	type	N	I-Premise
19	of	N	I-Premise
20	treatment	N	I-Premise
21	received	N	I-Premise
22	.	N	I-Premise

1	At	N	I-Premise
2	enrollment	N	I-Premise
3	,	N	I-Premise
4	symptoms	N	I-Premise
5	,	N	I-Premise
6	including	N	I-Premise
7	muscle	N	I-Premise
8	stiffness	N	I-Premise
9	,	N	I-Premise
10	breast	N	I-Premise
11	sensitivity	N	I-Premise
12	,	N	I-Premise
13	aches	N	I-Premise
14	and	N	I-Premise
15	pains	N	I-Premise
16	,	N	I-Premise
17	tendency	N	I-Premise
18	to	N	I-Premise
19	take	N	I-Premise
20	naps	N	I-Premise
21	,	N	I-Premise
22	and	N	I-Premise
23	difficulty	N	I-Premise
24	concentrating	N	I-Premise
25	,	N	I-Premise
26	were	N	I-Premise
27	common	N	I-Premise
28	among	N	I-Premise
29	patients	N	I-Premise
30	in	N	I-Premise
31	all	N	I-Premise
32	groups	N	I-Premise
33	and	N	I-Premise
34	were	N	I-Premise
35	statistically	N	I-Premise
36	significantly	N	I-Premise
37	associated	N	I-Premise
38	with	N	I-Premise
39	poor	N	I-Premise
40	physical	N	I-Premise
41	functioning	N	I-Premise
42	and	N	I-Premise
43	emotional	N	I-Premise
44	well-being	N	I-Premise
45	.	N	I-Premise

1	Sexual	N	I-Premise
2	functioning	N	I-Premise
3	was	N	I-Premise
4	worse	N	I-Premise
5	for	N	I-Premise
6	women	N	I-Premise
7	who	N	I-Premise
8	received	N	I-Premise
9	chemotherapy	N	I-Premise
10	than	N	I-Premise
11	for	N	I-Premise
12	those	N	I-Premise
13	who	N	I-Premise
14	did	N	I-Premise
15	not	N	I-Premise
16	,	N	I-Premise
17	regardless	N	I-Premise
18	of	N	I-Premise
19	type	N	I-Premise
20	of	N	I-Premise
21	surgery	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	<	N	I-Premise
25	.001	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	At	N	I-Claim
2	the	N	I-Claim
3	end	N	I-Claim
4	of	N	I-Claim
5	primary	N	I-Claim
6	treatment	N	I-Claim
7	for	N	I-Claim
8	breast	N	I-Claim
9	cancer	N	I-Claim
10	,	N	I-Claim
11	women	N	I-Claim
12	in	N	I-Claim
13	all	N	I-Claim
14	treatment	N	I-Claim
15	groups	N	I-Claim
16	report	N	I-Claim
17	good	N	I-Claim
18	emotional	N	I-Claim
19	functioning	N	I-Claim
20	but	N	I-Claim
21	report	N	I-Claim
22	decreased	N	I-Claim
23	physical	N	I-Claim
24	functioning	N	I-Claim
25	,	N	I-Claim
26	particularly	N	I-Claim
27	among	N	I-Claim
28	women	N	I-Claim
29	who	N	I-Claim
30	have	N	I-Claim
31	a	N	I-Claim
32	mastectomy	N	I-Claim
33	or	N	I-Claim
34	receive	N	I-Claim
35	chemotherapy	N	I-Claim
36	.	N	I-Claim

1	Clinical	N	I-Claim
2	interventions	N	I-Claim
3	to	N	I-Claim
4	address	N	I-Claim
5	common	N	I-Claim
6	symptoms	N	I-Claim
7	associated	N	I-Claim
8	with	N	I-Claim
9	treatment	N	I-Claim
10	should	N	I-Claim
11	be	N	I-Claim
12	considered	N	I-Claim
13	to	N	I-Claim
14	improve	N	I-Claim
15	physical	N	I-Claim
16	and	N	I-Claim
17	emotional	N	I-Claim
18	functioning	N	I-Claim
19	at	N	I-Claim
20	the	N	I-Claim
21	end	N	I-Claim
22	of	N	I-Claim
23	primary	N	I-Claim
24	treatment	N	I-Claim
25	for	N	I-Claim
26	breast	N	I-Claim
27	cancer	N	I-Claim
28	.	N	I-Claim

1	The	N	O
2	World	N	O
3	Health	N	O
4	Organization	N	O
5	(	N	O
6	WHO	N	O
7	)	N	O
8	guidelines	N	O
9	for	N	O
10	the	N	O
11	treatment	N	O
12	of	N	O
13	cancer	N	O
14	pain	N	O
15	recommend	N	O
16	nonopioid	N	O
17	analgesics	N	O
18	as	N	O
19	first-line	N	O
20	therapy	N	O
21	,	N	O
22	so-called	N	O
23	``	N	O
24	weak	N	O
25	''	N	O
26	analgesics	N	O
27	combined	N	O
28	with	N	O
29	nonopioid	N	O
30	analgesics	N	O
31	as	N	O
32	second-line	N	O
33	therapy	N	O
34	,	N	O
35	and	N	O
36	so-called	N	O
37	``	N	O
38	strong	N	O
39	''	N	O
40	opioids	N	O
41	(	N	O
42	with	N	O
43	nonopioid	N	O
44	analgesics	N	O
45	)	N	O
46	only	N	O
47	as	N	O
48	third-line	N	O
49	therapy	N	O
50	.	N	O

1	However	N	O
2	,	N	O
3	these	N	O
4	guidelines	N	O
5	can	N	O
6	be	N	O
7	questioned	N	O
8	with	N	O
9	regard	N	O
10	to	N	O
11	the	N	O
12	extent	N	O
13	of	N	O
14	efficacy	N	O
15	as	N	O
16	well	N	O
17	as	N	O
18	the	N	O
19	rationale	N	O
20	for	N	O
21	not	N	O
22	using	N	O
23	strong	N	O
24	opioids	N	O
25	as	N	O
26	first-line	N	O
27	treatment	N	O
28	,	N	O
29	especially	N	O
30	in	N	O
31	terminal	N	O
32	cancer	N	O
33	patients	N	O
34	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	randomized	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	prospectively	N	O
10	compare	N	O
11	the	N	O
12	efficacy	N	O
13	and	N	O
14	tolerability	N	O
15	of	N	O
16	strong	N	O
17	opioids	N	O
18	as	N	O
19	first-line	N	O
20	agents	N	O
21	with	N	O
22	the	N	O
23	recommendations	N	O
24	of	N	O
25	the	N	O
26	WHO	N	O
27	in	N	O
28	terminal	N	O
29	cancer	N	O
30	patients	N	O
31	.	N	O

1	One	N	O
2	hundred	N	O
3	patients	N	O
4	with	N	O
5	mild-moderate	N	O
6	pain	N	O
7	were	N	O
8	randomized	N	O
9	to	N	O
10	treatment	N	O
11	according	N	O
12	to	N	O
13	WHO	N	O
14	guidelines	N	O
15	or	N	O
16	to	N	O
17	treatment	N	O
18	with	N	O
19	strong	N	O
20	opioids	N	O
21	.	N	O

1	Evaluated	N	O
2	outcomes	N	O
3	included	N	O
4	pain	N	O
5	intensity	N	O
6	,	N	O
7	need	N	O
8	for	N	O
9	change	N	O
10	in	N	O
11	therapy	N	O
12	,	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	,	N	O
17	Karnofsky	N	O
18	Performance	N	O
19	Status	N	O
20	,	N	O
21	general	N	O
22	condition	N	O
23	of	N	O
24	the	N	O
25	patient	N	O
26	,	N	O
27	and	N	O
28	adverse	N	O
29	events	N	O
30	.	N	O

1	No	N	I-Premise
2	between-treatment	N	I-Premise
3	differences	N	I-Premise
4	were	N	I-Premise
5	observed	N	I-Premise
6	for	N	I-Premise
7	changes	N	I-Premise
8	in	N	I-Premise
9	quality	N	I-Premise
10	of	N	I-Premise
11	life	N	I-Premise
12	or	N	I-Premise
13	performance	N	I-Premise
14	status	N	I-Premise
15	,	N	I-Premise
16	but	N	O
17	patients	N	I-Premise
18	started	N	I-Premise
19	on	N	I-Premise
20	strong	N	I-Premise
21	opioids	N	I-Premise
22	had	N	I-Premise
23	significantly	N	I-Premise
24	better	N	I-Premise
25	pain	N	I-Premise
26	relief	N	I-Premise
27	than	N	I-Premise
28	patients	N	I-Premise
29	treated	N	I-Premise
30	according	N	I-Premise
31	to	N	I-Premise
32	WHO	N	I-Premise
33	guidelines	N	I-Premise
34	(	N	I-Premise
35	P=0.041	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	Additionally	N	I-Premise
2	,	N	I-Premise
3	patients	N	I-Premise
4	started	N	I-Premise
5	on	N	I-Premise
6	strong	N	I-Premise
7	opioids	N	I-Premise
8	required	N	I-Premise
9	significantly	N	I-Premise
10	fewer	N	I-Premise
11	changes	N	I-Premise
12	in	N	I-Premise
13	therapy	N	I-Premise
14	,	N	I-Premise
15	had	N	I-Premise
16	greater	N	I-Premise
17	reduction	N	I-Premise
18	in	N	I-Premise
19	pain	N	I-Premise
20	when	N	I-Premise
21	a	N	I-Premise
22	change	N	I-Premise
23	was	N	I-Premise
24	initiated	N	I-Premise
25	,	N	I-Premise
26	and	N	I-Premise
27	reported	N	I-Premise
28	greater	N	I-Premise
29	satisfaction	N	I-Premise
30	with	N	I-Premise
31	treatment	N	I-Premise
32	than	N	I-Premise
33	the	N	I-Premise
34	comparator	N	I-Premise
35	group	N	I-Premise
36	(	N	I-Premise
37	P=0.041	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	Strong	N	I-Claim
2	opioids	N	I-Claim
3	were	N	I-Claim
4	safe	N	I-Claim
5	and	N	I-Claim
6	well-tolerated	N	I-Claim
7	,	N	I-Claim
8	with	N	I-Claim
9	no	N	I-Claim
10	development	N	I-Claim
11	of	N	I-Claim
12	tolerance	N	I-Claim
13	or	N	I-Claim
14	serious	N	I-Claim
15	adverse	N	I-Claim
16	events	N	I-Claim
17	.	N	I-Claim

1	These	N	I-Claim
2	data	N	I-Claim
3	suggest	N	I-Claim
4	the	N	I-Claim
5	utility	N	I-Claim
6	of	N	I-Claim
7	strong	N	I-Claim
8	opioids	N	I-Claim
9	for	N	I-Claim
10	first-line	N	I-Claim
11	treatment	N	I-Claim
12	of	N	I-Claim
13	pain	N	I-Claim
14	in	N	I-Claim
15	patients	N	I-Claim
16	with	N	I-Claim
17	terminal	N	I-Claim
18	cancer	N	I-Claim
19	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	if	N	O
4	the	N	O
5	type	N	O
6	of	N	O
7	embolic	N	O
8	material	N	O
9	used	N	O
10	for	N	O
11	uterine	N	O
12	artery	N	O
13	embolization	N	O
14	(	N	O
15	UAE	N	O
16	)	N	O
17	for	N	O
18	leiomyomas	N	O
19	has	N	O
20	an	N	O
21	impact	N	O
22	on	N	O
23	short-term	N	O
24	recovery	N	O
25	or	N	O
26	the	N	O
27	effectiveness	N	O
28	of	N	O
29	embolization	N	O
30	.	N	O

1	One	N	O
2	hundred	N	O
3	patients	N	O
4	were	N	O
5	randomly	N	O
6	assigned	N	O
7	to	N	O
8	undergo	N	O
9	UAE	N	O
10	with	N	O
11	polyvinyl	N	O
12	alcohol	N	O
13	(	N	O
14	PVA	N	O
15	)	N	O
16	particles	N	O
17	or	N	O
18	tris-acryl	N	O
19	gelatin	N	O
20	microspheres	N	O
21	.	N	O

1	Short-term	N	O
2	,	N	O
3	in-hospital	N	O
4	medication	N	O
5	use	N	O
6	and	N	O
7	pain	N	O
8	levels	N	O
9	were	N	O
10	recorded	N	O
11	.	N	O

1	After	N	O
2	discharge	N	O
3	,	N	O
4	symptom	N	O
5	severity	N	O
6	,	N	O
7	temperature	N	O
8	,	N	O
9	and	N	O
10	medications	N	O
11	used	N	O
12	were	N	O
13	recorded	N	O
14	daily	N	O
15	for	N	O
16	1	N	O
17	week	N	O
18	and	N	O
19	symptom	N	O
20	levels	N	O
21	were	N	O
22	measured	N	O
23	for	N	O
24	weeks	N	O
25	2-4	N	O
26	.	N	O

1	Three	N	O
2	months	N	O
3	after	N	O
4	embolization	N	O
5	,	N	O
6	contrast	N	O
7	material-enhanced	N	O
8	magnetic	N	O
9	resonance	N	O
10	imaging	N	O
11	examinations	N	O
12	were	N	O
13	evaluated	N	O
14	blindly	N	O
15	to	N	O
16	determine	N	O
17	the	N	O
18	extent	N	O
19	of	N	O
20	leiomyoma	N	O
21	infarction	N	O
22	.	N	O

1	Symptom	N	O
2	and	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	(	N	O
7	QOL	N	O
8	)	N	O
9	status	N	O
10	was	N	O
11	determined	N	O
12	with	N	O
13	use	N	O
14	of	N	O
15	questionnaires	N	O
16	.	N	O

1	Analysis	N	O
2	was	N	O
3	completed	N	O
4	with	N	O
5	use	N	O
6	of	N	O
7	chi	N	O
8	(	N	O
9	2	N	O
10	)	N	O
11	analysis	N	O
12	,	N	O
13	Fisher	N	O
14	exact	N	O
15	tests	N	O
16	,	N	O
17	Student	N	O
18	t	N	O
19	tests	N	O
20	,	N	O
21	and	N	O
22	analysis	N	O
23	of	N	O
24	variance	N	O
25	as	N	O
26	appropriate	N	O
27	.	N	O

1	Regression	N	O
2	analysis	N	O
3	was	N	O
4	used	N	O
5	to	N	O
6	analyze	N	O
7	the	N	O
8	impact	N	O
9	on	N	O
10	outcome	N	O
11	of	N	O
12	baseline	N	O
13	factors	N	O
14	(	N	O
15	other	N	O
16	than	N	O
17	type	N	O
18	of	N	O
19	embolic	N	O
20	agent	N	O
21	)	N	O
22	.	N	O

1	No	N	O
2	significant	N	O
3	differences	N	O
4	were	N	O
5	noted	N	O
6	at	N	O
7	baseline	N	O
8	between	N	O
9	the	N	O
10	two	N	O
11	treatment	N	O
12	groups	N	O
13	.	N	O

1	On	N	I-Premise
2	average	N	I-Premise
3	,	N	I-Premise
4	there	N	I-Premise
5	were	N	I-Premise
6	significantly	N	I-Premise
7	higher	N	I-Premise
8	volumes	N	I-Premise
9	of	N	I-Premise
10	tris-acryl	N	I-Premise
11	microspheres	N	I-Premise
12	used	N	I-Premise
13	(	N	I-Premise
14	9.0	N	I-Premise
15	mL	N	I-Premise
16	vs	N	I-Premise
17	3.0	N	I-Premise
18	mL	N	I-Premise
19	;	N	I-Premise
20	P	N	I-Premise
21	=.0001	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	whereas	N	O
25	microcatheter	N	I-Premise
26	occlusion	N	I-Premise
27	was	N	I-Premise
28	more	N	I-Premise
29	common	N	I-Premise
30	with	N	I-Premise
31	PVA	N	I-Premise
32	(	N	I-Premise
33	28	N	I-Premise
34	%	N	I-Premise
35	vs	N	I-Premise
36	4	N	I-Premise
37	%	N	I-Premise
38	,	N	I-Premise
39	P	N	I-Premise
40	=.001	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	differences	N	I-Premise
5	in	N	I-Premise
6	pain	N	I-Premise
7	severity	N	I-Premise
8	,	N	I-Premise
9	other	N	I-Premise
10	postprocedural	N	I-Premise
11	symptoms	N	I-Premise
12	,	N	I-Premise
13	or	N	I-Premise
14	medication	N	I-Premise
15	use	N	I-Premise
16	between	N	I-Premise
17	the	N	I-Premise
18	two	N	I-Premise
19	treatment	N	I-Premise
20	groups	N	I-Premise
21	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	also	N	I-Premise
4	no	N	I-Premise
5	differences	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	frequency	N	I-Premise
9	of	N	I-Premise
10	incompletely	N	I-Premise
11	infarcted	N	I-Premise
12	leiomyomas	N	I-Premise
13	,	N	I-Premise
14	degree	N	I-Premise
15	of	N	I-Premise
16	improvement	N	I-Premise
17	in	N	I-Premise
18	symptom	N	I-Premise
19	score	N	I-Premise
20	,	N	I-Premise
21	patient	N	I-Premise
22	satisfaction	N	I-Premise
23	,	N	I-Premise
24	or	N	I-Premise
25	QOL	N	I-Premise
26	.	N	I-Premise

1	No	N	I-Claim
2	substantive	N	I-Claim
3	differences	N	I-Claim
4	were	N	I-Claim
5	detected	N	I-Claim
6	between	N	I-Claim
7	outcomes	N	I-Claim
8	of	N	I-Claim
9	embolization	N	I-Claim
10	with	N	I-Claim
11	PVA	N	I-Claim
12	particles	N	I-Claim
13	or	N	I-Claim
14	tris-acryl	N	I-Claim
15	gelatin	N	I-Claim
16	microspheres	N	I-Claim
17	.	N	I-Claim

1	Fatigue	N	O
2	is	N	O
3	a	N	O
4	frequent	N	O
5	problem	N	O
6	after	N	O
7	surgical	N	O
8	treatment	N	O
9	of	N	O
10	solid	N	O
11	tumours	N	O
12	.	N	O

1	Aerobic	N	I-Claim
2	exercise	N	I-Claim
3	and	N	I-Claim
4	psychosocial	N	I-Claim
5	interventions	N	I-Claim
6	have	N	I-Claim
7	been	N	I-Claim
8	shown	N	I-Claim
9	to	N	I-Claim
10	reduce	N	I-Claim
11	the	N	I-Claim
12	severity	N	I-Claim
13	of	N	I-Claim
14	this	N	I-Claim
15	symptom	N	I-Claim
16	in	N	I-Claim
17	cancer	N	I-Claim
18	patients	N	I-Claim
19	.	N	I-Claim

1	Therefore	N	O
2	,	N	O
3	we	N	O
4	compared	N	O
5	the	N	O
6	effect	N	O
7	of	N	O
8	the	N	O
9	two	N	O
10	therapies	N	O
11	on	N	O
12	fatigue	N	O
13	in	N	O
14	a	N	O
15	randomised	N	O
16	controlled	N	O
17	study	N	O
18	.	N	O

1	Seventy-two	N	O
2	patients	N	O
3	who	N	O
4	underwent	N	O
5	surgery	N	O
6	for	N	O
7	lung	N	O
8	(	N	O
9	n=27	N	O
10	)	N	O
11	or	N	O
12	gastrointestinal	N	O
13	tumours	N	O
14	(	N	O
15	n=42	N	O
16	)	N	O
17	were	N	O
18	assigned	N	O
19	to	N	O
20	an	N	O
21	aerobic	N	O
22	exercise	N	O
23	group	N	O
24	(	N	O
25	stationary	N	O
26	biking	N	O
27	30	N	O
28	min	N	O
29	five	N	O
30	times	N	O
31	weekly	N	O
32	)	N	O
33	or	N	O
34	a	N	O
35	progressive	N	O
36	relaxation	N	O
37	training	N	O
38	group	N	O
39	(	N	O
40	45	N	O
41	min	N	O
42	three	N	O
43	times	N	O
44	per	N	O
45	week	N	O
46	)	N	O
47	.	N	O

1	Both	N	O
2	interventions	N	O
3	were	N	O
4	carried	N	O
5	out	N	O
6	for	N	O
7	3	N	O
8	weeks	N	O
9	.	N	O

1	At	N	O
2	the	N	O
3	beginning	N	O
4	and	N	O
5	the	N	O
6	end	N	O
7	of	N	O
8	the	N	O
9	study	N	O
10	,	N	O
11	we	N	O
12	evaluated	N	O
13	physical	N	O
14	,	N	O
15	cognitive	N	O
16	and	N	O
17	emotional	N	O
18	status	N	O
19	and	N	O
20	somatic	N	O
21	complaints	N	O
22	with	N	O
23	the	N	O
24	European	N	O
25	Organization	N	O
26	for	N	O
27	Research	N	O
28	and	N	O
29	Treatment	N	O
30	of	N	O
31	Cancer	N	O
32	Quality	N	O
33	of	N	O
34	Life	N	O
35	Questionnaire	N	O
36	Core	N	O
37	Module	N	O
38	(	N	O
39	EORTC-QLQ-30	N	O
40	)	N	O
41	questionnaire	N	O
42	,	N	O
43	and	N	O
44	maximal	N	O
45	physical	N	O
46	performance	N	O
47	with	N	O
48	an	N	O
49	ergometric	N	O
50	stress	N	O
51	test	N	O
52	.	N	O

1	Physical	N	I-Premise
2	performance	N	I-Premise
3	of	N	I-Premise
4	the	N	I-Premise
5	training	N	I-Premise
6	group	N	I-Premise
7	improved	N	I-Premise
8	significantly	N	I-Premise
9	during	N	I-Premise
10	the	N	I-Premise
11	programme	N	I-Premise
12	(	N	I-Premise
13	9.4+/-20	N	I-Premise
14	watts	N	I-Premise
15	,	N	I-Premise
16	p=0.01	N	I-Premise
17	)	N	I-Premise
18	but	N	I-Premise
19	remained	N	I-Premise
20	unchanged	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	relaxation	N	I-Premise
24	group	N	I-Premise
25	(	N	I-Premise
26	1.5+/-14.8	N	I-Premise
27	watts	N	I-Premise
28	,	N	I-Premise
29	p=0.37	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	Fatigue	N	I-Premise
2	and	N	I-Premise
3	global	N	I-Premise
4	health	N	I-Premise
5	scores	N	I-Premise
6	improved	N	I-Premise
7	in	N	I-Premise
8	both	N	I-Premise
9	groups	N	I-Premise
10	during	N	I-Premise
11	the	N	I-Premise
12	intervention	N	I-Premise
13	(	N	I-Premise
14	fatigue	N	I-Premise
15	:	N	I-Premise
16	training	N	I-Premise
17	group	N	I-Premise
18	21	N	I-Premise
19	%	N	I-Premise
20	,	N	I-Premise
21	relaxation	N	I-Premise
22	group	N	I-Premise
23	19	N	I-Premise
24	%	N	I-Premise
25	;	N	I-Premise
26	global	N	I-Premise
27	health	N	I-Premise
28	of	N	I-Premise
29	both	N	I-Premise
30	groups	N	I-Premise
31	19	N	I-Premise
32	%	N	I-Premise
33	,	N	I-Premise
34	p	N	I-Premise
35	for	N	I-Premise
36	all	N	I-Premise
37	<	N	I-Premise
38	or	N	I-Premise
39	=0.01	N	I-Premise
40	)	N	I-Premise
41	;	N	I-Premise
42	however	N	I-Premise
43	,	N	I-Premise
44	there	N	I-Premise
45	was	N	I-Premise
46	no	N	I-Premise
47	significant	N	I-Premise
48	difference	N	I-Premise
49	between	N	I-Premise
50	changes	N	I-Premise
51	in	N	I-Premise
52	the	N	I-Premise
53	scores	N	I-Premise
54	of	N	I-Premise
55	both	N	I-Premise
56	groups	N	I-Premise
57	(	N	I-Premise
58	p=0.67	N	I-Premise
59	)	N	I-Premise
60	.	N	I-Premise

1	We	N	I-Claim
2	conclude	N	I-Claim
3	that	N	I-Claim
4	a	N	I-Claim
5	structured	N	I-Claim
6	aerobic	N	I-Claim
7	training	N	I-Claim
8	programme	N	I-Claim
9	improves	N	I-Claim
10	the	N	I-Claim
11	physical	N	I-Claim
12	performance	N	I-Claim
13	of	N	I-Claim
14	patients	N	I-Claim
15	recovering	N	I-Claim
16	from	N	I-Claim
17	surgery	N	I-Claim
18	for	N	I-Claim
19	solid	N	I-Claim
20	tumours	N	I-Claim
21	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	exercise	N	I-Claim
4	is	N	I-Claim
5	not	N	I-Claim
6	better	N	I-Claim
7	than	N	I-Claim
8	progressive	N	I-Claim
9	relaxation	N	I-Claim
10	training	N	I-Claim
11	for	N	I-Claim
12	the	N	I-Claim
13	treatment	N	I-Claim
14	of	N	I-Claim
15	fatigue	N	I-Claim
16	in	N	I-Claim
17	this	N	I-Claim
18	setting	N	I-Claim
19	.	N	I-Claim

1	To	N	O
2	examine	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	a	N	O
7	seated	N	O
8	exercise	N	O
9	program	N	O
10	on	N	O
11	fatigue	N	O
12	and	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	(	N	O
17	QOL	N	O
18	)	N	O
19	in	N	O
20	women	N	O
21	with	N	O
22	metastatic	N	O
23	breast	N	O
24	cancer	N	O
25	.	N	O

1	Randomized	N	O
2	,	N	O
3	controlled	N	O
4	,	N	O
5	longitudinal	N	O
6	trial	N	O
7	.	N	O

1	Outpatient	N	O
2	clinic	N	O
3	of	N	O
4	a	N	O
5	comprehensive	N	O
6	cancer	N	O
7	center	N	O
8	.	N	O

1	Convenience	N	O
2	sample	N	O
3	of	N	O
4	38	N	O
5	women	N	O
6	who	N	O
7	were	N	O
8	beginning	N	O
9	outpatient	N	O
10	chemotherapy	N	O
11	.	N	O

1	Subjects	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	a	N	O
6	control	N	O
7	or	N	O
8	intervention	N	O
9	group	N	O
10	;	N	O
11	the	N	O
12	intervention	N	O
13	was	N	O
14	performance	N	O
15	of	N	O
16	a	N	O
17	seated	N	O
18	exercise	N	O
19	program	N	O
20	using	N	O
21	home	N	O
22	videotape	N	O
23	three	N	O
24	times	N	O
25	per	N	O
26	week	N	O
27	for	N	O
28	four	N	O
29	cycles	N	O
30	of	N	O
31	chemotherapy	N	O
32	.	N	O

1	All	N	O
2	subjects	N	O
3	completed	N	O
4	the	N	O
5	Functional	N	O
6	Assessment	N	O
7	of	N	O
8	Chronic	N	O
9	Illness	N	O
10	Therapy	N	O
11	Fatigue	N	O
12	Version	N	O
13	IV	N	O
14	(	N	O
15	FACIT	N	O
16	F	N	O
17	)	N	O
18	at	N	O
19	baseline	N	O
20	and	N	O
21	at	N	O
22	the	N	O
23	time	N	O
24	of	N	O
25	the	N	O
26	next	N	O
27	three	N	O
28	cycles	N	O
29	.	N	O

1	Subjects	N	O
2	were	N	O
3	asked	N	O
4	to	N	O
5	document	N	O
6	the	N	O
7	frequency	N	O
8	,	N	O
9	duration	N	O
10	,	N	O
11	and	N	O
12	intensity	N	O
13	of	N	O
14	all	N	O
15	exercise	N	O
16	participation	N	O
17	on	N	O
18	monthly	N	O
19	calendars	N	O
20	.	N	O

1	Exercise	N	O
2	,	N	O
3	fatigue	N	O
4	,	N	O
5	and	N	O
6	QOL	N	O
7	.	N	O

1	32	N	O
2	subjects	N	O
3	,	N	O
4	16	N	O
5	per	N	O
6	group	N	O
7	,	N	O
8	completed	N	O
9	the	N	O
10	study	N	O
11	follow-up	N	O
12	.	N	O

1	With	N	I-Premise
2	a	N	I-Premise
3	mixed	N	I-Premise
4	modeling	N	I-Premise
5	approach	N	I-Premise
6	,	N	I-Premise
7	total	N	I-Premise
8	FACIT	N	I-Premise
9	F	N	I-Premise
10	scores	N	I-Premise
11	for	N	I-Premise
12	the	N	I-Premise
13	entire	N	I-Premise
14	sample	N	I-Premise
15	declined	N	I-Premise
16	at	N	I-Premise
17	a	N	I-Premise
18	significant	N	I-Premise
19	rate	N	I-Premise
20	(	N	I-Premise
21	p	N	I-Premise
22	=	N	I-Premise
23	0.003	N	I-Premise
24	)	N	I-Premise
25	beginning	N	I-Premise
26	with	N	I-Premise
27	cycle	N	I-Premise
28	3	N	I-Premise
29	but	N	I-Premise
30	at	N	I-Premise
31	a	N	I-Premise
32	slower	N	I-Premise
33	rate	N	I-Premise
34	for	N	I-Premise
35	the	N	I-Premise
36	experimental	N	I-Premise
37	group	N	I-Premise
38	(	N	I-Premise
39	p	N	I-Premise
40	=	N	I-Premise
41	0.02	N	I-Premise
42	)	N	I-Premise
43	.	N	I-Premise

1	Fatigue	N	I-Premise
2	scores	N	I-Premise
3	indicated	N	I-Premise
4	less	N	I-Premise
5	increase	N	I-Premise
6	and	N	I-Premise
7	physical	N	I-Premise
8	well-being	N	I-Premise
9	subscale	N	I-Premise
10	scores	N	I-Premise
11	showed	N	I-Premise
12	less	N	I-Premise
13	decline	N	I-Premise
14	for	N	I-Premise
15	the	N	I-Premise
16	experimental	N	I-Premise
17	group	N	I-Premise
18	(	N	I-Premise
19	p	N	I-Premise
20	=	N	I-Premise
21	0.008	N	I-Premise
22	and	N	I-Premise
23	p	N	I-Premise
24	=	N	I-Premise
25	0.02	N	I-Premise
26	,	N	I-Premise
27	respectively	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Women	N	I-Premise
2	with	N	I-Premise
3	advanced	N	I-Premise
4	breast	N	I-Premise
5	cancer	N	I-Premise
6	randomized	N	I-Premise
7	to	N	I-Premise
8	the	N	I-Premise
9	seated	N	I-Premise
10	exercise	N	I-Premise
11	intervention	N	I-Premise
12	had	N	I-Premise
13	a	N	I-Premise
14	slower	N	I-Premise
15	decline	N	I-Premise
16	in	N	I-Premise
17	total	N	I-Premise
18	and	N	I-Premise
19	physical	N	I-Premise
20	well-being	N	I-Premise
21	and	N	I-Premise
22	less	N	I-Premise
23	increase	N	I-Premise
24	in	N	I-Premise
25	fatigue	N	I-Premise
26	scores	N	I-Premise
27	starting	N	I-Premise
28	with	N	I-Premise
29	the	N	I-Premise
30	third	N	I-Premise
31	cycle	N	I-Premise
32	of	N	I-Premise
33	chemotherapy	N	I-Premise
34	.	N	I-Premise

1	Seated	N	I-Claim
2	exercise	N	I-Claim
3	may	N	I-Claim
4	be	N	I-Claim
5	a	N	I-Claim
6	feasible	N	I-Claim
7	exercise	N	I-Claim
8	program	N	I-Claim
9	for	N	I-Claim
10	women	N	I-Claim
11	with	N	I-Claim
12	advanced	N	I-Claim
13	cancer	N	I-Claim
14	for	N	I-Claim
15	controlling	N	I-Claim
16	fatigue	N	I-Claim
17	and	N	I-Claim
18	improving	N	I-Claim
19	physical	N	I-Claim
20	well-being	N	I-Claim
21	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	weekly	N	O
5	epoetin	N	O
6	alfa	N	O
7	could	N	O
8	improve	N	O
9	hemoglobin	N	O
10	(	N	O
11	HgB	N	O
12	)	N	O
13	levels	N	O
14	,	N	O
15	reduce	N	O
16	RBC	N	O
17	transfusions	N	O
18	,	N	O
19	and	N	O
20	improve	N	O
21	quality	N	O
22	of	N	O
23	life	N	O
24	(	N	O
25	QOL	N	O
26	)	N	O
27	in	N	O
28	patients	N	O
29	with	N	O
30	advanced	N	O
31	cancer	N	O
32	and	N	O
33	with	N	O
34	anemia	N	O
35	after	N	O
36	receiving	N	O
37	myelosuppressive	N	O
38	chemotherapy	N	O
39	.	N	O

1	This	N	O
2	double-blind	N	O
3	,	N	O
4	placebo-controlled	N	O
5	study	N	O
6	randomly	N	O
7	assigned	N	O
8	patients	N	O
9	to	N	O
10	placebo	N	O
11	or	N	O
12	epoetin	N	O
13	alfa	N	O
14	(	N	O
15	Ortho	N	O
16	Biotech	N	O
17	,	N	O
18	Bridgewater	N	O
19	,	N	O
20	NJ	N	O
21	)	N	O
22	40,000	N	O
23	U	N	O
24	subcutaneous	N	O
25	weekly	N	O
26	for	N	O
27	16	N	O
28	weeks	N	O
29	.	N	O

1	QOL	N	O
2	,	N	O
3	HgB	N	O
4	,	N	O
5	and	N	O
6	RBC	N	O
7	transfusions	N	O
8	were	N	O
9	measured	N	O
10	pretreatment	N	O
11	and	N	O
12	monthly	N	O
13	.	N	O

1	The	N	O
2	study	N	O
3	accrued	N	O
4	344	N	O
5	patients	N	O
6	;	N	O
7	330	N	O
8	were	N	O
9	assessable	N	O
10	for	N	O
11	efficacy	N	O
12	and	N	O
13	305	N	O
14	were	N	O
15	assessable	N	O
16	for	N	O
17	QOL	N	O
18	.	N	O

1	Placebo-treated	N	I-Premise
2	patients	N	I-Premise
3	had	N	I-Premise
4	a	N	I-Premise
5	mean	N	I-Premise
6	increase	N	I-Premise
7	in	N	I-Premise
8	HgB	N	I-Premise
9	of	N	I-Premise
10	0.9	N	I-Premise
11	g/dL	N	I-Premise
12	(	N	I-Premise
13	range	N	I-Premise
14	,	N	I-Premise
15	-3.8	N	I-Premise
16	to	N	I-Premise
17	+5.3	N	I-Premise
18	)	N	I-Premise
19	compared	N	I-Premise
20	with	N	I-Premise
21	2.8	N	I-Premise
22	g/dL	N	I-Premise
23	(	N	I-Premise
24	range	N	I-Premise
25	,	N	I-Premise
26	-2.2	N	I-Premise
27	to	N	I-Premise
28	+7.5	N	I-Premise
29	)	N	I-Premise
30	for	N	I-Premise
31	epoetin-treated	N	I-Premise
32	patients	N	I-Premise
33	(	N	I-Premise
34	P	N	I-Premise
35	<	N	I-Premise
36	.0001	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	During	N	I-Premise
2	the	N	I-Premise
3	study	N	I-Premise
4	,	N	I-Premise
5	31.7	N	I-Premise
6	%	N	I-Premise
7	of	N	I-Premise
8	placebo-treated	N	I-Premise
9	patients	N	I-Premise
10	achieved	N	I-Premise
11	a	N	I-Premise
12	>	N	I-Premise
13	or	N	I-Premise
14	=	N	I-Premise
15	2	N	I-Premise
16	g/dL	N	I-Premise
17	HgB	N	I-Premise
18	increase	N	I-Premise
19	compared	N	I-Premise
20	with	N	I-Premise
21	72.7	N	I-Premise
22	%	N	I-Premise
23	of	N	I-Premise
24	epoetin-treated	N	I-Premise
25	patients	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	<	N	I-Premise
29	.0001	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	The	N	I-Premise
2	incidence	N	I-Premise
3	of	N	I-Premise
4	RBC	N	I-Premise
5	transfusion	N	I-Premise
6	for	N	I-Premise
7	placebo	N	I-Premise
8	and	N	I-Premise
9	epoetin	N	I-Premise
10	treatment	N	I-Premise
11	arms	N	I-Premise
12	was	N	I-Premise
13	39.6	N	I-Premise
14	%	N	I-Premise
15	and	N	I-Premise
16	25.3	N	I-Premise
17	%	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	.005	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	respectively	N	I-Premise
25	.	N	I-Premise

1	The	N	O
2	placebo	N	O
3	group	N	O
4	received	N	O
5	256	N	O
6	units	N	O
7	of	N	O
8	RBCs	N	O
9	compared	N	O
10	with	N	O
11	127	N	O
12	units	N	O
13	in	N	O
14	the	N	O
15	epoetin	N	O
16	group	N	O
17	(	N	O
18	P	N	O
19	<	N	O
20	.0001	N	O
21	)	N	O
22	.	N	O

1	The	N	I-Premise
2	incidence	N	I-Premise
3	of	N	I-Premise
4	toxicity	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	groups	N	I-Premise
8	was	N	I-Premise
9	similar	N	I-Premise
10	.	N	I-Premise

1	Changes	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	average	N	I-Premise
5	QOL	N	I-Premise
6	scores	N	I-Premise
7	from	N	I-Premise
8	baseline	N	I-Premise
9	to	N	I-Premise
10	the	N	I-Premise
11	end	N	I-Premise
12	of	N	I-Premise
13	the	N	I-Premise
14	study	N	I-Premise
15	were	N	I-Premise
16	similar	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	two	N	I-Premise
20	groups	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	not	N	I-Premise
25	significant	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	The	N	I-Premise
2	HgB	N	I-Premise
3	responders	N	I-Premise
4	(	N	I-Premise
5	irrespective	N	I-Premise
6	of	N	I-Premise
7	treatment	N	I-Premise
8	arm	N	I-Premise
9	)	N	I-Premise
10	had	N	I-Premise
11	a	N	I-Premise
12	mean	N	I-Premise
13	change	N	I-Premise
14	in	N	I-Premise
15	Functional	N	I-Premise
16	Assessment	N	I-Premise
17	of	N	I-Premise
18	Cancer	N	I-Premise
19	Therapy	N	I-Premise
20	(	N	I-Premise
21	FACT	N	I-Premise
22	)	N	I-Premise
23	fatigue	N	I-Premise
24	score	N	I-Premise
25	from	N	I-Premise
26	a	N	I-Premise
27	baseline	N	I-Premise
28	of	N	I-Premise
29	+5.1	N	I-Premise
30	compared	N	I-Premise
31	with	N	I-Premise
32	-2.1	N	I-Premise
33	for	N	I-Premise
34	the	N	I-Premise
35	nonresponders	N	I-Premise
36	(	N	I-Premise
37	P	N	I-Premise
38	=	N	I-Premise
39	.006	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	Epoetin	N	I-Claim
2	alfa	N	I-Claim
3	significantly	N	I-Claim
4	improved	N	I-Claim
5	HgB	N	I-Claim
6	and	N	I-Claim
7	reduced	N	I-Claim
8	transfusions	N	I-Claim
9	in	N	I-Claim
10	this	N	I-Claim
11	patient	N	I-Claim
12	population	N	I-Claim
13	.	N	I-Claim

1	These	N	I-Claim
2	results	N	I-Claim
3	support	N	I-Claim
4	the	N	I-Claim
5	use	N	I-Claim
6	of	N	I-Claim
7	weekly	N	I-Claim
8	epoetin	N	I-Claim
9	alfa	N	I-Claim
10	as	N	I-Claim
11	an	N	I-Claim
12	ameliorative	N	I-Claim
13	agent	N	I-Claim
14	for	N	I-Claim
15	cancer-related	N	I-Claim
16	anemia	N	I-Claim
17	.	N	I-Claim

1	Epoetin	N	I-Claim
2	alfa	N	I-Claim
3	administered	N	I-Claim
4	at	N	I-Claim
5	40,000	N	I-Claim
6	U	N	I-Claim
7	once	N	I-Claim
8	weekly	N	I-Claim
9	(	N	I-Claim
10	qw	N	I-Claim
11	)	N	I-Claim
12	to	N	I-Claim
13	anemic	N	I-Claim
14	cancer	N	I-Claim
15	patients	N	I-Claim
16	receiving	N	I-Claim
17	chemotherapy	N	I-Claim
18	increases	N	I-Claim
19	hemoglobin	N	I-Claim
20	levels	N	I-Claim
21	,	N	I-Claim
22	improves	N	I-Claim
23	quality	N	I-Claim
24	of	N	I-Claim
25	life	N	I-Claim
26	(	N	I-Claim
27	QOL	N	I-Claim
28	)	N	I-Claim
29	,	N	I-Claim
30	and	N	I-Claim
31	reduces	N	I-Claim
32	transfusions	N	I-Claim
33	.	N	I-Claim

1	The	N	O
2	benefit	N	O
3	of	N	O
4	epoetin	N	O
5	alfa	N	O
6	in	N	O
7	maintaining	N	O
8	hemoglobin	N	O
9	levels	N	O
10	in	N	O
11	cancer	N	O
12	patients	N	O
13	with	N	O
14	hemoglobin	N	O
15	less	N	O
16	than	N	O
17	12	N	O
18	g/dL	N	O
19	has	N	O
20	not	N	O
21	been	N	O
22	evaluated	N	O
23	.	N	O

1	Breast	N	O
2	cancer	N	O
3	patients	N	O
4	(	N	O
5	N	N	O
6	=	N	O
7	354	N	O
8	)	N	O
9	receiving	N	O
10	chemotherapy	N	O
11	were	N	O
12	randomly	N	O
13	assigned	N	O
14	in	N	O
15	1:1	N	O
16	ratio	N	O
17	to	N	O
18	epoetin	N	O
19	alfa	N	O
20	(	N	O
21	40,000	N	O
22	U	N	O
23	qw	N	O
24	)	N	O
25	or	N	O
26	standard	N	O
27	of	N	O
28	care	N	O
29	(	N	O
30	SOC	N	O
31	)	N	O
32	.	N	O

1	QOL	N	O
2	was	N	O
3	assessed	N	O
4	at	N	O
5	baseline	N	O
6	and	N	O
7	week	N	O
8	12	N	O
9	.	N	O

1	Hemoglobin	N	O
2	responses	N	O
3	,	N	O
4	transfusion	N	O
5	requirements	N	O
6	,	N	O
7	and	N	O
8	prognostic	N	O
9	factors	N	O
10	for	N	O
11	responses	N	O
12	were	N	O
13	measured	N	O
14	.	N	O

1	At	N	I-Premise
2	week	N	I-Premise
3	12	N	I-Premise
4	,	N	I-Premise
5	Functional	N	I-Premise
6	Assessment	N	I-Premise
7	of	N	I-Premise
8	Cancer	N	I-Premise
9	Therapy-Anemia	N	I-Premise
10	(	N	I-Premise
11	FACT-An	N	I-Premise
12	;	N	I-Premise
13	mean	N	I-Premise
14	,	N	I-Premise
15	2.16	N	I-Premise
16	+/-	N	I-Premise
17	12.84	N	I-Premise
18	for	N	I-Premise
19	epoetin	N	I-Premise
20	alfa	N	I-Premise
21	v	N	I-Premise
22	-4.43	N	I-Premise
23	+/-	N	I-Premise
24	13.42	N	I-Premise
25	for	N	I-Premise
26	SOC	N	I-Premise
27	)	N	I-Premise
28	and	N	I-Premise
29	FACT-An	N	I-Premise
30	fatigue	N	I-Premise
31	(	N	I-Premise
32	mean	N	I-Premise
33	,	N	I-Premise
34	1.85	N	I-Premise
35	+/-	N	I-Premise
36	10.52	N	I-Premise
37	for	N	I-Premise
38	epoetin	N	I-Premise
39	alfa	N	I-Premise
40	v	N	I-Premise
41	-3.55	N	I-Premise
42	+/-	N	I-Premise
43	11.14	N	I-Premise
44	for	N	I-Premise
45	SOC	N	I-Premise
46	)	N	I-Premise
47	change	N	I-Premise
48	scores	N	I-Premise
49	were	N	I-Premise
50	significantly	N	I-Premise
51	higher	N	I-Premise
52	in	N	I-Premise
53	the	N	I-Premise
54	epoetin	N	I-Premise
55	alfa	N	I-Premise
56	group	N	I-Premise
57	(	N	I-Premise
58	P	N	I-Premise
59	<	N	I-Premise
60	.0001	N	I-Premise
61	)	N	I-Premise
62	.	N	I-Premise

1	Hemoglobin	N	I-Premise
2	responses	N	I-Premise
3	defined	N	I-Premise
4	as	N	I-Premise
5	mean	N	I-Premise
6	hemoglobin	N	I-Premise
7	>	N	I-Premise
8	or	N	I-Premise
9	=	N	I-Premise
10	12	N	I-Premise
11	g/dL	N	I-Premise
12	or	N	I-Premise
13	a	N	I-Premise
14	>	N	I-Premise
15	or	N	I-Premise
16	=	N	I-Premise
17	2	N	I-Premise
18	g/dL	N	I-Premise
19	increase	N	I-Premise
20	compared	N	I-Premise
21	with	N	I-Premise
22	baseline	N	I-Premise
23	were	N	I-Premise
24	significantly	N	I-Premise
25	higher	N	I-Premise
26	in	N	I-Premise
27	the	N	I-Premise
28	epoetin	N	I-Premise
29	alfa	N	I-Premise
30	group	N	I-Premise
31	versus	N	I-Premise
32	SOC	N	I-Premise
33	:	N	I-Premise
34	52.0	N	I-Premise
35	%	N	I-Premise
36	v	N	I-Premise
37	5.1	N	I-Premise
38	%	N	I-Premise
39	and	N	I-Premise
40	65.7	N	I-Premise
41	%	N	I-Premise
42	v	N	I-Premise
43	6.3	N	I-Premise
44	%	N	I-Premise
45	,	N	I-Premise
46	respectively	N	I-Premise
47	(	N	I-Premise
48	P	N	I-Premise
49	<	N	I-Premise
50	.0001	N	I-Premise
51	for	N	I-Premise
52	both	N	I-Premise
53	comparisons	N	I-Premise
54	)	N	I-Premise
55	.	N	I-Premise

1	Percentage	N	I-Premise
2	transfused	N	I-Premise
3	was	N	I-Premise
4	significantly	N	I-Premise
5	lower	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	epoetin	N	I-Premise
9	alfa	N	I-Premise
10	group	N	I-Premise
11	compared	N	I-Premise
12	with	N	I-Premise
13	SOC	N	I-Premise
14	(	N	I-Premise
15	8.6	N	I-Premise
16	%	N	I-Premise
17	v	N	I-Premise
18	22.9	N	I-Premise
19	%	N	I-Premise
20	)	N	I-Premise
21	.	N	I-Premise

1	More	N	I-Premise
2	than	N	I-Premise
3	90	N	I-Premise
4	%	N	I-Premise
5	of	N	I-Premise
6	patients	N	I-Premise
7	did	N	I-Premise
8	not	N	I-Premise
9	require	N	I-Premise
10	a	N	I-Premise
11	dose	N	I-Premise
12	increase	N	I-Premise
13	and	N	I-Premise
14	28.7	N	I-Premise
15	%	N	I-Premise
16	had	N	I-Premise
17	a	N	I-Premise
18	dose	N	I-Premise
19	reduction	N	I-Premise
20	.	N	I-Premise

1	Epoetin	N	I-Claim
2	alfa	N	I-Claim
3	administered	N	I-Claim
4	at	N	I-Claim
5	40,000	N	I-Claim
6	U	N	I-Claim
7	qw	N	I-Claim
8	is	N	I-Claim
9	effective	N	I-Claim
10	in	N	I-Claim
11	improving	N	I-Claim
12	QOL	N	I-Claim
13	,	N	I-Claim
14	maintaining	N	I-Claim
15	hemoglobin	N	I-Claim
16	level	N	I-Claim
17	,	N	I-Claim
18	and	N	I-Claim
19	reducing	N	I-Claim
20	transfusion	N	I-Claim
21	requirements	N	I-Claim
22	in	N	I-Claim
23	breast	N	I-Claim
24	cancer	N	I-Claim
25	patients	N	I-Claim
26	.	N	I-Claim

1	The	N	I-Claim
2	high	N	I-Claim
3	effectiveness	N	I-Claim
4	observed	N	I-Claim
5	could	N	I-Claim
6	be	N	I-Claim
7	attributed	N	I-Claim
8	in	N	I-Claim
9	part	N	I-Claim
10	to	N	I-Claim
11	early	N	I-Claim
12	treatment	N	I-Claim
13	with	N	I-Claim
14	epoetin	N	I-Claim
15	alfa	N	I-Claim
16	.	N	I-Claim

1	Increased	N	O
2	attention	N	O
3	has	N	O
4	focused	N	O
5	on	N	O
6	exercise	N	O
7	as	N	O
8	a	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	intervention	N	O
13	for	N	O
14	breast	N	O
15	cancer	N	O
16	survivors	N	O
17	during	N	O
18	and	N	O
19	after	N	O
20	adjuvant	N	O
21	therapy	N	O
22	.	N	O

1	Our	N	O
2	objective	N	O
3	was	N	O
4	to	N	O
5	examine	N	O
6	the	N	O
7	effects	N	O
8	of	N	O
9	an	N	O
10	oncologist	N	O
11	's	N	O
12	recommendation	N	O
13	to	N	O
14	exercise	N	O
15	on	N	O
16	self-reported	N	O
17	exercise	N	O
18	behavior	N	O
19	in	N	O
20	newly	N	O
21	diagnosed	N	O
22	breast	N	O
23	cancer	N	O
24	survivors	N	O
25	attending	N	O
26	their	N	O
27	first	N	O
28	adjuvant	N	O
29	therapy	N	O
30	consultation	N	O
31	.	N	O

1	Using	N	O
2	a	N	O
3	single-blinded	N	O
4	,	N	O
5	3-armed	N	O
6	,	N	O
7	randomized	N	O
8	controlled	N	O
9	trial	N	O
10	,	N	O
11	450	N	O
12	breast	N	O
13	cancer	N	O
14	survivors	N	O
15	were	N	O
16	randomly	N	O
17	assigned	N	O
18	to	N	O
19	receive	N	O
20	an	N	O
21	oncologist	N	O
22	exercise	N	O
23	recommendation	N	O
24	only	N	O
25	,	N	O
26	an	N	O
27	oncologist	N	O
28	exercise	N	O
29	recommendation	N	O
30	plus	N	O
31	referral	N	O
32	to	N	O
33	an	N	O
34	exercise	N	O
35	specialist	N	O
36	,	N	O
37	or	N	O
38	usual	N	O
39	care	N	O
40	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	self-reported	N	O
6	total	N	O
7	exercise	N	O
8	(	N	O
9	in	N	O
10	metabolic	N	O
11	equivalent	N	O
12	[	N	O
13	MET	N	O
14	]	N	O
15	hours	N	O
16	per	N	O
17	week	N	O
18	)	N	O
19	at	N	O
20	5	N	O
21	weeks	N	O
22	postconsultation	N	O
23	.	N	O

1	The	N	O
2	follow-up	N	O
3	assessment	N	O
4	rate	N	O
5	was	N	O
6	73	N	O
7	%	N	O
8	(	N	O
9	329	N	O
10	of	N	O
11	450	N	O
12	)	N	O
13	.	N	O

1	Intention-to-treat	N	I-Premise
2	analysis	N	I-Premise
3	based	N	I-Premise
4	on	N	I-Premise
5	participants	N	I-Premise
6	with	N	I-Premise
7	follow-up	N	I-Premise
8	data	N	I-Premise
9	indicated	N	I-Premise
10	a	N	I-Premise
11	significant	N	I-Premise
12	difference	N	I-Premise
13	in	N	I-Premise
14	total	N	I-Premise
15	exercise	N	I-Premise
16	in	N	I-Premise
17	favor	N	I-Premise
18	of	N	I-Premise
19	the	N	I-Premise
20	recommendation-only	N	I-Premise
21	group	N	I-Premise
22	over	N	I-Premise
23	the	N	I-Premise
24	usual	N	I-Premise
25	care	N	I-Premise
26	group	N	I-Premise
27	(	N	I-Premise
28	mean	N	I-Premise
29	difference	N	I-Premise
30	,	N	I-Premise
31	3.4	N	I-Premise
32	MET	N	I-Premise
33	hr	N	I-Premise
34	per	N	I-Premise
35	week	N	I-Premise
36	;	N	I-Premise
37	95	N	I-Premise
38	%	N	I-Premise
39	confidence	N	I-Premise
40	interval	N	I-Premise
41	[	N	I-Premise
42	CI	N	I-Premise
43	]	N	I-Premise
44	,	N	I-Premise
45	0.7-6.1	N	I-Premise
46	MET	N	I-Premise
47	hr	N	I-Premise
48	per	N	I-Premise
49	week	N	I-Premise
50	;	N	I-Premise
51	p	N	I-Premise
52	=	N	I-Premise
53	.011	N	I-Premise
54	)	N	I-Premise
55	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	between	N	I-Premise
7	the	N	I-Premise
8	recommendation-plus-referral	N	I-Premise
9	group	N	I-Premise
10	and	N	I-Premise
11	the	N	I-Premise
12	usual	N	I-Premise
13	care	N	I-Premise
14	group	N	I-Premise
15	(	N	I-Premise
16	mean	N	I-Premise
17	difference	N	I-Premise
18	,	N	I-Premise
19	1.5	N	I-Premise
20	MET	N	I-Premise
21	hr	N	I-Premise
22	per	N	I-Premise
23	week	N	I-Premise
24	;	N	I-Premise
25	95	N	I-Premise
26	%	N	I-Premise
27	CI	N	I-Premise
28	,	N	I-Premise
29	-1.0	N	I-Premise
30	to	N	I-Premise
31	4.0	N	I-Premise
32	MET	N	I-Premise
33	hr	N	I-Premise
34	per	N	I-Premise
35	week	N	I-Premise
36	;	N	I-Premise
37	p	N	I-Premise
38	=	N	I-Premise
39	.244	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	Ancillary	N	I-Premise
2	``	N	I-Premise
3	on-treatment	N	I-Premise
4	''	N	I-Premise
5	analyzes	N	I-Premise
6	showed	N	I-Premise
7	that	N	I-Premise
8	participants	N	I-Premise
9	who	N	I-Premise
10	recalled	N	I-Premise
11	an	N	I-Premise
12	exercise	N	I-Premise
13	recommendation	N	I-Premise
14	reported	N	I-Premise
15	significantly	N	I-Premise
16	more	N	I-Premise
17	total	N	I-Premise
18	exercise	N	I-Premise
19	than	N	I-Premise
20	participants	N	I-Premise
21	who	N	I-Premise
22	did	N	I-Premise
23	not	N	I-Premise
24	recall	N	I-Premise
25	an	N	I-Premise
26	exercise	N	I-Premise
27	recommendation	N	I-Premise
28	(	N	I-Premise
29	mean	N	I-Premise
30	difference	N	I-Premise
31	,	N	I-Premise
32	4.1	N	I-Premise
33	MET	N	I-Premise
34	hr	N	I-Premise
35	per	N	I-Premise
36	week	N	I-Premise
37	:	N	I-Premise
38	95	N	I-Premise
39	%	N	I-Premise
40	CI	N	I-Premise
41	,	N	I-Premise
42	1.9-6.4	N	I-Premise
43	MET	N	I-Premise
44	hr	N	I-Premise
45	per	N	I-Premise
46	week	N	I-Premise
47	;	N	I-Premise
48	p	N	I-Premise
49	<	N	I-Premise
50	.001	N	I-Premise
51	)	N	I-Premise
52	.	N	I-Premise

1	Our	N	I-Claim
2	findings	N	I-Claim
3	suggest	N	I-Claim
4	that	N	I-Claim
5	an	N	I-Claim
6	oncologist	N	I-Claim
7	recommendation	N	I-Claim
8	may	N	I-Claim
9	increase	N	I-Claim
10	exercise	N	I-Claim
11	behavior	N	I-Claim
12	in	N	I-Claim
13	newly	N	I-Claim
14	diagnosed	N	I-Claim
15	breast	N	I-Claim
16	cancer	N	I-Claim
17	survivors	N	I-Claim
18	,	N	I-Claim
19	particularly	N	I-Claim
20	if	N	I-Claim
21	it	N	I-Claim
22	is	N	I-Claim
23	recalled	N	I-Claim
24	1	N	I-Claim
25	week	N	I-Claim
26	after	N	I-Claim
27	the	N	I-Claim
28	recommendation	N	I-Claim
29	.	N	I-Claim

1	Kaposi	N	O
2	's	N	O
3	sarcoma	N	O
4	is	N	O
5	currently	N	O
6	the	N	O
7	most	N	O
8	common	N	O
9	tumor	N	O
10	in	N	O
11	Zimbabwe	N	O
12	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	our	N	O
5	study	N	O
6	is	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	effectiveness	N	O
11	of	N	O
12	supportive	N	O
13	care	N	O
14	vs.	N	O
15	3	N	O
16	intervention	N	O
17	approaches	N	O
18	,	N	O
19	namely	N	O
20	oral	N	O
21	Etoposide	N	O
22	,	N	O
23	a	N	O
24	3-drug	N	O
25	combination	N	O
26	,	N	O
27	and	N	O
28	radiotherapy	N	O
29	using	N	O
30	quality	N	O
31	of	N	O
32	life	N	O
33	(	N	O
34	QOL	N	O
35	)	N	O
36	as	N	O
37	the	N	O
38	primary	N	O
39	measure	N	O
40	of	N	O
41	success	N	O
42	.	N	O

1	In	N	O
2	addition	N	O
3	,	N	O
4	our	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	determine	N	O
9	whether	N	O
10	a	N	O
11	disease-specific	N	O
12	module	N	O
13	has	N	O
14	greater	N	O
15	sensitivity	N	O
16	to	N	O
17	group	N	O
18	differences	N	O
19	than	N	O
20	a	N	O
21	generic	N	O
22	QOL	N	O
23	questionnaire	N	O
24	and	N	O
25	to	N	O
26	determine	N	O
27	the	N	O
28	most	N	O
29	pragmatic	N	O
30	approach	N	O
31	to	N	O
32	treating	N	O
33	epidemic	N	O
34	Kaposi	N	O
35	's	N	O
36	sarcoma	N	O
37	(	N	O
38	EKS	N	O
39	)	N	O
40	in	N	O
41	Zimbabwe	N	O
42	.	N	O

1	Histologically	N	O
2	confirmed	N	O
3	HIV-positive	N	O
4	patients	N	O
5	with	N	O
6	Kaposi	N	O
7	's	N	O
8	sarcoma	N	O
9	were	N	O
10	randomized	N	O
11	to	N	O
12	receive	N	O
13	supportive	N	O
14	care	N	O
15	only	N	O
16	or	N	O
17	supportive	N	O
18	care	N	O
19	plus	N	O
20	either	N	O
21	radiotherapy	N	O
22	,	N	O
23	oral	N	O
24	Etoposide	N	O
25	or	N	O
26	a	N	O
27	3-drug	N	O
28	combination	N	O
29	consisting	N	O
30	of	N	O
31	actinomycin-D	N	O
32	,	N	O
33	vincristine	N	O
34	and	N	O
35	bleomycin	N	O
36	.	N	O

1	No	N	O
2	patient	N	O
3	received	N	O
4	antiretroviral	N	O
5	therapy	N	O
6	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	QOL	N	O
6	measured	N	O
7	by	N	O
8	the	N	O
9	functional	N	O
10	living	N	O
11	index-cancer	N	O
12	(	N	O
13	FLI-C	N	O
14	)	N	O
15	and	N	O
16	supplemented	N	O
17	by	N	O
18	the	N	O
19	Kaposi	N	O
20	's	N	O
21	sarcoma	N	O
22	module	N	O
23	(	N	O
24	KSM	N	O
25	)	N	O
26	.	N	O

1	From	N	O
2	1994-1999	N	O
3	,	N	O
4	495	N	O
5	EKS	N	O
6	patients	N	O
7	were	N	O
8	accrued	N	O
9	,	N	O
10	and	N	O
11	470	N	O
12	were	N	O
13	evaluable	N	O
14	.	N	O

1	Of	N	O
2	these	N	O
3	,	N	O
4	433	N	O
5	are	N	O
6	known	N	O
7	to	N	O
8	be	N	O
9	dead	N	O
10	,	N	O
11	26	N	O
12	are	N	O
13	lost	N	O
14	to	N	O
15	follow-up	N	O
16	and	N	O
17	11	N	O
18	are	N	O
19	still	N	O
20	alive	N	O
21	.	N	O

1	The	N	I-Premise
2	group	N	I-Premise
3	treated	N	I-Premise
4	with	N	I-Premise
5	oral	N	I-Premise
6	Etoposide	N	I-Premise
7	had	N	I-Premise
8	a	N	I-Premise
9	significantly	N	I-Premise
10	better	N	I-Premise
11	QOL	N	I-Premise
12	than	N	I-Premise
13	the	N	I-Premise
14	radiotherapy	N	I-Premise
15	group	N	I-Premise
16	for	N	I-Premise
17	the	N	I-Premise
18	total	N	I-Premise
19	FLI-C	N	I-Premise
20	score	N	I-Premise
21	(	N	I-Premise
22	adjusted	N	I-Premise
23	mean	N	I-Premise
24	plus	N	I-Premise
25	standard	N	I-Premise
26	error	N	I-Premise
27	at	N	I-Premise
28	3-months	N	I-Premise
29	89	N	I-Premise
30	+/-	N	I-Premise
31	3	N	I-Premise
32	vs.	N	I-Premise
33	76	N	I-Premise
34	+/-	N	I-Premise
35	3	N	I-Premise
36	;	N	I-Premise
37	p	N	I-Premise
38	=	N	I-Premise
39	0.004	N	I-Premise
40	)	N	I-Premise
41	and	N	I-Premise
42	for	N	I-Premise
43	the	N	I-Premise
44	hardship	N	I-Premise
45	(	N	I-Premise
46	11	N	I-Premise
47	+/-	N	I-Premise
48	0.4	N	I-Premise
49	vs.	N	I-Premise
50	9	N	I-Premise
51	+/-	N	I-Premise
52	0.4	N	I-Premise
53	;	N	I-Premise
54	p	N	I-Premise
55	=	N	I-Premise
56	0.001	N	I-Premise
57	)	N	I-Premise
58	;	N	I-Premise
59	social	N	I-Premise
60	(	N	I-Premise
61	10	N	I-Premise
62	+/-	N	I-Premise
63	0.4	N	I-Premise
64	vs.	N	I-Premise
65	8	N	I-Premise
66	+/-	N	I-Premise
67	0.4	N	I-Premise
68	;	N	I-Premise
69	p	N	I-Premise
70	=	N	I-Premise
71	0.001	N	I-Premise
72	)	N	I-Premise
73	and	N	I-Premise
74	nausea	N	I-Premise
75	(	N	I-Premise
76	9	N	I-Premise
77	+/-	N	I-Premise
78	0.4	N	I-Premise
79	vs.	N	I-Premise
80	8	N	I-Premise
81	+/-	N	I-Premise
82	0.4	N	I-Premise
83	;	N	I-Premise
84	p	N	I-Premise
85	=	N	I-Premise
86	0.002	N	I-Premise
87	)	N	I-Premise
88	subscales	N	I-Premise
89	.	N	I-Premise

1	In	N	I-Premise
2	addition	N	I-Premise
3	,	N	I-Premise
4	on	N	I-Premise
5	the	N	I-Premise
6	physical	N	I-Premise
7	and	N	I-Premise
8	psychological	N	I-Premise
9	subscales	N	I-Premise
10	,	N	I-Premise
11	the	N	I-Premise
12	Etoposide	N	I-Premise
13	group	N	I-Premise
14	had	N	I-Premise
15	a	N	I-Premise
16	significantly	N	I-Premise
17	better	N	I-Premise
18	QOL	N	I-Premise
19	than	N	I-Premise
20	the	N	I-Premise
21	other	N	I-Premise
22	3	N	I-Premise
23	treatment	N	I-Premise
24	groups	N	I-Premise
25	(	N	I-Premise
26	p	N	I-Premise
27	<	N	I-Premise
28	0.04	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Premise
2	3-drug	N	I-Premise
3	combination	N	I-Premise
4	,	N	I-Premise
5	supportive	N	I-Premise
6	care	N	I-Premise
7	and	N	I-Premise
8	radiotherapy	N	I-Premise
9	groups	N	I-Premise
10	did	N	I-Premise
11	not	N	I-Premise
12	differ	N	I-Premise
13	significantly	N	I-Premise
14	from	N	I-Premise
15	each	N	I-Premise
16	other	N	I-Premise
17	with	N	I-Premise
18	respect	N	I-Premise
19	to	N	I-Premise
20	the	N	I-Premise
21	total	N	I-Premise
22	FLI-C	N	I-Premise
23	score	N	I-Premise
24	or	N	I-Premise
25	its	N	I-Premise
26	subscales	N	I-Premise
27	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	group	N	I-Premise
5	differences	N	I-Premise
6	with	N	I-Premise
7	respect	N	I-Premise
8	to	N	I-Premise
9	survival	N	I-Premise
10	.	N	I-Premise

1	Oral	N	I-Claim
2	Etoposide	N	I-Claim
3	therapy	N	I-Claim
4	resulted	N	I-Claim
5	in	N	I-Claim
6	better	N	I-Claim
7	total	N	I-Claim
8	FLI-C	N	I-Claim
9	QOL	N	I-Claim
10	score	N	I-Claim
11	than	N	I-Claim
12	radiotherapy	N	I-Claim
13	.	N	I-Claim

1	As	N	O
2	well	N	O
3	,	N	O
4	Etoposide	N	I-Claim
5	resulted	N	I-Claim
6	in	N	I-Claim
7	better	N	I-Claim
8	physical	N	I-Claim
9	and	N	I-Claim
10	psychological	N	I-Claim
11	subscale	N	I-Claim
12	scores	N	I-Claim
13	than	N	I-Claim
14	radiotherapy	N	I-Claim
15	,	N	I-Claim
16	3-drugs	N	I-Claim
17	and	N	I-Claim
18	supportive	N	I-Claim
19	care	N	I-Claim
20	.	N	I-Claim

1	Thus	N	I-Claim
2	,	N	I-Claim
3	funds	N	I-Claim
4	permitting	N	I-Claim
5	,	N	I-Claim
6	oral	N	I-Claim
7	Etoposide	N	I-Claim
8	is	N	I-Claim
9	a	N	I-Claim
10	pragmatic	N	I-Claim
11	approach	N	I-Claim
12	to	N	I-Claim
13	treating	N	I-Claim
14	EKS	N	I-Claim
15	in	N	I-Claim
16	an	N	I-Claim
17	environment	N	I-Claim
18	where	N	I-Claim
19	antiretroviral	N	I-Claim
20	drugs	N	I-Claim
21	are	N	I-Claim
22	not	N	I-Claim
23	universally	N	I-Claim
24	available	N	I-Claim
25	.	N	I-Claim

1	The	N	I-MajorClaim
2	study	N	I-MajorClaim
3	underscores	N	I-MajorClaim
4	the	N	I-MajorClaim
5	value	N	I-MajorClaim
6	of	N	I-MajorClaim
7	undertaking	N	I-MajorClaim
8	studies	N	I-MajorClaim
9	in	N	I-MajorClaim
10	areas	N	I-MajorClaim
11	of	N	I-MajorClaim
12	disease	N	I-MajorClaim
13	prevalence	N	I-MajorClaim
14	and	N	I-MajorClaim
15	the	N	I-MajorClaim
16	necessity	N	I-MajorClaim
17	of	N	I-MajorClaim
18	selecting	N	I-MajorClaim
19	appropriate	N	I-MajorClaim
20	outcome	N	I-MajorClaim
21	measures	N	I-MajorClaim
22	.	N	I-MajorClaim

1	To	N	O
2	determine	N	O
3	the	N	O
4	efficacy	N	O
5	and	N	O
6	safety	N	O
7	of	N	O
8	a	N	O
9	biweekly	N	O
10	regimen	N	O
11	of	N	O
12	leucovorin	N	O
13	(	N	O
14	LV	N	O
15	)	N	O
16	plus	N	O
17	fluorouracil	N	O
18	(	N	O
19	FU	N	O
20	)	N	O
21	alone	N	O
22	or	N	O
23	in	N	O
24	combination	N	O
25	with	N	O
26	cisplatin	N	O
27	or	N	O
28	irinotecan	N	O
29	in	N	O
30	patients	N	O
31	with	N	O
32	previously	N	O
33	untreated	N	O
34	metastatic	N	O
35	gastric	N	O
36	adenocarcinoma	N	O
37	and	N	O
38	to	N	O
39	select	N	O
40	the	N	O
41	best	N	O
42	arm	N	O
43	for	N	O
44	a	N	O
45	phase	N	O
46	III	N	O
47	study	N	O
48	.	N	O

1	One	N	O
2	hundred	N	O
3	thirty-six	N	O
4	patients	N	O
5	(	N	O
6	two	N	O
7	were	N	O
8	ineligible	N	O
9	)	N	O
10	were	N	O
11	enrolled	N	O
12	onto	N	O
13	the	N	O
14	randomized	N	O
15	multicenter	N	O
16	phase	N	O
17	II	N	O
18	trial	N	O
19	.	N	O

1	Patients	N	O
2	received	N	O
3	LV	N	O
4	200	N	O
5	mg/m	N	O
6	(	N	O
7	2	N	O
8	)	N	O
9	(	N	O
10	2-hour	N	O
11	infusion	N	O
12	)	N	O
13	followed	N	O
14	by	N	O
15	FU	N	O
16	400	N	O
17	mg/m	N	O
18	(	N	O
19	2	N	O
20	)	N	O
21	(	N	O
22	bolus	N	O
23	)	N	O
24	and	N	O
25	FU	N	O
26	600	N	O
27	mg/m	N	O
28	(	N	O
29	2	N	O
30	)	N	O
31	(	N	O
32	22-hour	N	O
33	continuous	N	O
34	infusion	N	O
35	)	N	O
36	on	N	O
37	days	N	O
38	1	N	O
39	and	N	O
40	2	N	O
41	every	N	O
42	14	N	O
43	days	N	O
44	(	N	O
45	LV5FU2	N	O
46	;	N	O
47	arm	N	O
48	A	N	O
49	)	N	O
50	,	N	O
51	LV5FU2	N	O
52	plus	N	O
53	cisplatin	N	O
54	50	N	O
55	mg/m	N	O
56	(	N	O
57	2	N	O
58	)	N	O
59	(	N	O
60	1-hour	N	O
61	infusion	N	O
62	)	N	O
63	on	N	O
64	day	N	O
65	1	N	O
66	or	N	O
67	2	N	O
68	(	N	O
69	arm	N	O
70	B	N	O
71	)	N	O
72	,	N	O
73	or	N	O
74	LV5FU2	N	O
75	plus	N	O
76	irinotecan	N	O
77	180	N	O
78	mg/m	N	O
79	(	N	O
80	2	N	O
81	)	N	O
82	(	N	O
83	2-hour	N	O
84	infusion	N	O
85	)	N	O
86	on	N	O
87	day	N	O
88	1	N	O
89	(	N	O
90	arm	N	O
91	C	N	O
92	)	N	O
93	.	N	O

1	The	N	I-Premise
2	overall	N	I-Premise
3	response	N	I-Premise
4	rates	N	I-Premise
5	,	N	I-Premise
6	which	N	I-Premise
7	were	N	I-Premise
8	confirmed	N	I-Premise
9	by	N	I-Premise
10	an	N	I-Premise
11	independent	N	I-Premise
12	expert	N	I-Premise
13	panel	N	I-Premise
14	,	N	I-Premise
15	were	N	I-Premise
16	13	N	I-Premise
17	%	N	I-Premise
18	(	N	I-Premise
19	95	N	I-Premise
20	%	N	I-Premise
21	CI	N	I-Premise
22	,	N	I-Premise
23	3.4	N	I-Premise
24	%	N	I-Premise
25	to	N	I-Premise
26	23.3	N	I-Premise
27	%	N	I-Premise
28	)	N	I-Premise
29	,	N	I-Premise
30	27	N	I-Premise
31	%	N	I-Premise
32	(	N	I-Premise
33	95	N	I-Premise
34	%	N	I-Premise
35	CI	N	I-Premise
36	,	N	I-Premise
37	14.1	N	I-Premise
38	%	N	I-Premise
39	to	N	I-Premise
40	40.4	N	I-Premise
41	%	N	I-Premise
42	)	N	I-Premise
43	,	N	I-Premise
44	and	N	I-Premise
45	40	N	I-Premise
46	%	N	I-Premise
47	(	N	I-Premise
48	95	N	I-Premise
49	%	N	I-Premise
50	CI	N	I-Premise
51	,	N	I-Premise
52	25.7	N	I-Premise
53	%	N	I-Premise
54	to	N	I-Premise
55	54.3	N	I-Premise
56	%	N	I-Premise
57	)	N	I-Premise
58	for	N	I-Premise
59	arms	N	I-Premise
60	A	N	I-Premise
61	,	N	I-Premise
62	B	N	I-Premise
63	,	N	I-Premise
64	and	N	I-Premise
65	C	N	I-Premise
66	,	N	I-Premise
67	respectively	N	I-Premise
68	.	N	I-Premise

1	Median	N	I-Premise
2	progression-free	N	I-Premise
3	survival	N	I-Premise
4	and	N	I-Premise
5	overall	N	I-Premise
6	survival	N	I-Premise
7	times	N	I-Premise
8	were	N	I-Premise
9	3.2	N	I-Premise
10	months	N	I-Premise
11	(	N	I-Premise
12	95	N	I-Premise
13	%	N	I-Premise
14	CI	N	I-Premise
15	,	N	I-Premise
16	1.8	N	I-Premise
17	to	N	I-Premise
18	4.6	N	I-Premise
19	months	N	I-Premise
20	)	N	I-Premise
21	and	N	I-Premise
22	6.8	N	I-Premise
23	months	N	I-Premise
24	(	N	I-Premise
25	95	N	I-Premise
26	%	N	I-Premise
27	CI	N	I-Premise
28	,	N	I-Premise
29	2.6	N	I-Premise
30	to	N	I-Premise
31	11.1	N	I-Premise
32	months	N	I-Premise
33	)	N	I-Premise
34	with	N	I-Premise
35	LV5FU2	N	I-Premise
36	,	N	I-Premise
37	respectively	N	I-Premise
38	;	N	I-Premise
39	4.9	N	I-Premise
40	months	N	I-Premise
41	(	N	I-Premise
42	95	N	I-Premise
43	%	N	I-Premise
44	CI	N	I-Premise
45	,	N	I-Premise
46	3.5	N	I-Premise
47	to	N	I-Premise
48	6.3	N	I-Premise
49	months	N	I-Premise
50	)	N	I-Premise
51	and	N	I-Premise
52	9.5	N	I-Premise
53	months	N	I-Premise
54	(	N	I-Premise
55	95	N	I-Premise
56	%	N	I-Premise
57	CI	N	I-Premise
58	,	N	I-Premise
59	6.9	N	I-Premise
60	to	N	I-Premise
61	12.2	N	I-Premise
62	months	N	I-Premise
63	)	N	I-Premise
64	with	N	I-Premise
65	LV5FU2-cisplatin	N	I-Premise
66	,	N	I-Premise
67	respectively	N	I-Premise
68	;	N	I-Premise
69	and	N	I-Premise
70	6.9	N	I-Premise
71	months	N	I-Premise
72	(	N	I-Premise
73	95	N	I-Premise
74	%	N	I-Premise
75	CI	N	I-Premise
76	,	N	I-Premise
77	5.5	N	I-Premise
78	to	N	I-Premise
79	8.3	N	I-Premise
80	months	N	I-Premise
81	)	N	I-Premise
82	and	N	I-Premise
83	11.3	N	I-Premise
84	months	N	I-Premise
85	(	N	I-Premise
86	95	N	I-Premise
87	%	N	I-Premise
88	CI	N	I-Premise
89	,	N	I-Premise
90	9.3	N	I-Premise
91	to	N	I-Premise
92	13.3	N	I-Premise
93	months	N	I-Premise
94	)	N	I-Premise
95	with	N	I-Premise
96	LV5FU2-irinotecan	N	I-Premise
97	,	N	I-Premise
98	respectively	N	I-Premise
99	.	N	I-Premise

1	Of	N	I-Claim
2	the	N	I-Claim
3	three	N	I-Claim
4	regimens	N	I-Claim
5	tested	N	I-Claim
6	,	N	I-Claim
7	the	N	I-Claim
8	combination	N	I-Claim
9	of	N	I-Claim
10	LV5FU2-irinotecan	N	I-Claim
11	is	N	I-Claim
12	the	N	I-Claim
13	most	N	I-Claim
14	promising	N	I-Claim
15	and	N	I-Claim
16	will	N	I-Claim
17	be	N	I-Claim
18	assessed	N	I-Claim
19	in	N	I-Claim
20	a	N	I-Claim
21	phase	N	I-Claim
22	III	N	I-Claim
23	trial	N	I-Claim
24	.	N	I-Claim

1	Treatment-induced	N	O
2	arm	N	O
3	lymphoedema	N	O
4	is	N	O
5	a	N	O
6	common	N	O
7	and	N	O
8	distressing	N	O
9	complication	N	O
10	of	N	O
11	curative	N	O
12	surgery	N	O
13	and	N	O
14	radiotherapy	N	O
15	for	N	O
16	early	N	O
17	breast	N	O
18	cancer	N	O
19	.	N	O

1	A	N	O
2	number	N	O
3	of	N	O
4	studies	N	O
5	testing	N	O
6	alpha-tocopherol	N	O
7	(	N	O
8	vitamin	N	O
9	E	N	O
10	)	N	O
11	and	N	O
12	pentoxifylline	N	O
13	suggest	N	O
14	evidence	N	O
15	of	N	O
16	clinical	N	O
17	regression	N	O
18	of	N	O
19	superficial	N	O
20	radiation-induced	N	O
21	fibrosis	N	O
22	but	N	O
23	there	N	O
24	is	N	O
25	only	N	O
26	very	N	O
27	limited	N	O
28	evidence	N	O
29	from	N	O
30	randomised	N	O
31	trials	N	O
32	.	N	O

1	Arm	N	O
2	lymphoedema	N	O
3	after	N	O
4	lymphatic	N	O
5	radiotherapy	N	O
6	and	N	O
7	surgery	N	O
8	has	N	O
9	been	N	O
10	used	N	O
11	in	N	O
12	the	N	O
13	present	N	O
14	study	N	O
15	as	N	O
16	a	N	O
17	clinical	N	O
18	system	N	O
19	for	N	O
20	testing	N	O
21	these	N	O
22	drugs	N	O
23	in	N	O
24	a	N	O
25	double-blind	N	O
26	placebo-controlled	N	O
27	randomised	N	O
28	phase	N	O
29	II	N	O
30	trial	N	O
31	.	N	O

1	Sixty-eight	N	O
2	eligible	N	O
3	research	N	O
4	volunteers	N	O
5	with	N	O
6	a	N	O
7	minimum	N	O
8	20	N	O
9	%	N	O
10	increase	N	O
11	in	N	O
12	arm	N	O
13	volume	N	O
14	at	N	O
15	a	N	O
16	median	N	O
17	15.5	N	O
18	years	N	O
19	(	N	O
20	range	N	O
21	2-41	N	O
22	)	N	O
23	after	N	O
24	axillary/supraclavicular	N	O
25	radiotherapy	N	O
26	(	N	O
27	plus	N	O
28	axillary	N	O
29	surgery	N	O
30	in	N	O
31	51/68	N	O
32	(	N	O
33	75	N	O
34	%	N	O
35	)	N	O
36	cases	N	O
37	)	N	O
38	were	N	O
39	randomised	N	O
40	to	N	O
41	active	N	O
42	drugs	N	O
43	or	N	O
44	placebo	N	O
45	.	N	O

1	All	N	O
2	volunteers	N	O
3	were	N	O
4	given	N	O
5	dl-alpha	N	O
6	tocopheryl	N	O
7	acetate	N	O
8	500	N	O
9	mg	N	O
10	twice	N	O
11	a	N	O
12	day	N	O
13	orally	N	O
14	plus	N	O
15	pentoxifylline	N	O
16	400	N	O
17	mg	N	O
18	twice	N	O
19	a	N	O
20	day	N	O
21	orally	N	O
22	,	N	O
23	or	N	O
24	corresponding	N	O
25	placebos	N	O
26	,	N	O
27	for	N	O
28	6	N	O
29	months	N	O
30	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	volume	N	O
6	of	N	O
7	the	N	O
8	ipsilateral	N	O
9	limb	N	O
10	measured	N	O
11	opto-electronically	N	O
12	using	N	O
13	a	N	O
14	perometer	N	O
15	and	N	O
16	expressed	N	O
17	as	N	O
18	a	N	O
19	percentage	N	O
20	of	N	O
21	the	N	O
22	contralateral	N	O
23	limb	N	O
24	volume	N	O
25	.	N	O

1	At	N	I-Premise
2	12	N	I-Premise
3	months	N	I-Premise
4	post-randomisation	N	I-Premise
5	,	N	I-Premise
6	there	N	I-Premise
7	was	N	I-Premise
8	no	N	I-Premise
9	significant	N	I-Premise
10	difference	N	I-Premise
11	between	N	I-Premise
12	treatment	N	I-Premise
13	and	N	I-Premise
14	control	N	I-Premise
15	groups	N	I-Premise
16	in	N	I-Premise
17	terms	N	I-Premise
18	of	N	I-Premise
19	arm	N	I-Premise
20	volume	N	I-Premise
21	.	N	I-Premise

1	Absolute	N	I-Premise
2	change	N	I-Premise
3	in	N	I-Premise
4	arm	N	I-Premise
5	volume	N	I-Premise
6	at	N	I-Premise
7	12	N	I-Premise
8	months	N	I-Premise
9	was	N	I-Premise
10	2.5	N	I-Premise
11	%	N	I-Premise
12	(	N	I-Premise
13	95	N	I-Premise
14	%	N	I-Premise
15	CI	N	I-Premise
16	-0.40	N	I-Premise
17	to	N	I-Premise
18	5.3	N	I-Premise
19	)	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	treatment	N	I-Premise
23	group	N	I-Premise
24	compared	N	I-Premise
25	to	N	I-Premise
26	1.2	N	I-Premise
27	%	N	I-Premise
28	(	N	I-Premise
29	95	N	I-Premise
30	%	N	I-Premise
31	CI	N	I-Premise
32	-2.8	N	I-Premise
33	to	N	I-Premise
34	5.1	N	I-Premise
35	)	N	I-Premise
36	in	N	I-Premise
37	the	N	I-Premise
38	placebo	N	I-Premise
39	group	N	I-Premise
40	.	N	I-Premise

1	The	N	I-Premise
2	difference	N	I-Premise
3	in	N	I-Premise
4	mean	N	I-Premise
5	volume	N	I-Premise
6	change	N	I-Premise
7	between	N	I-Premise
8	randomisation	N	I-Premise
9	groups	N	I-Premise
10	at	N	I-Premise
11	12	N	I-Premise
12	months	N	I-Premise
13	was	N	I-Premise
14	not	N	I-Premise
15	statistically	N	I-Premise
16	significant	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	0.6	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	-1.3	N	I-Premise
24	%	N	I-Premise
25	(	N	I-Premise
26	95	N	I-Premise
27	%	N	I-Premise
28	CI	N	I-Premise
29	-6.1	N	I-Premise
30	to	N	I-Premise
31	3.5	N	I-Premise
32	)	N	I-Premise
33	,	N	I-Premise
34	nor	N	I-Premise
35	was	N	I-Premise
36	there	N	I-Premise
37	a	N	I-Premise
38	significant	N	I-Premise
39	difference	N	I-Premise
40	in	N	I-Premise
41	response	N	I-Premise
42	at	N	I-Premise
43	6	N	I-Premise
44	months	N	I-Premise
45	(	N	I-Premise
46	P	N	I-Premise
47	=	N	I-Premise
48	0.7	N	I-Premise
49	)	N	I-Premise
50	,	N	I-Premise
51	where	N	I-Premise
52	mean	N	I-Premise
53	change	N	I-Premise
54	in	N	I-Premise
55	arm	N	I-Premise
56	volume	N	I-Premise
57	from	N	I-Premise
58	baseline	N	I-Premise
59	in	N	I-Premise
60	the	N	I-Premise
61	treatment	N	I-Premise
62	and	N	I-Premise
63	placebo	N	I-Premise
64	groups	N	I-Premise
65	was	N	I-Premise
66	-2.3	N	I-Premise
67	%	N	I-Premise
68	(	N	I-Premise
69	95	N	I-Premise
70	%	N	I-Premise
71	CI	N	I-Premise
72	-7.9	N	I-Premise
73	to	N	I-Premise
74	3.4	N	I-Premise
75	)	N	I-Premise
76	and	N	I-Premise
77	-1.1	N	I-Premise
78	%	N	I-Premise
79	(	N	I-Premise
80	95	N	I-Premise
81	%	N	I-Premise
82	CI	N	I-Premise
83	-3.9	N	I-Premise
84	to	N	I-Premise
85	1.7	N	I-Premise
86	)	N	I-Premise
87	,	N	I-Premise
88	respectively	N	I-Premise
89	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	between	N	I-Premise
7	randomised	N	I-Premise
8	groups	N	I-Premise
9	in	N	I-Premise
10	terms	N	I-Premise
11	of	N	I-Premise
12	secondary	N	I-Premise
13	endpoints	N	I-Premise
14	,	N	I-Premise
15	including	N	I-Premise
16	tissue	N	I-Premise
17	induration	N	I-Premise
18	(	N	I-Premise
19	fibrosis	N	I-Premise
20	)	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	irradiated	N	I-Premise
24	breast	N	I-Premise
25	or	N	I-Premise
26	chest	N	I-Premise
27	wall	N	I-Premise
28	,	N	I-Premise
29	pectoral	N	I-Premise
30	fold	N	I-Premise
31	or	N	I-Premise
32	supraclavicular	N	I-Premise
33	fossa	N	I-Premise
34	,	N	I-Premise
35	change	N	I-Premise
36	in	N	I-Premise
37	photographic	N	I-Premise
38	breast/chest	N	I-Premise
39	wall	N	I-Premise
40	appearance	N	I-Premise
41	or	N	I-Premise
42	patient	N	I-Premise
43	self-assessment	N	I-Premise
44	of	N	I-Premise
45	function	N	I-Premise
46	and	N	I-Premise
47	Quality	N	I-Premise
48	of	N	I-Premise
49	Life	N	I-Premise
50	at	N	I-Premise
51	either	N	I-Premise
52	6	N	I-Premise
53	or	N	I-Premise
54	12	N	I-Premise
55	months	N	I-Premise
56	.	N	I-Premise

1	The	N	I-Claim
2	study	N	I-Claim
3	fails	N	I-Claim
4	to	N	I-Claim
5	demonstrate	N	I-Claim
6	efficacy	N	I-Claim
7	of	N	I-Claim
8	dl-alpha	N	I-Claim
9	tocopheryl	N	I-Claim
10	acetate	N	I-Claim
11	plus	N	I-Claim
12	pentoxifylline	N	I-Claim
13	in	N	I-Claim
14	patients	N	I-Claim
15	with	N	I-Claim
16	arm	N	I-Claim
17	lymphoedema	N	I-Claim
18	following	N	I-Claim
19	axillary	N	I-Claim
20	surgery	N	I-Claim
21	and	N	I-Claim
22	lymphatic	N	I-Claim
23	radiotherapy	N	I-Claim
24	,	N	I-Claim
25	nor	N	I-Claim
26	does	N	I-Claim
27	it	N	I-Claim
28	suggest	N	I-Claim
29	any	N	I-Claim
30	benefits	N	I-Claim
31	of	N	I-Claim
32	these	N	I-Claim
33	drugs	N	I-Claim
34	in	N	I-Claim
35	radiation-induced	N	I-Claim
36	induration	N	I-Claim
37	(	N	I-Claim
38	fibrosis	N	I-Claim
39	)	N	I-Claim
40	in	N	I-Claim
41	the	N	I-Claim
42	breast	N	I-Claim
43	,	N	I-Claim
44	chest	N	I-Claim
45	wall	N	I-Claim
46	,	N	I-Claim
47	pectoral	N	I-Claim
48	fold	N	I-Claim
49	,	N	I-Claim
50	axilla	N	I-Claim
51	or	N	I-Claim
52	supraclavicular	N	I-Claim
53	fossa	N	I-Claim
54	.	N	I-Claim

1	Chemotherapy	N	O
2	with	N	O
3	a	N	O
4	platinum	N	O
5	agent	N	O
6	and	N	O
7	a	N	O
8	taxane	N	O
9	(	N	O
10	paclitaxel	N	O
11	)	N	O
12	is	N	O
13	considered	N	O
14	the	N	O
15	standard	N	O
16	of	N	O
17	care	N	O
18	for	N	O
19	treatment	N	O
20	of	N	O
21	ovarian	N	O
22	carcinoma	N	O
23	.	N	O

1	We	N	O
2	compared	N	O
3	the	N	O
4	combination	N	O
5	of	N	O
6	docetaxel-carboplatin	N	O
7	with	N	O
8	the	N	O
9	combination	N	O
10	of	N	O
11	paclitaxel-carboplatin	N	O
12	as	N	O
13	first-line	N	O
14	chemotherapy	N	O
15	for	N	O
16	stage	N	O
17	Ic-IV	N	O
18	epithelial	N	O
19	ovarian	N	O
20	or	N	O
21	primary	N	O
22	peritoneal	N	O
23	cancer	N	O
24	.	N	O

1	We	N	O
2	randomly	N	O
3	assigned	N	O
4	1077	N	O
5	patients	N	O
6	to	N	O
7	receive	N	O
8	docetaxel	N	O
9	at	N	O
10	75	N	O
11	mg/m2	N	O
12	of	N	O
13	body	N	O
14	surface	N	O
15	area	N	O
16	(	N	O
17	1-hour	N	O
18	intravenous	N	O
19	infusion	N	O
20	)	N	O
21	or	N	O
22	paclitaxel	N	O
23	at	N	O
24	175	N	O
25	mg/m2	N	O
26	(	N	O
27	3-hour	N	O
28	intravenous	N	O
29	infusion	N	O
30	)	N	O
31	.	N	O

1	Both	N	O
2	treatments	N	O
3	then	N	O
4	were	N	O
5	followed	N	O
6	by	N	O
7	carboplatin	N	O
8	to	N	O
9	an	N	O
10	area	N	O
11	under	N	O
12	the	N	O
13	plasma	N	O
14	concentration-time	N	O
15	curve	N	O
16	of	N	O
17	5	N	O
18	.	N	O

1	The	N	O
2	treatments	N	O
3	were	N	O
4	repeated	N	O
5	every	N	O
6	3	N	O
7	weeks	N	O
8	for	N	O
9	six	N	O
10	cycles	N	O
11	;	N	O
12	in	N	O
13	responding	N	O
14	patients	N	O
15	,	N	O
16	an	N	O
17	additional	N	O
18	three	N	O
19	cycles	N	O
20	of	N	O
21	single-agent	N	O
22	carboplatin	N	O
23	was	N	O
24	permitted	N	O
25	.	N	O

1	Survival	N	O
2	curves	N	O
3	were	N	O
4	calculated	N	O
5	by	N	O
6	the	N	O
7	Kaplan-Meier	N	O
8	method	N	O
9	,	N	O
10	and	N	O
11	hazard	N	O
12	ratios	N	O
13	were	N	O
14	estimated	N	O
15	with	N	O
16	the	N	O
17	Cox	N	O
18	proportional	N	O
19	hazards	N	O
20	model	N	O
21	.	N	O

1	All	N	O
2	statistical	N	O
3	tests	N	O
4	were	N	O
5	two-sided	N	O
6	.	N	O

1	After	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	23	N	I-Premise
7	months	N	I-Premise
8	,	N	I-Premise
9	both	N	I-Premise
10	groups	N	I-Premise
11	had	N	I-Premise
12	similar	N	I-Premise
13	progression-free	N	I-Premise
14	survival	N	I-Premise
15	(	N	I-Premise
16	medians	N	I-Premise
17	of	N	I-Premise
18	15.0	N	I-Premise
19	months	N	I-Premise
20	for	N	I-Premise
21	docetaxel-carboplatin	N	I-Premise
22	and	N	I-Premise
23	14.8	N	I-Premise
24	months	N	I-Premise
25	for	N	I-Premise
26	paclitaxel-carboplatin	N	I-Premise
27	;	N	I-Premise
28	hazard	N	I-Premise
29	ratio	N	I-Premise
30	[	N	I-Premise
31	HR	N	I-Premise
32	]	N	I-Premise
33	docetaxel-paclitaxel	N	I-Premise
34	=	N	I-Premise
35	0.97	N	I-Premise
36	,	N	I-Premise
37	95	N	I-Premise
38	%	N	I-Premise
39	confidence	N	I-Premise
40	interval	N	I-Premise
41	[	N	I-Premise
42	CI	N	I-Premise
43	]	N	I-Premise
44	=	N	I-Premise
45	0.83	N	I-Premise
46	to	N	I-Premise
47	1.13	N	I-Premise
48	;	N	I-Premise
49	P	N	I-Premise
50	=	N	I-Premise
51	.707	N	I-Premise
52	)	N	I-Premise
53	,	N	I-Premise
54	overall	N	I-Premise
55	survival	N	I-Premise
56	rates	N	I-Premise
57	at	N	I-Premise
58	2	N	I-Premise
59	years	N	I-Premise
60	(	N	I-Premise
61	64.2	N	I-Premise
62	%	N	I-Premise
63	and	N	I-Premise
64	68.9	N	I-Premise
65	%	N	I-Premise
66	,	N	I-Premise
67	respectively	N	I-Premise
68	;	N	I-Premise
69	HR	N	I-Premise
70	=	N	I-Premise
71	1.13	N	I-Premise
72	,	N	I-Premise
73	95	N	I-Premise
74	%	N	I-Premise
75	CI	N	I-Premise
76	=	N	I-Premise
77	0.92	N	I-Premise
78	to	N	I-Premise
79	1.39	N	I-Premise
80	;	N	I-Premise
81	P	N	I-Premise
82	=	N	I-Premise
83	.238	N	I-Premise
84	)	N	I-Premise
85	,	N	I-Premise
86	and	N	I-Premise
87	objective	N	I-Premise
88	tumor	N	I-Premise
89	(	N	I-Premise
90	58.7	N	I-Premise
91	%	N	I-Premise
92	and	N	I-Premise
93	59.5	N	I-Premise
94	%	N	I-Premise
95	,	N	I-Premise
96	respectively	N	I-Premise
97	;	N	I-Premise
98	difference	N	I-Premise
99	between	N	I-Premise
100	docetaxel	N	I-Premise
101	and	N	I-Premise
102	paclitaxel	N	I-Premise
103	=	N	I-Premise
104	-0.8	N	I-Premise
105	%	N	I-Premise
106	,	N	I-Premise
107	95	N	I-Premise
108	%	N	I-Premise
109	CI	N	I-Premise
110	=	N	I-Premise
111	-8.6	N	I-Premise
112	%	N	I-Premise
113	to	N	I-Premise
114	7.1	N	I-Premise
115	%	N	I-Premise
116	;	N	I-Premise
117	P	N	I-Premise
118	=	N	I-Premise
119	.868	N	I-Premise
120	)	N	I-Premise
121	and	N	I-Premise
122	CA-125	N	I-Premise
123	(	N	I-Premise
124	75.8	N	I-Premise
125	%	N	I-Premise
126	and	N	I-Premise
127	76.8	N	I-Premise
128	%	N	I-Premise
129	,	N	I-Premise
130	respectively	N	I-Premise
131	;	N	I-Premise
132	difference	N	I-Premise
133	docetaxel-paclitaxel	N	I-Premise
134	=	N	I-Premise
135	-1.0	N	I-Premise
136	%	N	I-Premise
137	,	N	I-Premise
138	95	N	I-Premise
139	%	N	I-Premise
140	CI	N	I-Premise
141	=	N	I-Premise
142	-7.2	N	I-Premise
143	%	N	I-Premise
144	to	N	I-Premise
145	5.1	N	I-Premise
146	%	N	I-Premise
147	;	N	I-Premise
148	P	N	I-Premise
149	=	N	I-Premise
150	.794	N	I-Premise
151	)	N	I-Premise
152	response	N	I-Premise
153	rates	N	I-Premise
154	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	docetaxel-carboplatin	N	I-Premise
4	was	N	I-Premise
5	associated	N	I-Premise
6	with	N	I-Premise
7	substantially	N	I-Premise
8	less	N	I-Premise
9	overall	N	I-Premise
10	and	N	I-Premise
11	grade	N	I-Premise
12	2	N	I-Premise
13	or	N	I-Premise
14	higher	N	I-Premise
15	neurotoxicity	N	I-Premise
16	than	N	I-Premise
17	paclitaxel-carboplatin	N	I-Premise
18	(	N	I-Premise
19	grade	N	I-Premise
20	>	N	I-Premise
21	or	N	I-Premise
22	=2	N	I-Premise
23	neurosensory	N	I-Premise
24	toxicity	N	I-Premise
25	in	N	I-Premise
26	11	N	I-Premise
27	%	N	I-Premise
28	versus	N	I-Premise
29	30	N	I-Premise
30	%	N	I-Premise
31	,	N	I-Premise
32	difference	N	I-Premise
33	=	N	I-Premise
34	19	N	I-Premise
35	%	N	I-Premise
36	,	N	I-Premise
37	95	N	I-Premise
38	%	N	I-Premise
39	CI	N	I-Premise
40	=	N	I-Premise
41	15	N	I-Premise
42	%	N	I-Premise
43	to	N	I-Premise
44	24	N	I-Premise
45	%	N	I-Premise
46	;	N	I-Premise
47	P	N	I-Premise
48	<	N	I-Premise
49	.001	N	I-Premise
50	;	N	I-Premise
51	grade	N	I-Premise
52	>	N	I-Premise
53	or	N	I-Premise
54	=2	N	I-Premise
55	neuromotor	N	I-Premise
56	toxicity	N	I-Premise
57	in	N	I-Premise
58	3	N	I-Premise
59	%	N	I-Premise
60	versus	N	I-Premise
61	7	N	I-Premise
62	%	N	I-Premise
63	,	N	I-Premise
64	difference	N	I-Premise
65	=	N	I-Premise
66	4	N	I-Premise
67	%	N	I-Premise
68	,	N	I-Premise
69	95	N	I-Premise
70	%	N	I-Premise
71	CI	N	I-Premise
72	=	N	I-Premise
73	1	N	I-Premise
74	%	N	I-Premise
75	to	N	I-Premise
76	7	N	I-Premise
77	%	N	I-Premise
78	;	N	I-Premise
79	P	N	I-Premise
80	<	N	I-Premise
81	.001	N	I-Premise
82	)	N	I-Premise
83	.	N	I-Premise

1	Treatment	N	I-Premise
2	with	N	I-Premise
3	docetaxel-carboplatin	N	I-Premise
4	was	N	I-Premise
5	associated	N	I-Premise
6	with	N	I-Premise
7	statistically	N	I-Premise
8	significantly	N	I-Premise
9	more	N	I-Premise
10	grade	N	I-Premise
11	3-4	N	I-Premise
12	neutropenia	N	I-Premise
13	(	N	I-Premise
14	94	N	I-Premise
15	%	N	I-Premise
16	versus	N	I-Premise
17	84	N	I-Premise
18	%	N	I-Premise
19	,	N	I-Premise
20	difference	N	I-Premise
21	=	N	I-Premise
22	11	N	I-Premise
23	%	N	I-Premise
24	,	N	I-Premise
25	95	N	I-Premise
26	%	N	I-Premise
27	CI	N	I-Premise
28	=	N	I-Premise
29	7	N	I-Premise
30	%	N	I-Premise
31	to	N	I-Premise
32	14	N	I-Premise
33	%	N	I-Premise
34	;	N	I-Premise
35	P	N	I-Premise
36	<	N	I-Premise
37	.001	N	I-Premise
38	)	N	I-Premise
39	and	N	I-Premise
40	neutropenic	N	I-Premise
41	complications	N	I-Premise
42	than	N	I-Premise
43	treatment	N	I-Premise
44	with	N	I-Premise
45	paclitaxel-carboplatin	N	I-Premise
46	,	N	I-Premise
47	although	N	I-Premise
48	myelosuppression	N	I-Premise
49	did	N	I-Premise
50	not	N	I-Premise
51	influence	N	I-Premise
52	dose	N	I-Premise
53	delivery	N	I-Premise
54	or	N	I-Premise
55	patient	N	I-Premise
56	safety	N	I-Premise
57	.	N	I-Premise

1	Global	N	I-Premise
2	quality	N	I-Premise
3	of	N	I-Premise
4	life	N	I-Premise
5	was	N	I-Premise
6	similar	N	I-Premise
7	in	N	I-Premise
8	both	N	I-Premise
9	arms	N	I-Premise
10	,	N	I-Premise
11	but	N	I-Premise
12	substantive	N	I-Premise
13	differences	N	I-Premise
14	in	N	I-Premise
15	many	N	I-Premise
16	symptom	N	I-Premise
17	scores	N	I-Premise
18	favored	N	I-Premise
19	docetaxel	N	I-Premise
20	.	N	I-Premise

1	Docetaxel-carboplatin	N	I-Claim
2	appears	N	I-Claim
3	to	N	I-Claim
4	be	N	I-Claim
5	similar	N	I-Claim
6	to	N	I-Claim
7	paclitaxel-carboplatin	N	I-Claim
8	in	N	I-Claim
9	terms	N	I-Claim
10	of	N	I-Claim
11	progression-free	N	I-Claim
12	survival	N	I-Claim
13	and	N	I-Claim
14	response	N	I-Claim
15	,	N	I-Claim
16	although	N	I-Claim
17	longer	N	I-Claim
18	follow-up	N	I-Claim
19	is	N	I-Claim
20	required	N	I-Claim
21	for	N	I-Claim
22	a	N	I-Claim
23	definitive	N	I-Claim
24	statement	N	I-Claim
25	on	N	I-Claim
26	survival	N	I-Claim
27	.	N	I-Claim

1	Thus	N	I-MajorClaim
2	,	N	I-MajorClaim
3	docetaxel-carboplatin	N	I-MajorClaim
4	represents	N	I-MajorClaim
5	an	N	I-MajorClaim
6	alternative	N	I-MajorClaim
7	first-line	N	I-MajorClaim
8	chemotherapy	N	I-MajorClaim
9	regimen	N	I-MajorClaim
10	for	N	I-MajorClaim
11	patients	N	I-MajorClaim
12	with	N	I-MajorClaim
13	newly	N	I-MajorClaim
14	diagnosed	N	I-MajorClaim
15	ovarian	N	I-MajorClaim
16	cancer	N	I-MajorClaim
17	.	N	I-MajorClaim

1	This	N	O
2	phase	N	O
3	III	N	O
4	randomized	N	O
5	trial	N	O
6	compared	N	O
7	two	N	O
8	chemotherapy	N	O
9	regimens	N	O
10	,	N	O
11	gemcitabine	N	O
12	plus	N	O
13	carboplatin	N	O
14	and	N	O
15	mitomycin	N	O
16	,	N	O
17	ifosfamide	N	O
18	,	N	O
19	and	N	O
20	cisplatin	N	O
21	,	N	O
22	in	N	O
23	chemotherapy-naive	N	O
24	patients	N	O
25	with	N	O
26	advanced	N	O
27	non-small-cell	N	O
28	lung	N	O
29	cancer	N	O
30	(	N	O
31	NSCLC	N	O
32	)	N	O
33	.	N	O

1	The	N	O
2	regimens	N	O
3	were	N	O
4	compared	N	O
5	with	N	O
6	regard	N	O
7	to	N	O
8	effects	N	O
9	on	N	O
10	survival	N	O
11	,	N	O
12	response	N	O
13	rates	N	O
14	,	N	O
15	toxicity	N	O
16	,	N	O
17	and	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	.	N	O

1	Eligible	N	O
2	patients	N	O
3	had	N	O
4	previously	N	O
5	untreated	N	O
6	stage	N	O
7	IIIB	N	O
8	or	N	O
9	IV	N	O
10	NSCLC	N	O
11	suitable	N	O
12	for	N	O
13	cisplatin-based	N	O
14	chemotherapy	N	O
15	.	N	O

1	Randomly	N	O
2	assigned	N	O
3	patients	N	O
4	were	N	O
5	to	N	O
6	receive	N	O
7	four	N	O
8	cycles	N	O
9	,	N	O
10	each	N	O
11	at	N	O
12	3-week	N	O
13	intervals	N	O
14	,	N	O
15	of	N	O
16	carboplatin	N	O
17	area	N	O
18	under	N	O
19	the	N	O
20	curve	N	O
21	of	N	O
22	5	N	O
23	on	N	O
24	day	N	O
25	1	N	O
26	plus	N	O
27	gemcitabine	N	O
28	1,200	N	O
29	mg/m	N	O
30	(	N	O
31	2	N	O
32	)	N	O
33	on	N	O
34	days	N	O
35	1	N	O
36	and	N	O
37	8	N	O
38	(	N	O
39	GCa	N	O
40	)	N	O
41	or	N	O
42	mitomycin	N	O
43	6	N	O
44	mg/m	N	O
45	(	N	O
46	2	N	O
47	)	N	O
48	,	N	O
49	ifosfamide	N	O
50	3g/m	N	O
51	(	N	O
52	2	N	O
53	)	N	O
54	,	N	O
55	and	N	O
56	cisplatin	N	O
57	50	N	O
58	mg/m	N	O
59	(	N	O
60	2	N	O
61	)	N	O
62	on	N	O
63	day	N	O
64	1	N	O
65	(	N	O
66	MIC	N	O
67	)	N	O
68	.	N	O

1	Between	N	O
2	February	N	O
3	1999	N	O
4	and	N	O
5	August	N	O
6	2001	N	O
7	,	N	O
8	422	N	O
9	patients	N	O
10	(	N	O
11	GCa	N	O
12	,	N	O
13	n	N	O
14	=	N	O
15	212	N	O
16	;	N	O
17	MIC	N	O
18	,	N	O
19	n	N	O
20	=	N	O
21	210	N	O
22	)	N	O
23	were	N	O
24	randomly	N	O
25	assigned	N	O
26	in	N	O
27	the	N	O
28	United	N	O
29	Kingdom	N	O
30	.	N	O

1	The	N	O
2	majority	N	O
3	of	N	O
4	patients	N	O
5	received	N	O
6	the	N	O
7	intended	N	O
8	four	N	O
9	cycles	N	O
10	(	N	O
11	GCa	N	O
12	,	N	O
13	64	N	O
14	%	N	O
15	;	N	O
16	MIC	N	O
17	,	N	O
18	61	N	O
19	%	N	O
20	)	N	O
21	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	survival	N	I-Premise
6	advantage	N	I-Premise
7	for	N	I-Premise
8	GCa	N	I-Premise
9	compared	N	I-Premise
10	with	N	I-Premise
11	MIC	N	I-Premise
12	(	N	I-Premise
13	hazard	N	I-Premise
14	ratio	N	I-Premise
15	,	N	I-Premise
16	0.76	N	I-Premise
17	;	N	I-Premise
18	95	N	I-Premise
19	%	N	I-Premise
20	CI	N	I-Premise
21	,	N	I-Premise
22	0.61	N	I-Premise
23	to	N	I-Premise
24	0	N	I-Premise
25	.	N	I-Premise

1	93	N	I-Premise
2	;	N	I-Premise
3	P	N	I-Premise
4	=	N	I-Premise
5	.008	N	I-Premise
6	)	N	I-Premise
7	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	10	N	I-Premise
5	months	N	I-Premise
6	with	N	I-Premise
7	GCa	N	I-Premise
8	and	N	I-Premise
9	7.6	N	I-Premise
10	months	N	I-Premise
11	with	N	I-Premise
12	MIC	N	I-Premise
13	(	N	I-Premise
14	difference	N	I-Premise
15	,	N	I-Premise
16	2.4	N	I-Premise
17	months	N	I-Premise
18	;	N	I-Premise
19	95	N	I-Premise
20	%	N	I-Premise
21	CI	N	I-Premise
22	,	N	I-Premise
23	1.0	N	I-Premise
24	to	N	I-Premise
25	4.0	N	I-Premise
26	)	N	I-Premise
27	,	N	I-Premise
28	and	N	I-Premise
29	1-year	N	I-Premise
30	survival	N	I-Premise
31	was	N	I-Premise
32	40	N	I-Premise
33	%	N	I-Premise
34	with	N	I-Premise
35	GCa	N	I-Premise
36	and	N	I-Premise
37	30	N	I-Premise
38	%	N	I-Premise
39	with	N	I-Premise
40	MIC	N	I-Premise
41	(	N	I-Premise
42	difference	N	I-Premise
43	,	N	I-Premise
44	10	N	I-Premise
45	%	N	I-Premise
46	;	N	I-Premise
47	95	N	I-Premise
48	%	N	I-Premise
49	CI	N	I-Premise
50	,	N	I-Premise
51	3	N	I-Premise
52	%	N	I-Premise
53	to	N	I-Premise
54	18	N	I-Premise
55	%	N	I-Premise
56	)	N	I-Premise
57	.	N	I-Premise

1	Overall	N	I-Premise
2	response	N	I-Premise
3	rates	N	I-Premise
4	were	N	I-Premise
5	similar	N	I-Premise
6	(	N	I-Premise
7	42	N	I-Premise
8	%	N	I-Premise
9	for	N	I-Premise
10	GCa	N	I-Premise
11	v	N	I-Premise
12	41	N	I-Premise
13	%	N	I-Premise
14	for	N	I-Premise
15	MIC	N	I-Premise
16	;	N	I-Premise
17	P	N	I-Premise
18	=	N	I-Premise
19	.84	N	I-Premise
20	)	N	I-Premise
21	.	N	I-Premise

1	More	N	I-Premise
2	thrombocytopenia	N	I-Premise
3	occurred	N	I-Premise
4	with	N	I-Premise
5	GCa	N	I-Premise
6	(	N	I-Premise
7	P	N	I-Premise
8	=	N	I-Premise
9	.03	N	I-Premise
10	)	N	I-Premise
11	,	N	I-Premise
12	but	N	I-Premise
13	this	N	I-Premise
14	was	N	I-Premise
15	not	N	I-Premise
16	associated	N	I-Premise
17	with	N	I-Premise
18	increased	N	I-Premise
19	hospital	N	I-Premise
20	admission	N	I-Premise
21	or	N	I-Premise
22	fatality	N	I-Premise
23	.	N	I-Premise

1	GCa	N	I-Premise
2	caused	N	I-Premise
3	less	N	I-Premise
4	nausea	N	I-Premise
5	,	N	I-Premise
6	vomiting	N	I-Premise
7	,	N	I-Premise
8	constipation	N	I-Premise
9	,	N	I-Premise
10	and	N	I-Premise
11	alopecia	N	I-Premise
12	and	N	I-Premise
13	was	N	I-Premise
14	associated	N	I-Premise
15	with	N	I-Premise
16	fewer	N	I-Premise
17	admissions	N	I-Premise
18	for	N	I-Premise
19	administration	N	I-Premise
20	and	N	I-Premise
21	better	N	I-Premise
22	quality	N	I-Premise
23	of	N	I-Premise
24	life	N	I-Premise
25	.	N	I-Premise

1	In	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	advanced	N	I-Claim
5	NSCLC	N	I-Claim
6	,	N	I-Claim
7	GCa	N	I-Claim
8	chemotherapy	N	I-Claim
9	was	N	I-Claim
10	shown	N	I-Claim
11	to	N	I-Claim
12	be	N	I-Claim
13	a	N	I-Claim
14	better-tolerated	N	I-Claim
15	treatment	N	I-Claim
16	that	N	I-Claim
17	conferred	N	I-Claim
18	a	N	I-Claim
19	survival	N	I-Claim
20	advantage	N	I-Claim
21	over	N	I-Claim
22	MIC	N	I-Claim
23	.	N	I-Claim

1	The	N	I-MajorClaim
2	role	N	I-MajorClaim
3	of	N	I-MajorClaim
4	high-dose	N	I-MajorClaim
5	chemotherapy	N	I-MajorClaim
6	(	N	I-MajorClaim
7	HDCT	N	I-MajorClaim
8	)	N	I-MajorClaim
9	in	N	I-MajorClaim
10	metastatic	N	I-MajorClaim
11	breast	N	I-MajorClaim
12	cancer	N	I-MajorClaim
13	remains	N	I-MajorClaim
14	controversial	N	I-MajorClaim
15	.	N	I-MajorClaim

1	Trials	N	I-Claim
2	with	N	I-Claim
3	late	N	I-Claim
4	intensification	N	I-Claim
5	HDCT	N	I-Claim
6	have	N	I-Claim
7	failed	N	I-Claim
8	to	N	I-Claim
9	show	N	I-Claim
10	an	N	I-Claim
11	advantage	N	I-Claim
12	in	N	I-Claim
13	overall	N	I-Claim
14	survival	N	I-Claim
15	.	N	I-Claim

1	This	N	O
2	study	N	O
3	was	N	O
4	initiated	N	O
5	to	N	O
6	compare	N	O
7	up-front	N	O
8	tandem	N	O
9	HDCT	N	O
10	and	N	O
11	standard	N	O
12	combination	N	O
13	therapy	N	O
14	in	N	O
15	patients	N	O
16	with	N	O
17	metastatic	N	O
18	breast	N	O
19	cancer	N	O
20	.	N	O

1	Patients	N	O
2	without	N	O
3	prior	N	O
4	chemotherapy	N	O
5	for	N	O
6	metastatic	N	O
7	disease	N	O
8	were	N	O
9	randomly	N	O
10	assigned	N	O
11	to	N	O
12	standard	N	O
13	combination	N	O
14	therapy	N	O
15	with	N	O
16	doxorubicin	N	O
17	and	N	O
18	paclitaxel	N	O
19	(	N	O
20	AT	N	O
21	)	N	O
22	or	N	O
23	double	N	O
24	HDCT	N	O
25	with	N	O
26	cyclophosphamide	N	O
27	,	N	O
28	mitoxantrone	N	O
29	,	N	O
30	and	N	O
31	etoposide	N	O
32	followed	N	O
33	by	N	O
34	peripheral-blood	N	O
35	stem-cell	N	O
36	transplantation	N	O
37	.	N	O

1	HDCT	N	O
2	was	N	O
3	repeated	N	O
4	after	N	O
5	6	N	O
6	weeks	N	O
7	.	N	O

1	Patients	N	O
2	were	N	O
3	stratified	N	O
4	by	N	O
5	menopausal	N	O
6	and	N	O
7	hormone-receptor	N	O
8	status	N	O
9	.	N	O

1	The	N	O
2	primary	N	O
3	objective	N	O
4	was	N	O
5	to	N	O
6	compare	N	O
7	complete	N	O
8	response	N	O
9	(	N	O
10	CR	N	O
11	)	N	O
12	rates	N	O
13	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	93	N	O
5	patients	N	O
6	were	N	O
7	enrolled	N	O
8	onto	N	O
9	the	N	O
10	trial	N	O
11	.	N	O

1	Intent-to-treat	N	I-Premise
2	CR	N	I-Premise
3	rates	N	I-Premise
4	for	N	I-Premise
5	patients	N	I-Premise
6	randomized	N	I-Premise
7	to	N	I-Premise
8	HDCT	N	I-Premise
9	and	N	I-Premise
10	AT	N	I-Premise
11	were	N	I-Premise
12	12.5	N	I-Premise
13	%	N	I-Premise
14	and	N	I-Premise
15	11.1	N	I-Premise
16	%	N	I-Premise
17	,	N	I-Premise
18	respectively	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	.84	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Objective	N	I-Premise
2	response	N	I-Premise
3	rates	N	I-Premise
4	were	N	I-Premise
5	66.7	N	I-Premise
6	%	N	I-Premise
7	for	N	I-Premise
8	patients	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	high-dose	N	I-Premise
12	group	N	I-Premise
13	and	N	I-Premise
14	64.4	N	I-Premise
15	%	N	I-Premise
16	for	N	I-Premise
17	patients	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	AT	N	I-Premise
21	arm	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	=	N	I-Premise
25	.82	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	In	N	I-Premise
2	an	N	I-Premise
3	intent-to-treat	N	I-Premise
4	analysis	N	I-Premise
5	,	N	I-Premise
6	there	N	I-Premise
7	were	N	I-Premise
8	no	N	I-Premise
9	significant	N	I-Premise
10	differences	N	I-Premise
11	between	N	I-Premise
12	the	N	I-Premise
13	two	N	I-Premise
14	treatments	N	I-Premise
15	in	N	I-Premise
16	median	N	I-Premise
17	time	N	I-Premise
18	to	N	I-Premise
19	progression	N	I-Premise
20	(	N	I-Premise
21	HDCT	N	I-Premise
22	,	N	I-Premise
23	11.1	N	I-Premise
24	months	N	I-Premise
25	;	N	I-Premise
26	AT	N	I-Premise
27	,	N	I-Premise
28	10.6	N	I-Premise
29	months	N	I-Premise
30	;	N	I-Premise
31	P	N	I-Premise
32	=	N	I-Premise
33	.67	N	I-Premise
34	)	N	I-Premise
35	,	N	I-Premise
36	duration	N	I-Premise
37	of	N	I-Premise
38	response	N	I-Premise
39	(	N	I-Premise
40	HDCT	N	I-Premise
41	,	N	I-Premise
42	13.9	N	I-Premise
43	months	N	I-Premise
44	;	N	I-Premise
45	AT	N	I-Premise
46	,	N	I-Premise
47	14.3	N	I-Premise
48	months	N	I-Premise
49	;	N	I-Premise
50	P	N	I-Premise
51	=	N	I-Premise
52	.98	N	I-Premise
53	)	N	I-Premise
54	,	N	I-Premise
55	and	N	I-Premise
56	overall	N	I-Premise
57	survival	N	I-Premise
58	(	N	I-Premise
59	HDCT	N	I-Premise
60	,	N	I-Premise
61	26.9	N	I-Premise
62	months	N	I-Premise
63	;	N	I-Premise
64	AT	N	I-Premise
65	,	N	I-Premise
66	23.4	N	I-Premise
67	months	N	I-Premise
68	;	N	I-Premise
69	P	N	I-Premise
70	=	N	I-Premise
71	.60	N	I-Premise
72	)	N	I-Premise
73	.	N	I-Premise

1	HDCT	N	I-Premise
2	was	N	I-Premise
3	associated	N	I-Premise
4	with	N	I-Premise
5	significantly	N	I-Premise
6	more	N	I-Premise
7	myelosuppression	N	I-Premise
8	,	N	I-Premise
9	infection	N	I-Premise
10	,	N	I-Premise
11	diarrhea	N	I-Premise
12	,	N	I-Premise
13	stomatitis	N	I-Premise
14	,	N	I-Premise
15	and	N	I-Premise
16	nausea	N	I-Premise
17	and	N	I-Premise
18	vomiting	N	I-Premise
19	,	N	I-Premise
20	whereas	N	I-Premise
21	patients	N	I-Premise
22	treated	N	I-Premise
23	with	N	I-Premise
24	AT	N	I-Premise
25	developed	N	I-Premise
26	more	N	I-Premise
27	neurotoxicity	N	I-Premise
28	.	N	I-Premise

1	This	N	I-Claim
2	trial	N	I-Claim
3	failed	N	I-Claim
4	to	N	I-Claim
5	show	N	I-Claim
6	a	N	I-Claim
7	benefit	N	I-Claim
8	for	N	I-Claim
9	up-front	N	I-Claim
10	tandem	N	I-Claim
11	HDCT	N	I-Claim
12	compared	N	I-Claim
13	with	N	I-Claim
14	standard	N	I-Claim
15	combination	N	I-Claim
16	therapy	N	I-Claim
17	.	N	I-Claim

1	HDCT	N	I-Claim
2	was	N	I-Claim
3	associated	N	I-Claim
4	with	N	I-Claim
5	more	N	I-Claim
6	acute	N	I-Claim
7	adverse	N	I-Claim
8	effects	N	I-Claim
9	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	efficacy	N	O
5	,	N	O
6	impact	N	O
7	on	N	O
8	quality-of-life	N	O
9	(	N	O
10	QoL	N	O
11	)	N	O
12	and	N	O
13	tolerability	N	O
14	of	N	O
15	two	N	O
16	different	N	O
17	irinotecan	N	O
18	administration	N	O
19	schedules	N	O
20	in	N	O
21	combination	N	O
22	with	N	O
23	capecitabine	N	O
24	as	N	O
25	first-line	N	O
26	treatment	N	O
27	of	N	O
28	metastatic	N	O
29	colorectal	N	O
30	cancer	N	O
31	.	N	O

1	We	N	O
2	carried	N	O
3	out	N	O
4	a	N	O
5	randomized	N	O
6	phase	N	O
7	II	N	O
8	trial	N	O
9	to	N	O
10	select	N	O
11	one	N	O
12	of	N	O
13	the	N	O
14	following	N	O
15	treatment	N	O
16	regimens	N	O
17	for	N	O
18	further	N	O
19	investigation	N	O
20	:	N	O
21	weekly	N	O
22	irinotecan	N	O
23	at	N	O
24	a	N	O
25	dose	N	O
26	of	N	O
27	70	N	O
28	mg/m	N	O
29	(	N	O
30	2	N	O
31	)	N	O
32	days	N	O
33	1	N	O
34	,	N	O
35	8	N	O
36	,	N	O
37	15	N	O
38	,	N	O
39	22	N	O
40	,	N	O
41	29	N	O
42	(	N	O
43	arm	N	O
44	A	N	O
45	)	N	O
46	or	N	O
47	3-weekly	N	O
48	irinotecan	N	O
49	at	N	O
50	a	N	O
51	dose	N	O
52	of	N	O
53	300/240	N	O
54	mg/m	N	O
55	(	N	O
56	2	N	O
57	)	N	O
58	day	N	O
59	1	N	O
60	and	N	O
61	days	N	O
62	22	N	O
63	(	N	O
64	arm	N	O
65	B	N	O
66	)	N	O
67	in	N	O
68	combination	N	O
69	with	N	O
70	capecitabine	N	O
71	1000	N	O
72	mg/m	N	O
73	(	N	O
74	2	N	O
75	)	N	O
76	twice	N	O
77	daily	N	O
78	days	N	O
79	1-14	N	O
80	and	N	O
81	days	N	O
82	22-35	N	O
83	every	N	O
84	6	N	O
85	weeks	N	O
86	.	N	O

1	Seventy-five	N	O
2	patients	N	O
3	with	N	O
4	good	N	O
5	performance	N	O
6	status	N	O
7	entered	N	O
8	the	N	O
9	trial	N	O
10	.	N	O

1	The	N	O
2	two	N	O
3	arms	N	O
4	were	N	O
5	well	N	O
6	balanced	N	O
7	for	N	O
8	relevant	N	O
9	patient	N	O
10	and	N	O
11	disease	N	O
12	characteristics	N	O
13	.	N	O

1	The	N	I-Premise
2	most	N	I-Premise
3	frequent	N	I-Premise
4	toxic	N	I-Premise
5	effects	N	I-Premise
6	were	N	I-Premise
7	grade	N	I-Premise
8	3/4	N	I-Premise
9	diarrhea	N	I-Premise
10	(	N	I-Premise
11	arm	N	I-Premise
12	A	N	I-Premise
13	:	N	I-Premise
14	34	N	I-Premise
15	%	N	I-Premise
16	,	N	I-Premise
17	B	N	I-Premise
18	:	N	I-Premise
19	19	N	I-Premise
20	%	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	grade	N	I-Premise
24	3/4	N	I-Premise
25	neutropenia	N	I-Premise
26	(	N	I-Premise
27	A	N	I-Premise
28	:	N	I-Premise
29	5	N	I-Premise
30	%	N	I-Premise
31	,	N	I-Premise
32	B	N	I-Premise
33	:	N	I-Premise
34	19	N	I-Premise
35	%	N	I-Premise
36	)	N	I-Premise
37	and	N	I-Premise
38	grade	N	I-Premise
39	2/3	N	I-Premise
40	alopecia	N	I-Premise
41	(	N	I-Premise
42	A	N	I-Premise
43	:	N	I-Premise
44	26	N	I-Premise
45	%	N	I-Premise
46	,	N	I-Premise
47	B	N	I-Premise
48	:	N	I-Premise
49	65	N	I-Premise
50	%	N	I-Premise
51	)	N	I-Premise
52	.	N	I-Premise

1	Other	N	I-Premise
2	grade	N	I-Premise
3	3/4	N	I-Premise
4	toxic	N	I-Premise
5	effects	N	I-Premise
6	were	N	I-Premise
7	rare	N	I-Premise
8	(	N	I-Premise
9	<	N	I-Premise
10	5	N	I-Premise
11	%	N	I-Premise
12	)	N	I-Premise
13	.	N	I-Premise

1	Response	N	I-Premise
2	rates	N	I-Premise
3	were	N	I-Premise
4	34	N	I-Premise
5	%	N	I-Premise
6	[	N	I-Premise
7	95	N	I-Premise
8	%	N	I-Premise
9	confidence	N	I-Premise
10	interval	N	I-Premise
11	(	N	I-Premise
12	CI	N	I-Premise
13	)	N	I-Premise
14	20	N	I-Premise
15	%	N	I-Premise
16	to	N	I-Premise
17	51	N	I-Premise
18	%	N	I-Premise
19	]	N	I-Premise
20	in	N	I-Premise
21	arm	N	I-Premise
22	A	N	I-Premise
23	and	N	I-Premise
24	35	N	I-Premise
25	%	N	I-Premise
26	(	N	I-Premise
27	95	N	I-Premise
28	%	N	I-Premise
29	CI	N	I-Premise
30	:	N	I-Premise
31	20	N	I-Premise
32	%	N	I-Premise
33	to	N	I-Premise
34	53	N	I-Premise
35	%	N	I-Premise
36	)	N	I-Premise
37	in	N	I-Premise
38	arm	N	I-Premise
39	B	N	I-Premise
40	.	N	I-Premise

1	Median	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	progression	N	I-Premise
5	was	N	I-Premise
6	6.9	N	I-Premise
7	(	N	I-Premise
8	4.6-10.1	N	I-Premise
9	)	N	I-Premise
10	and	N	I-Premise
11	9.2	N	I-Premise
12	(	N	I-Premise
13	7.9-11.5	N	I-Premise
14	)	N	I-Premise
15	months	N	I-Premise
16	and	N	I-Premise
17	median	N	I-Premise
18	overall	N	I-Premise
19	survival	N	I-Premise
20	was	N	I-Premise
21	17.4	N	I-Premise
22	(	N	I-Premise
23	12.6-23.0+	N	I-Premise
24	)	N	I-Premise
25	and	N	I-Premise
26	24.7	N	I-Premise
27	(	N	I-Premise
28	16.3-26.4+	N	I-Premise
29	)	N	I-Premise
30	months	N	I-Premise
31	.	N	I-Premise

1	Patients	N	I-Premise
2	with	N	I-Premise
3	an	N	I-Premise
4	objective	N	I-Premise
5	tumor	N	I-Premise
6	response	N	I-Premise
7	reported	N	I-Premise
8	better	N	I-Premise
9	physical	N	I-Premise
10	well-being	N	I-Premise
11	(	N	I-Premise
12	P	N	I-Premise
13	<	N	I-Premise
14	0.01	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	mood	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	0.05	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	functional	N	I-Premise
25	performance	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	<	N	I-Premise
29	0.05	N	I-Premise
30	)	N	I-Premise
31	and	N	I-Premise
32	less	N	I-Premise
33	effort	N	I-Premise
34	to	N	I-Premise
35	cope	N	I-Premise
36	(	N	I-Premise
37	P	N	I-Premise
38	<	N	I-Premise
39	0.05	N	I-Premise
40	)	N	I-Premise
41	compared	N	I-Premise
42	with	N	I-Premise
43	the	N	I-Premise
44	non-responders	N	I-Premise
45	and	N	I-Premise
46	stable	N	I-Premise
47	disease	N	I-Premise
48	patients	N	I-Premise
49	.	N	I-Premise

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	of	N	O
6	this	N	O
7	study	N	O
8	was	N	O
9	the	N	O
10	objective	N	O
11	response	N	O
12	rate	N	O
13	and	N	O
14	based	N	O
15	on	N	O
16	the	N	O
17	statistical	N	O
18	design	N	O
19	of	N	O
20	the	N	O
21	trial	N	O
22	,	N	O
23	the	N	O
24	3-weekly	N	O
25	irinotecan	N	O
26	schedule	N	O
27	was	N	O
28	selected	N	O
29	over	N	O
30	weekly	N	O
31	irinotecan	N	O
32	administration	N	O
33	.	N	O

1	The	N	I-Claim
2	3-weekly	N	I-Claim
3	irinotecan	N	I-Claim
4	schedule	N	I-Claim
5	also	N	I-Claim
6	seemed	N	I-Claim
7	advantageous	N	I-Claim
8	in	N	I-Claim
9	terms	N	I-Claim
10	of	N	I-Claim
11	grade	N	I-Claim
12	3/4	N	I-Claim
13	diarrhea	N	I-Claim
14	,	N	I-Claim
15	time	N	I-Claim
16	to	N	I-Claim
17	progression	N	I-Claim
18	,	N	I-Claim
19	overall	N	I-Claim
20	survival	N	I-Claim
21	and	N	I-Claim
22	patient	N	I-Claim
23	convenience	N	I-Claim
24	,	N	I-Claim
25	but	N	I-Claim
26	the	N	I-Claim
27	study	N	I-Claim
28	was	N	I-Claim
29	not	N	I-Claim
30	designed	N	I-Claim
31	to	N	I-Claim
32	detect	N	I-Claim
33	differences	N	I-Claim
34	in	N	I-Claim
35	these	N	I-Claim
36	parameters	N	I-Claim
37	.	N	I-Claim

1	In	N	O
2	addition	N	O
3	,	N	O
4	tumor	N	I-Claim
5	response	N	I-Claim
6	was	N	I-Claim
7	shown	N	I-Claim
8	to	N	I-Claim
9	have	N	I-Claim
10	a	N	I-Claim
11	beneficial	N	I-Claim
12	effect	N	I-Claim
13	on	N	I-Claim
14	QoL	N	I-Claim
15	indicators	N	I-Claim
16	.	N	I-Claim

1	To	N	O
2	investigate	N	O
3	the	N	O
4	impact	N	O
5	of	N	O
6	dietary	N	O
7	counseling	N	O
8	or	N	O
9	nutritional	N	O
10	supplements	N	O
11	on	N	O
12	outcomes	N	O
13	in	N	O
14	cancer	N	O
15	patients	N	O
16	:	N	O
17	nutritional	N	O
18	,	N	O
19	morbidity	N	O
20	,	N	O
21	and	N	O
22	quality	N	O
23	of	N	O
24	life	N	O
25	(	N	O
26	QoL	N	O
27	)	N	O
28	during	N	O
29	and	N	O
30	3	N	O
31	months	N	O
32	after	N	O
33	radiotherapy	N	O
34	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	111	N	O
5	colorectal	N	O
6	cancer	N	O
7	outpatients	N	O
8	referred	N	O
9	for	N	O
10	radiotherapy	N	O
11	,	N	O
12	stratified	N	O
13	by	N	O
14	staging	N	O
15	,	N	O
16	were	N	O
17	randomly	N	O
18	assigned	N	O
19	:	N	O
20	group	N	O
21	1	N	O
22	(	N	O
23	G1	N	O
24	;	N	O
25	n	N	O
26	=	N	O
27	37	N	O
28	)	N	O
29	,	N	O
30	dietary	N	O
31	counseling	N	O
32	(	N	O
33	regular	N	O
34	foods	N	O
35	)	N	O
36	;	N	O
37	group	N	O
38	2	N	O
39	(	N	O
40	G2	N	O
41	;	N	O
42	n	N	O
43	=	N	O
44	37	N	O
45	)	N	O
46	,	N	O
47	protein	N	O
48	supplements	N	O
49	;	N	O
50	and	N	O
51	group	N	O
52	3	N	O
53	(	N	O
54	G3	N	O
55	;	N	O
56	n	N	O
57	=	N	O
58	37	N	O
59	)	N	O
60	,	N	O
61	ad	N	O
62	libitum	N	O
63	intake	N	O
64	.	N	O

1	Nutritional	N	O
2	intake	N	O
3	(	N	O
4	diet	N	O
5	history	N	O
6	)	N	O
7	,	N	O
8	status	N	O
9	(	N	O
10	Ottery	N	O
11	's	N	O
12	Subjective	N	O
13	Global	N	O
14	Assessment	N	O
15	)	N	O
16	,	N	O
17	and	N	O
18	QoL	N	O
19	(	N	O
20	European	N	O
21	Organisation	N	O
22	for	N	O
23	Research	N	O
24	and	N	O
25	Treatment	N	O
26	of	N	O
27	Cancer	N	O
28	Quality	N	O
29	of	N	O
30	Life	N	O
31	Questionnaire	N	O
32	version	N	O
33	3.0	N	O
34	)	N	O
35	were	N	O
36	evaluated	N	O
37	at	N	O
38	baseline	N	O
39	,	N	O
40	at	N	O
41	the	N	O
42	end	N	O
43	,	N	O
44	and	N	O
45	3	N	O
46	months	N	O
47	after	N	O
48	radiotherapy	N	O
49	.	N	O

1	At	N	I-Premise
2	radiotherapy	N	I-Premise
3	completion	N	I-Premise
4	,	N	I-Premise
5	energy	N	I-Premise
6	intake	N	I-Premise
7	increased	N	I-Premise
8	in	N	I-Premise
9	G1/G2	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	<	N	I-Premise
13	or	N	I-Premise
14	=	N	I-Premise
15	.04	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	G1	N	I-Premise
19	more	N	I-Premise
20	than	N	I-Premise
21	G2	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	=	N	I-Premise
25	.001	N	I-Premise
26	)	N	I-Premise
27	,	N	I-Premise
28	and	N	I-Premise
29	decreased	N	I-Premise
30	in	N	I-Premise
31	G3	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	<	N	I-Premise
35	.01	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	Protein	N	I-Premise
2	intake	N	I-Premise
3	increased	N	I-Premise
4	in	N	I-Premise
5	G1/G2	N	I-Premise
6	(	N	I-Premise
7	P	N	I-Premise
8	<	N	I-Premise
9	or	N	I-Premise
10	=	N	I-Premise
11	.007	N	I-Premise
12	)	N	I-Premise
13	,	N	I-Premise
14	G1	N	I-Premise
15	less	N	I-Premise
16	than	N	I-Premise
17	G2	N	I-Premise
18	(	N	I-Premise
19	not	N	I-Premise
20	significant	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	decreased	N	I-Premise
25	in	N	I-Premise
26	G3	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	.01	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	At	N	I-Premise
2	3	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	G1	N	I-Premise
6	maintained	N	I-Premise
7	nutritional	N	I-Premise
8	intake	N	I-Premise
9	and	N	I-Premise
10	G2/G3	N	I-Premise
11	returned	N	I-Premise
12	to	N	I-Premise
13	baseline	N	I-Premise
14	.	N	I-Premise

1	After	N	I-Premise
2	radiotherapy	N	I-Premise
3	and	N	I-Premise
4	at	N	I-Premise
5	3	N	I-Premise
6	months	N	I-Premise
7	,	N	I-Premise
8	rates	N	I-Premise
9	of	N	I-Premise
10	anorexia	N	I-Premise
11	,	N	I-Premise
12	nausea	N	I-Premise
13	,	N	I-Premise
14	vomiting	N	I-Premise
15	,	N	I-Premise
16	and	N	I-Premise
17	diarrhea	N	I-Premise
18	were	N	I-Premise
19	higher	N	I-Premise
20	in	N	I-Premise
21	G3	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	<	N	I-Premise
25	.05	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	At	N	I-Premise
2	radiotherapy	N	I-Premise
3	completion	N	I-Premise
4	,	N	I-Premise
5	in	N	I-Premise
6	G1	N	I-Premise
7	all	N	I-Premise
8	QoL	N	I-Premise
9	function	N	I-Premise
10	scores	N	I-Premise
11	improved	N	I-Premise
12	proportionally	N	I-Premise
13	to	N	I-Premise
14	adequate	N	I-Premise
15	intake	N	I-Premise
16	or	N	I-Premise
17	nutritional	N	I-Premise
18	status	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	<	N	I-Premise
22	.05	N	I-Premise
23	)	N	I-Premise
24	;	N	I-Premise
25	whereas	N	I-Premise
26	in	N	I-Premise
27	G2	N	I-Premise
28	only	N	I-Premise
29	three	N	I-Premise
30	of	N	I-Premise
31	six	N	I-Premise
32	function	N	I-Premise
33	scores	N	I-Premise
34	improved	N	I-Premise
35	proportionally	N	I-Premise
36	to	N	I-Premise
37	protein	N	I-Premise
38	intake	N	I-Premise
39	(	N	I-Premise
40	P	N	I-Premise
41	=	N	I-Premise
42	.04	N	I-Premise
43	)	N	I-Premise
44	,	N	I-Premise
45	and	N	I-Premise
46	in	N	I-Premise
47	G3	N	I-Premise
48	all	N	I-Premise
49	scores	N	I-Premise
50	worsened	N	I-Premise
51	(	N	I-Premise
52	P	N	I-Premise
53	<	N	I-Premise
54	.05	N	I-Premise
55	)	N	I-Premise
56	.	N	I-Premise

1	At	N	I-Premise
2	3	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	G1	N	I-Premise
6	patients	N	I-Premise
7	maintained/improved	N	I-Premise
8	function	N	I-Premise
9	,	N	I-Premise
10	symptoms	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	single-item	N	I-Premise
14	scores	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	<	N	I-Premise
18	.02	N	I-Premise
19	)	N	I-Premise
20	;	N	I-Premise
21	in	N	I-Premise
22	G2	N	I-Premise
23	,	N	I-Premise
24	only	N	I-Premise
25	few	N	I-Premise
26	function	N	I-Premise
27	and	N	I-Premise
28	symptom	N	I-Premise
29	scales	N	I-Premise
30	improved	N	I-Premise
31	(	N	I-Premise
32	P	N	I-Premise
33	<	N	I-Premise
34	.05	N	I-Premise
35	)	N	I-Premise
36	;	N	I-Premise
37	in	N	I-Premise
38	G3	N	I-Premise
39	,	N	I-Premise
40	QoL	N	I-Premise
41	remained	N	I-Premise
42	as	N	I-Premise
43	poor	N	I-Premise
44	as	N	I-Premise
45	after	N	I-Premise
46	radiotherapy	N	I-Premise
47	.	N	I-Premise

1	In	N	I-Premise
2	G1/G2	N	I-Premise
3	,	N	I-Premise
4	respectively	N	I-Premise
5	,	N	I-Premise
6	improvement/deterioration	N	I-Premise
7	of	N	I-Premise
8	QoL	N	I-Premise
9	correlated	N	I-Premise
10	with	N	I-Premise
11	better	N	I-Premise
12	or	N	I-Premise
13	poorer	N	I-Premise
14	intake	N	I-Premise
15	or	N	I-Premise
16	nutritional	N	I-Premise
17	status	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	.003	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	During	N	I-Claim
2	radiotherapy	N	I-Claim
3	,	N	I-Claim
4	both	N	I-Claim
5	interventions	N	I-Claim
6	positively	N	I-Claim
7	influenced	N	I-Claim
8	outcomes	N	I-Claim
9	;	N	I-Claim
10	dietary	N	I-Claim
11	counseling	N	I-Claim
12	was	N	I-Claim
13	of	N	I-Claim
14	similar	N	I-Claim
15	or	N	I-Claim
16	higher	N	I-Claim
17	benefit	N	I-Claim
18	,	N	I-Claim
19	whereas	N	I-Claim
20	even	N	I-Claim
21	3	N	I-Claim
22	months	N	I-Claim
23	after	N	I-Claim
24	RT	N	I-Claim
25	,	N	I-Claim
26	it	N	I-Claim
27	was	N	I-Claim
28	the	N	I-Claim
29	only	N	I-Claim
30	method	N	I-Claim
31	to	N	I-Claim
32	sustain	N	I-Claim
33	a	N	I-Claim
34	significant	N	I-Claim
35	impact	N	I-Claim
36	on	N	I-Claim
37	patient	N	I-Claim
38	outcomes	N	I-Claim
39	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	incidence	N	O
5	and	N	O
6	temporal	N	O
7	resolution	N	O
8	of	N	O
9	dysuria	N	O
10	after	N	O
11	permanent	N	O
12	prostate	N	O
13	brachytherapy	N	O
14	,	N	O
15	and	N	O
16	to	N	O
17	identify	N	O
18	predictors	N	O
19	of	N	O
20	brachytherapy-related	N	O
21	dysuria	N	O
22	.	N	O

1	The	N	O
2	study	N	O
3	included	N	O
4	130	N	O
5	patients	N	O
6	with	N	O
7	no	N	O
8	history	N	O
9	of	N	O
10	transurethral	N	O
11	resection	N	O
12	of	N	O
13	the	N	O
14	prostate	N	O
15	before	N	O
16	treatment	N	O
17	,	N	O
18	who	N	O
19	had	N	O
20	brachytherapy	N	O
21	on	N	O
22	one	N	O
23	of	N	O
24	two	N	O
25	prospective	N	O
26	randomized	N	O
27	trials	N	O
28	,	N	O
29	with	N	O
30	explicitly	N	O
31	planned	N	O
32	and	N	O
33	executed	N	O
34	urethral-sparing	N	O
35	techniques	N	O
36	(	N	O
37	100-150	N	O
38	%	N	O
39	minimum	N	O
40	peripheral	N	O
41	dose	N	O
42	)	N	O
43	using	N	O
44	either	N	O
45	103Pd	N	O
46	or	N	O
47	125I	N	O
48	for	N	O
49	clinical	N	O
50	T1c-T2c	N	O
51	prostate	N	O
52	cancer	N	O
53	.	N	O

1	The	N	O
2	median	N	O
3	follow-up	N	O
4	was	N	O
5	22.6	N	O
6	months	N	O
7	.	N	O

1	An	N	O
2	alpha-blocker	N	O
3	was	N	O
4	initiated	N	O
5	either	N	O
6	prophylactically	N	O
7	2	N	O
8	weeks	N	O
9	before	N	O
10	implantation	N	O
11	and	N	O
12	continued	N	O
13	at	N	O
14	least	N	O
15	until	N	O
16	the	N	O
17	International	N	O
18	Prostate	N	O
19	Symptom	N	O
20	Score	N	O
21	(	N	O
22	IPSS	N	O
23	)	N	O
24	returned	N	O
25	to	N	O
26	normal	N	O
27	,	N	O
28	or	N	O
29	withheld	N	O
30	until	N	O
31	the	N	O
32	onset	N	O
33	of	N	O
34	significant	N	O
35	brachytherapy-related	N	O
36	urinary	N	O
37	morbidity	N	O
38	.	N	O

1	Dysuria	N	O
2	was	N	O
3	evaluated	N	O
4	on	N	O
5	a	N	O
6	0-10	N	O
7	scale	N	O
8	,	N	O
9	before	N	O
10	brachytherapy	N	O
11	and	N	O
12	then	N	O
13	at	N	O
14	1	N	O
15	,	N	O
16	3	N	O
17	,	N	O
18	6	N	O
19	and	N	O
20	12	N	O
21	months	N	O
22	afterward	N	O
23	,	N	O
24	with	N	O
25	a	N	O
26	median	N	O
27	of	N	O
28	four	N	O
29	dysuria	N	O
30	questionnaires	N	O
31	per	N	O
32	patient	N	O
33	.	N	O

1	Clinical	N	O
2	,	N	O
3	treatment	N	O
4	and	N	O
5	dosimetric	N	O
6	variables	N	O
7	evaluated	N	O
8	included	N	O
9	alpha-blocker	N	O
10	,	N	O
11	age	N	O
12	,	N	O
13	IPSS	N	O
14	before	N	O
15	and	N	O
16	the	N	O
17	maximum	N	O
18	after	N	O
19	treatment	N	O
20	,	N	O
21	prostate	N	O
22	volume	N	O
23	on	N	O
24	ultrasonography	N	O
25	,	N	O
26	hormonal	N	O
27	status	N	O
28	,	N	O
29	supplemental	N	O
30	radiotherapy	N	O
31	,	N	O
32	isotope	N	O
33	,	N	O
34	urethral	N	O
35	dose	N	O
36	,	N	O
37	V	N	O
38	(	N	O
39	100/200	N	O
40	)	N	O
41	,	N	O
42	D90	N	O
43	,	N	O
44	and	N	O
45	time	N	O
46	to	N	O
47	obtaining	N	O
48	a	N	O
49	normal	N	O
50	IPSS	N	O
51	.	N	O

1	The	N	O
2	maximum	N	O
3	incidence	N	O
4	of	N	O
5	dysuria	N	O
6	was	N	O
7	85	N	O
8	%	N	O
9	at	N	O
10	1	N	O
11	month	N	O
12	after	N	O
13	brachytherapy	N	O
14	,	N	O
15	with	N	O
16	subsequent	N	O
17	resolution	N	O
18	over	N	O
19	time	N	O
20	.	N	O

1	The	N	I-Premise
2	use	N	I-Premise
3	of	N	I-Premise
4	prophylactic	N	I-Premise
5	tamsulosin	N	I-Premise
6	resulted	N	I-Premise
7	in	N	I-Premise
8	a	N	I-Premise
9	statistically	N	I-Premise
10	lower	N	I-Premise
11	dysuria	N	I-Premise
12	severity	N	I-Premise
13	score	N	I-Premise
14	(	N	I-Premise
15	difference	N	I-Premise
16	of	N	I-Premise
17	2.7	N	I-Premise
18	vs	N	I-Premise
19	4.2	N	I-Premise
20	,	N	I-Premise
21	P	N	I-Premise
22	<	N	I-Premise
23	0.005	N	I-Premise
24	)	N	I-Premise
25	at	N	I-Premise
26	1	N	I-Premise
27	month	N	I-Premise
28	,	N	I-Premise
29	with	N	I-Premise
30	no	N	I-Premise
31	discernible	N	I-Premise
32	differences	N	I-Premise
33	at	N	I-Premise
34	3	N	I-Premise
35	,	N	I-Premise
36	6	N	I-Premise
37	,	N	I-Premise
38	12	N	I-Premise
39	and	N	I-Premise
40	18	N	I-Premise
41	months	N	I-Premise
42	.	N	I-Premise

1	Patients	N	I-Premise
2	with	N	I-Premise
3	dysuria	N	I-Premise
4	had	N	I-Premise
5	a	N	I-Premise
6	statistically	N	I-Premise
7	higher	N	I-Premise
8	IPSS	N	I-Premise
9	.	N	I-Premise

1	The	N	I-Premise
2	dysuria	N	I-Premise
3	resolved	N	I-Premise
4	faster	N	I-Premise
5	in	N	I-Premise
6	patients	N	I-Premise
7	implanted	N	I-Premise
8	with	N	I-Premise
9	103Pd	N	I-Premise
10	but	N	I-Premise
11	was	N	I-Premise
12	unaffected	N	I-Premise
13	by	N	I-Premise
14	the	N	I-Premise
15	use	N	I-Premise
16	of	N	I-Premise
17	supplemental	N	I-Premise
18	radiotherapy	N	I-Premise
19	and/or	N	I-Premise
20	androgen	N	I-Premise
21	deprivation	N	I-Premise
22	therapy	N	I-Premise
23	.	N	I-Premise

1	In	N	I-Premise
2	multivariate	N	I-Premise
3	analysis	N	I-Premise
4	,	N	I-Premise
5	prophylactic	N	I-Premise
6	alpha-blockers	N	I-Premise
7	resulted	N	I-Premise
8	in	N	I-Premise
9	statistically	N	I-Premise
10	lower	N	I-Premise
11	maximum	N	I-Premise
12	dysuria	N	I-Premise
13	scores	N	I-Premise
14	,	N	I-Premise
15	while	N	I-Premise
16	the	N	I-Premise
17	maximum	N	I-Premise
18	IPSS	N	I-Premise
19	after	N	I-Premise
20	implantation	N	I-Premise
21	and	N	I-Premise
22	isotope	N	I-Premise
23	type	N	I-Premise
24	(	N	I-Premise
25	but	N	I-Premise
26	only	N	I-Premise
27	at	N	I-Premise
28	6	N	I-Premise
29	months	N	I-Premise
30	)	N	I-Premise
31	were	N	I-Premise
32	the	N	I-Premise
33	best	N	I-Premise
34	predictors	N	I-Premise
35	of	N	I-Premise
36	the	N	I-Premise
37	resolution	N	I-Premise
38	of	N	I-Premise
39	dysuria	N	I-Premise
40	.	N	I-Premise

1	Dysuria	N	I-Claim
2	is	N	I-Claim
3	common	N	I-Claim
4	after	N	I-Claim
5	brachytherapy	N	I-Claim
6	but	N	I-Claim
7	is	N	I-Claim
8	typically	N	I-Claim
9	mild	N	I-Claim
10	.	N	I-Claim

1	Prophylactic	N	I-Claim
2	alpha-blockers	N	I-Claim
3	gave	N	I-Claim
4	significantly	N	I-Claim
5	lower	N	I-Claim
6	maximum	N	I-Claim
7	dysuria	N	I-Claim
8	scores	N	I-Claim
9	but	N	I-Claim
10	did	N	I-Claim
11	not	N	I-Claim
12	affect	N	I-Claim
13	the	N	I-Claim
14	time	N	I-Claim
15	to	N	I-Claim
16	the	N	I-Claim
17	resolution	N	I-Claim
18	of	N	I-Claim
19	dysuria	N	I-Claim
20	.	N	I-Claim

1	The	N	I-Claim
2	maximum	N	I-Claim
3	IPSS	N	I-Claim
4	after	N	I-Claim
5	the	N	I-Claim
6	implant	N	I-Claim
7	was	N	I-Claim
8	the	N	I-Claim
9	best	N	I-Claim
10	predictor	N	I-Claim
11	of	N	I-Claim
12	the	N	I-Claim
13	resolution	N	I-Claim
14	of	N	I-Claim
15	dysuria	N	I-Claim
16	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	phase	N	O
4	II	N	O
5	study	N	O
6	compared	N	O
7	two	N	O
8	treatment	N	O
9	schedules	N	O
10	of	N	O
11	gemcitabine	N	O
12	in	N	O
13	patients	N	O
14	with	N	O
15	non-small-cell	N	O
16	lung	N	O
17	cancer	N	O
18	(	N	O
19	NSCLC	N	O
20	)	N	O
21	and	N	O
22	impaired	N	O
23	Karnofsky	N	O
24	performance	N	O
25	status	N	O
26	(	N	O
27	KP	N	O
28	)	N	O
29	.	N	O

1	Primary	N	O
2	objectives	N	O
3	were	N	O
4	to	N	O
5	record	N	O
6	changes	N	O
7	from	N	O
8	baseline	N	O
9	KP	N	O
10	and	N	O
11	to	N	O
12	assess	N	O
13	symptom	N	O
14	palliation	N	O
15	.	N	O

1	Secondary	N	O
2	objectives	N	O
3	were	N	O
4	overall	N	O
5	survival	N	O
6	,	N	O
7	tumor	N	O
8	response	N	O
9	,	N	O
10	and	N	O
11	toxicity	N	O
12	.	N	O

1	Patients	N	O
2	with	N	O
3	stage	N	O
4	IIIb	N	O
5	and	N	O
6	IV	N	O
7	NSCLC	N	O
8	and	N	O
9	KP	N	O
10	<	N	O
11	/=	N	O
12	70	N	O
13	were	N	O
14	randomly	N	O
15	assigned	N	O
16	to	N	O
17	receive	N	O
18	gemcitabine	N	O
19	1,000	N	O
20	mg/m	N	O
21	(	N	O
22	2	N	O
23	)	N	O
24	on	N	O
25	days	N	O
26	1	N	O
27	,	N	O
28	8	N	O
29	,	N	O
30	and	N	O
31	15	N	O
32	of	N	O
33	each	N	O
34	28-day	N	O
35	cycle	N	O
36	(	N	O
37	3w4	N	O
38	)	N	O
39	or	N	O
40	gemcitabine	N	O
41	1,500	N	O
42	mg/m	N	O
43	(	N	O
44	2	N	O
45	)	N	O
46	on	N	O
47	days	N	O
48	1	N	O
49	and	N	O
50	8	N	O
51	of	N	O
52	each	N	O
53	21-day	N	O
54	cycle	N	O
55	(	N	O
56	2w3	N	O
57	)	N	O
58	,	N	O
59	both	N	O
60	for	N	O
61	up	N	O
62	to	N	O
63	six	N	O
64	cycles	N	O
65	.	N	O

1	KP	N	O
2	,	N	O
3	toxicity	N	O
4	,	N	O
5	and	N	O
6	SS14	N	O
7	lung	N	O
8	cancer	N	O
9	specific	N	O
10	questions	N	O
11	were	N	O
12	recorded	N	O
13	before	N	O
14	each	N	O
15	cycle	N	O
16	of	N	O
17	treatment	N	O
18	.	N	O

1	Response	N	O
2	was	N	O
3	evaluated	N	O
4	4	N	O
5	weeks	N	O
6	after	N	O
7	the	N	O
8	last	N	O
9	cycle	N	O
10	.	N	O

1	One	N	O
2	hundred	N	O
3	seventy-four	N	O
4	patients	N	O
5	were	N	O
6	enrolled	N	O
7	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	significant	N	I-Premise
4	early	N	I-Premise
5	attrition	N	I-Premise
6	due	N	I-Premise
7	to	N	I-Premise
8	disease	N	I-Premise
9	progression	N	I-Premise
10	;	N	I-Premise
11	only	N	I-Premise
12	61.5	N	I-Premise
13	%	N	I-Premise
14	of	N	I-Premise
15	patients	N	I-Premise
16	were	N	I-Premise
17	alive	N	I-Premise
18	at	N	I-Premise
19	2	N	I-Premise
20	months	N	I-Premise
21	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	improvement	N	I-Premise
6	in	N	I-Premise
7	KP	N	I-Premise
8	from	N	I-Premise
9	baseline	N	I-Premise
10	to	N	I-Premise
11	pre-cycle	N	I-Premise
12	3	N	I-Premise
13	in	N	I-Premise
14	both	N	I-Premise
15	arms	N	I-Premise
16	,	N	I-Premise
17	with	N	I-Premise
18	a	N	I-Premise
19	trend	N	I-Premise
20	in	N	I-Premise
21	favor	N	I-Premise
22	of	N	I-Premise
23	the	N	I-Premise
24	3w4	N	I-Premise
25	regimen	N	I-Premise
26	for	N	I-Premise
27	duration	N	I-Premise
28	and	N	I-Premise
29	faster	N	I-Premise
30	onset	N	I-Premise
31	of	N	I-Premise
32	improvement	N	I-Premise
33	.	N	I-Premise

1	Eight	N	I-Premise
2	of	N	I-Premise
3	the	N	I-Premise
4	17	N	I-Premise
5	quality-of-life	N	I-Premise
6	(	N	I-Premise
7	QOL	N	I-Premise
8	)	N	I-Premise
9	variables	N	I-Premise
10	assessed	N	I-Premise
11	showed	N	I-Premise
12	an	N	I-Premise
13	improvement	N	I-Premise
14	of	N	I-Premise
15	more	N	I-Premise
16	than	N	I-Premise
17	10	N	I-Premise
18	%	N	I-Premise
19	between	N	I-Premise
20	baseline	N	I-Premise
21	and	N	I-Premise
22	the	N	I-Premise
23	start	N	I-Premise
24	of	N	I-Premise
25	the	N	I-Premise
26	third	N	I-Premise
27	cycle	N	I-Premise
28	of	N	I-Premise
29	treatment	N	I-Premise
30	.	N	I-Premise

1	Response	N	I-Premise
2	rate	N	I-Premise
3	,	N	I-Premise
4	survival	N	I-Premise
5	,	N	I-Premise
6	and	N	I-Premise
7	duration	N	I-Premise
8	were	N	I-Premise
9	similar	N	I-Premise
10	in	N	I-Premise
11	both	N	I-Premise
12	arms	N	I-Premise
13	.	N	I-Premise

1	There	N	I-Claim
2	was	N	I-Claim
3	no	N	I-Claim
4	significant	N	I-Claim
5	difference	N	I-Claim
6	between	N	I-Claim
7	the	N	I-Claim
8	two	N	I-Claim
9	schedules	N	I-Claim
10	examined	N	I-Claim
11	in	N	I-Claim
12	terms	N	I-Claim
13	of	N	I-Claim
14	improvement	N	I-Claim
15	in	N	I-Claim
16	KP	N	I-Claim
17	or	N	I-Claim
18	QOL	N	I-Claim
19	,	N	I-Claim
20	but	N	I-Claim
21	there	N	I-Claim
22	seemed	N	I-Claim
23	to	N	I-Claim
24	be	N	I-Claim
25	a	N	I-Claim
26	trend	N	I-Claim
27	in	N	I-Claim
28	favor	N	I-Claim
29	of	N	I-Claim
30	the	N	I-Claim
31	3w4	N	I-Claim
32	schedule	N	I-Claim
33	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	palliation	N	O
5	of	N	O
6	chest	N	O
7	symptoms	N	O
8	from	N	O
9	a	N	O
10	10	N	O
11	Gy	N	O
12	single	N	O
13	fraction	N	O
14	(	N	O
15	regimen	N	O
16	1	N	O
17	)	N	O
18	was	N	O
19	equivalent	N	O
20	to	N	O
21	that	N	O
22	from	N	O
23	30	N	O
24	Gy	N	O
25	in	N	O
26	10	N	O
27	fractions	N	O
28	(	N	O
29	regimen	N	O
30	2	N	O
31	)	N	O
32	.	N	O

1	Patients	N	O
2	with	N	O
3	cytologically	N	O
4	proven	N	O
5	,	N	O
6	symptomatic	N	O
7	lung	N	O
8	cancer	N	O
9	not	N	O
10	amenable	N	O
11	to	N	O
12	curative	N	O
13	therapy	N	O
14	,	N	O
15	with	N	O
16	performance	N	O
17	status	N	O
18	0-3	N	O
19	,	N	O
20	were	N	O
21	randomised	N	O
22	to	N	O
23	receive	N	O
24	either	N	O
25	30	N	O
26	Gy	N	O
27	in	N	O
28	10	N	O
29	fractions	N	O
30	or	N	O
31	a	N	O
32	10	N	O
33	Gy	N	O
34	single	N	O
35	fraction	N	O
36	.	N	O

1	Local	N	O
2	symptoms	N	O
3	were	N	O
4	scored	N	O
5	on	N	O
6	a	N	O
7	physician-assessed	N	O
8	,	N	O
9	five-point	N	O
10	categorical	N	O
11	scale	N	O
12	and	N	O
13	summed	N	O
14	to	N	O
15	produce	N	O
16	a	N	O
17	total	N	O
18	symptom	N	O
19	score	N	O
20	(	N	O
21	TSS	N	O
22	)	N	O
23	.	N	O

1	This	N	O
2	,	N	O
3	performance	N	O
4	status	N	O
5	,	N	O
6	Hospital	N	O
7	Anxiety	N	O
8	and	N	O
9	Depression	N	O
10	(	N	O
11	HAD	N	O
12	)	N	O
13	score	N	O
14	and	N	O
15	Spitzer	N	O
16	's	N	O
17	quality-of-life	N	O
18	index	N	O
19	were	N	O
20	noted	N	O
21	before	N	O
22	treatment	N	O
23	,	N	O
24	at	N	O
25	1	N	O
26	month	N	O
27	after	N	O
28	treatment	N	O
29	and	N	O
30	every	N	O
31	2	N	O
32	months	N	O
33	thereafter	N	O
34	.	N	O

1	Palliation	N	O
2	was	N	O
3	defined	N	O
4	as	N	O
5	an	N	O
6	improvement	N	O
7	of	N	O
8	one	N	O
9	point	N	O
10	or	N	O
11	more	N	O
12	in	N	O
13	the	N	O
14	categorical	N	O
15	scale	N	O
16	.	N	O

1	Equivalence	N	O
2	was	N	O
3	defined	N	O
4	as	N	O
5	less	N	O
6	than	N	O
7	20	N	O
8	%	N	O
9	difference	N	O
10	in	N	O
11	the	N	O
12	number	N	O
13	achieving	N	O
14	an	N	O
15	improvement	N	O
16	in	N	O
17	the	N	O
18	TSS	N	O
19	.	N	O

1	We	N	O
2	randomised	N	O
3	149	N	O
4	patients	N	O
5	and	N	O
6	analysed	N	O
7	74	N	O
8	in	N	O
9	each	N	O
10	arm	N	O
11	.	N	O

1	According	N	O
2	to	N	O
3	the	N	O
4	design	N	O
5	criteria	N	O
6	,	N	O
7	palliation	N	O
8	was	N	O
9	equivalent	N	O
10	between	N	O
11	the	N	O
12	two	N	O
13	arms	N	O
14	.	N	O

1	TSS	N	I-Premise
2	improved	N	I-Premise
3	in	N	I-Premise
4	49	N	I-Premise
5	patients	N	I-Premise
6	(	N	I-Premise
7	77	N	I-Premise
8	%	N	I-Premise
9	)	N	I-Premise
10	on	N	I-Premise
11	regimen	N	I-Premise
12	1	N	I-Premise
13	,	N	I-Premise
14	and	N	I-Premise
15	in	N	I-Premise
16	57	N	I-Premise
17	(	N	I-Premise
18	92	N	I-Premise
19	%	N	I-Premise
20	)	N	I-Premise
21	patients	N	I-Premise
22	on	N	I-Premise
23	regimen	N	I-Premise
24	2	N	I-Premise
25	,	N	I-Premise
26	a	N	I-Premise
27	difference	N	I-Premise
28	of	N	I-Premise
29	15	N	I-Premise
30	%	N	I-Premise
31	(	N	I-Premise
32	95	N	I-Premise
33	%	N	I-Premise
34	confidence	N	I-Premise
35	interval	N	I-Premise
36	[	N	I-Premise
37	CI	N	I-Premise
38	]	N	I-Premise
39	3-28	N	I-Premise
40	)	N	I-Premise
41	in	N	I-Premise
42	the	N	I-Premise
43	proportion	N	I-Premise
44	improving	N	I-Premise
45	between	N	I-Premise
46	the	N	I-Premise
47	two	N	I-Premise
48	regimens	N	I-Premise
49	.	N	I-Premise

1	A	N	I-Premise
2	complete	N	I-Premise
3	resolution	N	I-Premise
4	of	N	I-Premise
5	all	N	I-Premise
6	symptoms	N	I-Premise
7	was	N	I-Premise
8	achieved	N	I-Premise
9	in	N	I-Premise
10	three	N	I-Premise
11	(	N	I-Premise
12	5	N	I-Premise
13	%	N	I-Premise
14	)	N	I-Premise
15	on	N	I-Premise
16	regimen	N	I-Premise
17	1	N	I-Premise
18	,	N	I-Premise
19	and	N	I-Premise
20	in	N	I-Premise
21	14	N	I-Premise
22	(	N	I-Premise
23	23	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	patients	N	I-Premise
27	on	N	I-Premise
28	regimen	N	I-Premise
29	2	N	I-Premise
30	(	N	I-Premise
31	P	N	I-Premise
32	<	N	I-Premise
33	0.001	N	I-Premise
34	)	N	I-Premise
35	,	N	I-Premise
36	a	N	I-Premise
37	difference	N	I-Premise
38	in	N	I-Premise
39	the	N	I-Premise
40	proportion	N	I-Premise
41	between	N	I-Premise
42	the	N	I-Premise
43	two	N	I-Premise
44	regimens	N	I-Premise
45	of	N	I-Premise
46	21	N	I-Premise
47	%	N	I-Premise
48	(	N	I-Premise
49	95	N	I-Premise
50	%	N	I-Premise
51	CI	N	I-Premise
52	10-33	N	I-Premise
53	)	N	I-Premise
54	.	N	I-Premise

1	A	N	I-Premise
2	significantly	N	I-Premise
3	higher	N	I-Premise
4	proportion	N	I-Premise
5	of	N	I-Premise
6	patients	N	I-Premise
7	experienced	N	I-Premise
8	palliation	N	I-Premise
9	and	N	I-Premise
10	complete	N	I-Premise
11	resolution	N	I-Premise
12	of	N	I-Premise
13	chest	N	I-Premise
14	pain	N	I-Premise
15	and	N	I-Premise
16	dyspnoea	N	I-Premise
17	with	N	I-Premise
18	regimen	N	I-Premise
19	2	N	I-Premise
20	.	N	I-Premise

1	No	N	I-Premise
2	differences	N	I-Premise
3	were	N	I-Premise
4	observed	N	I-Premise
5	in	N	I-Premise
6	toxicity	N	I-Premise
7	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	was	N	I-Premise
5	22.7	N	I-Premise
6	weeks	N	I-Premise
7	for	N	I-Premise
8	regimen	N	I-Premise
9	1	N	I-Premise
10	and	N	I-Premise
11	28.3	N	I-Premise
12	weeks	N	I-Premise
13	for	N	I-Premise
14	regimen	N	I-Premise
15	2	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	=	N	I-Premise
19	0.197	N	I-Premise
20	)	N	I-Premise
21	.	N	I-Premise

1	Although	N	I-Claim
2	this	N	I-Claim
3	trial	N	I-Claim
4	met	N	I-Claim
5	the	N	I-Claim
6	pre-determined	N	I-Claim
7	criteria	N	I-Claim
8	for	N	I-Claim
9	equivalence	N	I-Claim
10	between	N	I-Claim
11	the	N	I-Claim
12	two	N	I-Claim
13	palliative	N	I-Claim
14	regimens	N	I-Claim
15	,	N	I-Claim
16	significantly	N	I-Claim
17	more	N	I-Claim
18	patients	N	I-Claim
19	achieved	N	I-Claim
20	complete	N	I-Claim
21	resolution	N	I-Claim
22	of	N	I-Claim
23	symptoms	N	I-Claim
24	and	N	I-Claim
25	palliation	N	I-Claim
26	of	N	I-Claim
27	chest	N	I-Claim
28	pain	N	I-Claim
29	and	N	I-Claim
30	dyspnoea	N	I-Claim
31	with	N	I-Claim
32	the	N	I-Claim
33	fractionated	N	I-Claim
34	regimen	N	I-Claim
35	.	N	I-Claim

1	Bevacizumab	N	I-Claim
2	,	N	I-Claim
3	a	N	I-Claim
4	monoclonal	N	I-Claim
5	antibody	N	I-Claim
6	against	N	I-Claim
7	vascular	N	I-Claim
8	endothelial	N	I-Claim
9	growth	N	I-Claim
10	factor	N	I-Claim
11	,	N	I-Claim
12	increases	N	I-Claim
13	survival	N	I-Claim
14	when	N	I-Claim
15	combined	N	I-Claim
16	with	N	I-Claim
17	irinotecan-based	N	I-Claim
18	chemotherapy	N	I-Claim
19	in	N	I-Claim
20	first-line	N	I-Claim
21	treatment	N	I-Claim
22	of	N	I-Claim
23	metastatic	N	I-Claim
24	colorectal	N	I-Claim
25	cancer	N	I-Claim
26	(	N	I-Claim
27	CRC	N	I-Claim
28	)	N	I-Claim
29	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	,	N	O
4	phase	N	O
5	II	N	O
6	trial	N	O
7	compared	N	O
8	bevacizumab	N	O
9	plus	N	O
10	fluorouracil	N	O
11	and	N	O
12	leucovorin	N	O
13	(	N	O
14	FU/LV	N	O
15	)	N	O
16	versus	N	O
17	placebo	N	O
18	plus	N	O
19	FU/LV	N	O
20	as	N	O
21	first-line	N	O
22	therapy	N	O
23	in	N	O
24	patients	N	O
25	considered	N	O
26	nonoptimal	N	O
27	candidates	N	O
28	for	N	O
29	first-line	N	O
30	irinotecan	N	O
31	.	N	O

1	Patients	N	O
2	had	N	O
3	metastatic	N	O
4	CRC	N	O
5	and	N	O
6	one	N	O
7	of	N	O
8	the	N	O
9	following	N	O
10	characteristics	N	O
11	:	N	O
12	age	N	O
13	>	N	O
14	or	N	O
15	=	N	O
16	65	N	O
17	years	N	O
18	,	N	O
19	Eastern	N	O
20	Cooperative	N	O
21	Oncology	N	O
22	Group	N	O
23	performance	N	O
24	status	N	O
25	1	N	O
26	or	N	O
27	2	N	O
28	,	N	O
29	serum	N	O
30	albumin	N	O
31	<	N	O
32	or	N	O
33	=	N	O
34	3.5	N	O
35	g/dL	N	O
36	,	N	O
37	or	N	O
38	prior	N	O
39	abdominal/pelvic	N	O
40	radiotherapy	N	O
41	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	FU/LV/placebo	N	O
7	(	N	O
8	n	N	O
9	=	N	O
10	105	N	O
11	)	N	O
12	or	N	O
13	FU/LV/bevacizumab	N	O
14	(	N	O
15	n	N	O
16	=	N	O
17	104	N	O
18	)	N	O
19	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	overall	N	O
7	survival	N	O
8	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	were	N	O
5	progression-free	N	O
6	survival	N	O
7	,	N	O
8	response	N	O
9	rate	N	O
10	,	N	O
11	response	N	O
12	duration	N	O
13	,	N	O
14	and	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	.	N	O

1	Safety	N	O
2	was	N	O
3	also	N	O
4	assessed	N	O
5	.	N	O

1	Median	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	16.6	N	I-Premise
5	months	N	I-Premise
6	for	N	I-Premise
7	the	N	I-Premise
8	FU/LV/bevacizumab	N	I-Premise
9	group	N	I-Premise
10	and	N	I-Premise
11	12.9	N	I-Premise
12	months	N	I-Premise
13	for	N	I-Premise
14	the	N	I-Premise
15	FU/LV/placebo	N	I-Premise
16	group	N	I-Premise
17	(	N	I-Premise
18	hazard	N	I-Premise
19	ratio	N	I-Premise
20	,	N	I-Premise
21	0.79	N	I-Premise
22	;	N	I-Premise
23	P	N	I-Premise
24	=	N	I-Premise
25	.16	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	Median	N	I-Premise
2	progression-free	N	I-Premise
3	survival	N	I-Premise
4	was	N	I-Premise
5	9.2	N	I-Premise
6	months	N	I-Premise
7	(	N	I-Premise
8	FU/LV/bevacizumab	N	I-Premise
9	)	N	I-Premise
10	and	N	I-Premise
11	5.5	N	I-Premise
12	months	N	I-Premise
13	(	N	I-Premise
14	FU/LV/placebo	N	I-Premise
15	)	N	I-Premise
16	;	N	I-Premise
17	hazard	N	I-Premise
18	ratio	N	I-Premise
19	was	N	I-Premise
20	0.50	N	I-Premise
21	;	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	.0002	N	I-Premise
25	.	N	O

1	Response	N	I-Premise
2	rates	N	I-Premise
3	were	N	I-Premise
4	26.0	N	I-Premise
5	%	N	I-Premise
6	(	N	I-Premise
7	FU/LV/bevacizumab	N	I-Premise
8	)	N	I-Premise
9	and	N	I-Premise
10	15.2	N	I-Premise
11	%	N	I-Premise
12	(	N	I-Premise
13	FU/LV/placebo	N	I-Premise
14	)	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	=	N	I-Premise
18	.055	N	I-Premise
19	)	N	I-Premise
20	;	N	I-Premise
21	duration	N	I-Premise
22	of	N	I-Premise
23	response	N	I-Premise
24	was	N	I-Premise
25	9.2	N	I-Premise
26	months	N	I-Premise
27	(	N	I-Premise
28	FU/LV/bevacizumab	N	I-Premise
29	)	N	I-Premise
30	and	N	I-Premise
31	6.8	N	I-Premise
32	months	N	I-Premise
33	(	N	I-Premise
34	FU/LV/placebo	N	I-Premise
35	)	N	I-Premise
36	;	N	I-Premise
37	hazard	N	I-Premise
38	ratio	N	I-Premise
39	was	N	I-Premise
40	0.42	N	I-Premise
41	;	N	I-Premise
42	P	N	I-Premise
43	=	N	I-Premise
44	.088	N	I-Premise
45	.	N	I-Premise

1	Grade	N	I-Premise
2	3	N	I-Premise
3	hypertension	N	I-Premise
4	was	N	I-Premise
5	more	N	I-Premise
6	common	N	I-Premise
7	with	N	I-Premise
8	bevacizumab	N	I-Premise
9	treatment	N	I-Premise
10	(	N	I-Premise
11	16	N	I-Premise
12	%	N	I-Premise
13	v	N	I-Premise
14	3	N	I-Premise
15	%	N	I-Premise
16	)	N	I-Premise
17	but	N	I-Premise
18	was	N	I-Premise
19	controlled	N	I-Premise
20	with	N	I-Premise
21	oral	N	I-Premise
22	medication	N	I-Premise
23	and	N	I-Premise
24	did	N	I-Premise
25	not	N	I-Premise
26	cause	N	I-Premise
27	study	N	I-Premise
28	drug	N	I-Premise
29	discontinuation	N	I-Premise
30	.	N	I-Premise

1	Addition	N	I-Claim
2	of	N	I-Claim
3	bevacizumab	N	I-Claim
4	to	N	I-Claim
5	FU/LV	N	I-Claim
6	as	N	I-Claim
7	first-line	N	I-Claim
8	therapy	N	I-Claim
9	in	N	I-Claim
10	CRC	N	I-Claim
11	patients	N	I-Claim
12	who	N	I-Claim
13	were	N	I-Claim
14	not	N	I-Claim
15	considered	N	I-Claim
16	optimal	N	I-Claim
17	candidates	N	I-Claim
18	for	N	I-Claim
19	first-line	N	I-Claim
20	irinotecan	N	I-Claim
21	treatment	N	I-Claim
22	provided	N	I-Claim
23	clinically	N	I-Claim
24	significant	N	I-Claim
25	patient	N	I-Claim
26	benefit	N	I-Claim
27	,	N	I-Claim
28	including	N	I-Claim
29	statistically	N	I-Claim
30	significant	N	I-Claim
31	improvement	N	I-Claim
32	in	N	I-Claim
33	progression-free	N	I-Claim
34	survival	N	I-Claim
35	.	N	I-Claim

1	Impaired	N	I-Claim
2	cognition	N	I-Claim
3	,	N	I-Claim
4	fatigue	N	I-Claim
5	,	N	I-Claim
6	and	N	I-Claim
7	diminished	N	I-Claim
8	quality	N	I-Claim
9	of	N	I-Claim
10	life	N	I-Claim
11	(	N	I-Claim
12	QOL	N	I-Claim
13	)	N	I-Claim
14	are	N	I-Claim
15	commonly	N	I-Claim
16	associated	N	I-Claim
17	with	N	I-Claim
18	breast	N	I-Claim
19	cancer	N	I-Claim
20	chemotherapy	N	I-Claim
21	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	,	N	O
4	double-blind	N	O
5	,	N	O
6	placebo-controlled	N	O
7	pilot	N	O
8	trial	N	O
9	assessed	N	O
10	the	N	O
11	feasibility	N	O
12	of	N	O
13	quantifying	N	O
14	the	N	O
15	effects	N	O
16	of	N	O
17	epoetin	N	O
18	alfa	N	O
19	on	N	O
20	cognitive	N	O
21	function	N	O
22	and	N	O
23	mood	N	O
24	,	N	O
25	and	N	O
26	evaluated	N	O
27	its	N	O
28	effects	N	O
29	on	N	O
30	fatigue	N	O
31	and	N	O
32	QOL	N	O
33	in	N	O
34	patients	N	O
35	with	N	O
36	breast	N	O
37	cancer	N	O
38	treated	N	O
39	with	N	O
40	anthracycline-based	N	O
41	adjuvant	N	O
42	or	N	O
43	neoadjuvant	N	O
44	chemotherapy	N	O
45	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	receive	N	O
6	epoetin	N	O
7	alfa	N	O
8	40,000	N	O
9	U	N	O
10	subcutaneously	N	O
11	once	N	O
12	weekly	N	O
13	or	N	O
14	placebo	N	O
15	at	N	O
16	the	N	O
17	beginning	N	O
18	of	N	O
19	4	N	O
20	cycles	N	O
21	of	N	O
22	chemotherapy	N	O
23	administered	N	O
24	over	N	O
25	12	N	O
26	weeks	N	O
27	.	N	O

1	Cognitive	N	O
2	function	N	O
3	was	N	O
4	assessed	N	O
5	by	N	O
6	Executive	N	O
7	Interview	N	O
8	(	N	O
9	EXIT25	N	O
10	)	N	O
11	and	N	O
12	Clock	N	O
13	Drawing	N	O
14	Tasks	N	O
15	;	N	O
16	mood	N	O
17	by	N	O
18	Profile	N	O
19	of	N	O
20	Mood	N	O
21	States	N	O
22	;	N	O
23	anemia-related	N	O
24	symptoms	N	O
25	,	N	O
26	including	N	O
27	fatigue	N	O
28	,	N	O
29	by	N	O
30	the	N	O
31	Functional	N	O
32	Assessment	N	O
33	of	N	O
34	Cancer	N	O
35	Therapy-Anemia	N	O
36	(	N	O
37	FACT-An	N	O
38	)	N	O
39	subscale	N	O
40	;	N	O
41	and	N	O
42	QOL	N	O
43	by	N	O
44	Linear	N	O
45	Analog	N	O
46	Scale	N	O
47	Assessment	N	O
48	.	N	O

1	Ninety-four	N	O
2	patients	N	O
3	were	N	O
4	evaluable	N	O
5	for	N	O
6	efficacy	N	O
7	and	N	O
8	safety	N	O
9	.	N	O

1	Mean	N	I-Premise
2	change	N	I-Premise
3	in	N	I-Premise
4	EXIT25	N	I-Premise
5	scores	N	I-Premise
6	from	N	I-Premise
7	baseline	N	I-Premise
8	to	N	I-Premise
9	cycle	N	I-Premise
10	4	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	epoetin	N	I-Premise
14	alfa	N	I-Premise
15	group	N	I-Premise
16	was	N	I-Premise
17	1.3	N	I-Premise
18	+/-	N	I-Premise
19	3.3	N	I-Premise
20	;	N	I-Premise
21	the	N	I-Premise
22	mean	N	I-Premise
23	change	N	I-Premise
24	was	N	I-Premise
25	0.3	N	I-Premise
26	+/-	N	I-Premise
27	2.4	N	I-Premise
28	in	N	I-Premise
29	the	N	I-Premise
30	placebo	N	I-Premise
31	group	N	I-Premise
32	(	N	I-Premise
33	a	N	I-Premise
34	negative	N	I-Premise
35	change	N	I-Premise
36	indicates	N	I-Premise
37	improved	N	I-Premise
38	executive	N	I-Premise
39	function	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	between	N	I-Premise
6	groups	N	I-Premise
7	in	N	I-Premise
8	mean	N	I-Premise
9	change	N	I-Premise
10	in	N	I-Premise
11	EXIT25	N	I-Premise
12	score	N	I-Premise
13	from	N	I-Premise
14	baseline	N	I-Premise
15	to	N	I-Premise
16	6-month	N	I-Premise
17	follow-up	N	I-Premise
18	assessment	N	I-Premise
19	.	N	I-Premise

1	Mean	N	I-Premise
2	hemoglobin	N	I-Premise
3	levels	N	I-Premise
4	were	N	I-Premise
5	higher	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	epoetin	N	I-Premise
9	alfa	N	I-Premise
10	group	N	I-Premise
11	compared	N	I-Premise
12	with	N	I-Premise
13	the	N	I-Premise
14	placebo	N	I-Premise
15	group	N	I-Premise
16	after	N	I-Premise
17	4	N	I-Premise
18	cycles	N	I-Premise
19	of	N	I-Premise
20	chemotherapy	N	I-Premise
21	.	N	I-Premise

1	Epoetin	N	I-Premise
2	alfa	N	I-Premise
3	recipients	N	I-Premise
4	had	N	I-Premise
5	less	N	I-Premise
6	of	N	I-Premise
7	a	N	I-Premise
8	decrease	N	I-Premise
9	in	N	I-Premise
10	FACT-An	N	I-Premise
11	subscale	N	I-Premise
12	scores	N	I-Premise
13	from	N	I-Premise
14	baseline	N	I-Premise
15	to	N	I-Premise
16	cycle	N	I-Premise
17	4	N	I-Premise
18	and	N	I-Premise
19	improvement	N	I-Premise
20	in	N	I-Premise
21	FACT-An	N	I-Premise
22	subscale	N	I-Premise
23	scores	N	I-Premise
24	at	N	I-Premise
25	6-month	N	I-Premise
26	follow-up	N	I-Premise
27	assessment	N	I-Premise
28	compared	N	I-Premise
29	with	N	I-Premise
30	placebo	N	I-Premise
31	.	N	I-Premise

1	Epoetin	N	I-Claim
2	alfa	N	I-Claim
3	therapy	N	I-Claim
4	was	N	I-Claim
5	well	N	I-Claim
6	tolerated	N	I-Claim
7	.	N	I-Claim

1	These	N	I-Claim
2	data	N	I-Claim
3	suggest	N	I-Claim
4	that	N	I-Claim
5	epoetin	N	I-Claim
6	alfa	N	I-Claim
7	may	N	I-Claim
8	have	N	I-Claim
9	attenuated	N	I-Claim
10	the	N	I-Claim
11	cognitive	N	I-Claim
12	impairment	N	I-Claim
13	and	N	I-Claim
14	fatigue	N	I-Claim
15	that	N	I-Claim
16	occurred	N	I-Claim
17	during	N	I-Claim
18	adjuvant	N	I-Claim
19	breast	N	I-Claim
20	cancer	N	I-Claim
21	chemotherapy	N	I-Claim
22	.	N	I-Claim

1	To	N	O
2	pilot	N	O
3	an	N	O
4	investigation	N	O
5	of	N	O
6	individualized	N	O
7	homeopathy	N	O
8	for	N	O
9	symptoms	N	O
10	of	N	O
11	estrogen	N	O
12	withdrawal	N	O
13	in	N	O
14	breast	N	O
15	cancer	N	O
16	survivors	N	O
17	.	N	O

1	Randomized	N	O
2	,	N	O
3	double-blinded	N	O
4	,	N	O
5	placebo-controlled	N	O
6	trial	N	O
7	.	N	O

1	Outpatient	N	O
2	department	N	O
3	of	N	O
4	a	N	O
5	National	N	O
6	Health	N	O
7	Service	N	O
8	(	N	O
9	NHS	N	O
10	)	N	O
11	homeopathic	N	O
12	hospital	N	O
13	.	N	O

1	Fifty-seven	N	O
2	(	N	O
3	57	N	O
4	)	N	O
5	women	N	O
6	met	N	O
7	inclusion	N	O
8	criteria	N	O
9	and	N	O
10	53	N	O
11	were	N	O
12	randomized	N	O
13	to	N	O
14	the	N	O
15	study	N	O
16	.	N	O

1	After	N	O
2	2	N	O
3	weeks	N	O
4	of	N	O
5	baseline	N	O
6	assessment	N	O
7	,	N	O
8	all	N	O
9	participants	N	O
10	received	N	O
11	a	N	O
12	consultation	N	O
13	plus	N	O
14	either	N	O
15	oral	N	O
16	homeopathic	N	O
17	medicine	N	O
18	or	N	O
19	placebo	N	O
20	,	N	O
21	assessed	N	O
22	every	N	O
23	4	N	O
24	weeks	N	O
25	for	N	O
26	16	N	O
27	weeks	N	O
28	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	measures	N	O
5	were	N	O
6	the	N	O
7	activity	N	O
8	score	N	O
9	and	N	O
10	profile	N	O
11	score	N	O
12	of	N	O
13	the	N	O
14	Measure	N	O
15	Yourself	N	O
16	Medical	N	O
17	Outcome	N	O
18	Profile	N	O
19	(	N	O
20	MYMOP	N	O
21	)	N	O
22	.	N	O

1	Eighty-five	N	O
2	percent	N	O
3	(	N	O
4	85	N	O
5	%	N	O
6	)	N	O
7	(	N	O
8	45/53	N	O
9	)	N	O
10	of	N	O
11	women	N	O
12	completed	N	O
13	the	N	O
14	study	N	O
15	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	evidence	N	I-Premise
5	of	N	I-Premise
6	a	N	I-Premise
7	difference	N	I-Premise
8	seen	N	I-Premise
9	between	N	I-Premise
10	groups	N	I-Premise
11	for	N	I-Premise
12	either	N	I-Premise
13	activity	N	I-Premise
14	(	N	I-Premise
15	adjusted	N	I-Premise
16	difference	N	I-Premise
17	=-0.4	N	I-Premise
18	,	N	I-Premise
19	95	N	I-Premise
20	%	N	I-Premise
21	confidence	N	I-Premise
22	interval	N	I-Premise
23	CI	N	I-Premise
24	-1.0	N	I-Premise
25	to	N	I-Premise
26	0.2	N	I-Premise
27	,	N	I-Premise
28	p	N	I-Premise
29	=	N	I-Premise
30	0.17	N	I-Premise
31	)	N	I-Premise
32	or	N	I-Premise
33	profile	N	I-Premise
34	scores	N	I-Premise
35	(	N	I-Premise
36	adjusted	N	I-Premise
37	difference	N	I-Premise
38	=	N	I-Premise
39	-0.4	N	I-Premise
40	,	N	I-Premise
41	95	N	I-Premise
42	%	N	I-Premise
43	CI	N	I-Premise
44	-0.9	N	I-Premise
45	to	N	I-Premise
46	0.1	N	I-Premise
47	,	N	I-Premise
48	p	N	I-Premise
49	=	N	I-Premise
50	0.13	N	I-Premise
51	)	N	I-Premise
52	using	N	I-Premise
53	this	N	I-Premise
54	trial	N	I-Premise
55	design	N	I-Premise
56	,	N	I-Premise
57	although	N	I-Claim
58	post	N	I-Claim
59	hoc	N	I-Claim
60	power	N	I-Claim
61	calculations	N	I-Claim
62	suggests	N	I-Claim
63	that	N	I-Claim
64	65-175	N	I-Claim
65	would	N	I-Claim
66	be	N	I-Claim
67	needed	N	I-Claim
68	per	N	I-Claim
69	group	N	I-Claim
70	to	N	I-Claim
71	detect	N	I-Claim
72	differences	N	I-Claim
73	of	N	I-Claim
74	this	N	I-Claim
75	magnitude	N	I-Claim
76	with	N	I-Claim
77	sufficient	N	I-Claim
78	precision	N	I-Claim
79	.	N	I-Claim

1	Clinically	N	I-Premise
2	relevant	N	I-Premise
3	improvements	N	I-Premise
4	in	N	I-Premise
5	symptoms	N	I-Premise
6	and	N	I-Premise
7	mood	N	I-Premise
8	disturbance	N	I-Premise
9	were	N	I-Premise
10	seen	N	I-Premise
11	for	N	I-Premise
12	both	N	I-Premise
13	groups	N	I-Premise
14	over	N	I-Premise
15	the	N	I-Premise
16	study	N	I-Premise
17	period	N	I-Premise
18	.	N	I-Premise

1	Improvements	N	I-Claim
2	were	N	I-Claim
3	seen	N	I-Claim
4	for	N	I-Claim
5	symptom	N	I-Claim
6	scores	N	I-Claim
7	over	N	I-Claim
8	the	N	I-Claim
9	study	N	I-Claim
10	period	N	I-Claim
11	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	presuming	N	I-Claim
4	these	N	I-Claim
5	improvements	N	I-Claim
6	were	N	I-Claim
7	caused	N	I-Claim
8	by	N	I-Claim
9	the	N	I-Claim
10	individualized	N	I-Claim
11	homeopathic	N	I-Claim
12	approach	N	I-Claim
13	,	N	I-Claim
14	the	N	I-Claim
15	study	N	I-Claim
16	failed	N	I-Claim
17	to	N	I-Claim
18	show	N	I-Claim
19	clearly	N	I-Claim
20	that	N	I-Claim
21	the	N	I-Claim
22	specific	N	I-Claim
23	effect	N	I-Claim
24	of	N	I-Claim
25	the	N	I-Claim
26	remedy	N	I-Claim
27	added	N	I-Claim
28	further	N	I-Claim
29	to	N	I-Claim
30	the	N	I-Claim
31	nonspecific	N	I-Claim
32	effects	N	I-Claim
33	of	N	I-Claim
34	the	N	I-Claim
35	consultation	N	I-Claim
36	.	N	I-Claim

1	Future	N	I-Claim
2	trial	N	I-Claim
3	design	N	I-Claim
4	must	N	I-Claim
5	ensure	N	I-Claim
6	adequate	N	I-Claim
7	power	N	I-Claim
8	to	N	I-Claim
9	account	N	I-Claim
10	for	N	I-Claim
11	the	N	I-Claim
12	nonspecific	N	I-Claim
13	impact	N	I-Claim
14	of	N	I-Claim
15	such	N	I-Claim
16	complex	N	I-Claim
17	individualized	N	I-Claim
18	interventions	N	I-Claim
19	while	N	I-Claim
20	pragmatic	N	I-Claim
21	designs	N	I-Claim
22	may	N	I-Claim
23	more	N	I-Claim
24	readily	N	I-Claim
25	answer	N	I-Claim
26	questions	N	I-Claim
27	of	N	I-Claim
28	clinical	N	I-Claim
29	and	N	I-Claim
30	cost	N	I-Claim
31	effectiveness	N	I-Claim
32	.	N	O

1	To	N	O
2	carry	N	O
3	out	N	O
4	a	N	O
5	preliminary	N	O
6	trial	N	O
7	evaluating	N	O
8	the	N	O
9	effectiveness	N	O
10	of	N	O
11	two	N	O
12	types	N	O
13	of	N	O
14	homeopathy	N	O
15	for	N	O
16	the	N	O
17	treatment	N	O
18	of	N	O
19	menopausal	N	O
20	symptoms	N	O
21	in	N	O
22	breast	N	O
23	cancer	N	O
24	survivors	N	O
25	.	N	O

1	Randomized	N	O
2	,	N	O
3	double-blinded	N	O
4	,	N	O
5	placebo-controlled	N	O
6	.	N	O

1	Private	N	O
2	medical	N	O
3	clinic	N	O
4	,	N	O
5	Seattle	N	O
6	,	N	O
7	WA	N	O
8	.	N	O

1	Women	N	O
2	with	N	O
3	a	N	O
4	history	N	O
5	of	N	O
6	breast	N	O
7	cancer	N	O
8	who	N	O
9	had	N	O
10	completed	N	O
11	all	N	O
12	surgery	N	O
13	,	N	O
14	chemotherapy	N	O
15	,	N	O
16	and	N	O
17	radiation	N	O
18	treatment	N	O
19	and	N	O
20	who	N	O
21	had	N	O
22	an	N	O
23	average	N	O
24	of	N	O
25	at	N	O
26	least	N	O
27	three	N	O
28	hot	N	O
29	flashes	N	O
30	per	N	O
31	day	N	O
32	for	N	O
33	the	N	O
34	previous	N	O
35	month	N	O
36	.	N	O

1	Subjects	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	receive	N	O
6	either	N	O
7	an	N	O
8	individualized	N	O
9	homeopathic	N	O
10	single	N	O
11	remedy	N	O
12	,	N	O
13	a	N	O
14	homeopathic	N	O
15	combination	N	O
16	medicine	N	O
17	,	N	O
18	or	N	O
19	placebo	N	O
20	.	N	O

1	Patients	N	O
2	were	N	O
3	seen	N	O
4	by	N	O
5	homeopathic	N	O
6	providers	N	O
7	every	N	O
8	2	N	O
9	months	N	O
10	for	N	O
11	1	N	O
12	year	N	O
13	.	N	O

1	Hot	N	O
2	flash	N	O
3	frequency	N	O
4	and	N	O
5	severity	N	O
6	,	N	O
7	Kupperman	N	O
8	Menopausal	N	O
9	Index	N	O
10	(	N	O
11	KMI	N	O
12	)	N	O
13	,	N	O
14	Short	N	O
15	Form	N	O
16	36	N	O
17	(	N	O
18	SF-36	N	O
19	)	N	O
20	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	found	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	primary	N	I-Premise
10	outcome	N	I-Premise
11	measure	N	I-Premise
12	,	N	I-Premise
13	the	N	I-Premise
14	hot	N	I-Premise
15	flash	N	I-Premise
16	severity	N	I-Premise
17	score	N	I-Premise
18	,	N	I-Premise
19	although	N	I-Premise
20	there	N	I-Premise
21	was	N	I-Premise
22	a	N	I-Premise
23	positive	N	I-Premise
24	trend	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	single	N	I-Premise
28	remedy	N	I-Premise
29	group	N	I-Premise
30	during	N	I-Premise
31	the	N	I-Premise
32	first	N	I-Premise
33	3	N	I-Premise
34	months	N	I-Premise
35	of	N	I-Premise
36	the	N	I-Premise
37	study	N	I-Premise
38	(	N	I-Premise
39	p	N	I-Premise
40	=	N	I-Premise
41	0.1	N	I-Premise
42	)	N	I-Premise
43	.	N	I-Premise

1	A	N	I-Premise
2	statistically	N	I-Premise
3	significant	N	I-Premise
4	improvement	N	I-Premise
5	in	N	I-Premise
6	general	N	I-Premise
7	health	N	I-Premise
8	score	N	I-Premise
9	in	N	I-Premise
10	both	N	I-Premise
11	homeopathy	N	I-Premise
12	groups	N	I-Premise
13	(	N	I-Premise
14	p	N	I-Premise
15	<	N	I-Premise
16	0.05	N	I-Premise
17	)	N	I-Premise
18	on	N	I-Premise
19	the	N	I-Premise
20	SF-36	N	I-Premise
21	after	N	I-Premise
22	1	N	I-Premise
23	year	N	I-Premise
24	was	N	I-Premise
25	found	N	I-Premise
26	.	N	I-Premise

1	Evidence	N	I-Premise
2	of	N	I-Premise
3	a	N	I-Premise
4	homeopathic	N	I-Premise
5	``	N	I-Premise
6	drug	N	I-Premise
7	proving	N	I-Premise
8	''	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	subjects	N	I-Premise
12	receiving	N	I-Premise
13	the	N	I-Premise
14	homeopathic	N	I-Premise
15	combination	N	I-Premise
16	medicine	N	I-Premise
17	who	N	I-Premise
18	were	N	I-Premise
19	not	N	I-Premise
20	taking	N	I-Premise
21	tamoxifen	N	I-Premise
22	also	N	I-Premise
23	was	N	I-Premise
24	found	N	I-Premise
25	.	N	I-Premise

1	Small	N	I-Claim
2	sample	N	I-Claim
3	size	N	I-Claim
4	precludes	N	I-Claim
5	definitive	N	I-Claim
6	answers	N	I-Claim
7	,	N	I-Claim
8	but	N	I-Claim
9	results	N	I-Claim
10	from	N	I-Claim
11	this	N	I-Claim
12	preliminary	N	I-Claim
13	trial	N	I-Claim
14	suggest	N	I-Claim
15	that	N	I-Claim
16	homeopathy	N	I-Claim
17	may	N	I-Claim
18	be	N	I-Claim
19	of	N	I-Claim
20	value	N	I-Claim
21	in	N	I-Claim
22	the	N	I-Claim
23	treatment	N	I-Claim
24	of	N	I-Claim
25	menopausal	N	I-Claim
26	symptoms	N	I-Claim
27	and	N	I-Claim
28	improving	N	I-Claim
29	quality	N	I-Claim
30	of	N	I-Claim
31	life	N	I-Claim
32	,	N	I-Claim
33	especially	N	I-Claim
34	in	N	I-Claim
35	those	N	I-Claim
36	women	N	I-Claim
37	not	N	I-Claim
38	on	N	I-Claim
39	tamoxifen	N	I-Claim
40	.	N	I-Claim

1	Larger	N	I-Claim
2	studies	N	I-Claim
3	should	N	I-Claim
4	be	N	I-Claim
5	carried	N	I-Claim
6	out	N	I-Claim
7	that	N	I-Claim
8	also	N	I-Claim
9	include	N	I-Claim
10	healthy	N	I-Claim
11	women	N	I-Claim
12	who	N	I-Claim
13	want	N	I-Claim
14	to	N	I-Claim
15	avoid	N	I-Claim
16	hormone	N	I-Claim
17	replacement	N	I-Claim
18	therapy	N	I-Claim
19	.	N	I-Claim

1	Proinflammatory	N	O
2	cytokines	N	O
3	,	N	O
4	especially	N	O
5	tumour	N	O
6	necrosis	N	O
7	factor	N	O
8	alpha	N	O
9	(	N	O
10	TNF-alpha	N	O
11	)	N	O
12	,	N	O
13	play	N	O
14	a	N	O
15	prominent	N	O
16	role	N	O
17	in	N	O
18	the	N	O
19	pathogenesis	N	O
20	of	N	O
21	cancer	N	O
22	cachexia	N	O
23	.	N	O

1	Thalidomide	N	I-MajorClaim
2	,	N	I-MajorClaim
3	which	N	I-MajorClaim
4	is	N	I-MajorClaim
5	an	N	I-MajorClaim
6	inhibitor	N	I-MajorClaim
7	of	N	I-MajorClaim
8	TNF-alpha	N	I-MajorClaim
9	synthesis	N	I-MajorClaim
10	,	N	I-MajorClaim
11	may	N	I-MajorClaim
12	represent	N	I-MajorClaim
13	a	N	I-MajorClaim
14	novel	N	I-MajorClaim
15	and	N	I-MajorClaim
16	rational	N	I-MajorClaim
17	approach	N	I-MajorClaim
18	to	N	I-MajorClaim
19	the	N	I-MajorClaim
20	treatment	N	I-MajorClaim
21	of	N	I-MajorClaim
22	cancer	N	I-MajorClaim
23	cachexia	N	I-MajorClaim
24	.	N	I-MajorClaim

1	To	N	O
2	assess	N	O
3	the	N	O
4	safety	N	O
5	and	N	O
6	efficacy	N	O
7	of	N	O
8	thalidomide	N	O
9	in	N	O
10	attenuating	N	O
11	weight	N	O
12	loss	N	O
13	in	N	O
14	patients	N	O
15	with	N	O
16	cachexia	N	O
17	secondary	N	O
18	to	N	O
19	advanced	N	O
20	pancreatic	N	O
21	cancer	N	O
22	.	N	O

1	Fifty	N	O
2	patients	N	O
3	with	N	O
4	advanced	N	O
5	pancreatic	N	O
6	cancer	N	O
7	who	N	O
8	had	N	O
9	lost	N	O
10	at	N	O
11	least	N	O
12	10	N	O
13	%	N	O
14	of	N	O
15	their	N	O
16	body	N	O
17	weight	N	O
18	were	N	O
19	randomised	N	O
20	to	N	O
21	receive	N	O
22	thalidomide	N	O
23	200	N	O
24	mg	N	O
25	daily	N	O
26	or	N	O
27	placebo	N	O
28	for	N	O
29	24	N	O
30	weeks	N	O
31	in	N	O
32	a	N	O
33	single	N	O
34	centre	N	O
35	,	N	O
36	double	N	O
37	blind	N	O
38	,	N	O
39	randomised	N	O
40	controlled	N	O
41	trial	N	O
42	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	change	N	O
6	in	N	O
7	weight	N	O
8	and	N	O
9	nutritional	N	O
10	status	N	O
11	.	N	O

1	Thirty	N	O
2	three	N	O
3	patients	N	O
4	(	N	O
5	16	N	O
6	control	N	O
7	,	N	O
8	17	N	O
9	thalidomide	N	O
10	)	N	O
11	were	N	O
12	evaluated	N	O
13	at	N	O
14	four	N	O
15	weeks	N	O
16	,	N	O
17	and	N	O
18	20	N	O
19	patients	N	O
20	(	N	O
21	eight	N	O
22	control	N	O
23	,	N	O
24	12	N	O
25	thalidomide	N	O
26	)	N	O
27	at	N	O
28	eight	N	O
29	weeks	N	O
30	.	N	O

1	At	N	I-Premise
2	four	N	I-Premise
3	weeks	N	I-Premise
4	,	N	I-Premise
5	patients	N	I-Premise
6	who	N	I-Premise
7	received	N	I-Premise
8	thalidomide	N	I-Premise
9	had	N	I-Premise
10	gained	N	I-Premise
11	on	N	I-Premise
12	average	N	I-Premise
13	0.37	N	I-Premise
14	kg	N	I-Premise
15	in	N	I-Premise
16	weight	N	I-Premise
17	and	N	I-Premise
18	1.0	N	I-Premise
19	cm	N	I-Premise
20	(	N	I-Premise
21	3	N	I-Premise
22	)	N	I-Premise
23	in	N	I-Premise
24	arm	N	I-Premise
25	muscle	N	I-Premise
26	mass	N	I-Premise
27	(	N	I-Premise
28	AMA	N	I-Premise
29	)	N	I-Premise
30	compared	N	I-Premise
31	with	N	I-Premise
32	a	N	I-Premise
33	loss	N	I-Premise
34	of	N	I-Premise
35	2.21	N	I-Premise
36	kg	N	I-Premise
37	(	N	I-Premise
38	absolute	N	I-Premise
39	difference	N	I-Premise
40	-2.59	N	I-Premise
41	kg	N	I-Premise
42	(	N	I-Premise
43	95	N	I-Premise
44	%	N	I-Premise
45	confidence	N	I-Premise
46	interval	N	I-Premise
47	(	N	I-Premise
48	CI	N	I-Premise
49	)	N	I-Premise
50	-4.3	N	I-Premise
51	to	N	I-Premise
52	-0.8	N	I-Premise
53	)	N	I-Premise
54	;	N	I-Premise
55	p	N	I-Premise
56	=	N	I-Premise
57	0.005	N	I-Premise
58	)	N	I-Premise
59	and	N	I-Premise
60	4.46	N	I-Premise
61	cm	N	I-Premise
62	(	N	I-Premise
63	3	N	I-Premise
64	)	N	I-Premise
65	(	N	I-Premise
66	absolute	N	I-Premise
67	difference	N	I-Premise
68	-5.6	N	I-Premise
69	cm	N	I-Premise
70	(	N	I-Premise
71	3	N	I-Premise
72	)	N	I-Premise
73	(	N	I-Premise
74	95	N	I-Premise
75	%	N	I-Premise
76	CI	N	I-Premise
77	-8.9	N	I-Premise
78	to	N	I-Premise
79	-2.2	N	I-Premise
80	)	N	I-Premise
81	;	N	I-Premise
82	p	N	I-Premise
83	=	N	I-Premise
84	0.002	N	I-Premise
85	)	N	I-Premise
86	in	N	I-Premise
87	the	N	I-Premise
88	placebo	N	I-Premise
89	group	N	I-Premise
90	.	N	I-Premise

1	At	N	I-Premise
2	eight	N	I-Premise
3	weeks	N	I-Premise
4	,	N	I-Premise
5	patients	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	thalidomide	N	I-Premise
9	group	N	I-Premise
10	had	N	I-Premise
11	lost	N	I-Premise
12	0.06	N	I-Premise
13	kg	N	I-Premise
14	in	N	I-Premise
15	weight	N	I-Premise
16	and	N	I-Premise
17	0.5	N	I-Premise
18	cm	N	I-Premise
19	(	N	I-Premise
20	3	N	I-Premise
21	)	N	I-Premise
22	in	N	I-Premise
23	AMA	N	I-Premise
24	compared	N	I-Premise
25	with	N	I-Premise
26	a	N	I-Premise
27	loss	N	I-Premise
28	of	N	I-Premise
29	3.62	N	I-Premise
30	kg	N	I-Premise
31	(	N	I-Premise
32	absolute	N	I-Premise
33	difference	N	I-Premise
34	-3.57	N	I-Premise
35	kg	N	I-Premise
36	(	N	I-Premise
37	95	N	I-Premise
38	%	N	I-Premise
39	CI	N	I-Premise
40	-6.8	N	I-Premise
41	to	N	I-Premise
42	-0.3	N	I-Premise
43	)	N	I-Premise
44	;	N	I-Premise
45	p	N	I-Premise
46	=	N	I-Premise
47	0.034	N	I-Premise
48	)	N	I-Premise
49	and	N	I-Premise
50	8.4	N	I-Premise
51	cm	N	I-Premise
52	(	N	I-Premise
53	3	N	I-Premise
54	)	N	I-Premise
55	(	N	I-Premise
56	absolute	N	I-Premise
57	difference	N	I-Premise
58	-7.9	N	I-Premise
59	cm	N	I-Premise
60	(	N	I-Premise
61	3	N	I-Premise
62	)	N	I-Premise
63	(	N	I-Premise
64	95	N	I-Premise
65	%	N	I-Premise
66	CI	N	I-Premise
67	-14.0	N	I-Premise
68	to	N	I-Premise
69	-1.8	N	I-Premise
70	)	N	I-Premise
71	;	N	I-Premise
72	p	N	I-Premise
73	=	N	I-Premise
74	0.014	N	I-Premise
75	)	N	I-Premise
76	in	N	I-Premise
77	the	N	I-Premise
78	placebo	N	I-Premise
79	group	N	I-Premise
80	.	N	I-Premise

1	Improvement	N	I-Premise
2	in	N	I-Premise
3	physical	N	I-Premise
4	functioning	N	I-Premise
5	correlated	N	I-Premise
6	positively	N	I-Premise
7	with	N	I-Premise
8	weight	N	I-Premise
9	gain	N	I-Premise
10	(	N	I-Premise
11	r	N	I-Premise
12	=	N	I-Premise
13	0.56	N	I-Premise
14	,	N	I-Premise
15	p	N	I-Premise
16	=	N	I-Premise
17	0.001	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	Thalidomide	N	I-Claim
2	was	N	I-Claim
3	well	N	I-Claim
4	tolerated	N	I-Claim
5	and	N	I-Claim
6	effective	N	I-Claim
7	at	N	I-Claim
8	attenuating	N	I-Claim
9	loss	N	I-Claim
10	of	N	I-Claim
11	weight	N	I-Claim
12	and	N	I-Claim
13	lean	N	I-Claim
14	body	N	I-Claim
15	mass	N	I-Claim
16	in	N	I-Claim
17	patients	N	I-Claim
18	with	N	I-Claim
19	cachexia	N	I-Claim
20	due	N	I-Claim
21	to	N	I-Claim
22	advanced	N	I-Claim
23	pancreatic	N	I-Claim
24	cancer	N	I-Claim
25	.	N	I-Claim

1	To	N	O
2	test	N	O
3	the	N	O
4	ability	N	O
5	of	N	O
6	the	N	O
7	cytoprotectant	N	O
8	,	N	O
9	amifostine	N	O
10	,	N	O
11	to	N	O
12	reduce	N	O
13	chemoradiotherapy-induced	N	O
14	esophagitis	N	O
15	and	N	O
16	evaluate	N	O
17	its	N	O
18	influence	N	O
19	on	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	(	N	O
24	QOL	N	O
25	)	N	O
26	and	N	O
27	swallowing	N	O
28	symptoms	N	O
29	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	243	N	O
5	patients	N	O
6	with	N	O
7	stage	N	O
8	II	N	O
9	to	N	O
10	IIIA/B	N	O
11	non-small-cell	N	O
12	lung	N	O
13	cancer	N	O
14	received	N	O
15	induction	N	O
16	paclitaxel	N	O
17	225	N	O
18	mg/m	N	O
19	(	N	O
20	2	N	O
21	)	N	O
22	intravenously	N	O
23	(	N	O
24	IV	N	O
25	)	N	O
26	days	N	O
27	1	N	O
28	and	N	O
29	22	N	O
30	and	N	O
31	carboplatin	N	O
32	area	N	O
33	under	N	O
34	the	N	O
35	curve	N	O
36	(	N	O
37	AUC	N	O
38	)	N	O
39	days	N	O
40	1	N	O
41	and	N	O
42	22	N	O
43	,	N	O
44	followed	N	O
45	by	N	O
46	concurrent	N	O
47	weekly	N	O
48	paclitaxel	N	O
49	(	N	O
50	50	N	O
51	mg/m	N	O
52	(	N	O
53	2	N	O
54	)	N	O
55	IV	N	O
56	)	N	O
57	and	N	O
58	carboplatin	N	O
59	(	N	O
60	AUC	N	O
61	2	N	O
62	)	N	O
63	,	N	O
64	and	N	O
65	hyperfractionated	N	O
66	radiation	N	O
67	therapy	N	O
68	(	N	O
69	69.6	N	O
70	Gy	N	O
71	at	N	O
72	1.2	N	O
73	Gy	N	O
74	bid	N	O
75	)	N	O
76	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	at	N	O
6	registration	N	O
7	to	N	O
8	amifostine	N	O
9	(	N	O
10	AM	N	O
11	)	N	O
12	500	N	O
13	mg	N	O
14	IV	N	O
15	four	N	O
16	times	N	O
17	per	N	O
18	week	N	O
19	or	N	O
20	no	N	O
21	AM	N	O
22	during	N	O
23	chemoradiotherapy	N	O
24	.	N	O

1	Beyond	N	O
2	standard	N	O
3	toxicity	N	O
4	end	N	O
5	points	N	O
6	,	N	O
7	physician	N	O
8	dysphagia	N	O
9	logs	N	O
10	(	N	O
11	PDLs	N	O
12	)	N	O
13	,	N	O
14	daily	N	O
15	patient	N	O
16	swallowing	N	O
17	diaries	N	O
18	,	N	O
19	and	N	O
20	QOL	N	O
21	(	N	O
22	EORTC	N	O
23	QLQ-C30/LC-13	N	O
24	)	N	O
25	were	N	O
26	also	N	O
27	collected	N	O
28	.	N	O

1	Swallowing	N	O
2	AUC	N	O
3	analyses	N	O
4	were	N	O
5	calculated	N	O
6	from	N	O
7	patient	N	O
8	diaries	N	O
9	and	N	O
10	PDLs	N	O
11	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	120	N	O
5	patients	N	O
6	were	N	O
7	randomly	N	O
8	assigned	N	O
9	to	N	O
10	receive	N	O
11	AM	N	O
12	,	N	O
13	and	N	O
14	122	N	O
15	,	N	O
16	to	N	O
17	receive	N	O
18	no	N	O
19	AM	N	O
20	(	N	O
21	one	N	O
22	patient	N	O
23	was	N	O
24	ineligible	N	O
25	)	N	O
26	;	N	O
27	72	N	O
28	%	N	O
29	received	N	O
30	AM	N	O
31	per	N	O
32	protocol	N	O
33	or	N	O
34	with	N	O
35	a	N	O
36	minor	N	O
37	deviation	N	O
38	.	N	O

1	AM	N	I-Premise
2	was	N	I-Premise
3	associated	N	I-Premise
4	with	N	I-Premise
5	higher	N	I-Premise
6	rates	N	I-Premise
7	of	N	I-Premise
8	acute	N	I-Premise
9	nausea	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	=	N	I-Premise
13	.03	N	I-Premise
14	)	N	I-Premise
15	,	N	I-Premise
16	vomiting	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	.007	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	cardiovascular	N	I-Premise
24	toxicity	N	I-Premise
25	(	N	I-Premise
26	P	N	I-Premise
27	=	N	I-Premise
28	.0001	N	I-Premise
29	)	N	I-Premise
30	,	N	I-Premise
31	and	N	I-Premise
32	infection	N	I-Premise
33	or	N	I-Premise
34	febrile	N	I-Premise
35	neutropenia	N	I-Premise
36	(	N	I-Premise
37	P	N	I-Premise
38	=	N	I-Premise
39	.03	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	The	N	I-Premise
2	rate	N	I-Premise
3	of	N	I-Premise
4	>	N	I-Premise
5	/=	N	I-Premise
6	grade	N	I-Premise
7	3	N	I-Premise
8	esophagitis	N	I-Premise
9	was	N	I-Premise
10	30	N	I-Premise
11	%	N	I-Premise
12	with	N	I-Premise
13	AM	N	I-Premise
14	versus	N	I-Premise
15	34	N	I-Premise
16	%	N	I-Premise
17	without	N	I-Premise
18	AM	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	.9	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Patient	N	I-Premise
2	diaries	N	I-Premise
3	demonstrated	N	I-Premise
4	lower	N	I-Premise
5	swallowing	N	I-Premise
6	dysfunction	N	I-Premise
7	AUC	N	I-Premise
8	with	N	I-Premise
9	amifostine	N	I-Premise
10	(	N	I-Premise
11	z	N	I-Premise
12	test	N	I-Premise
13	P	N	I-Premise
14	=	N	I-Premise
15	.025	N	I-Premise
16	)	N	I-Premise
17	.	N	I-Premise

1	QOL	N	I-Premise
2	was	N	I-Premise
3	not	N	I-Premise
4	significantly	N	I-Premise
5	different	N	I-Premise
6	between	N	I-Premise
7	the	N	I-Premise
8	two	N	I-Premise
9	arms	N	I-Premise
10	,	N	I-Premise
11	except	N	I-Premise
12	for	N	I-Premise
13	pain	N	I-Premise
14	,	N	I-Premise
15	which	N	I-Premise
16	showed	N	I-Premise
17	more	N	I-Premise
18	clinically	N	I-Premise
19	meaningful	N	I-Premise
20	improvement	N	I-Premise
21	and	N	I-Premise
22	less	N	I-Premise
23	deterioration	N	I-Premise
24	at	N	I-Premise
25	6	N	I-Premise
26	weeks	N	I-Premise
27	follow-up	N	I-Premise
28	(	N	I-Premise
29	v	N	I-Premise
30	pretreatment	N	I-Premise
31	)	N	I-Premise
32	in	N	I-Premise
33	the	N	I-Premise
34	AM	N	I-Premise
35	arm	N	I-Premise
36	(	N	I-Premise
37	P	N	I-Premise
38	=	N	I-Premise
39	.003	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	rates	N	I-Premise
5	for	N	I-Premise
6	both	N	I-Premise
7	arms	N	I-Premise
8	were	N	I-Premise
9	comparable	N	I-Premise
10	(	N	I-Premise
11	AM	N	I-Premise
12	,	N	I-Premise
13	17.3	N	I-Premise
14	v	N	I-Premise
15	no	N	I-Premise
16	AM	N	I-Premise
17	,	N	I-Premise
18	17.9	N	I-Premise
19	months	N	I-Premise
20	;	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	.87	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	AM	N	I-Claim
2	did	N	I-Claim
3	not	N	I-Claim
4	significantly	N	I-Claim
5	reduce	N	I-Claim
6	esophagitis	N	I-Claim
7	>	N	I-Claim
8	/=	N	I-Claim
9	grade	N	I-Claim
10	3	N	I-Claim
11	in	N	I-Claim
12	patients	N	I-Claim
13	receiving	N	I-Claim
14	hyperfractionated	N	I-Claim
15	radiation	N	I-Claim
16	and	N	I-Claim
17	chemotherapy	N	I-Claim
18	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	patient	N	I-Claim
4	self-assessments	N	I-Claim
5	suggested	N	I-Claim
6	a	N	I-Claim
7	possible	N	I-Claim
8	advantage	N	I-Claim
9	to	N	I-Claim
10	AM	N	I-Claim
11	that	N	I-Claim
12	is	N	I-Claim
13	being	N	I-Claim
14	explored	N	I-Claim
15	with	N	I-Claim
16	modified	N	I-Claim
17	dosing	N	I-Claim
18	route	N	I-Claim
19	strategies	N	I-Claim
20	.	N	I-Claim

1	Many	N	O
2	patients	N	O
3	with	N	O
4	advanced	N	O
5	ovarian	N	O
6	cancer	N	O
7	will	N	O
8	develop	N	O
9	recurrent	N	O
10	disease	N	O
11	.	N	O

1	For	N	I-Premise
2	those	N	I-Premise
3	patients	N	I-Premise
4	who	N	I-Premise
5	have	N	I-Premise
6	recurrence	N	I-Premise
7	of	N	I-Premise
8	disease	N	I-Premise
9	at	N	I-Premise
10	least	N	I-Premise
11	6	N	I-Premise
12	months	N	I-Premise
13	after	N	I-Premise
14	initial	N	I-Premise
15	therapy	N	I-Premise
16	,	N	I-Premise
17	the	N	I-Premise
18	paclitaxel-platinum	N	I-Premise
19	combination	N	I-Premise
20	has	N	I-Premise
21	been	N	I-Premise
22	shown	N	I-Premise
23	to	N	I-Premise
24	be	N	I-Premise
25	a	N	I-Premise
26	superior	N	I-Premise
27	treatment	N	I-Premise
28	to	N	I-Premise
29	platinum	N	I-Premise
30	monotherapy	N	I-Premise
31	.	N	I-Premise

1	However	N	I-Claim
2	,	N	I-Claim
3	many	N	I-Claim
4	patients	N	I-Claim
5	develop	N	I-Claim
6	clinically	N	I-Claim
7	relevant	N	I-Claim
8	neurotoxicity	N	I-Claim
9	,	N	I-Claim
10	frequently	N	I-Claim
11	resulting	N	I-Claim
12	in	N	I-Claim
13	treatment	N	I-Claim
14	discontinuation	N	I-Claim
15	.	N	I-Claim

1	The	N	O
2	efficacy	N	O
3	and	N	O
4	safety	N	O
5	of	N	O
6	an	N	O
7	alternative	N	O
8	regimen	N	O
9	that	N	O
10	does	N	O
11	not	N	O
12	show	N	O
13	significant	N	O
14	neurotoxicity	N	O
15	were	N	O
16	evaluated	N	O
17	by	N	O
18	comparing	N	O
19	gemcitabine-carboplatin	N	O
20	with	N	O
21	carboplatin	N	O
22	in	N	O
23	platinum-sensitive	N	O
24	recurrent	N	O
25	ovarian	N	O
26	cancer	N	O
27	patients	N	O
28	in	N	O
29	a	N	O
30	Gynecologic	N	O
31	Cancer	N	O
32	InterGroup	N	O
33	trial	N	O
34	of	N	O
35	the	N	O
36	Arbeitsgemeinschaft	N	O
37	Gynakologische	N	O
38	Onkologie	N	O
39	Ovarian	N	O
40	Cancer	N	O
41	Study	N	O
42	Group	N	O
43	,	N	O
44	the	N	O
45	National	N	O
46	Cancer	N	O
47	Institute	N	O
48	of	N	O
49	Canada	N	O
50	Clinical	N	O
51	Trials	N	O
52	Group	N	O
53	,	N	O
54	and	N	O
55	the	N	O
56	European	N	O
57	Organisation	N	O
58	for	N	O
59	Research	N	O
60	and	N	O
61	Treatment	N	O
62	of	N	O
63	Cancer	N	O
64	Gynaecological	N	O
65	Cancer	N	O
66	Group	N	O
67	.	N	O

1	Participants	N	O
2	with	N	O
3	recurrent	N	O
4	platinum-sensitive	N	O
5	ovarian	N	O
6	cancer	N	O
7	were	N	O
8	randomly	N	O
9	assigned	N	O
10	to	N	O
11	receive	N	O
12	either	N	O
13	gemcitabine-carboplatin	N	O
14	or	N	O
15	carboplatin	N	O
16	every	N	O
17	21	N	O
18	days	N	O
19	.	N	O

1	The	N	O
2	primary	N	O
3	objective	N	O
4	was	N	O
5	to	N	O
6	compare	N	O
7	progression-free	N	O
8	survival	N	O
9	(	N	O
10	PFS	N	O
11	)	N	O
12	between	N	O
13	the	N	O
14	groups	N	O
15	.	N	O

1	From	N	O
2	September	N	O
3	1999	N	O
4	to	N	O
5	April	N	O
6	2002	N	O
7	,	N	O
8	356	N	O
9	patients	N	O
10	(	N	O
11	178	N	O
12	participants	N	O
13	received	N	O
14	gemcitabine-carboplatin	N	O
15	,	N	O
16	178	N	O
17	received	N	O
18	carboplatin	N	O
19	only	N	O
20	)	N	O
21	were	N	O
22	randomized	N	O
23	to	N	O
24	treatment	N	O
25	.	N	O

1	Patients	N	O
2	received	N	O
3	six	N	O
4	cycles	N	O
5	of	N	O
6	either	N	O
7	gemcitabine-carboplatin	N	O
8	or	N	O
9	carboplatin	N	O
10	.	N	O

1	With	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	17	N	I-Premise
7	months	N	I-Premise
8	,	N	I-Premise
9	median	N	I-Premise
10	PFS	N	I-Premise
11	was	N	I-Premise
12	8.6	N	I-Premise
13	months	N	I-Premise
14	for	N	I-Premise
15	gemcitabine-carboplatin	N	I-Premise
16	(	N	I-Premise
17	95	N	I-Premise
18	%	N	I-Premise
19	confidence	N	I-Premise
20	interval	N	I-Premise
21	[	N	I-Premise
22	CI	N	I-Premise
23	]	N	I-Premise
24	7.9-9.7	N	I-Premise
25	months	N	I-Premise
26	)	N	I-Premise
27	and	N	I-Premise
28	5.8	N	I-Premise
29	months	N	I-Premise
30	for	N	I-Premise
31	carboplatin	N	I-Premise
32	(	N	I-Premise
33	95	N	I-Premise
34	%	N	I-Premise
35	CI	N	I-Premise
36	5.2-7.1	N	I-Premise
37	months	N	I-Premise
38	;	N	I-Premise
39	hazard	N	I-Premise
40	ratio	N	I-Premise
41	[	N	I-Premise
42	HR	N	I-Premise
43	]	N	I-Premise
44	0.72	N	I-Premise
45	[	N	I-Premise
46	95	N	I-Premise
47	%	N	I-Premise
48	CI	N	I-Premise
49	0.58-0.90	N	I-Premise
50	;	N	I-Premise
51	P	N	I-Premise
52	=	N	I-Premise
53	0.0032	N	I-Premise
54	]	N	I-Premise
55	)	N	I-Premise
56	.	N	I-Premise

1	The	N	I-Premise
2	response	N	I-Premise
3	rate	N	I-Premise
4	for	N	I-Premise
5	the	N	I-Premise
6	gemcitabine-carboplatin	N	I-Premise
7	group	N	I-Premise
8	was	N	I-Premise
9	47.2	N	I-Premise
10	%	N	I-Premise
11	(	N	I-Premise
12	95	N	I-Premise
13	%	N	I-Premise
14	CI	N	I-Premise
15	39.9-54.5	N	I-Premise
16	%	N	I-Premise
17	)	N	I-Premise
18	and	N	I-Premise
19	30.9	N	I-Premise
20	%	N	I-Premise
21	for	N	I-Premise
22	carboplatin	N	I-Premise
23	group	N	I-Premise
24	(	N	I-Premise
25	95	N	I-Premise
26	%	N	I-Premise
27	CI	N	I-Premise
28	24.1-37.7	N	I-Premise
29	%	N	I-Premise
30	;	N	I-Premise
31	P	N	I-Premise
32	=	N	I-Premise
33	0.0016	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	The	N	I-Premise
2	HR	N	I-Premise
3	for	N	I-Premise
4	overall	N	I-Premise
5	survival	N	I-Premise
6	was	N	I-Premise
7	0.96	N	I-Premise
8	(	N	I-Premise
9	95	N	I-Premise
10	%	N	I-Premise
11	CI	N	I-Premise
12	0.75-1.23	N	I-Premise
13	;	N	I-Premise
14	P	N	I-Premise
15	=	N	I-Premise
16	0.7349	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	Patients	N	I-Premise
2	treated	N	I-Premise
3	with	N	I-Premise
4	gemcitabine-carboplatin	N	I-Premise
5	reported	N	I-Premise
6	significantly	N	I-Premise
7	faster	N	I-Premise
8	palliation	N	I-Premise
9	of	N	I-Premise
10	abdominal	N	I-Premise
11	symptoms	N	I-Premise
12	and	N	I-Premise
13	a	N	I-Premise
14	significantly	N	I-Premise
15	improved	N	I-Premise
16	global	N	I-Premise
17	quality	N	I-Premise
18	of	N	I-Premise
19	life	N	I-Premise
20	.	N	I-Premise

1	Gemcitabine-carboplatin	N	I-Claim
2	treatment	N	I-Claim
3	significantly	N	I-Claim
4	improves	N	I-Claim
5	the	N	I-Claim
6	PFS	N	I-Claim
7	of	N	I-Claim
8	patients	N	I-Claim
9	with	N	I-Claim
10	platinum-sensitive	N	I-Claim
11	recurrent	N	I-Claim
12	ovarian	N	I-Claim
13	cancer	N	I-Claim
14	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	investigate	N	O
9	whether	N	O
10	specialized	N	O
11	supportive	N	O
12	enteral	N	O
13	and	N	O
14	parenteral	N	O
15	feeding	N	O
16	have	N	O
17	superior	N	O
18	effects	N	O
19	compared	N	O
20	to	N	O
21	oral	N	O
22	nutrition	N	O
23	on	N	O
24	recovery	N	O
25	during	N	O
26	long-term	N	O
27	postoperative	N	O
28	treatment	N	O
29	of	N	O
30	cancer	N	O
31	patients	N	O
32	with	N	O
33	preoperative	N	O
34	weight	N	O
35	loss	N	O
36	and	N	O
37	reduced	N	O
38	maximum	N	O
39	exercise	N	O
40	capacity	N	O
41	.	N	O

1	One	N	O
2	hundred	N	O
3	twenty-six	N	O
4	patients	N	O
5	referred	N	O
6	for	N	O
7	resection	N	O
8	of	N	O
9	the	N	O
10	esophagus	N	O
11	(	N	O
12	n	N	O
13	=	N	O
14	48	N	O
15	)	N	O
16	,	N	O
17	stomach	N	O
18	(	N	O
19	n	N	O
20	=	N	O
21	28	N	O
22	)	N	O
23	,	N	O
24	or	N	O
25	pancreas	N	O
26	(	N	O
27	n	N	O
28	=	N	O
29	50	N	O
30	)	N	O
31	were	N	O
32	considered	N	O
33	to	N	O
34	be	N	O
35	included	N	O
36	before	N	O
37	operation	N	O
38	.	N	O

1	Included	N	O
2	patients	N	O
3	(	N	O
4	n	N	O
5	=	N	O
6	80	N	O
7	)	N	O
8	received	N	O
9	supportive	N	O
10	enteral	N	O
11	or	N	O
12	parenteral	N	O
13	nutrition	N	O
14	postoperatively	N	O
15	at	N	O
16	home	N	O
17	corresponding	N	O
18	to	N	O
19	1000	N	O
20	kcal/d	N	O
21	until	N	O
22	the	N	O
23	patients	N	O
24	did	N	O
25	not	N	O
26	wish	N	O
27	to	N	O
28	continue	N	O
29	with	N	O
30	artificial	N	O
31	nutrition	N	O
32	for	N	O
33	any	N	O
34	reason	N	O
35	.	N	O

1	Patients	N	O
2	randomized	N	O
3	to	N	O
4	oral	N	O
5	nutrition	N	O
6	only	N	O
7	served	N	O
8	as	N	O
9	control	N	O
10	subjects	N	O
11	.	N	O

1	Caloric	N	O
2	intake	N	O
3	,	N	O
4	body	N	O
5	composition	N	O
6	(	N	O
7	dual-energy	N	O
8	x-ray	N	O
9	absorptiometry	N	O
10	)	N	O
11	,	N	O
12	and	N	O
13	respiratory	N	O
14	gas	N	O
15	exchanges	N	O
16	at	N	O
17	rest	N	O
18	and	N	O
19	during	N	O
20	exercise	N	O
21	were	N	O
22	measured	N	O
23	including	N	O
24	health-related	N	O
25	quality	N	O
26	of	N	O
27	life	N	O
28	.	N	O

1	Survival	N	I-Premise
2	and	N	I-Premise
3	hospital	N	I-Premise
4	stay	N	I-Premise
5	did	N	I-Premise
6	not	N	I-Premise
7	differ	N	I-Premise
8	among	N	I-Premise
9	the	N	I-Premise
10	groups	N	I-Premise
11	,	N	I-Premise
12	whereas	N	I-Premise
13	overall	N	I-Premise
14	complications	N	I-Premise
15	were	N	I-Premise
16	higher	N	I-Premise
17	on	N	I-Premise
18	artificial	N	I-Premise
19	nutrition	N	I-Premise
20	(	N	I-Premise
21	P	N	I-Premise
22	<	N	I-Premise
23	.05	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	Changes	N	I-Premise
2	in	N	I-Premise
3	resting	N	I-Premise
4	energy	N	I-Premise
5	expenditure	N	I-Premise
6	and	N	I-Premise
7	biochemical	N	I-Premise
8	tests	N	I-Premise
9	did	N	I-Premise
10	not	N	I-Premise
11	differ	N	I-Premise
12	during	N	I-Premise
13	follow-up	N	I-Premise
14	among	N	I-Premise
15	the	N	I-Premise
16	groups	N	I-Premise
17	.	N	I-Premise

1	Body	N	I-Premise
2	weight	N	I-Premise
3	and	N	I-Premise
4	whole	N	I-Premise
5	body	N	I-Premise
6	fat	N	I-Premise
7	declined	N	I-Premise
8	similarly	N	I-Premise
9	over	N	I-Premise
10	time	N	I-Premise
11	in	N	I-Premise
12	all	N	I-Premise
13	groups	N	I-Premise
14	(	N	I-Premise
15	P	N	I-Premise
16	<	N	I-Premise
17	.005	N	I-Premise
18	)	N	I-Premise
19	,	N	I-Premise
20	whereas	N	O
21	lean	N	I-Premise
22	body	N	I-Premise
23	mass	N	I-Premise
24	was	N	I-Premise
25	unchanged	N	I-Premise
26	during	N	I-Premise
27	follow-up	N	I-Premise
28	compared	N	I-Premise
29	to	N	I-Premise
30	preoperative	N	I-Premise
31	values	N	I-Premise
32	.	N	I-Premise

1	Maximum	N	I-Premise
2	exercise	N	I-Premise
3	capacity	N	I-Premise
4	and	N	I-Premise
5	maximum	N	I-Premise
6	oxygen	N	I-Premise
7	consumption	N	I-Premise
8	were	N	I-Premise
9	normalized	N	I-Premise
10	within	N	I-Premise
11	6	N	I-Premise
12	months	N	I-Premise
13	postoperatively	N	I-Premise
14	in	N	I-Premise
15	all	N	I-Premise
16	groups	N	I-Premise
17	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	recovery	N	I-Premise
7	of	N	I-Premise
8	food	N	I-Premise
9	intake	N	I-Premise
10	among	N	I-Premise
11	the	N	I-Premise
12	groups	N	I-Premise
13	.	N	I-Premise

1	Parenteral	N	I-Claim
2	feeding	N	I-Claim
3	was	N	I-Claim
4	associated	N	I-Claim
5	with	N	I-Claim
6	the	N	I-Claim
7	highest	N	I-Claim
8	rate	N	I-Claim
9	of	N	I-Claim
10	nutrition-related	N	I-Claim
11	complications	N	I-Claim
12	,	N	I-Claim
13	whereas	N	O
14	enteral	N	I-Claim
15	feeding	N	I-Claim
16	reduced	N	I-Claim
17	quality	N	I-Claim
18	of	N	I-Claim
19	life	N	I-Claim
20	most	N	I-Claim
21	extensively	N	I-Claim
22	.	N	I-Claim

1	After	N	I-Claim
2	major	N	I-Claim
3	surgery	N	I-Claim
4	,	N	I-Claim
5	specialized	N	I-Claim
6	supportive	N	I-Claim
7	enteral	N	I-Claim
8	and	N	I-Claim
9	parenteral	N	I-Claim
10	nutrition	N	I-Claim
11	are	N	I-Claim
12	not	N	I-Claim
13	superior	N	I-Claim
14	to	N	I-Claim
15	oral	N	I-Claim
16	nutrition	N	I-Claim
17	only	N	I-Claim
18	when	N	I-Claim
19	guided	N	I-Claim
20	by	N	I-Claim
21	a	N	I-Claim
22	dietitian	N	I-Claim
23	.	N	I-Claim

1	Facial	N	I-Claim
2	hirsutism	N	I-Claim
3	is	N	I-Claim
4	one	N	I-Claim
5	of	N	I-Claim
6	the	N	I-Claim
7	characteristic	N	I-Claim
8	features	N	I-Claim
9	of	N	I-Claim
10	polycystic	N	I-Claim
11	ovary	N	I-Claim
12	syndrome	N	I-Claim
13	(	N	I-Claim
14	PCOS	N	I-Claim
15	)	N	I-Claim
16	,	N	I-Claim
17	and	N	I-Claim
18	this	N	I-Claim
19	can	N	I-Claim
20	lead	N	I-Claim
21	to	N	I-Claim
22	high	N	I-Claim
23	levels	N	I-Claim
24	of	N	I-Claim
25	depression	N	I-Claim
26	and	N	I-Claim
27	anxiety	N	I-Claim
28	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	impact	N	O
5	of	N	O
6	laser	N	O
7	treatment	N	O
8	on	N	O
9	the	N	O
10	severity	N	O
11	of	N	O
12	facial	N	O
13	hirsutism	N	O
14	and	N	O
15	on	N	O
16	psychological	N	O
17	morbidity	N	O
18	in	N	O
19	women	N	O
20	with	N	O
21	PCOS	N	O
22	.	N	O

1	A	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	of	N	O
6	five	N	O
7	high-fluence	N	O
8	treatments	N	O
9	(	N	O
10	intervention	N	O
11	)	N	O
12	vs.	N	O
13	five	N	O
14	low-fluence	N	O
15	treatments	N	O
16	(	N	O
17	control	N	O
18	)	N	O
19	was	N	O
20	performed	N	O
21	over	N	O
22	6	N	O
23	months	N	O
24	in	N	O
25	a	N	O
26	National	N	O
27	Health	N	O
28	Service	N	O
29	teaching	N	O
30	hospital	N	O
31	.	N	O

1	Subjects	N	O
2	were	N	O
3	88	N	O
4	women	N	O
5	with	N	O
6	facial	N	O
7	hirsutism	N	O
8	due	N	O
9	to	N	O
10	PCOS	N	O
11	recruited	N	O
12	from	N	O
13	hospital	N	O
14	outpatient	N	O
15	clinics	N	O
16	and	N	O
17	a	N	O
18	patient	N	O
19	support	N	O
20	group	N	O
21	in	N	O
22	2001-2002	N	O
23	.	N	O

1	The	N	O
2	main	N	O
3	outcomes	N	O
4	were	N	O
5	self-reported	N	O
6	severity	N	O
7	of	N	O
8	facial	N	O
9	hair	N	O
10	(	N	O
11	measured	N	O
12	on	N	O
13	a	N	O
14	scale	N	O
15	of	N	O
16	1-10	N	O
17	)	N	O
18	,	N	O
19	depression	N	O
20	,	N	O
21	anxiety	N	O
22	(	N	O
23	measured	N	O
24	on	N	O
25	the	N	O
26	Hospital	N	O
27	Anxiety	N	O
28	and	N	O
29	Depression	N	O
30	Scale	N	O
31	)	N	O
32	and	N	O
33	quality	N	O
34	of	N	O
35	life	N	O
36	(	N	O
37	measured	N	O
38	on	N	O
39	the	N	O
40	WHOQOL-BREF	N	O
41	)	N	O
42	.	N	O

1	Self-reported	N	I-Premise
2	severity	N	I-Premise
3	of	N	I-Premise
4	facial	N	I-Premise
5	hair	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	intervention	N	I-Premise
9	group	N	I-Premise
10	(	N	I-Premise
11	n	N	I-Premise
12	=	N	I-Premise
13	51	N	I-Premise
14	)	N	I-Premise
15	fell	N	I-Premise
16	from	N	I-Premise
17	7.3	N	I-Premise
18	to	N	I-Premise
19	3.6	N	I-Premise
20	over	N	I-Premise
21	the	N	I-Premise
22	6-month	N	I-Premise
23	study	N	I-Premise
24	period	N	I-Premise
25	;	N	I-Premise
26	for	N	I-Premise
27	the	N	I-Premise
28	control	N	I-Premise
29	group	N	I-Premise
30	(	N	I-Premise
31	n	N	I-Premise
32	=	N	I-Premise
33	37	N	I-Premise
34	)	N	I-Premise
35	the	N	I-Premise
36	corresponding	N	I-Premise
37	scores	N	I-Premise
38	were	N	I-Premise
39	7.1	N	I-Premise
40	and	N	I-Premise
41	6.1	N	I-Premise
42	.	N	I-Premise

1	The	N	I-Premise
2	change	N	I-Premise
3	was	N	I-Premise
4	significantly	N	I-Premise
5	greater	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	intervention	N	I-Premise
9	group	N	I-Premise
10	[	N	I-Premise
11	ancova	N	I-Premise
12	F	N	I-Premise
13	(	N	I-Premise
14	(	N	I-Premise
15	1,83	N	I-Premise
16	)	N	I-Premise
17	)	N	I-Premise
18	=	N	I-Premise
19	24.5	N	I-Premise
20	,	N	I-Premise
21	P	N	I-Premise
22	<	N	I-Premise
23	0.05	N	I-Premise
24	]	N	I-Premise
25	.	N	I-Premise

1	Self-reported	N	I-Premise
2	time	N	I-Premise
3	spent	N	I-Premise
4	on	N	I-Premise
5	hair	N	I-Premise
6	removal	N	I-Premise
7	declined	N	I-Premise
8	from	N	I-Premise
9	112	N	I-Premise
10	to	N	I-Premise
11	21	N	I-Premise
12	min	N	I-Premise
13	per	N	I-Premise
14	week	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	intervention	N	I-Premise
18	group	N	I-Premise
19	and	N	I-Premise
20	from	N	I-Premise
21	92	N	I-Premise
22	to	N	I-Premise
23	56	N	I-Premise
24	min	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	control	N	I-Premise
28	group	N	I-Premise
29	[	N	I-Premise
30	F	N	I-Premise
31	(	N	I-Premise
32	(	N	I-Premise
33	1,80	N	I-Premise
34	)	N	I-Premise
35	)	N	I-Premise
36	=	N	I-Premise
37	10.2	N	I-Premise
38	,	N	I-Premise
39	P	N	I-Premise
40	<	N	I-Premise
41	/=	N	I-Premise
42	0.05	N	I-Premise
43	]	N	I-Premise
44	.	N	I-Premise

1	Mean	N	I-Premise
2	depression	N	I-Premise
3	scores	N	I-Premise
4	fell	N	I-Premise
5	from	N	I-Premise
6	6.7	N	I-Premise
7	to	N	I-Premise
8	3.6	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	intervention	N	I-Premise
12	group	N	I-Premise
13	,	N	I-Premise
14	compared	N	I-Premise
15	with	N	I-Premise
16	6.1	N	I-Premise
17	to	N	I-Premise
18	5.4	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	control	N	I-Premise
22	group	N	I-Premise
23	[	N	I-Premise
24	F	N	I-Premise
25	(	N	I-Premise
26	(	N	I-Premise
27	1,83	N	I-Premise
28	)	N	I-Premise
29	)	N	I-Premise
30	=	N	I-Premise
31	14.7	N	I-Premise
32	,	N	I-Premise
33	P	N	I-Premise
34	<	N	I-Premise
35	0.05	N	I-Premise
36	]	N	I-Premise
37	.	N	I-Premise

1	A	N	I-Premise
2	similar	N	I-Premise
3	change	N	I-Premise
4	was	N	I-Premise
5	seen	N	I-Premise
6	for	N	I-Premise
7	mean	N	I-Premise
8	anxiety	N	I-Premise
9	scores	N	I-Premise
10	:	N	I-Premise
11	intervention	N	I-Premise
12	11.1	N	I-Premise
13	to	N	I-Premise
14	8.2	N	I-Premise
15	,	N	I-Premise
16	control	N	I-Premise
17	9.6	N	I-Premise
18	to	N	I-Premise
19	9.3	N	I-Premise
20	[	N	I-Premise
21	F	N	I-Premise
22	(	N	I-Premise
23	(	N	I-Premise
24	1,84	N	I-Premise
25	)	N	I-Premise
26	)	N	I-Premise
27	=	N	I-Premise
28	17.8	N	I-Premise
29	,	N	I-Premise
30	P	N	I-Premise
31	<	N	I-Premise
32	0.05	N	I-Premise
33	]	N	I-Premise
34	.	N	I-Premise

1	Psychological	N	I-Premise
2	quality	N	I-Premise
3	of	N	I-Premise
4	life	N	I-Premise
5	also	N	I-Premise
6	improved	N	I-Premise
7	more	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	intervention	N	I-Premise
11	group	N	I-Premise
12	,	N	I-Premise
13	from	N	I-Premise
14	49.6	N	I-Premise
15	to	N	I-Premise
16	61.2	N	I-Premise
17	vs.	N	I-Premise
18	50.1	N	I-Premise
19	to	N	I-Premise
20	51.5	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	control	N	I-Premise
24	group	N	I-Premise
25	[	N	I-Premise
26	F	N	I-Premise
27	(	N	I-Premise
28	(	N	I-Premise
29	1,84	N	I-Premise
30	)	N	I-Premise
31	)	N	I-Premise
32	=	N	I-Premise
33	10.9	N	I-Premise
34	,	N	I-Premise
35	P	N	I-Premise
36	<	N	I-Premise
37	0.05	N	I-Premise
38	]	N	I-Premise
39	.	N	I-Premise

1	Laser	N	I-Claim
2	treatment	N	I-Claim
3	appeared	N	I-Claim
4	to	N	I-Claim
5	reduce	N	I-Claim
6	the	N	I-Claim
7	severity	N	I-Claim
8	of	N	I-Claim
9	facial	N	I-Claim
10	hair	N	I-Claim
11	and	N	I-Claim
12	time	N	I-Claim
13	spent	N	I-Claim
14	on	N	I-Claim
15	hair	N	I-Claim
16	removal	N	I-Claim
17	as	N	I-Claim
18	well	N	I-Claim
19	as	N	I-Claim
20	alleviating	N	I-Claim
21	depression	N	I-Claim
22	and	N	I-Claim
23	anxiety	N	I-Claim
24	in	N	I-Claim
25	women	N	I-Claim
26	with	N	I-Claim
27	PCOS	N	I-Claim
28	.	N	I-Claim

1	These	N	I-Claim
2	findings	N	I-Claim
3	suggest	N	I-Claim
4	that	N	I-Claim
5	ways	N	I-Claim
6	of	N	I-Claim
7	making	N	I-Claim
8	this	N	I-Claim
9	method	N	I-Claim
10	of	N	I-Claim
11	hair	N	I-Claim
12	removal	N	I-Claim
13	more	N	I-Claim
14	widely	N	I-Claim
15	available	N	I-Claim
16	to	N	I-Claim
17	women	N	I-Claim
18	with	N	I-Claim
19	facial	N	I-Claim
20	hirsutism	N	I-Claim
21	should	N	I-Claim
22	be	N	I-Claim
23	considered	N	I-Claim
24	.	N	I-Claim

1	For	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	anthracycline-pretreated	N	I-Claim
5	metastatic	N	I-Claim
6	breast	N	I-Claim
7	carcinoma	N	I-Claim
8	,	N	I-Claim
9	capecitabine	N	I-Claim
10	plus	N	I-Claim
11	docetaxel	N	I-Claim
12	significantly	N	I-Claim
13	increased	N	I-Claim
14	overall	N	I-Claim
15	survival	N	I-Claim
16	compared	N	I-Claim
17	with	N	I-Claim
18	docetaxel	N	I-Claim
19	alone	N	I-Claim
20	.	N	I-Claim

1	The	N	O
2	current	N	O
3	study	N	O
4	evaluated	N	O
5	the	N	O
6	cost-effectiveness	N	O
7	of	N	O
8	the	N	O
9	capecitabine/docetaxel	N	O
10	combination	N	O
11	versus	N	O
12	docetaxel	N	O
13	monotherapy	N	O
14	,	N	O
15	comparing	N	O
16	the	N	O
17	gain	N	O
18	in	N	O
19	quality-adjusted	N	O
20	survival	N	O
21	with	N	O
22	associated	N	O
23	health	N	O
24	care	N	O
25	costs	N	O
26	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	receive	N	O
6	21-day	N	O
7	cycles	N	O
8	of	N	O
9	oral	N	O
10	capecitabine	N	O
11	1250	N	O
12	mg/m2	N	O
13	twice	N	O
14	daily	N	O
15	,	N	O
16	on	N	O
17	Days	N	O
18	1-14	N	O
19	,	N	O
20	plus	N	O
21	docetaxel	N	O
22	75	N	O
23	mg/m2	N	O
24	Day	N	O
25	1	N	O
26	(	N	O
27	n	N	O
28	=	N	O
29	255	N	O
30	)	N	O
31	,	N	O
32	or	N	O
33	docetaxel	N	O
34	100	N	O
35	mg/m2	N	O
36	on	N	O
37	Day	N	O
38	1	N	O
39	(	N	O
40	n	N	O
41	=	N	O
42	256	N	O
43	)	N	O
44	.	N	O

1	Health	N	O
2	and	N	O
3	cost	N	O
4	outcomes	N	O
5	in	N	O
6	the	N	O
7	two	N	O
8	arms	N	O
9	were	N	O
10	compared	N	O
11	,	N	O
12	and	N	O
13	cost-effectiveness	N	O
14	was	N	O
15	estimated	N	O
16	.	N	O

1	Data	N	O
2	on	N	O
3	survival	N	O
4	time	N	O
5	and	N	O
6	medical	N	O
7	care	N	O
8	resource	N	O
9	use	N	O
10	were	N	O
11	prospectively	N	O
12	collected	N	O
13	in	N	O
14	the	N	O
15	trial	N	O
16	.	N	O

1	Costs	N	O
2	associated	N	O
3	with	N	O
4	medical	N	O
5	care	N	O
6	resource	N	O
7	use	N	O
8	and	N	O
9	quality-of-life	N	O
10	adjustments	N	O
11	were	N	O
12	obtained	N	O
13	from	N	O
14	the	N	O
15	published	N	O
16	literature	N	O
17	.	N	O

1	The	N	O
2	incremental	N	O
3	cost-effectiveness	N	O
4	ratio	N	O
5	was	N	O
6	calculated	N	O
7	as	N	O
8	the	N	O
9	cost	N	O
10	per	N	O
11	quality-adjusted	N	O
12	life	N	O
13	year	N	O
14	(	N	O
15	QALY	N	O
16	)	N	O
17	gained	N	O
18	.	N	O

1	Capecitabine/docetaxel	N	I-Premise
2	increased	N	I-Premise
3	the	N	I-Premise
4	median	N	I-Premise
5	overall	N	I-Premise
6	survival	N	I-Premise
7	by	N	I-Premise
8	3	N	I-Premise
9	months	N	I-Premise
10	compared	N	I-Premise
11	with	N	I-Premise
12	docetaxel	N	I-Premise
13	alone	N	I-Premise
14	(	N	I-Premise
15	14.5	N	I-Premise
16	vs.	N	I-Premise
17	11.5	N	I-Premise
18	months	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	mean	N	I-Premise
3	quality-adjusted	N	I-Premise
4	survival	N	I-Premise
5	was	N	I-Premise
6	increased	N	I-Premise
7	by	N	I-Premise
8	1.8	N	I-Premise
9	months	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	capecitabine/docetaxel	N	I-Premise
13	group	N	I-Premise
14	.	N	I-Premise

1	The	N	I-Premise
2	total	N	I-Premise
3	medical-resource	N	I-Premise
4	utilization	N	I-Premise
5	cost	N	I-Premise
6	per	N	I-Premise
7	patient	N	I-Premise
8	was	N	I-Premise
9	8.9	N	I-Premise
10	%	N	I-Premise
11	higher	N	I-Premise
12	with	N	I-Premise
13	the	N	I-Premise
14	combination	N	I-Premise
15	:	N	I-Premise
16	24,475	N	I-Premise
17	dollars	N	I-Premise
18	for	N	I-Premise
19	combination	N	I-Premise
20	therapy	N	I-Premise
21	versus	N	I-Premise
22	22,477	N	I-Premise
23	dollars	N	I-Premise
24	for	N	I-Premise
25	single-agent	N	I-Premise
26	docetaxel	N	I-Premise
27	.	N	I-Premise

1	The	N	I-Premise
2	mean	N	I-Premise
3	cost	N	I-Premise
4	per	N	I-Premise
5	QALY	N	I-Premise
6	gained	N	I-Premise
7	with	N	I-Premise
8	combination	N	I-Premise
9	therapy	N	I-Premise
10	was	N	I-Premise
11	13,558	N	I-Premise
12	dollars	N	I-Premise
13	(	N	I-Premise
14	standard	N	I-Premise
15	deviation	N	I-Premise
16	,	N	I-Premise
17	6742	N	I-Premise
18	dollars	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	Cost	N	I-Premise
2	savings	N	I-Premise
3	due	N	I-Premise
4	to	N	I-Premise
5	reduced	N	I-Premise
6	docetaxel	N	I-Premise
7	dose	N	I-Premise
8	and	N	I-Premise
9	hospital	N	I-Premise
10	use	N	I-Premise
11	were	N	I-Premise
12	the	N	I-Premise
13	major	N	I-Premise
14	cost	N	I-Premise
15	offsets	N	I-Premise
16	with	N	I-Premise
17	the	N	I-Premise
18	combination	N	I-Premise
19	.	N	I-Premise

1	Sensitivity	N	I-Premise
2	analyses	N	I-Premise
3	showed	N	I-Premise
4	that	N	I-Premise
5	varying	N	I-Premise
6	the	N	I-Premise
7	mean	N	I-Premise
8	hospital	N	I-Premise
9	cost	N	I-Premise
10	per	N	I-Premise
11	day	N	I-Premise
12	from	N	I-Premise
13	the	N	I-Premise
14	5th	N	I-Premise
15	to	N	I-Premise
16	the	N	I-Premise
17	95th	N	I-Premise
18	percentile	N	I-Premise
19	resulted	N	I-Premise
20	in	N	I-Premise
21	cost-utility	N	I-Premise
22	ratios	N	I-Premise
23	ranging	N	I-Premise
24	from	N	I-Premise
25	20,326	N	I-Premise
26	dollars	N	I-Premise
27	to	N	I-Premise
28	as	N	I-Premise
29	low	N	I-Premise
30	as	N	I-Premise
31	6360	N	I-Premise
32	dollars	N	I-Premise
33	.	N	I-Premise

1	Capecitabine/docetaxel	N	I-Claim
2	was	N	I-Claim
3	a	N	I-Claim
4	cost-effective	N	I-Claim
5	treatment	N	I-Claim
6	in	N	I-Claim
7	patients	N	I-Claim
8	with	N	I-Claim
9	anthracycline-pretreated	N	I-Claim
10	advanced	N	I-Claim
11	breast	N	I-Claim
12	carcinoma	N	I-Claim
13	,	N	I-Claim
14	and	N	I-Claim
15	had	N	I-Claim
16	an	N	I-Claim
17	incremental	N	I-Claim
18	cost-effectiveness	N	I-Claim
19	ratio	N	I-Claim
20	that	N	I-Claim
21	compares	N	I-Claim
22	very	N	I-Claim
23	favorably	N	I-Claim
24	with	N	I-Claim
25	that	N	I-Claim
26	of	N	I-Claim
27	many	N	I-Claim
28	other	N	I-Claim
29	oncology	N	I-Claim
30	therapies	N	I-Claim
31	.	N	I-Claim

1	We	N	O
2	aimed	N	O
3	to	N	O
4	determine	N	O
5	the	N	O
6	effect	N	O
7	of	N	O
8	dietary	N	O
9	counseling	N	O
10	or	N	O
11	oral	N	O
12	supplements	N	O
13	on	N	O
14	outcome	N	O
15	for	N	O
16	patients	N	O
17	with	N	O
18	cancer	N	O
19	,	N	O
20	specifically	N	O
21	,	N	O
22	nutritional	N	O
23	outcome	N	O
24	,	N	O
25	morbidity	N	O
26	,	N	O
27	and	N	O
28	quality	N	O
29	of	N	O
30	life	N	O
31	(	N	O
32	QOL	N	O
33	)	N	O
34	,	N	O
35	during	N	O
36	and	N	O
37	3	N	O
38	months	N	O
39	after	N	O
40	radiotherapy	N	O
41	.	N	O

1	Seventy-five	N	O
2	patients	N	O
3	with	N	O
4	head	N	O
5	and	N	O
6	neck	N	O
7	cancer	N	O
8	who	N	O
9	were	N	O
10	referred	N	O
11	for	N	O
12	radiotherapy	N	O
13	(	N	O
14	RT	N	O
15	)	N	O
16	were	N	O
17	randomized	N	O
18	to	N	O
19	the	N	O
20	following	N	O
21	groups	N	O
22	:	N	O
23	group	N	O
24	1	N	O
25	(	N	O
26	n	N	O
27	=	N	O
28	25	N	O
29	)	N	O
30	,	N	O
31	patients	N	O
32	who	N	O
33	received	N	O
34	dietary	N	O
35	counseling	N	O
36	with	N	O
37	regular	N	O
38	foods	N	O
39	;	N	O
40	group	N	O
41	2	N	O
42	(	N	O
43	n	N	O
44	=	N	O
45	25	N	O
46	)	N	O
47	,	N	O
48	patients	N	O
49	who	N	O
50	maintained	N	O
51	usual	N	O
52	diet	N	O
53	plus	N	O
54	supplements	N	O
55	;	N	O
56	and	N	O
57	group	N	O
58	3	N	O
59	(	N	O
60	n	N	O
61	=	N	O
62	25	N	O
63	)	N	O
64	,	N	O
65	patients	N	O
66	who	N	O
67	maintained	N	O
68	intake	N	O
69	ad	N	O
70	lib	N	O
71	.	N	O

1	Nutritional	N	O
2	intake	N	O
3	(	N	O
4	determined	N	O
5	by	N	O
6	diet	N	O
7	history	N	O
8	)	N	O
9	and	N	O
10	status	N	O
11	(	N	O
12	determined	N	O
13	by	N	O
14	Ottery	N	O
15	's	N	O
16	Subjective	N	O
17	Global	N	O
18	Assessment	N	O
19	)	N	O
20	,	N	O
21	and	N	O
22	QOL	N	O
23	(	N	O
24	determined	N	O
25	by	N	O
26	the	N	O
27	European	N	O
28	Organization	N	O
29	for	N	O
30	the	N	O
31	Research	N	O
32	and	N	O
33	Treatment	N	O
34	of	N	O
35	Cancer	N	O
36	Quality	N	O
37	of	N	O
38	Life	N	O
39	Questionnaire	N	O
40	version	N	O
41	3.0	N	O
42	[	N	O
43	EORTC	N	O
44	QLQ-C30	N	O
45	]	N	O
46	)	N	O
47	were	N	O
48	evaluated	N	O
49	at	N	O
50	baseline	N	O
51	,	N	O
52	at	N	O
53	the	N	O
54	end	N	O
55	of	N	O
56	RT	N	O
57	,	N	O
58	and	N	O
59	at	N	O
60	3	N	O
61	months	N	O
62	.	N	O

1	Energy	N	I-Premise
2	intake	N	I-Premise
3	after	N	I-Premise
4	RT	N	I-Premise
5	increased	N	I-Premise
6	in	N	I-Premise
7	both	N	I-Premise
8	groups	N	I-Premise
9	1	N	I-Premise
10	and	N	I-Premise
11	2	N	I-Premise
12	(	N	I-Premise
13	p	N	I-Premise
14	<	N	I-Premise
15	or	N	I-Premise
16	=	N	I-Premise
17	.05	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	Protein	N	I-Premise
2	intake	N	I-Premise
3	also	N	I-Premise
4	increased	N	I-Premise
5	in	N	I-Premise
6	both	N	I-Premise
7	groups	N	I-Premise
8	1	N	I-Premise
9	and	N	I-Premise
10	2	N	I-Premise
11	(	N	I-Premise
12	p	N	I-Premise
13	<	N	I-Premise
14	or	N	I-Premise
15	=	N	I-Premise
16	.006	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	Both	N	I-Premise
2	energy	N	I-Premise
3	and	N	I-Premise
4	protein	N	I-Premise
5	intake	N	I-Premise
6	decreased	N	I-Premise
7	significantly	N	I-Premise
8	in	N	I-Premise
9	group	N	I-Premise
10	3	N	I-Premise
11	(	N	I-Premise
12	p	N	I-Premise
13	<	N	I-Premise
14	.01	N	I-Premise
15	)	N	I-Premise
16	.	N	I-Premise

1	At	N	I-Premise
2	3	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	group	N	I-Premise
6	1	N	I-Premise
7	maintained	N	I-Premise
8	intakes	N	I-Premise
9	,	N	I-Premise
10	whereas	N	I-Premise
11	groups	N	I-Premise
12	2	N	I-Premise
13	and	N	I-Premise
14	3	N	I-Premise
15	returned	N	I-Premise
16	to	N	I-Premise
17	or	N	I-Premise
18	below	N	I-Premise
19	baseline	N	I-Premise
20	levels	N	I-Premise
21	.	N	I-Premise

1	After	N	I-Premise
2	RT	N	I-Premise
3	,	N	I-Premise
4	>	N	I-Premise
5	90	N	I-Premise
6	%	N	I-Premise
7	of	N	I-Premise
8	patients	N	I-Premise
9	experienced	N	I-Premise
10	RT	N	I-Premise
11	toxicity	N	I-Premise
12	;	N	I-Premise
13	this	N	I-Premise
14	was	N	I-Premise
15	not	N	I-Premise
16	significantly	N	I-Premise
17	different	N	I-Premise
18	between	N	I-Premise
19	groups	N	I-Premise
20	,	N	I-Premise
21	with	N	I-Premise
22	a	N	I-Premise
23	trend	N	I-Premise
24	for	N	I-Premise
25	reduced	N	I-Premise
26	symptomatology	N	I-Premise
27	in	N	I-Premise
28	group	N	I-Premise
29	1	N	I-Premise
30	versus	N	I-Premise
31	group	N	I-Premise
32	2/group	N	I-Premise
33	3	N	I-Premise
34	(	N	I-Premise
35	p	N	I-Premise
36	<	N	I-Premise
37	.07	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	At	N	I-Premise
2	3	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	the	N	I-Premise
6	reduction	N	I-Premise
7	of	N	I-Premise
8	incidence/severity	N	I-Premise
9	of	N	I-Premise
10	grade	N	I-Premise
11	1+2	N	I-Premise
12	anorexia	N	I-Premise
13	,	N	I-Premise
14	nausea/vomiting	N	I-Premise
15	,	N	I-Premise
16	xerostomia	N	I-Premise
17	,	N	I-Premise
18	and	N	I-Premise
19	dysgeusia	N	I-Premise
20	was	N	I-Premise
21	different	N	I-Premise
22	:	N	I-Premise
23	90	N	I-Premise
24	%	N	I-Premise
25	of	N	I-Premise
26	the	N	I-Premise
27	patients	N	I-Premise
28	improved	N	I-Premise
29	in	N	I-Premise
30	group	N	I-Premise
31	1	N	I-Premise
32	versus	N	I-Premise
33	67	N	I-Premise
34	%	N	I-Premise
35	in	N	I-Premise
36	group	N	I-Premise
37	2	N	I-Premise
38	versus	N	I-Premise
39	51	N	I-Premise
40	%	N	I-Premise
41	in	N	I-Premise
42	group	N	I-Premise
43	3	N	I-Premise
44	(	N	I-Premise
45	p	N	I-Premise
46	<	N	I-Premise
47	.0001	N	I-Premise
48	)	N	I-Premise
49	.	N	I-Premise

1	After	N	I-Premise
2	RT	N	I-Premise
3	,	N	I-Premise
4	QOL	N	I-Premise
5	function	N	I-Premise
6	scores	N	I-Premise
7	improved	N	I-Premise
8	(	N	I-Premise
9	p	N	I-Premise
10	<	N	I-Premise
11	.003	N	I-Premise
12	)	N	I-Premise
13	proportionally	N	I-Premise
14	with	N	I-Premise
15	improved	N	I-Premise
16	nutritional	N	I-Premise
17	intake	N	I-Premise
18	and	N	I-Premise
19	status	N	I-Premise
20	in	N	I-Premise
21	group	N	I-Premise
22	1/group	N	I-Premise
23	2	N	I-Premise
24	(	N	I-Premise
25	p	N	I-Premise
26	<	N	I-Premise
27	.05	N	I-Premise
28	)	N	I-Premise
29	and	N	I-Premise
30	worsened	N	I-Premise
31	in	N	I-Premise
32	group	N	I-Premise
33	3	N	I-Premise
34	(	N	I-Premise
35	p	N	I-Premise
36	<	N	I-Premise
37	.05	N	I-Premise
38	)	N	I-Premise
39	;	N	I-Premise
40	at	N	I-Premise
41	3	N	I-Premise
42	months	N	I-Premise
43	,	N	I-Premise
44	patients	N	I-Premise
45	in	N	I-Premise
46	group	N	I-Premise
47	1	N	I-Premise
48	maintained	N	I-Premise
49	or	N	I-Premise
50	improved	N	I-Premise
51	overall	N	I-Premise
52	QOL	N	I-Premise
53	,	N	I-Premise
54	whereas	N	I-Premise
55	patients	N	I-Premise
56	in	N	I-Premise
57	groups	N	I-Premise
58	2	N	I-Premise
59	and	N	I-Premise
60	3	N	I-Premise
61	maintained	N	I-Premise
62	or	N	I-Premise
63	worsened	N	I-Premise
64	overall	N	I-Premise
65	QOL	N	I-Premise
66	.	N	I-Premise

1	During	N	I-Claim
2	RT	N	I-Claim
3	,	N	I-Claim
4	nutritional	N	I-Claim
5	interventions	N	I-Claim
6	positively	N	I-Claim
7	influenced	N	I-Claim
8	outcomes	N	I-Claim
9	,	N	I-Claim
10	and	N	I-Claim
11	counseling	N	I-Claim
12	was	N	I-Claim
13	of	N	I-Claim
14	similar/higher	N	I-Claim
15	benefit	N	I-Claim
16	;	N	I-Claim
17	in	N	I-Claim
18	the	N	I-Claim
19	medium	N	I-Claim
20	term	N	I-Claim
21	,	N	I-Claim
22	only	N	I-Claim
23	counseling	N	I-Claim
24	exerted	N	I-Claim
25	a	N	I-Claim
26	significant	N	I-Claim
27	impact	N	I-Claim
28	on	N	I-Claim
29	patient	N	I-Claim
30	outcomes	N	I-Claim
31	.	N	I-Claim

1	This	N	O
2	is	N	O
3	a	N	O
4	randomized	N	O
5	phase	N	O
6	II	N	O
7	study	N	O
8	designed	N	O
9	to	N	O
10	compare	N	O
11	the	N	O
12	toxicity	N	O
13	profile	N	O
14	of	N	O
15	a	N	O
16	non-platinum-based	N	O
17	with	N	O
18	a	N	O
19	platinum-based	N	O
20	regimen	N	O
21	in	N	O
22	the	N	O
23	treatment	N	O
24	of	N	O
25	advanced	N	O
26	non-small	N	O
27	cell	N	O
28	lung	N	O
29	cancer	N	O
30	.	N	O

1	Eighty-nine	N	O
2	chemotherapy-naïve	N	O
3	patients	N	O
4	were	N	O
5	randomized	N	O
6	either	N	O
7	to	N	O
8	gemcitabine	N	O
9	(	N	O
10	1,000	N	O
11	mg/m2	N	O
12	,	N	O
13	30-min	N	O
14	infusion	N	O
15	on	N	O
16	days	N	O
17	1	N	O
18	,	N	O
19	8	N	O
20	and	N	O
21	15	N	O
22	)	N	O
23	and	N	O
24	oral	N	O
25	etoposide	N	O
26	(	N	O
27	50	N	O
28	mg	N	O
29	,	N	O
30	days	N	O
31	1-14	N	O
32	;	N	O
33	GE	N	O
34	group	N	O
35	)	N	O
36	or	N	O
37	gemcitabine	N	O
38	at	N	O
39	the	N	O
40	same	N	O
41	schedule	N	O
42	and	N	O
43	cisplatin	N	O
44	(	N	O
45	75	N	O
46	mg/m2	N	O
47	on	N	O
48	day	N	O
49	15	N	O
50	;	N	O
51	GP	N	O
52	group	N	O
53	)	N	O
54	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	is	N	O
5	toxicity	N	O
6	,	N	O
7	and	N	O
8	secondary	N	O
9	endpoints	N	O
10	include	N	O
11	response	N	O
12	rate	N	O
13	,	N	O
14	survival	N	O
15	outcome	N	O
16	and	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QOL	N	O
22	)	N	O
23	.	N	O

1	The	N	I-Premise
2	incidence	N	I-Premise
3	of	N	I-Premise
4	WHO	N	I-Premise
5	grade	N	I-Premise
6	3	N	I-Premise
7	or	N	I-Premise
8	4	N	I-Premise
9	anemia	N	I-Premise
10	,	N	I-Premise
11	neutropenia	N	I-Premise
12	and	N	I-Premise
13	thrombocytopenia	N	I-Premise
14	was	N	I-Premise
15	29	N	I-Premise
16	,	N	I-Premise
17	44	N	I-Premise
18	and	N	I-Premise
19	22	N	I-Premise
20	%	N	I-Premise
21	(	N	I-Premise
22	GE	N	I-Premise
23	group	N	I-Premise
24	)	N	I-Premise
25	,	N	I-Premise
26	and	N	I-Premise
27	28	N	I-Premise
28	,	N	I-Premise
29	49	N	I-Premise
30	and	N	I-Premise
31	23	N	I-Premise
32	%	N	I-Premise
33	(	N	I-Premise
34	GP	N	I-Premise
35	group	N	I-Premise
36	)	N	I-Premise
37	,	N	I-Premise
38	respectively	N	I-Premise
39	(	N	I-Premise
40	p	N	I-Premise
41	=	N	I-Premise
42	0.75	N	I-Premise
43	,	N	I-Premise
44	0.95	N	I-Premise
45	and	N	I-Premise
46	0.87	N	I-Premise
47	,	N	I-Premise
48	respectively	N	I-Premise
49	)	N	I-Premise
50	.	N	I-Premise

1	The	N	I-Premise
2	rate	N	I-Premise
3	of	N	I-Premise
4	grade	N	I-Premise
5	2	N	I-Premise
6	or	N	I-Premise
7	above	N	I-Premise
8	nausea	N	I-Premise
9	was	N	I-Premise
10	numerically	N	I-Premise
11	higher	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	GP	N	I-Premise
15	arm	N	I-Premise
16	,	N	I-Premise
17	but	N	I-Premise
18	the	N	I-Premise
19	difference	N	I-Premise
20	was	N	I-Premise
21	not	N	I-Premise
22	statistically	N	I-Premise
23	significant	N	I-Premise
24	(	N	I-Premise
25	GE	N	I-Premise
26	15.5	N	I-Premise
27	%	N	I-Premise
28	,	N	I-Premise
29	GP	N	I-Premise
30	27.7	N	I-Premise
31	%	N	I-Premise
32	,	N	I-Premise
33	p	N	I-Premise
34	=	N	I-Premise
35	0.20	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	The	N	I-Premise
2	rate	N	I-Premise
3	of	N	I-Premise
4	vomiting	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	GE	N	I-Premise
8	and	N	I-Premise
9	GP	N	I-Premise
10	arms	N	I-Premise
11	was	N	I-Premise
12	20.0	N	I-Premise
13	and	N	I-Premise
14	20.5	N	I-Premise
15	%	N	I-Premise
16	,	N	I-Premise
17	respectively	N	I-Premise
18	(	N	I-Premise
19	p	N	I-Premise
20	=	N	I-Premise
21	0.96	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	subjective	N	I-Premise
4	changes	N	I-Premise
5	in	N	I-Premise
6	QOL	N	I-Premise
7	scores	N	I-Premise
8	on	N	I-Premise
9	nausea	N	I-Premise
10	and	N	I-Premise
11	vomiting	N	I-Premise
12	were	N	I-Premise
13	significantly	N	I-Premise
14	higher	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	GP	N	I-Premise
18	arm	N	I-Premise
19	(	N	I-Premise
20	p	N	I-Premise
21	=	N	I-Premise
22	0.001	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Other	N	I-Premise
2	symptoms	N	I-Premise
3	including	N	I-Premise
4	sore	N	I-Premise
5	mouth	N	I-Premise
6	and	N	I-Premise
7	hair	N	I-Premise
8	loss	N	I-Premise
9	were	N	I-Premise
10	significantly	N	I-Premise
11	higher	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	GE	N	I-Premise
15	arm	N	I-Premise
16	(	N	I-Premise
17	p	N	I-Premise
18	=	N	I-Premise
19	0.003	N	I-Premise
20	and	N	I-Premise
21	0.007	N	I-Premise
22	,	N	I-Premise
23	respectively	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	also	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	observed	N	I-Premise
7	in	N	I-Premise
8	emotional	N	I-Premise
9	(	N	I-Premise
10	p	N	I-Premise
11	=	N	I-Premise
12	0.014	N	I-Premise
13	)	N	I-Premise
14	,	N	I-Premise
15	cognitive	N	I-Premise
16	(	N	I-Premise
17	p	N	I-Premise
18	=	N	I-Premise
19	0.028	N	I-Premise
20	)	N	I-Premise
21	and	N	I-Premise
22	social	N	I-Premise
23	functioning	N	I-Premise
24	(	N	I-Premise
25	p	N	I-Premise
26	=	N	I-Premise
27	0.034	N	I-Premise
28	)	N	I-Premise
29	in	N	I-Premise
30	favor	N	I-Premise
31	of	N	I-Premise
32	GP	N	I-Premise
33	.	N	I-Premise

1	The	N	I-Premise
2	differences	N	I-Premise
3	in	N	I-Premise
4	tumor	N	I-Premise
5	response	N	I-Premise
6	(	N	I-Premise
7	35.5	N	I-Premise
8	and	N	I-Premise
9	46.5	N	I-Premise
10	%	N	I-Premise
11	for	N	I-Premise
12	GE	N	I-Premise
13	and	N	I-Premise
14	GP	N	I-Premise
15	,	N	I-Premise
16	respectively	N	I-Premise
17	)	N	I-Premise
18	were	N	I-Premise
19	not	N	I-Premise
20	significantly	N	I-Premise
21	different	N	I-Premise
22	.	N	I-Premise

1	Median	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	disease	N	I-Premise
5	progression	N	I-Premise
6	(	N	I-Premise
7	33.8	N	I-Premise
8	and	N	I-Premise
9	40.7	N	I-Premise
10	weeks	N	I-Premise
11	,	N	I-Premise
12	respectively	N	I-Premise
13	)	N	I-Premise
14	and	N	I-Premise
15	overall	N	I-Premise
16	survival	N	I-Premise
17	(	N	I-Premise
18	41.4	N	I-Premise
19	and	N	I-Premise
20	57.3	N	I-Premise
21	weeks	N	I-Premise
22	,	N	I-Premise
23	respectively	N	I-Premise
24	)	N	I-Premise
25	were	N	I-Premise
26	of	N	I-Premise
27	borderline	N	I-Premise
28	significance	N	I-Premise
29	in	N	I-Premise
30	favor	N	I-Premise
31	of	N	I-Premise
32	the	N	I-Premise
33	GP	N	I-Premise
34	arm	N	I-Premise
35	(	N	I-Premise
36	p	N	I-Premise
37	=	N	I-Premise
38	0.055	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	This	N	I-Claim
2	toxicity	N	I-Claim
3	profile	N	I-Claim
4	of	N	I-Claim
5	GE	N	I-Claim
6	is	N	I-Claim
7	similar	N	I-Claim
8	to	N	I-Claim
9	GP	N	I-Claim
10	,	N	I-Claim
11	but	N	I-Claim
12	the	N	I-Claim
13	apparent	N	I-Claim
14	inferior	N	I-Claim
15	efficacy	N	I-Claim
16	may	N	I-Claim
17	discourage	N	I-Claim
18	further	N	I-Claim
19	investigation	N	I-Claim
20	.	N	O

1	A	N	O
2	multidimensional	N	O
3	rehabilitation	N	O
4	program	N	O
5	for	N	O
6	cancer	N	O
7	survivors	N	O
8	was	N	O
9	developed	N	O
10	to	N	O
11	overcome	N	O
12	cancer-related	N	O
13	problems	N	O
14	and	N	O
15	to	N	O
16	improve	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	.	N	O

1	The	N	O
2	two	N	O
3	purposes	N	O
4	of	N	O
5	the	N	O
6	study	N	O
7	were	N	O
8	to	N	O
9	describe	N	O
10	the	N	O
11	effectiveness	N	O
12	of	N	O
13	the	N	O
14	program	N	O
15	and	N	O
16	to	N	O
17	obtain	N	O
18	information	N	O
19	about	N	O
20	patient	N	O
21	preferences	N	O
22	for	N	O
23	multi	N	O
24	or	N	O
25	mono	N	O
26	dimensional	N	O
27	rehabilitation	N	O
28	programs	N	O
29	.	N	O

1	cancer	N	O
2	survivors	N	O
3	with	N	O
4	different	N	O
5	diagnoses	N	O
6	,	N	O
7	and	N	O
8	cancer-related	N	O
9	physical	N	O
10	and	N	O
11	psychosocial	N	O
12	problems	N	O
13	.	N	O

1	a	N	O
2	15-week	N	O
3	rehabilitation	N	O
4	program	N	O
5	including	N	O
6	individual	N	O
7	exercise	N	O
8	,	N	O
9	sports	N	O
10	,	N	O
11	psycho-education	N	O
12	,	N	O
13	and	N	O
14	information	N	O
15	.	N	O

1	Group-wise	N	O
2	randomization	N	O
3	was	N	O
4	implemented	N	O
5	by	N	O
6	assigning	N	O
7	one	N	O
8	half	N	O
9	of	N	O
10	the	N	O
11	patients	N	O
12	to	N	O
13	the	N	O
14	complete	N	O
15	program	N	O
16	while	N	O
17	the	N	O
18	other	N	O
19	half	N	O
20	were	N	O
21	allowed	N	O
22	to	N	O
23	choose	N	O
24	which	N	O
25	program	N	O
26	components	N	O
27	they	N	O
28	considered	N	O
29	relevant	N	O
30	.	N	O

1	Health-Related	N	O
2	Quality	N	O
3	of	N	O
4	Life	N	O
5	[	N	O
6	RAND-36	N	O
7	and	N	O
8	Rotterdam	N	O
9	Symptom	N	O
10	Check	N	O
11	List	N	O
12	(	N	O
13	RSCL	N	O
14	)	N	O
15	]	N	O
16	,	N	O
17	exercise	N	O
18	capacity	N	O
19	(	N	O
20	symptom	N	O
21	limited	N	O
22	bicycle	N	O
23	ergometry	N	O
24	)	N	O
25	,	N	O
26	muscle	N	O
27	force	N	O
28	(	N	O
29	hand-held	N	O
30	dynamometry	N	O
31	)	N	O
32	,	N	O
33	and	N	O
34	patient	N	O
35	preferences	N	O
36	.	N	O

1	Measurements	N	O
2	were	N	O
3	performed	N	O
4	before	N	O
5	(	N	O
6	T0	N	O
7	)	N	O
8	and	N	O
9	after	N	O
10	the	N	O
11	rehabilitation	N	O
12	program	N	O
13	(	N	O
14	T1	N	O
15	)	N	O
16	,	N	O
17	and	N	O
18	at	N	O
19	a	N	O
20	3-month	N	O
21	follow-up	N	O
22	(	N	O
23	T2	N	O
24	)	N	O
25	.	N	O

1	After	N	I-Premise
2	the	N	I-Premise
3	rehabilitation	N	I-Premise
4	program	N	I-Premise
5	,	N	I-Premise
6	cancer	N	I-Premise
7	survivors	N	I-Premise
8	(	N	I-Premise
9	n=63	N	I-Premise
10	)	N	I-Premise
11	displayed	N	I-Premise
12	statistically	N	I-Premise
13	significant	N	I-Premise
14	improvements	N	I-Premise
15	on	N	I-Premise
16	health-related	N	I-Premise
17	quality	N	I-Premise
18	of	N	I-Premise
19	life	N	I-Premise
20	with	N	I-Premise
21	effect	N	I-Premise
22	sizes	N	I-Premise
23	(	N	I-Premise
24	ES	N	I-Premise
25	)	N	I-Premise
26	varying	N	I-Premise
27	from	N	I-Premise
28	0.38	N	I-Premise
29	to	N	I-Premise
30	0.99	N	I-Premise
31	(	N	I-Premise
32	RAND-36	N	I-Premise
33	)	N	I-Premise
34	and	N	I-Premise
35	from	N	I-Premise
36	-0.34	N	I-Premise
37	to	N	I-Premise
38	-0.57	N	I-Premise
39	(	N	I-Premise
40	RSCL	N	I-Premise
41	)	N	I-Premise
42	,	N	I-Premise
43	most	N	I-Premise
44	persistent	N	I-Premise
45	at	N	I-Premise
46	3-month	N	I-Premise
47	follow-up	N	I-Premise
48	.	N	I-Premise

1	Furthermore	N	I-Premise
2	,	N	I-Premise
3	statistically	N	I-Premise
4	significant	N	I-Premise
5	improvements	N	I-Premise
6	in	N	I-Premise
7	exercise	N	I-Premise
8	capacity	N	I-Premise
9	and	N	I-Premise
10	muscle	N	I-Premise
11	force	N	I-Premise
12	of	N	I-Premise
13	upper	N	I-Premise
14	and	N	I-Premise
15	lower	N	I-Premise
16	extremities	N	I-Premise
17	were	N	I-Premise
18	displayed	N	I-Premise
19	after	N	I-Premise
20	rehabilitation	N	I-Premise
21	.	N	I-Premise

1	If	N	I-Premise
2	offered	N	I-Premise
3	a	N	I-Premise
4	choice	N	I-Premise
5	,	N	I-Premise
6	80	N	I-Premise
7	%	N	I-Premise
8	of	N	I-Premise
9	the	N	I-Premise
10	patients	N	I-Premise
11	prior	N	I-Premise
12	to	N	I-Premise
13	start	N	I-Premise
14	and	N	I-Premise
15	58	N	I-Premise
16	%	N	I-Premise
17	of	N	I-Premise
18	the	N	I-Premise
19	patients	N	I-Premise
20	after	N	I-Premise
21	completion	N	I-Premise
22	of	N	I-Premise
23	the	N	I-Premise
24	program	N	I-Premise
25	indicated	N	I-Premise
26	that	N	I-Premise
27	they	N	I-Premise
28	preferred	N	I-Premise
29	the	N	I-Premise
30	entire	N	I-Premise
31	multidimensional	N	I-Premise
32	program	N	I-Premise
33	.	N	I-Premise

1	A	N	I-Claim
2	multidimensional	N	I-Claim
3	rehabilitation	N	I-Claim
4	program	N	I-Claim
5	has	N	I-Claim
6	statistically	N	I-Claim
7	and	N	I-Claim
8	clinically	N	I-Claim
9	relevant	N	I-Claim
10	beneficial	N	I-Claim
11	effects	N	I-Claim
12	on	N	I-Claim
13	health-related	N	I-Claim
14	quality	N	I-Claim
15	of	N	I-Claim
16	life	N	I-Claim
17	,	N	I-Claim
18	exercise	N	I-Claim
19	capacity	N	I-Claim
20	,	N	I-Claim
21	and	N	I-Claim
22	muscle	N	I-Claim
23	force	N	I-Claim
24	in	N	I-Claim
25	cancer	N	I-Claim
26	patients	N	I-Claim
27	with	N	I-Claim
28	different	N	I-Claim
29	diagnoses	N	I-Claim
30	.	N	I-Claim

1	Furthermore	N	O
2	,	N	O
3	if	N	I-Claim
4	offered	N	I-Claim
5	the	N	I-Claim
6	choice	N	I-Claim
7	,	N	I-Claim
8	the	N	I-Claim
9	majority	N	I-Claim
10	of	N	I-Claim
11	cancer	N	I-Claim
12	survivors	N	I-Claim
13	seem	N	I-Claim
14	to	N	I-Claim
15	prefer	N	I-Claim
16	multidimensional	N	I-Claim
17	programs	N	I-Claim
18	to	N	I-Claim
19	programs	N	I-Claim
20	with	N	I-Claim
21	only	N	I-Claim
22	one	N	I-Claim
23	component	N	I-Claim
24	.	N	I-Claim

1	Evidence	N	I-Claim
2	suggests	N	I-Claim
3	that	N	I-Claim
4	the	N	I-Claim
5	re-entry	N	I-Claim
6	phase	N	I-Claim
7	(	N	I-Claim
8	ie	N	I-Claim
9	,	N	I-Claim
10	early	N	I-Claim
11	period	N	I-Claim
12	after	N	I-Claim
13	medical	N	I-Claim
14	treatment	N	I-Claim
15	completion	N	I-Claim
16	)	N	I-Claim
17	presents	N	I-Claim
18	distinct	N	I-Claim
19	challenges	N	I-Claim
20	for	N	I-Claim
21	cancer	N	I-Claim
22	patients	N	I-Claim
23	.	N	I-Claim

1	To	N	O
2	facilitate	N	O
3	the	N	O
4	transition	N	O
5	to	N	O
6	recovery	N	O
7	,	N	O
8	we	N	O
9	conducted	N	O
10	the	N	O
11	Moving	N	O
12	Beyond	N	O
13	Cancer	N	O
14	(	N	O
15	MBC	N	O
16	)	N	O
17	trial	N	O
18	,	N	O
19	a	N	O
20	multisite	N	O
21	,	N	O
22	randomized	N	O
23	,	N	O
24	controlled	N	O
25	trial	N	O
26	of	N	O
27	psychoeducational	N	O
28	interventions	N	O
29	for	N	O
30	breast	N	O
31	cancer	N	O
32	patients	N	O
33	.	N	O

1	Breast	N	O
2	cancer	N	O
3	patients	N	O
4	were	N	O
5	registered	N	O
6	within	N	O
7	6	N	O
8	weeks	N	O
9	after	N	O
10	surgery	N	O
11	.	N	O

1	After	N	O
2	medical	N	O
3	treatment	N	O
4	,	N	O
5	they	N	O
6	completed	N	O
7	baseline	N	O
8	measures	N	O
9	and	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	to	N	O
14	standard	N	O
15	National	N	O
16	Cancer	N	O
17	Institute	N	O
18	print	N	O
19	material	N	O
20	(	N	O
21	CTL	N	O
22	)	N	O
23	;	N	O
24	standard	N	O
25	print	N	O
26	material	N	O
27	and	N	O
28	peer-modeling	N	O
29	videotape	N	O
30	(	N	O
31	VID	N	O
32	)	N	O
33	;	N	O
34	or	N	O
35	standard	N	O
36	print	N	O
37	material	N	O
38	,	N	O
39	videotape	N	O
40	,	N	O
41	two	N	O
42	sessions	N	O
43	with	N	O
44	a	N	O
45	trained	N	O
46	cancer	N	O
47	educator	N	O
48	,	N	O
49	and	N	O
50	informational	N	O
51	workbook	N	O
52	(	N	O
53	EDU	N	O
54	)	N	O
55	.	N	O

1	Two	N	O
2	primary	N	O
3	end	N	O
4	points	N	O
5	were	N	O
6	examined	N	O
7	:	N	O
8	energy/fatigue	N	O
9	and	N	O
10	cancer-specific	N	O
11	distress	N	O
12	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	were	N	O
5	depressive	N	O
6	symptoms	N	O
7	and	N	O
8	post-traumatic	N	O
9	growth	N	O
10	.	N	O

1	Perceived	N	O
2	preparedness	N	O
3	for	N	O
4	re-entry	N	O
5	was	N	O
6	analyzed	N	O
7	as	N	O
8	a	N	O
9	moderator	N	O
10	of	N	O
11	effects	N	O
12	.	N	O

1	Of	N	O
2	558	N	O
3	women	N	O
4	randomly	N	O
5	assigned	N	O
6	to	N	O
7	treatment	N	O
8	,	N	O
9	418	N	O
10	completed	N	O
11	the	N	O
12	6-month	N	O
13	assessment	N	O
14	and	N	O
15	399	N	O
16	completed	N	O
17	the	N	O
18	12-month	N	O
19	assessment	N	O
20	.	N	O

1	In	N	I-Premise
2	analyses	N	I-Premise
3	controlling	N	I-Premise
4	for	N	I-Premise
5	study	N	I-Premise
6	site	N	I-Premise
7	and	N	I-Premise
8	baseline	N	I-Premise
9	depressive	N	I-Premise
10	symptoms	N	I-Premise
11	,	N	I-Premise
12	VID	N	I-Premise
13	produced	N	I-Premise
14	significant	N	I-Premise
15	improvement	N	I-Premise
16	in	N	I-Premise
17	energy/fatigue	N	I-Premise
18	at	N	I-Premise
19	6	N	I-Premise
20	months	N	I-Premise
21	relative	N	I-Premise
22	to	N	I-Premise
23	CTL	N	I-Premise
24	,	N	I-Premise
25	particularly	N	I-Premise
26	among	N	I-Premise
27	women	N	I-Premise
28	who	N	I-Premise
29	felt	N	I-Premise
30	less	N	I-Premise
31	prepared	N	I-Premise
32	for	N	I-Premise
33	re-entry	N	I-Premise
34	at	N	I-Premise
35	baseline	N	I-Premise
36	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	main	N	I-Premise
4	effect	N	I-Premise
5	of	N	I-Premise
6	the	N	I-Premise
7	interventions	N	I-Premise
8	emerged	N	I-Premise
9	on	N	I-Premise
10	cancer-specific	N	I-Premise
11	distress	N	I-Premise
12	,	N	I-Premise
13	but	N	I-Premise
14	EDU	N	I-Premise
15	prompted	N	I-Premise
16	greater	N	I-Premise
17	reduction	N	I-Premise
18	in	N	I-Premise
19	this	N	I-Premise
20	outcome	N	I-Premise
21	relative	N	I-Premise
22	to	N	I-Premise
23	CTL	N	I-Premise
24	at	N	I-Premise
25	6	N	I-Premise
26	months	N	I-Premise
27	for	N	I-Premise
28	patients	N	I-Premise
29	who	N	I-Premise
30	felt	N	I-Premise
31	more	N	I-Premise
32	prepared	N	I-Premise
33	for	N	I-Premise
34	re-entry	N	I-Premise
35	.	N	I-Premise

1	Between-group	N	I-Premise
2	differences	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	primary	N	I-Premise
6	outcomes	N	I-Premise
7	were	N	I-Premise
8	not	N	I-Premise
9	significant	N	I-Premise
10	at	N	I-Premise
11	12	N	I-Premise
12	months	N	I-Premise
13	,	N	I-Premise
14	and	N	I-Premise
15	no	N	I-Premise
16	significant	N	I-Premise
17	effects	N	I-Premise
18	emerged	N	I-Premise
19	on	N	I-Premise
20	the	N	I-Premise
21	secondary	N	I-Premise
22	end	N	I-Premise
23	points	N	I-Premise
24	.	N	I-Premise

1	A	N	I-Claim
2	peer-modeling	N	I-Claim
3	videotape	N	I-Claim
4	can	N	I-Claim
5	accelerate	N	I-Claim
6	the	N	I-Claim
7	recovery	N	I-Claim
8	of	N	I-Claim
9	energy	N	I-Claim
10	during	N	I-Claim
11	the	N	I-Claim
12	re-entry	N	I-Claim
13	phase	N	I-Claim
14	in	N	I-Claim
15	women	N	I-Claim
16	treated	N	I-Claim
17	for	N	I-Claim
18	breast	N	I-Claim
19	cancer	N	I-Claim
20	,	N	I-Claim
21	particularly	N	I-Claim
22	among	N	I-Claim
23	those	N	I-Claim
24	who	N	I-Claim
25	feel	N	I-Claim
26	less	N	I-Claim
27	prepared	N	I-Claim
28	for	N	I-Claim
29	re-entry	N	I-Claim
30	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	a	N	O
7	psychoeducational	N	O
8	intervention	N	O
9	in	N	O
10	improving	N	O
11	cancer-related	N	O
12	fatigue	N	O
13	.	N	O

1	This	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	involved	N	O
6	109	N	O
7	women	N	O
8	commencing	N	O
9	adjuvant	N	O
10	chemotherapy	N	O
11	for	N	O
12	stage	N	O
13	I	N	O
14	or	N	O
15	II	N	O
16	breast	N	O
17	cancer	N	O
18	in	N	O
19	five	N	O
20	chemotherapy	N	O
21	treatment	N	O
22	centers	N	O
23	.	N	O

1	Intervention	N	O
2	group	N	O
3	patients	N	O
4	received	N	O
5	an	N	O
6	individualized	N	O
7	fatigue	N	O
8	education	N	O
9	and	N	O
10	support	N	O
11	program	N	O
12	delivered	N	O
13	in	N	O
14	the	N	O
15	clinic	N	O
16	and	N	O
17	by	N	O
18	phone	N	O
19	over	N	O
20	three	N	O
21	10-	N	O
22	to	N	O
23	20-minute	N	O
24	sessions	N	O
25	1	N	O
26	week	N	O
27	apart	N	O
28	.	N	O

1	Instruments	N	O
2	included	N	O
3	a	N	O
4	numeric	N	O
5	rating	N	O
6	scale	N	O
7	assessing	N	O
8	confidence	N	O
9	with	N	O
10	managing	N	O
11	fatigue	N	O
12	;	N	O
13	11-point	N	O
14	numeric	N	O
15	rating	N	O
16	scales	N	O
17	measuring	N	O
18	fatigue	N	O
19	at	N	O
20	worst	N	O
21	,	N	O
22	average	N	O
23	,	N	O
24	and	N	O
25	best	N	O
26	;	N	O
27	the	N	O
28	Functional	N	O
29	Assessment	N	O
30	of	N	O
31	Cancer	N	O
32	Therapy-Fatigue	N	O
33	and	N	O
34	Piper	N	O
35	Fatigue	N	O
36	Scales	N	O
37	;	N	O
38	the	N	O
39	Cancer	N	O
40	Self-Efficacy	N	O
41	Scale	N	O
42	;	N	O
43	the	N	O
44	European	N	O
45	Organisation	N	O
46	for	N	O
47	Research	N	O
48	and	N	O
49	Treatment	N	O
50	of	N	O
51	Cancer	N	O
52	Quality	N	O
53	of	N	O
54	Life	N	O
55	Questionnaire	N	O
56	C30	N	O
57	;	N	O
58	and	N	O
59	the	N	O
60	Hospital	N	O
61	Anxiety	N	O
62	and	N	O
63	Depression	N	O
64	Scale	N	O
65	.	N	O

1	For	N	O
2	each	N	O
3	outcome	N	O
4	,	N	O
5	separate	N	O
6	analyses	N	O
7	of	N	O
8	covariance	N	O
9	of	N	O
10	change	N	O
11	scores	N	O
12	between	N	O
13	baseline	N	O
14	(	N	O
15	T1	N	O
16	)	N	O
17	and	N	O
18	the	N	O
19	three	N	O
20	follow-up	N	O
21	time	N	O
22	points	N	O
23	(	N	O
24	T2	N	O
25	,	N	O
26	T3	N	O
27	,	N	O
28	and	N	O
29	T4	N	O
30	)	N	O
31	were	N	O
32	conducted	N	O
33	,	N	O
34	controlling	N	O
35	for	N	O
36	the	N	O
37	variable	N	O
38	's	N	O
39	corresponding	N	O
40	baseline	N	O
41	value	N	O
42	.	N	O

1	Compared	N	I-Premise
2	with	N	I-Premise
3	the	N	I-Premise
4	intervention	N	I-Premise
5	group	N	I-Premise
6	,	N	I-Premise
7	mean	N	I-Premise
8	difference	N	I-Premise
9	scores	N	I-Premise
10	between	N	I-Premise
11	the	N	I-Premise
12	baseline	N	I-Premise
13	(	N	I-Premise
14	T1	N	I-Premise
15	)	N	I-Premise
16	and	N	I-Premise
17	immediate	N	I-Premise
18	after	N	I-Premise
19	the	N	I-Premise
20	test	N	I-Premise
21	(	N	I-Premise
22	T2	N	I-Premise
23	)	N	I-Premise
24	assessments	N	I-Premise
25	increased	N	I-Premise
26	significantly	N	I-Premise
27	more	N	I-Premise
28	for	N	I-Premise
29	the	N	I-Premise
30	control	N	I-Premise
31	group	N	I-Premise
32	for	N	I-Premise
33	worst	N	I-Premise
34	and	N	I-Premise
35	average	N	I-Premise
36	fatigue	N	I-Premise
37	,	N	I-Premise
38	Functional	N	I-Premise
39	Assessment	N	I-Premise
40	of	N	I-Premise
41	Cancer	N	I-Premise
42	Therapy-Fatigue	N	I-Premise
43	,	N	I-Premise
44	and	N	I-Premise
45	Piper	N	I-Premise
46	fatigue	N	I-Premise
47	severity	N	I-Premise
48	and	N	I-Premise
49	interference	N	I-Premise
50	measures	N	I-Premise
51	.	N	I-Premise

1	These	N	I-Premise
2	differences	N	I-Premise
3	were	N	I-Premise
4	not	N	I-Premise
5	observed	N	I-Premise
6	between	N	I-Premise
7	baseline	N	I-Premise
8	and	N	I-Premise
9	T3	N	I-Premise
10	and	N	I-Premise
11	T4	N	I-Premise
12	assessments	N	I-Premise
13	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	differences	N	I-Premise
4	were	N	I-Premise
5	identified	N	I-Premise
6	for	N	I-Premise
7	any	N	I-Premise
8	pre-	N	I-Premise
9	or	N	I-Premise
10	post-test	N	I-Premise
11	change	N	I-Premise
12	scores	N	I-Premise
13	for	N	I-Premise
14	confidence	N	I-Premise
15	with	N	I-Premise
16	managing	N	I-Premise
17	fatigue	N	I-Premise
18	,	N	I-Premise
19	cancer	N	I-Premise
20	self-efficacy	N	I-Premise
21	,	N	I-Premise
22	anxiety	N	I-Premise
23	,	N	I-Premise
24	depression	N	I-Premise
25	,	N	I-Premise
26	or	N	I-Premise
27	quality	N	I-Premise
28	of	N	I-Premise
29	life	N	I-Premise
30	.	N	I-Premise

1	Preparatory	N	I-Claim
2	education	N	I-Claim
3	and	N	I-Claim
4	support	N	I-Claim
5	has	N	I-Claim
6	the	N	I-Claim
7	potential	N	I-Claim
8	to	N	I-Claim
9	assist	N	I-Claim
10	women	N	I-Claim
11	to	N	I-Claim
12	cope	N	I-Claim
13	with	N	I-Claim
14	cancer-related	N	I-Claim
15	fatigue	N	I-Claim
16	in	N	I-Claim
17	the	N	I-Claim
18	short	N	I-Claim
19	term	N	I-Claim
20	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	further	N	I-Claim
4	research	N	I-Claim
5	is	N	I-Claim
6	needed	N	I-Claim
7	to	N	I-Claim
8	identify	N	I-Claim
9	ways	N	I-Claim
10	to	N	I-Claim
11	improve	N	I-Claim
12	the	N	I-Claim
13	potency	N	I-Claim
14	and	N	I-Claim
15	sustainability	N	I-Claim
16	of	N	I-Claim
17	psychoeducational	N	I-Claim
18	interventions	N	I-Claim
19	for	N	I-Claim
20	managing	N	I-Claim
21	cancer-related	N	I-Claim
22	fatigue	N	I-Claim
23	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	impact	N	O
5	of	N	O
6	letrozole	N	O
7	compared	N	O
8	with	N	O
9	placebo	N	O
10	after	N	O
11	adjuvant	N	O
12	tamoxifen	N	O
13	on	N	O
14	quality	N	O
15	of	N	O
16	life	N	O
17	(	N	O
18	QOL	N	O
19	)	N	O
20	in	N	O
21	the	N	O
22	MA.17	N	O
23	trial	N	O
24	.	N	O

1	Patients	N	O
2	completed	N	O
3	the	N	O
4	Short	N	O
5	Form	N	O
6	36-item	N	O
7	Health	N	O
8	Survey	N	O
9	(	N	O
10	SF-36	N	O
11	)	N	O
12	and	N	O
13	the	N	O
14	Menopause	N	O
15	Specific	N	O
16	Quality	N	O
17	of	N	O
18	Life	N	O
19	Questionnaire	N	O
20	(	N	O
21	MENQOL	N	O
22	)	N	O
23	at	N	O
24	baseline	N	O
25	,	N	O
26	6	N	O
27	months	N	O
28	,	N	O
29	and	N	O
30	annually	N	O
31	.	N	O

1	Mean	N	O
2	change	N	O
3	scores	N	O
4	from	N	O
5	baseline	N	O
6	were	N	O
7	compared	N	O
8	between	N	O
9	groups	N	O
10	for	N	O
11	summary	N	O
12	measures	N	O
13	and	N	O
14	domains	N	O
15	.	N	O

1	A	N	O
2	response	N	O
3	analysis	N	O
4	compared	N	O
5	the	N	O
6	proportion	N	O
7	of	N	O
8	patients	N	O
9	who	N	O
10	demonstrated	N	O
11	an	N	O
12	important	N	O
13	change	N	O
14	in	N	O
15	QOL	N	O
16	.	N	O

1	Of	N	O
2	5,187	N	O
3	randomly	N	O
4	assigned	N	O
5	women	N	O
6	in	N	O
7	the	N	O
8	trial	N	O
9	,	N	O
10	3,612	N	O
11	(	N	O
12	69.9	N	O
13	%	N	O
14	)	N	O
15	participated	N	O
16	in	N	O
17	the	N	O
18	QOL	N	O
19	substudy	N	O
20	:	N	O
21	1,799	N	O
22	were	N	O
23	allocated	N	O
24	to	N	O
25	placebo	N	O
26	and	N	O
27	1,813	N	O
28	were	N	O
29	allocated	N	O
30	to	N	O
31	letrozole	N	O
32	.	N	O

1	No	N	I-Premise
2	differences	N	I-Premise
3	were	N	I-Premise
4	seen	N	I-Premise
5	between	N	I-Premise
6	groups	N	I-Premise
7	in	N	I-Premise
8	mean	N	I-Premise
9	change	N	I-Premise
10	scores	N	I-Premise
11	from	N	I-Premise
12	baseline	N	I-Premise
13	for	N	I-Premise
14	the	N	I-Premise
15	SF-36	N	I-Premise
16	physical	N	I-Premise
17	and	N	I-Premise
18	mental	N	I-Premise
19	component	N	I-Premise
20	summary	N	I-Premise
21	scores	N	I-Premise
22	at	N	I-Premise
23	6	N	I-Premise
24	,	N	I-Premise
25	12	N	I-Premise
26	,	N	I-Premise
27	24	N	I-Premise
28	,	N	I-Premise
29	and	N	I-Premise
30	36	N	I-Premise
31	months	N	I-Premise
32	.	N	I-Premise

1	Small	N	I-Premise
2	(	N	I-Premise
3	<	N	I-Premise
4	0.2	N	I-Premise
5	standard	N	I-Premise
6	deviations	N	I-Premise
7	)	N	I-Premise
8	but	N	I-Premise
9	statistically	N	I-Premise
10	significant	N	I-Premise
11	differences	N	I-Premise
12	in	N	I-Premise
13	mean	N	I-Premise
14	change	N	I-Premise
15	scores	N	I-Premise
16	from	N	I-Premise
17	baseline	N	I-Premise
18	were	N	I-Premise
19	seen	N	I-Premise
20	for	N	I-Premise
21	the	N	I-Premise
22	SF-36	N	I-Premise
23	domains	N	I-Premise
24	of	N	I-Premise
25	physical	N	I-Premise
26	functioning	N	I-Premise
27	(	N	I-Premise
28	12	N	I-Premise
29	months	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	bodily	N	I-Premise
33	pain	N	I-Premise
34	(	N	I-Premise
35	6	N	I-Premise
36	months	N	I-Premise
37	)	N	I-Premise
38	and	N	I-Premise
39	vitality	N	I-Premise
40	(	N	I-Premise
41	6	N	I-Premise
42	and	N	I-Premise
43	12	N	I-Premise
44	months	N	I-Premise
45	)	N	I-Premise
46	,	N	I-Premise
47	and	N	I-Premise
48	the	N	I-Premise
49	MENQOL	N	I-Premise
50	vasomotor	N	I-Premise
51	(	N	I-Premise
52	6	N	I-Premise
53	,	N	I-Premise
54	12	N	I-Premise
55	,	N	I-Premise
56	and	N	I-Premise
57	24	N	I-Premise
58	months	N	I-Premise
59	)	N	I-Premise
60	and	N	I-Premise
61	sexual	N	I-Premise
62	domains	N	I-Premise
63	(	N	I-Premise
64	12	N	I-Premise
65	and	N	I-Premise
66	24	N	I-Premise
67	months	N	I-Premise
68	)	N	I-Premise
69	.	N	I-Premise

1	On	N	I-Premise
2	the	N	I-Premise
3	response	N	I-Premise
4	analysis	N	I-Premise
5	,	N	I-Premise
6	a	N	I-Premise
7	significant	N	I-Premise
8	difference	N	I-Premise
9	was	N	I-Premise
10	seen	N	I-Premise
11	between	N	I-Premise
12	groups	N	I-Premise
13	for	N	I-Premise
14	the	N	I-Premise
15	bodily	N	I-Premise
16	pain	N	I-Premise
17	domain	N	I-Premise
18	(	N	I-Premise
19	percentage	N	I-Premise
20	of	N	I-Premise
21	patients	N	I-Premise
22	reporting	N	I-Premise
23	a	N	I-Premise
24	worsening	N	I-Premise
25	of	N	I-Premise
26	QOL	N	I-Premise
27	,	N	I-Premise
28	47	N	I-Premise
29	%	N	I-Premise
30	placebo	N	I-Premise
31	v	N	I-Premise
32	51	N	I-Premise
33	%	N	I-Premise
34	letrozole	N	I-Premise
35	;	N	I-Premise
36	P	N	I-Premise
37	=	N	I-Premise
38	.009	N	I-Premise
39	)	N	I-Premise
40	and	N	I-Premise
41	the	N	I-Premise
42	vasomotor	N	I-Premise
43	domain	N	I-Premise
44	(	N	I-Premise
45	22	N	I-Premise
46	%	N	I-Premise
47	placebo	N	I-Premise
48	v	N	I-Premise
49	29	N	I-Premise
50	%	N	I-Premise
51	letrozole	N	I-Premise
52	;	N	I-Premise
53	P	N	I-Premise
54	=	N	I-Premise
55	.001	N	I-Premise
56	)	N	I-Premise
57	.	N	I-Premise

1	Letrozole	N	I-Claim
2	did	N	I-Claim
3	not	N	I-Claim
4	have	N	I-Claim
5	an	N	I-Claim
6	adverse	N	I-Claim
7	impact	N	I-Claim
8	on	N	I-Claim
9	overall	N	I-Claim
10	QOL	N	I-Claim
11	.	N	I-Claim

1	Small	N	I-Claim
2	effects	N	I-Claim
3	were	N	I-Claim
4	seen	N	I-Claim
5	in	N	I-Claim
6	some	N	I-Claim
7	domains	N	I-Claim
8	consistent	N	I-Claim
9	with	N	I-Claim
10	a	N	I-Claim
11	minority	N	I-Claim
12	of	N	I-Claim
13	patients	N	I-Claim
14	experiencing	N	I-Claim
15	changes	N	I-Claim
16	in	N	I-Claim
17	QOL	N	I-Claim
18	compatible	N	I-Claim
19	with	N	I-Claim
20	a	N	I-Claim
21	reduction	N	I-Claim
22	in	N	I-Claim
23	estrogen	N	I-Claim
24	synthesis	N	I-Claim
25	.	N	I-Claim

1	This	N	O
2	study	N	O
3	is	N	O
4	the	N	O
5	first	N	O
6	large	N	O
7	prospective	N	O
8	RCT	N	O
9	of	N	O
10	sentinel	N	O
11	node	N	O
12	biopsy	N	O
13	(	N	O
14	SNB	N	O
15	)	N	O
16	compared	N	O
17	with	N	O
18	standard	N	O
19	axillary	N	O
20	treatment	N	O
21	(	N	O
22	level	N	O
23	I-III	N	O
24	axillary	N	O
25	lymph	N	O
26	node	N	O
27	dissection	N	O
28	or	N	O
29	four	N	O
30	node	N	O
31	sampling	N	O
32	)	N	O
33	,	N	O
34	which	N	O
35	includes	N	O
36	comprehensive	N	O
37	and	N	O
38	repeated	N	O
39	quality	N	O
40	of	N	O
41	life	N	O
42	(	N	O
43	QOL	N	O
44	)	N	O
45	assessments	N	O
46	over	N	O
47	18	N	O
48	months	N	O
49	.	N	O

1	Patients	N	O
2	(	N	O
3	n	N	O
4	=	N	O
5	829	N	O
6	)	N	O
7	completed	N	O
8	the	N	O
9	Functional	N	O
10	Assessment	N	O
11	of	N	O
12	Cancer	N	O
13	Therapy	N	O
14	-	N	O
15	Breast	N	O
16	(	N	O
17	FACT-B+4	N	O
18	)	N	O
19	and	N	O
20	the	N	O
21	Spielberger	N	O
22	State/Trait	N	O
23	Anxiety	N	O
24	Inventory	N	O
25	(	N	O
26	STAI	N	O
27	)	N	O
28	at	N	O
29	baseline	N	O
30	(	N	O
31	pre-surgery	N	O
32	)	N	O
33	and	N	O
34	at	N	O
35	1	N	O
36	,	N	O
37	3	N	O
38	,	N	O
39	6	N	O
40	,	N	O
41	12	N	O
42	,	N	O
43	and	N	O
44	18	N	O
45	months	N	O
46	post-surgery	N	O
47	.	N	O

1	There	N	I-Claim
2	were	N	I-Claim
3	significant	N	I-Claim
4	differences	N	I-Claim
5	between	N	I-Claim
6	treatment	N	I-Claim
7	groups	N	I-Claim
8	favouring	N	I-Claim
9	the	N	I-Claim
10	SNB	N	I-Claim
11	group	N	I-Claim
12	throughout	N	I-Claim
13	the	N	I-Claim
14	18	N	I-Claim
15	months	N	I-Claim
16	assessment	N	I-Claim
17	.	N	I-Claim

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	standard	N	I-Premise
5	treatment	N	I-Premise
6	group	N	I-Premise
7	showed	N	I-Premise
8	a	N	I-Premise
9	greater	N	I-Premise
10	decline	N	I-Premise
11	in	N	I-Premise
12	Trial	N	I-Premise
13	Outcome	N	I-Premise
14	Index	N	I-Premise
15	(	N	I-Premise
16	TOI	N	I-Premise
17	)	N	I-Premise
18	scores	N	I-Premise
19	(	N	I-Premise
20	physical	N	I-Premise
21	well-being	N	I-Premise
22	,	N	I-Premise
23	functional	N	I-Premise
24	well-being	N	I-Premise
25	and	N	I-Premise
26	breast	N	I-Premise
27	cancer	N	I-Premise
28	concerns	N	I-Premise
29	subscales	N	I-Premise
30	in	N	I-Premise
31	FACT-B+4	N	I-Premise
32	)	N	I-Premise
33	and	N	I-Premise
34	recovered	N	I-Premise
35	more	N	I-Premise
36	slowly	N	I-Premise
37	than	N	I-Premise
38	patients	N	I-Premise
39	in	N	I-Premise
40	the	N	I-Premise
41	SNB	N	I-Premise
42	group	N	I-Premise
43	(	N	I-Premise
44	p	N	I-Premise
45	<	N	I-Premise
46	0.01	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	The	N	I-Premise
2	change	N	I-Premise
3	in	N	I-Premise
4	total	N	I-Premise
5	FACT-B+4	N	I-Premise
6	scores	N	I-Premise
7	(	N	I-Premise
8	measuring	N	I-Premise
9	global	N	I-Premise
10	QOL	N	I-Premise
11	)	N	I-Premise
12	closely	N	I-Premise
13	resembled	N	I-Premise
14	the	N	I-Premise
15	TOI	N	I-Premise
16	results	N	I-Premise
17	.	N	I-Premise

1	18	N	I-Premise
2	months	N	I-Premise
3	post-surgery	N	I-Premise
4	approximately	N	I-Premise
5	twice	N	I-Premise
6	as	N	I-Premise
7	many	N	I-Premise
8	patients	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	standard	N	I-Premise
12	group	N	I-Premise
13	compared	N	I-Premise
14	with	N	I-Premise
15	the	N	I-Premise
16	SNB	N	I-Premise
17	group	N	I-Premise
18	reported	N	I-Premise
19	substantial	N	I-Premise
20	arm	N	I-Premise
21	swelling	N	I-Premise
22	(	N	I-Premise
23	14	N	I-Premise
24	%	N	I-Premise
25	versus	N	I-Premise
26	7	N	I-Premise
27	%	N	I-Premise
28	)	N	I-Premise
29	(	N	I-Premise
30	p	N	I-Premise
31	=	N	I-Premise
32	0.002	N	I-Premise
33	)	N	I-Premise
34	or	N	I-Premise
35	numbness	N	I-Premise
36	(	N	I-Premise
37	19	N	I-Premise
38	%	N	I-Premise
39	versus	N	I-Premise
40	8.7	N	I-Premise
41	%	N	I-Premise
42	)	N	I-Premise
43	(	N	I-Premise
44	p	N	I-Premise
45	<	N	I-Premise
46	0.001	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	Despite	N	O
2	the	N	O
3	uncertainty	N	O
4	about	N	O
5	undergoing	N	O
6	a	N	O
7	relatively	N	O
8	new	N	O
9	procedure	N	O
10	and	N	O
11	the	N	O
12	possible	N	O
13	need	N	O
14	for	N	O
15	further	N	O
16	surgery	N	O
17	,	N	O
18	there	N	I-Premise
19	was	N	I-Premise
20	no	N	I-Premise
21	evidence	N	I-Premise
22	of	N	I-Premise
23	increased	N	I-Premise
24	anxiety	N	I-Premise
25	amongst	N	I-Premise
26	patients	N	I-Premise
27	randomised	N	I-Premise
28	to	N	I-Premise
29	SNB	N	I-Premise
30	(	N	I-Premise
31	p	N	I-Premise
32	>	N	I-Premise
33	0.05	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	For	N	I-Premise
2	6	N	I-Premise
3	months	N	I-Premise
4	post-surgery	N	I-Premise
5	younger	N	I-Premise
6	patients	N	I-Premise
7	reported	N	I-Premise
8	less	N	I-Premise
9	favourable	N	I-Premise
10	QOL	N	I-Premise
11	scores	N	I-Premise
12	(	N	I-Premise
13	p	N	I-Premise
14	<	N	I-Premise
15	0.001	N	I-Premise
16	)	N	I-Premise
17	and	N	I-Premise
18	greater	N	I-Premise
19	levels	N	I-Premise
20	of	N	I-Premise
21	anxiety	N	I-Premise
22	(	N	I-Premise
23	p	N	I-Premise
24	<	N	I-Premise
25	0.01	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	In	N	I-Claim
2	view	N	I-Claim
3	of	N	I-Claim
4	the	N	I-Claim
5	benefits	N	I-Claim
6	regarding	N	I-Claim
7	arm	N	I-Claim
8	functioning	N	I-Claim
9	and	N	I-Claim
10	quality	N	I-Claim
11	of	N	I-Claim
12	life	N	I-Claim
13	,	N	I-Claim
14	the	N	I-Claim
15	data	N	I-Claim
16	from	N	I-Claim
17	this	N	I-Claim
18	randomised	N	I-Claim
19	study	N	I-Claim
20	support	N	I-Claim
21	the	N	I-Claim
22	use	N	I-Claim
23	of	N	I-Claim
24	SNB	N	I-Claim
25	in	N	I-Claim
26	patients	N	I-Claim
27	with	N	I-Claim
28	clinically	N	I-Claim
29	node	N	I-Claim
30	negative	N	I-Claim
31	breast	N	I-Claim
32	cancer	N	I-Claim
33	.	N	I-Claim

1	To	N	O
2	describe	N	O
3	the	N	O
4	Food	N	O
5	and	N	O
6	Drug	N	O
7	Administration	N	O
8	(	N	O
9	FDA	N	O
10	)	N	O
11	review	N	O
12	and	N	O
13	approval	N	O
14	of	N	O
15	erlotinib	N	O
16	(	N	O
17	Tarceva	N	O
18	,	N	O
19	OSI	N	O
20	Pharmaceuticals	N	O
21	,	N	O
22	Melville	N	O
23	,	N	O
24	NY	N	O
25	)	N	O
26	for	N	O
27	treatment	N	O
28	of	N	O
29	patients	N	O
30	with	N	O
31	locally	N	O
32	advanced	N	O
33	or	N	O
34	metastatic	N	O
35	non-small	N	O
36	cell	N	O
37	lung	N	O
38	cancer	N	O
39	(	N	O
40	NSCLC	N	O
41	)	N	O
42	after	N	O
43	failure	N	O
44	of	N	O
45	at	N	O
46	least	N	O
47	one	N	O
48	prior	N	O
49	chemotherapy	N	O
50	regimen	N	O
51	.	N	O

1	The	N	O
2	FDA	N	O
3	reviewed	N	O
4	raw	N	O
5	data	N	O
6	in	N	O
7	electronic	N	O
8	format	N	O
9	from	N	O
10	a	N	O
11	randomized	N	O
12	controlled	N	O
13	clinical	N	O
14	trial	N	O
15	comparing	N	O
16	erlotinib	N	O
17	with	N	O
18	placebo	N	O
19	in	N	O
20	patients	N	O
21	with	N	O
22	locally	N	O
23	advanced	N	O
24	or	N	O
25	metastatic	N	O
26	NSCLC	N	O
27	after	N	O
28	failure	N	O
29	of	N	O
30	at	N	O
31	least	N	O
32	one	N	O
33	prior	N	O
34	chemotherapy	N	O
35	regimen	N	O
36	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	in	N	O
5	a	N	O
6	2:1	N	O
7	ratio	N	O
8	(	N	O
9	erlotinib	N	O
10	,	N	O
11	n	N	O
12	=	N	O
13	488	N	O
14	and	N	O
15	placebo	N	O
16	,	N	O
17	n	N	O
18	=	N	O
19	243	N	O
20	)	N	O
21	.	N	O

1	Erlotinib	N	I-Claim
2	was	N	I-Claim
3	superior	N	I-Claim
4	to	N	I-Claim
5	placebo	N	I-Claim
6	for	N	I-Claim
7	survival	N	I-Claim
8	,	N	I-Claim
9	progression-free	N	I-Claim
10	survival	N	I-Claim
11	,	N	I-Claim
12	and	N	I-Claim
13	tumor	N	I-Claim
14	response	N	I-Claim
15	rate	N	I-Claim
16	.	N	I-Claim

1	Exploratory	N	I-Claim
2	analyses	N	I-Claim
3	indicate	N	I-Claim
4	that	N	I-Claim
5	epidermal	N	I-Claim
6	growth	N	I-Claim
7	factor	N	I-Claim
8	receptor	N	I-Claim
9	status	N	I-Claim
10	may	N	I-Claim
11	be	N	I-Claim
12	an	N	I-Claim
13	important	N	I-Claim
14	predictor	N	I-Claim
15	of	N	I-Claim
16	the	N	I-Claim
17	erlotinib	N	I-Claim
18	survival	N	I-Claim
19	effect	N	I-Claim
20	.	N	I-Claim

1	Rash	N	I-Premise
2	(	N	I-Premise
3	75	N	I-Premise
4	%	N	I-Premise
5	versus	N	I-Premise
6	17	N	I-Premise
7	%	N	I-Premise
8	)	N	I-Premise
9	and	N	I-Premise
10	diarrhea	N	I-Premise
11	(	N	I-Premise
12	54	N	I-Premise
13	%	N	I-Premise
14	versus	N	I-Premise
15	18	N	I-Premise
16	%	N	I-Premise
17	)	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	erlotnib	N	I-Premise
21	and	N	I-Premise
22	placebo	N	I-Premise
23	group	N	I-Premise
24	respectively	N	I-Premise
25	were	N	I-Premise
26	the	N	I-Premise
27	most	N	I-Premise
28	common	N	I-Premise
29	adverse	N	I-Premise
30	events	N	I-Premise
31	.	N	I-Premise

1	Severe	N	I-Premise
2	rash	N	I-Premise
3	occurred	N	I-Premise
4	in	N	I-Premise
5	9	N	I-Premise
6	%	N	I-Premise
7	and	N	I-Premise
8	severe	N	I-Premise
9	diarrhea	N	I-Premise
10	in	N	I-Premise
11	6	N	I-Premise
12	%	N	I-Premise
13	of	N	I-Premise
14	erlotinib-treated	N	I-Premise
15	patients	N	I-Premise
16	and	N	I-Premise
17	each	N	I-Premise
18	resulted	N	I-Premise
19	in	N	I-Premise
20	study	N	I-Premise
21	discontinuation	N	I-Premise
22	in	N	I-Premise
23	1	N	I-Premise
24	%	N	I-Premise
25	of	N	I-Premise
26	patients	N	I-Premise
27	.	N	I-Premise

1	Dose	N	I-Premise
2	reductions	N	I-Premise
3	were	N	I-Premise
4	required	N	I-Premise
5	for	N	I-Premise
6	10	N	I-Premise
7	%	N	I-Premise
8	of	N	I-Premise
9	patients	N	I-Premise
10	with	N	I-Premise
11	rash	N	I-Premise
12	and	N	I-Premise
13	4	N	I-Premise
14	%	N	I-Premise
15	of	N	I-Premise
16	patients	N	I-Premise
17	with	N	I-Premise
18	diarrhea	N	I-Premise
19	.	N	I-Premise

1	On	N	O
2	November	N	O
3	18	N	O
4	,	N	O
5	2004	N	O
6	,	N	O
7	the	N	O
8	FDA	N	O
9	granted	N	O
10	erlotinib	N	O
11	regular	N	O
12	approval	N	O
13	for	N	O
14	treatment	N	O
15	of	N	O
16	patients	N	O
17	with	N	O
18	locally	N	O
19	advanced	N	O
20	or	N	O
21	metastatic	N	O
22	NSCLC	N	O
23	after	N	O
24	failure	N	O
25	of	N	O
26	at	N	O
27	least	N	O
28	one	N	O
29	prior	N	O
30	chemotherapy	N	O
31	regimen	N	O
32	.	N	O

1	The	N	O
2	applicant	N	O
3	has	N	O
4	committed	N	O
5	to	N	O
6	conduct	N	O
7	post-marketing	N	O
8	clinical	N	O
9	trials	N	O
10	to	N	O
11	assess	N	O
12	further	N	O
13	the	N	O
14	effect	N	O
15	of	N	O
16	epidermal	N	O
17	growth	N	O
18	factor	N	O
19	receptor	N	O
20	expression	N	O
21	,	N	O
22	measured	N	O
23	with	N	O
24	immunohistochemical	N	O
25	staining	N	O
26	,	N	O
27	on	N	O
28	erlotinib	N	O
29	treatment	N	O
30	effect	N	O
31	.	N	O

1	Approximately	N	O
2	30	N	O
3	%	N	O
4	of	N	O
5	lung	N	O
6	cancer	N	O
7	cases	N	O
8	are	N	O
9	diagnosed	N	O
10	in	N	O
11	patients	N	O
12	>	N	O
13	70	N	O
14	years	N	O
15	of	N	O
16	age	N	O
17	.	N	O

1	Standard	N	I-MajorClaim
2	chemotherapy	N	I-MajorClaim
3	regimens	N	I-MajorClaim
4	are	N	I-MajorClaim
5	generally	N	I-MajorClaim
6	considered	N	I-MajorClaim
7	too	N	I-MajorClaim
8	toxic	N	I-MajorClaim
9	for	N	I-MajorClaim
10	elderly	N	I-MajorClaim
11	patients	N	I-MajorClaim
12	.	N	I-MajorClaim

1	We	N	O
2	conducted	N	O
3	a	N	O
4	multicenter	N	O
5	phase	N	O
6	II	N	O
7	trial	N	O
8	to	N	O
9	determine	N	O
10	the	N	O
11	efficacy	N	O
12	and	N	O
13	safety	N	O
14	of	N	O
15	carboplatin	N	O
16	combined	N	O
17	with	N	O
18	vinorelbine	N	O
19	every	N	O
20	4	N	O
21	weeks	N	O
22	as	N	O
23	first-line	N	O
24	treatment	N	O
25	for	N	O
26	advanced	N	O
27	non-small-cell	N	O
28	lung	N	O
29	cancer	N	O
30	(	N	O
31	NSCLC	N	O
32	)	N	O
33	in	N	O
34	elderly	N	O
35	patients	N	O
36	.	N	O

1	Patients	N	O
2	were	N	O
3	eligible	N	O
4	if	N	O
5	they	N	O
6	were	N	O
7	aged	N	O
8	>	N	O
9	OR=	N	O
10	70	N	O
11	years	N	O
12	,	N	O
13	had	N	O
14	stage	N	O
15	IIIB	N	O
16	(	N	O
17	with	N	O
18	pleural	N	O
19	effusion	N	O
20	)	N	O
21	or	N	O
22	stage	N	O
23	IV	N	O
24	NSCLC	N	O
25	,	N	O
26	had	N	O
27	a	N	O
28	performance	N	O
29	status	N	O
30	of	N	O
31	0/1	N	O
32	,	N	O
33	had	N	O
34	not	N	O
35	previously	N	O
36	received	N	O
37	chemotherapy	N	O
38	,	N	O
39	and	N	O
40	had	N	O
41	normal	N	O
42	organ	N	O
43	function	N	O
44	.	N	O

1	Forty	N	O
2	patients	N	O
3	(	N	O
4	31	N	O
5	men	N	O
6	and	N	O
7	9	N	O
8	women	N	O
9	)	N	O
10	were	N	O
11	enrolled	N	O
12	and	N	O
13	received	N	O
14	3-5	N	O
15	courses	N	O
16	of	N	O
17	treatment	N	O
18	.	N	O

1	Median	N	O
2	age	N	O
3	was	N	O
4	72	N	O
5	years	N	O
6	(	N	O
7	range	N	O
8	,	N	O
9	70-82	N	O
10	years	N	O
11	)	N	O
12	.	N	O

1	Eighty	N	O
2	percent	N	O
3	of	N	O
4	patients	N	O
5	had	N	O
6	stage	N	O
7	IV	N	O
8	NSCLC	N	O
9	,	N	O
10	with	N	O
11	squamous	N	O
12	cell	N	O
13	(	N	O
14	n=21	N	O
15	)	N	O
16	,	N	O
17	adenocarcinoma	N	O
18	(	N	O
19	n=12	N	O
20	)	N	O
21	,	N	O
22	and	N	O
23	undifferentiated	N	O
24	(	N	O
25	n=7	N	O
26	)	N	O
27	histologies	N	O
28	.	N	O

1	Forty	N	O
2	patients	N	O
3	were	N	O
4	assessable	N	O
5	for	N	O
6	toxicity	N	O
7	and	N	O
8	32	N	O
9	for	N	O
10	treatment	N	O
11	response	N	O
12	.	N	O

1	Among	N	I-Premise
2	these	N	I-Premise
3	32	N	I-Premise
4	patients	N	I-Premise
5	,	N	I-Premise
6	8	N	I-Premise
7	had	N	I-Premise
8	a	N	I-Premise
9	partial	N	I-Premise
10	response	N	I-Premise
11	(	N	I-Premise
12	intent-to-treat	N	I-Premise
13	response	N	I-Premise
14	rate	N	I-Premise
15	,	N	I-Premise
16	20	N	I-Premise
17	%	N	I-Premise
18	)	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	10	N	I-Premise
22	(	N	I-Premise
23	25	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	had	N	I-Premise
27	stable	N	I-Premise
28	disease	N	I-Premise
29	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	was	N	I-Premise
5	7.8	N	I-Premise
6	months	N	I-Premise
7	(	N	I-Premise
8	range	N	I-Premise
9	,	N	I-Premise
10	4-11.6	N	I-Premise
11	months	N	I-Premise
12	)	N	I-Premise
13	.	N	I-Premise

1	The	N	I-Premise
2	1-	N	I-Premise
3	and	N	I-Premise
4	2-year	N	I-Premise
5	survival	N	I-Premise
6	rates	N	I-Premise
7	were	N	I-Premise
8	25	N	I-Premise
9	%	N	I-Premise
10	and	N	I-Premise
11	7	N	I-Premise
12	%	N	I-Premise
13	,	N	I-Premise
14	respectively	N	I-Premise
15	;	N	I-Premise
16	median	N	I-Premise
17	time	N	I-Premise
18	to	N	I-Premise
19	progression	N	I-Premise
20	was	N	I-Premise
21	4.3	N	I-Premise
22	months	N	I-Premise
23	(	N	I-Premise
24	range	N	I-Premise
25	,	N	I-Premise
26	0.2-13.8	N	I-Premise
27	months	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Grade	N	I-Premise
2	3/4	N	I-Premise
3	neutropenia	N	I-Premise
4	was	N	I-Premise
5	seen	N	I-Premise
6	in	N	I-Premise
7	27	N	I-Premise
8	patients	N	I-Premise
9	(	N	I-Premise
10	68	N	I-Premise
11	%	N	I-Premise
12	)	N	I-Premise
13	,	N	I-Premise
14	and	N	I-Premise
15	grade	N	I-Premise
16	3/4	N	I-Premise
17	anemia	N	I-Premise
18	was	N	I-Premise
19	seen	N	I-Premise
20	in	N	I-Premise
21	5	N	I-Premise
22	patients	N	I-Premise
23	(	N	I-Premise
24	13	N	I-Premise
25	%	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	One	N	I-Premise
2	patient	N	I-Premise
3	died	N	I-Premise
4	of	N	I-Premise
5	febrile	N	I-Premise
6	neutropenia	N	I-Premise
7	during	N	I-Premise
8	treatment	N	I-Premise
9	.	N	I-Premise

1	The	N	I-Premise
2	main	N	I-Premise
3	nonhematologic	N	I-Premise
4	adverse	N	I-Premise
5	effect	N	I-Premise
6	was	N	I-Premise
7	fatigue	N	I-Premise
8	(	N	I-Premise
9	grade	N	I-Premise
10	3/4	N	I-Premise
11	in	N	I-Premise
12	18	N	I-Premise
13	%	N	I-Premise
14	of	N	I-Premise
15	patients	N	I-Premise
16	)	N	I-Premise
17	.	N	I-Premise

1	Carboplatin/vinorelbine	N	I-Claim
2	is	N	I-Claim
3	well	N	I-Claim
4	tolerated	N	I-Claim
5	by	N	I-Claim
6	elderly	N	I-Claim
7	patients	N	I-Claim
8	with	N	I-Claim
9	extensive-stage	N	I-Claim
10	NSCLC	N	I-Claim
11	.	N	I-Claim

1	Efficacy	N	I-Claim
2	is	N	I-Claim
3	low	N	I-Claim
4	but	N	I-Claim
5	similar	N	I-Claim
6	to	N	I-Claim
7	that	N	I-Claim
8	of	N	I-Claim
9	other	N	I-Claim
10	treatments	N	I-Claim
11	used	N	I-Claim
12	in	N	I-Claim
13	this	N	I-Claim
14	setting	N	I-Claim
15	.	N	I-Claim

1	On	N	O
2	March	N	O
3	15	N	O
4	,	N	O
5	2005	N	O
6	,	N	O
7	the	N	O
8	US	N	O
9	Food	N	O
10	and	N	O
11	Drug	N	O
12	Administration	N	O
13	approved	N	O
14	temozolomide	N	O
15	(	N	O
16	Temodar	N	O
17	capsules	N	O
18	,	N	O
19	Schering-Plough	N	O
20	Research	N	O
21	Institute	N	O
22	)	N	O
23	for	N	O
24	the	N	O
25	treatment	N	O
26	of	N	O
27	adult	N	O
28	patients	N	O
29	with	N	O
30	newly	N	O
31	diagnosed	N	O
32	glioblastoma	N	O
33	multiforme	N	O
34	concomitantly	N	O
35	with	N	O
36	radiotherapy	N	O
37	and	N	O
38	then	N	O
39	as	N	O
40	maintenance	N	O
41	treatment	N	O
42	.	N	O

1	Five	N	O
2	hundred	N	O
3	seventy-three	N	O
4	glioblastoma	N	O
5	multiforme	N	O
6	patients	N	O
7	were	N	O
8	randomized	N	O
9	to	N	O
10	receive	N	O
11	either	N	O
12	temozolomide	N	O
13	+	N	O
14	radiotherapy	N	O
15	(	N	O
16	n	N	O
17	=	N	O
18	287	N	O
19	)	N	O
20	or	N	O
21	radiotherapy	N	O
22	alone	N	O
23	(	N	O
24	n	N	O
25	=	N	O
26	286	N	O
27	)	N	O
28	.	N	O

1	Patients	N	O
2	in	N	O
3	the	N	O
4	temozolomide	N	O
5	+	N	O
6	radiotherapy	N	O
7	arm	N	O
8	received	N	O
9	concomitant	N	O
10	temozolomide	N	O
11	(	N	O
12	75	N	O
13	mg/m2	N	O
14	)	N	O
15	once	N	O
16	daily	N	O
17	for	N	O
18	the	N	O
19	duration	N	O
20	of	N	O
21	radiation	N	O
22	therapy	N	O
23	(	N	O
24	42-49	N	O
25	days	N	O
26	)	N	O
27	.	N	O

1	This	N	O
2	was	N	O
3	followed	N	O
4	,	N	O
5	4	N	O
6	weeks	N	O
7	later	N	O
8	,	N	O
9	by	N	O
10	six	N	O
11	cycles	N	O
12	of	N	O
13	temozolomide	N	O
14	,	N	O
15	150	N	O
16	or	N	O
17	200	N	O
18	mg/m2	N	O
19	daily	N	O
20	for	N	O
21	5	N	O
22	days	N	O
23	,	N	O
24	every	N	O
25	4	N	O
26	weeks	N	O
27	.	N	O

1	Patients	N	O
2	in	N	O
3	the	N	O
4	control	N	O
5	arm	N	O
6	received	N	O
7	radiotherapy	N	O
8	only	N	O
9	.	N	O

1	In	N	O
2	both	N	O
3	arms	N	O
4	,	N	O
5	radiotherapy	N	O
6	was	N	O
7	delivered	N	O
8	as	N	O
9	60	N	O
10	Gy/30	N	O
11	fractions	N	O
12	to	N	O
13	the	N	O
14	tumor	N	O
15	site	N	O
16	with	N	O
17	a	N	O
18	2	N	O
19	to	N	O
20	3	N	O
21	cm	N	O
22	margin	N	O
23	.	N	O

1	Pneumocystis	N	O
2	carinii	N	O
3	pneumonia	N	O
4	prophylaxis	N	O
5	was	N	O
6	required	N	O
7	during	N	O
8	temozolomide	N	O
9	+	N	O
10	radiotherapy	N	O
11	treatment	N	O
12	and	N	O
13	was	N	O
14	continued	N	O
15	until	N	O
16	recovery	N	O
17	of	N	O
18	lymphocytopenia	N	O
19	(	N	O
20	Common	N	O
21	Toxicity	N	O
22	Criteria	N	O
23	grade	N	O
24	<	N	O
25	1	N	O
26	)	N	O
27	.	N	O

1	At	N	O
2	disease	N	O
3	progression	N	O
4	,	N	O
5	temozolomide	N	O
6	salvage	N	O
7	treatment	N	O
8	was	N	O
9	given	N	O
10	to	N	O
11	161	N	O
12	of	N	O
13	282	N	O
14	patients	N	O
15	(	N	O
16	57	N	O
17	%	N	O
18	)	N	O
19	in	N	O
20	the	N	O
21	radiotherapy	N	O
22	alone	N	O
23	arm	N	O
24	,	N	O
25	and	N	O
26	to	N	O
27	62	N	O
28	of	N	O
29	277	N	O
30	patients	N	O
31	(	N	O
32	22	N	O
33	%	N	O
34	)	N	O
35	in	N	O
36	the	N	O
37	temozolomide	N	O
38	+	N	O
39	radiotherapy	N	O
40	arm	N	O
41	.	N	O

1	Patients	N	I-Claim
2	receiving	N	I-Claim
3	concomitant	N	I-Claim
4	and	N	I-Claim
5	maintenance	N	I-Claim
6	temozolomide	N	I-Claim
7	+	N	I-Claim
8	radiotherapy	N	I-Claim
9	had	N	I-Claim
10	significantly	N	I-Claim
11	improved	N	I-Claim
12	overall	N	I-Claim
13	survival	N	I-Claim
14	.	N	I-Claim

1	The	N	I-Premise
2	hazard	N	I-Premise
3	ratio	N	I-Premise
4	was	N	I-Premise
5	0.63	N	I-Premise
6	(	N	I-Premise
7	95	N	I-Premise
8	%	N	I-Premise
9	confidence	N	I-Premise
10	interval	N	I-Premise
11	,	N	I-Premise
12	0.52-0.75	N	I-Premise
13	;	N	I-Premise
14	log-rank	N	I-Premise
15	,	N	I-Premise
16	P	N	I-Premise
17	<	N	I-Premise
18	0.0001	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	14.6	N	I-Premise
5	months	N	I-Premise
6	(	N	I-Premise
7	temozolomide	N	I-Premise
8	+	N	I-Premise
9	radiotherapy	N	I-Premise
10	)	N	I-Premise
11	versus	N	I-Premise
12	12.1	N	I-Premise
13	months	N	I-Premise
14	(	N	I-Premise
15	radiotherapy	N	I-Premise
16	alone	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	Adverse	N	I-Claim
2	events	N	I-Claim
3	during	N	I-Claim
4	temozolomide	N	I-Claim
5	treatment	N	I-Claim
6	included	N	I-Claim
7	thrombocytopenia	N	I-Claim
8	,	N	I-Claim
9	nausea	N	I-Claim
10	,	N	I-Claim
11	vomiting	N	I-Claim
12	,	N	I-Claim
13	anorexia	N	I-Claim
14	,	N	I-Claim
15	constipation	N	I-Claim
16	,	N	I-Claim
17	alopecia	N	I-Claim
18	,	N	I-Claim
19	headache	N	I-Claim
20	,	N	I-Claim
21	fatigue	N	I-Claim
22	,	N	I-Claim
23	and	N	I-Claim
24	convulsions	N	I-Claim
25	.	N	I-Claim

1	The	N	I-Claim
2	combination	N	I-Claim
3	of	N	I-Claim
4	interferon	N	I-Claim
5	alfa	N	I-Claim
6	(	N	I-Claim
7	IFNalpha	N	I-Claim
8	)	N	I-Claim
9	and	N	I-Claim
10	isotretinoin	N	I-Claim
11	has	N	I-Claim
12	shown	N	I-Claim
13	a	N	I-Claim
14	direct	N	I-Claim
15	antiproliferative	N	I-Claim
16	effect	N	I-Claim
17	on	N	I-Claim
18	human	N	I-Claim
19	melanoma	N	I-Claim
20	cell	N	I-Claim
21	lines	N	I-Claim
22	,	N	I-Claim
23	but	N	I-Claim
24	it	N	I-Claim
25	remained	N	I-Claim
26	unclear	N	I-Claim
27	whether	N	I-Claim
28	this	N	I-Claim
29	combination	N	I-Claim
30	is	N	I-Claim
31	more	N	I-Claim
32	effective	N	I-Claim
33	than	N	I-Claim
34	IFNalpha	N	I-Claim
35	alone	N	I-Claim
36	in	N	I-Claim
37	patients	N	I-Claim
38	with	N	I-Claim
39	metastatic	N	I-Claim
40	melanoma	N	I-Claim
41	.	N	I-Claim

1	We	N	O
2	evaluated	N	O
3	safety	N	O
4	and	N	O
5	efficacy	N	O
6	of	N	O
7	IFNalpha	N	O
8	and	N	O
9	isotretinoin	N	O
10	compared	N	O
11	with	N	O
12	IFNalpha	N	O
13	alone	N	O
14	as	N	O
15	adjuvant	N	O
16	treatment	N	O
17	in	N	O
18	patients	N	O
19	with	N	O
20	primary	N	O
21	malignant	N	O
22	melanoma	N	O
23	stage	N	O
24	IIA	N	O
25	and	N	O
26	IIB	N	O
27	.	N	O

1	In	N	O
2	a	N	O
3	prospective	N	O
4	,	N	O
5	randomized	N	O
6	,	N	O
7	double-blind	N	O
8	,	N	O
9	placebo-controlled	N	O
10	trial	N	O
11	,	N	O
12	407	N	O
13	melanoma	N	O
14	patients	N	O
15	in	N	O
16	stage	N	O
17	IIA	N	O
18	(	N	O
19	301	N	O
20	patients	N	O
21	)	N	O
22	and	N	O
23	IIB	N	O
24	(	N	O
25	106	N	O
26	patients	N	O
27	)	N	O
28	were	N	O
29	randomly	N	O
30	assigned	N	O
31	to	N	O
32	either	N	O
33	IFNalpha	N	O
34	and	N	O
35	isotretinoin	N	O
36	(	N	O
37	isotretinoin	N	O
38	group	N	O
39	;	N	O
40	206	N	O
41	patients	N	O
42	)	N	O
43	or	N	O
44	IFNalpha	N	O
45	and	N	O
46	placebo	N	O
47	(	N	O
48	placebo	N	O
49	group	N	O
50	;	N	O
51	201	N	O
52	patients	N	O
53	)	N	O
54	after	N	O
55	excision	N	O
56	of	N	O
57	the	N	O
58	primary	N	O
59	tumor	N	O
60	.	N	O

1	IFNalpha	N	O
2	was	N	O
3	administered	N	O
4	three	N	O
5	times	N	O
6	a	N	O
7	week	N	O
8	at	N	O
9	a	N	O
10	dose	N	O
11	of	N	O
12	3	N	O
13	million	N	O
14	units	N	O
15	subcutaneously	N	O
16	for	N	O
17	24	N	O
18	months	N	O
19	.	N	O

1	Isotretinoin	N	O
2	at	N	O
3	a	N	O
4	dose	N	O
5	of	N	O
6	20	N	O
7	mg	N	O
8	for	N	O
9	patients	N	O
10	<	N	O
11	or	N	O
12	=	N	O
13	73	N	O
14	kg	N	O
15	,	N	O
16	30	N	O
17	mg	N	O
18	for	N	O
19	patients	N	O
20	greater	N	O
21	than	N	O
22	73	N	O
23	kg	N	O
24	,	N	O
25	or	N	O
26	placebo	N	O
27	daily	N	O
28	for	N	O
29	24	N	O
30	months	N	O
31	.	N	O

1	A	N	I-Premise
2	scheduled	N	I-Premise
3	interim	N	I-Premise
4	analysis	N	I-Premise
5	revealed	N	I-Premise
6	no	N	I-Premise
7	significant	N	I-Premise
8	differences	N	I-Premise
9	in	N	I-Premise
10	survival	N	I-Premise
11	rates	N	I-Premise
12	,	N	I-Premise
13	with	N	I-Premise
14	the	N	I-Premise
15	isotretinoin	N	I-Premise
16	group	N	I-Premise
17	and	N	I-Premise
18	the	N	I-Premise
19	placebo	N	I-Premise
20	group	N	I-Premise
21	showing	N	I-Premise
22	5-year	N	I-Premise
23	disease-free	N	I-Premise
24	survival	N	I-Premise
25	rates	N	I-Premise
26	of	N	I-Premise
27	55	N	I-Premise
28	%	N	I-Premise
29	(	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	CI	N	I-Premise
33	,	N	I-Premise
34	46	N	I-Premise
35	%	N	I-Premise
36	to	N	I-Premise
37	65	N	I-Premise
38	%	N	I-Premise
39	)	N	I-Premise
40	and	N	I-Premise
41	67	N	I-Premise
42	%	N	I-Premise
43	(	N	I-Premise
44	95	N	I-Premise
45	%	N	I-Premise
46	CI	N	I-Premise
47	,	N	I-Premise
48	59	N	I-Premise
49	%	N	I-Premise
50	to	N	I-Premise
51	75	N	I-Premise
52	%	N	I-Premise
53	)	N	I-Premise
54	,	N	I-Premise
55	respectively	N	I-Premise
56	,	N	I-Premise
57	and	N	I-Premise
58	overall	N	I-Premise
59	5-year	N	I-Premise
60	survival	N	I-Premise
61	rates	N	I-Premise
62	of	N	I-Premise
63	76	N	I-Premise
64	%	N	I-Premise
65	(	N	I-Premise
66	95	N	I-Premise
67	%	N	I-Premise
68	CI	N	I-Premise
69	,	N	I-Premise
70	67	N	I-Premise
71	%	N	I-Premise
72	to	N	I-Premise
73	84	N	I-Premise
74	%	N	I-Premise
75	)	N	I-Premise
76	and	N	I-Premise
77	81	N	I-Premise
78	%	N	I-Premise
79	(	N	I-Premise
80	95	N	I-Premise
81	%	N	I-Premise
82	CI	N	I-Premise
83	,	N	I-Premise
84	74	N	I-Premise
85	%	N	I-Premise
86	to	N	I-Premise
87	88	N	I-Premise
88	%	N	I-Premise
89	)	N	I-Premise
90	,	N	I-Premise
91	respectively	N	I-Premise
92	.	N	I-Premise

1	The	N	O
2	trial	N	O
3	was	N	O
4	stopped	N	O
5	for	N	O
6	futility	N	O
7	.	N	O

1	The	N	I-Claim
2	addition	N	I-Claim
3	of	N	I-Claim
4	isotretinoin	N	I-Claim
5	to	N	I-Claim
6	an	N	I-Claim
7	adjuvant	N	I-Claim
8	treatment	N	I-Claim
9	of	N	I-Claim
10	low-dose	N	I-Claim
11	IFNalpha	N	I-Claim
12	in	N	I-Claim
13	patients	N	I-Claim
14	with	N	I-Claim
15	stage	N	I-Claim
16	IIA	N	I-Claim
17	and	N	I-Claim
18	IIB	N	I-Claim
19	melanoma	N	I-Claim
20	had	N	I-Claim
21	no	N	I-Claim
22	significant	N	I-Claim
23	effect	N	I-Claim
24	on	N	I-Claim
25	disease-free	N	I-Claim
26	or	N	I-Claim
27	overall	N	I-Claim
28	survival	N	I-Claim
29	and	N	I-Claim
30	is	N	I-Claim
31	therefore	N	I-Claim
32	not	N	I-Claim
33	recommended	N	I-Claim
34	.	N	I-Claim

1	We	N	O
2	investigated	N	O
3	the	N	O
4	role	N	O
5	of	N	O
6	tamoxifen	N	O
7	and	N	O
8	radiotherapy	N	O
9	(	N	O
10	RT	N	O
11	)	N	O
12	for	N	O
13	the	N	O
14	prevention	N	O
15	and	N	O
16	treatment	N	O
17	of	N	O
18	gynecomastia	N	O
19	and	N	O
20	breast	N	O
21	pain	N	O
22	during	N	O
23	adjuvant	N	O
24	bicalutamide	N	O
25	monotherapy	N	O
26	after	N	O
27	radical	N	O
28	prostatectomy	N	O
29	(	N	O
30	RP	N	O
31	)	N	O
32	in	N	O
33	patients	N	O
34	with	N	O
35	prostate	N	O
36	cancer	N	O
37	.	N	O

1	Also	N	O
2	,	N	O
3	we	N	O
4	evaluated	N	O
5	their	N	O
6	effects	N	O
7	on	N	O
8	patient	N	O
9	hormonal	N	O
10	status	N	O
11	,	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	(	N	O
16	QOL	N	O
17	)	N	O
18	,	N	O
19	sexual	N	O
20	function	N	O
21	and	N	O
22	prostate	N	O
23	specific	N	O
24	antigen	N	O
25	relapse-free	N	O
26	survival	N	O
27	.	N	O

1	This	N	O
2	was	N	O
3	a	N	O
4	multicenter	N	O
5	prospective	N	O
6	trial	N	O
7	.	N	O

1	From	N	O
2	January	N	O
3	2002	N	O
4	to	N	O
5	February	N	O
6	2004	N	O
7	,	N	O
8	102	N	O
9	patients	N	O
10	who	N	O
11	had	N	O
12	undergone	N	O
13	RP	N	O
14	for	N	O
15	localized	N	O
16	or	N	O
17	locally	N	O
18	advanced	N	O
19	prostate	N	O
20	cancer	N	O
21	were	N	O
22	recruited	N	O
23	and	N	O
24	randomized	N	O
25	into	N	O
26	3	N	O
27	groups	N	O
28	,	N	O
29	namely	N	O
30	group	N	O
31	1-those	N	O
32	receiving	N	O
33	only	N	O
34	150	N	O
35	mg	N	O
36	bicalutamide	N	O
37	as	N	O
38	adjuvant	N	O
39	hormonal	N	O
40	therapy	N	O
41	,	N	O
42	group	N	O
43	2-those	N	O
44	receiving	N	O
45	bicalutamide	N	O
46	and	N	O
47	10	N	O
48	mg	N	O
49	tamoxifen	N	O
50	,	N	O
51	and	N	O
52	group	N	O
53	3-those	N	O
54	receiving	N	O
55	bicalutamide	N	O
56	and	N	O
57	RT	N	O
58	.	N	O

1	Patients	N	O
2	in	N	O
3	group	N	O
4	1	N	O
5	in	N	O
6	whom	N	O
7	gynecomastia	N	O
8	or	N	O
9	breast	N	O
10	pain	N	O
11	developed	N	O
12	were	N	O
13	subsequently	N	O
14	randomized	N	O
15	to	N	O
16	receive	N	O
17	tamoxifen	N	O
18	or	N	O
19	RT	N	O
20	soon	N	O
21	after	N	O
22	symptoms	N	O
23	started	N	O
24	.	N	O

1	Gynecomastia	N	O
2	,	N	O
3	breast	N	O
4	pain	N	O
5	,	N	O
6	prostate	N	O
7	specific	N	O
8	antigen	N	O
9	,	N	O
10	QOL	N	O
11	,	N	O
12	sexual	N	O
13	function	N	O
14	and	N	O
15	hormonal	N	O
16	levels	N	O
17	were	N	O
18	assessed	N	O
19	.	N	O

1	Minimum	N	O
2	followup	N	O
3	was	N	O
4	12	N	O
5	months	N	O
6	.	N	O

1	Of	N	I-Premise
2	group	N	I-Premise
3	1	N	I-Premise
4	patients	N	I-Premise
5	67	N	I-Premise
6	%	N	I-Premise
7	had	N	I-Premise
8	gynecomastia	N	I-Premise
9	compared	N	I-Premise
10	with	N	I-Premise
11	8	N	I-Premise
12	%	N	I-Premise
13	in	N	I-Premise
14	group	N	I-Premise
15	2	N	I-Premise
16	and	N	I-Premise
17	34	N	I-Premise
18	%	N	I-Premise
19	in	N	I-Premise
20	group	N	I-Premise
21	3	N	I-Premise
22	.	N	I-Premise

1	Breast	N	I-Premise
2	pain	N	I-Premise
3	was	N	I-Premise
4	more	N	I-Premise
5	frequent	N	I-Premise
6	in	N	I-Premise
7	group	N	I-Premise
8	1	N	I-Premise
9	than	N	I-Premise
10	in	N	I-Premise
11	groups	N	I-Premise
12	2	N	I-Premise
13	and	N	I-Premise
14	3	N	I-Premise
15	(	N	I-Premise
16	58	N	I-Premise
17	%	N	I-Premise
18	vs	N	I-Premise
19	7	N	I-Premise
20	%	N	I-Premise
21	and	N	I-Premise
22	30	N	I-Premise
23	%	N	I-Premise
24	,	N	I-Premise
25	respectively	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	Differences	N	I-Premise
2	were	N	I-Premise
3	significant	N	I-Premise
4	between	N	I-Premise
5	groups	N	I-Premise
6	1	N	I-Premise
7	and	N	I-Premise
8	2	N	I-Premise
9	(	N	I-Premise
10	OR	N	I-Premise
11	0.12	N	I-Premise
12	p	N	I-Premise
13	<	N	I-Premise
14	0.001	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	and	N	I-Premise
18	groups	N	I-Premise
19	1	N	I-Premise
20	and	N	I-Premise
21	3	N	I-Premise
22	(	N	I-Premise
23	OR	N	I-Premise
24	0.52	N	I-Premise
25	p	N	I-Premise
26	<	N	I-Premise
27	0.01	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	In	N	I-Premise
2	patients	N	I-Premise
3	in	N	I-Premise
4	group	N	I-Premise
5	1	N	I-Premise
6	who	N	I-Premise
7	had	N	I-Premise
8	gynecomastia	N	I-Premise
9	or	N	I-Premise
10	breast	N	I-Premise
11	pain	N	I-Premise
12	a	N	I-Premise
13	significant	N	I-Premise
14	decrease	N	I-Premise
15	in	N	I-Premise
16	symptoms	N	I-Premise
17	was	N	I-Premise
18	achieved	N	I-Premise
19	in	N	I-Premise
20	those	N	I-Premise
21	receiving	N	I-Premise
22	tamoxifen	N	I-Premise
23	(	N	I-Premise
24	p	N	I-Premise
25	<	N	I-Premise
26	0.05	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	Treatments	N	I-Premise
2	were	N	I-Premise
3	well	N	I-Premise
4	tolerated	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	3	N	I-Premise
8	groups	N	I-Premise
9	.	N	I-Premise

1	No	N	I-Premise
2	differences	N	I-Premise
3	in	N	I-Premise
4	QOL	N	I-Premise
5	between	N	I-Premise
6	groups	N	I-Premise
7	2	N	I-Premise
8	and	N	I-Premise
9	3	N	I-Premise
10	were	N	I-Premise
11	found	N	I-Premise
12	.	N	I-Premise

1	At	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	followup	N	I-Premise
5	of	N	I-Premise
6	26	N	I-Premise
7	months	N	I-Premise
8	we	N	I-Premise
9	observed	N	I-Premise
10	12	N	I-Premise
11	biochemical	N	I-Premise
12	relapses	N	I-Premise
13	.	N	I-Premise

1	Gynecomastia	N	I-Claim
2	and	N	I-Claim
3	breast	N	I-Claim
4	pain	N	I-Claim
5	induced	N	I-Claim
6	by	N	I-Claim
7	bicalutamide	N	I-Claim
8	monotherapy	N	I-Claim
9	after	N	I-Claim
10	RP	N	I-Claim
11	can	N	I-Claim
12	be	N	I-Claim
13	prevented	N	I-Claim
14	and	N	I-Claim
15	treated	N	I-Claim
16	.	N	I-Claim

1	Tamoxifen	N	I-Claim
2	has	N	I-Claim
3	been	N	I-Claim
4	shown	N	I-Claim
5	to	N	I-Claim
6	be	N	I-Claim
7	more	N	I-Claim
8	effective	N	I-Claim
9	and	N	I-Claim
10	safe	N	I-Claim
11	than	N	I-Claim
12	RT	N	I-Claim
13	in	N	I-Claim
14	this	N	I-Claim
15	setting	N	I-Claim
16	.	N	I-Claim

1	QOL	N	I-Claim
2	and	N	I-Claim
3	sexual	N	I-Claim
4	function	N	I-Claim
5	are	N	I-Claim
6	not	N	I-Claim
7	negatively	N	I-Claim
8	influenced	N	I-Claim
9	by	N	I-Claim
10	these	N	I-Claim
11	2	N	I-Claim
12	treatment	N	I-Claim
13	options	N	I-Claim
14	.	N	O

1	The	N	O
2	majority	N	O
3	of	N	O
4	prostate	N	O
5	carcinoma	N	O
6	survivors	N	O
7	experience	N	O
8	enduring	N	O
9	sexual	N	O
10	difficulties	N	O
11	and	N	O
12	associated	N	O
13	distress	N	O
14	in	N	O
15	the	N	O
16	years	N	O
17	after	N	O
18	definitive	N	O
19	treatment	N	O
20	.	N	O

1	A	N	O
2	counseling	N	O
3	intervention	N	O
4	aimed	N	O
5	at	N	O
6	improving	N	O
7	levels	N	O
8	of	N	O
9	sexual	N	O
10	satisfaction	N	O
11	and	N	O
12	increasing	N	O
13	successful	N	O
14	utilization	N	O
15	of	N	O
16	medical	N	O
17	treatment	N	O
18	for	N	O
19	erectile	N	O
20	dysfunction	N	O
21	(	N	O
22	ED	N	O
23	)	N	O
24	was	N	O
25	developed	N	O
26	and	N	O
27	pilot-tested	N	O
28	for	N	O
29	both	N	O
30	the	N	O
31	survivor	N	O
32	of	N	O
33	prostate	N	O
34	carcinoma	N	O
35	and	N	O
36	his	N	O
37	partner	N	O
38	.	N	O

1	All	N	O
2	male	N	O
3	participants	N	O
4	were	N	O
5	3-month	N	O
6	to	N	O
7	5-year	N	O
8	survivors	N	O
9	of	N	O
10	localized	N	O
11	prostate	N	O
12	carcinoma	N	O
13	who	N	O
14	had	N	O
15	been	N	O
16	treated	N	O
17	with	N	O
18	radical	N	O
19	prostatectomy	N	O
20	or	N	O
21	radiation	N	O
22	therapy	N	O
23	,	N	O
24	and	N	O
25	were	N	O
26	married	N	O
27	or	N	O
28	in	N	O
29	a	N	O
30	committed	N	O
31	relationship	N	O
32	.	N	O

1	Couples	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	attend	N	O
6	four	N	O
7	sessions	N	O
8	of	N	O
9	counseling	N	O
10	together	N	O
11	or	N	O
12	to	N	O
13	have	N	O
14	the	N	O
15	man	N	O
16	attend	N	O
17	alone	N	O
18	.	N	O

1	In	N	O
2	both	N	O
3	groups	N	O
4	,	N	O
5	partners	N	O
6	completed	N	O
7	behavioral	N	O
8	homework	N	O
9	.	N	O

1	The	N	O
2	sessions	N	O
3	included	N	O
4	education	N	O
5	on	N	O
6	prostate	N	O
7	carcinoma	N	O
8	and	N	O
9	sexual	N	O
10	function	N	O
11	and	N	O
12	options	N	O
13	to	N	O
14	treat	N	O
15	ED	N	O
16	as	N	O
17	well	N	O
18	as	N	O
19	sexual	N	O
20	communication	N	O
21	and	N	O
22	stimulation	N	O
23	skills	N	O
24	.	N	O

1	Standardized	N	O
2	questionnaires	N	O
3	at	N	O
4	baseline	N	O
5	,	N	O
6	posttreatment	N	O
7	,	N	O
8	and	N	O
9	at	N	O
10	3-month	N	O
11	and	N	O
12	6-month	N	O
13	follow-up	N	O
14	assessed	N	O
15	sexual	N	O
16	function	N	O
17	,	N	O
18	marital	N	O
19	adjustment	N	O
20	,	N	O
21	psychologic	N	O
22	distress	N	O
23	,	N	O
24	and	N	O
25	utilization	N	O
26	of	N	O
27	treatments	N	O
28	for	N	O
29	ED	N	O
30	.	N	O

1	Fifty-one	N	O
2	of	N	O
3	84	N	O
4	couples	N	O
5	randomized	N	O
6	to	N	O
7	treatment	N	O
8	completed	N	O
9	the	N	O
10	intervention	N	O
11	(	N	O
12	61	N	O
13	%	N	O
14	)	N	O
15	.	N	O

1	Attendance	N	O
2	by	N	O
3	the	N	O
4	partner	N	O
5	did	N	O
6	not	N	O
7	affect	N	O
8	outcomes	N	O
9	.	N	O

1	Participants	N	I-Premise
2	completing	N	I-Premise
3	the	N	I-Premise
4	intervention	N	I-Premise
5	demonstrated	N	I-Premise
6	improvement	N	I-Premise
7	in	N	I-Premise
8	male	N	I-Premise
9	overall	N	I-Premise
10	distress	N	I-Premise
11	(	N	I-Premise
12	P	N	I-Premise
13	<	N	I-Premise
14	0.01	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	male	N	I-Premise
18	global	N	I-Premise
19	sexual	N	I-Premise
20	function	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	<	N	I-Premise
24	0.0001	N	I-Premise
25	)	N	I-Premise
26	,	N	I-Premise
27	and	N	I-Premise
28	female	N	I-Premise
29	global	N	I-Premise
30	sexual	N	I-Premise
31	function	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	<	N	I-Premise
35	0.05	N	I-Premise
36	)	N	I-Premise
37	at	N	I-Premise
38	3-month	N	I-Premise
39	follow-up	N	I-Premise
40	,	N	I-Premise
41	but	N	I-Premise
42	regression	N	I-Premise
43	toward	N	I-Premise
44	baseline	N	I-Premise
45	was	N	I-Premise
46	noted	N	I-Premise
47	at	N	I-Premise
48	6-month	N	I-Premise
49	follow-up	N	I-Premise
50	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	utilization	N	I-Premise
4	of	N	I-Premise
5	ED	N	I-Premise
6	treatments	N	I-Premise
7	increased	N	I-Premise
8	from	N	I-Premise
9	31	N	I-Premise
10	%	N	I-Premise
11	at	N	I-Premise
12	the	N	I-Premise
13	time	N	I-Premise
14	of	N	I-Premise
15	study	N	I-Premise
16	entry	N	I-Premise
17	to	N	I-Premise
18	49	N	I-Premise
19	%	N	I-Premise
20	at	N	I-Premise
21	the	N	I-Premise
22	6-month	N	I-Premise
23	follow-up	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	=	N	I-Premise
27	0.003	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	The	N	I-Claim
2	results	N	I-Claim
3	of	N	I-Claim
4	this	N	I-Claim
5	brief	N	I-Claim
6	pilot	N	I-Claim
7	counseling	N	I-Claim
8	intervention	N	I-Claim
9	demonstrated	N	I-Claim
10	significant	N	I-Claim
11	gains	N	I-Claim
12	in	N	I-Claim
13	sexual	N	I-Claim
14	function	N	I-Claim
15	and	N	I-Claim
16	satisfaction	N	I-Claim
17	and	N	I-Claim
18	increased	N	I-Claim
19	utilization	N	I-Claim
20	of	N	I-Claim
21	treatments	N	I-Claim
22	for	N	I-Claim
23	ED	N	I-Claim
24	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	modifications	N	I-Claim
4	are	N	I-Claim
5	needed	N	I-Claim
6	in	N	I-Claim
7	future	N	I-Claim
8	randomized	N	I-Claim
9	trials	N	I-Claim
10	to	N	I-Claim
11	reduce	N	I-Claim
12	the	N	I-Claim
13	rate	N	I-Claim
14	of	N	I-Claim
15	premature	N	I-Claim
16	termination	N	I-Claim
17	and	N	I-Claim
18	to	N	I-Claim
19	improve	N	I-Claim
20	long-term	N	I-Claim
21	maintenance	N	I-Claim
22	of	N	I-Claim
23	gains	N	I-Claim
24	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	outcomes	N	O
5	of	N	O
6	uterine	N	O
7	artery	N	O
8	embolization	N	O
9	(	N	O
10	UAE	N	O
11	)	N	O
12	for	N	O
13	leiomyomas	N	O
14	with	N	O
15	use	N	O
16	of	N	O
17	tris-acryl	N	O
18	gelatin	N	O
19	microspheres	N	O
20	(	N	O
21	TAGM	N	O
22	)	N	O
23	versus	N	O
24	spherical	N	O
25	polyvinyl	N	O
26	alcohol	N	O
27	(	N	O
28	PVA	N	O
29	)	N	O
30	particles	N	O
31	.	N	O

1	Patients	N	O
2	undergoing	N	O
3	UAE	N	O
4	were	N	O
5	randomly	N	O
6	assigned	N	O
7	to	N	O
8	receive	N	O
9	TAGMs	N	O
10	or	N	O
11	PVA	N	O
12	.	N	O

1	Embolization	N	O
2	was	N	O
3	performed	N	O
4	in	N	O
5	a	N	O
6	standardized	N	O
7	manner	N	O
8	.	N	O

1	Outcome	N	O
2	data	N	O
3	were	N	O
4	collected	N	O
5	at	N	O
6	3	N	O
7	months	N	O
8	after	N	O
9	embolization	N	O
10	,	N	O
11	including	N	O
12	assessment	N	O
13	of	N	O
14	clinical	N	O
15	symptoms	N	O
16	,	N	O
17	scores	N	O
18	from	N	O
19	a	N	O
20	fibroid	N	O
21	tumor-specific	N	O
22	symptom	N	O
23	and	N	O
24	quality	N	O
25	of	N	O
26	life	N	O
27	(	N	O
28	QOL	N	O
29	)	N	O
30	questionnaire	N	O
31	,	N	O
32	and	N	O
33	findings	N	O
34	on	N	O
35	contrast	N	O
36	material-enhanced	N	O
37	magnetic	N	O
38	resonance	N	O
39	(	N	O
40	MR	N	O
41	)	N	O
42	imaging	N	O
43	,	N	O
44	including	N	O
45	the	N	O
46	degree	N	O
47	of	N	O
48	tumor	N	O
49	infarction	N	O
50	and	N	O
51	volume	N	O
52	reduction	N	O
53	.	N	O

1	Data	N	O
2	were	N	O
3	analyzed	N	O
4	with	N	O
5	use	N	O
6	of	N	O
7	t	N	O
8	tests	N	O
9	,	N	O
10	the	N	O
11	Mann-Whitney	N	O
12	U	N	O
13	test	N	O
14	,	N	O
15	and	N	O
16	chi2	N	O
17	tests	N	O
18	as	N	O
19	appropriate	N	O
20	.	N	O

1	Thirty-six	N	O
2	patients	N	O
3	were	N	O
4	treated	N	O
5	.	N	O

1	There	N	O
2	were	N	O
3	no	N	O
4	differences	N	O
5	in	N	O
6	the	N	O
7	two	N	O
8	treatment	N	O
9	groups	N	O
10	at	N	O
11	baseline	N	O
12	.	N	O

1	Clinical	N	O
2	follow-up	N	O
3	was	N	O
4	obtained	N	O
5	in	N	O
6	35	N	O
7	patients	N	O
8	.	N	O

1	Among	N	I-Premise
2	the	N	I-Premise
3	clinical	N	I-Premise
4	outcome	N	I-Premise
5	measures	N	I-Premise
6	,	N	I-Premise
7	QOL	N	I-Premise
8	score	N	I-Premise
9	improvement	N	I-Premise
10	was	N	I-Premise
11	greater	N	I-Premise
12	for	N	I-Premise
13	UAE	N	I-Premise
14	with	N	I-Premise
15	TAGMs	N	I-Premise
16	compared	N	I-Premise
17	with	N	I-Premise
18	PVA	N	I-Premise
19	(	N	I-Premise
20	49.0	N	I-Premise
21	vs	N	I-Premise
22	27.9	N	I-Premise
23	;	N	I-Premise
24	P	N	I-Premise
25	=	N	I-Premise
26	.02	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	but	N	I-Premise
30	no	N	I-Premise
31	other	N	I-Premise
32	differences	N	I-Premise
33	were	N	I-Premise
34	noted	N	I-Premise
35	.	N	I-Premise

1	Of	N	I-Premise
2	the	N	I-Premise
3	25	N	I-Premise
4	patients	N	I-Premise
5	in	N	I-Premise
6	whom	N	I-Premise
7	3-month	N	I-Premise
8	MR	N	I-Premise
9	imaging	N	I-Premise
10	follow-up	N	I-Premise
11	was	N	I-Premise
12	completed	N	I-Premise
13	,	N	I-Premise
14	those	N	I-Premise
15	treated	N	I-Premise
16	with	N	I-Premise
17	TAGM	N	I-Premise
18	were	N	I-Premise
19	significantly	N	I-Premise
20	more	N	I-Premise
21	likely	N	I-Premise
22	to	N	I-Premise
23	have	N	I-Premise
24	complete	N	I-Premise
25	infarction	N	I-Premise
26	of	N	I-Premise
27	all	N	I-Premise
28	leiomyomas	N	I-Premise
29	(	N	I-Premise
30	six	N	I-Premise
31	patients	N	I-Premise
32	vs	N	I-Premise
33	one	N	I-Premise
34	patient	N	I-Premise
35	;	N	I-Premise
36	P	N	I-Premise
37	=	N	I-Premise
38	.02	N	I-Premise
39	)	N	I-Premise
40	,	N	I-Premise
41	were	N	I-Premise
42	more	N	I-Premise
43	likely	N	I-Premise
44	to	N	I-Premise
45	have	N	I-Premise
46	at	N	I-Premise
47	least	N	I-Premise
48	90	N	I-Premise
49	%	N	I-Premise
50	tumor	N	I-Premise
51	infarction	N	I-Premise
52	(	N	I-Premise
53	eight	N	I-Premise
54	patients	N	I-Premise
55	vs	N	I-Premise
56	four	N	I-Premise
57	patients	N	I-Premise
58	;	N	I-Premise
59	P	N	I-Premise
60	=	N	I-Premise
61	.03	N	I-Premise
62	)	N	I-Premise
63	,	N	I-Premise
64	and	N	I-Premise
65	had	N	I-Premise
66	a	N	I-Premise
67	lower	N	I-Premise
68	mean	N	I-Premise
69	percent	N	I-Premise
70	of	N	I-Premise
71	residual	N	I-Premise
72	perfused	N	I-Premise
73	fibroid	N	I-Premise
74	tumor	N	I-Premise
75	tissue	N	I-Premise
76	(	N	I-Premise
77	9.6	N	I-Premise
78	%	N	I-Premise
79	vs	N	I-Premise
80	44.3	N	I-Premise
81	%	N	I-Premise
82	;	N	I-Premise
83	P	N	I-Premise
84	=	N	I-Premise
85	.004	N	I-Premise
86	)	N	I-Premise
87	compared	N	I-Premise
88	with	N	I-Premise
89	patients	N	I-Premise
90	treated	N	I-Premise
91	with	N	I-Premise
92	PVA	N	I-Premise
93	.	N	I-Premise

1	Based	N	O
2	on	N	O
3	these	N	O
4	differences	N	O
5	between	N	O
6	the	N	O
7	embolic	N	O
8	agents	N	O
9	,	N	O
10	enrollment	N	O
11	in	N	O
12	this	N	O
13	study	N	O
14	was	N	O
15	terminated	N	O
16	.	N	O

1	The	N	I-Claim
2	use	N	I-Claim
3	of	N	I-Claim
4	spherical	N	I-Claim
5	PVA	N	I-Claim
6	particles	N	I-Claim
7	in	N	I-Claim
8	the	N	I-Claim
9	manner	N	I-Claim
10	described	N	I-Claim
11	herein	N	I-Claim
12	results	N	I-Claim
13	in	N	I-Claim
14	an	N	I-Claim
15	unacceptably	N	I-Claim
16	high	N	I-Claim
17	rate	N	I-Claim
18	of	N	I-Claim
19	failed	N	I-Claim
20	tumor	N	I-Claim
21	infarction	N	I-Claim
22	in	N	I-Claim
23	UAE	N	I-Claim
24	.	N	I-Claim

1	A	N	O
2	randomised	N	O
3	controlled	N	O
4	trial	N	O
5	of	N	O
6	radiotherapy	N	O
7	alone	N	O
8	versus	N	O
9	radiotherapy	N	O
10	with	N	O
11	concomitant	N	O
12	and	N	O
13	adjuvant	N	O
14	temozolomide	N	O
15	for	N	O
16	patients	N	O
17	with	N	O
18	glioblastoma	N	O
19	showed	N	O
20	that	N	O
21	survival	N	O
22	was	N	O
23	higher	N	O
24	for	N	O
25	patients	N	O
26	assigned	N	O
27	combination	N	O
28	treatment	N	O
29	compared	N	O
30	with	N	O
31	those	N	O
32	assigned	N	O
33	standard	N	O
34	radiotherapy	N	O
35	alone	N	O
36	.	N	O

1	This	N	O
2	paper	N	O
3	reports	N	O
4	the	N	O
5	health-related	N	O
6	quality	N	O
7	of	N	O
8	life	N	O
9	(	N	O
10	HRQOL	N	O
11	)	N	O
12	of	N	O
13	the	N	O
14	patients	N	O
15	in	N	O
16	this	N	O
17	trial	N	O
18	.	N	O

1	573	N	O
2	patients	N	O
3	with	N	O
4	newly	N	O
5	diagnosed	N	O
6	glioblastoma	N	O
7	were	N	O
8	randomly	N	O
9	allocated	N	O
10	either	N	O
11	radiotherapy	N	O
12	alone	N	O
13	or	N	O
14	radiotherapy	N	O
15	and	N	O
16	temozolomide	N	O
17	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	survival	N	O
6	,	N	O
7	and	N	O
8	HRQOL	N	O
9	was	N	O
10	a	N	O
11	secondary	N	O
12	endpoint	N	O
13	.	N	O

1	We	N	O
2	assessed	N	O
3	HRQOL	N	O
4	at	N	O
5	baseline	N	O
6	and	N	O
7	at	N	O
8	every	N	O
9	3	N	O
10	months	N	O
11	during	N	O
12	treatment	N	O
13	until	N	O
14	progression	N	O
15	using	N	O
16	the	N	O
17	European	N	O
18	Organisation	N	O
19	for	N	O
20	Research	N	O
21	and	N	O
22	Treatment	N	O
23	of	N	O
24	Cancer	N	O
25	(	N	O
26	EORTC	N	O
27	)	N	O
28	quality	N	O
29	of	N	O
30	life	N	O
31	questionnaire	N	O
32	core-30	N	O
33	(	N	O
34	QLQ-C30	N	O
35	)	N	O
36	and	N	O
37	the	N	O
38	EORTC	N	O
39	brain	N	O
40	cancer	N	O
41	module	N	O
42	(	N	O
43	EORTC	N	O
44	BN-20	N	O
45	)	N	O
46	.	N	O

1	We	N	O
2	calculated	N	O
3	changes	N	O
4	from	N	O
5	baseline	N	O
6	score	N	O
7	for	N	O
8	seven	N	O
9	predefined	N	O
10	HRQOL	N	O
11	measures	N	O
12	(	N	O
13	fatigue	N	O
14	,	N	O
15	overall	N	O
16	health	N	O
17	,	N	O
18	social	N	O
19	function	N	O
20	,	N	O
21	emotional	N	O
22	function	N	O
23	,	N	O
24	future	N	O
25	uncertainty	N	O
26	,	N	O
27	insomnia	N	O
28	,	N	O
29	and	N	O
30	communication	N	O
31	deficit	N	O
32	)	N	O
33	and	N	O
34	differences	N	O
35	between	N	O
36	groups	N	O
37	for	N	O
38	these	N	O
39	measures	N	O
40	at	N	O
41	every	N	O
42	time	N	O
43	point	N	O
44	.	N	O

1	The	N	O
2	significance	N	O
3	of	N	O
4	,	N	O
5	and	N	O
6	proportions	N	O
7	of	N	O
8	patients	N	O
9	with	N	O
10	,	N	O
11	improved	N	O
12	HRQOL	N	O
13	scores	N	O
14	--	N	O
15	defined	N	O
16	as	N	O
17	a	N	O
18	change	N	O
19	of	N	O
20	10	N	O
21	points	N	O
22	or	N	O
23	more	N	O
24	--	N	O
25	were	N	O
26	recorded	N	O
27	.	N	O

1	Baseline	N	O
2	questionnaires	N	O
3	were	N	O
4	available	N	O
5	for	N	O
6	490	N	O
7	(	N	O
8	86	N	O
9	%	N	O
10	)	N	O
11	patients	N	O
12	.	N	O

1	Baseline	N	O
2	HRQOL	N	O
3	scores	N	O
4	did	N	O
5	not	N	O
6	differ	N	O
7	between	N	O
8	groups	N	O
9	.	N	O

1	At	N	I-Premise
2	first	N	I-Premise
3	follow-up	N	I-Premise
4	,	N	I-Premise
5	groups	N	I-Premise
6	differed	N	I-Premise
7	only	N	I-Premise
8	in	N	I-Premise
9	social	N	I-Premise
10	functioning	N	I-Premise
11	,	N	I-Premise
12	favouring	N	I-Premise
13	the	N	I-Premise
14	radiotherapy-only	N	I-Premise
15	group	N	I-Premise
16	(	N	I-Premise
17	mean	N	I-Premise
18	score	N	I-Premise
19	79.0	N	I-Premise
20	[	N	I-Premise
21	SD	N	I-Premise
22	3.2	N	I-Premise
23	]	N	I-Premise
24	for	N	I-Premise
25	patients	N	I-Premise
26	assigned	N	I-Premise
27	radiotherapy	N	I-Premise
28	vs	N	I-Premise
29	67.4	N	I-Premise
30	[	N	I-Premise
31	2.7	N	I-Premise
32	]	N	I-Premise
33	for	N	I-Premise
34	those	N	I-Premise
35	assigned	N	I-Premise
36	radiotherapy	N	I-Premise
37	and	N	I-Premise
38	temozolomide	N	I-Premise
39	;	N	I-Premise
40	difference	N	I-Premise
41	between	N	I-Premise
42	groups	N	I-Premise
43	11.6	N	I-Premise
44	points	N	I-Premise
45	[	N	I-Premise
46	95	N	I-Premise
47	%	N	I-Premise
48	CI	N	I-Premise
49	3.5-19.7	N	I-Premise
50	]	N	I-Premise
51	,	N	I-Premise
52	p=0.0052	N	I-Premise
53	)	N	I-Premise
54	.	N	I-Premise

1	Over	N	I-Premise
2	subsequent	N	I-Premise
3	assessments	N	I-Premise
4	,	N	I-Premise
5	HRQOL	N	I-Premise
6	was	N	I-Premise
7	much	N	I-Premise
8	the	N	I-Premise
9	same	N	I-Premise
10	between	N	I-Premise
11	treatment	N	I-Premise
12	groups	N	I-Premise
13	.	N	I-Premise

1	Addition	N	I-Claim
2	of	N	I-Claim
3	temozolomide	N	I-Claim
4	during	N	I-Claim
5	and	N	I-Claim
6	after	N	I-Claim
7	radiotherapy	N	I-Claim
8	for	N	I-Claim
9	patients	N	I-Claim
10	with	N	I-Claim
11	newly	N	I-Claim
12	diagnosed	N	I-Claim
13	glioblastoma	N	I-Claim
14	significantly	N	I-Claim
15	improved	N	I-Claim
16	survival	N	I-Claim
17	without	N	I-Claim
18	a	N	I-Claim
19	negative	N	I-Claim
20	effect	N	I-Claim
21	on	N	I-Claim
22	HRQOL	N	I-Claim
23	.	N	I-Claim

1	Axillary	N	I-Claim
2	clearance	N	I-Claim
3	in	N	I-Claim
4	early	N	I-Claim
5	breast	N	I-Claim
6	cancer	N	I-Claim
7	aims	N	I-Claim
8	to	N	I-Claim
9	improve	N	I-Claim
10	locoregional	N	I-Claim
11	control	N	I-Claim
12	and	N	I-Claim
13	provide	N	I-Claim
14	staging	N	I-Claim
15	information	N	I-Claim
16	but	N	O
17	is	N	O
18	associated	N	O
19	with	N	O
20	undesirable	N	O
21	morbidity	N	O
22	.	N	O

1	We	N	O
2	therefore	N	O
3	investigated	N	O
4	whether	N	O
5	avoiding	N	O
6	axillary	N	O
7	surgery	N	O
8	in	N	O
9	older	N	O
10	women	N	O
11	would	N	O
12	result	N	O
13	in	N	O
14	improved	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	(	N	O
19	QL	N	O
20	)	N	O
21	with	N	O
22	similar	N	O
23	disease-free	N	O
24	survival	N	O
25	(	N	O
26	DFS	N	O
27	)	N	O
28	and	N	O
29	overall	N	O
30	survival	N	O
31	(	N	O
32	OS	N	O
33	)	N	O
34	.	N	O

1	Between	N	O
2	1993	N	O
3	and	N	O
4	2002	N	O
5	,	N	O
6	women	N	O
7	>	N	O
8	or	N	O
9	=	N	O
10	60	N	O
11	years	N	O
12	old	N	O
13	with	N	O
14	clinically	N	O
15	node-negative	N	O
16	operable	N	O
17	breast	N	O
18	cancer	N	O
19	in	N	O
20	whom	N	O
21	adjuvant	N	O
22	tamoxifen	N	O
23	was	N	O
24	considered	N	O
25	indicated	N	O
26	regardless	N	O
27	of	N	O
28	pathologic	N	O
29	nodal	N	O
30	status	N	O
31	were	N	O
32	randomly	N	O
33	assigned	N	O
34	to	N	O
35	primary	N	O
36	surgery	N	O
37	plus	N	O
38	axillary	N	O
39	clearance	N	O
40	(	N	O
41	Sx	N	O
42	+	N	O
43	Ax	N	O
44	)	N	O
45	followed	N	O
46	by	N	O
47	tamoxifen	N	O
48	(	N	O
49	Tam	N	O
50	)	N	O
51	versus	N	O
52	Sx	N	O
53	without	N	O
54	Ax	N	O
55	followed	N	O
56	by	N	O
57	Tam	N	O
58	for	N	O
59	5	N	O
60	consecutive	N	O
61	years	N	O
62	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	QL	N	O
7	reported	N	O
8	by	N	O
9	the	N	O
10	patient	N	O
11	and	N	O
12	by	N	O
13	physician	N	O
14	assessment	N	O
15	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	473	N	O
5	patients	N	O
6	(	N	O
7	234	N	O
8	to	N	O
9	Sx	N	O
10	+	N	O
11	Ax	N	O
12	,	N	O
13	239	N	O
14	to	N	O
15	Sx	N	O
16	)	N	O
17	were	N	O
18	randomly	N	O
19	assigned	N	O
20	.	N	O

1	The	N	O
2	median	N	O
3	age	N	O
4	was	N	O
5	74	N	O
6	years	N	O
7	;	N	O
8	80	N	O
9	%	N	O
10	had	N	O
11	estrogen	N	O
12	receptor-positive	N	O
13	disease	N	O
14	.	N	O

1	In	N	I-Premise
2	both	N	I-Premise
3	the	N	I-Premise
4	patients	N	I-Premise
5	'	N	I-Premise
6	subjective	N	I-Premise
7	assessment	N	I-Premise
8	of	N	I-Premise
9	their	N	I-Premise
10	QL	N	I-Premise
11	and	N	I-Premise
12	the	N	I-Premise
13	physicians	N	I-Premise
14	'	N	I-Premise
15	perception	N	I-Premise
16	of	N	I-Premise
17	the	N	I-Premise
18	patients	N	I-Premise
19	'	N	I-Premise
20	QL	N	I-Premise
21	,	N	I-Premise
22	the	N	I-Premise
23	largest	N	I-Premise
24	adverse	N	I-Premise
25	QL	N	I-Premise
26	effects	N	I-Premise
27	of	N	I-Premise
28	Ax	N	I-Premise
29	were	N	I-Premise
30	observed	N	I-Premise
31	from	N	I-Premise
32	baseline	N	I-Premise
33	to	N	I-Premise
34	the	N	I-Premise
35	first	N	I-Premise
36	postoperative	N	I-Premise
37	assessment	N	I-Premise
38	,	N	I-Premise
39	but	N	I-Premise
40	the	N	I-Premise
41	differences	N	I-Premise
42	tended	N	I-Premise
43	to	N	I-Premise
44	disappear	N	I-Premise
45	in	N	I-Premise
46	6	N	I-Premise
47	to	N	I-Premise
48	12	N	I-Premise
49	months	N	I-Premise
50	.	N	I-Premise

1	At	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	6.6	N	I-Premise
7	years	N	I-Premise
8	,	N	I-Premise
9	results	N	I-Premise
10	for	N	I-Premise
11	Sx	N	I-Premise
12	+	N	I-Premise
13	Ax	N	I-Premise
14	and	N	I-Premise
15	Sx	N	I-Premise
16	yielded	N	I-Premise
17	similar	N	I-Premise
18	DFS	N	I-Premise
19	(	N	I-Premise
20	6-year	N	I-Premise
21	DFS	N	I-Premise
22	,	N	I-Premise
23	67	N	I-Premise
24	%	N	I-Premise
25	v	N	I-Premise
26	66	N	I-Premise
27	%	N	I-Premise
28	;	N	I-Premise
29	hazard	N	I-Premise
30	ratio	N	I-Premise
31	[	N	I-Premise
32	HR	N	I-Premise
33	]	N	I-Premise
34	Sx	N	I-Premise
35	+	N	I-Premise
36	Ax/Sx	N	I-Premise
37	,	N	I-Premise
38	1.06	N	I-Premise
39	;	N	I-Premise
40	95	N	I-Premise
41	%	N	I-Premise
42	CI	N	I-Premise
43	,	N	I-Premise
44	0.79	N	I-Premise
45	to	N	I-Premise
46	1.42	N	I-Premise
47	;	N	I-Premise
48	P	N	I-Premise
49	=	N	I-Premise
50	.69	N	I-Premise
51	)	N	I-Premise
52	and	N	I-Premise
53	OS	N	I-Premise
54	(	N	I-Premise
55	6-year	N	I-Premise
56	OS	N	I-Premise
57	,	N	I-Premise
58	75	N	I-Premise
59	%	N	I-Premise
60	v	N	I-Premise
61	73	N	I-Premise
62	%	N	I-Premise
63	;	N	I-Premise
64	HR	N	I-Premise
65	Sx	N	I-Premise
66	+	N	I-Premise
67	Ax/Sx	N	I-Premise
68	,	N	I-Premise
69	1.05	N	I-Premise
70	;	N	I-Premise
71	95	N	I-Premise
72	%	N	I-Premise
73	CI	N	I-Premise
74	,	N	I-Premise
75	0.76	N	I-Premise
76	to	N	I-Premise
77	1.46	N	I-Premise
78	;	N	I-Premise
79	P	N	I-Premise
80	=	N	I-Premise
81	.77	N	I-Premise
82	)	N	I-Premise
83	.	N	I-Premise

1	Avoiding	N	I-Claim
2	axillary	N	I-Claim
3	clearance	N	I-Claim
4	for	N	I-Claim
5	women	N	I-Claim
6	>	N	I-Claim
7	or	N	I-Claim
8	=	N	I-Claim
9	60	N	I-Claim
10	years	N	I-Claim
11	old	N	I-Claim
12	who	N	I-Claim
13	have	N	I-Claim
14	clinically	N	I-Claim
15	node-negative	N	I-Claim
16	disease	N	I-Claim
17	and	N	I-Claim
18	receive	N	I-Claim
19	Tam	N	I-Claim
20	for	N	I-Claim
21	endocrine-responsive	N	I-Claim
22	disease	N	I-Claim
23	yields	N	I-Claim
24	similar	N	I-Claim
25	efficacy	N	I-Claim
26	with	N	I-Claim
27	better	N	I-Claim
28	early	N	I-Claim
29	QL	N	I-Claim
30	.	N	I-Claim

1	Chemotherapy	N	I-Claim
2	can	N	I-Claim
3	profoundly	N	I-Claim
4	affect	N	I-Claim
5	patients	N	I-Claim
6	'	N	I-Claim
7	quality	N	I-Claim
8	of	N	I-Claim
9	life	N	I-Claim
10	(	N	I-Claim
11	QOL	N	I-Claim
12	)	N	I-Claim
13	,	N	I-Claim
14	yet	N	O
15	few	N	O
16	clinical	N	O
17	trials	N	O
18	in	N	O
19	advanced	N	O
20	cervical	N	O
21	cancer	N	O
22	have	N	O
23	included	N	O
24	QOL	N	O
25	outcomes	N	O
26	.	N	O

1	Our	N	O
2	purpose	N	O
3	was	N	O
4	to	N	O
5	assess	N	O
6	the	N	O
7	impact	N	O
8	of	N	O
9	cisplatin	N	O
10	(	N	O
11	C	N	O
12	)	N	O
13	versus	N	O
14	cisplatin	N	O
15	plus	N	O
16	paclitaxel	N	O
17	(	N	O
18	CP	N	O
19	)	N	O
20	on	N	O
21	overall	N	O
22	QOL	N	O
23	and	N	O
24	pain	N	O
25	in	N	O
26	cervical	N	O
27	cancer	N	O
28	patients	N	O
29	.	N	O

1	QOL	N	O
2	was	N	O
3	assessed	N	O
4	using	N	O
5	FACT-Cx	N	O
6	,	N	O
7	consisting	N	O
8	of	N	O
9	the	N	O
10	Functional	N	O
11	Assessment	N	O
12	of	N	O
13	Cancer	N	O
14	Therapy	N	O
15	(	N	O
16	FACT-G	N	O
17	)	N	O
18	plus	N	O
19	a	N	O
20	cervix	N	O
21	cancer-specific	N	O
22	subscale	N	O
23	,	N	O
24	the	N	O
25	Brief	N	O
26	Pain	N	O
27	Inventory-Short	N	O
28	Form	N	O
29	(	N	O
30	BPI-SF	N	O
31	)	N	O
32	,	N	O
33	and	N	O
34	a	N	O
35	neurotoxicity	N	O
36	subscale	N	O
37	.	N	O

1	Time	N	O
2	points	N	O
3	were	N	O
4	:	N	O
5	baseline	N	O
6	(	N	O
7	prior	N	O
8	to	N	O
9	randomization	N	O
10	)	N	O
11	and	N	O
12	prior	N	O
13	to	N	O
14	chemotherapy	N	O
15	cycles	N	O
16	2	N	O
17	,	N	O
18	3	N	O
19	,	N	O
20	and	N	O
21	4	N	O
22	.	N	O

1	Overall	N	I-Premise
2	(	N	I-Premise
3	FACT-G	N	I-Premise
4	)	N	I-Premise
5	scores	N	I-Premise
6	did	N	I-Premise
7	not	N	I-Premise
8	differ	N	I-Premise
9	significantly	N	I-Premise
10	between	N	I-Premise
11	arms	N	I-Premise
12	at	N	I-Premise
13	the	N	I-Premise
14	fourth	N	I-Premise
15	assessment	N	I-Premise
16	(	N	I-Premise
17	C	N	I-Premise
18	=	N	I-Premise
19	70.3	N	I-Premise
20	(	N	I-Premise
21	19.6	N	I-Premise
22	)	N	I-Premise
23	;	N	I-Premise
24	CP	N	I-Premise
25	=	N	I-Premise
26	72.8	N	I-Premise
27	(	N	I-Premise
28	17.4	N	I-Premise
29	)	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	Scores	N	I-Premise
2	were	N	I-Premise
3	stable	N	I-Premise
4	over	N	I-Premise
5	time	N	I-Premise
6	and	N	I-Premise
7	considerably	N	I-Premise
8	lower	N	I-Premise
9	than	N	I-Premise
10	the	N	I-Premise
11	general	N	I-Premise
12	population	N	I-Premise
13	norms	N	I-Premise
14	.	N	I-Premise

1	The	N	I-Premise
2	BPI-SF	N	I-Premise
3	revealed	N	I-Premise
4	a	N	I-Premise
5	decline	N	I-Premise
6	in	N	I-Premise
7	pain	N	I-Premise
8	scores	N	I-Premise
9	in	N	I-Premise
10	both	N	I-Premise
11	arms	N	I-Premise
12	from	N	I-Premise
13	the	N	I-Premise
14	first	N	I-Premise
15	to	N	I-Premise
16	fourth	N	I-Premise
17	assessments	N	I-Premise
18	.	N	I-Premise

1	The	N	I-Premise
2	CP	N	I-Premise
3	arm	N	I-Premise
4	produced	N	I-Premise
5	a	N	I-Premise
6	significantly	N	I-Premise
7	higher	N	I-Premise
8	response	N	I-Premise
9	rate	N	I-Premise
10	and	N	I-Premise
11	progression-free	N	I-Premise
12	survival	N	I-Premise
13	(	N	I-Premise
14	PFS	N	I-Premise
15	)	N	I-Premise
16	but	N	I-Premise
17	not	N	I-Premise
18	overall	N	I-Premise
19	survival	N	I-Premise
20	(	N	I-Premise
21	OS	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	Greater	N	I-Premise
2	myelosuppression	N	I-Premise
3	was	N	I-Premise
4	reported	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	combination	N	I-Premise
8	arm	N	I-Premise
9	.	N	I-Premise

1	The	N	I-Premise
2	rate	N	I-Premise
3	of	N	I-Premise
4	QOL	N	I-Premise
5	drop-out	N	I-Premise
6	for	N	I-Premise
7	any	N	I-Premise
8	reason	N	I-Premise
9	was	N	I-Premise
10	higher	N	I-Premise
11	for	N	I-Premise
12	C	N	I-Premise
13	(	N	I-Premise
14	53	N	I-Premise
15	%	N	I-Premise
16	)	N	I-Premise
17	compared	N	I-Premise
18	to	N	I-Premise
19	CP	N	I-Premise
20	(	N	I-Premise
21	38	N	I-Premise
22	%	N	I-Premise
23	)	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	<	N	I-Premise
27	0.05	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	At	N	O
2	the	N	O
3	fourth	N	O
4	time	N	O
5	point	N	O
6	,	N	O
7	60	N	O
8	%	N	O
9	of	N	O
10	living	N	O
11	patients	N	O
12	in	N	O
13	both	N	O
14	arms	N	O
15	completed	N	O
16	a	N	O
17	QOL	N	O
18	assessment	N	O
19	.	N	O

1	There	N	I-Claim
2	was	N	I-Claim
3	no	N	I-Claim
4	significant	N	I-Claim
5	difference	N	I-Claim
6	in	N	I-Claim
7	overall	N	I-Claim
8	QOL	N	I-Claim
9	scores	N	I-Claim
10	between	N	I-Claim
11	treatment	N	I-Claim
12	arms	N	I-Claim
13	or	N	I-Claim
14	serially	N	I-Claim
15	.	N	I-Claim

1	Combined	N	I-Claim
2	with	N	I-Claim
3	QOL	N	I-Claim
4	results	N	I-Claim
5	,	N	I-Claim
6	the	N	I-Claim
7	significant	N	I-Claim
8	increase	N	I-Claim
9	in	N	I-Claim
10	response	N	I-Claim
11	and	N	I-Claim
12	PFS	N	I-Claim
13	in	N	I-Claim
14	the	N	I-Claim
15	CP	N	I-Claim
16	arm	N	I-Claim
17	and	N	I-Claim
18	the	N	I-Claim
19	higher	N	I-Claim
20	drop-out	N	I-Claim
21	rate	N	I-Claim
22	in	N	I-Claim
23	the	N	I-Claim
24	C	N	I-Claim
25	arm	N	I-Claim
26	suggest	N	I-Claim
27	a	N	I-Claim
28	better	N	I-Claim
29	outcome	N	I-Claim
30	for	N	I-Claim
31	the	N	I-Claim
32	combination	N	I-Claim
33	regimen	N	I-Claim
34	despite	N	I-Claim
35	its	N	I-Claim
36	increased	N	I-Claim
37	myelosuppression	N	I-Claim
38	.	N	I-Claim

1	After	N	O
2	surgery	N	O
3	for	N	O
4	differentiated	N	O
5	thyroid	N	O
6	carcinoma	N	O
7	,	N	O
8	many	N	O
9	patients	N	O
10	are	N	O
11	treated	N	O
12	with	N	O
13	radioiodine	N	O
14	to	N	O
15	ablate	N	O
16	remnant	N	O
17	thyroid	N	O
18	tissue	N	O
19	.	N	O

1	This	N	I-Claim
2	procedure	N	I-Claim
3	has	N	I-Claim
4	been	N	I-Claim
5	performed	N	I-Claim
6	with	N	I-Claim
7	the	N	I-Claim
8	patient	N	I-Claim
9	in	N	I-Claim
10	the	N	I-Claim
11	hypothyroid	N	I-Claim
12	state	N	I-Claim
13	to	N	I-Claim
14	promote	N	I-Claim
15	endogenous	N	I-Claim
16	TSH	N	I-Claim
17	stimulation	N	I-Claim
18	and	N	I-Claim
19	is	N	I-Claim
20	often	N	I-Claim
21	associated	N	I-Claim
22	with	N	I-Claim
23	hypothyroid	N	I-Claim
24	symptoms	N	I-Claim
25	and	N	I-Claim
26	impaired	N	I-Claim
27	quality	N	I-Claim
28	of	N	I-Claim
29	life	N	I-Claim
30	.	N	I-Claim

1	This	N	O
2	international	N	O
3	,	N	O
4	randomized	N	O
5	,	N	O
6	controlled	N	O
7	,	N	O
8	multicenter	N	O
9	trial	N	O
10	aimed	N	O
11	to	N	O
12	compare	N	O
13	the	N	O
14	efficacy	N	O
15	and	N	O
16	safety	N	O
17	of	N	O
18	recombinant	N	O
19	human	N	O
20	TSH	N	O
21	(	N	O
22	rhTSH	N	O
23	)	N	O
24	to	N	O
25	prepare	N	O
26	euthyroid	N	O
27	patients	N	O
28	on	N	O
29	L-thyroxine	N	O
30	therapy	N	O
31	(	N	O
32	euthyroid	N	O
33	group	N	O
34	)	N	O
35	to	N	O
36	ablate	N	O
37	remnant	N	O
38	thyroid	N	O
39	tissue	N	O
40	with	N	O
41	3.7	N	O
42	GBq	N	O
43	(	N	O
44	100	N	O
45	mCi	N	O
46	)	N	O
47	131I	N	O
48	,	N	O
49	compared	N	O
50	with	N	O
51	that	N	O
52	with	N	O
53	conventional	N	O
54	remnant	N	O
55	ablation	N	O
56	performed	N	O
57	in	N	O
58	the	N	O
59	hypothyroid	N	O
60	state	N	O
61	(	N	O
62	hypothyroid	N	O
63	group	N	O
64	)	N	O
65	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	determined	N	O
6	at	N	O
7	the	N	O
8	time	N	O
9	of	N	O
10	randomization	N	O
11	and	N	O
12	ablation	N	O
13	.	N	O

1	After	N	O
2	the	N	O
3	administration	N	O
4	of	N	O
5	the	N	O
6	131-I	N	O
7	dose	N	O
8	,	N	O
9	the	N	O
10	rate	N	O
11	of	N	O
12	radiation	N	O
13	clearance	N	O
14	from	N	O
15	blood	N	O
16	,	N	O
17	thyroid	N	O
18	remnant	N	O
19	,	N	O
20	and	N	O
21	whole	N	O
22	body	N	O
23	was	N	O
24	measured	N	O
25	.	N	O

1	The	N	O
2	predefined	N	O
3	primary	N	O
4	criterion	N	O
5	for	N	O
6	successful	N	O
7	ablation	N	O
8	was	N	O
9	``	N	O
10	no	N	O
11	visible	N	O
12	uptake	N	O
13	in	N	O
14	the	N	O
15	thyroid	N	O
16	bed	N	O
17	,	N	O
18	or	N	O
19	if	N	O
20	visible	N	O
21	,	N	O
22	fractional	N	O
23	uptake	N	O
24	less	N	O
25	than	N	O
26	0.1	N	O
27	%	N	O
28	''	N	O
29	on	N	O
30	neck	N	O
31	scans	N	O
32	performed	N	O
33	8	N	O
34	months	N	O
35	after	N	O
36	therapy	N	O
37	and	N	O
38	was	N	O
39	satisfied	N	O
40	in	N	O
41	100	N	O
42	%	N	O
43	of	N	O
44	patients	N	O
45	in	N	O
46	both	N	O
47	groups	N	O
48	.	N	O

1	A	N	O
2	secondary	N	O
3	criterion	N	O
4	for	N	O
5	ablation	N	O
6	,	N	O
7	an	N	O
8	rhTSH-stimulated	N	O
9	serum	N	O
10	thyroglobulin	N	O
11	concentration	N	O
12	less	N	O
13	than	N	O
14	2	N	O
15	ng/ml	N	O
16	,	N	O
17	was	N	O
18	fulfilled	N	O
19	by	N	O
20	23	N	O
21	of	N	O
22	24	N	O
23	(	N	O
24	96	N	O
25	%	N	O
26	)	N	O
27	euthyroid	N	O
28	patients	N	O
29	and	N	O
30	18	N	O
31	of	N	O
32	21	N	O
33	(	N	O
34	86	N	O
35	%	N	O
36	)	N	O
37	hypothyroid	N	O
38	patients	N	O
39	(	N	O
40	P	N	O
41	=	N	O
42	0.2341	N	O
43	)	N	O
44	.	N	O

1	Quality	N	I-Premise
2	of	N	I-Premise
3	life	N	I-Premise
4	was	N	I-Premise
5	well	N	I-Premise
6	preserved	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	euthyroid	N	I-Premise
10	group	N	I-Premise
11	,	N	I-Premise
12	compared	N	I-Premise
13	with	N	I-Premise
14	the	N	I-Premise
15	hypothyroid	N	I-Premise
16	group	N	I-Premise
17	,	N	I-Premise
18	as	N	I-Premise
19	demonstrated	N	I-Premise
20	by	N	I-Premise
21	their	N	I-Premise
22	lower	N	I-Premise
23	pretreatment	N	I-Premise
24	scores	N	I-Premise
25	on	N	I-Premise
26	the	N	I-Premise
27	Billewicz	N	I-Premise
28	scale	N	I-Premise
29	for	N	I-Premise
30	hypothyroid	N	I-Premise
31	signs	N	I-Premise
32	and	N	I-Premise
33	symptoms	N	I-Premise
34	,	N	I-Premise
35	27	N	I-Premise
36	+/-	N	I-Premise
37	7	N	I-Premise
38	vs.	N	I-Premise
39	18	N	I-Premise
40	+/-	N	I-Premise
41	4	N	I-Premise
42	(	N	I-Premise
43	P	N	I-Premise
44	<	N	I-Premise
45	0.0001	N	I-Premise
46	)	N	I-Premise
47	and	N	I-Premise
48	their	N	I-Premise
49	significantly	N	I-Premise
50	higher	N	I-Premise
51	Short	N	I-Premise
52	Form-36	N	I-Premise
53	Health	N	I-Premise
54	Assessment	N	I-Premise
55	Scale	N	I-Premise
56	scores	N	I-Premise
57	in	N	I-Premise
58	five	N	I-Premise
59	of	N	I-Premise
60	eight	N	I-Premise
61	categories	N	I-Premise
62	.	N	I-Premise

1	Euthyroid	N	I-Premise
2	patients	N	I-Premise
3	had	N	I-Premise
4	a	N	I-Premise
5	statistically	N	I-Premise
6	significant	N	I-Premise
7	one	N	I-Premise
8	third	N	I-Premise
9	lower	N	I-Premise
10	radiation	N	I-Premise
11	dose	N	I-Premise
12	to	N	I-Premise
13	the	N	I-Premise
14	blood	N	I-Premise
15	,	N	I-Premise
16	compared	N	I-Premise
17	with	N	I-Premise
18	patients	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	hypothyroid	N	I-Premise
22	group	N	I-Premise
23	.	N	I-Premise

1	This	N	I-Claim
2	study	N	I-Claim
3	demonstrates	N	I-Claim
4	comparable	N	I-Claim
5	remnant	N	I-Claim
6	ablation	N	I-Claim
7	rates	N	I-Claim
8	in	N	I-Claim
9	patients	N	I-Claim
10	prepared	N	I-Claim
11	for	N	I-Claim
12	131I	N	I-Claim
13	remnant	N	I-Claim
14	ablation	N	I-Claim
15	with	N	I-Claim
16	3.7	N	I-Claim
17	GBq	N	I-Claim
18	by	N	I-Claim
19	either	N	I-Claim
20	administering	N	I-Claim
21	rhTSH	N	I-Claim
22	or	N	I-Claim
23	withholding	N	I-Claim
24	thyroid	N	I-Claim
25	hormone	N	I-Claim
26	.	N	I-Claim

1	rhTSH-prepared	N	I-Claim
2	patients	N	I-Claim
3	maintained	N	I-Claim
4	a	N	I-Claim
5	higher	N	I-Claim
6	quality	N	I-Claim
7	of	N	I-Claim
8	life	N	I-Claim
9	and	N	I-Claim
10	received	N	I-Claim
11	less	N	I-Claim
12	radiation	N	I-Claim
13	exposure	N	I-Claim
14	to	N	I-Claim
15	the	N	I-Claim
16	blood	N	I-Claim
17	.	N	I-Claim

1	Patients	N	O
2	with	N	O
3	cancer	N	O
4	are	N	O
5	characterized	N	O
6	by	N	O
7	a	N	O
8	profound	N	O
9	impairment	N	O
10	of	N	O
11	glucose	N	O
12	utilization	N	O
13	,	N	O
14	with	N	O
15	lipids	N	O
16	being	N	O
17	the	N	O
18	preferred	N	O
19	metabolic	N	O
20	fuel	N	O
21	.	N	O

1	In	N	O
2	contrast	N	O
3	,	N	O
4	the	N	O
5	energy	N	O
6	needs	N	O
7	of	N	O
8	malignant	N	O
9	tumors	N	O
10	are	N	O
11	almost	N	O
12	entirely	N	O
13	met	N	O
14	by	N	O
15	glucose	N	O
16	.	N	O

1	We	N	O
2	therefore	N	O
3	studied	N	O
4	the	N	O
5	effects	N	O
6	of	N	O
7	a	N	O
8	high-fat	N	O
9	diet	N	O
10	,	N	O
11	particularly	N	O
12	on	N	O
13	body	N	O
14	composition	N	O
15	.	N	O

1	Twenty-three	N	O
2	moderately	N	O
3	malnourished	N	O
4	patients	N	O
5	with	N	O
6	gastrointestinal	N	O
7	carcinomas	N	O
8	were	N	O
9	randomized	N	O
10	to	N	O
11	receive	N	O
12	either	N	O
13	a	N	O
14	conventional	N	O
15	diet	N	O
16	supplying	N	O
17	35	N	O
18	nonprotein	N	O
19	kcal	N	O
20	and	N	O
21	1.1	N	O
22	g	N	O
23	of	N	O
24	protein/kg	N	O
25	per	N	O
26	day	N	O
27	(	N	O
28	group	N	O
29	A	N	O
30	,	N	O
31	n	N	O
32	=	N	O
33	11	N	O
34	)	N	O
35	or	N	O
36	a	N	O
37	fat-enriched	N	O
38	artificial	N	O
39	liquid	N	O
40	diet	N	O
41	(	N	O
42	20	N	O
43	nonprotein	N	O
44	kcal/kg	N	O
45	per	N	O
46	day	N	O
47	)	N	O
48	plus	N	O
49	normal	N	O
50	meals	N	O
51	(	N	O
52	group	N	O
53	B	N	O
54	,	N	O
55	n	N	O
56	=	N	O
57	12	N	O
58	)	N	O
59	for	N	O
60	a	N	O
61	period	N	O
62	of	N	O
63	eight	N	O
64	weeks	N	O
65	,	N	O
66	i.e.	N	O
67	,	N	O
68	from	N	O
69	the	N	O
70	first	N	O
71	to	N	O
72	the	N	O
73	third	N	O
74	chemotherapy	N	O
75	cycle	N	O
76	.	N	O

1	The	N	O
2	fat	N	O
3	content	N	O
4	of	N	O
5	the	N	O
6	artificial	N	O
7	diet	N	O
8	was	N	O
9	66	N	O
10	%	N	O
11	of	N	O
12	the	N	O
13	nonprotein	N	O
14	calories	N	O
15	.	N	O

1	The	N	O
2	day	N	O
3	before	N	O
4	the	N	O
5	nutritional	N	O
6	interventions	N	O
7	,	N	O
8	and	N	O
9	again	N	O
10	after	N	O
11	four	N	O
12	and	N	O
13	eight	N	O
14	weeks	N	O
15	,	N	O
16	body	N	O
17	compartments	N	O
18	were	N	O
19	determined	N	O
20	using	N	O
21	bioelectrical	N	O
22	impedance	N	O
23	analysis	N	O
24	,	N	O
25	lymphocyte	N	O
26	subpopulations	N	O
27	were	N	O
28	quantified	N	O
29	using	N	O
30	flow	N	O
31	cytometry	N	O
32	,	N	O
33	and	N	O
34	some	N	O
35	aspects	N	O
36	of	N	O
37	the	N	O
38	quality	N	O
39	of	N	O
40	life	N	O
41	were	N	O
42	rated	N	O
43	using	N	O
44	four	N	O
45	linear	N	O
46	analog	N	O
47	self-assessment	N	O
48	(	N	O
49	LASA	N	O
50	)	N	O
51	scales	N	O
52	.	N	O

1	The	N	O
2	statistical	N	O
3	calculations	N	O
4	were	N	O
5	done	N	O
6	as	N	O
7	an	N	O
8	exploratory	N	O
9	data	N	O
10	analysis	N	O
11	.	N	O

1	The	N	O
2	consumption	N	O
3	of	N	O
4	non-protein	N	O
5	calories	N	O
6	did	N	O
7	not	N	O
8	differ	N	O
9	significantly	N	O
10	between	N	O
11	the	N	O
12	two	N	O
13	patient	N	O
14	groups	N	O
15	.	N	O

1	An	N	I-Premise
2	average	N	I-Premise
3	weight	N	I-Premise
4	gain	N	I-Premise
5	in	N	I-Premise
6	group	N	I-Premise
7	B	N	I-Premise
8	contrasted	N	I-Premise
9	with	N	I-Premise
10	an	N	I-Premise
11	average	N	I-Premise
12	weight	N	I-Premise
13	loss	N	I-Premise
14	in	N	I-Premise
15	group	N	I-Premise
16	A	N	I-Premise
17	after	N	I-Premise
18	four	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	<	N	I-Premise
22	0.01	N	I-Premise
23	)	N	I-Premise
24	and	N	I-Premise
25	eight	N	I-Premise
26	weeks	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	0.05	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Fat-free	N	I-Premise
2	mass	N	I-Premise
3	showed	N	I-Premise
4	an	N	I-Premise
5	intergroup	N	I-Premise
6	difference	N	I-Premise
7	in	N	I-Premise
8	favor	N	I-Premise
9	of	N	I-Premise
10	group	N	I-Premise
11	B	N	I-Premise
12	after	N	I-Premise
13	eight	N	I-Premise
14	weeks	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	<	N	I-Premise
18	0.05	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	Body	N	I-Premise
2	cell	N	I-Premise
3	mass	N	I-Premise
4	was	N	I-Premise
5	maintained	N	I-Premise
6	throughout	N	I-Premise
7	the	N	I-Premise
8	study	N	I-Premise
9	in	N	I-Premise
10	group	N	I-Premise
11	B	N	I-Premise
12	,	N	I-Premise
13	but	N	I-Premise
14	declined	N	I-Premise
15	significantly	N	I-Premise
16	up	N	I-Premise
17	to	N	I-Premise
18	weeks	N	I-Premise
19	4	N	I-Premise
20	and	N	I-Premise
21	8	N	I-Premise
22	in	N	I-Premise
23	group	N	I-Premise
24	A	N	I-Premise
25	(	N	I-Premise
26	intergroup	N	I-Premise
27	difference	N	I-Premise
28	:	N	I-Premise
29	P	N	I-Premise
30	<	N	I-Premise
31	0.05	N	I-Premise
32	and	N	I-Premise
33	0.01	N	I-Premise
34	,	N	I-Premise
35	respectively	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	A	N	I-Premise
2	decrease	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	total	N	I-Premise
6	lymphocyte	N	I-Premise
7	count	N	I-Premise
8	by	N	I-Premise
9	559	N	I-Premise
10	cells/mul	N	I-Premise
11	occurred	N	I-Premise
12	with	N	I-Premise
13	the	N	I-Premise
14	fat-enriched	N	I-Premise
15	diet	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	<	N	I-Premise
19	0.05	N	I-Premise
20	)	N	I-Premise
21	.	N	I-Premise

1	Several	N	I-Premise
2	aspects	N	I-Premise
3	of	N	I-Premise
4	the	N	I-Premise
5	quality	N	I-Premise
6	of	N	I-Premise
7	life	N	I-Premise
8	were	N	I-Premise
9	rated	N	I-Premise
10	to	N	I-Premise
11	be	N	I-Premise
12	better	N	I-Premise
13	in	N	I-Premise
14	group	N	I-Premise
15	B	N	I-Premise
16	than	N	I-Premise
17	in	N	I-Premise
18	group	N	I-Premise
19	A	N	I-Premise
20	,	N	I-Premise
21	although	N	I-Premise
22	not	N	I-Premise
23	all	N	I-Premise
24	differences	N	I-Premise
25	reached	N	I-Premise
26	statistical	N	I-Premise
27	significance	N	I-Premise
28	.	N	I-Premise

1	In	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	cancer	N	I-Claim
5	,	N	I-Claim
6	a	N	I-Claim
7	high-fat	N	I-Claim
8	diet	N	I-Claim
9	may	N	I-Claim
10	possibly	N	I-Claim
11	support	N	I-Claim
12	the	N	I-Claim
13	maintenance	N	I-Claim
14	of	N	I-Claim
15	both	N	I-Claim
16	body	N	I-Claim
17	weight	N	I-Claim
18	and	N	I-Claim
19	body	N	I-Claim
20	cell	N	I-Claim
21	mass	N	I-Claim
22	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	monitoring	N	I-Claim
4	the	N	I-Claim
5	lymphocyte	N	I-Claim
6	count	N	I-Claim
7	is	N	I-Claim
8	advisable	N	I-Claim
9	.	N	I-Claim

1	For	N	I-MajorClaim
2	malignant	N	I-MajorClaim
3	pleural	N	I-MajorClaim
4	mesothelioma	N	I-MajorClaim
5	(	N	I-MajorClaim
6	MPM	N	I-MajorClaim
7	)	N	I-MajorClaim
8	patients	N	I-MajorClaim
9	with	N	I-MajorClaim
10	a	N	I-MajorClaim
11	poor	N	I-MajorClaim
12	prognosis	N	I-MajorClaim
13	,	N	I-MajorClaim
14	maintaining	N	I-MajorClaim
15	health-related	N	I-MajorClaim
16	quality	N	I-MajorClaim
17	of	N	I-MajorClaim
18	life	N	I-MajorClaim
19	(	N	I-MajorClaim
20	HRQOL	N	I-MajorClaim
21	)	N	I-MajorClaim
22	is	N	I-MajorClaim
23	important	N	I-MajorClaim
24	.	N	I-MajorClaim

1	This	N	O
2	article	N	O
3	compares	N	O
4	the	N	O
5	impact	N	O
6	on	N	O
7	HRQOL	N	O
8	of	N	O
9	first-line	N	O
10	treatment	N	O
11	with	N	O
12	cisplatin	N	O
13	versus	N	O
14	raltitrexed	N	O
15	and	N	O
16	cisplatin	N	O
17	.	N	O

1	Patients	N	O
2	with	N	O
3	histologically-proven	N	O
4	unresectable	N	O
5	MPM	N	O
6	,	N	O
7	not	N	O
8	pretreated	N	O
9	with	N	O
10	chemotherapy	N	O
11	were	N	O
12	randomly	N	O
13	assigned	N	O
14	to	N	O
15	receive	N	O
16	cisplatin	N	O
17	80	N	O
18	mg/m2	N	O
19	intravenously	N	O
20	on	N	O
21	day	N	O
22	1	N	O
23	,	N	O
24	with	N	O
25	or	N	O
26	without	N	O
27	preceding	N	O
28	infusion	N	O
29	of	N	O
30	raltitrexed	N	O
31	3	N	O
32	mg/m2	N	O
33	.	N	O

1	HRQOL	N	O
2	was	N	O
3	assessed	N	O
4	with	N	O
5	the	N	O
6	European	N	O
7	Organisation	N	O
8	for	N	O
9	Research	N	O
10	and	N	O
11	Treatment	N	O
12	of	N	O
13	Cancer	N	O
14	Core	N	O
15	Quality	N	O
16	of	N	O
17	Life	N	O
18	Questionnaire	N	O
19	C30	N	O
20	(	N	O
21	EORTC	N	O
22	QLQ-C30	N	O
23	)	N	O
24	and	N	O
25	EORTC	N	O
26	Lung	N	O
27	Cancer	N	O
28	Module	N	O
29	(	N	O
30	QLQ-LC13	N	O
31	)	N	O
32	tools	N	O
33	.	N	O

1	Assessments	N	O
2	were	N	O
3	conducted	N	O
4	at	N	O
5	baseline	N	O
6	,	N	O
7	immediately	N	O
8	before	N	O
9	every	N	O
10	treatment	N	O
11	cycle	N	O
12	,	N	O
13	at	N	O
14	the	N	O
15	end	N	O
16	of	N	O
17	treatment	N	O
18	,	N	O
19	and	N	O
20	every	N	O
21	six	N	O
22	weeks	N	O
23	for	N	O
24	12	N	O
25	months	N	O
26	.	N	O

1	Two	N	O
2	hundred	N	O
3	fifty	N	O
4	patients	N	O
5	were	N	O
6	randomly	N	O
7	assigned	N	O
8	,	N	O
9	80	N	O
10	%	N	O
11	were	N	O
12	male	N	O
13	with	N	O
14	a	N	O
15	median	N	O
16	age	N	O
17	of	N	O
18	58	N	O
19	years	N	O
20	,	N	O
21	WHO	N	O
22	performance	N	O
23	status	N	O
24	0	N	O
25	,	N	O
26	1	N	O
27	,	N	O
28	and	N	O
29	2	N	O
30	,	N	O
31	in	N	O
32	25	N	O
33	%	N	O
34	,	N	O
35	62	N	O
36	%	N	O
37	,	N	O
38	and	N	O
39	13	N	O
40	%	N	O
41	of	N	O
42	cases	N	O
43	.	N	O

1	The	N	I-Premise
2	clinical	N	I-Premise
3	results	N	I-Premise
4	found	N	I-Premise
5	raltitrexed	N	I-Premise
6	and	N	I-Premise
7	cisplatin	N	I-Premise
8	to	N	I-Premise
9	be	N	I-Premise
10	superior	N	I-Premise
11	to	N	I-Premise
12	cisplatin	N	I-Premise
13	with	N	I-Premise
14	regard	N	I-Premise
15	to	N	I-Premise
16	overall	N	I-Premise
17	survival	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	.048	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	The	N	I-Premise
2	global	N	I-Premise
3	HRQOL	N	I-Premise
4	scale	N	I-Premise
5	was	N	I-Premise
6	comparable	N	I-Premise
7	at	N	I-Premise
8	baseline	N	I-Premise
9	on	N	I-Premise
10	both	N	I-Premise
11	treatment	N	I-Premise
12	arms	N	I-Premise
13	(	N	I-Premise
14	P	N	I-Premise
15	=	N	I-Premise
16	.848	N	I-Premise
17	)	N	I-Premise
18	;	N	I-Premise
19	at	N	I-Premise
20	no	N	I-Premise
21	point	N	I-Premise
22	was	N	I-Premise
23	any	N	I-Premise
24	significant	N	I-Premise
25	difference	N	I-Premise
26	apparent	N	I-Premise
27	on	N	I-Premise
28	this	N	I-Premise
29	end	N	I-Premise
30	point	N	I-Premise
31	.	N	I-Premise

1	Both	N	I-Premise
2	treatments	N	I-Premise
3	led	N	I-Premise
4	to	N	I-Premise
5	an	N	I-Premise
6	improvement	N	I-Premise
7	,	N	I-Premise
8	over	N	I-Premise
9	time	N	I-Premise
10	,	N	I-Premise
11	in	N	I-Premise
12	dyspnoea	N	I-Premise
13	.	N	I-Premise

1	This	N	I-Claim
2	effect	N	I-Claim
3	is	N	I-Claim
4	an	N	I-Claim
5	important	N	I-Claim
6	clinically	N	I-Claim
7	meaningful	N	I-Claim
8	reduction	N	I-Claim
9	from	N	I-Claim
10	baseline	N	I-Claim
11	in	N	I-Claim
12	the	N	I-Claim
13	cisplatin/raltitrexed	N	I-Claim
14	arm	N	I-Claim
15	.	N	I-Claim

1	However	N	I-Premise
2	,	N	I-Premise
3	the	N	I-Premise
4	majority	N	I-Premise
5	of	N	I-Premise
6	scales	N	I-Premise
7	of	N	I-Premise
8	the	N	I-Premise
9	EORTC	N	I-Premise
10	QLQ-C30	N	I-Premise
11	or	N	I-Premise
12	LC13	N	I-Premise
13	showed	N	I-Premise
14	stabilization	N	I-Premise
15	of	N	I-Premise
16	HRQOL	N	I-Premise
17	with	N	I-Premise
18	few	N	I-Premise
19	clinically	N	I-Premise
20	significant	N	I-Premise
21	differences	N	I-Premise
22	between	N	I-Premise
23	the	N	I-Premise
24	treatment	N	I-Premise
25	arms	N	I-Premise
26	.	N	I-Premise

1	This	N	I-MajorClaim
2	study	N	I-MajorClaim
3	provides	N	I-MajorClaim
4	important	N	I-MajorClaim
5	information	N	I-MajorClaim
6	about	N	I-MajorClaim
7	the	N	I-MajorClaim
8	HRQOL	N	I-MajorClaim
9	of	N	I-MajorClaim
10	chemotherapy-treated	N	I-MajorClaim
11	MPM	N	I-MajorClaim
12	patients	N	I-MajorClaim
13	.	N	I-MajorClaim

1	The	N	O
2	goal	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	the	N	O
10	impact	N	O
11	of	N	O
12	neuronavigation	N	O
13	on	N	O
14	the	N	O
15	cytoreductive	N	O
16	treatment	N	O
17	of	N	O
18	solitary	N	O
19	contrast-enhancing	N	O
20	intracerebral	N	O
21	tumors	N	O
22	and	N	O
23	outcomes	N	O
24	of	N	O
25	this	N	O
26	treatment	N	O
27	in	N	O
28	cases	N	O
29	in	N	O
30	which	N	O
31	neuronavigation	N	O
32	was	N	O
33	preoperatively	N	O
34	judged	N	O
35	to	N	O
36	be	N	O
37	redundant	N	O
38	.	N	O

1	The	N	O
2	authors	N	O
3	conducted	N	O
4	a	N	O
5	prospective	N	O
6	randomized	N	O
7	study	N	O
8	in	N	O
9	which	N	O
10	45	N	O
11	patients	N	O
12	,	N	O
13	each	N	O
14	harboring	N	O
15	a	N	O
16	solitary	N	O
17	contrast-enhancing	N	O
18	intracerebral	N	O
19	tumor	N	O
20	,	N	O
21	were	N	O
22	randomized	N	O
23	for	N	O
24	surgery	N	O
25	with	N	O
26	or	N	O
27	without	N	O
28	neuronavigation	N	O
29	.	N	O

1	Peri-	N	O
2	and	N	O
3	postoperative	N	O
4	parameters	N	O
5	under	N	O
6	investigation	N	O
7	included	N	O
8	the	N	O
9	following	N	O
10	:	N	O
11	duration	N	O
12	of	N	O
13	the	N	O
14	procedure	N	O
15	;	N	O
16	surgeon	N	O
17	's	N	O
18	estimate	N	O
19	of	N	O
20	the	N	O
21	usefulness	N	O
22	of	N	O
23	neuronavigation	N	O
24	;	N	O
25	quantification	N	O
26	of	N	O
27	the	N	O
28	extent	N	O
29	of	N	O
30	resection	N	O
31	,	N	O
32	determined	N	O
33	using	N	O
34	magnetic	N	O
35	resonance	N	O
36	imaging	N	O
37	;	N	O
38	and	N	O
39	the	N	O
40	postoperative	N	O
41	course	N	O
42	,	N	O
43	as	N	O
44	evaluated	N	O
45	by	N	O
46	neurological	N	O
47	examinations	N	O
48	,	N	O
49	the	N	O
50	patient	N	O
51	's	N	O
52	quality-of-life	N	O
53	self-assessment	N	O
54	,	N	O
55	application	N	O
56	of	N	O
57	the	N	O
58	Barthel	N	O
59	index	N	O
60	and	N	O
61	the	N	O
62	Karnofsky	N	O
63	Performance	N	O
64	Scale	N	O
65	score	N	O
66	,	N	O
67	and	N	O
68	the	N	O
69	patient	N	O
70	's	N	O
71	time	N	O
72	of	N	O
73	death	N	O
74	.	N	O

1	The	N	I-Premise
2	mean	N	I-Premise
3	amount	N	I-Premise
4	of	N	I-Premise
5	residual	N	I-Premise
6	tumor	N	I-Premise
7	tissue	N	I-Premise
8	was	N	I-Premise
9	28.9	N	I-Premise
10	%	N	I-Premise
11	for	N	I-Premise
12	standard	N	I-Premise
13	surgery	N	I-Premise
14	(	N	I-Premise
15	SS	N	I-Premise
16	)	N	I-Premise
17	and	N	I-Premise
18	13.8	N	I-Premise
19	%	N	I-Premise
20	for	N	I-Premise
21	surgery	N	I-Premise
22	involving	N	I-Premise
23	neuronavigation	N	I-Premise
24	(	N	I-Premise
25	SN	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	The	N	I-Premise
2	corresponding	N	I-Premise
3	mean	N	I-Premise
4	amounts	N	I-Premise
5	of	N	I-Premise
6	residual	N	I-Premise
7	contrast-enhancing	N	I-Premise
8	tumor	N	I-Premise
9	tissue	N	I-Premise
10	were	N	I-Premise
11	29.2	N	I-Premise
12	and	N	I-Premise
13	24.4	N	I-Premise
14	%	N	I-Premise
15	,	N	I-Premise
16	respectively	N	I-Premise
17	.	N	I-Premise

1	These	N	I-Premise
2	differences	N	I-Premise
3	were	N	I-Premise
4	not	N	I-Premise
5	significant	N	I-Premise
6	.	N	I-Premise

1	Gross-total	N	I-Premise
2	removal	N	I-Premise
3	(	N	I-Premise
4	GTR	N	I-Premise
5	)	N	I-Premise
6	was	N	I-Premise
7	achieved	N	I-Premise
8	in	N	I-Premise
9	five	N	I-Premise
10	patients	N	I-Premise
11	who	N	I-Premise
12	underwent	N	I-Premise
13	SS	N	I-Premise
14	and	N	I-Premise
15	in	N	I-Premise
16	three	N	I-Premise
17	who	N	I-Premise
18	underwent	N	I-Premise
19	SN	N	I-Premise
20	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	significantly	N	I-Premise
5	shorter	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	SN	N	I-Premise
9	group	N	I-Premise
10	(	N	I-Premise
11	5.6	N	I-Premise
12	months	N	I-Premise
13	compared	N	I-Premise
14	with	N	I-Premise
15	9	N	I-Premise
16	months	N	I-Premise
17	,	N	I-Premise
18	unadjusted	N	I-Premise
19	hazard	N	I-Premise
20	ratio	N	I-Premise
21	=	N	I-Premise
22	1.6	N	I-Premise
23	)	N	I-Premise
24	;	N	I-Premise
25	however	N	I-Premise
26	,	N	I-Premise
27	this	N	I-Premise
28	difference	N	I-Premise
29	may	N	I-Premise
30	be	N	I-Premise
31	attributable	N	I-Premise
32	to	N	I-Premise
33	the	N	I-Premise
34	coincidental	N	I-Premise
35	early	N	I-Premise
36	death	N	I-Premise
37	of	N	I-Premise
38	three	N	I-Premise
39	patients	N	I-Premise
40	in	N	I-Premise
41	the	N	I-Premise
42	SN	N	I-Premise
43	group	N	I-Premise
44	.	N	I-Premise

1	No	N	I-Premise
2	discernible	N	I-Premise
3	important	N	I-Premise
4	effect	N	I-Premise
5	on	N	I-Premise
6	the	N	I-Premise
7	patients	N	I-Premise
8	'	N	I-Premise
9	3-month	N	I-Premise
10	postoperative	N	I-Premise
11	course	N	I-Premise
12	was	N	I-Premise
13	identified	N	I-Premise
14	.	N	I-Premise

1	There	N	I-Claim
2	is	N	I-Claim
3	no	N	I-Claim
4	rationale	N	I-Claim
5	for	N	I-Claim
6	the	N	I-Claim
7	routine	N	I-Claim
8	use	N	I-Claim
9	of	N	I-Claim
10	neuronavigation	N	I-Claim
11	to	N	I-Claim
12	improve	N	I-Claim
13	the	N	I-Claim
14	extent	N	I-Claim
15	of	N	I-Claim
16	tumor	N	I-Claim
17	resection	N	I-Claim
18	and	N	I-Claim
19	prognosis	N	I-Claim
20	in	N	I-Claim
21	patients	N	I-Claim
22	harboring	N	I-Claim
23	a	N	I-Claim
24	solitary	N	I-Claim
25	enhancing	N	I-Claim
26	intracerebral	N	I-Claim
27	lesion	N	I-Claim
28	when	N	I-Claim
29	neuronavigation	N	I-Claim
30	is	N	I-Claim
31	not	N	I-Claim
32	already	N	I-Claim
33	deemed	N	I-Claim
34	advantageous	N	I-Claim
35	because	N	I-Claim
36	of	N	I-Claim
37	the	N	I-Claim
38	size	N	I-Claim
39	or	N	I-Claim
40	location	N	I-Claim
41	of	N	I-Claim
42	the	N	I-Claim
43	lesion	N	I-Claim
44	.	N	I-Claim

1	Experimental	N	I-MajorClaim
2	and	N	I-MajorClaim
3	early	N	I-MajorClaim
4	clinical	N	I-MajorClaim
5	investigations	N	I-MajorClaim
6	have	N	I-MajorClaim
7	demonstrated	N	I-MajorClaim
8	encouraging	N	I-MajorClaim
9	results	N	I-MajorClaim
10	for	N	I-MajorClaim
11	estramustine	N	I-MajorClaim
12	in	N	I-MajorClaim
13	the	N	I-MajorClaim
14	treatment	N	I-MajorClaim
15	of	N	I-MajorClaim
16	malignant	N	I-MajorClaim
17	glioma	N	I-MajorClaim
18	.	N	O

1	The	N	O
2	present	N	O
3	study	N	O
4	is	N	O
5	an	N	O
6	open	N	O
7	randomized	N	O
8	clinical	N	O
9	trial	N	O
10	comparing	N	O
11	estramustine	N	O
12	phosphate	N	O
13	(	N	O
14	Estracyt	N	O
15	)	N	O
16	in	N	O
17	addition	N	O
18	to	N	O
19	radiotherapy	N	O
20	with	N	O
21	radiotherapy	N	O
22	alone	N	O
23	as	N	O
24	first	N	O
25	line	N	O
26	treatment	N	O
27	of	N	O
28	astrocytoma	N	O
29	grade	N	O
30	III	N	O
31	and	N	O
32	IV	N	O
33	.	N	O

1	The	N	O
2	140	N	O
3	patients	N	O
4	included	N	O
5	were	N	O
6	in	N	O
7	a	N	O
8	good	N	O
9	clinical	N	O
10	condition	N	O
11	with	N	O
12	a	N	O
13	median	N	O
14	age	N	O
15	of	N	O
16	55	N	O
17	years	N	O
18	(	N	O
19	range	N	O
20	22-87	N	O
21	)	N	O
22	.	N	O

1	Estramustine	N	O
2	was	N	O
3	given	N	O
4	orally	N	O
5	,	N	O
6	280	N	O
7	mg	N	O
8	twice	N	O
9	daily	N	O
10	,	N	O
11	as	N	O
12	soon	N	O
13	as	N	O
14	the	N	O
15	diagnosis	N	O
16	was	N	O
17	established	N	O
18	,	N	O
19	during	N	O
20	and	N	O
21	after	N	O
22	the	N	O
23	radiotherapy	N	O
24	for	N	O
25	a	N	O
26	period	N	O
27	of	N	O
28	in	N	O
29	total	N	O
30	3	N	O
31	months	N	O
32	.	N	O

1	Radiotherapy	N	O
2	was	N	O
3	delivered	N	O
4	on	N	O
5	weekdays	N	O
6	2	N	O
7	Gy	N	O
8	daily	N	O
9	up	N	O
10	to	N	O
11	56	N	O
12	Gy	N	O
13	.	N	O

1	Eighteen	N	O
2	patients	N	O
3	were	N	O
4	excluded	N	O
5	due	N	O
6	to	N	O
7	misclassification	N	O
8	,	N	O
9	leaving	N	O
10	122	N	O
11	patients	N	O
12	eligible	N	O
13	for	N	O
14	evaluation	N	O
15	.	N	O

1	Overall	N	I-Premise
2	the	N	I-Premise
3	treatment	N	I-Premise
4	was	N	I-Premise
5	well	N	I-Premise
6	tolerated	N	I-Premise
7	.	N	O

1	Mild	N	I-Premise
2	or	N	I-Premise
3	moderate	N	I-Premise
4	nausea	N	I-Premise
5	was	N	I-Premise
6	the	N	I-Premise
7	most	N	I-Premise
8	common	N	I-Premise
9	side	N	I-Premise
10	effect	N	I-Premise
11	of	N	I-Premise
12	estramustine	N	I-Premise
13	.	N	I-Premise

1	The	N	O
2	minimum	N	O
3	follow-up	N	O
4	time	N	O
5	was	N	O
6	5.2	N	O
7	years	N	O
8	for	N	O
9	the	N	O
10	surviving	N	O
11	patients	N	O
12	.	N	O

1	For	N	I-Premise
2	astrocytoma	N	I-Premise
3	grade	N	I-Premise
4	III	N	I-Premise
5	the	N	I-Premise
6	median	N	I-Premise
7	survival	N	I-Premise
8	time	N	I-Premise
9	was	N	I-Premise
10	10.6	N	I-Premise
11	(	N	I-Premise
12	1.3-92.7	N	I-Premise
13	)	N	I-Premise
14	months	N	I-Premise
15	for	N	I-Premise
16	the	N	I-Premise
17	radiotherapy	N	I-Premise
18	only	N	I-Premise
19	group	N	I-Premise
20	and	N	I-Premise
21	17.3	N	I-Premise
22	(	N	I-Premise
23	0.4-96.9+	N	I-Premise
24	)	N	I-Premise
25	months	N	I-Premise
26	for	N	I-Premise
27	the	N	I-Premise
28	estramustine	N	I-Premise
29	+	N	I-Premise
30	radiotherapy	N	I-Premise
31	group	N	I-Premise
32	.	N	I-Premise

1	In	N	I-Premise
2	grade	N	I-Premise
3	IV	N	I-Premise
4	the	N	I-Premise
5	corresponding	N	I-Premise
6	median	N	I-Premise
7	survival	N	I-Premise
8	time	N	I-Premise
9	was	N	I-Premise
10	12.3	N	I-Premise
11	(	N	I-Premise
12	2.1-89.2	N	I-Premise
13	)	N	I-Premise
14	and	N	I-Premise
15	10.3	N	I-Premise
16	(	N	I-Premise
17	0.3-91.7+	N	I-Premise
18	)	N	I-Premise
19	months	N	I-Premise
20	,	N	I-Premise
21	respectively	N	I-Premise
22	.	N	I-Premise

1	Median	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	progress	N	I-Premise
5	for	N	I-Premise
6	radiotherapy	N	I-Premise
7	only	N	I-Premise
8	and	N	I-Premise
9	radiotherapy	N	I-Premise
10	and	N	I-Premise
11	estramustin	N	I-Premise
12	group	N	I-Premise
13	in	N	I-Premise
14	grade	N	I-Premise
15	III	N	I-Premise
16	tumours	N	I-Premise
17	was	N	I-Premise
18	6.5	N	I-Premise
19	and	N	I-Premise
20	10.1	N	I-Premise
21	months	N	I-Premise
22	,	N	I-Premise
23	respectively	N	I-Premise
24	.	N	I-Premise

1	In	N	I-Premise
2	grade	N	I-Premise
3	IV	N	I-Premise
4	tumours	N	I-Premise
5	the	N	I-Premise
6	corresponding	N	I-Premise
7	figures	N	I-Premise
8	were	N	I-Premise
9	5.1	N	I-Premise
10	and	N	I-Premise
11	3.3	N	I-Premise
12	months	N	I-Premise
13	,	N	I-Premise
14	respectively	N	I-Premise
15	.	N	I-Premise

1	Although	N	I-Premise
2	there	N	I-Premise
3	was	N	I-Premise
4	a	N	I-Premise
5	tendency	N	I-Premise
6	for	N	I-Premise
7	improved	N	I-Premise
8	survival	N	I-Premise
9	in	N	I-Premise
10	grade	N	I-Premise
11	III	N	I-Premise
12	,	N	I-Premise
13	no	N	I-Premise
14	statistical	N	I-Premise
15	significant	N	I-Premise
16	differences	N	I-Premise
17	were	N	I-Premise
18	found	N	I-Premise
19	between	N	I-Premise
20	the	N	I-Premise
21	treatment	N	I-Premise
22	groups	N	I-Premise
23	.	N	I-Premise

1	No	N	I-Premise
2	differences	N	I-Premise
3	between	N	I-Premise
4	the	N	I-Premise
5	two	N	I-Premise
6	treatment	N	I-Premise
7	groups	N	I-Premise
8	were	N	I-Premise
9	evident	N	I-Premise
10	with	N	I-Premise
11	respect	N	I-Premise
12	to	N	I-Premise
13	quality	N	I-Premise
14	of	N	I-Premise
15	life	N	I-Premise
16	according	N	I-Premise
17	to	N	I-Premise
18	the	N	I-Premise
19	EORTC	N	I-Premise
20	QLQ-protocol	N	I-Premise
21	.	N	I-Premise

1	In	N	I-Claim
2	conclusion	N	I-Claim
3	,	N	I-Claim
4	this	N	I-Claim
5	first	N	I-Claim
6	randomized	N	I-Claim
7	study	N	I-Claim
8	did	N	I-Claim
9	not	N	I-Claim
10	demonstrate	N	I-Claim
11	any	N	I-Claim
12	significant	N	I-Claim
13	improvement	N	I-Claim
14	of	N	I-Claim
15	using	N	I-Claim
16	estramustine	N	I-Claim
17	in	N	I-Claim
18	addition	N	I-Claim
19	to	N	I-Claim
20	conventional	N	I-Claim
21	radiotherapy	N	I-Claim
22	,	N	I-Claim
23	however	N	I-Claim
24	,	N	I-Claim
25	a	N	I-Claim
26	trend	N	I-Claim
27	for	N	I-Claim
28	a	N	I-Claim
29	positive	N	I-Claim
30	response	N	I-Claim
31	for	N	I-Claim
32	the	N	I-Claim
33	estramustine	N	I-Claim
34	group	N	I-Claim
35	was	N	I-Claim
36	found	N	I-Claim
37	in	N	I-Claim
38	patients	N	I-Claim
39	with	N	I-Claim
40	grade	N	I-Claim
41	III	N	I-Claim
42	glioma	N	I-Claim
43	.	N	I-Claim

1	Sentinel	N	I-MajorClaim
2	lymph	N	I-MajorClaim
3	node	N	I-MajorClaim
4	biopsy	N	I-MajorClaim
5	in	N	I-MajorClaim
6	women	N	I-MajorClaim
7	with	N	I-MajorClaim
8	operable	N	I-MajorClaim
9	breast	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	is	N	I-MajorClaim
12	routinely	N	I-MajorClaim
13	used	N	I-MajorClaim
14	in	N	I-MajorClaim
15	some	N	I-MajorClaim
16	countries	N	I-MajorClaim
17	for	N	I-MajorClaim
18	staging	N	I-MajorClaim
19	the	N	I-MajorClaim
20	axilla	N	I-MajorClaim
21	despite	N	I-MajorClaim
22	limited	N	I-MajorClaim
23	data	N	I-MajorClaim
24	from	N	I-MajorClaim
25	randomized	N	I-MajorClaim
26	trials	N	I-MajorClaim
27	on	N	I-MajorClaim
28	morbidity	N	I-MajorClaim
29	and	N	I-MajorClaim
30	mortality	N	I-MajorClaim
31	outcomes	N	I-MajorClaim
32	.	N	I-MajorClaim

1	We	N	O
2	conducted	N	O
3	a	N	O
4	multicenter	N	O
5	randomized	N	O
6	trial	N	O
7	to	N	O
8	compare	N	O
9	quality-of-life	N	O
10	outcomes	N	O
11	between	N	O
12	patients	N	O
13	with	N	O
14	clinically	N	O
15	node-negative	N	O
16	invasive	N	O
17	breast	N	O
18	cancer	N	O
19	who	N	O
20	received	N	O
21	sentinel	N	O
22	lymph	N	O
23	node	N	O
24	biopsy	N	O
25	and	N	O
26	patients	N	O
27	who	N	O
28	received	N	O
29	standard	N	O
30	axillary	N	O
31	treatment	N	O
32	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	measures	N	O
5	were	N	O
6	arm	N	O
7	and	N	O
8	shoulder	N	O
9	morbidity	N	O
10	and	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	.	N	O

1	From	N	O
2	November	N	O
3	1999	N	O
4	to	N	O
5	October	N	O
6	2003	N	O
7	,	N	O
8	1031	N	O
9	patients	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	to	N	O
14	undergo	N	O
15	sentinel	N	O
16	lymph	N	O
17	node	N	O
18	biopsy	N	O
19	(	N	O
20	n	N	O
21	=	N	O
22	515	N	O
23	)	N	O
24	or	N	O
25	standard	N	O
26	axillary	N	O
27	surgery	N	O
28	(	N	O
29	n	N	O
30	=	N	O
31	516	N	O
32	)	N	O
33	.	N	O

1	Patients	N	O
2	with	N	O
3	sentinel	N	O
4	lymph	N	O
5	node	N	O
6	metastases	N	O
7	proceeded	N	O
8	to	N	O
9	delayed	N	O
10	axillary	N	O
11	clearance	N	O
12	or	N	O
13	received	N	O
14	axillary	N	O
15	radiotherapy	N	O
16	(	N	O
17	depending	N	O
18	on	N	O
19	the	N	O
20	protocol	N	O
21	at	N	O
22	the	N	O
23	treating	N	O
24	institution	N	O
25	)	N	O
26	.	N	O

1	Intention-to-treat	N	O
2	analyses	N	O
3	of	N	O
4	data	N	O
5	at	N	O
6	1	N	O
7	,	N	O
8	3	N	O
9	,	N	O
10	6	N	O
11	,	N	O
12	and	N	O
13	12	N	O
14	months	N	O
15	after	N	O
16	surgery	N	O
17	are	N	O
18	presented	N	O
19	.	N	O

1	All	N	O
2	statistical	N	O
3	tests	N	O
4	were	N	O
5	two-sided	N	O
6	.	N	O

1	The	N	I-Premise
2	relative	N	I-Premise
3	risks	N	I-Premise
4	of	N	I-Premise
5	any	N	I-Premise
6	lymphedema	N	I-Premise
7	and	N	I-Premise
8	sensory	N	I-Premise
9	loss	N	I-Premise
10	for	N	I-Premise
11	the	N	I-Premise
12	sentinel	N	I-Premise
13	lymph	N	I-Premise
14	node	N	I-Premise
15	biopsy	N	I-Premise
16	group	N	I-Premise
17	compared	N	I-Premise
18	with	N	I-Premise
19	the	N	I-Premise
20	standard	N	I-Premise
21	axillary	N	I-Premise
22	treatment	N	I-Premise
23	group	N	I-Premise
24	at	N	I-Premise
25	12	N	I-Premise
26	months	N	I-Premise
27	were	N	I-Premise
28	0.37	N	I-Premise
29	(	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	confidence	N	I-Premise
33	interval	N	I-Premise
34	[	N	I-Premise
35	CI	N	I-Premise
36	]	N	I-Premise
37	=	N	I-Premise
38	0.23	N	I-Premise
39	to	N	I-Premise
40	0.60	N	I-Premise
41	;	N	I-Premise
42	absolute	N	I-Premise
43	rates	N	I-Premise
44	:	N	I-Premise
45	5	N	I-Premise
46	%	N	I-Premise
47	versus	N	I-Premise
48	13	N	I-Premise
49	%	N	I-Premise
50	)	N	I-Premise
51	and	N	I-Premise
52	0.37	N	I-Premise
53	(	N	I-Premise
54	95	N	I-Premise
55	%	N	I-Premise
56	CI	N	I-Premise
57	=	N	I-Premise
58	0.27	N	I-Premise
59	to	N	I-Premise
60	0.50	N	I-Premise
61	;	N	I-Premise
62	absolute	N	I-Premise
63	rates	N	I-Premise
64	:	N	I-Premise
65	11	N	I-Premise
66	%	N	I-Premise
67	versus	N	I-Premise
68	31	N	I-Premise
69	%	N	I-Premise
70	)	N	I-Premise
71	,	N	I-Premise
72	respectively	N	I-Premise
73	.	N	I-Premise

1	Drain	N	I-Premise
2	usage	N	I-Premise
3	,	N	I-Premise
4	length	N	I-Premise
5	of	N	I-Premise
6	hospital	N	I-Premise
7	stay	N	I-Premise
8	,	N	I-Premise
9	and	N	I-Premise
10	time	N	I-Premise
11	to	N	I-Premise
12	resumption	N	I-Premise
13	of	N	I-Premise
14	normal	N	I-Premise
15	day-to-day	N	I-Premise
16	activities	N	I-Premise
17	after	N	I-Premise
18	surgery	N	I-Premise
19	were	N	I-Premise
20	statistically	N	I-Premise
21	significantly	N	I-Premise
22	lower	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	sentinel	N	I-Premise
26	lymph	N	I-Premise
27	node	N	I-Premise
28	biopsy	N	I-Premise
29	group	N	I-Premise
30	(	N	I-Premise
31	all	N	I-Premise
32	P	N	I-Premise
33	<	N	I-Premise
34	.001	N	I-Premise
35	)	N	I-Premise
36	,	N	I-Premise
37	and	N	I-Premise
38	axillary	N	I-Premise
39	operative	N	I-Premise
40	time	N	I-Premise
41	was	N	I-Premise
42	reduced	N	I-Premise
43	(	N	I-Premise
44	P	N	I-Premise
45	=	N	I-Premise
46	.055	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	Overall	N	I-Premise
2	patient-recorded	N	I-Premise
3	quality	N	I-Premise
4	of	N	I-Premise
5	life	N	I-Premise
6	and	N	I-Premise
7	arm	N	I-Premise
8	functioning	N	I-Premise
9	scores	N	I-Premise
10	were	N	I-Premise
11	statistically	N	I-Premise
12	significantly	N	I-Premise
13	better	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	sentinel	N	I-Premise
17	lymph	N	I-Premise
18	node	N	I-Premise
19	biopsy	N	I-Premise
20	group	N	I-Premise
21	throughout	N	I-Premise
22	(	N	I-Premise
23	all	N	I-Premise
24	P	N	I-Premise
25	<	N	I-Premise
26	or	N	I-Premise
27	=	N	I-Premise
28	.003	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	These	N	I-Premise
2	benefits	N	I-Premise
3	were	N	I-Premise
4	seen	N	I-Premise
5	with	N	I-Premise
6	no	N	I-Premise
7	increase	N	I-Premise
8	in	N	I-Premise
9	anxiety	N	I-Premise
10	levels	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	sentinel	N	I-Premise
14	lymph	N	I-Premise
15	node	N	I-Premise
16	biopsy	N	I-Premise
17	group	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	>	N	I-Premise
21	.05	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	Sentinel	N	I-Claim
2	lymph	N	I-Claim
3	node	N	I-Claim
4	biopsy	N	I-Claim
5	is	N	I-Claim
6	associated	N	I-Claim
7	with	N	I-Claim
8	reduced	N	I-Claim
9	arm	N	I-Claim
10	morbidity	N	I-Claim
11	and	N	I-Claim
12	better	N	I-Claim
13	quality	N	I-Claim
14	of	N	I-Claim
15	life	N	I-Claim
16	than	N	I-Claim
17	standard	N	I-Claim
18	axillary	N	I-Claim
19	treatment	N	I-Claim
20	and	N	I-Claim
21	should	N	I-Claim
22	be	N	I-Claim
23	the	N	I-Claim
24	treatment	N	I-Claim
25	of	N	I-Claim
26	choice	N	I-Claim
27	for	N	I-Claim
28	patients	N	I-Claim
29	who	N	I-Claim
30	have	N	I-Claim
31	early-stage	N	I-Claim
32	breast	N	I-Claim
33	cancer	N	I-Claim
34	with	N	I-Claim
35	clinically	N	I-Claim
36	negative	N	I-Claim
37	nodes	N	I-Claim
38	.	N	I-Claim

1	Patients	N	I-Claim
2	with	N	I-Claim
3	advanced	N	I-Claim
4	non-small	N	I-Claim
5	cell	N	I-Claim
6	lung	N	I-Claim
7	cancer	N	I-Claim
8	(	N	I-Claim
9	NSCLC	N	I-Claim
10	)	N	I-Claim
11	do	N	I-Claim
12	not	N	I-Claim
13	have	N	I-Claim
14	curative	N	I-Claim
15	treatment	N	I-Claim
16	options	N	I-Claim
17	;	N	I-Claim
18	therefore	N	O
19	,	N	O
20	treatments	N	O
21	should	N	O
22	prolong	N	O
23	survival	N	O
24	and	N	O
25	improve	N	O
26	quality	N	O
27	of	N	O
28	life	N	O
29	(	N	O
30	QoL	N	O
31	)	N	O
32	.	N	O

1	We	N	O
2	compared	N	O
3	the	N	O
4	effect	N	O
5	on	N	O
6	QoL	N	O
7	of	N	O
8	two	N	O
9	docetaxel-platinum	N	O
10	regimens	N	O
11	with	N	O
12	vinorelbine-cisplatin	N	O
13	.	N	O

1	QoL	N	O
2	was	N	O
3	assessed	N	O
4	by	N	O
5	the	N	O
6	Lung	N	O
7	Cancer	N	O
8	Symptom	N	O
9	Scale	N	O
10	(	N	O
11	LCSS	N	O
12	)	N	O
13	and	N	O
14	the	N	O
15	general	N	O
16	EuroQol	N	O
17	five-dimensional	N	O
18	questionnaire	N	O
19	(	N	O
20	EQ-5D	N	O
21	)	N	O
22	in	N	O
23	926	N	O
24	chemotherapy-naïve	N	O
25	patients	N	O
26	with	N	O
27	stages	N	O
28	IIIB	N	O
29	to	N	O
30	IV	N	O
31	NSCLC	N	O
32	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	receive	N	O
7	:	N	O
8	docetaxel	N	O
9	75	N	O
10	mg/m2	N	O
11	plus	N	O
12	cisplatin	N	O
13	75	N	O
14	mg/m2	N	O
15	,	N	O
16	every	N	O
17	3	N	O
18	weeks	N	O
19	(	N	O
20	DC	N	O
21	)	N	O
22	;	N	O
23	docetaxel	N	O
24	75	N	O
25	mg/m2	N	O
26	and	N	O
27	carboplatin	N	O
28	6	N	O
29	mg/ml	N	O
30	min	N	O
31	,	N	O
32	every	N	O
33	3	N	O
34	weeks	N	O
35	(	N	O
36	DCb	N	O
37	)	N	O
38	;	N	O
39	or	N	O
40	vinorelbine	N	O
41	25	N	O
42	mg/m2/week	N	O
43	plus	N	O
44	cisplatin	N	O
45	100	N	O
46	mg/m2	N	O
47	,	N	O
48	every	N	O
49	4	N	O
50	weeks	N	O
51	(	N	O
52	VC	N	O
53	)	N	O
54	.	N	O

1	Overall	N	I-Premise
2	,	N	I-Premise
3	patients	N	I-Premise
4	treated	N	I-Premise
5	with	N	I-Premise
6	either	N	I-Premise
7	docetaxel-containing	N	I-Premise
8	regimen	N	I-Premise
9	had	N	I-Premise
10	better	N	I-Premise
11	QoL	N	I-Premise
12	than	N	I-Premise
13	VC-treated	N	I-Premise
14	patients	N	I-Premise
15	(	N	I-Premise
16	LCSS	N	I-Premise
17	global	N	I-Premise
18	item	N	I-Premise
19	``	N	I-Premise
20	QoL	N	I-Premise
21	today	N	I-Premise
22	''	N	I-Premise
23	:	N	I-Premise
24	P=0.064	N	I-Premise
25	for	N	I-Premise
26	DC	N	I-Premise
27	and	N	I-Premise
28	P=0.016	N	I-Premise
29	for	N	I-Premise
30	DCb	N	I-Premise
31	versus	N	I-Premise
32	VC	N	I-Premise
33	;	N	I-Premise
34	EQ-5D	N	I-Premise
35	global	N	I-Premise
36	item	N	I-Premise
37	``	N	I-Premise
38	health	N	I-Premise
39	state	N	I-Premise
40	today	N	I-Premise
41	''	N	I-Premise
42	:	N	I-Premise
43	P=0.016	N	I-Premise
44	for	N	I-Premise
45	DC	N	I-Premise
46	and	N	I-Premise
47	P	N	I-Premise
48	<	N	I-Premise
49	0.001	N	I-Premise
50	for	N	I-Premise
51	DCb	N	I-Premise
52	versus	N	I-Premise
53	VC	N	I-Premise
54	)	N	I-Premise
55	.	N	I-Premise

1	DC-treated	N	I-Premise
2	patients	N	I-Premise
3	experienced	N	I-Premise
4	improved	N	I-Premise
5	pain	N	I-Premise
6	relief	N	I-Premise
7	compared	N	I-Premise
8	with	N	I-Premise
9	VC	N	I-Premise
10	(	N	I-Premise
11	P=0.033	N	I-Premise
12	)	N	I-Premise
13	,	N	I-Premise
14	whereas	N	O
15	pain	N	I-Premise
16	relief	N	I-Premise
17	with	N	I-Premise
18	DCb	N	I-Premise
19	and	N	I-Premise
20	VC	N	I-Premise
21	was	N	I-Premise
22	similar	N	I-Premise
23	.	N	I-Premise

1	Patients	N	I-Premise
2	treated	N	I-Premise
3	with	N	I-Premise
4	either	N	I-Premise
5	docetaxel	N	I-Premise
6	regimen	N	I-Premise
7	had	N	I-Premise
8	more	N	I-Premise
9	favorable	N	I-Premise
10	changes	N	I-Premise
11	in	N	I-Premise
12	performance	N	I-Premise
13	status	N	I-Premise
14	(	N	I-Premise
15	P=0.065	N	I-Premise
16	for	N	I-Premise
17	DC	N	I-Premise
18	and	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	0.001	N	I-Premise
22	for	N	I-Premise
23	DCb	N	I-Premise
24	versus	N	I-Premise
25	VC	N	I-Premise
26	)	N	I-Premise
27	and	N	I-Premise
28	mean	N	I-Premise
29	weight	N	I-Premise
30	loss	N	I-Premise
31	(	N	I-Premise
32	0.06	N	I-Premise
33	kg	N	I-Premise
34	,	N	I-Premise
35	gain	N	I-Premise
36	of	N	I-Premise
37	0.08	N	I-Premise
38	kg	N	I-Premise
39	,	N	I-Premise
40	and	N	I-Premise
41	2.27	N	I-Premise
42	kg	N	I-Premise
43	for	N	I-Premise
44	DC	N	I-Premise
45	,	N	I-Premise
46	DCb	N	I-Premise
47	,	N	I-Premise
48	and	N	I-Premise
49	VC	N	I-Premise
50	,	N	I-Premise
51	respectively	N	I-Premise
52	;	N	I-Premise
53	P	N	I-Premise
54	<	N	I-Premise
55	0.001	N	I-Premise
56	for	N	I-Premise
57	both	N	I-Premise
58	DC	N	I-Premise
59	versus	N	I-Premise
60	VC	N	I-Premise
61	and	N	I-Premise
62	DCb	N	I-Premise
63	versus	N	I-Premise
64	VC	N	I-Premise
65	)	N	I-Premise
66	.	N	I-Premise

1	The	N	I-Claim
2	TAX	N	I-Claim
3	326	N	I-Claim
4	study	N	I-Claim
5	shows	N	I-Claim
6	that	N	I-Claim
7	docetaxel-platinum	N	I-Claim
8	regimens	N	I-Claim
9	relieve	N	I-Claim
10	symptoms	N	I-Claim
11	and	N	I-Claim
12	improve	N	I-Claim
13	QoL	N	I-Claim
14	in	N	I-Claim
15	patients	N	I-Claim
16	with	N	I-Claim
17	advanced	N	I-Claim
18	NSCLC	N	I-Claim
19	.	N	I-Claim

1	DCb	N	I-Claim
2	and	N	I-Claim
3	DC	N	I-Claim
4	were	N	I-Claim
5	superior	N	I-Claim
6	to	N	I-Claim
7	VC	N	I-Claim
8	in	N	I-Claim
9	all	N	I-Claim
10	QoL	N	I-Claim
11	outcomes	N	I-Claim
12	assessed	N	I-Claim
13	except	N	I-Claim
14	for	N	I-Claim
15	the	N	I-Claim
16	difference	N	I-Claim
17	between	N	I-Claim
18	DC	N	I-Claim
19	and	N	I-Claim
20	VC	N	I-Claim
21	in	N	I-Claim
22	LCSS	N	I-Claim
23	``	N	I-Claim
24	QoL	N	I-Claim
25	today	N	I-Claim
26	''	N	I-Claim
27	,	N	I-Claim
28	which	N	I-Claim
29	was	N	I-Claim
30	not	N	I-Claim
31	significant	N	I-Claim
32	.	N	I-Claim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	pilot	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	examine	N	O
10	the	N	O
11	effects	N	O
12	of	N	O
13	a	N	O
14	combined	N	O
15	cardiorespiratory	N	O
16	and	N	O
17	resistance	N	O
18	exercise	N	O
19	training	N	O
20	program	N	O
21	of	N	O
22	short	N	O
23	duration	N	O
24	on	N	O
25	the	N	O
26	cardiorespiratory	N	O
27	fitness	N	O
28	,	N	O
29	strength	N	O
30	endurance	N	O
31	,	N	O
32	task	N	O
33	specific	N	O
34	functional	N	O
35	muscle	N	O
36	capacity	N	O
37	,	N	O
38	body	N	O
39	composition	N	O
40	and	N	O
41	quality	N	O
42	of	N	O
43	life	N	O
44	(	N	O
45	QOL	N	O
46	)	N	O
47	in	N	O
48	women	N	O
49	breast	N	O
50	cancer	N	O
51	survivors	N	O
52	.	N	O

1	Sixteen	N	O
2	subjects	N	O
3	were	N	O
4	randomly	N	O
5	assigned	N	O
6	to	N	O
7	either	N	O
8	a	N	O
9	training	N	O
10	(	N	O
11	n	N	O
12	=	N	O
13	8	N	O
14	;	N	O
15	age	N	O
16	:	N	O
17	50	N	O
18	+/-	N	O
19	5	N	O
20	yrs	N	O
21	)	N	O
22	or	N	O
23	control	N	O
24	non-exercising	N	O
25	group	N	O
26	(	N	O
27	n	N	O
28	=	N	O
29	8	N	O
30	;	N	O
31	age	N	O
32	:	N	O
33	51	N	O
34	+/-	N	O
35	10	N	O
36	yrs	N	O
37	)	N	O
38	.	N	O

1	The	N	O
2	training	N	O
3	group	N	O
4	followed	N	O
5	an	N	O
6	8-week	N	O
7	exercise	N	O
8	program	N	O
9	consisting	N	O
10	of	N	O
11	3	N	O
12	weekly	N	O
13	sessions	N	O
14	of	N	O
15	90-min	N	O
16	duration	N	O
17	,	N	O
18	supervised	N	O
19	by	N	O
20	an	N	O
21	experienced	N	O
22	investigator	N	O
23	and	N	O
24	divided	N	O
25	into	N	O
26	resistance	N	O
27	exercises	N	O
28	and	N	O
29	aerobic	N	O
30	training	N	O
31	.	N	O

1	Before	N	O
2	and	N	O
3	after	N	O
4	the	N	O
5	intervention	N	O
6	period	N	O
7	,	N	O
8	all	N	O
9	of	N	O
10	the	N	O
11	subjects	N	O
12	performed	N	O
13	a	N	O
14	cardiorespiratory	N	O
15	test	N	O
16	to	N	O
17	measure	N	O
18	peak	N	O
19	oxygen	N	O
20	uptake	N	O
21	(	N	O
22	VO2peak	N	O
23	)	N	O
24	,	N	O
25	a	N	O
26	dynamic	N	O
27	strength	N	O
28	endurance	N	O
29	test	N	O
30	(	N	O
31	maximum	N	O
32	number	N	O
33	of	N	O
34	repetitions	N	O
35	for	N	O
36	chest	N	O
37	and	N	O
38	leg	N	O
39	press	N	O
40	exercise	N	O
41	at	N	O
42	30	N	O
43	-	N	O
44	35	N	O
45	%	N	O
46	and	N	O
47	100	N	O
48	-	N	O
49	110	N	O
50	%	N	O
51	of	N	O
52	body	N	O
53	mass	N	O
54	,	N	O
55	respectively	N	O
56	)	N	O
57	and	N	O
58	a	N	O
59	sit-stand	N	O
60	test	N	O
61	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	assessed	N	O
6	using	N	O
7	the	N	O
8	European	N	O
9	Organization	N	O
10	for	N	O
11	Research	N	O
12	and	N	O
13	Treatment	N	O
14	of	N	O
15	Cancer	N	O
16	QLQ-C30	N	O
17	(	N	O
18	EORTC-C30	N	O
19	)	N	O
20	questionnaire	N	O
21	.	N	O

1	In	N	I-Premise
2	response	N	I-Premise
3	to	N	I-Premise
4	training	N	I-Premise
5	,	N	I-Premise
6	QOL	N	I-Premise
7	,	N	I-Premise
8	VO2peak	N	I-Premise
9	(	N	I-Premise
10	mean	N	I-Premise
11	3.9	N	I-Premise
12	ml/kg/min	N	I-Premise
13	;	N	I-Premise
14	95	N	I-Premise
15	%	N	I-Premise
16	CI	N	I-Premise
17	,	N	I-Premise
18	0.93	N	I-Premise
19	,	N	I-Premise
20	6.90	N	I-Premise
21	)	N	I-Premise
22	performance	N	I-Premise
23	in	N	I-Premise
24	leg	N	I-Premise
25	press	N	I-Premise
26	(	N	I-Premise
27	17.9	N	I-Premise
28	kg	N	I-Premise
29	;	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	CI	N	I-Premise
33	,	N	I-Premise
34	12.8	N	I-Premise
35	,	N	I-Premise
36	22.4	N	I-Premise
37	)	N	I-Premise
38	and	N	I-Premise
39	sit-stand	N	I-Premise
40	test	N	I-Premise
41	(	N	I-Premise
42	-	N	I-Premise
43	0.67	N	I-Premise
44	s	N	I-Premise
45	;	N	I-Premise
46	95	N	I-Premise
47	%	N	I-Premise
48	CI	N	I-Premise
49	,	N	I-Premise
50	-	N	I-Premise
51	0.52	N	I-Premise
52	,	N	I-Premise
53	-	N	I-Premise
54	1.2	N	I-Premise
55	)	N	I-Premise
56	improved	N	I-Premise
57	(	N	I-Premise
58	p	N	I-Premise
59	<	N	I-Premise
60	or	N	I-Premise
61	=	N	I-Premise
62	0.05	N	I-Premise
63	)	N	I-Premise
64	.	N	I-Premise

1	We	N	I-Premise
2	observed	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	changes	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	control	N	I-Premise
9	group	N	I-Premise
10	.	N	I-Premise

1	Combined	N	I-Claim
2	cardiorespiratory	N	I-Claim
3	and	N	I-Claim
4	resistance	N	I-Claim
5	training	N	I-Claim
6	,	N	I-Claim
7	even	N	I-Claim
8	of	N	I-Claim
9	very	N	I-Claim
10	brief	N	I-Claim
11	duration	N	I-Claim
12	,	N	I-Claim
13	improves	N	I-Claim
14	the	N	I-Claim
15	QOL	N	I-Claim
16	and	N	I-Claim
17	the	N	I-Claim
18	overall	N	I-Claim
19	physical	N	I-Claim
20	fitness	N	I-Claim
21	of	N	I-Claim
22	women	N	I-Claim
23	breast	N	I-Claim
24	cancer	N	I-Claim
25	survivors	N	I-Claim
26	.	N	I-Claim

1	LV5FU2	N	O
2	with	N	O
3	high-dose	N	O
4	leucovorin	N	O
5	(	N	O
6	LV	N	O
7	)	N	O
8	,	N	O
9	weekly	N	O
10	infusional	N	O
11	5-fluorouracil	N	O
12	(	N	O
13	5FU	N	O
14	)	N	O
15	(	N	O
16	AIO	N	O
17	schedule	N	O
18	)	N	O
19	and	N	O
20	raltitrexed	N	O
21	have	N	O
22	been	N	O
23	demonstrated	N	O
24	to	N	O
25	be	N	O
26	active	N	O
27	agents	N	O
28	in	N	O
29	first-line	N	O
30	treatment	N	O
31	of	N	O
32	colorectal	N	O
33	cancer	N	O
34	.	N	O

1	We	N	O
2	performed	N	O
3	a	N	O
4	4-arm	N	O
5	randomised	N	O
6	trial	N	O
7	to	N	O
8	compare	N	O
9	(	N	O
10	1	N	O
11	)	N	O
12	a	N	O
13	low-dose	N	O
14	intravenous	N	O
15	bolus	N	O
16	of	N	O
17	LV	N	O
18	(	N	O
19	20	N	O
20	mg/m2	N	O
21	)	N	O
22	,	N	O
23	followed	N	O
24	by	N	O
25	an	N	O
26	intravenous	N	O
27	bolus	N	O
28	of	N	O
29	5FU	N	O
30	(	N	O
31	400	N	O
32	mg/m2	N	O
33	)	N	O
34	,	N	O
35	followed	N	O
36	by	N	O
37	a	N	O
38	22-hour	N	O
39	continuous	N	O
40	infusion	N	O
41	of	N	O
42	5FU	N	O
43	(	N	O
44	600	N	O
45	mg/m2	N	O
46	)	N	O
47	on	N	O
48	day	N	O
49	1	N	O
50	and	N	O
51	day	N	O
52	2/2	N	O
53	weeks	N	O
54	(	N	O
55	ldLV5FU2	N	O
56	arm	N	O
57	)	N	O
58	,	N	O
59	(	N	O
60	2	N	O
61	)	N	O
62	a	N	O
63	weekly	N	O
64	continuous	N	O
65	infusion	N	O
66	of	N	O
67	high-dose	N	O
68	5FU	N	O
69	(	N	O
70	2.6	N	O
71	g/m2/week	N	O
72	)	N	O
73	for	N	O
74	6	N	O
75	weeks	N	O
76	followed	N	O
77	by	N	O
78	a	N	O
79	rest	N	O
80	week	N	O
81	(	N	O
82	HD-FU	N	O
83	arm	N	O
84	)	N	O
85	and	N	O
86	(	N	O
87	3	N	O
88	)	N	O
89	raltitrexed	N	O
90	(	N	O
91	Tomudex	N	O
92	arm	N	O
93	;	N	O
94	3	N	O
95	mg/m2/3	N	O
96	weeks	N	O
97	)	N	O
98	to	N	O
99	standard	N	O
100	LV5FU2	N	O
101	.	N	O

1	From	N	O
2	1997	N	O
3	to	N	O
4	2001	N	O
5	,	N	O
6	294	N	O
7	patients	N	O
8	were	N	O
9	included	N	O
10	.	N	O

1	The	N	O
2	4	N	O
3	arms	N	O
4	were	N	O
5	well	N	O
6	balanced	N	O
7	for	N	O
8	sex	N	O
9	ratio	N	O
10	,	N	O
11	age	N	O
12	,	N	O
13	WHO	N	O
14	performance	N	O
15	status	N	O
16	,	N	O
17	the	N	O
18	primary	N	O
19	tumour	N	O
20	site	N	O
21	and	N	O
22	prior	N	O
23	adjuvant	N	O
24	chemotherapy	N	O
25	.	N	O

1	Treatment	N	O
2	was	N	O
3	stopped	N	O
4	due	N	O
5	to	N	O
6	low	N	O
7	accrual	N	O
8	.	N	O

1	Two	N	I-Premise
2	toxicity-related	N	I-Premise
3	deaths	N	I-Premise
4	were	N	I-Premise
5	observed	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	Tomudex	N	I-Premise
9	arm	N	I-Premise
10	.	N	I-Premise

1	The	N	I-Premise
2	treatments	N	I-Premise
3	gave	N	I-Premise
4	rise	N	I-Premise
5	to	N	I-Premise
6	different	N	I-Premise
7	rates	N	I-Premise
8	of	N	I-Premise
9	grade	N	I-Premise
10	3-4	N	I-Premise
11	neutropenia	N	I-Premise
12	(	N	I-Premise
13	3	N	I-Premise
14	,	N	I-Premise
15	4	N	I-Premise
16	,	N	I-Premise
17	11	N	I-Premise
18	and	N	I-Premise
19	14	N	I-Premise
20	%	N	I-Premise
21	of	N	I-Premise
22	the	N	I-Premise
23	patients	N	I-Premise
24	in	N	I-Premise
25	the	N	I-Premise
26	LV5FU2	N	I-Premise
27	,	N	I-Premise
28	ldLV5FU2	N	I-Premise
29	,	N	I-Premise
30	HD-FU	N	I-Premise
31	and	N	I-Premise
32	Tomudex	N	I-Premise
33	arms	N	I-Premise
34	,	N	I-Premise
35	respectively	N	I-Premise
36	,	N	I-Premise
37	p	N	I-Premise
38	=	N	I-Premise
39	0.028	N	I-Premise
40	)	N	I-Premise
41	,	N	I-Premise
42	leucopenia	N	I-Premise
43	and	N	I-Premise
44	vomiting	N	I-Premise
45	.	N	I-Premise

1	At	N	I-Premise
2	least	N	I-Premise
3	one	N	I-Premise
4	episode	N	I-Premise
5	of	N	I-Premise
6	grade	N	I-Premise
7	3-4	N	I-Premise
8	toxicity	N	I-Premise
9	was	N	I-Premise
10	observed	N	I-Premise
11	in	N	I-Premise
12	27	N	I-Premise
13	,	N	I-Premise
14	25	N	I-Premise
15	,	N	I-Premise
16	38	N	I-Premise
17	and	N	I-Premise
18	47	N	I-Premise
19	%	N	I-Premise
20	of	N	I-Premise
21	the	N	I-Premise
22	patients	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	LV5FU2	N	I-Premise
26	,	N	I-Premise
27	ldLV5FU2	N	I-Premise
28	,	N	I-Premise
29	HD-FU	N	I-Premise
30	and	N	I-Premise
31	Tomudex	N	I-Premise
32	arms	N	I-Premise
33	,	N	I-Premise
34	respectively	N	I-Premise
35	(	N	I-Premise
36	p	N	I-Premise
37	=	N	I-Premise
38	0.016	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	An	N	I-Premise
2	objective	N	I-Premise
3	response	N	I-Premise
4	was	N	I-Premise
5	observed	N	I-Premise
6	in	N	I-Premise
7	28	N	I-Premise
8	,	N	I-Premise
9	21	N	I-Premise
10	,	N	I-Premise
11	22	N	I-Premise
12	and	N	I-Premise
13	10	N	I-Premise
14	%	N	I-Premise
15	of	N	I-Premise
16	the	N	I-Premise
17	patients	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	LV5FU2	N	I-Premise
21	,	N	I-Premise
22	ldLV5FU2	N	I-Premise
23	,	N	I-Premise
24	HD-FU	N	I-Premise
25	and	N	I-Premise
26	Tomudex	N	I-Premise
27	arms	N	I-Premise
28	,	N	I-Premise
29	respectively	N	I-Premise
30	(	N	I-Premise
31	p	N	I-Premise
32	=	N	I-Premise
33	0.04	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	Progression-free	N	I-Premise
2	survival	N	I-Premise
3	(	N	I-Premise
4	PFS	N	I-Premise
5	)	N	I-Premise
6	of	N	I-Premise
7	the	N	I-Premise
8	patients	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	Tomudex	N	I-Premise
12	arm	N	I-Premise
13	was	N	I-Premise
14	statistically	N	I-Premise
15	lower	N	I-Premise
16	compared	N	I-Premise
17	to	N	I-Premise
18	that	N	I-Premise
19	of	N	I-Premise
20	patients	N	I-Premise
21	treated	N	I-Premise
22	with	N	I-Premise
23	LV5FU2	N	I-Premise
24	or	N	I-Premise
25	ldLV5FU2	N	I-Premise
26	(	N	I-Premise
27	combined	N	I-Premise
28	group	N	I-Premise
29	;	N	I-Premise
30	p	N	I-Premise
31	=	N	I-Premise
32	0.013	N	I-Premise
33	,	N	I-Premise
34	log	N	I-Premise
35	rank	N	I-Premise
36	test	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	In	N	I-Claim
2	conclusion	N	I-Claim
3	,	N	I-Claim
4	Tomudex	N	I-Claim
5	is	N	I-Claim
6	more	N	I-Claim
7	toxic	N	I-Claim
8	and	N	I-Claim
9	yields	N	I-Claim
10	shorter	N	I-Claim
11	PFS	N	I-Claim
12	than	N	I-Claim
13	infusional	N	I-Claim
14	5FU	N	I-Claim
15	.	N	I-Claim

1	Despite	N	I-Claim
2	the	N	I-Claim
3	early	N	I-Claim
4	closure	N	I-Claim
5	of	N	I-Claim
6	the	N	I-Claim
7	study	N	I-Claim
8	and	N	I-Claim
9	the	N	I-Claim
10	lack	N	I-Claim
11	of	N	I-Claim
12	power	N	I-Claim
13	of	N	I-Claim
14	the	N	I-Claim
15	comparison	N	I-Claim
16	,	N	I-Claim
17	it	N	I-Claim
18	seems	N	I-Claim
19	that	N	I-Claim
20	ldLV5FU2	N	I-Claim
21	could	N	I-Claim
22	be	N	I-Claim
23	considered	N	I-Claim
24	as	N	I-Claim
25	an	N	I-Claim
26	active	N	I-Claim
27	,	N	I-Claim
28	easier	N	I-Claim
29	and	N	I-Claim
30	less	N	I-Claim
31	expensive	N	I-Claim
32	option	N	I-Claim
33	for	N	I-Claim
34	the	N	I-Claim
35	treatment	N	I-Claim
36	of	N	I-Claim
37	metastatic	N	I-Claim
38	colorectal	N	I-Claim
39	cancer	N	I-Claim
40	compared	N	I-Claim
41	to	N	I-Claim
42	classic	N	I-Claim
43	LV5FU2	N	I-Claim
44	or	N	I-Claim
45	weekly	N	I-Claim
46	HD-FU	N	I-Claim
47	.	N	I-Claim

1	DPPE	N	I-Claim
2	(	N	I-Claim
3	tesmilifene	N	I-Claim
4	)	N	I-Claim
5	plus	N	I-Claim
6	doxorubicin	N	I-Claim
7	(	N	I-Claim
8	DOX	N	I-Claim
9	)	N	I-Claim
10	demonstrated	N	I-Claim
11	a	N	I-Claim
12	significant	N	I-Claim
13	improvement	N	I-Claim
14	in	N	I-Claim
15	survival	N	I-Claim
16	versus	N	I-Claim
17	DOX	N	I-Claim
18	in	N	I-Claim
19	a	N	I-Claim
20	phase	N	I-Claim
21	III	N	I-Claim
22	clinical	N	I-Claim
23	trial	N	I-Claim
24	in	N	I-Claim
25	advanced	N	I-Claim
26	breast	N	I-Claim
27	cancer	N	I-Claim
28	.	N	I-Claim

1	However	N	I-Premise
2	,	N	I-Premise
3	DPPE	N	I-Premise
4	is	N	I-Premise
5	associated	N	I-Premise
6	with	N	I-Premise
7	unusual	N	I-Premise
8	toxicity	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	form	N	I-Premise
12	of	N	I-Premise
13	hallucinations	N	I-Premise
14	,	N	I-Premise
15	nausea	N	I-Premise
16	and	N	I-Premise
17	vomiting	N	I-Premise
18	which	N	I-Premise
19	were	N	I-Premise
20	anticipated	N	I-Premise
21	to	N	I-Premise
22	impact	N	I-Premise
23	on	N	I-Premise
24	short-term	N	I-Premise
25	quality	N	I-Premise
26	of	N	I-Premise
27	life	N	I-Premise
28	(	N	I-Premise
29	QOL	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	Standard	N	O
2	National	N	O
3	Cancer	N	O
4	Institute	N	O
5	of	N	O
6	Canada	N	O
7	Clinical	N	O
8	Trials	N	O
9	Group	N	O
10	(	N	O
11	NCIC	N	O
12	CTG	N	O
13	)	N	O
14	approaches	N	O
15	were	N	O
16	applied	N	O
17	as	N	O
18	the	N	O
19	primary	N	O
20	method	N	O
21	to	N	O
22	analyze	N	O
23	the	N	O
24	QOL	N	O
25	data	N	O
26	from	N	O
27	this	N	O
28	trial	N	O
29	.	N	O

1	This	N	O
2	includes	N	O
3	cross-sectional	N	O
4	comparisons	N	O
5	,	N	O
6	together	N	O
7	with	N	O
8	a	N	O
9	global	N	O
10	test	N	O
11	for	N	O
12	the	N	O
13	QOL	N	O
14	response	N	O
15	rate	N	O
16	.	N	O

1	Sensitivity	N	O
2	analyses	N	O
3	were	N	O
4	also	N	O
5	performed	N	O
6	for	N	O
7	selected	N	O
8	QOL	N	O
9	domains	N	O
10	and	N	O
11	items	N	O
12	,	N	O
13	using	N	O
14	other	N	O
15	types	N	O
16	of	N	O
17	summary	N	O
18	measures	N	O
19	and	N	O
20	statistics	N	O
21	.	N	O

1	Two	N	O
2	hundred	N	O
3	seventy	N	O
4	one	N	O
5	patients	N	O
6	(	N	O
7	89	N	O
8	%	N	O
9	of	N	O
10	randomized	N	O
11	)	N	O
12	submitted	N	O
13	the	N	O
14	baseline	N	O
15	QOL	N	O
16	questionnaires	N	O
17	and	N	O
18	were	N	O
19	included	N	O
20	in	N	O
21	the	N	O
22	QOL	N	O
23	analysis	N	O
24	.	N	O

1	No	N	I-Premise
2	statistically	N	I-Premise
3	significant	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	QOL	N	I-Premise
7	response	N	I-Premise
8	between	N	I-Premise
9	treatment	N	I-Premise
10	arms	N	I-Premise
11	was	N	I-Premise
12	found	N	I-Premise
13	for	N	I-Premise
14	any	N	I-Premise
15	domain	N	I-Premise
16	or	N	I-Premise
17	item	N	I-Premise
18	except	N	I-Premise
19	nausea	N	I-Premise
20	and	N	I-Premise
21	vomiting	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	=	N	I-Premise
25	0.04	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	Cross-sectional	N	I-Premise
2	comparisons	N	I-Premise
3	showed	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	differences	N	I-Premise
7	for	N	I-Premise
8	some	N	I-Premise
9	domains/items	N	I-Premise
10	at	N	I-Premise
11	specific	N	I-Premise
12	assessment	N	I-Premise
13	times	N	I-Premise
14	with	N	I-Premise
15	all	N	I-Premise
16	differences	N	I-Premise
17	favoring	N	I-Premise
18	the	N	I-Premise
19	DOX	N	I-Premise
20	alone	N	I-Premise
21	arm	N	I-Premise
22	.	N	I-Premise

1	Patients	N	I-Premise
2	on	N	I-Premise
3	DPPE/DOX	N	I-Premise
4	arm	N	I-Premise
5	were	N	I-Premise
6	significantly	N	I-Premise
7	worse	N	I-Premise
8	in	N	I-Premise
9	terms	N	I-Premise
10	of	N	I-Premise
11	average	N	I-Premise
12	and	N	I-Premise
13	median	N	I-Premise
14	pain	N	I-Premise
15	change	N	I-Premise
16	scores	N	I-Premise
17	.	N	I-Premise

1	Different	N	I-Claim
2	analyses	N	I-Claim
3	yielded	N	I-Claim
4	slightly	N	I-Claim
5	different	N	I-Claim
6	conclusions	N	I-Claim
7	but	N	O
8	,	N	O
9	in	N	I-Claim
10	general	N	I-Claim
11	,	N	I-Claim
12	the	N	I-Claim
13	QOL	N	I-Claim
14	analyses	N	I-Claim
15	were	N	I-Claim
16	concordant	N	I-Claim
17	and	N	I-Claim
18	showed	N	I-Claim
19	that	N	I-Claim
20	patients	N	I-Claim
21	on	N	I-Claim
22	DOX	N	I-Claim
23	alone	N	I-Claim
24	had	N	I-Claim
25	fewer	N	I-Claim
26	disease	N	I-Claim
27	and	N	I-Claim
28	treatment	N	I-Claim
29	related	N	I-Claim
30	adverse	N	I-Claim
31	events	N	I-Claim
32	and	N	I-Claim
33	better	N	I-Claim
34	QOL	N	I-Claim
35	.	N	I-Claim

1	Interestingly	N	I-Claim
2	,	N	I-Claim
3	the	N	I-Claim
4	QOL	N	I-Claim
5	response	N	I-Claim
6	analysis	N	I-Claim
7	also	N	I-Claim
8	showed	N	I-Claim
9	that	N	I-Claim
10	aggressive	N	I-Claim
11	premedication	N	I-Claim
12	regimens	N	I-Claim
13	appear	N	I-Claim
14	to	N	I-Claim
15	ameliorate	N	I-Claim
16	potential	N	I-Claim
17	negative	N	I-Claim
18	effects	N	I-Claim
19	of	N	I-Claim
20	DPPE	N	I-Claim
21	on	N	I-Claim
22	emesis	N	I-Claim
23	and	N	I-Claim
24	nausea	N	I-Claim
25	as	N	I-Claim
26	measured	N	I-Claim
27	by	N	I-Claim
28	patient	N	I-Claim
29	assessed	N	I-Claim
30	QOL	N	I-Claim
31	.	N	I-Claim

1	Recent	N	I-Claim
2	studies	N	I-Claim
3	have	N	I-Claim
4	shown	N	I-Claim
5	that	N	I-Claim
6	administering	N	I-Claim
7	the	N	I-Claim
8	aromatase	N	I-Claim
9	inhibitor	N	I-Claim
10	exemestane	N	I-Claim
11	after	N	I-Claim
12	2-3	N	I-Claim
13	years	N	I-Claim
14	of	N	I-Claim
15	tamoxifen	N	I-Claim
16	therapy	N	I-Claim
17	significantly	N	I-Claim
18	improves	N	I-Claim
19	disease-free	N	I-Claim
20	survival	N	I-Claim
21	in	N	I-Claim
22	postmenopausal	N	I-Claim
23	women	N	I-Claim
24	with	N	I-Claim
25	primary	N	I-Claim
26	breast	N	I-Claim
27	cancer	N	I-Claim
28	in	N	I-Claim
29	comparison	N	I-Claim
30	with	N	I-Claim
31	standard	N	I-Claim
32	5-year	N	I-Claim
33	tamoxifen	N	I-Claim
34	treatment	N	I-Claim
35	.	N	I-Claim

1	Although	N	O
2	many	N	O
3	of	N	O
4	the	N	O
5	adverse	N	O
6	effects	N	O
7	associated	N	O
8	with	N	O
9	exemestane	N	O
10	and	N	O
11	tamoxifen	N	O
12	have	N	O
13	been	N	O
14	analysed	N	O
15	,	N	O
16	there	N	O
17	are	N	O
18	no	N	O
19	comparative	N	O
20	data	N	O
21	concerning	N	O
22	body	N	O
23	weight	N	O
24	and	N	O
25	body	N	O
26	composition	N	O
27	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	randomised	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	evaluate	N	O
10	the	N	O
11	longitudinal	N	O
12	changes	N	O
13	in	N	O
14	body	N	O
15	composition	N	O
16	and	N	O
17	lipid	N	O
18	profiles	N	O
19	in	N	O
20	postmenopausal	N	O
21	women	N	O
22	switched	N	O
23	from	N	O
24	tamoxifen	N	O
25	to	N	O
26	exemestane	N	O
27	.	N	O

1	In	N	O
2	total	N	O
3	,	N	O
4	60	N	O
5	overweight	N	O
6	or	N	O
7	obese	N	O
8	postmenopausal	N	O
9	patients	N	O
10	were	N	O
11	enrolled	N	O
12	.	N	O

1	Their	N	O
2	anthropometric	N	O
3	data	N	O
4	,	N	O
5	body	N	O
6	composition	N	O
7	,	N	O
8	including	N	O
9	fat	N	O
10	mass	N	O
11	(	N	O
12	FM	N	O
13	)	N	O
14	and	N	O
15	fat-free	N	O
16	mass	N	O
17	(	N	O
18	FFM	N	O
19	)	N	O
20	,	N	O
21	and	N	O
22	lipid	N	O
23	profiles	N	O
24	,	N	O
25	caloric	N	O
26	intake	N	O
27	and	N	O
28	physical	N	O
29	activity	N	O
30	were	N	O
31	assessed	N	O
32	1	N	O
33	week	N	O
34	before	N	O
35	randomisation	N	O
36	,	N	O
37	and	N	O
38	6	N	O
39	and	N	O
40	12	N	O
41	months	N	O
42	later	N	O
43	.	N	O

1	In	N	O
2	all	N	O
3	,	N	O
4	55	N	O
5	patients	N	O
6	(	N	O
7	27	N	O
8	on	N	O
9	tamoxifen	N	O
10	and	N	O
11	28	N	O
12	on	N	O
13	exemestane	N	O
14	)	N	O
15	completed	N	O
16	the	N	O
17	1-year	N	O
18	study	N	O
19	period	N	O
20	.	N	O

1	Fat	N	I-Premise
2	mass	N	I-Premise
3	had	N	I-Premise
4	significantly	N	I-Premise
5	decreased	N	I-Premise
6	by	N	I-Premise
7	month	N	I-Premise
8	12	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	exemestane	N	I-Premise
12	,	N	I-Premise
13	but	N	I-Premise
14	not	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	tamoxifen	N	I-Premise
18	group	N	I-Premise
19	;	N	I-Premise
20	the	N	I-Premise
21	between-group	N	I-Premise
22	difference	N	I-Premise
23	was	N	I-Premise
24	statistically	N	I-Premise
25	significant	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	<	N	I-Premise
29	0.01	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	The	N	I-Premise
2	FFM/FM	N	I-Premise
3	ratio	N	I-Premise
4	had	N	I-Premise
5	significantly	N	I-Premise
6	increased	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	exemestane	N	I-Premise
10	group	N	I-Premise
11	,	N	I-Premise
12	but	N	I-Premise
13	not	N	I-Premise
14	the	N	I-Premise
15	tamoxifen	N	I-Premise
16	group	N	I-Premise
17	;	N	I-Premise
18	the	N	I-Premise
19	between-group	N	I-Premise
20	difference	N	I-Premise
21	was	N	I-Premise
22	statistically	N	I-Premise
23	significant	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	<	N	I-Premise
27	0.05	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Triglycerides	N	I-Premise
2	and	N	I-Premise
3	high-density	N	I-Premise
4	lipoprotein	N	I-Premise
5	cholesterol	N	I-Premise
6	significantly	N	I-Premise
7	decreased	N	I-Premise
8	(	N	I-Premise
9	P	N	I-Premise
10	<	N	I-Premise
11	0.01	N	I-Premise
12	;	N	I-Premise
13	P	N	I-Premise
14	<	N	I-Premise
15	0.05	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	and	N	O
19	low-density	N	I-Premise
20	lipoprotein	N	I-Premise
21	cholesterol	N	I-Premise
22	significantly	N	I-Premise
23	increased	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	<	N	I-Premise
27	0.01	N	I-Premise
28	)	N	I-Premise
29	in	N	I-Premise
30	the	N	I-Premise
31	exemestane	N	I-Premise
32	group	N	I-Premise
33	at	N	I-Premise
34	the	N	I-Premise
35	end	N	I-Premise
36	of	N	I-Premise
37	the	N	I-Premise
38	1-year	N	I-Premise
39	study	N	I-Premise
40	period	N	I-Premise
41	.	N	I-Premise

1	Our	N	I-Claim
2	findings	N	I-Claim
3	suggest	N	I-Claim
4	that	N	I-Claim
5	switching	N	I-Claim
6	patients	N	I-Claim
7	to	N	I-Claim
8	adjuvant	N	I-Claim
9	exemestane	N	I-Claim
10	treatment	N	I-Claim
11	after	N	I-Claim
12	at	N	I-Claim
13	least	N	I-Claim
14	2	N	I-Claim
15	years	N	I-Claim
16	of	N	I-Claim
17	tamoxifen	N	I-Claim
18	therapy	N	I-Claim
19	may	N	I-Claim
20	be	N	I-Claim
21	associated	N	I-Claim
22	with	N	I-Claim
23	an	N	I-Claim
24	advantage	N	I-Claim
25	over	N	I-Claim
26	continuing	N	I-Claim
27	adjuvant	N	I-Claim
28	tamoxifen	N	I-Claim
29	treatment	N	I-Claim
30	in	N	I-Claim
31	terms	N	I-Claim
32	of	N	I-Claim
33	body	N	I-Claim
34	composition	N	I-Claim
35	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	cannabis	N	O
7	extract	N	O
8	(	N	O
9	CE	N	O
10	)	N	O
11	,	N	O
12	delta-9-tetrahydrocannabinol	N	O
13	(	N	O
14	THC	N	O
15	)	N	O
16	,	N	O
17	and	N	O
18	placebo	N	O
19	(	N	O
20	PL	N	O
21	)	N	O
22	on	N	O
23	appetite	N	O
24	and	N	O
25	quality	N	O
26	of	N	O
27	life	N	O
28	(	N	O
29	QOL	N	O
30	)	N	O
31	in	N	O
32	patients	N	O
33	with	N	O
34	cancer-related	N	O
35	anorexia-cachexia	N	O
36	syndrome	N	O
37	(	N	O
38	CACS	N	O
39	)	N	O
40	.	N	O

1	Adult	N	O
2	patients	N	O
3	with	N	O
4	advanced	N	O
5	cancer	N	O
6	,	N	O
7	CACS	N	O
8	,	N	O
9	weight	N	O
10	loss	N	O
11	(	N	O
12	>	N	O
13	or	N	O
14	=	N	O
15	5	N	O
16	%	N	O
17	over	N	O
18	6	N	O
19	months	N	O
20	)	N	O
21	,	N	O
22	and	N	O
23	Eastern	N	O
24	Cooperative	N	O
25	Oncology	N	O
26	Group	N	O
27	(	N	O
28	ECOG	N	O
29	)	N	O
30	performance	N	O
31	status	N	O
32	(	N	O
33	PS	N	O
34	)	N	O
35	<	N	O
36	or	N	O
37	=	N	O
38	2	N	O
39	were	N	O
40	randomly	N	O
41	assigned	N	O
42	(	N	O
43	2:2:1	N	O
44	)	N	O
45	to	N	O
46	receive	N	O
47	CE	N	O
48	(	N	O
49	standardized	N	O
50	for	N	O
51	2.5	N	O
52	mg	N	O
53	THC	N	O
54	and	N	O
55	1	N	O
56	mg	N	O
57	cannabidiol	N	O
58	)	N	O
59	or	N	O
60	THC	N	O
61	(	N	O
62	2.5	N	O
63	mg	N	O
64	)	N	O
65	or	N	O
66	PL	N	O
67	orally	N	O
68	,	N	O
69	twice	N	O
70	daily	N	O
71	for	N	O
72	6	N	O
73	weeks	N	O
74	.	N	O

1	Appetite	N	O
2	,	N	O
3	mood	N	O
4	,	N	O
5	and	N	O
6	nausea	N	O
7	were	N	O
8	monitored	N	O
9	daily	N	O
10	with	N	O
11	a	N	O
12	visual	N	O
13	analog	N	O
14	scale	N	O
15	(	N	O
16	VAS	N	O
17	)	N	O
18	;	N	O
19	QOL	N	O
20	was	N	O
21	assessed	N	O
22	with	N	O
23	the	N	O
24	European	N	O
25	Organisation	N	O
26	for	N	O
27	Research	N	O
28	and	N	O
29	Treatment	N	O
30	of	N	O
31	Cancer	N	O
32	Quality	N	O
33	of	N	O
34	Life	N	O
35	Questionnaire	N	O
36	C30	N	O
37	(	N	O
38	composite	N	O
39	score	N	O
40	:	N	O
41	questions	N	O
42	29	N	O
43	and	N	O
44	30	N	O
45	)	N	O
46	.	N	O

1	Cannabinoid-related	N	O
2	toxicity	N	O
3	was	N	O
4	assessed	N	O
5	every	N	O
6	2	N	O
7	weeks	N	O
8	.	N	O

1	Of	N	O
2	289	N	O
3	patients	N	O
4	screened	N	O
5	,	N	O
6	243	N	O
7	were	N	O
8	randomly	N	O
9	assigned	N	O
10	and	N	O
11	164	N	O
12	(	N	O
13	CE	N	O
14	,	N	O
15	66	N	O
16	of	N	O
17	95	N	O
18	patients	N	O
19	;	N	O
20	THC	N	O
21	,	N	O
22	65	N	O
23	of	N	O
24	100	N	O
25	patients	N	O
26	;	N	O
27	and	N	O
28	PL	N	O
29	,	N	O
30	33	N	O
31	of	N	O
32	48	N	O
33	patients	N	O
34	)	N	O
35	completed	N	O
36	treatment	N	O
37	.	N	O

1	At	N	O
2	baseline	N	O
3	,	N	O
4	groups	N	O
5	were	N	O
6	comparable	N	O
7	for	N	O
8	age	N	O
9	(	N	O
10	mean	N	O
11	,	N	O
12	61	N	O
13	years	N	O
14	)	N	O
15	,	N	O
16	sex	N	O
17	(	N	O
18	54	N	O
19	%	N	O
20	men	N	O
21	)	N	O
22	,	N	O
23	weight	N	O
24	loss	N	O
25	(	N	O
26	32	N	O
27	%	N	O
28	>	N	O
29	or	N	O
30	=	N	O
31	10	N	O
32	%	N	O
33	)	N	O
34	,	N	O
35	PS	N	O
36	(	N	O
37	13	N	O
38	%	N	O
39	ECOG	N	O
40	=	N	O
41	2	N	O
42	)	N	O
43	,	N	O
44	antineoplastic	N	O
45	treatment	N	O
46	(	N	O
47	50	N	O
48	%	N	O
49	)	N	O
50	,	N	O
51	appetite	N	O
52	(	N	O
53	mean	N	O
54	VAS	N	O
55	score	N	O
56	,	N	O
57	31/100	N	O
58	mm	N	O
59	)	N	O
60	,	N	O
61	and	N	O
62	QOL	N	O
63	(	N	O
64	mean	N	O
65	score	N	O
66	,	N	O
67	30/100	N	O
68	)	N	O
69	.	N	O

1	Intent-to-treat	N	I-Premise
2	analysis	N	I-Premise
3	showed	N	I-Premise
4	no	N	I-Premise
5	significant	N	I-Premise
6	differences	N	I-Premise
7	between	N	I-Premise
8	the	N	I-Premise
9	three	N	I-Premise
10	arms	N	I-Premise
11	for	N	I-Premise
12	appetite	N	I-Premise
13	,	N	I-Premise
14	QOL	N	I-Premise
15	,	N	I-Premise
16	or	N	I-Premise
17	cannabinoid-related	N	I-Premise
18	toxicity	N	I-Premise
19	.	N	I-Premise

1	Increased	N	I-Premise
2	appetite	N	I-Premise
3	was	N	I-Premise
4	reported	N	I-Premise
5	by	N	I-Premise
6	73	N	I-Premise
7	%	N	I-Premise
8	,	N	I-Premise
9	58	N	I-Premise
10	%	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	69	N	I-Premise
14	%	N	I-Premise
15	of	N	I-Premise
16	patients	N	I-Premise
17	receiving	N	I-Premise
18	CE	N	I-Premise
19	,	N	I-Premise
20	THC	N	I-Premise
21	,	N	I-Premise
22	or	N	I-Premise
23	PL	N	I-Premise
24	,	N	I-Premise
25	respectively	N	I-Premise
26	.	N	I-Premise

1	An	N	O
2	independent	N	O
3	data	N	O
4	review	N	O
5	board	N	O
6	recommended	N	O
7	termination	N	O
8	of	N	O
9	recruitment	N	O
10	because	N	O
11	of	N	O
12	insufficient	N	O
13	differences	N	O
14	between	N	O
15	study	N	O
16	arms	N	O
17	.	N	O

1	CE	N	I-Premise
2	at	N	I-Premise
3	the	N	I-Premise
4	oral	N	I-Premise
5	dose	N	I-Premise
6	administered	N	I-Premise
7	was	N	I-Premise
8	well	N	I-Premise
9	tolerated	N	I-Premise
10	by	N	I-Premise
11	these	N	I-Premise
12	patients	N	I-Premise
13	with	N	I-Premise
14	CACS	N	I-Premise
15	.	N	I-Premise

1	No	N	I-Claim
2	differences	N	I-Claim
3	in	N	I-Claim
4	patients	N	I-Claim
5	'	N	I-Claim
6	appetite	N	I-Claim
7	or	N	I-Claim
8	QOL	N	I-Claim
9	were	N	I-Claim
10	found	N	I-Claim
11	either	N	I-Claim
12	between	N	I-Claim
13	CE	N	I-Claim
14	,	N	I-Claim
15	THC	N	I-Claim
16	,	N	I-Claim
17	and	N	I-Claim
18	PL	N	I-Claim
19	or	N	I-Claim
20	between	N	I-Claim
21	CE	N	I-Claim
22	and	N	I-Claim
23	THC	N	I-Claim
24	at	N	I-Claim
25	the	N	I-Claim
26	dosages	N	I-Claim
27	investigated	N	I-Claim
28	.	N	I-Claim

1	Docetaxel	N	I-Claim
2	has	N	I-Claim
3	shown	N	I-Claim
4	activity	N	I-Claim
5	in	N	I-Claim
6	elderly	N	I-Claim
7	patients	N	I-Claim
8	with	N	I-Claim
9	advanced	N	I-Claim
10	non-small-cell	N	I-Claim
11	lung	N	I-Claim
12	cancer	N	I-Claim
13	(	N	I-Claim
14	NSCLC	N	I-Claim
15	)	N	I-Claim
16	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	phase	N	O
4	III	N	O
5	trial	N	O
6	evaluated	N	O
7	the	N	O
8	efficacy	N	O
9	and	N	O
10	safety	N	O
11	of	N	O
12	docetaxel	N	O
13	versus	N	O
14	vinorelbine	N	O
15	(	N	O
16	the	N	O
17	current	N	O
18	standard	N	O
19	treatment	N	O
20	)	N	O
21	in	N	O
22	elderly	N	O
23	patients	N	O
24	.	N	O

1	Chemotherapy-naïve	N	O
2	patients	N	O
3	age	N	O
4	70	N	O
5	years	N	O
6	or	N	O
7	older	N	O
8	with	N	O
9	stage	N	O
10	IIIB/IV	N	O
11	NSCLC	N	O
12	and	N	O
13	performance	N	O
14	status	N	O
15	2	N	O
16	or	N	O
17	lower	N	O
18	were	N	O
19	eligible	N	O
20	.	N	O

1	Patients	N	O
2	randomly	N	O
3	received	N	O
4	docetaxel	N	O
5	60	N	O
6	mg/m2	N	O
7	(	N	O
8	day	N	O
9	1	N	O
10	)	N	O
11	or	N	O
12	vinorelbine	N	O
13	25	N	O
14	mg/m2	N	O
15	(	N	O
16	days	N	O
17	1	N	O
18	and	N	O
19	8	N	O
20	)	N	O
21	every	N	O
22	21	N	O
23	days	N	O
24	for	N	O
25	four	N	O
26	cycles	N	O
27	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	overall	N	O
7	survival	N	O
8	.	N	O

1	Overall	N	O
2	disease-related	N	O
3	symptom	N	O
4	improvement	N	O
5	was	N	O
6	assessed	N	O
7	using	N	O
8	an	N	O
9	eight-item	N	O
10	questionnaire	N	O
11	.	N	O

1	In	N	O
2	total	N	O
3	,	N	O
4	182	N	O
5	patients	N	O
6	were	N	O
7	enrolled	N	O
8	.	N	O

1	Median	N	O
2	age	N	O
3	was	N	O
4	76	N	O
5	years	N	O
6	(	N	O
7	range	N	O
8	,	N	O
9	70	N	O
10	years	N	O
11	to	N	O
12	86	N	O
13	years	N	O
14	)	N	O
15	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	statistical	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	median	N	I-Premise
8	overall	N	I-Premise
9	survival	N	I-Premise
10	with	N	I-Premise
11	docetaxel	N	I-Premise
12	versus	N	I-Premise
13	vinorelbine	N	I-Premise
14	(	N	I-Premise
15	14.3	N	I-Premise
16	months	N	I-Premise
17	v	N	I-Premise
18	9.9	N	I-Premise
19	months	N	I-Premise
20	;	N	I-Premise
21	hazard	N	I-Premise
22	ratio	N	I-Premise
23	,	N	I-Premise
24	0.780	N	I-Premise
25	;	N	I-Premise
26	95	N	I-Premise
27	%	N	I-Premise
28	CI	N	I-Premise
29	,	N	I-Premise
30	0.561	N	I-Premise
31	to	N	I-Premise
32	1.085	N	I-Premise
33	;	N	I-Premise
34	P	N	I-Premise
35	=	N	I-Premise
36	.138	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	median	N	I-Premise
8	progression-free	N	I-Premise
9	survival	N	I-Premise
10	(	N	I-Premise
11	5.5	N	I-Premise
12	months	N	I-Premise
13	v	N	I-Premise
14	3.1	N	I-Premise
15	months	N	I-Premise
16	;	N	I-Premise
17	P	N	I-Premise
18	<	N	I-Premise
19	.001	N	I-Premise
20	)	N	I-Premise
21	.	N	I-Premise

1	Response	N	I-Premise
2	rates	N	I-Premise
3	were	N	I-Premise
4	also	N	I-Premise
5	significantly	N	I-Premise
6	improved	N	I-Premise
7	with	N	I-Premise
8	docetaxel	N	I-Premise
9	versus	N	I-Premise
10	vinorelbine	N	I-Premise
11	(	N	I-Premise
12	22.7	N	I-Premise
13	%	N	I-Premise
14	v	N	I-Premise
15	9.9	N	I-Premise
16	%	N	I-Premise
17	;	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	.019	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	The	N	I-Premise
2	most	N	I-Premise
3	common	N	I-Premise
4	grade	N	I-Premise
5	3	N	I-Premise
6	to	N	I-Premise
7	4	N	I-Premise
8	toxicities	N	I-Premise
9	were	N	I-Premise
10	neutropenia	N	I-Premise
11	(	N	I-Premise
12	82.9	N	I-Premise
13	%	N	I-Premise
14	for	N	I-Premise
15	docetaxel	N	I-Premise
16	;	N	I-Premise
17	69.2	N	I-Premise
18	%	N	I-Premise
19	for	N	I-Premise
20	vinorelbine	N	I-Premise
21	;	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	.031	N	I-Premise
25	)	N	I-Premise
26	and	N	I-Premise
27	leukopenia	N	I-Premise
28	(	N	I-Premise
29	58.0	N	I-Premise
30	%	N	I-Premise
31	for	N	I-Premise
32	docetaxel	N	I-Premise
33	;	N	I-Premise
34	51.7	N	I-Premise
35	%	N	I-Premise
36	for	N	I-Premise
37	vinorelbine	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	Other	N	I-Premise
2	toxicities	N	I-Premise
3	were	N	I-Premise
4	mild	N	I-Premise
5	and	N	I-Premise
6	generally	N	I-Premise
7	well	N	I-Premise
8	tolerated	N	I-Premise
9	.	N	I-Premise

1	Docetaxel	N	I-Premise
2	improved	N	I-Premise
3	overall	N	I-Premise
4	disease-related	N	I-Premise
5	symptoms	N	I-Premise
6	over	N	I-Premise
7	vinorelbine	N	I-Premise
8	(	N	I-Premise
9	odds	N	I-Premise
10	ratio	N	I-Premise
11	,	N	I-Premise
12	1.86	N	I-Premise
13	;	N	I-Premise
14	95	N	I-Premise
15	%	N	I-Premise
16	CI	N	I-Premise
17	,	N	I-Premise
18	1.09	N	I-Premise
19	to	N	I-Premise
20	3.20	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	Docetaxel	N	I-Premise
2	improved	N	I-Premise
3	progression-free	N	I-Premise
4	survival	N	I-Premise
5	,	N	I-Premise
6	response	N	I-Premise
7	rate	N	I-Premise
8	,	N	I-Premise
9	and	N	I-Premise
10	disease-related	N	I-Premise
11	symptoms	N	I-Premise
12	versus	N	I-Premise
13	vinorelbine	N	I-Premise
14	.	N	I-Premise

1	Overall	N	I-Claim
2	survival	N	I-Claim
3	was	N	I-Claim
4	not	N	I-Claim
5	statistically	N	I-Claim
6	significantly	N	I-Claim
7	improved	N	I-Claim
8	at	N	I-Claim
9	this	N	I-Claim
10	time	N	I-Claim
11	.	N	I-Claim

1	Docetaxel	N	I-Claim
2	monotherapy	N	I-Claim
3	may	N	I-Claim
4	be	N	I-Claim
5	considered	N	I-Claim
6	as	N	I-Claim
7	an	N	I-Claim
8	option	N	I-Claim
9	in	N	I-Claim
10	the	N	I-Claim
11	standard	N	I-Claim
12	treatment	N	I-Claim
13	of	N	I-Claim
14	elderly	N	I-Claim
15	patients	N	I-Claim
16	with	N	I-Claim
17	advanced	N	I-Claim
18	NSCLC	N	I-Claim
19	.	N	I-Claim

1	The	N	O
2	combination	N	O
3	of	N	O
4	carboplatin	N	O
5	and	N	O
6	paclitaxel	N	O
7	is	N	O
8	the	N	O
9	standard	N	O
10	of	N	O
11	care	N	O
12	for	N	O
13	the	N	O
14	treatment	N	O
15	of	N	O
16	ovarian	N	O
17	cancer	N	O
18	,	N	O
19	yet	N	O
20	rates	N	O
21	of	N	O
22	recurrence	N	O
23	and	N	O
24	death	N	O
25	remain	N	O
26	high	N	O
27	.	N	O

1	We	N	O
2	performed	N	O
3	a	N	O
4	prospective	N	O
5	randomized	N	O
6	phase	N	O
7	III	N	O
8	study	N	O
9	to	N	O
10	examine	N	O
11	whether	N	O
12	sequential	N	O
13	administration	N	O
14	of	N	O
15	topotecan	N	O
16	can	N	O
17	improve	N	O
18	the	N	O
19	efficacy	N	O
20	of	N	O
21	carboplatin	N	O
22	and	N	O
23	paclitaxel	N	O
24	in	N	O
25	first-line	N	O
26	treatment	N	O
27	of	N	O
28	advanced	N	O
29	epithelial	N	O
30	ovarian	N	O
31	cancer	N	O
32	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	1308	N	O
5	patients	N	O
6	with	N	O
7	previously	N	O
8	untreated	N	O
9	ovarian	N	O
10	cancer	N	O
11	(	N	O
12	International	N	O
13	Federation	N	O
14	of	N	O
15	Gynecology	N	O
16	and	N	O
17	Obstetrics	N	O
18	stages	N	O
19	IIB-IV	N	O
20	)	N	O
21	were	N	O
22	randomly	N	O
23	assigned	N	O
24	to	N	O
25	receive	N	O
26	six	N	O
27	cycles	N	O
28	of	N	O
29	paclitaxel	N	O
30	and	N	O
31	carboplatin	N	O
32	followed	N	O
33	by	N	O
34	either	N	O
35	four	N	O
36	cycles	N	O
37	of	N	O
38	topotecan	N	O
39	(	N	O
40	TC-Top	N	O
41	;	N	O
42	658	N	O
43	patients	N	O
44	)	N	O
45	or	N	O
46	surveillance	N	O
47	(	N	O
48	TC	N	O
49	;	N	O
50	650	N	O
51	patients	N	O
52	)	N	O
53	on	N	O
54	a	N	O
55	3-week	N	O
56	per	N	O
57	cycle	N	O
58	schedule	N	O
59	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	overall	N	O
6	survival	N	O
7	,	N	O
8	and	N	O
9	secondary	N	O
10	endpoints	N	O
11	were	N	O
12	progression-free	N	O
13	survival	N	O
14	,	N	O
15	response	N	O
16	rate	N	O
17	,	N	O
18	toxicity	N	O
19	,	N	O
20	and	N	O
21	quality	N	O
22	of	N	O
23	life	N	O
24	.	N	O

1	Time-to-event	N	O
2	data	N	O
3	were	N	O
4	analyzed	N	O
5	using	N	O
6	the	N	O
7	Kaplan-Meier	N	O
8	method	N	O
9	,	N	O
10	and	N	O
11	a	N	O
12	stratified	N	O
13	log-rank	N	O
14	test	N	O
15	was	N	O
16	used	N	O
17	to	N	O
18	compare	N	O
19	distributions	N	O
20	between	N	O
21	treatment	N	O
22	groups	N	O
23	.	N	O

1	Hazard	N	O
2	ratios	N	O
3	(	N	O
4	HRs	N	O
5	)	N	O
6	with	N	O
7	95	N	O
8	%	N	O
9	confidence	N	O
10	intervals	N	O
11	(	N	O
12	CIs	N	O
13	)	N	O
14	were	N	O
15	estimated	N	O
16	using	N	O
17	a	N	O
18	Cox	N	O
19	proportional	N	O
20	hazards	N	O
21	model	N	O
22	.	N	O

1	Categorical	N	O
2	data	N	O
3	were	N	O
4	compared	N	O
5	using	N	O
6	a	N	O
7	stratified	N	O
8	Cochran-Mantel-Haenszel	N	O
9	test	N	O
10	.	N	O

1	All	N	O
2	statistical	N	O
3	tests	N	O
4	were	N	O
5	two-sided	N	O
6	.	N	O

1	Median	N	I-Premise
2	progression-free	N	I-Premise
3	survival	N	I-Premise
4	was	N	I-Premise
5	18.2	N	I-Premise
6	months	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	TC-Top	N	I-Premise
10	arm	N	I-Premise
11	versus	N	I-Premise
12	18.5	N	I-Premise
13	months	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	TC	N	I-Premise
17	arm	N	I-Premise
18	(	N	I-Premise
19	stratum-adjusted	N	I-Premise
20	HR	N	I-Premise
21	=	N	I-Premise
22	0.97	N	I-Premise
23	[	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	CI	N	I-Premise
27	=	N	I-Premise
28	0.85	N	I-Premise
29	to	N	I-Premise
30	1.10	N	I-Premise
31	]	N	I-Premise
32	;	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	.688	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	Median	N	I-Premise
2	overall	N	I-Premise
3	survival	N	I-Premise
4	was	N	I-Premise
5	43.1	N	I-Premise
6	months	N	I-Premise
7	for	N	I-Premise
8	the	N	I-Premise
9	TC-Top	N	I-Premise
10	arm	N	I-Premise
11	versus	N	I-Premise
12	44.5	N	I-Premise
13	months	N	I-Premise
14	for	N	I-Premise
15	the	N	I-Premise
16	TC	N	I-Premise
17	arm	N	I-Premise
18	(	N	I-Premise
19	stratum-adjusted	N	I-Premise
20	HR	N	I-Premise
21	=	N	I-Premise
22	1.01	N	I-Premise
23	[	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	CI	N	I-Premise
27	=	N	I-Premise
28	0.86	N	I-Premise
29	to	N	I-Premise
30	1.18	N	I-Premise
31	]	N	I-Premise
32	;	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	.885	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	At	N	I-Premise
2	3	N	I-Premise
3	years	N	I-Premise
4	,	N	I-Premise
5	overall	N	I-Premise
6	survival	N	I-Premise
7	in	N	I-Premise
8	both	N	I-Premise
9	arms	N	I-Premise
10	was	N	I-Premise
11	57	N	I-Premise
12	%	N	I-Premise
13	(	N	I-Premise
14	58.5	N	I-Premise
15	%	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	TC	N	I-Premise
19	arm	N	I-Premise
20	and	N	I-Premise
21	55.7	N	I-Premise
22	%	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	TC-Top	N	I-Premise
26	arm	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	Compared	N	I-Premise
2	with	N	I-Premise
3	patients	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	TC	N	I-Premise
7	arm	N	I-Premise
8	,	N	I-Premise
9	patients	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	TC-Top	N	I-Premise
13	arm	N	I-Premise
14	had	N	I-Premise
15	more	N	I-Premise
16	grade	N	I-Premise
17	3-4	N	I-Premise
18	hematologic	N	I-Premise
19	toxic	N	I-Premise
20	effects	N	I-Premise
21	(	N	I-Premise
22	requiring	N	I-Premise
23	more	N	I-Premise
24	supportive	N	I-Premise
25	care	N	I-Premise
26	)	N	I-Premise
27	and	N	I-Premise
28	more	N	I-Premise
29	grade	N	I-Premise
30	3-4	N	I-Premise
31	infections	N	I-Premise
32	(	N	I-Premise
33	5.1	N	I-Premise
34	%	N	I-Premise
35	versus	N	I-Premise
36	2.7	N	I-Premise
37	%	N	I-Premise
38	;	N	I-Premise
39	P	N	I-Premise
40	=	N	I-Premise
41	.034	N	I-Premise
42	)	N	I-Premise
43	but	N	I-Premise
44	did	N	I-Premise
45	not	N	I-Premise
46	have	N	I-Premise
47	a	N	I-Premise
48	statistically	N	I-Premise
49	significant	N	I-Premise
50	increase	N	I-Premise
51	in	N	I-Premise
52	febrile	N	I-Premise
53	neutropenia	N	I-Premise
54	(	N	I-Premise
55	3.3	N	I-Premise
56	%	N	I-Premise
57	versus	N	I-Premise
58	3.1	N	I-Premise
59	%	N	I-Premise
60	;	N	I-Premise
61	P	N	I-Premise
62	=	N	I-Premise
63	.80	N	I-Premise
64	)	N	I-Premise
65	.	N	I-Premise

1	Among	N	I-Premise
2	patients	N	I-Premise
3	who	N	I-Premise
4	had	N	I-Premise
5	measurable	N	I-Premise
6	disease	N	I-Premise
7	(	N	I-Premise
8	TC	N	I-Premise
9	,	N	I-Premise
10	n	N	I-Premise
11	=	N	I-Premise
12	147	N	I-Premise
13	;	N	I-Premise
14	TC-Top	N	I-Premise
15	,	N	I-Premise
16	n	N	I-Premise
17	=	N	I-Premise
18	145	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	overall	N	I-Premise
22	(	N	I-Premise
23	i.e.	N	I-Premise
24	,	N	I-Premise
25	complete	N	I-Premise
26	or	N	I-Premise
27	partial	N	I-Premise
28	)	N	I-Premise
29	response	N	I-Premise
30	was	N	I-Premise
31	69.0	N	I-Premise
32	%	N	I-Premise
33	(	N	I-Premise
34	95	N	I-Premise
35	%	N	I-Premise
36	CI	N	I-Premise
37	=	N	I-Premise
38	61.4	N	I-Premise
39	%	N	I-Premise
40	to	N	I-Premise
41	76.5	N	I-Premise
42	%	N	I-Premise
43	)	N	I-Premise
44	in	N	I-Premise
45	the	N	I-Premise
46	TC-Top	N	I-Premise
47	arm	N	I-Premise
48	and	N	I-Premise
49	76.2	N	I-Premise
50	%	N	I-Premise
51	(	N	I-Premise
52	95	N	I-Premise
53	%	N	I-Premise
54	CI	N	I-Premise
55	=	N	I-Premise
56	69.3	N	I-Premise
57	%	N	I-Premise
58	to	N	I-Premise
59	83.1	N	I-Premise
60	%	N	I-Premise
61	)	N	I-Premise
62	in	N	I-Premise
63	the	N	I-Premise
64	TC	N	I-Premise
65	arm	N	I-Premise
66	(	N	I-Premise
67	P	N	I-Premise
68	=	N	I-Premise
69	.166	N	I-Premise
70	)	N	I-Premise
71	.	N	I-Premise

1	The	N	I-Claim
2	sequential	N	I-Claim
3	addition	N	I-Claim
4	of	N	I-Claim
5	topotecan	N	I-Claim
6	to	N	I-Claim
7	carboplatin-paclitaxel	N	I-Claim
8	did	N	I-Claim
9	not	N	I-Claim
10	result	N	I-Claim
11	in	N	I-Claim
12	superior	N	I-Claim
13	overall	N	I-Claim
14	response	N	I-Claim
15	or	N	I-Claim
16	progression-free	N	I-Claim
17	or	N	I-Claim
18	overall	N	I-Claim
19	survival	N	I-Claim
20	.	N	I-Claim

1	Therefore	N	I-Claim
2	,	N	I-Claim
3	this	N	I-Claim
4	regimen	N	I-Claim
5	is	N	I-Claim
6	not	N	I-Claim
7	recommended	N	I-Claim
8	as	N	I-Claim
9	standard	N	I-Claim
10	of	N	I-Claim
11	care	N	I-Claim
12	treatment	N	I-Claim
13	for	N	I-Claim
14	ovarian	N	I-Claim
15	cancer	N	I-Claim
16	.	N	I-Claim

1	This	N	O
2	report	N	O
3	describes	N	O
4	the	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	(	N	O
9	QOL	N	O
10	)	N	O
11	findings	N	O
12	of	N	O
13	a	N	O
14	randomized	N	O
15	placebo	N	O
16	controlled	N	O
17	study	N	O
18	of	N	O
19	erlotinib	N	O
20	,	N	O
21	an	N	O
22	epidermal	N	O
23	growth	N	O
24	factor	N	O
25	receptor	N	O
26	inhibitor	N	O
27	,	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	non-small-cell	N	O
32	lung	N	O
33	cancer	N	O
34	(	N	O
35	NSCLC	N	O
36	)	N	O
37	.	N	O

1	This	N	O
2	double-blind	N	O
3	phase	N	O
4	III	N	O
5	trial	N	O
6	randomly	N	O
7	assigned	N	O
8	731	N	O
9	patients	N	O
10	with	N	O
11	NSCLC	N	O
12	who	N	O
13	had	N	O
14	progressed	N	O
15	after	N	O
16	prior	N	O
17	chemotherapy	N	O
18	to	N	O
19	erlotinib	N	O
20	150	N	O
21	mg	N	O
22	daily	N	O
23	or	N	O
24	placebo	N	O
25	,	N	O
26	with	N	O
27	survival	N	O
28	as	N	O
29	the	N	O
30	primary	N	O
31	study	N	O
32	outcome	N	O
33	.	N	O

1	QOL	N	O
2	was	N	O
3	assessed	N	O
4	by	N	O
5	European	N	O
6	Organisation	N	O
7	for	N	O
8	Research	N	O
9	and	N	O
10	Treatment	N	O
11	of	N	O
12	Cancer	N	O
13	QLQ-C30	N	O
14	and	N	O
15	the	N	O
16	lung	N	O
17	cancer	N	O
18	module	N	O
19	QLQ-LC13	N	O
20	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	points	N	O
5	for	N	O
6	QOL	N	O
7	analysis	N	O
8	were	N	O
9	time	N	O
10	to	N	O
11	deterioration	N	O
12	of	N	O
13	three	N	O
14	common	N	O
15	lung	N	O
16	cancer	N	O
17	symptoms	N	O
18	:	N	O
19	cough	N	O
20	,	N	O
21	dyspnea	N	O
22	,	N	O
23	and	N	O
24	pain	N	O
25	.	N	O

1	Survival	N	I-Premise
2	was	N	I-Premise
3	significantly	N	I-Premise
4	longer	N	I-Premise
5	(	N	I-Premise
6	hazard	N	I-Premise
7	ratio	N	I-Premise
8	,	N	I-Premise
9	0.70	N	I-Premise
10	;	N	I-Premise
11	P	N	I-Premise
12	<	N	I-Premise
13	.0001	N	I-Premise
14	)	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	erlotinib	N	I-Premise
18	arm	N	I-Premise
19	.	N	I-Premise

1	Compliance	N	I-Premise
2	with	N	I-Premise
3	QOL	N	I-Premise
4	was	N	I-Premise
5	87	N	I-Premise
6	%	N	I-Premise
7	at	N	I-Premise
8	baseline	N	I-Premise
9	and	N	I-Premise
10	more	N	I-Premise
11	than	N	I-Premise
12	70	N	I-Premise
13	%	N	I-Premise
14	during	N	I-Premise
15	treatment	N	I-Premise
16	.	N	I-Premise

1	Patients	N	I-Premise
2	receiving	N	I-Premise
3	erlotinib	N	I-Premise
4	had	N	I-Premise
5	significantly	N	I-Premise
6	longer	N	I-Premise
7	median	N	I-Premise
8	time	N	I-Premise
9	to	N	I-Premise
10	deterioration	N	I-Premise
11	for	N	I-Premise
12	all	N	I-Premise
13	three	N	I-Premise
14	symptoms	N	I-Premise
15	(	N	I-Premise
16	4.9	N	I-Premise
17	v	N	I-Premise
18	3.7	N	I-Premise
19	months	N	I-Premise
20	for	N	I-Premise
21	cough	N	I-Premise
22	[	N	I-Premise
23	P	N	I-Premise
24	=	N	I-Premise
25	.04	N	I-Premise
26	]	N	I-Premise
27	;	N	I-Premise
28	4.7	N	I-Premise
29	v	N	I-Premise
30	2.9	N	I-Premise
31	months	N	I-Premise
32	for	N	I-Premise
33	dyspnea	N	I-Premise
34	[	N	I-Premise
35	P	N	I-Premise
36	=	N	I-Premise
37	.04	N	I-Premise
38	]	N	I-Premise
39	,	N	I-Premise
40	and	N	I-Premise
41	2.8	N	I-Premise
42	v	N	I-Premise
43	1.9	N	I-Premise
44	months	N	I-Premise
45	for	N	I-Premise
46	pain	N	I-Premise
47	[	N	I-Premise
48	P	N	I-Premise
49	=	N	I-Premise
50	.03	N	I-Premise
51	]	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	QOL	N	I-Premise
2	response	N	I-Premise
3	analyses	N	I-Premise
4	showed	N	I-Premise
5	that	N	I-Premise
6	44	N	I-Premise
7	%	N	I-Premise
8	,	N	I-Premise
9	34	N	I-Premise
10	%	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	42	N	I-Premise
14	%	N	I-Premise
15	of	N	I-Premise
16	patients	N	I-Premise
17	receiving	N	I-Premise
18	erlotinib	N	I-Premise
19	had	N	I-Premise
20	improvement	N	I-Premise
21	in	N	I-Premise
22	these	N	I-Premise
23	three	N	I-Premise
24	symptoms	N	I-Premise
25	,	N	I-Premise
26	respectively	N	I-Premise
27	.	N	I-Premise

1	This	N	I-Premise
2	was	N	I-Premise
3	accompanied	N	I-Premise
4	by	N	I-Premise
5	a	N	I-Premise
6	significant	N	I-Premise
7	improvement	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	physical	N	I-Premise
11	function	N	I-Premise
12	(	N	I-Premise
13	31	N	I-Premise
14	%	N	I-Premise
15	erlotinib	N	I-Premise
16	v	N	I-Premise
17	19	N	I-Premise
18	%	N	I-Premise
19	placebo	N	I-Premise
20	,	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	.01	N	I-Premise
24	)	N	I-Premise
25	,	N	I-Premise
26	and	N	I-Premise
27	global	N	I-Premise
28	QOL	N	I-Premise
29	(	N	I-Premise
30	35	N	I-Premise
31	%	N	I-Premise
32	v	N	I-Premise
33	26	N	I-Premise
34	%	N	I-Premise
35	,	N	I-Premise
36	P	N	I-Premise
37	<	N	I-Premise
38	.0001	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	Patients	N	I-Premise
2	with	N	I-Premise
3	complete	N	I-Premise
4	or	N	I-Premise
5	partial	N	I-Premise
6	response	N	I-Premise
7	were	N	I-Premise
8	more	N	I-Premise
9	likely	N	I-Premise
10	to	N	I-Premise
11	have	N	I-Premise
12	improvement	N	I-Premise
13	in	N	I-Premise
14	the	N	I-Premise
15	QOL	N	I-Premise
16	response	N	I-Premise
17	than	N	I-Premise
18	patients	N	I-Premise
19	with	N	I-Premise
20	stable	N	I-Premise
21	or	N	I-Premise
22	progressive	N	I-Premise
23	disease	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	<	N	I-Premise
27	.01	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Erlotinib	N	I-Claim
2	not	N	I-Claim
3	only	N	I-Claim
4	improves	N	I-Claim
5	survival	N	I-Claim
6	in	N	I-Claim
7	previously	N	I-Claim
8	treated	N	I-Claim
9	patients	N	I-Claim
10	with	N	I-Claim
11	NSCLC	N	I-Claim
12	,	N	I-Claim
13	but	N	I-Claim
14	also	N	I-Claim
15	improves	N	I-Claim
16	tumor-related	N	I-Claim
17	symptoms	N	I-Claim
18	and	N	I-Claim
19	important	N	I-Claim
20	aspects	N	I-Claim
21	of	N	I-Claim
22	QOL	N	I-Claim
23	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	effectiveness	N	O
5	and	N	O
6	tolerability	N	O
7	of	N	O
8	gemcitabine	N	O
9	plus	N	O
10	cisplatin	N	O
11	with	N	O
12	single-agent	N	O
13	gemcitabine	N	O
14	as	N	O
15	first-line	N	O
16	chemotherapy	N	O
17	for	N	O
18	locally	N	O
19	advanced	N	O
20	or	N	O
21	metastatic	N	O
22	pancreatic	N	O
23	cancer	N	O
24	.	N	O

1	Patients	N	O
2	with	N	O
3	advanced	N	O
4	adenocarcinoma	N	O
5	of	N	O
6	the	N	O
7	pancreas	N	O
8	were	N	O
9	randomly	N	O
10	assigned	N	O
11	to	N	O
12	receive	N	O
13	either	N	O
14	gemcitabine	N	O
15	1,000	N	O
16	mg/m2	N	O
17	and	N	O
18	cisplatin	N	O
19	50	N	O
20	mg/m2	N	O
21	given	N	O
22	on	N	O
23	days	N	O
24	1	N	O
25	and	N	O
26	15	N	O
27	of	N	O
28	a	N	O
29	4-week	N	O
30	cycle	N	O
31	(	N	O
32	GemCis	N	O
33	arm	N	O
34	)	N	O
35	or	N	O
36	gemcitabine	N	O
37	alone	N	O
38	at	N	O
39	a	N	O
40	dose	N	O
41	of	N	O
42	1,000	N	O
43	mg/m2	N	O
44	on	N	O
45	days	N	O
46	1	N	O
47	,	N	O
48	8	N	O
49	,	N	O
50	and	N	O
51	15	N	O
52	of	N	O
53	a	N	O
54	4-week	N	O
55	regimen	N	O
56	(	N	O
57	Gem	N	O
58	arm	N	O
59	)	N	O
60	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	overall	N	O
7	survival	N	O
8	;	N	O
9	secondary	N	O
10	end	N	O
11	points	N	O
12	were	N	O
13	progression-free	N	O
14	survival	N	O
15	,	N	O
16	response	N	O
17	rate	N	O
18	,	N	O
19	safety	N	O
20	,	N	O
21	and	N	O
22	quality	N	O
23	of	N	O
24	life	N	O
25	.	N	O

1	One	N	O
2	hundred	N	O
3	ninety-five	N	O
4	patients	N	O
5	were	N	O
6	enrolled	N	O
7	and	N	O
8	showed	N	O
9	baseline	N	O
10	characteristics	N	O
11	well	N	O
12	balanced	N	O
13	between	N	O
14	treatment	N	O
15	arms	N	O
16	.	N	O

1	Combination	N	I-Premise
2	treatment	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	GemCis	N	I-Premise
6	arm	N	I-Premise
7	was	N	I-Premise
8	associated	N	I-Premise
9	with	N	I-Premise
10	a	N	I-Premise
11	prolonged	N	I-Premise
12	median	N	I-Premise
13	progression-free	N	I-Premise
14	survival	N	I-Premise
15	(	N	I-Premise
16	5.3	N	I-Premise
17	months	N	I-Premise
18	v	N	I-Premise
19	3.1	N	I-Premise
20	months	N	I-Premise
21	;	N	I-Premise
22	hazard	N	I-Premise
23	ratio	N	I-Premise
24	[	N	I-Premise
25	HR	N	I-Premise
26	]	N	I-Premise
27	=	N	I-Premise
28	0.75	N	I-Premise
29	;	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.053	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	Also	N	I-Premise
2	,	N	I-Premise
3	median	N	I-Premise
4	overall	N	I-Premise
5	survival	N	I-Premise
6	was	N	I-Premise
7	superior	N	I-Premise
8	for	N	I-Premise
9	patients	N	I-Premise
10	treated	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	GemCis	N	I-Premise
14	arm	N	I-Premise
15	as	N	I-Premise
16	compared	N	I-Premise
17	with	N	I-Premise
18	the	N	I-Premise
19	Gem	N	I-Premise
20	arm	N	I-Premise
21	(	N	I-Premise
22	7.5	N	I-Premise
23	v	N	I-Premise
24	6.0	N	I-Premise
25	months	N	I-Premise
26	)	N	I-Premise
27	,	N	I-Premise
28	an	N	I-Premise
29	advantage	N	I-Premise
30	which	N	I-Premise
31	did	N	I-Premise
32	not	N	I-Premise
33	,	N	I-Premise
34	however	N	I-Premise
35	,	N	I-Premise
36	reach	N	I-Premise
37	statistical	N	I-Premise
38	significance	N	I-Premise
39	(	N	I-Premise
40	HR	N	I-Premise
41	=	N	I-Premise
42	0.80	N	I-Premise
43	;	N	I-Premise
44	P	N	I-Premise
45	=	N	I-Premise
46	.15	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	Tumor	N	I-Premise
2	response	N	I-Premise
3	rates	N	I-Premise
4	were	N	I-Premise
5	comparable	N	I-Premise
6	between	N	I-Premise
7	treatment	N	I-Premise
8	arms	N	I-Premise
9	(	N	I-Premise
10	10.2	N	I-Premise
11	%	N	I-Premise
12	v	N	I-Premise
13	8.2	N	I-Premise
14	%	N	I-Premise
15	)	N	I-Premise
16	.	N	I-Premise

1	The	N	I-Premise
2	rate	N	I-Premise
3	of	N	I-Premise
4	stable	N	I-Premise
5	disease	N	I-Premise
6	was	N	I-Premise
7	,	N	I-Premise
8	however	N	I-Premise
9	,	N	I-Premise
10	greater	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	combination	N	I-Premise
14	arm	N	I-Premise
15	(	N	I-Premise
16	60.2	N	I-Premise
17	%	N	I-Premise
18	v	N	I-Premise
19	40.2	N	I-Premise
20	%	N	I-Premise
21	;	N	I-Premise
22	P	N	I-Premise
23	<	N	I-Premise
24	.001	N	I-Premise
25	)	N	I-Premise
26	.	N	O

1	Grade	N	I-Premise
2	3	N	I-Premise
3	to	N	I-Premise
4	4	N	I-Premise
5	hematologic	N	I-Premise
6	toxicity	N	I-Premise
7	did	N	I-Premise
8	not	N	I-Premise
9	exceed	N	I-Premise
10	15	N	I-Premise
11	%	N	I-Premise
12	in	N	I-Premise
13	both	N	I-Premise
14	treatment	N	I-Premise
15	arms	N	I-Premise
16	.	N	I-Premise

1	These	N	I-Claim
2	results	N	I-Claim
3	support	N	I-Claim
4	the	N	I-Claim
5	efficacy	N	I-Claim
6	and	N	I-Claim
7	safety	N	I-Claim
8	of	N	I-Claim
9	an	N	I-Claim
10	every-2-weeks	N	I-Claim
11	treatment	N	I-Claim
12	with	N	I-Claim
13	gemcitabine	N	I-Claim
14	plus	N	I-Claim
15	cisplatin	N	I-Claim
16	.	N	I-Claim

1	Median	N	I-Claim
2	overall	N	I-Claim
3	survival	N	I-Claim
4	and	N	I-Claim
5	progression-free	N	I-Claim
6	survival	N	I-Claim
7	were	N	I-Claim
8	more	N	I-Claim
9	favorable	N	I-Claim
10	in	N	I-Claim
11	the	N	I-Claim
12	combination	N	I-Claim
13	arm	N	I-Claim
14	as	N	I-Claim
15	compared	N	I-Claim
16	with	N	I-Claim
17	gemcitabine	N	I-Claim
18	alone	N	I-Claim
19	,	N	I-Claim
20	although	N	I-Premise
21	the	N	I-Premise
22	difference	N	I-Premise
23	did	N	I-Premise
24	not	N	I-Premise
25	attain	N	I-Premise
26	statistical	N	I-Premise
27	significance	N	I-Premise
28	.	N	I-Premise

1	Chemotherapy	N	I-Claim
2	prolongs	N	I-Claim
3	survival	N	I-Claim
4	and	N	I-Claim
5	improves	N	I-Claim
6	quality	N	I-Claim
7	of	N	I-Claim
8	life	N	I-Claim
9	(	N	I-Claim
10	QOL	N	I-Claim
11	)	N	I-Claim
12	for	N	I-Claim
13	good	N	I-Claim
14	performance	N	I-Claim
15	status	N	I-Claim
16	(	N	I-Claim
17	PS	N	I-Claim
18	)	N	I-Claim
19	patients	N	I-Claim
20	with	N	I-Claim
21	advanced	N	I-Claim
22	non-small	N	I-Claim
23	cell	N	I-Claim
24	lung	N	I-Claim
25	cancer	N	I-Claim
26	(	N	I-Claim
27	NSCLC	N	I-Claim
28	)	N	I-Claim
29	.	N	I-Claim

1	Targeted	N	I-MajorClaim
2	therapies	N	I-MajorClaim
3	may	N	I-MajorClaim
4	improve	N	I-MajorClaim
5	chemotherapy	N	I-MajorClaim
6	effectiveness	N	I-MajorClaim
7	without	N	I-MajorClaim
8	worsening	N	I-MajorClaim
9	toxicity	N	I-MajorClaim
10	.	N	I-MajorClaim

1	SGN-15	N	O
2	is	N	O
3	an	N	O
4	antibody-drug	N	O
5	conjugate	N	O
6	(	N	O
7	ADC	N	O
8	)	N	O
9	,	N	O
10	consisting	N	O
11	of	N	O
12	a	N	O
13	chimeric	N	O
14	murine	N	O
15	monoclonal	N	O
16	antibody	N	O
17	recognizing	N	O
18	the	N	O
19	Lewis	N	O
20	Y	N	O
21	(	N	O
22	Le	N	O
23	(	N	O
24	y	N	O
25	)	N	O
26	)	N	O
27	antigen	N	O
28	,	N	O
29	conjugated	N	O
30	to	N	O
31	doxorubicin	N	O
32	.	N	O

1	Le	N	I-Claim
2	(	N	I-Claim
3	y	N	I-Claim
4	)	N	I-Claim
5	is	N	I-Claim
6	an	N	I-Claim
7	attractive	N	I-Claim
8	target	N	I-Claim
9	since	N	I-Claim
10	it	N	I-Claim
11	is	N	I-Claim
12	expressed	N	I-Claim
13	by	N	I-Claim
14	most	N	I-Claim
15	NSCLC	N	I-Claim
16	.	N	I-Claim

1	SGN-15	N	I-Premise
2	was	N	I-Premise
3	active	N	I-Premise
4	against	N	I-Premise
5	Le	N	I-Premise
6	(	N	I-Premise
7	y	N	I-Premise
8	)	N	I-Premise
9	-positive	N	I-Premise
10	tumors	N	I-Premise
11	in	N	I-Premise
12	early	N	I-Premise
13	phase	N	I-Premise
14	clinical	N	I-Premise
15	trials	N	I-Premise
16	and	N	I-Premise
17	was	N	I-Premise
18	synergistic	N	I-Premise
19	with	N	I-Premise
20	docetaxel	N	I-Premise
21	in	N	I-Premise
22	preclinical	N	I-Premise
23	experiments	N	I-Premise
24	.	N	I-Premise

1	This	N	O
2	Phase	N	O
3	II	N	O
4	,	N	O
5	open-label	N	O
6	study	N	O
7	was	N	O
8	conducted	N	O
9	to	N	O
10	confirm	N	O
11	the	N	O
12	activity	N	O
13	of	N	O
14	SGN-15	N	O
15	plus	N	O
16	docetaxel	N	O
17	in	N	O
18	previously	N	O
19	treated	N	O
20	NSCLC	N	O
21	patients	N	O
22	.	N	O

1	Sixty-two	N	O
2	patients	N	O
3	with	N	O
4	recurrent	N	O
5	or	N	O
6	metastatic	N	O
7	NSCLC	N	O
8	expressing	N	O
9	Le	N	O
10	(	N	O
11	y	N	O
12	)	N	O
13	,	N	O
14	one	N	O
15	or	N	O
16	two	N	O
17	prior	N	O
18	chemotherapy	N	O
19	regimens	N	O
20	,	N	O
21	and	N	O
22	PS	N	O
23	<	N	O
24	or	N	O
25	=2	N	O
26	were	N	O
27	randomized	N	O
28	2:1	N	O
29	to	N	O
30	receive	N	O
31	SGN-15	N	O
32	200	N	O
33	mg/m2/week	N	O
34	with	N	O
35	docetaxel	N	O
36	35	N	O
37	mg/m2/week	N	O
38	(	N	O
39	Arm	N	O
40	A	N	O
41	)	N	O
42	or	N	O
43	docetaxel	N	O
44	35	N	O
45	mg/m2/week	N	O
46	alone	N	O
47	(	N	O
48	Arm	N	O
49	B	N	O
50	)	N	O
51	for	N	O
52	6	N	O
53	of	N	O
54	8	N	O
55	weeks	N	O
56	.	N	O

1	Intrapatient	N	O
2	dose-escalation	N	O
3	of	N	O
4	SGN-15	N	O
5	to	N	O
6	350	N	O
7	mg/m2	N	O
8	was	N	O
9	permitted	N	O
10	in	N	O
11	the	N	O
12	second	N	O
13	half	N	O
14	of	N	O
15	the	N	O
16	study	N	O
17	.	N	O

1	Endpoints	N	O
2	were	N	O
3	survival	N	O
4	,	N	O
5	safety	N	O
6	,	N	O
7	efficacy	N	O
8	,	N	O
9	and	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	.	N	O

1	Forty	N	O
2	patients	N	O
3	on	N	O
4	Arm	N	O
5	A	N	O
6	and	N	O
7	19	N	O
8	on	N	O
9	Arm	N	O
10	B	N	O
11	received	N	O
12	at	N	O
13	least	N	O
14	one	N	O
15	treatment	N	O
16	.	N	O

1	Patients	N	I-Premise
2	on	N	I-Premise
3	Arms	N	I-Premise
4	A	N	I-Premise
5	and	N	I-Premise
6	B	N	I-Premise
7	had	N	I-Premise
8	median	N	I-Premise
9	survivals	N	I-Premise
10	of	N	I-Premise
11	31.4	N	I-Premise
12	and	N	I-Premise
13	25.3	N	I-Premise
14	weeks	N	I-Premise
15	,	N	I-Premise
16	12-month	N	I-Premise
17	survivals	N	I-Premise
18	of	N	I-Premise
19	29	N	I-Premise
20	%	N	I-Premise
21	and	N	I-Premise
22	24	N	I-Premise
23	%	N	I-Premise
24	,	N	I-Premise
25	and	N	I-Premise
26	18-month	N	I-Premise
27	survivals	N	I-Premise
28	of	N	I-Premise
29	18	N	I-Premise
30	%	N	I-Premise
31	and	N	I-Premise
32	8	N	I-Premise
33	%	N	I-Premise
34	,	N	I-Premise
35	respectively	N	I-Premise
36	.	N	O

1	Toxicity	N	I-Premise
2	was	N	I-Premise
3	mild	N	I-Premise
4	in	N	I-Premise
5	both	N	I-Premise
6	arms	N	I-Premise
7	.	N	I-Premise

1	QOL	N	I-Premise
2	analyses	N	I-Premise
3	favored	N	I-Premise
4	Arm	N	I-Premise
5	A.	N	I-Premise
6	SGN-15	N	I-Claim
7	plus	N	I-Claim
8	docetaxel	N	I-Claim
9	is	N	I-Claim
10	a	N	I-Claim
11	well-tolerated	N	I-Claim
12	and	N	I-Claim
13	active	N	I-Claim
14	second	N	I-Claim
15	and	N	I-Claim
16	third	N	I-Claim
17	line	N	I-Claim
18	treatment	N	I-Claim
19	for	N	I-Claim
20	NSCLC	N	I-Claim
21	patients	N	I-Claim
22	.	N	O

1	Ongoing	N	O
2	studies	N	O
3	are	N	O
4	exploring	N	O
5	alternate	N	O
6	schedules	N	O
7	to	N	O
8	maximize	N	O
9	synergy	N	O
10	between	N	O
11	these	N	O
12	agents	N	O
13	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	efficacy	N	O
10	and	N	O
11	safety	N	O
12	of	N	O
13	association	N	O
14	of	N	O
15	duloxetine	N	O
16	and	N	O
17	rehabilitation	N	O
18	compared	N	O
19	with	N	O
20	rehabilitation	N	O
21	alone	N	O
22	in	N	O
23	men	N	O
24	with	N	O
25	SUI	N	O
26	after	N	O
27	radical	N	O
28	retropubic	N	O
29	prostatectomy	N	O
30	(	N	O
31	RRP	N	O
32	)	N	O
33	,	N	O
34	and	N	O
35	to	N	O
36	compare	N	O
37	continence	N	O
38	rate	N	O
39	even	N	O
40	after	N	O
41	planned	N	O
42	duloxetine	N	O
43	suspension	N	O
44	.	N	O

1	After	N	O
2	catheter	N	O
3	removal	N	O
4	,	N	O
5	112	N	O
6	patients	N	O
7	were	N	O
8	randomized	N	O
9	to	N	O
10	receive	N	O
11	rehabilitation	N	O
12	and	N	O
13	duloxetine	N	O
14	(	N	O
15	group	N	O
16	A	N	O
17	)	N	O
18	or	N	O
19	rehabilitation	N	O
20	alone	N	O
21	(	N	O
22	group	N	O
23	B	N	O
24	)	N	O
25	,	N	O
26	for	N	O
27	16	N	O
28	wk	N	O
29	.	N	O

1	postprostatectomy	N	O
2	SUI	N	O
3	with	N	O
4	daily	N	O
5	incontinent	N	O
6	episodes	N	O
7	frequency	N	O
8	(	N	O
9	IEF	N	O
10	)	N	O
11	of	N	O
12	four	N	O
13	or	N	O
14	greater	N	O
15	.	N	O

1	After	N	O
2	16	N	O
3	wk	N	O
4	both	N	O
5	groups	N	O
6	suspended	N	O
7	duloxetine/placebo	N	O
8	and	N	O
9	continued	N	O
10	rehabilitation	N	O
11	.	N	O

1	All	N	O
2	patients	N	O
3	completed	N	O
4	incontinence	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	(	N	O
9	I-QoL	N	O
10	)	N	O
11	questionnaire	N	O
12	and	N	O
13	bladder	N	O
14	diary	N	O
15	.	N	O

1	Wilcoxon	N	O
2	test	N	O
3	was	N	O
4	used	N	O
5	to	N	O
6	analyse	N	O
7	changes	N	O
8	in	N	O
9	IEF	N	O
10	and	N	O
11	in	N	O
12	I-QoL	N	O
13	score	N	O
14	;	N	O
15	Fisher	N	O
16	exact	N	O
17	test	N	O
18	was	N	O
19	used	N	O
20	to	N	O
21	compare	N	O
22	continent	N	O
23	patients	N	O
24	between	N	O
25	the	N	O
26	groups	N	O
27	.	N	O

1	Adverse	N	O
2	events	N	O
3	for	N	O
4	duloxetine	N	O
5	was	N	O
6	15.2	N	O
7	%	N	O
8	.	N	O

1	102	N	O
2	men	N	O
3	completed	N	O
4	the	N	O
5	study	N	O
6	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	decrease	N	I-Premise
6	in	N	I-Premise
7	pad	N	I-Premise
8	use	N	I-Premise
9	in	N	I-Premise
10	group	N	I-Premise
11	A	N	I-Premise
12	.	N	I-Premise

1	After	N	I-Premise
2	16	N	I-Premise
3	wk	N	I-Premise
4	,	N	I-Premise
5	39	N	I-Premise
6	patients	N	I-Premise
7	versus	N	I-Premise
8	27	N	I-Premise
9	were	N	I-Premise
10	dry	N	I-Premise
11	(	N	I-Premise
12	p=0.007	N	I-Premise
13	)	N	I-Premise
14	.	N	I-Premise

1	At	N	I-Premise
2	20	N	I-Premise
3	wk	N	I-Premise
4	,	N	I-Premise
5	4	N	I-Premise
6	wk	N	I-Premise
7	after	N	I-Premise
8	planned	N	I-Premise
9	interruption	N	I-Premise
10	of	N	I-Premise
11	duloxetine	N	I-Premise
12	,	N	I-Premise
13	we	N	I-Premise
14	observed	N	I-Premise
15	a	N	I-Premise
16	U-turn	N	I-Premise
17	,	N	I-Premise
18	23	N	I-Premise
19	patients	N	I-Premise
20	were	N	I-Premise
21	completely	N	I-Premise
22	dry	N	I-Premise
23	in	N	I-Premise
24	group	N	I-Premise
25	A	N	I-Premise
26	versus	N	I-Premise
27	38	N	I-Premise
28	in	N	I-Premise
29	group	N	I-Premise
30	B	N	I-Premise
31	(	N	I-Premise
32	p=0.008	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	Whereas	N	I-Premise
2	,	N	I-Premise
3	after	N	I-Premise
4	24	N	I-Premise
5	wk	N	I-Premise
6	,	N	I-Premise
7	31	N	I-Premise
8	in	N	I-Premise
9	group	N	I-Premise
10	A	N	I-Premise
11	versus	N	I-Premise
12	41	N	I-Premise
13	in	N	I-Premise
14	group	N	I-Premise
15	B	N	I-Premise
16	were	N	I-Premise
17	dry	N	I-Premise
18	(	N	I-Premise
19	p=0.08	N	I-Premise
20	)	N	I-Premise
21	.	N	O

1	The	N	I-Claim
2	decrease	N	I-Claim
3	in	N	I-Claim
4	IEF	N	I-Claim
5	and	N	I-Claim
6	improvements	N	I-Claim
7	in	N	I-Claim
8	I-QoL	N	I-Claim
9	scores	N	I-Claim
10	were	N	I-Claim
11	significantly	N	I-Claim
12	greater	N	I-Claim
13	in	N	I-Claim
14	group	N	I-Claim
15	A	N	I-Claim
16	for	N	I-Claim
17	the	N	I-Claim
18	first	N	I-Claim
19	16	N	I-Claim
20	wk	N	I-Claim
21	.	N	I-Claim

1	The	N	I-Claim
2	data	N	I-Claim
3	suggest	N	I-Claim
4	that	N	I-Claim
5	combination	N	I-Claim
6	therapy	N	I-Claim
7	might	N	I-Claim
8	provide	N	I-Claim
9	another	N	I-Claim
10	treatment	N	I-Claim
11	option	N	I-Claim
12	for	N	I-Claim
13	SUI	N	I-Claim
14	in	N	I-Claim
15	men	N	I-Claim
16	that	N	I-Claim
17	might	N	I-Claim
18	increase	N	I-Claim
19	the	N	I-Claim
20	percentage	N	I-Claim
21	of	N	I-Claim
22	early	N	I-Claim
23	postsurgery	N	I-Claim
24	continence	N	I-Claim
25	.	N	I-Claim

1	The	N	I-MajorClaim
2	impact	N	I-MajorClaim
3	of	N	I-MajorClaim
4	treatment	N	I-MajorClaim
5	on	N	I-MajorClaim
6	health-related	N	I-MajorClaim
7	quality	N	I-MajorClaim
8	of	N	I-MajorClaim
9	life	N	I-MajorClaim
10	(	N	I-MajorClaim
11	HRQoL	N	I-MajorClaim
12	)	N	I-MajorClaim
13	is	N	I-MajorClaim
14	an	N	I-MajorClaim
15	important	N	I-MajorClaim
16	consideration	N	I-MajorClaim
17	in	N	I-MajorClaim
18	the	N	I-MajorClaim
19	adjuvant	N	I-MajorClaim
20	treatment	N	I-MajorClaim
21	of	N	I-MajorClaim
22	operable	N	I-MajorClaim
23	breast	N	I-MajorClaim
24	cancer	N	I-MajorClaim
25	.	N	I-MajorClaim

1	Here	N	O
2	we	N	O
3	report	N	O
4	mature	N	O
5	HRQoL	N	O
6	outcomes	N	O
7	from	N	O
8	the	N	O
9	ATAC	N	O
10	trial	N	O
11	,	N	O
12	comparing	N	O
13	anastrozole	N	O
14	with	N	O
15	tamoxifen	N	O
16	as	N	O
17	primary	N	O
18	adjuvant	N	O
19	therapy	N	O
20	for	N	O
21	postmenopausal	N	O
22	women	N	O
23	with	N	O
24	localized	N	O
25	breast	N	O
26	cancer	N	O
27	.	N	O

1	Patients	N	O
2	completed	N	O
3	the	N	O
4	Functional	N	O
5	Assessment	N	O
6	of	N	O
7	Cancer	N	O
8	Therapy-Breast	N	O
9	(	N	O
10	FACT-B	N	O
11	)	N	O
12	questionnaire	N	O
13	plus	N	O
14	endocrine	N	O
15	subscale	N	O
16	(	N	O
17	ES	N	O
18	)	N	O
19	at	N	O
20	baseline	N	O
21	,	N	O
22	3	N	O
23	and	N	O
24	6	N	O
25	months	N	O
26	,	N	O
27	and	N	O
28	every	N	O
29	6	N	O
30	months	N	O
31	thereafter	N	O
32	.	N	O

1	Baseline	N	O
2	characteristics	N	O
3	in	N	O
4	the	N	O
5	HRQoL	N	O
6	sub-protocol	N	O
7	were	N	O
8	well	N	O
9	balanced	N	O
10	between	N	O
11	the	N	O
12	anastrozole	N	O
13	(	N	O
14	n	N	O
15	=	N	O
16	335	N	O
17	)	N	O
18	and	N	O
19	tamoxifen	N	O
20	(	N	O
21	n	N	O
22	=	N	O
23	347	N	O
24	)	N	O
25	groups	N	O
26	in	N	O
27	the	N	O
28	primary	N	O
29	analysis	N	O
30	population	N	O
31	.	N	O

1	As	N	I-Premise
2	with	N	I-Premise
3	previously	N	I-Premise
4	published	N	I-Premise
5	results	N	I-Premise
6	at	N	I-Premise
7	2	N	I-Premise
8	years	N	I-Premise
9	,	N	I-Premise
10	there	N	I-Premise
11	was	N	I-Premise
12	no	N	I-Premise
13	statistically	N	I-Premise
14	significant	N	I-Premise
15	difference	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	Trial	N	I-Premise
19	Outcome	N	I-Premise
20	Index	N	I-Premise
21	of	N	I-Premise
22	the	N	I-Premise
23	FACT-B	N	I-Premise
24	,	N	I-Premise
25	the	N	I-Premise
26	primary	N	I-Premise
27	endpoint	N	I-Premise
28	of	N	I-Premise
29	the	N	I-Premise
30	study	N	I-Premise
31	,	N	I-Premise
32	between	N	I-Premise
33	treatments	N	I-Premise
34	at	N	I-Premise
35	5	N	I-Premise
36	years	N	I-Premise
37	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	differences	N	I-Premise
7	between	N	I-Premise
8	treatment	N	I-Premise
9	groups	N	I-Premise
10	in	N	I-Premise
11	ES	N	I-Premise
12	total	N	I-Premise
13	scores	N	I-Premise
14	.	N	I-Premise

1	Consistent	N	O
2	with	N	O
3	the	N	O
4	2-year	N	O
5	analysis	N	O
6	,	N	O
7	there	N	I-Claim
8	were	N	I-Claim
9	differences	N	I-Claim
10	between	N	I-Claim
11	treatment	N	I-Claim
12	groups	N	I-Claim
13	in	N	I-Claim
14	patient-reported	N	I-Claim
15	side	N	I-Claim
16	effects	N	I-Claim
17	:	N	I-Claim
18	diarrhea	N	I-Premise
19	(	N	I-Premise
20	anastrozole	N	I-Premise
21	3.1	N	I-Premise
22	%	N	I-Premise
23	vs.	N	I-Premise
24	tamoxifen	N	I-Premise
25	1.3	N	I-Premise
26	%	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	vaginal	N	I-Premise
30	dryness	N	I-Premise
31	(	N	I-Premise
32	18.5	N	I-Premise
33	%	N	I-Premise
34	vs.	N	I-Premise
35	9.1	N	I-Premise
36	%	N	I-Premise
37	)	N	I-Premise
38	,	N	I-Premise
39	diminished	N	I-Premise
40	libido	N	I-Premise
41	(	N	I-Premise
42	34.0	N	I-Premise
43	%	N	I-Premise
44	vs.	N	I-Premise
45	26.1	N	I-Premise
46	%	N	I-Premise
47	)	N	I-Premise
48	,	N	I-Premise
49	and	N	I-Premise
50	dyspareunia	N	I-Premise
51	(	N	I-Premise
52	17.3	N	I-Premise
53	%	N	I-Premise
54	vs.	N	I-Premise
55	8.1	N	I-Premise
56	%	N	I-Premise
57	)	N	I-Premise
58	were	N	I-Premise
59	significantly	N	I-Premise
60	more	N	I-Premise
61	frequent	N	I-Premise
62	with	N	I-Premise
63	anastrozole	N	I-Premise
64	compared	N	I-Premise
65	to	N	I-Premise
66	tamoxifen	N	I-Premise
67	.	N	I-Premise

1	Dizziness	N	I-Premise
2	(	N	I-Premise
3	3.1	N	I-Premise
4	%	N	I-Premise
5	vs.	N	I-Premise
6	5.4	N	I-Premise
7	%	N	I-Premise
8	)	N	I-Premise
9	and	N	I-Premise
10	vaginal	N	I-Premise
11	discharge	N	I-Premise
12	(	N	I-Premise
13	1.2	N	I-Premise
14	%	N	I-Premise
15	vs.	N	I-Premise
16	5.2	N	I-Premise
17	%	N	I-Premise
18	)	N	I-Premise
19	were	N	I-Premise
20	significantly	N	I-Premise
21	less	N	I-Premise
22	frequent	N	I-Premise
23	with	N	I-Premise
24	anastrozole	N	I-Premise
25	compared	N	I-Premise
26	to	N	I-Premise
27	tamoxifen	N	I-Premise
28	.	N	I-Premise

1	In	N	I-Claim
2	this	N	I-Claim
3	,	N	I-Claim
4	the	N	I-Claim
5	first	N	I-Claim
6	report	N	I-Claim
7	of	N	I-Claim
8	HRQoL	N	I-Claim
9	over	N	I-Claim
10	5	N	I-Claim
11	years	N	I-Claim
12	of	N	I-Claim
13	initial	N	I-Claim
14	adjuvant	N	I-Claim
15	therapy	N	I-Claim
16	with	N	I-Claim
17	an	N	I-Claim
18	aromatase	N	I-Claim
19	inhibitor	N	I-Claim
20	,	N	I-Claim
21	we	N	I-Claim
22	conclude	N	I-Claim
23	that	N	I-Claim
24	anastrozole	N	I-Claim
25	and	N	I-Claim
26	tamoxifen	N	I-Claim
27	had	N	I-Claim
28	similar	N	I-Claim
29	impacts	N	I-Claim
30	on	N	I-Claim
31	HRQoL	N	I-Claim
32	,	N	I-Claim
33	which	N	I-Claim
34	was	N	I-Claim
35	maintained	N	I-Claim
36	or	N	I-Claim
37	slightly	N	I-Claim
38	improved	N	I-Claim
39	during	N	I-Claim
40	the	N	I-Claim
41	treatment	N	I-Claim
42	period	N	I-Claim
43	for	N	I-Claim
44	both	N	I-Claim
45	groups	N	I-Claim
46	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	safety	N	O
5	and	N	O
6	health-related	N	O
7	quality	N	O
8	of	N	O
9	life	N	O
10	(	N	O
11	HRQOL	N	O
12	)	N	O
13	of	N	O
14	continuous	N	O
15	combined	N	O
16	hormone	N	O
17	replacement	N	O
18	therapy	N	O
19	(	N	O
20	ccHRT	N	O
21	)	N	O
22	with	N	O
23	estradiol	N	O
24	valerate/medroxyprogesterone	N	O
25	acetate	N	O
26	(	N	O
27	E	N	O
28	(	N	O
29	2	N	O
30	)	N	O
31	V/MPA	N	O
32	)	N	O
33	over	N	O
34	nine	N	O
35	years	N	O
36	and	N	O
37	at	N	O
38	follow-up	N	O
39	one	N	O
40	year	N	O
41	after	N	O
42	discontinuation	N	O
43	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	419	N	O
5	women	N	O
6	were	N	O
7	randomized	N	O
8	to	N	O
9	one	N	O
10	of	N	O
11	four	N	O
12	treatments	N	O
13	:	N	O
14	once-daily	N	O
15	1	N	O
16	mg	N	O
17	E2V/2.5	N	O
18	mg	N	O
19	MPA	N	O
20	(	N	O
21	1	N	O
22	+	N	O
23	2.5	N	O
24	group	N	O
25	)	N	O
26	;	N	O
27	1	N	O
28	mg	N	O
29	E2V/5	N	O
30	mg	N	O
31	MPA	N	O
32	daily	N	O
33	(	N	O
34	1	N	O
35	+	N	O
36	5	N	O
37	group	N	O
38	)	N	O
39	;	N	O
40	2	N	O
41	mg	N	O
42	E2V/2.5	N	O
43	mg	N	O
44	MPA	N	O
45	daily	N	O
46	(	N	O
47	2	N	O
48	+	N	O
49	2.5	N	O
50	group	N	O
51	)	N	O
52	;	N	O
53	2	N	O
54	mg	N	O
55	E2V/5	N	O
56	mg	N	O
57	MPA	N	O
58	daily	N	O
59	(	N	O
60	2	N	O
61	+	N	O
62	5	N	O
63	group	N	O
64	)	N	O
65	(	N	O
66	Indivina	N	O
67	,	N	O
68	Orion	N	O
69	Pharma	N	O
70	)	N	O
71	.	N	O

1	For	N	O
2	the	N	O
3	last	N	O
4	six	N	O
5	months	N	O
6	,	N	O
7	all	N	O
8	received	N	O
9	the	N	O
10	1	N	O
11	+	N	O
12	2.5	N	O
13	dosage	N	O
14	.	N	O

1	The	N	O
2	2	N	O
3	+	N	O
4	2.5	N	O
5	dosage	N	O
6	was	N	O
7	discontinued	N	O
8	at	N	O
9	the	N	O
10	end	N	O
11	of	N	O
12	year	N	O
13	7	N	O
14	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	198	N	O
5	women	N	O
6	continued	N	O
7	after	N	O
8	year	N	O
9	7	N	O
10	.	N	O

1	Annualized	N	O
2	percentage	N	O
3	rates	N	O
4	for	N	O
5	cardiovascular	N	O
6	events	N	O
7	[	N	O
8	corrected	N	O
9	]	N	O
10	and	N	O
11	endometrial	N	O
12	cancers	N	O
13	[	N	O
14	corrected	N	O
15	]	N	O
16	were	N	O
17	below	N	O
18	national	N	O
19	rates	N	O
20	for	N	O
21	Finland	N	O
22	and	N	O
23	those	N	O
24	reported	N	O
25	for	N	O
26	the	N	O
27	Women	N	O
28	's	N	O
29	Health	N	O
30	Initiative	N	O
31	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	serious	N	I-Premise
5	events	N	I-Premise
6	with	N	I-Premise
7	the	N	I-Premise
8	1	N	I-Premise
9	+	N	I-Premise
10	2.5	N	I-Premise
11	dosage	N	I-Premise
12	or	N	I-Premise
13	after	N	I-Premise
14	ccHRT	N	I-Premise
15	discontinuation	N	I-Premise
16	.	N	I-Premise

1	Climacteric	N	I-Premise
2	symptoms	N	I-Premise
3	remained	N	I-Premise
4	significantly	N	I-Premise
5	below	N	I-Premise
6	baseline	N	I-Premise
7	values	N	I-Premise
8	after	N	I-Premise
9	dosage	N	I-Premise
10	reduction	N	I-Premise
11	;	N	I-Premise
12	some	N	I-Premise
13	symptoms	N	I-Premise
14	recurred	N	I-Premise
15	after	N	I-Premise
16	discontinuation	N	I-Premise
17	of	N	I-Premise
18	ccHRT	N	I-Premise
19	.	N	I-Premise

1	HRQOL	N	I-Premise
2	ratings	N	I-Premise
3	improved	N	I-Premise
4	with	N	I-Premise
5	ccHRT	N	I-Premise
6	,	N	I-Premise
7	irrespective	N	I-Premise
8	of	N	I-Premise
9	dosage	N	I-Premise
10	,	N	I-Premise
11	including	N	I-Premise
12	depressed	N	I-Premise
13	mood	N	I-Premise
14	,	N	I-Premise
15	anxiety	N	I-Premise
16	,	N	I-Premise
17	health	N	I-Premise
18	perception	N	I-Premise
19	and	N	I-Premise
20	sexual	N	I-Premise
21	interest	N	I-Premise
22	.	N	I-Premise

1	Scores	N	I-Premise
2	on	N	I-Premise
3	a	N	I-Premise
4	scale	N	I-Premise
5	assessing	N	I-Premise
6	daily	N	I-Premise
7	functioning	N	I-Premise
8	and	N	I-Premise
9	enjoyment	N	I-Premise
10	(	N	I-Premise
11	Q-LES-Q	N	I-Premise
12	)	N	I-Premise
13	improved	N	I-Premise
14	from	N	I-Premise
15	year	N	I-Premise
16	7	N	I-Premise
17	to	N	I-Premise
18	year	N	I-Premise
19	9	N	I-Premise
20	.	N	I-Premise

1	They	N	I-Premise
2	deteriorated	N	I-Premise
3	during	N	I-Premise
4	follow-up	N	I-Premise
5	in	N	I-Premise
6	women	N	I-Premise
7	not	N	I-Premise
8	continuing	N	I-Premise
9	ccHRT	N	I-Premise
10	.	N	I-Premise

1	Lower	N	I-Claim
2	dosages	N	I-Claim
3	of	N	I-Claim
4	HRT	N	I-Claim
5	were	N	I-Claim
6	as	N	I-Claim
7	effective	N	I-Claim
8	as	N	I-Claim
9	higher	N	I-Claim
10	doses	N	I-Claim
11	in	N	I-Claim
12	improving	N	I-Claim
13	climacteric	N	I-Claim
14	symptoms	N	I-Claim
15	and	N	I-Claim
16	HRQOL	N	I-Claim
17	ratings	N	I-Claim
18	and	N	I-Claim
19	had	N	I-Claim
20	fewer	N	I-Claim
21	safety	N	I-Claim
22	concerns	N	I-Claim
23	.	N	I-Claim

1	Following	N	I-Premise
2	discontinuation	N	I-Premise
3	of	N	I-Premise
4	ccHRT	N	I-Premise
5	,	N	I-Premise
6	patient	N	I-Premise
7	satisfaction	N	I-Premise
8	was	N	I-Premise
9	variable	N	I-Premise
10	,	N	I-Premise
11	with	N	I-Premise
12	15	N	I-Premise
13	%	N	I-Premise
14	electing	N	I-Premise
15	to	N	I-Premise
16	continue	N	I-Premise
17	or	N	I-Premise
18	restart	N	I-Premise
19	HRT	N	I-Premise
20	and	N	I-Premise
21	7	N	I-Premise
22	%	N	I-Premise
23	resuming	N	I-Premise
24	at	N	I-Premise
25	follow-up	N	I-Premise
26	.	N	I-Premise

1	This	N	I-Claim
2	supports	N	I-Claim
3	the	N	I-Claim
4	need	N	I-Claim
5	for	N	I-Claim
6	an	N	I-Claim
7	individualized	N	I-Claim
8	approach	N	I-Claim
9	to	N	I-Claim
10	therapy	N	I-Claim
11	recommendations	N	I-Claim
12	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	toxicity	N	O
11	and	N	O
12	efficacy	N	O
13	of	N	O
14	radiation	N	O
15	therapy	N	O
16	(	N	O
17	RT	N	O
18	)	N	O
19	for	N	O
20	localized	N	O
21	carcinoma	N	O
22	of	N	O
23	the	N	O
24	prostate	N	O
25	,	N	O
26	using	N	O
27	a	N	O
28	hypofractionated	N	O
29	(	N	O
30	55	N	O
31	Gy/20	N	O
32	fractions/4	N	O
33	weeks	N	O
34	)	N	O
35	vs.	N	O
36	a	N	O
37	conventionally	N	O
38	fractionated	N	O
39	(	N	O
40	64	N	O
41	Gy/32	N	O
42	fractions/6.5	N	O
43	weeks	N	O
44	)	N	O
45	dose	N	O
46	schedule	N	O
47	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	217	N	O
5	patients	N	O
6	were	N	O
7	randomized	N	O
8	to	N	O
9	either	N	O
10	the	N	O
11	hypofractionated	N	O
12	(	N	O
13	108	N	O
14	patients	N	O
15	)	N	O
16	or	N	O
17	the	N	O
18	conventional	N	O
19	(	N	O
20	109	N	O
21	patients	N	O
22	)	N	O
23	dose	N	O
24	schedule	N	O
25	,	N	O
26	with	N	O
27	planning	N	O
28	with	N	O
29	two-dimensional	N	O
30	(	N	O
31	2D	N	O
32	)	N	O
33	CT	N	O
34	scan	N	O
35	planning	N	O
36	methodology	N	O
37	in	N	O
38	the	N	O
39	majority	N	O
40	of	N	O
41	cases	N	O
42	.	N	O

1	All	N	O
2	patients	N	O
3	were	N	O
4	followed	N	O
5	for	N	O
6	a	N	O
7	median	N	O
8	of	N	O
9	48	N	O
10	(	N	O
11	6-108	N	O
12	)	N	O
13	months	N	O
14	.	N	O

1	Gastrointestinal	N	O
2	(	N	O
3	GI	N	O
4	)	N	O
5	and	N	O
6	genitourinary	N	O
7	(	N	O
8	GU	N	O
9	)	N	O
10	toxicity	N	O
11	was	N	O
12	evaluated	N	O
13	before	N	O
14	RT	N	O
15	and	N	O
16	after	N	O
17	its	N	O
18	completion	N	O
19	using	N	O
20	modified	N	O
21	late	N	O
22	effects	N	O
23	of	N	O
24	normal	N	O
25	tissue-subjective	N	O
26	,	N	O
27	objective	N	O
28	,	N	O
29	management	N	O
30	,	N	O
31	analytic	N	O
32	(	N	O
33	LENT-SOMA	N	O
34	)	N	O
35	scales	N	O
36	and	N	O
37	the	N	O
38	European	N	O
39	Organization	N	O
40	for	N	O
41	Research	N	O
42	and	N	O
43	Treatment	N	O
44	of	N	O
45	Cancer	N	O
46	sexual	N	O
47	function	N	O
48	questionnaire	N	O
49	.	N	O

1	Efficacy	N	O
2	of	N	O
3	RT	N	O
4	based	N	O
5	on	N	O
6	clinical	N	O
7	,	N	O
8	radiologic	N	O
9	,	N	O
10	and	N	O
11	prostate-specific	N	O
12	antigen	N	O
13	data	N	O
14	were	N	O
15	also	N	O
16	evaluated	N	O
17	at	N	O
18	baseline	N	O
19	and	N	O
20	after	N	O
21	RT	N	O
22	.	N	O

1	Gastrointestinal	N	I-Premise
2	and	N	I-Premise
3	GU	N	I-Premise
4	toxicity	N	I-Premise
5	persisted	N	I-Premise
6	5	N	I-Premise
7	years	N	I-Premise
8	after	N	I-Premise
9	RT	N	I-Premise
10	and	N	I-Premise
11	did	N	I-Premise
12	not	N	I-Premise
13	differ	N	I-Premise
14	between	N	I-Premise
15	the	N	I-Premise
16	two	N	I-Premise
17	dose	N	I-Premise
18	schedules	N	I-Premise
19	other	N	I-Premise
20	than	N	I-Premise
21	in	N	I-Premise
22	regard	N	I-Premise
23	to	N	I-Premise
24	urgency	N	I-Premise
25	of	N	I-Premise
26	defecation	N	I-Premise
27	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	1-month	N	I-Premise
4	GI	N	I-Premise
5	toxicity	N	I-Premise
6	was	N	I-Premise
7	not	N	I-Premise
8	only	N	I-Premise
9	worse	N	I-Premise
10	in	N	I-Premise
11	patients	N	I-Premise
12	with	N	I-Premise
13	the	N	I-Premise
14	hypofractionated	N	I-Premise
15	RT	N	I-Premise
16	schedule	N	I-Premise
17	but	N	I-Premise
18	also	N	I-Premise
19	adversely	N	I-Premise
20	affected	N	I-Premise
21	daily	N	I-Premise
22	activities	N	I-Premise
23	.	N	I-Premise

1	Nadir	N	I-Premise
2	prostate-specific	N	I-Premise
3	antigen	N	I-Premise
4	values	N	I-Premise
5	occurred	N	I-Premise
6	at	N	I-Premise
7	a	N	I-Premise
8	median	N	I-Premise
9	of	N	I-Premise
10	18.0	N	I-Premise
11	(	N	I-Premise
12	3.0-54.0	N	I-Premise
13	)	N	I-Premise
14	months	N	I-Premise
15	after	N	I-Premise
16	RT	N	I-Premise
17	.	N	I-Premise

1	A	N	I-Premise
2	total	N	I-Premise
3	of	N	I-Premise
4	76	N	I-Premise
5	biochemical	N	I-Premise
6	relapses	N	I-Premise
7	,	N	I-Premise
8	with	N	I-Premise
9	or	N	I-Premise
10	without	N	I-Premise
11	clinical	N	I-Premise
12	relapses	N	I-Premise
13	,	N	I-Premise
14	have	N	I-Premise
15	occurred	N	I-Premise
16	since	N	I-Premise
17	;	N	I-Premise
18	of	N	I-Premise
19	these	N	I-Premise
20	,	N	I-Premise
21	37	N	I-Premise
22	were	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	hypofractionated	N	I-Premise
26	and	N	I-Premise
27	39	N	I-Premise
28	in	N	I-Premise
29	the	N	I-Premise
30	conventional	N	I-Premise
31	schedule	N	I-Premise
32	.	N	I-Premise

1	The	N	I-Premise
2	5-year	N	I-Premise
3	biochemical	N	I-Premise
4	+/-	N	I-Premise
5	clinical	N	I-Premise
6	relapse-free	N	I-Premise
7	and	N	I-Premise
8	overall	N	I-Premise
9	survival	N	I-Premise
10	was	N	I-Premise
11	55.9	N	I-Premise
12	%	N	I-Premise
13	and	N	I-Premise
14	85.3	N	I-Premise
15	%	N	I-Premise
16	respectively	N	I-Premise
17	for	N	I-Premise
18	all	N	I-Premise
19	patients	N	I-Premise
20	,	N	I-Premise
21	and	N	I-Premise
22	did	N	I-Premise
23	not	N	I-Premise
24	differ	N	I-Premise
25	between	N	I-Premise
26	the	N	I-Premise
27	two	N	I-Premise
28	schedules	N	I-Premise
29	.	N	I-Premise

1	Radiation	N	I-Claim
2	therapy	N	I-Claim
3	for	N	I-Claim
4	prostate	N	I-Claim
5	carcinoma	N	I-Claim
6	causes	N	I-Claim
7	persistent	N	I-Claim
8	GI	N	I-Claim
9	toxicity	N	I-Claim
10	that	N	I-Claim
11	is	N	I-Claim
12	largely	N	I-Claim
13	independent	N	I-Claim
14	of	N	I-Claim
15	the	N	I-Claim
16	two	N	I-Claim
17	dose	N	I-Claim
18	schedules	N	I-Claim
19	.	N	I-Claim

1	The	N	I-Claim
2	hypofractionated	N	I-Claim
3	schedule	N	I-Claim
4	is	N	I-Claim
5	equivalent	N	I-Claim
6	in	N	I-Claim
7	efficacy	N	I-Claim
8	to	N	I-Claim
9	the	N	I-Claim
10	conventional	N	I-Claim
11	schedule	N	I-Claim
12	.	N	I-Claim

1	Most	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	advanced	N	I-Claim
5	ovarian	N	I-Claim
6	cancer	N	I-Claim
7	develop	N	I-Claim
8	recurrent	N	I-Claim
9	disease	N	I-Claim
10	.	N	I-Claim

1	For	N	I-Claim
2	those	N	I-Claim
3	patients	N	I-Claim
4	who	N	I-Claim
5	recur	N	I-Claim
6	at	N	I-Claim
7	least	N	I-Claim
8	6	N	I-Claim
9	months	N	I-Claim
10	after	N	I-Claim
11	initial	N	I-Claim
12	therapy	N	I-Claim
13	,	N	I-Claim
14	paclitaxel	N	I-Claim
15	platinum	N	I-Claim
16	has	N	I-Claim
17	shown	N	I-Claim
18	a	N	I-Claim
19	modest	N	I-Claim
20	survival	N	I-Claim
21	advantage	N	I-Claim
22	over	N	I-Claim
23	platinum	N	I-Claim
24	without	N	I-Claim
25	paclitaxel	N	I-Claim
26	;	N	I-Claim
27	however	N	I-Premise
28	,	N	I-Premise
29	many	N	I-Premise
30	patients	N	I-Premise
31	develop	N	I-Premise
32	clinically	N	I-Premise
33	relevant	N	I-Premise
34	neurotoxicity	N	I-Premise
35	,	N	I-Premise
36	frequently	N	I-Premise
37	resulting	N	I-Premise
38	in	N	I-Premise
39	treatment	N	I-Premise
40	discontinuation	N	I-Premise
41	.	N	O

1	Thus	N	O
2	,	N	O
3	an	N	O
4	alternative	N	O
5	regimen	N	O
6	without	N	O
7	significant	N	O
8	neurotoxicity	N	O
9	was	N	O
10	evaluated	N	O
11	by	N	O
12	comparing	N	O
13	gemcitabine	N	O
14	plus	N	O
15	carboplatin	N	O
16	with	N	O
17	single-agent	N	O
18	carboplatin	N	O
19	in	N	O
20	platinum-sensitive	N	O
21	recurrent	N	O
22	ovarian	N	O
23	cancer	N	O
24	patients	N	O
25	.	N	O

1	Patients	N	O
2	with	N	O
3	platinum-sensitive	N	O
4	recurrent	N	O
5	ovarian	N	O
6	cancer	N	O
7	were	N	O
8	randomly	N	O
9	assigned	N	O
10	to	N	O
11	receive	N	O
12	either	N	O
13	gemcitabine	N	O
14	plus	N	O
15	carboplatin	N	O
16	or	N	O
17	carboplatin	N	O
18	alone	N	O
19	,	N	O
20	every	N	O
21	21	N	O
22	days	N	O
23	.	N	O

1	The	N	O
2	primary	N	O
3	objective	N	O
4	was	N	O
5	to	N	O
6	compare	N	O
7	progression-free	N	O
8	survival	N	O
9	(	N	O
10	PFS	N	O
11	)	N	O
12	.	N	O

1	Three	N	O
2	hundred	N	O
3	fifty-six	N	O
4	patients	N	O
5	(	N	O
6	178	N	O
7	gemcitabine	N	O
8	plus	N	O
9	carboplatin	N	O
10	;	N	O
11	178	N	O
12	carboplatin	N	O
13	)	N	O
14	were	N	O
15	randomly	N	O
16	assigned	N	O
17	.	N	O

1	Patients	N	O
2	received	N	O
3	a	N	O
4	median	N	O
5	of	N	O
6	six	N	O
7	cycles	N	O
8	in	N	O
9	both	N	O
10	arms	N	O
11	.	N	O

1	With	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	17	N	I-Premise
7	months	N	I-Premise
8	,	N	I-Premise
9	median	N	I-Premise
10	PFS	N	I-Premise
11	was	N	I-Premise
12	8.6	N	I-Premise
13	months	N	I-Premise
14	(	N	I-Premise
15	95	N	I-Premise
16	%	N	I-Premise
17	CI	N	I-Premise
18	,	N	I-Premise
19	7.9	N	I-Premise
20	to	N	I-Premise
21	9.7	N	I-Premise
22	months	N	I-Premise
23	)	N	I-Premise
24	for	N	I-Premise
25	gemcitabine	N	I-Premise
26	plus	N	I-Premise
27	carboplatin	N	I-Premise
28	and	N	I-Premise
29	5.8	N	I-Premise
30	months	N	I-Premise
31	(	N	I-Premise
32	95	N	I-Premise
33	%	N	I-Premise
34	CI	N	I-Premise
35	,	N	I-Premise
36	5.2	N	I-Premise
37	to	N	I-Premise
38	7.1	N	I-Premise
39	months	N	I-Premise
40	)	N	I-Premise
41	for	N	I-Premise
42	carboplatin	N	I-Premise
43	.	N	I-Premise

1	The	N	I-Premise
2	hazard	N	I-Premise
3	ration	N	I-Premise
4	(	N	I-Premise
5	HR	N	I-Premise
6	)	N	I-Premise
7	for	N	I-Premise
8	PFS	N	I-Premise
9	was	N	I-Premise
10	0.72	N	I-Premise
11	(	N	I-Premise
12	95	N	I-Premise
13	%	N	I-Premise
14	CI	N	I-Premise
15	,	N	I-Premise
16	0.58	N	I-Premise
17	to	N	I-Premise
18	0.90	N	I-Premise
19	;	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	.0031	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Response	N	I-Premise
2	rate	N	I-Premise
3	was	N	I-Premise
4	47.2	N	I-Premise
5	%	N	I-Premise
6	(	N	I-Premise
7	95	N	I-Premise
8	%	N	I-Premise
9	CI	N	I-Premise
10	,	N	I-Premise
11	39.9	N	I-Premise
12	%	N	I-Premise
13	to	N	I-Premise
14	54.5	N	I-Premise
15	%	N	I-Premise
16	)	N	I-Premise
17	for	N	I-Premise
18	gemcitabine	N	I-Premise
19	plus	N	I-Premise
20	carboplatin	N	I-Premise
21	and	N	I-Premise
22	30.9	N	I-Premise
23	%	N	I-Premise
24	(	N	I-Premise
25	95	N	I-Premise
26	%	N	I-Premise
27	CI	N	I-Premise
28	,	N	I-Premise
29	24.1	N	I-Premise
30	%	N	I-Premise
31	to	N	I-Premise
32	37.7	N	I-Premise
33	%	N	I-Premise
34	)	N	I-Premise
35	for	N	I-Premise
36	carboplatin	N	I-Premise
37	(	N	I-Premise
38	P	N	I-Premise
39	=	N	I-Premise
40	.0016	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	The	N	I-Premise
2	HR	N	I-Premise
3	for	N	I-Premise
4	overall	N	I-Premise
5	survival	N	I-Premise
6	was	N	I-Premise
7	0.96	N	I-Premise
8	(	N	I-Premise
9	95	N	I-Premise
10	%	N	I-Premise
11	CI	N	I-Premise
12	,	N	I-Premise
13	0.75	N	I-Premise
14	to1.23	N	I-Premise
15	;	N	I-Premise
16	P	N	I-Premise
17	=	N	I-Premise
18	.7349	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	While	N	I-Premise
2	myelosuppression	N	I-Premise
3	was	N	I-Premise
4	significantly	N	I-Premise
5	more	N	I-Premise
6	common	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	combination	N	I-Premise
10	,	N	I-Premise
11	sequelae	N	I-Premise
12	such	N	I-Premise
13	as	N	I-Premise
14	febrile	N	I-Premise
15	neutropenia	N	I-Premise
16	or	N	I-Premise
17	infections	N	I-Premise
18	were	N	I-Premise
19	uncommon	N	I-Premise
20	.	N	I-Premise

1	No	N	I-Premise
2	statistically	N	I-Premise
3	significant	N	I-Premise
4	differences	N	I-Premise
5	in	N	I-Premise
6	quality	N	I-Premise
7	of	N	I-Premise
8	life	N	I-Premise
9	scores	N	I-Premise
10	between	N	I-Premise
11	arms	N	I-Premise
12	were	N	I-Premise
13	noted	N	I-Premise
14	.	N	I-Premise

1	Gemcitabine	N	I-Claim
2	plus	N	I-Claim
3	carboplatin	N	I-Claim
4	significantly	N	I-Claim
5	improves	N	I-Claim
6	PFS	N	I-Claim
7	and	N	I-Claim
8	response	N	I-Claim
9	rate	N	I-Claim
10	without	N	I-Claim
11	worsening	N	I-Claim
12	quality	N	I-Claim
13	of	N	I-Claim
14	life	N	I-Claim
15	for	N	I-Claim
16	patients	N	I-Claim
17	with	N	I-Claim
18	platinum-sensitive	N	I-Claim
19	recurrent	N	I-Claim
20	ovarian	N	I-Claim
21	cancer	N	I-Claim
22	.	N	I-Claim

1	Radiation-induced	N	O
2	mucositis	N	O
3	is	N	O
4	an	N	O
5	acute	N	O
6	reaction	N	O
7	of	N	O
8	the	N	O
9	mucosa	N	O
10	of	N	O
11	patients	N	O
12	undergoing	N	O
13	head	N	O
14	and	N	O
15	neck	N	O
16	radiotherapy	N	O
17	.	N	O

1	It	N	O
2	can	N	O
3	have	N	O
4	debilitating	N	O
5	and	N	O
6	dose-limiting	N	O
7	consequences	N	O
8	.	N	O

1	There	N	I-MajorClaim
2	is	N	I-MajorClaim
3	no	N	I-MajorClaim
4	consensus	N	I-MajorClaim
5	on	N	I-MajorClaim
6	an	N	I-MajorClaim
7	accepted	N	I-MajorClaim
8	intervention	N	I-MajorClaim
9	that	N	I-MajorClaim
10	significantly	N	I-MajorClaim
11	reduces	N	I-MajorClaim
12	its	N	I-MajorClaim
13	severity	N	I-MajorClaim
14	.	N	I-MajorClaim

1	Misoprostol	N	O
2	is	N	O
3	a	N	O
4	synthetic	N	O
5	prostaglandin	N	O
6	E1	N	O
7	analogue	N	O
8	,	N	O
9	with	N	O
10	properties	N	O
11	of	N	O
12	a	N	O
13	mucosal	N	O
14	cytoprotectant	N	O
15	.	N	O

1	We	N	O
2	designed	N	O
3	a	N	O
4	randomized	N	O
5	,	N	O
6	double-blind	N	O
7	,	N	O
8	placebo-controlled	N	O
9	trial	N	O
10	of	N	O
11	misoprostol	N	O
12	in	N	O
13	patients	N	O
14	with	N	O
15	head	N	O
16	and	N	O
17	neck	N	O
18	cancer	N	O
19	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	determine	N	O
9	if	N	O
10	topical	N	O
11	misoprostol	N	O
12	was	N	O
13	effective	N	O
14	in	N	O
15	reducing	N	O
16	the	N	O
17	severity	N	O
18	of	N	O
19	radiation-induced	N	O
20	mucositis	N	O
21	in	N	O
22	patients	N	O
23	receiving	N	O
24	radical	N	O
25	dose	N	O
26	radiotherapy	N	O
27	.	N	O

1	The	N	O
2	effect	N	O
3	of	N	O
4	this	N	O
5	intervention	N	O
6	on	N	O
7	a	N	O
8	patient	N	O
9	's	N	O
10	general	N	O
11	well-being	N	O
12	was	N	O
13	also	N	O
14	investigated	N	O
15	.	N	O

1	The	N	O
2	primary	N	O
3	end-point	N	O
4	of	N	O
5	the	N	O
6	study	N	O
7	was	N	O
8	the	N	O
9	incidence	N	O
10	of	N	O
11	Radiation	N	O
12	Therapy	N	O
13	Oncology	N	O
14	Group	N	O
15	grade	N	O
16	3	N	O
17	mucositis	N	O
18	.	N	O

1	Between	N	O
2	1999	N	O
3	and	N	O
4	2002	N	O
5	,	N	O
6	83	N	O
7	patients	N	O
8	were	N	O
9	recruited	N	O
10	into	N	O
11	the	N	O
12	study	N	O
13	at	N	O
14	Westmead	N	O
15	and	N	O
16	Nepean	N	O
17	Hospitals	N	O
18	,	N	O
19	Sydney	N	O
20	.	N	O

1	Forty-two	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	to	N	O
6	receive	N	O
7	misoprostol	N	O
8	and	N	O
9	41	N	O
10	to	N	O
11	receive	N	O
12	a	N	O
13	placebo	N	O
14	.	N	O

1	Most	N	O
2	patients	N	O
3	received	N	O
4	radiotherapy	N	O
5	in	N	O
6	the	N	O
7	adjuvant	N	O
8	setting	N	O
9	(	N	O
10	52	N	O
11	of	N	O
12	the	N	O
13	83	N	O
14	)	N	O
15	and	N	O
16	had	N	O
17	either	N	O
18	an	N	O
19	oral	N	O
20	cavity	N	O
21	(	N	O
22	42	N	O
23	of	N	O
24	the	N	O
25	83	N	O
26	)	N	O
27	or	N	O
28	an	N	O
29	oropharyngeal	N	O
30	(	N	O
31	16	N	O
32	of	N	O
33	the	N	O
34	83	N	O
35	)	N	O
36	cancer	N	O
37	.	N	O

1	We	N	I-Claim
2	could	N	I-Claim
3	not	N	I-Claim
4	identify	N	I-Claim
5	any	N	I-Claim
6	significant	N	I-Claim
7	difference	N	I-Claim
8	in	N	I-Claim
9	the	N	I-Claim
10	incidence	N	I-Claim
11	of	N	I-Claim
12	severe	N	I-Claim
13	mucositis	N	I-Claim
14	based	N	I-Claim
15	on	N	I-Claim
16	whether	N	I-Claim
17	patients	N	I-Claim
18	were	N	I-Claim
19	allocated	N	I-Claim
20	to	N	I-Claim
21	receive	N	I-Claim
22	misoprostol	N	I-Claim
23	or	N	I-Claim
24	placebo	N	I-Claim
25	.	N	I-Claim

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	mean	N	I-Premise
9	area	N	I-Premise
10	under	N	I-Premise
11	the	N	I-Premise
12	mucositis	N	I-Premise
13	curve	N	I-Premise
14	(	N	I-Premise
15	13.2	N	I-Premise
16	vs	N	I-Premise
17	16.6	N	I-Premise
18	;	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	0.1	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	Patients	N	I-Premise
2	allocated	N	I-Premise
3	to	N	I-Premise
4	misoprostol	N	I-Premise
5	did	N	I-Premise
6	report	N	I-Premise
7	slightly	N	I-Premise
8	increased	N	I-Premise
9	soreness	N	I-Premise
10	(	N	I-Premise
11	7.6	N	I-Premise
12	vs	N	I-Premise
13	6.9	N	I-Premise
14	;	N	I-Premise
15	P	N	I-Premise
16	=	N	I-Premise
17	0.04	N	I-Premise
18	)	N	I-Premise
19	and	N	I-Premise
20	a	N	I-Premise
21	greater	N	I-Premise
22	use	N	I-Premise
23	of	N	I-Premise
24	analgesics	N	I-Premise
25	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	this	N	I-Premise
4	difference	N	I-Premise
5	did	N	I-Premise
6	not	N	I-Premise
7	translate	N	I-Premise
8	into	N	I-Premise
9	a	N	I-Premise
10	worse	N	I-Premise
11	feeling	N	I-Premise
12	of	N	I-Premise
13	general	N	I-Premise
14	well-being	N	I-Premise
15	as	N	I-Premise
16	measured	N	I-Premise
17	by	N	I-Premise
18	a	N	I-Premise
19	simple	N	I-Premise
20	visual	N	I-Premise
21	analogue	N	I-Premise
22	scale	N	I-Premise
23	(	N	I-Premise
24	5.8	N	I-Premise
25	vs	N	I-Premise
26	5.2	N	I-Premise
27	;	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	0.3	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	In	N	I-Claim
2	conclusion	N	I-Claim
3	,	N	I-Claim
4	we	N	I-Claim
5	were	N	I-Claim
6	unable	N	I-Claim
7	to	N	I-Claim
8	identify	N	I-Claim
9	a	N	I-Claim
10	reduction	N	I-Claim
11	in	N	I-Claim
12	radiation-induced	N	I-Claim
13	mucositis	N	I-Claim
14	in	N	I-Claim
15	patients	N	I-Claim
16	receiving	N	I-Claim
17	misoprostol	N	I-Claim
18	.	N	I-Claim

1	There	N	I-MajorClaim
2	is	N	I-MajorClaim
3	a	N	I-MajorClaim
4	paucity	N	I-MajorClaim
5	of	N	I-MajorClaim
6	high-level	N	I-MajorClaim
7	evidence	N	I-MajorClaim
8	on	N	I-MajorClaim
9	potentially	N	I-MajorClaim
10	useful	N	I-MajorClaim
11	interventions	N	I-MajorClaim
12	and	N	I-MajorClaim
13	a	N	I-MajorClaim
14	continued	N	I-MajorClaim
15	need	N	I-MajorClaim
16	for	N	I-MajorClaim
17	new	N	I-MajorClaim
18	and	N	I-MajorClaim
19	innovative	N	I-MajorClaim
20	research	N	I-MajorClaim
21	,	N	I-MajorClaim
22	incorporating	N	I-MajorClaim
23	quality-of-life	N	I-MajorClaim
24	measurements	N	I-MajorClaim
25	,	N	I-MajorClaim
26	in	N	I-MajorClaim
27	patients	N	I-MajorClaim
28	experiencing	N	I-MajorClaim
29	radiation-induced	N	I-MajorClaim
30	mucositis	N	I-MajorClaim
31	.	N	I-MajorClaim

1	In	N	I-Claim
2	vivo	N	I-Claim
3	data	N	I-Claim
4	have	N	I-Claim
5	shown	N	I-Claim
6	a	N	I-Claim
7	more	N	I-Claim
8	potent	N	I-Claim
9	antiangiogenic	N	I-Claim
10	effect	N	I-Claim
11	and	N	I-Claim
12	a	N	I-Claim
13	higher	N	I-Claim
14	antitumor	N	I-Claim
15	activity	N	I-Claim
16	of	N	I-Claim
17	low-dose	N	I-Claim
18	interferon	N	I-Claim
19	(	N	I-Claim
20	IFN	N	I-Claim
21	)	N	I-Claim
22	given	N	I-Claim
23	twice	N	I-Claim
24	daily	N	I-Claim
25	.	N	I-Claim

1	In	N	O
2	a	N	O
3	randomized	N	O
4	Phase	N	O
5	II	N	O
6	trial	N	O
7	,	N	O
8	the	N	O
9	authors	N	O
10	tested	N	O
11	the	N	O
12	hypothesis	N	O
13	that	N	O
14	twice-daily	N	O
15	low-dose	N	O
16	IFN	N	O
17	is	N	O
18	more	N	O
19	effective	N	O
20	than	N	O
21	daily	N	O
22	intermediate-dose	N	O
23	IFN	N	O
24	in	N	O
25	patients	N	O
26	with	N	O
27	metastatic	N	O
28	renal	N	O
29	cell	N	O
30	cancer	N	O
31	(	N	O
32	MRCC	N	O
33	)	N	O
34	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	118	N	O
5	patients	N	O
6	(	N	O
7	59	N	O
8	per	N	O
9	arm	N	O
10	)	N	O
11	were	N	O
12	randomly	N	O
13	assigned	N	O
14	to	N	O
15	receive	N	O
16	IFN	N	O
17	at	N	O
18	a	N	O
19	dose	N	O
20	of	N	O
21	0.5	N	O
22	million	N	O
23	units	N	O
24	(	N	O
25	MU	N	O
26	)	N	O
27	given	N	O
28	subcutaneously	N	O
29	twice	N	O
30	daily	N	O
31	(	N	O
32	IFN1	N	O
33	)	N	O
34	or	N	O
35	IFN	N	O
36	at	N	O
37	a	N	O
38	dose	N	O
39	of	N	O
40	5	N	O
41	MU	N	O
42	given	N	O
43	subcutaneously	N	O
44	daily	N	O
45	(	N	O
46	IFN5	N	O
47	)	N	O
48	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	progression-free	N	O
6	survival	N	O
7	(	N	O
8	PFS	N	O
9	)	N	O
10	.	N	O

1	Secondary	N	O
2	endpoints	N	O
3	included	N	O
4	response	N	O
5	rate	N	O
6	(	N	O
7	RR	N	O
8	)	N	O
9	,	N	O
10	overall	N	O
11	survival	N	O
12	(	N	O
13	OS	N	O
14	)	N	O
15	,	N	O
16	toxicity	N	O
17	,	N	O
18	and	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	(	N	O
23	QOL	N	O
24	)	N	O
25	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	in	N	I-Premise
7	either	N	I-Premise
8	PFS	N	I-Premise
9	or	N	I-Premise
10	OS	N	I-Premise
11	between	N	I-Premise
12	IFN1	N	I-Premise
13	and	N	I-Premise
14	IFN5	N	I-Premise
15	(	N	I-Premise
16	median	N	I-Premise
17	of	N	I-Premise
18	3.7	N	I-Premise
19	months	N	I-Premise
20	and	N	I-Premise
21	median	N	I-Premise
22	of	N	I-Premise
23	3.4	N	I-Premise
24	months	N	I-Premise
25	PFS	N	I-Premise
26	,	N	I-Premise
27	respectively	N	I-Premise
28	;	N	I-Premise
29	median	N	I-Premise
30	of	N	I-Premise
31	25.5	N	I-Premise
32	months	N	I-Premise
33	and	N	I-Premise
34	median	N	I-Premise
35	of	N	I-Premise
36	17.5	N	I-Premise
37	months	N	I-Premise
38	OS	N	I-Premise
39	,	N	I-Premise
40	respectively	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	The	N	I-Premise
2	RRs	N	I-Premise
3	were	N	I-Premise
4	identical	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	2	N	I-Premise
8	arms	N	I-Premise
9	(	N	I-Premise
10	6.7	N	I-Premise
11	%	N	I-Premise
12	;	N	I-Premise
13	95	N	I-Premise
14	%	N	I-Premise
15	confidence	N	I-Premise
16	interval	N	I-Premise
17	[	N	I-Premise
18	95	N	I-Premise
19	%	N	I-Premise
20	CI	N	I-Premise
21	]	N	I-Premise
22	,	N	I-Premise
23	1.8-16.5	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	Two	N	I-Premise
2	patients	N	I-Premise
3	,	N	I-Premise
4	1	N	I-Premise
5	in	N	I-Premise
6	each	N	I-Premise
7	arm	N	I-Premise
8	,	N	I-Premise
9	remained	N	I-Premise
10	in	N	I-Premise
11	complete	N	I-Premise
12	remission	N	I-Premise
13	at	N	I-Premise
14	the	N	I-Premise
15	time	N	I-Premise
16	of	N	I-Premise
17	last	N	I-Premise
18	follow-up	N	I-Premise
19	,	N	I-Premise
20	at	N	I-Premise
21	45+	N	I-Premise
22	and	N	I-Premise
23	38+	N	I-Premise
24	months	N	I-Premise
25	from	N	I-Premise
26	treatment	N	I-Premise
27	.	N	I-Premise

1	Thirty-two	N	I-Premise
2	patients	N	I-Premise
3	receiving	N	I-Premise
4	IFN5	N	I-Premise
5	and	N	I-Premise
6	19	N	I-Premise
7	patients	N	I-Premise
8	receiving	N	I-Premise
9	IFN1	N	I-Premise
10	experienced	N	I-Premise
11	Grade	N	I-Premise
12	3	N	I-Premise
13	or	N	I-Premise
14	higher	N	I-Premise
15	adverse	N	I-Premise
16	events	N	I-Premise
17	(	N	I-Premise
18	graded	N	I-Premise
19	using	N	I-Premise
20	the	N	I-Premise
21	National	N	I-Premise
22	Cancer	N	I-Premise
23	Institute	N	I-Premise
24	Common	N	I-Premise
25	Toxicity	N	I-Premise
26	Criteria	N	I-Premise
27	[	N	I-Premise
28	version	N	I-Premise
29	2.0	N	I-Premise
30	]	N	I-Premise
31	)	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	.025	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	Eighteen	N	I-Premise
2	patients	N	I-Premise
3	receiving	N	I-Premise
4	IFN5	N	I-Premise
5	and	N	I-Premise
6	4	N	I-Premise
7	patients	N	I-Premise
8	receiving	N	I-Premise
9	IFN1	N	I-Premise
10	had	N	I-Premise
11	dose	N	I-Premise
12	reductions	N	I-Premise
13	(	N	I-Premise
14	P	N	I-Premise
15	=	N	I-Premise
16	.002	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	deterioration	N	I-Premise
6	in	N	I-Premise
7	QOL	N	I-Premise
8	and	N	I-Premise
9	an	N	I-Premise
10	increase	N	I-Premise
11	in	N	I-Premise
12	depression	N	I-Premise
13	associated	N	I-Premise
14	with	N	I-Premise
15	IFN5	N	I-Premise
16	but	N	I-Premise
17	no	N	I-Premise
18	change	N	I-Premise
19	was	N	I-Premise
20	noted	N	I-Premise
21	with	N	I-Premise
22	IFN1	N	I-Premise
23	.	N	I-Premise

1	Compared	N	I-Claim
2	with	N	I-Claim
3	IFN5	N	I-Claim
4	,	N	I-Claim
5	IFN1	N	I-Claim
6	is	N	I-Claim
7	neither	N	I-Claim
8	more	N	I-Claim
9	nor	N	I-Claim
10	less	N	I-Claim
11	effective	N	I-Claim
12	but	N	I-Claim
13	is	N	I-Claim
14	less	N	I-Claim
15	toxic	N	I-Claim
16	,	N	I-Claim
17	with	N	I-Claim
18	a	N	I-Claim
19	better	N	I-Claim
20	reported	N	I-Claim
21	QOL	N	I-Claim
22	.	N	I-Claim

1	These	N	I-Claim
2	results	N	I-Claim
3	may	N	I-Claim
4	have	N	I-Claim
5	implications	N	I-Claim
6	for	N	I-Claim
7	the	N	I-Claim
8	design	N	I-Claim
9	of	N	I-Claim
10	combination	N	I-Claim
11	regimens	N	I-Claim
12	incorporating	N	I-Claim
13	IFN	N	I-Claim
14	with	N	I-Claim
15	targeted	N	I-Claim
16	agents	N	I-Claim
17	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	whether	N	O
4	the	N	O
5	impact	N	O
6	of	N	O
7	``	N	O
8	laying	N	O
9	on	N	O
10	of	N	O
11	hands	N	O
12	''	N	O
13	on	N	O
14	the	N	O
15	well-being	N	O
16	of	N	O
17	patients	N	O
18	with	N	O
19	advanced	N	O
20	cancer	N	O
21	is	N	O
22	more	N	O
23	efficient	N	O
24	when	N	O
25	performed	N	O
26	by	N	O
27	a	N	O
28	person	N	O
29	with	N	O
30	self-declared	N	O
31	``	N	O
32	healing	N	O
33	powers	N	O
34	''	N	O
35	as	N	O
36	compared	N	O
37	to	N	O
38	an	N	O
39	actor	N	O
40	mimicking	N	O
41	the	N	O
42	healer	N	O
43	in	N	O
44	close	N	O
45	detail	N	O
46	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	80	N	O
5	patients	N	O
6	were	N	O
7	registered	N	O
8	to	N	O
9	participate	N	O
10	in	N	O
11	a	N	O
12	randomized	N	O
13	,	N	O
14	single-blind	N	O
15	phase	N	O
16	III	N	O
17	trial	N	O
18	to	N	O
19	evaluate	N	O
20	the	N	O
21	difference	N	O
22	in	N	O
23	efficacy	N	O
24	of	N	O
25	``	N	O
26	laying	N	O
27	on	N	O
28	of	N	O
29	hands	N	O
30	''	N	O
31	by	N	O
32	either	N	O
33	a	N	O
34	``	N	O
35	healer	N	O
36	''	N	O
37	or	N	O
38	an	N	O
39	actor	N	O
40	.	N	O

1	Each	N	O
2	group	N	O
3	consisted	N	O
4	of	N	O
5	40	N	O
6	patients	N	O
7	,	N	O
8	scheduled	N	O
9	to	N	O
10	receive	N	O
11	treatment	N	O
12	for	N	O
13	5	N	O
14	min	N	O
15	,	N	O
16	three	N	O
17	times	N	O
18	a	N	O
19	week	N	O
20	.	N	O

1	The	N	O
2	effect	N	O
3	of	N	O
4	treatment	N	O
5	was	N	O
6	measured	N	O
7	using	N	O
8	a	N	O
9	``	N	O
10	Well-Being	N	O
11	scale	N	O
12	''	N	O
13	,	N	O
14	with	N	O
15	the	N	O
16	difference	N	O
17	of	N	O
18	the	N	O
19	average	N	O
20	score	N	O
21	of	N	O
22	the	N	O
23	``	N	O
24	Well-Being	N	O
25	scale	N	O
26	''	N	O
27	on	N	O
28	day	N	O
29	10	N	O
30	being	N	O
31	defined	N	O
32	as	N	O
33	primary	N	O
34	and	N	O
35	that	N	O
36	on	N	O
37	day	N	O
38	5	N	O
39	as	N	O
40	secondary	N	O
41	endpoint	N	O
42	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	average	N	I-Premise
8	score	N	I-Premise
9	values	N	I-Premise
10	between	N	I-Premise
11	the	N	I-Premise
12	``	N	I-Premise
13	healer	N	I-Premise
14	''	N	I-Premise
15	and	N	I-Premise
16	the	N	I-Premise
17	actor	N	I-Premise
18	with	N	I-Premise
19	regard	N	I-Premise
20	to	N	I-Premise
21	the	N	I-Premise
22	primary	N	I-Premise
23	(	N	I-Premise
24	p	N	I-Premise
25	=	N	I-Premise
26	0.34	N	I-Premise
27	)	N	I-Premise
28	or	N	I-Premise
29	the	N	I-Premise
30	secondary	N	I-Premise
31	endpoint	N	I-Premise
32	(	N	I-Premise
33	p	N	I-Premise
34	=	N	I-Premise
35	0.94	N	I-Premise
36	)	N	I-Premise
37	,	N	I-Premise
38	but	N	I-Premise
39	the	N	I-Premise
40	comparison	N	I-Premise
41	was	N	I-Premise
42	limited	N	I-Premise
43	due	N	I-Premise
44	to	N	I-Premise
45	major	N	I-Premise
46	protocol	N	I-Premise
47	violations	N	I-Premise
48	by	N	I-Premise
49	the	N	I-Premise
50	``	N	I-Premise
51	healer	N	I-Premise
52	''	N	I-Premise
53	who	N	I-Premise
54	unblinded	N	I-Premise
55	his	N	I-Premise
56	status	N	I-Premise
57	after	N	I-Premise
58	the	N	I-Premise
59	first	N	I-Premise
60	run	N	I-Premise
61	and	N	I-Premise
62	quit	N	I-Premise
63	the	N	I-Premise
64	study	N	I-Premise
65	.	N	I-Premise

1	The	N	O
2	study	N	O
3	was	N	O
4	completed	N	O
5	by	N	O
6	the	N	O
7	actor	N	O
8	as	N	O
9	a	N	O
10	descriptive	N	O
11	,	N	O
12	explorative	N	O
13	study	N	O
14	on	N	O
15	the	N	O
16	impact	N	O
17	of	N	O
18	``	N	O
19	laying	N	O
20	on	N	O
21	of	N	O
22	hands	N	O
23	''	N	O
24	.	N	I-Premise

1	A	N	I-Premise
2	significant	N	I-Premise
3	improvement	N	I-Premise
4	in	N	I-Premise
5	symptoms	N	I-Premise
6	after	N	I-Premise
7	treatment	N	I-Premise
8	was	N	I-Premise
9	found	N	I-Premise
10	on	N	I-Premise
11	day	N	I-Premise
12	5	N	I-Premise
13	(	N	I-Premise
14	p	N	I-Premise
15	<	N	I-Premise
16	0.001	N	I-Premise
17	)	N	I-Premise
18	and	N	I-Premise
19	on	N	I-Premise
20	day	N	I-Premise
21	10	N	I-Premise
22	(	N	I-Premise
23	p	N	I-Premise
24	=	N	I-Premise
25	0.0002	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	``	N	I-Claim
2	Laying	N	I-Claim
3	on	N	I-Claim
4	of	N	I-Claim
5	hands	N	I-Claim
6	''	N	I-Claim
7	resulted	N	I-Claim
8	in	N	I-Claim
9	a	N	I-Claim
10	significant	N	I-Claim
11	improvement	N	I-Claim
12	of	N	I-Claim
13	cancer-	N	I-Claim
14	or	N	I-Claim
15	cancer-therapy-associated	N	I-Claim
16	symptoms	N	I-Claim
17	.	N	I-Claim

1	The	N	I-Claim
2	magnitude	N	I-Claim
3	of	N	I-Claim
4	improvement	N	I-Claim
5	obtained	N	I-Claim
6	was	N	I-Claim
7	similar	N	I-Claim
8	whether	N	I-Claim
9	on	N	I-Claim
10	a	N	I-Claim
11	self-declared-healer-	N	I-Claim
12	or	N	I-Claim
13	an	N	I-Claim
14	actor-provided	N	I-Claim
15	``	N	I-Claim
16	treatment	N	I-Claim
17	''	N	O
18	.	N	O

1	This	N	O
2	randomised	N	O
3	multicentre	N	O
4	trial	N	O
5	was	N	O
6	conducted	N	O
7	to	N	O
8	establish	N	O
9	the	N	O
10	optimal	N	O
11	duration	N	O
12	of	N	O
13	palliative	N	O
14	chemotherapy	N	O
15	in	N	O
16	advanced	N	O
17	non-small-cell	N	O
18	lung	N	O
19	cancer	N	O
20	(	N	O
21	NSCLC	N	O
22	)	N	O
23	.	N	O

1	We	N	O
2	compared	N	O
3	a	N	O
4	policy	N	O
5	of	N	O
6	three	N	O
7	vs	N	O
8	six	N	O
9	courses	N	O
10	of	N	O
11	new-generation	N	O
12	platinum-based	N	O
13	combination	N	O
14	chemotherapy	N	O
15	with	N	O
16	regard	N	O
17	to	N	O
18	effects	N	O
19	on	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	(	N	O
24	QoL	N	O
25	)	N	O
26	and	N	O
27	survival	N	O
28	.	N	O

1	Patients	N	O
2	with	N	O
3	stage	N	O
4	IIIB	N	O
5	or	N	O
6	IV	N	O
7	NSCLC	N	O
8	and	N	O
9	WHO	N	O
10	performance	N	O
11	status	N	O
12	(	N	O
13	PS	N	O
14	)	N	O
15	0-2	N	O
16	were	N	O
17	randomised	N	O
18	to	N	O
19	receive	N	O
20	three	N	O
21	(	N	O
22	C3	N	O
23	)	N	O
24	or	N	O
25	six	N	O
26	(	N	O
27	C6	N	O
28	)	N	O
29	courses	N	O
30	of	N	O
31	carboplatin	N	O
32	(	N	O
33	area	N	O
34	under	N	O
35	the	N	O
36	curve	N	O
37	(	N	O
38	AUC	N	O
39	)	N	O
40	4	N	O
41	,	N	O
42	Chatelut	N	O
43	's	N	O
44	formula	N	O
45	,	N	O
46	equivalent	N	O
47	to	N	O
48	Calvert	N	O
49	's	N	O
50	AUC	N	O
51	5	N	O
52	)	N	O
53	on	N	O
54	day	N	O
55	1	N	O
56	and	N	O
57	vinorelbine	N	O
58	25	N	O
59	mg	N	O
60	m	N	O
61	(	N	O
62	-2	N	O
63	)	N	O
64	on	N	O
65	days	N	O
66	1	N	O
67	and	N	O
68	8	N	O
69	of	N	O
70	a	N	O
71	3-week	N	O
72	cycle	N	O
73	.	N	O

1	Key	N	O
2	end	N	O
3	points	N	O
4	were	N	O
5	QoL	N	O
6	at	N	O
7	18	N	O
8	weeks	N	O
9	,	N	O
10	measured	N	O
11	with	N	O
12	EORTC	N	O
13	Quality	N	O
14	of	N	O
15	Life	N	O
16	Questionnaire	N	O
17	(	N	O
18	QLQ	N	O
19	)	N	O
20	-C30	N	O
21	and	N	O
22	QLQ-LC13	N	O
23	,	N	O
24	and	N	O
25	overall	N	O
26	survival	N	O
27	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	were	N	O
5	progression-free	N	O
6	survival	N	O
7	and	N	O
8	need	N	O
9	of	N	O
10	palliative	N	O
11	radiotherapy	N	O
12	.	N	O

1	Two	N	O
2	hundred	N	O
3	and	N	O
4	ninety-seven	N	O
5	patients	N	O
6	were	N	O
7	randomised	N	O
8	(	N	O
9	C3	N	O
10	150	N	O
11	,	N	O
12	C6	N	O
13	147	N	O
14	)	N	O
15	.	N	O

1	Their	N	O
2	median	N	O
3	age	N	O
4	was	N	O
5	65	N	O
6	years	N	O
7	,	N	O
8	30	N	O
9	%	N	O
10	had	N	O
11	PS	N	O
12	2	N	O
13	and	N	O
14	76	N	O
15	%	N	O
16	stage	N	O
17	IV	N	O
18	disease	N	O
19	.	N	O

1	Seventy-eight	N	O
2	and	N	O
3	54	N	O
4	%	N	O
5	of	N	O
6	C3	N	O
7	and	N	O
8	C6	N	O
9	patients	N	O
10	,	N	O
11	respectively	N	O
12	,	N	O
13	completed	N	O
14	all	N	O
15	scheduled	N	O
16	chemotherapy	N	O
17	courses	N	O
18	.	N	O

1	Compliance	N	O
2	with	N	O
3	QoL	N	O
4	questionnaires	N	O
5	was	N	O
6	88	N	O
7	%	N	O
8	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	group	N	I-Premise
6	differences	N	I-Premise
7	in	N	I-Premise
8	global	N	I-Premise
9	QoL	N	I-Premise
10	,	N	I-Premise
11	pain	N	I-Premise
12	or	N	I-Premise
13	fatigue	N	I-Premise
14	up	N	I-Premise
15	to	N	I-Premise
16	26	N	I-Premise
17	weeks	N	I-Premise
18	.	N	I-Premise

1	The	N	I-Premise
2	dyspnoea	N	I-Premise
3	palliation	N	I-Premise
4	rate	N	I-Premise
5	was	N	I-Premise
6	lower	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	C3	N	I-Premise
10	arm	N	I-Premise
11	at	N	I-Premise
12	18	N	I-Premise
13	and	N	I-Premise
14	26	N	I-Premise
15	weeks	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	<	N	I-Premise
19	0.05	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	but	N	I-Premise
23	this	N	I-Premise
24	finding	N	I-Premise
25	was	N	I-Premise
26	inconsistent	N	I-Premise
27	across	N	I-Premise
28	different	N	I-Premise
29	methods	N	I-Premise
30	of	N	I-Premise
31	analysis	N	I-Premise
32	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	C3	N	I-Premise
6	group	N	I-Premise
7	was	N	I-Premise
8	28	N	I-Premise
9	vs	N	I-Premise
10	32	N	I-Premise
11	weeks	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	C6	N	I-Premise
15	group	N	I-Premise
16	(	N	I-Premise
17	P=0.75	N	I-Premise
18	,	N	I-Premise
19	HR	N	I-Premise
20	1.04	N	I-Premise
21	,	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	0.82-1.31	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	One-	N	I-Premise
2	and	N	I-Premise
3	2-year	N	I-Premise
4	survival	N	I-Premise
5	rates	N	I-Premise
6	were	N	I-Premise
7	25	N	I-Premise
8	and	N	I-Premise
9	9	N	I-Premise
10	%	N	I-Premise
11	vs	N	I-Premise
12	25	N	I-Premise
13	and	N	I-Premise
14	5	N	I-Premise
15	%	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	C3	N	I-Premise
19	and	N	I-Premise
20	C6	N	I-Premise
21	arm	N	I-Premise
22	,	N	I-Premise
23	respectively	N	I-Premise
24	.	N	I-Premise

1	Median	N	I-Premise
2	progression-free	N	I-Premise
3	survival	N	I-Premise
4	was	N	I-Premise
5	16	N	I-Premise
6	and	N	I-Premise
7	21	N	I-Premise
8	weeks	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	C3	N	I-Premise
12	and	N	I-Premise
13	C6	N	I-Premise
14	groups	N	I-Premise
15	,	N	I-Premise
16	respectively	N	I-Premise
17	(	N	I-Premise
18	P=0.21	N	I-Premise
19	,	N	I-Premise
20	HR	N	I-Premise
21	0.86	N	I-Premise
22	,	N	I-Premise
23	95	N	I-Premise
24	%	N	I-Premise
25	CI	N	I-Premise
26	0.68-1.08	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	In	N	I-Claim
2	conclusion	N	I-Claim
3	,	N	I-Claim
4	palliative	N	I-Claim
5	chemotherapy	N	I-Claim
6	with	N	I-Claim
7	carboplatin	N	I-Claim
8	and	N	I-Claim
9	vinorelbine	N	I-Claim
10	beyond	N	I-Claim
11	three	N	I-Claim
12	courses	N	I-Claim
13	conveys	N	I-Claim
14	no	N	I-Claim
15	survival	N	I-Claim
16	or	N	I-Claim
17	consistent	N	I-Claim
18	QoL	N	I-Claim
19	benefits	N	I-Claim
20	in	N	I-Claim
21	advanced	N	I-Claim
22	NSCLC	N	I-Claim
23	.	N	I-Claim

1	In	N	O
2	the	N	O
3	randomized	N	O
4	,	N	O
5	multinational	N	O
6	phase	N	O
7	II/III	N	O
8	trial	N	O
9	(	N	O
10	V325	N	O
11	)	N	O
12	of	N	O
13	untreated	N	O
14	advanced	N	O
15	gastric	N	O
16	cancer	N	O
17	patients	N	O
18	,	N	O
19	the	N	O
20	phase	N	O
21	II	N	O
22	part	N	O
23	selected	N	O
24	docetaxel	N	O
25	,	N	O
26	cisplatin	N	O
27	,	N	O
28	and	N	O
29	fluorouracil	N	O
30	(	N	O
31	DCF	N	O
32	)	N	O
33	over	N	O
34	docetaxel	N	O
35	and	N	O
36	cisplatin	N	O
37	for	N	O
38	comparison	N	O
39	against	N	O
40	cisplatin	N	O
41	and	N	O
42	fluorouracil	N	O
43	(	N	O
44	CF	N	O
45	;	N	O
46	reference	N	O
47	regimen	N	O
48	)	N	O
49	in	N	O
50	the	N	O
51	phase	N	O
52	III	N	O
53	part	N	O
54	.	N	O

1	Advanced	N	O
2	gastric	N	O
3	cancer	N	O
4	patients	N	O
5	were	N	O
6	randomly	N	O
7	assigned	N	O
8	to	N	O
9	docetaxel	N	O
10	75	N	O
11	mg/m2	N	O
12	and	N	O
13	cisplatin	N	O
14	75	N	O
15	mg/m2	N	O
16	(	N	O
17	day	N	O
18	1	N	O
19	)	N	O
20	plus	N	O
21	fluorouracil	N	O
22	750	N	O
23	mg/m2/d	N	O
24	(	N	O
25	days	N	O
26	1	N	O
27	to	N	O
28	5	N	O
29	)	N	O
30	every	N	O
31	3	N	O
32	weeks	N	O
33	or	N	O
34	cisplatin	N	O
35	100	N	O
36	mg/m2	N	O
37	(	N	O
38	day	N	O
39	1	N	O
40	)	N	O
41	plus	N	O
42	fluorouracil	N	O
43	1,000	N	O
44	mg/m2/d	N	O
45	(	N	O
46	days	N	O
47	1	N	O
48	to	N	O
49	5	N	O
50	)	N	O
51	every	N	O
52	4	N	O
53	weeks	N	O
54	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	time-to-progression	N	O
7	(	N	O
8	TTP	N	O
9	)	N	O
10	.	N	O

1	In	N	O
2	445	N	O
3	randomly	N	O
4	assigned	N	O
5	and	N	O
6	treated	N	O
7	patients	N	O
8	(	N	O
9	DCF	N	O
10	=	N	O
11	221	N	O
12	;	N	O
13	CF	N	O
14	=	N	O
15	224	N	O
16	)	N	O
17	,	N	O
18	TTP	N	O
19	was	N	O
20	longer	N	O
21	with	N	O
22	DCF	N	O
23	versus	N	O
24	CF	N	O
25	(	N	O
26	32	N	O
27	%	N	O
28	risk	N	O
29	reduction	N	O
30	;	N	O
31	log-rank	N	O
32	P	N	O
33	<	N	O
34	.001	N	O
35	)	N	O
36	.	N	O

1	Overall	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	longer	N	I-Premise
5	with	N	I-Premise
6	DCF	N	I-Premise
7	versus	N	I-Premise
8	CF	N	I-Premise
9	(	N	I-Premise
10	23	N	I-Premise
11	%	N	I-Premise
12	risk	N	I-Premise
13	reduction	N	I-Premise
14	;	N	I-Premise
15	log-rank	N	I-Premise
16	P	N	I-Premise
17	=	N	I-Premise
18	.02	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	Two-year	N	I-Premise
2	survival	N	I-Premise
3	rate	N	I-Premise
4	was	N	I-Premise
5	18	N	I-Premise
6	%	N	I-Premise
7	with	N	I-Premise
8	DCF	N	I-Premise
9	and	N	I-Premise
10	9	N	I-Premise
11	%	N	I-Premise
12	with	N	I-Premise
13	CF	N	I-Premise
14	.	N	I-Premise

1	Overall	N	I-Premise
2	response	N	I-Premise
3	rate	N	I-Premise
4	was	N	I-Premise
5	higher	N	I-Premise
6	with	N	I-Premise
7	DCF	N	I-Premise
8	(	N	I-Premise
9	chi2	N	I-Premise
10	P	N	I-Premise
11	=	N	I-Premise
12	.01	N	I-Premise
13	)	N	I-Premise
14	.	N	I-Premise

1	Grade	N	I-Premise
2	3	N	I-Premise
3	to	N	I-Premise
4	4	N	I-Premise
5	treatment-related	N	I-Premise
6	adverse	N	I-Premise
7	events	N	I-Premise
8	occurred	N	I-Premise
9	in	N	I-Premise
10	69	N	I-Premise
11	%	N	I-Premise
12	(	N	I-Premise
13	DCF	N	I-Premise
14	)	N	I-Premise
15	v	N	I-Premise
16	59	N	I-Premise
17	%	N	I-Premise
18	(	N	I-Premise
19	CF	N	I-Premise
20	)	N	I-Premise
21	of	N	I-Premise
22	patients	N	I-Premise
23	.	N	I-Premise

1	Frequent	N	I-Premise
2	grade	N	I-Premise
3	3	N	I-Premise
4	to	N	I-Premise
5	4	N	I-Premise
6	toxicities	N	I-Premise
7	for	N	I-Premise
8	DCF	N	I-Premise
9	v	N	I-Premise
10	CF	N	I-Premise
11	were	N	I-Premise
12	:	N	I-Premise
13	neutropenia	N	I-Premise
14	(	N	I-Premise
15	82	N	I-Premise
16	%	N	I-Premise
17	v	N	I-Premise
18	57	N	I-Premise
19	%	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	stomatitis	N	I-Premise
23	(	N	I-Premise
24	21	N	I-Premise
25	%	N	I-Premise
26	v	N	I-Premise
27	27	N	I-Premise
28	%	N	I-Premise
29	)	N	I-Premise
30	,	N	I-Premise
31	diarrhea	N	I-Premise
32	(	N	I-Premise
33	19	N	I-Premise
34	%	N	I-Premise
35	v	N	I-Premise
36	8	N	I-Premise
37	%	N	I-Premise
38	)	N	I-Premise
39	,	N	I-Premise
40	lethargy	N	I-Premise
41	(	N	I-Premise
42	19	N	I-Premise
43	%	N	I-Premise
44	v	N	I-Premise
45	14	N	I-Premise
46	%	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	Complicated	N	I-Premise
2	neutropenia	N	I-Premise
3	was	N	I-Premise
4	more	N	I-Premise
5	frequent	N	I-Premise
6	with	N	I-Premise
7	DCF	N	I-Premise
8	than	N	I-Premise
9	CF	N	I-Premise
10	(	N	I-Premise
11	29	N	I-Premise
12	%	N	I-Premise
13	v	N	I-Premise
14	12	N	I-Premise
15	%	N	I-Premise
16	)	N	I-Premise
17	.	N	I-Premise

1	Adding	N	I-Claim
2	docetaxel	N	I-Claim
3	to	N	I-Claim
4	CF	N	I-Claim
5	significantly	N	I-Claim
6	improved	N	I-Claim
7	TTP	N	I-Claim
8	,	N	I-Claim
9	survival	N	I-Claim
10	,	N	I-Claim
11	and	N	I-Claim
12	response	N	I-Claim
13	rate	N	I-Claim
14	in	N	I-Claim
15	gastric	N	I-Claim
16	cancer	N	I-Claim
17	patients	N	I-Claim
18	,	N	I-Claim
19	but	N	I-Claim
20	resulted	N	I-Claim
21	in	N	I-Claim
22	some	N	I-Claim
23	increase	N	I-Claim
24	in	N	I-Claim
25	toxicity	N	I-Claim
26	.	N	I-Claim

1	Incorporation	N	I-Claim
2	of	N	I-Claim
3	docetaxel	N	I-Claim
4	,	N	I-Claim
5	as	N	I-Claim
6	in	N	I-Claim
7	DCF	N	I-Claim
8	or	N	I-Claim
9	with	N	I-Claim
10	other	N	I-Claim
11	active	N	I-Claim
12	drug	N	I-Claim
13	(	N	I-Claim
14	s	N	I-Claim
15	)	N	I-Claim
16	,	N	I-Claim
17	is	N	I-Claim
18	a	N	I-Claim
19	new	N	I-Claim
20	therapy	N	I-Claim
21	option	N	I-Claim
22	for	N	I-Claim
23	patients	N	I-Claim
24	with	N	I-Claim
25	untreated	N	I-Claim
26	advanced	N	I-Claim
27	gastric	N	I-Claim
28	cancer	N	I-Claim
29	.	N	I-Claim

1	In	N	O
2	Lithuania	N	O
3	,	N	O
4	about	N	O
5	400	N	O
6	cases	N	O
7	of	N	O
8	pancreatic	N	O
9	cancer	N	O
10	are	N	O
11	diagnosed	N	O
12	each	N	O
13	year	N	O
14	,	N	O
15	and	N	O
16	more	N	O
17	than	N	O
18	50	N	O
19	%	N	O
20	of	N	O
21	patients	N	O
22	are	N	O
23	diagnosed	N	O
24	with	N	O
25	stage	N	O
26	IV	N	O
27	disease	N	O
28	.	N	O

1	Quality	N	I-MajorClaim
2	of	N	I-MajorClaim
3	life	N	I-MajorClaim
4	is	N	I-MajorClaim
5	an	N	I-MajorClaim
6	important	N	I-MajorClaim
7	issue	N	I-MajorClaim
8	in	N	I-MajorClaim
9	pancreatic	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	patients	N	I-MajorClaim
12	.	N	I-MajorClaim

1	A	N	O
2	prospective	N	O
3	randomized	N	O
4	clinical	N	O
5	study	N	O
6	on	N	O
7	the	N	O
8	treatment	N	O
9	of	N	O
10	patients	N	O
11	with	N	O
12	resectable	N	O
13	and	N	O
14	unresectable	N	O
15	pancreatic	N	O
16	cancer	N	O
17	was	N	O
18	conducted	N	O
19	at	N	O
20	the	N	O
21	Department	N	O
22	of	N	O
23	Oncology	N	O
24	of	N	O
25	Kaunas	N	O
26	University	N	O
27	of	N	O
28	Medicine	N	O
29	Hospital	N	O
30	,	N	O
31	and	N	O
32	in	N	O
33	this	N	O
34	study	N	O
35	,	N	O
36	quality	N	O
37	of	N	O
38	life	N	O
39	was	N	O
40	analyzed	N	O
41	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	analyze	N	O
9	the	N	O
10	effect	N	O
11	of	N	O
12	combined	N	O
13	treatment	N	O
14	methods	N	O
15	on	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	in	N	O
20	patients	N	O
21	diagnosed	N	O
22	with	N	O
23	pancreatic	N	O
24	cancer	N	O
25	.	N	O

1	During	N	O
2	2000-2005	N	O
3	,	N	O
4	two	N	O
5	concomitant	N	O
6	chemoradiation	N	O
7	treatment	N	O
8	methods	N	O
9	(	N	O
10	radiotherapy	N	O
11	with	N	O
12	5-fluorouracil	N	O
13	and	N	O
14	radiotherapy	N	O
15	with	N	O
16	gemcitabine	N	O
17	)	N	O
18	were	N	O
19	analyzed	N	O
20	in	N	O
21	the	N	O
22	study	N	O
23	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	60	N	O
5	patients	N	O
6	were	N	O
7	enrolled	N	O
8	:	N	O
9	41	N	O
10	patients	N	O
11	diagnosed	N	O
12	with	N	O
13	resectable	N	O
14	and	N	O
15	19	N	O
16	patients	N	O
17	diagnosed	N	O
18	with	N	O
19	unresectable	N	O
20	pancreatic	N	O
21	cancer	N	O
22	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	assessed	N	O
6	using	N	O
7	European	N	O
8	Organization	N	O
9	for	N	O
10	Research	N	O
11	and	N	O
12	Treatment	N	O
13	of	N	O
14	Cancer	N	O
15	Quality	N	O
16	of	N	O
17	Life	N	O
18	Core	N	O
19	30	N	O
20	(	N	O
21	EORTC	N	O
22	QLQ-C30	N	O
23	)	N	O
24	questionnaire	N	O
25	.	N	O

1	Three	N	O
2	main	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	scales	N	O
7	(	N	O
8	general	N	O
9	health	N	O
10	status	N	O
11	,	N	O
12	functional	N	O
13	,	N	O
14	and	N	O
15	symptom	N	O
16	scales	N	O
17	)	N	O
18	were	N	O
19	assessed	N	O
20	and	N	O
21	compared	N	O
22	between	N	O
23	two	N	O
24	treatment	N	O
25	groups	N	O
26	.	N	O

1	The	N	I-Premise
2	analysis	N	I-Premise
3	of	N	I-Premise
4	quality	N	I-Premise
5	of	N	I-Premise
6	live	N	I-Premise
7	assessment	N	I-Premise
8	showed	N	I-Premise
9	a	N	I-Premise
10	statistically	N	I-Premise
11	significant	N	I-Premise
12	decrease	N	I-Premise
13	in	N	I-Premise
14	quality	N	I-Premise
15	of	N	I-Premise
16	life	N	I-Premise
17	after	N	I-Premise
18	treatment	N	I-Premise
19	in	N	I-Premise
20	patients	N	I-Premise
21	with	N	I-Premise
22	resectable	N	I-Premise
23	pancreatic	N	I-Premise
24	cancer	N	I-Premise
25	and	N	I-Premise
26	treated	N	I-Premise
27	with	N	I-Premise
28	radiotherapy	N	I-Premise
29	and	N	I-Premise
30	gemcitabine	N	I-Premise
31	.	N	I-Premise

1	Decreased	N	I-Premise
2	quality	N	I-Premise
3	of	N	I-Premise
4	life	N	I-Premise
5	later	N	I-Premise
6	after	N	I-Premise
7	treatment	N	I-Premise
8	was	N	I-Premise
9	also	N	I-Premise
10	observed	N	I-Premise
11	in	N	I-Premise
12	patients	N	I-Premise
13	diagnosed	N	I-Premise
14	with	N	I-Premise
15	unresectable	N	I-Premise
16	pancreatic	N	I-Premise
17	cancer	N	I-Premise
18	and	N	I-Premise
19	treated	N	I-Premise
20	with	N	I-Premise
21	the	N	I-Premise
22	same	N	I-Premise
23	regimen	N	I-Premise
24	.	N	I-Premise

1	Treatment	N	I-Claim
2	with	N	I-Claim
3	radiotherapy	N	I-Claim
4	and	N	I-Claim
5	5-fluorouracil	N	I-Claim
6	changed	N	I-Claim
7	only	N	I-Claim
8	some	N	I-Claim
9	aspects	N	I-Claim
10	of	N	I-Claim
11	quality	N	I-Claim
12	of	N	I-Claim
13	life	N	I-Claim
14	and	N	I-Claim
15	did	N	I-Claim
16	not	N	I-Claim
17	have	N	I-Claim
18	a	N	I-Claim
19	significant	N	I-Claim
20	impact	N	I-Claim
21	on	N	I-Claim
22	quality	N	I-Claim
23	of	N	I-Claim
24	life	N	I-Claim
25	.	N	I-Claim

1	Surgery	N	O
2	and	N	O
3	radiotherapy	N	O
4	commonly	N	O
5	cause	N	O
6	adverse	N	O
7	musculoskeletal	N	O
8	problems	N	O
9	,	N	O
10	particularly	N	O
11	loss	N	O
12	of	N	O
13	strength	N	O
14	and	N	O
15	range	N	O
16	of	N	O
17	motion	N	O
18	,	N	O
19	in	N	O
20	the	N	O
21	upper	N	O
22	quadrant	N	O
23	of	N	O
24	breast	N	O
25	cancer	N	O
26	patients	N	O
27	.	N	O

1	Few	N	O
2	well-designed	N	O
3	studies	N	O
4	have	N	O
5	investigated	N	O
6	whether	N	O
7	these	N	O
8	impairments	N	O
9	can	N	O
10	be	N	O
11	prevented	N	O
12	.	N	O

1	Stretching	N	I-Claim
2	is	N	I-Claim
3	an	N	I-Claim
4	effective	N	I-Claim
5	technique	N	I-Claim
6	for	N	I-Claim
7	increasing	N	I-Claim
8	range	N	I-Claim
9	of	N	I-Claim
10	motion	N	I-Claim
11	,	N	I-Claim
12	hence	N	O
13	the	N	O
14	aim	N	O
15	of	N	O
16	this	N	O
17	study	N	O
18	was	N	O
19	to	N	O
20	investigate	N	O
21	whether	N	O
22	a	N	O
23	stretching	N	O
24	program	N	O
25	reduced	N	O
26	acute	N	O
27	musculoskeletal	N	O
28	impairments	N	O
29	in	N	O
30	patients	N	O
31	undergoing	N	O
32	radiotherapy	N	O
33	for	N	O
34	breast	N	O
35	cancer	N	O
36	.	N	O

1	Sixty-four	N	O
2	women	N	O
3	were	N	O
4	recruited	N	O
5	prior	N	O
6	to	N	O
7	commencement	N	O
8	of	N	O
9	radiotherapy	N	O
10	following	N	O
11	breast	N	O
12	cancer	N	O
13	surgery	N	O
14	.	N	O

1	Participants	N	O
2	were	N	O
3	randomised	N	O
4	to	N	O
5	either	N	O
6	a	N	O
7	control	N	O
8	or	N	O
9	stretch	N	O
10	group	N	O
11	.	N	O

1	Participants	N	O
2	in	N	O
3	both	N	O
4	groups	N	O
5	were	N	O
6	reviewed	N	O
7	by	N	O
8	the	N	O
9	physical	N	O
10	therapist	N	O
11	on	N	O
12	a	N	O
13	weekly	N	O
14	basis	N	O
15	for	N	O
16	approximately	N	O
17	6	N	O
18	weeks	N	O
19	,	N	O
20	and	N	O
21	were	N	O
22	given	N	O
23	general	N	O
24	information	N	O
25	about	N	O
26	skin	N	O
27	care	N	O
28	and	N	O
29	lymphedema	N	O
30	.	N	O

1	The	N	O
2	control	N	O
3	group	N	O
4	received	N	O
5	no	N	O
6	advice	N	O
7	about	N	O
8	exercise	N	O
9	.	N	O

1	The	N	O
2	stretch	N	O
3	group	N	O
4	received	N	O
5	instruction	N	O
6	on	N	O
7	low-load	N	O
8	,	N	O
9	prolonged	N	O
10	pectoral	N	O
11	stretches	N	O
12	,	N	O
13	which	N	O
14	were	N	O
15	to	N	O
16	be	N	O
17	performed	N	O
18	daily	N	O
19	and	N	O
20	were	N	O
21	checked	N	O
22	at	N	O
23	weekly	N	O
24	visits	N	O
25	.	N	O

1	Shoulder	N	O
2	range	N	O
3	of	N	O
4	motion	N	O
5	,	N	O
6	strength	N	O
7	,	N	O
8	arm	N	O
9	circumference	N	O
10	,	N	O
11	and	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	measurements	N	O
16	were	N	O
17	taken	N	O
18	prior	N	O
19	to	N	O
20	,	N	O
21	and	N	O
22	at	N	O
23	completion	N	O
24	of	N	O
25	radiotherapy	N	O
26	,	N	O
27	and	N	O
28	at	N	O
29	7	N	O
30	months	N	O
31	after	N	O
32	radiotherapy	N	O
33	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	any	N	I-Premise
7	outcome	N	I-Premise
8	between	N	I-Premise
9	groups	N	I-Premise
10	.	N	I-Premise

1	Breast	N	I-Premise
2	symptoms	N	I-Premise
3	increased	N	I-Premise
4	for	N	I-Premise
5	both	N	I-Premise
6	groups	N	I-Premise
7	during	N	I-Premise
8	radiotherapy	N	I-Premise
9	,	N	I-Premise
10	without	N	I-Premise
11	loss	N	I-Premise
12	of	N	I-Premise
13	strength	N	I-Premise
14	or	N	I-Premise
15	range	N	I-Premise
16	of	N	I-Premise
17	movement	N	I-Premise
18	.	N	I-Premise

1	The	N	I-Premise
2	incidence	N	I-Premise
3	of	N	I-Premise
4	lymphedema	N	I-Premise
5	during	N	I-Premise
6	the	N	I-Premise
7	study	N	I-Premise
8	was	N	I-Premise
9	low	N	I-Premise
10	for	N	I-Premise
11	both	N	I-Premise
12	groups	N	I-Premise
13	and	N	I-Premise
14	did	N	I-Premise
15	not	N	I-Premise
16	differ	N	I-Premise
17	between	N	I-Premise
18	groups	N	I-Premise
19	.	N	I-Premise

1	The	N	I-Premise
2	pectoral	N	I-Premise
3	stretching	N	I-Premise
4	program	N	I-Premise
5	did	N	I-Premise
6	not	N	I-Premise
7	influence	N	I-Premise
8	the	N	I-Premise
9	outcomes	N	I-Premise
10	measured	N	I-Premise
11	because	N	I-Premise
12	the	N	I-Premise
13	symptoms	N	I-Premise
14	reported	N	I-Premise
15	by	N	I-Premise
16	patients	N	I-Premise
17	were	N	I-Premise
18	not	N	I-Premise
19	a	N	I-Premise
20	consequence	N	I-Premise
21	of	N	I-Premise
22	contracture	N	I-Premise
23	.	N	I-Premise

1	To	N	O
2	compare	N	O
3	directly	N	O
4	the	N	O
5	effect	N	O
6	of	N	O
7	intensity-modulated	N	O
8	radiotherapy	N	O
9	(	N	O
10	IMRT	N	O
11	)	N	O
12	vs.	N	O
13	conventional	N	O
14	radiotherapy	N	O
15	(	N	O
16	CRT	N	O
17	)	N	O
18	on	N	O
19	salivary	N	O
20	flow	N	O
21	and	N	O
22	quality	N	O
23	of	N	O
24	life	N	O
25	(	N	O
26	QoL	N	O
27	)	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	early-stage	N	O
32	nasopharyngeal	N	O
33	carcinoma	N	O
34	(	N	O
35	NPC	N	O
36	)	N	O
37	.	N	O

1	Fifty-one	N	O
2	patients	N	O
3	with	N	O
4	T2	N	O
5	,	N	O
6	N0/N1	N	O
7	,	N	O
8	M0	N	O
9	NPC	N	O
10	took	N	O
11	part	N	O
12	in	N	O
13	a	N	O
14	randomized	N	O
15	controlled	N	O
16	clinical	N	O
17	study	N	O
18	and	N	O
19	received	N	O
20	IMRT	N	O
21	or	N	O
22	CRT	N	O
23	.	N	O

1	Stimulated	N	O
2	whole	N	O
3	(	N	O
4	SWS	N	O
5	)	N	O
6	and	N	O
7	parotid	N	O
8	(	N	O
9	SPS	N	O
10	)	N	O
11	saliva	N	O
12	flow	N	O
13	were	N	O
14	measured	N	O
15	and	N	O
16	Medical	N	O
17	Outcomes	N	O
18	Short	N	O
19	Form	N	O
20	36	N	O
21	(	N	O
22	SF-36	N	O
23	)	N	O
24	,	N	O
25	European	N	O
26	Organization	N	O
27	for	N	O
28	Research	N	O
29	and	N	O
30	Treatment	N	O
31	of	N	O
32	Cancer	N	O
33	(	N	O
34	EORTC	N	O
35	)	N	O
36	core	N	O
37	quetionnaire	N	O
38	,	N	O
39	and	N	O
40	EORTC	N	O
41	head-and-neck	N	O
42	module	N	O
43	(	N	O
44	QLQ-H	N	O
45	&	N	O
46	amp	N	O
47	;	N	O
48	N35	N	O
49	)	N	O
50	were	N	O
51	completed	N	O
52	at	N	O
53	baseline	N	O
54	and	N	O
55	2	N	O
56	,	N	O
57	6	N	O
58	,	N	O
59	and	N	O
60	12	N	O
61	months	N	O
62	after	N	O
63	radiotherapy	N	O
64	.	N	O

1	Forty-six	N	I-Premise
2	patients	N	I-Premise
3	(	N	I-Premise
4	88	N	I-Premise
5	%	N	I-Premise
6	)	N	I-Premise
7	were	N	I-Premise
8	in	N	I-Premise
9	disease	N	I-Premise
10	remission	N	I-Premise
11	12	N	I-Premise
12	months	N	I-Premise
13	after	N	I-Premise
14	radiotherapy	N	I-Premise
15	.	N	I-Premise

1	At	N	I-Premise
2	12	N	I-Premise
3	months	N	I-Premise
4	postradiotherapy	N	I-Premise
5	,	N	I-Premise
6	12	N	I-Premise
7	(	N	I-Premise
8	50.0	N	I-Premise
9	%	N	I-Premise
10	)	N	I-Premise
11	and	N	I-Premise
12	20	N	I-Premise
13	patients	N	I-Premise
14	(	N	I-Premise
15	83.3	N	I-Premise
16	%	N	I-Premise
17	)	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	IMRT	N	I-Premise
21	group	N	I-Premise
22	had	N	I-Premise
23	recovered	N	I-Premise
24	at	N	I-Premise
25	least	N	I-Premise
26	25	N	I-Premise
27	%	N	I-Premise
28	of	N	I-Premise
29	preradiotherapy	N	I-Premise
30	SWS	N	I-Premise
31	and	N	I-Premise
32	SPS	N	I-Premise
33	flow	N	I-Premise
34	respectively	N	I-Premise
35	,	N	I-Premise
36	compared	N	I-Premise
37	with	N	I-Premise
38	1	N	I-Premise
39	(	N	I-Premise
40	4.8	N	I-Premise
41	%	N	I-Premise
42	)	N	I-Premise
43	and	N	I-Premise
44	2	N	I-Premise
45	patients	N	I-Premise
46	(	N	I-Premise
47	9.5	N	I-Premise
48	%	N	I-Premise
49	)	N	I-Premise
50	,	N	I-Premise
51	respectively	N	I-Premise
52	,	N	I-Premise
53	in	N	I-Premise
54	the	N	I-Premise
55	CRT	N	I-Premise
56	group	N	I-Premise
57	.	N	I-Premise

1	Global	N	I-Premise
2	health	N	I-Premise
3	scores	N	I-Premise
4	showed	N	I-Premise
5	continuous	N	I-Premise
6	improvement	N	I-Premise
7	in	N	I-Premise
8	QoL	N	I-Premise
9	after	N	I-Premise
10	both	N	I-Premise
11	treatments	N	I-Premise
12	(	N	I-Premise
13	p	N	I-Premise
14	<	N	I-Premise
15	0.001	N	I-Premise
16	)	N	I-Premise
17	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	after	N	I-Premise
4	12	N	I-Premise
5	months	N	I-Premise
6	subscale	N	I-Premise
7	scores	N	I-Premise
8	for	N	I-Premise
9	role-physical	N	I-Premise
10	,	N	I-Premise
11	bodily	N	I-Premise
12	pain	N	I-Premise
13	,	N	I-Premise
14	and	N	I-Premise
15	physical	N	I-Premise
16	function	N	I-Premise
17	were	N	I-Premise
18	significantly	N	I-Premise
19	higher	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	IMRT	N	I-Premise
23	group	N	I-Premise
24	,	N	I-Premise
25	indicating	N	I-Premise
26	a	N	I-Premise
27	better	N	I-Premise
28	condition	N	I-Premise
29	(	N	I-Premise
30	p	N	I-Premise
31	<	N	I-Premise
32	0.05	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	Dry	N	I-Premise
2	mouth	N	I-Premise
3	and	N	I-Premise
4	sticky	N	I-Premise
5	saliva	N	I-Premise
6	were	N	I-Premise
7	problems	N	I-Premise
8	in	N	I-Premise
9	both	N	I-Premise
10	groups	N	I-Premise
11	2	N	I-Premise
12	months	N	I-Premise
13	after	N	I-Premise
14	treatment	N	I-Premise
15	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	IMRT	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	there	N	I-Premise
7	was	N	I-Premise
8	consistent	N	I-Premise
9	improvement	N	I-Premise
10	over	N	I-Premise
11	time	N	I-Premise
12	with	N	I-Premise
13	xerostomia-related	N	I-Premise
14	symptoms	N	I-Premise
15	significantly	N	I-Premise
16	less	N	I-Premise
17	common	N	I-Premise
18	than	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	CRT	N	I-Premise
22	group	N	I-Premise
23	at	N	I-Premise
24	12	N	I-Premise
25	months	N	I-Premise
26	postradiotherapy	N	I-Premise
27	.	N	I-Premise

1	IMRT	N	I-Claim
2	was	N	I-Claim
3	significantly	N	I-Claim
4	better	N	I-Claim
5	than	N	I-Claim
6	CRT	N	I-Claim
7	in	N	I-Claim
8	terms	N	I-Claim
9	of	N	I-Claim
10	parotid	N	I-Claim
11	sparing	N	I-Claim
12	and	N	I-Claim
13	improved	N	I-Claim
14	QoL	N	I-Claim
15	for	N	I-Claim
16	early-stage	N	I-Claim
17	disease	N	I-Claim
18	.	N	I-Claim

1	The	N	I-Claim
2	findings	N	I-Claim
3	support	N	I-Claim
4	the	N	I-Claim
5	case	N	I-Claim
6	for	N	I-Claim
7	assessment	N	I-Claim
8	of	N	I-Claim
9	health-related	N	I-Claim
10	QoL	N	I-Claim
11	in	N	I-Claim
12	relation	N	I-Claim
13	to	N	I-Claim
14	head-and-neck	N	I-Claim
15	cancer	N	I-Claim
16	using	N	I-Claim
17	a	N	I-Claim
18	site-specific	N	I-Claim
19	approach	N	I-Claim
20	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	article	N	O
6	is	N	O
7	to	N	O
8	compare	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	(	N	O
13	QOL	N	O
14	)	N	O
15	and	N	O
16	menopausal	N	O
17	symptoms	N	O
18	among	N	O
19	premenopausal	N	O
20	patients	N	O
21	with	N	O
22	lymph	N	O
23	node-negative	N	O
24	breast	N	O
25	cancer	N	O
26	receiving	N	O
27	chemotherapy	N	O
28	,	N	O
29	goserelin	N	O
30	,	N	O
31	or	N	O
32	their	N	O
33	sequential	N	O
34	combination	N	O
35	,	N	O
36	and	N	O
37	to	N	O
38	investigate	N	O
39	differential	N	O
40	effects	N	O
41	by	N	O
42	age	N	O
43	.	N	O

1	We	N	O
2	evaluated	N	O
3	QOL	N	O
4	data	N	O
5	from	N	O
6	874	N	O
7	pre-	N	O
8	and	N	O
9	perimenopausal	N	O
10	women	N	O
11	with	N	O
12	lymph	N	O
13	node-negative	N	O
14	breast	N	O
15	cancer	N	O
16	who	N	O
17	were	N	O
18	randomly	N	O
19	assigned	N	O
20	to	N	O
21	receive	N	O
22	six	N	O
23	courses	N	O
24	of	N	O
25	classical	N	O
26	cyclophosphamide	N	O
27	,	N	O
28	methotrexate	N	O
29	,	N	O
30	and	N	O
31	fluorouracil	N	O
32	(	N	O
33	CMF	N	O
34	)	N	O
35	chemotherapy	N	O
36	,	N	O
37	ovarian	N	O
38	suppression	N	O
39	with	N	O
40	goserelin	N	O
41	for	N	O
42	24	N	O
43	months	N	O
44	,	N	O
45	or	N	O
46	six	N	O
47	courses	N	O
48	of	N	O
49	classical	N	O
50	CMF	N	O
51	followed	N	O
52	by	N	O
53	18	N	O
54	months	N	O
55	of	N	O
56	goserelin	N	O
57	.	N	O

1	We	N	O
2	report	N	O
3	QOL	N	O
4	data	N	O
5	collected	N	O
6	during	N	O
7	3	N	O
8	years	N	O
9	after	N	O
10	random	N	O
11	assignment	N	O
12	in	N	O
13	patients	N	O
14	without	N	O
15	disease	N	O
16	recurrence	N	O
17	.	N	O

1	Overall	N	I-Premise
2	,	N	I-Premise
3	patients	N	I-Premise
4	receiving	N	I-Premise
5	goserelin	N	I-Premise
6	alone	N	I-Premise
7	showed	N	I-Premise
8	a	N	I-Premise
9	marked	N	I-Premise
10	improvement	N	I-Premise
11	or	N	I-Premise
12	less	N	I-Premise
13	deterioration	N	I-Premise
14	in	N	I-Premise
15	QOL	N	I-Premise
16	measures	N	I-Premise
17	over	N	I-Premise
18	the	N	I-Premise
19	first	N	I-Premise
20	6	N	I-Premise
21	months	N	I-Premise
22	than	N	I-Premise
23	those	N	I-Premise
24	patients	N	I-Premise
25	treated	N	I-Premise
26	with	N	I-Premise
27	CMF	N	I-Premise
28	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	differences	N	I-Premise
5	at	N	I-Premise
6	3	N	I-Premise
7	years	N	I-Premise
8	after	N	I-Premise
9	random	N	I-Premise
10	assignment	N	I-Premise
11	according	N	I-Premise
12	to	N	I-Premise
13	treatment	N	I-Premise
14	except	N	I-Premise
15	for	N	I-Premise
16	hot	N	I-Premise
17	flashes	N	I-Premise
18	.	N	I-Premise

1	As	N	I-Premise
2	reflected	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	hot	N	I-Premise
6	flashes	N	I-Premise
7	scores	N	I-Premise
8	,	N	I-Premise
9	patients	N	I-Premise
10	in	N	I-Premise
11	all	N	I-Premise
12	three	N	I-Premise
13	treatment	N	I-Premise
14	groups	N	I-Premise
15	experienced	N	I-Premise
16	induced	N	I-Premise
17	amenorrhea	N	I-Premise
18	,	N	I-Premise
19	but	N	I-Premise
20	the	N	I-Premise
21	onset	N	I-Premise
22	of	N	I-Premise
23	ovarian	N	I-Premise
24	function	N	I-Premise
25	suppression	N	I-Premise
26	was	N	I-Premise
27	slightly	N	I-Premise
28	delayed	N	I-Premise
29	for	N	I-Premise
30	patients	N	I-Premise
31	receiving	N	I-Premise
32	chemotherapy	N	I-Premise
33	.	N	I-Premise

1	Younger	N	I-Premise
2	patients	N	I-Premise
3	(	N	I-Premise
4	<	N	I-Premise
5	40	N	I-Premise
6	years	N	I-Premise
7	)	N	I-Premise
8	who	N	I-Premise
9	received	N	I-Premise
10	goserelin	N	I-Premise
11	alone	N	I-Premise
12	returned	N	I-Premise
13	to	N	I-Premise
14	their	N	I-Premise
15	premenopausal	N	I-Premise
16	status	N	I-Premise
17	at	N	I-Premise
18	6	N	I-Premise
19	months	N	I-Premise
20	after	N	I-Premise
21	the	N	I-Premise
22	cessation	N	I-Premise
23	of	N	I-Premise
24	therapy	N	I-Premise
25	,	N	I-Premise
26	while	N	I-Premise
27	those	N	I-Premise
28	who	N	I-Premise
29	received	N	I-Premise
30	CMF	N	I-Premise
31	showed	N	I-Premise
32	marginal	N	I-Premise
33	changes	N	I-Premise
34	from	N	I-Premise
35	their	N	I-Premise
36	baseline	N	I-Premise
37	hot	N	I-Premise
38	flashes	N	I-Premise
39	scores	N	I-Premise
40	.	N	I-Premise

1	Age-adjusted	N	I-Claim
2	risk	N	I-Claim
3	profiles	N	I-Claim
4	that	N	I-Claim
5	consider	N	I-Claim
6	patient-reported	N	I-Claim
7	outcomes	N	I-Claim
8	enable	N	I-Claim
9	patients	N	I-Claim
10	to	N	I-Claim
11	adapt	N	I-Claim
12	to	N	I-Claim
13	their	N	I-Claim
14	disease	N	I-Claim
15	and	N	I-Claim
16	treatment	N	I-Claim
17	,	N	I-Claim
18	such	N	I-Claim
19	as	N	I-Claim
20	considering	N	I-Claim
21	the	N	I-Claim
22	trade-offs	N	I-Claim
23	between	N	I-Claim
24	delayed	N	I-Claim
25	endocrine	N	I-Claim
26	symptoms	N	I-Claim
27	,	N	I-Claim
28	but	N	I-Claim
29	higher	N	I-Claim
30	risk	N	I-Claim
31	of	N	I-Claim
32	permanent	N	I-Claim
33	menopause	N	I-Claim
34	with	N	I-Claim
35	chemotherapy	N	I-Claim
36	,	N	I-Claim
37	and	N	I-Claim
38	immediate	N	I-Claim
39	but	N	I-Claim
40	reversible	N	I-Claim
41	endocrine	N	I-Claim
42	symptoms	N	I-Claim
43	with	N	I-Claim
44	goserelin	N	I-Claim
45	,	N	I-Claim
46	in	N	I-Claim
47	younger	N	I-Claim
48	premenopausal	N	I-Claim
49	patients	N	I-Claim
50	.	N	I-Claim

1	Although	N	O
2	numerous	N	O
3	treatment	N	O
4	modalities	N	O
5	have	N	O
6	been	N	O
7	explored	N	O
8	in	N	O
9	patients	N	O
10	with	N	O
11	advanced	N	O
12	HCC	N	O
13	,	N	O
14	the	N	O
15	therapeutic	N	O
16	options	N	O
17	are	N	O
18	still	N	O
19	limited	N	O
20	.	N	O

1	Somatostatin	N	I-Claim
2	has	N	I-Claim
3	been	N	I-Claim
4	shown	N	I-Claim
5	to	N	I-Claim
6	have	N	I-Claim
7	antimitotic	N	I-Claim
8	activity	N	I-Claim
9	in	N	I-Claim
10	endocrine	N	I-Claim
11	as	N	I-Claim
12	well	N	I-Claim
13	as	N	I-Claim
14	in	N	I-Claim
15	a	N	I-Claim
16	variety	N	I-Claim
17	of	N	I-Claim
18	nonendocrine	N	I-Claim
19	tumors	N	I-Claim
20	.	N	I-Claim

1	Expression	N	I-Premise
2	of	N	I-Premise
3	somatostatin	N	I-Premise
4	receptors	N	I-Premise
5	is	N	I-Premise
6	found	N	I-Premise
7	in	N	I-Premise
8	HCCs	N	I-Premise
9	,	N	I-Premise
10	but	N	O
11	the	N	I-Claim
12	efficacy	N	I-Claim
13	of	N	I-Claim
14	the	N	I-Claim
15	somatostatin	N	I-Claim
16	analogue	N	I-Claim
17	octreotide	N	I-Claim
18	remains	N	I-Claim
19	controversial	N	I-Claim
20	.	N	I-Claim

1	Therefore	N	O
2	,	N	O
3	a	N	O
4	randomized	N	O
5	double-blind	N	O
6	placebo-controlled	N	O
7	multicenter	N	O
8	trial	N	O
9	was	N	O
10	performed	N	O
11	to	N	O
12	assess	N	O
13	the	N	O
14	efficacy	N	O
15	of	N	O
16	long-acting	N	O
17	octreotide	N	O
18	for	N	O
19	the	N	O
20	treatment	N	O
21	of	N	O
22	advanced	N	O
23	HCC	N	O
24	.	N	O

1	One	N	O
2	hundred	N	O
3	twenty	N	O
4	untreated	N	O
5	patients	N	O
6	with	N	O
7	histologically	N	O
8	confirmed	N	O
9	HCC	N	O
10	were	N	O
11	randomized	N	O
12	to	N	O
13	receive	N	O
14	either	N	O
15	long-acting	N	O
16	octreotide	N	O
17	(	N	O
18	Sandostation	N	O
19	LAR	N	O
20	30	N	O
21	mg	N	O
22	)	N	O
23	intramuscularly	N	O
24	every	N	O
25	4	N	O
26	weeks	N	O
27	or	N	O
28	placebo	N	O
29	.	N	O

1	The	N	O
2	study	N	O
3	groups	N	O
4	were	N	O
5	comparable	N	O
6	with	N	O
7	respect	N	O
8	to	N	O
9	clinical	N	O
10	characteristics	N	O
11	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	cumulative	N	I-Premise
8	survival	N	I-Premise
9	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	time	N	I-Premise
5	was	N	I-Premise
6	4.7	N	I-Premise
7	months	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	octreotide	N	I-Premise
11	group	N	I-Premise
12	compared	N	I-Premise
13	with	N	I-Premise
14	5.3	N	I-Premise
15	months	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	control	N	I-Premise
19	group	N	I-Premise
20	.	N	I-Premise

1	Six-month	N	I-Premise
2	survival	N	I-Premise
3	rates	N	I-Premise
4	were	N	I-Premise
5	41	N	I-Premise
6	%	N	I-Premise
7	for	N	I-Premise
8	octreotide	N	I-Premise
9	patients	N	I-Premise
10	and	N	I-Premise
11	42	N	I-Premise
12	%	N	I-Premise
13	for	N	I-Premise
14	control	N	I-Premise
15	patients	N	I-Premise
16	,	N	I-Premise
17	respectively	N	I-Premise
18	.	N	I-Premise

1	The	N	I-Premise
2	unadjusted	N	I-Premise
3	relative	N	I-Premise
4	risk	N	I-Premise
5	for	N	I-Premise
6	mortality	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	octreotide	N	I-Premise
10	group	N	I-Premise
11	compared	N	I-Premise
12	with	N	I-Premise
13	patients	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	control	N	I-Premise
17	group	N	I-Premise
18	was	N	I-Premise
19	1.11	N	I-Premise
20	(	N	I-Premise
21	95	N	I-Premise
22	%	N	I-Premise
23	CI	N	I-Premise
24	0.76-1.63	N	I-Premise
25	;	N	I-Premise
26	P	N	I-Premise
27	=	N	I-Premise
28	0.59	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	When	N	I-Premise
2	adjusted	N	I-Premise
3	for	N	I-Premise
4	Okuda	N	I-Premise
5	,	N	I-Premise
6	CTP	N	I-Premise
7	,	N	I-Premise
8	and	N	I-Premise
9	Cancer	N	I-Premise
10	of	N	I-Premise
11	the	N	I-Premise
12	Liver	N	I-Premise
13	Italian	N	I-Premise
14	Program	N	I-Premise
15	(	N	I-Premise
16	CLIP	N	I-Premise
17	)	N	I-Premise
18	scores	N	I-Premise
19	,	N	I-Premise
20	the	N	I-Premise
21	relative	N	I-Premise
22	risk	N	I-Premise
23	for	N	I-Premise
24	octreotide	N	I-Premise
25	did	N	I-Premise
26	not	N	I-Premise
27	change	N	I-Premise
28	markedly	N	I-Premise
29	and	N	I-Premise
30	was	N	I-Premise
31	1.05	N	I-Premise
32	(	N	I-Premise
33	95	N	I-Premise
34	%	N	I-Premise
35	CI	N	I-Premise
36	0.71-1.55	N	I-Premise
37	;	N	I-Premise
38	P	N	I-Premise
39	=	N	I-Premise
40	0.83	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	The	N	I-Claim
2	CLIP	N	I-Claim
3	score	N	I-Claim
4	seems	N	I-Claim
5	to	N	I-Claim
6	predict	N	I-Claim
7	survival	N	I-Claim
8	better	N	I-Claim
9	than	N	I-Claim
10	both	N	I-Claim
11	Okuda	N	I-Claim
12	and	N	I-Claim
13	CTP	N	I-Claim
14	score	N	I-Claim
15	.	N	I-Claim

1	The	N	I-Claim
2	randomized	N	I-Claim
3	controlled	N	I-Claim
4	double-blind	N	I-Claim
5	HECTOR	N	I-Claim
6	trial	N	I-Claim
7	showed	N	I-Claim
8	no	N	I-Claim
9	survival	N	I-Claim
10	benefit	N	I-Claim
11	for	N	I-Claim
12	HCC	N	I-Claim
13	patients	N	I-Claim
14	treated	N	I-Claim
15	with	N	I-Claim
16	long-acting	N	I-Claim
17	octreotide	N	I-Claim
18	compared	N	I-Claim
19	with	N	I-Claim
20	placebo	N	I-Claim
21	.	N	I-Claim

1	This	N	O
2	study	N	O
3	was	N	O
4	designed	N	O
5	to	N	O
6	evaluate	N	O
7	the	N	O
8	impact	N	O
9	of	N	O
10	laparoscopic	N	O
11	rectal	N	O
12	resection	N	O
13	on	N	O
14	short-term	N	O
15	postoperative	N	O
16	morbidity	N	O
17	and	N	O
18	costs	N	O
19	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	168	N	O
5	patients	N	O
6	with	N	O
7	rectal	N	O
8	cancer	N	O
9	were	N	O
10	randomly	N	O
11	assigned	N	O
12	to	N	O
13	laparoscopic	N	O
14	(	N	O
15	n	N	O
16	=	N	O
17	83	N	O
18	)	N	O
19	or	N	O
20	open	N	O
21	(	N	O
22	n	N	O
23	=	N	O
24	85	N	O
25	)	N	O
26	resection	N	O
27	.	N	O

1	Outcome	N	O
2	parameters	N	O
3	were	N	O
4	:	N	O
5	postoperative	N	O
6	morbidity	N	O
7	,	N	O
8	length	N	O
9	of	N	O
10	hospital	N	O
11	stay	N	O
12	,	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	,	N	O
17	long-term	N	O
18	survival	N	O
19	,	N	O
20	and	N	O
21	local	N	O
22	recurrences	N	O
23	.	N	O

1	The	N	O
2	mean	N	O
3	follow-up	N	O
4	period	N	O
5	was	N	O
6	53.6	N	O
7	months	N	O
8	.	N	O

1	Cost-benefit	N	O
2	analysis	N	O
3	was	N	O
4	based	N	O
5	on	N	O
6	hospital	N	O
7	costs	N	O
8	.	N	O

1	Operative	N	I-Premise
2	time	N	I-Premise
3	was	N	I-Premise
4	53	N	I-Premise
5	minutes	N	I-Premise
6	longer	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	laparoscopic	N	I-Premise
10	group	N	I-Premise
11	(	N	I-Premise
12	P	N	I-Premise
13	<	N	I-Premise
14	0.0001	N	I-Premise
15	)	N	I-Premise
16	.	N	I-Premise

1	Postoperative	N	I-Premise
2	morbidity	N	I-Premise
3	rate	N	I-Premise
4	was	N	I-Premise
5	28.9	N	I-Premise
6	percent	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	laparoscopic	N	I-Premise
10	vs.	N	I-Premise
11	40	N	I-Premise
12	percent	N	I-Premise
13	in	N	I-Premise
14	the	N	I-Premise
15	open	N	I-Premise
16	group	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	0.18	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	The	N	I-Premise
2	mean	N	I-Premise
3	length	N	I-Premise
4	of	N	I-Premise
5	hospital	N	I-Premise
6	stay	N	I-Premise
7	was	N	I-Premise
8	10	N	I-Premise
9	(	N	I-Premise
10	4.9	N	I-Premise
11	)	N	I-Premise
12	days	N	I-Premise
13	in	N	I-Premise
14	the	N	I-Premise
15	laparoscopic	N	I-Premise
16	group	N	I-Premise
17	and	N	I-Premise
18	13.6	N	I-Premise
19	(	N	I-Premise
20	10	N	I-Premise
21	)	N	I-Premise
22	days	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	open	N	I-Premise
26	group	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	0.004	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Local	N	I-Premise
2	recurrence	N	I-Premise
3	rate	N	I-Premise
4	and	N	I-Premise
5	five-year	N	I-Premise
6	survival	N	I-Premise
7	were	N	I-Premise
8	similar	N	I-Premise
9	in	N	I-Premise
10	both	N	I-Premise
11	groups	N	I-Premise
12	;	N	I-Premise
13	however	N	I-Claim
14	,	N	I-Claim
15	the	N	I-Claim
16	limited	N	I-Claim
17	number	N	I-Claim
18	of	N	I-Claim
19	patients	N	I-Claim
20	does	N	I-Claim
21	not	N	I-Claim
22	allow	N	I-Claim
23	firm	N	I-Claim
24	conclusions	N	I-Claim
25	.	N	I-Claim

1	Quality	N	I-Premise
2	of	N	I-Premise
3	life	N	I-Premise
4	was	N	I-Premise
5	better	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	laparoscopic	N	I-Premise
9	group	N	I-Premise
10	only	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	first	N	I-Premise
14	year	N	I-Premise
15	after	N	I-Premise
16	surgery	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	<	N	I-Premise
20	0.0001	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	The	N	I-Premise
2	additional	N	I-Premise
3	charge	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	laparoscopic	N	I-Premise
7	group	N	I-Premise
8	was	N	I-Premise
9	$	N	I-Premise
10	1,748	N	I-Premise
11	per	N	I-Premise
12	patient	N	I-Premise
13	randomized	N	I-Premise
14	(	N	I-Premise
15	$	N	I-Premise
16	1,194	N	I-Premise
17	the	N	I-Premise
18	result	N	I-Premise
19	of	N	I-Premise
20	surgical	N	I-Premise
21	instruments	N	I-Premise
22	and	N	I-Premise
23	$	N	I-Premise
24	554	N	I-Premise
25	the	N	I-Premise
26	result	N	I-Premise
27	of	N	I-Premise
28	longer	N	I-Premise
29	operative	N	I-Premise
30	time	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	The	N	I-Premise
2	saving	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	laparoscopic	N	I-Premise
6	group	N	I-Premise
7	was	N	I-Premise
8	$	N	I-Premise
9	1,396	N	I-Premise
10	per	N	I-Premise
11	patient	N	I-Premise
12	randomized	N	I-Premise
13	(	N	I-Premise
14	$	N	I-Premise
15	647	N	I-Premise
16	the	N	I-Premise
17	result	N	I-Premise
18	of	N	I-Premise
19	shorter	N	I-Premise
20	length	N	I-Premise
21	of	N	I-Premise
22	hospital	N	I-Premise
23	stay	N	I-Premise
24	and	N	I-Premise
25	$	N	I-Premise
26	749	N	I-Premise
27	the	N	I-Premise
28	result	N	I-Premise
29	of	N	I-Premise
30	the	N	I-Premise
31	lower	N	I-Premise
32	cost	N	I-Premise
33	of	N	I-Premise
34	postoperative	N	I-Premise
35	complications	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	The	N	I-Premise
2	net	N	I-Premise
3	balance	N	I-Premise
4	resulted	N	I-Premise
5	in	N	I-Premise
6	$	N	I-Premise
7	351	N	I-Premise
8	extra	N	I-Premise
9	cost	N	I-Premise
10	per	N	I-Premise
11	patient	N	I-Premise
12	randomly	N	I-Premise
13	allocated	N	I-Premise
14	to	N	I-Premise
15	the	N	I-Premise
16	laparoscopic	N	I-Premise
17	group	N	I-Premise
18	.	N	I-Premise

1	Short-term	N	I-Claim
2	postoperative	N	I-Claim
3	morbidity	N	I-Claim
4	was	N	I-Claim
5	similar	N	I-Claim
6	in	N	I-Claim
7	the	N	I-Claim
8	two	N	I-Claim
9	groups	N	I-Claim
10	.	N	I-Claim

1	Laparoscopic	N	I-Claim
2	resection	N	I-Claim
3	reduced	N	I-Claim
4	length	N	I-Claim
5	of	N	I-Claim
6	hospital	N	I-Claim
7	stay	N	I-Claim
8	,	N	I-Claim
9	improved	N	I-Claim
10	first-year	N	I-Claim
11	quality	N	I-Claim
12	of	N	I-Claim
13	life	N	I-Claim
14	,	N	I-Claim
15	and	N	I-Claim
16	slightly	N	I-Claim
17	increased	N	I-Claim
18	hospital	N	I-Claim
19	costs	N	I-Claim
20	.	N	I-Claim

1	The	N	I-MajorClaim
2	efficacy	N	I-MajorClaim
3	and	N	I-MajorClaim
4	safety	N	I-MajorClaim
5	of	N	I-MajorClaim
6	uterine-artery	N	I-MajorClaim
7	embolization	N	I-MajorClaim
8	,	N	I-MajorClaim
9	as	N	I-MajorClaim
10	compared	N	I-MajorClaim
11	with	N	I-MajorClaim
12	standard	N	I-MajorClaim
13	surgical	N	I-MajorClaim
14	methods	N	I-MajorClaim
15	,	N	I-MajorClaim
16	for	N	I-MajorClaim
17	the	N	I-MajorClaim
18	treatment	N	I-MajorClaim
19	of	N	I-MajorClaim
20	symptomatic	N	I-MajorClaim
21	uterine	N	I-MajorClaim
22	fibroids	N	I-MajorClaim
23	remain	N	I-MajorClaim
24	uncertain	N	I-MajorClaim
25	.	N	I-MajorClaim

1	We	N	O
2	conducted	N	O
3	a	N	O
4	randomized	N	O
5	trial	N	O
6	comparing	N	O
7	uterine-artery	N	O
8	embolization	N	O
9	and	N	O
10	surgery	N	O
11	in	N	O
12	women	N	O
13	with	N	O
14	symptomatic	N	O
15	uterine	N	O
16	fibroids	N	O
17	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	at	N	O
9	1	N	O
10	year	N	O
11	of	N	O
12	follow-up	N	O
13	,	N	O
14	as	N	O
15	measured	N	O
16	by	N	O
17	the	N	O
18	Medical	N	O
19	Outcomes	N	O
20	Study	N	O
21	36-Item	N	O
22	Short-Form	N	O
23	General	N	O
24	Health	N	O
25	Survey	N	O
26	(	N	O
27	SF-36	N	O
28	)	N	O
29	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	in	N	O
6	a	N	O
7	2:1	N	O
8	ratio	N	O
9	to	N	O
10	undergo	N	O
11	either	N	O
12	uterine-artery	N	O
13	embolization	N	O
14	or	N	O
15	surgery	N	O
16	,	N	O
17	with	N	O
18	106	N	O
19	patients	N	O
20	undergoing	N	O
21	embolization	N	O
22	and	N	O
23	51	N	O
24	undergoing	N	O
25	surgery	N	O
26	(	N	O
27	43	N	O
28	hysterectomies	N	O
29	and	N	O
30	8	N	O
31	myomectomies	N	O
32	)	N	O
33	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	between	N	I-Premise
7	groups	N	I-Premise
8	in	N	I-Premise
9	any	N	I-Premise
10	of	N	I-Premise
11	the	N	I-Premise
12	eight	N	I-Premise
13	components	N	I-Premise
14	of	N	I-Premise
15	the	N	I-Premise
16	SF-36	N	I-Premise
17	scores	N	I-Premise
18	at	N	I-Premise
19	1	N	I-Premise
20	year	N	I-Premise
21	.	N	I-Premise

1	The	N	I-Premise
2	embolization	N	I-Premise
3	group	N	I-Premise
4	had	N	I-Premise
5	a	N	I-Premise
6	shorter	N	I-Premise
7	median	N	I-Premise
8	duration	N	I-Premise
9	of	N	I-Premise
10	hospitalization	N	I-Premise
11	than	N	I-Premise
12	the	N	I-Premise
13	surgical	N	I-Premise
14	group	N	I-Premise
15	(	N	I-Premise
16	1	N	I-Premise
17	day	N	I-Premise
18	vs.	N	I-Premise
19	5	N	I-Premise
20	days	N	I-Premise
21	,	N	I-Premise
22	P	N	I-Premise
23	<	N	I-Premise
24	0.001	N	I-Premise
25	)	N	I-Premise
26	and	N	I-Premise
27	a	N	I-Premise
28	shorter	N	I-Premise
29	time	N	I-Premise
30	before	N	I-Premise
31	returning	N	I-Premise
32	to	N	I-Premise
33	work	N	I-Premise
34	(	N	I-Premise
35	P	N	I-Premise
36	<	N	I-Premise
37	0.001	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	At	N	I-Premise
2	1	N	I-Premise
3	year	N	I-Premise
4	,	N	I-Premise
5	symptom	N	I-Premise
6	scores	N	I-Premise
7	were	N	I-Premise
8	better	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	surgical	N	I-Premise
12	group	N	I-Premise
13	(	N	I-Premise
14	P=0.03	N	I-Premise
15	)	N	I-Premise
16	.	N	I-Premise

1	During	N	I-Premise
2	the	N	I-Premise
3	first	N	I-Premise
4	year	N	I-Premise
5	of	N	I-Premise
6	follow-up	N	I-Premise
7	,	N	I-Premise
8	there	N	I-Premise
9	were	N	I-Premise
10	13	N	I-Premise
11	major	N	I-Premise
12	adverse	N	I-Premise
13	events	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	embolization	N	I-Premise
17	group	N	I-Premise
18	(	N	I-Premise
19	12	N	I-Premise
20	%	N	I-Premise
21	)	N	I-Premise
22	and	N	I-Premise
23	10	N	I-Premise
24	in	N	I-Premise
25	the	N	I-Premise
26	surgical	N	I-Premise
27	group	N	I-Premise
28	(	N	I-Premise
29	20	N	I-Premise
30	%	N	I-Premise
31	)	N	I-Premise
32	(	N	I-Premise
33	P=0.22	N	I-Premise
34	)	N	I-Premise
35	,	N	I-Premise
36	mostly	N	I-Premise
37	related	N	I-Premise
38	to	N	I-Premise
39	the	N	I-Premise
40	intervention	N	I-Premise
41	.	N	I-Premise

1	Ten	N	I-Premise
2	patients	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	embolization	N	I-Premise
6	group	N	I-Premise
7	(	N	I-Premise
8	9	N	I-Premise
9	%	N	I-Premise
10	)	N	I-Premise
11	required	N	I-Premise
12	repeated	N	I-Premise
13	embolization	N	I-Premise
14	or	N	I-Premise
15	hysterectomy	N	I-Premise
16	for	N	I-Premise
17	inadequate	N	I-Premise
18	symptom	N	I-Premise
19	control	N	I-Premise
20	.	N	I-Premise

1	After	N	I-Premise
2	the	N	I-Premise
3	first	N	I-Premise
4	year	N	I-Premise
5	of	N	I-Premise
6	follow-up	N	I-Premise
7	,	N	I-Premise
8	14	N	I-Premise
9	women	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	embolization	N	I-Premise
13	group	N	I-Premise
14	(	N	I-Premise
15	13	N	I-Premise
16	%	N	I-Premise
17	)	N	I-Premise
18	required	N	I-Premise
19	hospitalization	N	I-Premise
20	,	N	I-Premise
21	3	N	I-Premise
22	of	N	I-Premise
23	them	N	I-Premise
24	for	N	I-Premise
25	major	N	I-Premise
26	adverse	N	I-Premise
27	events	N	I-Premise
28	and	N	I-Premise
29	11	N	I-Premise
30	for	N	I-Premise
31	reintervention	N	I-Premise
32	for	N	I-Premise
33	treatment	N	I-Premise
34	failure	N	I-Premise
35	.	N	I-Premise

1	In	N	I-Claim
2	women	N	I-Claim
3	with	N	I-Claim
4	symptomatic	N	I-Claim
5	fibroids	N	I-Claim
6	,	N	I-Claim
7	the	N	I-Claim
8	faster	N	I-Claim
9	recovery	N	I-Claim
10	after	N	I-Claim
11	embolization	N	I-Claim
12	must	N	I-Claim
13	be	N	I-Claim
14	weighed	N	I-Claim
15	against	N	I-Claim
16	the	N	I-Claim
17	need	N	I-Claim
18	for	N	I-Claim
19	further	N	I-Claim
20	treatment	N	I-Claim
21	in	N	I-Claim
22	a	N	I-Claim
23	minority	N	I-Claim
24	of	N	I-Claim
25	patients	N	I-Claim
26	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	functional	N	O
4	and	N	O
5	psychological	N	O
6	benefits	N	O
7	of	N	O
8	a	N	O
9	12	N	O
10	week	N	O
11	supervised	N	O
12	group	N	O
13	exercise	N	O
14	programme	N	O
15	during	N	O
16	treatment	N	O
17	for	N	O
18	early	N	O
19	stage	N	O
20	breast	N	O
21	cancer	N	O
22	,	N	O
23	with	N	O
24	six	N	O
25	month	N	O
26	follow-up	N	O
27	.	N	O

1	Pragmatic	N	O
2	randomised	N	O
3	controlled	N	O
4	prospective	N	O
5	open	N	O
6	trial	N	O
7	.	N	O

1	Three	N	O
2	National	N	O
3	Health	N	O
4	Service	N	O
5	oncology	N	O
6	clinics	N	O
7	in	N	O
8	Scotland	N	O
9	and	N	O
10	community	N	O
11	exercise	N	O
12	facilities	N	O
13	.	N	O

1	203	N	O
2	women	N	O
3	entered	N	O
4	the	N	O
5	study	N	O
6	;	N	O
7	177	N	O
8	completed	N	O
9	the	N	O
10	six	N	O
11	month	N	O
12	follow-up	N	O
13	.	N	O

1	Supervised	N	O
2	12	N	O
3	week	N	O
4	group	N	O
5	exercise	N	O
6	programme	N	O
7	in	N	O
8	addition	N	O
9	to	N	O
10	usual	N	O
11	care	N	O
12	,	N	O
13	compared	N	O
14	with	N	O
15	usual	N	O
16	care	N	O
17	.	N	O

1	Functional	N	O
2	assessment	N	O
3	of	N	O
4	cancer	N	O
5	therapy	N	O
6	(	N	O
7	FACT	N	O
8	)	N	O
9	questionnaire	N	O
10	,	N	O
11	Beck	N	O
12	depression	N	O
13	inventory	N	O
14	,	N	O
15	positive	N	O
16	and	N	O
17	negative	N	O
18	affect	N	O
19	scale	N	O
20	,	N	O
21	body	N	O
22	mass	N	O
23	index	N	O
24	,	N	O
25	seven	N	O
26	day	N	O
27	recall	N	O
28	of	N	O
29	physical	N	O
30	activity	N	O
31	,	N	O
32	12	N	O
33	minute	N	O
34	walk	N	O
35	test	N	O
36	,	N	O
37	and	N	O
38	assessment	N	O
39	of	N	O
40	shoulder	N	O
41	mobility	N	O
42	.	N	O

1	Mixed	N	I-Premise
2	effects	N	I-Premise
3	models	N	I-Premise
4	with	N	I-Premise
5	adjustment	N	I-Premise
6	for	N	I-Premise
7	baseline	N	I-Premise
8	values	N	I-Premise
9	,	N	I-Premise
10	study	N	I-Premise
11	site	N	I-Premise
12	,	N	I-Premise
13	treatment	N	I-Premise
14	at	N	I-Premise
15	baseline	N	I-Premise
16	,	N	I-Premise
17	and	N	I-Premise
18	age	N	I-Premise
19	gave	N	I-Premise
20	intervention	N	I-Premise
21	effect	N	I-Premise
22	estimates	N	I-Premise
23	(	N	I-Premise
24	intervention	N	I-Premise
25	minus	N	I-Premise
26	control	N	I-Premise
27	)	N	I-Premise
28	at	N	I-Premise
29	12	N	I-Premise
30	weeks	N	I-Premise
31	of	N	I-Premise
32	129	N	I-Premise
33	(	N	I-Premise
34	95	N	I-Premise
35	%	N	I-Premise
36	confidence	N	I-Premise
37	interval	N	I-Premise
38	83	N	I-Premise
39	to	N	I-Premise
40	176	N	I-Premise
41	)	N	I-Premise
42	for	N	I-Premise
43	metres	N	I-Premise
44	walked	N	I-Premise
45	in	N	I-Premise
46	12	N	I-Premise
47	minutes	N	I-Premise
48	,	N	I-Premise
49	182	N	I-Premise
50	(	N	I-Premise
51	75	N	I-Premise
52	to	N	I-Premise
53	289	N	I-Premise
54	)	N	I-Premise
55	for	N	I-Premise
56	minutes	N	I-Premise
57	of	N	I-Premise
58	moderate	N	I-Premise
59	intensity	N	I-Premise
60	activity	N	I-Premise
61	reported	N	I-Premise
62	in	N	I-Premise
63	a	N	I-Premise
64	week	N	I-Premise
65	,	N	I-Premise
66	2.6	N	I-Premise
67	(	N	I-Premise
68	1.6	N	I-Premise
69	to	N	I-Premise
70	3.7	N	I-Premise
71	)	N	I-Premise
72	for	N	I-Premise
73	shoulder	N	I-Premise
74	mobility	N	I-Premise
75	,	N	I-Premise
76	2.5	N	I-Premise
77	(	N	I-Premise
78	1.0	N	I-Premise
79	to	N	I-Premise
80	3.9	N	I-Premise
81	)	N	I-Premise
82	for	N	I-Premise
83	breast	N	I-Premise
84	cancer	N	I-Premise
85	specific	N	I-Premise
86	subscale	N	I-Premise
87	of	N	I-Premise
88	quality	N	I-Premise
89	of	N	I-Premise
90	life	N	I-Premise
91	,	N	I-Premise
92	and	N	I-Premise
93	4.0	N	I-Premise
94	(	N	I-Premise
95	1.8	N	I-Premise
96	to	N	I-Premise
97	6.3	N	I-Premise
98	)	N	I-Premise
99	for	N	I-Premise
100	positive	N	I-Premise
101	mood	N	I-Premise
102	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	effect	N	I-Premise
4	was	N	I-Premise
5	seen	N	I-Premise
6	for	N	I-Premise
7	general	N	I-Premise
8	quality	N	I-Premise
9	of	N	I-Premise
10	life	N	I-Premise
11	(	N	I-Premise
12	FACT-G	N	I-Premise
13	)	N	I-Premise
14	,	N	I-Premise
15	which	N	I-Premise
16	was	N	I-Premise
17	the	N	I-Premise
18	primary	N	I-Premise
19	outcome	N	I-Premise
20	.	N	I-Premise

1	At	N	I-Premise
2	the	N	I-Premise
3	six	N	I-Premise
4	month	N	I-Premise
5	follow-up	N	I-Premise
6	,	N	I-Premise
7	most	N	I-Premise
8	of	N	I-Premise
9	these	N	I-Premise
10	effects	N	I-Premise
11	were	N	I-Premise
12	maintained	N	I-Premise
13	and	N	I-Premise
14	an	N	I-Premise
15	intervention	N	I-Premise
16	effect	N	I-Premise
17	for	N	I-Premise
18	breast	N	I-Premise
19	cancer	N	I-Premise
20	specific	N	I-Premise
21	quality	N	I-Premise
22	of	N	I-Premise
23	life	N	I-Premise
24	emerged	N	I-Premise
25	.	N	I-Premise

1	No	N	I-Premise
2	adverse	N	I-Premise
3	effects	N	I-Premise
4	were	N	I-Premise
5	noted	N	I-Premise
6	.	N	I-Premise

1	Supervised	N	I-Claim
2	group	N	I-Claim
3	exercise	N	I-Claim
4	provided	N	I-Claim
5	functional	N	I-Claim
6	and	N	I-Claim
7	psychological	N	I-Claim
8	benefit	N	I-Claim
9	after	N	I-Claim
10	a	N	I-Claim
11	12	N	I-Claim
12	week	N	I-Claim
13	intervention	N	I-Claim
14	and	N	I-Claim
15	six	N	I-Claim
16	months	N	I-Claim
17	later	N	I-Claim
18	.	N	I-Claim

1	Clinicians	N	I-Claim
2	should	N	I-Claim
3	encourage	N	I-Claim
4	activity	N	I-Claim
5	for	N	I-Claim
6	their	N	I-Claim
7	patients	N	I-Claim
8	.	N	I-Claim

1	Policy	N	I-Claim
2	makers	N	I-Claim
3	should	N	I-Claim
4	consider	N	I-Claim
5	the	N	I-Claim
6	inclusion	N	I-Claim
7	of	N	I-Claim
8	exercise	N	I-Claim
9	opportunities	N	I-Claim
10	in	N	I-Claim
11	cancer	N	I-Claim
12	rehabilitation	N	I-Claim
13	services	N	I-Claim
14	.	N	I-Claim

1	Previous	N	I-Claim
2	trials	N	I-Claim
3	have	N	I-Claim
4	suggested	N	I-Claim
5	a	N	I-Claim
6	quality-of-life	N	I-Claim
7	(	N	I-Claim
8	QOL	N	I-Claim
9	)	N	I-Claim
10	improvement	N	I-Claim
11	for	N	I-Claim
12	anemic	N	I-Claim
13	cancer	N	I-Claim
14	patients	N	I-Claim
15	treated	N	I-Claim
16	with	N	I-Claim
17	erythropoietin	N	I-Claim
18	,	N	I-Claim
19	but	N	I-Claim
20	few	N	I-Claim
21	used	N	I-Claim
22	QOL	N	I-Claim
23	as	N	I-Claim
24	the	N	I-Claim
25	primary	N	I-Claim
26	outcome	N	I-Claim
27	.	N	I-Claim

1	We	N	O
2	designed	N	O
3	a	N	O
4	trial	N	O
5	to	N	O
6	investigate	N	O
7	the	N	O
8	effects	N	O
9	of	N	O
10	epoetin	N	O
11	alfa	N	O
12	therapy	N	O
13	on	N	O
14	the	N	O
15	QOL	N	O
16	of	N	O
17	anemic	N	O
18	patients	N	O
19	with	N	O
20	advanced	N	O
21	non-small-cell	N	O
22	carcinoma	N	O
23	of	N	O
24	the	N	O
25	lung	N	O
26	(	N	O
27	NSCLC	N	O
28	)	N	O
29	.	N	O

1	A	N	O
2	multicenter	N	O
3	,	N	O
4	randomized	N	O
5	,	N	O
6	double-blind	N	O
7	,	N	O
8	placebo-controlled	N	O
9	trial	N	O
10	was	N	O
11	conducted	N	O
12	.	N	O

1	The	N	O
2	proposed	N	O
3	sample	N	O
4	size	N	O
5	was	N	O
6	300	N	O
7	patients	N	O
8	.	N	O

1	Eligible	N	O
2	patients	N	O
3	were	N	O
4	required	N	O
5	to	N	O
6	have	N	O
7	NSCLC	N	O
8	unsuitable	N	O
9	for	N	O
10	curative	N	O
11	therapy	N	O
12	and	N	O
13	baseline	N	O
14	hemoglobin	N	O
15	(	N	O
16	Hgb	N	O
17	)	N	O
18	levels	N	O
19	less	N	O
20	than	N	O
21	121	N	O
22	g/L	N	O
23	.	N	O

1	Patients	N	O
2	were	N	O
3	assigned	N	O
4	to	N	O
5	12	N	O
6	weekly	N	O
7	injections	N	O
8	of	N	O
9	subcutaneous	N	O
10	epoetin	N	O
11	alpha	N	O
12	or	N	O
13	placebo	N	O
14	,	N	O
15	targeting	N	O
16	Hgb	N	O
17	levels	N	O
18	between	N	O
19	120	N	O
20	and	N	O
21	140	N	O
22	g/L	N	O
23	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	the	N	O
6	difference	N	O
7	in	N	O
8	the	N	O
9	change	N	O
10	in	N	O
11	Functional	N	O
12	Assessment	N	O
13	of	N	O
14	Cancer	N	O
15	Therapy-Anemia	N	O
16	scores	N	O
17	between	N	O
18	baseline	N	O
19	and	N	O
20	12	N	O
21	weeks	N	O
22	.	N	O

1	Reports	N	O
2	of	N	O
3	thrombotic	N	O
4	events	N	O
5	in	N	O
6	other	N	O
7	epoetin	N	O
8	trials	N	O
9	prompted	N	O
10	an	N	O
11	unplanned	N	O
12	safety	N	O
13	analysis	N	O
14	after	N	O
15	70	N	O
16	patients	N	O
17	had	N	O
18	been	N	O
19	randomly	N	O
20	assigned	N	O
21	(	N	O
22	33	N	O
23	to	N	O
24	the	N	O
25	active	N	O
26	arm	N	O
27	and	N	O
28	37	N	O
29	to	N	O
30	the	N	O
31	placebo	N	O
32	arm	N	O
33	)	N	O
34	.	N	O

1	This	N	I-Premise
2	revealed	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	median	N	I-Premise
9	survival	N	I-Premise
10	in	N	I-Premise
11	favor	N	I-Premise
12	of	N	I-Premise
13	the	N	I-Premise
14	patients	N	I-Premise
15	on	N	I-Premise
16	the	N	I-Premise
17	placebo	N	I-Premise
18	arm	N	I-Premise
19	of	N	I-Premise
20	the	N	I-Premise
21	trial	N	I-Premise
22	(	N	I-Premise
23	63	N	I-Premise
24	v	N	I-Premise
25	129	N	I-Premise
26	days	N	I-Premise
27	;	N	I-Premise
28	hazard	N	I-Premise
29	ratio	N	I-Premise
30	,	N	I-Premise
31	1.84	N	I-Premise
32	;	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	.04	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	The	N	O
2	Steering	N	O
3	Committee	N	O
4	closed	N	O
5	the	N	O
6	trial	N	O
7	.	N	O

1	Patient	N	I-Premise
2	numbers	N	I-Premise
3	compromised	N	I-Premise
4	the	N	I-Premise
5	interpretation	N	I-Premise
6	of	N	I-Premise
7	the	N	I-Premise
8	QOL	N	I-Premise
9	analysis	N	I-Premise
10	,	N	I-Premise
11	but	N	O
12	a	N	I-Premise
13	positive	N	I-Premise
14	Hgb	N	I-Premise
15	response	N	I-Premise
16	was	N	I-Premise
17	noted	N	I-Premise
18	with	N	I-Premise
19	epoetin	N	I-Premise
20	alfa	N	I-Premise
21	treatment	N	I-Premise
22	.	N	I-Premise

1	An	N	I-Claim
2	unplanned	N	I-Claim
3	safety	N	I-Claim
4	analysis	N	I-Claim
5	suggested	N	I-Claim
6	decreased	N	I-Claim
7	overall	N	I-Claim
8	survival	N	I-Claim
9	in	N	I-Claim
10	patients	N	I-Claim
11	with	N	I-Claim
12	advanced	N	I-Claim
13	NSCLC	N	I-Claim
14	treated	N	I-Claim
15	with	N	I-Claim
16	epoetin	N	I-Claim
17	alfa	N	I-Claim
18	.	N	I-Claim

1	Although	N	O
2	infrequent	N	O
3	,	N	O
4	other	N	O
5	similar	N	O
6	reports	N	O
7	highlight	N	O
8	the	N	O
9	need	N	O
10	for	N	O
11	ongoing	N	O
12	trials	N	O
13	evaluating	N	O
14	erythropoietin	N	O
15	receptor	N	O
16	agonists	N	O
17	to	N	O
18	ensure	N	O
19	that	N	O
20	overall	N	O
21	survival	N	O
22	is	N	O
23	monitored	N	O
24	closely	N	O
25	.	N	O

1	A	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	previously	N	O
6	conducted	N	O
7	in	N	O
8	radiation	N	O
9	oncology	N	O
10	patients	N	O
11	demonstrated	N	O
12	that	N	O
13	nutrition	N	O
14	intervention	N	O
15	had	N	O
16	a	N	O
17	beneficial	N	O
18	impact	N	O
19	on	N	O
20	body	N	O
21	weight	N	O
22	,	N	O
23	nutritional	N	O
24	status	N	O
25	,	N	O
26	and	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	compared	N	O
31	with	N	O
32	standard	N	O
33	practice	N	O
34	,	N	O
35	but	N	O
36	it	N	O
37	did	N	O
38	not	N	O
39	report	N	O
40	on	N	O
41	dietary	N	O
42	intake	N	O
43	data	N	O
44	.	N	O

1	To	N	O
2	determine	N	O
3	the	N	O
4	impact	N	O
5	of	N	O
6	nutrition	N	O
7	intervention	N	O
8	compared	N	O
9	with	N	O
10	standard	N	O
11	practice	N	O
12	on	N	O
13	dietary	N	O
14	intake	N	O
15	in	N	O
16	outpatients	N	O
17	receiving	N	O
18	radiotherapy	N	O
19	.	N	O

1	Prospective	N	O
2	,	N	O
3	randomized	N	O
4	,	N	O
5	controlled	N	O
6	trial	N	O
7	.	N	O

1	Sixty	N	O
2	consecutive	N	O
3	radiation	N	O
4	oncology	N	O
5	outpatients	N	O
6	(	N	O
7	51	N	O
8	men	N	O
9	and	N	O
10	nine	N	O
11	women	N	O
12	;	N	O
13	age	N	O
14	61.9+/-14	N	O
15	years	N	O
16	[	N	O
17	mean+/-standard	N	O
18	deviation	N	O
19	]	N	O
20	)	N	O
21	.	N	O

1	Australian	N	O
2	private	N	O
3	radiotherapy	N	O
4	facility	N	O
5	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	receive	N	O
7	either	N	O
8	nutrition	N	O
9	intervention	N	O
10	(	N	O
11	n=29	N	O
12	)	N	O
13	(	N	O
14	nutrition	N	O
15	counseling	N	O
16	following	N	O
17	the	N	O
18	American	N	O
19	Dietetic	N	O
20	Association	N	O
21	[	N	O
22	ADA	N	O
23	]	N	O
24	medical	N	O
25	nutrition	N	O
26	therapy	N	O
27	[	N	O
28	MNT	N	O
29	]	N	O
30	protocol	N	O
31	for	N	O
32	radiation	N	O
33	oncology	N	O
34	)	N	O
35	or	N	O
36	standard	N	O
37	practice	N	O
38	(	N	O
39	n=31	N	O
40	)	N	O
41	(	N	O
42	general	N	O
43	nutrition	N	O
44	talk	N	O
45	and	N	O
46	booklet	N	O
47	)	N	O
48	.	N	O

1	Dietary	N	O
2	intake	N	O
3	(	N	O
4	protein	N	O
5	,	N	O
6	energy	N	O
7	,	N	O
8	fiber	N	O
9	)	N	O
10	assessed	N	O
11	at	N	O
12	baseline	N	O
13	and	N	O
14	at	N	O
15	4	N	O
16	,	N	O
17	8	N	O
18	,	N	O
19	and	N	O
20	12	N	O
21	weeks	N	O
22	after	N	O
23	starting	N	O
24	radiotherapy	N	O
25	.	N	O

1	Repeated-measures	N	O
2	analysis	N	O
3	of	N	O
4	variance	N	O
5	done	N	O
6	on	N	O
7	an	N	O
8	intention	N	O
9	to	N	O
10	treat	N	O
11	basis	N	O
12	.	N	O

1	The	N	I-Premise
2	nutrition	N	I-Premise
3	intervention	N	I-Premise
4	group	N	I-Premise
5	had	N	I-Premise
6	a	N	I-Premise
7	higher	N	I-Premise
8	mean	N	I-Premise
9	total	N	I-Premise
10	energy	N	I-Premise
11	(	N	I-Premise
12	P=0.029	N	I-Premise
13	)	N	I-Premise
14	and	N	I-Premise
15	protein	N	I-Premise
16	intake	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	<	N	I-Premise
20	0.001	N	I-Premise
21	)	N	I-Premise
22	compared	N	I-Premise
23	with	N	I-Premise
24	the	N	I-Premise
25	standard	N	I-Premise
26	practice	N	I-Premise
27	group	N	I-Premise
28	.	N	I-Premise

1	Mean	N	I-Premise
2	intake	N	I-Premise
3	per	N	I-Premise
4	kilogram	N	I-Premise
5	of	N	I-Premise
6	body	N	I-Premise
7	weight	N	I-Premise
8	for	N	I-Premise
9	the	N	I-Premise
10	nutrition	N	I-Premise
11	intervention	N	I-Premise
12	group	N	I-Premise
13	ranged	N	I-Premise
14	from	N	I-Premise
15	28	N	I-Premise
16	to	N	I-Premise
17	31	N	I-Premise
18	kcal/kg/day	N	I-Premise
19	compared	N	I-Premise
20	with	N	I-Premise
21	25	N	I-Premise
22	to	N	I-Premise
23	29	N	I-Premise
24	kcal/kg/day	N	I-Premise
25	for	N	I-Premise
26	the	N	I-Premise
27	standard	N	I-Premise
28	practice	N	I-Premise
29	group	N	I-Premise
30	(	N	I-Premise
31	P=0.022	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	The	N	I-Premise
2	nutrition	N	I-Premise
3	intervention	N	I-Premise
4	group	N	I-Premise
5	had	N	I-Premise
6	a	N	I-Premise
7	higher	N	I-Premise
8	mean	N	I-Premise
9	protein	N	I-Premise
10	intake	N	I-Premise
11	(	N	I-Premise
12	1.1	N	I-Premise
13	to	N	I-Premise
14	1.3	N	I-Premise
15	g/kg/day	N	I-Premise
16	)	N	I-Premise
17	compared	N	I-Premise
18	with	N	I-Premise
19	the	N	I-Premise
20	standard	N	I-Premise
21	practice	N	I-Premise
22	group	N	I-Premise
23	(	N	I-Premise
24	1.0	N	I-Premise
25	to	N	I-Premise
26	1.1	N	I-Premise
27	g/kg/day	N	I-Premise
28	)	N	I-Premise
29	(	N	I-Premise
30	P=0.001	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Although	N	I-Premise
2	the	N	I-Premise
3	change	N	I-Premise
4	in	N	I-Premise
5	fiber	N	I-Premise
6	intake	N	I-Premise
7	between	N	I-Premise
8	the	N	I-Premise
9	groups	N	I-Premise
10	was	N	I-Premise
11	not	N	I-Premise
12	significant	N	I-Premise
13	,	N	I-Premise
14	there	N	I-Premise
15	was	N	I-Premise
16	a	N	I-Premise
17	trend	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	anticipated	N	I-Premise
21	direction	N	I-Premise
22	(	N	I-Premise
23	P=0.083	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	Intensive	N	I-Claim
2	nutrition	N	I-Claim
3	intervention	N	I-Claim
4	following	N	I-Claim
5	the	N	I-Claim
6	ADA	N	I-Claim
7	MNT	N	I-Claim
8	protocol	N	I-Claim
9	results	N	I-Claim
10	in	N	I-Claim
11	improved	N	I-Claim
12	dietary	N	I-Claim
13	intake	N	I-Claim
14	compared	N	I-Claim
15	with	N	I-Claim
16	standard	N	I-Claim
17	practice	N	I-Claim
18	and	N	I-Claim
19	seems	N	I-Claim
20	to	N	I-Claim
21	beneficially	N	I-Claim
22	impact	N	I-Claim
23	nutrition-related	N	I-Claim
24	outcomes	N	I-Claim
25	previously	N	I-Claim
26	observed	N	I-Claim
27	in	N	I-Claim
28	oncology	N	I-Claim
29	outpatients	N	I-Claim
30	receiving	N	I-Claim
31	radiotherapy	N	I-Claim
32	.	N	I-Claim

1	The	N	I-MajorClaim
2	ADA	N	I-MajorClaim
3	MNT	N	I-MajorClaim
4	protocol	N	I-MajorClaim
5	for	N	I-MajorClaim
6	radiation	N	I-MajorClaim
7	oncology	N	I-MajorClaim
8	is	N	I-MajorClaim
9	a	N	I-MajorClaim
10	useful	N	I-MajorClaim
11	guide	N	I-MajorClaim
12	to	N	I-MajorClaim
13	the	N	I-MajorClaim
14	level	N	I-MajorClaim
15	of	N	I-MajorClaim
16	nutrition	N	I-MajorClaim
17	support	N	I-MajorClaim
18	required	N	I-MajorClaim
19	.	N	I-MajorClaim

1	Imatinib	N	O
2	is	N	O
3	the	N	O
4	standard	N	O
5	treatment	N	O
6	of	N	O
7	advanced	N	O
8	GI	N	O
9	stromal	N	O
10	tumors	N	O
11	(	N	O
12	GISTs	N	O
13	)	N	O
14	.	N	O

1	It	N	I-Claim
2	is	N	I-Claim
3	not	N	I-Claim
4	known	N	I-Claim
5	whether	N	I-Claim
6	imatinib	N	I-Claim
7	may	N	I-Claim
8	be	N	I-Claim
9	stopped	N	I-Claim
10	in	N	I-Claim
11	patients	N	I-Claim
12	in	N	I-Claim
13	whom	N	I-Claim
14	disease	N	I-Claim
15	is	N	I-Claim
16	controlled	N	I-Claim
17	.	N	I-Claim

1	This	N	O
2	prospective	N	O
3	,	N	O
4	randomized	N	O
5	,	N	O
6	multicentric	N	O
7	phase	N	O
8	III	N	O
9	study	N	O
10	was	N	O
11	designed	N	O
12	to	N	O
13	compare	N	O
14	continuous	N	O
15	(	N	O
16	CONT	N	O
17	)	N	O
18	compared	N	O
19	with	N	O
20	interrupted	N	O
21	(	N	O
22	INT	N	O
23	)	N	O
24	imatinib	N	O
25	beyond	N	O
26	1	N	O
27	year	N	O
28	of	N	O
29	treatment	N	O
30	in	N	O
31	patients	N	O
32	with	N	O
33	advanced	N	O
34	GIST	N	O
35	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	progression-free	N	O
7	survival	N	O
8	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	included	N	O
5	overall	N	O
6	survival	N	O
7	,	N	O
8	response	N	O
9	rate	N	O
10	after	N	O
11	reinitiation	N	O
12	of	N	O
13	imatinib	N	O
14	,	N	O
15	and	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	.	N	O

1	Early	N	O
2	stopping	N	O
3	rules	N	O
4	in	N	O
5	cases	N	O
6	of	N	O
7	rapid	N	O
8	progression	N	O
9	of	N	O
10	disease	N	O
11	were	N	O
12	defined	N	O
13	,	N	O
14	with	N	O
15	preplanned	N	O
16	interim	N	O
17	analyses	N	O
18	.	N	O

1	Between	N	O
2	May	N	O
3	2002	N	O
4	and	N	O
5	April	N	O
6	2004	N	O
7	,	N	O
8	182	N	O
9	patients	N	O
10	with	N	O
11	advanced	N	O
12	GIST	N	O
13	were	N	O
14	enrolled	N	O
15	.	N	O

1	Between	N	O
2	May	N	O
3	2003	N	O
4	and	N	O
5	April	N	O
6	2004	N	O
7	,	N	O
8	98	N	O
9	patients	N	O
10	in	N	O
11	response	N	O
12	or	N	O
13	stable	N	O
14	disease	N	O
15	under	N	O
16	imatinib	N	O
17	reached	N	O
18	more	N	O
19	than	N	O
20	1	N	O
21	year	N	O
22	of	N	O
23	follow-up	N	O
24	.	N	O

1	Forty	N	O
2	were	N	O
3	not	N	O
4	eligible	N	O
5	for	N	O
6	randomization	N	O
7	,	N	O
8	and	N	O
9	58	N	O
10	patients	N	O
11	were	N	O
12	randomly	N	O
13	assigned	N	O
14	,	N	O
15	32	N	O
16	and	N	O
17	26	N	O
18	patients	N	O
19	in	N	O
20	the	N	O
21	INT	N	O
22	and	N	O
23	CONT	N	O
24	arms	N	O
25	,	N	O
26	respectively	N	O
27	.	N	O

1	As	N	I-Premise
2	of	N	I-Premise
3	October	N	I-Premise
4	15	N	I-Premise
5	,	N	I-Premise
6	2005	N	I-Premise
7	,	N	I-Premise
8	eight	N	I-Premise
9	of	N	I-Premise
10	26	N	I-Premise
11	patients	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	CONT	N	I-Premise
15	group	N	I-Premise
16	and	N	I-Premise
17	26	N	I-Premise
18	of	N	I-Premise
19	32	N	I-Premise
20	patients	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	INT	N	I-Premise
24	group	N	I-Premise
25	had	N	I-Premise
26	documented	N	I-Premise
27	disease	N	I-Premise
28	progression	N	I-Premise
29	(	N	I-Premise
30	P	N	I-Premise
31	<	N	I-Premise
32	.0001	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	Twenty-four	N	I-Premise
2	of	N	I-Premise
3	26	N	I-Premise
4	patients	N	I-Premise
5	with	N	I-Premise
6	documented	N	I-Premise
7	progression	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	INT	N	I-Premise
11	arm	N	I-Premise
12	responded	N	I-Premise
13	to	N	I-Premise
14	imatinib	N	I-Premise
15	reintroduction	N	I-Premise
16	.	N	I-Premise

1	No	N	I-Premise
2	differences	N	I-Premise
3	in	N	I-Premise
4	overall	N	I-Premise
5	survival	N	I-Premise
6	or	N	I-Premise
7	imatinib	N	I-Premise
8	resistance	N	I-Premise
9	were	N	I-Premise
10	observed	N	I-Premise
11	between	N	I-Premise
12	the	N	I-Premise
13	two	N	I-Premise
14	arms	N	I-Premise
15	.	N	I-Premise

1	Quality	N	I-Premise
2	of	N	I-Premise
3	life	N	I-Premise
4	evaluated	N	I-Premise
5	6	N	I-Premise
6	months	N	I-Premise
7	after	N	I-Premise
8	random	N	I-Premise
9	assignment	N	I-Premise
10	using	N	I-Premise
11	the	N	I-Premise
12	30-item	N	I-Premise
13	Quality	N	I-Premise
14	of	N	I-Premise
15	Life	N	I-Premise
16	Questionnaire	N	I-Premise
17	was	N	I-Premise
18	not	N	I-Premise
19	significantly	N	I-Premise
20	different	N	I-Premise
21	between	N	I-Premise
22	the	N	I-Premise
23	two	N	I-Premise
24	groups	N	I-Premise
25	of	N	I-Premise
26	randomly	N	I-Premise
27	assigned	N	I-Premise
28	patients	N	I-Premise
29	.	N	I-Premise

1	Imatinib	N	I-Claim
2	interruption	N	I-Claim
3	results	N	I-Claim
4	in	N	I-Claim
5	rapid	N	I-Claim
6	progression	N	I-Claim
7	in	N	I-Claim
8	most	N	I-Claim
9	patients	N	I-Claim
10	with	N	I-Claim
11	advanced	N	I-Claim
12	GIST	N	I-Claim
13	,	N	I-Claim
14	and	N	I-Claim
15	can	N	I-Claim
16	not	N	I-Claim
17	be	N	I-Claim
18	recommended	N	I-Claim
19	in	N	I-Claim
20	routine	N	I-Claim
21	practice	N	I-Claim
22	unless	N	I-Claim
23	patient	N	I-Claim
24	experience	N	I-Claim
25	significant	N	I-Claim
26	toxicity	N	I-Claim
27	.	N	I-Claim

1	Psychological	N	I-Claim
2	interventions	N	I-Claim
3	are	N	I-Claim
4	efficacious	N	I-Claim
5	in	N	I-Claim
6	reducing	N	I-Claim
7	emotional	N	I-Claim
8	distress	N	I-Claim
9	for	N	I-Claim
10	cancer	N	I-Claim
11	patients	N	I-Claim
12	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	it	N	I-Claim
4	is	N	I-Claim
5	not	N	I-Claim
6	clear	N	I-Claim
7	whether	N	I-Claim
8	psychological	N	I-Claim
9	improvements	N	I-Claim
10	are	N	I-Claim
11	,	N	I-Claim
12	in	N	I-Claim
13	turn	N	I-Claim
14	,	N	I-Claim
15	related	N	I-Claim
16	to	N	I-Claim
17	improved	N	I-Claim
18	health	N	I-Claim
19	.	N	I-Claim

1	A	N	O
2	clinical	N	O
3	trial	N	O
4	tests	N	O
5	whether	N	O
6	a	N	O
7	psychological	N	O
8	intervention	N	O
9	for	N	O
10	cancer	N	O
11	patients	N	O
12	can	N	O
13	do	N	O
14	so	N	O
15	,	N	O
16	and	N	O
17	also	N	O
18	tests	N	O
19	two	N	O
20	routes	N	O
21	to	N	O
22	achieve	N	O
23	better	N	O
24	health	N	O
25	:	N	O
26	(	N	O
27	a	N	O
28	)	N	O
29	reducing	N	O
30	patients	N	O
31	'	N	O
32	Emotional	N	O
33	Distress	N	O
34	,	N	O
35	and/or	N	O
36	(	N	O
37	b	N	O
38	)	N	O
39	enhancing	N	O
40	their	N	O
41	functional	N	O
42	immunity	N	O
43	.	N	O

1	Post-surgery	N	O
2	,	N	O
3	227	N	O
4	breast	N	O
5	cancer	N	O
6	patients	N	O
7	were	N	O
8	randomized	N	O
9	to	N	O
10	intervention	N	O
11	or	N	O
12	assessment	N	O
13	only	N	O
14	Study	N	O
15	Arms	N	O
16	.	N	O

1	Conducted	N	O
2	in	N	O
3	small	N	O
4	groups	N	O
5	,	N	O
6	intervention	N	O
7	sessions	N	O
8	were	N	O
9	offered	N	O
10	weekly	N	O
11	for	N	O
12	4	N	O
13	months	N	O
14	and	N	O
15	followed	N	O
16	by	N	O
17	monthly	N	O
18	sessions	N	O
19	for	N	O
20	8	N	O
21	months	N	O
22	.	N	O

1	Measures	N	O
2	included	N	O
3	psychological	N	O
4	(	N	O
5	distress	N	O
6	)	N	O
7	,	N	O
8	biological	N	O
9	(	N	O
10	immune	N	O
11	)	N	O
12	,	N	O
13	and	N	O
14	health	N	O
15	outcomes	N	O
16	(	N	O
17	performance	N	O
18	status	N	O
19	and	N	O
20	evaluations	N	O
21	of	N	O
22	patient	N	O
23	's	N	O
24	symptomatology	N	O
25	,	N	O
26	including	N	O
27	toxicity	N	O
28	from	N	O
29	cancer	N	O
30	treatment	N	O
31	,	N	O
32	lab	N	O
33	values	N	O
34	)	N	O
35	collected	N	O
36	at	N	O
37	baseline	N	O
38	,	N	O
39	4	N	O
40	months	N	O
41	,	N	O
42	and	N	O
43	12	N	O
44	months	N	O
45	.	N	O

1	A	N	I-Premise
2	path	N	I-Premise
3	model	N	I-Premise
4	revealed	N	I-Premise
5	that	N	I-Premise
6	intervention	N	I-Premise
7	participation	N	I-Premise
8	directly	N	I-Premise
9	improved	N	I-Premise
10	health	N	I-Premise
11	(	N	I-Premise
12	p	N	I-Premise
13	<	N	I-Premise
14	.05	N	I-Premise
15	)	N	I-Premise
16	at	N	I-Premise
17	12	N	I-Premise
18	months	N	I-Premise
19	.	N	I-Premise

1	These	N	I-Premise
2	effects	N	I-Premise
3	remained	N	I-Premise
4	when	N	I-Premise
5	statistically	N	I-Premise
6	controlling	N	I-Premise
7	for	N	I-Premise
8	baseline	N	I-Premise
9	levels	N	I-Premise
10	of	N	I-Premise
11	distress	N	I-Premise
12	,	N	I-Premise
13	immunity	N	I-Premise
14	,	N	I-Premise
15	and	N	I-Premise
16	health	N	I-Premise
17	as	N	I-Premise
18	well	N	I-Premise
19	as	N	I-Premise
20	sociodemographic	N	I-Premise
21	,	N	I-Premise
22	disease	N	I-Premise
23	,	N	I-Premise
24	and	N	I-Premise
25	cancer	N	I-Premise
26	treatment	N	I-Premise
27	variables	N	I-Premise
28	.	N	I-Premise

1	Regarding	N	I-Premise
2	the	N	I-Premise
3	mechanisms	N	I-Premise
4	for	N	I-Premise
5	achieving	N	I-Premise
6	better	N	I-Premise
7	health	N	I-Premise
8	,	N	I-Premise
9	support	N	I-Premise
10	was	N	I-Premise
11	found	N	I-Premise
12	for	N	I-Premise
13	an	N	I-Premise
14	indirect	N	I-Premise
15	effect	N	I-Premise
16	of	N	I-Premise
17	distress	N	I-Premise
18	reduction	N	I-Premise
19	.	N	I-Premise

1	That	N	I-Premise
2	is	N	I-Premise
3	,	N	I-Premise
4	by	N	I-Premise
5	specifically	N	I-Premise
6	lowering	N	I-Premise
7	intervention	N	I-Premise
8	patients	N	I-Premise
9	'	N	I-Premise
10	distress	N	I-Premise
11	at	N	I-Premise
12	4	N	I-Premise
13	months	N	I-Premise
14	,	N	I-Premise
15	their	N	I-Premise
16	health	N	I-Premise
17	was	N	I-Premise
18	improved	N	I-Premise
19	at	N	I-Premise
20	12	N	I-Premise
21	months	N	I-Premise
22	(	N	I-Premise
23	p	N	I-Premise
24	<	N	I-Premise
25	.05	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	Although	N	I-Premise
2	the	N	I-Premise
3	intervention	N	I-Premise
4	simultaneously	N	I-Premise
5	improved	N	I-Premise
6	patients	N	I-Premise
7	'	N	I-Premise
8	T-cell	N	I-Premise
9	blastogenesis	N	I-Premise
10	in	N	I-Premise
11	response	N	I-Premise
12	to	N	I-Premise
13	phytohemagglutinin	N	I-Premise
14	(	N	I-Premise
15	PHA	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	the	N	I-Premise
19	latter	N	I-Premise
20	increases	N	I-Premise
21	were	N	I-Premise
22	unrelated	N	I-Premise
23	to	N	I-Premise
24	improved	N	I-Premise
25	health	N	I-Premise
26	.	N	I-Premise

1	A	N	I-Premise
2	convergence	N	I-Premise
3	of	N	I-Premise
4	biobehavioral	N	I-Premise
5	effects	N	I-Premise
6	and	N	I-Premise
7	health	N	I-Premise
8	improvements	N	I-Premise
9	were	N	I-Premise
10	observed	N	I-Premise
11	.	N	I-Premise

1	Behavioral	N	I-Claim
2	change	N	I-Claim
3	,	N	I-Claim
4	rather	N	I-Claim
5	than	N	I-Claim
6	immunity	N	I-Claim
7	change	N	I-Claim
8	,	N	I-Claim
9	was	N	I-Claim
10	influential	N	I-Claim
11	in	N	I-Claim
12	achieving	N	I-Claim
13	lower	N	I-Claim
14	levels	N	I-Claim
15	of	N	I-Claim
16	symptomatology	N	I-Claim
17	and	N	I-Claim
18	higher	N	I-Claim
19	functional	N	I-Claim
20	status	N	I-Claim
21	.	N	I-Claim

1	Distress	N	I-Claim
2	reduction	N	I-Claim
3	is	N	I-Claim
4	highlighted	N	I-Claim
5	as	N	I-Claim
6	an	N	I-Claim
7	important	N	I-Claim
8	mechanism	N	I-Claim
9	by	N	I-Claim
10	which	N	I-Claim
11	health	N	I-Claim
12	can	N	I-Claim
13	be	N	I-Claim
14	improved	N	I-Claim
15	.	N	I-Claim

1	This	N	O
2	study	N	O
3	aimed	N	O
4	to	N	O
5	compare	N	O
6	quality	N	O
7	of	N	O
8	life	N	O
9	(	N	O
10	QOL	N	O
11	)	N	O
12	,	N	O
13	functional	N	O
14	outcome	N	O
15	,	N	O
16	body	N	O
17	image	N	O
18	,	N	O
19	and	N	O
20	cosmesis	N	O
21	after	N	O
22	hand-assisted	N	O
23	laparoscopic	N	O
24	(	N	O
25	LRP	N	O
26	)	N	O
27	versus	N	O
28	open	N	O
29	restorative	N	O
30	proctocolectomy	N	O
31	(	N	O
32	ORP	N	O
33	)	N	O
34	.	N	O

1	The	N	O
2	potential	N	O
3	long-term	N	O
4	advantages	N	O
5	of	N	O
6	LRP	N	O
7	over	N	O
8	ORP	N	O
9	remain	N	O
10	to	N	O
11	be	N	O
12	determined	N	O
13	.	N	O

1	The	N	O
2	most	N	O
3	likely	N	O
4	advantage	N	O
5	of	N	O
6	LRP	N	O
7	is	N	O
8	the	N	O
9	superior	N	O
10	cosmetic	N	O
11	result	N	O
12	.	N	O

1	It	N	O
2	is	N	O
3	,	N	O
4	however	N	O
5	,	N	O
6	unclear	N	O
7	whether	N	O
8	the	N	O
9	size	N	O
10	and	N	O
11	location	N	O
12	of	N	O
13	incisions	N	O
14	affect	N	O
15	body	N	O
16	image	N	O
17	and	N	O
18	QOL	N	O
19	.	N	O

1	In	N	O
2	a	N	O
3	previously	N	O
4	conducted	N	O
5	randomized	N	O
6	trial	N	O
7	comparing	N	O
8	LRP	N	O
9	with	N	O
10	ORP	N	O
11	,	N	O
12	60	N	O
13	patients	N	O
14	were	N	O
15	prospectively	N	O
16	evaluated	N	O
17	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	points	N	O
5	were	N	O
6	body	N	O
7	image	N	O
8	and	N	O
9	cosmesis	N	O
10	.	N	O

1	The	N	O
2	secondary	N	O
3	end	N	O
4	points	N	O
5	were	N	O
6	morbidity	N	O
7	,	N	O
8	QOL	N	O
9	,	N	O
10	and	N	O
11	functional	N	O
12	outcome	N	O
13	.	N	O

1	A	N	O
2	body	N	O
3	image	N	O
4	questionnaire	N	O
5	was	N	O
6	used	N	O
7	to	N	O
8	evaluate	N	O
9	body	N	O
10	image	N	O
11	and	N	O
12	cosmesis	N	O
13	.	N	O

1	The	N	O
2	Short	N	O
3	Form-36	N	O
4	Health	N	O
5	Survey	N	O
6	and	N	O
7	the	N	O
8	Gastrointestinal	N	O
9	Quality	N	O
10	of	N	O
11	Life	N	O
12	Inventory	N	O
13	were	N	O
14	used	N	O
15	to	N	O
16	assess	N	O
17	QOL	N	O
18	.	N	O

1	Body	N	O
2	image	N	O
3	and	N	O
4	QOL	N	O
5	also	N	O
6	were	N	O
7	assessed	N	O
8	preoperatively	N	O
9	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	53	N	O
5	patients	N	O
6	completed	N	O
7	the	N	O
8	QOL	N	O
9	and	N	O
10	functional	N	O
11	outcome	N	O
12	questionnaires	N	O
13	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	differences	N	I-Premise
5	in	N	I-Premise
6	functional	N	I-Premise
7	outcome	N	I-Premise
8	,	N	I-Premise
9	morbidity	N	I-Premise
10	,	N	I-Premise
11	or	N	I-Premise
12	QOL	N	I-Premise
13	between	N	I-Premise
14	LRP	N	I-Premise
15	and	N	I-Premise
16	ORP	N	I-Premise
17	.	N	I-Premise

1	At	N	O
2	a	N	O
3	median	N	O
4	of	N	O
5	2.7	N	O
6	years	N	O
7	after	N	O
8	surgery	N	O
9	,	N	O
10	46	N	O
11	patients	N	O
12	returned	N	O
13	the	N	O
14	questionnaires	N	O
15	regarding	N	O
16	body	N	O
17	image	N	O
18	,	N	O
19	cosmesis	N	O
20	,	N	O
21	and	N	O
22	morbidity	N	O
23	.	N	O

1	The	N	I-Premise
2	body	N	I-Premise
3	image	N	I-Premise
4	and	N	I-Premise
5	cosmesis	N	I-Premise
6	scores	N	I-Premise
7	of	N	I-Premise
8	female	N	I-Premise
9	patients	N	I-Premise
10	were	N	I-Premise
11	significantly	N	I-Premise
12	higher	N	I-Premise
13	in	N	I-Premise
14	the	N	I-Premise
15	LRP	N	I-Premise
16	group	N	I-Premise
17	than	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	ORP	N	I-Premise
21	group	N	I-Premise
22	(	N	I-Premise
23	body	N	I-Premise
24	image	N	I-Premise
25	,	N	I-Premise
26	17.4	N	I-Premise
27	vs	N	I-Premise
28	14.9	N	I-Premise
29	;	N	I-Premise
30	cosmesis	N	I-Premise
31	,	N	I-Premise
32	19.1	N	I-Premise
33	vs	N	I-Premise
34	13.0	N	I-Premise
35	,	N	I-Premise
36	respectively	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	The	N	I-Premise
2	female	N	I-Premise
3	patients	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	ORP	N	I-Premise
7	group	N	I-Premise
8	had	N	I-Premise
9	significantly	N	I-Premise
10	lower	N	I-Premise
11	body	N	I-Premise
12	image	N	I-Premise
13	scores	N	I-Premise
14	than	N	I-Premise
15	the	N	I-Premise
16	male	N	I-Premise
17	patients	N	I-Premise
18	(	N	I-Premise
19	14.9	N	I-Premise
20	vs	N	I-Premise
21	18.3	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	This	N	I-Claim
2	study	N	I-Claim
3	is	N	I-Claim
4	the	N	I-Claim
5	first	N	I-Claim
6	to	N	I-Claim
7	show	N	I-Claim
8	that	N	I-Claim
9	ORP	N	I-Claim
10	has	N	I-Claim
11	a	N	I-Claim
12	negative	N	I-Claim
13	impact	N	I-Claim
14	on	N	I-Claim
15	body	N	I-Claim
16	image	N	I-Claim
17	and	N	I-Claim
18	cosmesis	N	I-Claim
19	as	N	I-Claim
20	compared	N	I-Claim
21	with	N	I-Claim
22	LRP	N	I-Claim
23	.	N	I-Claim

1	Functional	N	I-Claim
2	outcome	N	I-Claim
3	,	N	I-Claim
4	QOL	N	I-Claim
5	,	N	I-Claim
6	and	N	I-Claim
7	morbidity	N	I-Claim
8	are	N	I-Claim
9	similar	N	I-Claim
10	for	N	I-Claim
11	the	N	I-Claim
12	two	N	I-Claim
13	approaches	N	I-Claim
14	.	N	I-Claim

1	The	N	I-Claim
2	advantages	N	I-Claim
3	of	N	I-Claim
4	a	N	I-Claim
5	long-lasting	N	I-Claim
6	improved	N	I-Claim
7	body	N	I-Claim
8	image	N	I-Claim
9	and	N	I-Claim
10	cosmesis	N	I-Claim
11	for	N	I-Claim
12	this	N	I-Claim
13	relatively	N	I-Claim
14	young	N	I-Claim
15	patient	N	I-Claim
16	population	N	I-Claim
17	may	N	I-Claim
18	compensate	N	I-Claim
19	for	N	I-Claim
20	the	N	I-Claim
21	longer	N	I-Claim
22	operating	N	I-Claim
23	times	N	I-Claim
24	and	N	I-Claim
25	higher	N	I-Claim
26	costs	N	I-Claim
27	,	N	I-Claim
28	particularly	N	I-Claim
29	for	N	I-Claim
30	women	N	I-Claim
31	.	N	I-Claim

1	Depression	N	I-Claim
2	,	N	I-Claim
3	anxiety	N	I-Claim
4	,	N	I-Claim
5	fatigue	N	I-Claim
6	,	N	I-Claim
7	and	N	I-Claim
8	impaired	N	I-Claim
9	wellbeing	N	I-Claim
10	are	N	I-Claim
11	common	N	I-Claim
12	,	N	I-Claim
13	important	N	I-Claim
14	,	N	I-Claim
15	and	N	I-Claim
16	closely	N	I-Claim
17	related	N	I-Claim
18	in	N	I-Claim
19	advanced	N	I-Claim
20	cancer	N	I-Claim
21	.	N	I-Claim

1	We	N	O
2	aimed	N	O
3	to	N	O
4	identify	N	O
5	the	N	O
6	effects	N	O
7	of	N	O
8	an	N	O
9	established	N	O
10	antidepressant	N	O
11	on	N	O
12	these	N	O
13	symptoms	N	O
14	and	N	O
15	survival	N	O
16	in	N	O
17	patients	N	O
18	with	N	O
19	advanced	N	O
20	cancer	N	O
21	who	N	O
22	did	N	O
23	not	N	O
24	have	N	O
25	major	N	O
26	depression	N	O
27	as	N	O
28	assessed	N	O
29	by	N	O
30	clinicians	N	O
31	.	N	O

1	Between	N	O
2	July	N	O
3	,	N	O
4	2001	N	O
5	,	N	O
6	and	N	O
7	February	N	O
8	,	N	O
9	2006	N	O
10	,	N	O
11	189	N	O
12	patients	N	O
13	with	N	O
14	advanced	N	O
15	cancer	N	O
16	were	N	O
17	randomly	N	O
18	assigned	N	O
19	sertraline	N	O
20	50	N	O
21	mg	N	O
22	(	N	O
23	n=95	N	O
24	)	N	O
25	,	N	O
26	or	N	O
27	placebo	N	O
28	(	N	O
29	n=94	N	O
30	)	N	O
31	,	N	O
32	once	N	O
33	per	N	O
34	day	N	O
35	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	depression	N	O
6	as	N	O
7	assessed	N	O
8	by	N	O
9	the	N	O
10	Centre	N	O
11	for	N	O
12	Epidemiologic	N	O
13	Studies	N	O
14	Depression	N	O
15	scale	N	O
16	(	N	O
17	CES-D	N	O
18	)	N	O
19	;	N	O
20	the	N	O
21	main	N	O
22	secondary	N	O
23	outcomes	N	O
24	were	N	O
25	:	N	O
26	anxiety	N	O
27	as	N	O
28	assessed	N	O
29	by	N	O
30	Hospital	N	O
31	Anxiety	N	O
32	and	N	O
33	Depression	N	O
34	Scales	N	O
35	(	N	O
36	HADS-A	N	O
37	)	N	O
38	;	N	O
39	overall	N	O
40	quality	N	O
41	of	N	O
42	life	N	O
43	and	N	O
44	fatigue	N	O
45	as	N	O
46	assessed	N	O
47	by	N	O
48	Functional	N	O
49	Assessment	N	O
50	of	N	O
51	Cancer	N	O
52	Therapy	N	O
53	General	N	O
54	and	N	O
55	Fatigue	N	O
56	scales	N	O
57	(	N	O
58	FACT-G	N	O
59	and	N	O
60	FACT-F	N	O
61	,	N	O
62	respectively	N	O
63	)	N	O
64	;	N	O
65	and	N	O
66	clinicians	N	O
67	'	N	O
68	ratings	N	O
69	of	N	O
70	quality	N	O
71	of	N	O
72	life	N	O
73	by	N	O
74	use	N	O
75	of	N	O
76	Spizter	N	O
77	's	N	O
78	Quality	N	O
79	of	N	O
80	Life	N	O
81	Index	N	O
82	(	N	O
83	SQLI	N	O
84	)	N	O
85	.	N	O

1	Multiple	N	O
2	measures	N	O
3	were	N	O
4	used	N	O
5	for	N	O
6	corroboration	N	O
7	of	N	O
8	the	N	O
9	most	N	O
10	important	N	O
11	outcomes	N	O
12	.	N	O

1	Primary	N	O
2	analyses	N	O
3	were	N	O
4	done	N	O
5	by	N	O
6	intention	N	O
7	to	N	O
8	treat	N	O
9	and	N	O
10	were	N	O
11	based	N	O
12	on	N	O
13	scale	N	O
14	scores	N	O
15	at	N	O
16	4	N	O
17	weeks	N	O
18	and	N	O
19	8	N	O
20	weeks	N	O
21	.	N	O

1	The	N	O
2	benefits	N	O
3	of	N	O
4	sertraline	N	O
5	compared	N	O
6	with	N	O
7	placebo	N	O
8	are	N	O
9	expressed	N	O
10	on	N	O
11	a	N	O
12	range	N	O
13	from	N	O
14	+100	N	O
15	(	N	O
16	ie	N	O
17	,	N	O
18	maximum	N	O
19	benefit	N	O
20	)	N	O
21	to	N	O
22	-100	N	O
23	(	N	O
24	ie	N	O
25	,	N	O
26	maximum	N	O
27	harm	N	O
28	)	N	O
29	;	N	O
30	a	N	O
31	difference	N	O
32	of	N	O
33	10	N	O
34	was	N	O
35	deemed	N	O
36	clinically	N	O
37	significant	N	O
38	.	N	O

1	This	N	O
2	clinical	N	O
3	trial	N	O
4	is	N	O
5	registered	N	O
6	at	N	O
7	Current	N	O
8	Controlled	N	O
9	Trials	N	O
10	website	N	O
11	http	N	O
12	:	N	O
13	//www.controlled-trials.com/ISRCTN72466475	N	O
14	.	N	O

1	Sertraline	N	I-Premise
2	had	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	effect	N	I-Premise
6	(	N	I-Premise
7	scale	N	I-Premise
8	,	N	I-Premise
9	benefit	N	I-Premise
10	over	N	I-Premise
11	placebo	N	I-Premise
12	[	N	I-Premise
13	95	N	I-Premise
14	%	N	I-Premise
15	CI	N	I-Premise
16	]	N	I-Premise
17	)	N	I-Premise
18	on	N	I-Premise
19	depression	N	I-Premise
20	(	N	I-Premise
21	CES-D	N	I-Premise
22	0.4	N	I-Premise
23	[	N	I-Premise
24	-2.6	N	I-Premise
25	to	N	I-Premise
26	3.4	N	I-Premise
27	]	N	I-Premise
28	)	N	I-Premise
29	,	N	I-Premise
30	anxiety	N	I-Premise
31	(	N	I-Premise
32	HADS-A	N	I-Premise
33	2.0	N	I-Premise
34	[	N	I-Premise
35	-1.5	N	I-Premise
36	to	N	I-Premise
37	5.5	N	I-Premise
38	]	N	I-Premise
39	)	N	I-Premise
40	,	N	I-Premise
41	fatigue	N	I-Premise
42	(	N	I-Premise
43	FACT-F	N	I-Premise
44	0.3	N	I-Premise
45	[	N	I-Premise
46	-4.3	N	I-Premise
47	to	N	I-Premise
48	4.9	N	I-Premise
49	]	N	I-Premise
50	)	N	I-Premise
51	,	N	I-Premise
52	overall	N	I-Premise
53	quality	N	I-Premise
54	of	N	I-Premise
55	life	N	I-Premise
56	(	N	I-Premise
57	FACT-G	N	I-Premise
58	1.7	N	I-Premise
59	[	N	I-Premise
60	-1.3	N	I-Premise
61	to	N	I-Premise
62	4.7	N	I-Premise
63	]	N	I-Premise
64	)	N	I-Premise
65	,	N	I-Premise
66	or	N	I-Premise
67	clinicians	N	I-Premise
68	'	N	I-Premise
69	ratings	N	I-Premise
70	(	N	I-Premise
71	SQLI	N	I-Premise
72	2.0	N	I-Premise
73	[	N	I-Premise
74	-2.5	N	I-Premise
75	to	N	I-Premise
76	6.5	N	I-Premise
77	]	N	I-Premise
78	)	N	I-Premise
79	,	N	I-Premise
80	and	N	I-Premise
81	the	N	I-Premise
82	95	N	I-Premise
83	%	N	I-Premise
84	CI	N	I-Premise
85	ruled	N	I-Premise
86	out	N	I-Premise
87	a	N	I-Premise
88	clinically	N	I-Premise
89	significant	N	I-Premise
90	benefit	N	I-Premise
91	for	N	I-Premise
92	all	N	I-Premise
93	main	N	I-Premise
94	outcomes	N	I-Premise
95	.	N	I-Premise

1	Sertraline	N	I-Premise
2	was	N	I-Premise
3	discontinued	N	I-Premise
4	more	N	I-Premise
5	often	N	I-Premise
6	and	N	I-Premise
7	earlier	N	I-Premise
8	than	N	I-Premise
9	was	N	I-Premise
10	placebo	N	I-Premise
11	(	N	I-Premise
12	hazard	N	I-Premise
13	ratio	N	I-Premise
14	1.46	N	I-Premise
15	[	N	I-Premise
16	1.03-2.06	N	I-Premise
17	]	N	I-Premise
18	,	N	I-Premise
19	p=0.03	N	I-Premise
20	)	N	I-Premise
21	.	N	I-Premise

1	Recruitment	N	O
2	was	N	O
3	stopped	N	O
4	after	N	O
5	the	N	I-Premise
6	first	N	I-Premise
7	planned	N	I-Premise
8	interim	N	I-Premise
9	analysis	N	I-Premise
10	in	N	I-Premise
11	February	N	I-Premise
12	2006	N	I-Premise
13	(	N	I-Premise
14	n=150	N	I-Premise
15	)	N	I-Premise
16	showed	N	I-Premise
17	that	N	I-Premise
18	survival	N	I-Premise
19	was	N	I-Premise
20	longer	N	I-Premise
21	in	N	I-Premise
22	patients	N	I-Premise
23	assigned	N	I-Premise
24	placebo	N	I-Premise
25	than	N	I-Premise
26	in	N	I-Premise
27	patients	N	I-Premise
28	assigned	N	I-Premise
29	sertraline	N	I-Premise
30	(	N	I-Premise
31	unadjusted	N	I-Premise
32	hazard	N	I-Premise
33	ratio	N	I-Premise
34	1.60	N	I-Premise
35	[	N	I-Premise
36	95	N	I-Premise
37	%	N	I-Premise
38	CI	N	I-Premise
39	1.04-2.45	N	I-Premise
40	]	N	I-Premise
41	,	N	I-Premise
42	log-rank	N	I-Premise
43	p=0.04	N	I-Premise
44	;	N	I-Premise
45	adjusted	N	I-Premise
46	hazard	N	I-Premise
47	ratio	N	I-Premise
48	1.62	N	I-Premise
49	[	N	I-Premise
50	1.06-2.41	N	I-Premise
51	]	N	I-Premise
52	,	N	I-Premise
53	Cox	N	I-Premise
54	model	N	I-Premise
55	p=0.02	N	I-Premise
56	)	N	I-Premise
57	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	at	N	I-Premise
4	the	N	I-Premise
5	final	N	I-Premise
6	analysis	N	I-Premise
7	in	N	I-Premise
8	July	N	I-Premise
9	2006	N	I-Premise
10	of	N	I-Premise
11	all	N	I-Premise
12	patients	N	I-Premise
13	(	N	I-Premise
14	n=189	N	I-Premise
15	)	N	I-Premise
16	and	N	I-Premise
17	with	N	I-Premise
18	longer	N	I-Premise
19	follow-up	N	I-Premise
20	,	N	I-Premise
21	survival	N	I-Premise
22	did	N	I-Premise
23	not	N	I-Premise
24	differ	N	I-Premise
25	significantly	N	I-Premise
26	between	N	I-Premise
27	the	N	I-Premise
28	treatment	N	I-Premise
29	groups	N	I-Premise
30	(	N	I-Premise
31	unadjusted	N	I-Premise
32	hazard	N	I-Premise
33	ratio	N	I-Premise
34	1.35	N	I-Premise
35	[	N	I-Premise
36	0.95-1.91	N	I-Premise
37	]	N	I-Premise
38	,	N	I-Premise
39	log-rank	N	I-Premise
40	p=0.09	N	I-Premise
41	;	N	I-Premise
42	adjusted	N	I-Premise
43	hazard	N	I-Premise
44	ratio	N	I-Premise
45	1.27	N	I-Premise
46	[	N	I-Premise
47	0.87-1.84	N	I-Premise
48	]	N	I-Premise
49	,	N	I-Premise
50	Cox	N	I-Premise
51	model	N	I-Premise
52	p=0.20	N	I-Premise
53	)	N	I-Premise
54	.	N	I-Premise

1	The	N	O
2	trial	N	O
3	was	N	O
4	closed	N	O
5	because	N	O
6	it	N	O
7	had	N	O
8	ruled	N	O
9	out	N	O
10	a	N	O
11	significant	N	O
12	benefit	N	O
13	of	N	O
14	sertraline	N	O
15	.	N	O

1	Sertraline	N	I-Claim
2	did	N	I-Claim
3	not	N	I-Claim
4	improve	N	I-Claim
5	symptoms	N	I-Claim
6	,	N	I-Claim
7	wellbeing	N	I-Claim
8	,	N	I-Claim
9	or	N	I-Claim
10	survival	N	I-Claim
11	in	N	I-Claim
12	patients	N	I-Claim
13	with	N	I-Claim
14	advanced	N	I-Claim
15	cancer	N	I-Claim
16	who	N	I-Claim
17	do	N	I-Claim
18	not	N	I-Claim
19	have	N	I-Claim
20	major	N	I-Claim
21	depression	N	I-Claim
22	,	N	I-Claim
23	and	N	I-Claim
24	should	N	I-Claim
25	be	N	I-Claim
26	reserved	N	I-Claim
27	for	N	I-Claim
28	those	N	I-Claim
29	with	N	I-Claim
30	a	N	I-Claim
31	proven	N	I-Claim
32	indication	N	I-Claim
33	.	N	I-Claim

1	Recently	N	I-Claim
2	,	N	I-Claim
3	the	N	I-Claim
4	treatment	N	I-Claim
5	of	N	I-Claim
6	advanced	N	I-Claim
7	gastric	N	I-Claim
8	cancer	N	I-Claim
9	by	N	I-Claim
10	continuous	N	I-Claim
11	infusion	N	I-Claim
12	of	N	I-Claim
13	5-fluorouracil	N	I-Claim
14	(	N	I-Claim
15	5-FU	N	I-Claim
16	)	N	I-Claim
17	with	N	I-Claim
18	low-dose	N	I-Claim
19	cisplatin	N	I-Claim
20	(	N	I-Claim
21	CDDP	N	I-Claim
22	)	N	I-Claim
23	has	N	I-Claim
24	improved	N	I-Claim
25	efficacy	N	I-Claim
26	without	N	I-Claim
27	severe	N	I-Claim
28	toxicities	N	I-Claim
29	.	N	I-Claim

1	The	N	I-Claim
2	possible	N	I-Claim
3	effectiveness	N	I-Claim
4	of	N	I-Claim
5	5-FU+low-dose	N	I-Claim
6	CDDP	N	I-Claim
7	for	N	I-Claim
8	colorectal	N	I-Claim
9	cancer	N	I-Claim
10	(	N	I-Claim
11	CRC	N	I-Claim
12	)	N	I-Claim
13	is	N	I-Claim
14	intriguing	N	I-Claim
15	.	N	I-Claim

1	One	N	O
2	hundred	N	O
3	fifty-five	N	O
4	patients	N	O
5	with	N	O
6	far-advanced	N	O
7	CRC	N	O
8	including	N	O
9	at	N	O
10	least	N	O
11	one	N	O
12	measurable	N	O
13	lesion	N	O
14	were	N	O
15	enrolled	N	O
16	in	N	O
17	a	N	O
18	prospective	N	O
19	randomized	N	O
20	clinical	N	O
21	trial	N	O
22	funded	N	O
23	by	N	O
24	the	N	O
25	Japanese	N	O
26	Foundation	N	O
27	for	N	O
28	Multidisciplinary	N	O
29	Treatment	N	O
30	of	N	O
31	Cancer	N	O
32	.	N	O

1	These	N	O
2	patients	N	O
3	were	N	O
4	assigned	N	O
5	to	N	O
6	the	N	O
7	two	N	O
8	arms	N	O
9	to	N	O
10	assess	N	O
11	the	N	O
12	value	N	O
13	of	N	O
14	low-dose	N	O
15	CDDP	N	O
16	when	N	O
17	added	N	O
18	to	N	O
19	a	N	O
20	continuous	N	O
21	intravenous	N	O
22	infusion	N	O
23	of	N	O
24	5-FU	N	O
25	at	N	O
26	a	N	O
27	dose	N	O
28	of	N	O
29	300	N	O
30	mg/m	N	O
31	(	N	O
32	2	N	O
33	)	N	O
34	/24	N	O
35	hrs	N	O
36	in	N	O
37	a	N	O
38	one-week	N	O
39	cycle	N	O
40	consisting	N	O
41	of	N	O
42	5	N	O
43	days	N	O
44	of	N	O
45	treatment	N	O
46	and	N	O
47	2	N	O
48	days	N	O
49	of	N	O
50	rest	N	O
51	for	N	O
52	at	N	O
53	least	N	O
54	12	N	O
55	weeks	N	O
56	.	N	O

1	CD-DP	N	O
2	was	N	O
3	given	N	O
4	intravenously	N	O
5	at	N	O
6	a	N	O
7	dose	N	O
8	of	N	O
9	3	N	O
10	mg/m	N	O
11	(	N	O
12	2	N	O
13	)	N	O
14	on	N	O
15	days	N	O
16	1-5	N	O
17	and	N	O
18	days	N	O
19	8-12	N	O
20	,	N	O
21	and	N	O
22	then	N	O
23	at	N	O
24	a	N	O
25	dose	N	O
26	of	N	O
27	7	N	O
28	mg/m	N	O
29	(	N	O
30	2	N	O
31	)	N	O
32	twice	N	O
33	a	N	O
34	week	N	O
35	.	N	O

1	Three	N	O
2	patients	N	O
3	were	N	O
4	excluded	N	O
5	from	N	O
6	the	N	O
7	trial	N	O
8	.	N	O

1	The	N	I-Premise
2	response	N	I-Premise
3	rate	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	5-FU+low-dose	N	I-Premise
7	CDDP	N	I-Premise
8	arm	N	I-Premise
9	(	N	I-Premise
10	n=75	N	I-Premise
11	)	N	I-Premise
12	was	N	I-Premise
13	significantly	N	I-Premise
14	higher	N	I-Premise
15	than	N	I-Premise
16	that	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	5-FU	N	I-Premise
20	arm	N	I-Premise
21	(	N	I-Premise
22	n=77	N	I-Premise
23	)	N	I-Premise
24	(	N	I-Premise
25	25.3	N	I-Premise
26	%	N	I-Premise
27	vs.	N	I-Premise
28	11.7	N	I-Premise
29	%	N	I-Premise
30	;	N	I-Premise
31	P	N	I-Premise
32	=	N	I-Premise
33	0.037	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	median	N	I-Premise
9	overall	N	I-Premise
10	survival	N	I-Premise
11	time	N	I-Premise
12	between	N	I-Premise
13	the	N	I-Premise
14	5-FU+low-dose	N	I-Premise
15	CDDP	N	I-Premise
16	arm	N	I-Premise
17	and	N	I-Premise
18	the	N	I-Premise
19	5-FU	N	I-Premise
20	arm	N	I-Premise
21	(	N	I-Premise
22	479	N	I-Premise
23	and	N	I-Premise
24	491	N	I-Premise
25	days	N	I-Premise
26	,	N	I-Premise
27	respectively	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Grades	N	I-Premise
2	3/4	N	I-Premise
3	toxicities	N	I-Premise
4	occurred	N	I-Premise
5	infrequently	N	I-Premise
6	in	N	I-Premise
7	both	N	I-Premise
8	arms	N	I-Premise
9	.	N	I-Premise

1	The	N	I-Premise
2	quality	N	I-Premise
3	of	N	I-Premise
4	life	N	I-Premise
5	was	N	I-Premise
6	almost	N	I-Premise
7	the	N	I-Premise
8	same	N	I-Premise
9	between	N	I-Premise
10	the	N	I-Premise
11	arms	N	I-Premise
12	.	N	O

1	Low-dose	N	I-Claim
2	CDDP	N	I-Claim
3	improved	N	I-Claim
4	the	N	I-Claim
5	response	N	I-Claim
6	rate	N	I-Claim
7	while	N	I-Claim
8	keeping	N	I-Claim
9	toxicities	N	I-Claim
10	within	N	I-Claim
11	clinically	N	I-Claim
12	acceptable	N	I-Claim
13	limits	N	I-Claim
14	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	this	N	I-Claim
4	combined	N	I-Claim
5	treatment	N	I-Claim
6	did	N	I-Claim
7	not	N	I-Claim
8	confer	N	I-Claim
9	a	N	I-Claim
10	survival	N	I-Claim
11	advantage	N	I-Claim
12	over	N	I-Claim
13	treatment	N	I-Claim
14	with	N	I-Claim
15	continuous	N	I-Claim
16	infusion	N	I-Claim
17	of	N	I-Claim
18	5-FU	N	I-Claim
19	alone	N	I-Claim
20	for	N	I-Claim
21	patients	N	I-Claim
22	with	N	I-Claim
23	far-advanced	N	I-Claim
24	CRC	N	I-Claim
25	;	N	I-Claim
26	that	N	I-Claim
27	might	N	I-Claim
28	be	N	I-Claim
29	attributable	N	I-Claim
30	to	N	I-Claim
31	the	N	I-Claim
32	short	N	I-Claim
33	CDDP	N	I-Claim
34	administration	N	I-Claim
35	setting	N	I-Claim
36	of	N	I-Claim
37	12	N	I-Claim
38	weeks	N	I-Claim
39	.	N	I-Claim

1	The	N	O
2	impact	N	O
3	of	N	O
4	psychotherapeutic	N	O
5	support	N	O
6	on	N	O
7	survival	N	O
8	for	N	O
9	patients	N	O
10	with	N	O
11	gastrointestinal	N	O
12	cancer	N	O
13	undergoing	N	O
14	surgery	N	O
15	was	N	O
16	studied	N	O
17	.	N	O

1	A	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	was	N	O
6	conducted	N	O
7	in	N	O
8	cooperation	N	O
9	with	N	O
10	the	N	O
11	Departments	N	O
12	of	N	O
13	General	N	O
14	Surgery	N	O
15	and	N	O
16	Medical	N	O
17	Psychology	N	O
18	,	N	O
19	University	N	O
20	Hospital	N	O
21	of	N	O
22	Hamburg	N	O
23	,	N	O
24	Germany	N	O
25	,	N	O
26	from	N	O
27	January	N	O
28	1991	N	O
29	to	N	O
30	January	N	O
31	1993	N	O
32	.	N	O

1	Consenting	N	O
2	patients	N	O
3	(	N	O
4	N	N	O
5	=	N	O
6	271	N	O
7	)	N	O
8	with	N	O
9	a	N	O
10	preliminary	N	O
11	diagnosis	N	O
12	of	N	O
13	cancer	N	O
14	of	N	O
15	the	N	O
16	esophagus	N	O
17	,	N	O
18	stomach	N	O
19	,	N	O
20	liver/gallbladder	N	O
21	,	N	O
22	pancreas	N	O
23	,	N	O
24	or	N	O
25	colon/rectum	N	O
26	were	N	O
27	stratified	N	O
28	by	N	O
29	sex	N	O
30	and	N	O
31	randomly	N	O
32	assigned	N	O
33	to	N	O
34	a	N	O
35	control	N	O
36	group	N	O
37	that	N	O
38	received	N	O
39	standard	N	O
40	care	N	O
41	as	N	O
42	provided	N	O
43	on	N	O
44	the	N	O
45	surgical	N	O
46	wards	N	O
47	,	N	O
48	or	N	O
49	to	N	O
50	an	N	O
51	experimental	N	O
52	group	N	O
53	that	N	O
54	received	N	O
55	formal	N	O
56	psychotherapeutic	N	O
57	support	N	O
58	in	N	O
59	addition	N	O
60	to	N	O
61	routine	N	O
62	care	N	O
63	during	N	O
64	the	N	O
65	hospital	N	O
66	stay	N	O
67	.	N	O

1	From	N	O
2	June	N	O
3	2003	N	O
4	to	N	O
5	December	N	O
6	2003	N	O
7	,	N	O
8	the	N	O
9	10-year	N	O
10	follow-up	N	O
11	was	N	O
12	conducted	N	O
13	.	N	O

1	Survival	N	O
2	status	N	O
3	for	N	O
4	all	N	O
5	patients	N	O
6	was	N	O
7	determined	N	O
8	from	N	O
9	our	N	O
10	own	N	O
11	records	N	O
12	and	N	O
13	from	N	O
14	three	N	O
15	external	N	O
16	sources	N	O
17	:	N	O
18	the	N	O
19	Hamburg	N	O
20	cancer	N	O
21	registry	N	O
22	,	N	O
23	family	N	O
24	doctors	N	O
25	,	N	O
26	and	N	O
27	the	N	O
28	general	N	O
29	citizen	N	O
30	registration	N	O
31	offices	N	O
32	.	N	O

1	Kaplan-Meier	N	I-Premise
2	survival	N	I-Premise
3	curves	N	I-Premise
4	demonstrated	N	I-Premise
5	better	N	I-Premise
6	survival	N	I-Premise
7	for	N	I-Premise
8	the	N	I-Premise
9	experimental	N	I-Premise
10	group	N	I-Premise
11	than	N	I-Premise
12	the	N	I-Premise
13	control	N	I-Premise
14	group	N	I-Premise
15	.	N	I-Premise

1	The	N	I-Premise
2	unadjusted	N	I-Premise
3	significance	N	I-Premise
4	level	N	I-Premise
5	for	N	I-Premise
6	group	N	I-Premise
7	differences	N	I-Premise
8	was	N	I-Premise
9	P	N	I-Premise
10	=	N	I-Premise
11	.0006	N	I-Premise
12	for	N	I-Premise
13	survival	N	I-Premise
14	to	N	I-Premise
15	10	N	I-Premise
16	years	N	I-Premise
17	.	N	I-Premise

1	Cox	N	I-Premise
2	regression	N	I-Premise
3	models	N	I-Premise
4	that	N	I-Premise
5	took	N	I-Premise
6	TNM	N	I-Premise
7	staging	N	I-Premise
8	or	N	I-Premise
9	the	N	I-Premise
10	residual	N	I-Premise
11	tumor	N	I-Premise
12	classification	N	I-Premise
13	and	N	I-Premise
14	tumor	N	I-Premise
15	site	N	I-Premise
16	into	N	I-Premise
17	account	N	I-Premise
18	also	N	I-Premise
19	found	N	I-Premise
20	significant	N	I-Premise
21	differences	N	I-Premise
22	at	N	I-Premise
23	10	N	I-Premise
24	years	N	I-Premise
25	.	N	I-Premise

1	Secondary	N	I-Premise
2	analyses	N	I-Premise
3	found	N	I-Premise
4	that	N	I-Premise
5	differences	N	I-Premise
6	in	N	I-Premise
7	favor	N	I-Premise
8	of	N	I-Premise
9	the	N	I-Premise
10	experimental	N	I-Premise
11	group	N	I-Premise
12	occurred	N	I-Premise
13	in	N	I-Premise
14	patients	N	I-Premise
15	with	N	I-Premise
16	stomach	N	I-Premise
17	,	N	I-Premise
18	pancreatic	N	I-Premise
19	,	N	I-Premise
20	primary	N	I-Premise
21	liver	N	I-Premise
22	,	N	I-Premise
23	or	N	I-Premise
24	colorectal	N	I-Premise
25	cancer	N	I-Premise
26	.	N	I-Premise

1	The	N	I-Claim
2	results	N	I-Claim
3	of	N	I-Claim
4	this	N	I-Claim
5	study	N	I-Claim
6	indicate	N	I-Claim
7	that	N	I-Claim
8	patients	N	I-Claim
9	with	N	I-Claim
10	gastrointestinal	N	I-Claim
11	cancer	N	I-Claim
12	,	N	I-Claim
13	who	N	I-Claim
14	undergo	N	I-Claim
15	surgery	N	I-Claim
16	for	N	I-Claim
17	stomach	N	I-Claim
18	,	N	I-Claim
19	pancreatic	N	I-Claim
20	,	N	I-Claim
21	primary	N	I-Claim
22	liver	N	I-Claim
23	,	N	I-Claim
24	or	N	I-Claim
25	colorectal	N	I-Claim
26	cancer	N	I-Claim
27	,	N	I-Claim
28	benefit	N	I-Claim
29	from	N	I-Claim
30	a	N	I-Claim
31	formal	N	I-Claim
32	program	N	I-Claim
33	of	N	I-Claim
34	psychotherapeutic	N	I-Claim
35	support	N	I-Claim
36	during	N	I-Claim
37	the	N	I-Claim
38	inpatient	N	I-Claim
39	hospital	N	I-Claim
40	stay	N	I-Claim
41	in	N	I-Claim
42	terms	N	I-Claim
43	of	N	I-Claim
44	long-term	N	I-Claim
45	survival	N	I-Claim
46	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	long	N	O
5	term	N	O
6	risks	N	O
7	and	N	O
8	benefits	N	O
9	of	N	O
10	hormone	N	O
11	replacement	N	O
12	therapy	N	O
13	(	N	O
14	combined	N	O
15	hormone	N	O
16	therapy	N	O
17	versus	N	O
18	placebo	N	O
19	,	N	O
20	and	N	O
21	oestrogen	N	O
22	alone	N	O
23	versus	N	O
24	combined	N	O
25	hormone	N	O
26	therapy	N	O
27	)	N	O
28	.	N	O

1	Multicentre	N	O
2	,	N	O
3	randomised	N	O
4	,	N	O
5	placebo	N	O
6	controlled	N	O
7	,	N	O
8	double	N	O
9	blind	N	O
10	trial	N	O
11	.	N	O

1	General	N	O
2	practices	N	O
3	in	N	O
4	UK	N	O
5	(	N	O
6	384	N	O
7	)	N	O
8	,	N	O
9	Australia	N	O
10	(	N	O
11	91	N	O
12	)	N	O
13	,	N	O
14	and	N	O
15	New	N	O
16	Zealand	N	O
17	(	N	O
18	24	N	O
19	)	N	O
20	.	N	O

1	Postmenopausal	N	O
2	women	N	O
3	aged	N	O
4	50-69	N	O
5	years	N	O
6	at	N	O
7	randomisation	N	O
8	.	N	O

1	At	N	O
2	early	N	O
3	closure	N	O
4	of	N	O
5	the	N	O
6	trial	N	O
7	,	N	O
8	56,583	N	O
9	had	N	O
10	been	N	O
11	screened	N	O
12	,	N	O
13	8980	N	O
14	entered	N	O
15	run-in	N	O
16	,	N	O
17	and	N	O
18	5692	N	O
19	(	N	O
20	26	N	O
21	%	N	O
22	of	N	O
23	target	N	O
24	of	N	O
25	22,300	N	O
26	)	N	O
27	started	N	O
28	treatment	N	O
29	.	N	O

1	Oestrogen	N	O
2	only	N	O
3	therapy	N	O
4	(	N	O
5	conjugated	N	O
6	equine	N	O
7	oestrogens	N	O
8	0.625	N	O
9	mg	N	O
10	orally	N	O
11	daily	N	O
12	)	N	O
13	or	N	O
14	combined	N	O
15	hormone	N	O
16	therapy	N	O
17	(	N	O
18	conjugated	N	O
19	equine	N	O
20	oestrogens	N	O
21	plus	N	O
22	medroxyprogesterone	N	O
23	acetate	N	O
24	2.5/5.0	N	O
25	mg	N	O
26	orally	N	O
27	daily	N	O
28	)	N	O
29	.	N	O

1	Ten	N	O
2	years	N	O
3	of	N	O
4	treatment	N	O
5	planned	N	O
6	.	N	O

1	major	N	O
2	cardiovascular	N	O
3	disease	N	O
4	,	N	O
5	osteoporotic	N	O
6	fractures	N	O
7	,	N	O
8	and	N	O
9	breast	N	O
10	cancer	N	O
11	.	N	O

1	other	N	O
2	cancers	N	O
3	,	N	O
4	death	N	O
5	from	N	O
6	all	N	O
7	causes	N	O
8	,	N	O
9	venous	N	O
10	thromboembolism	N	O
11	,	N	O
12	cerebrovascular	N	O
13	disease	N	O
14	,	N	O
15	dementia	N	O
16	,	N	O
17	and	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	.	N	O

1	The	N	O
2	trial	N	O
3	was	N	O
4	prematurely	N	O
5	closed	N	O
6	during	N	O
7	recruitment	N	O
8	,	N	O
9	after	N	O
10	a	N	O
11	median	N	O
12	follow-up	N	O
13	of	N	O
14	11.9	N	O
15	months	N	O
16	(	N	O
17	interquartile	N	O
18	range	N	O
19	7.1-19.6	N	O
20	,	N	O
21	total	N	O
22	6498	N	O
23	women	N	O
24	years	N	O
25	)	N	O
26	in	N	O
27	those	N	O
28	enrolled	N	O
29	,	N	O
30	after	N	O
31	the	N	O
32	publication	N	O
33	of	N	O
34	early	N	O
35	results	N	O
36	from	N	O
37	the	N	O
38	women	N	O
39	's	N	O
40	health	N	O
41	initiative	N	O
42	study	N	O
43	.	N	O

1	The	N	O
2	mean	N	O
3	age	N	O
4	of	N	O
5	randomised	N	O
6	women	N	O
7	was	N	O
8	62.8	N	O
9	(	N	O
10	SD	N	O
11	4.8	N	O
12	)	N	O
13	years	N	O
14	.	N	O

1	When	N	I-Premise
2	combined	N	I-Premise
3	hormone	N	I-Premise
4	therapy	N	I-Premise
5	(	N	I-Premise
6	n=2196	N	I-Premise
7	)	N	I-Premise
8	was	N	I-Premise
9	compared	N	I-Premise
10	with	N	I-Premise
11	placebo	N	I-Premise
12	(	N	I-Premise
13	n=2189	N	I-Premise
14	)	N	I-Premise
15	,	N	I-Premise
16	there	N	I-Premise
17	was	N	I-Premise
18	a	N	I-Premise
19	significant	N	I-Premise
20	increase	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	number	N	I-Premise
24	of	N	I-Premise
25	major	N	I-Premise
26	cardiovascular	N	I-Premise
27	events	N	I-Premise
28	(	N	I-Premise
29	7	N	I-Premise
30	v	N	I-Premise
31	0	N	I-Premise
32	,	N	I-Premise
33	P=0.016	N	I-Premise
34	)	N	I-Premise
35	and	N	I-Premise
36	venous	N	I-Premise
37	thromboembolisms	N	I-Premise
38	(	N	I-Premise
39	22	N	I-Premise
40	v	N	I-Premise
41	3	N	I-Premise
42	,	N	I-Premise
43	hazard	N	I-Premise
44	ratio	N	I-Premise
45	7.36	N	I-Premise
46	(	N	I-Premise
47	95	N	I-Premise
48	%	N	I-Premise
49	CI	N	I-Premise
50	2.20	N	I-Premise
51	to	N	I-Premise
52	24.60	N	I-Premise
53	)	N	I-Premise
54	)	N	I-Premise
55	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	differences	N	I-Premise
7	in	N	I-Premise
8	numbers	N	I-Premise
9	of	N	I-Premise
10	breast	N	I-Premise
11	or	N	I-Premise
12	other	N	I-Premise
13	cancers	N	I-Premise
14	(	N	I-Premise
15	22	N	I-Premise
16	v	N	I-Premise
17	25	N	I-Premise
18	,	N	I-Premise
19	hazard	N	I-Premise
20	ratio	N	I-Premise
21	0.88	N	I-Premise
22	(	N	I-Premise
23	0.49	N	I-Premise
24	to	N	I-Premise
25	1.56	N	I-Premise
26	)	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	cerebrovascular	N	I-Premise
30	events	N	I-Premise
31	(	N	I-Premise
32	14	N	I-Premise
33	v	N	I-Premise
34	19	N	I-Premise
35	,	N	I-Premise
36	0.73	N	I-Premise
37	(	N	I-Premise
38	0.37	N	I-Premise
39	to	N	I-Premise
40	1.46	N	I-Premise
41	)	N	I-Premise
42	)	N	I-Premise
43	,	N	I-Premise
44	fractures	N	I-Premise
45	(	N	I-Premise
46	40	N	I-Premise
47	v	N	I-Premise
48	58	N	I-Premise
49	,	N	I-Premise
50	0.69	N	I-Premise
51	(	N	I-Premise
52	0.46	N	I-Premise
53	to	N	I-Premise
54	1.03	N	I-Premise
55	)	N	I-Premise
56	)	N	I-Premise
57	,	N	I-Premise
58	and	N	I-Premise
59	overall	N	I-Premise
60	deaths	N	I-Premise
61	(	N	I-Premise
62	8	N	I-Premise
63	v	N	I-Premise
64	5	N	I-Premise
65	,	N	I-Premise
66	1.60	N	I-Premise
67	(	N	I-Premise
68	0.52	N	I-Premise
69	to	N	I-Premise
70	4.89	N	I-Premise
71	)	N	I-Premise
72	)	N	I-Premise
73	.	N	I-Premise

1	Comparison	N	I-Premise
2	of	N	I-Premise
3	combined	N	I-Premise
4	hormone	N	I-Premise
5	therapy	N	I-Premise
6	(	N	I-Premise
7	n=815	N	I-Premise
8	)	N	I-Premise
9	versus	N	I-Premise
10	oestrogen	N	I-Premise
11	therapy	N	I-Premise
12	(	N	I-Premise
13	n=826	N	I-Premise
14	)	N	I-Premise
15	outcomes	N	I-Premise
16	revealed	N	I-Premise
17	no	N	I-Premise
18	significant	N	I-Premise
19	differences	N	I-Premise
20	.	N	I-Premise

1	Hormone	N	I-Claim
2	replacement	N	I-Claim
3	therapy	N	I-Claim
4	increases	N	I-Claim
5	cardiovascular	N	I-Claim
6	and	N	I-Claim
7	thromboembolic	N	I-Claim
8	risk	N	I-Claim
9	when	N	I-Claim
10	started	N	I-Claim
11	many	N	I-Claim
12	years	N	I-Claim
13	after	N	I-Claim
14	the	N	I-Claim
15	menopause	N	I-Claim
16	.	N	I-Claim

1	The	N	I-Claim
2	results	N	I-Claim
3	are	N	I-Claim
4	consistent	N	I-Claim
5	with	N	I-Claim
6	the	N	I-Claim
7	findings	N	I-Claim
8	of	N	I-Claim
9	the	N	I-Claim
10	women	N	I-Claim
11	's	N	I-Claim
12	health	N	I-Claim
13	initiative	N	I-Claim
14	study	N	I-Claim
15	and	N	I-Claim
16	secondary	N	I-Claim
17	prevention	N	I-Claim
18	studies	N	I-Claim
19	.	N	I-Claim

1	Research	N	I-Claim
2	is	N	I-Claim
3	needed	N	I-Claim
4	to	N	I-Claim
5	assess	N	I-Claim
6	the	N	I-Claim
7	long	N	I-Claim
8	term	N	I-Claim
9	risks	N	I-Claim
10	and	N	I-Claim
11	benefits	N	I-Claim
12	of	N	I-Claim
13	starting	N	I-Claim
14	hormone	N	I-Claim
15	replacement	N	I-Claim
16	therapy	N	I-Claim
17	near	N	I-Claim
18	the	N	I-Claim
19	menopause	N	I-Claim
20	,	N	I-Claim
21	when	N	I-Claim
22	the	N	I-Claim
23	effect	N	I-Claim
24	may	N	I-Claim
25	be	N	I-Claim
26	different	N	I-Claim
27	.	N	I-Claim

1	It	N	I-Claim
2	has	N	I-Claim
3	been	N	I-Claim
4	shown	N	I-Claim
5	that	N	I-Claim
6	nonpharmacologic	N	I-Claim
7	interventions	N	I-Claim
8	are	N	I-Claim
9	effective	N	I-Claim
10	management	N	I-Claim
11	techniques	N	I-Claim
12	for	N	I-Claim
13	cancer-related	N	I-Claim
14	fatigue	N	I-Claim
15	(	N	I-Claim
16	CRF	N	I-Claim
17	)	N	I-Claim
18	in	N	I-Claim
19	cancer	N	I-Claim
20	survivors	N	I-Claim
21	.	N	I-Claim

1	However	N	O
2	,	N	O
3	few	N	O
4	studies	N	O
5	have	N	O
6	investigated	N	O
7	their	N	O
8	effectiveness	N	O
9	in	N	O
10	patients	N	O
11	who	N	O
12	are	N	O
13	receiving	N	O
14	chemotherapy	N	O
15	.	N	O

1	In	N	O
2	this	N	O
3	study	N	O
4	,	N	O
5	the	N	O
6	authors	N	O
7	tested	N	O
8	the	N	O
9	effectiveness	N	O
10	of	N	O
11	a	N	O
12	brief	N	O
13	behaviorally	N	O
14	oriented	N	O
15	intervention	N	O
16	in	N	O
17	reducing	N	O
18	CRF	N	O
19	and	N	O
20	improving	N	O
21	physical	N	O
22	function	N	O
23	and	N	O
24	associated	N	O
25	distress	N	O
26	in	N	O
27	individuals	N	O
28	who	N	O
29	were	N	O
30	receiving	N	O
31	chemotherapy	N	O
32	.	N	O

1	For	N	O
2	this	N	O
3	randomized	N	O
4	controlled	N	O
5	trial	N	O
6	,	N	O
7	60	N	O
8	patients	N	O
9	with	N	O
10	cancer	N	O
11	were	N	O
12	recruited	N	O
13	and	N	O
14	received	N	O
15	either	N	O
16	usual	N	O
17	care	N	O
18	or	N	O
19	the	N	O
20	intervention	N	O
21	.	N	O

1	The	N	O
2	intervention	N	O
3	was	N	O
4	delivered	N	O
5	on	N	O
6	an	N	O
7	individual	N	O
8	basis	N	O
9	on	N	O
10	3	N	O
11	occasions	N	O
12	over	N	O
13	a	N	O
14	period	N	O
15	from	N	O
16	9	N	O
17	weeks	N	O
18	to	N	O
19	12	N	O
20	weeks	N	O
21	,	N	O
22	and	N	O
23	the	N	O
24	objective	N	O
25	of	N	O
26	the	N	O
27	intervention	N	O
28	was	N	O
29	to	N	O
30	alter	N	O
31	fatigue-related	N	O
32	thoughts	N	O
33	and	N	O
34	behavior	N	O
35	.	N	O

1	Primary	N	O
2	outcomes	N	O
3	were	N	O
4	assessed	N	O
5	as	N	O
6	follows	N	O
7	:	N	O
8	CRF	N	O
9	using	N	O
10	the	N	O
11	Visual	N	O
12	Analogue	N	O
13	Scale-Global	N	O
14	Fatigue	N	O
15	;	N	O
16	physical	N	O
17	functioning	N	O
18	using	N	O
19	the	N	O
20	European	N	O
21	Organization	N	O
22	for	N	O
23	Research	N	O
24	and	N	O
25	Treatment	N	O
26	of	N	O
27	Cancer	N	O
28	Quality-of-Life	N	O
29	Core	N	O
30	30	N	O
31	Questionnaire	N	O
32	,	N	O
33	and	N	O
34	CRF-associated	N	O
35	distress	N	O
36	using	N	O
37	the	N	O
38	Fatigue	N	O
39	Outcome	N	O
40	Measure	N	O
41	.	N	O

1	Assessments	N	O
2	were	N	O
3	made	N	O
4	on	N	O
5	4	N	O
6	occasions	N	O
7	:	N	O
8	at	N	O
9	baseline	N	O
10	(	N	O
11	T0	N	O
12	)	N	O
13	,	N	O
14	at	N	O
15	the	N	O
16	end	N	O
17	of	N	O
18	chemotherapy	N	O
19	(	N	O
20	T1	N	O
21	)	N	O
22	,	N	O
23	1	N	O
24	month	N	O
25	after	N	O
26	chemotherapy	N	O
27	(	N	O
28	T2	N	O
29	)	N	O
30	,	N	O
31	and	N	O
32	9	N	O
33	months	N	O
34	after	N	O
35	recruitment	N	O
36	(	N	O
37	T3	N	O
38	)	N	O
39	.	N	O

1	Normally	N	O
2	distributed	N	O
3	data	N	O
4	were	N	O
5	analyzed	N	O
6	using	N	O
7	t	N	O
8	tests	N	O
9	and	N	O
10	random-slope/random-intercept	N	O
11	mixed	N	O
12	models	N	O
13	.	N	O

1	The	N	I-Premise
2	intervention	N	I-Premise
3	demonstrated	N	I-Premise
4	a	N	I-Premise
5	trend	N	I-Premise
6	toward	N	I-Premise
7	improved	N	I-Premise
8	CRF	N	I-Premise
9	,	N	I-Premise
10	although	N	I-Premise
11	this	N	I-Premise
12	effect	N	I-Premise
13	was	N	I-Premise
14	reduced	N	I-Premise
15	once	N	I-Premise
16	confounders	N	I-Premise
17	had	N	I-Premise
18	been	N	I-Premise
19	controlled	N	I-Premise
20	statistically	N	I-Premise
21	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	improvement	N	I-Premise
6	in	N	I-Premise
7	physical	N	I-Premise
8	functioning	N	I-Premise
9	(	N	I-Premise
10	coefficient	N	I-Premise
11	,	N	I-Premise
12	10.0	N	I-Premise
13	;	N	I-Premise
14	95	N	I-Premise
15	%	N	I-Premise
16	confidence	N	I-Premise
17	interval	N	I-Premise
18	,	N	I-Premise
19	2.5-17.5	N	I-Premise
20	;	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	.009	N	I-Premise
24	)	N	I-Premise
25	,	N	I-Premise
26	and	N	I-Premise
27	this	N	I-Premise
28	effect	N	I-Premise
29	remained	N	I-Premise
30	once	N	I-Premise
31	the	N	I-Premise
32	confounding	N	I-Premise
33	effects	N	I-Premise
34	of	N	I-Premise
35	mood	N	I-Premise
36	disturbance	N	I-Premise
37	and	N	I-Premise
38	comorbid	N	I-Premise
39	disorders	N	I-Premise
40	were	N	I-Premise
41	controlled	N	I-Premise
42	statistically	N	I-Premise
43	.	N	I-Premise

1	No	N	I-Premise
2	decrease	N	I-Premise
3	in	N	I-Premise
4	fatigue-related	N	I-Premise
5	distress	N	I-Premise
6	was	N	I-Premise
7	detected	N	I-Premise
8	.	N	I-Premise

1	The	N	I-Claim
2	behaviorally	N	I-Claim
3	oriented	N	I-Claim
4	intervention	N	I-Claim
5	brought	N	I-Claim
6	about	N	I-Claim
7	significant	N	I-Claim
8	improvements	N	I-Claim
9	in	N	I-Claim
10	physical	N	I-Claim
11	functioning	N	I-Claim
12	,	N	I-Claim
13	indicated	N	I-Claim
14	a	N	I-Claim
15	trend	N	I-Claim
16	toward	N	I-Claim
17	improved	N	I-Claim
18	CRF	N	I-Claim
19	,	N	I-Claim
20	but	N	I-Claim
21	detected	N	I-Claim
22	no	N	I-Claim
23	effect	N	I-Claim
24	for	N	I-Claim
25	fatigue-related	N	I-Claim
26	distress	N	I-Claim
27	.	N	I-Claim

1	Therapy	N	I-MajorClaim
2	of	N	I-MajorClaim
3	patients	N	I-MajorClaim
4	with	N	I-MajorClaim
5	advanced	N	I-MajorClaim
6	gastric	N	I-MajorClaim
7	or	N	I-MajorClaim
8	gastroesophageal	N	I-MajorClaim
9	junction	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	should	N	I-MajorClaim
12	provide	N	I-MajorClaim
13	symptom	N	I-MajorClaim
14	relief	N	I-MajorClaim
15	and	N	I-MajorClaim
16	improve	N	I-MajorClaim
17	quality	N	I-MajorClaim
18	of	N	I-MajorClaim
19	life	N	I-MajorClaim
20	(	N	I-MajorClaim
21	QOL	N	I-MajorClaim
22	)	N	I-MajorClaim
23	because	N	I-MajorClaim
24	most	N	I-MajorClaim
25	patients	N	I-MajorClaim
26	are	N	I-MajorClaim
27	symptomatic	N	I-MajorClaim
28	at	N	I-MajorClaim
29	baseline	N	I-MajorClaim
30	.	N	I-MajorClaim

1	Using	N	O
2	validated	N	O
3	instruments	N	O
4	,	N	O
5	we	N	O
6	prospectively	N	O
7	assessed	N	O
8	QOL	N	O
9	(	N	O
10	even	N	O
11	after	N	O
12	completion	N	O
13	of	N	O
14	protocol	N	O
15	treatment	N	O
16	)	N	O
17	as	N	O
18	one	N	O
19	of	N	O
20	the	N	O
21	secondary	N	O
22	end	N	O
23	points	N	O
24	of	N	O
25	the	N	O
26	V325	N	O
27	phase	N	O
28	III	N	O
29	trial	N	O
30	.	N	O

1	Four	N	O
2	hundred	N	O
3	forty-five	N	O
4	patients	N	O
5	randomly	N	O
6	received	N	O
7	either	N	O
8	docetaxel	N	O
9	75	N	O
10	mg/m	N	O
11	(	N	O
12	2	N	O
13	)	N	O
14	and	N	O
15	cisplatin	N	O
16	75	N	O
17	mg/m	N	O
18	(	N	O
19	2	N	O
20	)	N	O
21	each	N	O
22	on	N	O
23	day	N	O
24	1	N	O
25	plus	N	O
26	fluorouracil	N	O
27	750	N	O
28	mg/m	N	O
29	(	N	O
30	2	N	O
31	)	N	O
32	/d	N	O
33	continuous	N	O
34	infusion	N	O
35	on	N	O
36	days	N	O
37	1	N	O
38	to	N	O
39	5	N	O
40	every	N	O
41	3	N	O
42	weeks	N	O
43	(	N	O
44	DCF	N	O
45	)	N	O
46	or	N	O
47	cisplatin	N	O
48	100	N	O
49	mg/m	N	O
50	(	N	O
51	2	N	O
52	)	N	O
53	on	N	O
54	day	N	O
55	1	N	O
56	plus	N	O
57	fluorouracil	N	O
58	1,000	N	O
59	mg/m	N	O
60	(	N	O
61	2	N	O
62	)	N	O
63	/d	N	O
64	continuous	N	O
65	infusion	N	O
66	on	N	O
67	days	N	O
68	1	N	O
69	to	N	O
70	5	N	O
71	every	N	O
72	4	N	O
73	weeks	N	O
74	(	N	O
75	CF	N	O
76	)	N	O
77	.	N	O

1	The	N	O
2	European	N	O
3	Organisation	N	O
4	for	N	O
5	Research	N	O
6	and	N	O
7	Treatment	N	O
8	of	N	O
9	Cancer	N	O
10	Quality	N	O
11	of	N	O
12	Life	N	O
13	Questionnaire	N	O
14	C30	N	O
15	(	N	O
16	EORTC	N	O
17	QLQ-C30	N	O
18	)	N	O
19	and	N	O
20	,	N	O
21	where	N	O
22	available	N	O
23	,	N	O
24	the	N	O
25	EuroQOL	N	O
26	EQ-5D	N	O
27	questionnaire	N	O
28	were	N	O
29	administered	N	O
30	every	N	O
31	8	N	O
32	weeks	N	O
33	from	N	O
34	baseline	N	O
35	until	N	O
36	progression	N	O
37	and	N	O
38	then	N	O
39	every	N	O
40	3	N	O
41	months	N	O
42	.	N	O

1	Time	N	O
2	to	N	O
3	definitive	N	O
4	deterioration	N	O
5	of	N	O
6	QOL	N	O
7	parameters	N	O
8	was	N	O
9	analyzed	N	O
10	.	N	O

1	The	N	O
2	proportions	N	O
3	of	N	O
4	patients	N	O
5	having	N	O
6	assessable	N	O
7	EORTC	N	O
8	QLQ-C30	N	O
9	and	N	O
10	EQ-5D	N	O
11	questionnaires	N	O
12	at	N	O
13	baseline	N	O
14	were	N	O
15	86.0	N	O
16	%	N	O
17	and	N	O
18	78.7	N	O
19	%	N	O
20	with	N	O
21	DCF	N	O
22	,	N	O
23	respectively	N	O
24	,	N	O
25	and	N	O
26	89.7	N	O
27	%	N	O
28	and	N	O
29	92.8	N	O
30	%	N	O
31	with	N	O
32	CF	N	O
33	,	N	O
34	respectively	N	O
35	.	N	O

1	Time	N	I-Premise
2	to	N	I-Premise
3	5	N	I-Premise
4	%	N	I-Premise
5	deterioration	N	I-Premise
6	of	N	I-Premise
7	global	N	I-Premise
8	health	N	I-Premise
9	status	N	I-Premise
10	(	N	I-Premise
11	primary	N	I-Premise
12	end	N	I-Premise
13	point	N	I-Premise
14	)	N	I-Premise
15	significantly	N	I-Premise
16	favored	N	I-Premise
17	DCF	N	I-Premise
18	over	N	I-Premise
19	CF	N	I-Premise
20	(	N	I-Premise
21	log-rank	N	I-Premise
22	test	N	I-Premise
23	,	N	I-Premise
24	P	N	I-Premise
25	=	N	I-Premise
26	.01	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	QOL	N	I-Premise
2	was	N	I-Premise
3	preserved	N	I-Premise
4	longer	N	I-Premise
5	for	N	I-Premise
6	patients	N	I-Premise
7	on	N	I-Premise
8	DCF	N	I-Premise
9	than	N	I-Premise
10	those	N	I-Premise
11	on	N	I-Premise
12	CF	N	I-Premise
13	for	N	I-Premise
14	all	N	I-Premise
15	time	N	I-Premise
16	to	N	I-Premise
17	deterioration	N	I-Premise
18	analyses	N	I-Premise
19	,	N	I-Premise
20	demonstrating	N	I-Premise
21	the	N	I-Premise
22	statistical	N	I-Premise
23	superiority	N	I-Premise
24	of	N	I-Premise
25	DCF	N	I-Premise
26	compared	N	I-Premise
27	with	N	I-Premise
28	CF	N	I-Premise
29	.	N	I-Premise

1	V325	N	O
2	represents	N	O
3	the	N	O
4	largest	N	O
5	trial	N	O
6	with	N	O
7	the	N	O
8	longest	N	O
9	prospectively	N	O
10	controlled	N	O
11	evaluations	N	O
12	of	N	O
13	QOL	N	O
14	during	N	O
15	protocol	N	O
16	chemotherapy	N	O
17	and	N	O
18	follow-up	N	O
19	in	N	O
20	patients	N	O
21	with	N	O
22	advanced	N	O
23	gastric	N	O
24	or	N	O
25	gastroesophageal	N	O
26	junction	N	O
27	cancer	N	O
28	.	N	O

1	In	N	I-Claim
2	V325	N	I-Claim
3	,	N	I-Claim
4	advanced	N	I-Claim
5	gastric	N	I-Claim
6	or	N	I-Claim
7	gastroesophageal	N	I-Claim
8	junction	N	I-Claim
9	cancer	N	I-Claim
10	patients	N	I-Claim
11	receiving	N	I-Claim
12	DCF	N	I-Claim
13	not	N	I-Claim
14	only	N	I-Claim
15	had	N	I-Claim
16	statistically	N	I-Claim
17	improved	N	I-Claim
18	overall	N	I-Claim
19	survival	N	I-Claim
20	and	N	I-Claim
21	time	N	I-Claim
22	to	N	I-Claim
23	tumor-progression	N	I-Claim
24	,	N	I-Claim
25	but	N	I-Claim
26	they	N	I-Claim
27	also	N	I-Claim
28	had	N	I-Claim
29	better	N	I-Claim
30	preservation	N	I-Claim
31	of	N	I-Claim
32	QOL	N	I-Claim
33	compared	N	I-Claim
34	with	N	I-Claim
35	patients	N	I-Claim
36	receiving	N	I-Claim
37	CF	N	I-Claim
38	.	N	I-Claim

1	This	N	O
2	randomized	N	O
3	phase	N	O
4	II	N	O
5	trial	N	O
6	evaluated	N	O
7	two	N	O
8	docetaxel-based	N	O
9	regimens	N	O
10	to	N	O
11	see	N	O
12	which	N	O
13	would	N	O
14	be	N	O
15	most	N	O
16	promising	N	O
17	according	N	O
18	to	N	O
19	overall	N	O
20	response	N	O
21	rate	N	O
22	(	N	O
23	ORR	N	O
24	)	N	O
25	for	N	O
26	comparison	N	O
27	in	N	O
28	a	N	O
29	phase	N	O
30	III	N	O
31	trial	N	O
32	with	N	O
33	epirubicin-cisplatin-fluorouracil	N	O
34	(	N	O
35	ECF	N	O
36	)	N	O
37	as	N	O
38	first-line	N	O
39	advanced	N	O
40	gastric	N	O
41	cancer	N	O
42	therapy	N	O
43	.	N	O

1	Chemotherapy-naïve	N	O
2	patients	N	O
3	with	N	O
4	measurable	N	O
5	unresectable	N	O
6	and/or	N	O
7	metastatic	N	O
8	gastric	N	O
9	carcinoma	N	O
10	,	N	O
11	a	N	O
12	performance	N	O
13	status	N	O
14	<	N	O
15	or=	N	O
16	1	N	O
17	,	N	O
18	and	N	O
19	adequate	N	O
20	hematologic	N	O
21	,	N	O
22	hepatic	N	O
23	,	N	O
24	and	N	O
25	renal	N	O
26	function	N	O
27	randomly	N	O
28	received	N	O
29	<	N	O
30	or=	N	O
31	eight	N	O
32	3-weekly	N	O
33	cycles	N	O
34	of	N	O
35	ECF	N	O
36	(	N	O
37	epirubicin	N	O
38	50	N	O
39	mg/m	N	O
40	(	N	O
41	2	N	O
42	)	N	O
43	on	N	O
44	day	N	O
45	1	N	O
46	,	N	O
47	cisplatin	N	O
48	60	N	O
49	mg/m	N	O
50	(	N	O
51	2	N	O
52	)	N	O
53	on	N	O
54	day	N	O
55	1	N	O
56	,	N	O
57	and	N	O
58	fluorouracil	N	O
59	[	N	O
60	FU	N	O
61	]	N	O
62	200	N	O
63	mg/m	N	O
64	(	N	O
65	2	N	O
66	)	N	O
67	/d	N	O
68	on	N	O
69	days	N	O
70	1	N	O
71	to	N	O
72	21	N	O
73	)	N	O
74	,	N	O
75	TC	N	O
76	(	N	O
77	docetaxel	N	O
78	initially	N	O
79	85	N	O
80	mg/m	N	O
81	(	N	O
82	2	N	O
83	)	N	O
84	on	N	O
85	day	N	O
86	1	N	O
87	[	N	O
88	later	N	O
89	reduced	N	O
90	to	N	O
91	75	N	O
92	mg/m	N	O
93	(	N	O
94	2	N	O
95	)	N	O
96	as	N	O
97	a	N	O
98	result	N	O
99	of	N	O
100	toxicity	N	O
101	]	N	O
102	and	N	O
103	cisplatin	N	O
104	75	N	O
105	mg/m	N	O
106	(	N	O
107	2	N	O
108	)	N	O
109	on	N	O
110	day	N	O
111	1	N	O
112	)	N	O
113	,	N	O
114	or	N	O
115	TCF	N	O
116	(	N	O
117	TC	N	O
118	plus	N	O
119	FU	N	O
120	300	N	O
121	mg/m	N	O
122	(	N	O
123	2	N	O
124	)	N	O
125	/d	N	O
126	on	N	O
127	days	N	O
128	1	N	O
129	to	N	O
130	14	N	O
131	)	N	O
132	.	N	O

1	Study	N	O
2	objectives	N	O
3	included	N	O
4	response	N	O
5	(	N	O
6	primary	N	O
7	)	N	O
8	,	N	O
9	survival	N	O
10	,	N	O
11	toxicity	N	O
12	,	N	O
13	and	N	O
14	quality	N	O
15	of	N	O
16	life	N	O
17	(	N	O
18	QOL	N	O
19	)	N	O
20	.	N	O

1	ORR	N	I-Premise
2	was	N	I-Premise
3	25.0	N	I-Premise
4	%	N	I-Premise
5	(	N	I-Premise
6	95	N	I-Premise
7	%	N	I-Premise
8	CI	N	I-Premise
9	,	N	I-Premise
10	13	N	I-Premise
11	%	N	I-Premise
12	to	N	I-Premise
13	41	N	I-Premise
14	%	N	I-Premise
15	)	N	I-Premise
16	for	N	I-Premise
17	ECF	N	I-Premise
18	,	N	I-Premise
19	18.5	N	I-Premise
20	%	N	I-Premise
21	(	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	,	N	I-Premise
26	9	N	I-Premise
27	%	N	I-Premise
28	to	N	I-Premise
29	34	N	I-Premise
30	%	N	I-Premise
31	)	N	I-Premise
32	for	N	I-Premise
33	TC	N	I-Premise
34	,	N	I-Premise
35	and	N	I-Premise
36	36.6	N	I-Premise
37	%	N	I-Premise
38	(	N	I-Premise
39	95	N	I-Premise
40	%	N	I-Premise
41	CI	N	I-Premise
42	,	N	I-Premise
43	23	N	I-Premise
44	%	N	I-Premise
45	to	N	I-Premise
46	53	N	I-Premise
47	%	N	I-Premise
48	)	N	I-Premise
49	for	N	I-Premise
50	TCF	N	I-Premise
51	(	N	I-Premise
52	n	N	I-Premise
53	=	N	I-Premise
54	119	N	I-Premise
55	)	N	I-Premise
56	.	N	I-Premise

1	Median	N	I-Premise
2	overall	N	I-Premise
3	survival	N	I-Premise
4	times	N	I-Premise
5	were	N	I-Premise
6	8.3	N	I-Premise
7	,	N	I-Premise
8	11.0	N	I-Premise
9	,	N	I-Premise
10	and	N	I-Premise
11	10.4	N	I-Premise
12	months	N	I-Premise
13	for	N	I-Premise
14	ECF	N	I-Premise
15	,	N	I-Premise
16	TC	N	I-Premise
17	,	N	I-Premise
18	and	N	I-Premise
19	TCF	N	I-Premise
20	,	N	I-Premise
21	respectively	N	I-Premise
22	.	N	I-Premise

1	Toxicity	N	I-Premise
2	was	N	I-Premise
3	acceptable	N	I-Premise
4	,	N	I-Premise
5	with	N	I-Premise
6	one	N	I-Premise
7	toxic	N	I-Premise
8	death	N	I-Premise
9	(	N	I-Premise
10	TC	N	I-Premise
11	arm	N	I-Premise
12	)	N	I-Premise
13	.	N	I-Premise

1	Grade	N	I-Premise
2	3	N	I-Premise
3	or	N	I-Premise
4	4	N	I-Premise
5	neutropenia	N	I-Premise
6	occurred	N	I-Premise
7	in	N	I-Premise
8	more	N	I-Premise
9	treatment	N	I-Premise
10	cycles	N	I-Premise
11	with	N	I-Premise
12	docetaxel	N	I-Premise
13	(	N	I-Premise
14	TC	N	I-Premise
15	,	N	I-Premise
16	49	N	I-Premise
17	%	N	I-Premise
18	;	N	I-Premise
19	TCF	N	I-Premise
20	,	N	I-Premise
21	57	N	I-Premise
22	%	N	I-Premise
23	;	N	I-Premise
24	ECF	N	I-Premise
25	,	N	I-Premise
26	34	N	I-Premise
27	%	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Global	N	I-Claim
2	health	N	I-Claim
3	status/QOL	N	I-Claim
4	substantially	N	I-Claim
5	improved	N	I-Claim
6	with	N	I-Claim
7	ECF	N	I-Claim
8	and	N	I-Claim
9	remained	N	I-Claim
10	similar	N	I-Claim
11	to	N	I-Claim
12	baseline	N	I-Claim
13	with	N	I-Claim
14	both	N	I-Claim
15	docetaxel	N	I-Claim
16	regimens	N	I-Claim
17	.	N	I-Claim

1	Time	N	I-Premise
2	to	N	I-Premise
3	response	N	I-Premise
4	and	N	I-Premise
5	ORR	N	I-Premise
6	favor	N	I-Premise
7	TCF	N	I-Premise
8	over	N	I-Premise
9	TC	N	I-Premise
10	for	N	I-Premise
11	further	N	I-Premise
12	evaluation	N	I-Premise
13	,	N	I-Premise
14	particularly	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	neoadjuvant	N	I-Premise
18	setting	N	I-Premise
19	.	N	I-Premise

1	A	N	I-Premise
2	trend	N	I-Premise
3	towards	N	I-Premise
4	increased	N	I-Premise
5	myelosuppression	N	I-Premise
6	and	N	I-Premise
7	infectious	N	I-Premise
8	complications	N	I-Premise
9	with	N	I-Premise
10	TCF	N	I-Premise
11	versus	N	I-Premise
12	TC	N	I-Premise
13	or	N	I-Premise
14	ECF	N	I-Premise
15	was	N	I-Premise
16	observed	N	I-Premise
17	.	N	I-Premise

1	To	N	O
2	assess	N	O
3	whether	N	O
4	omission	N	O
5	of	N	O
6	postoperative	N	O
7	radiotherapy	N	O
8	in	N	O
9	women	N	O
10	with	N	O
11	'low-risk	N	O
12	'	N	O
13	axillary	N	O
14	node	N	O
15	negative	N	O
16	breast	N	O
17	cancer	N	O
18	(	N	O
19	T0-2	N	O
20	)	N	O
21	treated	N	O
22	by	N	O
23	breast-conserving	N	O
24	surgery	N	O
25	and	N	O
26	endocrine	N	O
27	therapy	N	O
28	improves	N	O
29	quality	N	O
30	of	N	O
31	life	N	O
32	and	N	O
33	is	N	O
34	more	N	O
35	cost-effective	N	O
36	.	N	O

1	A	N	O
2	randomised	N	O
3	controlled	N	O
4	clinical	N	O
5	trial	N	O
6	,	N	O
7	using	N	O
8	a	N	O
9	method	N	O
10	of	N	O
11	minimisation	N	O
12	balanced	N	O
13	by	N	O
14	centre	N	O
15	,	N	O
16	grade	N	O
17	of	N	O
18	cancer	N	O
19	,	N	O
20	age	N	O
21	,	N	O
22	lymphatic/vascular	N	O
23	invasion	N	O
24	and	N	O
25	preoperative	N	O
26	endocrine	N	O
27	therapy	N	O
28	,	N	O
29	was	N	O
30	performed	N	O
31	.	N	O

1	A	N	O
2	non-randomised	N	O
3	cohort	N	O
4	was	N	O
5	also	N	O
6	recruited	N	O
7	,	N	O
8	in	N	O
9	order	N	O
10	to	N	O
11	complete	N	O
12	a	N	O
13	comprehensive	N	O
14	cohort	N	O
15	study	N	O
16	.	N	O

1	The	N	O
2	setting	N	O
3	was	N	O
4	breast	N	O
5	cancer	N	O
6	clinics	N	O
7	in	N	O
8	cancer	N	O
9	centres	N	O
10	in	N	O
11	the	N	O
12	UK	N	O
13	.	N	O

1	Patients	N	O
2	aged	N	O
3	65	N	O
4	years	N	O
5	or	N	O
6	more	N	O
7	were	N	O
8	eligible	N	O
9	provided	N	O
10	that	N	O
11	their	N	O
12	cancers	N	O
13	were	N	O
14	considered	N	O
15	to	N	O
16	be	N	O
17	at	N	O
18	low	N	O
19	risk	N	O
20	of	N	O
21	local	N	O
22	recurrence	N	O
23	,	N	O
24	were	N	O
25	suitable	N	O
26	for	N	O
27	breast-conservation	N	O
28	surgery	N	O
29	,	N	O
30	were	N	O
31	receiving	N	O
32	endocrine	N	O
33	therapy	N	O
34	and	N	O
35	were	N	O
36	able	N	O
37	and	N	O
38	willing	N	O
39	to	N	O
40	give	N	O
41	informed	N	O
42	consent	N	O
43	.	N	O

1	The	N	O
2	standard	N	O
3	treatment	N	O
4	of	N	O
5	postoperative	N	O
6	breast	N	O
7	irradiation	N	O
8	or	N	O
9	the	N	O
10	omission	N	O
11	of	N	O
12	radiotherapy	N	O
13	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	the	N	O
6	primary	N	O
7	outcome	N	O
8	measure	N	O
9	,	N	O
10	together	N	O
11	with	N	O
12	anxiety	N	O
13	and	N	O
14	depression	N	O
15	and	N	O
16	cost-effectiveness	N	O
17	.	N	O

1	Secondary	N	O
2	outcome	N	O
3	measures	N	O
4	were	N	O
5	recurrence	N	O
6	rates	N	O
7	,	N	O
8	functional	N	O
9	status	N	O
10	,	N	O
11	treatment-related	N	O
12	morbidity	N	O
13	and	N	O
14	cosmesis	N	O
15	.	N	O

1	The	N	O
2	principal	N	O
3	method	N	O
4	of	N	O
5	data	N	O
6	collection	N	O
7	was	N	O
8	by	N	O
9	questionnaire	N	O
10	,	N	O
11	completed	N	O
12	at	N	O
13	home	N	O
14	with	N	O
15	a	N	O
16	research	N	O
17	nurse	N	O
18	at	N	O
19	four	N	O
20	times	N	O
21	over	N	O
22	15	N	O
23	months	N	O
24	.	N	O

1	The	N	I-Claim
2	hypothesised	N	I-Claim
3	improvement	N	I-Claim
4	in	N	I-Claim
5	overall	N	I-Claim
6	quality	N	I-Claim
7	of	N	I-Claim
8	life	N	I-Claim
9	with	N	I-Claim
10	the	N	I-Claim
11	omission	N	I-Claim
12	of	N	I-Claim
13	radiotherapy	N	I-Claim
14	was	N	I-Claim
15	not	N	I-Claim
16	seen	N	I-Claim
17	in	N	I-Claim
18	the	N	I-Claim
19	EuroQol	N	I-Claim
20	assessment	N	I-Claim
21	or	N	I-Claim
22	in	N	I-Claim
23	the	N	I-Claim
24	functionality	N	I-Claim
25	and	N	I-Claim
26	symptoms	N	I-Claim
27	summary	N	I-Claim
28	domains	N	I-Claim
29	of	N	I-Claim
30	the	N	I-Claim
31	European	N	I-Claim
32	Organisation	N	I-Claim
33	for	N	I-Claim
34	Research	N	I-Claim
35	in	N	I-Claim
36	the	N	I-Claim
37	Treatment	N	I-Claim
38	of	N	I-Claim
39	Cancer	N	I-Claim
40	(	N	I-Claim
41	EORTC	N	I-Claim
42	)	N	I-Claim
43	scales	N	I-Claim
44	.	N	I-Claim

1	Some	N	O
2	differences	N	O
3	were	N	O
4	apparent	N	O
5	within	N	O
6	subscales	N	O
7	of	N	O
8	the	N	O
9	EORTC	N	O
10	questionnaires	N	O
11	,	N	O
12	and	N	O
13	insights	N	O
14	into	N	O
15	the	N	O
16	impact	N	O
17	of	N	O
18	treatment	N	O
19	were	N	O
20	also	N	O
21	provided	N	O
22	by	N	O
23	the	N	O
24	qualitative	N	O
25	data	N	O
26	obtained	N	O
27	by	N	O
28	open-ended	N	O
29	questions	N	O
30	.	N	O

1	Differences	N	I-Premise
2	were	N	I-Premise
3	most	N	I-Premise
4	apparent	N	I-Premise
5	shortly	N	I-Premise
6	after	N	I-Premise
7	the	N	I-Premise
8	time	N	I-Premise
9	of	N	I-Premise
10	completion	N	I-Premise
11	of	N	I-Premise
12	radiotherapy	N	I-Premise
13	.	N	I-Premise

1	Radiotherapy	N	I-Claim
2	was	N	I-Claim
3	then	N	I-Claim
4	associated	N	I-Claim
5	with	N	I-Claim
6	increased	N	I-Claim
7	breast	N	I-Claim
8	symptoms	N	I-Claim
9	and	N	I-Claim
10	with	N	I-Claim
11	greater	N	I-Claim
12	fatigue	N	I-Claim
13	but	N	I-Claim
14	with	N	I-Claim
15	less	N	I-Claim
16	insomnia	N	I-Claim
17	and	N	I-Claim
18	endocrine	N	I-Claim
19	side-effects	N	I-Claim
20	.	N	I-Claim

1	Patients	N	I-Premise
2	had	N	I-Premise
3	significant	N	I-Premise
4	concerns	N	I-Premise
5	about	N	I-Premise
6	the	N	I-Premise
7	delivery	N	I-Premise
8	of	N	I-Premise
9	radiotherapy	N	I-Premise
10	services	N	I-Premise
11	,	N	I-Premise
12	such	N	I-Premise
13	as	N	I-Premise
14	transport	N	I-Premise
15	,	N	I-Premise
16	accommodation	N	I-Premise
17	and	N	I-Premise
18	travel	N	I-Premise
19	costs	N	I-Premise
20	associated	N	I-Premise
21	with	N	I-Premise
22	receiving	N	I-Premise
23	radiotherapy	N	I-Premise
24	.	N	I-Premise

1	By	N	I-Premise
2	the	N	I-Premise
3	end	N	I-Premise
4	of	N	I-Premise
5	follow-up	N	I-Premise
6	,	N	I-Premise
7	patients	N	I-Premise
8	receiving	N	I-Premise
9	radiotherapy	N	I-Premise
10	were	N	I-Premise
11	expressing	N	I-Premise
12	less	N	I-Premise
13	anxiety	N	I-Premise
14	about	N	I-Premise
15	recurrence	N	I-Premise
16	than	N	I-Premise
17	those	N	I-Premise
18	who	N	I-Premise
19	had	N	I-Premise
20	not	N	I-Premise
21	received	N	I-Premise
22	radiotherapy	N	I-Premise
23	.	N	I-Premise

1	Functionality	N	I-Premise
2	was	N	I-Premise
3	not	N	I-Premise
4	greatly	N	I-Premise
5	affected	N	I-Premise
6	by	N	I-Premise
7	treatment	N	I-Premise
8	.	N	I-Premise

1	Within	N	I-Premise
2	the	N	I-Premise
3	randomised	N	I-Premise
4	controlled	N	I-Premise
5	trial	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	Barthel	N	I-Premise
9	Index	N	I-Premise
10	demonstrated	N	I-Premise
11	a	N	I-Premise
12	small	N	I-Premise
13	but	N	I-Premise
14	significant	N	I-Premise
15	fall	N	I-Premise
16	in	N	I-Premise
17	functionality	N	I-Premise
18	with	N	I-Premise
19	radiotherapy	N	I-Premise
20	compared	N	I-Premise
21	with	N	I-Premise
22	the	N	I-Premise
23	no	N	I-Premise
24	radiotherapy	N	I-Premise
25	arm	N	I-Premise
26	of	N	I-Premise
27	the	N	I-Premise
28	trial	N	I-Premise
29	.	N	I-Premise

1	Results	N	I-Premise
2	from	N	I-Premise
3	the	N	I-Premise
4	non-randomised	N	I-Premise
5	patients	N	I-Premise
6	did	N	I-Premise
7	not	N	I-Premise
8	confirm	N	I-Premise
9	this	N	I-Premise
10	effect	N	I-Premise
11	,	N	I-Premise
12	however	N	I-Premise
13	.	N	I-Premise

1	Cosmetic	N	I-Premise
2	results	N	I-Premise
3	were	N	I-Premise
4	better	N	I-Premise
5	in	N	I-Premise
6	those	N	I-Premise
7	not	N	I-Premise
8	receiving	N	I-Premise
9	radiotherapy	N	I-Premise
10	but	N	I-Premise
11	this	N	I-Premise
12	did	N	I-Premise
13	not	N	I-Premise
14	appear	N	I-Premise
15	to	N	I-Premise
16	be	N	I-Premise
17	an	N	I-Premise
18	important	N	I-Premise
19	issue	N	I-Premise
20	to	N	I-Premise
21	the	N	I-Premise
22	patients	N	I-Premise
23	.	N	I-Premise

1	The	N	I-Claim
2	use	N	I-Claim
3	of	N	I-Claim
4	home-based	N	I-Claim
5	assessments	N	I-Claim
6	by	N	I-Claim
7	a	N	I-Claim
8	research	N	I-Claim
9	nurse	N	I-Claim
10	proved	N	I-Claim
11	to	N	I-Claim
12	be	N	I-Claim
13	an	N	I-Claim
14	effective	N	I-Claim
15	way	N	I-Claim
16	of	N	I-Claim
17	obtaining	N	I-Claim
18	high-quality	N	I-Claim
19	data	N	I-Claim
20	.	N	I-Claim

1	Costs	N	O
2	to	N	O
3	the	N	O
4	NHS	N	O
5	associated	N	O
6	with	N	O
7	postoperative	N	O
8	radiotherapy	N	O
9	were	N	O
10	calculated	N	O
11	to	N	O
12	be	N	O
13	of	N	O
14	the	N	O
15	order	N	O
16	of	N	O
17	2000	N	O
18	pounds	N	O
19	per	N	O
20	patient	N	O
21	.	N	O

1	In	N	I-Premise
2	the	N	I-Premise
3	follow-up	N	I-Premise
4	in	N	I-Premise
5	this	N	I-Premise
6	study	N	I-Premise
7	,	N	I-Premise
8	there	N	I-Premise
9	were	N	I-Premise
10	no	N	I-Premise
11	recurrences	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	the	N	I-Premise
15	quality	N	I-Premise
16	of	N	I-Premise
17	life	N	I-Premise
18	utilities	N	I-Premise
19	from	N	I-Premise
20	EuroQol	N	I-Premise
21	were	N	I-Premise
22	almost	N	I-Premise
23	identical	N	I-Premise
24	.	N	I-Premise

1	Although	N	I-Premise
2	there	N	I-Premise
3	are	N	I-Premise
4	no	N	I-Premise
5	differences	N	I-Premise
6	in	N	I-Premise
7	overall	N	I-Premise
8	quality	N	I-Premise
9	of	N	I-Premise
10	life	N	I-Premise
11	scores	N	I-Premise
12	between	N	I-Premise
13	the	N	I-Premise
14	patients	N	I-Premise
15	treated	N	I-Premise
16	with	N	I-Premise
17	and	N	I-Premise
18	without	N	I-Premise
19	radiotherapy	N	I-Premise
20	,	N	I-Premise
21	there	N	I-Premise
22	are	N	I-Premise
23	several	N	I-Premise
24	dimensions	N	I-Premise
25	that	N	I-Premise
26	exhibit	N	I-Premise
27	significant	N	I-Premise
28	advantage	N	I-Premise
29	to	N	I-Premise
30	the	N	I-Premise
31	omission	N	I-Premise
32	of	N	I-Premise
33	irradiation	N	I-Premise
34	.	N	I-Premise

1	Over	N	I-Premise
2	the	N	I-Premise
3	first	N	I-Premise
4	15	N	I-Premise
5	months	N	I-Premise
6	,	N	I-Premise
7	radiotherapy	N	I-Premise
8	for	N	I-Premise
9	this	N	I-Premise
10	population	N	I-Premise
11	is	N	I-Premise
12	not	N	I-Premise
13	a	N	I-Premise
14	cost-effective	N	I-Premise
15	treatment	N	I-Premise
16	.	N	I-Premise

1	However	N	O
2	,	N	O
3	the	N	O
4	early	N	I-Claim
5	postoperative	N	I-Claim
6	outcome	N	I-Claim
7	does	N	I-Claim
8	not	N	I-Claim
9	give	N	I-Claim
10	a	N	I-Claim
11	complete	N	I-Claim
12	answer	N	I-Claim
13	and	N	O
14	the	N	I-Claim
15	eventual	N	I-Claim
16	cost-effectiveness	N	I-Claim
17	will	N	I-Claim
18	only	N	I-Claim
19	become	N	I-Claim
20	clear	N	I-Claim
21	after	N	I-Claim
22	long-term	N	I-Claim
23	follow-up	N	I-Claim
24	.	N	I-Claim

1	Extrapolations	N	I-Claim
2	from	N	I-Claim
3	these	N	I-Claim
4	data	N	I-Claim
5	suggest	N	I-Claim
6	that	N	I-Claim
7	radiotherapy	N	I-Claim
8	may	N	I-Claim
9	not	N	I-Claim
10	be	N	I-Claim
11	a	N	I-Claim
12	cost-effective	N	I-Claim
13	treatment	N	I-Claim
14	unless	N	I-Claim
15	it	N	I-Claim
16	results	N	I-Claim
17	in	N	I-Claim
18	a	N	I-Claim
19	recurrence	N	I-Claim
20	rate	N	I-Claim
21	that	N	I-Claim
22	is	N	I-Claim
23	at	N	I-Claim
24	least	N	I-Claim
25	5	N	I-Claim
26	%	N	I-Claim
27	lower	N	I-Claim
28	in	N	I-Claim
29	absolute	N	I-Claim
30	terms	N	I-Claim
31	than	N	I-Claim
32	those	N	I-Claim
33	treated	N	I-Claim
34	without	N	I-Claim
35	radiotherapy	N	I-Claim
36	.	N	I-Claim

1	Further	N	I-Claim
2	research	N	I-Claim
3	is	N	I-Claim
4	needed	N	I-Claim
5	into	N	I-Claim
6	a	N	I-Claim
7	number	N	I-Claim
8	of	N	I-Claim
9	areas	N	I-Claim
10	including	N	I-Claim
11	the	N	I-Claim
12	long-term	N	I-Claim
13	aspects	N	I-Claim
14	of	N	I-Claim
15	quality	N	I-Claim
16	of	N	I-Claim
17	life	N	I-Claim
18	,	N	I-Claim
19	clinical	N	I-Claim
20	outcomes	N	I-Claim
21	,	N	I-Claim
22	costs	N	I-Claim
23	and	N	I-Claim
24	consequences	N	I-Claim
25	of	N	I-Claim
26	omitting	N	I-Claim
27	radiotherapy	N	I-Claim
28	.	N	I-Claim

1	This	N	O
2	double-blind	N	O
3	randomized	N	O
4	phase	N	O
5	II	N	O
6	trial	N	O
7	examined	N	O
8	whether	N	O
9	vandetanib	N	O
10	,	N	O
11	an	N	O
12	inhibitor	N	O
13	of	N	O
14	vascular	N	O
15	endothelial	N	O
16	and	N	O
17	epidermal	N	O
18	growth	N	O
19	factor	N	O
20	receptors	N	O
21	,	N	O
22	could	N	O
23	prolong	N	O
24	progression-free	N	O
25	survival	N	O
26	in	N	O
27	responding	N	O
28	patients	N	O
29	with	N	O
30	small-cell	N	O
31	lung	N	O
32	cancer	N	O
33	.	N	O

1	Eligible	N	O
2	patients	N	O
3	with	N	O
4	complete	N	O
5	response	N	O
6	(	N	O
7	CR	N	O
8	)	N	O
9	or	N	O
10	partial	N	O
11	response	N	O
12	(	N	O
13	PR	N	O
14	)	N	O
15	to	N	O
16	combination	N	O
17	chemotherapy	N	O
18	(	N	O
19	+/-	N	O
20	thoracic	N	O
21	or	N	O
22	prophylactic	N	O
23	cranial	N	O
24	radiation	N	O
25	)	N	O
26	received	N	O
27	oral	N	O
28	vandetanib	N	O
29	300	N	O
30	mg/d	N	O
31	or	N	O
32	matched	N	O
33	placebo	N	O
34	.	N	O

1	With	N	O
2	100	N	O
3	patients	N	O
4	and	N	O
5	77	N	O
6	events	N	O
7	,	N	O
8	the	N	O
9	study	N	O
10	had	N	O
11	80	N	O
12	%	N	O
13	power	N	O
14	to	N	O
15	detect	N	O
16	an	N	O
17	improvement	N	O
18	in	N	O
19	median	N	O
20	progression-free	N	O
21	survival	N	O
22	from	N	O
23	4	N	O
24	to	N	O
25	6.5	N	O
26	months	N	O
27	(	N	O
28	one-sided	N	O
29	,	N	O
30	10	N	O
31	%	N	O
32	-level	N	O
33	test	N	O
34	)	N	O
35	.	N	O

1	Between	N	O
2	May	N	O
3	2003	N	O
4	and	N	O
5	March	N	O
6	2006	N	O
7	,	N	O
8	107	N	O
9	patients	N	O
10	were	N	O
11	accrued	N	O
12	;	N	O
13	46	N	O
14	had	N	O
15	limited	N	O
16	disease	N	O
17	and	N	O
18	61	N	O
19	extensive	N	O
20	disease	N	O
21	.	N	O

1	There	N	O
2	were	N	O
3	fewer	N	O
4	patients	N	O
5	with	N	O
6	a	N	O
7	performance	N	O
8	status	N	O
9	of	N	O
10	0	N	O
11	(	N	O
12	n	N	O
13	=	N	O
14	11	N	O
15	v	N	O
16	20	N	O
17	)	N	O
18	,	N	O
19	and	N	O
20	fewer	N	O
21	had	N	O
22	CR	N	O
23	to	N	O
24	initial	N	O
25	therapy	N	O
26	(	N	O
27	n	N	O
28	=	N	O
29	4	N	O
30	v	N	O
31	8	N	O
32	)	N	O
33	in	N	O
34	the	N	O
35	vandetanib	N	O
36	arm	N	O
37	.	N	O

1	Vandetanib	N	I-Premise
2	patients	N	I-Premise
3	had	N	I-Premise
4	more	N	I-Premise
5	toxicity	N	I-Premise
6	and	N	I-Premise
7	required	N	I-Premise
8	more	N	I-Premise
9	dose	N	I-Premise
10	modifications	N	I-Premise
11	for	N	I-Premise
12	gastrointestinal	N	I-Premise
13	toxicity	N	I-Premise
14	and	N	I-Premise
15	rash	N	I-Premise
16	.	N	I-Premise

1	Asymptomatic	N	I-Premise
2	Corrected	N	I-Premise
3	QT	N	I-Premise
4	interval	N	I-Premise
5	(	N	I-Premise
6	QTC	N	I-Premise
7	)	N	I-Premise
8	prolongation	N	I-Premise
9	was	N	I-Premise
10	observed	N	I-Premise
11	in	N	I-Premise
12	eight	N	I-Premise
13	vandetanib	N	I-Premise
14	patients	N	I-Premise
15	.	N	I-Premise

1	Median	N	I-Premise
2	progression-free	N	I-Premise
3	survival	N	I-Premise
4	for	N	I-Premise
5	vandetanib	N	I-Premise
6	and	N	I-Premise
7	placebo	N	I-Premise
8	was	N	I-Premise
9	2.7	N	I-Premise
10	and	N	I-Premise
11	2.8	N	I-Premise
12	months	N	I-Premise
13	,	N	I-Premise
14	respectively	N	I-Premise
15	(	N	I-Premise
16	hazard	N	I-Premise
17	ratio	N	I-Premise
18	[	N	I-Premise
19	HR	N	I-Premise
20	]	N	I-Premise
21	,	N	I-Premise
22	1.01	N	I-Premise
23	;	N	I-Premise
24	80	N	I-Premise
25	%	N	I-Premise
26	CI	N	I-Premise
27	,	N	I-Premise
28	0.75	N	I-Premise
29	to	N	I-Premise
30	1.36	N	I-Premise
31	;	N	I-Premise
32	one-sided	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	.51	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	Overall	N	I-Premise
2	survival	N	I-Premise
3	for	N	I-Premise
4	vandetanib	N	I-Premise
5	was	N	I-Premise
6	10.6	N	I-Premise
7	versus	N	I-Premise
8	11.9	N	I-Premise
9	months	N	I-Premise
10	for	N	I-Premise
11	placebo	N	I-Premise
12	(	N	I-Premise
13	HR	N	I-Premise
14	,	N	I-Premise
15	1.43	N	I-Premise
16	;	N	I-Premise
17	80	N	I-Premise
18	%	N	I-Premise
19	CI	N	I-Premise
20	,	N	I-Premise
21	1.00	N	I-Premise
22	to	N	I-Premise
23	2.05	N	I-Premise
24	;	N	I-Premise
25	one-sided	N	I-Premise
26	P	N	I-Premise
27	=	N	I-Premise
28	0.9	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	In	N	I-Premise
2	planned	N	I-Premise
3	subgroup	N	I-Premise
4	analyses	N	I-Premise
5	,	N	I-Premise
6	a	N	I-Premise
7	significant	N	I-Premise
8	interaction	N	I-Premise
9	was	N	I-Premise
10	noted	N	I-Premise
11	(	N	I-Premise
12	P	N	I-Premise
13	=	N	I-Premise
14	.01	N	I-Premise
15	)	N	I-Premise
16	:	N	I-Premise
17	limited-stage	N	I-Premise
18	vandetanib	N	I-Premise
19	patients	N	I-Premise
20	had	N	I-Premise
21	longer	N	I-Premise
22	overall	N	I-Premise
23	survival	N	I-Premise
24	(	N	I-Premise
25	HR	N	I-Premise
26	,	N	I-Premise
27	0.45	N	I-Premise
28	;	N	I-Premise
29	one-sided	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.07	N	I-Premise
33	)	N	I-Premise
34	and	N	I-Premise
35	extensive-stage	N	I-Premise
36	vandetanib	N	I-Premise
37	patients	N	I-Premise
38	shorter	N	I-Premise
39	survival	N	I-Premise
40	compared	N	I-Premise
41	with	N	I-Premise
42	placebo	N	I-Premise
43	(	N	I-Premise
44	HR	N	I-Premise
45	,	N	I-Premise
46	2.27	N	I-Premise
47	;	N	I-Premise
48	one-sided	N	I-Premise
49	P	N	I-Premise
50	=	N	I-Premise
51	.996	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	Vandetanib	N	I-Claim
2	failed	N	I-Claim
3	to	N	I-Claim
4	demonstrate	N	I-Claim
5	efficacy	N	I-Claim
6	as	N	I-Claim
7	maintenance	N	I-Claim
8	therapy	N	I-Claim
9	for	N	I-Claim
10	small-cell	N	I-Claim
11	lung	N	I-Claim
12	cancer	N	I-Claim
13	.	N	I-Claim

1	To	N	O
2	analyze	N	O
3	the	N	O
4	prospectively	N	O
5	collected	N	O
6	health-related	N	O
7	quality-of-life	N	O
8	(	N	O
9	HRQOL	N	O
10	)	N	O
11	data	N	O
12	from	N	O
13	patients	N	O
14	enrolled	N	O
15	in	N	O
16	two	N	O
17	Radiation	N	O
18	Therapy	N	O
19	Oncology	N	O
20	Group	N	O
21	randomized	N	O
22	Phase	N	O
23	III	N	O
24	head	N	O
25	and	N	O
26	neck	N	O
27	cancer	N	O
28	trials	N	O
29	(	N	O
30	90-03	N	O
31	and	N	O
32	91-11	N	O
33	)	N	O
34	to	N	O
35	assess	N	O
36	their	N	O
37	value	N	O
38	as	N	O
39	an	N	O
40	independent	N	O
41	prognostic	N	O
42	factor	N	O
43	for	N	O
44	locoregional	N	O
45	control	N	O
46	(	N	O
47	LRC	N	O
48	)	N	O
49	and/or	N	O
50	overall	N	O
51	survival	N	O
52	(	N	O
53	OS	N	O
54	)	N	O
55	.	N	O

1	HRQOL	N	O
2	questionnaires	N	O
3	,	N	O
4	using	N	O
5	a	N	O
6	validated	N	O
7	instrument	N	O
8	,	N	O
9	the	N	O
10	Functional	N	O
11	Assessment	N	O
12	of	N	O
13	Cancer	N	O
14	Therapy-Head	N	O
15	and	N	O
16	Neck	N	O
17	(	N	O
18	FACT-H	N	O
19	&	N	O
20	amp	N	O
21	;	N	O
22	N	N	O
23	)	N	O
24	,	N	O
25	version	N	O
26	2	N	O
27	,	N	O
28	were	N	O
29	completed	N	O
30	by	N	O
31	patients	N	O
32	before	N	O
33	the	N	O
34	start	N	O
35	of	N	O
36	treatment	N	O
37	.	N	O

1	OS	N	O
2	and	N	O
3	LRC	N	O
4	were	N	O
5	the	N	O
6	outcome	N	O
7	measures	N	O
8	analyzed	N	O
9	using	N	O
10	a	N	O
11	multivariate	N	O
12	Cox	N	O
13	proportional	N	O
14	hazard	N	O
15	model	N	O
16	.	N	O

1	Baseline	N	O
2	FACT-H	N	O
3	&	N	O
4	amp	N	O
5	;	N	O
6	N	N	O
7	data	N	O
8	were	N	O
9	available	N	O
10	for	N	O
11	1,093	N	O
12	patients	N	O
13	and	N	O
14	missing	N	O
15	for	N	O
16	417	N	O
17	patients	N	O
18	.	N	O

1	No	N	O
2	significant	N	O
3	difference	N	O
4	in	N	O
5	outcome	N	O
6	was	N	O
7	found	N	O
8	between	N	O
9	the	N	O
10	patients	N	O
11	with	N	O
12	and	N	O
13	without	N	O
14	baseline	N	O
15	FACT-H	N	O
16	&	N	O
17	amp	N	O
18	;	N	O
19	N	N	O
20	data	N	O
21	(	N	O
22	p	N	O
23	=	N	O
24	0.58	N	O
25	)	N	O
26	.	N	O

1	The	N	O
2	median	N	O
3	follow-up	N	O
4	time	N	O
5	was	N	O
6	27.2	N	O
7	months	N	O
8	for	N	O
9	all	N	O
10	patients	N	O
11	and	N	O
12	49	N	O
13	months	N	O
14	for	N	O
15	surviving	N	O
16	patients	N	O
17	.	N	O

1	Multivariate	N	O
2	analyses	N	O
3	were	N	O
4	performed	N	O
5	for	N	O
6	both	N	O
7	OS	N	O
8	and	N	O
9	LRC	N	O
10	.	N	O

1	Beyond	N	I-Premise
2	tumor	N	I-Premise
3	and	N	I-Premise
4	nodal	N	I-Premise
5	stage	N	I-Premise
6	,	N	I-Premise
7	Karnofsky	N	I-Premise
8	performance	N	I-Premise
9	status	N	I-Premise
10	,	N	I-Premise
11	primary	N	I-Premise
12	site	N	I-Premise
13	,	N	I-Premise
14	cigarette	N	I-Premise
15	use	N	I-Premise
16	,	N	I-Premise
17	use	N	I-Premise
18	of	N	I-Premise
19	concurrent	N	I-Premise
20	chemotherapy	N	I-Premise
21	,	N	I-Premise
22	and	N	I-Premise
23	altered	N	I-Premise
24	fractionation	N	I-Premise
25	schedules	N	I-Premise
26	,	N	I-Premise
27	the	N	I-Premise
28	FACT-H	N	I-Premise
29	&	N	I-Premise
30	amp	N	I-Premise
31	;	N	I-Premise
32	N	N	I-Premise
33	score	N	I-Premise
34	was	N	I-Premise
35	independently	N	I-Premise
36	predictive	N	I-Premise
37	of	N	I-Premise
38	LRC	N	I-Premise
39	(	N	I-Premise
40	but	N	I-Premise
41	not	N	I-Premise
42	OS	N	I-Premise
43	)	N	I-Premise
44	,	N	I-Premise
45	with	N	I-Premise
46	p	N	I-Premise
47	=	N	I-Premise
48	0.0038	N	I-Premise
49	.	N	I-Premise

1	The	N	I-Premise
2	functional	N	I-Premise
3	well-being	N	I-Premise
4	component	N	I-Premise
5	of	N	I-Premise
6	the	N	I-Premise
7	FACT-H	N	I-Premise
8	&	N	I-Premise
9	amp	N	I-Premise
10	;	N	I-Premise
11	N	N	I-Premise
12	predicted	N	I-Premise
13	most	N	I-Premise
14	significantly	N	I-Premise
15	for	N	I-Premise
16	LRC	N	I-Premise
17	(	N	I-Premise
18	p	N	I-Premise
19	=	N	I-Premise
20	0.0004	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	This	N	I-Claim
2	study	N	I-Claim
3	represents	N	I-Claim
4	,	N	I-Claim
5	to	N	I-Claim
6	our	N	I-Claim
7	knowledge	N	I-Claim
8	,	N	I-Claim
9	the	N	I-Claim
10	largest	N	I-Claim
11	analysis	N	I-Claim
12	of	N	I-Claim
13	HRQOL	N	I-Claim
14	as	N	I-Claim
15	a	N	I-Claim
16	prognostic	N	I-Claim
17	factor	N	I-Claim
18	in	N	I-Claim
19	locally	N	I-Claim
20	advanced	N	I-Claim
21	head	N	I-Claim
22	and	N	I-Claim
23	neck	N	I-Claim
24	cancer	N	I-Claim
25	patients	N	I-Claim
26	.	N	I-Claim

1	The	N	I-Claim
2	results	N	I-Claim
3	of	N	I-Claim
4	this	N	I-Claim
5	study	N	I-Claim
6	have	N	I-Claim
7	demonstrated	N	I-Claim
8	the	N	I-Claim
9	importance	N	I-Claim
10	of	N	I-Claim
11	baseline	N	I-Claim
12	HRQOL	N	I-Claim
13	as	N	I-Claim
14	a	N	I-Claim
15	significant	N	I-Claim
16	and	N	I-Claim
17	independent	N	I-Claim
18	predictor	N	I-Claim
19	of	N	I-Claim
20	LRC	N	I-Claim
21	in	N	I-Claim
22	patients	N	I-Claim
23	with	N	I-Claim
24	locally	N	I-Claim
25	advanced	N	I-Claim
26	head	N	I-Claim
27	and	N	I-Claim
28	neck	N	I-Claim
29	cancer	N	I-Claim
30	.	N	I-Claim

1	Relapse	N	I-MajorClaim
2	after	N	I-MajorClaim
3	completing	N	I-MajorClaim
4	adjuvant	N	I-MajorClaim
5	tamoxifen	N	I-MajorClaim
6	therapy	N	I-MajorClaim
7	is	N	I-MajorClaim
8	a	N	I-MajorClaim
9	persistent	N	I-MajorClaim
10	threat	N	I-MajorClaim
11	for	N	I-MajorClaim
12	women	N	I-MajorClaim
13	with	N	I-MajorClaim
14	hormone-responsive	N	I-MajorClaim
15	breast	N	I-MajorClaim
16	cancer	N	I-MajorClaim
17	.	N	I-MajorClaim

1	Third-generation	N	O
2	aromatase	N	O
3	inhibitors	N	O
4	,	N	O
5	such	N	O
6	as	N	O
7	letrozole	N	O
8	,	N	O
9	provide	N	O
10	a	N	O
11	new	N	O
12	option	N	O
13	for	N	O
14	extended	N	O
15	adjuvant	N	O
16	hormonal	N	O
17	therapy	N	O
18	after	N	O
19	5	N	O
20	years	N	O
21	of	N	O
22	tamoxifen	N	O
23	.	N	O

1	MA.17	N	O
2	was	N	O
3	conducted	N	O
4	to	N	O
5	determine	N	O
6	whether	N	O
7	letrozole	N	O
8	improves	N	O
9	outcome	N	O
10	after	N	O
11	discontinuation	N	O
12	of	N	O
13	tamoxifen	N	O
14	.	N	O

1	Postmenopausal	N	O
2	women	N	O
3	with	N	O
4	hormone	N	O
5	receptor-positive	N	O
6	breast	N	O
7	cancer	N	O
8	(	N	O
9	N=5,187	N	O
10	)	N	O
11	were	N	O
12	randomized	N	O
13	to	N	O
14	letrozole	N	O
15	2.5	N	O
16	mg	N	O
17	or	N	O
18	placebo	N	O
19	once	N	O
20	daily	N	O
21	for	N	O
22	5	N	O
23	years	N	O
24	.	N	O

1	At	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	30	N	I-Premise
7	months	N	I-Premise
8	,	N	I-Premise
9	letrozole	N	I-Premise
10	significantly	N	I-Premise
11	improved	N	I-Premise
12	disease-free	N	I-Premise
13	survival	N	I-Premise
14	(	N	I-Premise
15	DFS	N	I-Premise
16	;	N	I-Premise
17	P	N	I-Premise
18	<	N	I-Premise
19	0.001	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	the	N	I-Premise
23	primary	N	I-Premise
24	end	N	I-Premise
25	point	N	I-Premise
26	,	N	I-Premise
27	compared	N	I-Premise
28	with	N	I-Premise
29	placebo	N	I-Premise
30	(	N	I-Premise
31	hazard	N	I-Premise
32	ratio	N	I-Premise
33	[	N	I-Premise
34	HR	N	I-Premise
35	]	N	I-Premise
36	for	N	I-Premise
37	recurrence	N	I-Premise
38	or	N	I-Premise
39	contralateral	N	I-Premise
40	breast	N	I-Premise
41	cancer	N	I-Premise
42	0.58	N	I-Premise
43	;	N	I-Premise
44	95	N	I-Premise
45	%	N	I-Premise
46	confidence	N	I-Premise
47	interval	N	I-Premise
48	[	N	I-Premise
49	CI	N	I-Premise
50	]	N	I-Premise
51	0.45	N	I-Premise
52	,	N	I-Premise
53	0.76	N	I-Premise
54	]	N	I-Premise
55	P	N	I-Premise
56	<	N	I-Premise
57	0.001	N	I-Premise
58	)	N	I-Premise
59	.	N	I-Premise

1	Furthermore	N	I-Premise
2	,	N	I-Premise
3	letrozole	N	I-Premise
4	significantly	N	I-Premise
5	improved	N	I-Premise
6	distant	N	I-Premise
7	DFS	N	I-Premise
8	(	N	I-Premise
9	HR=0.60	N	I-Premise
10	;	N	I-Premise
11	95	N	I-Premise
12	%	N	I-Premise
13	CI	N	I-Premise
14	0.43	N	I-Premise
15	,	N	I-Premise
16	0.84	N	I-Premise
17	;	N	I-Premise
18	P=0.002	N	I-Premise
19	)	N	I-Premise
20	and	N	I-Premise
21	,	N	I-Premise
22	in	N	I-Premise
23	women	N	I-Premise
24	with	N	I-Premise
25	node-positive	N	I-Premise
26	tumors	N	I-Premise
27	,	N	I-Premise
28	overall	N	I-Premise
29	survival	N	I-Premise
30	(	N	I-Premise
31	HR=0.61	N	I-Premise
32	;	N	I-Premise
33	95	N	I-Premise
34	%	N	I-Premise
35	CI	N	I-Premise
36	0.38	N	I-Premise
37	,	N	I-Premise
38	0.98	N	I-Premise
39	;	N	I-Premise
40	P=0.04	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	Clinical	N	I-Premise
2	benefits	N	I-Premise
3	,	N	I-Premise
4	including	N	I-Premise
5	an	N	I-Premise
6	overall	N	I-Premise
7	survival	N	I-Premise
8	advantage	N	I-Premise
9	,	N	I-Premise
10	were	N	I-Premise
11	also	N	I-Premise
12	seen	N	I-Premise
13	in	N	I-Premise
14	women	N	I-Premise
15	who	N	I-Premise
16	crossed	N	I-Premise
17	over	N	I-Premise
18	from	N	I-Premise
19	placebo	N	I-Premise
20	to	N	I-Premise
21	letrozole	N	I-Premise
22	after	N	I-Premise
23	unblinding	N	I-Premise
24	,	N	I-Premise
25	indicating	N	I-Premise
26	that	N	I-Premise
27	tumors	N	I-Premise
28	remain	N	I-Premise
29	sensitive	N	I-Premise
30	to	N	I-Premise
31	hormone	N	I-Premise
32	therapy	N	I-Premise
33	despite	N	I-Premise
34	a	N	I-Premise
35	prolonged	N	I-Premise
36	period	N	I-Premise
37	since	N	I-Premise
38	discontinuation	N	I-Premise
39	of	N	I-Premise
40	tamoxifen	N	I-Premise
41	.	N	I-Premise

1	The	N	O
2	efficacy	N	O
3	and	N	O
4	safety	N	O
5	of	N	O
6	letrozole	N	O
7	therapy	N	O
8	beyond	N	O
9	5	N	O
10	years	N	O
11	is	N	O
12	being	N	O
13	assessed	N	O
14	in	N	O
15	a	N	O
16	re-randomization	N	O
17	study	N	O
18	,	N	O
19	following	N	O
20	the	N	O
21	emergence	N	O
22	of	N	O
23	new	N	O
24	data	N	O
25	suggesting	N	O
26	that	N	O
27	clinical	N	O
28	benefit	N	O
29	correlates	N	O
30	with	N	O
31	the	N	O
32	duration	N	O
33	of	N	O
34	letrozole	N	O
35	.	N	O

1	MA.17	N	I-Claim
2	showed	N	I-Claim
3	that	N	I-Claim
4	letrozole	N	I-Claim
5	is	N	I-Claim
6	extremely	N	I-Claim
7	well-tolerated	N	I-Claim
8	relative	N	I-Claim
9	to	N	I-Claim
10	placebo	N	I-Claim
11	.	N	I-Claim

1	Letrozole	N	I-Claim
2	should	N	I-Claim
3	be	N	I-Claim
4	considered	N	I-Claim
5	for	N	I-Claim
6	all	N	I-Claim
7	women	N	I-Claim
8	completing	N	I-Claim
9	tamoxifen	N	I-Claim
10	;	N	I-Claim
11	new	N	I-Claim
12	results	N	I-Claim
13	from	N	I-Claim
14	the	N	I-Claim
15	post-unblinding	N	I-Claim
16	analysis	N	I-Claim
17	suggest	N	I-Claim
18	that	N	I-Claim
19	letrozole	N	I-Claim
20	treatment	N	I-Claim
21	should	N	I-Claim
22	also	N	I-Claim
23	be	N	I-Claim
24	considered	N	I-Claim
25	for	N	I-Claim
26	all	N	I-Claim
27	disease-free	N	I-Claim
28	women	N	I-Claim
29	for	N	I-Claim
30	periods	N	I-Claim
31	up	N	I-Claim
32	to	N	I-Claim
33	5	N	I-Claim
34	years	N	I-Claim
35	following	N	I-Claim
36	completion	N	I-Claim
37	of	N	I-Claim
38	adjuvant	N	I-Claim
39	tamoxifen	N	I-Claim
40	.	N	I-Claim

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	safety	N	O
5	and	N	O
6	efficacy	N	O
7	of	N	O
8	abatacept	N	O
9	during	N	O
10	2	N	O
11	years	N	O
12	of	N	O
13	the	N	O
14	ATTAIN	N	O
15	(	N	O
16	Abatacept	N	O
17	Trial	N	O
18	in	N	O
19	Treatment	N	O
20	of	N	O
21	Anti-TNF	N	O
22	INadequate	N	O
23	responders	N	O
24	)	N	O
25	trial	N	O
26	in	N	O
27	patients	N	O
28	with	N	O
29	rheumatoid	N	O
30	arthritis	N	O
31	.	N	O

1	Patients	N	O
2	completing	N	O
3	the	N	O
4	6-month	N	O
5	,	N	O
6	double-blind	N	O
7	period	N	O
8	were	N	O
9	eligible	N	O
10	to	N	O
11	enter	N	O
12	the	N	O
13	long-term	N	O
14	extension	N	O
15	;	N	O
16	patients	N	O
17	received	N	O
18	abatacept	N	O
19	approximately	N	O
20	10	N	O
21	mg/kg	N	O
22	,	N	O
23	plus	N	O
24	disease-modifying	N	O
25	antirheumatic	N	O
26	drugs	N	O
27	.	N	O

1	Safety	N	O
2	and	N	O
3	efficacy	N	O
4	(	N	O
5	American	N	O
6	College	N	O
7	of	N	O
8	Rheumatology	N	O
9	(	N	O
10	ACR	N	O
11	)	N	O
12	criteria	N	O
13	responses	N	O
14	,	N	O
15	DAS28	N	O
16	(	N	O
17	C-reactive	N	O
18	protein	N	O
19	)	N	O
20	,	N	O
21	HAQ-DI	N	O
22	,	N	O
23	SF-36	N	O
24	,	N	O
25	Medical	N	O
26	Outcomes	N	O
27	Study	N	O
28	Sleep	N	O
29	Problems	N	O
30	Index	N	O
31	,	N	O
32	fatigue	N	O
33	VAS	N	O
34	)	N	O
35	were	N	O
36	assessed	N	O
37	through	N	O
38	2	N	O
39	years	N	O
40	.	N	O

1	317	N	O
2	patients	N	O
3	(	N	O
4	218	N	O
5	from	N	O
6	the	N	O
7	abatacept	N	O
8	and	N	O
9	99	N	O
10	from	N	O
11	the	N	O
12	placebo	N	O
13	group	N	O
14	)	N	O
15	entered	N	O
16	and	N	O
17	222	N	O
18	(	N	O
19	70	N	O
20	%	N	O
21	)	N	O
22	completed	N	O
23	18	N	O
24	months	N	O
25	of	N	O
26	long-term	N	O
27	extension	N	O
28	treatment	N	O
29	.	N	O

1	The	N	I-Premise
2	incidence	N	I-Premise
3	and	N	I-Premise
4	type	N	I-Premise
5	of	N	I-Premise
6	adverse	N	I-Premise
7	events	N	I-Premise
8	were	N	I-Premise
9	consistent	N	I-Premise
10	between	N	I-Premise
11	the	N	I-Premise
12	double-blind	N	I-Premise
13	and	N	I-Premise
14	cumulative	N	I-Premise
15	(	N	I-Premise
16	double-blind	N	I-Premise
17	plus	N	I-Premise
18	long-term	N	I-Premise
19	extension	N	I-Premise
20	)	N	I-Premise
21	periods	N	I-Premise
22	.	N	I-Premise

1	Rates	N	I-Premise
2	of	N	I-Premise
3	serious	N	I-Premise
4	adverse	N	I-Premise
5	events	N	I-Premise
6	were	N	I-Premise
7	25.6	N	I-Premise
8	and	N	I-Premise
9	23.4	N	I-Premise
10	per	N	I-Premise
11	100	N	I-Premise
12	patient-years	N	I-Premise
13	in	N	I-Premise
14	the	N	I-Premise
15	double-blind	N	I-Premise
16	versus	N	I-Premise
17	cumulative	N	I-Premise
18	period	N	I-Premise
19	.	N	I-Premise

1	At	N	I-Premise
2	6	N	I-Premise
3	months	N	I-Premise
4	and	N	I-Premise
5	2	N	I-Premise
6	years	N	I-Premise
7	,	N	I-Premise
8	using	N	I-Premise
9	non-responder	N	I-Premise
10	analyses	N	I-Premise
11	,	N	I-Premise
12	ACR	N	I-Premise
13	responses	N	I-Premise
14	in	N	I-Premise
15	abatacept-treated	N	I-Premise
16	patients	N	I-Premise
17	were	N	I-Premise
18	:	N	I-Premise
19	ACR	N	I-Premise
20	20	N	I-Premise
21	,	N	I-Premise
22	59.4	N	I-Premise
23	%	N	I-Premise
24	and	N	I-Premise
25	56.2	N	I-Premise
26	%	N	I-Premise
27	;	N	I-Premise
28	ACR	N	I-Premise
29	50	N	I-Premise
30	,	N	I-Premise
31	23.5	N	I-Premise
32	%	N	I-Premise
33	and	N	I-Premise
34	33.2	N	I-Premise
35	%	N	I-Premise
36	;	N	I-Premise
37	ACR	N	I-Premise
38	70	N	I-Premise
39	,	N	I-Premise
40	11.5	N	I-Premise
41	%	N	I-Premise
42	and	N	I-Premise
43	16.1	N	I-Premise
44	%	N	I-Premise
45	;	N	I-Premise
46	HAQ-DI	N	I-Premise
47	responses	N	I-Premise
48	were	N	I-Premise
49	54.4	N	I-Premise
50	%	N	I-Premise
51	and	N	I-Premise
52	47.9	N	I-Premise
53	%	N	I-Premise
54	.	N	I-Premise

1	At	N	I-Premise
2	6	N	I-Premise
3	months	N	I-Premise
4	and	N	I-Premise
5	2	N	I-Premise
6	years	N	I-Premise
7	,	N	I-Premise
8	using	N	I-Premise
9	post-hoc	N	I-Premise
10	as-observed	N	I-Premise
11	analyses	N	I-Premise
12	,	N	I-Premise
13	the	N	I-Premise
14	percentage	N	I-Premise
15	of	N	I-Premise
16	patients	N	I-Premise
17	(	N	I-Premise
18	95	N	I-Premise
19	%	N	I-Premise
20	confidence	N	I-Premise
21	interval	N	I-Premise
22	)	N	I-Premise
23	achieving	N	I-Premise
24	DAS28	N	I-Premise
25	(	N	I-Premise
26	C-reactive	N	I-Premise
27	protein	N	I-Premise
28	)	N	I-Premise
29	low	N	I-Premise
30	disease	N	I-Premise
31	activity	N	I-Premise
32	score	N	I-Premise
33	(	N	I-Premise
34	<	N	I-Premise
35	or	N	I-Premise
36	=	N	I-Premise
37	3.2	N	I-Premise
38	)	N	I-Premise
39	and	N	I-Premise
40	DAS28	N	I-Premise
41	(	N	I-Premise
42	C-reactive	N	I-Premise
43	protein	N	I-Premise
44	)	N	I-Premise
45	-defined	N	I-Premise
46	remission	N	I-Premise
47	(	N	I-Premise
48	<	N	I-Premise
49	2.6	N	I-Premise
50	)	N	I-Premise
51	increased	N	I-Premise
52	from	N	I-Premise
53	18.3	N	I-Premise
54	%	N	I-Premise
55	(	N	I-Premise
56	13.0	N	I-Premise
57	,	N	I-Premise
58	23.5	N	I-Premise
59	)	N	I-Premise
60	to	N	I-Premise
61	32.0	N	I-Premise
62	%	N	I-Premise
63	(	N	I-Premise
64	24.6	N	I-Premise
65	,	N	I-Premise
66	39.4	N	I-Premise
67	)	N	I-Premise
68	and	N	I-Premise
69	11.1	N	I-Premise
70	%	N	I-Premise
71	(	N	I-Premise
72	6.8	N	I-Premise
73	,	N	I-Premise
74	15.3	N	I-Premise
75	)	N	I-Premise
76	to	N	I-Premise
77	20.3	N	I-Premise
78	%	N	I-Premise
79	(	N	I-Premise
80	13.9	N	I-Premise
81	,	N	I-Premise
82	26.6	N	I-Premise
83	)	N	I-Premise
84	.	N	I-Premise

1	Clinically	N	I-Premise
2	meaningful	N	I-Premise
3	improvements	N	I-Premise
4	in	N	I-Premise
5	SF-36	N	I-Premise
6	,	N	I-Premise
7	pain	N	I-Premise
8	,	N	I-Premise
9	fatigue	N	I-Premise
10	and	N	I-Premise
11	sleep	N	I-Premise
12	problems	N	I-Premise
13	were	N	I-Premise
14	also	N	I-Premise
15	maintained	N	I-Premise
16	throughout	N	I-Premise
17	the	N	I-Premise
18	2	N	I-Premise
19	years	N	I-Premise
20	of	N	I-Premise
21	abatacept	N	I-Premise
22	treatment	N	I-Premise
23	.	N	I-Premise

1	No	N	I-Premise
2	unique	N	I-Premise
3	safety	N	I-Premise
4	observations	N	I-Premise
5	were	N	I-Premise
6	reported	N	I-Premise
7	during	N	I-Premise
8	open-label	N	I-Premise
9	exposure	N	I-Premise
10	.	N	I-Premise

1	Improvements	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	signs	N	I-Premise
5	and	N	I-Premise
6	symptoms	N	I-Premise
7	of	N	I-Premise
8	rheumatoid	N	I-Premise
9	arthritis	N	I-Premise
10	,	N	I-Premise
11	physical	N	I-Premise
12	function	N	I-Premise
13	and	N	I-Premise
14	health-related	N	I-Premise
15	quality	N	I-Premise
16	of	N	I-Premise
17	life	N	I-Premise
18	observed	N	I-Premise
19	after	N	I-Premise
20	6	N	I-Premise
21	months	N	I-Premise
22	,	N	I-Premise
23	were	N	I-Premise
24	maintained	N	I-Premise
25	throughout	N	I-Premise
26	the	N	I-Premise
27	2	N	I-Premise
28	years	N	I-Premise
29	in	N	I-Premise
30	this	N	I-Premise
31	population	N	I-Premise
32	with	N	I-Premise
33	difficult-to-treat	N	I-Premise
34	disease	N	I-Premise
35	.	N	I-Premise

1	Few	N	O
2	randomized	N	O
3	trials	N	O
4	have	N	O
5	compared	N	O
6	the	N	O
7	survival	N	O
8	benefit	N	O
9	of	N	O
10	interferon-alfa	N	O
11	over	N	O
12	controls	N	O
13	in	N	O
14	metastatic	N	O
15	renal	N	O
16	cell	N	O
17	carcinoma	N	O
18	,	N	O
19	and	N	O
20	none	N	O
21	has	N	O
22	been	N	O
23	performed	N	O
24	using	N	O
25	interleukin-2	N	O
26	.	N	O

1	The	N	O
2	Programme	N	O
3	Etude	N	O
4	Rein	N	O
5	Cytokines	N	O
6	(	N	O
7	PERCY	N	O
8	)	N	O
9	Quattro	N	O
10	trial	N	O
11	was	N	O
12	designed	N	O
13	to	N	O
14	evaluate	N	O
15	both	N	O
16	cytokines	N	O
17	for	N	O
18	their	N	O
19	survival	N	O
20	benefit	N	O
21	to	N	O
22	intermediate	N	O
23	prognosis	N	O
24	patients	N	O
25	,	N	O
26	who	N	O
27	represent	N	O
28	the	N	O
29	majority	N	O
30	of	N	O
31	candidates	N	O
32	for	N	O
33	these	N	O
34	treatments	N	O
35	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	in	N	O
5	a	N	O
6	2-by-2	N	O
7	factorial	N	O
8	design	N	O
9	to	N	O
10	medroxyprogesterone	N	O
11	acetate	N	O
12	200	N	O
13	mg	N	O
14	daily	N	O
15	,	N	O
16	interferon-alfa	N	O
17	9	N	O
18	million	N	O
19	IU	N	O
20	3	N	O
21	times	N	O
22	a	N	O
23	week	N	O
24	,	N	O
25	subcutaneous	N	O
26	interleukin-2	N	O
27	9	N	O
28	million	N	O
29	IU	N	O
30	daily	N	O
31	,	N	O
32	or	N	O
33	a	N	O
34	combination	N	O
35	of	N	O
36	both	N	O
37	cytokines	N	O
38	.	N	O

1	Tumor	N	O
2	response	N	O
3	was	N	O
4	evaluated	N	O
5	at	N	O
6	Week	N	O
7	12	N	O
8	and	N	O
9	Month	N	O
10	6	N	O
11	;	N	O
12	progression-free	N	O
13	patients	N	O
14	received	N	O
15	further	N	O
16	identical	N	O
17	treatment	N	O
18	for	N	O
19	a	N	O
20	maximum	N	O
21	of	N	O
22	3	N	O
23	additional	N	O
24	months	N	O
25	.	N	O

1	Primary	N	O
2	endpoint	N	O
3	was	N	O
4	overall	N	O
5	survival	N	O
6	;	N	O
7	secondary	N	O
8	endpoints	N	O
9	were	N	O
10	disease-free	N	O
11	survival	N	O
12	,	N	O
13	response	N	O
14	rate	N	O
15	,	N	O
16	toxicity	N	O
17	,	N	O
18	and	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	.	N	O

1	Survival	N	O
2	was	N	O
3	analyzed	N	O
4	on	N	O
5	an	N	O
6	intent-to-treat	N	O
7	basis	N	O
8	.	N	O

1	From	N	O
2	January	N	O
3	2000	N	O
4	to	N	O
5	July	N	O
6	2004	N	O
7	,	N	O
8	492	N	O
9	patients	N	O
10	were	N	O
11	enrolled	N	O
12	.	N	O

1	Analysis	N	O
2	was	N	O
3	performed	N	O
4	after	N	O
5	a	N	O
6	29.2-month	N	O
7	median	N	O
8	follow-up	N	O
9	(	N	O
10	range	N	O
11	,	N	O
12	0	N	O
13	months	N	O
14	to	N	O
15	54.6	N	O
16	months	N	O
17	)	N	O
18	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	survival	N	I-Premise
6	differences	N	I-Premise
7	between	N	I-Premise
8	the	N	I-Premise
9	244	N	I-Premise
10	interferon-alfa-treated	N	I-Premise
11	patients	N	I-Premise
12	and	N	I-Premise
13	248	N	I-Premise
14	noninterferon-alfa	N	I-Premise
15	patients	N	I-Premise
16	(	N	I-Premise
17	hazard	N	I-Premise
18	ratio	N	I-Premise
19	,	N	I-Premise
20	1.00	N	I-Premise
21	;	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	,	N	I-Premise
26	0.81-1.24	N	I-Premise
27	)	N	I-Premise
28	or	N	I-Premise
29	between	N	I-Premise
30	the	N	I-Premise
31	247	N	I-Premise
32	interleukin-2	N	I-Premise
33	and	N	I-Premise
34	245	N	I-Premise
35	noninterleukin-2-treated	N	I-Premise
36	patients	N	I-Premise
37	(	N	I-Premise
38	hazard	N	I-Premise
39	ratio	N	I-Premise
40	,	N	I-Premise
41	1.07	N	I-Premise
42	;	N	I-Premise
43	95	N	I-Premise
44	%	N	I-Premise
45	CI	N	I-Premise
46	,	N	I-Premise
47	0.87-1.33	N	I-Premise
48	;	N	I-Premise
49	log	N	I-Premise
50	rank	N	I-Premise
51	,	N	I-Premise
52	0.99	N	I-Premise
53	and	N	I-Premise
54	0.52	N	I-Premise
55	,	N	I-Premise
56	respectively	N	I-Premise
57	)	N	I-Premise
58	.	N	I-Premise

1	Grade	N	I-Premise
2	3-4	N	I-Premise
3	toxicities	N	I-Premise
4	were	N	I-Premise
5	significantly	N	I-Premise
6	more	N	I-Premise
7	frequent	N	I-Premise
8	in	N	I-Premise
9	cytokine-treated	N	I-Premise
10	patients	N	I-Premise
11	than	N	I-Premise
12	in	N	I-Premise
13	medroxyprogesterone-treated	N	I-Premise
14	patients	N	I-Premise
15	.	N	I-Premise

1	Subcutaneous	N	I-Claim
2	interleukin-2	N	I-Claim
3	and/or	N	I-Claim
4	interferon-alfa	N	I-Claim
5	provide	N	I-Claim
6	no	N	I-Claim
7	survival	N	I-Claim
8	benefit	N	I-Claim
9	in	N	I-Claim
10	metastatic	N	I-Claim
11	renal	N	I-Claim
12	cancers	N	I-Claim
13	of	N	I-Claim
14	intermediate	N	I-Claim
15	prognosis	N	I-Claim
16	,	N	I-Claim
17	and	N	I-Claim
18	they	N	I-Claim
19	induce	N	I-Claim
20	a	N	I-Claim
21	significant	N	I-Claim
22	risk	N	I-Claim
23	of	N	I-Claim
24	toxicity	N	I-Claim
25	.	N	I-Claim

1	Newly	N	I-Claim
2	available	N	I-Claim
3	angiogenesis	N	I-Claim
4	inhibitors	N	I-Claim
5	should	N	I-Claim
6	be	N	I-Claim
7	preferred	N	I-Claim
8	for	N	I-Claim
9	these	N	I-Claim
10	patients	N	I-Claim
11	.	N	I-Claim

1	Hormonal	N	I-Claim
2	breast	N	I-Claim
3	cancer	N	I-Claim
4	treatment	N	I-Claim
5	increases	N	I-Claim
6	menopausal	N	I-Claim
7	symptoms	N	I-Claim
8	in	N	I-Claim
9	women	N	I-Claim
10	.	N	I-Claim

1	This	N	O
2	study	N	O
3	investigated	N	O
4	differences	N	O
5	between	N	O
6	the	N	O
7	symptoms	N	O
8	associated	N	O
9	with	N	O
10	either	N	O
11	adjuvant	N	O
12	tamoxifen	N	O
13	or	N	O
14	exemestane	N	O
15	.	N	O

1	Ten	N	O
2	common	N	O
3	symptoms	N	O
4	were	N	O
5	assessed	N	O
6	by	N	O
7	self-report	N	O
8	questionnaire	N	O
9	administered	N	O
10	to	N	O
11	1,614	N	O
12	consecutive	N	O
13	patients	N	O
14	at	N	O
15	baseline	N	O
16	and	N	O
17	every	N	O
18	3	N	O
19	months	N	O
20	during	N	O
21	the	N	O
22	first	N	O
23	year	N	O
24	of	N	O
25	a	N	O
26	double-blind	N	O
27	,	N	O
28	randomized	N	O
29	trial	N	O
30	of	N	O
31	postmenopausal	N	O
32	women	N	O
33	with	N	O
34	early	N	O
35	hormone	N	O
36	receptor-positive	N	O
37	breast	N	O
38	cancer	N	O
39	.	N	O

1	Symptoms	N	O
2	were	N	O
3	categorized	N	O
4	as	N	O
5	none	N	O
6	,	N	O
7	mild	N	O
8	,	N	O
9	moderate	N	O
10	,	N	O
11	or	N	O
12	severe	N	O
13	.	N	O

1	A	N	O
2	hot	N	O
3	flash	N	O
4	score	N	O
5	was	N	O
6	calculated	N	O
7	at	N	O
8	each	N	O
9	time	N	O
10	point	N	O
11	.	N	O

1	Symptoms	N	O
2	were	N	O
3	analyzed	N	O
4	by	N	O
5	repeated-measures	N	O
6	analysis	N	O
7	of	N	O
8	variance	N	O
9	.	N	O

1	Each	N	O
2	time	N	O
3	period	N	O
4	was	N	O
5	tested	N	O
6	repeatedly	N	O
7	against	N	O
8	the	N	O
9	baseline	N	O
10	;	N	O
11	an	N	O
12	overall	N	O
13	P	N	O
14	value	N	O
15	was	N	O
16	assigned	N	O
17	for	N	O
18	each	N	O
19	reported	N	O
20	symptom	N	O
21	.	N	O

1	Compliance	N	O
2	was	N	O
3	excellent	N	O
4	,	N	O
5	with	N	O
6	7,286	N	O
7	questionnaires	N	O
8	analyzed	N	O
9	.	N	O

1	Baseline	N	O
2	symptom	N	O
3	prevalence	N	O
4	ranged	N	O
5	from	N	O
6	2	N	O
7	%	N	O
8	(	N	O
9	vaginal	N	O
10	bleeding	N	O
11	)	N	O
12	to	N	O
13	60	N	O
14	%	N	O
15	to	N	O
16	70	N	O
17	%	N	O
18	(	N	O
19	bone/muscle	N	O
20	aches	N	O
21	and	N	O
22	low	N	O
23	energy	N	O
24	)	N	O
25	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	in	N	I-Premise
7	vaginal	N	I-Premise
8	bleeding	N	I-Premise
9	,	N	I-Premise
10	mood	N	I-Premise
11	alteration	N	I-Premise
12	,	N	I-Premise
13	or	N	I-Premise
14	low	N	I-Premise
15	energy	N	I-Premise
16	.	N	I-Premise

1	Patients	N	I-Premise
2	receiving	N	I-Premise
3	tamoxifen	N	I-Premise
4	had	N	I-Premise
5	significantly	N	I-Premise
6	more	N	I-Premise
7	vaginal	N	I-Premise
8	discharge	N	I-Premise
9	(	N	I-Premise
10	P	N	I-Premise
11	<	N	I-Premise
12	.0001	N	I-Premise
13	)	N	I-Premise
14	.	N	I-Premise

1	Exemestane	N	I-Premise
2	patients	N	I-Premise
3	reported	N	I-Premise
4	more	N	I-Premise
5	bone/muscle	N	I-Premise
6	aches	N	I-Premise
7	(	N	I-Premise
8	P	N	I-Premise
9	<	N	I-Premise
10	.0001	N	I-Premise
11	)	N	I-Premise
12	,	N	I-Premise
13	vaginal	N	I-Premise
14	dryness	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	=	N	I-Premise
18	.0004	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	and	N	I-Premise
22	difficulty	N	I-Premise
23	sleeping	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	=	N	I-Premise
27	.03	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	In	N	I-Premise
2	both	N	I-Premise
3	groups	N	I-Premise
4	,	N	I-Premise
5	the	N	I-Premise
6	hot	N	I-Premise
7	flash	N	I-Premise
8	score	N	I-Premise
9	peaked	N	I-Premise
10	at	N	I-Premise
11	3	N	I-Premise
12	months	N	I-Premise
13	and	N	I-Premise
14	decreased	N	I-Premise
15	thereafter	N	I-Premise
16	.	N	I-Premise

1	At	N	I-Premise
2	12	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	patients	N	I-Premise
6	receiving	N	I-Premise
7	tamoxifen	N	I-Premise
8	had	N	I-Premise
9	a	N	I-Premise
10	significantly	N	I-Premise
11	higher	N	I-Premise
12	mean	N	I-Premise
13	hot	N	I-Premise
14	flash	N	I-Premise
15	score	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	=	N	I-Premise
19	.03	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	with	N	I-Premise
23	daily	N	I-Premise
24	hot	N	I-Premise
25	flashes	N	I-Premise
26	increasing	N	I-Premise
27	from	N	I-Premise
28	baseline	N	I-Premise
29	by	N	I-Premise
30	33	N	I-Premise
31	%	N	I-Premise
32	compared	N	I-Premise
33	with	N	I-Premise
34	a	N	I-Premise
35	7	N	I-Premise
36	%	N	I-Premise
37	increase	N	I-Premise
38	from	N	I-Premise
39	baseline	N	I-Premise
40	with	N	I-Premise
41	exemestane	N	I-Premise
42	.	N	I-Premise

1	At	N	I-Premise
2	12	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	exemestane	N	I-Premise
6	was	N	I-Premise
7	associated	N	I-Premise
8	with	N	I-Premise
9	fewer	N	I-Premise
10	hot	N	I-Premise
11	flashes	N	I-Premise
12	and	N	I-Premise
13	less	N	I-Premise
14	vaginal	N	I-Premise
15	discharge	N	I-Premise
16	than	N	I-Premise
17	tamoxifen	N	I-Premise
18	,	N	I-Premise
19	but	N	I-Premise
20	with	N	I-Premise
21	more	N	I-Premise
22	vaginal	N	I-Premise
23	dryness	N	I-Premise
24	,	N	I-Premise
25	bone/muscle	N	I-Premise
26	aches	N	I-Premise
27	,	N	I-Premise
28	and	N	I-Premise
29	difficulty	N	I-Premise
30	sleeping	N	I-Premise
31	.	N	I-Premise

1	Symptoms	N	I-Claim
2	were	N	I-Claim
3	common	N	I-Claim
4	in	N	I-Claim
5	both	N	I-Claim
6	groups	N	I-Claim
7	.	N	I-Claim

1	Few	N	O
2	intervention	N	O
3	studies	N	O
4	have	N	O
5	been	N	O
6	conducted	N	O
7	to	N	O
8	help	N	O
9	couples	N	O
10	manage	N	O
11	the	N	O
12	effects	N	O
13	of	N	O
14	prostate	N	O
15	cancer	N	O
16	and	N	O
17	maintain	N	O
18	their	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	.	N	O

1	The	N	O
2	objective	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	determine	N	O
9	whether	N	O
10	a	N	O
11	family-based	N	O
12	intervention	N	O
13	could	N	O
14	improve	N	O
15	appraisal	N	O
16	variables	N	O
17	(	N	O
18	appraisal	N	O
19	of	N	O
20	illness	N	O
21	or	N	O
22	caregiving	N	O
23	,	N	O
24	uncertainty	N	O
25	,	N	O
26	hopelessness	N	O
27	)	N	O
28	,	N	O
29	coping	N	O
30	resources	N	O
31	(	N	O
32	coping	N	O
33	strategies	N	O
34	,	N	O
35	self-efficacy	N	O
36	,	N	O
37	communication	N	O
38	)	N	O
39	,	N	O
40	symptom	N	O
41	distress	N	O
42	,	N	O
43	and	N	O
44	quality	N	O
45	of	N	O
46	life	N	O
47	in	N	O
48	men	N	O
49	with	N	O
50	prostate	N	O
51	cancer	N	O
52	and	N	O
53	their	N	O
54	spouses	N	O
55	.	N	O

1	For	N	O
2	this	N	O
3	clinical	N	O
4	trial	N	O
5	,	N	O
6	263	N	O
7	patient-spouse	N	O
8	dyads	N	O
9	were	N	O
10	stratified	N	O
11	by	N	O
12	research	N	O
13	site	N	O
14	,	N	O
15	phase	N	O
16	of	N	O
17	illness	N	O
18	,	N	O
19	and	N	O
20	treatment	N	O
21	;	N	O
22	then	N	O
23	,	N	O
24	they	N	O
25	were	N	O
26	randomized	N	O
27	to	N	O
28	the	N	O
29	control	N	O
30	group	N	O
31	(	N	O
32	standard	N	O
33	care	N	O
34	)	N	O
35	or	N	O
36	the	N	O
37	experimental	N	O
38	group	N	O
39	(	N	O
40	standard	N	O
41	care	N	O
42	plus	N	O
43	a	N	O
44	5-session	N	O
45	family	N	O
46	intervention	N	O
47	)	N	O
48	.	N	O

1	The	N	O
2	intervention	N	O
3	targeted	N	O
4	couples	N	O
5	'	N	O
6	communication	N	O
7	,	N	O
8	hope	N	O
9	,	N	O
10	coping	N	O
11	,	N	O
12	uncertainty	N	O
13	,	N	O
14	and	N	O
15	symptom	N	O
16	management	N	O
17	.	N	O

1	The	N	O
2	final	N	O
3	sample	N	O
4	consisted	N	O
5	of	N	O
6	235	N	O
7	couples	N	O
8	:	N	O
9	123	N	O
10	couples	N	O
11	in	N	O
12	the	N	O
13	control	N	O
14	group	N	O
15	and	N	O
16	112	N	O
17	couples	N	O
18	in	N	O
19	the	N	O
20	experimental	N	O
21	group	N	O
22	.	N	O

1	Data	N	O
2	collection	N	O
3	occurred	N	O
4	at	N	O
5	baseline	N	O
6	before	N	O
7	randomization	N	O
8	and	N	O
9	at	N	O
10	4	N	O
11	months	N	O
12	,	N	O
13	8	N	O
14	months	N	O
15	,	N	O
16	and	N	O
17	12	N	O
18	months	N	O
19	.	N	O

1	At	N	I-Premise
2	4-month	N	I-Premise
3	follow-up	N	I-Premise
4	,	N	I-Premise
5	intervention	N	I-Premise
6	patients	N	I-Premise
7	reported	N	I-Premise
8	less	N	I-Premise
9	uncertainty	N	I-Premise
10	and	N	I-Premise
11	better	N	I-Premise
12	communication	N	I-Premise
13	with	N	I-Premise
14	spouses	N	I-Premise
15	than	N	I-Premise
16	control	N	I-Premise
17	patients	N	I-Premise
18	,	N	I-Premise
19	but	N	I-Premise
20	they	N	I-Premise
21	reported	N	I-Premise
22	no	N	I-Premise
23	other	N	I-Premise
24	effects	N	I-Premise
25	.	N	I-Premise

1	Intervention	N	I-Premise
2	spouses	N	I-Premise
3	reported	N	I-Premise
4	higher	N	I-Premise
5	quality	N	I-Premise
6	of	N	I-Premise
7	life	N	I-Premise
8	,	N	I-Premise
9	more	N	I-Premise
10	self-efficacy	N	I-Premise
11	,	N	I-Premise
12	better	N	I-Premise
13	communication	N	I-Premise
14	,	N	I-Premise
15	and	N	I-Premise
16	less	N	I-Premise
17	negative	N	I-Premise
18	appraisal	N	I-Premise
19	of	N	I-Premise
20	caregiving	N	I-Premise
21	,	N	I-Premise
22	uncertainty	N	I-Premise
23	,	N	I-Premise
24	hopelessness	N	I-Premise
25	,	N	I-Premise
26	and	N	I-Premise
27	symptom	N	I-Premise
28	distress	N	I-Premise
29	at	N	I-Premise
30	4	N	I-Premise
31	months	N	I-Premise
32	compared	N	I-Premise
33	with	N	I-Premise
34	controls	N	I-Premise
35	,	N	I-Premise
36	and	N	I-Premise
37	some	N	I-Premise
38	effects	N	I-Premise
39	were	N	I-Premise
40	sustained	N	I-Premise
41	to	N	I-Premise
42	8	N	I-Premise
43	months	N	I-Premise
44	and	N	I-Premise
45	12	N	I-Premise
46	months	N	I-Premise
47	.	N	I-Premise

1	Men	N	I-Premise
2	with	N	I-Premise
3	prostate	N	I-Premise
4	cancer	N	I-Premise
5	and	N	I-Premise
6	their	N	I-Premise
7	spouses	N	I-Premise
8	reported	N	I-Premise
9	positive	N	I-Premise
10	outcomes	N	I-Premise
11	from	N	I-Premise
12	a	N	I-Premise
13	family	N	I-Premise
14	intervention	N	I-Premise
15	that	N	I-Premise
16	offered	N	I-Premise
17	them	N	I-Premise
18	information	N	I-Premise
19	and	N	I-Premise
20	support	N	I-Premise
21	.	N	I-Premise

1	Programs	N	I-Claim
2	of	N	I-Claim
3	care	N	I-Claim
4	need	N	I-Claim
5	to	N	I-Claim
6	be	N	I-Claim
7	extended	N	I-Claim
8	to	N	I-Claim
9	spouses	N	I-Claim
10	who	N	I-Claim
11	likely	N	I-Claim
12	will	N	I-Claim
13	experience	N	I-Claim
14	multiple	N	I-Claim
15	benefits	N	I-Claim
16	from	N	I-Claim
17	intervention	N	I-Claim
18	.	N	I-Claim

1	We	N	O
2	conducted	N	O
3	a	N	O
4	multicenter	N	O
5	,	N	O
6	randomized	N	O
7	trial	N	O
8	to	N	O
9	compare	N	O
10	progression-free	N	O
11	survival	N	O
12	(	N	O
13	PFS	N	O
14	)	N	O
15	,	N	O
16	overall	N	O
17	survival	N	O
18	(	N	O
19	OS	N	O
20	)	N	O
21	,	N	O
22	and	N	O
23	quality	N	O
24	of	N	O
25	life	N	O
26	in	N	O
27	women	N	O
28	with	N	O
29	metastatic	N	O
30	breast	N	O
31	cancer	N	O
32	(	N	O
33	MBC	N	O
34	)	N	O
35	receiving	N	O
36	high-dose	N	O
37	chemotherapy	N	O
38	plus	N	O
39	autologous	N	O
40	stem-cell	N	O
41	transplantation	N	O
42	(	N	O
43	ASCT	N	O
44	;	N	O
45	HDCT	N	O
46	)	N	O
47	compared	N	O
48	with	N	O
49	standard-dose	N	O
50	therapy	N	O
51	.	N	O

1	Between	N	O
2	April	N	O
3	1997	N	O
4	and	N	O
5	December	N	O
6	2000	N	O
7	,	N	O
8	386	N	O
9	women	N	O
10	with	N	O
11	MBC	N	O
12	and	N	O
13	no	N	O
14	prior	N	O
15	chemotherapy	N	O
16	for	N	O
17	metastatic	N	O
18	disease	N	O
19	were	N	O
20	registered	N	O
21	.	N	O

1	After	N	O
2	initial	N	O
3	response	N	O
4	to	N	O
5	anthracycline-	N	O
6	or	N	O
7	taxane-based	N	O
8	induction	N	O
9	chemotherapy	N	O
10	,	N	O
11	224	N	O
12	patients	N	O
13	were	N	O
14	randomly	N	O
15	assigned	N	O
16	:	N	O
17	112	N	O
18	to	N	O
19	high-dose	N	O
20	cyclophosphamide	N	O
21	,	N	O
22	mitoxantrone	N	O
23	,	N	O
24	and	N	O
25	carboplatin	N	O
26	chemotherapy	N	O
27	and	N	O
28	ASCT	N	O
29	(	N	O
30	HDCT	N	O
31	)	N	O
32	,	N	O
33	and	N	O
34	112	N	O
35	to	N	O
36	standard	N	O
37	therapy	N	O
38	(	N	O
39	ST	N	O
40	)	N	O
41	.	N	O

1	Median	N	O
2	age	N	O
3	was	N	O
4	47	N	O
5	years	N	O
6	(	N	O
7	range	N	O
8	,	N	O
9	25	N	O
10	to	N	O
11	67	N	O
12	years	N	O
13	)	N	O
14	.	N	O

1	Thirty	N	O
2	two	N	O
3	percent	N	O
4	of	N	O
5	women	N	O
6	randomly	N	O
7	assigned	N	O
8	had	N	O
9	estrogen	N	O
10	and	N	O
11	progesterone	N	O
12	receptor-negative	N	O
13	breast	N	O
14	cancer	N	O
15	,	N	O
16	42	N	O
17	%	N	O
18	had	N	O
19	visceral	N	O
20	metastases	N	O
21	,	N	O
22	and	N	O
23	58	N	O
24	%	N	O
25	had	N	O
26	bone	N	O
27	metastases	N	O
28	.	N	O

1	Complete	N	O
2	remission	N	O
3	rates	N	O
4	before	N	O
5	random	N	O
6	assignment	N	O
7	were	N	O
8	11	N	O
9	%	N	O
10	for	N	O
11	those	N	O
12	receiving	N	O
13	HDCT	N	O
14	and	N	O
15	12	N	O
16	%	N	O
17	for	N	O
18	those	N	O
19	receiving	N	O
20	ST.	N	O
21	After	N	I-Premise
22	a	N	I-Premise
23	median	N	I-Premise
24	follow-up	N	I-Premise
25	of	N	I-Premise
26	48	N	I-Premise
27	months	N	I-Premise
28	,	N	I-Premise
29	79	N	I-Premise
30	deaths	N	I-Premise
31	were	N	I-Premise
32	observed	N	I-Premise
33	in	N	I-Premise
34	the	N	I-Premise
35	HDCT	N	I-Premise
36	arm	N	I-Premise
37	and	N	I-Premise
38	77	N	I-Premise
39	deaths	N	I-Premise
40	were	N	I-Premise
41	observed	N	I-Premise
42	in	N	I-Premise
43	the	N	I-Premise
44	ST	N	I-Premise
45	arm	N	I-Premise
46	;	N	I-Premise
47	seven	N	I-Premise
48	patients	N	I-Premise
49	(	N	I-Premise
50	6	N	I-Premise
51	%	N	I-Premise
52	)	N	I-Premise
53	in	N	I-Premise
54	the	N	I-Premise
55	HDCT	N	I-Premise
56	arm	N	I-Premise
57	died	N	I-Premise
58	as	N	I-Premise
59	a	N	I-Premise
60	result	N	I-Premise
61	of	N	I-Premise
62	toxicity	N	I-Premise
63	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	OS	N	I-Premise
4	was	N	I-Premise
5	24	N	I-Premise
6	months	N	I-Premise
7	for	N	I-Premise
8	the	N	I-Premise
9	HDCT	N	I-Premise
10	arm	N	I-Premise
11	(	N	I-Premise
12	95	N	I-Premise
13	%	N	I-Premise
14	CI	N	I-Premise
15	,	N	I-Premise
16	21	N	I-Premise
17	to	N	I-Premise
18	35	N	I-Premise
19	months	N	I-Premise
20	)	N	I-Premise
21	and	N	I-Premise
22	28	N	I-Premise
23	months	N	I-Premise
24	for	N	I-Premise
25	ST	N	I-Premise
26	(	N	I-Premise
27	95	N	I-Premise
28	%	N	I-Premise
29	CI	N	I-Premise
30	,	N	I-Premise
31	22	N	I-Premise
32	to	N	I-Premise
33	33	N	I-Premise
34	months	N	I-Premise
35	;	N	I-Premise
36	hazard	N	I-Premise
37	ratio	N	I-Premise
38	[	N	I-Premise
39	HR	N	I-Premise
40	]	N	I-Premise
41	,	N	I-Premise
42	0.9	N	I-Premise
43	;	N	I-Premise
44	95	N	I-Premise
45	%	N	I-Premise
46	CI	N	I-Premise
47	,	N	I-Premise
48	0.6	N	I-Premise
49	to	N	I-Premise
50	1.2	N	I-Premise
51	;	N	I-Premise
52	P	N	I-Premise
53	=	N	I-Premise
54	.43	N	I-Premise
55	)	N	I-Premise
56	.	N	I-Premise

1	PFS	N	I-Premise
2	was	N	I-Premise
3	11	N	I-Premise
4	months	N	I-Premise
5	for	N	I-Premise
6	HDCT	N	I-Premise
7	and	N	I-Premise
8	9	N	I-Premise
9	months	N	I-Premise
10	for	N	I-Premise
11	ST	N	I-Premise
12	(	N	I-Premise
13	HR	N	I-Premise
14	,	N	I-Premise
15	0.6	N	I-Premise
16	in	N	I-Premise
17	favor	N	I-Premise
18	of	N	I-Premise
19	HDCT	N	I-Premise
20	;	N	I-Premise
21	95	N	I-Premise
22	%	N	I-Premise
23	CI	N	I-Premise
24	,	N	I-Premise
25	0.5	N	I-Premise
26	to	N	I-Premise
27	0.9	N	I-Premise
28	;	N	I-Premise
29	P	N	I-Premise
30	=	N	I-Premise
31	.006	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	HDCT	N	I-Claim
2	did	N	I-Claim
3	not	N	I-Claim
4	improve	N	I-Claim
5	OS	N	I-Claim
6	in	N	I-Claim
7	women	N	I-Claim
8	with	N	I-Claim
9	MBC	N	I-Claim
10	when	N	I-Claim
11	used	N	I-Claim
12	as	N	I-Claim
13	consolidation	N	I-Claim
14	after	N	I-Claim
15	response	N	I-Claim
16	to	N	I-Claim
17	induction	N	I-Claim
18	chemotherapy	N	I-Claim
19	.	N	I-Claim

1	Studies	N	O
2	have	N	O
3	shown	N	O
4	that	N	O
5	there	N	O
6	is	N	O
7	a	N	O
8	high	N	O
9	prevalence	N	O
10	of	N	O
11	depression	N	O
12	in	N	O
13	cancer	N	O
14	patients	N	O
15	.	N	O

1	Women	N	I-MajorClaim
2	with	N	I-MajorClaim
3	breast	N	I-MajorClaim
4	cancer	N	I-MajorClaim
5	may	N	I-MajorClaim
6	have	N	I-MajorClaim
7	an	N	I-MajorClaim
8	even	N	I-MajorClaim
9	higher	N	I-MajorClaim
10	risk	N	I-MajorClaim
11	of	N	I-MajorClaim
12	depression	N	I-MajorClaim
13	particularly	N	I-MajorClaim
14	in	N	I-MajorClaim
15	a	N	I-MajorClaim
16	postmenopausal	N	I-MajorClaim
17	or	N	I-MajorClaim
18	estrogen	N	I-MajorClaim
19	deficiency	N	I-MajorClaim
20	state	N	I-MajorClaim
21	.	N	I-MajorClaim

1	A	N	O
2	small	N	O
3	number	N	O
4	of	N	O
5	randomized	N	O
6	controlled	N	O
7	trials	N	O
8	have	N	O
9	examined	N	O
10	the	N	O
11	efficacy	N	O
12	of	N	O
13	antidepressants	N	O
14	compared	N	O
15	to	N	O
16	that	N	O
17	of	N	O
18	a	N	O
19	placebo	N	O
20	in	N	O
21	cancer	N	O
22	patients	N	O
23	,	N	O
24	but	N	O
25	some	N	O
26	results	N	O
27	have	N	O
28	been	N	O
29	difficult	N	O
30	to	N	O
31	interpret	N	O
32	due	N	O
33	to	N	O
34	a	N	O
35	heterogeneous	N	O
36	patient	N	O
37	group	N	O
38	.	N	O

1	In	N	O
2	the	N	O
3	current	N	O
4	investigation	N	O
5	,	N	O
6	we	N	O
7	screened	N	O
8	newly	N	O
9	diagnosed	N	O
10	early	N	O
11	stage	N	O
12	breast	N	O
13	cancer	N	O
14	patients	N	O
15	for	N	O
16	depressive	N	O
17	symptoms	N	O
18	prior	N	O
19	to	N	O
20	the	N	O
21	initiation	N	O
22	of	N	O
23	adjuvant	N	O
24	therapy	N	O
25	and	N	O
26	investigated	N	O
27	whether	N	O
28	the	N	O
29	oral	N	O
30	antidepressant	N	O
31	fluoxetine	N	O
32	affected	N	O
33	depressive	N	O
34	symptoms	N	O
35	,	N	O
36	completion	N	O
37	of	N	O
38	adjuvant	N	O
39	treatment	N	O
40	,	N	O
41	and	N	O
42	quality	N	O
43	of	N	O
44	life	N	O
45	.	N	O

1	Patients	N	O
2	with	N	O
3	newly	N	O
4	diagnosed	N	O
5	early	N	O
6	stage	N	O
7	breast	N	O
8	cancer	N	O
9	were	N	O
10	screened	N	O
11	for	N	O
12	depressive	N	O
13	symptoms	N	O
14	prior	N	O
15	to	N	O
16	the	N	O
17	initiation	N	O
18	of	N	O
19	adjuvant	N	O
20	therapy	N	O
21	.	N	O

1	Patients	N	O
2	with	N	O
3	depressive	N	O
4	symptoms	N	O
5	were	N	O
6	randomized	N	O
7	to	N	O
8	a	N	O
9	daily	N	O
10	oral	N	O
11	fluoxetine	N	O
12	or	N	O
13	a	N	O
14	placebo	N	O
15	.	N	O

1	Patients	N	O
2	were	N	O
3	then	N	O
4	followed	N	O
5	for	N	O
6	6	N	O
7	months	N	O
8	and	N	O
9	evaluated	N	O
10	for	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	,	N	O
15	completion	N	O
16	of	N	O
17	adjuvant	N	O
18	treatment	N	O
19	,	N	O
20	and	N	O
21	depressive	N	O
22	symptoms	N	O
23	.	N	O

1	A	N	O
2	high	N	O
3	percentage	N	O
4	of	N	O
5	patients	N	O
6	with	N	O
7	newly	N	O
8	diagnosed	N	O
9	early	N	O
10	stage	N	O
11	breast	N	O
12	cancer	N	O
13	were	N	O
14	found	N	O
15	to	N	O
16	have	N	O
17	depressive	N	O
18	symptoms	N	O
19	prior	N	O
20	to	N	O
21	the	N	O
22	initiation	N	O
23	of	N	O
24	adjuvant	N	O
25	therapy	N	O
26	.	N	O

1	The	N	I-Premise
2	use	N	I-Premise
3	of	N	I-Premise
4	fluoxetine	N	I-Premise
5	for	N	I-Premise
6	6	N	I-Premise
7	months	N	I-Premise
8	resulted	N	I-Premise
9	in	N	I-Premise
10	an	N	I-Premise
11	improvement	N	I-Premise
12	in	N	I-Premise
13	quality	N	I-Premise
14	of	N	I-Premise
15	life	N	I-Premise
16	,	N	I-Premise
17	a	N	I-Premise
18	higher	N	I-Premise
19	completion	N	I-Premise
20	of	N	I-Premise
21	adjuvant	N	I-Premise
22	treatment	N	I-Premise
23	(	N	I-Premise
24	chemotherapy	N	I-Premise
25	,	N	I-Premise
26	hormonal	N	I-Premise
27	therapy	N	I-Premise
28	,	N	I-Premise
29	chemotherapy	N	I-Premise
30	plus	N	I-Premise
31	hormonal	N	I-Premise
32	therapy	N	I-Premise
33	)	N	I-Premise
34	,	N	I-Premise
35	and	N	I-Premise
36	a	N	I-Premise
37	reduction	N	I-Premise
38	in	N	I-Premise
39	depressive	N	I-Premise
40	symptoms	N	I-Premise
41	compared	N	I-Premise
42	to	N	I-Premise
43	patients	N	I-Premise
44	who	N	I-Premise
45	received	N	I-Premise
46	placebo	N	I-Premise
47	.	N	I-Premise

1	An	N	I-Claim
2	antidepressant	N	I-Claim
3	should	N	I-Claim
4	be	N	I-Claim
5	considered	N	I-Claim
6	for	N	I-Claim
7	early	N	I-Claim
8	stage	N	I-Claim
9	breast	N	I-Claim
10	cancer	N	I-Claim
11	patients	N	I-Claim
12	with	N	I-Claim
13	depressive	N	I-Claim
14	symptoms	N	I-Claim
15	who	N	I-Claim
16	are	N	I-Claim
17	receiving	N	I-Claim
18	adjuvant	N	I-Claim
19	treatment	N	I-Claim
20	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	immediate	N	O
5	and	N	O
6	long-term	N	O
7	effects	N	O
8	of	N	O
9	true	N	O
10	acupuncture	N	O
11	versus	N	O
12	sham	N	O
13	acupuncture	N	O
14	on	N	O
15	hot	N	O
16	flash	N	O
17	frequency	N	O
18	in	N	O
19	women	N	O
20	with	N	O
21	breast	N	O
22	cancer	N	O
23	.	N	O

1	Seventy-two	N	O
2	women	N	O
3	with	N	O
4	breast	N	O
5	cancer	N	O
6	experiencing	N	O
7	three	N	O
8	or	N	O
9	more	N	O
10	hot	N	O
11	flashes	N	O
12	per	N	O
13	day	N	O
14	were	N	O
15	randomly	N	O
16	assigned	N	O
17	to	N	O
18	receive	N	O
19	either	N	O
20	true	N	O
21	or	N	O
22	sham	N	O
23	acupuncture	N	O
24	.	N	O

1	Interventions	N	O
2	were	N	O
3	given	N	O
4	twice	N	O
5	weekly	N	O
6	for	N	O
7	4	N	O
8	consecutive	N	O
9	weeks	N	O
10	.	N	O

1	Hot	N	O
2	flash	N	O
3	frequency	N	O
4	was	N	O
5	evaluated	N	O
6	at	N	O
7	baseline	N	O
8	,	N	O
9	at	N	O
10	6	N	O
11	weeks	N	O
12	,	N	O
13	and	N	O
14	at	N	O
15	6	N	O
16	months	N	O
17	after	N	O
18	initiation	N	O
19	of	N	O
20	treatment	N	O
21	.	N	O

1	Patients	N	O
2	initially	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	the	N	O
7	sham	N	O
8	group	N	O
9	were	N	O
10	crossed	N	O
11	over	N	O
12	to	N	O
13	true	N	O
14	acupuncture	N	O
15	starting	N	O
16	at	N	O
17	week	N	O
18	7	N	O
19	.	N	O

1	The	N	O
2	mean	N	O
3	number	N	O
4	of	N	O
5	hot	N	O
6	flashes	N	O
7	per	N	O
8	day	N	O
9	was	N	O
10	reduced	N	O
11	from	N	O
12	8.7	N	O
13	(	N	O
14	standard	N	O
15	deviation	N	O
16	[	N	O
17	SD	N	O
18	]	N	O
19	,	N	O
20	3.9	N	O
21	)	N	O
22	to	N	O
23	6.2	N	O
24	(	N	O
25	SD	N	O
26	,	N	O
27	4.2	N	O
28	)	N	O
29	in	N	O
30	the	N	O
31	true	N	O
32	acupuncture	N	O
33	group	N	O
34	and	N	O
35	from	N	O
36	10.0	N	O
37	(	N	O
38	SD	N	O
39	,	N	O
40	6.1	N	O
41	)	N	O
42	to	N	O
43	7.6	N	O
44	(	N	O
45	SD	N	O
46	,	N	O
47	5.7	N	O
48	)	N	O
49	in	N	O
50	the	N	O
51	sham	N	O
52	group	N	O
53	.	N	O

1	True	N	I-Premise
2	acupuncture	N	I-Premise
3	was	N	I-Premise
4	associated	N	I-Premise
5	with	N	I-Premise
6	0.8	N	I-Premise
7	fewer	N	I-Premise
8	hot	N	I-Premise
9	flashes	N	I-Premise
10	per	N	I-Premise
11	day	N	I-Premise
12	than	N	I-Premise
13	sham	N	I-Premise
14	at	N	I-Premise
15	6	N	I-Premise
16	weeks	N	I-Premise
17	,	N	O
18	but	N	I-Premise
19	the	N	I-Premise
20	difference	N	I-Premise
21	did	N	I-Premise
22	not	N	I-Premise
23	reach	N	I-Premise
24	statistical	N	I-Premise
25	significance	N	I-Premise
26	(	N	I-Premise
27	95	N	I-Premise
28	%	N	I-Premise
29	CI	N	I-Premise
30	,	N	I-Premise
31	-0.7	N	I-Premise
32	to	N	I-Premise
33	2.4	N	I-Premise
34	;	N	I-Premise
35	P	N	I-Premise
36	=	N	I-Premise
37	.3	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	When	N	I-Premise
2	participants	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	sham	N	I-Premise
6	acupuncture	N	I-Premise
7	group	N	I-Premise
8	were	N	I-Premise
9	crossed	N	I-Premise
10	over	N	I-Premise
11	to	N	I-Premise
12	true	N	I-Premise
13	acupuncture	N	I-Premise
14	,	N	I-Premise
15	a	N	I-Premise
16	further	N	I-Premise
17	reduction	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	frequency	N	I-Premise
21	of	N	I-Premise
22	hot	N	I-Premise
23	flashes	N	I-Premise
24	was	N	I-Premise
25	seen	N	I-Premise
26	.	N	I-Premise

1	This	N	O
2	reduction	N	O
3	in	N	O
4	hot	N	O
5	flash	N	O
6	frequency	N	O
7	persisted	N	O
8	for	N	O
9	up	N	O
10	to	N	O
11	6	N	O
12	months	N	O
13	after	N	O
14	the	N	O
15	completion	N	O
16	of	N	O
17	treatment	N	O
18	.	N	O

1	Hot	N	I-Claim
2	flash	N	I-Claim
3	frequency	N	I-Claim
4	in	N	I-Claim
5	breast	N	I-Claim
6	cancer	N	I-Claim
7	patients	N	I-Claim
8	was	N	I-Claim
9	reduced	N	I-Claim
10	following	N	I-Claim
11	acupuncture	N	I-Claim
12	.	N	I-Claim

1	However	N	O
2	,	N	O
3	when	N	I-Premise
4	compared	N	I-Premise
5	with	N	I-Premise
6	sham	N	I-Premise
7	acupuncture	N	I-Premise
8	,	N	I-Premise
9	the	N	I-Premise
10	reduction	N	I-Premise
11	by	N	I-Premise
12	the	N	I-Premise
13	acupuncture	N	I-Premise
14	regimen	N	I-Premise
15	as	N	I-Premise
16	provided	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	current	N	I-Premise
20	study	N	I-Premise
21	did	N	I-Premise
22	not	N	I-Premise
23	reach	N	I-Premise
24	statistical	N	I-Premise
25	significance	N	I-Premise
26	.	N	I-Premise

1	We	N	I-Claim
2	can	N	I-Claim
3	not	N	I-Claim
4	exclude	N	I-Claim
5	the	N	I-Claim
6	possibility	N	I-Claim
7	that	N	I-Claim
8	a	N	I-Claim
9	longer	N	I-Claim
10	and	N	I-Claim
11	more	N	I-Claim
12	intense	N	I-Claim
13	acupuncture	N	I-Claim
14	intervention	N	I-Claim
15	could	N	I-Claim
16	produce	N	I-Claim
17	a	N	I-Claim
18	larger	N	I-Claim
19	reduction	N	I-Claim
20	of	N	I-Claim
21	these	N	I-Claim
22	symptoms	N	I-Claim
23	.	N	I-Claim

1	Few	N	O
2	exercise	N	O
3	trials	N	O
4	in	N	O
5	cancer	N	O
6	patients	N	O
7	have	N	O
8	reported	N	O
9	longer-term	N	O
10	follow-up	N	O
11	.	N	O

1	Here	N	O
2	,	N	O
3	we	N	O
4	report	N	O
5	a	N	O
6	6-month	N	O
7	follow-up	N	O
8	of	N	O
9	exercise	N	O
10	behavior	N	O
11	and	N	O
12	patient-rated	N	O
13	outcomes	N	O
14	from	N	O
15	an	N	O
16	exercise	N	O
17	trial	N	O
18	in	N	O
19	breast	N	O
20	cancer	N	O
21	patients	N	O
22	.	N	O

1	Breast	N	O
2	cancer	N	O
3	patients	N	O
4	initiating	N	O
5	adjuvant	N	O
6	chemotherapy	N	O
7	(	N	O
8	n	N	O
9	=	N	O
10	242	N	O
11	)	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	to	N	O
16	usual	N	O
17	care	N	O
18	(	N	O
19	n	N	O
20	=	N	O
21	82	N	O
22	)	N	O
23	,	N	O
24	resistance	N	O
25	exercise	N	O
26	training	N	O
27	(	N	O
28	RET	N	O
29	;	N	O
30	n	N	O
31	=	N	O
32	82	N	O
33	)	N	O
34	,	N	O
35	or	N	O
36	aerobic	N	O
37	exercise	N	O
38	training	N	O
39	(	N	O
40	AET	N	O
41	;	N	O
42	n	N	O
43	=	N	O
44	78	N	O
45	)	N	O
46	for	N	O
47	the	N	O
48	duration	N	O
49	of	N	O
50	their	N	O
51	chemotherapy	N	O
52	.	N	O

1	At	N	O
2	6-month	N	O
3	follow-up	N	O
4	,	N	O
5	participants	N	O
6	were	N	O
7	mailed	N	O
8	a	N	O
9	questionnaire	N	O
10	that	N	O
11	assessed	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	,	N	O
16	self-esteem	N	O
17	,	N	O
18	fatigue	N	O
19	,	N	O
20	anxiety	N	O
21	,	N	O
22	depression	N	O
23	,	N	O
24	and	N	O
25	exercise	N	O
26	behavior	N	O
27	.	N	O

1	Two	N	O
2	hundred	N	O
3	one	N	O
4	(	N	O
5	83.1	N	O
6	%	N	O
7	)	N	O
8	participants	N	O
9	provided	N	O
10	6-month	N	O
11	follow-up	N	O
12	data	N	O
13	.	N	O

1	Adjusted	N	I-Premise
2	linear	N	I-Premise
3	mixed-model	N	I-Premise
4	analyses	N	I-Premise
5	showed	N	I-Premise
6	that	N	I-Premise
7	,	N	I-Premise
8	at	N	I-Premise
9	6-month	N	I-Premise
10	follow-up	N	I-Premise
11	,	N	I-Premise
12	the	N	I-Premise
13	RET	N	I-Premise
14	group	N	I-Premise
15	reported	N	I-Premise
16	higher	N	I-Premise
17	self-esteem	N	I-Premise
18	[	N	I-Premise
19	adjusted	N	I-Premise
20	mean	N	I-Premise
21	difference	N	I-Premise
22	,	N	I-Premise
23	1.6	N	I-Premise
24	;	N	I-Premise
25	95	N	I-Premise
26	%	N	I-Premise
27	confidence	N	I-Premise
28	interval	N	I-Premise
29	(	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	CI	N	I-Premise
33	)	N	I-Premise
34	,	N	I-Premise
35	0.1-3.2	N	I-Premise
36	;	N	I-Premise
37	P	N	I-Premise
38	=	N	I-Premise
39	0.032	N	I-Premise
40	]	N	I-Premise
41	and	N	I-Premise
42	the	N	I-Premise
43	AET	N	I-Premise
44	group	N	I-Premise
45	reported	N	I-Premise
46	lower	N	I-Premise
47	anxiety	N	I-Premise
48	(	N	I-Premise
49	adjusted	N	I-Premise
50	mean	N	I-Premise
51	difference	N	I-Premise
52	,	N	I-Premise
53	-4.7	N	I-Premise
54	;	N	I-Premise
55	95	N	I-Premise
56	%	N	I-Premise
57	CI	N	I-Premise
58	,	N	I-Premise
59	-0.0	N	I-Premise
60	to	N	I-Premise
61	-9.3	N	I-Premise
62	;	N	I-Premise
63	P	N	I-Premise
64	=	N	I-Premise
65	0.049	N	I-Premise
66	)	N	I-Premise
67	compared	N	I-Premise
68	with	N	I-Premise
69	the	N	I-Premise
70	usual	N	I-Premise
71	care	N	I-Premise
72	group	N	I-Premise
73	.	N	I-Premise

1	Moreover	N	O
2	,	N	O
3	compared	N	I-Premise
4	with	N	I-Premise
5	participants	N	I-Premise
6	reporting	N	I-Premise
7	no	N	I-Premise
8	regular	N	I-Premise
9	exercise	N	I-Premise
10	during	N	I-Premise
11	the	N	I-Premise
12	follow-up	N	I-Premise
13	period	N	I-Premise
14	,	N	I-Premise
15	those	N	I-Premise
16	reporting	N	I-Premise
17	regular	N	I-Premise
18	aerobic	N	I-Premise
19	and	N	I-Premise
20	resistance	N	I-Premise
21	exercise	N	I-Premise
22	also	N	I-Premise
23	reported	N	I-Premise
24	better	N	I-Premise
25	patient-rated	N	I-Premise
26	outcomes	N	I-Premise
27	,	N	I-Premise
28	including	N	I-Premise
29	quality	N	I-Premise
30	of	N	I-Premise
31	life	N	I-Premise
32	(	N	I-Premise
33	adjusted	N	I-Premise
34	mean	N	I-Premise
35	difference	N	I-Premise
36	,	N	I-Premise
37	9.5	N	I-Premise
38	;	N	I-Premise
39	95	N	I-Premise
40	%	N	I-Premise
41	CI	N	I-Premise
42	,	N	I-Premise
43	1.2-17.8	N	I-Premise
44	;	N	I-Premise
45	P	N	I-Premise
46	=	N	I-Premise
47	0.025	N	I-Premise
48	)	N	I-Premise
49	.	N	I-Premise

1	Improvements	N	I-Premise
2	in	N	I-Premise
3	self-esteem	N	I-Premise
4	observed	N	I-Premise
5	with	N	I-Premise
6	RET	N	I-Premise
7	during	N	I-Premise
8	breast	N	I-Premise
9	cancer	N	I-Premise
10	chemotherapy	N	I-Premise
11	were	N	I-Premise
12	maintained	N	I-Premise
13	at	N	I-Premise
14	6-month	N	I-Premise
15	follow-up	N	I-Premise
16	whereas	N	O
17	reductions	N	I-Premise
18	in	N	I-Premise
19	anxiety	N	I-Premise
20	not	N	I-Premise
21	observed	N	I-Premise
22	with	N	I-Premise
23	AET	N	I-Premise
24	during	N	I-Premise
25	breast	N	I-Premise
26	cancer	N	I-Premise
27	chemotherapy	N	I-Premise
28	emerged	N	I-Premise
29	at	N	I-Premise
30	6-month	N	I-Premise
31	follow-up	N	I-Premise
32	.	N	I-Premise

1	Moreover	N	O
2	,	N	O
3	adopting	N	I-Premise
4	a	N	I-Premise
5	combined	N	I-Premise
6	aerobic	N	I-Premise
7	and	N	I-Premise
8	resistance	N	I-Premise
9	exercise	N	I-Premise
10	program	N	I-Premise
11	after	N	I-Premise
12	breast	N	I-Premise
13	cancer	N	I-Premise
14	chemotherapy	N	I-Premise
15	was	N	I-Premise
16	associated	N	I-Premise
17	with	N	I-Premise
18	further	N	I-Premise
19	improvements	N	I-Premise
20	in	N	I-Premise
21	patient-rated	N	I-Premise
22	outcomes	N	I-Premise
23	.	N	I-Premise

1	Exercise	N	I-Claim
2	training	N	I-Claim
3	during	N	I-Claim
4	breast	N	I-Claim
5	cancer	N	I-Claim
6	chemotherapy	N	I-Claim
7	may	N	I-Claim
8	result	N	I-Claim
9	in	N	I-Claim
10	some	N	I-Claim
11	longer-term	N	I-Claim
12	and	N	I-Claim
13	late	N	I-Claim
14	effects	N	I-Claim
15	for	N	I-Claim
16	selected	N	I-Claim
17	patient-rated	N	I-Claim
18	outcomes	N	I-Claim
19	.	N	I-Claim

1	Standard	N	O
2	guidelines	N	O
3	for	N	O
4	cancer	N	O
5	pain	N	O
6	treatment	N	O
7	routinely	N	O
8	recommend	N	O
9	training	N	O
10	patients	N	O
11	to	N	O
12	reduce	N	O
13	barriers	N	O
14	to	N	O
15	pain	N	O
16	relief	N	O
17	,	N	O
18	use	N	O
19	medications	N	O
20	appropriately	N	O
21	,	N	O
22	and	N	O
23	communicate	N	O
24	their	N	O
25	pain-related	N	O
26	needs	N	O
27	.	N	O

1	Methods	N	I-MajorClaim
2	are	N	I-MajorClaim
3	needed	N	I-MajorClaim
4	to	N	I-MajorClaim
5	reduce	N	I-MajorClaim
6	professional	N	I-MajorClaim
7	time	N	I-MajorClaim
8	required	N	I-MajorClaim
9	while	N	I-MajorClaim
10	achieving	N	I-MajorClaim
11	sustained	N	I-MajorClaim
12	intervention	N	I-MajorClaim
13	effectiveness	N	I-MajorClaim
14	.	N	I-MajorClaim

1	In	N	O
2	a	N	O
3	multisite	N	O
4	,	N	O
5	randomized	N	O
6	controlled	N	O
7	trial	N	O
8	,	N	O
9	this	N	O
10	study	N	O
11	tested	N	O
12	a	N	O
13	pain	N	O
14	training	N	O
15	method	N	O
16	versus	N	O
17	a	N	O
18	nutrition	N	O
19	control	N	O
20	.	N	O

1	At	N	O
2	six	N	O
3	oncology	N	O
4	clinics	N	O
5	,	N	O
6	physicians	N	O
7	(	N	O
8	N=22	N	O
9	)	N	O
10	and	N	O
11	nurses	N	O
12	(	N	O
13	N=23	N	O
14	)	N	O
15	enrolled	N	O
16	patients	N	O
17	(	N	O
18	N=93	N	O
19	)	N	O
20	who	N	O
21	were	N	O
22	over	N	O
23	18	N	O
24	years	N	O
25	of	N	O
26	age	N	O
27	,	N	O
28	with	N	O
29	cancer	N	O
30	diagnoses	N	O
31	,	N	O
32	pain	N	O
33	,	N	O
34	and	N	O
35	a	N	O
36	life	N	O
37	expectancy	N	O
38	of	N	O
39	at	N	O
40	least	N	O
41	6	N	O
42	months	N	O
43	.	N	O

1	Pain	N	O
2	training	N	O
3	and	N	O
4	control	N	O
5	interventions	N	O
6	were	N	O
7	matched	N	O
8	for	N	O
9	materials	N	O
10	and	N	O
11	method	N	O
12	.	N	O

1	Patients	N	O
2	watched	N	O
3	a	N	O
4	video	N	O
5	followed	N	O
6	by	N	O
7	about	N	O
8	20	N	O
9	min	N	O
10	of	N	O
11	manual-standardized	N	O
12	training	N	O
13	with	N	O
14	an	N	O
15	oncology	N	O
16	nurse	N	O
17	focused	N	O
18	on	N	O
19	reviewing	N	O
20	the	N	O
21	printed	N	O
22	material	N	O
23	and	N	O
24	adapted	N	O
25	to	N	O
26	individual	N	O
27	concerns	N	O
28	of	N	O
29	patients	N	O
30	.	N	O

1	A	N	O
2	follow-up	N	O
3	phone	N	O
4	call	N	O
5	after	N	O
6	72	N	O
7	h	N	O
8	addressed	N	O
9	individualized	N	O
10	treatment	N	O
11	content	N	O
12	and	N	O
13	pain	N	O
14	communication	N	O
15	.	N	O

1	Assessments	N	O
2	at	N	O
3	baseline	N	O
4	,	N	O
5	one	N	O
6	,	N	O
7	three	N	O
8	,	N	O
9	and	N	O
10	6	N	O
11	months	N	O
12	included	N	O
13	barriers	N	O
14	,	N	O
15	the	N	O
16	Brief	N	O
17	Pain	N	O
18	Inventory	N	O
19	,	N	O
20	opioid	N	O
21	use	N	O
22	,	N	O
23	and	N	O
24	physician	N	O
25	and	N	O
26	nurse	N	O
27	ratings	N	O
28	of	N	O
29	their	N	O
30	patients	N	O
31	'	N	O
32	pain	N	O
33	.	N	O

1	Trained	N	I-Premise
2	versus	N	I-Premise
3	control	N	I-Premise
4	patients	N	I-Premise
5	reported	N	I-Premise
6	reduced	N	I-Premise
7	barriers	N	I-Premise
8	to	N	I-Premise
9	pain	N	I-Premise
10	relief	N	I-Premise
11	(	N	I-Premise
12	P	N	I-Premise
13	<	N	I-Premise
14	.001	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	lower	N	I-Premise
18	usual	N	I-Premise
19	pain	N	I-Premise
20	(	N	I-Premise
21	P=.03	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	and	N	I-Premise
25	greater	N	I-Premise
26	opioid	N	I-Premise
27	use	N	I-Premise
28	(	N	I-Premise
29	P	N	I-Premise
30	<	N	I-Premise
31	.001	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	No	N	I-Premise
2	pain	N	I-Premise
3	training	N	I-Premise
4	patients	N	I-Premise
5	reported	N	I-Premise
6	severe	N	I-Premise
7	pain	N	I-Premise
8	(	N	I-Premise
9	>	N	I-Premise
10	6	N	I-Premise
11	on	N	I-Premise
12	a	N	I-Premise
13	0-10	N	I-Premise
14	scale	N	I-Premise
15	)	N	I-Premise
16	at	N	I-Premise
17	1-month	N	I-Premise
18	outcomes	N	I-Premise
19	(	N	I-Premise
20	P=.03	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	Physician	N	O
2	and	N	O
3	nurse	N	O
4	ratings	N	O
5	were	N	O
6	closer	N	O
7	to	N	O
8	patients	N	O
9	'	N	O
10	ratings	N	O
11	of	N	O
12	pain	N	O
13	for	N	O
14	trained	N	O
15	versus	N	O
16	nutrition	N	O
17	groups	N	O
18	(	N	O
19	P=.04	N	O
20	and	N	O
21	<	N	O
22	.001	N	O
23	,	N	O
24	respectively	N	O
25	)	N	O
26	.	N	O

1	Training	N	O
2	efficacy	N	O
3	was	N	O
4	not	N	O
5	modified	N	O
6	by	N	O
7	patient	N	O
8	characteristics	N	O
9	.	N	O

1	Using	N	I-Claim
2	video	N	I-Claim
3	and	N	I-Claim
4	print	N	I-Claim
5	materials	N	I-Claim
6	,	N	I-Claim
7	with	N	I-Claim
8	brief	N	I-Claim
9	individualized	N	I-Claim
10	training	N	I-Claim
11	,	N	I-Claim
12	effectively	N	I-Claim
13	improved	N	I-Claim
14	pain	N	I-Claim
15	management	N	I-Claim
16	over	N	I-Claim
17	time	N	I-Claim
18	for	N	I-Claim
19	cancer	N	I-Claim
20	patients	N	I-Claim
21	of	N	I-Claim
22	varying	N	I-Claim
23	diagnostic	N	I-Claim
24	and	N	I-Claim
25	demographic	N	I-Claim
26	groups	N	I-Claim
27	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	short-	N	O
4	and	N	O
5	long-term	N	O
6	effects	N	O
7	of	N	O
8	adjuvant	N	O
9	treatment	N	O
10	versus	N	O
11	observation	N	O
12	after	N	O
13	surgery	N	O
14	on	N	O
15	health-related	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	HRQL	N	O
21	)	N	O
22	of	N	O
23	prostate	N	O
24	cancer	N	O
25	patients	N	O
26	.	N	O

1	The	N	O
2	Southwest	N	O
3	Oncology	N	O
4	Group	N	O
5	(	N	O
6	SWOG	N	O
7	)	N	O
8	intergroup	N	O
9	trial	N	O
10	compared	N	O
11	radical	N	O
12	prostatectomy	N	O
13	(	N	O
14	RP	N	O
15	)	N	O
16	plus	N	O
17	observation	N	O
18	versus	N	O
19	RP	N	O
20	plus	N	O
21	adjuvant	N	O
22	radiation	N	O
23	therapy	N	O
24	(	N	O
25	RT	N	O
26	)	N	O
27	.	N	O

1	Two-hundred	N	O
2	seventeen	N	O
3	of	N	O
4	425	N	O
5	therapeutic	N	O
6	trial	N	O
7	patients	N	O
8	were	N	O
9	eligible	N	O
10	and	N	O
11	registered	N	O
12	to	N	O
13	the	N	O
14	HRQL	N	O
15	study	N	O
16	.	N	O

1	Patients	N	O
2	completed	N	O
3	the	N	O
4	SWOG	N	O
5	Quality	N	O
6	of	N	O
7	Life	N	O
8	Questionnaire	N	O
9	(	N	O
10	emotional	N	O
11	,	N	O
12	physical	N	O
13	,	N	O
14	social	N	O
15	,	N	O
16	and	N	O
17	role	N	O
18	function	N	O
19	;	N	O
20	general	N	O
21	symptom	N	O
22	status	N	O
23	;	N	O
24	treatment/disease-specific	N	O
25	symptoms	N	O
26	;	N	O
27	and	N	O
28	global	N	O
29	HRQL	N	O
30	[	N	O
31	GHRQL	N	O
32	]	N	O
33	)	N	O
34	at	N	O
35	baseline	N	O
36	,	N	O
37	6	N	O
38	weeks	N	O
39	,	N	O
40	6	N	O
41	months	N	O
42	,	N	O
43	and	N	O
44	annually	N	O
45	for	N	O
46	5	N	O
47	years	N	O
48	.	N	O

1	Prespecified	N	O
2	outcomes	N	O
3	were	N	O
4	three	N	O
5	genitourinary	N	O
6	symptoms	N	O
7	(	N	O
8	bowel	N	O
9	function	N	O
10	tenderness	N	O
11	,	N	O
12	frequent	N	O
13	urination	N	O
14	,	N	O
15	and	N	O
16	erectile	N	O
17	dysfunction	N	O
18	[	N	O
19	ED	N	O
20	]	N	O
21	)	N	O
22	and	N	O
23	measures	N	O
24	of	N	O
25	physical	N	O
26	and	N	O
27	emotional	N	O
28	function	N	O
29	.	N	O

1	Adjustments	N	O
2	were	N	O
3	made	N	O
4	for	N	O
5	the	N	O
6	baseline	N	O
7	score	N	O
8	.	N	O

1	Patients	N	O
2	receiving	N	O
3	adjuvant	N	O
4	RT	N	O
5	reported	N	O
6	worse	N	O
7	bowel	N	O
8	function	N	O
9	(	N	O
10	through	N	O
11	approximately	N	O
12	2	N	O
13	years	N	O
14	)	N	O
15	and	N	O
16	worse	N	O
17	urinary	N	O
18	function	N	O
19	.	N	O

1	There	N	O
2	were	N	O
3	no	N	O
4	statistically	N	O
5	significant	N	O
6	differences	N	O
7	for	N	O
8	ED	N	O
9	.	N	O

1	GHRQL	N	I-Premise
2	was	N	I-Premise
3	initially	N	I-Premise
4	worse	N	I-Premise
5	for	N	I-Premise
6	the	N	I-Premise
7	RP+RT	N	I-Premise
8	arm	N	I-Premise
9	but	N	I-Premise
10	improved	N	I-Premise
11	over	N	I-Premise
12	time	N	I-Premise
13	and	N	I-Premise
14	was	N	I-Premise
15	better	N	I-Premise
16	at	N	I-Premise
17	the	N	I-Premise
18	end	N	I-Premise
19	of	N	I-Premise
20	the	N	I-Premise
21	period	N	I-Premise
22	than	N	I-Premise
23	the	N	I-Premise
24	GHRQL	N	I-Premise
25	reported	N	I-Premise
26	for	N	I-Premise
27	RP	N	I-Premise
28	alone	N	I-Premise
29	(	N	I-Premise
30	treatment	N	I-Premise
31	arm	N	I-Premise
32	x	N	I-Premise
33	time	N	I-Premise
34	interaction	N	I-Premise
35	,	N	I-Premise
36	P	N	I-Premise
37	=	N	I-Premise
38	.0004	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	Symptom	N	I-Premise
2	distress	N	I-Premise
3	was	N	I-Premise
4	significantly	N	I-Premise
5	worse	N	I-Premise
6	for	N	I-Premise
7	the	N	I-Premise
8	RP+RT	N	I-Premise
9	arm	N	I-Premise
10	compared	N	I-Premise
11	with	N	I-Premise
12	the	N	I-Premise
13	RP	N	I-Premise
14	alone	N	I-Premise
15	arm	N	I-Premise
16	,	N	O
17	but	N	I-Premise
18	the	N	I-Premise
19	treatment	N	I-Premise
20	arms	N	I-Premise
21	did	N	I-Premise
22	not	N	I-Premise
23	differ	N	I-Premise
24	with	N	I-Premise
25	respect	N	I-Premise
26	to	N	I-Premise
27	other	N	I-Premise
28	general	N	I-Premise
29	measures	N	I-Premise
30	of	N	I-Premise
31	HRQL	N	I-Premise
32	.	N	I-Premise

1	The	N	I-Premise
2	addition	N	I-Premise
3	of	N	I-Premise
4	RT	N	I-Premise
5	to	N	I-Premise
6	surgery	N	I-Premise
7	resulted	N	I-Premise
8	in	N	I-Premise
9	more	N	I-Premise
10	frequent	N	I-Premise
11	urination	N	I-Premise
12	,	N	I-Premise
13	as	N	I-Premise
14	well	N	I-Premise
15	as	N	I-Premise
16	early	N	I-Premise
17	report	N	I-Premise
18	of	N	I-Premise
19	more	N	I-Premise
20	bowel	N	I-Premise
21	dysfunction	N	I-Premise
22	,	N	O
23	although	N	I-Premise
24	bowel	N	I-Premise
25	function	N	I-Premise
26	differences	N	I-Premise
27	disappeared	N	I-Premise
28	over	N	I-Premise
29	the	N	I-Premise
30	5-year	N	I-Premise
31	period	N	I-Premise
32	.	N	I-Premise

1	The	N	I-Claim
2	addition	N	I-Claim
3	of	N	I-Claim
4	RT	N	I-Claim
5	did	N	I-Claim
6	not	N	I-Claim
7	negatively	N	I-Claim
8	impact	N	I-Claim
9	ED	N	I-Claim
10	.	N	I-Claim

1	The	N	O
2	TAX	N	O
3	327	N	O
4	study	N	O
5	compared	N	O
6	docetaxel	N	O
7	administered	N	O
8	every	N	O
9	3	N	O
10	weeks	N	O
11	(	N	O
12	D3	N	O
13	)	N	O
14	,	N	O
15	weekly	N	O
16	docetaxel	N	O
17	(	N	O
18	D1	N	O
19	)	N	O
20	,	N	O
21	and	N	O
22	mitoxantrone	N	O
23	(	N	O
24	M	N	O
25	)	N	O
26	,	N	O
27	each	N	O
28	with	N	O
29	prednisone	N	O
30	(	N	O
31	P	N	O
32	)	N	O
33	,	N	O
34	in	N	O
35	1,006	N	O
36	men	N	O
37	with	N	O
38	metastatic	N	O
39	hormone-resistant	N	O
40	prostate	N	O
41	cancer	N	O
42	(	N	O
43	HRPC	N	O
44	)	N	O
45	.	N	O

1	The	N	O
2	original	N	O
3	analysis	N	O
4	,	N	O
5	undertaken	N	O
6	in	N	O
7	August	N	O
8	2003	N	O
9	when	N	O
10	557	N	O
11	deaths	N	O
12	had	N	O
13	occurred	N	O
14	,	N	O
15	showed	N	O
16	significantly	N	O
17	better	N	O
18	survival	N	O
19	and	N	O
20	response	N	O
21	rates	N	O
22	for	N	O
23	pain	N	O
24	,	N	O
25	prostate-specific	N	O
26	antigen	N	O
27	(	N	O
28	PSA	N	O
29	)	N	O
30	,	N	O
31	and	N	O
32	quality	N	O
33	of	N	O
34	life	N	O
35	for	N	O
36	D3P	N	O
37	when	N	O
38	compared	N	O
39	with	N	O
40	MP	N	O
41	.	N	O

1	Here	N	O
2	,	N	O
3	we	N	O
4	report	N	O
5	an	N	O
6	updated	N	O
7	analysis	N	O
8	of	N	O
9	survival	N	O
10	.	N	O

1	Investigators	N	O
2	were	N	O
3	asked	N	O
4	to	N	O
5	provide	N	O
6	the	N	O
7	date	N	O
8	of	N	O
9	death	N	O
10	or	N	O
11	last	N	O
12	follow-up	N	O
13	for	N	O
14	all	N	O
15	participants	N	O
16	who	N	O
17	were	N	O
18	alive	N	O
19	in	N	O
20	August	N	O
21	2003	N	O
22	.	N	O

1	By	N	O
2	March	N	O
3	2007	N	O
4	,	N	O
5	data	N	O
6	on	N	O
7	310	N	O
8	additional	N	O
9	deaths	N	O
10	were	N	O
11	obtained	N	O
12	(	N	O
13	total	N	O
14	=	N	O
15	867	N	O
16	deaths	N	O
17	)	N	O
18	.	N	O

1	The	N	I-Premise
2	survival	N	I-Premise
3	benefit	N	I-Premise
4	of	N	I-Premise
5	D3P	N	I-Premise
6	compared	N	I-Premise
7	with	N	I-Premise
8	MP	N	I-Premise
9	has	N	I-Premise
10	persisted	N	I-Premise
11	with	N	I-Premise
12	extended	N	I-Premise
13	follow-up	N	I-Premise
14	(	N	I-Premise
15	P	N	I-Premise
16	=	N	I-Premise
17	.004	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	Median	N	O
2	survival	N	O
3	time	N	O
4	was	N	O
5	19.2	N	O
6	months	N	O
7	(	N	O
8	95	N	O
9	%	N	O
10	CI	N	O
11	,	N	O
12	17.5	N	O
13	to	N	O
14	21.3	N	O
15	months	N	O
16	)	N	O
17	in	N	O
18	the	N	O
19	D3P	N	O
20	arm	N	O
21	,	N	O
22	17.8	N	O
23	months	N	O
24	(	N	O
25	95	N	O
26	%	N	O
27	CI	N	O
28	,	N	O
29	16.2	N	O
30	to	N	O
31	19.2	N	O
32	months	N	O
33	)	N	O
34	in	N	O
35	the	N	O
36	D1P	N	O
37	arm	N	O
38	,	N	O
39	and	N	O
40	16.3	N	O
41	months	N	O
42	(	N	O
43	95	N	O
44	%	N	O
45	CI	N	O
46	,	N	O
47	14.3	N	O
48	to	N	O
49	17.9	N	O
50	months	N	O
51	)	N	O
52	in	N	O
53	the	N	O
54	MP	N	O
55	arm	N	O
56	.	N	O

1	More	N	I-Premise
2	patients	N	I-Premise
3	survived	N	I-Premise
4	>	N	I-Premise
5	/=	N	I-Premise
6	3	N	I-Premise
7	years	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	D3P	N	I-Premise
11	and	N	I-Premise
12	D1P	N	I-Premise
13	arms	N	I-Premise
14	(	N	I-Premise
15	18.6	N	I-Premise
16	%	N	I-Premise
17	and	N	I-Premise
18	16.6	N	I-Premise
19	%	N	I-Premise
20	,	N	I-Premise
21	respectively	N	I-Premise
22	)	N	I-Premise
23	compared	N	I-Premise
24	with	N	I-Premise
25	the	N	I-Premise
26	MP	N	I-Premise
27	arm	N	I-Premise
28	(	N	I-Premise
29	13.5	N	I-Premise
30	%	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Similar	N	I-Premise
2	trends	N	I-Premise
3	in	N	I-Premise
4	survival	N	I-Premise
5	between	N	I-Premise
6	treatment	N	I-Premise
7	arms	N	I-Premise
8	were	N	I-Premise
9	seen	N	I-Premise
10	for	N	I-Premise
11	men	N	I-Premise
12	greater	N	I-Premise
13	than	N	I-Premise
14	and	N	I-Premise
15	less	N	I-Premise
16	than	N	I-Premise
17	65	N	I-Premise
18	years	N	I-Premise
19	of	N	I-Premise
20	age	N	I-Premise
21	,	N	I-Premise
22	for	N	I-Premise
23	those	N	I-Premise
24	with	N	I-Premise
25	and	N	I-Premise
26	without	N	I-Premise
27	pain	N	I-Premise
28	at	N	I-Premise
29	baseline	N	I-Premise
30	,	N	I-Premise
31	and	N	I-Premise
32	for	N	I-Premise
33	those	N	I-Premise
34	with	N	I-Premise
35	baseline	N	I-Premise
36	PSA	N	I-Premise
37	greater	N	I-Premise
38	than	N	I-Premise
39	and	N	I-Premise
40	less	N	I-Premise
41	than	N	I-Premise
42	the	N	I-Premise
43	median	N	I-Premise
44	value	N	I-Premise
45	of	N	I-Premise
46	115	N	I-Premise
47	ng/mL	N	I-Premise
48	.	N	I-Premise

1	The	N	I-Claim
2	present	N	I-Claim
3	analysis	N	I-Claim
4	confirms	N	I-Claim
5	that	N	I-Claim
6	survival	N	I-Claim
7	of	N	I-Claim
8	men	N	I-Claim
9	with	N	I-Claim
10	metastatic	N	I-Claim
11	HRPC	N	I-Claim
12	is	N	I-Claim
13	significantly	N	I-Claim
14	longer	N	I-Claim
15	after	N	I-Claim
16	treatment	N	I-Claim
17	with	N	I-Claim
18	D3P	N	I-Claim
19	than	N	I-Claim
20	with	N	I-Claim
21	MP	N	I-Claim
22	.	N	I-Claim

1	Consistent	N	O
2	results	N	O
3	are	N	O
4	observed	N	O
5	across	N	O
6	subgroups	N	O
7	of	N	O
8	patients	N	O
9	.	N	O

1	To	N	O
2	prospectively	N	O
3	evaluate	N	O
4	health-related	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	(	N	O
9	HRQOL	N	O
10	)	N	O
11	outcomes	N	O
12	for	N	O
13	uterine	N	O
14	artery	N	O
15	embolization	N	O
16	(	N	O
17	UAE	N	O
18	)	N	O
19	and	N	O
20	hysterectomy	N	O
21	up	N	O
22	to	N	O
23	24	N	O
24	months	N	O
25	after	N	O
26	the	N	O
27	intervention	N	O
28	in	N	O
29	terms	N	O
30	of	N	O
31	mental	N	O
32	and	N	O
33	physical	N	O
34	health	N	O
35	,	N	O
36	urinary	N	O
37	and	N	O
38	defecatory	N	O
39	function	N	O
40	,	N	O
41	and	N	O
42	overall	N	O
43	patient	N	O
44	satisfaction	N	O
45	.	N	O

1	Ethics	N	O
2	committee	N	O
3	approval	N	O
4	and	N	O
5	informed	N	O
6	consent	N	O
7	were	N	O
8	obtained	N	O
9	for	N	O
10	the	N	O
11	Embolisation	N	O
12	versus	N	O
13	Hysterectomy	N	O
14	Trial	N	O
15	.	N	O

1	Women	N	O
2	(	N	O
3	n	N	O
4	=	N	O
5	177	N	O
6	)	N	O
7	with	N	O
8	uterine	N	O
9	fibroids	N	O
10	and	N	O
11	heavy	N	O
12	menstrual	N	O
13	bleeding	N	O
14	who	N	O
15	were	N	O
16	scheduled	N	O
17	to	N	O
18	undergo	N	O
19	hysterectomy	N	O
20	were	N	O
21	randomly	N	O
22	assigned	N	O
23	to	N	O
24	undergo	N	O
25	UAE	N	O
26	(	N	O
27	n	N	O
28	=	N	O
29	88	N	O
30	)	N	O
31	or	N	O
32	hysterectomy	N	O
33	(	N	O
34	n	N	O
35	=	N	O
36	89	N	O
37	)	N	O
38	.	N	O

1	HRQOL	N	O
2	was	N	O
3	measured	N	O
4	six	N	O
5	times	N	O
6	during	N	O
7	a	N	O
8	24-month	N	O
9	follow-up	N	O
10	period	N	O
11	with	N	O
12	the	N	O
13	following	N	O
14	validated	N	O
15	questionnaires	N	O
16	:	N	O
17	Medical	N	O
18	Outcome	N	O
19	Study	N	O
20	Short	N	O
21	Form	N	O
22	36	N	O
23	(	N	O
24	SF-36	N	O
25	)	N	O
26	mental	N	O
27	component	N	O
28	summary	N	O
29	(	N	O
30	MCS	N	O
31	)	N	O
32	and	N	O
33	physical	N	O
34	component	N	O
35	summary	N	O
36	(	N	O
37	PCS	N	O
38	)	N	O
39	,	N	O
40	Health	N	O
41	Utilities	N	O
42	Index	N	O
43	Mark	N	O
44	3	N	O
45	,	N	O
46	EuroQol	N	O
47	5D	N	O
48	,	N	O
49	urogenital	N	O
50	distress	N	O
51	inventory	N	O
52	(	N	O
53	UDI	N	O
54	)	N	O
55	,	N	O
56	incontinence	N	O
57	impact	N	O
58	questionnaire	N	O
59	,	N	O
60	and	N	O
61	defecation	N	O
62	distress	N	O
63	inventory	N	O
64	(	N	O
65	DDI	N	O
66	)	N	O
67	.	N	O

1	Satisfaction	N	O
2	was	N	O
3	assessed	N	O
4	with	N	O
5	a	N	O
6	seven-point	N	O
7	Likert	N	O
8	scale	N	O
9	.	N	O

1	Repeated	N	O
2	measurement	N	O
3	analysis	N	O
4	was	N	O
5	performed	N	O
6	for	N	O
7	between-group	N	O
8	analysis	N	O
9	.	N	O

1	Paired	N	O
2	t	N	O
3	tests	N	O
4	were	N	O
5	performed	N	O
6	for	N	O
7	within-group	N	O
8	analysis	N	O
9	.	N	O

1	Satisfaction	N	O
2	was	N	O
3	analyzed	N	O
4	with	N	O
5	the	N	O
6	Fisher	N	O
7	exact	N	O
8	test	N	O
9	.	N	O

1	The	N	I-Premise
2	SF-36	N	I-Premise
3	MCS	N	I-Premise
4	and	N	I-Premise
5	PCS	N	I-Premise
6	,	N	I-Premise
7	Health	N	I-Premise
8	Utilities	N	I-Premise
9	Index	N	I-Premise
10	Mark	N	I-Premise
11	3	N	I-Premise
12	,	N	I-Premise
13	EuroQol	N	I-Premise
14	5D	N	I-Premise
15	,	N	I-Premise
16	and	N	I-Premise
17	UDI	N	I-Premise
18	scores	N	I-Premise
19	were	N	I-Premise
20	improved	N	I-Premise
21	significantly	N	I-Premise
22	in	N	I-Premise
23	both	N	I-Premise
24	groups	N	I-Premise
25	at	N	I-Premise
26	6	N	I-Premise
27	months	N	I-Premise
28	and	N	I-Premise
29	afterward	N	I-Premise
30	(	N	I-Premise
31	P	N	I-Premise
32	<	N	I-Premise
33	.05	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	The	N	O
2	DDI	N	O
3	score	N	O
4	was	N	O
5	improved	N	O
6	significantly	N	O
7	in	N	O
8	only	N	O
9	the	N	O
10	UAE	N	O
11	group	N	O
12	at	N	O
13	6	N	O
14	months	N	O
15	and	N	O
16	afterward	N	O
17	(	N	O
18	P	N	O
19	<	N	O
20	.05	N	O
21	)	N	O
22	.	N	O

1	No	N	O
2	differences	N	O
3	between	N	O
4	groups	N	O
5	were	N	O
6	observed	N	O
7	,	N	O
8	with	N	O
9	the	N	O
10	exception	N	O
11	of	N	O
12	PCS	N	O
13	scores	N	O
14	at	N	O
15	6-week	N	O
16	follow-up	N	O
17	:	N	O
18	Patients	N	O
19	in	N	O
20	the	N	O
21	UAE	N	O
22	group	N	O
23	had	N	O
24	significantly	N	O
25	better	N	O
26	scores	N	O
27	than	N	O
28	did	N	O
29	patients	N	O
30	in	N	O
31	the	N	O
32	hysterectomy	N	O
33	group	N	O
34	(	N	O
35	P	N	O
36	<	N	O
37	.001	N	O
38	)	N	O
39	.	N	O

1	Improvement	N	O
2	in	N	O
3	PCS	N	O
4	score	N	O
5	at	N	O
6	24-month	N	O
7	follow-up	N	O
8	was	N	O
9	significantly	N	O
10	higher	N	O
11	for	N	O
12	patients	N	O
13	who	N	O
14	were	N	O
15	employed	N	O
16	at	N	O
17	baseline	N	O
18	(	N	O
19	P	N	O
20	=	N	O
21	.035	N	O
22	)	N	O
23	.	N	O

1	At	N	I-Premise
2	24-month	N	I-Premise
3	follow-up	N	I-Premise
4	,	N	I-Premise
5	patients	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	hysterectomy	N	I-Premise
9	group	N	I-Premise
10	were	N	I-Premise
11	significantly	N	I-Premise
12	more	N	I-Premise
13	satisfied	N	I-Premise
14	than	N	I-Premise
15	those	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	UAE	N	I-Premise
19	group	N	I-Premise
20	(	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	.02	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	Both	N	I-Claim
2	UAE	N	I-Claim
3	and	N	I-Claim
4	hysterectomy	N	I-Claim
5	improved	N	I-Claim
6	HRQOL	N	I-Claim
7	.	N	I-Claim

1	No	N	I-Claim
2	differences	N	I-Claim
3	were	N	I-Claim
4	observed	N	I-Claim
5	between	N	I-Claim
6	groups	N	I-Claim
7	regarding	N	I-Claim
8	HRQOL	N	I-Claim
9	at	N	I-Claim
10	24-month	N	I-Claim
11	follow-up	N	I-Claim
12	.	N	I-Claim

1	On	N	I-Claim
2	the	N	I-Claim
3	basis	N	I-Claim
4	of	N	I-Claim
5	HRQOL	N	I-Claim
6	results	N	I-Claim
7	,	N	I-Claim
8	the	N	I-Claim
9	authors	N	I-Claim
10	determined	N	I-Claim
11	that	N	I-Claim
12	UAE	N	I-Claim
13	is	N	I-Claim
14	a	N	I-Claim
15	good	N	I-Claim
16	alternative	N	I-Claim
17	to	N	I-Claim
18	hysterectomy	N	I-Claim
19	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	(	N	O
14	QOL	N	O
15	)	N	O
16	of	N	O
17	high-risk	N	O
18	breast	N	O
19	cancer	N	O
20	patients	N	O
21	included	N	O
22	in	N	O
23	a	N	O
24	randomized	N	O
25	clinical	N	O
26	trial	N	O
27	(	N	O
28	PEGASE	N	O
29	01	N	O
30	)	N	O
31	comparing	N	O
32	conventional	N	O
33	chemotherapy	N	O
34	versus	N	O
35	adding	N	O
36	an	N	O
37	additional	N	O
38	high-dose	N	O
39	chemotherapy	N	O
40	(	N	O
41	HDC	N	O
42	)	N	O
43	cycle	N	O
44	with	N	O
45	blood	N	O
46	stem	N	O
47	cell	N	O
48	support	N	O
49	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	314	N	O
5	patients	N	O
6	were	N	O
7	included	N	O
8	in	N	O
9	the	N	O
10	clinical	N	O
11	trial	N	O
12	.	N	O

1	QOL	N	O
2	evaluations	N	O
3	were	N	O
4	available	N	O
5	for	N	O
6	199	N	O
7	patients	N	O
8	.	N	O

1	QOL	N	O
2	was	N	O
3	assessed	N	O
4	over	N	O
5	a	N	O
6	1-year	N	O
7	follow-up	N	O
8	period	N	O
9	,	N	O
10	using	N	O
11	the	N	O
12	European	N	O
13	Organization	N	O
14	for	N	O
15	Research	N	O
16	and	N	O
17	Treatment	N	O
18	of	N	O
19	Cancer	N	O
20	Quality	N	O
21	of	N	O
22	Life	N	O
23	Questionnaire	N	O
24	C-30	N	O
25	.	N	O

1	The	N	O
2	results	N	O
3	were	N	O
4	analyzed	N	O
5	using	N	O
6	a	N	O
7	linear	N	O
8	mixed-effects	N	O
9	model	N	O
10	.	N	O

1	Toxicity	N	I-Premise
2	of	N	I-Premise
3	HDC	N	I-Premise
4	has	N	I-Premise
5	a	N	I-Premise
6	strong	N	I-Premise
7	negative	N	I-Premise
8	impact	N	I-Premise
9	on	N	I-Premise
10	patients	N	I-Premise
11	'	N	I-Premise
12	QOL	N	I-Premise
13	during	N	I-Premise
14	the	N	I-Premise
15	treatment	N	I-Premise
16	phase	N	I-Premise
17	.	N	I-Premise

1	This	N	I-Premise
2	negative	N	I-Premise
3	impact	N	I-Premise
4	tended	N	I-Premise
5	to	N	I-Premise
6	last	N	I-Premise
7	longer	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	HDC	N	I-Premise
11	group	N	I-Premise
12	,	N	I-Premise
13	as	N	I-Premise
14	for	N	I-Premise
15	most	N	I-Premise
16	of	N	I-Premise
17	the	N	I-Premise
18	QLQ-C30	N	I-Premise
19	scales	N	I-Premise
20	,	N	I-Premise
21	the	N	I-Premise
22	QOL	N	I-Premise
23	scores	N	I-Premise
24	of	N	I-Premise
25	HDC	N	I-Premise
26	patients	N	I-Premise
27	tend	N	I-Premise
28	to	N	I-Premise
29	improve	N	I-Premise
30	at	N	I-Premise
31	a	N	I-Premise
32	slower	N	I-Premise
33	rate	N	I-Premise
34	than	N	I-Premise
35	that	N	I-Premise
36	of	N	I-Premise
37	patients	N	I-Premise
38	receiving	N	I-Premise
39	standard	N	I-Premise
40	chemotherapy	N	I-Premise
41	.	N	I-Premise

1	In	N	O
2	particular	N	O
3	,	N	O
4	physical	N	I-Premise
5	functioning	N	I-Premise
6	remains	N	I-Premise
7	deteriorated	N	I-Premise
8	1	N	I-Premise
9	year	N	I-Premise
10	after	N	I-Premise
11	inclusion	N	I-Premise
12	for	N	I-Premise
13	HDC	N	I-Premise
14	patients	N	I-Premise
15	comparatively	N	I-Premise
16	to	N	I-Premise
17	conventional	N	I-Premise
18	chemotherapy	N	I-Premise
19	patients	N	I-Premise
20	(	N	I-Premise
21	85.99	N	I-Premise
22	vs.	N	I-Premise
23	76.65	N	I-Premise
24	,	N	I-Premise
25	P	N	I-Premise
26	=	N	I-Premise
27	0.021	N	I-Premise
28	)	N	I-Premise
29	,	N	O
30	and	N	I-Premise
31	the	N	I-Premise
32	pain	N	I-Premise
33	score	N	I-Premise
34	was	N	I-Premise
35	still	N	I-Premise
36	higher	N	I-Premise
37	in	N	I-Premise
38	the	N	I-Premise
39	HDC	N	I-Premise
40	group	N	I-Premise
41	at	N	I-Premise
42	that	N	I-Premise
43	time	N	I-Premise
44	(	N	I-Premise
45	28.32	N	I-Premise
46	vs.	N	I-Premise
47	15.97	N	I-Premise
48	,	N	I-Premise
49	P	N	I-Premise
50	=	N	I-Premise
51	0.004	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	HDC	N	I-Claim
2	has	N	I-Claim
3	a	N	I-Claim
4	negative	N	I-Claim
5	impact	N	I-Claim
6	on	N	I-Claim
7	QOL	N	I-Claim
8	even	N	I-Claim
9	after	N	I-Claim
10	treatment	N	I-Claim
11	phase	N	I-Claim
12	.	N	I-Claim

1	In	N	O
2	the	N	O
3	absence	N	O
4	of	N	O
5	an	N	O
6	overall	N	O
7	survival	N	O
8	benefit	N	O
9	of	N	O
10	using	N	O
11	HDC	N	O
12	for	N	O
13	high-risk	N	O
14	breast	N	O
15	cancer	N	O
16	patients	N	O
17	,	N	O
18	QOL	N	O
19	studies	N	O
20	with	N	O
21	a	N	O
22	longer	N	O
23	follow-up	N	O
24	play	N	O
25	an	N	O
26	important	N	O
27	role	N	O
28	in	N	O
29	informing	N	O
30	the	N	O
31	complex	N	O
32	trade-off	N	O
33	implied	N	O
34	by	N	O
35	HDC	N	O
36	between	N	O
37	higher	N	O
38	toxicity	N	O
39	,	N	O
40	reduced	N	O
41	risk	N	O
42	of	N	O
43	relapse	N	O
44	,	N	O
45	and	N	O
46	QOL	N	O
47	decrease	N	O
48	after	N	O
49	the	N	O
50	active	N	O
51	phase	N	O
52	of	N	O
53	treatment	N	O
54	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	multicenter	N	O
6	randomized	N	O
7	trial	N	O
8	was	N	O
9	to	N	O
10	assess	N	O
11	the	N	O
12	efficacy	N	O
13	and	N	O
14	safety	N	O
15	of	N	O
16	sentinel	N	O
17	lymph	N	O
18	node	N	O
19	(	N	O
20	SLN	N	O
21	)	N	O
22	biopsy	N	O
23	compared	N	O
24	with	N	O
25	axillary	N	O
26	lymph	N	O
27	node	N	O
28	dissection	N	O
29	(	N	O
30	ALND	N	O
31	)	N	O
32	.	N	O

1	All	N	O
2	studies	N	O
3	on	N	O
4	SLN	N	O
5	biopsy	N	O
6	in	N	O
7	breast	N	O
8	cancer	N	O
9	report	N	O
10	a	N	O
11	variable	N	O
12	false	N	O
13	negative	N	O
14	rate	N	O
15	,	N	O
16	whose	N	O
17	prognostic	N	O
18	consequences	N	O
19	are	N	O
20	still	N	O
21	unclear	N	O
22	.	N	O

1	From	N	O
2	May	N	O
3	1999	N	O
4	to	N	O
5	December	N	O
6	2004	N	O
7	,	N	O
8	patients	N	O
9	with	N	O
10	breast	N	O
11	cancer	N	O
12	<	N	O
13	or	N	O
14	=3	N	O
15	cm	N	O
16	were	N	O
17	randomly	N	O
18	assigned	N	O
19	to	N	O
20	receive	N	O
21	SLN	N	O
22	biopsy	N	O
23	associated	N	O
24	with	N	O
25	ALND	N	O
26	(	N	O
27	ALND	N	O
28	arm	N	O
29	)	N	O
30	or	N	O
31	SLN	N	O
32	biopsy	N	O
33	followed	N	O
34	by	N	O
35	ALND	N	O
36	only	N	O
37	if	N	O
38	the	N	O
39	SLN	N	O
40	was	N	O
41	metastatic	N	O
42	(	N	O
43	SLN	N	O
44	arm	N	O
45	)	N	O
46	.	N	O

1	The	N	O
2	main	N	O
3	aim	N	O
4	was	N	O
5	the	N	O
6	comparison	N	O
7	of	N	O
8	disease-free	N	O
9	survival	N	O
10	in	N	O
11	the	N	O
12	2	N	O
13	arms	N	O
14	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	749	N	O
5	patients	N	O
6	were	N	O
7	randomized	N	O
8	and	N	O
9	697	N	O
10	were	N	O
11	available	N	O
12	for	N	O
13	analysis	N	O
14	.	N	O

1	SLNs	N	O
2	were	N	O
3	identified	N	O
4	in	N	O
5	662	N	O
6	of	N	O
7	697	N	O
8	patients	N	O
9	(	N	O
10	95	N	O
11	%	N	O
12	)	N	O
13	and	N	O
14	positive	N	O
15	SLNs	N	O
16	were	N	O
17	found	N	O
18	in	N	O
19	189	N	O
20	of	N	O
21	662	N	O
22	patients	N	O
23	(	N	O
24	28.5	N	O
25	%	N	O
26	)	N	O
27	.	N	O

1	In	N	O
2	the	N	O
3	ALND	N	O
4	group	N	O
5	,	N	O
6	positive	N	O
7	non-SLNs	N	O
8	were	N	O
9	found	N	O
10	in	N	O
11	18	N	O
12	patients	N	O
13	with	N	O
14	negative	N	O
15	SLN	N	O
16	,	N	O
17	giving	N	O
18	a	N	O
19	false	N	O
20	negative	N	O
21	rate	N	O
22	of	N	O
23	16.7	N	O
24	%	N	O
25	(	N	O
26	18	N	O
27	of	N	O
28	108	N	O
29	)	N	O
30	.	N	O

1	Postoperative	N	I-Premise
2	side	N	I-Premise
3	effects	N	I-Premise
4	were	N	I-Premise
5	significantly	N	I-Premise
6	less	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	SLN	N	I-Premise
10	group	N	I-Premise
11	and	N	I-Premise
12	there	N	I-Premise
13	was	N	I-Premise
14	no	N	I-Premise
15	negative	N	I-Premise
16	impact	N	I-Premise
17	of	N	I-Premise
18	the	N	I-Premise
19	SLN	N	I-Premise
20	procedure	N	I-Premise
21	on	N	I-Premise
22	psychologic	N	I-Premise
23	well	N	I-Premise
24	being	N	I-Premise
25	.	N	I-Premise

1	At	N	O
2	a	N	O
3	median	N	O
4	follow-up	N	O
5	of	N	O
6	56	N	O
7	months	N	O
8	,	N	O
9	there	N	O
10	were	N	O
11	more	N	O
12	locoregional	N	O
13	recurrences	N	O
14	in	N	O
15	the	N	O
16	SLN	N	O
17	arm	N	O
18	,	N	O
19	and	N	O
20	the	N	O
21	5-year	N	O
22	disease-free	N	O
23	survival	N	O
24	was	N	O
25	89.9	N	O
26	%	N	O
27	in	N	O
28	the	N	O
29	ALND	N	O
30	arm	N	O
31	and	N	O
32	87.6	N	O
33	%	N	O
34	in	N	O
35	the	N	O
36	SLN	N	O
37	arm	N	O
38	,	N	O
39	with	N	O
40	a	N	O
41	difference	N	O
42	of	N	O
43	2.3	N	O
44	%	N	O
45	(	N	O
46	95	N	O
47	%	N	O
48	confidence	N	O
49	interval	N	O
50	:	N	O
51	-3.1	N	O
52	%	N	O
53	to	N	O
54	7.6	N	O
55	%	N	O
56	)	N	O
57	.	N	O

1	However	N	I-Premise
2	,	N	I-Premise
3	the	N	I-Premise
4	number	N	I-Premise
5	of	N	I-Premise
6	enrolled	N	I-Premise
7	patients	N	I-Premise
8	was	N	I-Premise
9	not	N	I-Premise
10	sufficient	N	I-Premise
11	to	N	I-Premise
12	draw	N	I-Premise
13	definitive	N	I-Premise
14	conclusions	N	I-Premise
15	.	N	I-Premise

1	SLN	N	I-Claim
2	biopsy	N	I-Claim
3	is	N	I-Claim
4	an	N	I-Claim
5	effective	N	I-Claim
6	and	N	I-Claim
7	well-tolerated	N	I-Claim
8	procedure	N	I-Claim
9	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	its	N	I-Claim
4	safety	N	I-Claim
5	should	N	I-Claim
6	be	N	I-Claim
7	confirmed	N	I-Claim
8	by	N	I-Claim
9	the	N	I-Claim
10	results	N	I-Claim
11	of	N	I-Claim
12	larger	N	I-Claim
13	randomized	N	I-Claim
14	trials	N	I-Claim
15	and	N	I-Claim
16	meta-analyses	N	I-Claim
17	.	N	I-Claim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	analysis	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	the	N	O
10	impact	N	O
11	of	N	O
12	pretreatment	N	O
13	factors	N	O
14	on	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	(	N	O
19	QOL	N	O
20	)	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	locally	N	O
25	advanced	N	O
26	nonsmall	N	O
27	cell	N	O
28	lung	N	O
29	cancer	N	O
30	(	N	O
31	NSCLC	N	O
32	)	N	O
33	.	N	O

1	In	N	O
2	particular	N	O
3	,	N	O
4	this	N	O
5	study	N	O
6	focused	N	O
7	on	N	O
8	the	N	O
9	possible	N	O
10	interaction	N	O
11	between	N	O
12	gender-specific	N	O
13	baseline	N	O
14	health-related	N	O
15	QOL	N	O
16	and	N	O
17	Karnofsky	N	O
18	performance	N	O
19	score	N	O
20	(	N	O
21	KPS	N	O
22	)	N	O
23	in	N	O
24	a	N	O
25	prospective	N	O
26	randomized	N	O
27	lung	N	O
28	cancer	N	O
29	trial	N	O
30	.	N	O

1	QOL	N	O
2	information	N	O
3	,	N	O
4	using	N	O
5	validated	N	O
6	instruments	N	O
7	(	N	O
8	Functional	N	O
9	Assessment	N	O
10	of	N	O
11	Cancer	N	O
12	Therapy-Lung	N	O
13	[	N	O
14	FACT-L	N	O
15	]	N	O
16	,	N	O
17	version	N	O
18	2	N	O
19	,	N	O
20	and	N	O
21	Functional	N	O
22	Living	N	O
23	Index-Cancer	N	O
24	[	N	O
25	FLIC	N	O
26	]	N	O
27	)	N	O
28	,	N	O
29	was	N	O
30	prospectively	N	O
31	collected	N	O
32	in	N	O
33	patients	N	O
34	with	N	O
35	locally	N	O
36	advanced	N	O
37	NSCLC	N	O
38	treated	N	O
39	on	N	O
40	Radiation	N	O
41	Therapy	N	O
42	Oncology	N	O
43	Group	N	O
44	(	N	O
45	RTOG	N	O
46	)	N	O
47	trial	N	O
48	89-01	N	O
49	.	N	O

1	Between	N	O
2	April	N	O
3	1990	N	O
4	and	N	O
5	April	N	O
6	1994	N	O
7	,	N	O
8	70	N	O
9	eligible	N	O
10	patients	N	O
11	participated	N	O
12	in	N	O
13	a	N	O
14	phase	N	O
15	III	N	O
16	trial	N	O
17	comparing	N	O
18	a	N	O
19	regimen	N	O
20	containing	N	O
21	sequential	N	O
22	chemotherapy	N	O
23	and	N	O
24	radiation	N	O
25	therapy	N	O
26	versus	N	O
27	sequential	N	O
28	chemotherapy	N	O
29	plus	N	O
30	surgery	N	O
31	.	N	O

1	Of	N	O
2	these	N	O
3	70	N	O
4	patients	N	O
5	,	N	O
6	46	N	O
7	underwent	N	O
8	pretreatment	N	O
9	FLIC	N	O
10	and	N	O
11	49	N	O
12	underwent	N	O
13	pretreatment	N	O
14	FACT-L	N	O
15	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	interaction	N	I-Premise
6	between	N	I-Premise
7	gender	N	I-Premise
8	and	N	I-Premise
9	KPS	N	I-Premise
10	using	N	I-Premise
11	FLIC	N	I-Premise
12	(	N	I-Premise
13	P	N	I-Premise
14	=	N	I-Premise
15	0.009	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	which	N	I-Premise
19	also	N	I-Premise
20	showed	N	I-Premise
21	a	N	I-Premise
22	trend	N	I-Premise
23	toward	N	I-Premise
24	significance	N	I-Premise
25	with	N	I-Premise
26	FACT	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	0.09	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Significant	N	I-Premise
2	KPS-by-gender	N	I-Premise
3	interactions	N	I-Premise
4	were	N	I-Premise
5	noted	N	I-Premise
6	for	N	I-Premise
7	FACT-L	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	physical	N	I-Premise
11	well-being	N	I-Premise
12	and	N	I-Premise
13	additional	N	I-Premise
14	concerns-lung	N	I-Premise
15	subscales	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	=	N	I-Premise
19	0.012	N	I-Premise
20	and	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	0.0003	N	I-Premise
24	,	N	I-Premise
25	respectively	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	The	N	I-Premise
2	results	N	I-Premise
3	of	N	I-Premise
4	both	N	I-Premise
5	the	N	I-Premise
6	FLIC	N	I-Premise
7	and	N	I-Premise
8	FACT-L	N	I-Premise
9	demonstrated	N	I-Premise
10	significantly	N	I-Premise
11	lower	N	I-Premise
12	scores	N	I-Premise
13	corresponding	N	I-Premise
14	to	N	I-Premise
15	lower	N	I-Premise
16	KPS	N	I-Premise
17	values	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	0.009	N	I-Premise
22	and	N	I-Premise
23	P	N	I-Premise
24	=	N	I-Premise
25	0.016	N	I-Premise
26	,	N	I-Premise
27	respectively	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Results	N	I-Claim
2	of	N	I-Claim
3	this	N	I-Claim
4	randomized	N	I-Claim
5	study	N	I-Claim
6	incorporating	N	I-Claim
7	prospective	N	I-Claim
8	QOL	N	I-Claim
9	measurements	N	I-Claim
10	suggested	N	I-Claim
11	that	N	I-Claim
12	in	N	I-Claim
13	patients	N	I-Claim
14	with	N	I-Claim
15	locally	N	I-Claim
16	advanced	N	I-Claim
17	NSCLC	N	I-Claim
18	,	N	I-Claim
19	analyzing	N	I-Claim
20	QOL	N	I-Claim
21	data	N	I-Claim
22	by	N	I-Claim
23	either	N	I-Claim
24	gender	N	I-Claim
25	or	N	I-Claim
26	performance	N	I-Claim
27	status	N	I-Claim
28	alone	N	I-Claim
29	may	N	I-Claim
30	not	N	I-Claim
31	accurately	N	I-Claim
32	reflect	N	I-Claim
33	how	N	I-Claim
34	these	N	I-Claim
35	factors	N	I-Claim
36	depend	N	I-Claim
37	upon	N	I-Claim
38	each	N	I-Claim
39	another	N	I-Claim
40	.	N	I-Claim

1	Understanding	N	O
2	the	N	O
3	interaction	N	O
4	between	N	O
5	gender	N	O
6	and	N	O
7	performance	N	O
8	status	N	O
9	could	N	O
10	lead	N	O
11	to	N	O
12	better	N	O
13	prognosticators	N	O
14	and	N	O
15	potentially	N	O
16	could	N	O
17	tailor	N	O
18	interventions	N	O
19	for	N	O
20	specific	N	O
21	groups	N	O
22	of	N	O
23	patients	N	O
24	with	N	O
25	lung	N	O
26	cancer	N	O
27	.	N	O

1	We	N	O
2	aimed	N	O
3	at	N	O
4	investigating	N	O
5	the	N	O
6	efficacy	N	O
7	,	N	O
8	tolerability	N	O
9	,	N	O
10	and	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	(	N	O
15	QOL	N	O
16	)	N	O
17	of	N	O
18	gemcitabine	N	O
19	(	N	O
20	GEM	N	O
21	)	N	O
22	compared	N	O
23	with	N	O
24	pegylated	N	O
25	liposomal	N	O
26	doxorubicin	N	O
27	(	N	O
28	PLD	N	O
29	)	N	O
30	in	N	O
31	the	N	O
32	salvage	N	O
33	treatment	N	O
34	of	N	O
35	recurrent	N	O
36	ovarian	N	O
37	cancer	N	O
38	.	N	O

1	A	N	O
2	phase	N	O
3	III	N	O
4	randomized	N	O
5	multicenter	N	O
6	trial	N	O
7	was	N	O
8	planned	N	O
9	to	N	O
10	compare	N	O
11	GEM	N	O
12	(	N	O
13	1,000	N	O
14	mg/m	N	O
15	(	N	O
16	2	N	O
17	)	N	O
18	on	N	O
19	days	N	O
20	1	N	O
21	,	N	O
22	8	N	O
23	,	N	O
24	and	N	O
25	15	N	O
26	every	N	O
27	28	N	O
28	days	N	O
29	)	N	O
30	with	N	O
31	PLD	N	O
32	(	N	O
33	40	N	O
34	mg/m	N	O
35	(	N	O
36	2	N	O
37	)	N	O
38	every	N	O
39	28	N	O
40	days	N	O
41	)	N	O
42	in	N	O
43	ovarian	N	O
44	cancer	N	O
45	patients	N	O
46	who	N	O
47	experienced	N	O
48	treatment	N	O
49	failure	N	O
50	with	N	O
51	only	N	O
52	one	N	O
53	platinum/paclitaxel	N	O
54	regimen	N	O
55	and	N	O
56	who	N	O
57	experienced	N	O
58	recurrence	N	O
59	or	N	O
60	progression	N	O
61	within	N	O
62	12	N	O
63	months	N	O
64	after	N	O
65	completion	N	O
66	of	N	O
67	primary	N	O
68	treatment	N	O
69	.	N	O

1	One	N	O
2	hundred	N	O
3	fifty-three	N	O
4	patients	N	O
5	were	N	O
6	randomly	N	O
7	assigned	N	O
8	to	N	O
9	PLD	N	O
10	(	N	O
11	n	N	O
12	=	N	O
13	76	N	O
14	)	N	O
15	or	N	O
16	GEM	N	O
17	(	N	O
18	n	N	O
19	=	N	O
20	77	N	O
21	)	N	O
22	.	N	O

1	Treatment	N	O
2	arms	N	O
3	were	N	O
4	well	N	O
5	balanced	N	O
6	for	N	O
7	clinicopathologic	N	O
8	characteristics	N	O
9	.	N	O

1	Grade	N	O
2	3	N	O
3	or	N	O
4	4	N	O
5	neutropenia	N	O
6	was	N	O
7	more	N	O
8	frequent	N	O
9	in	N	O
10	GEM-treated	N	O
11	patients	N	O
12	versus	N	O
13	PLD-treated	N	O
14	patients	N	O
15	(	N	O
16	P	N	O
17	=	N	O
18	.007	N	O
19	)	N	O
20	.	N	O

1	Grade	N	O
2	3	N	O
3	or	N	O
4	4	N	O
5	palmar-plantar	N	O
6	erythrodysesthesia	N	O
7	was	N	O
8	documented	N	O
9	in	N	O
10	a	N	O
11	higher	N	O
12	proportion	N	O
13	of	N	O
14	PLD	N	O
15	patients	N	O
16	(	N	O
17	6	N	O
18	%	N	O
19	)	N	O
20	versus	N	O
21	GEM	N	O
22	patients	N	O
23	(	N	O
24	0	N	O
25	%	N	O
26	;	N	O
27	P	N	O
28	=	N	O
29	.061	N	O
30	)	N	O
31	.	N	O

1	The	N	I-Premise
2	overall	N	I-Premise
3	response	N	I-Premise
4	rate	N	I-Premise
5	was	N	I-Premise
6	16	N	I-Premise
7	%	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	PLD	N	I-Premise
11	arm	N	I-Premise
12	compared	N	I-Premise
13	with	N	I-Premise
14	29	N	I-Premise
15	%	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	GEM	N	I-Premise
19	arm	N	I-Premise
20	(	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	.056	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	No	N	I-Premise
2	statistically	N	I-Premise
3	significant	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	time	N	I-Premise
7	to	N	I-Premise
8	progression	N	I-Premise
9	(	N	I-Premise
10	TTP	N	I-Premise
11	)	N	I-Premise
12	curves	N	I-Premise
13	according	N	I-Premise
14	to	N	I-Premise
15	treatment	N	I-Premise
16	allocation	N	I-Premise
17	was	N	I-Premise
18	documented	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	.411	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	a	N	I-Premise
4	trend	N	I-Premise
5	for	N	I-Premise
6	more	N	I-Premise
7	favorable	N	I-Premise
8	overall	N	I-Premise
9	survival	N	I-Premise
10	was	N	I-Premise
11	documented	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	PLD	N	I-Premise
15	arm	N	I-Premise
16	compared	N	I-Premise
17	with	N	I-Premise
18	the	N	I-Premise
19	GEM	N	I-Premise
20	arm	N	I-Premise
21	,	N	I-Premise
22	although	N	I-Premise
23	the	N	I-Premise
24	P	N	I-Premise
25	value	N	I-Premise
26	was	N	I-Premise
27	of	N	I-Premise
28	borderline	N	I-Premise
29	statistical	N	I-Premise
30	significance	N	I-Premise
31	(	N	I-Premise
32	P	N	I-Premise
33	=	N	I-Premise
34	.048	N	I-Premise
35	)	N	I-Premise
36	.	N	I-Premise

1	Statistically	N	I-Premise
2	significantly	N	I-Premise
3	higher	N	I-Premise
4	global	N	I-Premise
5	QOL	N	I-Premise
6	scores	N	I-Premise
7	were	N	I-Premise
8	found	N	I-Premise
9	in	N	I-Premise
10	PLD-treated	N	I-Premise
11	patients	N	I-Premise
12	at	N	I-Premise
13	the	N	I-Premise
14	first	N	I-Premise
15	and	N	I-Premise
16	second	N	I-Premise
17	postbaseline	N	I-Premise
18	QOL	N	I-Premise
19	assessments	N	I-Premise
20	.	N	I-Premise

1	GEM	N	I-Claim
2	does	N	I-Claim
3	not	N	I-Claim
4	provide	N	I-Claim
5	an	N	I-Claim
6	advantage	N	I-Claim
7	compared	N	I-Claim
8	with	N	I-Claim
9	PLD	N	I-Claim
10	in	N	I-Claim
11	terms	N	I-Claim
12	of	N	I-Claim
13	TTP	N	I-Claim
14	in	N	I-Claim
15	ovarian	N	I-Claim
16	cancer	N	I-Claim
17	patients	N	I-Claim
18	who	N	I-Claim
19	experience	N	I-Claim
20	recurrence	N	I-Claim
21	within	N	I-Claim
22	12	N	I-Claim
23	months	N	I-Claim
24	after	N	I-Claim
25	primary	N	I-Claim
26	treatment	N	I-Claim
27	but	N	I-Claim
28	should	N	I-Claim
29	be	N	I-Claim
30	considered	N	I-Claim
31	in	N	I-Claim
32	the	N	I-Claim
33	spectrum	N	I-Claim
34	of	N	I-Claim
35	drugs	N	I-Claim
36	to	N	I-Claim
37	be	N	I-Claim
38	possibly	N	I-Claim
39	used	N	I-Claim
40	in	N	I-Claim
41	the	N	I-Claim
42	salvage	N	I-Claim
43	setting	N	I-Claim
44	.	N	I-Claim

1	Dermatitis	N	I-MajorClaim
2	is	N	I-MajorClaim
3	a	N	I-MajorClaim
4	frequent	N	I-MajorClaim
5	adverse	N	I-MajorClaim
6	effect	N	I-MajorClaim
7	of	N	I-MajorClaim
8	adjuvant	N	I-MajorClaim
9	breast	N	I-MajorClaim
10	radiotherapy	N	I-MajorClaim
11	.	N	I-MajorClaim

1	It	N	I-MajorClaim
2	is	N	I-MajorClaim
3	more	N	I-MajorClaim
4	likely	N	I-MajorClaim
5	in	N	I-MajorClaim
6	full-breasted	N	I-MajorClaim
7	women	N	I-MajorClaim
8	and	N	I-MajorClaim
9	when	N	I-MajorClaim
10	the	N	I-MajorClaim
11	radiation	N	I-MajorClaim
12	is	N	I-MajorClaim
13	distributed	N	I-MajorClaim
14	nonhomogeneously	N	I-MajorClaim
15	in	N	I-MajorClaim
16	the	N	I-MajorClaim
17	breast	N	I-MajorClaim
18	.	N	I-MajorClaim

1	Breast	N	O
2	intensity-modulated	N	O
3	radiation	N	O
4	therapy	N	O
5	(	N	O
6	IMRT	N	O
7	)	N	O
8	is	N	O
9	a	N	O
10	technique	N	O
11	that	N	O
12	ensures	N	O
13	a	N	O
14	more	N	O
15	homogeneous	N	O
16	dose	N	O
17	distribution	N	O
18	.	N	O

1	A	N	O
2	multicenter	N	O
3	,	N	O
4	double-blind	N	O
5	,	N	O
6	randomized	N	O
7	clinical	N	O
8	trial	N	O
9	was	N	O
10	performed	N	O
11	to	N	O
12	test	N	O
13	if	N	O
14	breast	N	O
15	IMRT	N	O
16	would	N	O
17	reduce	N	O
18	the	N	O
19	rate	N	O
20	of	N	O
21	acute	N	O
22	skin	N	O
23	reaction	N	O
24	(	N	O
25	notably	N	O
26	moist	N	O
27	desquamation	N	O
28	)	N	O
29	,	N	O
30	decrease	N	O
31	pain	N	O
32	,	N	O
33	and	N	O
34	improve	N	O
35	quality	N	O
36	of	N	O
37	life	N	O
38	compared	N	O
39	with	N	O
40	standard	N	O
41	radiotherapy	N	O
42	using	N	O
43	wedges	N	O
44	.	N	O

1	Patients	N	O
2	were	N	O
3	assessed	N	O
4	each	N	O
5	week	N	O
6	during	N	O
7	and	N	O
8	up	N	O
9	to	N	O
10	6	N	O
11	weeks	N	O
12	after	N	O
13	radiotherapy	N	O
14	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	358	N	O
5	patients	N	O
6	were	N	O
7	randomly	N	O
8	assigned	N	O
9	between	N	O
10	July	N	O
11	2003	N	O
12	and	N	O
13	March	N	O
14	2005	N	O
15	in	N	O
16	two	N	O
17	Canadian	N	O
18	centers	N	O
19	,	N	O
20	and	N	O
21	331	N	O
22	were	N	O
23	included	N	O
24	in	N	O
25	the	N	O
26	analysis	N	O
27	.	N	O

1	Breast	N	I-Premise
2	IMRT	N	I-Premise
3	significantly	N	I-Premise
4	improved	N	I-Premise
5	the	N	I-Premise
6	dose	N	I-Premise
7	distribution	N	I-Premise
8	compared	N	I-Premise
9	with	N	I-Premise
10	standard	N	I-Premise
11	radiation	N	I-Premise
12	.	N	I-Premise

1	This	N	I-Premise
2	translated	N	I-Premise
3	into	N	I-Premise
4	a	N	I-Premise
5	lower	N	I-Premise
6	proportion	N	I-Premise
7	of	N	I-Premise
8	patients	N	I-Premise
9	experiencing	N	I-Premise
10	moist	N	I-Premise
11	desquamation	N	I-Premise
12	during	N	I-Premise
13	or	N	I-Premise
14	up	N	I-Premise
15	to	N	I-Premise
16	6	N	I-Premise
17	weeks	N	I-Premise
18	after	N	I-Premise
19	their	N	I-Premise
20	radiation	N	I-Premise
21	treatment	N	I-Premise
22	;	N	I-Premise
23	31.2	N	I-Premise
24	%	N	I-Premise
25	with	N	I-Premise
26	IMRT	N	I-Premise
27	compared	N	I-Premise
28	with	N	I-Premise
29	47.8	N	I-Premise
30	%	N	I-Premise
31	with	N	I-Premise
32	standard	N	I-Premise
33	treatment	N	I-Premise
34	(	N	I-Premise
35	P	N	I-Premise
36	=	N	I-Premise
37	.002	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	A	N	I-Premise
2	multivariate	N	I-Premise
3	analysis	N	I-Premise
4	found	N	I-Premise
5	the	N	I-Premise
6	use	N	I-Premise
7	of	N	I-Premise
8	breast	N	I-Premise
9	IMRT	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	=	N	I-Premise
13	.003	N	I-Premise
14	)	N	I-Premise
15	and	N	I-Premise
16	smaller	N	I-Premise
17	breast	N	I-Premise
18	size	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	<	N	I-Premise
22	.001	N	I-Premise
23	)	N	I-Premise
24	were	N	I-Premise
25	significantly	N	I-Premise
26	associated	N	I-Premise
27	with	N	I-Premise
28	a	N	I-Premise
29	decreased	N	I-Premise
30	risk	N	I-Premise
31	of	N	I-Premise
32	moist	N	I-Premise
33	desquamation	N	I-Premise
34	.	N	I-Premise

1	The	N	I-Premise
2	use	N	I-Premise
3	of	N	I-Premise
4	IMRT	N	I-Premise
5	did	N	I-Premise
6	not	N	I-Premise
7	correlate	N	I-Premise
8	with	N	I-Premise
9	pain	N	I-Premise
10	and	N	I-Premise
11	quality	N	I-Premise
12	of	N	I-Premise
13	life	N	I-Premise
14	,	N	O
15	but	N	O
16	the	N	I-Premise
17	presence	N	I-Premise
18	of	N	I-Premise
19	moist	N	I-Premise
20	desquamation	N	I-Premise
21	did	N	I-Premise
22	significantly	N	I-Premise
23	correlate	N	I-Premise
24	with	N	I-Premise
25	pain	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	=	N	I-Premise
29	.002	N	I-Premise
30	)	N	I-Premise
31	and	N	I-Premise
32	a	N	I-Premise
33	reduced	N	I-Premise
34	quality	N	I-Premise
35	of	N	I-Premise
36	life	N	I-Premise
37	(	N	I-Premise
38	P	N	I-Premise
39	=	N	I-Premise
40	.003	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	Breast	N	I-Claim
2	IMRT	N	I-Claim
3	significantly	N	I-Claim
4	reduced	N	I-Claim
5	the	N	I-Claim
6	occurrence	N	I-Claim
7	of	N	I-Claim
8	moist	N	I-Claim
9	desquamation	N	I-Claim
10	compared	N	I-Claim
11	with	N	I-Claim
12	a	N	I-Claim
13	standard	N	I-Claim
14	wedged	N	I-Claim
15	technique	N	I-Claim
16	.	N	I-Claim

1	Moist	N	I-Claim
2	desquamation	N	I-Claim
3	was	N	I-Claim
4	correlated	N	I-Claim
5	with	N	I-Claim
6	increased	N	I-Claim
7	pain	N	I-Claim
8	and	N	I-Claim
9	reduction	N	I-Claim
10	in	N	I-Claim
11	the	N	I-Claim
12	quality	N	I-Claim
13	of	N	I-Claim
14	life	N	I-Claim
15	.	N	I-Claim

1	Cancer	N	O
2	cachexia	N	O
3	is	N	O
4	a	N	O
5	common	N	O
6	problem	N	O
7	among	N	O
8	advanced	N	O
9	cancer	N	O
10	patients	N	O
11	.	N	O

1	A	N	O
2	mixture	N	O
3	of	N	O
4	beta-hydroxyl	N	O
5	beta-methyl	N	O
6	butyrate	N	O
7	,	N	O
8	glutamine	N	O
9	,	N	O
10	and	N	O
11	arginine	N	O
12	(	N	O
13	HMB/Arg/Gln	N	O
14	)	N	O
15	previously	N	O
16	showed	N	O
17	activity	N	O
18	for	N	O
19	increasing	N	O
20	lean	N	O
21	body	N	O
22	mass	N	O
23	(	N	O
24	LBM	N	O
25	)	N	O
26	among	N	O
27	patients	N	O
28	with	N	O
29	cancer	N	O
30	cachexia	N	O
31	.	N	O

1	Therefore	N	O
2	a	N	O
3	phase	N	O
4	III	N	O
5	trial	N	O
6	was	N	O
7	implemented	N	O
8	to	N	O
9	confirm	N	O
10	this	N	O
11	activity	N	O
12	.	N	O

1	Four	N	O
2	hundred	N	O
3	seventy-two	N	O
4	advanced	N	O
5	cancer	N	O
6	patients	N	O
7	with	N	O
8	between	N	O
9	2	N	O
10	%	N	O
11	and	N	O
12	10	N	O
13	%	N	O
14	weight	N	O
15	loss	N	O
16	were	N	O
17	randomized	N	O
18	to	N	O
19	a	N	O
20	mixture	N	O
21	of	N	O
22	beta-hydroxyl	N	O
23	beta-methyl	N	O
24	butyrate	N	O
25	,	N	O
26	glutamine	N	O
27	,	N	O
28	and	N	O
29	arginine	N	O
30	or	N	O
31	an	N	O
32	isonitrogenous	N	O
33	,	N	O
34	isocaloric	N	O
35	control	N	O
36	mixture	N	O
37	taken	N	O
38	twice	N	O
39	a	N	O
40	day	N	O
41	for	N	O
42	8	N	O
43	weeks	N	O
44	.	N	O

1	Lean	N	O
2	body	N	O
3	mass	N	O
4	was	N	O
5	estimated	N	O
6	by	N	O
7	bioimpedance	N	O
8	and	N	O
9	skin-fold	N	O
10	measurements	N	O
11	.	N	O

1	Body	N	O
2	plethysmography	N	O
3	was	N	O
4	used	N	O
5	when	N	O
6	available	N	O
7	.	N	O

1	Weight	N	O
2	,	N	O
3	the	N	O
4	Schwartz	N	O
5	Fatigue	N	O
6	Scale	N	O
7	,	N	O
8	and	N	O
9	the	N	O
10	Spitzer	N	O
11	Quality	N	O
12	of	N	O
13	Life	N	O
14	Scale	N	O
15	were	N	O
16	also	N	O
17	measured	N	O
18	.	N	O

1	Only	N	O
2	37	N	O
3	%	N	O
4	of	N	O
5	the	N	O
6	patients	N	O
7	completed	N	O
8	protocol	N	O
9	treatment	N	O
10	.	N	O

1	The	N	O
2	majority	N	O
3	of	N	O
4	the	N	O
5	patient	N	O
6	loss	N	O
7	was	N	O
8	because	N	O
9	of	N	O
10	patient	N	O
11	preference	N	O
12	(	N	O
13	45	N	O
14	%	N	O
15	of	N	O
16	enrolled	N	O
17	patients	N	O
18	)	N	O
19	.	N	O

1	However	N	O
2	,	N	O
3	loss	N	O
4	of	N	O
5	power	N	O
6	was	N	O
7	not	N	O
8	an	N	O
9	issue	N	O
10	because	N	O
11	of	N	O
12	the	N	O
13	planned	N	O
14	large	N	O
15	target	N	O
16	sample	N	O
17	size	N	O
18	.	N	O

1	Based	N	O
2	on	N	O
3	an	N	O
4	intention	N	O
5	to	N	O
6	treat	N	O
7	analysis	N	O
8	,	N	O
9	there	N	O
10	was	N	O
11	no	N	O
12	statistically	N	O
13	significant	N	O
14	difference	N	O
15	in	N	O
16	the	N	O
17	8-week	N	O
18	lean	N	O
19	body	N	O
20	mass	N	O
21	between	N	O
22	the	N	O
23	two	N	O
24	arms	N	O
25	.	N	O

1	The	N	O
2	secondary	N	O
3	endpoints	N	O
4	were	N	O
5	also	N	O
6	not	N	O
7	significantly	N	O
8	different	N	O
9	between	N	O
10	the	N	O
11	arms	N	O
12	.	N	O

1	Based	N	I-Premise
2	on	N	I-Premise
3	the	N	I-Premise
4	results	N	I-Premise
5	of	N	I-Premise
6	the	N	I-Premise
7	area	N	I-Premise
8	under	N	I-Premise
9	the	N	I-Premise
10	curve	N	I-Premise
11	(	N	I-Premise
12	AUC	N	I-Premise
13	)	N	I-Premise
14	analysis	N	I-Premise
15	,	N	I-Premise
16	patients	N	I-Premise
17	receiving	N	I-Premise
18	HMB/Arg/Gln	N	I-Premise
19	had	N	I-Premise
20	a	N	I-Premise
21	strong	N	I-Premise
22	trend	N	I-Premise
23	higher	N	I-Premise
24	LBM	N	I-Premise
25	throughout	N	I-Premise
26	the	N	I-Premise
27	study	N	I-Premise
28	as	N	I-Premise
29	measured	N	I-Premise
30	by	N	I-Premise
31	both	N	I-Premise
32	bioimpedance	N	I-Premise
33	(	N	I-Premise
34	p	N	I-Premise
35	=	N	I-Premise
36	0.08	N	I-Premise
37	)	N	I-Premise
38	and	N	I-Premise
39	skin-fold	N	I-Premise
40	measurements	N	I-Premise
41	(	N	I-Premise
42	p	N	I-Premise
43	=	N	I-Premise
44	0.08	N	I-Premise
45	)	N	I-Premise
46	.	N	I-Premise

1	Among	N	I-Premise
2	the	N	I-Premise
3	subset	N	I-Premise
4	of	N	I-Premise
5	patients	N	I-Premise
6	receiving	N	I-Premise
7	concurrent	N	I-Premise
8	chemotherapy	N	I-Premise
9	,	N	I-Premise
10	there	N	I-Premise
11	were	N	I-Premise
12	again	N	I-Premise
13	no	N	I-Premise
14	significant	N	I-Premise
15	differences	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	endpoints	N	I-Premise
19	.	N	I-Premise

1	The	N	I-Premise
2	secondary	N	I-Premise
3	endpoints	N	I-Premise
4	were	N	I-Premise
5	also	N	I-Premise
6	not	N	I-Premise
7	significantly	N	I-Premise
8	different	N	I-Premise
9	between	N	I-Premise
10	the	N	I-Premise
11	arms	N	I-Premise
12	.	N	I-Premise

1	This	N	I-Claim
2	trial	N	I-Claim
3	was	N	I-Claim
4	unable	N	I-Claim
5	to	N	I-Claim
6	adequately	N	I-Claim
7	test	N	I-Claim
8	the	N	I-Claim
9	ability	N	I-Claim
10	of	N	I-Claim
11	beta-hydroxy	N	I-Claim
12	beta-methylbutyrate	N	I-Claim
13	,	N	I-Claim
14	glutamine	N	I-Claim
15	,	N	I-Claim
16	and	N	I-Claim
17	arginine	N	I-Claim
18	to	N	I-Claim
19	reverse	N	I-Claim
20	or	N	I-Claim
21	prevent	N	I-Claim
22	lean	N	I-Claim
23	body	N	I-Claim
24	mass	N	I-Claim
25	wasting	N	I-Claim
26	among	N	I-Claim
27	cancer	N	I-Claim
28	patients	N	I-Claim
29	.	N	I-Claim

1	Possible	N	O
2	contributing	N	O
3	factors	N	O
4	beyond	N	O
5	the	N	O
6	efficacy	N	O
7	of	N	O
8	the	N	O
9	intervention	N	O
10	were	N	O
11	the	N	O
12	inability	N	O
13	of	N	O
14	patients	N	O
15	to	N	O
16	complete	N	O
17	an	N	O
18	8-week	N	O
19	course	N	O
20	of	N	O
21	treatment	N	O
22	and	N	O
23	return	N	O
24	in	N	O
25	a	N	O
26	timely	N	O
27	fashion	N	O
28	for	N	O
29	follow-up	N	O
30	assessment	N	O
31	,	N	O
32	and	N	O
33	because	N	O
34	the	N	O
35	patients	N	O
36	may	N	O
37	have	N	O
38	only	N	O
39	had	N	O
40	weight	N	O
41	loss	N	O
42	possible	N	O
43	not	N	O
44	related	N	O
45	to	N	O
46	cachexia	N	O
47	,	N	O
48	but	N	O
49	other	N	O
50	causes	N	O
51	of	N	O
52	weight	N	O
53	loss	N	O
54	,	N	O
55	such	N	O
56	as	N	O
57	decreased	N	O
58	appetite	N	O
59	.	N	O

1	However	N	O
2	,	N	O
3	there	N	O
4	was	N	O
5	a	N	O
6	strong	N	O
7	trend	N	O
8	towards	N	O
9	an	N	O
10	increased	N	O
11	body	N	O
12	mass	N	O
13	among	N	O
14	patients	N	O
15	taking	N	O
16	the	N	O
17	Juven	N	O
18	compound	N	O
19	using	N	O
20	the	N	O
21	secondary	N	O
22	endpoint	N	O
23	of	N	O
24	AUC	N	O
25	.	N	O

1	Exercise	N	O
2	training	N	O
3	improves	N	O
4	supportive	N	O
5	care	N	O
6	outcomes	N	O
7	in	N	O
8	patients	N	O
9	with	N	O
10	breast	N	O
11	cancer	N	O
12	who	N	O
13	are	N	O
14	receiving	N	O
15	adjuvant	N	O
16	therapy	N	O
17	,	N	O
18	but	N	O
19	the	N	O
20	responses	N	O
21	are	N	O
22	heterogeneous	N	O
23	.	N	O

1	In	N	O
2	this	N	O
3	study	N	O
4	,	N	O
5	the	N	O
6	authors	N	O
7	examined	N	O
8	personal	N	O
9	and	N	O
10	clinical	N	O
11	factors	N	O
12	that	N	O
13	may	N	O
14	predict	N	O
15	exercise	N	O
16	training	N	O
17	responses	N	O
18	.	N	O

1	Breast	N	O
2	cancer	N	O
3	patients	N	O
4	who	N	O
5	were	N	O
6	initiating	N	O
7	adjuvant	N	O
8	chemotherapy	N	O
9	(	N	O
10	N=242	N	O
11	)	N	O
12	were	N	O
13	assigned	N	O
14	randomly	N	O
15	to	N	O
16	receive	N	O
17	usual	N	O
18	care	N	O
19	(	N	O
20	UC	N	O
21	)	N	O
22	(	N	O
23	n=82	N	O
24	)	N	O
25	,	N	O
26	resistance	N	O
27	exercise	N	O
28	training	N	O
29	(	N	O
30	RET	N	O
31	)	N	O
32	(	N	O
33	n=82	N	O
34	)	N	O
35	,	N	O
36	or	N	O
37	aerobic	N	O
38	exercise	N	O
39	training	N	O
40	(	N	O
41	AET	N	O
42	)	N	O
43	(	N	O
44	n=78	N	O
45	)	N	O
46	for	N	O
47	the	N	O
48	duration	N	O
49	of	N	O
50	chemotherapy	N	O
51	.	N	O

1	Endpoints	N	O
2	were	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	(	N	O
7	QoL	N	O
8	)	N	O
9	,	N	O
10	aerobic	N	O
11	fitness	N	O
12	,	N	O
13	muscular	N	O
14	strength	N	O
15	,	N	O
16	lean	N	O
17	body	N	O
18	mass	N	O
19	,	N	O
20	and	N	O
21	body	N	O
22	fat	N	O
23	.	N	O

1	Moderators	N	O
2	were	N	O
3	patient	N	O
4	preference	N	O
5	for	N	O
6	group	N	O
7	assignment	N	O
8	,	N	O
9	marital	N	O
10	status	N	O
11	,	N	O
12	age	N	O
13	,	N	O
14	disease	N	O
15	stage	N	O
16	,	N	O
17	and	N	O
18	chemotherapy	N	O
19	regimen	N	O
20	.	N	O

1	Adjusted	N	O
2	linear	N	O
3	mixed-model	N	O
4	analyses	N	O
5	demonstrated	N	O
6	that	N	O
7	patient	N	O
8	preference	N	O
9	moderated	N	O
10	QoL	N	O
11	response	N	O
12	(	N	O
13	P=	N	O
14	.005	N	O
15	)	N	O
16	.	N	O

1	Patients	N	I-Premise
2	who	N	I-Premise
3	preferred	N	I-Premise
4	RET	N	I-Premise
5	improved	N	I-Premise
6	QoL	N	I-Premise
7	when	N	I-Premise
8	they	N	I-Premise
9	were	N	I-Premise
10	assigned	N	I-Premise
11	to	N	I-Premise
12	receive	N	I-Premise
13	RET	N	I-Premise
14	compared	N	I-Premise
15	with	N	I-Premise
16	UC	N	I-Premise
17	(	N	I-Premise
18	mean	N	I-Premise
19	difference	N	I-Premise
20	,	N	I-Premise
21	16.5	N	I-Premise
22	;	N	I-Premise
23	95	N	I-Premise
24	%	N	I-Premise
25	confidence	N	I-Premise
26	interval	N	I-Premise
27	[	N	I-Premise
28	95	N	I-Premise
29	%	N	I-Premise
30	CI	N	I-Premise
31	]	N	I-Premise
32	,	N	I-Premise
33	4.3-28.7	N	I-Premise
34	;	N	I-Premise
35	P=	N	I-Premise
36	.008	N	I-Premise
37	)	N	I-Premise
38	or	N	I-Premise
39	AET	N	I-Premise
40	(	N	I-Premise
41	mean	N	I-Premise
42	difference	N	I-Premise
43	,	N	I-Premise
44	11	N	I-Premise
45	;	N	I-Premise
46	95	N	I-Premise
47	%	N	I-Premise
48	CI	N	I-Premise
49	,	N	I-Premise
50	-1.1-23.4	N	I-Premise
51	;	N	I-Premise
52	P=	N	I-Premise
53	.076	N	I-Premise
54	)	N	I-Premise
55	.	N	I-Premise

1	Patients	N	I-Premise
2	who	N	I-Premise
3	had	N	I-Premise
4	no	N	I-Premise
5	preference	N	I-Premise
6	had	N	I-Premise
7	improved	N	I-Premise
8	QoL	N	I-Premise
9	when	N	I-Premise
10	they	N	I-Premise
11	were	N	I-Premise
12	assigned	N	I-Premise
13	to	N	I-Premise
14	receive	N	I-Premise
15	AET	N	I-Premise
16	compared	N	I-Premise
17	with	N	I-Premise
18	RET	N	I-Premise
19	(	N	I-Premise
20	mean	N	I-Premise
21	difference	N	I-Premise
22	,	N	I-Premise
23	23	N	I-Premise
24	;	N	I-Premise
25	95	N	I-Premise
26	%	N	I-Premise
27	CI	N	I-Premise
28	,	N	I-Premise
29	4.9-41	N	I-Premise
30	;	N	I-Premise
31	P=	N	I-Premise
32	.014	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	Marital	N	I-Premise
2	status	N	I-Premise
3	also	N	I-Premise
4	moderated	N	I-Premise
5	QoL	N	I-Premise
6	response	N	I-Premise
7	(	N	I-Premise
8	P=	N	I-Premise
9	.026	N	I-Premise
10	)	N	I-Premise
11	,	N	I-Premise
12	age	N	I-Premise
13	moderated	N	I-Premise
14	aerobic	N	I-Premise
15	fitness	N	I-Premise
16	response	N	I-Premise
17	(	N	I-Premise
18	P=	N	I-Premise
19	.029	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	chemotherapy	N	I-Premise
23	regimen	N	I-Premise
24	moderated	N	I-Premise
25	strength	N	I-Premise
26	gain	N	I-Premise
27	(	N	I-Premise
28	P=	N	I-Premise
29	.009	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	and	N	I-Premise
33	disease	N	I-Premise
34	stage	N	I-Premise
35	moderated	N	I-Premise
36	both	N	I-Premise
37	lean	N	I-Premise
38	body	N	I-Premise
39	mass	N	I-Premise
40	gain	N	I-Premise
41	(	N	I-Premise
42	P	N	I-Premise
43	<	N	I-Premise
44	.001	N	I-Premise
45	)	N	I-Premise
46	and	N	I-Premise
47	fat	N	I-Premise
48	loss	N	I-Premise
49	(	N	I-Premise
50	P=	N	I-Premise
51	.059	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	Unmarried	N	I-Premise
2	,	N	I-Premise
3	younger	N	I-Premise
4	patients	N	I-Premise
5	who	N	I-Premise
6	were	N	I-Premise
7	receiving	N	I-Premise
8	nontaxane-based	N	I-Premise
9	therapies	N	I-Premise
10	and	N	I-Premise
11	had	N	I-Premise
12	more	N	I-Premise
13	advanced	N	I-Premise
14	disease	N	I-Premise
15	stage	N	I-Premise
16	experienced	N	I-Premise
17	better	N	I-Premise
18	outcomes	N	I-Premise
19	.	N	I-Premise

1	The	N	O
2	findings	N	O
3	were	N	O
4	not	N	O
5	explained	N	O
6	by	N	O
7	differences	N	O
8	in	N	O
9	adherence	N	O
10	.	N	O

1	Patient	N	I-Claim
2	preference	N	I-Claim
3	,	N	I-Claim
4	demographic	N	I-Claim
5	variables	N	I-Claim
6	,	N	I-Claim
7	and	N	I-Claim
8	medical	N	I-Claim
9	variables	N	I-Claim
10	moderated	N	I-Claim
11	the	N	I-Claim
12	effects	N	I-Claim
13	of	N	I-Claim
14	exercise	N	I-Claim
15	training	N	I-Claim
16	in	N	I-Claim
17	breast	N	I-Claim
18	cancer	N	I-Claim
19	patients	N	I-Claim
20	who	N	I-Claim
21	were	N	I-Claim
22	receiving	N	I-Claim
23	chemotherapy	N	I-Claim
24	.	N	I-Claim

1	If	N	O
2	replicated	N	O
3	,	N	O
4	these	N	O
5	results	N	O
6	may	N	O
7	inform	N	O
8	clinical	N	O
9	practice	N	O
10	.	N	O

1	A	N	O
2	phase	N	O
3	III	N	O
4	randomized	N	O
5	trial	N	O
6	was	N	O
7	carried	N	O
8	out	N	O
9	to	N	O
10	compare	N	O
11	two	N	O
12	schedules	N	O
13	of	N	O
14	the	N	O
15	vinorelbine	N	O
16	(	N	O
17	VNR	N	O
18	)	N	O
19	-cisplatin	N	O
20	(	N	O
21	CDDP	N	O
22	)	N	O
23	regimen	N	O
24	in	N	O
25	patients	N	O
26	with	N	O
27	locally	N	O
28	advanced	N	O
29	unresectable	N	O
30	poor	N	O
31	prognosis	N	O
32	stage	N	O
33	IIIB	N	O
34	or	N	O
35	metastatic	N	O
36	stage	N	O
37	IV	N	O
38	non-small	N	O
39	cell	N	O
40	lung	N	O
41	cancer	N	O
42	.	N	O

1	The	N	O
2	primary	N	O
3	endpoints	N	O
4	were	N	O
5	overall	N	O
6	survival	N	O
7	(	N	O
8	OS	N	O
9	)	N	O
10	and	N	O
11	analysis	N	O
12	of	N	O
13	toxicity	N	O
14	,	N	O
15	while	N	O
16	secondary	N	O
17	endpoints	N	O
18	included	N	O
19	response	N	O
20	rates	N	O
21	,	N	O
22	time-to-progression	N	O
23	(	N	O
24	TTP	N	O
25	)	N	O
26	and	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	(	N	O
31	QoL	N	O
32	)	N	O
33	.	N	O

1	Eligible	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	to	N	O
6	receive	N	O
7	:	N	O
8	(	N	O
9	a	N	O
10	)	N	O
11	VNR	N	O
12	25mg/m	N	O
13	(	N	O
14	2	N	O
15	)	N	O
16	on	N	O
17	day	N	O
18	1	N	O
19	,	N	O
20	8	N	O
21	and	N	O
22	15	N	O
23	plus	N	O
24	CDDP	N	O
25	100mg/m	N	O
26	(	N	O
27	2	N	O
28	)	N	O
29	on	N	O
30	day	N	O
31	1	N	O
32	every	N	O
33	4	N	O
34	weeks	N	O
35	or	N	O
36	(	N	O
37	b	N	O
38	)	N	O
39	VNR	N	O
40	30	N	O
41	mg/m	N	O
42	(	N	O
43	2	N	O
44	)	N	O
45	on	N	O
46	day	N	O
47	1	N	O
48	and	N	O
49	8	N	O
50	plus	N	O
51	CDDP	N	O
52	80	N	O
53	mg/m	N	O
54	(	N	O
55	2	N	O
56	)	N	O
57	on	N	O
58	day	N	O
59	1	N	O
60	every	N	O
61	3	N	O
62	weeks	N	O
63	.	N	O

1	All	N	O
2	patients	N	O
3	were	N	O
4	chemotherapy-naïve	N	O
5	and	N	O
6	had	N	O
7	an	N	O
8	ECOG	N	O
9	performance	N	O
10	status	N	O
11	(	N	O
12	PS	N	O
13	)	N	O
14	of	N	O
15	0-1	N	O
16	.	N	O

1	Overall	N	O
2	278	N	O
3	patients	N	O
4	were	N	O
5	enrolled	N	O
6	into	N	O
7	the	N	O
8	trial	N	O
9	.	N	O

1	Overall	N	O
2	response	N	O
3	rate	N	O
4	was	N	O
5	34	N	O
6	%	N	O
7	(	N	O
8	95	N	O
9	%	N	O
10	CL	N	O
11	26-42	N	O
12	%	N	O
13	)	N	O
14	in	N	O
15	the	N	O
16	weekly	N	O
17	VNR/CDDP	N	O
18	arm	N	O
19	,	N	O
20	and	N	O
21	32	N	O
22	%	N	O
23	(	N	O
24	95	N	O
25	%	N	O
26	CL	N	O
27	24-40	N	O
28	%	N	O
29	)	N	O
30	in	N	O
31	patients	N	O
32	treated	N	O
33	with	N	O
34	day	N	O
35	1-8	N	O
36	VNR/CDDP	N	O
37	without	N	O
38	any	N	O
39	statistically	N	O
40	significant	N	O
41	difference	N	O
42	.	N	O

1	Median	N	I-Premise
2	TTP	N	I-Premise
3	was	N	I-Premise
4	4.5	N	I-Premise
5	and	N	I-Premise
6	4.6	N	I-Premise
7	months	N	I-Premise
8	respectively	N	I-Premise
9	for	N	I-Premise
10	weekly	N	I-Premise
11	VNR/CDDP	N	I-Premise
12	arm	N	I-Premise
13	and	N	I-Premise
14	the	N	I-Premise
15	day	N	I-Premise
16	1-8	N	I-Premise
17	VNR/CDDP	N	I-Premise
18	one	N	I-Premise
19	.	N	I-Premise

1	This	N	I-Premise
2	difference	N	I-Premise
3	was	N	I-Premise
4	not	N	I-Premise
5	statistically	N	I-Premise
6	significant	N	I-Premise
7	(	N	I-Premise
8	log-rank	N	I-Premise
9	test	N	I-Premise
10	,	N	I-Premise
11	p=0.818	N	I-Premise
12	)	N	I-Premise
13	.	N	I-Premise

1	Median	N	I-Premise
2	OS	N	I-Premise
3	was	N	I-Premise
4	9.45	N	I-Premise
5	and	N	I-Premise
6	10	N	I-Premise
7	months	N	I-Premise
8	respectively	N	I-Premise
9	for	N	I-Premise
10	weekly	N	I-Premise
11	VNR/CDDP	N	I-Premise
12	arm	N	I-Premise
13	and	N	I-Premise
14	the	N	I-Premise
15	day	N	I-Premise
16	1-8	N	I-Premise
17	VNR/CDDP	N	I-Premise
18	one	N	I-Premise
19	without	N	I-Premise
20	statistically	N	I-Premise
21	a	N	I-Premise
22	significant	N	I-Premise
23	difference	N	I-Premise
24	(	N	I-Premise
25	log-rank	N	I-Premise
26	test	N	I-Premise
27	,	N	I-Premise
28	p=0.259	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Premise
2	1-	N	I-Premise
3	and	N	I-Premise
4	2-year	N	I-Premise
5	survival	N	I-Premise
6	rates	N	I-Premise
7	were	N	I-Premise
8	31	N	I-Premise
9	and	N	I-Premise
10	36	N	I-Premise
11	%	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	10	N	I-Premise
15	and	N	I-Premise
16	11	N	I-Premise
17	%	N	I-Premise
18	respectively	N	I-Premise
19	.	N	I-Premise

1	The	N	I-Premise
2	incidence	N	I-Premise
3	of	N	I-Premise
4	severe	N	I-Premise
5	neutropenia	N	I-Premise
6	(	N	I-Premise
7	34	N	I-Premise
8	%	N	I-Premise
9	versus	N	I-Premise
10	68	N	I-Premise
11	%	N	I-Premise
12	;	N	I-Premise
13	p=0.0001	N	I-Premise
14	)	N	I-Premise
15	and	N	I-Premise
16	of	N	I-Premise
17	febrile	N	I-Premise
18	neutropenia	N	I-Premise
19	(	N	I-Premise
20	5	N	I-Premise
21	%	N	I-Premise
22	versus	N	I-Premise
23	12	N	I-Premise
24	%	N	I-Premise
25	;	N	I-Premise
26	p=0.026	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	as	N	I-Premise
30	well	N	I-Premise
31	as	N	I-Premise
32	the	N	I-Premise
33	rate	N	I-Premise
34	of	N	I-Premise
35	therapy	N	I-Premise
36	omissions	N	I-Premise
37	(	N	I-Premise
38	10	N	I-Premise
39	%	N	I-Premise
40	versus	N	I-Premise
41	24	N	I-Premise
42	%	N	I-Premise
43	;	N	I-Premise
44	p=0.0037	N	I-Premise
45	)	N	I-Premise
46	were	N	I-Premise
47	higher	N	I-Premise
48	in	N	I-Premise
49	the	N	I-Premise
50	weekly	N	I-Premise
51	VNR/CDDP	N	I-Premise
52	arm	N	I-Premise
53	than	N	I-Premise
54	in	N	I-Premise
55	the	N	I-Premise
56	day	N	I-Premise
57	1-8	N	I-Premise
58	VNR/CDDP	N	I-Premise
59	one	N	I-Premise
60	.	N	I-Premise

1	The	N	I-Premise
2	weekly	N	I-Premise
3	VNR/CDDP	N	I-Premise
4	regimen	N	I-Premise
5	was	N	I-Premise
6	associated	N	I-Premise
7	with	N	I-Premise
8	a	N	I-Premise
9	lower	N	I-Premise
10	received	N	I-Premise
11	dose	N	I-Premise
12	intensity	N	I-Premise
13	in	N	I-Premise
14	a	N	I-Premise
15	statistically	N	I-Premise
16	significant	N	I-Premise
17	fashion	N	I-Premise
18	(	N	I-Premise
19	9	N	I-Premise
20	%	N	I-Premise
21	versus	N	I-Premise
22	22	N	I-Premise
23	%	N	I-Premise
24	;	N	I-Premise
25	p=0.0001	N	I-Premise
26	)	N	I-Premise
27	and	N	I-Premise
28	with	N	I-Premise
29	a	N	I-Premise
30	lower	N	I-Premise
31	non-statistically	N	I-Premise
32	significant	N	I-Premise
33	quality	N	I-Premise
34	of	N	I-Premise
35	life	N	I-Premise
36	score	N	I-Premise
37	as	N	I-Premise
38	compared	N	I-Premise
39	to	N	I-Premise
40	the	N	I-Premise
41	day	N	I-Premise
42	1-8	N	I-Premise
43	VNR/CDDP	N	I-Premise
44	schedule	N	I-Premise
45	.	N	I-Premise

1	The	N	I-Claim
2	combination	N	I-Claim
3	of	N	I-Claim
4	day	N	I-Claim
5	1-8	N	I-Claim
6	VNR	N	I-Claim
7	plus	N	I-Claim
8	CDDP	N	I-Claim
9	every	N	I-Claim
10	3	N	I-Claim
11	weeks	N	I-Claim
12	is	N	I-Claim
13	less	N	I-Claim
14	toxic	N	I-Claim
15	and	N	I-Claim
16	better	N	I-Claim
17	tolerated	N	I-Claim
18	than	N	I-Claim
19	the	N	I-Claim
20	regimen	N	I-Claim
21	of	N	I-Claim
22	weekly	N	I-Claim
23	VNR	N	I-Claim
24	plus	N	I-Claim
25	CDDP	N	I-Claim
26	every	N	I-Claim
27	4	N	I-Claim
28	weeks	N	I-Claim
29	.	N	I-Claim

1	The	N	I-Claim
2	two	N	I-Claim
3	schedules	N	I-Claim
4	are	N	I-Claim
5	equivalent	N	I-Claim
6	in	N	I-Claim
7	terms	N	I-Claim
8	of	N	I-Claim
9	overall	N	I-Claim
10	response	N	I-Claim
11	rate	N	I-Claim
12	,	N	I-Claim
13	median	N	I-Claim
14	time-to-progression	N	I-Claim
15	and	N	I-Claim
16	overall	N	I-Claim
17	survival	N	I-Claim
18	.	N	I-Claim

1	The	N	I-Claim
2	combination	N	I-Claim
3	of	N	I-Claim
4	VNR	N	I-Claim
5	on	N	I-Claim
6	day	N	I-Claim
7	1-8	N	I-Claim
8	plus	N	I-Claim
9	CDDP	N	I-Claim
10	every	N	I-Claim
11	3	N	I-Claim
12	weeks	N	I-Claim
13	may	N	I-Claim
14	be	N	I-Claim
15	considered	N	I-Claim
16	as	N	I-Claim
17	a	N	I-Claim
18	reference	N	I-Claim
19	regimen	N	I-Claim
20	for	N	I-Claim
21	the	N	I-Claim
22	treatment	N	I-Claim
23	of	N	I-Claim
24	patients	N	I-Claim
25	with	N	I-Claim
26	advanced	N	I-Claim
27	disease	N	I-Claim
28	and	N	I-Claim
29	those	N	I-Claim
30	who	N	I-Claim
31	deserve	N	I-Claim
32	a	N	I-Claim
33	postoperative	N	I-Claim
34	therapy	N	I-Claim
35	,	N	I-Claim
36	and	N	I-Claim
37	for	N	I-Claim
38	future	N	I-Claim
39	studies	N	I-Claim
40	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	analgesic	N	O
11	and	N	O
12	adverse	N	O
13	effects	N	O
14	,	N	O
15	doses	N	O
16	,	N	O
17	as	N	O
18	well	N	O
19	as	N	O
20	cost	N	O
21	of	N	O
22	opioid	N	O
23	drugs	N	O
24	,	N	O
25	supportive	N	O
26	drug	N	O
27	therapy	N	O
28	and	N	O
29	other	N	O
30	analgesic	N	O
31	drugs	N	O
32	in	N	O
33	patients	N	O
34	treated	N	O
35	with	N	O
36	oral	N	O
37	sustained-release	N	O
38	morphine	N	O
39	,	N	O
40	transdermal	N	O
41	fentanyl	N	O
42	,	N	O
43	and	N	O
44	oral	N	O
45	methadone	N	O
46	.	N	O

1	One	N	O
2	hundred	N	O
3	and	N	O
4	eight	N	O
5	cancer	N	O
6	patients	N	O
7	,	N	O
8	no	N	O
9	longer	N	O
10	responsive	N	O
11	to	N	O
12	opioids	N	O
13	for	N	O
14	moderate	N	O
15	pain	N	O
16	,	N	O
17	were	N	O
18	selected	N	O
19	to	N	O
20	randomly	N	O
21	receive	N	O
22	initial	N	O
23	daily	N	O
24	doses	N	O
25	of	N	O
26	60	N	O
27	mg	N	O
28	of	N	O
29	oral	N	O
30	sustained-release	N	O
31	morphine	N	O
32	,	N	O
33	15	N	O
34	mg	N	O
35	of	N	O
36	oral	N	O
37	methadone	N	O
38	,	N	O
39	or	N	O
40	0.6	N	O
41	mg	N	O
42	(	N	O
43	25	N	O
44	microg/h	N	O
45	)	N	O
46	of	N	O
47	transdermal	N	O
48	fentanyl	N	O
49	.	N	O

1	Oral	N	O
2	morphine	N	O
3	was	N	O
4	used	N	O
5	as	N	O
6	breakthrough	N	O
7	pain	N	O
8	medication	N	O
9	during	N	O
10	opioid	N	O
11	titration	N	O
12	.	N	O

1	Opioid	N	O
2	doses	N	O
3	,	N	O
4	pain	N	O
5	intensity	N	O
6	,	N	O
7	adverse	N	O
8	effects	N	O
9	,	N	O
10	symptomatic	N	O
11	drugs	N	O
12	,	N	O
13	were	N	O
14	recorded	N	O
15	at	N	O
16	week	N	O
17	intervals	N	O
18	for	N	O
19	4	N	O
20	weeks	N	O
21	.	N	O

1	Costs	N	O
2	of	N	O
3	opioid	N	O
4	therapy	N	O
5	,	N	O
6	supportive	N	O
7	drugs	N	O
8	,	N	O
9	and	N	O
10	other	N	O
11	analgesic	N	O
12	drugs	N	O
13	were	N	O
14	also	N	O
15	evaluated	N	O
16	.	N	O

1	Seventy	N	O
2	patients	N	O
3	completed	N	O
4	the	N	O
5	4	N	O
6	weeks	N	O
7	period	N	O
8	of	N	O
9	study	N	O
10	.	N	O

1	Five	N	O
2	,	N	O
3	five	N	O
4	,	N	O
5	and	N	O
6	four	N	O
7	patients	N	O
8	,	N	O
9	treated	N	O
10	with	N	O
11	oral	N	O
12	morphine	N	O
13	,	N	O
14	transdermal	N	O
15	fentanyl	N	O
16	,	N	O
17	and	N	O
18	oral	N	O
19	methadone	N	O
20	,	N	O
21	respectively	N	O
22	,	N	O
23	required	N	O
24	opioid	N	O
25	switching	N	O
26	.	N	O

1	No	N	I-Premise
2	differences	N	I-Premise
3	in	N	I-Premise
4	pain	N	I-Premise
5	and	N	I-Premise
6	symptom	N	I-Premise
7	intensity	N	I-Premise
8	were	N	I-Premise
9	observed	N	I-Premise
10	.	N	I-Premise

1	Opioid	N	I-Premise
2	escalation	N	I-Premise
3	index	N	I-Premise
4	was	N	I-Premise
5	significantly	N	I-Premise
6	lower	N	I-Premise
7	in	N	I-Premise
8	patients	N	I-Premise
9	receiving	N	I-Premise
10	methadone	N	I-Premise
11	(	N	I-Premise
12	p	N	I-Premise
13	<	N	I-Premise
14	0.0001	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	although	N	I-Premise
18	requiring	N	I-Premise
19	up	N	I-Premise
20	and	N	I-Premise
21	down	N	I-Premise
22	changes	N	I-Premise
23	in	N	I-Premise
24	doses	N	I-Premise
25	.	N	I-Premise

1	At	N	I-Premise
2	the	N	I-Premise
3	doses	N	I-Premise
4	used	N	I-Premise
5	,	N	I-Premise
6	methadone	N	I-Premise
7	was	N	I-Premise
8	significantly	N	I-Premise
9	less	N	I-Premise
10	expensive	N	I-Premise
11	(	N	I-Premise
12	p	N	I-Premise
13	<	N	I-Premise
14	0.0001	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	while	N	I-Premise
18	the	N	I-Premise
19	use	N	I-Premise
20	and	N	I-Premise
21	costs	N	I-Premise
22	of	N	I-Premise
23	supportive	N	I-Premise
24	drugs	N	I-Premise
25	and	N	I-Premise
26	other	N	I-Premise
27	analgesics	N	I-Premise
28	were	N	I-Premise
29	similar	N	I-Premise
30	in	N	I-Premise
31	the	N	I-Premise
32	three	N	I-Premise
33	groups	N	I-Premise
34	.	N	I-Premise

1	No	N	I-Premise
2	relevant	N	I-Premise
3	differences	N	I-Premise
4	in	N	I-Premise
5	adverse	N	I-Premise
6	effects	N	I-Premise
7	were	N	I-Premise
8	observed	N	I-Premise
9	among	N	I-Premise
10	the	N	I-Premise
11	groups	N	I-Premise
12	during	N	I-Premise
13	either	N	I-Premise
14	the	N	I-Premise
15	titration	N	I-Premise
16	phase	N	I-Premise
17	and	N	I-Premise
18	chronic	N	I-Premise
19	treatment	N	I-Premise
20	.	N	I-Premise

1	All	N	I-Claim
2	the	N	I-Claim
3	three	N	I-Claim
4	opioids	N	I-Claim
5	used	N	I-Claim
6	as	N	I-Claim
7	first-line	N	I-Claim
8	therapy	N	I-Claim
9	were	N	I-Claim
10	effective	N	I-Claim
11	,	N	I-Claim
12	well	N	I-Claim
13	tolerated	N	I-Claim
14	,	N	I-Claim
15	and	N	I-Claim
16	required	N	I-Claim
17	similar	N	I-Claim
18	amounts	N	I-Claim
19	of	N	I-Claim
20	symptomatic	N	I-Claim
21	drugs	N	I-Claim
22	or	N	I-Claim
23	co-analgesics	N	I-Claim
24	.	N	I-Claim

1	Methadone	N	I-Claim
2	was	N	I-Claim
3	significantly	N	I-Claim
4	less	N	I-Claim
5	expensive	N	I-Claim
6	,	N	I-Claim
7	but	N	I-Claim
8	required	N	I-Claim
9	more	N	I-Claim
10	changes	N	I-Claim
11	,	N	I-Claim
12	up	N	I-Claim
13	and	N	I-Claim
14	down	N	I-Claim
15	,	N	I-Claim
16	of	N	I-Claim
17	the	N	I-Claim
18	doses	N	I-Claim
19	,	N	I-Claim
20	suggesting	N	I-Claim
21	that	N	I-Claim
22	dose	N	I-Claim
23	titration	N	I-Claim
24	of	N	I-Claim
25	this	N	I-Claim
26	drug	N	I-Claim
27	requires	N	I-Claim
28	major	N	I-Claim
29	clinical	N	I-Claim
30	expertise	N	I-Claim
31	.	N	I-Claim

1	To	N	O
2	observe	N	O
3	the	N	O
4	clinical	N	O
5	efficacy	N	O
6	of	N	O
7	Shenqi	N	O
8	Fuzheng	N	O
9	Injection	N	O
10	(	N	O
11	SFI	N	O
12	)	N	O
13	combined	N	O
14	with	N	O
15	chemotherapy	N	O
16	in	N	O
17	treating	N	O
18	patients	N	O
19	with	N	O
20	advanced	N	O
21	breast	N	O
22	cancer	N	O
23	.	N	O

1	Sixty	N	O
2	patients	N	O
3	were	N	O
4	randomly	N	O
5	assigned	N	O
6	to	N	O
7	two	N	O
8	groups	N	O
9	by	N	O
10	digital	N	O
11	table	N	O
12	,	N	O
13	the	N	O
14	control	N	O
15	group	N	O
16	and	N	O
17	the	N	O
18	treatment	N	O
19	group	N	O
20	,	N	O
21	30	N	O
22	in	N	O
23	each	N	O
24	group	N	O
25	.	N	O

1	All	N	O
2	patients	N	O
3	were	N	O
4	treated	N	O
5	with	N	O
6	the	N	O
7	same	N	O
8	CTF	N	O
9	regimen	N	O
10	of	N	O
11	chemotherapy	N	O
12	for	N	O
13	21	N	O
14	days	N	O
15	as	N	O
16	one	N	O
17	therapeutic	N	O
18	cycle	N	O
19	,	N	O
20	while	N	O
21	those	N	O
22	in	N	O
23	the	N	O
24	treatment	N	O
25	group	N	O
26	were	N	O
27	given	N	O
28	SFI	N	O
29	additionally	N	O
30	in	N	O
31	the	N	O
32	meanwhite	N	O
33	.	N	O

1	The	N	O
2	therapeutic	N	O
3	efficacy	N	O
4	was	N	O
5	evaluated	N	O
6	after	N	O
7	2	N	O
8	cycles	N	O
9	of	N	O
10	treatment	N	O
11	by	N	O
12	observing	N	O
13	the	N	O
14	changes	N	O
15	of	N	O
16	short-term	N	O
17	efficacy	N	O
18	,	N	O
19	TCM	N	O
20	syndrome	N	O
21	,	N	O
22	quality	N	O
23	of	N	O
24	life	N	O
25	and	N	O
26	immune	N	O
27	function	N	O
28	,	N	O
29	as	N	O
30	well	N	O
31	as	N	O
32	the	N	O
33	adverse	N	O
34	reaction	N	O
35	.	N	O

1	The	N	I-Premise
2	total	N	I-Premise
3	short-term	N	I-Premise
4	remission	N	I-Premise
5	rate	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	improvement	N	I-Premise
9	rate	N	I-Premise
10	of	N	I-Premise
11	clinical	N	I-Premise
12	syndrome	N	I-Premise
13	and	N	I-Premise
14	quality	N	I-Premise
15	of	N	I-Premise
16	life	N	I-Premise
17	was	N	I-Premise
18	50.0	N	I-Premise
19	%	N	I-Premise
20	,	N	I-Premise
21	70.0	N	I-Premise
22	%	N	I-Premise
23	and	N	I-Premise
24	76.7	N	I-Premise
25	%	N	I-Premise
26	in	N	I-Premise
27	the	N	I-Premise
28	treatment	N	I-Premise
29	group	N	I-Premise
30	,	N	I-Premise
31	and	N	I-Premise
32	43.3	N	I-Premise
33	%	N	I-Premise
34	,	N	I-Premise
35	46.7	N	I-Premise
36	%	N	I-Premise
37	and	N	I-Premise
38	50.0	N	I-Premise
39	%	N	I-Premise
40	in	N	I-Premise
41	the	N	I-Premise
42	control	N	I-Premise
43	group	N	I-Premise
44	,	N	I-Premise
45	respectively	N	I-Premise
46	,	N	I-Premise
47	showing	N	I-Premise
48	significant	N	I-Premise
49	difference	N	I-Premise
50	between	N	I-Premise
51	the	N	I-Premise
52	two	N	I-Premise
53	groups	N	I-Premise
54	(	N	I-Premise
55	all	N	I-Premise
56	P	N	I-Premise
57	<	N	I-Premise
58	0.05	N	I-Premise
59	)	N	I-Premise
60	.	N	I-Premise

1	The	N	I-Premise
2	occurrence	N	I-Premise
3	of	N	I-Premise
4	adverse	N	I-Premise
5	reaction	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	treatment	N	I-Premise
9	group	N	I-Premise
10	was	N	I-Premise
11	lower	N	I-Premise
12	than	N	I-Premise
13	that	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	control	N	I-Premise
17	group	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	0.05	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	The	N	I-Premise
2	level	N	I-Premise
3	of	N	I-Premise
4	CD3+	N	I-Premise
5	CD4+	N	I-Premise
6	and	N	I-Premise
7	CD4+/CD8+	N	I-Premise
8	ratio	N	I-Premise
9	increased	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	<	N	I-Premise
13	0.05	N	I-Premise
14	)	N	I-Premise
15	and	N	I-Premise
16	CD8+	N	I-Premise
17	decreased	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	treatment	N	I-Premise
21	group	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	<	N	I-Premise
25	0.01	N	I-Premise
26	)	N	I-Premise
27	,	N	I-Premise
28	while	N	I-Premise
29	they	N	I-Premise
30	showed	N	I-Premise
31	insignificant	N	I-Premise
32	change	N	I-Premise
33	in	N	I-Premise
34	the	N	I-Premise
35	control	N	I-Premise
36	group	N	I-Premise
37	.	N	I-Premise

1	For	N	I-Claim
2	treatment	N	I-Claim
3	of	N	I-Claim
4	advanced	N	I-Claim
5	breast	N	I-Claim
6	cancer	N	I-Claim
7	,	N	I-Claim
8	SFI	N	I-Claim
9	can	N	I-Claim
10	alleviate	N	I-Claim
11	the	N	I-Claim
12	bone	N	I-Claim
13	marrow	N	I-Claim
14	inhibition	N	I-Claim
15	caused	N	I-Claim
16	by	N	I-Claim
17	chemotherapy	N	I-Claim
18	,	N	I-Claim
19	improve	N	I-Claim
20	clinical	N	I-Claim
21	symptoms	N	I-Claim
22	and	N	I-Claim
23	quality	N	I-Claim
24	of	N	I-Claim
25	life	N	I-Claim
26	and	N	I-Claim
27	prolong	N	I-Claim
28	the	N	I-Claim
29	survival	N	I-Claim
30	period	N	I-Claim
31	by	N	I-Claim
32	regulating	N	I-Claim
33	cellular	N	I-Claim
34	immune	N	I-Claim
35	function	N	I-Claim
36	of	N	I-Claim
37	patients	N	I-Claim
38	,	N	I-Claim
39	so	N	I-Claim
40	as	N	I-Claim
41	to	N	I-Claim
42	enhance	N	I-Claim
43	the	N	I-Claim
44	therapeutic	N	I-Claim
45	effect	N	I-Claim
46	of	N	I-Claim
47	chemotherapy	N	I-Claim
48	.	N	I-Claim

1	To	N	O
2	observe	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	TCM	N	O
7	therapy	N	O
8	for	N	O
9	removing	N	O
10	toxic	N	O
11	substance	N	O
12	and	N	O
13	unblocking	N	O
14	meridians	N	O
15	on	N	O
16	post-radiation	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QOF	N	O
22	)	N	O
23	in	N	O
24	55	N	O
25	patients	N	O
26	with	N	O
27	lung	N	O
28	cancer	N	O
29	.	N	O

1	All	N	O
2	patients	N	O
3	were	N	O
4	randomly	N	O
5	assigned	N	O
6	to	N	O
7	two	N	O
8	groups	N	O
9	,	N	O
10	the	N	O
11	55	N	O
12	patients	N	O
13	in	N	O
14	the	N	O
15	treated	N	O
16	group	N	O
17	were	N	O
18	treated	N	O
19	with	N	O
20	radiotherapy	N	O
21	combined	N	O
22	with	N	O
23	the	N	O
24	TCM	N	O
25	therapy	N	O
26	,	N	O
27	and	N	O
28	the	N	O
29	53	N	O
30	in	N	O
31	the	N	O
32	control	N	O
33	group	N	O
34	were	N	O
35	given	N	O
36	radiotherapy	N	O
37	alone	N	O
38	.	N	O

1	The	N	O
2	clinical	N	O
3	efficacy	N	O
4	was	N	O
5	evaluated	N	O
6	by	N	O
7	indexes	N	O
8	including	N	O
9	KPS	N	O
10	scores	N	O
11	,	N	O
12	QLQ-C30	N	O
13	questionnaire	N	O
14	,	N	O
15	LC13	N	O
16	specific	N	O
17	scale	N	O
18	for	N	O
19	lung	N	O
20	cancer	N	O
21	,	N	O
22	evaluation	N	O
23	criteria	N	O
24	for	N	O
25	TCM	N	O
26	efficacy	N	O
27	,	N	O
28	the	N	O
29	6-min	N	O
30	walking	N	O
31	distance	N	O
32	,	N	O
33	and	N	O
34	body	N	O
35	weight	N	O
36	,	N	O
37	etc	N	O
38	.	N	O

1	The	N	I-Premise
2	KPS	N	I-Premise
3	score	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	treated	N	I-Premise
7	group	N	I-Premise
8	after	N	I-Premise
9	treatment	N	I-Premise
10	was	N	I-Premise
11	improved	N	I-Premise
12	in	N	I-Premise
13	13	N	I-Premise
14	patients	N	I-Premise
15	(	N	I-Premise
16	23.6	N	I-Premise
17	%	N	I-Premise
18	)	N	I-Premise
19	,	N	I-Premise
20	stabilized	N	I-Premise
21	in	N	I-Premise
22	27	N	I-Premise
23	(	N	I-Premise
24	49.6	N	I-Premise
25	%	N	I-Premise
26	)	N	I-Premise
27	and	N	I-Premise
28	declined	N	I-Premise
29	in	N	I-Premise
30	15	N	I-Premise
31	(	N	I-Premise
32	27.3	N	I-Premise
33	%	N	I-Premise
34	)	N	I-Premise
35	,	N	I-Premise
36	while	N	I-Premise
37	in	N	I-Premise
38	the	N	I-Premise
39	control	N	I-Premise
40	group	N	I-Premise
41	,	N	I-Premise
42	it	N	I-Premise
43	was	N	I-Premise
44	improved	N	I-Premise
45	in	N	I-Premise
46	7	N	I-Premise
47	(	N	I-Premise
48	13.2	N	I-Premise
49	%	N	I-Premise
50	)	N	I-Premise
51	,	N	I-Premise
52	stabilized	N	I-Premise
53	in	N	I-Premise
54	21	N	I-Premise
55	(	N	I-Premise
56	39.6	N	I-Premise
57	%	N	I-Premise
58	)	N	I-Premise
59	and	N	I-Premise
60	declined	N	I-Premise
61	in	N	I-Premise
62	25	N	I-Premise
63	(	N	I-Premise
64	47.2	N	I-Premise
65	%	N	I-Premise
66	)	N	I-Premise
67	,	N	I-Premise
68	the	N	I-Premise
69	difference	N	I-Premise
70	between	N	I-Premise
71	the	N	I-Premise
72	two	N	I-Premise
73	groups	N	I-Premise
74	was	N	I-Premise
75	significant	N	I-Premise
76	(	N	I-Premise
77	P	N	I-Premise
78	<	N	I-Premise
79	0.05	N	I-Premise
80	)	N	I-Premise
81	.	N	I-Premise

1	The	N	I-Premise
2	results	N	I-Premise
3	from	N	I-Premise
4	evaluation	N	I-Premise
5	with	N	I-Premise
6	QLQ-C30	N	I-Premise
7	questionnaire	N	I-Premise
8	and	N	I-Premise
9	LC30	N	I-Premise
10	scale	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	treated	N	I-Premise
14	group	N	I-Premise
15	was	N	I-Premise
16	also	N	I-Premise
17	superior	N	I-Premise
18	to	N	I-Premise
19	those	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	control	N	I-Premise
23	group	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	<	N	I-Premise
27	0.05	N	I-Premise
28	)	N	I-Premise
29	,	N	I-Premise
30	respectively	N	I-Premise
31	.	N	I-Premise

1	The	N	I-Premise
2	scores	N	I-Premise
3	of	N	I-Premise
4	TCM	N	I-Premise
5	efficacy	N	I-Premise
6	(	N	I-Premise
7	24.52	N	I-Premise
8	+/-	N	I-Premise
9	8.98	N	I-Premise
10	vs	N	I-Premise
11	29.76	N	I-Premise
12	+/-	N	I-Premise
13	7.09	N	I-Premise
14	,	N	I-Premise
15	P	N	I-Premise
16	<	N	I-Premise
17	0.05	N	I-Premise
18	)	N	I-Premise
19	and	N	I-Premise
20	the	N	I-Premise
21	6-min	N	I-Premise
22	walking	N	I-Premise
23	distance	N	I-Premise
24	(	N	I-Premise
25	233.4	N	I-Premise
26	+/-	N	I-Premise
27	29.2	N	I-Premise
28	m	N	I-Premise
29	vs	N	I-Premise
30	205.8	N	I-Premise
31	+/-	N	I-Premise
32	31.9	N	I-Premise
33	m	N	I-Premise
34	,	N	I-Premise
35	P	N	I-Premise
36	<	N	I-Premise
37	0.05	N	I-Premise
38	)	N	I-Premise
39	were	N	I-Premise
40	better	N	I-Premise
41	in	N	I-Premise
42	the	N	I-Premise
43	treated	N	I-Premise
44	group	N	I-Premise
45	.	N	I-Premise

1	After	N	I-Premise
2	treatment	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	treated	N	I-Premise
6	group	N	I-Premise
7	,	N	I-Premise
8	the	N	I-Premise
9	body	N	I-Premise
10	weight	N	I-Premise
11	was	N	I-Premise
12	increased	N	I-Premise
13	in	N	I-Premise
14	11	N	I-Premise
15	patients	N	I-Premise
16	(	N	I-Premise
17	20.0	N	I-Premise
18	%	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	stabilized	N	I-Premise
22	in	N	I-Premise
23	28	N	I-Premise
24	(	N	I-Premise
25	50.9	N	I-Premise
26	%	N	I-Premise
27	)	N	I-Premise
28	and	N	I-Premise
29	decreased	N	I-Premise
30	in	N	I-Premise
31	16	N	I-Premise
32	(	N	I-Premise
33	29.1	N	I-Premise
34	%	N	I-Premise
35	)	N	I-Premise
36	,	N	I-Premise
37	while	N	I-Premise
38	in	N	I-Premise
39	the	N	I-Premise
40	control	N	I-Premise
41	group	N	I-Premise
42	it	N	I-Premise
43	was	N	I-Premise
44	increased	N	I-Premise
45	in	N	I-Premise
46	5	N	I-Premise
47	(	N	I-Premise
48	9.4	N	I-Premise
49	%	N	I-Premise
50	)	N	I-Premise
51	,	N	I-Premise
52	stabilized	N	I-Premise
53	in	N	I-Premise
54	26	N	I-Premise
55	(	N	I-Premise
56	49.1	N	I-Premise
57	%	N	I-Premise
58	)	N	I-Premise
59	and	N	I-Premise
60	decreased	N	I-Premise
61	in	N	I-Premise
62	22	N	I-Premise
63	(	N	I-Premise
64	41.5	N	I-Premise
65	%	N	I-Premise
66	)	N	I-Premise
67	,	N	I-Premise
68	difference	N	I-Premise
69	between	N	I-Premise
70	the	N	I-Premise
71	two	N	I-Premise
72	groups	N	I-Premise
73	was	N	I-Premise
74	significant	N	I-Premise
75	,	N	I-Premise
76	too	N	I-Premise
77	(	N	I-Premise
78	P	N	I-Premise
79	<	N	I-Premise
80	0.05	N	I-Premise
81	)	N	I-Premise
82	.	N	I-Premise

1	TCM	N	I-Claim
2	therapy	N	I-Claim
3	for	N	I-Claim
4	removing	N	I-Claim
5	toxic	N	I-Claim
6	substance	N	I-Claim
7	and	N	I-Claim
8	unblocking	N	I-Claim
9	meridians	N	I-Claim
10	can	N	I-Claim
11	improve	N	I-Claim
12	the	N	I-Claim
13	post-radiation	N	I-Claim
14	QOL	N	I-Claim
15	of	N	I-Claim
16	patients	N	I-Claim
17	with	N	I-Claim
18	lung	N	I-Claim
19	cancer	N	I-Claim
20	to	N	I-Claim
21	some	N	I-Claim
22	extent	N	I-Claim
23	.	N	I-Claim

1	Anaemia	N	O
2	is	N	O
3	common	N	O
4	in	N	O
5	patients	N	O
6	receiving	N	O
7	chemotherapy	N	O
8	,	N	O
9	causing	N	O
10	symptoms	N	O
11	that	N	O
12	have	N	O
13	a	N	O
14	major	N	O
15	impact	N	O
16	on	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QoL	N	O
22	)	N	O
23	.	N	O

1	Epoetin	N	O
2	beta	N	O
3	rapidly	N	O
4	increases	N	O
5	haemoglobin	N	O
6	(	N	O
7	Hb	N	O
8	)	N	O
9	levels	N	O
10	and	N	O
11	improves	N	O
12	QoL	N	O
13	in	N	O
14	anaemic	N	O
15	patients	N	O
16	with	N	O
17	a	N	O
18	variety	N	O
19	of	N	O
20	tumours	N	O
21	.	N	O

1	This	N	O
2	was	N	O
3	a	N	O
4	randomized	N	O
5	,	N	O
6	double-blind	N	O
7	,	N	O
8	parallel-group	N	O
9	,	N	O
10	dose-finding	N	O
11	study	N	O
12	assessing	N	O
13	the	N	O
14	efficacy	N	O
15	and	N	O
16	safety	N	O
17	of	N	O
18	once-weekly	N	O
19	epoetin	N	O
20	beta	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	solid	N	O
25	tumours	N	O
26	receiving	N	O
27	chemotherapy	N	O
28	.	N	O

1	Adult	N	O
2	patients	N	O
3	with	N	O
4	anaemia	N	O
5	(	N	O
6	Hb	N	O
7	<	N	O
8	11	N	O
9	g/dL	N	O
10	)	N	O
11	were	N	O
12	randomized	N	O
13	to	N	O
14	receive	N	O
15	epoetin	N	O
16	beta	N	O
17	30,000	N	O
18	IU	N	O
19	or	N	O
20	20,000	N	O
21	IU	N	O
22	once	N	O
23	weekly	N	O
24	for	N	O
25	12	N	O
26	weeks	N	O
27	.	N	O

1	All	N	O
2	patients	N	O
3	received	N	O
4	oral	N	O
5	iron	N	O
6	supplementation	N	O
7	.	N	O

1	Haemoglobin	N	O
2	levels	N	O
3	,	N	O
4	transfusion	N	O
5	need	N	O
6	and	N	O
7	QoL	N	O
8	[	N	O
9	Functional	N	O
10	Assessment	N	O
11	of	N	O
12	Cancer	N	O
13	Therapy-fatigue	N	O
14	(	N	O
15	FACT-F	N	O
16	)	N	O
17	subscale	N	O
18	score	N	O
19	]	N	O
20	were	N	O
21	assessed	N	O
22	at	N	O
23	regular	N	O
24	intervals	N	O
25	.	N	O

1	Fifty	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	;	N	O
6	30	N	O
7	patients	N	O
8	received	N	O
9	epoetin	N	O
10	beta	N	O
11	30,000	N	O
12	IU	N	O
13	once	N	O
14	weekly	N	O
15	and	N	O
16	20	N	O
17	received	N	O
18	20,000	N	O
19	IU	N	O
20	once	N	O
21	weekly	N	O
22	.	N	O

1	Mean	N	I-Premise
2	(	N	I-Premise
3	+/-	N	I-Premise
4	SD	N	I-Premise
5	)	N	I-Premise
6	increase	N	I-Premise
7	in	N	I-Premise
8	Hb	N	I-Premise
9	from	N	I-Premise
10	baseline	N	I-Premise
11	to	N	I-Premise
12	week	N	I-Premise
13	12	N	I-Premise
14	was	N	I-Premise
15	1.75	N	I-Premise
16	+/-	N	I-Premise
17	2.15	N	I-Premise
18	g/dL	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	30,000	N	I-Premise
22	IU	N	I-Premise
23	group	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	=	N	I-Premise
27	0.008	N	I-Premise
28	vs.	N	I-Premise
29	baseline	N	I-Premise
30	)	N	I-Premise
31	and	N	I-Premise
32	1.04	N	I-Premise
33	+/-	N	I-Premise
34	1.75	N	I-Premise
35	g/dL	N	I-Premise
36	in	N	I-Premise
37	the	N	I-Premise
38	20,000	N	I-Premise
39	IU	N	I-Premise
40	group	N	I-Premise
41	(	N	I-Premise
42	non-significant	N	I-Premise
43	)	N	I-Premise
44	.	N	I-Premise

1	Haemoglobin	N	I-Premise
2	response	N	I-Premise
3	(	N	I-Premise
4	increase	N	I-Premise
5	in	N	I-Premise
6	Hb	N	I-Premise
7	>	N	I-Premise
8	or=2	N	I-Premise
9	g/dL	N	I-Premise
10	from	N	I-Premise
11	baseline	N	I-Premise
12	)	N	I-Premise
13	was	N	I-Premise
14	observed	N	I-Premise
15	in	N	I-Premise
16	78.3	N	I-Premise
17	%	N	I-Premise
18	of	N	I-Premise
19	patients	N	I-Premise
20	receiving	N	I-Premise
21	epoetin	N	I-Premise
22	beta	N	I-Premise
23	30,000	N	I-Premise
24	IU	N	I-Premise
25	and	N	I-Premise
26	66.7	N	I-Premise
27	%	N	I-Premise
28	receiving	N	I-Premise
29	epoetin	N	I-Premise
30	beta	N	I-Premise
31	20,000	N	I-Premise
32	IU	N	I-Premise
33	.	N	I-Premise

1	Improvements	N	O
2	in	N	O
3	FACT-F	N	O
4	subscale	N	O
5	score	N	O
6	were	N	O
7	significantly	N	O
8	(	N	O
9	P	N	O
10	<	N	O
11	0.001	N	O
12	)	N	O
13	correlated	N	O
14	with	N	O
15	increases	N	O
16	in	N	O
17	Hb	N	O
18	level	N	O
19	.	N	O

1	Transfusion	N	O
2	use	N	O
3	was	N	O
4	low	N	O
5	during	N	O
6	the	N	O
7	study	N	O
8	in	N	O
9	both	N	O
10	groups	N	O
11	.	N	O

1	Both	N	I-Premise
2	epoetin	N	I-Premise
3	beta	N	I-Premise
4	regiments	N	I-Premise
5	were	N	I-Premise
6	well	N	I-Premise
7	tolerated	N	I-Premise
8	and	N	I-Premise
9	there	N	I-Premise
10	were	N	I-Premise
11	no	N	I-Premise
12	dose-dependent	N	I-Premise
13	adverse	N	I-Premise
14	events	N	I-Premise
15	.	N	I-Premise

1	Epoetin	N	I-Claim
2	beta	N	I-Claim
3	30,000	N	I-Claim
4	IU	N	I-Claim
5	once	N	I-Claim
6	weekly	N	I-Claim
7	is	N	I-Claim
8	an	N	I-Claim
9	effective	N	I-Claim
10	and	N	I-Claim
11	well-tolerated	N	I-Claim
12	treatment	N	I-Claim
13	of	N	I-Claim
14	anaemia	N	I-Claim
15	in	N	I-Claim
16	patients	N	I-Claim
17	with	N	I-Claim
18	solid	N	I-Claim
19	tumours	N	I-Claim
20	.	N	I-Claim

1	The	N	O
2	combination	N	O
3	of	N	O
4	cisplatin	N	O
5	and	N	O
6	etoposide	N	O
7	(	N	O
8	PE	N	O
9	)	N	O
10	has	N	O
11	been	N	O
12	a	N	O
13	standard	N	O
14	treatment	N	O
15	for	N	O
16	patients	N	O
17	with	N	O
18	poor-prognosis	N	O
19	small	N	O
20	cell	N	O
21	lung	N	O
22	cancer	N	O
23	(	N	O
24	SCLC	N	O
25	)	N	O
26	.	N	O

1	This	N	O
2	non-inferiority	N	O
3	design	N	O
4	trial	N	O
5	aimed	N	O
6	to	N	O
7	determine	N	O
8	whether	N	O
9	the	N	O
10	combination	N	O
11	of	N	O
12	gemcitabine	N	O
13	and	N	O
14	carboplatin	N	O
15	(	N	O
16	GC	N	O
17	)	N	O
18	results	N	O
19	in	N	O
20	similar	N	O
21	survival	N	O
22	but	N	O
23	is	N	O
24	less	N	O
25	toxic	N	O
26	with	N	O
27	better	N	O
28	quality	N	O
29	of	N	O
30	life	N	O
31	.	N	O

1	Previously	N	O
2	untreated	N	O
3	patients	N	O
4	with	N	O
5	SCLC	N	O
6	with	N	O
7	extensive	N	O
8	disease	N	O
9	or	N	O
10	limited	N	O
11	stage	N	O
12	with	N	O
13	poor	N	O
14	prognostic	N	O
15	factors	N	O
16	were	N	O
17	randomly	N	O
18	assigned	N	O
19	to	N	O
20	six	N	O
21	3-weekly	N	O
22	cycles	N	O
23	of	N	O
24	GC	N	O
25	or	N	O
26	PE	N	O
27	.	N	O

1	241	N	O
2	patients	N	O
3	(	N	O
4	121	N	O
5	GC	N	O
6	,	N	O
7	120	N	O
8	PE	N	O
9	)	N	O
10	were	N	O
11	recruited	N	O
12	,	N	O
13	of	N	O
14	which	N	O
15	216	N	O
16	(	N	O
17	90	N	O
18	%	N	O
19	)	N	O
20	had	N	O
21	died	N	O
22	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	overall	N	I-Premise
7	survival	N	I-Premise
8	(	N	I-Premise
9	HR	N	I-Premise
10	1.01	N	I-Premise
11	,	N	I-Premise
12	95	N	I-Premise
13	%	N	I-Premise
14	CI	N	I-Premise
15	0.77	N	I-Premise
16	to	N	I-Premise
17	1.32	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	with	N	I-Premise
4	GC	N	I-Premise
5	and	N	I-Premise
6	PE	N	I-Premise
7	was	N	I-Premise
8	8.0	N	I-Premise
9	and	N	I-Premise
10	8.1	N	I-Premise
11	months	N	I-Premise
12	,	N	I-Premise
13	respectively	N	I-Premise
14	.	N	I-Premise

1	Median	N	I-Premise
2	progression-free	N	I-Premise
3	survival	N	I-Premise
4	was	N	I-Premise
5	5.9	N	I-Premise
6	months	N	I-Premise
7	with	N	I-Premise
8	GC	N	I-Premise
9	and	N	I-Premise
10	6.3	N	I-Premise
11	months	N	I-Premise
12	with	N	I-Premise
13	PE	N	I-Premise
14	.	N	I-Premise

1	Grade	N	I-Premise
2	3	N	I-Premise
3	or	N	I-Premise
4	4	N	I-Premise
5	myelosuppressions	N	I-Premise
6	were	N	I-Premise
7	more	N	I-Premise
8	frequent	N	I-Premise
9	with	N	I-Premise
10	GC	N	I-Premise
11	(	N	I-Premise
12	anaemia	N	I-Premise
13	:	N	I-Premise
14	14	N	I-Premise
15	%	N	I-Premise
16	GC	N	I-Premise
17	vs	N	I-Premise
18	2	N	I-Premise
19	%	N	I-Premise
20	PE	N	I-Premise
21	;	N	I-Premise
22	leucopenia	N	I-Premise
23	:	N	I-Premise
24	32	N	I-Premise
25	%	N	I-Premise
26	GC	N	I-Premise
27	vs	N	I-Premise
28	13	N	I-Premise
29	%	N	I-Premise
30	PE	N	I-Premise
31	;	N	I-Premise
32	thrombocytopenia	N	I-Premise
33	:	N	I-Premise
34	22	N	I-Premise
35	%	N	I-Premise
36	GC	N	I-Premise
37	vs	N	I-Premise
38	4	N	I-Premise
39	%	N	I-Premise
40	PE	N	I-Premise
41	)	N	I-Premise
42	,	N	I-Premise
43	but	N	I-Premise
44	these	N	I-Premise
45	were	N	I-Premise
46	not	N	I-Premise
47	associated	N	I-Premise
48	with	N	I-Premise
49	increased	N	I-Premise
50	hospital	N	I-Premise
51	admissions	N	I-Premise
52	,	N	I-Premise
53	infections	N	I-Premise
54	or	N	I-Premise
55	fatalities	N	I-Premise
56	.	N	I-Premise

1	Grade	N	I-Premise
2	2-3	N	I-Premise
3	alopecia	N	I-Premise
4	(	N	I-Premise
5	68	N	I-Premise
6	%	N	I-Premise
7	PE	N	I-Premise
8	vs	N	I-Premise
9	17	N	I-Premise
10	%	N	I-Premise
11	GC	N	I-Premise
12	)	N	I-Premise
13	and	N	I-Premise
14	nausea	N	I-Premise
15	(	N	I-Premise
16	43	N	I-Premise
17	%	N	I-Premise
18	PE	N	I-Premise
19	vs	N	I-Premise
20	26	N	I-Premise
21	%	N	I-Premise
22	GC	N	I-Premise
23	)	N	I-Premise
24	were	N	I-Premise
25	more	N	I-Premise
26	frequent	N	I-Premise
27	with	N	I-Premise
28	PE	N	I-Premise
29	.	N	I-Premise

1	Patients	N	O
2	given	N	O
3	GC	N	O
4	received	N	O
5	more	N	O
6	chemotherapy	N	O
7	as	N	O
8	outpatients	N	O
9	(	N	O
10	89	N	O
11	%	N	O
12	GC	N	O
13	vs	N	O
14	66	N	O
15	%	N	O
16	PE	N	O
17	of	N	O
18	treatment	N	O
19	cycles	N	O
20	)	N	O
21	.	N	O

1	In	N	I-Premise
2	QoL	N	I-Premise
3	questionnaires	N	I-Premise
4	,	N	I-Premise
5	more	N	I-Premise
6	patients	N	I-Premise
7	receiving	N	I-Premise
8	PE	N	I-Premise
9	reported	N	I-Premise
10	being	N	I-Premise
11	upset	N	I-Premise
12	by	N	I-Premise
13	hair	N	I-Premise
14	loss	N	I-Premise
15	(	N	I-Premise
16	p	N	I-Premise
17	=	N	I-Premise
18	0.004	N	I-Premise
19	)	N	I-Premise
20	and	N	I-Premise
21	impaired	N	I-Premise
22	cognitive	N	I-Premise
23	functioning	N	I-Premise
24	(	N	I-Premise
25	p	N	I-Premise
26	=	N	I-Premise
27	0.04	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	GC	N	I-Claim
2	is	N	I-Claim
3	as	N	I-Claim
4	effective	N	I-Claim
5	as	N	I-Claim
6	PE	N	I-Claim
7	in	N	I-Claim
8	terms	N	I-Claim
9	of	N	I-Claim
10	overall	N	I-Claim
11	survival	N	I-Claim
12	and	N	I-Claim
13	progression-free	N	I-Claim
14	survival	N	I-Claim
15	and	N	I-Claim
16	has	N	I-Claim
17	a	N	I-Claim
18	toxicity	N	I-Claim
19	profile	N	I-Claim
20	more	N	I-Claim
21	acceptable	N	I-Claim
22	to	N	I-Claim
23	patients	N	I-Claim
24	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	effectiveness	N	O
5	of	N	O
6	the	N	O
7	Alleviating	N	O
8	Depression	N	O
9	Among	N	O
10	Patients	N	O
11	With	N	O
12	Cancer	N	O
13	(	N	O
14	ADAPt-C	N	O
15	)	N	O
16	collaborative	N	O
17	care	N	O
18	management	N	O
19	for	N	O
20	major	N	O
21	depression	N	O
22	or	N	O
23	dysthymia	N	O
24	.	N	O

1	Study	N	O
2	patients	N	O
3	included	N	O
4	472	N	O
5	low-income	N	O
6	,	N	O
7	predominantly	N	O
8	female	N	O
9	Hispanic	N	O
10	patients	N	O
11	with	N	O
12	cancer	N	O
13	age	N	O
14	>	N	O
15	or=	N	O
16	18	N	O
17	years	N	O
18	with	N	O
19	major	N	O
20	depression	N	O
21	(	N	O
22	49	N	O
23	%	N	O
24	)	N	O
25	,	N	O
26	dysthymia	N	O
27	(	N	O
28	5	N	O
29	%	N	O
30	)	N	O
31	,	N	O
32	or	N	O
33	both	N	O
34	(	N	O
35	46	N	O
36	%	N	O
37	)	N	O
38	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	intervention	N	O
7	(	N	O
8	n	N	O
9	=	N	O
10	242	N	O
11	)	N	O
12	or	N	O
13	enhanced	N	O
14	usual	N	O
15	care	N	O
16	(	N	O
17	EUC	N	O
18	;	N	O
19	n	N	O
20	=	N	O
21	230	N	O
22	)	N	O
23	.	N	O

1	Intervention	N	O
2	patients	N	O
3	had	N	O
4	access	N	O
5	for	N	O
6	up	N	O
7	to	N	O
8	12	N	O
9	months	N	O
10	to	N	O
11	a	N	O
12	depression	N	O
13	clinical	N	O
14	specialist	N	O
15	(	N	O
16	supervised	N	O
17	by	N	O
18	a	N	O
19	psychiatrist	N	O
20	)	N	O
21	who	N	O
22	offered	N	O
23	education	N	O
24	,	N	O
25	structured	N	O
26	psychotherapy	N	O
27	,	N	O
28	and	N	O
29	maintenance/relapse	N	O
30	prevention	N	O
31	support	N	O
32	.	N	O

1	The	N	O
2	psychiatrist	N	O
3	prescribed	N	O
4	antidepressant	N	O
5	medications	N	O
6	for	N	O
7	patients	N	O
8	preferring	N	O
9	or	N	O
10	assessed	N	O
11	to	N	O
12	require	N	O
13	medication	N	O
14	.	N	O

1	At	N	I-Premise
2	12	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	63	N	I-Premise
6	%	N	I-Premise
7	of	N	I-Premise
8	intervention	N	I-Premise
9	patients	N	I-Premise
10	had	N	I-Premise
11	a	N	I-Premise
12	50	N	I-Premise
13	%	N	I-Premise
14	or	N	I-Premise
15	greater	N	I-Premise
16	reduction	N	I-Premise
17	in	N	I-Premise
18	depressive	N	I-Premise
19	symptoms	N	I-Premise
20	from	N	I-Premise
21	baseline	N	I-Premise
22	as	N	I-Premise
23	assessed	N	I-Premise
24	by	N	I-Premise
25	the	N	I-Premise
26	Patient	N	I-Premise
27	Health	N	I-Premise
28	Questionnaire-9	N	I-Premise
29	(	N	I-Premise
30	PHQ-9	N	I-Premise
31	)	N	I-Premise
32	depression	N	I-Premise
33	scale	N	I-Premise
34	compared	N	I-Premise
35	with	N	I-Premise
36	50	N	I-Premise
37	%	N	I-Premise
38	of	N	I-Premise
39	EUC	N	I-Premise
40	patients	N	I-Premise
41	(	N	I-Premise
42	odds	N	I-Premise
43	ratio	N	I-Premise
44	[	N	I-Premise
45	OR	N	I-Premise
46	]	N	I-Premise
47	=	N	I-Premise
48	1.98	N	I-Premise
49	;	N	I-Premise
50	95	N	I-Premise
51	%	N	I-Premise
52	CI	N	I-Premise
53	,	N	I-Premise
54	1.16	N	I-Premise
55	to	N	I-Premise
56	3.38	N	I-Premise
57	;	N	I-Premise
58	P	N	I-Premise
59	=	N	I-Premise
60	.01	N	I-Premise
61	)	N	I-Premise
62	.	N	I-Premise

1	Improvement	N	I-Premise
2	was	N	I-Premise
3	also	N	I-Premise
4	found	N	I-Premise
5	for	N	I-Premise
6	5-point	N	I-Premise
7	decrease	N	I-Premise
8	in	N	I-Premise
9	PHQ-9	N	I-Premise
10	score	N	I-Premise
11	among	N	I-Premise
12	72.2	N	I-Premise
13	%	N	I-Premise
14	of	N	I-Premise
15	intervention	N	I-Premise
16	patients	N	I-Premise
17	compared	N	I-Premise
18	with	N	I-Premise
19	59.7	N	I-Premise
20	%	N	I-Premise
21	of	N	I-Premise
22	EUC	N	I-Premise
23	patients	N	I-Premise
24	(	N	I-Premise
25	OR	N	I-Premise
26	=	N	I-Premise
27	1.99	N	I-Premise
28	;	N	I-Premise
29	95	N	I-Premise
30	%	N	I-Premise
31	CI	N	I-Premise
32	,	N	I-Premise
33	1.14	N	I-Premise
34	to	N	I-Premise
35	3.50	N	I-Premise
36	;	N	I-Premise
37	P	N	I-Premise
38	=	N	I-Premise
39	.02	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	Intervention	N	I-Premise
2	patients	N	I-Premise
3	also	N	I-Premise
4	experienced	N	I-Premise
5	greater	N	I-Premise
6	rates	N	I-Premise
7	of	N	I-Premise
8	depression	N	I-Premise
9	treatment	N	I-Premise
10	(	N	I-Premise
11	72.3	N	I-Premise
12	%	N	I-Premise
13	v	N	I-Premise
14	10.4	N	I-Premise
15	%	N	I-Premise
16	of	N	I-Premise
17	EUC	N	I-Premise
18	patients	N	I-Premise
19	;	N	I-Premise
20	P	N	I-Premise
21	<	N	I-Premise
22	.0001	N	I-Premise
23	)	N	I-Premise
24	and	N	I-Premise
25	significantly	N	I-Premise
26	better	N	I-Premise
27	quality-of-life	N	I-Premise
28	outcomes	N	I-Premise
29	,	N	I-Premise
30	including	N	I-Premise
31	social/family	N	I-Premise
32	(	N	I-Premise
33	adjusted	N	I-Premise
34	mean	N	I-Premise
35	difference	N	I-Premise
36	between	N	I-Premise
37	groups	N	I-Premise
38	,	N	I-Premise
39	2.7	N	I-Premise
40	;	N	I-Premise
41	95	N	I-Premise
42	%	N	I-Premise
43	CI	N	I-Premise
44	,	N	I-Premise
45	1.22	N	I-Premise
46	to	N	I-Premise
47	4.17	N	I-Premise
48	;	N	I-Premise
49	P	N	I-Premise
50	<	N	I-Premise
51	.001	N	I-Premise
52	)	N	I-Premise
53	,	N	I-Premise
54	emotional	N	I-Premise
55	(	N	I-Premise
56	adjusted	N	I-Premise
57	mean	N	I-Premise
58	difference	N	I-Premise
59	,	N	I-Premise
60	1.29	N	I-Premise
61	;	N	I-Premise
62	95	N	I-Premise
63	%	N	I-Premise
64	CI	N	I-Premise
65	,	N	I-Premise
66	0.26	N	I-Premise
67	to	N	I-Premise
68	2.22	N	I-Premise
69	;	N	I-Premise
70	P	N	I-Premise
71	=	N	I-Premise
72	.01	N	I-Premise
73	)	N	I-Premise
74	,	N	I-Premise
75	functional	N	I-Premise
76	(	N	I-Premise
77	adjusted	N	I-Premise
78	mean	N	I-Premise
79	difference	N	I-Premise
80	,	N	I-Premise
81	1.34	N	I-Premise
82	;	N	I-Premise
83	95	N	I-Premise
84	%	N	I-Premise
85	CI	N	I-Premise
86	,	N	I-Premise
87	0.08	N	I-Premise
88	to	N	I-Premise
89	2.59	N	I-Premise
90	;	N	I-Premise
91	P	N	I-Premise
92	=	N	I-Premise
93	.04	N	I-Premise
94	)	N	I-Premise
95	,	N	I-Premise
96	and	N	I-Premise
97	physical	N	I-Premise
98	well-being	N	I-Premise
99	(	N	I-Premise
100	adjusted	N	I-Premise
101	mean	N	I-Premise
102	difference	N	I-Premise
103	,	N	I-Premise
104	2.79	N	I-Premise
105	;	N	I-Premise
106	95	N	I-Premise
107	%	N	I-Premise
108	CI	N	I-Premise
109	,	N	I-Premise
110	0.49	N	I-Premise
111	to	N	I-Premise
112	5.1	N	I-Premise
113	;	N	I-Premise
114	P	N	I-Premise
115	=	N	I-Premise
116	.02	N	I-Premise
117	)	N	I-Premise
118	.	N	I-Premise

1	ADAPt-C	N	I-Claim
2	collaborative	N	I-Claim
3	care	N	I-Claim
4	is	N	I-Claim
5	feasible	N	I-Claim
6	and	N	I-Claim
7	results	N	I-Claim
8	in	N	I-Claim
9	significant	N	I-Claim
10	reduction	N	I-Claim
11	in	N	I-Claim
12	depressive	N	I-Claim
13	symptoms	N	I-Claim
14	,	N	I-Claim
15	improvement	N	I-Claim
16	in	N	I-Claim
17	quality	N	I-Claim
18	of	N	I-Claim
19	life	N	I-Claim
20	,	N	I-Claim
21	and	N	I-Claim
22	lower	N	I-Claim
23	pain	N	I-Claim
24	levels	N	I-Claim
25	compared	N	I-Claim
26	with	N	I-Claim
27	EUC	N	I-Claim
28	for	N	I-Claim
29	patients	N	I-Claim
30	with	N	I-Claim
31	depressive	N	I-Claim
32	disorders	N	I-Claim
33	in	N	I-Claim
34	a	N	I-Claim
35	low-income	N	I-Claim
36	,	N	I-Claim
37	predominantly	N	I-Claim
38	Hispanic	N	I-Claim
39	population	N	I-Claim
40	in	N	I-Claim
41	public	N	I-Claim
42	sector	N	I-Claim
43	oncology	N	I-Claim
44	clinics	N	I-Claim
45	.	N	I-Claim

1	Recombinant	N	O
2	human	N	O
3	TSH	N	O
4	(	N	O
5	rhTSH	N	O
6	)	N	O
7	has	N	O
8	become	N	O
9	the	N	O
10	modality	N	O
11	of	N	O
12	choice	N	O
13	for	N	O
14	radioiodine	N	O
15	remnant	N	O
16	ablation	N	O
17	(	N	O
18	RRA	N	O
19	)	N	O
20	in	N	O
21	low-risk	N	O
22	thyroid	N	O
23	cancer	N	O
24	patients	N	O
25	.	N	O

1	The	N	O
2	aims	N	O
3	of	N	O
4	the	N	O
5	present	N	O
6	prospective	N	O
7	randomized	N	O
8	study	N	O
9	were	N	O
10	to	N	O
11	evaluate	N	O
12	the	N	O
13	impact	N	O
14	of	N	O
15	TSH	N	O
16	stimulation	N	O
17	procedure	N	O
18	(	N	O
19	hypothyroidism	N	O
20	vs.	N	O
21	rhTSH	N	O
22	)	N	O
23	on	N	O
24	quality	N	O
25	of	N	O
26	life	N	O
27	(	N	O
28	QoL	N	O
29	)	N	O
30	of	N	O
31	thyroid	N	O
32	cancer	N	O
33	patients	N	O
34	undergoing	N	O
35	RRA	N	O
36	and	N	O
37	to	N	O
38	evaluate	N	O
39	efficacy	N	O
40	of	N	O
41	both	N	O
42	procedures	N	O
43	.	N	O

1	L-T4	N	O
2	was	N	O
3	initiated	N	O
4	in	N	O
5	both	N	O
6	groups	N	O
7	after	N	O
8	thyroidectomy	N	O
9	.	N	O

1	After	N	O
2	randomization	N	O
3	,	N	O
4	L-T4	N	O
5	was	N	O
6	discontinued	N	O
7	in	N	O
8	hypothyroid	N	O
9	(	N	O
10	hypo	N	O
11	)	N	O
12	group	N	O
13	and	N	O
14	continued	N	O
15	in	N	O
16	rhTSH	N	O
17	group	N	O
18	.	N	O

1	A	N	O
2	measure	N	O
3	of	N	O
4	3.7	N	O
5	GBq	N	O
6	of	N	O
7	radioiodine	N	O
8	was	N	O
9	given	N	O
10	to	N	O
11	both	N	O
12	groups	N	O
13	.	N	O

1	The	N	O
2	functional	N	O
3	assessment	N	O
4	of	N	O
5	chronic	N	O
6	illness	N	O
7	therapy-fatigue	N	O
8	(	N	O
9	FACIT-F	N	O
10	)	N	O
11	was	N	O
12	administered	N	O
13	from	N	O
14	the	N	O
15	early	N	O
16	postoperative	N	O
17	period	N	O
18	to	N	O
19	9	N	O
20	months	N	O
21	.	N	O

1	Socio-demographic	N	O
2	parameters	N	O
3	,	N	O
4	anxiety	N	O
5	and	N	O
6	depression	N	O
7	scales	N	O
8	were	N	O
9	also	N	O
10	evaluated	N	O
11	(	N	O
12	CES-D	N	O
13	,	N	O
14	BDI	N	O
15	and	N	O
16	Spielberger	N	O
17	state-trait	N	O
18	questionnaires	N	O
19	)	N	O
20	.	N	O

1	At	N	O
2	9	N	O
3	months	N	O
4	,	N	O
5	patients	N	O
6	underwent	N	O
7	an	N	O
8	rhTSH	N	O
9	stimulation	N	O
10	test	N	O
11	,	N	O
12	diagnostic	N	O
13	(	N	O
14	131	N	O
15	)	N	O
16	I	N	O
17	whole	N	O
18	body	N	O
19	scan	N	O
20	(	N	O
21	dxWBS	N	O
22	)	N	O
23	and	N	O
24	neck	N	O
25	ultrasonography	N	O
26	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	74	N	O
5	patients	N	O
6	were	N	O
7	enrolled	N	O
8	for	N	O
9	the	N	O
10	study	N	O
11	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	decrease	N	I-Premise
6	in	N	I-Premise
7	QoL	N	I-Premise
8	from	N	I-Premise
9	baseline	N	I-Premise
10	(	N	I-Premise
11	t0	N	I-Premise
12	)	N	I-Premise
13	to	N	I-Premise
14	t1	N	I-Premise
15	(	N	I-Premise
16	RRA	N	I-Premise
17	period	N	I-Premise
18	)	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	hypothyroid	N	I-Premise
22	group	N	I-Premise
23	with	N	I-Premise
24	significant	N	I-Premise
25	differences	N	I-Premise
26	in	N	I-Premise
27	FACIT-F	N	I-Premise
28	TOI	N	I-Premise
29	(	N	I-Premise
30	P	N	I-Premise
31	<	N	I-Premise
32	10	N	I-Premise
33	(	N	I-Premise
34	-3	N	I-Premise
35	)	N	I-Premise
36	)	N	I-Premise
37	,	N	I-Premise
38	FACT-G	N	I-Premise
39	total	N	I-Premise
40	score	N	I-Premise
41	(	N	I-Premise
42	P	N	I-Premise
43	=	N	I-Premise
44	0.005	N	I-Premise
45	)	N	I-Premise
46	and	N	I-Premise
47	FACIT-F	N	I-Premise
48	total	N	I-Premise
49	score	N	I-Premise
50	(	N	I-Premise
51	P	N	I-Premise
52	=	N	I-Premise
53	0.003	N	I-Premise
54	)	N	I-Premise
55	.	N	I-Premise

1	By	N	I-Premise
2	contrast	N	I-Premise
3	,	N	I-Premise
4	QoL	N	I-Premise
5	was	N	I-Premise
6	preserved	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	rhTSH	N	I-Premise
10	group	N	I-Premise
11	.	N	I-Premise

1	In	N	O
2	the	N	O
3	multivariate	N	O
4	analysis	N	O
5	,	N	O
6	FACIT-TOI	N	O
7	changes	N	O
8	were	N	O
9	only	N	O
10	affected	N	O
11	by	N	O
12	the	N	O
13	modality	N	O
14	of	N	O
15	TSH	N	O
16	stimulation	N	O
17	performed	N	O
18	for	N	O
19	RRA	N	O
20	.	N	O

1	From	N	I-Premise
2	3	N	I-Premise
3	to	N	I-Premise
4	9	N	I-Premise
5	months	N	I-Premise
6	,	N	I-Premise
7	changes	N	I-Premise
8	of	N	I-Premise
9	QoL	N	I-Premise
10	scales	N	I-Premise
11	and	N	I-Premise
12	subscales	N	I-Premise
13	were	N	I-Premise
14	no	N	I-Premise
15	longer	N	I-Premise
16	statistically	N	I-Premise
17	different	N	I-Premise
18	in	N	I-Premise
19	both	N	I-Premise
20	groups	N	I-Premise
21	of	N	I-Premise
22	patients	N	I-Premise
23	.	N	I-Premise

1	Based	N	I-Premise
2	on	N	I-Premise
3	serum	N	I-Premise
4	rhTSH-stimulated	N	I-Premise
5	Tg	N	I-Premise
6	alone	N	I-Premise
7	(	N	I-Premise
8	Tg	N	I-Premise
9	<	N	I-Premise
10	0.8	N	I-Premise
11	microg/l	N	I-Premise
12	,	N	I-Premise
13	BRAHMS	N	I-Premise
14	Tg	N	I-Premise
15	Kryptor	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	no	N	I-Premise
19	difference	N	I-Premise
20	in	N	I-Premise
21	ablation	N	I-Premise
22	success	N	I-Premise
23	was	N	I-Premise
24	observed	N	I-Premise
25	between	N	I-Premise
26	rhTSH	N	I-Premise
27	and	N	I-Premise
28	hypothyroidism	N	I-Premise
29	groups	N	I-Premise
30	,	N	I-Premise
31	91.7	N	I-Premise
32	%	N	I-Premise
33	and	N	I-Premise
34	97.1	N	I-Premise
35	%	N	I-Premise
36	,	N	I-Premise
37	respectively	N	I-Premise
38	.	N	I-Premise

1	A	N	I-Premise
2	higher	N	I-Premise
3	rate	N	I-Premise
4	of	N	I-Premise
5	persistent	N	I-Premise
6	thyroid	N	I-Premise
7	remnants	N	I-Premise
8	was	N	I-Premise
9	observed	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	rhTSH	N	I-Premise
13	arm	N	I-Premise
14	,	N	I-Premise
15	although	N	I-Premise
16	in	N	I-Premise
17	most	N	I-Premise
18	cases	N	I-Premise
19	uptake	N	I-Premise
20	was	N	I-Premise
21	<	N	I-Premise
22	0.1	N	I-Premise
23	%	N	I-Premise
24	and	N	I-Premise
25	of	N	I-Premise
26	no	N	I-Premise
27	clinical	N	I-Premise
28	significance	N	I-Premise
29	.	N	I-Premise

1	rhTSH	N	I-Claim
2	preserves	N	I-Claim
3	QoL	N	I-Claim
4	of	N	I-Claim
5	patients	N	I-Claim
6	undergoing	N	I-Claim
7	RRA	N	I-Claim
8	with	N	I-Claim
9	similar	N	I-Claim
10	rates	N	I-Claim
11	of	N	I-Claim
12	ablation	N	I-Claim
13	success	N	I-Claim
14	compared	N	I-Claim
15	to	N	I-Claim
16	hypothyrodism	N	I-Claim
17	.	N	I-Claim

1	However	N	O
2	,	N	O
3	there	N	O
4	is	N	O
5	a	N	O
6	wide	N	O
7	heterogeneity	N	O
8	in	N	O
9	the	N	O
10	clinical	N	O
11	impact	N	O
12	of	N	O
13	hypothyroidism	N	O
14	.	N	O

1	Hot	N	I-MajorClaim
2	flashes	N	I-MajorClaim
3	are	N	I-MajorClaim
4	a	N	I-MajorClaim
5	significant	N	I-MajorClaim
6	problem	N	I-MajorClaim
7	for	N	I-MajorClaim
8	many	N	I-MajorClaim
9	breast	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	survivors	N	I-MajorClaim
12	.	N	I-MajorClaim

1	Hot	N	I-MajorClaim
2	flashes	N	I-MajorClaim
3	can	N	I-MajorClaim
4	cause	N	I-MajorClaim
5	discomfort	N	I-MajorClaim
6	,	N	I-MajorClaim
7	disrupted	N	I-MajorClaim
8	sleep	N	I-MajorClaim
9	,	N	I-MajorClaim
10	anxiety	N	I-MajorClaim
11	,	N	I-MajorClaim
12	and	N	I-MajorClaim
13	decreased	N	I-MajorClaim
14	quality	N	I-MajorClaim
15	of	N	I-MajorClaim
16	life	N	I-MajorClaim
17	.	N	I-MajorClaim

1	A	N	O
2	well-tolerated	N	O
3	and	N	O
4	effective	N	O
5	mind-body	N	O
6	treatment	N	O
7	for	N	O
8	hot	N	O
9	flashes	N	O
10	would	N	O
11	be	N	O
12	of	N	O
13	great	N	O
14	value	N	O
15	.	N	O

1	On	N	O
2	the	N	O
3	basis	N	O
4	of	N	O
5	previous	N	O
6	case	N	O
7	studies	N	O
8	,	N	O
9	this	N	O
10	study	N	O
11	was	N	O
12	developed	N	O
13	to	N	O
14	evaluate	N	O
15	the	N	O
16	effect	N	O
17	of	N	O
18	a	N	O
19	hypnosis	N	O
20	intervention	N	O
21	for	N	O
22	hot	N	O
23	flashes	N	O
24	.	N	O

1	Sixty	N	O
2	female	N	O
3	breast	N	O
4	cancer	N	O
5	survivors	N	O
6	with	N	O
7	hot	N	O
8	flashes	N	O
9	were	N	O
10	randomly	N	O
11	assigned	N	O
12	to	N	O
13	receive	N	O
14	hypnosis	N	O
15	intervention	N	O
16	(	N	O
17	five	N	O
18	weekly	N	O
19	sessions	N	O
20	)	N	O
21	or	N	O
22	no	N	O
23	treatment	N	O
24	.	N	O

1	Eligible	N	O
2	patients	N	O
3	had	N	O
4	to	N	O
5	have	N	O
6	a	N	O
7	history	N	O
8	of	N	O
9	primary	N	O
10	breast	N	O
11	cancer	N	O
12	without	N	O
13	evidence	N	O
14	of	N	O
15	detectable	N	O
16	disease	N	O
17	and	N	O
18	14	N	O
19	or	N	O
20	more	N	O
21	weekly	N	O
22	hot	N	O
23	flashes	N	O
24	for	N	O
25	at	N	O
26	least	N	O
27	1	N	O
28	month	N	O
29	.	N	O

1	The	N	O
2	major	N	O
3	outcome	N	O
4	measure	N	O
5	was	N	O
6	a	N	O
7	bivariate	N	O
8	construct	N	O
9	that	N	O
10	represented	N	O
11	hot	N	O
12	flash	N	O
13	frequency	N	O
14	and	N	O
15	hot	N	O
16	flash	N	O
17	score	N	O
18	,	N	O
19	which	N	O
20	was	N	O
21	analyzed	N	O
22	by	N	O
23	a	N	O
24	classic	N	O
25	sums	N	O
26	and	N	O
27	differences	N	O
28	comparison	N	O
29	.	N	O

1	Secondary	N	O
2	outcome	N	O
3	measures	N	O
4	were	N	O
5	self-reports	N	O
6	of	N	O
7	interference	N	O
8	of	N	O
9	hot	N	O
10	flashes	N	O
11	on	N	O
12	daily	N	O
13	activities	N	O
14	.	N	O

1	Fifty-one	N	O
2	randomly	N	O
3	assigned	N	O
4	women	N	O
5	completed	N	O
6	the	N	O
7	study	N	O
8	.	N	O

1	By	N	I-Premise
2	the	N	I-Premise
3	end	N	I-Premise
4	of	N	I-Premise
5	the	N	I-Premise
6	treatment	N	I-Premise
7	period	N	I-Premise
8	,	N	I-Premise
9	hot	N	I-Premise
10	flash	N	I-Premise
11	scores	N	I-Premise
12	(	N	I-Premise
13	frequency	N	I-Premise
14	x	N	I-Premise
15	average	N	I-Premise
16	severity	N	I-Premise
17	)	N	I-Premise
18	decreased	N	I-Premise
19	68	N	I-Premise
20	%	N	I-Premise
21	from	N	I-Premise
22	baseline	N	I-Premise
23	to	N	I-Premise
24	end	N	I-Premise
25	point	N	I-Premise
26	in	N	I-Premise
27	the	N	I-Premise
28	hypnosis	N	I-Premise
29	arm	N	I-Premise
30	(	N	I-Premise
31	P	N	I-Premise
32	<	N	I-Premise
33	.001	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	Significant	N	I-Premise
2	improvements	N	I-Premise
3	in	N	I-Premise
4	self-reported	N	I-Premise
5	anxiety	N	I-Premise
6	,	N	I-Premise
7	depression	N	I-Premise
8	,	N	I-Premise
9	interference	N	I-Premise
10	of	N	I-Premise
11	hot	N	I-Premise
12	flashes	N	I-Premise
13	on	N	I-Premise
14	daily	N	I-Premise
15	activities	N	I-Premise
16	,	N	I-Premise
17	and	N	I-Premise
18	sleep	N	I-Premise
19	were	N	I-Premise
20	observed	N	I-Premise
21	for	N	I-Premise
22	patients	N	I-Premise
23	who	N	I-Premise
24	received	N	I-Premise
25	the	N	I-Premise
26	hypnosis	N	I-Premise
27	intervention	N	I-Premise
28	(	N	I-Premise
29	P	N	I-Premise
30	<	N	I-Premise
31	.005	N	I-Premise
32	)	N	I-Premise
33	in	N	I-Premise
34	comparison	N	I-Premise
35	to	N	I-Premise
36	the	N	I-Premise
37	no	N	I-Premise
38	treatment	N	I-Premise
39	control	N	I-Premise
40	group	N	I-Premise
41	.	N	I-Premise

1	Hypnosis	N	I-Claim
2	appears	N	I-Claim
3	to	N	I-Claim
4	reduce	N	I-Claim
5	perceived	N	I-Claim
6	hot	N	I-Claim
7	flashes	N	I-Claim
8	in	N	I-Claim
9	breast	N	I-Claim
10	cancer	N	I-Claim
11	survivors	N	I-Claim
12	and	N	I-Claim
13	may	N	I-Claim
14	have	N	I-Claim
15	additional	N	I-Claim
16	benefits	N	I-Claim
17	such	N	I-Claim
18	as	N	I-Claim
19	reduced	N	I-Claim
20	anxiety	N	I-Claim
21	and	N	I-Claim
22	depression	N	I-Claim
23	,	N	I-Claim
24	and	N	I-Claim
25	improved	N	I-Claim
26	sleep	N	I-Claim
27	.	N	I-Claim

1	Adjuvant	N	O
2	chemotherapy	N	O
3	for	N	O
4	early	N	O
5	stage	N	O
6	non-small-cell	N	O
7	lung	N	O
8	cancer	N	O
9	(	N	O
10	NSCLC	N	O
11	)	N	O
12	is	N	O
13	now	N	O
14	the	N	O
15	standard	N	O
16	of	N	O
17	care	N	O
18	,	N	O
19	but	N	O
20	there	N	O
21	is	N	O
22	little	N	O
23	information	N	O
24	regarding	N	O
25	its	N	O
26	impact	N	O
27	on	N	O
28	quality	N	O
29	of	N	O
30	life	N	O
31	(	N	O
32	QOL	N	O
33	)	N	O
34	.	N	O

1	We	N	O
2	report	N	O
3	the	N	O
4	QOL	N	O
5	results	N	O
6	of	N	O
7	JBR.10	N	O
8	,	N	O
9	a	N	O
10	North	N	O
11	American	N	O
12	,	N	O
13	intergroup	N	O
14	,	N	O
15	randomized	N	O
16	trial	N	O
17	of	N	O
18	adjuvant	N	O
19	cisplatin	N	O
20	and	N	O
21	vinorelbine	N	O
22	compared	N	O
23	with	N	O
24	observation	N	O
25	in	N	O
26	patients	N	O
27	who	N	O
28	have	N	O
29	completely	N	O
30	resected	N	O
31	,	N	O
32	stages	N	O
33	IB	N	O
34	to	N	O
35	II	N	O
36	NSCLC	N	O
37	.	N	O

1	QOL	N	O
2	was	N	O
3	assessed	N	O
4	with	N	O
5	the	N	O
6	European	N	O
7	Organisation	N	O
8	for	N	O
9	Research	N	O
10	and	N	O
11	Treatment	N	O
12	of	N	O
13	Cancer	N	O
14	Quality	N	O
15	of	N	O
16	Life	N	O
17	Questionnaire	N	O
18	C30	N	O
19	and	N	O
20	a	N	O
21	trial-specific	N	O
22	checklist	N	O
23	at	N	O
24	baseline	N	O
25	and	N	O
26	at	N	O
27	weeks	N	O
28	5	N	O
29	and	N	O
30	9	N	O
31	for	N	O
32	those	N	O
33	who	N	O
34	received	N	O
35	chemotherapy	N	O
36	and	N	O
37	at	N	O
38	follow-up	N	O
39	months	N	O
40	3	N	O
41	,	N	O
42	6	N	O
43	,	N	O
44	9	N	O
45	,	N	O
46	12	N	O
47	,	N	O
48	18	N	O
49	,	N	O
50	24	N	O
51	,	N	O
52	30	N	O
53	and	N	O
54	36	N	O
55	.	N	O

1	A	N	O
2	10-point	N	O
3	change	N	O
4	in	N	O
5	QOL	N	O
6	scores	N	O
7	from	N	O
8	baseline	N	O
9	was	N	O
10	considered	N	O
11	clinically	N	O
12	significant	N	O
13	.	N	O

1	Four	N	O
2	hundred	N	O
3	eighty-two	N	O
4	patients	N	O
5	were	N	O
6	randomly	N	O
7	assigned	N	O
8	on	N	O
9	JBR.10	N	O
10	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	173	N	O
5	patients	N	O
6	(	N	O
7	82	N	O
8	%	N	O
9	of	N	O
10	the	N	O
11	expected	N	O
12	)	N	O
13	in	N	O
14	the	N	O
15	observation	N	O
16	arm	N	O
17	and	N	O
18	186	N	O
19	(	N	O
20	85	N	O
21	%	N	O
22	of	N	O
23	expected	N	O
24	)	N	O
25	in	N	O
26	the	N	O
27	chemotherapy	N	O
28	arm	N	O
29	completed	N	O
30	baseline	N	O
31	QOL	N	O
32	assessments	N	O
33	.	N	O

1	The	N	I-Premise
2	two	N	I-Premise
3	groups	N	I-Premise
4	were	N	I-Premise
5	comparable	N	I-Premise
6	,	N	I-Premise
7	with	N	I-Premise
8	low	N	I-Premise
9	global	N	I-Premise
10	QOL	N	I-Premise
11	scores	N	I-Premise
12	and	N	I-Premise
13	significant	N	I-Premise
14	symptom	N	I-Premise
15	burden	N	I-Premise
16	,	N	I-Premise
17	especially	N	I-Premise
18	pain	N	I-Premise
19	and	N	I-Premise
20	fatigue	N	I-Premise
21	,	N	I-Premise
22	after	N	I-Premise
23	thoracotomy	N	I-Premise
24	.	N	I-Premise

1	Changes	N	O
2	in	N	O
3	QOL	N	O
4	during	N	O
5	chemotherapy	N	O
6	were	N	O
7	relatively	N	O
8	modest	N	O
9	;	N	O
10	fatigue	N	I-Premise
11	,	N	I-Premise
12	nausea	N	I-Premise
13	,	N	I-Premise
14	and	N	I-Premise
15	vomiting	N	I-Premise
16	worsened	N	I-Premise
17	,	N	I-Premise
18	but	N	I-Premise
19	there	N	I-Premise
20	was	N	I-Premise
21	a	N	I-Premise
22	reduction	N	I-Premise
23	in	N	I-Premise
24	pain	N	I-Premise
25	and	N	I-Premise
26	no	N	I-Premise
27	change	N	I-Premise
28	in	N	I-Premise
29	global	N	I-Premise
30	QOL	N	I-Premise
31	.	N	I-Premise

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	observation	N	I-Premise
5	arm	N	I-Premise
6	showed	N	I-Premise
7	considerable	N	I-Premise
8	improvements	N	I-Premise
9	in	N	I-Premise
10	QOL	N	I-Premise
11	by	N	I-Premise
12	3	N	I-Premise
13	months	N	I-Premise
14	.	N	I-Premise

1	QOL	N	I-Premise
2	,	N	I-Premise
3	except	N	I-Premise
4	for	N	I-Premise
5	symptoms	N	I-Premise
6	of	N	I-Premise
7	sensory	N	I-Premise
8	neuropathy	N	I-Premise
9	and	N	I-Premise
10	hearing	N	I-Premise
11	loss	N	I-Premise
12	,	N	I-Premise
13	in	N	I-Premise
14	those	N	I-Premise
15	treated	N	I-Premise
16	with	N	I-Premise
17	chemotherapy	N	I-Premise
18	returned	N	I-Premise
19	to	N	I-Premise
20	baseline	N	I-Premise
21	by	N	I-Premise
22	9	N	I-Premise
23	months	N	I-Premise
24	.	N	I-Premise

1	The	N	I-Claim
2	findings	N	I-Claim
3	of	N	I-Claim
4	this	N	I-Claim
5	trial	N	I-Claim
6	indicate	N	I-Claim
7	that	N	I-Claim
8	the	N	I-Claim
9	negative	N	I-Claim
10	effects	N	I-Claim
11	of	N	I-Claim
12	adjuvant	N	I-Claim
13	chemotherapy	N	I-Claim
14	on	N	I-Claim
15	QOL	N	I-Claim
16	appear	N	I-Claim
17	to	N	I-Claim
18	be	N	I-Claim
19	temporary	N	I-Claim
20	,	N	I-Claim
21	and	N	I-Claim
22	that	N	I-Claim
23	improvements	N	I-Claim
24	(	N	I-Claim
25	with	N	I-Claim
26	a	N	I-Claim
27	return	N	I-Claim
28	to	N	I-Claim
29	baseline	N	I-Claim
30	function	N	I-Claim
31	)	N	I-Claim
32	are	N	I-Claim
33	likely	N	I-Claim
34	in	N	I-Claim
35	most	N	I-Claim
36	patients	N	I-Claim
37	.	N	I-Claim

1	The	N	O
2	physiological	N	O
3	and	N	O
4	psychological	N	O
5	stress	N	O
6	that	N	O
7	brain	N	O
8	tumor	N	O
9	patients	N	O
10	undergo	N	O
11	during	N	O
12	the	N	O
13	entire	N	O
14	surgical	N	O
15	experience	N	O
16	can	N	O
17	considerably	N	O
18	affect	N	O
19	several	N	O
20	aspects	N	O
21	of	N	O
22	their	N	O
23	hospitalization	N	O
24	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	examine	N	O
9	the	N	O
10	effects	N	O
11	of	N	O
12	live	N	O
13	music	N	O
14	therapy	N	O
15	on	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	indicators	N	O
20	,	N	O
21	amount	N	O
22	of	N	O
23	medications	N	O
24	administered	N	O
25	and	N	O
26	length	N	O
27	of	N	O
28	stay	N	O
29	for	N	O
30	persons	N	O
31	receiving	N	O
32	elective	N	O
33	surgical	N	O
34	procedures	N	O
35	of	N	O
36	the	N	O
37	brain	N	O
38	.	N	O

1	Subjects	N	O
2	(	N	O
3	N	N	O
4	=	N	O
5	27	N	O
6	)	N	O
7	were	N	O
8	patients	N	O
9	admitted	N	O
10	for	N	O
11	some	N	O
12	type	N	O
13	of	N	O
14	surgical	N	O
15	procedure	N	O
16	of	N	O
17	the	N	O
18	brain	N	O
19	.	N	O

1	Subjects	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	either	N	O
7	the	N	O
8	control	N	O
9	group	N	O
10	receiving	N	O
11	no	N	O
12	music	N	O
13	intervention	N	O
14	(	N	O
15	n	N	O
16	=	N	O
17	13	N	O
18	)	N	O
19	or	N	O
20	the	N	O
21	experimental	N	O
22	group	N	O
23	receiving	N	O
24	pre	N	O
25	and	N	O
26	postoperative	N	O
27	live	N	O
28	music	N	O
29	therapy	N	O
30	sessions	N	O
31	(	N	O
32	n	N	O
33	=	N	O
34	14	N	O
35	)	N	O
36	.	N	O

1	Anxiety	N	O
2	,	N	O
3	mood	N	O
4	,	N	O
5	pain	N	O
6	,	N	O
7	perception	N	O
8	of	N	O
9	hospitalization	N	O
10	or	N	O
11	procedure	N	O
12	,	N	O
13	relaxation	N	O
14	,	N	O
15	and	N	O
16	stress	N	O
17	were	N	O
18	measured	N	O
19	using	N	O
20	a	N	O
21	self-report	N	O
22	Visual	N	O
23	Analog	N	O
24	Scale	N	O
25	(	N	O
26	VAS	N	O
27	)	N	O
28	for	N	O
29	each	N	O
30	of	N	O
31	the	N	O
32	variables	N	O
33	.	N	O

1	The	N	O
2	documented	N	O
3	administration	N	O
4	of	N	O
5	postoperative	N	O
6	pain	N	O
7	medications	N	O
8	;	N	O
9	the	N	O
10	frequency	N	O
11	,	N	O
12	dosage	N	O
13	,	N	O
14	type	N	O
15	,	N	O
16	and	N	O
17	how	N	O
18	it	N	O
19	was	N	O
20	given	N	O
21	was	N	O
22	also	N	O
23	compared	N	O
24	between	N	O
25	groups	N	O
26	.	N	O

1	Experimental	N	O
2	subjects	N	O
3	live	N	O
4	and	N	O
5	interactive	N	O
6	music	N	O
7	therapy	N	O
8	sessions	N	O
9	,	N	O
10	including	N	O
11	a	N	O
12	pre-operative	N	O
13	session	N	O
14	and	N	O
15	continuing	N	O
16	with	N	O
17	daily	N	O
18	sessions	N	O
19	until	N	O
20	the	N	O
21	patient	N	O
22	was	N	O
23	discharged	N	O
24	home	N	O
25	.	N	O

1	Control	N	O
2	subjects	N	O
3	received	N	O
4	routine	N	O
5	hospital	N	O
6	care	N	O
7	without	N	O
8	any	N	O
9	music	N	O
10	therapy	N	O
11	intervention	N	O
12	.	N	O

1	Differences	N	O
2	in	N	O
3	experimental	N	O
4	pretest	N	O
5	and	N	O
6	posttest	N	O
7	scores	N	O
8	were	N	O
9	analyzed	N	O
10	using	N	O
11	a	N	O
12	Wilcoxon	N	O
13	Matched-Pairs	N	O
14	Signed-Rank	N	O
15	test	N	O
16	.	N	O

1	Results	N	I-Premise
2	indicated	N	I-Premise
3	statistically	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	for	N	I-Premise
7	4	N	I-Premise
8	of	N	I-Premise
9	the	N	I-Premise
10	6	N	I-Premise
11	quality	N	I-Premise
12	of	N	I-Premise
13	life	N	I-Premise
14	measures	N	I-Premise
15	:	N	I-Premise
16	anxiety	N	I-Premise
17	(	N	I-Premise
18	p	N	I-Premise
19	=	N	I-Premise
20	.03	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	perception	N	I-Premise
24	of	N	I-Premise
25	hospitalization	N	I-Premise
26	(	N	I-Premise
27	p	N	I-Premise
28	=	N	I-Premise
29	.03	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	relaxation	N	I-Premise
33	(	N	I-Premise
34	p	N	I-Premise
35	=	N	I-Premise
36	.001	N	I-Premise
37	)	N	I-Premise
38	,	N	I-Premise
39	and	N	I-Premise
40	stress	N	I-Premise
41	(	N	I-Premise
42	p	N	I-Premise
43	=	N	I-Premise
44	.001	N	I-Premise
45	)	N	I-Premise
46	.	N	I-Premise

1	No	N	I-Premise
2	statistically	N	I-Premise
3	significant	N	I-Premise
4	differences	N	I-Premise
5	were	N	I-Premise
6	found	N	I-Premise
7	for	N	I-Premise
8	mood	N	I-Premise
9	(	N	I-Premise
10	p	N	I-Premise
11	>	N	I-Premise
12	.05	N	I-Premise
13	)	N	I-Premise
14	or	N	I-Premise
15	pain	N	I-Premise
16	(	N	I-Premise
17	p	N	I-Premise
18	>	N	I-Premise
19	.05	N	I-Premise
20	)	N	I-Premise
21	levels	N	I-Premise
22	.	N	I-Premise

1	Administration	N	O
2	amounts	N	O
3	of	N	O
4	nausea	N	O
5	and	N	O
6	pain	N	O
7	medications	N	O
8	were	N	O
9	compared	N	O
10	with	N	O
11	a	N	O
12	Two-Way	N	O
13	ANOVA	N	O
14	with	N	O
15	One	N	O
16	Repeated	N	O
17	Measure	N	O
18	resulting	N	O
19	in	N	O
20	no	N	O
21	significant	N	O
22	differences	N	O
23	between	N	O
24	groups	N	O
25	and	N	O
26	medications	N	O
27	,	N	O
28	F	N	O
29	(	N	O
30	1	N	O
31	,	N	O
32	51	N	O
33	)	N	O
34	=	N	O
35	0.03	N	O
36	;	N	O
37	p	N	O
38	>	N	O
39	.05	N	O
40	.	N	O

1	Results	N	O
2	indicate	N	O
3	no	N	O
4	significant	N	O
5	differences	N	O
6	between	N	O
7	groups	N	O
8	for	N	O
9	length	N	O
10	of	N	O
11	stay	N	O
12	(	N	O
13	t	N	O
14	=	N	O
15	.97	N	O
16	,	N	O
17	df	N	O
18	=	N	O
19	25	N	O
20	,	N	O
21	p	N	O
22	>	N	O
23	.05	N	O
24	)	N	O
25	.	N	O

1	This	N	I-Claim
2	research	N	I-Claim
3	study	N	I-Claim
4	indicates	N	I-Claim
5	that	N	I-Claim
6	live	N	I-Claim
7	music	N	I-Claim
8	therapy	N	I-Claim
9	using	N	I-Claim
10	patient-preferred	N	I-Claim
11	music	N	I-Claim
12	can	N	I-Claim
13	be	N	I-Claim
14	beneficial	N	I-Claim
15	in	N	I-Claim
16	improving	N	I-Claim
17	quality	N	I-Claim
18	of	N	I-Claim
19	life	N	I-Claim
20	indicators	N	I-Claim
21	such	N	I-Claim
22	as	N	I-Claim
23	anxiety	N	I-Claim
24	,	N	I-Claim
25	perception	N	I-Claim
26	of	N	I-Claim
27	the	N	I-Claim
28	hospitalization	N	I-Claim
29	or	N	I-Claim
30	procedure	N	I-Claim
31	,	N	I-Claim
32	relaxation	N	I-Claim
33	,	N	I-Claim
34	and	N	I-Claim
35	stress	N	I-Claim
36	in	N	I-Claim
37	patients	N	I-Claim
38	undergoing	N	I-Claim
39	surgical	N	I-Claim
40	procedures	N	I-Claim
41	of	N	I-Claim
42	the	N	I-Claim
43	brain	N	I-Claim
44	.	N	I-Claim

1	Many	N	O
2	women	N	O
3	with	N	O
4	breast	N	O
5	cancer	N	O
6	need	N	O
7	psychological	N	O
8	help	N	O
9	to	N	O
10	cope	N	O
11	more	N	O
12	effectively	N	O
13	after	N	O
14	treatment	N	O
15	.	N	O

1	Cognitive	N	O
2	and	N	O
3	behavioural	N	O
4	techniques	N	O
5	are	N	O
6	not	N	O
7	yet	N	O
8	well	N	O
9	established	N	O
10	in	N	O
11	France	N	O
12	.	N	O

1	A	N	O
2	multi-site	N	O
3	randomized	N	O
4	study	N	O
5	was	N	O
6	conducted	N	O
7	to	N	O
8	evaluate	N	O
9	the	N	O
10	effects	N	O
11	of	N	O
12	a	N	O
13	psycho-educational	N	O
14	group	N	O
15	intervention	N	O
16	in	N	O
17	this	N	O
18	population	N	O
19	.	N	O

1	Two	N	O
2	hundred	N	O
3	and	N	O
4	three	N	O
5	patients	N	O
6	,	N	O
7	recruited	N	O
8	after	N	O
9	primary	N	O
10	treatment	N	O
11	,	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	either	N	O
16	to	N	O
17	a	N	O
18	treatment	N	O
19	group	N	O
20	(	N	O
21	psycho-educational	N	O
22	intervention	N	O
23	)	N	O
24	or	N	O
25	to	N	O
26	a	N	O
27	waiting-list	N	O
28	control	N	O
29	group	N	O
30	.	N	O

1	The	N	O
2	8-week	N	O
3	programme	N	O
4	of	N	O
5	2	N	O
6	h	N	O
7	sessions	N	O
8	comprised	N	O
9	of	N	O
10	thematic	N	O
11	discussions	N	O
12	,	N	O
13	information	N	O
14	and	N	O
15	training	N	O
16	in	N	O
17	stress	N	O
18	management	N	O
19	techniques	N	O
20	.	N	O

1	Evaluation	N	O
2	at	N	O
3	baseline	N	O
4	,	N	O
5	after	N	O
6	8	N	O
7	sessions	N	O
8	,	N	O
9	and	N	O
10	1	N	O
11	month	N	O
12	after	N	O
13	programme	N	O
14	completion	N	O
15	,	N	O
16	included	N	O
17	evaluations	N	O
18	using	N	O
19	the	N	O
20	STAI	N	O
21	,	N	O
22	POMS	N	O
23	,	N	O
24	MAC	N	O
25	,	N	O
26	EORTC	N	O
27	QLQ-C30	N	O
28	and	N	O
29	EORTC	N	O
30	QLQ-BR23	N	O
31	breast	N	O
32	module	N	O
33	scales	N	O
34	.	N	O

1	We	N	I-Premise
2	observed	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	reduction	N	I-Premise
6	in	N	I-Premise
7	anxiety	N	I-Premise
8	(	N	I-Premise
9	STAI	N	I-Premise
10	,	N	I-Premise
11	POMS	N	I-Premise
12	)	N	I-Premise
13	among	N	I-Premise
14	group	N	I-Premise
15	participants	N	I-Premise
16	,	N	I-Premise
17	a	N	I-Premise
18	reduction	N	I-Premise
19	in	N	I-Premise
20	anger	N	I-Premise
21	,	N	I-Premise
22	depression	N	I-Premise
23	and	N	I-Premise
24	fatigue	N	I-Premise
25	(	N	I-Premise
26	POMS	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	a	N	I-Premise
30	significant	N	I-Premise
31	improvement	N	I-Premise
32	in	N	I-Premise
33	vigor	N	I-Premise
34	and	N	I-Premise
35	interpersonal	N	I-Premise
36	relationships	N	I-Premise
37	(	N	I-Premise
38	POMS	N	I-Premise
39	)	N	I-Premise
40	,	N	I-Premise
41	in	N	I-Premise
42	emotional	N	I-Premise
43	and	N	I-Premise
44	role	N	I-Premise
45	functioning	N	I-Premise
46	,	N	I-Premise
47	in	N	I-Premise
48	health	N	I-Premise
49	status	N	I-Premise
50	and	N	I-Premise
51	fatigue	N	I-Premise
52	level	N	I-Premise
53	(	N	I-Premise
54	EORTC	N	I-Premise
55	QLQ-C30	N	I-Premise
56	)	N	I-Premise
57	.	N	I-Premise

1	In	N	O
2	contrast	N	O
3	,	N	O
4	coping	N	I-Premise
5	strategies	N	I-Premise
6	(	N	I-Premise
7	MAC	N	I-Premise
8	)	N	I-Premise
9	were	N	I-Premise
10	not	N	I-Premise
11	significantly	N	I-Premise
12	different	N	I-Premise
13	between	N	I-Premise
14	groups	N	I-Premise
15	.	N	I-Premise

1	No	N	I-Premise
2	group-related	N	I-Premise
3	negative	N	I-Premise
4	effects	N	I-Premise
5	were	N	I-Premise
6	observed	N	I-Premise
7	and	N	I-Premise
8	the	N	I-Premise
9	global	N	I-Premise
10	satisfaction	N	I-Premise
11	levels	N	I-Premise
12	were	N	I-Premise
13	very	N	I-Premise
14	high	N	I-Premise
15	.	N	I-Premise

1	This	N	I-Claim
2	study	N	I-Claim
3	demonstrates	N	I-Claim
4	the	N	I-Claim
5	feasibility	N	I-Claim
6	and	N	I-Claim
7	effectiveness	N	I-Claim
8	of	N	I-Claim
9	a	N	I-Claim
10	psycho-educational	N	I-Claim
11	intervention	N	I-Claim
12	,	N	I-Claim
13	which	N	I-Claim
14	can	N	I-Claim
15	accelerate	N	I-Claim
16	the	N	I-Claim
17	reduction	N	I-Claim
18	of	N	I-Claim
19	those	N	I-Claim
20	negative	N	I-Claim
21	affects	N	I-Claim
22	which	N	I-Claim
23	are	N	I-Claim
24	present	N	I-Claim
25	at	N	I-Claim
26	the	N	I-Claim
27	end	N	I-Claim
28	of	N	I-Claim
29	treatment	N	I-Claim
30	.	N	I-Claim

1	It	N	I-Claim
2	represents	N	I-Claim
3	an	N	I-Claim
4	excellent	N	I-Claim
5	complement	N	I-Claim
6	or	N	I-Claim
7	an	N	I-Claim
8	alternative	N	I-Claim
9	to	N	I-Claim
10	individual	N	I-Claim
11	psycho-oncologic	N	I-Claim
12	therapeutic	N	I-Claim
13	support	N	I-Claim
14	,	N	I-Claim
15	widely	N	O
16	proposed	N	O
17	in	N	O
18	France	N	O
19	,	N	O
20	and	N	O
21	should	N	O
22	now	N	O
23	be	N	O
24	tested	N	O
25	in	N	O
26	groups	N	O
27	with	N	O
28	other	N	O
29	types	N	O
30	of	N	O
31	cancer	N	O
32	and	N	O
33	at	N	O
34	other	N	O
35	disease	N	O
36	phases	N	O
37	.	N	O

1	We	N	O
2	sought	N	O
3	the	N	O
4	extent	N	O
5	to	N	O
6	which	N	O
7	arm	N	O
8	morbidity	N	O
9	could	N	O
10	be	N	O
11	reduced	N	O
12	by	N	O
13	using	N	O
14	sentinel-lymph-node-based	N	O
15	management	N	O
16	in	N	O
17	women	N	O
18	with	N	O
19	clinically	N	O
20	node-negative	N	O
21	early	N	O
22	breast	N	O
23	cancer	N	O
24	.	N	O

1	One	N	O
2	thousand	N	O
3	eighty-eight	N	O
4	women	N	O
5	were	N	O
6	randomly	N	O
7	allocated	N	O
8	to	N	O
9	sentinel-lymph-node	N	O
10	biopsy	N	O
11	followed	N	O
12	by	N	O
13	axillary	N	O
14	clearance	N	O
15	if	N	O
16	the	N	O
17	sentinel	N	O
18	node	N	O
19	was	N	O
20	positive	N	O
21	or	N	O
22	not	N	O
23	detected	N	O
24	(	N	O
25	SNBM	N	O
26	)	N	O
27	or	N	O
28	routine	N	O
29	axillary	N	O
30	clearance	N	O
31	(	N	O
32	RAC	N	O
33	,	N	O
34	sentinel-lymph-node	N	O
35	biopsy	N	O
36	followed	N	O
37	immediately	N	O
38	by	N	O
39	axillary	N	O
40	clearance	N	O
41	)	N	O
42	.	N	O

1	Sentinel	N	O
2	nodes	N	O
3	were	N	O
4	located	N	O
5	using	N	O
6	blue	N	O
7	dye	N	O
8	,	N	O
9	alone	N	O
10	or	N	O
11	with	N	O
12	technetium-labeled	N	O
13	antimony	N	O
14	sulfide	N	O
15	colloid	N	O
16	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	increase	N	O
6	in	N	O
7	arm	N	O
8	volume	N	O
9	from	N	O
10	baseline	N	O
11	to	N	O
12	the	N	O
13	average	N	O
14	of	N	O
15	measurements	N	O
16	at	N	O
17	6	N	O
18	and	N	O
19	12	N	O
20	months	N	O
21	.	N	O

1	Secondary	N	O
2	endpoints	N	O
3	were	N	O
4	the	N	O
5	proportions	N	O
6	of	N	O
7	women	N	O
8	with	N	O
9	at	N	O
10	least	N	O
11	15	N	O
12	%	N	O
13	increase	N	O
14	in	N	O
15	arm	N	O
16	volume	N	O
17	or	N	O
18	early	N	O
19	axillary	N	O
20	morbidity	N	O
21	,	N	O
22	and	N	O
23	average	N	O
24	scores	N	O
25	for	N	O
26	arm	N	O
27	symptoms	N	O
28	,	N	O
29	dysfunctions	N	O
30	,	N	O
31	and	N	O
32	disabilities	N	O
33	assessed	N	O
34	at	N	O
35	6	N	O
36	and	N	O
37	12	N	O
38	months	N	O
39	by	N	O
40	patients	N	O
41	with	N	O
42	the	N	O
43	SNAC	N	O
44	Study-Specific	N	O
45	Scales	N	O
46	and	N	O
47	other	N	O
48	quality-of-life	N	O
49	instruments	N	O
50	.	N	O

1	Sensitivity	N	O
2	,	N	O
3	false-negative	N	O
4	rates	N	O
5	,	N	O
6	and	N	O
7	negative	N	O
8	predictive	N	O
9	values	N	O
10	for	N	O
11	sentinel-lymph-node	N	O
12	biopsy	N	O
13	were	N	O
14	estimated	N	O
15	in	N	O
16	the	N	O
17	RAC	N	O
18	group	N	O
19	.	N	O

1	The	N	I-Premise
2	average	N	I-Premise
3	increase	N	I-Premise
4	in	N	I-Premise
5	arm	N	I-Premise
6	volume	N	I-Premise
7	was	N	I-Premise
8	2.8	N	I-Premise
9	%	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	SNBM	N	I-Premise
13	group	N	I-Premise
14	and	N	I-Premise
15	4.2	N	I-Premise
16	%	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	RAC	N	I-Premise
20	group	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	0.002	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	SNBM	N	I-Premise
5	group	N	I-Premise
6	gave	N	I-Premise
7	lower	N	I-Premise
8	ratings	N	I-Premise
9	for	N	I-Premise
10	arm	N	I-Premise
11	swelling	N	I-Premise
12	(	N	I-Premise
13	P	N	I-Premise
14	<	N	I-Premise
15	0.001	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	symptoms	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	<	N	I-Premise
22	0.001	N	I-Premise
23	)	N	I-Premise
24	,	N	I-Premise
25	and	N	I-Premise
26	dysfunctions	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	0.02	N	I-Premise
31	)	N	I-Premise
32	,	N	I-Premise
33	but	N	I-Premise
34	not	N	I-Premise
35	disabilities	N	I-Premise
36	(	N	I-Premise
37	P	N	I-Premise
38	=	N	I-Premise
39	0.5	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	Sentinel	N	I-Premise
2	nodes	N	I-Premise
3	were	N	I-Premise
4	found	N	I-Premise
5	in	N	I-Premise
6	95	N	I-Premise
7	%	N	I-Premise
8	of	N	I-Premise
9	the	N	I-Premise
10	SNBM	N	I-Premise
11	group	N	I-Premise
12	(	N	I-Premise
13	29	N	I-Premise
14	%	N	I-Premise
15	positive	N	I-Premise
16	)	N	I-Premise
17	and	N	I-Premise
18	93	N	I-Premise
19	%	N	I-Premise
20	of	N	I-Premise
21	the	N	I-Premise
22	RAC	N	I-Premise
23	group	N	I-Premise
24	(	N	I-Premise
25	25	N	I-Premise
26	%	N	I-Premise
27	positive	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	SNB	N	O
2	had	N	O
3	sensitivity	N	O
4	94.5	N	O
5	%	N	O
6	,	N	O
7	false-negative	N	O
8	rate	N	O
9	5.5	N	O
10	%	N	O
11	,	N	O
12	and	N	O
13	negative	N	O
14	predictive	N	O
15	value	N	O
16	98	N	O
17	%	N	O
18	.	N	O

1	SNBM	N	I-Claim
2	was	N	I-Claim
3	successfully	N	I-Claim
4	undertaken	N	I-Claim
5	in	N	I-Claim
6	a	N	I-Claim
7	wide	N	I-Claim
8	range	N	I-Claim
9	of	N	I-Claim
10	surgical	N	I-Claim
11	centers	N	I-Claim
12	and	N	I-Claim
13	caused	N	I-Claim
14	significantly	N	I-Claim
15	less	N	I-Claim
16	morbidity	N	I-Claim
17	than	N	I-Claim
18	RAC	N	I-Claim
19	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	toxicities	N	O
5	,	N	O
6	tumor	N	O
7	control	N	O
8	,	N	O
9	survival	N	O
10	,	N	O
11	and	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	of	N	O
16	nasopharyngeal	N	O
17	cancer	N	O
18	(	N	O
19	NPC	N	O
20	)	N	O
21	patients	N	O
22	treated	N	O
23	with	N	O
24	sequential	N	O
25	neoadjuvant	N	O
26	chemotherapy	N	O
27	followed	N	O
28	by	N	O
29	concurrent	N	O
30	cisplatin-radiotherapy	N	O
31	(	N	O
32	CRT	N	O
33	)	N	O
34	or	N	O
35	CRT	N	O
36	alone	N	O
37	.	N	O

1	Previously	N	O
2	untreated	N	O
3	stage	N	O
4	III	N	O
5	to	N	O
6	IVB	N	O
7	NPC	N	O
8	were	N	O
9	randomly	N	O
10	assigned	N	O
11	to	N	O
12	(	N	O
13	1	N	O
14	)	N	O
15	neoadjuvant	N	O
16	docetaxel	N	O
17	75	N	O
18	mg/m	N	O
19	(	N	O
20	2	N	O
21	)	N	O
22	and	N	O
23	cisplatin	N	O
24	75	N	O
25	mg/m	N	O
26	(	N	O
27	2	N	O
28	)	N	O
29	every	N	O
30	3	N	O
31	weeks	N	O
32	for	N	O
33	two	N	O
34	cycles	N	O
35	,	N	O
36	followed	N	O
37	by	N	O
38	cisplatin	N	O
39	40	N	O
40	mg/m	N	O
41	(	N	O
42	2	N	O
43	)	N	O
44	/wk	N	O
45	concurrent	N	O
46	with	N	O
47	radiotherapy	N	O
48	,	N	O
49	or	N	O
50	(	N	O
51	2	N	O
52	)	N	O
53	CRT	N	O
54	alone	N	O
55	.	N	O

1	Planned	N	O
2	accrual	N	O
3	was	N	O
4	30	N	O
5	patients	N	O
6	per	N	O
7	arm	N	O
8	to	N	O
9	detect	N	O
10	20	N	O
11	%	N	O
12	difference	N	O
13	of	N	O
14	toxicities	N	O
15	based	N	O
16	on	N	O
17	95	N	O
18	%	N	O
19	CIs	N	O
20	.	N	O

1	From	N	O
2	November	N	O
3	2002	N	O
4	to	N	O
5	November	N	O
6	2004	N	O
7	,	N	O
8	65	N	O
9	eligible	N	O
10	patients	N	O
11	were	N	O
12	randomly	N	O
13	assigned	N	O
14	to	N	O
15	neoadjuvant	N	O
16	chemotherapy	N	O
17	followed	N	O
18	by	N	O
19	CRT	N	O
20	(	N	O
21	n	N	O
22	=	N	O
23	34	N	O
24	)	N	O
25	or	N	O
26	CRT	N	O
27	alone	N	O
28	(	N	O
29	n	N	O
30	=	N	O
31	31	N	O
32	)	N	O
33	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	high	N	I-Premise
5	rate	N	I-Premise
6	of	N	I-Premise
7	grade	N	I-Premise
8	3/4	N	I-Premise
9	neutropenia	N	I-Premise
10	(	N	I-Premise
11	97	N	I-Premise
12	%	N	I-Premise
13	)	N	I-Premise
14	but	N	I-Premise
15	not	N	I-Premise
16	neutropenic	N	I-Premise
17	fever	N	I-Premise
18	(	N	I-Premise
19	12	N	I-Premise
20	%	N	I-Premise
21	)	N	I-Premise
22	during	N	I-Premise
23	neoadjuvant	N	I-Premise
24	chemotherapy	N	I-Premise
25	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	differences	N	I-Premise
4	in	N	I-Premise
5	rates	N	I-Premise
6	of	N	I-Premise
7	acute	N	I-Premise
8	toxicities	N	I-Premise
9	were	N	I-Premise
10	observed	N	I-Premise
11	between	N	I-Premise
12	the	N	I-Premise
13	two	N	I-Premise
14	arms	N	I-Premise
15	during	N	I-Premise
16	CRT	N	I-Premise
17	.	N	I-Premise

1	Dose	N	I-Premise
2	intensities	N	I-Premise
3	of	N	I-Premise
4	concurrent	N	I-Premise
5	cisplatin	N	I-Premise
6	,	N	I-Premise
7	late	N	I-Premise
8	RT	N	I-Premise
9	toxicities	N	I-Premise
10	and	N	I-Premise
11	quality	N	I-Premise
12	of	N	I-Premise
13	life	N	I-Premise
14	scores	N	I-Premise
15	were	N	I-Premise
16	comparable	N	I-Premise
17	in	N	I-Premise
18	both	N	I-Premise
19	arms	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	3-year	N	I-Premise
3	progression-free	N	I-Premise
4	survival	N	I-Premise
5	for	N	I-Premise
6	neoadjuvant	N	I-Premise
7	versus	N	I-Premise
8	control	N	I-Premise
9	arm	N	I-Premise
10	was	N	I-Premise
11	88.2	N	I-Premise
12	%	N	I-Premise
13	and	N	I-Premise
14	59.5	N	I-Premise
15	%	N	I-Premise
16	(	N	I-Premise
17	hazard	N	I-Premise
18	ratio	N	I-Premise
19	=	N	I-Premise
20	0.49	N	I-Premise
21	;	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	,	N	I-Premise
26	0.20	N	I-Premise
27	to	N	I-Premise
28	1.19	N	I-Premise
29	;	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.12	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	The	N	I-Premise
2	3-year	N	I-Premise
3	overall	N	I-Premise
4	survival	N	I-Premise
5	for	N	I-Premise
6	neoadjuvant	N	I-Premise
7	versus	N	I-Premise
8	control	N	I-Premise
9	arm	N	I-Premise
10	was	N	I-Premise
11	94.1	N	I-Premise
12	%	N	I-Premise
13	and	N	I-Premise
14	67.7	N	I-Premise
15	%	N	I-Premise
16	(	N	I-Premise
17	hazard	N	I-Premise
18	ratio	N	I-Premise
19	=	N	I-Premise
20	0.24	N	I-Premise
21	;	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	,	N	I-Premise
26	0.078	N	I-Premise
27	to	N	I-Premise
28	0.73	N	I-Premise
29	;	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.012	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	Neoadjuvant	N	I-Claim
2	docetaxel-cisplatin	N	I-Claim
3	followed	N	I-Claim
4	by	N	I-Claim
5	CRT	N	I-Claim
6	was	N	I-Claim
7	well	N	I-Claim
8	tolerated	N	I-Claim
9	with	N	I-Claim
10	a	N	I-Claim
11	manageable	N	I-Claim
12	toxicity	N	I-Claim
13	profile	N	I-Claim
14	that	N	I-Claim
15	allowed	N	I-Claim
16	subsequent	N	I-Claim
17	delivery	N	I-Claim
18	of	N	I-Claim
19	full-dose	N	I-Claim
20	CRT	N	I-Claim
21	.	N	I-Claim

1	Preliminary	N	I-Claim
2	results	N	I-Claim
3	suggested	N	I-Claim
4	a	N	I-Claim
5	positive	N	I-Claim
6	impact	N	I-Claim
7	on	N	I-Claim
8	survival	N	I-Claim
9	.	N	I-Claim

1	A	N	O
2	phase	N	O
3	III	N	O
4	study	N	O
5	to	N	O
6	definitively	N	O
7	test	N	O
8	this	N	O
9	neoadjuvant-concurrent	N	O
10	strategy	N	O
11	is	N	O
12	warranted	N	O
13	.	N	O

1	To	N	O
2	assess	N	O
3	the	N	O
4	safety	N	O
5	,	N	O
6	tolerability	N	O
7	and	N	O
8	efficacy	N	O
9	of	N	O
10	abatacept	N	O
11	in	N	O
12	patients	N	O
13	with	N	O
14	rheumatoid	N	O
15	arthritis	N	O
16	(	N	O
17	RA	N	O
18	)	N	O
19	who	N	O
20	had	N	O
21	failed	N	O
22	anti-tumour	N	O
23	necrosis	N	O
24	factor	N	O
25	(	N	O
26	TNF	N	O
27	)	N	O
28	therapy	N	O
29	and	N	O
30	were	N	O
31	switched	N	O
32	to	N	O
33	abatacept	N	O
34	directly	N	O
35	or	N	O
36	after	N	O
37	completing	N	O
38	washout	N	O
39	.	N	O

1	In	N	O
2	this	N	O
3	international	N	O
4	,	N	O
5	6-month	N	O
6	,	N	O
7	open-label	N	O
8	trial	N	O
9	,	N	O
10	patients	N	O
11	had	N	O
12	active	N	O
13	RA	N	O
14	,	N	O
15	an	N	O
16	inadequate	N	O
17	response	N	O
18	to	N	O
19	anti-TNF	N	O
20	therapy	N	O
21	for	N	O
22	3	N	O
23	months	N	O
24	or	N	O
25	longer	N	O
26	and	N	O
27	a	N	O
28	disease	N	O
29	activity	N	O
30	score	N	O
31	in	N	O
32	28	N	O
33	joints	N	O
34	(	N	O
35	DAS28	N	O
36	(	N	O
37	C-reactive	N	O
38	protein	N	O
39	;	N	O
40	CRP	N	O
41	)	N	O
42	of	N	O
43	5.1	N	O
44	or	N	O
45	greater	N	O
46	.	N	O

1	``	N	O
2	Washout	N	O
3	''	N	O
4	patients	N	O
5	discontinued	N	O
6	anti-TNF	N	O
7	therapy	N	O
8	2	N	O
9	months	N	O
10	or	N	O
11	longer	N	O
12	pre-screening	N	O
13	;	N	O
14	``	N	O
15	direct-switch	N	O
16	''	N	O
17	patients	N	O
18	began	N	O
19	abatacept	N	O
20	(	N	O
21	approximately	N	O
22	10	N	O
23	mg/kg	N	O
24	)	N	O
25	at	N	O
26	their	N	O
27	next	N	O
28	scheduled	N	O
29	anti-TNF	N	O
30	therapy	N	O
31	dose	N	O
32	.	N	O

1	1046	N	O
2	patients	N	O
3	were	N	O
4	treated	N	O
5	(	N	O
6	449	N	O
7	washout	N	O
8	,	N	O
9	597	N	O
10	direct-switch	N	O
11	;	N	O
12	baseline	N	O
13	characteristics	N	O
14	were	N	O
15	similar	N	O
16	between	N	O
17	groups	N	O
18	)	N	O
19	.	N	O

1	At	N	I-Premise
2	6	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	adverse	N	I-Premise
6	events	N	I-Premise
7	(	N	I-Premise
8	AE	N	I-Premise
9	;	N	I-Premise
10	78.0	N	I-Premise
11	%	N	I-Premise
12	vs	N	I-Premise
13	79.2	N	I-Premise
14	%	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	serious	N	I-Premise
18	AE	N	I-Premise
19	(	N	I-Premise
20	11.1	N	I-Premise
21	%	N	I-Premise
22	vs	N	I-Premise
23	9.9	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	and	N	I-Premise
27	discontinuations	N	I-Premise
28	due	N	I-Premise
29	to	N	I-Premise
30	AE	N	I-Premise
31	(	N	I-Premise
32	3.8	N	I-Premise
33	%	N	I-Premise
34	vs	N	I-Premise
35	4.0	N	I-Premise
36	%	N	I-Premise
37	)	N	I-Premise
38	and	N	I-Premise
39	serious	N	I-Premise
40	AE	N	I-Premise
41	(	N	I-Premise
42	2.0	N	I-Premise
43	%	N	I-Premise
44	vs	N	I-Premise
45	1.3	N	I-Premise
46	%	N	I-Premise
47	)	N	I-Premise
48	were	N	I-Premise
49	comparable	N	I-Premise
50	in	N	I-Premise
51	washout	N	I-Premise
52	versus	N	I-Premise
53	direct-switch	N	I-Premise
54	patients	N	I-Premise
55	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	opportunistic	N	I-Premise
5	infections	N	I-Premise
6	.	N	I-Premise

1	At	N	I-Premise
2	6	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	in	N	I-Premise
6	washout	N	I-Premise
7	versus	N	I-Premise
8	direct-switch	N	I-Premise
9	patients	N	I-Premise
10	,	N	I-Premise
11	similar	N	I-Premise
12	clinically	N	I-Premise
13	meaningful	N	I-Premise
14	improvements	N	I-Premise
15	were	N	I-Premise
16	seen	N	I-Premise
17	in	N	I-Premise
18	DAS28	N	I-Premise
19	(	N	I-Premise
20	CRP	N	I-Premise
21	)	N	I-Premise
22	(	N	I-Premise
23	>	N	I-Premise
24	or	N	I-Premise
25	=1.2	N	I-Premise
26	unit	N	I-Premise
27	improvement	N	I-Premise
28	,	N	I-Premise
29	59.5	N	I-Premise
30	%	N	I-Premise
31	vs	N	I-Premise
32	53.6	N	I-Premise
33	%	N	I-Premise
34	,	N	I-Premise
35	respectively	N	I-Premise
36	;	N	I-Premise
37	low	N	I-Premise
38	disease	N	I-Premise
39	activity	N	I-Premise
40	state	N	I-Premise
41	,	N	I-Premise
42	22.5	N	I-Premise
43	%	N	I-Premise
44	vs	N	I-Premise
45	22.3	N	I-Premise
46	%	N	I-Premise
47	;	N	I-Premise
48	DAS28-defined	N	I-Premise
49	remission	N	I-Premise
50	,	N	I-Premise
51	12.0	N	I-Premise
52	%	N	I-Premise
53	vs	N	I-Premise
54	13.7	N	I-Premise
55	%	N	I-Premise
56	)	N	I-Premise
57	,	N	I-Premise
58	physical	N	I-Premise
59	function	N	I-Premise
60	(	N	I-Premise
61	health	N	I-Premise
62	assessment	N	I-Premise
63	questionnaire	N	I-Premise
64	disability	N	I-Premise
65	index	N	I-Premise
66	>	N	I-Premise
67	or	N	I-Premise
68	=0.22	N	I-Premise
69	improvement	N	I-Premise
70	;	N	I-Premise
71	46.3	N	I-Premise
72	%	N	I-Premise
73	vs	N	I-Premise
74	47.1	N	I-Premise
75	%	N	I-Premise
76	)	N	I-Premise
77	and	N	I-Premise
78	health-related	N	I-Premise
79	quality	N	I-Premise
80	of	N	I-Premise
81	life	N	I-Premise
82	(	N	I-Premise
83	mean	N	I-Premise
84	change	N	I-Premise
85	in	N	I-Premise
86	short-form	N	I-Premise
87	36	N	I-Premise
88	scores	N	I-Premise
89	:	N	I-Premise
90	physical	N	I-Premise
91	component	N	I-Premise
92	summary	N	I-Premise
93	,	N	I-Premise
94	5.5	N	I-Premise
95	vs	N	I-Premise
96	6.1	N	I-Premise
97	;	N	I-Premise
98	mental	N	I-Premise
99	component	N	I-Premise
100	summary	N	I-Premise
101	,	N	I-Premise
102	4.8	N	I-Premise
103	vs	N	I-Premise
104	5.4	N	I-Premise
105	)	N	I-Premise
106	.	N	I-Premise

1	Abatacept	N	I-Claim
2	demonstrated	N	I-Claim
3	acceptable	N	I-Claim
4	safety	N	I-Claim
5	and	N	I-Claim
6	tolerability	N	I-Claim
7	and	N	I-Claim
8	clinically	N	I-Claim
9	meaningful	N	I-Claim
10	efficacy	N	I-Claim
11	over	N	I-Claim
12	6	N	I-Claim
13	months	N	I-Claim
14	in	N	I-Claim
15	patients	N	I-Claim
16	with	N	I-Claim
17	inadequate	N	I-Claim
18	response	N	I-Claim
19	to	N	I-Claim
20	anti-TNF	N	I-Claim
21	therapy	N	I-Claim
22	.	N	I-Claim

1	Results	N	I-Claim
2	were	N	I-Claim
3	comparable	N	I-Claim
4	with	N	I-Claim
5	or	N	I-Claim
6	without	N	I-Claim
7	a	N	I-Claim
8	washout	N	I-Claim
9	,	N	I-Claim
10	supporting	N	I-Claim
11	direct	N	I-Claim
12	switching	N	I-Claim
13	from	N	I-Claim
14	anti-TNF	N	I-Claim
15	therapy	N	I-Claim
16	to	N	I-Claim
17	abatacept	N	I-Claim
18	as	N	I-Claim
19	an	N	I-Claim
20	option	N	I-Claim
21	in	N	I-Claim
22	clinical	N	I-Claim
23	practice	N	I-Claim
24	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	an	N	O
7	expressive	N	O
8	writing	N	O
9	(	N	O
10	EW	N	O
11	)	N	O
12	intervention	N	O
13	on	N	O
14	perceptions	N	O
15	of	N	O
16	emotional	N	O
17	support	N	O
18	in	N	O
19	women	N	O
20	completing	N	O
21	treatment	N	O
22	for	N	O
23	early	N	O
24	stage	N	O
25	breast	N	O
26	cancer	N	O
27	.	N	O

1	Women	N	O
2	were	N	O
3	recruited	N	O
4	to	N	O
5	the	N	O
6	study	N	O
7	during	N	O
8	their	N	O
9	final	N	O
10	week	N	O
11	of	N	O
12	treatment	N	O
13	.	N	O

1	Of	N	O
2	260	N	O
3	eligible	N	O
4	patients	N	O
5	,	N	O
6	104	N	O
7	(	N	O
8	40	N	O
9	%	N	O
10	)	N	O
11	agreed	N	O
12	to	N	O
13	participate	N	O
14	,	N	O
15	and	N	O
16	93	N	O
17	were	N	O
18	randomised	N	O
19	.	N	O

1	Women	N	O
2	in	N	O
3	the	N	O
4	writing	N	O
5	group	N	O
6	wrote	N	O
7	for	N	O
8	20	N	O
9	min	N	O
10	on	N	O
11	four	N	O
12	consecutive	N	O
13	days	N	O
14	.	N	O

1	The	N	O
2	control	N	O
3	group	N	O
4	received	N	O
5	normal	N	O
6	care	N	O
7	.	N	O

1	Women	N	O
2	's	N	O
3	perceptions	N	O
4	of	N	O
5	emotional	N	O
6	support	N	O
7	,	N	O
8	quality	N	O
9	of	N	O
10	life	N	O
11	(	N	O
12	QOL	N	O
13	)	N	O
14	,	N	O
15	mood	N	O
16	,	N	O
17	and	N	O
18	healthcare	N	O
19	utilisation	N	O
20	were	N	O
21	assessed	N	O
22	at	N	O
23	baseline	N	O
24	,	N	O
25	1	N	O
26	month	N	O
27	,	N	O
28	3	N	O
29	months	N	O
30	and	N	O
31	6	N	O
32	months	N	O
33	.	N	O

1	Interviews	N	O
2	were	N	O
3	conducted	N	O
4	to	N	O
5	explore	N	O
6	women	N	O
7	's	N	O
8	experience	N	O
9	of	N	O
10	writing	N	O
11	.	N	O

1	Eighty	N	O
2	participants	N	O
3	completed	N	O
4	all	N	O
5	follow-ups	N	O
6	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	effect	N	I-Premise
6	of	N	I-Premise
7	group	N	I-Premise
8	on	N	I-Premise
9	women	N	I-Premise
10	's	N	I-Premise
11	perceptions	N	I-Premise
12	of	N	I-Premise
13	social	N	I-Premise
14	support	N	I-Premise
15	with	N	I-Premise
16	those	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	intervention	N	I-Premise
20	group	N	I-Premise
21	being	N	I-Premise
22	more	N	I-Premise
23	satisfied	N	I-Premise
24	with	N	I-Premise
25	the	N	I-Premise
26	emotional	N	I-Premise
27	support	N	I-Premise
28	they	N	I-Premise
29	received	N	I-Premise
30	(	N	I-Premise
31	p	N	I-Premise
32	<	N	I-Premise
33	0.05	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	Satisfaction	N	I-Premise
2	with	N	I-Premise
3	emotional	N	I-Premise
4	support	N	I-Premise
5	was	N	I-Premise
6	negatively	N	I-Premise
7	correlated	N	I-Premise
8	with	N	I-Premise
9	depression/dejection	N	I-Premise
10	(	N	I-Premise
11	p	N	I-Premise
12	<	N	I-Premise
13	0.05	N	I-Premise
14	)	N	I-Premise
15	and	N	I-Premise
16	anger/hostility	N	I-Premise
17	(	N	I-Premise
18	p	N	I-Premise
19	<	N	I-Premise
20	0.05	N	I-Premise
21	)	N	I-Premise
22	and	N	I-Premise
23	positively	N	I-Premise
24	correlated	N	I-Premise
25	with	N	I-Premise
26	social	N	I-Premise
27	and	N	I-Premise
28	family	N	I-Premise
29	well-being	N	I-Premise
30	(	N	I-Premise
31	p	N	I-Premise
32	<	N	I-Premise
33	0.001	N	I-Premise
34	)	N	I-Premise
35	6	N	I-Premise
36	months	N	I-Premise
37	post	N	I-Premise
38	intervention	N	I-Premise
39	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	effects	N	I-Premise
6	of	N	I-Premise
7	the	N	I-Premise
8	intervention	N	I-Premise
9	on	N	I-Premise
10	mood	N	I-Premise
11	,	N	I-Premise
12	QOL	N	I-Premise
13	or	N	I-Premise
14	healthcare	N	I-Premise
15	utilisation	N	I-Premise
16	.	N	I-Premise

1	Most	N	I-Premise
2	participants	N	I-Premise
3	found	N	I-Premise
4	writing	N	I-Premise
5	valuable	N	I-Premise
6	and	N	I-Premise
7	did	N	I-Premise
8	not	N	I-Premise
9	report	N	I-Premise
10	any	N	I-Premise
11	long-term	N	I-Premise
12	negative	N	I-Premise
13	effects	N	I-Premise
14	.	N	I-Premise

1	EW	N	I-Claim
2	was	N	I-Claim
3	associated	N	I-Claim
4	with	N	I-Claim
5	a	N	I-Claim
6	higher	N	I-Claim
7	level	N	I-Claim
8	of	N	I-Claim
9	satisfaction	N	I-Claim
10	with	N	I-Claim
11	emotional	N	I-Claim
12	support	N	I-Claim
13	compared	N	I-Claim
14	with	N	I-Claim
15	controls	N	I-Claim
16	.	N	I-Claim

1	Given	N	O
2	the	N	O
3	existing	N	O
4	evidence	N	O
5	supporting	N	O
6	the	N	O
7	importance	N	O
8	of	N	O
9	social	N	O
10	support	N	O
11	in	N	O
12	adjustment	N	O
13	to	N	O
14	breast	N	O
15	cancer	N	O
16	,	N	O
17	it	N	I-MajorClaim
18	seems	N	I-MajorClaim
19	feasible	N	I-MajorClaim
20	to	N	I-MajorClaim
21	suggest	N	I-MajorClaim
22	that	N	I-MajorClaim
23	EW	N	I-MajorClaim
24	may	N	I-MajorClaim
25	be	N	I-MajorClaim
26	a	N	I-MajorClaim
27	cost	N	I-MajorClaim
28	effective	N	I-MajorClaim
29	accessible	N	I-MajorClaim
30	treatment	N	I-MajorClaim
31	that	N	I-MajorClaim
32	could	N	I-MajorClaim
33	be	N	I-MajorClaim
34	incorporated	N	I-MajorClaim
35	into	N	I-MajorClaim
36	the	N	I-MajorClaim
37	ongoing	N	I-MajorClaim
38	care	N	I-MajorClaim
39	of	N	I-MajorClaim
40	women	N	I-MajorClaim
41	.	N	I-MajorClaim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	is	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	treatment	N	O
11	and	N	O
12	retention	N	O
13	effects	N	O
14	between	N	O
15	standard	N	O
16	decongestive	N	O
17	lymphatic	N	O
18	therapy	N	O
19	(	N	O
20	DLT	N	O
21	)	N	O
22	combined	N	O
23	with	N	O
24	pneumatic	N	O
25	compression	N	O
26	(	N	O
27	PC	N	O
28	)	N	O
29	and	N	O
30	modified	N	O
31	DLT	N	O
32	,	N	O
33	in	N	O
34	which	N	O
35	the	N	O
36	use	N	O
37	of	N	O
38	a	N	O
39	short-stretch	N	O
40	bandage	N	O
41	is	N	O
42	replaced	N	O
43	with	N	O
44	the	N	O
45	use	N	O
46	of	N	O
47	Kinesio	N	O
48	tape	N	O
49	(	N	O
50	K-tape	N	O
51	)	N	O
52	combined	N	O
53	with	N	O
54	PC	N	O
55	.	N	O

1	Forty-one	N	O
2	patients	N	O
3	with	N	O
4	unilateral	N	O
5	breast-cancer-related	N	O
6	lymphedema	N	O
7	for	N	O
8	at	N	O
9	least	N	O
10	3	N	O
11	months	N	O
12	were	N	O
13	randomly	N	O
14	grouped	N	O
15	into	N	O
16	the	N	O
17	DLT	N	O
18	group	N	O
19	(	N	O
20	bandage	N	O
21	group	N	O
22	,	N	O
23	N	N	O
24	=	N	O
25	21	N	O
26	)	N	O
27	or	N	O
28	the	N	O
29	modified	N	O
30	DLT	N	O
31	group	N	O
32	(	N	O
33	K-tape	N	O
34	group	N	O
35	,	N	O
36	N	N	O
37	=	N	O
38	20	N	O
39	)	N	O
40	.	N	O

1	Skin	N	O
2	care	N	O
3	,	N	O
4	30-min	N	O
5	manual	N	O
6	lymphatic	N	O
7	drainage	N	O
8	,	N	O
9	1-h	N	O
10	pneumatic	N	O
11	compression	N	O
12	therapy	N	O
13	,	N	O
14	application	N	O
15	of	N	O
16	a	N	O
17	short-stretch	N	O
18	bandage	N	O
19	or	N	O
20	K-tape	N	O
21	for	N	O
22	each	N	O
23	group	N	O
24	,	N	O
25	and	N	O
26	a	N	O
27	20-min	N	O
28	physical	N	O
29	therapy	N	O
30	exercise	N	O
31	were	N	O
32	given	N	O
33	during	N	O
34	every	N	O
35	treatment	N	O
36	session	N	O
37	.	N	O

1	Patient	N	O
2	evaluation	N	O
3	items	N	O
4	included	N	O
5	physical	N	O
6	therapy	N	O
7	assessment	N	O
8	,	N	O
9	limb	N	O
10	size	N	O
11	,	N	O
12	water	N	O
13	composition	N	O
14	of	N	O
15	the	N	O
16	upper	N	O
17	extremity	N	O
18	,	N	O
19	lymphedema-related	N	O
20	symptoms	N	O
21	,	N	O
22	quality	N	O
23	of	N	O
24	life	N	O
25	,	N	O
26	and	N	O
27	patients	N	O
28	'	N	O
29	acceptance	N	O
30	to	N	O
31	the	N	O
32	bandage	N	O
33	or	N	O
34	tape	N	O
35	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	between	N	I-Premise
7	groups	N	I-Premise
8	in	N	I-Premise
9	all	N	I-Premise
10	outcome	N	I-Premise
11	variables	N	I-Premise
12	(	N	I-Premise
13	P	N	I-Premise
14	>	N	I-Premise
15	0.05	N	I-Premise
16	)	N	I-Premise
17	through	N	I-Premise
18	the	N	I-Premise
19	whole	N	I-Premise
20	study	N	I-Premise
21	period	N	I-Premise
22	.	N	I-Premise

1	Excess	N	I-Premise
2	limb	N	I-Premise
3	size	N	I-Premise
4	(	N	I-Premise
5	circumference	N	I-Premise
6	and	N	I-Premise
7	water	N	I-Premise
8	displacement	N	I-Premise
9	)	N	I-Premise
10	and	N	I-Premise
11	excess	N	I-Premise
12	water	N	I-Premise
13	composition	N	I-Premise
14	were	N	I-Premise
15	reduced	N	I-Premise
16	significantly	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	bandage	N	I-Premise
20	group	N	I-Premise
21	;	N	I-Premise
22	excess	N	I-Premise
23	circumference	N	I-Premise
24	and	N	I-Premise
25	excess	N	I-Premise
26	water	N	I-Premise
27	composition	N	I-Premise
28	were	N	I-Premise
29	reduced	N	I-Premise
30	significantly	N	I-Premise
31	in	N	I-Premise
32	the	N	I-Premise
33	tape	N	I-Premise
34	group	N	I-Premise
35	.	N	I-Premise

1	The	N	I-Premise
2	acceptance	N	I-Premise
3	of	N	I-Premise
4	K-tape	N	I-Premise
5	was	N	I-Premise
6	better	N	I-Premise
7	than	N	I-Premise
8	the	N	I-Premise
9	bandage	N	I-Premise
10	,	N	I-Premise
11	and	N	I-Premise
12	benefits	N	I-Premise
13	included	N	I-Premise
14	longer	N	I-Premise
15	wearing	N	I-Premise
16	time	N	I-Premise
17	,	N	I-Premise
18	less	N	I-Premise
19	difficulty	N	I-Premise
20	in	N	I-Premise
21	usage	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	increased	N	I-Premise
25	comfort	N	I-Premise
26	and	N	I-Premise
27	convenience	N	I-Premise
28	(	N	I-Premise
29	P	N	I-Premise
30	<	N	I-Premise
31	0.05	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	The	N	I-Claim
2	study	N	I-Claim
3	results	N	I-Claim
4	suggest	N	I-Claim
5	that	N	I-Claim
6	K-tape	N	I-Claim
7	could	N	I-Claim
8	replace	N	I-Claim
9	the	N	I-Claim
10	bandage	N	I-Claim
11	in	N	I-Claim
12	DLT	N	I-Claim
13	,	N	I-Claim
14	and	N	I-Claim
15	it	N	I-Claim
16	could	N	I-Claim
17	be	N	I-Claim
18	an	N	I-Claim
19	alternative	N	I-Claim
20	choice	N	I-Claim
21	for	N	I-Claim
22	the	N	I-Claim
23	breast-cancer-related	N	I-Claim
24	lymphedema	N	I-Claim
25	patient	N	I-Claim
26	with	N	I-Claim
27	poor	N	I-Claim
28	short-stretch	N	I-Claim
29	bandage	N	I-Claim
30	compliance	N	I-Claim
31	after	N	I-Claim
32	1-month	N	I-Claim
33	intervention	N	I-Claim
34	.	N	I-Claim

1	If	N	O
2	the	N	O
3	intervention	N	O
4	period	N	O
5	was	N	O
6	prolonged	N	O
7	,	N	O
8	we	N	O
9	might	N	O
10	get	N	O
11	different	N	O
12	conclusion	N	O
13	.	N	O

1	Moreover	N	O
2	,	N	O
3	these	N	I-Claim
4	two	N	I-Claim
5	treatment	N	I-Claim
6	protocols	N	I-Claim
7	are	N	I-Claim
8	inefficient	N	I-Claim
9	and	N	I-Claim
10	cost	N	I-Claim
11	time	N	I-Claim
12	in	N	I-Claim
13	application	N	I-Claim
14	.	N	I-Claim

1	More	N	I-MajorClaim
2	efficient	N	I-MajorClaim
3	treatment	N	I-MajorClaim
4	protocol	N	I-MajorClaim
5	is	N	I-MajorClaim
6	needed	N	I-MajorClaim
7	for	N	I-MajorClaim
8	clinical	N	I-MajorClaim
9	practice	N	I-MajorClaim
10	.	N	I-MajorClaim

1	National	N	O
2	Cancer	N	O
3	Institute	N	O
4	of	N	O
5	Canada	N	O
6	Clinical	N	O
7	Trials	N	O
8	Group	N	O
9	CO.17	N	O
10	demonstrated	N	O
11	the	N	O
12	antiepidermal	N	O
13	growth	N	O
14	factor	N	O
15	receptor	N	O
16	(	N	O
17	anti-EGFR	N	O
18	)	N	O
19	monoclonal	N	O
20	antibody	N	O
21	cetuximab	N	O
22	improves	N	O
23	overall	N	O
24	and	N	O
25	progression-free	N	O
26	survival	N	O
27	in	N	O
28	patients	N	O
29	with	N	O
30	advanced	N	O
31	,	N	O
32	chemotherapy-refractory	N	O
33	colorectal	N	O
34	cancer	N	O
35	(	N	O
36	CRC	N	O
37	)	N	O
38	,	N	O
39	particularly	N	O
40	in	N	O
41	patients	N	O
42	with	N	O
43	wild-type	N	O
44	KRAS	N	O
45	tumors	N	O
46	.	N	O

1	This	N	O
2	article	N	O
3	reports	N	O
4	the	N	O
5	health-related	N	O
6	quality-of-life	N	O
7	(	N	O
8	HRQL	N	O
9	)	N	O
10	outcomes	N	O
11	from	N	O
12	CO.17	N	O
13	.	N	O

1	Patients	N	O
2	(	N	O
3	N	N	O
4	=	N	O
5	572	N	O
6	)	N	O
7	with	N	O
8	pretreated	N	O
9	EGFR-detectable	N	O
10	advanced	N	O
11	CRC	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	to	N	O
16	cetuximab	N	O
17	and	N	O
18	best	N	O
19	supportive	N	O
20	care	N	O
21	(	N	O
22	BSC	N	O
23	)	N	O
24	or	N	O
25	to	N	O
26	BSC	N	O
27	alone	N	O
28	.	N	O

1	HRQL	N	O
2	primary	N	O
3	end	N	O
4	points	N	O
5	assessed	N	O
6	by	N	O
7	the	N	O
8	EORTC	N	O
9	QLQ-C30	N	O
10	were	N	O
11	physical	N	O
12	function	N	O
13	(	N	O
14	PF	N	O
15	)	N	O
16	and	N	O
17	global	N	O
18	health	N	O
19	status	N	O
20	(	N	O
21	GHS	N	O
22	)	N	O
23	;	N	O
24	mean	N	O
25	changes	N	O
26	from	N	O
27	baseline	N	O
28	to	N	O
29	8	N	O
30	and	N	O
31	16	N	O
32	weeks	N	O
33	were	N	O
34	assessed	N	O
35	.	N	O

1	Post	N	O
2	hoc	N	O
3	analysis	N	O
4	by	N	O
5	KRAS	N	O
6	mutation	N	O
7	status	N	O
8	was	N	O
9	performed	N	O
10	.	N	O

1	Questionnaire	N	O
2	compliance	N	O
3	was	N	O
4	94	N	O
5	%	N	O
6	at	N	O
7	baseline	N	O
8	,	N	O
9	but	N	O
10	it	N	O
11	declined	N	O
12	differentially	N	O
13	(	N	O
14	67	N	O
15	%	N	O
16	v	N	O
17	47	N	O
18	%	N	O
19	for	N	O
20	cetuximab	N	O
21	v	N	O
22	BSC	N	O
23	at	N	O
24	16	N	O
25	weeks	N	O
26	)	N	O
27	.	N	O

1	PF	N	I-Premise
2	change	N	I-Premise
3	scores	N	I-Premise
4	were	N	I-Premise
5	-3.9	N	I-Premise
6	for	N	I-Premise
7	cetuximab	N	I-Premise
8	and	N	I-Premise
9	-8.6	N	I-Premise
10	for	N	I-Premise
11	BSC	N	I-Premise
12	(	N	I-Premise
13	P	N	I-Premise
14	=	N	I-Premise
15	.046	N	I-Premise
16	)	N	I-Premise
17	at	N	I-Premise
18	8	N	I-Premise
19	weeks	N	I-Premise
20	and	N	I-Premise
21	were	N	I-Premise
22	-5.9	N	I-Premise
23	and	N	I-Premise
24	-12.5	N	I-Premise
25	for	N	I-Premise
26	cetuximab	N	I-Premise
27	and	N	I-Premise
28	BSC	N	I-Premise
29	,	N	I-Premise
30	respectively	N	I-Premise
31	,	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	.027	N	I-Premise
36	)	N	I-Premise
37	at	N	I-Premise
38	16	N	I-Premise
39	weeks	N	I-Premise
40	.	N	I-Premise

1	GHS	N	I-Premise
2	change	N	I-Premise
3	scores	N	I-Premise
4	were	N	I-Premise
5	-0.5	N	I-Premise
6	and	N	I-Premise
7	-7.1	N	I-Premise
8	(	N	I-Premise
9	P	N	I-Premise
10	=	N	I-Premise
11	.008	N	I-Premise
12	)	N	I-Premise
13	at	N	I-Premise
14	8	N	I-Premise
15	weeks	N	I-Premise
16	and	N	I-Premise
17	were	N	I-Premise
18	-3.6	N	I-Premise
19	and	N	I-Premise
20	-15.2	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	.008	N	I-Premise
25	)	N	I-Premise
26	at	N	I-Premise
27	16	N	I-Premise
28	weeks	N	I-Premise
29	for	N	I-Premise
30	cetuximab	N	I-Premise
31	and	N	I-Premise
32	BSC	N	I-Premise
33	,	N	I-Premise
34	respectively	N	I-Premise
35	.	N	I-Premise

1	In	N	I-Premise
2	patients	N	I-Premise
3	who	N	I-Premise
4	had	N	I-Premise
5	tumors	N	I-Premise
6	with	N	I-Premise
7	wild-type	N	I-Premise
8	KRAS	N	I-Premise
9	status	N	I-Premise
10	,	N	I-Premise
11	cetuximab	N	I-Premise
12	resulted	N	I-Premise
13	in	N	I-Premise
14	less	N	I-Premise
15	PF	N	I-Premise
16	deterioration	N	I-Premise
17	at	N	I-Premise
18	8	N	I-Premise
19	weeks	N	I-Premise
20	(	N	I-Premise
21	-0.7	N	I-Premise
22	v	N	I-Premise
23	-7.2	N	I-Premise
24	;	N	I-Premise
25	P	N	I-Premise
26	=	N	I-Premise
27	.11	N	I-Premise
28	)	N	I-Premise
29	and	N	I-Premise
30	16	N	I-Premise
31	weeks	N	I-Premise
32	(	N	I-Premise
33	-3.4	N	I-Premise
34	v	N	I-Premise
35	-13.8	N	I-Premise
36	;	N	I-Premise
37	P	N	I-Premise
38	=	N	I-Premise
39	.008	N	I-Premise
40	)	N	I-Premise
41	compared	N	I-Premise
42	with	N	I-Premise
43	BSC	N	I-Premise
44	.	N	I-Premise

1	Patients	N	I-Premise
2	with	N	I-Premise
3	wild-type	N	I-Premise
4	status	N	I-Premise
5	who	N	I-Premise
6	received	N	I-Premise
7	cetuximab	N	I-Premise
8	experienced	N	I-Premise
9	improved	N	I-Premise
10	GHS	N	I-Premise
11	at	N	I-Premise
12	8	N	I-Premise
13	weeks	N	I-Premise
14	,	N	I-Premise
15	whereas	N	I-Premise
16	patients	N	I-Premise
17	who	N	I-Premise
18	received	N	I-Premise
19	BSC	N	I-Premise
20	alone	N	I-Premise
21	deteriorated	N	I-Premise
22	(	N	I-Premise
23	3.2	N	I-Premise
24	v	N	I-Premise
25	-7.7	N	I-Premise
26	;	N	I-Premise
27	P	N	I-Premise
28	=	N	I-Premise
29	.002	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	Cetuximab	N	I-Premise
2	preserved	N	I-Premise
3	GHS	N	I-Premise
4	at	N	I-Premise
5	16	N	I-Premise
6	weeks	N	I-Premise
7	(	N	I-Premise
8	-0.2	N	I-Premise
9	v	N	I-Premise
10	-18.1	N	I-Premise
11	;	N	I-Premise
12	P	N	I-Premise
13	<	N	I-Premise
14	.001	N	I-Premise
15	)	N	I-Premise
16	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	differences	N	I-Premise
4	were	N	I-Premise
5	noted	N	I-Premise
6	between	N	I-Premise
7	study	N	I-Premise
8	arms	N	I-Premise
9	for	N	I-Premise
10	patients	N	I-Premise
11	with	N	I-Premise
12	mutated	N	I-Premise
13	KRAS	N	I-Premise
14	tumors	N	I-Premise
15	.	N	I-Premise

1	Cetuximab	N	I-Claim
2	offers	N	I-Claim
3	important	N	I-Claim
4	HRQL	N	I-Claim
5	and	N	I-Claim
6	survival	N	I-Claim
7	benefits	N	I-Claim
8	for	N	I-Claim
9	pretreated	N	I-Claim
10	patients	N	I-Claim
11	with	N	I-Claim
12	advanced	N	I-Claim
13	,	N	I-Claim
14	wild-type	N	I-Claim
15	KRAS	N	I-Claim
16	CRC	N	I-Claim
17	.	N	I-Claim

1	Androgen	N	O
2	treatment	N	O
3	for	N	O
4	prostate	N	O
5	cancer	N	O
6	can	N	O
7	adversely	N	O
8	affect	N	O
9	functional	N	O
10	domains	N	O
11	of	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	.	N	O

1	We	N	O
2	aimed	N	O
3	to	N	O
4	assess	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	in	N	O
9	men	N	O
10	with	N	O
11	locally	N	O
12	advanced	N	O
13	prostate	N	O
14	cancer	N	O
15	in	N	O
16	an	N	O
17	open-label	N	O
18	phase	N	O
19	III	N	O
20	randomised	N	O
21	comparison	N	O
22	between	N	O
23	lifelong	N	O
24	endocrine	N	O
25	treatment	N	O
26	with	N	O
27	and	N	O
28	without	N	O
29	radiotherapy	N	O
30	.	N	O

1	We	N	O
2	obtained	N	O
3	quality-of-life	N	O
4	information	N	O
5	from	N	O
6	872	N	O
7	(	N	O
8	99	N	O
9	%	N	O
10	)	N	O
11	of	N	O
12	875	N	O
13	eligible	N	O
14	men	N	O
15	with	N	O
16	locally	N	O
17	advanced	N	O
18	prostate	N	O
19	cancer	N	O
20	(	N	O
21	T3	N	O
22	;	N	O
23	78	N	O
24	%	N	O
25	)	N	O
26	who	N	O
27	were	N	O
28	randomly	N	O
29	assigned	N	O
30	,	N	O
31	between	N	O
32	1996	N	O
33	and	N	O
34	2002	N	O
35	,	N	O
36	to	N	O
37	3	N	O
38	months	N	O
39	of	N	O
40	total	N	O
41	androgen	N	O
42	blockade	N	O
43	followed	N	O
44	by	N	O
45	continuous	N	O
46	endocrine	N	O
47	treatment	N	O
48	(	N	O
49	439	N	O
50	patients	N	O
51	)	N	O
52	or	N	O
53	the	N	O
54	same	N	O
55	hormonal	N	O
56	treatment	N	O
57	with	N	O
58	radiotherapy	N	O
59	3	N	O
60	months	N	O
61	after	N	O
62	randomisation	N	O
63	(	N	O
64	436	N	O
65	patients	N	O
66	)	N	O
67	.	N	O

1	Prospective	N	O
2	outcomes	N	O
3	included	N	O
4	patient-reported	N	O
5	symptoms	N	O
6	and	N	O
7	quality	N	O
8	of	N	O
9	life	N	O
10	assessed	N	O
11	with	N	O
12	questionnaires	N	O
13	from	N	O
14	baseline	N	O
15	to	N	O
16	4	N	O
17	years	N	O
18	after	N	O
19	randomisation	N	O
20	.	N	O

1	Analysis	N	O
2	was	N	O
3	by	N	O
4	intention	N	O
5	to	N	O
6	treat	N	O
7	.	N	O

1	This	N	O
2	study	N	O
3	is	N	O
4	registered	N	O
5	as	N	O
6	an	N	O
7	international	N	O
8	standard	N	O
9	randomised	N	O
10	controlled	N	O
11	trial	N	O
12	,	N	O
13	number	N	O
14	ISRCTN01534787	N	O
15	.	N	O

1	438	N	O
2	of	N	O
3	439	N	O
4	men	N	O
5	assigned	N	O
6	endocrine	N	O
7	treatment	N	O
8	and	N	O
9	434	N	O
10	of	N	O
11	436	N	O
12	assigned	N	O
13	endocrine	N	O
14	plus	N	O
15	radiotherapy	N	O
16	completed	N	O
17	at	N	O
18	least	N	O
19	one	N	O
20	questionnaire	N	O
21	.	N	O

1	Missing	N	O
2	data	N	O
3	at	N	O
4	baseline	N	O
5	and	N	O
6	during	N	O
7	follow-up	N	O
8	was	N	O
9	equally	N	O
10	distributed	N	O
11	between	N	O
12	groups	N	O
13	.	N	O

1	At	N	I-Premise
2	4	N	I-Premise
3	years	N	I-Premise
4	,	N	I-Premise
5	64	N	I-Premise
6	(	N	I-Premise
7	18	N	I-Premise
8	%	N	I-Premise
9	)	N	I-Premise
10	of	N	I-Premise
11	353	N	I-Premise
12	patients	N	I-Premise
13	on	N	I-Premise
14	combined	N	I-Premise
15	therapy	N	I-Premise
16	and	N	I-Premise
17	39	N	I-Premise
18	(	N	I-Premise
19	12	N	I-Premise
20	%	N	I-Premise
21	)	N	I-Premise
22	of	N	I-Premise
23	337	N	I-Premise
24	on	N	I-Premise
25	endocrine-alone	N	I-Premise
26	therapy	N	I-Premise
27	had	N	I-Premise
28	moderate	N	I-Premise
29	to	N	I-Premise
30	severe	N	I-Premise
31	urinary	N	I-Premise
32	bother	N	I-Premise
33	(	N	I-Premise
34	p=0.005	N	I-Premise
35	)	N	I-Premise
36	,	N	I-Premise
37	and	N	I-Premise
38	16	N	I-Premise
39	(	N	I-Premise
40	4	N	I-Premise
41	%	N	I-Premise
42	)	N	I-Premise
43	of	N	I-Premise
44	355	N	I-Premise
45	on	N	I-Premise
46	combined	N	I-Premise
47	therapy	N	I-Premise
48	and	N	I-Premise
49	five	N	I-Premise
50	(	N	I-Premise
51	2	N	I-Premise
52	%	N	I-Premise
53	)	N	I-Premise
54	of	N	I-Premise
55	338	N	I-Premise
56	on	N	I-Premise
57	endocrine	N	I-Premise
58	treatment	N	I-Premise
59	alone	N	I-Premise
60	had	N	I-Premise
61	pain	N	I-Premise
62	while	N	I-Premise
63	urinating	N	I-Premise
64	(	N	I-Premise
65	p=0.024	N	I-Premise
66	)	N	I-Premise
67	.	N	I-Premise

1	37	N	I-Premise
2	(	N	I-Premise
3	11	N	I-Premise
4	%	N	I-Premise
5	)	N	I-Premise
6	of	N	I-Premise
7	350	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	combined	N	I-Premise
11	group	N	I-Premise
12	and	N	I-Premise
13	23	N	I-Premise
14	(	N	I-Premise
15	7	N	I-Premise
16	%	N	I-Premise
17	)	N	I-Premise
18	of	N	I-Premise
19	35	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	endocrine-only	N	I-Premise
23	group	N	I-Premise
24	had	N	I-Premise
25	overall	N	I-Premise
26	bother	N	I-Premise
27	from	N	I-Premise
28	all	N	I-Premise
29	bowel	N	I-Premise
30	symptoms	N	I-Premise
31	(	N	I-Premise
32	p=0.022	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	281	N	I-Premise
2	(	N	I-Premise
3	85	N	I-Premise
4	%	N	I-Premise
5	)	N	I-Premise
6	of	N	I-Premise
7	332	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	combined-treatment	N	I-Premise
11	group	N	I-Premise
12	and	N	I-Premise
13	227	N	I-Premise
14	(	N	I-Premise
15	72	N	I-Premise
16	%	N	I-Premise
17	)	N	I-Premise
18	of	N	I-Premise
19	313	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	endocrine-only	N	I-Premise
23	group	N	I-Premise
24	had	N	I-Premise
25	erectile	N	I-Premise
26	dysfunction	N	I-Premise
27	(	N	I-Premise
28	p=0.0002	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	Quality	N	I-Premise
2	of	N	I-Premise
3	life	N	I-Premise
4	at	N	I-Premise
5	4	N	I-Premise
6	years	N	I-Premise
7	was	N	I-Premise
8	similar	N	I-Premise
9	,	N	I-Premise
10	with	N	I-Premise
11	the	N	I-Premise
12	exception	N	I-Premise
13	of	N	I-Premise
14	decreased	N	I-Premise
15	social	N	I-Premise
16	function	N	I-Premise
17	in	N	I-Premise
18	patients	N	I-Premise
19	receiving	N	I-Premise
20	endocrine	N	I-Premise
21	treatment	N	I-Premise
22	plus	N	I-Premise
23	radiotherapy	N	I-Premise
24	.	N	I-Premise

1	Although	N	I-Claim
2	addition	N	I-Claim
3	of	N	I-Claim
4	radiotherapy	N	I-Claim
5	to	N	I-Claim
6	endocrine	N	I-Claim
7	treatment	N	I-Claim
8	significantly	N	I-Claim
9	increased	N	I-Claim
10	some	N	I-Claim
11	treatment-related	N	I-Claim
12	symptoms	N	I-Claim
13	,	N	I-Claim
14	none	N	I-Claim
15	were	N	I-Claim
16	serious	N	I-Claim
17	.	N	I-Claim

1	Given	N	O
2	the	N	O
3	substantial	N	O
4	survival	N	O
5	benefit	N	O
6	of	N	O
7	combined	N	O
8	treatment	N	O
9	,	N	O
10	the	N	I-Claim
11	increase	N	I-Claim
12	of	N	I-Claim
13	symptoms	N	I-Claim
14	seems	N	I-Claim
15	acceptable	N	I-Claim
16	and	N	I-Claim
17	has	N	I-Claim
18	little	N	I-Claim
19	extra	N	I-Claim
20	effect	N	I-Claim
21	on	N	I-Claim
22	quality	N	I-Claim
23	of	N	I-Claim
24	life	N	I-Claim
25	after	N	I-Claim
26	4	N	I-Claim
27	years	N	I-Claim
28	compared	N	I-Claim
29	with	N	I-Claim
30	endocrine	N	I-Claim
31	treatment	N	I-Claim
32	alone	N	I-Claim
33	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	survival	N	O
4	in	N	O
5	patients	N	O
6	with	N	O
7	recurrent	N	O
8	or	N	O
9	metastatic	N	O
10	squamous	N	O
11	cell	N	O
12	carcinoma	N	O
13	of	N	O
14	the	N	O
15	head	N	O
16	and	N	O
17	neck	N	O
18	(	N	O
19	SCCHN	N	O
20	)	N	O
21	treated	N	O
22	with	N	O
23	gefitinib	N	O
24	250	N	O
25	or	N	O
26	500	N	O
27	mg/day	N	O
28	or	N	O
29	standard	N	O
30	methotrexate	N	O
31	.	N	O

1	Four	N	O
2	hundred	N	O
3	eighty-six	N	O
4	patients	N	O
5	with	N	O
6	recurrent	N	O
7	SCCHN	N	O
8	were	N	O
9	randomly	N	O
10	assigned	N	O
11	to	N	O
12	oral	N	O
13	gefitinib	N	O
14	250	N	O
15	mg/day	N	O
16	,	N	O
17	gefitinib	N	O
18	500	N	O
19	mg/day	N	O
20	,	N	O
21	or	N	O
22	methotrexate	N	O
23	40	N	O
24	mg/m	N	O
25	(	N	O
26	2	N	O
27	)	N	O
28	intravenously	N	O
29	weekly	N	O
30	.	N	O

1	Primary	N	O
2	end	N	O
3	point	N	O
4	was	N	O
5	overall	N	O
6	survival	N	O
7	,	N	O
8	secondary	N	O
9	end	N	O
10	points	N	O
11	were	N	O
12	objective	N	O
13	response	N	O
14	rate	N	O
15	(	N	O
16	ORR	N	O
17	)	N	O
18	,	N	O
19	safety	N	O
20	,	N	O
21	symptom	N	O
22	improvement	N	O
23	,	N	O
24	and	N	O
25	quality	N	O
26	of	N	O
27	life	N	O
28	(	N	O
29	QOL	N	O
30	)	N	O
31	.	N	O

1	Exploratory	N	O
2	end	N	O
3	points	N	O
4	included	N	O
5	association	N	O
6	of	N	O
7	efficacy	N	O
8	with	N	O
9	epidermal	N	O
10	growth	N	O
11	factor	N	O
12	receptor	N	O
13	gene	N	O
14	copy	N	O
15	number	N	O
16	and	N	O
17	other	N	O
18	biomarkers	N	O
19	.	N	O

1	Neither	N	I-Premise
2	gefitinib	N	I-Premise
3	250	N	I-Premise
4	nor	N	I-Premise
5	500	N	I-Premise
6	mg/day	N	I-Premise
7	improved	N	I-Premise
8	overall	N	I-Premise
9	survival	N	I-Premise
10	compared	N	I-Premise
11	with	N	I-Premise
12	methotrexate	N	I-Premise
13	(	N	I-Premise
14	hazard	N	I-Premise
15	ratio	N	I-Premise
16	[	N	I-Premise
17	HR	N	I-Premise
18	]	N	I-Premise
19	,	N	I-Premise
20	1.22	N	I-Premise
21	;	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	,	N	I-Premise
26	0.95	N	I-Premise
27	to	N	I-Premise
28	1.57	N	I-Premise
29	;	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.12	N	I-Premise
33	;	N	I-Premise
34	and	N	I-Premise
35	HR	N	I-Premise
36	,	N	I-Premise
37	1.12	N	I-Premise
38	;	N	I-Premise
39	95	N	I-Premise
40	%	N	I-Premise
41	CI	N	I-Premise
42	,	N	I-Premise
43	0.87	N	I-Premise
44	to	N	I-Premise
45	1.43	N	I-Premise
46	;	N	I-Premise
47	P	N	I-Premise
48	=	N	I-Premise
49	.39	N	I-Premise
50	,	N	I-Premise
51	respectively	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	gefitinib	N	I-Premise
4	250	N	I-Premise
5	mg/day	N	I-Premise
6	,	N	I-Premise
7	500	N	I-Premise
8	mg/day	N	I-Premise
9	,	N	I-Premise
10	and	N	I-Premise
11	methotrexate	N	I-Premise
12	groups	N	I-Premise
13	,	N	I-Premise
14	respectively	N	I-Premise
15	,	N	I-Premise
16	median	N	I-Premise
17	overall	N	I-Premise
18	survival	N	I-Premise
19	was	N	I-Premise
20	5.6	N	I-Premise
21	,	N	I-Premise
22	6.0	N	I-Premise
23	,	N	I-Premise
24	and	N	I-Premise
25	6.7	N	I-Premise
26	months	N	I-Premise
27	;	N	I-Premise
28	ORRs	N	I-Premise
29	(	N	I-Premise
30	Response	N	I-Premise
31	Evaluation	N	I-Premise
32	Criteria	N	I-Premise
33	in	N	I-Premise
34	Solid	N	I-Premise
35	Tumors	N	I-Premise
36	)	N	I-Premise
37	were	N	I-Premise
38	2.7	N	I-Premise
39	%	N	I-Premise
40	,	N	I-Premise
41	7.6	N	I-Premise
42	%	N	I-Premise
43	and	N	I-Premise
44	3.9	N	I-Premise
45	%	N	I-Premise
46	,	N	I-Premise
47	with	N	I-Premise
48	no	N	I-Premise
49	statistically	N	I-Premise
50	significant	N	I-Premise
51	difference	N	I-Premise
52	between	N	I-Premise
53	either	N	I-Premise
54	gefitinib	N	I-Premise
55	arm	N	I-Premise
56	and	N	I-Premise
57	methotrexate	N	I-Premise
58	.	N	I-Premise

1	No	N	I-Premise
2	unexpected	N	I-Premise
3	adverse	N	I-Premise
4	events	N	I-Premise
5	were	N	I-Premise
6	observed	N	I-Premise
7	,	N	I-Premise
8	except	N	I-Premise
9	for	N	I-Premise
10	tumor	N	I-Premise
11	hemorrhage-type	N	I-Premise
12	events	N	I-Premise
13	with	N	I-Premise
14	gefitinib	N	I-Premise
15	(	N	I-Premise
16	8.9	N	I-Premise
17	%	N	I-Premise
18	,	N	I-Premise
19	gefitinib	N	I-Premise
20	250	N	I-Premise
21	mg/day	N	I-Premise
22	;	N	I-Premise
23	11.4	N	I-Premise
24	%	N	I-Premise
25	,	N	I-Premise
26	gefitinib	N	I-Premise
27	500	N	I-Premise
28	mg/day	N	I-Premise
29	;	N	I-Premise
30	1.9	N	I-Premise
31	%	N	I-Premise
32	,	N	I-Premise
33	methotrexate	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	QOL	N	I-Premise
2	improvement	N	I-Premise
3	rates	N	I-Premise
4	(	N	I-Premise
5	Functional	N	I-Premise
6	Assessment	N	I-Premise
7	of	N	I-Premise
8	Cancer	N	I-Premise
9	Therapy-Head	N	I-Premise
10	&	N	I-Premise
11	amp	N	I-Premise
12	;	N	I-Premise
13	Neck	N	I-Premise
14	total	N	I-Premise
15	score	N	I-Premise
16	)	N	I-Premise
17	were	N	I-Premise
18	13.4	N	I-Premise
19	%	N	I-Premise
20	,	N	I-Premise
21	18.0	N	I-Premise
22	%	N	I-Premise
23	,	N	I-Premise
24	and	N	I-Premise
25	6.0	N	I-Premise
26	%	N	I-Premise
27	for	N	I-Premise
28	gefitinib	N	I-Premise
29	250	N	I-Premise
30	mg/day	N	I-Premise
31	,	N	I-Premise
32	500	N	I-Premise
33	mg/day	N	I-Premise
34	,	N	I-Premise
35	and	N	I-Premise
36	methotrexate	N	I-Premise
37	,	N	I-Premise
38	respectively	N	I-Premise
39	.	N	I-Premise

1	In	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	recurrent	N	I-Claim
5	or	N	I-Claim
6	metastatic	N	I-Claim
7	SCCHN	N	I-Claim
8	,	N	I-Claim
9	while	N	I-Claim
10	responses	N	I-Claim
11	with	N	I-Claim
12	gefitinib	N	I-Claim
13	were	N	I-Claim
14	seen	N	I-Claim
15	,	N	I-Claim
16	neither	N	I-Claim
17	gefitinib	N	I-Claim
18	250	N	I-Claim
19	nor	N	I-Claim
20	500	N	I-Claim
21	mg/day	N	I-Claim
22	improved	N	I-Claim
23	overall	N	I-Claim
24	survival	N	I-Claim
25	compared	N	I-Claim
26	with	N	I-Claim
27	methotrexate	N	I-Claim
28	.	N	I-Claim

1	With	N	I-Claim
2	the	N	I-Claim
3	exception	N	I-Claim
4	of	N	I-Claim
5	tumor	N	I-Claim
6	hemorrhage-type	N	I-Claim
7	events	N	I-Claim
8	with	N	I-Claim
9	gefitinib	N	I-Claim
10	,	N	I-Claim
11	the	N	I-Claim
12	adverse	N	I-Claim
13	event	N	I-Claim
14	profiles	N	I-Claim
15	were	N	I-Claim
16	generally	N	I-Claim
17	consistent	N	I-Claim
18	with	N	I-Claim
19	those	N	I-Claim
20	previously	N	I-Claim
21	observed	N	I-Claim
22	.	N	I-Claim

1	The	N	O
2	European	N	O
3	Study	N	O
4	Group	N	O
5	for	N	O
6	Pancreatic	N	O
7	Cancer	N	O
8	(	N	O
9	ESPAC-1	N	O
10	)	N	O
11	study	N	O
12	is	N	O
13	the	N	O
14	largest	N	O
15	study	N	O
16	of	N	O
17	adjuvant	N	O
18	treatment	N	O
19	for	N	O
20	pancreatic	N	O
21	ductal	N	O
22	adenocarcinoma	N	O
23	to	N	O
24	date	N	O
25	and	N	O
26	confirmed	N	O
27	a	N	O
28	survival	N	O
29	advantage	N	O
30	for	N	O
31	adjuvant	N	O
32	chemotherapy	N	O
33	but	N	O
34	not	N	O
35	for	N	O
36	chemoradiation	N	O
37	.	N	O

1	The	N	O
2	importance	N	O
3	of	N	O
4	parallel	N	O
5	evaluation	N	O
6	of	N	O
7	survival	N	O
8	and	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	(	N	O
13	QoL	N	O
14	)	N	O
15	has	N	O
16	been	N	O
17	recognized	N	O
18	as	N	O
19	fundamental	N	O
20	and	N	O
21	the	N	O
22	aim	N	O
23	was	N	O
24	to	N	O
25	assess	N	O
26	QoL	N	O
27	and	N	O
28	quality	N	O
29	adjusted	N	O
30	survival	N	O
31	.	N	O

1	A	N	O
2	longitudinal	N	O
3	QoL	N	O
4	study	N	O
5	on	N	O
6	a	N	O
7	subset	N	O
8	of	N	O
9	ESPAC-1	N	O
10	patients	N	O
11	who	N	O
12	prospectively	N	O
13	completed	N	O
14	the	N	O
15	EORTC	N	O
16	QLQ	N	O
17	C-30	N	O
18	questionnaire	N	O
19	during	N	O
20	treatment	N	O
21	and	N	O
22	follow-up	N	O
23	.	N	O

1	An	N	O
2	integrated	N	O
3	quality-survival	N	O
4	product	N	O
5	method	N	O
6	was	N	O
7	used	N	O
8	to	N	O
9	adjust	N	O
10	any	N	O
11	treatment	N	O
12	effect	N	O
13	on	N	O
14	survival	N	O
15	by	N	O
16	a	N	O
17	function	N	O
18	of	N	O
19	measured	N	O
20	QoL	N	O
21	,	N	O
22	calculated	N	O
23	over	N	O
24	a	N	O
25	restricted	N	O
26	24-month-period	N	O
27	(	N	O
28	QALM-24	N	O
29	)	N	O
30	.	N	O

1	Three	N	O
2	hundred	N	O
3	and	N	O
4	sixteen	N	O
5	patients	N	O
6	completed	N	O
7	1,201	N	O
8	questionnaires	N	O
9	.	N	O

1	There	N	O
2	were	N	O
3	no	N	O
4	differences	N	O
5	between	N	O
6	treatment	N	O
7	groups	N	O
8	in	N	O
9	dimension	N	O
10	scores	N	O
11	at	N	O
12	baseline	N	O
13	(	N	O
14	randomization	N	O
15	)	N	O
16	.	N	O

1	For	N	I-Premise
2	the	N	I-Premise
3	chemotherapy	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	mean	N	I-Premise
8	Quality	N	I-Premise
9	Adjusted	N	I-Premise
10	Life	N	I-Premise
11	Months	N	I-Premise
12	over	N	I-Premise
13	24	N	I-Premise
14	months	N	I-Premise
15	(	N	I-Premise
16	QALM-24	N	I-Premise
17	)	N	I-Premise
18	was	N	I-Premise
19	9.6	N	I-Premise
20	(	N	I-Premise
21	95	N	I-Premise
22	%	N	I-Premise
23	CI	N	I-Premise
24	:	N	I-Premise
25	8.7	N	I-Premise
26	,	N	I-Premise
27	11.2	N	I-Premise
28	)	N	I-Premise
29	months	N	I-Premise
30	compared	N	I-Premise
31	with	N	I-Premise
32	the	N	I-Premise
33	mean	N	I-Premise
34	QALM-24	N	I-Premise
35	of	N	I-Premise
36	8.6	N	I-Premise
37	(	N	I-Premise
38	95	N	I-Premise
39	%	N	I-Premise
40	CI	N	I-Premise
41	:	N	I-Premise
42	7.6	N	I-Premise
43	,	N	I-Premise
44	10.5	N	I-Premise
45	)	N	I-Premise
46	months	N	I-Premise
47	for	N	I-Premise
48	the	N	I-Premise
49	no	N	I-Premise
50	chemotherapy	N	I-Premise
51	group	N	I-Premise
52	.	N	I-Premise

1	For	N	I-Premise
2	the	N	I-Premise
3	chemoradiation	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	mean	N	I-Premise
8	QALM-24	N	I-Premise
9	was	N	I-Premise
10	7.1	N	I-Premise
11	(	N	I-Premise
12	95	N	I-Premise
13	%	N	I-Premise
14	CI	N	I-Premise
15	:	N	I-Premise
16	6.0	N	I-Premise
17	,	N	I-Premise
18	9.0	N	I-Premise
19	)	N	I-Premise
20	months	N	I-Premise
21	compared	N	I-Premise
22	with	N	I-Premise
23	the	N	I-Premise
24	mean	N	I-Premise
25	QALM-24	N	I-Premise
26	of	N	I-Premise
27	8.1	N	I-Premise
28	(	N	I-Premise
29	95	N	I-Premise
30	%	N	I-Premise
31	CI	N	I-Premise
32	:	N	I-Premise
33	7.0	N	I-Premise
34	,	N	I-Premise
35	10.0	N	I-Premise
36	)	N	I-Premise
37	months	N	I-Premise
38	for	N	I-Premise
39	the	N	I-Premise
40	no	N	I-Premise
41	chemoradiation	N	I-Premise
42	group	N	I-Premise
43	.	N	I-Premise

1	The	N	I-Claim
2	previously	N	I-Claim
3	reported	N	I-Claim
4	survival	N	I-Claim
5	advantage	N	I-Claim
6	supporting	N	I-Claim
7	the	N	I-Claim
8	use	N	I-Claim
9	of	N	I-Claim
10	adjuvant	N	I-Claim
11	chemotherapy	N	I-Claim
12	is	N	I-Claim
13	maintained	N	I-Claim
14	when	N	I-Claim
15	adjusted	N	I-Claim
16	using	N	I-Claim
17	quality	N	I-Claim
18	adjusted	N	I-Claim
19	survival	N	I-Claim
20	methodology	N	I-Claim
21	.	N	I-Claim

1	Chemotherapy	N	I-Claim
2	provided	N	I-Claim
3	on	N	I-Claim
4	average	N	I-Claim
5	an	N	I-Claim
6	additional	N	I-Claim
7	1.0	N	I-Claim
8	quality-adjusted	N	I-Claim
9	life	N	I-Claim
10	months	N	I-Claim
11	within	N	I-Claim
12	a	N	I-Claim
13	restricted	N	I-Claim
14	2-year	N	I-Claim
15	time	N	I-Claim
16	period	N	I-Claim
17	from	N	I-Claim
18	the	N	I-Claim
19	time	N	I-Claim
20	of	N	I-Claim
21	resection	N	I-Claim
22	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	clinical	N	O
10	outcomes	N	O
11	and	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	in	N	O
16	patients	N	O
17	undergoing	N	O
18	surgery	N	O
19	for	N	O
20	pilonidal	N	O
21	disease	N	O
22	with	N	O
23	unroofing	N	O
24	and	N	O
25	marsupialization	N	O
26	(	N	O
27	UM	N	O
28	)	N	O
29	or	N	O
30	rhomboid	N	O
31	excision	N	O
32	and	N	O
33	Limberg	N	O
34	flap	N	O
35	(	N	O
36	RELP	N	O
37	)	N	O
38	procedures	N	O
39	.	N	O

1	One	N	O
2	hundred	N	O
3	forty	N	O
4	consecutive	N	O
5	patients	N	O
6	with	N	O
7	pilonidal	N	O
8	sinus	N	O
9	were	N	O
10	randomly	N	O
11	assigned	N	O
12	to	N	O
13	receive	N	O
14	either	N	O
15	UM	N	O
16	or	N	O
17	RELP	N	O
18	procedures	N	O
19	.	N	O

1	A	N	O
2	specifically	N	O
3	designed	N	O
4	questionnaire	N	O
5	was	N	O
6	administered	N	O
7	at	N	O
8	three	N	O
9	months	N	O
10	to	N	O
11	assess	N	O
12	time	N	O
13	from	N	O
14	the	N	O
15	operation	N	O
16	until	N	O
17	the	N	O
18	patient	N	O
19	was	N	O
20	able	N	O
21	to	N	O
22	walk	N	O
23	,	N	O
24	return	N	O
25	to	N	O
26	daily	N	O
27	activities	N	O
28	,	N	O
29	or	N	O
30	sit	N	O
31	without	N	O
32	pain	N	O
33	,	N	O
34	time	N	O
35	to	N	O
36	return	N	O
37	to	N	O
38	work	N	O
39	or	N	O
40	school	N	O
41	,	N	O
42	and	N	O
43	time	N	O
44	to	N	O
45	healing	N	O
46	.	N	O

1	Postoperative	N	O
2	pain	N	O
3	was	N	O
4	assessed	N	O
5	with	N	O
6	a	N	O
7	visual	N	O
8	analog	N	O
9	scale	N	O
10	and	N	O
11	the	N	O
12	McGill	N	O
13	Pain	N	O
14	Questionnaire	N	O
15	.	N	O

1	Patients	N	O
2	'	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	was	N	O
7	evaluated	N	O
8	with	N	O
9	the	N	O
10	Cardiff	N	O
11	Wound	N	O
12	Impact	N	O
13	Schedule	N	O
14	(	N	O
15	CWIS	N	O
16	)	N	O
17	.	N	O

1	Questionnaires	N	O
2	were	N	O
3	administered	N	O
4	by	N	O
5	a	N	O
6	clinician	N	O
7	blinded	N	O
8	to	N	O
9	treatment	N	O
10	.	N	O

1	Compared	N	I-Premise
2	with	N	I-Premise
3	RELP	N	I-Premise
4	,	N	I-Premise
5	patients	N	I-Premise
6	receiving	N	I-Premise
7	UM	N	I-Premise
8	had	N	I-Premise
9	significantly	N	I-Premise
10	shorter	N	I-Premise
11	duration	N	I-Premise
12	of	N	I-Premise
13	operation	N	I-Premise
14	and	N	I-Premise
15	hospital	N	I-Premise
16	stay	N	I-Premise
17	,	N	I-Premise
18	shorter	N	I-Premise
19	time	N	I-Premise
20	periods	N	I-Premise
21	to	N	I-Premise
22	walk	N	I-Premise
23	,	N	I-Premise
24	return	N	I-Premise
25	to	N	I-Premise
26	daily	N	I-Premise
27	activities	N	I-Premise
28	,	N	I-Premise
29	or	N	I-Premise
30	sit	N	I-Premise
31	without	N	I-Premise
32	pain	N	I-Premise
33	and	N	I-Premise
34	to	N	I-Premise
35	return	N	I-Premise
36	to	N	I-Premise
37	work	N	I-Premise
38	or	N	I-Premise
39	school	N	I-Premise
40	,	N	I-Premise
41	and	N	I-Premise
42	fewer	N	I-Premise
43	complications	N	I-Premise
44	.	N	I-Premise

1	Time	N	I-Premise
2	to	N	I-Premise
3	final	N	I-Premise
4	healing	N	I-Premise
5	was	N	I-Premise
6	significantly	N	I-Premise
7	shorter	N	I-Premise
8	and	N	I-Premise
9	quality	N	I-Premise
10	of	N	I-Premise
11	life	N	I-Premise
12	scores	N	I-Premise
13	on	N	I-Premise
14	the	N	I-Premise
15	CWIS	N	I-Premise
16	were	N	I-Premise
17	higher	N	I-Premise
18	in	N	I-Premise
19	patients	N	I-Premise
20	receiving	N	I-Premise
21	RELP	N	I-Premise
22	than	N	I-Premise
23	in	N	I-Premise
24	those	N	I-Premise
25	receiving	N	I-Premise
26	UM	N	I-Premise
27	.	N	I-Premise

1	Patients	N	I-Premise
2	with	N	I-Premise
3	UM	N	I-Premise
4	had	N	I-Premise
5	lower	N	I-Premise
6	levels	N	I-Premise
7	of	N	I-Premise
8	pain	N	I-Premise
9	one	N	I-Premise
10	week	N	I-Premise
11	after	N	I-Premise
12	surgery	N	I-Premise
13	.	N	I-Premise

1	The	N	I-Claim
2	unroofing	N	I-Claim
3	and	N	I-Claim
4	marsupialization	N	I-Claim
5	procedure	N	I-Claim
6	provides	N	I-Claim
7	more	N	I-Claim
8	clinical	N	I-Claim
9	benefits	N	I-Claim
10	in	N	I-Claim
11	the	N	I-Claim
12	treatment	N	I-Claim
13	of	N	I-Claim
14	pilonidal	N	I-Claim
15	disease	N	I-Claim
16	than	N	I-Claim
17	rhomboid	N	I-Claim
18	excision	N	I-Claim
19	and	N	I-Claim
20	Limberg	N	I-Claim
21	flap	N	I-Claim
22	and	N	I-Claim
23	should	N	I-Claim
24	be	N	I-Claim
25	considered	N	I-Claim
26	the	N	I-Claim
27	procedure	N	I-Claim
28	of	N	I-Claim
29	choice	N	I-Claim
30	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	it	N	I-Claim
4	may	N	I-Claim
5	be	N	I-Claim
6	associated	N	I-Claim
7	with	N	I-Claim
8	more	N	I-Claim
9	inconvenience	N	I-Claim
10	in	N	I-Claim
11	wound	N	I-Claim
12	care	N	I-Claim
13	and	N	I-Claim
14	longer	N	I-Claim
15	healing	N	I-Claim
16	time	N	I-Claim
17	than	N	I-Claim
18	rhomboid	N	I-Claim
19	excision	N	I-Claim
20	and	N	I-Claim
21	Lindberg	N	I-Claim
22	flap	N	I-Claim
23	.	N	I-Claim

1	We	N	O
2	evaluated	N	O
3	the	N	O
4	role	N	O
5	of	N	O
6	glutathione-related	N	O
7	genotypes	N	O
8	on	N	O
9	overall	N	O
10	survival	N	O
11	,	N	O
12	time	N	O
13	to	N	O
14	progression	N	O
15	,	N	O
16	adverse	N	O
17	events	N	O
18	,	N	O
19	and	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	(	N	O
24	QOL	N	O
25	)	N	O
26	in	N	O
27	stage	N	O
28	IIIB/IV	N	O
29	non-small	N	O
30	cell	N	O
31	lung	N	O
32	cancer	N	O
33	patients	N	O
34	who	N	O
35	were	N	O
36	stable	N	O
37	or	N	O
38	responding	N	O
39	from	N	O
40	initial	N	O
41	treatment	N	O
42	with	N	O
43	platinum-based	N	O
44	chemotherapy	N	O
45	and	N	O
46	subsequently	N	O
47	randomized	N	O
48	to	N	O
49	receive	N	O
50	daily	N	O
51	oral	N	O
52	carboxyaminoimidazole	N	O
53	or	N	O
54	a	N	O
55	placebo	N	O
56	.	N	O

1	Of	N	O
2	the	N	O
3	186	N	O
4	total	N	O
5	patients	N	O
6	,	N	O
7	113	N	O
8	had	N	O
9	initial	N	O
10	treatment	N	O
11	with	N	O
12	platinum	N	O
13	therapy	N	O
14	and	N	O
15	DNA	N	O
16	samples	N	O
17	of	N	O
18	whom	N	O
19	46	N	O
20	also	N	O
21	had	N	O
22	QOL	N	O
23	data	N	O
24	.	N	O

1	These	N	O
2	samples	N	O
3	were	N	O
4	analyzed	N	O
5	using	N	O
6	six	N	O
7	polymorphic	N	O
8	DNA	N	O
9	markers	N	O
10	that	N	O
11	encode	N	O
12	five	N	O
13	important	N	O
14	enzymes	N	O
15	in	N	O
16	the	N	O
17	glutathione	N	O
18	metabolic	N	O
19	pathway	N	O
20	.	N	O

1	Patient	N	O
2	QOL	N	O
3	was	N	O
4	assessed	N	O
5	using	N	O
6	the	N	O
7	Functional	N	O
8	Assessment	N	O
9	of	N	O
10	Cancer	N	O
11	Therapy-Lung	N	O
12	and	N	O
13	the	N	O
14	UNISCALE	N	O
15	QOL	N	O
16	questionnaires	N	O
17	.	N	O

1	A	N	O
2	clinically	N	O
3	significant	N	O
4	decline	N	O
5	in	N	O
6	QOL	N	O
7	was	N	O
8	defined	N	O
9	as	N	O
10	a	N	O
11	10	N	O
12	%	N	O
13	decrease	N	O
14	from	N	O
15	baseline	N	O
16	to	N	O
17	week-8	N	O
18	.	N	O

1	Multivariate	N	O
2	analyses	N	O
3	were	N	O
4	used	N	O
5	to	N	O
6	evaluate	N	O
7	the	N	O
8	association	N	O
9	of	N	O
10	the	N	O
11	genotypes	N	O
12	on	N	O
13	the	N	O
14	four	N	O
15	endpoints	N	O
16	.	N	O

1	Patients	N	I-Premise
2	carrying	N	I-Premise
3	a	N	I-Premise
4	GCLC	N	I-Premise
5	77	N	I-Premise
6	genotype	N	I-Premise
7	had	N	I-Premise
8	a	N	I-Premise
9	worse	N	I-Premise
10	overall	N	I-Premise
11	survival	N	I-Premise
12	(	N	I-Premise
13	hazard	N	I-Premise
14	ratio	N	I-Premise
15	(	N	I-Premise
16	HR	N	I-Premise
17	)	N	I-Premise
18	=	N	I-Premise
19	1.5	N	I-Premise
20	,	N	I-Premise
21	p	N	I-Premise
22	=	N	I-Premise
23	0.05	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	Patients	N	I-Premise
2	carrying	N	I-Premise
3	the	N	I-Premise
4	GPX1-CC	N	I-Premise
5	genotype	N	I-Premise
6	had	N	I-Premise
7	a	N	I-Premise
8	clinically	N	I-Premise
9	significant	N	I-Premise
10	decline	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	UNISCALE	N	I-Premise
14	(	N	I-Premise
15	odds	N	I-Premise
16	ratio	N	I-Premise
17	(	N	I-Premise
18	OR	N	I-Premise
19	)	N	I-Premise
20	:	N	I-Premise
21	7.5	N	I-Premise
22	;	N	I-Premise
23	p	N	I-Premise
24	=	N	I-Premise
25	0.04	N	I-Premise
26	)	N	I-Premise
27	,	N	I-Premise
28	total	N	I-Premise
29	Functional	N	I-Premise
30	Assessment	N	I-Premise
31	of	N	I-Premise
32	Cancer	N	I-Premise
33	Therapy-Lung	N	I-Premise
34	score	N	I-Premise
35	(	N	I-Premise
36	OR	N	I-Premise
37	:	N	I-Premise
38	11.0	N	I-Premise
39	;	N	I-Premise
40	p	N	I-Premise
41	=	N	I-Premise
42	0.04	N	I-Premise
43	)	N	I-Premise
44	,	N	I-Premise
45	physical	N	I-Premise
46	(	N	I-Premise
47	OR	N	I-Premise
48	:	N	I-Premise
49	7.1	N	I-Premise
50	;	N	I-Premise
51	p	N	I-Premise
52	=	N	I-Premise
53	0.03	N	I-Premise
54	)	N	I-Premise
55	,	N	I-Premise
56	functional	N	I-Premise
57	(	N	I-Premise
58	OR	N	I-Premise
59	:	N	I-Premise
60	5.2	N	I-Premise
61	;	N	I-Premise
62	p	N	I-Premise
63	=	N	I-Premise
64	0.04	N	I-Premise
65	)	N	I-Premise
66	,	N	I-Premise
67	and	N	I-Premise
68	emotional	N	I-Premise
69	well-being	N	I-Premise
70	constructs	N	I-Premise
71	(	N	I-Premise
72	OR	N	I-Premise
73	:	N	I-Premise
74	23.8	N	I-Premise
75	;	N	I-Premise
76	p	N	I-Premise
77	=	N	I-Premise
78	0.01	N	I-Premise
79	)	N	I-Premise
80	.	N	I-Premise

1	Genotypes	N	I-Claim
2	of	N	I-Claim
3	glutathione-related	N	I-Claim
4	enzymes	N	I-Claim
5	,	N	I-Claim
6	especially	N	I-Claim
7	GCLC	N	I-Claim
8	,	N	I-Claim
9	may	N	I-Claim
10	be	N	I-Claim
11	used	N	I-Claim
12	as	N	I-Claim
13	host	N	I-Claim
14	factors	N	I-Claim
15	in	N	I-Claim
16	predicting	N	I-Claim
17	patients	N	I-Claim
18	'	N	I-Claim
19	survival	N	I-Claim
20	after	N	I-Claim
21	platinum-based	N	I-Claim
22	chemotherapy	N	I-Claim
23	.	N	I-Claim

1	GPX1	N	I-Claim
2	may	N	I-Claim
3	be	N	I-Claim
4	an	N	I-Claim
5	inherited	N	I-Claim
6	factor	N	I-Claim
7	in	N	I-Claim
8	predicting	N	I-Claim
9	patients	N	I-Claim
10	'	N	I-Claim
11	QOL	N	I-Claim
12	.	N	I-Claim

1	Further	N	I-Claim
2	investigation	N	I-Claim
3	to	N	I-Claim
4	define	N	I-Claim
5	and	N	I-Claim
6	measure	N	I-Claim
7	the	N	I-Claim
8	effects	N	I-Claim
9	of	N	I-Claim
10	these	N	I-Claim
11	genes	N	I-Claim
12	in	N	I-Claim
13	chemotherapeutic	N	I-Claim
14	regimens	N	I-Claim
15	,	N	I-Claim
16	drug	N	I-Claim
17	toxicities	N	I-Claim
18	,	N	I-Claim
19	disease	N	I-Claim
20	progression	N	I-Claim
21	,	N	I-Claim
22	and	N	I-Claim
23	QOL	N	I-Claim
24	are	N	I-Claim
25	critical	N	I-Claim
26	.	N	I-Claim

1	To	N	O
2	analyze	N	O
3	and	N	O
4	compare	N	O
5	radiologic	N	O
6	lung	N	O
7	expansion	N	O
8	after	N	O
9	talc	N	O
10	pleurodesis	N	O
11	performed	N	O
12	either	N	O
13	by	N	O
14	videothoracoscopy	N	O
15	or	N	O
16	chest	N	O
17	tube	N	O
18	and	N	O
19	correlate	N	O
20	it	N	O
21	with	N	O
22	clinical	N	O
23	outcome	N	O
24	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	evaluated	N	O
5	were	N	O
6	as	N	O
7	follows	N	O
8	:	N	O
9	clinical	N	O
10	efficacy	N	O
11	;	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	;	N	O
16	safety	N	O
17	;	N	O
18	and	N	O
19	survival	N	O
20	.	N	O

1	Prospective	N	O
2	randomized	N	O
3	study	N	O
4	that	N	O
5	included	N	O
6	60	N	O
7	patients	N	O
8	(	N	O
9	45	N	O
10	women	N	O
11	,	N	O
12	15	N	O
13	men	N	O
14	;	N	O
15	mean	N	O
16	age	N	O
17	,	N	O
18	55.2	N	O
19	years	N	O
20	)	N	O
21	with	N	O
22	recurrent	N	O
23	malignant	N	O
24	pleural	N	O
25	effusion	N	O
26	between	N	O
27	January	N	O
28	2005	N	O
29	and	N	O
30	January	N	O
31	2008	N	O
32	.	N	O

1	They	N	O
2	were	N	O
3	randomized	N	O
4	into	N	O
5	the	N	O
6	following	N	O
7	two	N	O
8	groups	N	O
9	:	N	O
10	video-assisted	N	O
11	thoracic	N	O
12	surgery	N	O
13	(	N	O
14	VATS	N	O
15	)	N	O
16	talc	N	O
17	poudrage	N	O
18	;	N	O
19	and	N	O
20	talc	N	O
21	slurry	N	O
22	(	N	O
23	TS	N	O
24	)	N	O
25	administered	N	O
26	through	N	O
27	a	N	O
28	chest	N	O
29	tube	N	O
30	.	N	O

1	Lung	N	O
2	expansion	N	O
3	was	N	O
4	evaluated	N	O
5	through	N	O
6	chest	N	O
7	CT	N	O
8	scans	N	O
9	obtained	N	O
10	0	N	O
11	,	N	O
12	1	N	O
13	,	N	O
14	3	N	O
15	and	N	O
16	6	N	O
17	months	N	O
18	after	N	O
19	pleurodesis	N	O
20	.	N	O

1	Complications	N	O
2	,	N	O
3	drainage	N	O
4	time	N	O
5	,	N	O
6	hospital	N	O
7	stay	N	O
8	,	N	O
9	and	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	(	N	O
14	Medical	N	O
15	Outcomes	N	O
16	Study	N	O
17	36-item	N	O
18	short	N	O
19	form	N	O
20	and	N	O
21	World	N	O
22	Health	N	O
23	Organization	N	O
24	quality-of-life	N	O
25	questionnaires	N	O
26	)	N	O
27	were	N	O
28	also	N	O
29	analyzed	N	O
30	.	N	O

1	There	N	O
2	were	N	O
3	no	N	O
4	significant	N	O
5	differences	N	O
6	in	N	O
7	preprocedure	N	O
8	clinical	N	O
9	and	N	O
10	pathologic	N	O
11	variables	N	O
12	between	N	O
13	groups	N	O
14	.	N	O

1	The	N	O
2	immediate	N	O
3	total	N	O
4	(	N	O
5	ie	N	O
6	,	N	O
7	>	N	O
8	90	N	O
9	%	N	O
10	)	N	O
11	lung	N	O
12	expansion	N	O
13	was	N	O
14	observed	N	O
15	in	N	O
16	27	N	O
17	patients	N	O
18	(	N	O
19	45	N	O
20	%	N	O
21	)	N	O
22	and	N	O
23	was	N	O
24	more	N	O
25	frequent	N	O
26	in	N	O
27	the	N	O
28	VATS	N	O
29	group	N	O
30	(	N	O
31	60	N	O
32	%	N	O
33	vs	N	O
34	30	N	O
35	%	N	O
36	,	N	O
37	respectively	N	O
38	;	N	O
39	p	N	O
40	=	N	O
41	0.027	N	O
42	)	N	O
43	.	N	O

1	During	N	I-Premise
2	follow-up	N	I-Premise
3	,	N	I-Premise
4	71	N	I-Premise
5	%	N	I-Premise
6	of	N	I-Premise
7	the	N	I-Premise
8	patients	N	I-Premise
9	showed	N	I-Premise
10	unaltered	N	I-Premise
11	or	N	I-Premise
12	improved	N	I-Premise
13	lung	N	I-Premise
14	expansion	N	I-Premise
15	and	N	I-Premise
16	9	N	I-Premise
17	patients	N	I-Premise
18	(	N	I-Premise
19	15	N	I-Premise
20	%	N	I-Premise
21	)	N	I-Premise
22	needed	N	I-Premise
23	new	N	I-Premise
24	pleural	N	I-Premise
25	procedures	N	I-Premise
26	(	N	I-Premise
27	VATS	N	I-Premise
28	group	N	I-Premise
29	,	N	I-Premise
30	5	N	I-Premise
31	recurrences	N	I-Premise
32	;	N	I-Premise
33	TS	N	I-Premise
34	group	N	I-Premise
35	,	N	I-Premise
36	4	N	I-Premise
37	recurrences	N	I-Premise
38	;	N	I-Premise
39	p	N	I-Premise
40	=	N	I-Premise
41	0.999	N	I-Premise
42	)	N	I-Premise
43	.	N	I-Premise

1	No	N	I-Premise
2	differences	N	I-Premise
3	were	N	I-Premise
4	found	N	I-Premise
5	between	N	I-Premise
6	groups	N	I-Premise
7	regarding	N	I-Premise
8	quality	N	I-Premise
9	of	N	I-Premise
10	life	N	I-Premise
11	,	N	I-Premise
12	complications	N	I-Premise
13	,	N	I-Premise
14	drainage	N	I-Premise
15	time	N	I-Premise
16	,	N	I-Premise
17	hospital	N	I-Premise
18	stay	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	survival	N	I-Premise
22	.	N	I-Premise

1	Immediate	N	I-Premise
2	lung	N	I-Premise
3	expansion	N	I-Premise
4	did	N	I-Premise
5	not	N	I-Premise
6	correlate	N	I-Premise
7	with	N	I-Premise
8	radiologic	N	I-Premise
9	recurrence	N	I-Premise
10	,	N	I-Premise
11	clinical	N	I-Premise
12	recurrence	N	I-Premise
13	,	N	I-Premise
14	or	N	I-Premise
15	complications	N	I-Premise
16	(	N	I-Premise
17	p	N	I-Premise
18	=	N	I-Premise
19	0.60	N	I-Premise
20	,	N	I-Premise
21	0.15	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	0.20	N	I-Premise
25	,	N	I-Premise
26	respectively	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	Immediate	N	I-Premise
2	partial	N	I-Premise
3	lung	N	I-Premise
4	expansion	N	I-Premise
5	was	N	I-Premise
6	a	N	I-Premise
7	frequent	N	I-Premise
8	finding	N	I-Premise
9	and	N	I-Premise
10	was	N	I-Premise
11	more	N	I-Premise
12	frequent	N	I-Premise
13	after	N	I-Premise
14	TS	N	I-Premise
15	.	N	I-Premise

1	Nonetheless	N	O
2	,	N	O
3	no	N	I-Claim
4	correlation	N	I-Claim
5	between	N	I-Claim
6	immediate	N	I-Claim
7	lung	N	I-Claim
8	expansion	N	I-Claim
9	and	N	I-Claim
10	clinical	N	I-Claim
11	outcome	N	I-Claim
12	was	N	I-Claim
13	found	N	I-Claim
14	in	N	I-Claim
15	this	N	I-Claim
16	study	N	I-Claim
17	.	N	I-Claim

1	A	N	O
2	dramatic	N	O
3	rise	N	O
4	in	N	O
5	incidence	N	O
6	,	N	O
7	an	N	O
8	aging	N	O
9	population	N	O
10	,	N	O
11	and	N	O
12	expensive	N	O
13	palliative	N	O
14	treatments	N	O
15	have	N	O
16	led	N	O
17	to	N	O
18	an	N	O
19	escalating	N	O
20	burden	N	O
21	on	N	O
22	clinicians	N	O
23	managing	N	O
24	inoperable	N	O
25	esophageal	N	O
26	cancer	N	O
27	with	N	O
28	only	N	O
29	limited	N	O
30	evidence	N	O
31	of	N	O
32	effectiveness	N	O
33	.	N	O

1	This	N	O
2	study	N	O
3	compares	N	O
4	the	N	O
5	clinical	N	O
6	effectiveness	N	O
7	and	N	O
8	cost-effectiveness	N	O
9	of	N	O
10	self-expanding	N	O
11	metal	N	O
12	stents	N	O
13	(	N	O
14	SEMSs	N	O
15	)	N	O
16	with	N	O
17	other	N	O
18	palliative	N	O
19	therapies	N	O
20	to	N	O
21	aid	N	O
22	clinicians	N	O
23	in	N	O
24	making	N	O
25	an	N	O
26	evidence-based	N	O
27	treatment	N	O
28	choice	N	O
29	.	N	O

1	We	N	O
2	conducted	N	O
3	a	N	O
4	prospective	N	O
5	,	N	O
6	multicenter	N	O
7	,	N	O
8	randomized	N	O
9	,	N	O
10	controlled	N	O
11	,	N	O
12	clinical	N	O
13	trial	N	O
14	with	N	O
15	215	N	O
16	patients	N	O
17	followed	N	O
18	until	N	O
19	death	N	O
20	or	N	O
21	study	N	O
22	closure	N	O
23	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	measures	N	O
5	were	N	O
6	dysphagia	N	O
7	,	N	O
8	quality	N	O
9	of	N	O
10	life	N	O
11	(	N	O
12	QL	N	O
13	)	N	O
14	6	N	O
15	weeks	N	O
16	following	N	O
17	treatment	N	O
18	,	N	O
19	and	N	O
20	total	N	O
21	cost	N	O
22	of	N	O
23	treatment	N	O
24	.	N	O

1	Secondary	N	O
2	outcome	N	O
3	measures	N	O
4	included	N	O
5	treatment-associated	N	O
6	morbidity	N	O
7	,	N	O
8	mortality	N	O
9	,	N	O
10	survival	N	O
11	,	N	O
12	and	N	O
13	cost-effectiveness	N	O
14	.	N	O

1	An	N	O
2	intention-to-treat	N	O
3	analysis	N	O
4	was	N	O
5	carried	N	O
6	out	N	O
7	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	mean	N	I-Premise
8	dysphagia	N	I-Premise
9	grade	N	I-Premise
10	between	N	I-Premise
11	treatment	N	I-Premise
12	arms	N	I-Premise
13	6	N	I-Premise
14	weeks	N	I-Premise
15	following	N	I-Premise
16	treatment	N	I-Premise
17	(	N	I-Premise
18	P=0.046	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	with	N	I-Premise
22	worse	N	I-Premise
23	swallowing	N	I-Premise
24	reported	N	I-Premise
25	by	N	I-Premise
26	rigid	N	I-Premise
27	stent-treated	N	I-Premise
28	patients	N	I-Premise
29	(	N	I-Premise
30	mean	N	I-Premise
31	dysphagia	N	I-Premise
32	score	N	I-Premise
33	difference=-0.49	N	I-Premise
34	;	N	I-Premise
35	95	N	I-Premise
36	%	N	I-Premise
37	confidence	N	I-Premise
38	interval	N	I-Premise
39	(	N	I-Premise
40	CI	N	I-Premise
41	)	N	I-Premise
42	-0.10	N	I-Premise
43	to	N	I-Premise
44	-0.89	N	I-Premise
45	,	N	I-Premise
46	P=0.014	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	Global	N	I-Premise
2	QL	N	I-Premise
3	scores	N	I-Premise
4	were	N	I-Premise
5	lower	N	I-Premise
6	at	N	I-Premise
7	both	N	I-Premise
8	1	N	I-Premise
9	and	N	I-Premise
10	6	N	I-Premise
11	weeks	N	I-Premise
12	following	N	I-Premise
13	treatment	N	I-Premise
14	for	N	I-Premise
15	patients	N	I-Premise
16	treated	N	I-Premise
17	by	N	I-Premise
18	SEMSs	N	I-Premise
19	(	N	I-Premise
20	mean	N	I-Premise
21	difference	N	I-Premise
22	QL	N	I-Premise
23	index	N	I-Premise
24	week	N	I-Premise
25	1=-0.66	N	I-Premise
26	;	N	I-Premise
27	95	N	I-Premise
28	%	N	I-Premise
29	CI	N	I-Premise
30	:	N	I-Premise
31	-0.02	N	I-Premise
32	to	N	I-Premise
33	-1.30	N	I-Premise
34	,	N	I-Premise
35	P=0.04	N	I-Premise
36	;	N	I-Premise
37	mean	N	I-Premise
38	difference	N	I-Premise
39	QL	N	I-Premise
40	index	N	I-Premise
41	week	N	I-Premise
42	6=-1.01	N	I-Premise
43	;	N	I-Premise
44	95	N	I-Premise
45	%	N	I-Premise
46	CI	N	I-Premise
47	-0.30	N	I-Premise
48	to	N	I-Premise
49	-1.72	N	I-Premise
50	,	N	I-Premise
51	P=0.006	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	These	N	I-Premise
2	findings	N	I-Premise
3	were	N	I-Premise
4	associated	N	I-Premise
5	with	N	I-Premise
6	higher	N	I-Premise
7	post-procedure	N	I-Premise
8	pain	N	I-Premise
9	scores	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	SEMS	N	I-Premise
13	patient	N	I-Premise
14	group	N	I-Premise
15	(	N	I-Premise
16	mean	N	I-Premise
17	difference	N	I-Premise
18	of	N	I-Premise
19	the	N	I-Premise
20	European	N	I-Premise
21	Organisation	N	I-Premise
22	for	N	I-Premise
23	Research	N	I-Premise
24	and	N	I-Premise
25	Treatment	N	I-Premise
26	of	N	I-Premise
27	Cancer	N	I-Premise
28	QLQ	N	I-Premise
29	C-30	N	I-Premise
30	pain	N	I-Premise
31	symptom	N	I-Premise
32	score	N	I-Premise
33	at	N	I-Premise
34	week	N	I-Premise
35	1=11.13	N	I-Premise
36	;	N	I-Premise
37	95	N	I-Premise
38	%	N	I-Premise
39	CI	N	I-Premise
40	:	N	I-Premise
41	2.89-19.4	N	I-Premise
42	;	N	I-Premise
43	P=0.01	N	I-Premise
44	)	N	I-Premise
45	.	N	I-Premise

1	Although	N	I-Premise
2	mean	N	I-Premise
3	EQ-5D	N	I-Premise
4	QL	N	I-Premise
5	values	N	I-Premise
6	differed	N	I-Premise
7	between	N	I-Premise
8	the	N	I-Premise
9	treatments	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	<	N	I-Premise
13	0.001	N	I-Premise
14	)	N	I-Premise
15	,	N	I-Premise
16	this	N	I-Premise
17	difference	N	I-Premise
18	dissipated	N	I-Premise
19	following	N	I-Premise
20	generation	N	I-Premise
21	of	N	I-Premise
22	quality-adjusted	N	I-Premise
23	life	N	I-Premise
24	year	N	I-Premise
25	values	N	I-Premise
26	.	N	I-Premise

1	Total	N	O
2	costs	N	O
3	varied	N	O
4	between	N	O
5	treatment	N	O
6	arms	N	O
7	but	N	O
8	these	N	O
9	findings	N	O
10	canceled	N	O
11	out	N	O
12	when	N	O
13	SEMSs	N	O
14	were	N	O
15	compared	N	O
16	with	N	O
17	non-SEMS	N	O
18	therapies	N	O
19	(	N	O
20	95	N	O
21	%	N	O
22	CI	N	O
23	-845.15-1,332.62	N	O
24	)	N	O
25	.	N	O

1	These	N	O
2	results	N	O
3	were	N	O
4	robust	N	O
5	to	N	O
6	sensitivity	N	O
7	analysis	N	O
8	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	differences	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	in-hospital	N	I-Premise
8	mortality	N	I-Premise
9	or	N	I-Premise
10	early	N	I-Premise
11	complication	N	I-Premise
12	rates	N	I-Premise
13	,	N	I-Premise
14	but	N	I-Premise
15	late	N	I-Premise
16	complications	N	I-Premise
17	were	N	I-Premise
18	more	N	I-Premise
19	frequent	N	I-Premise
20	after	N	I-Premise
21	rigid	N	I-Premise
22	stenting	N	I-Premise
23	(	N	I-Premise
24	risk	N	I-Premise
25	ratio=2.47	N	I-Premise
26	;	N	I-Premise
27	95	N	I-Premise
28	%	N	I-Premise
29	CI	N	I-Premise
30	1.88-3.04	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	survival	N	I-Premise
5	advantage	N	I-Premise
6	for	N	I-Premise
7	non-stent-treated	N	I-Premise
8	patients	N	I-Premise
9	(	N	I-Premise
10	log-rank	N	I-Premise
11	statistic=4.21	N	I-Premise
12	,	N	I-Premise
13	P=0.04	N	I-Premise
14	)	N	I-Premise
15	.	N	I-Premise

1	The	N	I-Claim
2	treatment	N	I-Claim
3	choice	N	I-Claim
4	for	N	I-Claim
5	patients	N	I-Claim
6	with	N	I-Claim
7	inoperable	N	I-Claim
8	esophageal	N	I-Claim
9	cancer	N	I-Claim
10	should	N	I-Claim
11	be	N	I-Claim
12	between	N	I-Claim
13	a	N	I-Claim
14	SEMS	N	I-Claim
15	or	N	I-Claim
16	a	N	I-Claim
17	non-stent	N	I-Claim
18	treatment	N	I-Claim
19	after	N	I-Claim
20	consideration	N	I-Claim
21	has	N	I-Claim
22	been	N	I-Claim
23	given	N	I-Claim
24	to	N	I-Claim
25	both	N	I-Claim
26	patient	N	I-Claim
27	and	N	I-Claim
28	tumor	N	I-Claim
29	characteristics	N	I-Claim
30	and	N	I-Claim
31	clinician	N	I-Claim
32	and	N	I-Claim
33	patient	N	I-Claim
34	preferences	N	I-Claim
35	.	N	I-Claim

1	Lymphedema	N	O
2	is	N	O
3	an	N	O
4	adverse	N	O
5	effect	N	O
6	of	N	O
7	breast	N	O
8	cancer	N	O
9	surgery	N	O
10	.	N	O

1	Aqua	N	O
2	lymphatic	N	O
3	therapy	N	O
4	(	N	O
5	ALT	N	O
6	)	N	O
7	is	N	O
8	a	N	O
9	novel	N	O
10	treatment	N	O
11	for	N	O
12	limb	N	O
13	volume	N	O
14	reduction	N	O
15	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	examine	N	O
9	whether	N	O
10	ALT	N	O
11	is	N	O
12	a	N	O
13	safe	N	O
14	method	N	O
15	and	N	O
16	whether	N	O
17	there	N	O
18	are	N	O
19	differences	N	O
20	in	N	O
21	adherence	N	O
22	,	N	O
23	limb	N	O
24	volume	N	O
25	,	N	O
26	and	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	between	N	O
31	women	N	O
32	who	N	O
33	perform	N	O
34	only	N	O
35	self-management	N	O
36	treatment	N	O
37	and	N	O
38	women	N	O
39	who	N	O
40	participate	N	O
41	as	N	O
42	well	N	O
43	in	N	O
44	ALT	N	O
45	.	N	O

1	Design	N	O
2	of	N	O
3	the	N	O
4	study	N	O
5	was	N	O
6	single-blind	N	O
7	randomized	N	O
8	clinical	N	O
9	trial	N	O
10	.	N	O

1	The	N	O
2	setting	N	O
3	was	N	O
4	in	N	O
5	a	N	O
6	hydrotherapy	N	O
7	pool	N	O
8	,	N	O
9	1.2	N	O
10	m	N	O
11	depth	N	O
12	,	N	O
13	and	N	O
14	a	N	O
15	temperature	N	O
16	of	N	O
17	32-33	N	O
18	degrees	N	O
19	capital	N	O
20	ES	N	O
21	,	N	O
22	Cyrillic	N	O
23	.	N	O

1	Forty-eight	N	O
2	women	N	O
3	(	N	O
4	56	N	O
5	+/-	N	O
6	10	N	O
7	years	N	O
8	)	N	O
9	,	N	O
10	with	N	O
11	a	N	O
12	12.8	N	O
13	%	N	O
14	lymphedema	N	O
15	relative	N	O
16	volume	N	O
17	,	N	O
18	participated	N	O
19	in	N	O
20	the	N	O
21	study	N	O
22	.	N	O

1	The	N	O
2	control	N	O
3	group	N	O
4	was	N	O
5	instructed	N	O
6	to	N	O
7	perform	N	O
8	the	N	O
9	self-management	N	O
10	treatment	N	O
11	.	N	O

1	The	N	O
2	study	N	O
3	group	N	O
4	joined	N	O
5	a	N	O
6	weekly	N	O
7	session	N	O
8	of	N	O
9	ALT	N	O
10	for	N	O
11	3	N	O
12	months	N	O
13	in	N	O
14	addition	N	O
15	to	N	O
16	the	N	O
17	self-management	N	O
18	therapy	N	O
19	.	N	O

1	Adherence	N	O
2	was	N	O
3	assessed	N	O
4	by	N	O
5	a	N	O
6	self-reported	N	O
7	diary	N	O
8	,	N	O
9	limb	N	O
10	volume	N	O
11	by	N	O
12	a	N	O
13	water	N	O
14	displacement	N	O
15	device	N	O
16	,	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	by	N	O
21	the	N	O
22	Upper	N	O
23	Limb	N	O
24	Lymphedema	N	O
25	Questionnaire	N	O
26	(	N	O
27	ULL27	N	O
28	)	N	O
29	,	N	O
30	prior	N	O
31	to	N	O
32	,	N	O
33	and	N	O
34	after	N	O
35	the	N	O
36	intervention	N	O
37	period	N	O
38	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	episode	N	I-Premise
5	of	N	I-Premise
6	arm	N	I-Premise
7	infection	N	I-Premise
8	or	N	I-Premise
9	aggravation	N	I-Premise
10	in	N	I-Premise
11	limb	N	I-Premise
12	volume	N	I-Premise
13	during	N	I-Premise
14	the	N	I-Premise
15	study	N	I-Premise
16	period	N	I-Premise
17	.	N	I-Premise

1	ALT	N	I-Premise
2	had	N	I-Premise
3	a	N	I-Premise
4	positive	N	I-Premise
5	,	N	I-Premise
6	statistically	N	I-Premise
7	and	N	I-Premise
8	clinically	N	I-Premise
9	significant	N	I-Premise
10	immediate	N	I-Premise
11	effect	N	I-Premise
12	on	N	I-Premise
13	limb	N	I-Premise
14	volume	N	I-Premise
15	but	N	I-Premise
16	no	N	I-Premise
17	long-term	N	I-Premise
18	effect	N	I-Premise
19	was	N	I-Premise
20	noted	N	I-Premise
21	.	N	I-Premise

1	The	N	I-Premise
2	adherence	N	I-Premise
3	rate	N	I-Premise
4	to	N	I-Premise
5	ALT	N	I-Premise
6	was	N	I-Premise
7	significantly	N	I-Premise
8	higher	N	I-Premise
9	than	N	I-Premise
10	the	N	I-Premise
11	adherence	N	I-Premise
12	to	N	I-Premise
13	self-management	N	I-Premise
14	therapy	N	I-Premise
15	.	N	I-Premise

1	QOL	N	I-Premise
2	improved	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	study	N	I-Premise
6	group	N	I-Premise
7	.	N	I-Premise

1	ALT	N	I-Claim
2	was	N	I-Claim
3	found	N	I-Claim
4	to	N	I-Claim
5	be	N	I-Claim
6	a	N	I-Claim
7	safe	N	I-Claim
8	method	N	I-Claim
9	,	N	I-Claim
10	with	N	I-Claim
11	high	N	I-Claim
12	adherence	N	I-Claim
13	,	N	I-Claim
14	in	N	I-Claim
15	treating	N	I-Claim
16	women	N	I-Claim
17	who	N	I-Claim
18	suffer	N	I-Claim
19	from	N	I-Claim
20	mild	N	I-Claim
21	to	N	I-Claim
22	moderate	N	I-Claim
23	lymphedema	N	I-Claim
24	.	N	I-Claim

1	A	N	I-Claim
2	significant	N	I-Claim
3	immediate	N	I-Claim
4	and	N	I-Claim
5	insignificant	N	I-Claim
6	long-term	N	I-Claim
7	effect	N	I-Claim
8	on	N	I-Claim
9	limb	N	I-Claim
10	volume	N	I-Claim
11	was	N	I-Claim
12	noted	N	I-Claim
13	.	N	I-Claim

1	The	N	O
2	combination	N	O
3	of	N	O
4	radiotherapy	N	O
5	plus	N	O
6	long-term	N	O
7	medical	N	O
8	suppression	N	O
9	of	N	O
10	androgens	N	O
11	(	N	O
12	>	N	O
13	or	N	O
14	=	N	O
15	2	N	O
16	years	N	O
17	)	N	O
18	improves	N	O
19	overall	N	O
20	survival	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	locally	N	O
25	advanced	N	O
26	prostate	N	O
27	cancer	N	O
28	.	N	O

1	We	N	O
2	compared	N	O
3	the	N	O
4	use	N	O
5	of	N	O
6	radiotherapy	N	O
7	plus	N	O
8	short-term	N	O
9	androgen	N	O
10	suppression	N	O
11	with	N	O
12	the	N	O
13	use	N	O
14	of	N	O
15	radiotherapy	N	O
16	plus	N	O
17	long-term	N	O
18	androgen	N	O
19	suppression	N	O
20	in	N	O
21	the	N	O
22	treatment	N	O
23	of	N	O
24	locally	N	O
25	advanced	N	O
26	prostate	N	O
27	cancer	N	O
28	.	N	O

1	We	N	O
2	randomly	N	O
3	assigned	N	O
4	patients	N	O
5	with	N	O
6	locally	N	O
7	advanced	N	O
8	prostate	N	O
9	cancer	N	O
10	who	N	O
11	had	N	O
12	received	N	O
13	external-beam	N	O
14	radiotherapy	N	O
15	plus	N	O
16	6	N	O
17	months	N	O
18	of	N	O
19	androgen	N	O
20	suppression	N	O
21	to	N	O
22	two	N	O
23	groups	N	O
24	,	N	O
25	one	N	O
26	to	N	O
27	receive	N	O
28	no	N	O
29	further	N	O
30	treatment	N	O
31	(	N	O
32	short-term	N	O
33	suppression	N	O
34	)	N	O
35	and	N	O
36	the	N	O
37	other	N	O
38	to	N	O
39	receive	N	O
40	2.5	N	O
41	years	N	O
42	of	N	O
43	further	N	O
44	treatment	N	O
45	with	N	O
46	a	N	O
47	luteinizing	N	O
48	hormone-releasing	N	O
49	hormone	N	O
50	agonist	N	O
51	(	N	O
52	long-term	N	O
53	suppression	N	O
54	)	N	O
55	.	N	O

1	An	N	O
2	outcome	N	O
3	of	N	O
4	noninferiority	N	O
5	of	N	O
6	short-term	N	O
7	androgen	N	O
8	suppression	N	O
9	as	N	O
10	compared	N	O
11	with	N	O
12	long-term	N	O
13	suppression	N	O
14	required	N	O
15	a	N	O
16	hazard	N	O
17	ratio	N	O
18	of	N	O
19	more	N	O
20	than	N	O
21	1.35	N	O
22	for	N	O
23	overall	N	O
24	survival	N	O
25	,	N	O
26	with	N	O
27	a	N	O
28	one-sided	N	O
29	alpha	N	O
30	level	N	O
31	of	N	O
32	0.05	N	O
33	.	N	O

1	An	N	O
2	interim	N	O
3	analysis	N	O
4	showed	N	O
5	futility	N	O
6	,	N	O
7	and	N	O
8	the	N	O
9	results	N	O
10	are	N	O
11	presented	N	O
12	with	N	O
13	an	N	O
14	adjusted	N	O
15	one-sided	N	O
16	alpha	N	O
17	level	N	O
18	of	N	O
19	0.0429	N	O
20	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	1113	N	O
5	men	N	O
6	were	N	O
7	registered	N	O
8	,	N	O
9	of	N	O
10	whom	N	O
11	970	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	,	N	O
16	483	N	O
17	to	N	O
18	short-term	N	O
19	suppression	N	O
20	and	N	O
21	487	N	O
22	to	N	O
23	long-term	N	O
24	suppression	N	O
25	.	N	O

1	After	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	6.4	N	I-Premise
7	years	N	I-Premise
8	,	N	I-Premise
9	132	N	I-Premise
10	patients	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	short-term	N	I-Premise
14	group	N	I-Premise
15	and	N	I-Premise
16	98	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	long-term	N	I-Premise
20	group	N	I-Premise
21	had	N	I-Premise
22	died	N	I-Premise
23	;	N	I-Premise
24	the	N	I-Premise
25	number	N	I-Premise
26	of	N	I-Premise
27	deaths	N	I-Premise
28	due	N	I-Premise
29	to	N	I-Premise
30	prostate	N	I-Premise
31	cancer	N	I-Premise
32	was	N	I-Premise
33	47	N	I-Premise
34	in	N	I-Premise
35	the	N	I-Premise
36	short-term	N	I-Premise
37	group	N	I-Premise
38	and	N	I-Premise
39	29	N	I-Premise
40	in	N	I-Premise
41	the	N	I-Premise
42	long-term	N	I-Premise
43	group	N	I-Premise
44	.	N	I-Premise

1	The	N	I-Premise
2	5-year	N	I-Premise
3	overall	N	I-Premise
4	mortality	N	I-Premise
5	for	N	I-Premise
6	short-term	N	I-Premise
7	and	N	I-Premise
8	long-term	N	I-Premise
9	suppression	N	I-Premise
10	was	N	I-Premise
11	19.0	N	I-Premise
12	%	N	I-Premise
13	and	N	I-Premise
14	15.2	N	I-Premise
15	%	N	I-Premise
16	,	N	I-Premise
17	respectively	N	I-Premise
18	;	N	I-Premise
19	the	N	O
20	observed	N	O
21	hazard	N	O
22	ratio	N	O
23	was	N	O
24	1.42	N	O
25	(	N	O
26	upper	N	O
27	95.71	N	O
28	%	N	O
29	confidence	N	O
30	limit	N	O
31	,	N	O
32	1.79	N	O
33	;	N	O
34	P=0.65	N	O
35	for	N	O
36	noninferiority	N	O
37	)	N	O
38	.	N	O

1	Adverse	N	I-Premise
2	events	N	I-Premise
3	in	N	I-Premise
4	both	N	I-Premise
5	groups	N	I-Premise
6	included	N	I-Premise
7	fatigue	N	I-Premise
8	,	N	I-Premise
9	diminished	N	I-Premise
10	sexual	N	I-Premise
11	function	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	hot	N	I-Premise
15	flushes	N	I-Premise
16	.	N	I-Premise

1	The	N	I-Claim
2	combination	N	I-Claim
3	of	N	I-Claim
4	radiotherapy	N	I-Claim
5	plus	N	I-Claim
6	6	N	I-Claim
7	months	N	I-Claim
8	of	N	I-Claim
9	androgen	N	I-Claim
10	suppression	N	I-Claim
11	provides	N	I-Claim
12	inferior	N	I-Claim
13	survival	N	I-Claim
14	as	N	I-Claim
15	compared	N	I-Claim
16	with	N	I-Claim
17	radiotherapy	N	I-Claim
18	plus	N	I-Claim
19	3	N	I-Claim
20	years	N	I-Claim
21	of	N	I-Claim
22	androgen	N	I-Claim
23	suppression	N	I-Claim
24	in	N	I-Claim
25	the	N	I-Claim
26	treatment	N	I-Claim
27	of	N	I-Claim
28	locally	N	I-Claim
29	advanced	N	I-Claim
30	prostate	N	I-Claim
31	cancer	N	I-Claim
32	.	N	I-Claim

1	Studies	N	O
2	on	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	(	N	O
7	QOL	N	O
8	)	N	O
9	among	N	O
10	women	N	O
11	with	N	O
12	endometrial	N	O
13	cancer	N	O
14	have	N	O
15	shown	N	O
16	that	N	O
17	patients	N	O
18	who	N	O
19	undergo	N	O
20	pelvic	N	O
21	radiotherapy	N	O
22	report	N	O
23	lower	N	O
24	role	N	O
25	functioning	N	O
26	and	N	O
27	more	N	O
28	diarrhea	N	O
29	and	N	O
30	fatigue	N	O
31	.	N	O

1	In	N	O
2	the	N	O
3	Post	N	O
4	Operative	N	O
5	Radiation	N	O
6	Therapy	N	O
7	in	N	O
8	Endometrial	N	O
9	Cancer	N	O
10	(	N	O
11	PORTEC	N	O
12	)	N	O
13	trial	N	O
14	,	N	O
15	patients	N	O
16	with	N	O
17	endometrial	N	O
18	carcinoma	N	O
19	were	N	O
20	randomly	N	O
21	assigned	N	O
22	to	N	O
23	receive	N	O
24	external-beam	N	O
25	radiotherapy	N	O
26	(	N	O
27	EBRT	N	O
28	)	N	O
29	or	N	O
30	vaginal	N	O
31	brachytherapy	N	O
32	(	N	O
33	VBT	N	O
34	)	N	O
35	.	N	O

1	QOL	N	O
2	was	N	O
3	evaluated	N	O
4	by	N	O
5	using	N	O
6	the	N	O
7	European	N	O
8	Organisation	N	O
9	for	N	O
10	Research	N	O
11	and	N	O
12	Treatment	N	O
13	of	N	O
14	Cancer	N	O
15	Quality	N	O
16	of	N	O
17	Life	N	O
18	Questionnaire	N	O
19	C30	N	O
20	and	N	O
21	subscales	N	O
22	from	N	O
23	the	N	O
24	prostate	N	O
25	cancer	N	O
26	module	N	O
27	,	N	O
28	PR-25	N	O
29	,	N	O
30	and	N	O
31	the	N	O
32	ovarian	N	O
33	cancer	N	O
34	module	N	O
35	,	N	O
36	OV-28	N	O
37	.	N	O

1	PORTEC-2	N	O
2	accrued	N	O
3	427	N	O
4	patients	N	O
5	between	N	O
6	2002	N	O
7	and	N	O
8	2006	N	O
9	,	N	O
10	of	N	O
11	whom	N	O
12	214	N	O
13	were	N	O
14	randomly	N	O
15	assigned	N	O
16	to	N	O
17	EBRT	N	O
18	,	N	O
19	and	N	O
20	213	N	O
21	were	N	O
22	randomly	N	O
23	assigned	N	O
24	to	N	O
25	VBT	N	O
26	.	N	O

1	Three-hundred	N	O
2	forty-eight	N	O
3	patients	N	O
4	(	N	O
5	81	N	O
6	%	N	O
7	)	N	O
8	were	N	O
9	evaluable	N	O
10	for	N	O
11	QOL	N	O
12	.	N	O

1	QOL	N	O
2	outcomes	N	O
3	were	N	O
4	analyzed	N	O
5	at	N	O
6	a	N	O
7	median	N	O
8	follow-up	N	O
9	of	N	O
10	2	N	O
11	years	N	O
12	.	N	O

1	At	N	O
2	baseline	N	O
3	after	N	O
4	surgery	N	O
5	,	N	O
6	patient	N	O
7	functioning	N	O
8	was	N	O
9	at	N	O
10	the	N	O
11	lowest	N	O
12	level	N	O
13	,	N	O
14	and	N	O
15	it	N	O
16	increased	N	O
17	during	N	O
18	and	N	O
19	after	N	O
20	radiotherapy	N	O
21	to	N	O
22	reach	N	O
23	a	N	O
24	plateau	N	O
25	after	N	O
26	12	N	O
27	months	N	O
28	.	N	O

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	VBT	N	I-Premise
5	group	N	I-Premise
6	reported	N	I-Premise
7	better	N	I-Premise
8	social	N	I-Premise
9	functioning	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	<	N	I-Premise
13	.002	N	I-Premise
14	)	N	I-Premise
15	and	N	I-Premise
16	lower	N	I-Premise
17	symptom	N	I-Premise
18	scores	N	I-Premise
19	for	N	I-Premise
20	diarrhea	N	I-Premise
21	,	N	I-Premise
22	fecal	N	I-Premise
23	leakage	N	I-Premise
24	,	N	I-Premise
25	the	N	I-Premise
26	need	N	I-Premise
27	to	N	I-Premise
28	stay	N	I-Premise
29	close	N	I-Premise
30	to	N	I-Premise
31	the	N	I-Premise
32	toilet	N	I-Premise
33	,	N	I-Premise
34	and	N	I-Premise
35	limitation	N	I-Premise
36	in	N	I-Premise
37	daily	N	I-Premise
38	activities	N	I-Premise
39	because	N	I-Premise
40	of	N	I-Premise
41	bowel	N	I-Premise
42	symptoms	N	I-Premise
43	(	N	I-Premise
44	P	N	I-Premise
45	<	N	I-Premise
46	.001	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	At	N	O
2	baseline	N	O
3	,	N	O
4	15	N	O
5	%	N	O
6	of	N	O
7	patients	N	O
8	were	N	O
9	sexually	N	O
10	active	N	O
11	;	N	O
12	this	N	O
13	increased	N	O
14	significantly	N	O
15	to	N	O
16	39	N	O
17	%	N	O
18	during	N	O
19	the	N	O
20	first	N	O
21	year	N	O
22	(	N	O
23	P	N	O
24	<	N	O
25	.001	N	O
26	)	N	O
27	.	N	O

1	Sexual	N	I-Premise
2	functioning	N	I-Premise
3	and	N	I-Premise
4	symptoms	N	I-Premise
5	did	N	I-Premise
6	not	N	I-Premise
7	differ	N	I-Premise
8	between	N	I-Premise
9	the	N	I-Premise
10	treatment	N	I-Premise
11	groups	N	I-Premise
12	.	N	I-Premise

1	Patients	N	I-Premise
2	who	N	I-Premise
3	received	N	I-Premise
4	EBRT	N	I-Premise
5	reported	N	I-Premise
6	significantly	N	I-Premise
7	higher	N	I-Premise
8	levels	N	I-Premise
9	of	N	I-Premise
10	diarrhea	N	I-Premise
11	and	N	I-Premise
12	bowel	N	I-Premise
13	symptoms	N	I-Premise
14	.	N	I-Premise

1	This	N	O
2	resulted	N	O
3	in	N	O
4	a	N	O
5	higher	N	O
6	need	N	O
7	to	N	O
8	remain	N	O
9	close	N	O
10	to	N	O
11	a	N	O
12	toilet	N	O
13	and	N	O
14	,	N	O
15	as	N	O
16	a	N	O
17	consequence	N	O
18	,	N	O
19	more	N	O
20	limitation	N	O
21	of	N	O
22	daily	N	O
23	activities	N	O
24	because	N	O
25	of	N	O
26	bowel	N	O
27	symptoms	N	O
28	and	N	O
29	decreased	N	O
30	social	N	O
31	functioning	N	O
32	.	N	O

1	Vaginal	N	I-Claim
2	brachytherapy	N	I-Claim
3	provides	N	I-Claim
4	a	N	I-Claim
5	better	N	I-Claim
6	QOL	N	I-Claim
7	,	N	I-Claim
8	and	N	I-Claim
9	should	N	I-Claim
10	be	N	I-Claim
11	the	N	I-Claim
12	preferred	N	I-Claim
13	treatment	N	I-Claim
14	from	N	I-Claim
15	a	N	I-Claim
16	QOL	N	I-Claim
17	perspective	N	I-Claim
18	.	N	I-Claim

1	Cancer	N	O
2	cells	N	O
3	rely	N	O
4	on	N	O
5	angiogenesis	N	O
6	for	N	O
7	growth	N	O
8	and	N	O
9	dissemination	N	O
10	,	N	O
11	and	N	O
12	small	N	O
13	cell	N	O
14	lung	N	O
15	cancer	N	O
16	(	N	O
17	SCLC	N	O
18	)	N	O
19	is	N	O
20	a	N	O
21	highly	N	O
22	angiogenic	N	O
23	tumor	N	O
24	.	N	O

1	We	N	O
2	evaluated	N	O
3	thalidomide	N	O
4	,	N	O
5	an	N	O
6	anti-angiogenic	N	O
7	agent	N	O
8	,	N	O
9	when	N	O
10	combined	N	O
11	with	N	O
12	chemotherapy	N	O
13	and	N	O
14	as	N	O
15	maintenance	N	O
16	treatment	N	O
17	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	724	N	O
5	patients	N	O
6	(	N	O
7	51	N	O
8	%	N	O
9	with	N	O
10	limited	N	O
11	and	N	O
12	49	N	O
13	%	N	O
14	with	N	O
15	extensive	N	O
16	disease	N	O
17	)	N	O
18	were	N	O
19	randomly	N	O
20	assigned	N	O
21	to	N	O
22	receive	N	O
23	placebo	N	O
24	or	N	O
25	thalidomide	N	O
26	capsules	N	O
27	,	N	O
28	100-200	N	O
29	mg	N	O
30	daily	N	O
31	for	N	O
32	up	N	O
33	to	N	O
34	2	N	O
35	years	N	O
36	.	N	O

1	All	N	O
2	patients	N	O
3	received	N	O
4	etoposide	N	O
5	and	N	O
6	carboplatin	N	O
7	every	N	O
8	3	N	O
9	weeks	N	O
10	for	N	O
11	up	N	O
12	to	N	O
13	six	N	O
14	cycles	N	O
15	.	N	O

1	Endpoints	N	O
2	were	N	O
3	overall	N	O
4	survival	N	O
5	,	N	O
6	progression-free	N	O
7	survival	N	O
8	,	N	O
9	tumor	N	O
10	response	N	O
11	rate	N	O
12	,	N	O
13	toxicity	N	O
14	,	N	O
15	and	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	QoL	N	O
21	)	N	O
22	.	N	O

1	Hazard	N	O
2	ratios	N	O
3	(	N	O
4	HRs	N	O
5	)	N	O
6	for	N	O
7	comparing	N	O
8	thalidomide	N	O
9	against	N	O
10	placebo	N	O
11	were	N	O
12	estimated	N	O
13	using	N	O
14	Cox	N	O
15	regression	N	O
16	modeling	N	O
17	.	N	O

1	Statistical	N	O
2	tests	N	O
3	were	N	O
4	two-sided	N	O
5	.	N	O

1	The	N	I-Premise
2	median	N	I-Premise
3	overall	N	I-Premise
4	survival	N	I-Premise
5	was	N	I-Premise
6	10.5	N	I-Premise
7	months	N	I-Premise
8	(	N	I-Premise
9	placebo	N	I-Premise
10	)	N	I-Premise
11	and	N	I-Premise
12	10.1	N	I-Premise
13	months	N	I-Premise
14	(	N	I-Premise
15	thalidomide	N	I-Premise
16	)	N	I-Premise
17	(	N	I-Premise
18	HR	N	I-Premise
19	for	N	I-Premise
20	death	N	I-Premise
21	=	N	I-Premise
22	1.09	N	I-Premise
23	,	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	confidence	N	I-Premise
27	interval	N	I-Premise
28	[	N	I-Premise
29	CI	N	I-Premise
30	]	N	I-Premise
31	=	N	I-Premise
32	0.93	N	I-Premise
33	to	N	I-Premise
34	1.27	N	I-Premise
35	;	N	I-Premise
36	P	N	I-Premise
37	=	N	I-Premise
38	.28	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	Among	N	I-Premise
2	patients	N	I-Premise
3	with	N	I-Premise
4	limited-stage	N	I-Premise
5	disease	N	I-Premise
6	,	N	I-Premise
7	there	N	I-Premise
8	was	N	I-Premise
9	no	N	I-Premise
10	evidence	N	I-Premise
11	of	N	I-Premise
12	a	N	I-Premise
13	survival	N	I-Premise
14	difference	N	I-Premise
15	(	N	I-Premise
16	HR	N	I-Premise
17	for	N	I-Premise
18	death	N	I-Premise
19	=	N	I-Premise
20	0.91	N	I-Premise
21	,	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	=	N	I-Premise
26	0.73	N	I-Premise
27	to	N	I-Premise
28	1.15	N	I-Premise
29	)	N	I-Premise
30	,	N	I-Premise
31	but	N	I-Premise
32	among	N	I-Premise
33	patients	N	I-Premise
34	with	N	I-Premise
35	extensive	N	I-Premise
36	disease	N	I-Premise
37	,	N	I-Premise
38	survival	N	I-Premise
39	was	N	I-Premise
40	worse	N	I-Premise
41	in	N	I-Premise
42	the	N	I-Premise
43	thalidomide	N	I-Premise
44	group	N	I-Premise
45	(	N	I-Premise
46	HR	N	I-Premise
47	for	N	I-Premise
48	death	N	I-Premise
49	=	N	I-Premise
50	1.36	N	I-Premise
51	,	N	I-Premise
52	95	N	I-Premise
53	%	N	I-Premise
54	CI	N	I-Premise
55	=	N	I-Premise
56	1.10	N	I-Premise
57	to	N	I-Premise
58	1.68	N	I-Premise
59	)	N	I-Premise
60	.	N	I-Premise

1	Progression-free	N	I-Premise
2	survival	N	I-Premise
3	rates	N	I-Premise
4	were	N	I-Premise
5	also	N	I-Premise
6	similar	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	two	N	I-Premise
10	groups	N	I-Premise
11	(	N	I-Premise
12	HR	N	I-Premise
13	=	N	I-Premise
14	1.07	N	I-Premise
15	,	N	I-Premise
16	95	N	I-Premise
17	%	N	I-Premise
18	CI	N	I-Premise
19	=	N	I-Premise
20	0.92	N	I-Premise
21	to	N	I-Premise
22	1.24	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Thalidomide	N	I-Premise
2	was	N	I-Premise
3	associated	N	I-Premise
4	with	N	I-Premise
5	an	N	I-Premise
6	increased	N	I-Premise
7	risk	N	I-Premise
8	of	N	I-Premise
9	having	N	I-Premise
10	a	N	I-Premise
11	thrombotic	N	I-Premise
12	event	N	I-Premise
13	,	N	I-Premise
14	mainly	N	I-Premise
15	pulmonary	N	I-Premise
16	embolus	N	I-Premise
17	and	N	I-Premise
18	deep	N	I-Premise
19	vein	N	I-Premise
20	thrombosis	N	I-Premise
21	(	N	I-Premise
22	19	N	I-Premise
23	%	N	I-Premise
24	thalidomide	N	I-Premise
25	vs	N	I-Premise
26	10	N	I-Premise
27	%	N	I-Premise
28	placebo	N	I-Premise
29	;	N	I-Premise
30	HR	N	I-Premise
31	=	N	I-Premise
32	2.13	N	I-Premise
33	,	N	I-Premise
34	95	N	I-Premise
35	%	N	I-Premise
36	CI	N	I-Premise
37	=	N	I-Premise
38	1.41	N	I-Premise
39	to	N	I-Premise
40	3.20	N	I-Premise
41	;	N	I-Premise
42	P	N	I-Premise
43	<	N	I-Premise
44	.001	N	I-Premise
45	)	N	I-Premise
46	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	differences	N	I-Premise
7	between	N	I-Premise
8	treatments	N	I-Premise
9	in	N	I-Premise
10	hematological	N	I-Premise
11	and	N	I-Premise
12	nonhematological	N	I-Premise
13	toxic	N	I-Premise
14	effects	N	I-Premise
15	,	N	I-Premise
16	except	N	I-Premise
17	more	N	I-Premise
18	patients	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	thalidomide	N	I-Premise
22	group	N	I-Premise
23	had	N	I-Premise
24	rash	N	I-Premise
25	,	N	I-Premise
26	constipation	N	I-Premise
27	,	N	I-Premise
28	or	N	I-Premise
29	neuropathy	N	I-Premise
30	.	N	I-Premise

1	Overall	N	O
2	,	N	O
3	QoL	N	I-Claim
4	scores	N	I-Claim
5	were	N	I-Claim
6	similar	N	I-Claim
7	in	N	I-Claim
8	the	N	I-Claim
9	two	N	I-Claim
10	treatment	N	I-Claim
11	groups	N	I-Claim
12	,	N	I-Claim
13	but	N	I-Claim
14	thalidomide	N	I-Claim
15	was	N	I-Claim
16	associated	N	I-Claim
17	with	N	I-Claim
18	less	N	I-Claim
19	insomnia	N	I-Claim
20	and	N	I-Claim
21	diarrhea	N	I-Claim
22	and	N	I-Claim
23	more	N	I-Claim
24	constipation	N	I-Claim
25	and	N	I-Claim
26	peripheral	N	I-Claim
27	neuropathy	N	I-Claim
28	.	N	I-Claim

1	In	N	O
2	this	N	O
3	large	N	O
4	randomized	N	O
5	trial	N	O
6	,	N	O
7	thalidomide	N	I-Claim
8	in	N	I-Claim
9	combination	N	I-Claim
10	with	N	I-Claim
11	chemotherapy	N	I-Claim
12	did	N	I-Claim
13	not	N	I-Claim
14	improve	N	I-Claim
15	survival	N	I-Claim
16	of	N	I-Claim
17	patients	N	I-Claim
18	with	N	I-Claim
19	SCLC	N	I-Claim
20	but	N	I-Claim
21	was	N	I-Claim
22	associated	N	I-Claim
23	with	N	I-Claim
24	an	N	I-Claim
25	increased	N	I-Claim
26	risk	N	I-Claim
27	of	N	I-Claim
28	thrombotic	N	I-Claim
29	events	N	I-Claim
30	.	N	I-Claim

1	Transthoracic	N	O
2	and	N	O
3	transhiatal	N	O
4	esophagectomy	N	O
5	are	N	O
6	two	N	O
7	common	N	O
8	procedures	N	O
9	for	N	O
10	esophageal	N	O
11	cancer	N	O
12	resection	N	O
13	.	N	O

1	Prospective	N	O
2	studies	N	O
3	comparing	N	O
4	the	N	O
5	two	N	O
6	methods	N	O
7	in	N	O
8	Asian	N	O
9	people	N	O
10	are	N	O
11	few	N	O
12	.	N	O

1	In	N	O
2	addition	N	O
3	,	N	O
4	the	N	O
5	data	N	O
6	comparing	N	O
7	their	N	O
8	effects	N	O
9	on	N	O
10	the	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	are	N	O
15	lacking	N	O
16	.	N	O

1	A	N	O
2	prospective	N	O
3	randomized	N	O
4	study	N	O
5	was	N	O
6	conducted	N	O
7	from	N	O
8	January	N	O
9	2003	N	O
10	.	N	O

1	Patients	N	O
2	of	N	O
3	resectable	N	O
4	esophageal	N	O
5	cancer	N	O
6	of	N	O
7	comparable	N	O
8	stage	N	O
9	were	N	O
10	allocated	N	O
11	to	N	O
12	undergo	N	O
13	the	N	O
14	transthoracic	N	O
15	or	N	O
16	transhiatal	N	O
17	procedure	N	O
18	in	N	O
19	turn	N	O
20	.	N	O

1	They	N	O
2	were	N	O
3	all	N	O
4	reconstructed	N	O
5	with	N	O
6	stomach	N	O
7	interposition	N	O
8	through	N	O
9	the	N	O
10	retrosternal	N	O
11	route	N	O
12	.	N	O

1	Discharged	N	O
2	patients	N	O
3	were	N	O
4	followed-up	N	O
5	in	N	O
6	the	N	O
7	outpatient	N	O
8	clinic	N	O
9	.	N	O

1	They	N	O
2	were	N	O
3	questioned	N	O
4	on	N	O
5	the	N	O
6	topics	N	O
7	of	N	O
8	(	N	O
9	i	N	O
10	)	N	O
11	severity	N	O
12	of	N	O
13	pain	N	O
14	,	N	O
15	(	N	O
16	ii	N	O
17	)	N	O
18	ease	N	O
19	of	N	O
20	swallowing	N	O
21	,	N	O
22	(	N	O
23	iii	N	O
24	)	N	O
25	satisfaction	N	O
26	of	N	O
27	daily	N	O
28	activities	N	O
29	,	N	O
30	(	N	O
31	iv	N	O
32	)	N	O
33	dependence	N	O
34	on	N	O
35	medications	N	O
36	,	N	O
37	(	N	O
38	v	N	O
39	)	N	O
40	working	N	O
41	ability	N	O
42	,	N	O
43	(	N	O
44	vi	N	O
45	)	N	O
46	fatigue	N	O
47	,	N	O
48	(	N	O
49	vii	N	O
50	)	N	O
51	appetite	N	O
52	,	N	O
53	(	N	O
54	viii	N	O
55	)	N	O
56	sociality	N	O
57	,	N	O
58	(	N	O
59	ix	N	O
60	)	N	O
61	happiness	N	O
62	and	N	O
63	(	N	O
64	x	N	O
65	)	N	O
66	self	N	O
67	respect	N	O
68	,	N	O
69	in	N	O
70	the	N	O
71	third	N	O
72	,	N	O
73	sixth	N	O
74	and	N	O
75	twelfth	N	O
76	month	N	O
77	.	N	O

1	Also	N	O
2	the	N	O
3	demographic	N	O
4	data	N	O
5	,	N	O
6	operative	N	O
7	results	N	O
8	and	N	O
9	survival	N	O
10	were	N	O
11	recorded	N	O
12	.	N	O

1	Up	N	O
2	to	N	O
3	December	N	O
4	2006	N	O
5	,	N	O
6	eighty-seven	N	O
7	patients	N	O
8	of	N	O
9	stage	N	O
10	II	N	O
11	and	N	O
12	III	N	O
13	,	N	O
14	including	N	O
15	71	N	O
16	patients	N	O
17	of	N	O
18	middle	N	O
19	third	N	O
20	lesions	N	O
21	and	N	O
22	16	N	O
23	lower	N	O
24	third	N	O
25	lesions	N	O
26	were	N	O
27	enrolled	N	O
28	.	N	O

1	The	N	I-Premise
2	operation	N	I-Premise
3	time	N	I-Premise
4	was	N	I-Premise
5	significantly	N	I-Premise
6	longer	N	I-Premise
7	,	N	I-Premise
8	and	N	I-Premise
9	the	N	I-Premise
10	leakage	N	I-Premise
11	rate	N	I-Premise
12	was	N	I-Premise
13	higher	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	transthoracic	N	I-Premise
17	group	N	I-Premise
18	(	N	I-Premise
19	Student	N	I-Premise
20	's	N	I-Premise
21	t-test	N	I-Premise
22	and	N	I-Premise
23	Fischer	N	I-Premise
24	's	N	I-Premise
25	exact	N	I-Premise
26	test	N	I-Premise
27	,	N	I-Premise
28	respectively	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	However	N	O
2	,	N	O
3	intraoperative	N	I-Premise
4	blood	N	I-Premise
5	loss	N	I-Premise
6	and	N	I-Premise
7	postoperative	N	I-Premise
8	hospital	N	I-Premise
9	stay	N	I-Premise
10	were	N	I-Premise
11	not	N	I-Premise
12	significantly	N	I-Premise
13	different	N	I-Premise
14	(	N	I-Premise
15	Student	N	I-Premise
16	t-test	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	Also	N	O
2	,	N	O
3	the	N	I-Premise
4	Kaplan-Meier	N	I-Premise
5	survival	N	I-Premise
6	curves	N	I-Premise
7	of	N	I-Premise
8	these	N	I-Premise
9	two	N	I-Premise
10	groups	N	I-Premise
11	were	N	I-Premise
12	not	N	I-Premise
13	significantly	N	I-Premise
14	different	N	I-Premise
15	by	N	I-Premise
16	log-rank	N	I-Premise
17	test	N	I-Premise
18	(	N	I-Premise
19	p=0.286	N	I-Premise
20	)	N	I-Premise
21	.	N	I-Premise

1	The	N	I-Premise
2	score	N	I-Premise
3	on	N	I-Premise
4	the	N	I-Premise
5	quality	N	I-Premise
6	of	N	I-Premise
7	life	N	I-Premise
8	of	N	I-Premise
9	transhiatal	N	I-Premise
10	patients	N	I-Premise
11	was	N	I-Premise
12	significantly	N	I-Premise
13	higher	N	I-Premise
14	than	N	I-Premise
15	that	N	I-Premise
16	of	N	I-Premise
17	transthoracic	N	I-Premise
18	patients	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	third	N	I-Premise
22	,	N	I-Premise
23	sixth	N	I-Premise
24	and	N	I-Premise
25	twelfth	N	I-Premise
26	month	N	I-Premise
27	.	N	I-Premise

1	Transhiatal	N	I-Claim
2	esophagectomy	N	I-Claim
3	is	N	I-Claim
4	a	N	I-Claim
5	safe	N	I-Claim
6	and	N	I-Claim
7	fast	N	I-Claim
8	procedure	N	I-Claim
9	.	N	I-Claim

1	The	N	I-Claim
2	survival	N	I-Claim
3	was	N	I-Claim
4	similar	N	I-Claim
5	to	N	I-Claim
6	that	N	I-Claim
7	of	N	I-Claim
8	transthoracic	N	I-Claim
9	approach	N	I-Claim
10	.	N	I-Claim

1	Its	N	I-Claim
2	leakage	N	I-Claim
3	rate	N	I-Claim
4	was	N	I-Claim
5	lower	N	I-Claim
6	and	N	I-Claim
7	quality	N	I-Claim
8	of	N	I-Claim
9	life	N	I-Claim
10	was	N	I-Claim
11	better	N	I-Claim
12	.	N	I-Claim

1	Therapy	N	O
2	for	N	O
3	polycystic	N	O
4	liver	N	O
5	is	N	O
6	invasive	N	O
7	,	N	O
8	expensive	N	O
9	,	N	O
10	and	N	O
11	has	N	O
12	disappointing	N	O
13	long-term	N	O
14	results	N	O
15	.	N	O

1	Treatment	N	O
2	with	N	O
3	somatostatin	N	O
4	analogues	N	O
5	slowed	N	O
6	kidney	N	O
7	growth	N	O
8	in	N	O
9	patients	N	O
10	with	N	O
11	polycystic	N	O
12	kidney	N	O
13	disease	N	O
14	(	N	O
15	PKD	N	O
16	)	N	O
17	and	N	O
18	reduced	N	O
19	liver	N	O
20	and	N	O
21	kidney	N	O
22	volume	N	O
23	in	N	O
24	a	N	O
25	PKD	N	O
26	rodent	N	O
27	model	N	O
28	.	N	O

1	We	N	O
2	evaluated	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	lanreotide	N	O
7	,	N	O
8	a	N	O
9	somatostatin	N	O
10	analogue	N	O
11	,	N	O
12	in	N	O
13	patients	N	O
14	with	N	O
15	polycystic	N	O
16	liver	N	O
17	because	N	O
18	of	N	O
19	autosomal-dominant	N	O
20	(	N	O
21	AD	N	O
22	)	N	O
23	PKD	N	O
24	or	N	O
25	autosomal-dominant	N	O
26	polycystic	N	O
27	liver	N	O
28	disease	N	O
29	(	N	O
30	PCLD	N	O
31	)	N	O
32	.	N	O

1	We	N	O
2	performed	N	O
3	a	N	O
4	randomized	N	O
5	,	N	O
6	double-blind	N	O
7	,	N	O
8	placebo-controlled	N	O
9	trial	N	O
10	in	N	O
11	2	N	O
12	tertiary	N	O
13	referral	N	O
14	centers	N	O
15	.	N	O

1	Patients	N	O
2	with	N	O
3	polycystic	N	O
4	liver	N	O
5	(	N	O
6	n	N	O
7	=	N	O
8	54	N	O
9	)	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	to	N	O
14	groups	N	O
15	given	N	O
16	lanreotide	N	O
17	(	N	O
18	120	N	O
19	mg	N	O
20	)	N	O
21	or	N	O
22	placebo	N	O
23	,	N	O
24	administered	N	O
25	every	N	O
26	28	N	O
27	days	N	O
28	for	N	O
29	24	N	O
30	weeks	N	O
31	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	the	N	O
7	difference	N	O
8	in	N	O
9	total	N	O
10	liver	N	O
11	volume	N	O
12	,	N	O
13	measured	N	O
14	by	N	O
15	computerized	N	O
16	tomography	N	O
17	at	N	O
18	weeks	N	O
19	0	N	O
20	and	N	O
21	24	N	O
22	.	N	O

1	Analyses	N	O
2	were	N	O
3	performed	N	O
4	on	N	O
5	an	N	O
6	intention-to-treat	N	O
7	basis	N	O
8	.	N	O

1	Baseline	N	I-Premise
2	characteristics	N	I-Premise
3	were	N	I-Premise
4	comparable	N	I-Premise
5	for	N	I-Premise
6	both	N	I-Premise
7	groups	N	I-Premise
8	,	N	I-Premise
9	except	N	I-Premise
10	that	N	I-Premise
11	more	N	I-Premise
12	patients	N	I-Premise
13	with	N	I-Premise
14	ADPKD	N	I-Premise
15	were	N	I-Premise
16	assigned	N	I-Premise
17	to	N	I-Premise
18	the	N	I-Premise
19	placebo	N	I-Premise
20	group	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	.03	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	The	N	I-Premise
2	mean	N	I-Premise
3	liver	N	I-Premise
4	volume	N	I-Premise
5	decreased	N	I-Premise
6	2.9	N	I-Premise
7	%	N	I-Premise
8	,	N	I-Premise
9	from	N	I-Premise
10	4606	N	I-Premise
11	mL	N	I-Premise
12	(	N	I-Premise
13	95	N	I-Premise
14	%	N	I-Premise
15	confidence	N	I-Premise
16	interval	N	I-Premise
17	(	N	I-Premise
18	CI	N	I-Premise
19	)	N	I-Premise
20	:	N	I-Premise
21	547-8665	N	I-Premise
22	)	N	I-Premise
23	to	N	I-Premise
24	4471	N	I-Premise
25	mL	N	I-Premise
26	(	N	I-Premise
27	95	N	I-Premise
28	%	N	I-Premise
29	CI	N	I-Premise
30	:	N	I-Premise
31	542-8401	N	I-Premise
32	mL	N	I-Premise
33	)	N	I-Premise
34	,	N	I-Premise
35	in	N	I-Premise
36	patients	N	I-Premise
37	given	N	I-Premise
38	lanreotide	N	I-Premise
39	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	placebo	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	mean	N	I-Premise
8	liver	N	I-Premise
9	volume	N	I-Premise
10	increased	N	I-Premise
11	1.6	N	I-Premise
12	%	N	I-Premise
13	,	N	I-Premise
14	from	N	I-Premise
15	4689	N	I-Premise
16	mL	N	I-Premise
17	(	N	I-Premise
18	95	N	I-Premise
19	%	N	I-Premise
20	CI	N	I-Premise
21	:	N	I-Premise
22	613-8765	N	I-Premise
23	mL	N	I-Premise
24	)	N	I-Premise
25	to	N	I-Premise
26	4895	N	I-Premise
27	mL	N	I-Premise
28	(	N	I-Premise
29	95	N	I-Premise
30	%	N	I-Premise
31	CI	N	I-Premise
32	:	N	I-Premise
33	739-9053	N	I-Premise
34	mL	N	I-Premise
35	)	N	I-Premise
36	(	N	I-Premise
37	P	N	I-Premise
38	<	N	I-Premise
39	.01	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	Post	N	I-Premise
2	hoc	N	I-Premise
3	stratification	N	I-Premise
4	for	N	I-Premise
5	patients	N	I-Premise
6	with	N	I-Premise
7	ADPKD	N	I-Premise
8	or	N	I-Premise
9	PCLD	N	I-Premise
10	revealed	N	I-Premise
11	similar	N	I-Premise
12	changes	N	I-Premise
13	in	N	I-Premise
14	liver	N	I-Premise
15	volume	N	I-Premise
16	,	N	I-Premise
17	with	N	I-Premise
18	statistically	N	I-Premise
19	significant	N	I-Premise
20	differences	N	I-Premise
21	in	N	I-Premise
22	patients	N	I-Premise
23	given	N	I-Premise
24	lanreotide	N	I-Premise
25	(	N	I-Premise
26	P	N	I-Premise
27	<	N	I-Premise
28	.01	N	I-Premise
29	for	N	I-Premise
30	both	N	I-Premise
31	diseases	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	In	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	polycystic	N	I-Claim
5	liver	N	I-Claim
6	,	N	I-Claim
7	6	N	I-Claim
8	months	N	I-Claim
9	of	N	I-Claim
10	treatment	N	I-Claim
11	with	N	I-Claim
12	lanreotide	N	I-Claim
13	reduces	N	I-Claim
14	liver	N	I-Claim
15	volume	N	I-Claim
16	.	N	I-Claim

1	Sunitinib	N	O
2	has	N	O
3	demonstrated	N	O
4	antitumor	N	O
5	activity	N	O
6	in	N	O
7	metastatic	N	O
8	renal	N	O
9	cell	N	O
10	carcinoma	N	O
11	(	N	O
12	mRCC	N	O
13	)	N	O
14	when	N	O
15	given	N	O
16	at	N	O
17	50	N	O
18	mg/d	N	O
19	on	N	O
20	a	N	O
21	4-weeks-on	N	O
22	2-weeks-off	N	O
23	regimen	N	O
24	.	N	O

1	Herein	N	O
2	,	N	O
3	we	N	O
4	report	N	O
5	results	N	O
6	of	N	O
7	an	N	O
8	open-label	N	O
9	,	N	O
10	multicenter	N	O
11	phase	N	O
12	II	N	O
13	mRCC	N	O
14	study	N	O
15	of	N	O
16	sunitinib	N	O
17	administered	N	O
18	on	N	O
19	a	N	O
20	continuous	N	O
21	once-daily	N	O
22	dosing	N	O
23	regimen	N	O
24	.	N	O

1	Eligibility	N	O
2	criteria	N	O
3	included	N	O
4	histologically	N	O
5	proven	N	O
6	mRCC	N	O
7	with	N	O
8	measurable	N	O
9	disease	N	O
10	,	N	O
11	failure	N	O
12	of	N	O
13	one	N	O
14	prior	N	O
15	cytokine	N	O
16	regimen	N	O
17	,	N	O
18	and	N	O
19	good	N	O
20	performance	N	O
21	status	N	O
22	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	a	N	O
7	sunitinib	N	O
8	starting	N	O
9	dose	N	O
10	of	N	O
11	37.5	N	O
12	mg/d	N	O
13	in	N	O
14	the	N	O
15	morning	N	O
16	(	N	O
17	AM	N	O
18	)	N	O
19	or	N	O
20	evening	N	O
21	(	N	O
22	PM	N	O
23	)	N	O
24	.	N	O

1	RECIST-defined	N	O
2	objective	N	O
3	response	N	O
4	rate	N	O
5	(	N	O
6	ORR	N	O
7	)	N	O
8	was	N	O
9	the	N	O
10	primary	N	O
11	end	N	O
12	point	N	O
13	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	included	N	O
5	progression-free	N	O
6	survival	N	O
7	(	N	O
8	PFS	N	O
9	)	N	O
10	,	N	O
11	overall	N	O
12	survival	N	O
13	(	N	O
14	OS	N	O
15	)	N	O
16	,	N	O
17	adverse	N	O
18	events	N	O
19	(	N	O
20	AEs	N	O
21	)	N	O
22	,	N	O
23	and	N	O
24	quality-of-life	N	O
25	measures	N	O
26	.	N	O

1	One	N	O
2	hundred	N	O
3	seven	N	O
4	patients	N	O
5	were	N	O
6	randomly	N	O
7	assigned	N	O
8	to	N	O
9	AM	N	O
10	(	N	O
11	n	N	O
12	=	N	O
13	54	N	O
14	)	N	O
15	or	N	O
16	PM	N	O
17	(	N	O
18	n	N	O
19	=	N	O
20	53	N	O
21	)	N	O
22	dosing	N	O
23	and	N	O
24	on	N	O
25	study	N	O
26	for	N	O
27	a	N	O
28	median	N	O
29	8.3	N	O
30	months	N	O
31	.	N	O

1	Eighty-three	N	O
2	patients	N	O
3	discontinued	N	O
4	,	N	O
5	65	N	O
6	due	N	O
7	to	N	O
8	disease	N	O
9	progression	N	O
10	and	N	O
11	16	N	O
12	because	N	O
13	of	N	O
14	AEs	N	O
15	;	N	O
16	two	N	O
17	patients	N	O
18	withdrew	N	O
19	consent	N	O
20	.	N	O

1	Dosing	N	O
2	was	N	O
3	reduced	N	O
4	to	N	O
5	25	N	O
6	mg/d	N	O
7	in	N	O
8	46	N	O
9	patients	N	O
10	(	N	O
11	43	N	O
12	%	N	O
13	)	N	O
14	due	N	O
15	to	N	O
16	grade	N	O
17	3/4	N	O
18	AEs	N	O
19	.	N	O

1	The	N	I-Premise
2	most	N	I-Premise
3	common	N	I-Premise
4	grade	N	I-Premise
5	3	N	I-Premise
6	treatment-related	N	I-Premise
7	AEs	N	I-Premise
8	were	N	I-Premise
9	asthenia/fatigue	N	I-Premise
10	(	N	I-Premise
11	16	N	I-Premise
12	%	N	I-Premise
13	)	N	I-Premise
14	,	N	I-Premise
15	diarrhea	N	I-Premise
16	(	N	I-Premise
17	11	N	I-Premise
18	%	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	hypertension	N	I-Premise
22	(	N	I-Premise
23	11	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	,	N	I-Premise
27	hand-foot	N	I-Premise
28	syndrome	N	I-Premise
29	(	N	I-Premise
30	9	N	I-Premise
31	%	N	I-Premise
32	)	N	I-Premise
33	,	N	I-Premise
34	and	N	I-Premise
35	anorexia	N	I-Premise
36	(	N	I-Premise
37	8	N	I-Premise
38	%	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	ORR	N	O
2	was	N	O
3	20	N	O
4	%	N	O
5	with	N	O
6	a	N	O
7	7.2-month	N	O
8	median	N	O
9	response	N	O
10	duration	N	O
11	.	N	O

1	Median	N	I-Premise
2	PFS	N	I-Premise
3	and	N	I-Premise
4	OS	N	I-Premise
5	were	N	I-Premise
6	8.2	N	I-Premise
7	and	N	I-Premise
8	19.8	N	I-Premise
9	months	N	I-Premise
10	,	N	I-Premise
11	respectively	N	I-Premise
12	,	N	I-Premise
13	at	N	I-Premise
14	median	N	I-Premise
15	follow-up	N	I-Premise
16	of	N	I-Premise
17	26.4	N	I-Premise
18	months	N	I-Premise
19	.	N	I-Premise

1	Efficacy	N	I-Premise
2	,	N	I-Premise
3	tolerability	N	I-Premise
4	,	N	I-Premise
5	and	N	I-Premise
6	quality-of-life	N	I-Premise
7	results	N	I-Premise
8	were	N	I-Premise
9	similar	N	I-Premise
10	between	N	I-Premise
11	patients	N	I-Premise
12	dosed	N	I-Premise
13	in	N	I-Premise
14	the	N	I-Premise
15	AM	N	I-Premise
16	or	N	I-Premise
17	PM	N	I-Premise
18	.	N	I-Premise

1	Sunitinib	N	I-Claim
2	37.5	N	I-Claim
3	mg	N	I-Claim
4	,	N	I-Claim
5	administered	N	I-Claim
6	on	N	I-Claim
7	a	N	I-Claim
8	continuous	N	I-Claim
9	once-daily	N	I-Claim
10	dosing	N	I-Claim
11	regimen	N	I-Claim
12	,	N	I-Claim
13	has	N	I-Claim
14	a	N	I-Claim
15	manageable	N	I-Claim
16	safety	N	I-Claim
17	profile	N	I-Claim
18	as	N	I-Claim
19	second-line	N	I-Claim
20	mRCC	N	I-Claim
21	therapy	N	I-Claim
22	,	N	I-Claim
23	providing	N	I-Claim
24	flexible	N	I-Claim
25	dosing	N	I-Claim
26	,	N	I-Claim
27	which	N	I-Claim
28	can	N	I-Claim
29	be	N	I-Claim
30	explored	N	I-Claim
31	in	N	I-Claim
32	combination	N	I-Claim
33	studies	N	I-Claim
34	.	N	I-Claim

1	Lymphoma	N	O
2	patients	N	O
3	commonly	N	O
4	experience	N	O
5	declines	N	O
6	in	N	O
7	physical	N	O
8	functioning	N	O
9	and	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	(	N	O
14	QoL	N	O
15	)	N	O
16	that	N	O
17	may	N	O
18	be	N	O
19	reversed	N	O
20	with	N	O
21	exercise	N	O
22	training	N	O
23	.	N	O

1	We	N	O
2	conducted	N	O
3	a	N	O
4	randomized	N	O
5	controlled	N	O
6	trial	N	O
7	in	N	O
8	Edmonton	N	O
9	,	N	O
10	Alberta	N	O
11	,	N	O
12	Canada	N	O
13	,	N	O
14	between	N	O
15	2005	N	O
16	and	N	O
17	2008	N	O
18	that	N	O
19	stratified	N	O
20	122	N	O
21	lymphoma	N	O
22	patients	N	O
23	by	N	O
24	major	N	O
25	disease	N	O
26	type	N	O
27	and	N	O
28	current	N	O
29	treatment	N	O
30	status	N	O
31	and	N	O
32	randomly	N	O
33	assigned	N	O
34	them	N	O
35	to	N	O
36	usual	N	O
37	care	N	O
38	(	N	O
39	UC	N	O
40	;	N	O
41	n	N	O
42	=	N	O
43	62	N	O
44	)	N	O
45	or	N	O
46	12	N	O
47	weeks	N	O
48	of	N	O
49	supervised	N	O
50	aerobic	N	O
51	exercise	N	O
52	training	N	O
53	(	N	O
54	AET	N	O
55	;	N	O
56	n	N	O
57	=	N	O
58	60	N	O
59	)	N	O
60	.	N	O

1	Our	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	patient-rated	N	O
7	physical	N	O
8	functioning	N	O
9	assessed	N	O
10	by	N	O
11	the	N	O
12	Trial	N	O
13	Outcome	N	O
14	Index-Anemia	N	O
15	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	were	N	O
5	overall	N	O
6	QoL	N	O
7	,	N	O
8	psychosocial	N	O
9	functioning	N	O
10	,	N	O
11	cardiovascular	N	O
12	fitness	N	O
13	,	N	O
14	and	N	O
15	body	N	O
16	composition	N	O
17	.	N	O

1	Follow-up	N	O
2	assessment	N	O
3	for	N	O
4	our	N	O
5	primary	N	O
6	end	N	O
7	point	N	O
8	was	N	O
9	96	N	O
10	%	N	O
11	(	N	O
12	117	N	O
13	of	N	O
14	122	N	O
15	)	N	O
16	at	N	O
17	postintervention	N	O
18	and	N	O
19	90	N	O
20	%	N	O
21	(	N	O
22	110	N	O
23	of	N	O
24	122	N	O
25	)	N	O
26	at	N	O
27	6-month	N	O
28	follow-up	N	O
29	.	N	O

1	Median	N	O
2	adherence	N	O
3	to	N	O
4	the	N	O
5	supervised	N	O
6	exercise	N	O
7	program	N	O
8	was	N	O
9	92	N	O
10	%	N	O
11	.	N	O

1	At	N	I-Premise
2	postintervention	N	I-Premise
3	,	N	I-Premise
4	AET	N	I-Premise
5	was	N	I-Premise
6	superior	N	I-Premise
7	to	N	I-Premise
8	UC	N	I-Premise
9	for	N	I-Premise
10	patient-rated	N	I-Premise
11	physical	N	I-Premise
12	functioning	N	I-Premise
13	(	N	I-Premise
14	mean	N	I-Premise
15	group	N	I-Premise
16	difference	N	I-Premise
17	,	N	I-Premise
18	+9.0	N	I-Premise
19	;	N	I-Premise
20	95	N	I-Premise
21	%	N	I-Premise
22	CI	N	I-Premise
23	,	N	I-Premise
24	2.0	N	I-Premise
25	to	N	I-Premise
26	16.0	N	I-Premise
27	;	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	.012	N	I-Premise
31	)	N	I-Premise
32	,	N	I-Premise
33	overall	N	I-Premise
34	QoL	N	I-Premise
35	(	N	I-Premise
36	P	N	I-Premise
37	=	N	I-Premise
38	.021	N	I-Premise
39	)	N	I-Premise
40	,	N	I-Premise
41	fatigue	N	I-Premise
42	(	N	I-Premise
43	P	N	I-Premise
44	=	N	I-Premise
45	.013	N	I-Premise
46	)	N	I-Premise
47	,	N	I-Premise
48	happiness	N	I-Premise
49	(	N	I-Premise
50	P	N	I-Premise
51	=	N	I-Premise
52	.004	N	I-Premise
53	)	N	I-Premise
54	,	N	I-Premise
55	depression	N	I-Premise
56	(	N	I-Premise
57	P	N	I-Premise
58	=	N	I-Premise
59	.005	N	I-Premise
60	)	N	I-Premise
61	,	N	I-Premise
62	general	N	I-Premise
63	health	N	I-Premise
64	(	N	I-Premise
65	P	N	I-Premise
66	<	N	I-Premise
67	.001	N	I-Premise
68	)	N	I-Premise
69	,	N	I-Premise
70	cardiovascular	N	I-Premise
71	fitness	N	I-Premise
72	(	N	I-Premise
73	P	N	I-Premise
74	<	N	I-Premise
75	.001	N	I-Premise
76	)	N	I-Premise
77	,	N	I-Premise
78	and	N	I-Premise
79	lean	N	I-Premise
80	body	N	I-Premise
81	mass	N	I-Premise
82	(	N	I-Premise
83	P	N	I-Premise
84	=	N	I-Premise
85	.008	N	I-Premise
86	)	N	I-Premise
87	.	N	I-Premise

1	Change	N	O
2	in	N	O
3	peak	N	O
4	cardiovascular	N	O
5	fitness	N	O
6	mediated	N	O
7	the	N	O
8	change	N	O
9	in	N	O
10	patient-rated	N	O
11	physical	N	O
12	functioning	N	O
13	.	N	O

1	AET	N	I-Premise
2	did	N	I-Premise
3	not	N	I-Premise
4	interfere	N	I-Premise
5	with	N	I-Premise
6	chemotherapy	N	I-Premise
7	completion	N	I-Premise
8	rate	N	I-Premise
9	or	N	I-Premise
10	treatment	N	I-Premise
11	response	N	I-Premise
12	.	N	I-Premise

1	At	N	I-Premise
2	6-month	N	I-Premise
3	follow-up	N	I-Premise
4	,	N	I-Premise
5	AET	N	I-Premise
6	was	N	I-Premise
7	still	N	I-Premise
8	borderline	N	I-Premise
9	or	N	I-Premise
10	significantly	N	I-Premise
11	superior	N	I-Premise
12	to	N	I-Premise
13	UC	N	I-Premise
14	for	N	I-Premise
15	overall	N	I-Premise
16	QoL	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	.054	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	happiness	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	=	N	I-Premise
27	.034	N	I-Premise
28	)	N	I-Premise
29	,	N	I-Premise
30	and	N	I-Premise
31	depression	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	.009	N	I-Premise
36	)	N	I-Premise
37	without	N	I-Premise
38	an	N	I-Premise
39	increased	N	I-Premise
40	risk	N	I-Premise
41	of	N	I-Premise
42	disease	N	I-Premise
43	recurrence/progression	N	I-Premise
44	.	N	I-Premise

1	AET	N	I-Claim
2	significantly	N	I-Claim
3	improved	N	I-Claim
4	important	N	I-Claim
5	patient-rated	N	I-Claim
6	outcomes	N	I-Claim
7	and	N	I-Claim
8	objective	N	I-Claim
9	physical	N	I-Claim
10	functioning	N	I-Claim
11	in	N	I-Claim
12	lymphoma	N	I-Claim
13	patients	N	I-Claim
14	without	N	I-Claim
15	interfering	N	I-Claim
16	with	N	I-Claim
17	medical	N	I-Claim
18	treatments	N	I-Claim
19	or	N	I-Claim
20	response	N	I-Claim
21	.	N	I-Claim

1	Exercise	N	I-MajorClaim
2	training	N	I-MajorClaim
3	to	N	I-MajorClaim
4	improve	N	I-MajorClaim
5	cardiovascular	N	I-MajorClaim
6	fitness	N	I-MajorClaim
7	should	N	I-MajorClaim
8	be	N	I-MajorClaim
9	considered	N	I-MajorClaim
10	in	N	I-MajorClaim
11	the	N	I-MajorClaim
12	management	N	I-MajorClaim
13	of	N	I-MajorClaim
14	lymphoma	N	I-MajorClaim
15	patients	N	I-MajorClaim
16	.	N	I-MajorClaim

1	There	N	O
2	are	N	O
3	few	N	O
4	randomized	N	O
5	controlled	N	O
6	trials	N	O
7	on	N	O
8	the	N	O
9	effectiveness	N	O
10	of	N	O
11	palliative	N	O
12	care	N	O
13	interventions	N	O
14	to	N	O
15	improve	N	O
16	the	N	O
17	care	N	O
18	of	N	O
19	patients	N	O
20	with	N	O
21	advanced	N	O
22	cancer	N	O
23	.	N	O

1	To	N	O
2	determine	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	a	N	O
7	nursing-led	N	O
8	intervention	N	O
9	on	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	,	N	O
14	symptom	N	O
15	intensity	N	O
16	,	N	O
17	mood	N	O
18	,	N	O
19	and	N	O
20	resource	N	O
21	use	N	O
22	in	N	O
23	patients	N	O
24	with	N	O
25	advanced	N	O
26	cancer	N	O
27	.	N	O

1	Randomized	N	O
2	controlled	N	O
3	trial	N	O
4	conducted	N	O
5	from	N	O
6	November	N	O
7	2003	N	O
8	through	N	O
9	May	N	O
10	2008	N	O
11	of	N	O
12	322	N	O
13	patients	N	O
14	with	N	O
15	advanced	N	O
16	cancer	N	O
17	in	N	O
18	a	N	O
19	rural	N	O
20	,	N	O
21	National	N	O
22	Cancer	N	O
23	Institute-designated	N	O
24	comprehensive	N	O
25	cancer	N	O
26	center	N	O
27	in	N	O
28	New	N	O
29	Hampshire	N	O
30	and	N	O
31	affiliated	N	O
32	outreach	N	O
33	clinics	N	O
34	and	N	O
35	a	N	O
36	VA	N	O
37	medical	N	O
38	center	N	O
39	in	N	O
40	Vermont	N	O
41	.	N	O

1	A	N	O
2	multicomponent	N	O
3	,	N	O
4	psychoeducational	N	O
5	intervention	N	O
6	(	N	O
7	Project	N	O
8	ENABLE	N	O
9	[	N	O
10	Educate	N	O
11	,	N	O
12	Nurture	N	O
13	,	N	O
14	Advise	N	O
15	,	N	O
16	Before	N	O
17	Life	N	O
18	Ends	N	O
19	]	N	O
20	)	N	O
21	conducted	N	O
22	by	N	O
23	advanced	N	O
24	practice	N	O
25	nurses	N	O
26	consisting	N	O
27	of	N	O
28	4	N	O
29	weekly	N	O
30	educational	N	O
31	sessions	N	O
32	and	N	O
33	monthly	N	O
34	follow-up	N	O
35	sessions	N	O
36	until	N	O
37	death	N	O
38	or	N	O
39	study	N	O
40	completion	N	O
41	(	N	O
42	n	N	O
43	=	N	O
44	161	N	O
45	)	N	O
46	vs	N	O
47	usual	N	O
48	care	N	O
49	(	N	O
50	n	N	O
51	=	N	O
52	161	N	O
53	)	N	O
54	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	measured	N	O
6	by	N	O
7	the	N	O
8	Functional	N	O
9	Assessment	N	O
10	of	N	O
11	Chronic	N	O
12	Illness	N	O
13	Therapy	N	O
14	for	N	O
15	Palliative	N	O
16	Care	N	O
17	(	N	O
18	score	N	O
19	range	N	O
20	,	N	O
21	0-184	N	O
22	)	N	O
23	.	N	O

1	Symptom	N	O
2	intensity	N	O
3	was	N	O
4	measured	N	O
5	by	N	O
6	the	N	O
7	Edmonton	N	O
8	Symptom	N	O
9	Assessment	N	O
10	Scale	N	O
11	(	N	O
12	score	N	O
13	range	N	O
14	,	N	O
15	0-900	N	O
16	)	N	O
17	.	N	O

1	Mood	N	O
2	was	N	O
3	measured	N	O
4	by	N	O
5	the	N	O
6	Center	N	O
7	for	N	O
8	Epidemiological	N	O
9	Studies	N	O
10	Depression	N	O
11	Scale	N	O
12	(	N	O
13	range	N	O
14	,	N	O
15	0-60	N	O
16	)	N	O
17	.	N	O

1	These	N	O
2	measures	N	O
3	were	N	O
4	assessed	N	O
5	at	N	O
6	baseline	N	O
7	,	N	O
8	1	N	O
9	month	N	O
10	,	N	O
11	and	N	O
12	every	N	O
13	3	N	O
14	months	N	O
15	until	N	O
16	death	N	O
17	or	N	O
18	study	N	O
19	completion	N	O
20	.	N	O

1	Intensity	N	O
2	of	N	O
3	service	N	O
4	was	N	O
5	measured	N	O
6	as	N	O
7	the	N	O
8	number	N	O
9	of	N	O
10	days	N	O
11	in	N	O
12	the	N	O
13	hospital	N	O
14	and	N	O
15	in	N	O
16	the	N	O
17	intensive	N	O
18	care	N	O
19	unit	N	O
20	(	N	O
21	ICU	N	O
22	)	N	O
23	and	N	O
24	the	N	O
25	number	N	O
26	of	N	O
27	emergency	N	O
28	department	N	O
29	visits	N	O
30	recorded	N	O
31	in	N	O
32	the	N	O
33	electronic	N	O
34	medical	N	O
35	record	N	O
36	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	322	N	O
5	participants	N	O
6	with	N	O
7	cancer	N	O
8	of	N	O
9	the	N	O
10	gastrointestinal	N	O
11	tract	N	O
12	(	N	O
13	41	N	O
14	%	N	O
15	;	N	O
16	67	N	O
17	in	N	O
18	the	N	O
19	usual	N	O
20	care	N	O
21	group	N	O
22	vs	N	O
23	66	N	O
24	in	N	O
25	the	N	O
26	intervention	N	O
27	group	N	O
28	)	N	O
29	,	N	O
30	lung	N	O
31	(	N	O
32	36	N	O
33	%	N	O
34	;	N	O
35	58	N	O
36	vs	N	O
37	59	N	O
38	)	N	O
39	,	N	O
40	genitourinary	N	O
41	tract	N	O
42	(	N	O
43	12	N	O
44	%	N	O
45	;	N	O
46	20	N	O
47	vs	N	O
48	19	N	O
49	)	N	O
50	,	N	O
51	and	N	O
52	breast	N	O
53	(	N	O
54	10	N	O
55	%	N	O
56	;	N	O
57	16	N	O
58	vs	N	O
59	17	N	O
60	)	N	O
61	were	N	O
62	randomized	N	O
63	.	N	O

1	The	N	I-Premise
2	estimated	N	I-Premise
3	treatment	N	I-Premise
4	effects	N	I-Premise
5	(	N	I-Premise
6	intervention	N	I-Premise
7	minus	N	I-Premise
8	usual	N	I-Premise
9	care	N	I-Premise
10	)	N	I-Premise
11	for	N	I-Premise
12	all	N	I-Premise
13	participants	N	I-Premise
14	were	N	I-Premise
15	a	N	I-Premise
16	mean	N	I-Premise
17	(	N	I-Premise
18	SE	N	I-Premise
19	)	N	I-Premise
20	of	N	I-Premise
21	4.6	N	I-Premise
22	(	N	I-Premise
23	2	N	I-Premise
24	)	N	I-Premise
25	for	N	I-Premise
26	quality	N	I-Premise
27	of	N	I-Premise
28	life	N	I-Premise
29	(	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.02	N	I-Premise
33	)	N	I-Premise
34	,	N	I-Premise
35	-27.8	N	I-Premise
36	(	N	I-Premise
37	15	N	I-Premise
38	)	N	I-Premise
39	for	N	I-Premise
40	symptom	N	I-Premise
41	intensity	N	I-Premise
42	(	N	I-Premise
43	P	N	I-Premise
44	=	N	I-Premise
45	.06	N	I-Premise
46	)	N	I-Premise
47	,	N	I-Premise
48	and	N	I-Premise
49	-1.8	N	I-Premise
50	(	N	I-Premise
51	0.81	N	I-Premise
52	)	N	I-Premise
53	for	N	I-Premise
54	depressed	N	I-Premise
55	mood	N	I-Premise
56	(	N	I-Premise
57	P	N	I-Premise
58	=	N	I-Premise
59	.02	N	I-Premise
60	)	N	I-Premise
61	.	N	I-Premise

1	The	N	I-Premise
2	estimated	N	I-Premise
3	treatment	N	I-Premise
4	effects	N	I-Premise
5	in	N	I-Premise
6	participants	N	I-Premise
7	who	N	I-Premise
8	died	N	I-Premise
9	during	N	I-Premise
10	the	N	I-Premise
11	study	N	I-Premise
12	were	N	I-Premise
13	a	N	I-Premise
14	mean	N	I-Premise
15	(	N	I-Premise
16	SE	N	I-Premise
17	)	N	I-Premise
18	of	N	I-Premise
19	8.6	N	I-Premise
20	(	N	I-Premise
21	3.6	N	I-Premise
22	)	N	I-Premise
23	for	N	I-Premise
24	quality	N	I-Premise
25	of	N	I-Premise
26	life	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	.02	N	I-Premise
31	)	N	I-Premise
32	,	N	I-Premise
33	-24.2	N	I-Premise
34	(	N	I-Premise
35	20.5	N	I-Premise
36	)	N	I-Premise
37	for	N	I-Premise
38	symptom	N	I-Premise
39	intensity	N	I-Premise
40	(	N	I-Premise
41	P	N	I-Premise
42	=	N	I-Premise
43	.24	N	I-Premise
44	)	N	I-Premise
45	,	N	I-Premise
46	and	N	I-Premise
47	-2.7	N	I-Premise
48	(	N	I-Premise
49	1.2	N	I-Premise
50	)	N	I-Premise
51	for	N	I-Premise
52	depressed	N	I-Premise
53	mood	N	I-Premise
54	(	N	I-Premise
55	P	N	I-Premise
56	=	N	I-Premise
57	.03	N	I-Premise
58	)	N	I-Premise
59	.	N	I-Premise

1	Intensity	N	O
2	of	N	O
3	service	N	O
4	did	N	O
5	not	N	O
6	differ	N	O
7	between	N	O
8	the	N	O
9	2	N	O
10	groups	N	O
11	.	N	O

1	Compared	N	I-Claim
2	with	N	I-Claim
3	participants	N	I-Claim
4	receiving	N	I-Claim
5	usual	N	I-Claim
6	oncology	N	I-Claim
7	care	N	I-Claim
8	,	N	I-Claim
9	those	N	I-Claim
10	receiving	N	I-Claim
11	a	N	I-Claim
12	nurse-led	N	I-Claim
13	,	N	I-Claim
14	palliative	N	I-Claim
15	care-focused	N	I-Claim
16	intervention	N	I-Claim
17	addressing	N	I-Claim
18	physical	N	I-Claim
19	,	N	I-Claim
20	psychosocial	N	I-Claim
21	,	N	I-Claim
22	and	N	I-Claim
23	care	N	I-Claim
24	coordination	N	I-Claim
25	provided	N	I-Claim
26	concurrently	N	I-Claim
27	with	N	I-Claim
28	oncology	N	I-Claim
29	care	N	I-Claim
30	had	N	I-Claim
31	higher	N	I-Claim
32	scores	N	I-Claim
33	for	N	I-Claim
34	quality	N	I-Claim
35	of	N	I-Claim
36	life	N	I-Claim
37	and	N	I-Claim
38	mood	N	I-Claim
39	,	N	I-Claim
40	but	N	I-Claim
41	did	N	I-Claim
42	not	N	I-Claim
43	have	N	I-Claim
44	improvements	N	I-Claim
45	in	N	I-Claim
46	symptom	N	I-Claim
47	intensity	N	I-Claim
48	scores	N	I-Claim
49	or	N	I-Claim
50	reduced	N	I-Claim
51	days	N	I-Claim
52	in	N	I-Claim
53	the	N	I-Claim
54	hospital	N	I-Claim
55	or	N	I-Claim
56	ICU	N	I-Claim
57	or	N	I-Claim
58	emergency	N	I-Claim
59	department	N	I-Claim
60	visits	N	I-Claim
61	.	N	I-Claim

1	A	N	O
2	recent	N	O
3	randomized	N	O
4	trial	N	O
5	to	N	O
6	compare	N	O
7	external	N	O
8	beam	N	O
9	radiation	N	O
10	therapy	N	O
11	(	N	O
12	EBRT	N	O
13	)	N	O
14	to	N	O
15	cryoablation	N	O
16	for	N	O
17	localized	N	O
18	disease	N	O
19	showed	N	O
20	cryoablation	N	O
21	to	N	O
22	be	N	O
23	noninferior	N	O
24	to	N	O
25	external	N	O
26	beam	N	O
27	EBRT	N	O
28	in	N	O
29	disease	N	O
30	progression	N	O
31	and	N	O
32	overall	N	O
33	and	N	O
34	disease-specific	N	O
35	survival	N	O
36	.	N	O

1	We	N	O
2	report	N	O
3	on	N	O
4	the	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	(	N	O
9	QOL	N	O
10	)	N	O
11	outcomes	N	O
12	for	N	O
13	this	N	O
14	trial	N	O
15	.	N	O

1	From	N	O
2	December	N	O
3	1997	N	O
4	through	N	O
5	February	N	O
6	2003	N	O
7	,	N	O
8	244	N	O
9	men	N	O
10	with	N	O
11	newly	N	O
12	diagnosed	N	O
13	localized	N	O
14	prostate	N	O
15	cancer	N	O
16	were	N	O
17	randomly	N	O
18	assigned	N	O
19	to	N	O
20	cryoablation	N	O
21	or	N	O
22	EBRT	N	O
23	(	N	O
24	median	N	O
25	dose	N	O
26	68	N	O
27	Gy	N	O
28	)	N	O
29	.	N	O

1	All	N	O
2	patients	N	O
3	received	N	O
4	neoadjuvant	N	O
5	antiandrogen	N	O
6	therapy	N	O
7	.	N	O

1	Patients	N	O
2	completed	N	O
3	the	N	O
4	EORTC	N	O
5	QLQ	N	O
6	C30	N	O
7	and	N	O
8	the	N	O
9	Prostate	N	O
10	Cancer	N	O
11	Index	N	O
12	(	N	O
13	PCI	N	O
14	)	N	O
15	before	N	O
16	treatment	N	O
17	and	N	O
18	at	N	O
19	1.5	N	O
20	,	N	O
21	3	N	O
22	,	N	O
23	6	N	O
24	,	N	O
25	12	N	O
26	,	N	O
27	18	N	O
28	,	N	O
29	24	N	O
30	,	N	O
31	and	N	O
32	36	N	O
33	months	N	O
34	post-treatment	N	O
35	.	N	O

1	Regardless	N	I-Premise
2	of	N	I-Premise
3	treatment	N	I-Premise
4	arm	N	I-Premise
5	,	N	I-Premise
6	participants	N	I-Premise
7	reported	N	I-Premise
8	high	N	I-Premise
9	levels	N	I-Premise
10	of	N	I-Premise
11	QOL	N	I-Premise
12	with	N	I-Premise
13	few	N	I-Premise
14	exceptions	N	I-Premise
15	.	N	I-Premise

1	cryoablation	N	I-Premise
2	was	N	I-Premise
3	associated	N	I-Premise
4	with	N	I-Premise
5	more	N	I-Premise
6	acute	N	I-Premise
7	urinary	N	I-Premise
8	dysfunction	N	I-Premise
9	(	N	I-Premise
10	mean	N	I-Premise
11	PCI	N	I-Premise
12	urinary	N	I-Premise
13	function	N	I-Premise
14	cryoablation=69.4	N	I-Premise
15	;	N	I-Premise
16	mean	N	I-Premise
17	EBRT=90.7	N	I-Premise
18	;	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	.001	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	which	N	I-Premise
25	resolved	N	I-Premise
26	over	N	I-Premise
27	time	N	I-Premise
28	.	N	I-Premise

1	No	N	I-Premise
2	late	N	I-Premise
3	arising	N	I-Premise
4	QOL	N	I-Premise
5	issues	N	I-Premise
6	were	N	I-Premise
7	observed	N	I-Premise
8	.	N	I-Premise

1	Both	N	I-Premise
2	EBRT	N	I-Premise
3	and	N	I-Premise
4	cryoablation	N	I-Premise
5	participants	N	I-Premise
6	reported	N	I-Premise
7	decreases	N	I-Premise
8	in	N	I-Premise
9	sexual	N	I-Premise
10	function	N	I-Premise
11	at	N	I-Premise
12	3	N	I-Premise
13	months	N	I-Premise
14	with	N	I-Premise
15	the	N	I-Premise
16	cryoablation	N	I-Premise
17	patients	N	I-Premise
18	reporting	N	I-Premise
19	poorer	N	I-Premise
20	functioning	N	I-Premise
21	(	N	I-Premise
22	mean	N	I-Premise
23	cryoablation=7.2	N	I-Premise
24	:	N	I-Premise
25	mean	N	I-Premise
26	EBRT=32.9	N	I-Premise
27	;	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	.001	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Mean	N	I-Premise
2	sexual	N	I-Premise
3	function	N	I-Premise
4	score	N	I-Premise
5	was	N	I-Premise
6	15	N	I-Premise
7	points	N	I-Premise
8	lower	N	I-Premise
9	at	N	I-Premise
10	3	N	I-Premise
11	years	N	I-Premise
12	for	N	I-Premise
13	the	N	I-Premise
14	cryoablation	N	I-Premise
15	group	N	I-Premise
16	and	N	I-Premise
17	13	N	I-Premise
18	%	N	I-Premise
19	more	N	I-Premise
20	of	N	I-Premise
21	the	N	I-Premise
22	cryoablation	N	I-Premise
23	men	N	I-Premise
24	said	N	I-Premise
25	that	N	I-Premise
26	sexuality	N	I-Premise
27	was	N	I-Premise
28	a	N	I-Premise
29	moderate	N	I-Premise
30	or	N	I-Premise
31	big	N	I-Premise
32	problem	N	I-Premise
33	.	N	I-Premise

1	In	N	I-Claim
2	this	N	I-Claim
3	randomized	N	I-Claim
4	trial	N	I-Claim
5	,	N	I-Claim
6	no	N	I-Claim
7	long-term	N	I-Claim
8	QOL	N	I-Claim
9	advantage	N	I-Claim
10	for	N	I-Claim
11	either	N	I-Claim
12	treatment	N	I-Claim
13	was	N	I-Claim
14	apparent	N	I-Claim
15	with	N	I-Claim
16	the	N	I-Claim
17	exception	N	I-Claim
18	of	N	I-Claim
19	poorer	N	I-Claim
20	sexual	N	I-Claim
21	function	N	I-Claim
22	reported	N	I-Claim
23	by	N	I-Claim
24	those	N	I-Claim
25	treated	N	I-Claim
26	with	N	I-Claim
27	cryoablation	N	I-Claim
28	.	N	I-Claim

1	Men	N	O
2	who	N	O
3	wish	N	O
4	to	N	O
5	increase	N	O
6	their	N	O
7	odds	N	O
8	of	N	O
9	retaining	N	O
10	sexual	N	O
11	function	N	O
12	might	N	O
13	be	N	O
14	counseled	N	O
15	to	N	O
16	choose	N	O
17	EBRT	N	O
18	over	N	O
19	cryoablation	N	O
20	.	N	O

1	Gemcitabine	N	O
2	(	N	O
3	G	N	O
4	)	N	O
5	is	N	O
6	standard	N	O
7	therapy	N	O
8	for	N	O
9	pancreatic	N	O
10	cancer	N	O
11	.	N	O

1	Enzastaurin	N	O
2	(	N	O
3	E	N	O
4	)	N	O
5	inhibits	N	O
6	PKCβ	N	O
7	and	N	O
8	PI3K/AKT	N	O
9	signaling	N	O
10	pathways	N	O
11	with	N	O
12	a	N	O
13	dose-dependent	N	O
14	effect	N	O
15	on	N	O
16	growth	N	O
17	of	N	O
18	pancreatic	N	O
19	carcinoma	N	O
20	xenografts	N	O
21	.	N	O

1	Data	N	I-Claim
2	suggest	N	I-Claim
3	that	N	I-Claim
4	the	N	I-Claim
5	GE	N	I-Claim
6	combination	N	I-Claim
7	may	N	I-Claim
8	improve	N	I-Claim
9	clinical	N	I-Claim
10	outcomes	N	I-Claim
11	.	N	I-Claim

1	Primary	N	O
2	objective	N	O
3	was	N	O
4	overall	N	O
5	survival	N	O
6	(	N	O
7	OS	N	O
8	)	N	O
9	;	N	O
10	secondary	N	O
11	objectives	N	O
12	assessed	N	O
13	progression-free	N	O
14	survival	N	O
15	(	N	O
16	PFS	N	O
17	)	N	O
18	,	N	O
19	response	N	O
20	rate	N	O
21	(	N	O
22	RR	N	O
23	)	N	O
24	,	N	O
25	quality	N	O
26	of	N	O
27	life	N	O
28	(	N	O
29	QOL	N	O
30	)	N	O
31	,	N	O
32	toxicity	N	O
33	,	N	O
34	and	N	O
35	relationships	N	O
36	between	N	O
37	biomarker	N	O
38	expression	N	O
39	and	N	O
40	clinical	N	O
41	outcomes	N	O
42	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	(	N	O
6	2:1	N	O
7	)	N	O
8	to	N	O
9	GE	N	O
10	or	N	O
11	G	N	O
12	treatment	N	O
13	;	N	O
14	GE	N	O
15	arm	N	O
16	:	N	O
17	E	N	O
18	500	N	O
19	mg	N	O
20	p.o	N	O
21	.	N	O

1	daily	N	O
2	;	N	O
3	loading-dose	N	O
4	(	N	O
5	1200	N	O
6	mg	N	O
7	;	N	O
8	Day	N	O
9	1	N	O
10	Cycle	N	O
11	1	N	O
12	only	N	O
13	)	N	O
14	and	N	O
15	G	N	O
16	1000	N	O
17	mg/m	N	O
18	(	N	O
19	2	N	O
20	)	N	O
21	i.v	N	O
22	.	N	O

1	Days	N	O
2	1	N	O
3	,	N	O
4	8	N	O
5	,	N	O
6	and	N	O
7	15	N	O
8	in	N	O
9	28-day	N	O
10	cycles	N	O
11	;	N	O
12	G	N	O
13	arm	N	O
14	:	N	O
15	G	N	O
16	as	N	O
17	in	N	O
18	GE	N	O
19	.	N	O

1	Biomarker	N	O
2	expression	N	O
3	was	N	O
4	assessed	N	O
5	by	N	O
6	immunohistochemistry	N	O
7	.	N	O

1	Randomization	N	O
2	totaled	N	O
3	130	N	O
4	patients	N	O
5	(	N	O
6	GE	N	O
7	=	N	O
8	86	N	O
9	,	N	O
10	G	N	O
11	=	N	O
12	44	N	O
13	)	N	O
14	;	N	O
15	121	N	O
16	patients	N	O
17	were	N	O
18	treated	N	O
19	(	N	O
20	GE	N	O
21	=	N	O
22	82	N	O
23	,	N	O
24	G	N	O
25	=	N	O
26	39	N	O
27	)	N	O
28	.	N	O

1	GE/G	N	O
2	median	N	O
3	OS	N	O
4	was	N	O
5	5.6/5.1	N	O
6	months	N	O
7	;	N	O
8	median	N	O
9	PFS	N	O
10	was	N	O
11	3.4/3.0	N	O
12	months	N	O
13	.	N	O

1	GE	N	O
2	responses	N	O
3	:	N	O
4	1	N	O
5	complete	N	O
6	response	N	O
7	(	N	O
8	CR	N	O
9	,	N	O
10	1.2	N	O
11	%	N	O
12	)	N	O
13	,	N	O
14	6	N	O
15	partial	N	O
16	response	N	O
17	(	N	O
18	PR	N	O
19	,	N	O
20	7.4	N	O
21	%	N	O
22	)	N	O
23	,	N	O
24	and	N	O
25	33	N	O
26	stable	N	O
27	disease	N	O
28	(	N	O
29	SD	N	O
30	,	N	O
31	40.7	N	O
32	%	N	O
33	)	N	O
34	;	N	O
35	disease	N	O
36	control	N	O
37	rate	N	O
38	(	N	O
39	DCR=CR+PR+SD	N	O
40	,	N	O
41	49.4	N	O
42	%	N	O
43	)	N	O
44	.	N	O

1	G	N	O
2	responses	N	O
3	:	N	O
4	2	N	O
5	PR	N	O
6	(	N	O
7	5.3	N	O
8	%	N	O
9	)	N	O
10	and	N	O
11	16	N	O
12	SD	N	O
13	(	N	O
14	42.1	N	O
15	%	N	O
16	)	N	O
17	;	N	O
18	DCR	N	O
19	(	N	O
20	47.4	N	O
21	%	N	O
22	)	N	O
23	.	N	O

1	No	N	I-Premise
2	QOL	N	I-Premise
3	differences	N	I-Premise
4	were	N	I-Premise
5	noted	N	I-Premise
6	between	N	I-Premise
7	arms	N	I-Premise
8	.	N	I-Premise

1	GE/G	N	I-Premise
2	Grade	N	I-Premise
3	3-4	N	I-Premise
4	toxicities	N	I-Premise
5	included	N	I-Premise
6	:	N	I-Premise
7	neutropenia	N	I-Premise
8	(	N	I-Premise
9	18.3	N	I-Premise
10	%	N	I-Premise
11	/28.2	N	I-Premise
12	%	N	I-Premise
13	)	N	I-Premise
14	;	N	I-Premise
15	thrombocytopenia	N	I-Premise
16	(	N	I-Premise
17	14.6	N	I-Premise
18	%	N	I-Premise
19	/25.6	N	I-Premise
20	%	N	I-Premise
21	)	N	I-Premise
22	;	N	I-Premise
23	and	N	I-Premise
24	fatigue	N	I-Premise
25	(	N	I-Premise
26	11.0	N	I-Premise
27	%	N	I-Premise
28	/7.7	N	I-Premise
29	%	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	No	N	I-Premise
2	statistically	N	I-Premise
3	significant	N	I-Premise
4	relationships	N	I-Premise
5	between	N	I-Premise
6	biomarker	N	I-Premise
7	expression	N	I-Premise
8	and	N	I-Premise
9	outcomes	N	I-Premise
10	were	N	I-Premise
11	observed	N	I-Premise
12	.	N	I-Premise

1	However	N	O
2	,	N	O
3	patients	N	I-Premise
4	with	N	I-Premise
5	low	N	I-Premise
6	expression	N	I-Premise
7	of	N	I-Premise
8	cytoplasmic	N	I-Premise
9	pGSK-3β	N	I-Premise
10	trended	N	I-Premise
11	toward	N	I-Premise
12	greater	N	I-Premise
13	OS	N	I-Premise
14	with	N	I-Premise
15	GE	N	I-Premise
16	treatment	N	I-Premise
17	.	N	I-Premise

1	OS	N	I-Premise
2	,	N	I-Premise
3	PFS	N	I-Premise
4	,	N	I-Premise
5	QOL	N	I-Premise
6	,	N	I-Premise
7	and	N	I-Premise
8	RR	N	I-Premise
9	were	N	I-Premise
10	comparable	N	I-Premise
11	between	N	I-Premise
12	arms	N	I-Premise
13	.	N	I-Premise

1	Adding	N	I-Claim
2	E	N	I-Claim
3	to	N	I-Claim
4	G	N	I-Claim
5	did	N	I-Claim
6	not	N	I-Claim
7	increase	N	I-Claim
8	hematologic	N	I-Claim
9	toxicities	N	I-Claim
10	.	N	I-Claim

1	GE	N	O
2	does	N	O
3	not	N	O
4	warrant	N	O
5	further	N	O
6	investigation	N	O
7	in	N	O
8	unselected	N	O
9	pancreatic	N	O
10	cancer	N	O
11	patients	N	O
12	.	N	O

1	Assess	N	O
2	toxicity	N	O
3	and	N	O
4	efficacy	N	O
5	of	N	O
6	cisplatin	N	O
7	(	N	O
8	Cis	N	O
9	)	N	O
10	doublet	N	O
11	combinations	N	O
12	in	N	O
13	advanced	N	O
14	and	N	O
15	recurrent	N	O
16	cervical	N	O
17	carcinoma	N	O
18	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	paclitaxel	N	O
7	135	N	O
8	mg/m	N	O
9	(	N	O
10	2	N	O
11	)	N	O
12	over	N	O
13	24	N	O
14	hours	N	O
15	plus	N	O
16	Cis	N	O
17	50	N	O
18	mg/m	N	O
19	(	N	O
20	2	N	O
21	)	N	O
22	day	N	O
23	2	N	O
24	every	N	O
25	3	N	O
26	weeks	N	O
27	(	N	O
28	PC	N	O
29	,	N	O
30	reference	N	O
31	arm	N	O
32	)	N	O
33	;	N	O
34	vinorelbine	N	O
35	30	N	O
36	mg/m	N	O
37	(	N	O
38	2	N	O
39	)	N	O
40	days	N	O
41	1	N	O
42	and	N	O
43	8	N	O
44	plus	N	O
45	Cis	N	O
46	50	N	O
47	mg/m	N	O
48	(	N	O
49	2	N	O
50	)	N	O
51	day	N	O
52	1	N	O
53	every	N	O
54	3	N	O
55	weeks	N	O
56	(	N	O
57	VC	N	O
58	)	N	O
59	;	N	O
60	gemcitabine	N	O
61	1,000	N	O
62	mg/m	N	O
63	(	N	O
64	2	N	O
65	)	N	O
66	day	N	O
67	1	N	O
68	and	N	O
69	8	N	O
70	plus	N	O
71	Cis	N	O
72	50	N	O
73	mg/m	N	O
74	(	N	O
75	2	N	O
76	)	N	O
77	day	N	O
78	1	N	O
79	every	N	O
80	3	N	O
81	weeks	N	O
82	(	N	O
83	GC	N	O
84	)	N	O
85	;	N	O
86	or	N	O
87	topotecan	N	O
88	0.75	N	O
89	mg/m	N	O
90	(	N	O
91	2	N	O
92	)	N	O
93	days	N	O
94	1	N	O
95	,	N	O
96	2	N	O
97	,	N	O
98	and	N	O
99	3	N	O
100	plus	N	O
101	Cis	N	O
102	50	N	O
103	mg/m	N	O
104	(	N	O
105	2	N	O
106	)	N	O
107	day	N	O
108	1	N	O
109	every	N	O
110	3	N	O
111	weeks	N	O
112	(	N	O
113	TC	N	O
114	)	N	O
115	.	N	O

1	Survival	N	O
2	was	N	O
3	the	N	O
4	primary	N	O
5	end	N	O
6	point	N	O
7	with	N	O
8	a	N	O
9	33	N	O
10	%	N	O
11	improvement	N	O
12	relative	N	O
13	to	N	O
14	PC	N	O
15	considered	N	O
16	important	N	O
17	(	N	O
18	85	N	O
19	%	N	O
20	power	N	O
21	,	N	O
22	alpha	N	O
23	=	N	O
24	5	N	O
25	%	N	O
26	)	N	O
27	.	N	O

1	Quality-of-life	N	O
2	data	N	O
3	were	N	O
4	prospectively	N	O
5	collected	N	O
6	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	513	N	O
5	patients	N	O
6	were	N	O
7	enrolled	N	O
8	when	N	O
9	a	N	O
10	planned	N	O
11	interim	N	O
12	analysis	N	O
13	recommended	N	O
14	early	N	O
15	closure	N	O
16	for	N	O
17	futility	N	O
18	.	N	O

1	The	N	I-Premise
2	experimental-to-PC	N	I-Premise
3	hazard	N	I-Premise
4	ratios	N	I-Premise
5	of	N	I-Premise
6	death	N	I-Premise
7	were	N	I-Premise
8	1.15	N	I-Premise
9	(	N	I-Premise
10	95	N	I-Premise
11	%	N	I-Premise
12	CI	N	I-Premise
13	,	N	I-Premise
14	0.79	N	I-Premise
15	to	N	I-Premise
16	1.67	N	I-Premise
17	)	N	I-Premise
18	for	N	I-Premise
19	VC	N	I-Premise
20	,	N	I-Premise
21	1.32	N	I-Premise
22	(	N	I-Premise
23	95	N	I-Premise
24	%	N	I-Premise
25	CI	N	I-Premise
26	,	N	I-Premise
27	0.91	N	I-Premise
28	to	N	I-Premise
29	1.92	N	I-Premise
30	)	N	I-Premise
31	for	N	I-Premise
32	GC	N	I-Premise
33	,	N	I-Premise
34	and	N	I-Premise
35	1.26	N	I-Premise
36	(	N	I-Premise
37	95	N	I-Premise
38	%	N	I-Premise
39	CI	N	I-Premise
40	,	N	I-Premise
41	0.86	N	I-Premise
42	to	N	I-Premise
43	1.82	N	I-Premise
44	)	N	I-Premise
45	for	N	I-Premise
46	TC	N	I-Premise
47	.	N	I-Premise

1	The	N	I-Premise
2	hazard	N	I-Premise
3	ratios	N	I-Premise
4	for	N	I-Premise
5	progression-free	N	I-Premise
6	survival	N	I-Premise
7	(	N	I-Premise
8	PFS	N	I-Premise
9	)	N	I-Premise
10	were	N	I-Premise
11	1.36	N	I-Premise
12	(	N	I-Premise
13	95	N	I-Premise
14	%	N	I-Premise
15	CI	N	I-Premise
16	,	N	I-Premise
17	0.97	N	I-Premise
18	to	N	I-Premise
19	1.90	N	I-Premise
20	)	N	I-Premise
21	for	N	I-Premise
22	VC	N	I-Premise
23	,	N	I-Premise
24	1.39	N	I-Premise
25	(	N	I-Premise
26	95	N	I-Premise
27	%	N	I-Premise
28	CI	N	I-Premise
29	,	N	I-Premise
30	0.99	N	I-Premise
31	to	N	I-Premise
32	1.96	N	I-Premise
33	)	N	I-Premise
34	for	N	I-Premise
35	GC	N	I-Premise
36	,	N	I-Premise
37	and	N	I-Premise
38	1.27	N	I-Premise
39	(	N	I-Premise
40	95	N	I-Premise
41	%	N	I-Premise
42	CI	N	I-Premise
43	,	N	I-Premise
44	0.90	N	I-Premise
45	to	N	I-Premise
46	1.78	N	I-Premise
47	)	N	I-Premise
48	for	N	I-Premise
49	TC	N	I-Premise
50	.	N	I-Premise

1	Response	N	I-Premise
2	rates	N	I-Premise
3	(	N	I-Premise
4	RRs	N	I-Premise
5	)	N	I-Premise
6	for	N	I-Premise
7	PC	N	I-Premise
8	,	N	I-Premise
9	VC	N	I-Premise
10	,	N	I-Premise
11	GC	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	TC	N	I-Premise
15	were	N	I-Premise
16	29.1	N	I-Premise
17	%	N	I-Premise
18	,	N	I-Premise
19	25.9	N	I-Premise
20	%	N	I-Premise
21	,	N	I-Premise
22	22.3	N	I-Premise
23	%	N	I-Premise
24	,	N	I-Premise
25	and	N	I-Premise
26	23.4	N	I-Premise
27	%	N	I-Premise
28	,	N	I-Premise
29	respectively	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Premise
2	arms	N	I-Premise
3	were	N	I-Premise
4	comparable	N	I-Premise
5	with	N	I-Premise
6	respect	N	I-Premise
7	to	N	I-Premise
8	toxicity	N	I-Premise
9	except	N	I-Premise
10	for	N	I-Premise
11	leucopenia	N	I-Premise
12	,	N	I-Premise
13	neutropenia	N	I-Premise
14	,	N	I-Premise
15	infection	N	I-Premise
16	,	N	I-Premise
17	and	N	I-Premise
18	alopecia	N	I-Premise
19	.	N	I-Premise

1	VC	N	I-Claim
2	,	N	I-Claim
3	GC	N	I-Claim
4	,	N	I-Claim
5	and	N	I-Claim
6	TC	N	I-Claim
7	are	N	I-Claim
8	not	N	I-Claim
9	superior	N	I-Claim
10	to	N	I-Claim
11	PC	N	I-Claim
12	in	N	I-Claim
13	terms	N	I-Claim
14	of	N	I-Claim
15	overall	N	I-Claim
16	survival	N	I-Claim
17	(	N	I-Claim
18	OS	N	I-Claim
19	)	N	I-Claim
20	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	the	N	I-Claim
4	trend	N	I-Claim
5	in	N	I-Claim
6	RR	N	I-Claim
7	,	N	I-Claim
8	PFS	N	I-Claim
9	,	N	I-Claim
10	and	N	I-Claim
11	OS	N	I-Claim
12	favors	N	I-Claim
13	PC	N	I-Claim
14	.	N	I-Claim

1	Differences	N	I-MajorClaim
2	in	N	I-MajorClaim
3	chemotherapy	N	I-MajorClaim
4	scheduling	N	I-MajorClaim
5	,	N	I-MajorClaim
6	pre-existing	N	I-MajorClaim
7	morbidity	N	I-MajorClaim
8	,	N	I-MajorClaim
9	and	N	I-MajorClaim
10	toxicity	N	I-MajorClaim
11	are	N	I-MajorClaim
12	important	N	I-MajorClaim
13	in	N	I-MajorClaim
14	individualizing	N	I-MajorClaim
15	therapy	N	I-MajorClaim
16	.	N	I-MajorClaim

1	A	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	was	N	O
6	performed	N	O
7	to	N	O
8	assess	N	O
9	the	N	O
10	outcome	N	O
11	of	N	O
12	early	N	O
13	oral	N	O
14	postoperative	N	O
15	feeding	N	O
16	(	N	O
17	EOF	N	O
18	)	N	O
19	compared	N	O
20	with	N	O
21	traditional	N	O
22	oral	N	O
23	feeding	N	O
24	(	N	O
25	TOF	N	O
26	)	N	O
27	in	N	O
28	gynecologic	N	O
29	oncology	N	O
30	patients	N	O
31	undergoing	N	O
32	a	N	O
33	complex	N	O
34	laparotomy	N	O
35	,	N	O
36	including	N	O
37	upper	N	O
38	abdominal	N	O
39	surgery	N	O
40	.	N	O

1	Patients	N	O
2	aged	N	O
3	18-75	N	O
4	years	N	O
5	,	N	O
6	undergoing	N	O
7	an	N	O
8	elective	N	O
9	laparotomy	N	O
10	and	N	O
11	with	N	O
12	a	N	O
13	preoperative	N	O
14	suspicion	N	O
15	of	N	O
16	gynecologic	N	O
17	malignancy	N	O
18	,	N	O
19	were	N	O
20	eligible	N	O
21	.	N	O

1	Exclusion	N	O
2	criteria	N	O
3	included	N	O
4	infectious	N	O
5	conditions	N	O
6	,	N	O
7	intestinal	N	O
8	obstruction	N	O
9	,	N	O
10	severe	N	O
11	malnutrition	N	O
12	,	N	O
13	American	N	O
14	Society	N	O
15	of	N	O
16	Anesthesiologists	N	O
17	score	N	O
18	C4	N	O
19	,	N	O
20	intestinal	N	O
21	resection	N	O
22	,	N	O
23	and	N	O
24	postoperative	N	O
25	stay	N	O
26	in	N	O
27	the	N	O
28	intensive	N	O
29	care	N	O
30	unit	N	O
31	lasting	N	O
32	24	N	O
33	h.	N	O
34	Patients	N	O
35	allocated	N	O
36	to	N	O
37	EOF	N	O
38	received	N	O
39	liquid	N	O
40	diet	N	O
41	in	N	O
42	the	N	O
43	first	N	O
44	postoperative	N	O
45	day	N	O
46	and	N	O
47	then	N	O
48	regular	N	O
49	diet	N	O
50	.	N	O

1	Patients	N	O
2	received	N	O
3	traditional	N	O
4	feeding	N	O
5	scheme	N	O
6	until	N	O
7	resolution	N	O
8	of	N	O
9	postoperative	N	O
10	ileus	N	O
11	to	N	O
12	start	N	O
13	liquid	N	O
14	diet	N	O
15	.	N	O

1	The	N	O
2	primary	N	O
3	end-point	N	O
4	of	N	O
5	the	N	O
6	trial	N	O
7	was	N	O
8	length	N	O
9	of	N	O
10	hospital	N	O
11	stay	N	O
12	.	N	O

1	Between	N	O
2	January	N	O
3	1	N	O
4	,	N	O
5	2007	N	O
6	,	N	O
7	and	N	O
8	November	N	O
9	17	N	O
10	,	N	O
11	2007	N	O
12	,	N	O
13	a	N	O
14	total	N	O
15	of	N	O
16	143	N	O
17	patients	N	O
18	were	N	O
19	randomized	N	O
20	to	N	O
21	receive	N	O
22	either	N	O
23	EOF	N	O
24	or	N	O
25	TOF	N	O
26	.	N	O

1	Hospital	N	I-Premise
2	stay	N	I-Premise
3	for	N	I-Premise
4	patients	N	I-Premise
5	who	N	I-Premise
6	received	N	I-Premise
7	EOF	N	I-Premise
8	(	N	I-Premise
9	n=71	N	I-Premise
10	)	N	I-Premise
11	was	N	I-Premise
12	4.7	N	I-Premise
13	vs.	N	I-Premise
14	5.8	N	I-Premise
15	days	N	I-Premise
16	for	N	I-Premise
17	the	N	I-Premise
18	TOF	N	I-Premise
19	group	N	I-Premise
20	(	N	I-Premise
21	n=72	N	I-Premise
22	)	N	I-Premise
23	(	N	I-Premise
24	P=0.006	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	The	N	I-Premise
2	mean	N	I-Premise
3	level	N	I-Premise
4	of	N	I-Premise
5	postoperative	N	I-Premise
6	satisfaction	N	I-Premise
7	was	N	I-Premise
8	significantly	N	I-Premise
9	higher	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	EOF	N	I-Premise
13	group	N	I-Premise
14	(	N	I-Premise
15	82.8	N	I-Premise
16	vs.	N	I-Premise
17	71.7	N	I-Premise
18	mm	N	I-Premise
19	,	N	I-Premise
20	P	N	I-Premise
21	B	N	I-Premise
22	0.001	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Patients	N	I-Premise
2	who	N	I-Premise
3	received	N	I-Premise
4	the	N	I-Premise
5	TOF	N	I-Premise
6	scheme	N	I-Premise
7	had	N	I-Premise
8	significantly	N	I-Premise
9	higher	N	I-Premise
10	overall	N	I-Premise
11	postoperative	N	I-Premise
12	complications	N	I-Premise
13	(	N	I-Premise
14	39	N	I-Premise
15	vs.	N	I-Premise
16	17	N	I-Premise
17	%	N	I-Premise
18	in	N	I-Premise
19	EOF	N	I-Premise
20	group	N	I-Premise
21	,	N	I-Premise
22	P=0.003	N	I-Premise
23	)	N	I-Premise
24	and	N	I-Premise
25	infective	N	I-Premise
26	complications	N	I-Premise
27	(	N	I-Premise
28	14	N	I-Premise
29	%	N	I-Premise
30	in	N	I-Premise
31	TOF	N	I-Premise
32	group	N	I-Premise
33	vs.	N	I-Premise
34	3	N	I-Premise
35	%	N	I-Premise
36	in	N	I-Premise
37	EOF	N	I-Premise
38	group	N	I-Premise
39	,	N	I-Premise
40	P=0.017	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	Variables	N	I-Premise
2	such	N	I-Premise
3	as	N	I-Premise
4	nausea	N	I-Premise
5	and	N	I-Premise
6	vomiting	N	I-Premise
7	,	N	I-Premise
8	analgesic	N	I-Premise
9	and	N	I-Premise
10	antiemetic	N	I-Premise
11	requirement	N	I-Premise
12	as	N	I-Premise
13	well	N	I-Premise
14	as	N	I-Premise
15	level	N	I-Premise
16	of	N	I-Premise
17	pain	N	I-Premise
18	and	N	I-Premise
19	quality	N	I-Premise
20	of	N	I-Premise
21	life	N	I-Premise
22	were	N	I-Premise
23	not	N	I-Premise
24	different	N	I-Premise
25	between	N	I-Premise
26	groups	N	I-Premise
27	.	N	I-Premise

1	On	N	I-Claim
2	the	N	I-Claim
3	basis	N	I-Claim
4	of	N	I-Claim
5	these	N	I-Claim
6	findings	N	I-Claim
7	,	N	I-Claim
8	the	N	I-Claim
9	policy	N	I-Claim
10	of	N	I-Claim
11	EOF	N	I-Claim
12	should	N	I-Claim
13	be	N	I-Claim
14	used	N	I-Claim
15	after	N	I-Claim
16	a	N	I-Claim
17	complex	N	I-Claim
18	gynecologic	N	I-Claim
19	oncologic	N	I-Claim
20	laparotomy	N	I-Claim
21	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	a	N	O
7	multimodal	N	O
8	group	N	O
9	exercise	N	O
10	intervention	N	O
11	,	N	O
12	as	N	O
13	an	N	O
14	adjunct	N	O
15	to	N	O
16	conventional	N	O
17	care	N	O
18	,	N	O
19	on	N	O
20	fatigue	N	O
21	,	N	O
22	physical	N	O
23	capacity	N	O
24	,	N	O
25	general	N	O
26	wellbeing	N	O
27	,	N	O
28	physical	N	O
29	activity	N	O
30	,	N	O
31	and	N	O
32	quality	N	O
33	of	N	O
34	life	N	O
35	in	N	O
36	patients	N	O
37	with	N	O
38	cancer	N	O
39	who	N	O
40	were	N	O
41	undergoing	N	O
42	adjuvant	N	O
43	chemotherapy	N	O
44	or	N	O
45	treatment	N	O
46	for	N	O
47	advanced	N	O
48	disease	N	O
49	.	N	O

1	Randomised	N	O
2	controlled	N	O
3	trial	N	O
4	.	N	O

1	Two	N	O
2	university	N	O
3	hospitals	N	O
4	in	N	O
5	Copenhagen	N	O
6	,	N	O
7	Denmark	N	O
8	.	N	O

1	269	N	O
2	patients	N	O
3	with	N	O
4	cancer	N	O
5	;	N	O
6	73	N	O
7	men	N	O
8	,	N	O
9	196	N	O
10	women	N	O
11	,	N	O
12	mean	N	O
13	age	N	O
14	47	N	O
15	years	N	O
16	(	N	O
17	range	N	O
18	20-65	N	O
19	)	N	O
20	representing	N	O
21	21	N	O
22	diagnoses	N	O
23	.	N	O

1	Main	N	O
2	exclusion	N	O
3	criteria	N	O
4	were	N	O
5	brain	N	O
6	or	N	O
7	bone	N	O
8	metastases	N	O
9	.	N	O

1	235	N	O
2	patients	N	O
3	completed	N	O
4	follow-up	N	O
5	.	N	O

1	Supervised	N	O
2	exercise	N	O
3	comprising	N	O
4	high	N	O
5	intensity	N	O
6	cardiovascular	N	O
7	and	N	O
8	resistance	N	O
9	training	N	O
10	,	N	O
11	relaxation	N	O
12	and	N	O
13	body	N	O
14	awareness	N	O
15	training	N	O
16	,	N	O
17	massage	N	O
18	,	N	O
19	nine	N	O
20	hours	N	O
21	weekly	N	O
22	for	N	O
23	six	N	O
24	weeks	N	O
25	in	N	O
26	addition	N	O
27	to	N	O
28	conventional	N	O
29	care	N	O
30	,	N	O
31	compared	N	O
32	with	N	O
33	conventional	N	O
34	care	N	O
35	.	N	O

1	The	N	O
2	general	N	O
3	linear	N	O
4	model	N	O
5	was	N	O
6	used	N	O
7	for	N	O
8	continuous	N	O
9	outcome	N	O
10	while	N	O
11	analysis	N	O
12	of	N	O
13	associates	N	O
14	between	N	O
15	categorical	N	O
16	outcomes	N	O
17	was	N	O
18	performed	N	O
19	as	N	O
20	analysis	N	O
21	of	N	O
22	marginal	N	O
23	homogeneity	N	O
24	in	N	O
25	contingency	N	O
26	tables	N	O
27	.	N	O

1	Adjusted	N	I-Premise
2	for	N	I-Premise
3	baseline	N	I-Premise
4	score	N	I-Premise
5	,	N	I-Premise
6	disease	N	I-Premise
7	,	N	I-Premise
8	and	N	I-Premise
9	demographic	N	I-Premise
10	covariates	N	I-Premise
11	,	N	I-Premise
12	the	N	I-Premise
13	intervention	N	I-Premise
14	group	N	I-Premise
15	showed	N	I-Premise
16	an	N	I-Premise
17	estimated	N	I-Premise
18	improvement	N	I-Premise
19	at	N	I-Premise
20	six	N	I-Premise
21	weeks	N	I-Premise
22	for	N	I-Premise
23	the	N	I-Premise
24	primary	N	I-Premise
25	outcome	N	I-Premise
26	,	N	I-Premise
27	fatigue	N	I-Premise
28	,	N	I-Premise
29	of	N	I-Premise
30	-6.6	N	I-Premise
31	points	N	I-Premise
32	(	N	I-Premise
33	95	N	I-Premise
34	%	N	I-Premise
35	confidence	N	I-Premise
36	interval	N	I-Premise
37	-12.3	N	I-Premise
38	to	N	I-Premise
39	-0.9	N	I-Premise
40	,	N	I-Premise
41	P=0.02	N	I-Premise
42	;	N	I-Premise
43	effect	N	I-Premise
44	size=0.33	N	I-Premise
45	,	N	I-Premise
46	0.04	N	I-Premise
47	to	N	I-Premise
48	0.61	N	I-Premise
49	)	N	I-Premise
50	.	N	I-Premise

1	Significant	N	I-Premise
2	effects	N	I-Premise
3	were	N	I-Premise
4	seen	N	I-Premise
5	on	N	I-Premise
6	vitality	N	I-Premise
7	(	N	I-Premise
8	effect	N	I-Premise
9	size	N	I-Premise
10	0.55	N	I-Premise
11	,	N	I-Premise
12	95	N	I-Premise
13	%	N	I-Premise
14	CI	N	I-Premise
15	0.27	N	I-Premise
16	to	N	I-Premise
17	0.82	N	I-Premise
18	)	N	I-Premise
19	,	N	I-Premise
20	physical	N	I-Premise
21	functioning	N	I-Premise
22	(	N	I-Premise
23	0.37	N	I-Premise
24	,	N	I-Premise
25	0.09	N	I-Premise
26	to	N	I-Premise
27	0.65	N	I-Premise
28	)	N	I-Premise
29	,	N	I-Premise
30	role	N	I-Premise
31	physical	N	I-Premise
32	(	N	I-Premise
33	0.37	N	I-Premise
34	,	N	I-Premise
35	0.10	N	I-Premise
36	to	N	I-Premise
37	0.64	N	I-Premise
38	)	N	I-Premise
39	,	N	I-Premise
40	role	N	I-Premise
41	emotional	N	I-Premise
42	(	N	I-Premise
43	0.32	N	I-Premise
44	,	N	I-Premise
45	0.05	N	I-Premise
46	to	N	I-Premise
47	0.59	N	I-Premise
48	)	N	I-Premise
49	,	N	I-Premise
50	and	N	I-Premise
51	mental	N	I-Premise
52	health	N	I-Premise
53	(	N	I-Premise
54	0.28	N	I-Premise
55	,	N	I-Premise
56	0.02	N	I-Premise
57	to	N	I-Premise
58	0.56	N	I-Premise
59	)	N	I-Premise
60	scores	N	I-Premise
61	.	N	I-Premise

1	Improvement	N	I-Premise
2	was	N	I-Premise
3	noted	N	I-Premise
4	in	N	I-Premise
5	physical	N	I-Premise
6	capacity	N	I-Premise
7	:	N	I-Premise
8	estimated	N	I-Premise
9	mean	N	I-Premise
10	difference	N	I-Premise
11	between	N	I-Premise
12	groups	N	I-Premise
13	for	N	I-Premise
14	maximum	N	I-Premise
15	oxygen	N	I-Premise
16	consumption	N	I-Premise
17	was	N	I-Premise
18	0.16	N	I-Premise
19	l/min	N	I-Premise
20	(	N	I-Premise
21	95	N	I-Premise
22	%	N	I-Premise
23	CI	N	I-Premise
24	0.1	N	I-Premise
25	to	N	I-Premise
26	0.2	N	I-Premise
27	,	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	0.0001	N	I-Premise
31	)	N	I-Premise
32	and	N	I-Premise
33	for	N	I-Premise
34	muscular	N	I-Premise
35	strength	N	I-Premise
36	(	N	I-Premise
37	leg	N	I-Premise
38	press	N	I-Premise
39	)	N	I-Premise
40	was	N	I-Premise
41	29.7	N	I-Premise
42	kg	N	I-Premise
43	(	N	I-Premise
44	23.4	N	I-Premise
45	to	N	I-Premise
46	34.9	N	I-Premise
47	,	N	I-Premise
48	P	N	I-Premise
49	<	N	I-Premise
50	0.0001	N	I-Premise
51	)	N	I-Premise
52	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	effect	N	I-Premise
4	was	N	I-Premise
5	seen	N	I-Premise
6	on	N	I-Premise
7	global	N	I-Premise
8	health	N	I-Premise
9	status/quality	N	I-Premise
10	of	N	I-Premise
11	life	N	I-Premise
12	.	N	I-Premise

1	A	N	I-Claim
2	supervised	N	I-Claim
3	multimodal	N	I-Claim
4	exercise	N	I-Claim
5	intervention	N	I-Claim
6	including	N	I-Claim
7	high	N	I-Claim
8	and	N	I-Claim
9	low	N	I-Claim
10	intensity	N	I-Claim
11	components	N	I-Claim
12	was	N	I-Claim
13	feasible	N	I-Claim
14	and	N	I-Claim
15	could	N	I-Claim
16	safely	N	I-Claim
17	be	N	I-Claim
18	used	N	I-Claim
19	in	N	I-Claim
20	patients	N	I-Claim
21	with	N	I-Claim
22	various	N	I-Claim
23	cancers	N	I-Claim
24	who	N	I-Claim
25	were	N	I-Claim
26	receiving	N	I-Claim
27	adjuvant	N	I-Claim
28	chemotherapy	N	I-Claim
29	or	N	I-Claim
30	treatment	N	I-Claim
31	for	N	I-Claim
32	advanced	N	I-Claim
33	disease	N	I-Claim
34	.	N	I-Claim

1	The	N	I-Claim
2	intervention	N	I-Claim
3	reduced	N	I-Claim
4	fatigue	N	I-Claim
5	and	N	I-Claim
6	improved	N	I-Claim
7	vitality	N	I-Claim
8	,	N	I-Claim
9	aerobic	N	I-Claim
10	capacity	N	I-Claim
11	,	N	I-Claim
12	muscular	N	I-Claim
13	strength	N	I-Claim
14	,	N	I-Claim
15	and	N	I-Claim
16	physical	N	I-Claim
17	and	N	I-Claim
18	functional	N	I-Claim
19	activity	N	I-Claim
20	,	N	I-Claim
21	and	N	I-Claim
22	emotional	N	I-Claim
23	wellbeing	N	I-Claim
24	,	N	I-Claim
25	but	N	I-Claim
26	not	N	I-Claim
27	quality	N	I-Claim
28	of	N	I-Claim
29	life	N	I-Claim
30	.	N	I-Claim

1	Depression	N	O
2	is	N	O
3	common	N	O
4	among	N	O
5	older	N	O
6	cancer	N	O
7	patients	N	O
8	,	N	O
9	but	N	O
10	little	N	O
11	is	N	O
12	known	N	O
13	about	N	O
14	the	N	O
15	optimal	N	O
16	approach	N	O
17	to	N	O
18	caring	N	O
19	for	N	O
20	this	N	O
21	population	N	O
22	.	N	O

1	This	N	O
2	analysis	N	O
3	evaluates	N	O
4	the	N	O
5	effectiveness	N	O
6	of	N	O
7	the	N	O
8	Improving	N	O
9	Mood-Promoting	N	O
10	Access	N	O
11	to	N	O
12	Collaborative	N	O
13	Treatment	N	O
14	(	N	O
15	IMPACT	N	O
16	)	N	O
17	program	N	O
18	,	N	O
19	a	N	O
20	stepped	N	O
21	care	N	O
22	management	N	O
23	program	N	O
24	for	N	O
25	depression	N	O
26	in	N	O
27	primary	N	O
28	care	N	O
29	patients	N	O
30	who	N	O
31	had	N	O
32	an	N	O
33	ICD-9	N	O
34	cancer	N	O
35	diagnosis	N	O
36	.	N	O

1	Two	N	O
2	hundred	N	O
3	fifteen	N	O
4	cancer	N	O
5	patients	N	O
6	were	N	O
7	identified	N	O
8	from	N	O
9	the	N	O
10	1,801	N	O
11	participants	N	O
12	in	N	O
13	the	N	O
14	parent	N	O
15	study	N	O
16	.	N	O

1	Subjects	N	O
2	were	N	O
3	60	N	O
4	years	N	O
5	or	N	O
6	older	N	O
7	with	N	O
8	major	N	O
9	depression	N	O
10	(	N	O
11	18	N	O
12	%	N	O
13	)	N	O
14	,	N	O
15	dysthymic	N	O
16	disorder	N	O
17	(	N	O
18	33	N	O
19	%	N	O
20	)	N	O
21	,	N	O
22	or	N	O
23	both	N	O
24	(	N	O
25	49	N	O
26	%	N	O
27	)	N	O
28	,	N	O
29	recruited	N	O
30	from	N	O
31	18	N	O
32	primary	N	O
33	care	N	O
34	clinics	N	O
35	belonging	N	O
36	to	N	O
37	8	N	O
38	health-care	N	O
39	organizations	N	O
40	in	N	O
41	5	N	O
42	states	N	O
43	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	the	N	O
7	IMPACT	N	O
8	intervention	N	O
9	(	N	O
10	n	N	O
11	=	N	O
12	112	N	O
13	)	N	O
14	or	N	O
15	usual	N	O
16	care	N	O
17	(	N	O
18	n	N	O
19	=	N	O
20	103	N	O
21	)	N	O
22	.	N	O

1	Intervention	N	O
2	patients	N	O
3	had	N	O
4	access	N	O
5	for	N	O
6	up	N	O
7	to	N	O
8	12	N	O
9	months	N	O
10	to	N	O
11	a	N	O
12	depression	N	O
13	care	N	O
14	manager	N	O
15	who	N	O
16	was	N	O
17	supervised	N	O
18	by	N	O
19	a	N	O
20	psychiatrist	N	O
21	and	N	O
22	a	N	O
23	primary	N	O
24	care	N	O
25	provider	N	O
26	and	N	O
27	who	N	O
28	offered	N	O
29	education	N	O
30	,	N	O
31	care	N	O
32	management	N	O
33	,	N	O
34	support	N	O
35	of	N	O
36	antidepressant	N	O
37	management	N	O
38	,	N	O
39	and	N	O
40	brief	N	O
41	,	N	O
42	structured	N	O
43	psychosocial	N	O
44	interventions	N	O
45	including	N	O
46	behavioral	N	O
47	activation	N	O
48	and	N	O
49	problem-solving	N	O
50	treatment	N	O
51	.	N	O

1	At	N	I-Premise
2	6	N	I-Premise
3	and	N	I-Premise
4	12	N	I-Premise
5	months	N	I-Premise
6	,	N	I-Premise
7	55	N	I-Premise
8	%	N	I-Premise
9	and	N	I-Premise
10	39	N	I-Premise
11	%	N	I-Premise
12	of	N	I-Premise
13	intervention	N	I-Premise
14	patients	N	I-Premise
15	had	N	I-Premise
16	a	N	I-Premise
17	50	N	I-Premise
18	%	N	I-Premise
19	or	N	I-Premise
20	greater	N	I-Premise
21	reduction	N	I-Premise
22	in	N	I-Premise
23	depressive	N	I-Premise
24	symptoms	N	I-Premise
25	(	N	I-Premise
26	SCL-20	N	I-Premise
27	)	N	I-Premise
28	from	N	I-Premise
29	baseline	N	I-Premise
30	compared	N	I-Premise
31	to	N	I-Premise
32	34	N	I-Premise
33	%	N	I-Premise
34	and	N	I-Premise
35	20	N	I-Premise
36	%	N	I-Premise
37	of	N	I-Premise
38	usual	N	I-Premise
39	care	N	I-Premise
40	participants	N	I-Premise
41	(	N	I-Premise
42	P	N	I-Premise
43	=	N	I-Premise
44	0.003	N	I-Premise
45	and	N	I-Premise
46	P	N	I-Premise
47	=	N	I-Premise
48	0.029	N	I-Premise
49	)	N	I-Premise
50	.	N	I-Premise

1	Intervention	N	I-Premise
2	patients	N	I-Premise
3	also	N	I-Premise
4	experienced	N	I-Premise
5	greater	N	I-Premise
6	remission	N	I-Premise
7	rates	N	I-Premise
8	(	N	I-Premise
9	P	N	I-Premise
10	=	N	I-Premise
11	0.031	N	I-Premise
12	)	N	I-Premise
13	,	N	I-Premise
14	more	N	I-Premise
15	depression-free	N	I-Premise
16	days	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	<	N	I-Premise
20	0.001	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	less	N	I-Premise
24	functional	N	I-Premise
25	impairment	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	=	N	I-Premise
29	0.011	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	and	N	I-Premise
33	greater	N	I-Premise
34	quality	N	I-Premise
35	of	N	I-Premise
36	life	N	I-Premise
37	(	N	I-Premise
38	P	N	I-Premise
39	=	N	I-Premise
40	0.039	N	I-Premise
41	)	N	I-Premise
42	at	N	I-Premise
43	12	N	I-Premise
44	months	N	I-Premise
45	than	N	I-Premise
46	usual	N	I-Premise
47	care	N	I-Premise
48	participants	N	I-Premise
49	.	N	I-Premise

1	The	N	I-Claim
2	IMPACT	N	I-Claim
3	collaborative	N	I-Claim
4	care	N	I-Claim
5	program	N	I-Claim
6	appears	N	I-Claim
7	to	N	I-Claim
8	be	N	I-Claim
9	feasible	N	I-Claim
10	and	N	I-Claim
11	effective	N	I-Claim
12	for	N	I-Claim
13	depression	N	I-Claim
14	among	N	I-Claim
15	older	N	I-Claim
16	cancer	N	I-Claim
17	patients	N	I-Claim
18	in	N	I-Claim
19	diverse	N	I-Claim
20	primary	N	I-Claim
21	care	N	I-Claim
22	settings	N	I-Claim
23	.	N	I-Claim

1	Both	N	O
2	gemcitabine	N	O
3	(	N	O
4	GEM	N	O
5	)	N	O
6	and	N	O
7	fluoropyrimidines	N	O
8	are	N	O
9	valuable	N	O
10	treatment	N	O
11	for	N	O
12	advanced	N	O
13	pancreatic	N	O
14	cancer	N	O
15	.	N	O

1	This	N	O
2	open-label	N	O
3	study	N	O
4	was	N	O
5	designed	N	O
6	to	N	O
7	compare	N	O
8	the	N	O
9	overall	N	O
10	survival	N	O
11	(	N	O
12	OS	N	O
13	)	N	O
14	of	N	O
15	patients	N	O
16	randomly	N	O
17	assigned	N	O
18	to	N	O
19	GEM	N	O
20	alone	N	O
21	or	N	O
22	GEM	N	O
23	plus	N	O
24	capecitabine	N	O
25	(	N	O
26	GEM-CAP	N	O
27	)	N	O
28	.	N	O

1	Patients	N	O
2	with	N	O
3	previously	N	O
4	untreated	N	O
5	histologically	N	O
6	or	N	O
7	cytologically	N	O
8	proven	N	O
9	locally	N	O
10	advanced	N	O
11	or	N	O
12	metastatic	N	O
13	carcinoma	N	O
14	of	N	O
15	the	N	O
16	pancreas	N	O
17	with	N	O
18	a	N	O
19	performance	N	O
20	status	N	O
21	<	N	O
22	or=	N	O
23	2	N	O
24	were	N	O
25	recruited	N	O
26	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	GEM	N	O
7	or	N	O
8	GEM-CAP	N	O
9	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	measure	N	O
5	was	N	O
6	survival	N	O
7	.	N	O

1	Meta-analysis	N	O
2	of	N	O
3	published	N	O
4	studies	N	O
5	was	N	O
6	also	N	O
7	conducted	N	O
8	.	N	O

1	Between	N	O
2	May	N	O
3	2002	N	O
4	and	N	O
5	January	N	O
6	2005	N	O
7	,	N	O
8	533	N	O
9	patients	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	to	N	O
14	GEM	N	O
15	(	N	O
16	n	N	O
17	=	N	O
18	266	N	O
19	)	N	O
20	and	N	O
21	GEM-CAP	N	O
22	(	N	O
23	n	N	O
24	=	N	O
25	267	N	O
26	)	N	O
27	arms	N	O
28	.	N	O

1	GEM-CAP	N	I-Premise
2	significantly	N	I-Premise
3	improved	N	I-Premise
4	objective	N	I-Premise
5	response	N	I-Premise
6	rate	N	I-Premise
7	(	N	I-Premise
8	19.1	N	I-Premise
9	%	N	I-Premise
10	v	N	I-Premise
11	12.4	N	I-Premise
12	%	N	I-Premise
13	;	N	I-Premise
14	P	N	I-Premise
15	=	N	I-Premise
16	.034	N	I-Premise
17	)	N	I-Premise
18	and	N	I-Premise
19	progression-free	N	I-Premise
20	survival	N	I-Premise
21	(	N	I-Premise
22	hazard	N	I-Premise
23	ratio	N	I-Premise
24	[	N	I-Premise
25	HR	N	I-Premise
26	]	N	I-Premise
27	,	N	I-Premise
28	0.78	N	I-Premise
29	;	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	CI	N	I-Premise
33	,	N	I-Premise
34	0.66	N	I-Premise
35	to	N	I-Premise
36	0.93	N	I-Premise
37	;	N	I-Premise
38	P	N	I-Premise
39	=	N	I-Premise
40	.004	N	I-Premise
41	)	N	I-Premise
42	and	N	I-Premise
43	was	N	I-Premise
44	associated	N	I-Premise
45	with	N	I-Premise
46	a	N	I-Premise
47	trend	N	I-Premise
48	toward	N	I-Premise
49	improved	N	I-Premise
50	OS	N	I-Premise
51	(	N	I-Premise
52	HR	N	I-Premise
53	,	N	I-Premise
54	0.86	N	I-Premise
55	;	N	I-Premise
56	95	N	I-Premise
57	%	N	I-Premise
58	CI	N	I-Premise
59	,	N	I-Premise
60	0.72	N	I-Premise
61	to	N	I-Premise
62	1.02	N	I-Premise
63	;	N	I-Premise
64	P	N	I-Premise
65	=	N	I-Premise
66	.08	N	I-Premise
67	)	N	I-Premise
68	compared	N	I-Premise
69	with	N	I-Premise
70	GEM	N	I-Premise
71	alone	N	I-Premise
72	.	N	I-Premise

1	This	N	I-Premise
2	trend	N	I-Premise
3	for	N	I-Premise
4	OS	N	I-Premise
5	benefit	N	I-Premise
6	for	N	I-Premise
7	GEM-CAP	N	I-Premise
8	was	N	I-Premise
9	consistent	N	I-Premise
10	across	N	I-Premise
11	different	N	I-Premise
12	prognostic	N	I-Premise
13	subgroups	N	I-Premise
14	according	N	I-Premise
15	to	N	I-Premise
16	baseline	N	I-Premise
17	stratification	N	I-Premise
18	factors	N	I-Premise
19	(	N	I-Premise
20	stage	N	I-Premise
21	and	N	I-Premise
22	performance	N	I-Premise
23	status	N	I-Premise
24	)	N	I-Premise
25	and	N	I-Premise
26	remained	N	I-Premise
27	after	N	I-Premise
28	adjusting	N	I-Premise
29	for	N	I-Premise
30	these	N	I-Premise
31	stratification	N	I-Premise
32	factors	N	I-Premise
33	(	N	I-Premise
34	P	N	I-Premise
35	=	N	I-Premise
36	.077	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	Moreover	N	O
2	,	N	O
3	the	N	I-Premise
4	meta-analysis	N	I-Premise
5	of	N	I-Premise
6	two	N	I-Premise
7	additional	N	I-Premise
8	studies	N	I-Premise
9	involving	N	I-Premise
10	935	N	I-Premise
11	patients	N	I-Premise
12	showed	N	I-Premise
13	a	N	I-Premise
14	significant	N	I-Premise
15	survival	N	I-Premise
16	benefit	N	I-Premise
17	in	N	I-Premise
18	favor	N	I-Premise
19	of	N	I-Premise
20	GEM-CAP	N	I-Premise
21	(	N	I-Premise
22	HR	N	I-Premise
23	,	N	I-Premise
24	0.86	N	I-Premise
25	;	N	I-Premise
26	95	N	I-Premise
27	%	N	I-Premise
28	CI	N	I-Premise
29	,	N	I-Premise
30	0.75	N	I-Premise
31	to	N	I-Premise
32	0.98	N	I-Premise
33	;	N	I-Premise
34	P	N	I-Premise
35	=	N	I-Premise
36	.02	N	I-Premise
37	)	N	I-Premise
38	with	N	I-Premise
39	no	N	I-Premise
40	intertrial	N	I-Premise
41	heterogeneity	N	I-Premise
42	.	N	I-Premise

1	On	N	I-MajorClaim
2	the	N	I-MajorClaim
3	basis	N	I-MajorClaim
4	of	N	I-MajorClaim
5	our	N	I-MajorClaim
6	trial	N	I-MajorClaim
7	and	N	I-MajorClaim
8	the	N	I-MajorClaim
9	meta-analysis	N	I-MajorClaim
10	,	N	I-MajorClaim
11	GEM-CAP	N	I-MajorClaim
12	should	N	I-MajorClaim
13	be	N	I-MajorClaim
14	considered	N	I-MajorClaim
15	as	N	I-MajorClaim
16	one	N	I-MajorClaim
17	of	N	I-MajorClaim
18	the	N	I-MajorClaim
19	standard	N	I-MajorClaim
20	first-line	N	I-MajorClaim
21	options	N	I-MajorClaim
22	in	N	I-MajorClaim
23	locally	N	I-MajorClaim
24	advanced	N	I-MajorClaim
25	and	N	I-MajorClaim
26	metastatic	N	I-MajorClaim
27	pancreatic	N	I-MajorClaim
28	cancer	N	I-MajorClaim
29	.	N	I-MajorClaim

1	To	N	O
2	determine	N	O
3	1-year	N	O
4	outcomes	N	O
5	of	N	O
6	a	N	O
7	four-component	N	O
8	behavioral	N	O
9	therapy	N	O
10	(	N	O
11	BT	N	O
12	)	N	O
13	sleep	N	O
14	intervention	N	O
15	(	N	O
16	Individualized	N	O
17	Sleep	N	O
18	Promotion	N	O
19	Plan	N	O
20	[	N	O
21	ISPP	N	O
22	]	N	O
23	)	N	O
24	versus	N	O
25	a	N	O
26	healthy	N	O
27	eating	N	O
28	control	N	O
29	(	N	O
30	HEC	N	O
31	)	N	O
32	on	N	O
33	cancer-related	N	O
34	fatigue	N	O
35	in	N	O
36	women	N	O
37	receiving	N	O
38	breast	N	O
39	cancer	N	O
40	adjuvant	N	O
41	chemotherapy	N	O
42	treatment	N	O
43	(	N	O
44	CTX	N	O
45	)	N	O
46	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	219	N	O
5	participants	N	O
6	from	N	O
7	12	N	O
8	oncology	N	O
9	clinics	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	in	N	O
14	a	N	O
15	clinical	N	O
16	trial	N	O
17	.	N	O

1	Before	N	O
2	CTX	N	O
3	,	N	O
4	research	N	O
5	nurses	N	O
6	coached	N	O
7	intervention	N	O
8	participants	N	O
9	to	N	O
10	develop	N	O
11	a	N	O
12	BT	N	O
13	plan	N	O
14	including	N	O
15	stimulus	N	O
16	control	N	O
17	,	N	O
18	modified	N	O
19	sleep	N	O
20	restriction	N	O
21	,	N	O
22	relaxation	N	O
23	therapy	N	O
24	,	N	O
25	and	N	O
26	sleep	N	O
27	hygiene	N	O
28	.	N	O

1	BT	N	O
2	plans	N	O
3	were	N	O
4	revised	N	O
5	before	N	O
6	each	N	O
7	CTX	N	O
8	and	N	O
9	30	N	O
10	,	N	O
11	60	N	O
12	,	N	O
13	and	N	O
14	90	N	O
15	days	N	O
16	after	N	O
17	the	N	O
18	last	N	O
19	CTX	N	O
20	and	N	O
21	reinforced	N	O
22	7	N	O
23	to	N	O
24	9	N	O
25	days	N	O
26	later	N	O
27	.	N	O

1	HEC	N	O
2	participants	N	O
3	received	N	O
4	nutritional	N	O
5	information	N	O
6	and	N	O
7	equal	N	O
8	attention	N	O
9	.	N	O

1	Pittsburgh	N	O
2	Sleep	N	O
3	Quality	N	O
4	Index	N	O
5	(	N	O
6	PSQI	N	O
7	)	N	O
8	,	N	O
9	Daily	N	O
10	Diary	N	O
11	,	N	O
12	Wrist	N	O
13	Actigraph	N	O
14	,	N	O
15	and	N	O
16	Piper	N	O
17	Fatigue	N	O
18	Scale	N	O
19	measures	N	O
20	and	N	O
21	Repeated	N	O
22	Linear	N	O
23	Mixed	N	O
24	Model	N	O
25	analysis	N	O
26	following	N	O
27	the	N	O
28	Intent	N	O
29	to	N	O
30	Treat	N	O
31	paradigm	N	O
32	were	N	O
33	used	N	O
34	.	N	O

1	Sleep	N	I-Premise
2	quality	N	I-Premise
3	differed	N	I-Premise
4	over	N	I-Premise
5	1	N	I-Premise
6	years	N	I-Premise
7	time	N	I-Premise
8	(	N	I-Premise
9	F	N	I-Premise
10	[	N	I-Premise
11	4,162	N	I-Premise
12	]	N	I-Premise
13	=	N	I-Premise
14	7.7	N	I-Premise
15	,	N	I-Premise
16	P	N	I-Premise
17	<	N	I-Premise
18	.001	N	I-Premise
19	;	N	I-Premise
20	by	N	I-Premise
21	group	N	I-Premise
22	,	N	I-Premise
23	F	N	I-Premise
24	[	N	I-Premise
25	1,173	N	I-Premise
26	]	N	I-Premise
27	=	N	I-Premise
28	4.8	N	I-Premise
29	,	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.029	N	I-Premise
33	;	N	I-Premise
34	and	N	I-Premise
35	over	N	I-Premise
36	time	N	I-Premise
37	by	N	I-Premise
38	group	N	I-Premise
39	,	N	I-Premise
40	F	N	I-Premise
41	[	N	I-Premise
42	4,162	N	I-Premise
43	]	N	I-Premise
44	=	N	I-Premise
45	3.3	N	I-Premise
46	,	N	I-Premise
47	P	N	I-Premise
48	=	N	I-Premise
49	.013	N	I-Premise
50	)	N	I-Premise
51	.	N	I-Premise

1	Pairwise	N	I-Premise
2	comparisons	N	I-Premise
3	revealed	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	between	N	I-Premise
7	groups	N	I-Premise
8	at	N	I-Premise
9	90	N	I-Premise
10	days	N	I-Premise
11	(	N	I-Premise
12	P	N	I-Premise
13	=	N	I-Premise
14	.002	N	I-Premise
15	)	N	I-Premise
16	but	N	I-Premise
17	not	N	I-Premise
18	at	N	I-Premise
19	1	N	I-Premise
20	year	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	.052	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	Seven	N	O
2	days	N	O
3	of	N	O
4	diary	N	O
5	and	N	O
6	actigraphy	N	O
7	data	N	O
8	did	N	O
9	not	N	O
10	corroborate	N	O
11	with	N	O
12	monthly	N	O
13	reflections	N	O
14	(	N	O
15	PSQI	N	O
16	)	N	O
17	.	N	O

1	The	N	I-Premise
2	night	N	I-Premise
3	awakenings	N	I-Premise
4	(	N	I-Premise
5	Actigraph	N	I-Premise
6	)	N	I-Premise
7	pattern	N	I-Premise
8	was	N	I-Premise
9	significantly	N	I-Premise
10	different	N	I-Premise
11	by	N	I-Premise
12	group	N	I-Premise
13	over	N	I-Premise
14	time	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	=	N	I-Premise
18	.046	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	with	N	I-Premise
22	no	N	I-Premise
23	differences	N	I-Premise
24	between	N	I-Premise
25	groups	N	I-Premise
26	at	N	I-Premise
27	90	N	I-Premise
28	days	N	I-Premise
29	or	N	I-Premise
30	at	N	I-Premise
31	1	N	I-Premise
32	year	N	I-Premise
33	.	N	I-Premise

1	Fatigue	N	I-Premise
2	was	N	I-Premise
3	lower	N	I-Premise
4	at	N	I-Premise
5	1	N	I-Premise
6	year	N	I-Premise
7	than	N	I-Premise
8	before	N	I-Premise
9	CTX	N	I-Premise
10	;	N	I-Premise
11	no	N	I-Premise
12	group	N	I-Premise
13	effects	N	I-Premise
14	were	N	I-Premise
15	found	N	I-Premise
16	.	N	I-Premise

1	The	N	I-Claim
2	BT	N	I-Claim
3	group	N	I-Claim
4	,	N	I-Claim
5	on	N	I-Claim
6	average	N	I-Claim
7	,	N	I-Claim
8	experienced	N	I-Claim
9	significant	N	I-Claim
10	improvement	N	I-Claim
11	on	N	I-Claim
12	global	N	I-Claim
13	sleep	N	I-Claim
14	quality	N	I-Claim
15	compared	N	I-Claim
16	with	N	I-Claim
17	the	N	I-Claim
18	HEC	N	I-Claim
19	group	N	I-Claim
20	,	N	I-Claim
21	but	N	I-Claim
22	not	N	I-Claim
23	on	N	I-Claim
24	objective	N	I-Claim
25	sleep	N	I-Claim
26	or	N	I-Claim
27	fatigue	N	I-Claim
28	outcomes	N	I-Claim
29	.	N	I-Claim

1	Both	N	O
2	gastrojejunostomy	N	O
3	(	N	O
4	GJJ	N	O
5	)	N	O
6	and	N	O
7	stent	N	O
8	placement	N	O
9	are	N	O
10	commonly	N	O
11	used	N	O
12	palliative	N	O
13	treatments	N	O
14	of	N	O
15	obstructive	N	O
16	symptoms	N	O
17	caused	N	O
18	by	N	O
19	malignant	N	O
20	gastric	N	O
21	outlet	N	O
22	obstruction	N	O
23	(	N	O
24	GOO	N	O
25	)	N	O
26	.	N	O

1	Compare	N	O
2	GJJ	N	O
3	and	N	O
4	stent	N	O
5	placement	N	O
6	.	N	O

1	Multicenter	N	O
2	,	N	O
3	randomized	N	O
4	trial	N	O
5	.	N	O

1	Twenty-one	N	O
2	centers	N	O
3	in	N	O
4	The	N	O
5	Netherlands	N	O
6	.	N	O

1	Patients	N	O
2	with	N	O
3	GOO	N	O
4	.	N	O

1	GJJ	N	O
2	and	N	O
3	stent	N	O
4	placement	N	O
5	.	N	O

1	Outcomes	N	O
2	were	N	O
3	medical	N	O
4	effects	N	O
5	,	N	O
6	quality	N	O
7	of	N	O
8	life	N	O
9	,	N	O
10	and	N	O
11	costs	N	O
12	.	N	O

1	Analysis	N	O
2	was	N	O
3	by	N	O
4	intent	N	O
5	to	N	O
6	treat	N	O
7	.	N	O

1	Eighteen	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	to	N	O
6	GJJ	N	O
7	and	N	O
8	21	N	O
9	to	N	O
10	stent	N	O
11	placement	N	O
12	.	N	O

1	Food	N	I-Premise
2	intake	N	I-Premise
3	improved	N	I-Premise
4	more	N	I-Premise
5	rapidly	N	I-Premise
6	after	N	I-Premise
7	stent	N	I-Premise
8	placement	N	I-Premise
9	than	N	I-Premise
10	after	N	I-Premise
11	GJJ	N	I-Premise
12	(	N	I-Premise
13	GOO	N	I-Premise
14	Scoring	N	I-Premise
15	System	N	I-Premise
16	score	N	I-Premise
17	>	N	I-Premise
18	or	N	I-Premise
19	=	N	I-Premise
20	2	N	I-Premise
21	:	N	I-Premise
22	median	N	I-Premise
23	5	N	I-Premise
24	vs	N	I-Premise
25	8	N	I-Premise
26	days	N	I-Premise
27	,	N	I-Premise
28	respectively	N	I-Premise
29	;	N	I-Premise
30	P	N	I-Premise
31	<	N	I-Premise
32	.01	N	I-Premise
33	)	N	I-Premise
34	but	N	I-Premise
35	long-term	N	I-Premise
36	relief	N	I-Premise
37	was	N	I-Premise
38	better	N	I-Premise
39	after	N	I-Premise
40	GJJ	N	I-Premise
41	,	N	I-Premise
42	with	N	I-Premise
43	more	N	I-Premise
44	patients	N	I-Premise
45	living	N	I-Premise
46	more	N	I-Premise
47	days	N	I-Premise
48	with	N	I-Premise
49	a	N	I-Premise
50	GOO	N	I-Premise
51	Scoring	N	I-Premise
52	System	N	I-Premise
53	score	N	I-Premise
54	of	N	I-Premise
55	2	N	I-Premise
56	or	N	I-Premise
57	more	N	I-Premise
58	than	N	I-Premise
59	after	N	I-Premise
60	stent	N	I-Premise
61	placement	N	I-Premise
62	(	N	I-Premise
63	72	N	I-Premise
64	vs	N	I-Premise
65	50	N	I-Premise
66	days	N	I-Premise
67	,	N	I-Premise
68	respectively	N	I-Premise
69	;	N	I-Premise
70	P	N	I-Premise
71	=	N	I-Premise
72	.05	N	I-Premise
73	)	N	I-Premise
74	.	N	I-Premise

1	More	N	I-Premise
2	major	N	I-Premise
3	complications	N	I-Premise
4	(	N	I-Premise
5	stent	N	I-Premise
6	:	N	I-Premise
7	6	N	I-Premise
8	in	N	I-Premise
9	4	N	I-Premise
10	patients	N	I-Premise
11	vs	N	I-Premise
12	GJJ	N	I-Premise
13	:	N	I-Premise
14	0	N	I-Premise
15	;	N	I-Premise
16	P	N	I-Premise
17	=	N	I-Premise
18	.02	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	recurrent	N	I-Premise
22	obstructive	N	I-Premise
23	symptoms	N	I-Premise
24	(	N	I-Premise
25	stent	N	I-Premise
26	:	N	I-Premise
27	8	N	I-Premise
28	in	N	I-Premise
29	5	N	I-Premise
30	patients	N	I-Premise
31	vs	N	I-Premise
32	GJJ	N	I-Premise
33	:	N	I-Premise
34	1	N	I-Premise
35	in	N	I-Premise
36	1	N	I-Premise
37	patient	N	I-Premise
38	;	N	I-Premise
39	P	N	I-Premise
40	=	N	I-Premise
41	.02	N	I-Premise
42	)	N	I-Premise
43	,	N	I-Premise
44	and	N	I-Premise
45	reinterventions	N	I-Premise
46	(	N	I-Premise
47	stent	N	I-Premise
48	:	N	I-Premise
49	10	N	I-Premise
50	in	N	I-Premise
51	7	N	I-Premise
52	patients	N	I-Premise
53	vs	N	I-Premise
54	GJJ	N	I-Premise
55	:	N	I-Premise
56	2	N	I-Premise
57	in	N	I-Premise
58	2	N	I-Premise
59	patients	N	I-Premise
60	;	N	I-Premise
61	P	N	I-Premise
62	<	N	I-Premise
63	.01	N	I-Premise
64	)	N	I-Premise
65	were	N	I-Premise
66	observed	N	I-Premise
67	after	N	I-Premise
68	stent	N	I-Premise
69	placement	N	I-Premise
70	compared	N	I-Premise
71	with	N	I-Premise
72	GJJ	N	I-Premise
73	.	N	I-Premise

1	When	N	I-Premise
2	stent	N	I-Premise
3	obstruction	N	I-Premise
4	was	N	I-Premise
5	not	N	I-Premise
6	regarded	N	I-Premise
7	as	N	I-Premise
8	a	N	I-Premise
9	major	N	I-Premise
10	complication	N	I-Premise
11	,	N	I-Premise
12	no	N	I-Premise
13	differences	N	I-Premise
14	in	N	I-Premise
15	complications	N	I-Premise
16	were	N	I-Premise
17	found	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	.4	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	also	N	I-Premise
4	no	N	I-Premise
5	differences	N	I-Premise
6	in	N	I-Premise
7	median	N	I-Premise
8	survival	N	I-Premise
9	(	N	I-Premise
10	stent	N	I-Premise
11	:	N	I-Premise
12	56	N	I-Premise
13	days	N	I-Premise
14	vs	N	I-Premise
15	GJJ	N	I-Premise
16	:	N	I-Premise
17	78	N	I-Premise
18	days	N	I-Premise
19	)	N	I-Premise
20	and	N	I-Premise
21	quality	N	I-Premise
22	of	N	I-Premise
23	life	N	I-Premise
24	.	N	I-Premise

1	Mean	N	I-Premise
2	total	N	I-Premise
3	costs	N	I-Premise
4	of	N	I-Premise
5	GJJ	N	I-Premise
6	were	N	I-Premise
7	higher	N	I-Premise
8	compared	N	I-Premise
9	with	N	I-Premise
10	stent	N	I-Premise
11	placement	N	I-Premise
12	(	N	I-Premise
13	$	N	I-Premise
14	16,535	N	I-Premise
15	vs	N	I-Premise
16	$	N	I-Premise
17	11,720	N	I-Premise
18	,	N	I-Premise
19	respectively	N	I-Premise
20	;	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	.049	N	I-Premise
24	[	N	I-Premise
25	comparing	N	I-Premise
26	medians	N	I-Premise
27	]	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Because	N	O
2	of	N	O
3	the	N	O
4	small	N	O
5	study	N	O
6	population	N	O
7	,	N	O
8	only	N	O
9	initial	N	O
10	hospital	N	O
11	costs	N	O
12	would	N	O
13	have	N	O
14	been	N	O
15	statistically	N	O
16	significant	N	O
17	if	N	O
18	the	N	O
19	Bonferroni	N	O
20	correction	N	O
21	for	N	O
22	multiple	N	O
23	testing	N	O
24	had	N	O
25	been	N	O
26	applied	N	O
27	.	N	O

1	Relatively	N	O
2	small	N	O
3	patient	N	O
4	population	N	O
5	.	N	O

1	Despite	N	I-Premise
2	slow	N	I-Premise
3	initial	N	I-Premise
4	symptom	N	I-Premise
5	improvement	N	I-Premise
6	,	N	I-Premise
7	GJJ	N	I-Claim
8	was	N	I-Claim
9	associated	N	I-Claim
10	with	N	I-Claim
11	better	N	I-Claim
12	long-term	N	I-Claim
13	results	N	I-Claim
14	and	N	I-Claim
15	is	N	I-Claim
16	therefore	N	I-Claim
17	the	N	I-Claim
18	treatment	N	I-Claim
19	of	N	I-Claim
20	choice	N	I-Claim
21	in	N	I-Claim
22	patients	N	I-Claim
23	with	N	I-Claim
24	a	N	I-Claim
25	life	N	I-Claim
26	expectancy	N	I-Claim
27	of	N	I-Claim
28	2	N	I-Claim
29	months	N	I-Claim
30	or	N	I-Claim
31	longer	N	I-Claim
32	.	N	I-Claim

1	Because	N	I-Claim
2	stent	N	I-Claim
3	placement	N	I-Claim
4	was	N	I-Claim
5	associated	N	I-Claim
6	with	N	I-Claim
7	better	N	I-Claim
8	short-term	N	I-Claim
9	outcomes	N	I-Claim
10	,	N	I-Claim
11	this	N	I-Claim
12	treatment	N	I-Claim
13	is	N	I-Claim
14	preferable	N	I-Claim
15	for	N	I-Claim
16	patients	N	I-Claim
17	expected	N	I-Claim
18	to	N	I-Claim
19	live	N	I-Claim
20	less	N	I-Claim
21	than	N	I-Claim
22	2	N	I-Claim
23	months	N	I-Claim
24	.	N	I-Claim

1	Gastrojejunostomy	N	O
2	(	N	O
3	GJJ	N	O
4	)	N	O
5	and	N	O
6	stent	N	O
7	placement	N	O
8	are	N	O
9	the	N	O
10	most	N	O
11	commonly	N	O
12	used	N	O
13	palliative	N	O
14	treatments	N	O
15	for	N	O
16	malignant	N	O
17	gastric	N	O
18	outlet	N	O
19	obstruction	N	O
20	(	N	O
21	GOO	N	O
22	)	N	O
23	.	N	O

1	In	N	O
2	a	N	O
3	recent	N	O
4	randomized	N	O
5	trial	N	O
6	,	N	O
7	stent	N	O
8	placement	N	O
9	was	N	O
10	preferred	N	O
11	in	N	O
12	patients	N	O
13	with	N	O
14	a	N	O
15	relatively	N	O
16	short	N	O
17	survival	N	O
18	and	N	O
19	GJJ	N	O
20	in	N	O
21	patients	N	O
22	with	N	O
23	a	N	O
24	longer	N	O
25	survival	N	O
26	.	N	O

1	As	N	O
2	health	N	O
3	economic	N	O
4	aspects	N	O
5	have	N	O
6	only	N	O
7	been	N	O
8	studied	N	O
9	in	N	O
10	general	N	O
11	terms	N	O
12	,	N	O
13	we	N	O
14	estimated	N	O
15	the	N	O
16	cost	N	O
17	of	N	O
18	GJJ	N	O
19	and	N	O
20	that	N	O
21	of	N	O
22	stent	N	O
23	placement	N	O
24	in	N	O
25	such	N	O
26	patients	N	O
27	.	N	O

1	In	N	O
2	the	N	O
3	SUSTENT	N	O
4	study	N	O
5	,	N	O
6	patients	N	O
7	were	N	O
8	randomized	N	O
9	to	N	O
10	GJJ	N	O
11	(	N	O
12	n	N	O
13	=	N	O
14	18	N	O
15	)	N	O
16	or	N	O
17	stent	N	O
18	placement	N	O
19	(	N	O
20	n	N	O
21	=	N	O
22	21	N	O
23	)	N	O
24	.	N	O

1	Pancreatic	N	O
2	cancer	N	O
3	was	N	O
4	the	N	O
5	most	N	O
6	common	N	O
7	cause	N	O
8	of	N	O
9	GOO	N	O
10	.	N	O

1	We	N	O
2	compared	N	O
3	initial	N	O
4	costs	N	O
5	and	N	O
6	costs	N	O
7	during	N	O
8	follow-up	N	O
9	.	N	O

1	For	N	O
2	cost-effectiveness	N	O
3	,	N	O
4	the	N	O
5	incremental	N	O
6	cost-effectiveness	N	O
7	ratio	N	O
8	was	N	O
9	calculated	N	O
10	.	N	O

1	Food	N	I-Premise
2	intake	N	I-Premise
3	improved	N	I-Premise
4	more	N	I-Premise
5	rapidly	N	I-Premise
6	after	N	I-Premise
7	stent	N	I-Premise
8	placement	N	I-Premise
9	than	N	I-Premise
10	after	N	I-Premise
11	GJJ	N	I-Premise
12	,	N	I-Premise
13	but	N	I-Premise
14	long-term	N	I-Premise
15	relief	N	I-Premise
16	of	N	I-Premise
17	obstructive	N	I-Premise
18	symptoms	N	I-Premise
19	was	N	I-Premise
20	better	N	I-Premise
21	after	N	I-Premise
22	GJJ	N	I-Premise
23	.	N	I-Premise

1	More	N	I-Premise
2	major	N	I-Premise
3	complications	N	I-Premise
4	(	N	I-Premise
5	P	N	I-Premise
6	=	N	I-Premise
7	0.02	N	I-Premise
8	)	N	I-Premise
9	occurred	N	I-Premise
10	and	N	I-Premise
11	more	N	I-Premise
12	reinterventions	N	I-Premise
13	were	N	I-Premise
14	performed	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	<	N	I-Premise
18	0.01	N	I-Premise
19	)	N	I-Premise
20	after	N	I-Premise
21	stent	N	I-Premise
22	placement	N	I-Premise
23	than	N	I-Premise
24	after	N	I-Premise
25	GJJ	N	I-Premise
26	.	N	I-Premise

1	Initial	N	I-Premise
2	costs	N	I-Premise
3	were	N	I-Premise
4	higher	N	I-Premise
5	for	N	I-Premise
6	GJJ	N	I-Premise
7	compared	N	I-Premise
8	to	N	I-Premise
9	stent	N	I-Premise
10	placement	N	I-Premise
11	(	N	I-Premise
12	euro8315	N	I-Premise
13	vs.	N	I-Premise
14	euro4820	N	I-Premise
15	,	N	I-Premise
16	P	N	I-Premise
17	<	N	I-Premise
18	0.001	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	We	N	I-Premise
2	found	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	follow-up	N	I-Premise
7	costs	N	I-Premise
8	.	N	I-Premise

1	Total	N	I-Premise
2	costs	N	I-Premise
3	per	N	I-Premise
4	patient	N	I-Premise
5	were	N	I-Premise
6	higher	N	I-Premise
7	for	N	I-Premise
8	GJJ	N	I-Premise
9	compared	N	I-Premise
10	to	N	I-Premise
11	stent	N	I-Premise
12	placement	N	I-Premise
13	(	N	I-Premise
14	euro12433	N	I-Premise
15	vs.	N	I-Premise
16	euro8819	N	I-Premise
17	,	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	0.049	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	The	N	I-Premise
2	incremental	N	I-Premise
3	cost-effectiveness	N	I-Premise
4	ratio	N	I-Premise
5	of	N	I-Premise
6	GJJ	N	I-Premise
7	compared	N	I-Premise
8	to	N	I-Premise
9	stent	N	I-Premise
10	placement	N	I-Premise
11	was	N	I-Premise
12	euro164	N	I-Premise
13	per	N	I-Premise
14	extra	N	I-Premise
15	day	N	I-Premise
16	with	N	I-Premise
17	a	N	I-Premise
18	gastric	N	I-Premise
19	outlet	N	I-Premise
20	obstruction	N	I-Premise
21	scoring	N	I-Premise
22	system	N	I-Premise
23	(	N	I-Premise
24	GOOSS	N	I-Premise
25	)	N	I-Premise
26	>	N	I-Premise
27	or=2	N	I-Premise
28	adjusted	N	I-Premise
29	for	N	I-Premise
30	survival	N	I-Premise
31	.	N	I-Premise

1	Medical	N	I-Claim
2	effects	N	I-Claim
3	were	N	I-Claim
4	better	N	I-Claim
5	after	N	I-Claim
6	GJJ	N	I-Claim
7	,	N	O
8	although	N	I-Claim
9	GJJ	N	I-Claim
10	had	N	I-Claim
11	higher	N	I-Claim
12	total	N	I-Claim
13	costs	N	I-Claim
14	.	N	I-Claim

1	Since	N	I-Claim
2	the	N	I-Claim
3	cost	N	I-Claim
4	difference	N	I-Claim
5	between	N	I-Claim
6	the	N	I-Claim
7	two	N	I-Claim
8	treatments	N	I-Claim
9	was	N	I-Claim
10	only	N	I-Claim
11	small	N	I-Claim
12	,	N	I-Claim
13	cost	N	I-Claim
14	should	N	I-Claim
15	not	N	I-Claim
16	play	N	I-Claim
17	a	N	I-Claim
18	predominant	N	I-Claim
19	role	N	I-Claim
20	when	N	I-Claim
21	deciding	N	I-Claim
22	on	N	I-Claim
23	the	N	I-Claim
24	type	N	I-Claim
25	of	N	I-Claim
26	treatment	N	I-Claim
27	assigned	N	I-Claim
28	to	N	I-Claim
29	patients	N	I-Claim
30	with	N	I-Claim
31	malignant	N	I-Claim
32	GOO	N	I-Claim
33	.	N	I-Claim

1	Vasomotor	N	O
2	symptoms	N	O
3	are	N	O
4	common	N	O
5	adverse	N	O
6	effects	N	O
7	of	N	O
8	antiestrogen	N	O
9	hormone	N	O
10	treatment	N	O
11	in	N	O
12	conventional	N	O
13	breast	N	O
14	cancer	N	O
15	care	N	O
16	.	N	O

1	Hormone	N	O
2	replacement	N	O
3	therapy	N	O
4	is	N	O
5	contraindicated	N	O
6	in	N	O
7	patients	N	O
8	with	N	O
9	breast	N	O
10	cancer	N	O
11	.	N	O

1	Venlafaxine	N	O
2	(	N	O
3	Effexor	N	O
4	)	N	O
5	,	N	O
6	the	N	O
7	therapy	N	O
8	of	N	O
9	choice	N	O
10	for	N	O
11	these	N	O
12	symptoms	N	O
13	,	N	O
14	has	N	O
15	numerous	N	O
16	adverse	N	O
17	effects	N	O
18	.	N	O

1	Recent	N	O
2	studies	N	O
3	suggest	N	O
4	acupuncture	N	O
5	may	N	O
6	be	N	O
7	effective	N	O
8	in	N	O
9	reducing	N	O
10	vasomotor	N	O
11	symptoms	N	O
12	in	N	O
13	menopausal	N	O
14	women	N	O
15	.	N	O

1	This	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	tested	N	O
6	whether	N	O
7	acupuncture	N	O
8	reduces	N	O
9	vasomotor	N	O
10	symptoms	N	O
11	and	N	O
12	produces	N	O
13	fewer	N	O
14	adverse	N	O
15	effects	N	O
16	than	N	O
17	venlafaxine	N	O
18	.	N	O

1	Fifty	N	O
2	patients	N	O
3	were	N	O
4	randomly	N	O
5	assigned	N	O
6	to	N	O
7	receive	N	O
8	12	N	O
9	weeks	N	O
10	of	N	O
11	acupuncture	N	O
12	(	N	O
13	n	N	O
14	=	N	O
15	25	N	O
16	)	N	O
17	or	N	O
18	venlafaxine	N	O
19	(	N	O
20	n	N	O
21	=	N	O
22	25	N	O
23	)	N	O
24	treatment	N	O
25	.	N	O

1	Health	N	O
2	outcomes	N	O
3	were	N	O
4	measured	N	O
5	for	N	O
6	up	N	O
7	to	N	O
8	1	N	O
9	year	N	O
10	post-treatment	N	O
11	.	N	O

1	Both	N	I-Premise
2	groups	N	I-Premise
3	exhibited	N	I-Premise
4	significant	N	I-Premise
5	decreases	N	I-Premise
6	in	N	I-Premise
7	hot	N	I-Premise
8	flashes	N	I-Premise
9	,	N	I-Premise
10	depressive	N	I-Premise
11	symptoms	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	other	N	I-Premise
15	quality-of-life	N	I-Premise
16	symptoms	N	I-Premise
17	,	N	I-Premise
18	including	N	I-Premise
19	significant	N	I-Premise
20	improvements	N	I-Premise
21	in	N	I-Premise
22	mental	N	I-Premise
23	health	N	I-Premise
24	from	N	I-Premise
25	pre-	N	I-Premise
26	to	N	I-Premise
27	post-treatment	N	I-Premise
28	.	N	I-Premise

1	These	N	I-Premise
2	changes	N	I-Premise
3	were	N	I-Premise
4	similar	N	I-Premise
5	in	N	I-Premise
6	both	N	I-Premise
7	groups	N	I-Premise
8	,	N	I-Premise
9	indicating	N	I-Premise
10	that	N	I-Premise
11	acupuncture	N	I-Premise
12	was	N	I-Premise
13	as	N	I-Premise
14	effective	N	I-Premise
15	as	N	I-Premise
16	venlafaxine	N	I-Premise
17	.	N	I-Premise

1	By	N	I-Premise
2	2	N	I-Premise
3	weeks	N	I-Premise
4	post-treatment	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	venlafaxine	N	I-Premise
8	group	N	I-Premise
9	experienced	N	I-Premise
10	significant	N	I-Premise
11	increases	N	I-Premise
12	in	N	I-Premise
13	hot	N	I-Premise
14	flashes	N	I-Premise
15	,	N	I-Premise
16	whereas	N	I-Premise
17	hot	N	I-Premise
18	flashes	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	acupuncture	N	I-Premise
22	group	N	I-Premise
23	remained	N	I-Premise
24	at	N	I-Premise
25	low	N	I-Premise
26	levels	N	I-Premise
27	.	N	I-Premise

1	The	N	I-Premise
2	venlafaxine	N	I-Premise
3	group	N	I-Premise
4	experienced	N	I-Premise
5	18	N	I-Premise
6	incidences	N	I-Premise
7	of	N	I-Premise
8	adverse	N	I-Premise
9	effects	N	I-Premise
10	(	N	I-Premise
11	eg	N	I-Premise
12	,	N	I-Premise
13	nausea	N	I-Premise
14	,	N	I-Premise
15	dry	N	I-Premise
16	mouth	N	I-Premise
17	,	N	I-Premise
18	dizziness	N	I-Premise
19	,	N	I-Premise
20	anxiety	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	whereas	N	I-Premise
24	the	N	I-Premise
25	acupuncture	N	I-Premise
26	group	N	I-Premise
27	experienced	N	I-Premise
28	no	N	I-Premise
29	negative	N	I-Premise
30	adverse	N	I-Premise
31	effects	N	I-Premise
32	.	N	I-Premise

1	Acupuncture	N	I-Premise
2	had	N	I-Premise
3	the	N	I-Premise
4	additional	N	I-Premise
5	benefit	N	I-Premise
6	of	N	I-Premise
7	increased	N	I-Premise
8	sex	N	I-Premise
9	drive	N	I-Premise
10	in	N	I-Premise
11	some	N	I-Premise
12	women	N	I-Premise
13	,	N	I-Premise
14	and	N	I-Premise
15	most	N	I-Premise
16	reported	N	I-Premise
17	an	N	I-Premise
18	improvement	N	I-Premise
19	in	N	I-Premise
20	their	N	I-Premise
21	energy	N	I-Premise
22	,	N	I-Premise
23	clarity	N	I-Premise
24	of	N	I-Premise
25	thought	N	I-Premise
26	,	N	I-Premise
27	and	N	I-Premise
28	sense	N	I-Premise
29	of	N	I-Premise
30	well-being	N	I-Premise
31	.	N	I-Premise

1	Acupuncture	N	I-Claim
2	appears	N	I-Claim
3	to	N	I-Claim
4	be	N	I-Claim
5	equivalent	N	I-Claim
6	to	N	I-Claim
7	drug	N	I-Claim
8	therapy	N	I-Claim
9	in	N	I-Claim
10	these	N	I-Claim
11	patients	N	I-Claim
12	.	N	I-Claim

1	It	N	I-Claim
2	is	N	I-Claim
3	a	N	I-Claim
4	safe	N	I-Claim
5	,	N	I-Claim
6	effective	N	I-Claim
7	and	N	I-Claim
8	durable	N	I-Claim
9	treatment	N	I-Claim
10	for	N	I-Claim
11	vasomotor	N	I-Claim
12	symptoms	N	I-Claim
13	secondary	N	I-Claim
14	to	N	I-Claim
15	long-term	N	I-Claim
16	antiestrogen	N	I-Claim
17	hormone	N	I-Claim
18	use	N	I-Claim
19	in	N	I-Claim
20	patients	N	I-Claim
21	with	N	I-Claim
22	breast	N	I-Claim
23	cancer	N	I-Claim
24	.	N	I-Claim

1	Few	N	O
2	reports	N	O
3	have	N	O
4	examined	N	O
5	the	N	O
6	use	N	O
7	of	N	O
8	recombinant	N	O
9	human	N	O
10	thyroid-stimulating	N	O
11	hormone	N	O
12	(	N	O
13	rhTSH	N	O
14	)	N	O
15	for	N	O
16	ablation	N	O
17	of	N	O
18	postsurgical	N	O
19	thyroid	N	O
20	remnants	N	O
21	after	N	O
22	low-dose	N	O
23	radioactive	N	O
24	iodine	N	O
25	(	N	O
26	RI	N	O
27	)	N	O
28	therapy	N	O
29	,	N	O
30	compared	N	O
31	with	N	O
32	conventional	N	O
33	thyroid	N	O
34	hormone	N	O
35	withdrawal	N	O
36	.	N	O

1	We	N	O
2	investigated	N	O
3	whether	N	O
4	patient	N	O
5	preparation	N	O
6	using	N	O
7	rhTSH	N	O
8	was	N	O
9	comparable	N	O
10	to	N	O
11	conventional	N	O
12	thyroid	N	O
13	hormone	N	O
14	withdrawal	N	O
15	with	N	O
16	respect	N	O
17	to	N	O
18	efficacy	N	O
19	of	N	O
20	postsurgical	N	O
21	remnant	N	O
22	ablation	N	O
23	in	N	O
24	low-risk	N	O
25	patients	N	O
26	receiving	N	O
27	a	N	O
28	30	N	O
29	mCi	N	O
30	RI	N	O
31	.	N	O

1	In	N	O
2	addition	N	O
3	,	N	O
4	we	N	O
5	also	N	O
6	evaluated	N	O
7	the	N	O
8	impact	N	O
9	of	N	O
10	rhTSH	N	O
11	(	N	O
12	rhTSH	N	O
13	vs.	N	O
14	conventional	N	O
15	thyroid	N	O
16	hormone	N	O
17	withdrawal	N	O
18	)	N	O
19	on	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	(	N	O
24	QoL	N	O
25	)	N	O
26	of	N	O
27	thyroid	N	O
28	cancer	N	O
29	patients	N	O
30	undergoing	N	O
31	RI	N	O
32	ablation	N	O
33	.	N	O

1	This	N	O
2	study	N	O
3	included	N	O
4	three	N	O
5	groups	N	O
6	of	N	O
7	patients	N	O
8	,	N	O
9	enrolled	N	O
10	consecutively	N	O
11	.	N	O

1	From	N	O
2	February	N	O
3	2006	N	O
4	to	N	O
5	March	N	O
6	2007	N	O
7	,	N	O
8	291	N	O
9	patients	N	O
10	were	N	O
11	enrolled	N	O
12	and	N	O
13	randomized	N	O
14	,	N	O
15	after	N	O
16	total	N	O
17	thyroidectomy	N	O
18	:	N	O
19	(	N	O
20	1	N	O
21	)	N	O
22	withdrawal	N	O
23	of	N	O
24	levothyroxine	N	O
25	(	N	O
26	LT4	N	O
27	)	N	O
28	for	N	O
29	4	N	O
30	weeks	N	O
31	(	N	O
32	T4-WD	N	O
33	Group	N	O
34	,	N	O
35	n	N	O
36	=	N	O
37	89	N	O
38	)	N	O
39	,	N	O
40	(	N	O
41	2	N	O
42	)	N	O
43	withdrawal	N	O
44	of	N	O
45	LT4	N	O
46	for	N	O
47	4	N	O
48	weeks	N	O
49	plus	N	O
50	2	N	O
51	weeks	N	O
52	on	N	O
53	and	N	O
54	then	N	O
55	2	N	O
56	weeks	N	O
57	off	N	O
58	liothyronine	N	O
59	(	N	O
60	LT3	N	O
61	)	N	O
62	(	N	O
63	T3-WD	N	O
64	Group	N	O
65	,	N	O
66	n	N	O
67	=	N	O
68	133	N	O
69	)	N	O
70	,	N	O
71	and	N	O
72	(	N	O
73	3	N	O
74	)	N	O
75	rhTSH	N	O
76	administration	N	O
77	(	N	O
78	rhTSH	N	O
79	Group	N	O
80	,	N	O
81	n	N	O
82	=	N	O
83	69	N	O
84	)	N	O
85	.	N	O

1	QoL	N	O
2	was	N	O
3	determined	N	O
4	at	N	O
5	the	N	O
6	time	N	O
7	of	N	O
8	ablation	N	O
9	.	N	O

1	Patients	N	O
2	in	N	O
3	the	N	O
4	three	N	O
5	groups	N	O
6	did	N	O
7	not	N	O
8	differ	N	O
9	significantly	N	O
10	in	N	O
11	baseline	N	O
12	characteristics	N	O
13	or	N	O
14	tumor	N	O
15	,	N	O
16	node	N	O
17	and	N	O
18	metastasis	N	O
19	(	N	O
20	TNM	N	O
21	)	N	O
22	staging	N	O
23	.	N	O

1	In	N	I-Premise
2	all	N	I-Premise
3	study	N	I-Premise
4	groups	N	I-Premise
5	,	N	I-Premise
6	serum	N	I-Premise
7	TSH	N	I-Premise
8	levels	N	I-Premise
9	showed	N	I-Premise
10	very	N	I-Premise
11	good	N	I-Premise
12	stimulation	N	I-Premise
13	(	N	I-Premise
14	mean	N	I-Premise
15	,	N	I-Premise
16	82.24	N	I-Premise
17	+/-	N	I-Premise
18	18.21	N	I-Premise
19	mU/L	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	without	N	I-Premise
23	significant	N	I-Premise
24	between-group	N	I-Premise
25	differences	N	I-Premise
26	(	N	I-Premise
27	p	N	I-Premise
28	=	N	I-Premise
29	0.5213	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	Follow-up	N	O
2	examinations	N	O
3	were	N	O
4	performed	N	O
5	12	N	O
6	months	N	O
7	after	N	O
8	ablation	N	O
9	to	N	O
10	assess	N	O
11	ablation	N	O
12	outcome	N	O
13	in	N	O
14	each	N	O
15	group	N	O
16	by	N	O
17	131	N	O
18	whole	N	O
19	body	N	O
20	scans	N	O
21	(	N	O
22	WBSs	N	O
23	)	N	O
24	,	N	O
25	serum	N	O
26	thyroglobulin	N	O
27	measurement	N	O
28	after	N	O
29	TSH	N	O
30	stimulation	N	O
31	,	N	O
32	and	N	O
33	neck	N	O
34	ultrasonography	N	O
35	.	N	O

1	The	N	I-Premise
2	successful	N	I-Premise
3	ablation	N	I-Premise
4	rate	N	I-Premise
5	was	N	I-Premise
6	91.0	N	I-Premise
7	%	N	I-Premise
8	in	N	I-Premise
9	T4-WD	N	I-Premise
10	Group	N	I-Premise
11	,	N	I-Premise
12	91.7	N	I-Premise
13	%	N	I-Premise
14	in	N	I-Premise
15	T3-WD	N	I-Premise
16	Group	N	I-Premise
17	,	N	I-Premise
18	and	N	I-Premise
19	91.3	N	I-Premise
20	%	N	I-Premise
21	in	N	I-Premise
22	rhTSH	N	I-Premise
23	Group	N	I-Premise
24	,	N	I-Premise
25	without	N	I-Premise
26	significant	N	I-Premise
27	between-preparation	N	I-Premise
28	differences	N	I-Premise
29	(	N	I-Premise
30	p	N	I-Premise
31	=	N	I-Premise
32	0.2061	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	QoL	N	I-Premise
2	was	N	I-Premise
3	better	N	I-Premise
4	preserved	N	I-Premise
5	in	N	I-Premise
6	rhTSH	N	I-Premise
7	Group	N	I-Premise
8	than	N	I-Premise
9	in	N	I-Premise
10	T4-WD	N	I-Premise
11	and	N	I-Premise
12	T3-WD	N	I-Premise
13	Groups	N	I-Premise
14	(	N	I-Premise
15	p	N	I-Premise
16	<	N	I-Premise
17	0.0001	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	there	N	I-Premise
4	was	N	I-Premise
5	no	N	I-Premise
6	QoL	N	I-Premise
7	difference	N	I-Premise
8	at	N	I-Premise
9	the	N	I-Premise
10	time	N	I-Premise
11	of	N	I-Premise
12	ablation	N	I-Premise
13	between	N	I-Premise
14	T4-WD	N	I-Premise
15	and	N	I-Premise
16	T3-WD	N	I-Premise
17	Groups	N	I-Premise
18	.	N	I-Premise

1	Our	N	I-Claim
2	study	N	I-Claim
3	indicates	N	I-Claim
4	that	N	I-Claim
5	use	N	I-Claim
6	of	N	I-Claim
7	rhTSH	N	I-Claim
8	preserves	N	I-Claim
9	QoL	N	I-Claim
10	in	N	I-Claim
11	patients	N	I-Claim
12	undergoing	N	I-Claim
13	RI	N	I-Claim
14	ablation	N	I-Claim
15	and	N	I-Claim
16	affords	N	I-Claim
17	an	N	I-Claim
18	ablation	N	I-Claim
19	success	N	I-Claim
20	rate	N	I-Claim
21	comparable	N	I-Claim
22	to	N	I-Claim
23	that	N	I-Claim
24	seen	N	I-Claim
25	after	N	I-Claim
26	thyroid	N	I-Claim
27	hormone	N	I-Claim
28	withdrawal	N	I-Claim
29	.	N	I-Claim

1	Notably	N	O
2	,	N	O
3	ablation	N	O
4	preparation	N	O
5	using	N	O
6	withdrawal	N	O
7	of	N	O
8	LT3	N	O
9	for	N	O
10	2	N	O
11	weeks	N	O
12	did	N	O
13	not	N	O
14	prevent	N	O
15	development	N	O
16	of	N	O
17	profound	N	O
18	hypothyroidism	N	O
19	,	N	O
20	as	N	O
21	also	N	O
22	occurred	N	O
23	when	N	O
24	LT4	N	O
25	alone	N	O
26	was	N	O
27	withdrawn	N	O
28	for	N	O
29	4	N	O
30	weeks	N	O
31	.	N	O

1	To	N	O
2	test	N	O
3	the	N	O
4	hypothesis	N	O
5	that	N	O
6	modulation	N	O
7	of	N	O
8	Bcl-2	N	O
9	with	N	O
10	13-cis	N	O
11	retinoic	N	O
12	acid	N	O
13	(	N	O
14	CRA	N	O
15	)	N	O
16	/interferon-alpha2b	N	O
17	(	N	O
18	IFN	N	O
19	)	N	O
20	with	N	O
21	paclitaxel	N	O
22	(	N	O
23	TAX	N	O
24	)	N	O
25	,	N	O
26	or	N	O
27	mitoxantrone	N	O
28	,	N	O
29	estramustine	N	O
30	and	N	O
31	vinorelbine	N	O
32	(	N	O
33	MEV	N	O
34	)	N	O
35	will	N	O
36	have	N	O
37	clinical	N	O
38	activity	N	O
39	in	N	O
40	men	N	O
41	with	N	O
42	metastatic	N	O
43	castrate-resistant	N	O
44	prostate	N	O
45	cancer	N	O
46	(	N	O
47	CRPC	N	O
48	)	N	O
49	.	N	O

1	70	N	O
2	patients	N	O
3	were	N	O
4	treated	N	O
5	with	N	O
6	either	N	O
7	MEV	N	O
8	(	N	O
9	Arm	N	O
10	A	N	O
11	)	N	O
12	in	N	O
13	a	N	O
14	3-week	N	O
15	cycle	N	O
16	or	N	O
17	CRA/IFN/TAX	N	O
18	with	N	O
19	an	N	O
20	8-week	N	O
21	cycle	N	O
22	(	N	O
23	Arm	N	O
24	B	N	O
25	)	N	O
26	.	N	O

1	Patients	N	O
2	were	N	O
3	assessed	N	O
4	for	N	O
5	response	N	O
6	,	N	O
7	toxicity	N	O
8	,	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	(	N	O
13	QOL	N	O
14	)	N	O
15	,	N	O
16	and	N	O
17	the	N	O
18	effect	N	O
19	of	N	O
20	treatment	N	O
21	on	N	O
22	Bcl-2	N	O
23	levels	N	O
24	in	N	O
25	peripheral	N	O
26	blood	N	O
27	mononuclear	N	O
28	cells	N	O
29	(	N	O
30	PBMC	N	O
31	)	N	O
32	.	N	O

1	The	N	I-Premise
2	PSA	N	I-Premise
3	response	N	I-Premise
4	rates	N	I-Premise
5	were	N	I-Premise
6	50	N	I-Premise
7	%	N	I-Premise
8	and	N	I-Premise
9	23	N	I-Premise
10	%	N	I-Premise
11	,	N	I-Premise
12	measurable	N	I-Premise
13	disease	N	I-Premise
14	response	N	I-Premise
15	rates	N	I-Premise
16	(	N	I-Premise
17	CR+PR	N	I-Premise
18	)	N	I-Premise
19	14	N	I-Premise
20	%	N	I-Premise
21	and	N	I-Premise
22	15	N	I-Premise
23	%	N	I-Premise
24	,	N	I-Premise
25	and	N	I-Premise
26	median	N	I-Premise
27	overall	N	I-Premise
28	survival	N	I-Premise
29	19.4	N	I-Premise
30	months	N	I-Premise
31	and	N	I-Premise
32	13.9	N	I-Premise
33	months	N	I-Premise
34	on	N	I-Premise
35	Arm	N	I-Premise
36	A	N	I-Premise
37	and	N	I-Premise
38	Arm	N	I-Premise
39	B	N	I-Premise
40	respectively	N	I-Premise
41	.	N	I-Premise

1	Transient	N	I-Premise
2	grade	N	I-Premise
3	4	N	I-Premise
4	neutropenia	N	I-Premise
5	occurred	N	I-Premise
6	in	N	I-Premise
7	18	N	I-Premise
8	and	N	I-Premise
9	2	N	I-Premise
10	patients	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	grade	N	I-Premise
14	3	N	I-Premise
15	to	N	I-Premise
16	4	N	I-Premise
17	thrombosis	N	I-Premise
18	in	N	I-Premise
19	7	N	I-Premise
20	patients	N	I-Premise
21	and	N	I-Premise
22	1	N	I-Premise
23	patient	N	I-Premise
24	in	N	I-Premise
25	Arm	N	I-Premise
26	A	N	I-Premise
27	and	N	I-Premise
28	Arm	N	I-Premise
29	B	N	I-Premise
30	respectively	N	I-Premise
31	.	N	I-Premise

1	Patients	N	I-Premise
2	on	N	I-Premise
3	Arm	N	I-Premise
4	B	N	I-Premise
5	reported	N	I-Premise
6	a	N	I-Premise
7	clinically	N	I-Premise
8	significant	N	I-Premise
9	decline	N	I-Premise
10	in	N	I-Premise
11	QOL	N	I-Premise
12	between	N	I-Premise
13	baseline	N	I-Premise
14	and	N	I-Premise
15	week	N	I-Premise
16	9/10	N	I-Premise
17	(	N	I-Premise
18	.71	N	I-Premise
19	s.d	N	I-Premise
20	.	N	I-Premise

1	)	N	I-Premise
2	,	N	I-Premise
3	and	N	I-Premise
4	a	N	I-Premise
5	significantly	N	I-Premise
6	lower	N	I-Premise
7	level	N	I-Premise
8	of	N	I-Premise
9	QOL	N	I-Premise
10	than	N	I-Premise
11	Arm	N	I-Premise
12	A	N	I-Premise
13	(	N	I-Premise
14	p	N	I-Premise
15	=	N	I-Premise
16	0.01	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	As	N	I-Premise
2	hypothesized	N	I-Premise
3	,	N	I-Premise
4	Bcl-2	N	I-Premise
5	levels	N	I-Premise
6	decreased	N	I-Premise
7	with	N	I-Premise
8	CRA/IFN	N	I-Premise
9	therapy	N	I-Premise
10	only	N	I-Premise
11	in	N	I-Premise
12	Arm	N	I-Premise
13	B	N	I-Premise
14	(	N	I-Premise
15	p	N	I-Premise
16	=	N	I-Premise
17	0.03	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	Treatment	N	I-Claim
2	with	N	I-Claim
3	MEV	N	I-Claim
4	was	N	I-Claim
5	well	N	I-Claim
6	tolerated	N	I-Claim
7	and	N	I-Claim
8	demonstrated	N	I-Claim
9	clinical	N	I-Claim
10	activity	N	I-Claim
11	in	N	I-Claim
12	patients	N	I-Claim
13	with	N	I-Claim
14	CRPC	N	I-Claim
15	.	N	I-Claim

1	Given	N	I-Claim
2	the	N	I-Claim
3	adverse	N	I-Claim
4	effect	N	I-Claim
5	of	N	I-Claim
6	CRA/IFN/TAX	N	I-Claim
7	on	N	I-Claim
8	QOL	N	I-Claim
9	,	N	I-Claim
10	the	N	I-Claim
11	study	N	I-Claim
12	of	N	I-Claim
13	other	N	I-Claim
14	novel	N	I-Claim
15	agents	N	I-Claim
16	that	N	I-Claim
17	target	N	I-Claim
18	Bcl-2	N	I-Claim
19	family	N	I-Claim
20	proteins	N	I-Claim
21	is	N	I-Claim
22	warranted	N	I-Claim
23	.	N	I-Claim

1	The	N	O
2	feasibility	N	O
3	of	N	O
4	measuring	N	O
5	Bcl-2	N	O
6	protein	N	O
7	in	N	O
8	a	N	O
9	cooperative	N	O
10	group	N	O
11	setting	N	O
12	is	N	O
13	hypothesis	N	O
14	generating	N	O
15	and	N	O
16	supports	N	O
17	further	N	O
18	study	N	O
19	as	N	O
20	a	N	O
21	marker	N	O
22	for	N	O
23	Bcl-2	N	O
24	targeted	N	O
25	therapy	N	O
26	.	N	O

1	To	N	O
2	determine	N	O
3	the	N	O
4	feasibility	N	O
5	of	N	O
6	administering	N	O
7	a	N	O
8	flavonoid-rich	N	O
9	adjunctive	N	O
10	treatment	N	O
11	(	N	O
12	Concord	N	O
13	grape	N	O
14	juice	N	O
15	)	N	O
16	for	N	O
17	the	N	O
18	management	N	O
19	of	N	O
20	chemotherapy-induced	N	O
21	nausea	N	O
22	and	N	O
23	vomiting	N	O
24	(	N	O
25	CINV	N	O
26	)	N	O
27	;	N	O
28	to	N	O
29	evaluate	N	O
30	the	N	O
31	usefulness	N	O
32	of	N	O
33	existing	N	O
34	measures	N	O
35	for	N	O
36	assessing	N	O
37	CINV	N	O
38	frequency	N	O
39	and	N	O
40	severity	N	O
41	,	N	O
42	quality	N	O
43	of	N	O
44	life	N	O
45	,	N	O
46	control	N	O
47	over	N	O
48	life	N	O
49	events	N	O
50	,	N	O
51	and	N	O
52	psychological	N	O
53	state	N	O
54	;	N	O
55	to	N	O
56	identify	N	O
57	any	N	O
58	actual	N	O
59	or	N	O
60	potential	N	O
61	adverse	N	O
62	events	N	O
63	associated	N	O
64	with	N	O
65	frequent	N	O
66	grape	N	O
67	juice	N	O
68	intake	N	O
69	;	N	O
70	and	N	O
71	to	N	O
72	provide	N	O
73	preliminary	N	O
74	data	N	O
75	concerning	N	O
76	the	N	O
77	effect	N	O
78	of	N	O
79	Concord	N	O
80	grape	N	O
81	juice	N	O
82	on	N	O
83	CINV	N	O
84	,	N	O
85	quality	N	O
86	of	N	O
87	life	N	O
88	,	N	O
89	perceived	N	O
90	control	N	O
91	over	N	O
92	life	N	O
93	events	N	O
94	,	N	O
95	and	N	O
96	psychological	N	O
97	state	N	O
98	.	N	O

1	Double-blind	N	O
2	,	N	O
3	randomized	N	O
4	clinical	N	O
5	trial	N	O
6	.	N	O

1	A	N	O
2	cancer	N	O
3	center	N	O
4	in	N	O
5	an	N	O
6	academic	N	O
7	health	N	O
8	science	N	O
9	center	N	O
10	in	N	O
11	the	N	O
12	northeastern	N	O
13	United	N	O
14	States	N	O
15	.	N	O

1	77	N	O
2	adult	N	O
3	patients	N	O
4	with	N	O
5	cancer	N	O
6	receiving	N	O
7	moderately	N	O
8	or	N	O
9	highly	N	O
10	emetogenic	N	O
11	chemotherapy	N	O
12	agents	N	O
13	.	N	O

1	Participants	N	O
2	drank	N	O
3	4	N	O
4	oz	N	O
5	.	N	O

1	of	N	O
2	grape	N	O
3	juice	N	O
4	or	N	O
5	placebo	N	O
6	prior	N	O
7	to	N	O
8	meals	N	O
9	for	N	O
10	one	N	O
11	week	N	O
12	following	N	O
13	each	N	O
14	of	N	O
15	four	N	O
16	chemotherapy	N	O
17	treatment	N	O
18	cycles	N	O
19	.	N	O

1	They	N	O
2	recorded	N	O
3	frequency	N	O
4	,	N	O
5	duration	N	O
6	,	N	O
7	and	N	O
8	distress	N	O
9	of	N	O
10	nausea	N	O
11	,	N	O
12	vomiting	N	O
13	,	N	O
14	and	N	O
15	retching	N	O
16	daily	N	O
17	,	N	O
18	beginning	N	O
19	the	N	O
20	evening	N	O
21	of	N	O
22	chemotherapy	N	O
23	administration	N	O
24	and	N	O
25	continuing	N	O
26	for	N	O
27	seven	N	O
28	days	N	O
29	.	N	O

1	Data	N	O
2	were	N	O
3	analyzed	N	O
4	with	N	O
5	generalized	N	O
6	estimating	N	O
7	equations	N	O
8	methodology	N	O
9	to	N	O
10	model	N	O
11	differences	N	O
12	between	N	O
13	groups	N	O
14	over	N	O
15	time	N	O
16	.	N	O

1	Nausea	N	I-Premise
2	and	N	I-Premise
3	vomiting	N	I-Premise
4	frequency	N	I-Premise
5	,	N	I-Premise
6	duration	N	I-Premise
7	,	N	I-Premise
8	and	N	I-Premise
9	distress	N	I-Premise
10	were	N	I-Premise
11	lower	N	I-Premise
12	for	N	I-Premise
13	experimental	N	I-Premise
14	group	N	I-Premise
15	members	N	I-Premise
16	,	N	I-Premise
17	although	N	I-Premise
18	a	N	I-Premise
19	high	N	I-Premise
20	attrition	N	I-Premise
21	rate	N	I-Premise
22	(	N	I-Premise
23	50	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	resulted	N	I-Premise
27	in	N	I-Premise
28	insufficient	N	I-Premise
29	power	N	I-Premise
30	to	N	I-Premise
31	detect	N	I-Premise
32	statistically	N	I-Premise
33	significant	N	I-Premise
34	differences	N	I-Premise
35	over	N	I-Premise
36	time	N	I-Premise
37	.	N	I-Premise

1	Greater	N	O
2	levels	N	O
3	of	N	O
4	anxiety	N	O
5	,	N	O
6	depression	N	O
7	,	N	O
8	and	N	O
9	hostility	N	O
10	at	N	O
11	baseline	N	O
12	were	N	O
13	related	N	O
14	to	N	O
15	nausea	N	O
16	and	N	O
17	vomiting	N	O
18	,	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	,	N	O
23	and	N	O
24	perceived	N	O
25	control	N	O
26	over	N	O
27	decision	N	O
28	making	N	O
29	.	N	O

1	The	N	I-Claim
2	effect	N	I-Claim
3	of	N	I-Claim
4	grape	N	I-Claim
5	juice	N	I-Claim
6	flavonoids	N	I-Claim
7	on	N	I-Claim
8	CINV	N	I-Claim
9	should	N	I-Claim
10	be	N	I-Claim
11	investigated	N	I-Claim
12	further	N	I-Claim
13	with	N	I-Claim
14	a	N	I-Claim
15	larger	N	I-Claim
16	sample	N	I-Claim
17	to	N	I-Claim
18	determine	N	I-Claim
19	whether	N	I-Claim
20	preliminary	N	I-Claim
21	findings	N	I-Claim
22	are	N	I-Claim
23	supported	N	I-Claim
24	.	N	I-Claim

1	Alterations	N	O
2	to	N	O
3	the	N	O
4	study	N	O
5	protocol	N	O
6	will	N	O
7	be	N	O
8	necessary	N	O
9	to	N	O
10	decrease	N	O
11	attrition	N	O
12	.	N	O

1	Flavonoid-rich	N	I-Claim
2	fruits	N	I-Claim
3	and	N	I-Claim
4	vegetables	N	I-Claim
5	may	N	I-Claim
6	provide	N	I-Claim
7	additional	N	I-Claim
8	protection	N	I-Claim
9	against	N	I-Claim
10	CINV	N	I-Claim
11	.	N	I-Claim

1	If	N	O
2	the	N	O
3	compounds	N	O
4	work	N	O
5	,	N	O
6	they	N	O
7	would	N	O
8	offer	N	O
9	a	N	O
10	low-cost	N	O
11	,	N	O
12	readily	N	O
13	available	N	O
14	adjunctive	N	O
15	treatment	N	O
16	for	N	O
17	the	N	O
18	management	N	O
19	of	N	O
20	CINV	N	O
21	.	N	O

1	Promising	N	O
2	results	N	O
3	in	N	O
4	a	N	O
5	randomized	N	O
6	phase	N	O
7	II	N	O
8	trial	N	O
9	with	N	O
10	the	N	O
11	hypoxic	N	O
12	cytotoxin	N	O
13	tirapazamine	N	O
14	(	N	O
15	TPZ	N	O
16	)	N	O
17	combined	N	O
18	with	N	O
19	cisplatin	N	O
20	(	N	O
21	CIS	N	O
22	)	N	O
23	and	N	O
24	radiation	N	O
25	led	N	O
26	to	N	O
27	this	N	O
28	phase	N	O
29	III	N	O
30	trial	N	O
31	.	N	O

1	Patients	N	O
2	with	N	O
3	previously	N	O
4	untreated	N	O
5	stage	N	O
6	III	N	O
7	or	N	O
8	IV	N	O
9	(	N	O
10	excluding	N	O
11	T1-2N1	N	O
12	and	N	O
13	M1	N	O
14	)	N	O
15	squamous	N	O
16	cell	N	O
17	carcinoma	N	O
18	of	N	O
19	the	N	O
20	oral	N	O
21	cavity	N	O
22	,	N	O
23	oropharynx	N	O
24	,	N	O
25	hypopharynx	N	O
26	,	N	O
27	or	N	O
28	larynx	N	O
29	were	N	O
30	randomly	N	O
31	assigned	N	O
32	to	N	O
33	receive	N	O
34	definitive	N	O
35	radiotherapy	N	O
36	(	N	O
37	70	N	O
38	Gy	N	O
39	in	N	O
40	7	N	O
41	weeks	N	O
42	)	N	O
43	concurrently	N	O
44	with	N	O
45	either	N	O
46	CIS	N	O
47	(	N	O
48	100	N	O
49	mg/m	N	O
50	(	N	O
51	2	N	O
52	)	N	O
53	)	N	O
54	on	N	O
55	day	N	O
56	1	N	O
57	of	N	O
58	weeks	N	O
59	1	N	O
60	,	N	O
61	4	N	O
62	,	N	O
63	and	N	O
64	7	N	O
65	or	N	O
66	CIS	N	O
67	(	N	O
68	75	N	O
69	mg/m	N	O
70	(	N	O
71	2	N	O
72	)	N	O
73	)	N	O
74	plus	N	O
75	TPZ	N	O
76	(	N	O
77	290	N	O
78	mg/m	N	O
79	(	N	O
80	2	N	O
81	)	N	O
82	/d	N	O
83	)	N	O
84	on	N	O
85	day	N	O
86	1	N	O
87	of	N	O
88	weeks	N	O
89	1	N	O
90	,	N	O
91	4	N	O
92	,	N	O
93	and	N	O
94	7	N	O
95	and	N	O
96	TPZ	N	O
97	alone	N	O
98	(	N	O
99	160	N	O
100	mg/m	N	O
101	(	N	O
102	2	N	O
103	)	N	O
104	/d	N	O
105	)	N	O
106	on	N	O
107	days	N	O
108	1	N	O
109	,	N	O
110	3	N	O
111	,	N	O
112	and	N	O
113	5	N	O
114	of	N	O
115	weeks	N	O
116	2	N	O
117	and	N	O
118	3	N	O
119	(	N	O
120	TPZ/CIS	N	O
121	)	N	O
122	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	overall	N	O
7	survival	N	O
8	(	N	O
9	OS	N	O
10	)	N	O
11	.	N	O

1	The	N	O
2	planned	N	O
3	sample	N	O
4	size	N	O
5	was	N	O
6	850	N	O
7	,	N	O
8	estimated	N	O
9	to	N	O
10	result	N	O
11	in	N	O
12	334	N	O
13	deaths	N	O
14	,	N	O
15	which	N	O
16	would	N	O
17	provide	N	O
18	90	N	O
19	%	N	O
20	power	N	O
21	to	N	O
22	detect	N	O
23	a	N	O
24	difference	N	O
25	in	N	O
26	2-year	N	O
27	survival	N	O
28	rates	N	O
29	of	N	O
30	60	N	O
31	%	N	O
32	v	N	O
33	70	N	O
34	%	N	O
35	for	N	O
36	CIS	N	O
37	versus	N	O
38	TPZ/CIS	N	O
39	,	N	O
40	respectively	N	O
41	(	N	O
42	hazard	N	O
43	ratio	N	O
44	=	N	O
45	0.69	N	O
46	)	N	O
47	.	N	O

1	Eight	N	O
2	hundred	N	O
3	sixty-one	N	O
4	patients	N	O
5	were	N	O
6	accrued	N	O
7	from	N	O
8	89	N	O
9	sites	N	O
10	in	N	O
11	16	N	O
12	countries	N	O
13	.	N	O

1	In	N	I-Premise
2	an	N	I-Premise
3	intent-to-treat	N	I-Premise
4	analysis	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	2-year	N	I-Premise
8	OS	N	I-Premise
9	rates	N	I-Premise
10	were	N	I-Premise
11	65.7	N	I-Premise
12	%	N	I-Premise
13	for	N	I-Premise
14	CIS	N	I-Premise
15	and	N	I-Premise
16	66.2	N	I-Premise
17	%	N	I-Premise
18	for	N	I-Premise
19	TPZ/CIS	N	I-Premise
20	(	N	I-Premise
21	TPZ/CIS	N	I-Premise
22	--	N	I-Premise
23	CIS	N	I-Premise
24	:	N	I-Premise
25	95	N	I-Premise
26	%	N	I-Premise
27	CI	N	I-Premise
28	,	N	I-Premise
29	-5.9	N	I-Premise
30	%	N	I-Premise
31	to	N	I-Premise
32	6.9	N	I-Premise
33	%	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	in	N	I-Premise
7	failure-free	N	I-Premise
8	survival	N	I-Premise
9	,	N	I-Premise
10	time	N	I-Premise
11	to	N	I-Premise
12	locoregional	N	I-Premise
13	failure	N	I-Premise
14	,	N	I-Premise
15	or	N	I-Premise
16	quality	N	I-Premise
17	of	N	I-Premise
18	life	N	I-Premise
19	as	N	I-Premise
20	measured	N	I-Premise
21	by	N	I-Premise
22	Functional	N	I-Premise
23	Assessment	N	I-Premise
24	of	N	I-Premise
25	Cancer	N	I-Premise
26	Therapy-Head	N	I-Premise
27	and	N	I-Premise
28	Neck	N	I-Premise
29	.	N	I-Premise

1	We	N	I-Claim
2	found	N	I-Claim
3	no	N	I-Claim
4	evidence	N	I-Claim
5	that	N	I-Claim
6	the	N	I-Claim
7	addition	N	I-Claim
8	of	N	I-Claim
9	TPZ	N	I-Claim
10	to	N	I-Claim
11	chemoradiotherapy	N	I-Claim
12	,	N	I-Claim
13	in	N	I-Claim
14	patients	N	I-Claim
15	with	N	I-Claim
16	advanced	N	I-Claim
17	head	N	I-Claim
18	and	N	I-Claim
19	neck	N	I-Claim
20	cancer	N	I-Claim
21	not	N	I-Claim
22	selected	N	I-Claim
23	for	N	I-Claim
24	the	N	I-Claim
25	presence	N	I-Claim
26	of	N	I-Claim
27	hypoxia	N	I-Claim
28	,	N	I-Claim
29	improves	N	I-Claim
30	OS	N	I-Claim
31	.	N	I-Claim

1	To	N	O
2	examine	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	a	N	O
7	scapula-oriented	N	O
8	exercise	N	O
9	on	N	O
10	upper	N	O
11	limb	N	O
12	dysfunction	N	O
13	in	N	O
14	breast	N	O
15	cancer	N	O
16	survivors	N	O
17	.	N	O

1	A	N	O
2	prospective	N	O
3	randomized	N	O
4	,	N	O
5	controlled	N	O
6	pilot	N	O
7	trial	N	O
8	with	N	O
9	historical	N	O
10	control	N	O
11	.	N	O

1	Rehabilitation	N	O
2	department	N	O
3	at	N	O
4	a	N	O
5	university	N	O
6	hospital	N	O
7	.	N	O

1	Thirty-two	N	O
2	women	N	O
3	with	N	O
4	breast	N	O
5	cancer	N	O
6	were	N	O
7	randomly	N	O
8	assigned	N	O
9	to	N	O
10	scapula-oriented	N	O
11	exercise	N	O
12	group	N	O
13	(	N	O
14	n	N	O
15	=	N	O
16	16	N	O
17	)	N	O
18	and	N	O
19	general	N	O
20	exercise	N	O
21	group	N	O
22	(	N	O
23	n	N	O
24	=	N	O
25	16	N	O
26	)	N	O
27	.	N	O

1	An	N	O
2	historical	N	O
3	control	N	O
4	group	N	O
5	(	N	O
6	n	N	O
7	=	N	O
8	18	N	O
9	)	N	O
10	without	N	O
11	exercise	N	O
12	was	N	O
13	enrolled	N	O
14	from	N	O
15	breast	N	O
16	cancer	N	O
17	survivors	N	O
18	.	N	O

1	The	N	O
2	scapula-oriented	N	O
3	exercises	N	O
4	were	N	O
5	designed	N	O
6	focusing	N	O
7	on	N	O
8	scapulothoracic	N	O
9	movement	N	O
10	.	N	O

1	The	N	O
2	general	N	O
3	exercise	N	O
4	group	N	O
5	performed	N	O
6	body	N	O
7	conditioning	N	O
8	exercise	N	O
9	.	N	O

1	Exercise	N	O
2	therapies	N	O
3	were	N	O
4	performed	N	O
5	for	N	O
6	one	N	O
7	session	N	O
8	per	N	O
9	week	N	O
10	for	N	O
11	eight	N	O
12	weeks	N	O
13	.	N	O

1	Pain	N	O
2	and	N	O
3	physical	N	O
4	disabilities	N	O
5	related	N	O
6	to	N	O
7	upper	N	O
8	limb	N	O
9	dysfunction	N	O
10	,	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	and	N	O
15	depression	N	O
16	were	N	O
17	used	N	O
18	as	N	O
19	subjective	N	O
20	outcomes	N	O
21	.	N	O

1	Objective	N	O
2	outcome	N	O
3	measures	N	O
4	included	N	O
5	shoulder	N	O
6	range	N	O
7	of	N	O
8	motion	N	O
9	and	N	O
10	strength	N	O
11	.	N	O

1	Outcomes	N	O
2	were	N	O
3	assessed	N	O
4	at	N	O
5	baseline	N	O
6	and	N	O
7	post	N	O
8	exercise	N	O
9	.	N	O

1	At	N	O
2	baseline	N	O
3	,	N	O
4	no	N	O
5	significant	N	O
6	difference	N	O
7	was	N	O
8	observed	N	O
9	among	N	O
10	the	N	O
11	three	N	O
12	groups	N	O
13	.	N	O

1	The	N	I-Premise
2	scapula-oriented	N	I-Premise
3	exercise	N	I-Premise
4	group	N	I-Premise
5	showed	N	I-Premise
6	improvements	N	I-Premise
7	in	N	I-Premise
8	pain	N	I-Premise
9	,	N	I-Premise
10	physical	N	I-Premise
11	function	N	I-Premise
12	,	N	I-Premise
13	social	N	I-Premise
14	function	N	I-Premise
15	,	N	I-Premise
16	and	N	I-Premise
17	global	N	I-Premise
18	quality	N	I-Premise
19	of	N	I-Premise
20	life	N	I-Premise
21	compared	N	I-Premise
22	with	N	I-Premise
23	baseline	N	I-Premise
24	,	N	I-Premise
25	whereas	N	I-Premise
26	the	N	I-Premise
27	general	N	I-Premise
28	exercise	N	I-Premise
29	group	N	I-Premise
30	showed	N	I-Premise
31	improved	N	I-Premise
32	fatigue	N	I-Premise
33	and	N	I-Premise
34	range	N	I-Premise
35	of	N	I-Premise
36	motion	N	I-Premise
37	.	N	I-Premise

1	The	N	I-Premise
2	change	N	I-Premise
3	in	N	I-Premise
4	global	N	I-Premise
5	quality	N	I-Premise
6	of	N	I-Premise
7	life	N	I-Premise
8	(	N	I-Premise
9	P	N	I-Premise
10	=	N	I-Premise
11	0.067	N	I-Premise
12	;	N	I-Premise
13	effect	N	I-Premise
14	size	N	I-Premise
15	,	N	I-Premise
16	0.33	N	I-Premise
17	)	N	I-Premise
18	and	N	I-Premise
19	strength	N	I-Premise
20	of	N	I-Premise
21	external	N	I-Premise
22	rotation	N	I-Premise
23	(	N	I-Premise
24	P	N	I-Premise
25	=	N	I-Premise
26	0.001	N	I-Premise
27	;	N	I-Premise
28	effect	N	I-Premise
29	size	N	I-Premise
30	,	N	I-Premise
31	0.55	N	I-Premise
32	)	N	I-Premise
33	were	N	I-Premise
34	significantly	N	I-Premise
35	greater	N	I-Premise
36	in	N	I-Premise
37	the	N	I-Premise
38	scapula-oriented	N	I-Premise
39	exercise	N	I-Premise
40	group	N	I-Premise
41	than	N	I-Premise
42	in	N	I-Premise
43	the	N	I-Premise
44	general	N	I-Premise
45	exercise	N	I-Premise
46	and	N	I-Premise
47	control	N	I-Premise
48	group	N	I-Premise
49	.	N	I-Premise

1	Scapula-oriented	N	I-Claim
2	exercise	N	I-Claim
3	had	N	I-Claim
4	beneficial	N	I-Claim
5	effects	N	I-Claim
6	on	N	I-Claim
7	pain	N	I-Claim
8	,	N	I-Claim
9	quality	N	I-Claim
10	of	N	I-Claim
11	life	N	I-Claim
12	and	N	I-Claim
13	aspects	N	I-Claim
14	of	N	I-Claim
15	strength	N	I-Claim
16	.	N	I-Claim

1	The	N	O
2	sample	N	O
3	size	N	O
4	required	N	O
5	in	N	O
6	a	N	O
7	larger	N	O
8	definitive	N	O
9	study	N	O
10	is	N	O
11	32	N	O
12	subjects	N	O
13	per	N	O
14	group	N	O
15	.	N	O

1	For	N	O
2	patients	N	O
3	undergoing	N	O
4	oncologic	N	O
5	surgery	N	O
6	,	N	O
7	the	N	O
8	quality	N	O
9	of	N	O
10	life	N	O
11	(	N	O
12	QoL	N	O
13	)	N	O
14	is	N	O
15	generally	N	O
16	accepted	N	O
17	as	N	O
18	an	N	O
19	important	N	O
20	outcome	N	O
21	parameter	N	O
22	in	N	O
23	addition	N	O
24	to	N	O
25	long-term	N	O
26	survival	N	O
27	,	N	O
28	mortality	N	O
29	and	N	O
30	complication	N	O
31	rates	N	O
32	.	N	O

1	This	N	O
2	study	N	O
3	focussed	N	O
4	on	N	O
5	the	N	O
6	QoL	N	O
7	in	N	O
8	patients	N	O
9	after	N	O
10	oesophagectomy	N	O
11	for	N	O
12	cancer	N	O
13	,	N	O
14	comparing	N	O
15	the	N	O
16	method	N	O
17	of	N	O
18	reconstruction	N	O
19	(	N	O
20	narrow	N	O
21	gastric	N	O
22	tube	N	O
23	vs	N	O
24	whole	N	O
25	stomach	N	O
26	)	N	O
27	.	N	O

1	In	N	O
2	a	N	O
3	prospective	N	O
4	randomised	N	O
5	single-centre	N	O
6	study	N	O
7	from	N	O
8	2007	N	O
9	to	N	O
10	2008	N	O
11	,	N	O
12	104	N	O
13	patients	N	O
14	underwent	N	O
15	oesophagectomy	N	O
16	for	N	O
17	cancer	N	O
18	.	N	O

1	To	N	O
2	assess	N	O
3	the	N	O
4	QoL	N	O
5	,	N	O
6	a	N	O
7	questionnaire	N	O
8	in	N	O
9	reference	N	O
10	to	N	O
11	the	N	O
12	EORTC-QLQ-C30	N	O
13	and	N	O
14	the	N	O
15	QLQ-OES24	N	O
16	was	N	O
17	administered	N	O
18	at	N	O
19	3	N	O
20	weeks	N	O
21	,	N	O
22	6	N	O
23	months	N	O
24	and	N	O
25	1	N	O
26	year	N	O
27	after	N	O
28	surgery	N	O
29	.	N	O

1	Clinical	N	O
2	data	N	O
3	were	N	O
4	collected	N	O
5	prospectively	N	O
6	,	N	O
7	and	N	O
8	follow-up	N	O
9	was	N	O
10	performed	N	O
11	regularly	N	O
12	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	between	N	I-Premise
7	the	N	I-Premise
8	narrow	N	I-Premise
9	gastric	N	I-Premise
10	tube	N	I-Premise
11	group	N	I-Premise
12	(	N	I-Premise
13	NGT	N	I-Premise
14	group	N	I-Premise
15	,	N	I-Premise
16	n=52	N	I-Premise
17	)	N	I-Premise
18	and	N	I-Premise
19	the	N	I-Premise
20	whole-stomach	N	I-Premise
21	group	N	I-Premise
22	(	N	I-Premise
23	WS	N	I-Premise
24	group	N	I-Premise
25	,	N	I-Premise
26	n=52	N	I-Premise
27	)	N	I-Premise
28	with	N	I-Premise
29	regard	N	I-Premise
30	to	N	I-Premise
31	patient	N	I-Premise
32	and	N	I-Premise
33	cancer	N	I-Premise
34	characteristics	N	I-Premise
35	,	N	I-Premise
36	operative	N	I-Premise
37	procedure	N	I-Premise
38	,	N	I-Premise
39	postoperative	N	I-Premise
40	intensive	N	I-Premise
41	care	N	I-Premise
42	unit	N	I-Premise
43	(	N	I-Premise
44	ICU	N	I-Premise
45	)	N	I-Premise
46	hospitalisation	N	I-Premise
47	,	N	I-Premise
48	and	N	I-Premise
49	overall	N	I-Premise
50	survival	N	I-Premise
51	at	N	I-Premise
52	1	N	I-Premise
53	year	N	I-Premise
54	.	N	I-Premise

1	Regarding	N	I-Premise
2	the	N	I-Premise
3	postoperative	N	I-Premise
4	complication	N	I-Premise
5	,	N	I-Premise
6	there	N	I-Premise
7	were	N	I-Premise
8	more	N	I-Premise
9	cases	N	I-Premise
10	of	N	I-Premise
11	postoperative	N	I-Premise
12	reflux	N	I-Premise
13	oesophagitis	N	I-Premise
14	and	N	I-Premise
15	impairment	N	I-Premise
16	of	N	I-Premise
17	pulmonary	N	I-Premise
18	function	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	WS	N	I-Premise
22	group	N	I-Premise
23	(	N	I-Premise
24	P	N	I-Premise
25	<	N	I-Premise
26	0.05	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	Regarding	N	I-Premise
2	the	N	I-Premise
3	QoL	N	I-Premise
4	investigation	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	scores	N	I-Premise
8	of	N	I-Premise
9	QoL	N	I-Premise
10	dropped	N	I-Premise
11	for	N	I-Premise
12	all	N	I-Premise
13	patients	N	I-Premise
14	at	N	I-Premise
15	3	N	I-Premise
16	weeks	N	I-Premise
17	after	N	I-Premise
18	surgery	N	I-Premise
19	.	N	I-Premise

1	Slowly	N	O
2	,	N	O
3	recovery	N	I-Premise
4	was	N	I-Premise
5	found	N	I-Premise
6	at	N	I-Premise
7	both	N	I-Premise
8	6	N	I-Premise
9	months	N	I-Premise
10	and	N	I-Premise
11	1	N	I-Premise
12	year	N	I-Premise
13	in	N	I-Premise
14	both	N	I-Premise
15	groups	N	I-Premise
16	.	N	I-Premise

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	NGT	N	I-Premise
5	group	N	I-Premise
6	reported	N	I-Premise
7	significantly	N	I-Premise
8	(	N	I-Premise
9	P	N	I-Premise
10	<	N	I-Premise
11	0.05	N	I-Premise
12	)	N	I-Premise
13	better	N	I-Premise
14	scores	N	I-Premise
15	of	N	I-Premise
16	QoL	N	I-Premise
17	at	N	I-Premise
18	both	N	I-Premise
19	6	N	I-Premise
20	months	N	I-Premise
21	and	N	I-Premise
22	1	N	I-Premise
23	year	N	I-Premise
24	.	N	I-Premise

1	Patients	N	I-Claim
2	who	N	I-Claim
3	underwent	N	I-Claim
4	gastric	N	I-Claim
5	tube	N	I-Claim
6	reconstruction	N	I-Claim
7	develop	N	I-Claim
8	less	N	I-Claim
9	postoperative	N	I-Claim
10	digestive	N	I-Claim
11	tract	N	I-Claim
12	complications	N	I-Claim
13	,	N	I-Claim
14	and	N	I-Claim
15	have	N	I-Claim
16	a	N	I-Claim
17	quicker	N	I-Claim
18	recovery	N	I-Claim
19	and	N	I-Claim
20	a	N	I-Claim
21	better	N	I-Claim
22	QoL	N	I-Claim
23	during	N	I-Claim
24	the	N	I-Claim
25	follow-up	N	I-Claim
26	period	N	I-Claim
27	.	N	I-Claim

1	Further	N	O
2	investigation	N	O
3	and	N	O
4	data	N	O
5	collection	N	O
6	will	N	O
7	allow	N	O
8	the	N	O
9	assessment	N	O
10	of	N	O
11	this	N	O
12	procedure	N	O
13	beyond	N	O
14	1	N	O
15	year	N	O
16	after	N	O
17	operation	N	O
18	.	N	O

1	Paclitaxel	N	O
2	and	N	O
3	pegylated	N	O
4	liposomal	N	O
5	doxorubicin	N	O
6	(	N	O
7	PLD	N	O
8	)	N	O
9	are	N	O
10	active	N	O
11	cytotoxic	N	O
12	agents	N	O
13	for	N	O
14	the	N	O
15	treatment	N	O
16	of	N	O
17	human	N	O
18	immunodeficiency	N	O
19	virus	N	O
20	(	N	O
21	HIV	N	O
22	)	N	O
23	-associated	N	O
24	Kaposi	N	O
25	sarcoma	N	O
26	(	N	O
27	KS	N	O
28	)	N	O
29	.	N	O

1	A	N	O
2	randomized	N	O
3	trial	N	O
4	comparing	N	O
5	the	N	O
6	efficacy	N	O
7	and	N	O
8	toxicity	N	O
9	of	N	O
10	paclitaxel	N	O
11	and	N	O
12	PLD	N	O
13	was	N	O
14	performed	N	O
15	,	N	O
16	and	N	O
17	the	N	O
18	effects	N	O
19	of	N	O
20	therapy	N	O
21	on	N	O
22	symptom	N	O
23	palliation	N	O
24	and	N	O
25	quality	N	O
26	of	N	O
27	life	N	O
28	were	N	O
29	determined	N	O
30	.	N	O

1	Patients	N	O
2	with	N	O
3	advanced	N	O
4	HIV-associated	N	O
5	KS	N	O
6	were	N	O
7	randomly	N	O
8	assigned	N	O
9	to	N	O
10	receive	N	O
11	paclitaxel	N	O
12	at	N	O
13	a	N	O
14	dose	N	O
15	of	N	O
16	100	N	O
17	mg/m2	N	O
18	intravenously	N	O
19	(	N	O
20	iv	N	O
21	)	N	O
22	every	N	O
23	2	N	O
24	weeks	N	O
25	or	N	O
26	PLD	N	O
27	at	N	O
28	a	N	O
29	dose	N	O
30	of	N	O
31	20	N	O
32	mg/m2	N	O
33	iv	N	O
34	every	N	O
35	3	N	O
36	weeks	N	O
37	.	N	O

1	The	N	O
2	KS	N	O
3	Functional	N	O
4	Assessment	N	O
5	of	N	O
6	HIV	N	O
7	(	N	O
8	FAHI	N	O
9	)	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	instrument	N	O
14	was	N	O
15	used	N	O
16	before	N	O
17	and	N	O
18	after	N	O
19	every	N	O
20	other	N	O
21	treatment	N	O
22	cycle	N	O
23	.	N	O

1	The	N	O
2	study	N	O
3	included	N	O
4	73	N	O
5	analyzable	N	O
6	patients	N	O
7	enrolled	N	O
8	between	N	O
9	1998	N	O
10	and	N	O
11	2002	N	O
12	,	N	O
13	including	N	O
14	36	N	O
15	in	N	O
16	the	N	O
17	paclitaxel	N	O
18	arm	N	O
19	and	N	O
20	37	N	O
21	in	N	O
22	the	N	O
23	PLD	N	O
24	arm	N	O
25	;	N	O
26	73	N	O
27	%	N	O
28	of	N	O
29	patients	N	O
30	received	N	O
31	highly	N	O
32	active	N	O
33	antiretroviral	N	O
34	therapy	N	O
35	(	N	O
36	HAART	N	O
37	)	N	O
38	and	N	O
39	32	N	O
40	%	N	O
41	had	N	O
42	an	N	O
43	undetectable	N	O
44	viral	N	O
45	load	N	O
46	(	N	O
47	<	N	O
48	400	N	O
49	copies/mL	N	O
50	)	N	O
51	.	N	O

1	Treatment	N	I-Premise
2	was	N	I-Premise
3	associated	N	I-Premise
4	with	N	I-Premise
5	significant	N	I-Premise
6	improvements	N	I-Premise
7	in	N	I-Premise
8	pain	N	I-Premise
9	(	N	I-Premise
10	P=.024	N	I-Premise
11	)	N	I-Premise
12	and	N	I-Premise
13	swelling	N	I-Premise
14	(	N	I-Premise
15	P	N	I-Premise
16	<	N	I-Premise
17	.001	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	Of	N	I-Premise
2	the	N	I-Premise
3	36	N	I-Premise
4	patients	N	I-Premise
5	who	N	I-Premise
6	reported	N	I-Premise
7	that	N	I-Premise
8	pain	N	I-Premise
9	interfered	N	I-Premise
10	with	N	I-Premise
11	their	N	I-Premise
12	normal	N	I-Premise
13	work	N	I-Premise
14	or	N	I-Premise
15	activities	N	I-Premise
16	at	N	I-Premise
17	baseline	N	I-Premise
18	,	N	I-Premise
19	25	N	I-Premise
20	(	N	I-Premise
21	69	N	I-Premise
22	%	N	I-Premise
23	)	N	I-Premise
24	improved	N	I-Premise
25	.	N	I-Premise

1	Of	N	I-Premise
2	the	N	I-Premise
3	41	N	I-Premise
4	patients	N	I-Premise
5	who	N	I-Premise
6	reported	N	I-Premise
7	swelling	N	I-Premise
8	at	N	I-Premise
9	baseline	N	I-Premise
10	,	N	I-Premise
11	38	N	I-Premise
12	(	N	I-Premise
13	93	N	I-Premise
14	%	N	I-Premise
15	)	N	I-Premise
16	improved	N	I-Premise
17	.	N	I-Premise

1	Comparing	N	I-Premise
2	the	N	I-Premise
3	paclitaxel	N	I-Premise
4	and	N	I-Premise
5	PLD	N	I-Premise
6	arms	N	I-Premise
7	revealed	N	I-Premise
8	comparable	N	I-Premise
9	response	N	I-Premise
10	rates	N	I-Premise
11	(	N	I-Premise
12	56	N	I-Premise
13	%	N	I-Premise
14	vs	N	I-Premise
15	46	N	I-Premise
16	%	N	I-Premise
17	;	N	I-Premise
18	P=.49	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	median	N	I-Premise
22	progression-free	N	I-Premise
23	survival	N	I-Premise
24	(	N	I-Premise
25	17.5	N	I-Premise
26	months	N	I-Premise
27	vs	N	I-Premise
28	12.2	N	I-Premise
29	months	N	I-Premise
30	;	N	I-Premise
31	P=.66	N	I-Premise
32	)	N	I-Premise
33	,	N	I-Premise
34	and	N	I-Premise
35	2-year	N	I-Premise
36	survival	N	I-Premise
37	rates	N	I-Premise
38	(	N	I-Premise
39	79	N	I-Premise
40	%	N	I-Premise
41	vs	N	I-Premise
42	78	N	I-Premise
43	%	N	I-Premise
44	;	N	I-Premise
45	P=.75	N	I-Premise
46	)	N	I-Premise
47	,	N	I-Premise
48	but	N	I-Premise
49	somewhat	N	I-Premise
50	more	N	I-Premise
51	grade	N	I-Premise
52	3	N	I-Premise
53	to	N	I-Premise
54	5	N	I-Premise
55	toxicity	N	I-Premise
56	for	N	I-Premise
57	paclitaxel	N	I-Premise
58	(	N	I-Premise
59	84	N	I-Premise
60	%	N	I-Premise
61	vs	N	I-Premise
62	66	N	I-Premise
63	%	N	I-Premise
64	;	N	I-Premise
65	P=.077	N	I-Premise
66	)	N	I-Premise
67	.	N	I-Premise

1	Treatment	N	I-Claim
2	with	N	I-Claim
3	either	N	I-Claim
4	paclitaxel	N	I-Claim
5	or	N	I-Claim
6	PLD	N	I-Claim
7	appears	N	I-Claim
8	to	N	I-Claim
9	produce	N	I-Claim
10	significant	N	I-Claim
11	improvements	N	I-Claim
12	in	N	I-Claim
13	pain	N	I-Claim
14	and	N	I-Claim
15	swelling	N	I-Claim
16	in	N	I-Claim
17	patients	N	I-Claim
18	with	N	I-Claim
19	advanced	N	I-Claim
20	,	N	I-Claim
21	symptomatic	N	I-Claim
22	,	N	I-Claim
23	HIV-associated	N	I-Claim
24	KS	N	I-Claim
25	treated	N	I-Claim
26	in	N	I-Claim
27	the	N	I-Claim
28	HAART	N	I-Claim
29	era	N	I-Claim
30	.	N	I-Claim

1	Lung	N	O
2	cancer	N	O
3	is	N	O
4	one	N	O
5	of	N	O
6	the	N	O
7	most	N	O
8	common	N	O
9	cancers	N	O
10	in	N	O
11	the	N	O
12	United	N	O
13	States	N	O
14	and	N	O
15	is	N	O
16	associated	N	O
17	with	N	O
18	high	N	O
19	levels	N	O
20	of	N	O
21	symptoms	N	O
22	,	N	O
23	including	N	O
24	pain	N	O
25	,	N	O
26	fatigue	N	O
27	,	N	O
28	shortness	N	O
29	of	N	O
30	breath	N	O
31	,	N	O
32	and	N	O
33	psychological	N	O
34	distress	N	O
35	.	N	O

1	Caregivers	N	O
2	and	N	O
3	patients	N	O
4	are	N	O
5	adversely	N	O
6	affected	N	O
7	.	N	O

1	However	N	O
2	,	N	O
3	previous	N	O
4	studies	N	O
5	of	N	O
6	coping	N	O
7	skills	N	O
8	training	N	O
9	(	N	O
10	CST	N	O
11	)	N	O
12	interventions	N	O
13	have	N	O
14	not	N	O
15	been	N	O
16	tested	N	O
17	in	N	O
18	patients	N	O
19	with	N	O
20	lung	N	O
21	cancer	N	O
22	nor	N	O
23	have	N	O
24	systematically	N	O
25	included	N	O
26	caregivers	N	O
27	.	N	O

1	This	N	O
2	study	N	O
3	tested	N	O
4	the	N	O
5	efficacy	N	O
6	of	N	O
7	a	N	O
8	caregiver-assisted	N	O
9	CST	N	O
10	protocol	N	O
11	in	N	O
12	a	N	O
13	sample	N	O
14	of	N	O
15	patients	N	O
16	with	N	O
17	lung	N	O
18	cancer	N	O
19	.	N	O

1	Two	N	O
2	hundred	N	O
3	thirty-three	N	O
4	lung	N	O
5	cancer	N	O
6	patients	N	O
7	and	N	O
8	their	N	O
9	caregivers	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	to	N	O
14	receive	N	O
15	14	N	O
16	telephone-based	N	O
17	sessions	N	O
18	of	N	O
19	either	N	O
20	caregiver-assisted	N	O
21	CST	N	O
22	or	N	O
23	education/support	N	O
24	involving	N	O
25	the	N	O
26	caregiver	N	O
27	.	N	O

1	Patients	N	O
2	completed	N	O
3	measures	N	O
4	assessing	N	O
5	pain	N	O
6	,	N	O
7	psychological	N	O
8	distress	N	O
9	,	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	(	N	O
14	QOL	N	O
15	)	N	O
16	,	N	O
17	and	N	O
18	self-efficacy	N	O
19	for	N	O
20	symptom	N	O
21	management	N	O
22	;	N	O
23	caregivers	N	O
24	completed	N	O
25	measures	N	O
26	assessing	N	O
27	psychological	N	O
28	distress	N	O
29	,	N	O
30	caregiver	N	O
31	strain	N	O
32	,	N	O
33	and	N	O
34	self-efficacy	N	O
35	for	N	O
36	helping	N	O
37	the	N	O
38	patient	N	O
39	manage	N	O
40	symptoms	N	O
41	.	N	O

1	Patients	N	I-Premise
2	in	N	I-Premise
3	both	N	I-Premise
4	treatment	N	I-Premise
5	conditions	N	I-Premise
6	showed	N	I-Premise
7	improvements	N	I-Premise
8	in	N	I-Premise
9	pain	N	I-Premise
10	,	N	I-Premise
11	depression	N	I-Premise
12	,	N	I-Premise
13	QOL	N	I-Premise
14	,	N	I-Premise
15	and	N	I-Premise
16	self-efficacy	N	I-Premise
17	,	N	I-Premise
18	and	N	I-Premise
19	caregivers	N	I-Premise
20	in	N	I-Premise
21	both	N	I-Premise
22	conditions	N	I-Premise
23	showed	N	I-Premise
24	improvements	N	I-Premise
25	in	N	I-Premise
26	anxiety	N	I-Premise
27	and	N	I-Premise
28	self-efficacy	N	I-Premise
29	from	N	I-Premise
30	baseline	N	I-Premise
31	to	N	I-Premise
32	four-month	N	I-Premise
33	follow-up	N	I-Premise
34	.	N	I-Premise

1	Results	N	I-Premise
2	of	N	I-Premise
3	exploratory	N	I-Premise
4	analyses	N	I-Premise
5	suggested	N	I-Premise
6	that	N	I-Premise
7	the	N	I-Premise
8	CST	N	I-Premise
9	intervention	N	I-Premise
10	was	N	I-Premise
11	more	N	I-Premise
12	beneficial	N	I-Premise
13	to	N	I-Premise
14	patients/caregivers	N	I-Premise
15	with	N	I-Premise
16	Stage	N	I-Premise
17	II	N	I-Premise
18	and	N	I-Premise
19	III	N	I-Premise
20	cancers	N	I-Premise
21	,	N	I-Premise
22	whereas	N	O
23	the	N	I-Premise
24	education/support	N	I-Premise
25	intervention	N	I-Premise
26	was	N	I-Premise
27	more	N	I-Premise
28	beneficial	N	I-Premise
29	to	N	I-Premise
30	patients/caregivers	N	I-Premise
31	with	N	I-Premise
32	Stage	N	I-Premise
33	I	N	I-Premise
34	cancer	N	I-Premise
35	.	N	I-Premise

1	Taken	N	I-Premise
2	together	N	I-Premise
3	with	N	I-Premise
4	the	N	I-Premise
5	broader	N	I-Premise
6	literature	N	I-Premise
7	in	N	I-Premise
8	this	N	I-Premise
9	area	N	I-Premise
10	,	N	I-Premise
11	results	N	I-Claim
12	from	N	I-Claim
13	this	N	I-Claim
14	study	N	I-Claim
15	suggest	N	I-Claim
16	that	N	I-Claim
17	psychosocial	N	I-Claim
18	interventions	N	I-Claim
19	can	N	I-Claim
20	lead	N	I-Claim
21	to	N	I-Claim
22	improvements	N	I-Claim
23	in	N	I-Claim
24	a	N	I-Claim
25	range	N	I-Claim
26	of	N	I-Claim
27	outcomes	N	I-Claim
28	for	N	I-Claim
29	cancer	N	I-Claim
30	patients	N	I-Claim
31	.	N	I-Claim

1	Suggestions	N	O
2	for	N	O
3	future	N	O
4	studies	N	O
5	include	N	O
6	the	N	O
7	use	N	O
8	of	N	O
9	three-group	N	O
10	designs	N	O
11	(	N	O
12	e.g.	N	O
13	,	N	O
14	comparing	N	O
15	two	N	O
16	active	N	O
17	interventions	N	O
18	with	N	O
19	a	N	O
20	standard-care	N	O
21	control	N	O
22	)	N	O
23	and	N	O
24	examining	N	O
25	mechanisms	N	O
26	of	N	O
27	change	N	O
28	.	N	O

1	The	N	O
2	EORTC	N	O
3	24971/TAX	N	O
4	323	N	O
5	,	N	O
6	a	N	O
7	phase	N	O
8	III	N	O
9	study	N	O
10	of	N	O
11	358	N	O
12	patients	N	O
13	with	N	O
14	unresectable	N	O
15	locoregionally	N	O
16	advanced	N	O
17	squamous	N	O
18	cell	N	O
19	carcinoma	N	O
20	of	N	O
21	the	N	O
22	head	N	O
23	and	N	O
24	neck	N	O
25	,	N	O
26	showed	N	O
27	an	N	O
28	improved	N	O
29	progression-free	N	O
30	and	N	O
31	overall	N	O
32	survival	N	O
33	(	N	O
34	OS	N	O
35	)	N	O
36	with	N	O
37	less	N	O
38	toxicity	N	O
39	when	N	O
40	docetaxel	N	O
41	(	N	O
42	T	N	O
43	)	N	O
44	was	N	O
45	added	N	O
46	to	N	O
47	cisplatin	N	O
48	and	N	O
49	5-fluorouracil	N	O
50	(	N	O
51	PF	N	O
52	)	N	O
53	for	N	O
54	induction	N	O
55	and	N	O
56	given	N	O
57	before	N	O
58	radiotherapy	N	O
59	(	N	O
60	RT	N	O
61	)	N	O
62	.	N	O

1	The	N	O
2	impact	N	O
3	of	N	O
4	the	N	O
5	addition	N	O
6	of	N	O
7	docetaxel	N	O
8	on	N	O
9	patients	N	O
10	'	N	O
11	health-related	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	(	N	O
16	HRQOL	N	O
17	)	N	O
18	and	N	O
19	symptoms	N	O
20	was	N	O
21	investigated	N	O
22	.	N	O

1	HRQOL	N	O
2	was	N	O
3	assessed	N	O
4	at	N	O
5	baseline	N	O
6	,	N	O
7	at	N	O
8	end	N	O
9	of	N	O
10	cycle	N	O
11	2	N	O
12	,	N	O
13	and	N	O
14	4	N	O
15	,	N	O
16	6	N	O
17	,	N	O
18	and	N	O
19	9	N	O
20	months	N	O
21	after	N	O
22	completion	N	O
23	of	N	O
24	RT	N	O
25	using	N	O
26	the	N	O
27	European	N	O
28	Organisation	N	O
29	for	N	O
30	Research	N	O
31	and	N	O
32	Treatment	N	O
33	of	N	O
34	Cancer	N	O
35	(	N	O
36	EORTC	N	O
37	)	N	O
38	Quality	N	O
39	of	N	O
40	Life	N	O
41	Questionnaire	N	O
42	C30	N	O
43	(	N	O
44	QLQ-C30	N	O
45	)	N	O
46	and	N	O
47	the	N	O
48	EORTC	N	O
49	QLQ	N	O
50	Head	N	O
51	and	N	O
52	Neck	N	O
53	Cancer-Specific	N	O
54	Module	N	O
55	(	N	O
56	EORTC	N	O
57	QLQ-H	N	O
58	&	N	O
59	amp	N	O
60	;	N	O
61	N35	N	O
62	)	N	O
63	.	N	O

1	The	N	O
2	primary	N	O
3	HRQOL	N	O
4	scale	N	O
5	was	N	O
6	global	N	O
7	HRQOL	N	O
8	per	N	O
9	protocol	N	O
10	.	N	O

1	Compliance	N	O
2	to	N	O
3	HRQOL	N	O
4	assessments	N	O
5	was	N	O
6	97	N	O
7	%	N	O
8	at	N	O
9	baseline	N	O
10	,	N	O
11	but	N	O
12	dropped	N	O
13	to	N	O
14	54	N	O
15	%	N	O
16	by	N	O
17	6	N	O
18	months	N	O
19	.	N	O

1	Data	N	O
2	were	N	O
3	analysed	N	O
4	up	N	O
5	to	N	O
6	6	N	O
7	months	N	O
8	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	trend	N	I-Premise
5	towards	N	I-Premise
6	improved	N	I-Premise
7	global	N	I-Premise
8	HRQOL	N	I-Premise
9	during	N	I-Premise
10	the	N	I-Premise
11	treatment	N	I-Premise
12	period	N	I-Premise
13	.	N	I-Premise

1	At	N	I-Premise
2	6	N	I-Premise
3	months	N	I-Premise
4	after	N	I-Premise
5	the	N	I-Premise
6	end	N	I-Premise
7	of	N	I-Premise
8	RT	N	I-Premise
9	,	N	I-Premise
10	global	N	I-Premise
11	HRQOL	N	I-Premise
12	was	N	I-Premise
13	higher	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	TPF	N	I-Premise
17	arm	N	I-Premise
18	than	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	PF	N	I-Premise
22	arm	N	I-Premise
23	,	N	I-Premise
24	but	N	I-Premise
25	the	N	I-Premise
26	low	N	I-Premise
27	compliance	N	I-Premise
28	does	N	I-Premise
29	not	N	I-Premise
30	allow	N	I-Premise
31	to	N	I-Premise
32	draw	N	I-Premise
33	definitive	N	I-Premise
34	conclusions	N	I-Premise
35	.	N	I-Premise

1	Swallowing	N	I-Premise
2	and	N	I-Premise
3	coughing	N	I-Premise
4	problems	N	I-Premise
5	decreased	N	I-Premise
6	more	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	TPF	N	I-Premise
10	arm	N	I-Premise
11	than	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	PF	N	I-Premise
15	arm	N	I-Premise
16	at	N	I-Premise
17	the	N	I-Premise
18	end	N	I-Premise
19	of	N	I-Premise
20	cycle	N	I-Premise
21	2	N	I-Premise
22	,	N	I-Premise
23	but	N	I-Premise
24	to	N	I-Premise
25	a	N	I-Premise
26	limited	N	I-Premise
27	extent	N	I-Premise
28	.	N	I-Premise

1	Induction	N	I-Claim
2	chemotherapy	N	I-Claim
3	with	N	I-Claim
4	TPF	N	I-Claim
5	before	N	I-Claim
6	RT	N	I-Claim
7	not	N	I-Claim
8	only	N	I-Claim
9	improves	N	I-Claim
10	survival	N	I-Claim
11	and	N	I-Claim
12	reduces	N	I-Claim
13	toxicity	N	I-Claim
14	compared	N	I-Claim
15	with	N	I-Claim
16	PF	N	I-Claim
17	but	N	I-Claim
18	also	N	I-Claim
19	seems	N	I-Claim
20	to	N	I-Claim
21	improve	N	I-Claim
22	global	N	I-Claim
23	HRQOL	N	I-Claim
24	in	N	I-Claim
25	a	N	I-Claim
26	more	N	I-Claim
27	sustainable	N	I-Claim
28	manner	N	I-Claim
29	.	N	I-Claim

1	We	N	O
2	compared	N	O
3	fulvestrant	N	O
4	500	N	O
5	mg	N	O
6	regimen	N	O
7	with	N	O
8	the	N	O
9	approved	N	O
10	dose	N	O
11	of	N	O
12	fulvestrant	N	O
13	250	N	O
14	mg	N	O
15	per	N	O
16	month	N	O
17	for	N	O
18	treatment	N	O
19	of	N	O
20	postmenopausal	N	O
21	women	N	O
22	with	N	O
23	estrogen	N	O
24	receptor-positive	N	O
25	advanced	N	O
26	breast	N	O
27	cancer	N	O
28	who	N	O
29	experienced	N	O
30	progression	N	O
31	after	N	O
32	prior	N	O
33	endocrine	N	O
34	therapy	N	O
35	.	N	O

1	Comparison	N	O
2	of	N	O
3	Faslodex	N	O
4	in	N	O
5	Recurrent	N	O
6	or	N	O
7	Metastatic	N	O
8	Breast	N	O
9	Cancer	N	O
10	(	N	O
11	CONFIRM	N	O
12	)	N	O
13	is	N	O
14	a	N	O
15	double-blind	N	O
16	,	N	O
17	parallel-group	N	O
18	,	N	O
19	multicenter	N	O
20	,	N	O
21	phase	N	O
22	III	N	O
23	study	N	O
24	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	fulvestrant	N	O
7	500	N	O
8	mg	N	O
9	(	N	O
10	500	N	O
11	mg	N	O
12	intramuscularly	N	O
13	[	N	O
14	IM	N	O
15	]	N	O
16	on	N	O
17	day	N	O
18	0	N	O
19	,	N	O
20	then	N	O
21	500	N	O
22	mg	N	O
23	IM	N	O
24	on	N	O
25	days	N	O
26	14	N	O
27	and	N	O
28	28	N	O
29	and	N	O
30	every	N	O
31	28	N	O
32	days	N	O
33	thereafter	N	O
34	)	N	O
35	or	N	O
36	250	N	O
37	mg	N	O
38	every	N	O
39	28	N	O
40	days	N	O
41	.	N	O

1	Primary	N	O
2	end	N	O
3	point	N	O
4	was	N	O
5	progression-free	N	O
6	survival	N	O
7	(	N	O
8	PFS	N	O
9	)	N	O
10	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	included	N	O
5	objective	N	O
6	response	N	O
7	rate	N	O
8	,	N	O
9	clinical	N	O
10	benefit	N	O
11	rate	N	O
12	(	N	O
13	CBR	N	O
14	)	N	O
15	,	N	O
16	duration	N	O
17	of	N	O
18	clinical	N	O
19	benefit	N	O
20	(	N	O
21	DoCB	N	O
22	)	N	O
23	,	N	O
24	overall	N	O
25	survival	N	O
26	(	N	O
27	OS	N	O
28	)	N	O
29	,	N	O
30	and	N	O
31	quality	N	O
32	of	N	O
33	life	N	O
34	(	N	O
35	QOL	N	O
36	)	N	O
37	.	N	O

1	PFS	N	I-Premise
2	was	N	I-Premise
3	significantly	N	I-Premise
4	longer	N	I-Premise
5	for	N	I-Premise
6	fulvestrant	N	I-Premise
7	500	N	I-Premise
8	mg	N	I-Premise
9	(	N	I-Premise
10	n	N	I-Premise
11	=	N	I-Premise
12	362	N	I-Premise
13	)	N	I-Premise
14	than	N	I-Premise
15	250	N	I-Premise
16	mg	N	I-Premise
17	(	N	I-Premise
18	n	N	I-Premise
19	=	N	I-Premise
20	374	N	I-Premise
21	)	N	I-Premise
22	(	N	I-Premise
23	hazard	N	I-Premise
24	ratio	N	I-Premise
25	[	N	I-Premise
26	HR	N	I-Premise
27	]	N	I-Premise
28	=	N	I-Premise
29	0.80	N	I-Premise
30	;	N	I-Premise
31	95	N	I-Premise
32	%	N	I-Premise
33	CI	N	I-Premise
34	,	N	I-Premise
35	0.68	N	I-Premise
36	to	N	I-Premise
37	0.94	N	I-Premise
38	;	N	I-Premise
39	P	N	I-Premise
40	=	N	I-Premise
41	.006	N	I-Premise
42	)	N	I-Premise
43	,	N	I-Premise
44	corresponding	N	I-Premise
45	to	N	I-Premise
46	a	N	I-Premise
47	20	N	I-Premise
48	%	N	I-Premise
49	reduction	N	I-Premise
50	in	N	I-Premise
51	risk	N	I-Premise
52	of	N	I-Premise
53	progression	N	I-Premise
54	.	N	I-Premise

1	Objective	N	I-Premise
2	response	N	I-Premise
3	rate	N	I-Premise
4	was	N	I-Premise
5	similar	N	I-Premise
6	for	N	I-Premise
7	fulvestrant	N	I-Premise
8	500	N	I-Premise
9	mg	N	I-Premise
10	and	N	I-Premise
11	250	N	I-Premise
12	mg	N	I-Premise
13	(	N	I-Premise
14	9.1	N	I-Premise
15	%	N	I-Premise
16	v	N	I-Premise
17	10.2	N	I-Premise
18	%	N	I-Premise
19	,	N	I-Premise
20	respectively	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	CBR	N	I-Premise
2	was	N	I-Premise
3	45.6	N	I-Premise
4	%	N	I-Premise
5	for	N	I-Premise
6	fulvestrant	N	I-Premise
7	500	N	I-Premise
8	mg	N	I-Premise
9	and	N	I-Premise
10	39.6	N	I-Premise
11	%	N	I-Premise
12	for	N	I-Premise
13	fulvestrant	N	I-Premise
14	250	N	I-Premise
15	mg.	N	I-Premise
16	DoCB	N	I-Premise
17	and	N	I-Premise
18	OS	N	I-Premise
19	were	N	I-Premise
20	16.6	N	I-Premise
21	and	N	I-Premise
22	25.1	N	I-Premise
23	months	N	I-Premise
24	,	N	I-Premise
25	respectively	N	I-Premise
26	,	N	I-Premise
27	for	N	I-Premise
28	the	N	I-Premise
29	500-mg	N	I-Premise
30	group	N	I-Premise
31	,	N	I-Premise
32	whereas	N	I-Premise
33	DoCB	N	I-Premise
34	and	N	I-Premise
35	OS	N	I-Premise
36	were	N	I-Premise
37	13.9	N	I-Premise
38	and	N	I-Premise
39	22.8	N	I-Premise
40	months	N	I-Premise
41	,	N	I-Premise
42	respectively	N	I-Premise
43	,	N	I-Premise
44	in	N	I-Premise
45	the	N	I-Premise
46	250-mg	N	I-Premise
47	group	N	I-Premise
48	.	N	I-Premise

1	Fulvestrant	N	I-Claim
2	500	N	I-Claim
3	mg	N	I-Claim
4	was	N	I-Claim
5	well	N	I-Claim
6	tolerated	N	I-Claim
7	with	N	I-Claim
8	no	N	I-Claim
9	dose-dependent	N	I-Claim
10	adverse	N	I-Claim
11	events	N	I-Claim
12	.	N	I-Claim

1	QOL	N	I-Claim
2	was	N	I-Claim
3	similar	N	I-Claim
4	for	N	I-Claim
5	both	N	I-Claim
6	arms	N	I-Claim
7	.	N	I-Claim

1	Fulvestrant	N	I-Claim
2	500	N	I-Claim
3	mg	N	I-Claim
4	was	N	I-Claim
5	associated	N	I-Claim
6	with	N	I-Claim
7	a	N	I-Claim
8	statistically	N	I-Claim
9	significant	N	I-Claim
10	increase	N	I-Claim
11	in	N	I-Claim
12	PFS	N	I-Claim
13	and	N	I-Claim
14	not	N	I-Claim
15	associated	N	I-Claim
16	with	N	I-Claim
17	increased	N	I-Claim
18	toxicity	N	I-Claim
19	,	N	I-Claim
20	corresponding	N	O
21	to	N	O
22	a	N	O
23	clinically	N	O
24	meaningful	N	O
25	improvement	N	O
26	in	N	O
27	benefit	N	O
28	versus	N	O
29	risk	N	O
30	compared	N	O
31	with	N	O
32	fulvestrant	N	O
33	250	N	O
34	mg	N	O
35	.	N	O

1	Temozolomide	N	O
2	(	N	O
3	TMZ	N	O
4	)	N	O
5	is	N	O
6	an	N	O
7	alkylating	N	O
8	agent	N	O
9	licensed	N	O
10	for	N	O
11	treatment	N	O
12	of	N	O
13	high-grade	N	O
14	glioma	N	O
15	(	N	O
16	HGG	N	O
17	)	N	O
18	.	N	O

1	No	N	O
2	prospective	N	O
3	comparison	N	O
4	with	N	O
5	nitrosourea-based	N	O
6	chemotherapy	N	O
7	exists	N	O
8	.	N	O

1	We	N	O
2	report	N	O
3	,	N	O
4	to	N	O
5	our	N	O
6	knowledge	N	O
7	,	N	O
8	the	N	O
9	first	N	O
10	randomized	N	O
11	trial	N	O
12	of	N	O
13	procarbazine	N	O
14	,	N	O
15	lomustine	N	O
16	,	N	O
17	and	N	O
18	vincristine	N	O
19	(	N	O
20	PCV	N	O
21	)	N	O
22	versus	N	O
23	TMZ	N	O
24	in	N	O
25	chemotherapy-naive	N	O
26	patients	N	O
27	with	N	O
28	recurrent	N	O
29	HGG	N	O
30	.	N	O

1	Four	N	O
2	hundred	N	O
3	forty-seven	N	O
4	patients	N	O
5	were	N	O
6	randomly	N	O
7	assigned	N	O
8	to	N	O
9	PCV	N	O
10	(	N	O
11	224	N	O
12	patients	N	O
13	)	N	O
14	or	N	O
15	TMZ	N	O
16	(	N	O
17	sub-random	N	O
18	assignment	N	O
19	:	N	O
20	TMZ-5	N	O
21	[	N	O
22	200	N	O
23	mg/m	N	O
24	(	N	O
25	2	N	O
26	)	N	O
27	for	N	O
28	5	N	O
29	days	N	O
30	,	N	O
31	112	N	O
32	patients	N	O
33	]	N	O
34	or	N	O
35	TMZ-21	N	O
36	[	N	O
37	100	N	O
38	mg/m	N	O
39	(	N	O
40	2	N	O
41	)	N	O
42	for	N	O
43	21	N	O
44	days	N	O
45	,	N	O
46	111	N	O
47	patients	N	O
48	]	N	O
49	)	N	O
50	for	N	O
51	up	N	O
52	to	N	O
53	9	N	O
54	months	N	O
55	or	N	O
56	until	N	O
57	progression	N	O
58	.	N	O

1	The	N	O
2	primary	N	O
3	outcomes	N	O
4	were	N	O
5	survival	N	O
6	(	N	O
7	PCV	N	O
8	v	N	O
9	TMZ	N	O
10	)	N	O
11	and	N	O
12	12-week	N	O
13	progression-free	N	O
14	survival	N	O
15	(	N	O
16	PFS	N	O
17	;	N	O
18	TMZ-5	N	O
19	v	N	O
20	TMZ-21	N	O
21	)	N	O
22	.	N	O

1	This	N	O
2	study	N	O
3	is	N	O
4	registered	N	O
5	as	N	O
6	ISRCTN83176944	N	O
7	.	N	O

1	Percentages	N	O
2	of	N	O
3	patients	N	O
4	completing	N	O
5	9	N	O
6	months	N	O
7	of	N	O
8	treatment	N	O
9	in	N	O
10	the	N	O
11	PCV	N	O
12	,	N	O
13	TMZ-5	N	O
14	,	N	O
15	and	N	O
16	TMZ-21	N	O
17	arms	N	O
18	were	N	O
19	17	N	O
20	%	N	O
21	,	N	O
22	26	N	O
23	%	N	O
24	,	N	O
25	and	N	O
26	13	N	O
27	%	N	O
28	,	N	O
29	respectively	N	O
30	.	N	O

1	Major	N	I-Premise
2	toxicity	N	I-Premise
3	was	N	I-Premise
4	similar	N	I-Premise
5	across	N	I-Premise
6	all	N	I-Premise
7	three	N	I-Premise
8	groups	N	I-Premise
9	.	N	I-Premise

1	With	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	time	N	I-Premise
6	of	N	I-Premise
7	12	N	I-Premise
8	months	N	I-Premise
9	and	N	I-Premise
10	382	N	I-Premise
11	deaths	N	I-Premise
12	,	N	I-Premise
13	there	N	I-Premise
14	was	N	I-Premise
15	no	N	I-Premise
16	clear	N	I-Premise
17	survival	N	I-Premise
18	benefit	N	I-Premise
19	when	N	I-Premise
20	comparing	N	I-Premise
21	PCV	N	I-Premise
22	with	N	I-Premise
23	TMZ	N	I-Premise
24	(	N	I-Premise
25	hazard	N	I-Premise
26	ratio	N	I-Premise
27	[	N	I-Premise
28	HR	N	I-Premise
29	]	N	I-Premise
30	,	N	I-Premise
31	0.91	N	I-Premise
32	;	N	I-Premise
33	95	N	I-Premise
34	%	N	I-Premise
35	CI	N	I-Premise
36	,	N	I-Premise
37	0.74	N	I-Premise
38	to	N	I-Premise
39	1.11	N	I-Premise
40	;	N	I-Premise
41	P	N	I-Premise
42	=	N	I-Premise
43	.350	N	I-Premise
44	)	N	I-Premise
45	.	N	I-Premise

1	For	N	I-Premise
2	TMZ-5	N	I-Premise
3	versus	N	I-Premise
4	TMZ-21	N	I-Premise
5	,	N	I-Premise
6	12-week	N	I-Premise
7	PFS	N	I-Premise
8	rates	N	I-Premise
9	were	N	I-Premise
10	similar	N	I-Premise
11	(	N	I-Premise
12	63.6	N	I-Premise
13	%	N	I-Premise
14	and	N	I-Premise
15	65.7	N	I-Premise
16	%	N	I-Premise
17	,	N	I-Premise
18	respectively	N	I-Premise
19	;	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	.745	N	I-Premise
23	)	N	I-Premise
24	,	N	I-Premise
25	but	N	I-Premise
26	TMZ-5	N	I-Premise
27	improved	N	I-Premise
28	overall	N	I-Premise
29	PFS	N	I-Premise
30	(	N	I-Premise
31	HR	N	I-Premise
32	,	N	I-Premise
33	1.38	N	I-Premise
34	;	N	I-Premise
35	95	N	I-Premise
36	%	N	I-Premise
37	CI	N	I-Premise
38	,	N	I-Premise
39	1.05	N	I-Premise
40	to	N	I-Premise
41	1.82	N	I-Premise
42	;	N	I-Premise
43	P	N	I-Premise
44	=	N	I-Premise
45	.023	N	I-Premise
46	)	N	I-Premise
47	,	N	I-Premise
48	survival	N	I-Premise
49	(	N	I-Premise
50	HR	N	I-Premise
51	,	N	I-Premise
52	1.32	N	I-Premise
53	;	N	I-Premise
54	95	N	I-Premise
55	%	N	I-Premise
56	CI	N	I-Premise
57	,	N	I-Premise
58	0.99	N	I-Premise
59	to	N	I-Premise
60	1.75	N	I-Premise
61	;	N	I-Premise
62	P	N	I-Premise
63	=	N	I-Premise
64	.056	N	I-Premise
65	)	N	I-Premise
66	,	N	I-Premise
67	and	N	I-Premise
68	global	N	I-Premise
69	quality	N	I-Premise
70	of	N	I-Premise
71	life	N	I-Premise
72	(	N	I-Premise
73	49	N	I-Premise
74	%	N	I-Premise
75	v	N	I-Premise
76	19	N	I-Premise
77	%	N	I-Premise
78	improved	N	I-Premise
79	>	N	I-Premise
80	10	N	I-Premise
81	points	N	I-Premise
82	at	N	I-Premise
83	6	N	I-Premise
84	months	N	I-Premise
85	,	N	I-Premise
86	respectively	N	I-Premise
87	;	N	I-Premise
88	P	N	I-Premise
89	=	N	I-Premise
90	.005	N	I-Premise
91	)	N	I-Premise
92	.	N	I-Premise

1	Although	N	I-Claim
2	TMZ	N	I-Claim
3	(	N	I-Claim
4	both	N	I-Claim
5	arms	N	I-Claim
6	combined	N	I-Claim
7	)	N	I-Claim
8	did	N	I-Claim
9	not	N	I-Claim
10	show	N	I-Claim
11	a	N	I-Claim
12	clear	N	I-Claim
13	benefit	N	I-Claim
14	compared	N	I-Claim
15	with	N	I-Claim
16	PCV	N	I-Claim
17	,	N	I-Claim
18	comparison	N	I-Claim
19	of	N	I-Claim
20	the	N	I-Claim
21	TMZ	N	I-Claim
22	schedules	N	I-Claim
23	demonstrated	N	I-Claim
24	that	N	I-Claim
25	the	N	I-Claim
26	21-day	N	I-Claim
27	schedule	N	I-Claim
28	was	N	I-Claim
29	inferior	N	I-Claim
30	to	N	I-Claim
31	the	N	I-Claim
32	5-day	N	I-Claim
33	schedule	N	I-Claim
34	in	N	I-Claim
35	this	N	I-Claim
36	setting	N	I-Claim
37	.	N	I-Claim

1	This	N	I-Claim
2	challenges	N	I-Claim
3	the	N	I-Claim
4	current	N	I-Claim
5	understanding	N	I-Claim
6	of	N	I-Claim
7	increasing	N	I-Claim
8	TMZ	N	I-Claim
9	dose-intensity	N	I-Claim
10	by	N	I-Claim
11	prolonged	N	I-Claim
12	scheduling	N	I-Claim
13	.	N	I-Claim

1	Compared	N	O
2	with	N	O
3	placebo	N	O
4	,	N	O
5	prophylactic	N	O
6	treatment	N	O
7	with	N	O
8	bisphosphonates	N	O
9	reduces	N	O
10	risk	N	O
11	of	N	O
12	skeletal	N	O
13	events	N	O
14	in	N	O
15	patients	N	O
16	with	N	O
17	multiple	N	O
18	myeloma	N	O
19	.	N	O

1	However	N	O
2	,	N	O
3	because	N	O
4	of	N	O
5	toxicity	N	O
6	associated	N	O
7	with	N	O
8	long-term	N	O
9	bisphosphonate	N	O
10	treatment	N	O
11	,	N	O
12	establishing	N	O
13	the	N	O
14	lowest	N	O
15	effective	N	O
16	dose	N	O
17	is	N	O
18	important	N	O
19	.	N	O

1	This	N	O
2	study	N	O
3	compared	N	O
4	the	N	O
5	effect	N	O
6	of	N	O
7	two	N	O
8	doses	N	O
9	of	N	O
10	pamidronate	N	O
11	on	N	O
12	health-related	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	and	N	O
17	skeletal	N	O
18	morbidity	N	O
19	in	N	O
20	patients	N	O
21	with	N	O
22	newly	N	O
23	diagnosed	N	O
24	multiple	N	O
25	myeloma	N	O
26	.	N	O

1	This	N	O
2	double-blind	N	O
3	,	N	O
4	randomised	N	O
5	,	N	O
6	phase	N	O
7	3	N	O
8	trial	N	O
9	was	N	O
10	undertaken	N	O
11	at	N	O
12	37	N	O
13	clinics	N	O
14	in	N	O
15	Denmark	N	O
16	,	N	O
17	Norway	N	O
18	,	N	O
19	and	N	O
20	Sweden	N	O
21	.	N	O

1	Patients	N	O
2	with	N	O
3	multiple	N	O
4	myeloma	N	O
5	who	N	O
6	were	N	O
7	starting	N	O
8	antimyeloma	N	O
9	treatment	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	in	N	O
14	a	N	O
15	1:1	N	O
16	ratio	N	O
17	to	N	O
18	receive	N	O
19	one	N	O
20	of	N	O
21	two	N	O
22	doses	N	O
23	of	N	O
24	pamidronate	N	O
25	(	N	O
26	30	N	O
27	mg	N	O
28	or	N	O
29	90	N	O
30	mg	N	O
31	)	N	O
32	given	N	O
33	by	N	O
34	intravenous	N	O
35	infusion	N	O
36	once	N	O
37	a	N	O
38	month	N	O
39	for	N	O
40	at	N	O
41	least	N	O
42	3	N	O
43	years	N	O
44	.	N	O

1	Randomisation	N	O
2	was	N	O
3	done	N	O
4	by	N	O
5	use	N	O
6	of	N	O
7	a	N	O
8	central	N	O
9	,	N	O
10	computerised	N	O
11	minimisation	N	O
12	system	N	O
13	.	N	O

1	Primary	N	O
2	outcome	N	O
3	was	N	O
4	physical	N	O
5	function	N	O
6	after	N	O
7	12	N	O
8	months	N	O
9	estimated	N	O
10	by	N	O
11	the	N	O
12	European	N	O
13	Organisation	N	O
14	for	N	O
15	Research	N	O
16	and	N	O
17	Treatment	N	O
18	of	N	O
19	Cancer	N	O
20	(	N	O
21	EORTC	N	O
22	)	N	O
23	QLQ-C30	N	O
24	questionnaire	N	O
25	(	N	O
26	scale	N	O
27	0-100	N	O
28	)	N	O
29	.	N	O

1	All	N	O
2	patients	N	O
3	who	N	O
4	returned	N	O
5	questionnaires	N	O
6	at	N	O
7	12	N	O
8	months	N	O
9	and	N	O
10	were	N	O
11	still	N	O
12	on	N	O
13	study	N	O
14	treatment	N	O
15	were	N	O
16	included	N	O
17	in	N	O
18	the	N	O
19	analysis	N	O
20	of	N	O
21	the	N	O
22	primary	N	O
23	endpoint	N	O
24	.	N	O

1	From	N	O
2	January	N	O
3	,	N	O
4	2001	N	O
5	,	N	O
6	until	N	O
7	August	N	O
8	,	N	O
9	2005	N	O
10	,	N	O
11	504	N	O
12	patients	N	O
13	were	N	O
14	randomly	N	O
15	assigned	N	O
16	to	N	O
17	pamidronate	N	O
18	30	N	O
19	mg	N	O
20	or	N	O
21	90	N	O
22	mg	N	O
23	(	N	O
24	252	N	O
25	in	N	O
26	each	N	O
27	group	N	O
28	)	N	O
29	.	N	O

1	157	N	O
2	patients	N	O
3	in	N	O
4	the	N	O
5	90	N	O
6	mg	N	O
7	group	N	O
8	and	N	O
9	156	N	O
10	in	N	O
11	the	N	O
12	30	N	O
13	mg	N	O
14	group	N	O
15	were	N	O
16	included	N	O
17	in	N	O
18	the	N	O
19	primary	N	O
20	analysis	N	O
21	.	N	O

1	Mean	N	I-Premise
2	physical	N	I-Premise
3	function	N	I-Premise
4	at	N	I-Premise
5	12	N	I-Premise
6	months	N	I-Premise
7	was	N	I-Premise
8	66	N	I-Premise
9	points	N	I-Premise
10	(	N	I-Premise
11	95	N	I-Premise
12	%	N	I-Premise
13	CI	N	I-Premise
14	62·9-70·0	N	I-Premise
15	)	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	90	N	I-Premise
19	mg	N	I-Premise
20	group	N	I-Premise
21	and	N	I-Premise
22	68	N	I-Premise
23	points	N	I-Premise
24	(	N	I-Premise
25	64·6-71·4	N	I-Premise
26	)	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	30	N	I-Premise
30	mg	N	I-Premise
31	group	N	I-Premise
32	(	N	I-Premise
33	95	N	I-Premise
34	%	N	I-Premise
35	CI	N	I-Premise
36	of	N	I-Premise
37	difference	N	I-Premise
38	-6·6	N	I-Premise
39	to	N	I-Premise
40	3·3	N	I-Premise
41	;	N	I-Premise
42	p=0·52	N	I-Premise
43	)	N	I-Premise
44	.	N	I-Premise

1	Median	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	first	N	I-Premise
5	skeletal-related	N	I-Premise
6	event	N	I-Premise
7	in	N	I-Premise
8	patients	N	I-Premise
9	who	N	I-Premise
10	had	N	I-Premise
11	such	N	I-Premise
12	an	N	I-Premise
13	event	N	I-Premise
14	was	N	I-Premise
15	9·2	N	I-Premise
16	months	N	I-Premise
17	(	N	I-Premise
18	8·1-10·7	N	I-Premise
19	)	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	90	N	I-Premise
23	mg	N	I-Premise
24	group	N	I-Premise
25	and	N	I-Premise
26	10·2	N	I-Premise
27	months	N	I-Premise
28	(	N	I-Premise
29	7·3-14·0	N	I-Premise
30	)	N	I-Premise
31	in	N	I-Premise
32	the	N	I-Premise
33	30	N	I-Premise
34	mg	N	I-Premise
35	group	N	I-Premise
36	(	N	I-Premise
37	p=0·63	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	In	N	O
2	a	N	O
3	retrospective	N	O
4	analysis	N	O
5	,	N	O
6	eight	N	I-Premise
7	patients	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	pamidronate	N	I-Premise
11	90	N	I-Premise
12	mg	N	I-Premise
13	group	N	I-Premise
14	developed	N	I-Premise
15	osteonecrosis	N	I-Premise
16	of	N	I-Premise
17	the	N	I-Premise
18	jaw	N	I-Premise
19	compared	N	I-Premise
20	with	N	I-Premise
21	two	N	I-Premise
22	patients	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	30	N	I-Premise
26	mg	N	I-Premise
27	group	N	I-Premise
28	.	N	I-Premise

1	Monthly	N	I-Claim
2	infusion	N	I-Claim
3	of	N	I-Claim
4	pamidronate	N	I-Claim
5	30	N	I-Claim
6	mg	N	I-Claim
7	should	N	I-Claim
8	be	N	I-Claim
9	the	N	I-Claim
10	recommended	N	I-Claim
11	dose	N	I-Claim
12	for	N	I-Claim
13	prevention	N	I-Claim
14	of	N	I-Claim
15	bone	N	I-Claim
16	disease	N	I-Claim
17	in	N	I-Claim
18	patients	N	I-Claim
19	with	N	I-Claim
20	multiple	N	I-Claim
21	myeloma	N	I-Claim
22	.	N	I-Claim

1	Before	N	O
2	the	N	O
3	knowledge	N	O
4	that	N	O
5	5	N	O
6	years	N	O
7	of	N	O
8	adjuvant	N	O
9	tamoxifen	N	O
10	is	N	O
11	less	N	O
12	efficacious	N	O
13	than	N	O
14	2	N	O
15	to	N	O
16	3	N	O
17	years	N	O
18	of	N	O
19	tamoxifen	N	O
20	followed	N	O
21	by	N	O
22	2	N	O
23	to	N	O
24	3	N	O
25	years	N	O
26	of	N	O
27	anastrozole/exemestane	N	O
28	,	N	O
29	we	N	O
30	designed	N	O
31	a	N	O
32	multicenter	N	O
33	double-blind	N	O
34	randomized	N	O
35	controlled	N	O
36	trial	N	O
37	in	N	O
38	women	N	O
39	taking	N	O
40	tamoxifen	N	O
41	with	N	O
42	a	N	O
43	thickened	N	O
44	endometrium	N	O
45	to	N	O
46	compare	N	O
47	uterine	N	O
48	and	N	O
49	quality-of-life	N	O
50	parameters	N	O
51	between	N	O
52	those	N	O
53	switching	N	O
54	to	N	O
55	anastrozole	N	O
56	and	N	O
57	those	N	O
58	continuing	N	O
59	tamoxifen	N	O
60	.	N	O

1	Asymptomatic	N	O
2	postmenopausal	N	O
3	women	N	O
4	who	N	O
5	took	N	O
6	adjuvant	N	O
7	tamoxifen	N	O
8	for	N	O
9	2	N	O
10	to	N	O
11	3	N	O
12	years	N	O
13	for	N	O
14	operable	N	O
15	breast	N	O
16	cancer	N	O
17	with	N	O
18	a	N	O
19	double	N	O
20	endometrial	N	O
21	thickness	N	O
22	greater	N	O
23	than	N	O
24	7	N	O
25	mm	N	O
26	were	N	O
27	randomized	N	O
28	to	N	O
29	20	N	O
30	mg	N	O
31	tamoxifen	N	O
32	or	N	O
33	1	N	O
34	mg	N	O
35	anastrozole	N	O
36	for	N	O
37	the	N	O
38	remaining	N	O
39	duration	N	O
40	,	N	O
41	totaling	N	O
42	5	N	O
43	years	N	O
44	.	N	O

1	Tablets	N	O
2	were	N	O
3	unrecognizable	N	O
4	for	N	O
5	drug	N	O
6	assignment	N	O
7	.	N	O

1	The	N	O
2	primary	N	O
3	endpoints	N	O
4	were	N	O
5	the	N	O
6	differences	N	O
7	in	N	O
8	double	N	O
9	endometrial	N	O
10	thickness	N	O
11	and	N	O
12	uterine	N	O
13	volume	N	O
14	after	N	O
15	1	N	O
16	year	N	O
17	.	N	O

1	Uterine	N	O
2	and	N	O
3	quality-of-life	N	O
4	data	N	O
5	were	N	O
6	analyzed	N	O
7	using	N	O
8	regression	N	O
9	methods	N	O
10	,	N	O
11	and	N	O
12	missing	N	O
13	values	N	O
14	were	N	O
15	handled	N	O
16	using	N	O
17	multiple	N	O
18	imputation	N	O
19	.	N	O

1	Seventy-two	N	O
2	women	N	O
3	(	N	O
4	median	N	O
5	age	N	O
6	,	N	O
7	60	N	O
8	y	N	O
9	)	N	O
10	were	N	O
11	randomized	N	O
12	in	N	O
13	five	N	O
14	hospitals	N	O
15	.	N	O

1	Relative	N	I-Premise
2	to	N	I-Premise
3	women	N	I-Premise
4	continuing	N	I-Premise
5	tamoxifen	N	I-Premise
6	,	N	I-Premise
7	women	N	I-Premise
8	switching	N	I-Premise
9	to	N	I-Premise
10	anastrozole	N	I-Premise
11	experienced	N	I-Premise
12	a	N	I-Premise
13	decrease	N	I-Premise
14	of	N	I-Premise
15	53	N	I-Premise
16	%	N	I-Premise
17	(	N	I-Premise
18	95	N	I-Premise
19	%	N	I-Premise
20	CI	N	I-Premise
21	,	N	I-Premise
22	41	N	I-Premise
23	%	N	I-Premise
24	-63	N	I-Premise
25	%	N	I-Premise
26	)	N	I-Premise
27	in	N	I-Premise
28	double	N	I-Premise
29	endometrial	N	I-Premise
30	thickness	N	I-Premise
31	and	N	I-Premise
32	a	N	I-Premise
33	decrease	N	I-Premise
34	of	N	I-Premise
35	51	N	I-Premise
36	%	N	I-Premise
37	(	N	I-Premise
38	95	N	I-Premise
39	%	N	I-Premise
40	CI	N	I-Premise
41	,	N	I-Premise
42	39	N	I-Premise
43	%	N	I-Premise
44	-60	N	I-Premise
45	%	N	I-Premise
46	)	N	I-Premise
47	in	N	I-Premise
48	uterine	N	I-Premise
49	volume	N	I-Premise
50	.	N	I-Premise

1	Vaginal	N	I-Premise
2	dryness	N	I-Premise
3	(	N	I-Premise
4	b	N	I-Premise
5	=	N	I-Premise
6	0.064	N	I-Premise
7	;	N	I-Premise
8	95	N	I-Premise
9	%	N	I-Premise
10	CI	N	I-Premise
11	,	N	I-Premise
12	0.016-0.112	N	I-Premise
13	)	N	I-Premise
14	and	N	I-Premise
15	sexual	N	I-Premise
16	problems	N	I-Premise
17	(	N	I-Premise
18	b	N	I-Premise
19	=	N	I-Premise
20	0.054	N	I-Premise
21	;	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	,	N	I-Premise
26	0.007-0.102	N	I-Premise
27	)	N	I-Premise
28	increased	N	I-Premise
29	in	N	I-Premise
30	women	N	I-Premise
31	taking	N	I-Premise
32	anastrozole	N	I-Premise
33	compared	N	I-Premise
34	with	N	I-Premise
35	women	N	I-Premise
36	taking	N	I-Premise
37	tamoxifen	N	I-Premise
38	.	N	I-Premise

1	Treatment	N	I-Premise
2	arms	N	I-Premise
3	did	N	I-Premise
4	not	N	I-Premise
5	differ	N	I-Premise
6	regarding	N	I-Premise
7	withdrawal	N	I-Premise
8	rate	N	I-Premise
9	and	N	I-Premise
10	the	N	I-Premise
11	experience	N	I-Premise
12	of	N	I-Premise
13	(	N	I-Premise
14	serious	N	I-Premise
15	)	N	I-Premise
16	adverse	N	I-Premise
17	events	N	I-Premise
18	.	N	I-Premise

1	Despite	N	O
2	premature	N	O
3	trial	N	O
4	closure	N	O
5	,	N	O
6	our	N	O
7	data	N	O
8	provided	N	O
9	valuable	N	O
10	insights	N	O
11	.	N	O

1	Switching	N	I-Claim
2	to	N	I-Claim
3	anastrozole	N	I-Claim
4	strongly	N	I-Claim
5	decreased	N	I-Claim
6	the	N	I-Claim
7	endometrial	N	I-Claim
8	thickness	N	I-Claim
9	and	N	I-Claim
10	uterine	N	I-Claim
11	volume	N	I-Claim
12	but	N	I-Claim
13	increased	N	I-Claim
14	sexual	N	I-Claim
15	disturbances	N	I-Claim
16	.	N	I-Claim

1	Safe	N	I-MajorClaim
2	and	N	I-MajorClaim
3	effective	N	I-MajorClaim
4	interventions	N	I-MajorClaim
5	are	N	I-MajorClaim
6	needed	N	I-MajorClaim
7	to	N	I-MajorClaim
8	alleviate	N	I-MajorClaim
9	sexual	N	I-MajorClaim
10	dysfunction	N	I-MajorClaim
11	.	N	I-MajorClaim

1	Systematic	N	I-MajorClaim
2	assessment	N	I-MajorClaim
3	is	N	I-MajorClaim
4	vital	N	I-MajorClaim
5	to	N	I-MajorClaim
6	palliative	N	I-MajorClaim
7	care	N	I-MajorClaim
8	,	N	O
9	but	N	O
10	documentation	N	O
11	confirming	N	O
12	completion	N	O
13	of	N	O
14	systematic	N	O
15	assessment	N	O
16	in	N	O
17	hospice	N	O
18	settings	N	O
19	is	N	O
20	often	N	O
21	inadequate	N	O
22	or	N	O
23	absent	N	O
24	.	N	O

1	The	N	O
2	objective	N	O
3	of	N	O
4	the	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	determine	N	O
9	the	N	O
10	efficacy	N	O
11	of	N	O
12	systematic	N	O
13	feedback	N	O
14	from	N	O
15	standardized	N	O
16	assessment	N	O
17	tools	N	O
18	for	N	O
19	hospice	N	O
20	patient-caregiver	N	O
21	dyads	N	O
22	in	N	O
23	improving	N	O
24	hospice	N	O
25	outcomes	N	O
26	compared	N	O
27	with	N	O
28	the	N	O
29	usual	N	O
30	clinical	N	O
31	practice	N	O
32	.	N	O

1	The	N	O
2	sample	N	O
3	of	N	O
4	patients	N	O
5	(	N	O
6	n	N	O
7	=	N	O
8	709	N	O
9	)	N	O
10	newly	N	O
11	admitted	N	O
12	to	N	O
13	hospice	N	O
14	home	N	O
15	care	N	O
16	in	N	O
17	2	N	O
18	hospices	N	O
19	had	N	O
20	designated	N	O
21	family	N	O
22	caregivers	N	O
23	.	N	O

1	The	N	O
2	interdisciplinary	N	O
3	teams	N	O
4	(	N	O
5	IDTs	N	O
6	)	N	O
7	caring	N	O
8	for	N	O
9	these	N	O
10	dyads	N	O
11	were	N	O
12	randomly	N	O
13	assigned	N	O
14	to	N	O
15	either	N	O
16	experimental	N	O
17	(	N	O
18	n	N	O
19	=	N	O
20	338	N	O
21	)	N	O
22	or	N	O
23	control	N	O
24	(	N	O
25	n	N	O
26	=	N	O
27	371	N	O
28	)	N	O
29	conditions	N	O
30	.	N	O

1	Data	N	O
2	were	N	O
3	collected	N	O
4	from	N	O
5	both	N	O
6	groups	N	O
7	of	N	O
8	dyads	N	O
9	using	N	O
10	standardized	N	O
11	assessments	N	O
12	on	N	O
13	admission	N	O
14	and	N	O
15	1	N	O
16	week	N	O
17	after	N	O
18	each	N	O
19	of	N	O
20	the	N	O
21	first	N	O
22	2	N	O
23	IDT	N	O
24	meetings	N	O
25	in	N	O
26	which	N	O
27	these	N	O
28	dyads	N	O
29	were	N	O
30	discussed	N	O
31	.	N	O

1	The	N	O
2	experimental	N	O
3	intervention	N	O
4	consisted	N	O
5	of	N	O
6	reporting	N	O
7	data	N	O
8	from	N	O
9	the	N	O
10	standardized	N	O
11	assessments	N	O
12	to	N	O
13	the	N	O
14	IDTs	N	O
15	.	N	O

1	Results	N	I-Premise
2	showed	N	I-Premise
3	improved	N	I-Premise
4	patient	N	I-Premise
5	depression	N	I-Premise
6	(	N	I-Premise
7	P	N	I-Premise
8	<	N	I-Premise
9	.001	N	I-Premise
10	)	N	I-Premise
11	as	N	I-Premise
12	a	N	I-Premise
13	result	N	I-Premise
14	of	N	I-Premise
15	the	N	I-Premise
16	intervention	N	I-Premise
17	and	N	I-Premise
18	improvement	N	I-Premise
19	in	N	I-Premise
20	both	N	I-Premise
21	groups	N	I-Premise
22	in	N	I-Premise
23	patients	N	I-Premise
24	'	N	I-Premise
25	quality	N	I-Premise
26	of	N	I-Premise
27	life	N	I-Premise
28	(	N	I-Premise
29	P	N	I-Premise
30	<	N	I-Premise
31	.001	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	No	N	I-Premise
2	other	N	I-Premise
3	patient	N	I-Premise
4	outcomes	N	I-Premise
5	(	N	I-Premise
6	symptom	N	I-Premise
7	distress	N	I-Premise
8	,	N	I-Premise
9	spiritual	N	I-Premise
10	needs	N	I-Premise
11	)	N	I-Premise
12	or	N	I-Premise
13	caregiver	N	I-Premise
14	outcomes	N	I-Premise
15	(	N	I-Premise
16	depression	N	I-Premise
17	,	N	I-Premise
18	support	N	I-Premise
19	,	N	I-Premise
20	spiritual	N	I-Premise
21	needs	N	I-Premise
22	)	N	I-Premise
23	were	N	I-Premise
24	significantly	N	I-Premise
25	different	N	I-Premise
26	.	N	I-Premise

1	Assessment	N	O
2	of	N	O
3	depression	N	O
4	added	N	O
5	to	N	O
6	usual	N	O
7	care	N	O
8	probably	N	O
9	had	N	O
10	an	N	O
11	effect	N	O
12	because	N	O
13	it	N	O
14	is	N	O
15	not	N	O
16	normally	N	O
17	a	N	O
18	focus	N	O
19	of	N	O
20	hospice	N	O
21	staff	N	O
22	.	N	O

1	Hospice	N	I-Premise
2	care	N	I-Premise
3	was	N	I-Premise
4	so	N	I-Premise
5	good	N	I-Premise
6	during	N	I-Premise
7	the	N	I-Premise
8	study	N	I-Premise
9	that	N	I-Premise
10	overall	N	I-Premise
11	quality	N	I-Premise
12	of	N	I-Premise
13	life	N	I-Premise
14	improved	N	I-Premise
15	as	N	I-Premise
16	a	N	I-Premise
17	result	N	I-Premise
18	of	N	I-Premise
19	standard	N	I-Premise
20	care	N	I-Premise
21	and	N	I-Premise
22	left	N	I-Premise
23	little	N	I-Premise
24	room	N	I-Premise
25	for	N	I-Premise
26	improvement	N	I-Premise
27	in	N	I-Premise
28	other	N	I-Premise
29	variables	N	I-Premise
30	.	N	I-Premise

1	Systematic	N	I-Claim
2	assessment	N	I-Claim
3	of	N	I-Claim
4	depression	N	I-Claim
5	is	N	I-Claim
6	needed	N	I-Claim
7	in	N	I-Claim
8	hospice	N	I-Claim
9	patients	N	I-Claim
10	.	N	I-Claim

1	No	N	O
2	caregiver	N	O
3	variables	N	O
4	changed	N	O
5	,	N	O
6	which	N	O
7	may	N	O
8	indicate	N	O
9	a	N	O
10	need	N	O
11	for	N	O
12	a	N	O
13	focus	N	O
14	on	N	O
15	caregivers	N	O
16	.	N	O

1	Serum	N	O
2	CA125	N	O
3	concentration	N	O
4	often	N	O
5	rises	N	O
6	several	N	O
7	months	N	O
8	before	N	O
9	clinical	N	O
10	or	N	O
11	symptomatic	N	O
12	relapse	N	O
13	in	N	O
14	women	N	O
15	with	N	O
16	ovarian	N	O
17	cancer	N	O
18	.	N	O

1	In	N	O
2	the	N	O
3	MRC	N	O
4	OV05/EORTC	N	O
5	55955	N	O
6	collaborative	N	O
7	trial	N	O
8	,	N	O
9	we	N	O
10	aimed	N	O
11	to	N	O
12	establish	N	O
13	the	N	O
14	benefits	N	O
15	of	N	O
16	early	N	O
17	treatment	N	O
18	on	N	O
19	the	N	O
20	basis	N	O
21	of	N	O
22	increased	N	O
23	CA125	N	O
24	concentrations	N	O
25	compared	N	O
26	with	N	O
27	delayed	N	O
28	treatment	N	O
29	on	N	O
30	the	N	O
31	basis	N	O
32	of	N	O
33	clinical	N	O
34	recurrence	N	O
35	.	N	O

1	Women	N	O
2	with	N	O
3	ovarian	N	O
4	cancer	N	O
5	in	N	O
6	complete	N	O
7	remission	N	O
8	after	N	O
9	first-line	N	O
10	platinum-based	N	O
11	chemotherapy	N	O
12	and	N	O
13	a	N	O
14	normal	N	O
15	CA125	N	O
16	concentration	N	O
17	were	N	O
18	registered	N	O
19	for	N	O
20	this	N	O
21	randomised	N	O
22	controlled	N	O
23	trial	N	O
24	.	N	O

1	Clinical	N	O
2	examination	N	O
3	and	N	O
4	CA125	N	O
5	measurement	N	O
6	were	N	O
7	done	N	O
8	every	N	O
9	3	N	O
10	months	N	O
11	.	N	O

1	Patients	N	O
2	and	N	O
3	investigators	N	O
4	were	N	O
5	masked	N	O
6	to	N	O
7	CA125	N	O
8	results	N	O
9	,	N	O
10	which	N	O
11	were	N	O
12	monitored	N	O
13	by	N	O
14	coordinating	N	O
15	centres	N	O
16	.	N	O

1	If	N	O
2	CA125	N	O
3	concentration	N	O
4	exceeded	N	O
5	twice	N	O
6	the	N	O
7	upper	N	O
8	limit	N	O
9	of	N	O
10	normal	N	O
11	,	N	O
12	patients	N	O
13	were	N	O
14	randomly	N	O
15	assigned	N	O
16	(	N	O
17	1:1	N	O
18	)	N	O
19	by	N	O
20	minimisation	N	O
21	to	N	O
22	early	N	O
23	or	N	O
24	delayed	N	O
25	chemotherapy	N	O
26	.	N	O

1	Patients	N	O
2	and	N	O
3	clinical	N	O
4	sites	N	O
5	were	N	O
6	informed	N	O
7	of	N	O
8	allocation	N	O
9	to	N	O
10	early	N	O
11	treatment	N	O
12	,	N	O
13	and	N	O
14	treatment	N	O
15	was	N	O
16	started	N	O
17	as	N	O
18	soon	N	O
19	as	N	O
20	possible	N	O
21	within	N	O
22	28	N	O
23	days	N	O
24	of	N	O
25	the	N	O
26	increased	N	O
27	CA125	N	O
28	measurement	N	O
29	.	N	O

1	Patients	N	O
2	assigned	N	O
3	to	N	O
4	delayed	N	O
5	treatment	N	O
6	continued	N	O
7	masked	N	O
8	CA125	N	O
9	measurements	N	O
10	,	N	O
11	with	N	O
12	treatment	N	O
13	commencing	N	O
14	at	N	O
15	clinical	N	O
16	or	N	O
17	symptomatic	N	O
18	relapse	N	O
19	.	N	O

1	All	N	O
2	patients	N	O
3	were	N	O
4	treated	N	O
5	according	N	O
6	to	N	O
7	standard	N	O
8	local	N	O
9	practice	N	O
10	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	overall	N	O
6	survival	N	O
7	.	N	O

1	Analysis	N	O
2	was	N	O
3	by	N	O
4	intention	N	O
5	to	N	O
6	treat	N	O
7	.	N	O

1	This	N	O
2	study	N	O
3	is	N	O
4	registered	N	O
5	,	N	O
6	ISRCTN87786644	N	O
7	.	N	O

1	1442	N	O
2	patients	N	O
3	were	N	O
4	registered	N	O
5	for	N	O
6	the	N	O
7	trial	N	O
8	,	N	O
9	of	N	O
10	whom	N	O
11	529	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	to	N	O
16	treatment	N	O
17	groups	N	O
18	and	N	O
19	were	N	O
20	included	N	O
21	in	N	O
22	our	N	O
23	analysis	N	O
24	(	N	O
25	265	N	O
26	early	N	O
27	,	N	O
28	264	N	O
29	delayed	N	O
30	)	N	O
31	.	N	O

1	With	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	56·9	N	I-Premise
7	months	N	I-Premise
8	(	N	I-Premise
9	IQR	N	I-Premise
10	37·4-81·8	N	I-Premise
11	)	N	I-Premise
12	from	N	I-Premise
13	randomisation	N	I-Premise
14	and	N	I-Premise
15	370	N	I-Premise
16	deaths	N	I-Premise
17	(	N	I-Premise
18	186	N	I-Premise
19	early	N	I-Premise
20	,	N	I-Premise
21	184	N	I-Premise
22	delayed	N	I-Premise
23	)	N	I-Premise
24	,	N	I-Premise
25	there	N	I-Premise
26	was	N	I-Premise
27	no	N	I-Premise
28	evidence	N	I-Premise
29	of	N	I-Premise
30	a	N	I-Premise
31	difference	N	I-Premise
32	in	N	I-Premise
33	overall	N	I-Premise
34	survival	N	I-Premise
35	between	N	I-Premise
36	early	N	I-Premise
37	and	N	I-Premise
38	delayed	N	I-Premise
39	treatment	N	I-Premise
40	(	N	I-Premise
41	HR	N	I-Premise
42	0·98	N	I-Premise
43	,	N	I-Premise
44	95	N	I-Premise
45	%	N	I-Premise
46	CI	N	I-Premise
47	0·80-1·20	N	I-Premise
48	,	N	I-Premise
49	p=0·85	N	I-Premise
50	)	N	I-Premise
51	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	from	N	I-Premise
4	randomisation	N	I-Premise
5	was	N	I-Premise
6	25·7	N	I-Premise
7	months	N	I-Premise
8	(	N	I-Premise
9	95	N	I-Premise
10	%	N	I-Premise
11	CI	N	I-Premise
12	23·0-27·9	N	I-Premise
13	)	N	I-Premise
14	for	N	I-Premise
15	patients	N	I-Premise
16	on	N	I-Premise
17	early	N	I-Premise
18	treatment	N	I-Premise
19	and	N	I-Premise
20	27·1	N	I-Premise
21	months	N	I-Premise
22	(	N	I-Premise
23	22·8-30·9	N	I-Premise
24	)	N	I-Premise
25	for	N	I-Premise
26	those	N	I-Premise
27	on	N	I-Premise
28	delayed	N	I-Premise
29	treatment	N	I-Premise
30	.	N	I-Premise

1	Our	N	I-Claim
2	findings	N	I-Claim
3	showed	N	I-Claim
4	no	N	I-Claim
5	evidence	N	I-Claim
6	of	N	I-Claim
7	a	N	I-Claim
8	survival	N	I-Claim
9	benefit	N	I-Claim
10	with	N	I-Claim
11	early	N	I-Claim
12	treatment	N	I-Claim
13	of	N	I-Claim
14	relapse	N	I-Claim
15	on	N	I-Claim
16	the	N	I-Claim
17	basis	N	I-Claim
18	of	N	I-Claim
19	a	N	I-Claim
20	raised	N	I-Claim
21	CA125	N	I-Claim
22	concentration	N	I-Claim
23	alone	N	I-Claim
24	,	N	I-Claim
25	and	N	I-Claim
26	therefore	N	I-Claim
27	the	N	I-Claim
28	value	N	I-Claim
29	of	N	I-Claim
30	routine	N	I-Claim
31	measurement	N	I-Claim
32	of	N	I-Claim
33	CA125	N	I-Claim
34	in	N	I-Claim
35	the	N	I-Claim
36	follow-up	N	I-Claim
37	of	N	I-Claim
38	patients	N	I-Claim
39	with	N	I-Claim
40	ovarian	N	I-Claim
41	cancer	N	I-Claim
42	who	N	I-Claim
43	attain	N	I-Claim
44	a	N	I-Claim
45	complete	N	I-Claim
46	response	N	I-Claim
47	after	N	I-Claim
48	first-line	N	I-Claim
49	treatment	N	I-Claim
50	is	N	I-Claim
51	not	N	I-Claim
52	proven	N	I-Claim
53	.	N	I-Claim

1	Chemotherapy-induced	N	O
2	anemia	N	O
3	(	N	O
4	CIA	N	O
5	)	N	O
6	is	N	O
7	responsive	N	O
8	to	N	O
9	treatment	N	O
10	with	N	O
11	erythropoiesis-stimulating	N	O
12	agents	N	O
13	(	N	O
14	ESAs	N	O
15	)	N	O
16	such	N	O
17	as	N	O
18	darbepoetin	N	O
19	alfa	N	O
20	.	N	O

1	Administration	N	O
2	of	N	O
3	ESAs	N	O
4	on	N	O
5	a	N	O
6	synchronous	N	O
7	schedule	N	O
8	with	N	O
9	chemotherapy	N	O
10	administration	N	O
11	could	N	O
12	benefit	N	O
13	patients	N	O
14	by	N	O
15	reducing	N	O
16	clinic	N	O
17	visits	N	O
18	and	N	O
19	potentially	N	O
20	enhancing	N	O
21	on-time	N	O
22	chemotherapy	N	O
23	delivery	N	O
24	.	N	O

1	This	N	O
2	phase	N	O
3	2	N	O
4	,	N	O
5	25-week	N	O
6	,	N	O
7	open-label	N	O
8	study	N	O
9	evaluated	N	O
10	the	N	O
11	noninferiority	N	O
12	of	N	O
13	darbepoetin	N	O
14	alfa	N	O
15	administered	N	O
16	weekly	N	O
17	vs.	N	O
18	as	N	O
19	an	N	O
20	extended	N	O
21	dosing	N	O
22	schedule	N	O
23	(	N	O
24	every	N	O
25	2	N	O
26	or	N	O
27	3	N	O
28	weeks	N	O
29	)	N	O
30	in	N	O
31	patients	N	O
32	with	N	O
33	CIA	N	O
34	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	1:1	N	O
5	to	N	O
6	an	N	O
7	extended	N	O
8	dosing	N	O
9	schedule	N	O
10	(	N	O
11	EDS	N	O
12	:	N	O
13	darbepoetin	N	O
14	alfa	N	O
15	300	N	O
16	μg	N	O
17	Q2W	N	O
18	if	N	O
19	chemotherapy	N	O
20	was	N	O
21	QW	N	O
22	,	N	O
23	Q2W	N	O
24	,	N	O
25	or	N	O
26	Q4W	N	O
27	or	N	O
28	darbepoetin	N	O
29	alfa	N	O
30	500	N	O
31	μg	N	O
32	Q3W	N	O
33	if	N	O
34	chemotherapy	N	O
35	was	N	O
36	Q3W	N	O
37	)	N	O
38	or	N	O
39	weekly	N	O
40	(	N	O
41	150	N	O
42	μg	N	O
43	QW	N	O
44	regardless	N	O
45	of	N	O
46	chemotherapy	N	O
47	schedule	N	O
48	)	N	O
49	.	N	O

1	Stratification	N	O
2	factors	N	O
3	included	N	O
4	chemotherapy	N	O
5	cycle	N	O
6	length	N	O
7	,	N	O
8	screening	N	O
9	hemoglobin	N	O
10	(	N	O
11	<	N	O
12	10	N	O
13	g/dL	N	O
14	vs.	N	O
15	≥10	N	O
16	g/dL	N	O
17	)	N	O
18	,	N	O
19	and	N	O
20	tumor	N	O
21	type	N	O
22	(	N	O
23	lung/gynecological	N	O
24	vs.	N	O
25	other	N	O
26	nonmyeloid	N	O
27	malignancies	N	O
28	)	N	O
29	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	change	N	O
6	in	N	O
7	hemoglobin	N	O
8	from	N	O
9	baseline	N	O
10	to	N	O
11	Week	N	O
12	13	N	O
13	.	N	O

1	Seven	N	O
2	hundred	N	O
3	fifty-two	N	O
4	patients	N	O
5	(	N	O
6	374	N	O
7	QW	N	O
8	patients	N	O
9	;	N	O
10	378	N	O
11	EDS	N	O
12	patients	N	O
13	)	N	O
14	received	N	O
15	≥1	N	O
16	dose	N	O
17	of	N	O
18	darbepoetin	N	O
19	alfa	N	O
20	and	N	O
21	were	N	O
22	included	N	O
23	in	N	O
24	the	N	O
25	analysis	N	O
26	.	N	O

1	Demographics	N	O
2	and	N	O
3	disease	N	O
4	state	N	O
5	were	N	O
6	similar	N	O
7	between	N	O
8	groups	N	O
9	.	N	O

1	Seventy-one	N	I-Premise
2	percent	N	I-Premise
3	of	N	I-Premise
4	patients	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	EDS	N	I-Premise
8	group	N	I-Premise
9	and	N	I-Premise
10	76	N	I-Premise
11	%	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	QW	N	I-Premise
15	group	N	I-Premise
16	achieved	N	I-Premise
17	the	N	I-Premise
18	target	N	I-Premise
19	hemoglobin	N	I-Premise
20	of	N	I-Premise
21	≥11.0	N	I-Premise
22	g/dL	N	I-Premise
23	.	N	I-Premise

1	There	N	O
2	was	N	O
3	a	N	O
4	minimal	N	O
5	difference	N	O
6	in	N	O
7	the	N	O
8	primary	N	O
9	endpoint	N	O
10	of	N	O
11	mean	N	O
12	change	N	O
13	in	N	O
14	hemoglobin	N	O
15	(	N	O
16	baseline	N	O
17	to	N	O
18	Week	N	O
19	13	N	O
20	)	N	O
21	between	N	O
22	the	N	O
23	QW	N	O
24	and	N	O
25	the	N	O
26	EDS	N	O
27	groups	N	O
28	(	N	O
29	-0.04	N	O
30	g/dL	N	O
31	;	N	O
32	95	N	O
33	%	N	O
34	confidence	N	O
35	interval	N	O
36	:	N	O
37	-0.26	N	O
38	,	N	O
39	0.17	N	O
40	g/dL	N	O
41	)	N	O
42	.	N	O

1	The	N	O
2	upper	N	O
3	limit	N	O
4	of	N	O
5	the	N	O
6	95	N	O
7	%	N	O
8	confidence	N	O
9	interval	N	O
10	was	N	O
11	less	N	O
12	than	N	O
13	the	N	O
14	prespecified	N	O
15	limit	N	O
16	of	N	O
17	<	N	O
18	0.75	N	O
19	g/dL	N	O
20	,	N	O
21	supporting	N	O
22	noninferiority	N	O
23	of	N	O
24	the	N	O
25	EDS	N	O
26	dosing	N	O
27	schedule	N	O
28	.	N	O

1	Reported	N	I-Premise
2	adverse	N	I-Premise
3	events	N	I-Premise
4	were	N	I-Premise
5	similar	N	I-Premise
6	between	N	I-Premise
7	groups	N	I-Premise
8	.	N	I-Premise

1	A	N	I-Premise
2	slight	N	I-Premise
3	increase	N	I-Premise
4	in	N	I-Premise
5	transfusions	N	I-Premise
6	was	N	I-Premise
7	reported	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	QW	N	I-Premise
11	group	N	I-Premise
12	.	N	I-Premise

1	Darbepoetin	N	I-Claim
2	alfa	N	I-Claim
3	,	N	I-Claim
4	when	N	I-Claim
5	administered	N	I-Claim
6	synchronously	N	I-Claim
7	with	N	I-Claim
8	chemotherapy	N	I-Claim
9	,	N	I-Claim
10	on	N	I-Claim
11	an	N	I-Claim
12	EDS	N	I-Claim
13	appears	N	I-Claim
14	to	N	I-Claim
15	be	N	I-Claim
16	similarly	N	I-Claim
17	efficacious	N	I-Claim
18	to	N	I-Claim
19	darbepoetin	N	I-Claim
20	alfa	N	I-Claim
21	weekly	N	I-Claim
22	dosing	N	I-Claim
23	with	N	I-Claim
24	no	N	I-Claim
25	unexpected	N	I-Claim
26	adverse	N	I-Claim
27	events	N	I-Claim
28	.	N	I-Claim

1	This	N	O
2	study	N	O
3	provides	N	O
4	prospective	N	O
5	data	N	O
6	on	N	O
7	how	N	O
8	multiple	N	O
9	dosing	N	O
10	regimens	N	O
11	available	N	O
12	with	N	O
13	darbepoetin	N	O
14	alfa	N	O
15	can	N	O
16	be	N	O
17	synchronized	N	O
18	with	N	O
19	chemotherapy	N	O
20	administered	N	O
21	across	N	O
22	a	N	O
23	range	N	O
24	of	N	O
25	dosing	N	O
26	schedules	N	O
27	.	N	O

1	To	N	O
2	perform	N	O
3	a	N	O
4	randomized	N	O
5	trial	N	O
6	comparing	N	O
7	70	N	O
8	and	N	O
9	80	N	O
10	Gy	N	O
11	radiotherapy	N	O
12	for	N	O
13	prostate	N	O
14	cancer	N	O
15	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	306	N	O
5	patients	N	O
6	with	N	O
7	localized	N	O
8	prostate	N	O
9	cancer	N	O
10	were	N	O
11	randomized	N	O
12	.	N	O

1	No	N	O
2	androgen	N	O
3	deprivation	N	O
4	was	N	O
5	allowed	N	O
6	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	biochemical	N	O
6	relapse	N	O
7	according	N	O
8	to	N	O
9	the	N	O
10	modified	N	O
11	1997-American	N	O
12	Society	N	O
13	for	N	O
14	Therapeutic	N	O
15	Radiology	N	O
16	and	N	O
17	Oncology	N	O
18	and	N	O
19	Phoenix	N	O
20	definitions	N	O
21	.	N	O

1	Toxicity	N	O
2	was	N	O
3	graded	N	O
4	using	N	O
5	the	N	O
6	Radiation	N	O
7	Therapy	N	O
8	Oncology	N	O
9	Group	N	O
10	1991	N	O
11	criteria	N	O
12	and	N	O
13	the	N	O
14	late	N	O
15	effects	N	O
16	on	N	O
17	normal	N	O
18	tissues-subjective	N	O
19	,	N	O
20	objective	N	O
21	,	N	O
22	management	N	O
23	,	N	O
24	analytic	N	O
25	scales	N	O
26	(	N	O
27	LENT-SOMA	N	O
28	)	N	O
29	scales	N	O
30	.	N	O

1	The	N	O
2	patients	N	O
3	'	N	O
4	quality	N	O
5	of	N	O
6	life	N	O
7	was	N	O
8	scored	N	O
9	using	N	O
10	the	N	O
11	European	N	O
12	Organization	N	O
13	for	N	O
14	Research	N	O
15	and	N	O
16	Treatment	N	O
17	of	N	O
18	Cancer	N	O
19	Quality	N	O
20	of	N	O
21	Life	N	O
22	Questionnaire	N	O
23	30-item	N	O
24	cancer-specific	N	O
25	and	N	O
26	25-item	N	O
27	prostate-specific	N	O
28	modules	N	O
29	.	N	O

1	The	N	O
2	median	N	O
3	follow-up	N	O
4	was	N	O
5	61	N	O
6	months	N	O
7	.	N	O

1	According	N	O
2	to	N	O
3	the	N	O
4	1997-American	N	O
5	Society	N	O
6	for	N	O
7	Therapeutic	N	O
8	Radiology	N	O
9	and	N	O
10	Oncology	N	O
11	definition	N	O
12	,	N	O
13	the	N	O
14	5-year	N	O
15	biochemical	N	O
16	relapse	N	O
17	rate	N	O
18	was	N	O
19	39	N	O
20	%	N	O
21	and	N	O
22	28	N	O
23	%	N	O
24	in	N	O
25	the	N	O
26	70-	N	O
27	and	N	O
28	80-Gy	N	O
29	arms	N	O
30	,	N	O
31	respectively	N	O
32	(	N	O
33	p	N	O
34	=	N	O
35	.036	N	O
36	)	N	O
37	.	N	O

1	Using	N	O
2	the	N	O
3	Phoenix	N	O
4	definition	N	O
5	,	N	O
6	the	N	O
7	5-year	N	O
8	biochemical	N	O
9	relapse	N	O
10	rate	N	O
11	was	N	O
12	32	N	O
13	%	N	O
14	and	N	O
15	23.5	N	O
16	%	N	O
17	,	N	O
18	respectively	N	O
19	(	N	O
20	p	N	O
21	=	N	O
22	.09	N	O
23	)	N	O
24	.	N	O

1	The	N	O
2	subgroup	N	O
3	analysis	N	O
4	showed	N	O
5	a	N	O
6	better	N	O
7	biochemical	N	O
8	outcome	N	O
9	for	N	O
10	the	N	O
11	higher	N	O
12	dose	N	O
13	group	N	O
14	with	N	O
15	an	N	O
16	initial	N	O
17	prostate-specific	N	O
18	antigen	N	O
19	level	N	O
20	>	N	O
21	15	N	O
22	ng/mL	N	O
23	.	N	O

1	At	N	O
2	the	N	O
3	last	N	O
4	follow-up	N	O
5	date	N	O
6	,	N	O
7	26	N	O
8	patients	N	O
9	had	N	O
10	died	N	O
11	,	N	O
12	10	N	O
13	of	N	O
14	their	N	O
15	disease	N	O
16	and	N	O
17	none	N	O
18	of	N	O
19	toxicity	N	O
20	,	N	O
21	with	N	O
22	no	N	O
23	differences	N	O
24	between	N	O
25	the	N	O
26	two	N	O
27	arms	N	O
28	.	N	O

1	According	N	I-Premise
2	to	N	I-Premise
3	the	N	I-Premise
4	Radiation	N	I-Premise
5	Therapy	N	I-Premise
6	Oncology	N	I-Premise
7	Group	N	I-Premise
8	scale	N	I-Premise
9	,	N	I-Premise
10	the	N	I-Premise
11	Grade	N	I-Premise
12	2	N	I-Premise
13	or	N	I-Premise
14	greater	N	I-Premise
15	rectal	N	I-Premise
16	toxicity	N	I-Premise
17	rate	N	I-Premise
18	was	N	I-Premise
19	14	N	I-Premise
20	%	N	I-Premise
21	and	N	I-Premise
22	19.5	N	I-Premise
23	%	N	I-Premise
24	for	N	I-Premise
25	the	N	I-Premise
26	70-	N	I-Premise
27	and	N	I-Premise
28	80-Gy	N	I-Premise
29	arms	N	I-Premise
30	(	N	I-Premise
31	p	N	I-Premise
32	=	N	I-Premise
33	.22	N	I-Premise
34	)	N	I-Premise
35	,	N	I-Premise
36	respectively	N	I-Premise
37	.	N	I-Premise

1	The	N	I-Premise
2	Grade	N	I-Premise
3	2	N	I-Premise
4	or	N	I-Premise
5	greater	N	I-Premise
6	urinary	N	I-Premise
7	toxicity	N	I-Premise
8	was	N	I-Premise
9	10	N	I-Premise
10	%	N	I-Premise
11	at	N	I-Premise
12	70	N	I-Premise
13	Gy	N	I-Premise
14	and	N	I-Premise
15	17.5	N	I-Premise
16	%	N	I-Premise
17	at	N	I-Premise
18	80	N	I-Premise
19	Gy	N	I-Premise
20	(	N	I-Premise
21	p	N	I-Premise
22	=	N	I-Premise
23	.046	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	Similar	N	I-Premise
2	results	N	I-Premise
3	were	N	I-Premise
4	observed	N	I-Premise
5	using	N	I-Premise
6	the	N	I-Premise
7	LENT-SOMA	N	I-Premise
8	scale	N	I-Premise
9	.	N	I-Premise

1	Bladder	N	I-Premise
2	toxicity	N	I-Premise
3	was	N	I-Premise
4	more	N	I-Premise
5	frequent	N	I-Premise
6	at	N	I-Premise
7	80	N	I-Premise
8	Gy	N	I-Premise
9	than	N	I-Premise
10	at	N	I-Premise
11	70	N	I-Premise
12	Gy	N	I-Premise
13	(	N	I-Premise
14	p	N	I-Premise
15	=	N	I-Premise
16	.039	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	The	N	I-Premise
2	quality-of-life	N	I-Premise
3	questionnaire	N	I-Premise
4	results	N	I-Premise
5	before	N	I-Premise
6	and	N	I-Premise
7	5	N	I-Premise
8	years	N	I-Premise
9	after	N	I-Premise
10	treatment	N	I-Premise
11	were	N	I-Premise
12	available	N	I-Premise
13	for	N	I-Premise
14	103	N	I-Premise
15	patients	N	I-Premise
16	with	N	I-Premise
17	no	N	I-Premise
18	differences	N	I-Premise
19	found	N	I-Premise
20	between	N	I-Premise
21	the	N	I-Premise
22	70-	N	I-Premise
23	and	N	I-Premise
24	80-Gy	N	I-Premise
25	arms	N	I-Premise
26	.	N	I-Premise

1	High-dose	N	I-Claim
2	radiotherapy	N	I-Claim
3	provided	N	I-Claim
4	a	N	I-Claim
5	better	N	I-Claim
6	5-year	N	I-Claim
7	biochemical	N	I-Claim
8	outcome	N	I-Claim
9	with	N	I-Claim
10	slightly	N	I-Claim
11	greater	N	I-Claim
12	toxicity	N	I-Claim
13	.	N	I-Claim

1	Numerous	N	O
2	studies	N	O
3	have	N	O
4	examined	N	O
5	the	N	O
6	comorbidity	N	O
7	of	N	O
8	depression	N	O
9	with	N	O
10	cancer	N	O
11	,	N	O
12	and	N	O
13	some	N	O
14	have	N	O
15	indicated	N	O
16	that	N	O
17	depression	N	O
18	may	N	O
19	be	N	O
20	associated	N	O
21	with	N	O
22	cancer	N	O
23	progression	N	O
24	or	N	O
25	survival	N	O
26	.	N	O

1	However	N	O
2	,	N	O
3	few	N	O
4	studies	N	O
5	have	N	O
6	assessed	N	O
7	whether	N	O
8	changes	N	O
9	in	N	O
10	depression	N	O
11	symptoms	N	O
12	are	N	O
13	associated	N	O
14	with	N	O
15	survival	N	O
16	.	N	O

1	In	N	O
2	a	N	O
3	secondary	N	O
4	analysis	N	O
5	of	N	O
6	a	N	O
7	randomized	N	O
8	trial	N	O
9	of	N	O
10	supportive-expressive	N	O
11	group	N	O
12	therapy	N	O
13	,	N	O
14	125	N	O
15	women	N	O
16	with	N	O
17	metastatic	N	O
18	breast	N	O
19	cancer	N	O
20	(	N	O
21	MBC	N	O
22	)	N	O
23	completed	N	O
24	a	N	O
25	depression	N	O
26	symptom	N	O
27	measure	N	O
28	(	N	O
29	Center	N	O
30	for	N	O
31	Epidemiologic	N	O
32	Studies-Depression	N	O
33	Scale	N	O
34	[	N	O
35	CES-D	N	O
36	]	N	O
37	)	N	O
38	at	N	O
39	baseline	N	O
40	and	N	O
41	were	N	O
42	randomly	N	O
43	assigned	N	O
44	to	N	O
45	a	N	O
46	treatment	N	O
47	group	N	O
48	or	N	O
49	to	N	O
50	a	N	O
51	control	N	O
52	group	N	O
53	that	N	O
54	received	N	O
55	educational	N	O
56	materials	N	O
57	.	N	O

1	At	N	O
2	baseline	N	O
3	and	N	O
4	three	N	O
5	follow-up	N	O
6	points	N	O
7	,	N	O
8	101	N	O
9	of	N	O
10	125	N	O
11	women	N	O
12	completed	N	O
13	a	N	O
14	depression	N	O
15	symptom	N	O
16	measure	N	O
17	.	N	O

1	We	N	O
2	used	N	O
3	these	N	O
4	data	N	O
5	in	N	O
6	a	N	O
7	Cox	N	O
8	proportional	N	O
9	hazards	N	O
10	analysis	N	O
11	to	N	O
12	examine	N	O
13	whether	N	O
14	decreasing	N	O
15	depression	N	O
16	symptoms	N	O
17	over	N	O
18	the	N	O
19	first	N	O
20	year	N	O
21	of	N	O
22	the	N	O
23	study	N	O
24	(	N	O
25	the	N	O
26	length	N	O
27	of	N	O
28	the	N	O
29	intervention	N	O
30	)	N	O
31	would	N	O
32	be	N	O
33	associated	N	O
34	with	N	O
35	longer	N	O
36	survival	N	O
37	.	N	O

1	Median	N	I-Premise
2	survival	N	I-Premise
3	time	N	I-Premise
4	was	N	I-Premise
5	53.6	N	I-Premise
6	months	N	I-Premise
7	for	N	I-Premise
8	women	N	I-Premise
9	with	N	I-Premise
10	decreasing	N	I-Premise
11	CES-D	N	I-Premise
12	scores	N	I-Premise
13	over	N	I-Premise
14	1	N	I-Premise
15	year	N	I-Premise
16	and	N	I-Premise
17	25.1	N	I-Premise
18	months	N	I-Premise
19	for	N	I-Premise
20	women	N	I-Premise
21	with	N	I-Premise
22	increasing	N	I-Premise
23	CES-D	N	I-Premise
24	scores	N	I-Premise
25	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	effect	N	I-Premise
6	of	N	I-Premise
7	change	N	I-Premise
8	in	N	I-Premise
9	CES-D	N	I-Premise
10	over	N	I-Premise
11	the	N	I-Premise
12	first	N	I-Premise
13	year	N	I-Premise
14	on	N	I-Premise
15	survival	N	I-Premise
16	out	N	I-Premise
17	to	N	I-Premise
18	14	N	I-Premise
19	years	N	I-Premise
20	(	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	.007	N	I-Premise
24	)	N	I-Premise
25	but	N	I-Premise
26	no	N	I-Premise
27	significant	N	I-Premise
28	interaction	N	I-Premise
29	between	N	I-Premise
30	treatment	N	I-Premise
31	condition	N	I-Premise
32	and	N	I-Premise
33	CES-D	N	I-Premise
34	change	N	I-Premise
35	on	N	I-Premise
36	survival	N	I-Premise
37	.	N	I-Premise

1	Neither	N	O
2	demographic	N	O
3	nor	N	O
4	medical	N	O
5	variables	N	O
6	explained	N	O
7	this	N	O
8	association	N	O
9	.	N	O

1	Decreasing	N	I-Claim
2	depression	N	I-Claim
3	symptoms	N	I-Claim
4	over	N	I-Claim
5	the	N	I-Claim
6	first	N	I-Claim
7	year	N	I-Claim
8	were	N	I-Claim
9	associated	N	I-Claim
10	with	N	I-Claim
11	longer	N	I-Claim
12	subsequent	N	I-Claim
13	survival	N	I-Claim
14	for	N	I-Claim
15	women	N	I-Claim
16	with	N	I-Claim
17	MBC	N	I-Claim
18	in	N	I-Claim
19	this	N	I-Claim
20	sample	N	I-Claim
21	.	N	I-Claim

1	Further	N	I-Claim
2	research	N	I-Claim
3	is	N	I-Claim
4	necessary	N	I-Claim
5	to	N	I-Claim
6	confirm	N	I-Claim
7	this	N	I-Claim
8	hypothesis	N	I-Claim
9	in	N	I-Claim
10	other	N	I-Claim
11	samples	N	I-Claim
12	,	N	I-Claim
13	and	N	I-Claim
14	causation	N	I-Claim
15	can	N	I-Claim
16	not	N	I-Claim
17	be	N	I-Claim
18	assumed	N	I-Claim
19	based	N	I-Claim
20	on	N	I-Claim
21	this	N	I-Claim
22	analysis	N	I-Claim
23	.	N	I-Claim

1	The	N	O
2	American	N	O
3	College	N	O
4	of	N	O
5	Surgeons	N	O
6	Oncology	N	O
7	Group	N	O
8	phase	N	O
9	III	N	O
10	Surgical	N	O
11	Prostatectomy	N	O
12	Versus	N	O
13	Interstitial	N	O
14	Radiation	N	O
15	Intervention	N	O
16	Trial	N	O
17	comparing	N	O
18	radical	N	O
19	prostatectomy	N	O
20	(	N	O
21	RP	N	O
22	)	N	O
23	and	N	O
24	brachytherapy	N	O
25	(	N	O
26	BT	N	O
27	)	N	O
28	closed	N	O
29	after	N	O
30	2	N	O
31	years	N	O
32	due	N	O
33	to	N	O
34	poor	N	O
35	accrual	N	O
36	.	N	O

1	We	N	O
2	report	N	O
3	health-related	N	O
4	quality	N	O
5	of	N	O
6	life	N	O
7	(	N	O
8	HRQOL	N	O
9	)	N	O
10	at	N	O
11	a	N	O
12	mean	N	O
13	of	N	O
14	5.3	N	O
15	years	N	O
16	for	N	O
17	168	N	O
18	trial-eligible	N	O
19	men	N	O
20	who	N	O
21	either	N	O
22	chose	N	O
23	or	N	O
24	were	N	O
25	randomly	N	O
26	assigned	N	O
27	to	N	O
28	RP	N	O
29	or	N	O
30	BT	N	O
31	following	N	O
32	a	N	O
33	multidisciplinary	N	O
34	educational	N	O
35	session	N	O
36	.	N	O

1	After	N	O
2	initial	N	O
3	lack	N	O
4	of	N	O
5	accrual	N	O
6	,	N	O
7	a	N	O
8	multidisciplinary	N	O
9	educational	N	O
10	session	N	O
11	was	N	O
12	introduced	N	O
13	for	N	O
14	eligible	N	O
15	patients	N	O
16	.	N	O

1	In	N	O
2	all	N	O
3	,	N	O
4	263	N	O
5	men	N	O
6	attended	N	O
7	47	N	O
8	sessions	N	O
9	.	N	O

1	Of	N	O
2	those	N	O
3	,	N	O
4	34	N	O
5	consented	N	O
6	to	N	O
7	random	N	O
8	assignment	N	O
9	,	N	O
10	62	N	O
11	chose	N	O
12	RP	N	O
13	,	N	O
14	and	N	O
15	94	N	O
16	chose	N	O
17	BT	N	O
18	.	N	O

1	Five	N	O
2	years	N	O
3	later	N	O
4	,	N	O
5	these	N	O
6	190	N	O
7	men	N	O
8	underwent	N	O
9	HRQOL	N	O
10	evaluation	N	O
11	by	N	O
12	using	N	O
13	the	N	O
14	cancer-specific	N	O
15	50-item	N	O
16	Expanded	N	O
17	Prostate	N	O
18	Cancer	N	O
19	Index	N	O
20	Composite	N	O
21	,	N	O
22	the	N	O
23	Short	N	O
24	Form	N	O
25	12	N	O
26	Physical	N	O
27	Component	N	O
28	Score	N	O
29	,	N	O
30	and	N	O
31	Short	N	O
32	Form	N	O
33	12	N	O
34	Mental	N	O
35	Component	N	O
36	Score	N	O
37	.	N	O

1	Response	N	O
2	rate	N	O
3	was	N	O
4	88.4	N	O
5	%	N	O
6	.	N	O

1	The	N	O
2	Wilcoxon	N	O
3	rank	N	O
4	sum	N	O
5	test	N	O
6	was	N	O
7	used	N	O
8	to	N	O
9	compare	N	O
10	summary	N	O
11	scores	N	O
12	between	N	O
13	the	N	O
14	two	N	O
15	interventions	N	O
16	.	N	O

1	Of	N	O
2	168	N	O
3	survey	N	O
4	responders	N	O
5	,	N	O
6	60.7	N	O
7	%	N	O
8	had	N	O
9	BT	N	O
10	(	N	O
11	9.5	N	O
12	%	N	O
13	randomly	N	O
14	assigned	N	O
15	)	N	O
16	and	N	O
17	39.3	N	O
18	%	N	O
19	had	N	O
20	RP	N	O
21	(	N	O
22	9.5	N	O
23	%	N	O
24	randomly	N	O
25	assigned	N	O
26	)	N	O
27	.	N	O

1	Median	N	O
2	age	N	O
3	was	N	O
4	61.4	N	O
5	years	N	O
6	for	N	O
7	BT	N	O
8	and	N	O
9	59.4	N	O
10	for	N	O
11	RP	N	O
12	(	N	O
13	P	N	O
14	=	N	O
15	.05	N	O
16	)	N	O
17	.	N	O

1	Median	N	O
2	follow-up	N	O
3	was	N	O
4	5.2	N	O
5	years	N	O
6	(	N	O
7	range	N	O
8	,	N	O
9	3.2	N	O
10	to	N	O
11	6.5	N	O
12	years	N	O
13	)	N	O
14	.	N	O

1	For	N	I-Premise
2	BT	N	I-Premise
3	versus	N	I-Premise
4	RP	N	I-Premise
5	,	N	I-Premise
6	there	N	I-Premise
7	was	N	I-Premise
8	no	N	I-Premise
9	difference	N	I-Premise
10	in	N	I-Premise
11	bowel	N	I-Premise
12	or	N	I-Premise
13	hormonal	N	I-Premise
14	domains	N	I-Premise
15	,	N	I-Premise
16	but	N	O
17	men	N	I-Premise
18	treated	N	I-Premise
19	with	N	I-Premise
20	BT	N	I-Premise
21	scored	N	I-Premise
22	better	N	I-Premise
23	in	N	I-Premise
24	urinary	N	I-Premise
25	(	N	I-Premise
26	91.8	N	I-Premise
27	v	N	I-Premise
28	88.1	N	I-Premise
29	;	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.02	N	I-Premise
33	)	N	I-Premise
34	and	N	I-Premise
35	sexual	N	I-Premise
36	(	N	I-Premise
37	52.5	N	I-Premise
38	v	N	I-Premise
39	39.2	N	I-Premise
40	;	N	I-Premise
41	P	N	I-Premise
42	=	N	I-Premise
43	.001	N	I-Premise
44	)	N	I-Premise
45	domains	N	I-Premise
46	,	N	I-Premise
47	and	N	I-Premise
48	in	N	I-Premise
49	patient	N	I-Premise
50	satisfaction	N	I-Premise
51	(	N	I-Premise
52	93.6	N	I-Premise
53	v	N	I-Premise
54	76.9	N	I-Premise
55	;	N	I-Premise
56	P	N	I-Premise
57	<	N	I-Premise
58	.001	N	I-Premise
59	)	N	I-Premise
60	.	N	I-Premise

1	Although	N	O
2	treatment	N	O
3	allocation	N	O
4	was	N	O
5	random	N	O
6	in	N	O
7	only	N	O
8	19	N	O
9	%	N	O
10	,	N	O
11	all	N	O
12	patients	N	O
13	received	N	O
14	identical	N	O
15	information	N	O
16	in	N	O
17	a	N	O
18	multidisciplinary	N	O
19	setting	N	O
20	before	N	O
21	selecting	N	O
22	RP	N	O
23	,	N	O
24	BT	N	O
25	,	N	O
26	or	N	O
27	random	N	O
28	assignment	N	O
29	.	N	O

1	HRQOL	N	I-Claim
2	evaluated	N	I-Claim
3	3.2	N	I-Claim
4	to	N	I-Claim
5	6.5	N	I-Claim
6	years	N	I-Claim
7	after	N	I-Claim
8	treatment	N	I-Claim
9	showed	N	I-Claim
10	an	N	I-Claim
11	advantage	N	I-Claim
12	for	N	I-Claim
13	BT	N	I-Claim
14	in	N	I-Claim
15	urinary	N	I-Claim
16	and	N	I-Claim
17	sexual	N	I-Claim
18	domains	N	I-Claim
19	and	N	I-Claim
20	in	N	I-Claim
21	patient	N	I-Claim
22	satisfaction	N	I-Claim
23	.	N	I-Claim

1	Bone-cancer	N	O
2	pain	N	O
3	is	N	O
4	a	N	O
5	common	N	O
6	and	N	O
7	refractory	N	O
8	cancer	N	O
9	pain	N	O
10	.	N	O

1	Opioids	N	O
2	,	N	O
3	on	N	O
4	their	N	O
5	own	N	O
6	,	N	O
7	do	N	O
8	not	N	O
9	control	N	O
10	this	N	O
11	type	N	O
12	of	N	O
13	pain	N	O
14	well	N	O
15	enough	N	O
16	,	N	O
17	and	N	O
18	co-analgesics	N	O
19	are	N	O
20	necessary	N	O
21	.	N	O

1	Patients	N	O
2	with	N	O
3	bone	N	O
4	metastasis-related	N	O
5	pain	N	O
6	at	N	O
7	Numeric	N	O
8	Rating	N	O
9	Scale	N	O
10	≥4	N	O
11	were	N	O
12	enrolled	N	O
13	to	N	O
14	this	N	O
15	randomized	N	O
16	placebo-controlled	N	O
17	trial	N	O
18	.	N	O

1	They	N	O
2	had	N	O
3	also	N	O
4	received	N	O
5	morphine	N	O
6	or	N	O
7	transdermal	N	O
8	fentanyl	N	O
9	patches	N	O
10	for	N	O
11	at	N	O
12	least	N	O
13	1	N	O
14	week	N	O
15	.	N	O

1	During	N	O
2	the	N	O
3	3-day	N	O
4	efficacy	N	O
5	phase	N	O
6	,	N	O
7	patients	N	O
8	received	N	O
9	placebo	N	O
10	or	N	O
11	1-3	N	O
12	tablets	N	O
13	of	N	O
14	oxycodone/paracetamol	N	O
15	(	N	O
16	5/325	N	O
17	mg	N	O
18	)	N	O
19	,	N	O
20	four	N	O
21	times	N	O
22	daily	N	O
23	for	N	O
24	3	N	O
25	days	N	O
26	.	N	O

1	All	N	O
2	patients	N	O
3	kept	N	O
4	a	N	O
5	daily	N	O
6	pain	N	O
7	diary	N	O
8	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	the	N	O
6	Pain	N	O
7	Intensity	N	O
8	Difference	N	O
9	(	N	O
10	PID	N	O
11	)	N	O
12	.	N	O

1	Secondary	N	O
2	endpoints	N	O
3	were	N	O
4	cases	N	O
5	of	N	O
6	breakthrough	N	O
7	pain	N	O
8	and	N	O
9	rescue	N	O
10	morphine	N	O
11	consumption	N	O
12	.	N	O

1	Additional	N	O
2	analyses	N	O
3	included	N	O
4	the	N	O
5	Short	N	O
6	Form-6	N	O
7	Dimensions	N	O
8	(	N	O
9	SF-6D	N	O
10	)	N	O
11	quality-of-life	N	O
12	scale	N	O
13	and	N	O
14	a	N	O
15	general	N	O
16	impression	N	O
17	(	N	O
18	GI	N	O
19	)	N	O
20	of	N	O
21	patient	N	O
22	satisfaction	N	O
23	with	N	O
24	treatment	N	O
25	at	N	O
26	the	N	O
27	end	N	O
28	of	N	O
29	the	N	O
30	phase	N	O
31	.	N	O

1	Of	N	O
2	the	N	O
3	246	N	O
4	patients	N	O
5	in	N	O
6	the	N	O
7	intent-to-treat	N	O
8	set	N	O
9	,	N	O
10	89·4	N	O
11	%	N	O
12	completed	N	O
13	the	N	O
14	3-day	N	O
15	efficacy	N	O
16	phase	N	O
17	.	N	O

1	PIDs	N	I-Premise
2	were	N	I-Premise
3	0·9	N	I-Premise
4	and	N	I-Premise
5	0·3	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	oxycodone/paracetamol	N	I-Premise
9	and	N	I-Premise
10	placebo	N	I-Premise
11	groups	N	I-Premise
12	respectively	N	I-Premise
13	,	N	I-Premise
14	on	N	I-Premise
15	day	N	I-Premise
16	1	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	<	N	I-Premise
20	0·001	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	1·5	N	I-Premise
25	and	N	I-Premise
26	0·3	N	I-Premise
27	respectively	N	I-Premise
28	on	N	I-Premise
29	day	N	I-Premise
30	3	N	I-Premise
31	(	N	I-Premise
32	P	N	I-Premise
33	<	N	I-Premise
34	0·001	N	I-Premise
35	)	N	I-Premise
36	.	N	I-Premise

1	Thirty-eight	N	I-Premise
2	patients	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	treatment	N	I-Premise
6	group	N	I-Premise
7	,	N	I-Premise
8	and	N	I-Premise
9	58	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	placebo	N	I-Premise
13	group	N	I-Premise
14	,	N	I-Premise
15	suffered	N	I-Premise
16	breakthrough	N	I-Premise
17	pain	N	I-Premise
18	on	N	I-Premise
19	day	N	I-Premise
20	3	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	<	N	I-Premise
24	0·001	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	The	N	I-Premise
2	SF-6D	N	I-Premise
3	score	N	I-Premise
4	decreased	N	I-Premise
5	to	N	I-Premise
6	21·2	N	I-Premise
7	±	N	I-Premise
8	2·5	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	oxycodone/paracetamol	N	I-Premise
12	group	N	I-Premise
13	at	N	I-Premise
14	the	N	I-Premise
15	end	N	I-Premise
16	of	N	I-Premise
17	the	N	I-Premise
18	phase	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	0·001	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	oxycodone/paracetamol	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	67	N	I-Premise
7	%	N	I-Premise
8	rated	N	I-Premise
9	GI	N	I-Premise
10	as	N	I-Premise
11	good	N	I-Premise
12	,	N	I-Premise
13	very	N	I-Premise
14	good	N	I-Premise
15	,	N	I-Premise
16	or	N	I-Premise
17	excellent	N	I-Premise
18	.	N	I-Premise

1	Patients	N	I-Claim
2	with	N	I-Claim
3	bone-cancer	N	I-Claim
4	pain	N	I-Claim
5	,	N	I-Claim
6	already	N	I-Claim
7	on	N	I-Claim
8	opioids	N	I-Claim
9	,	N	I-Claim
10	obtain	N	I-Claim
11	clinically	N	I-Claim
12	important	N	I-Claim
13	,	N	I-Claim
14	additional	N	I-Claim
15	pain-control	N	I-Claim
16	,	N	I-Claim
17	with	N	I-Claim
18	regular	N	I-Claim
19	oxycodone/paracetamol	N	I-Claim
20	dosing	N	I-Claim
21	.	N	I-Claim

1	There	N	O
2	are	N	O
3	very	N	O
4	few	N	O
5	randomized	N	O
6	controlled	N	O
7	studies	N	O
8	on	N	O
9	exercise	N	O
10	in	N	O
11	cancer	N	O
12	patients	N	O
13	.	N	O

1	Consequently	N	O
2	,	N	O
3	there	N	O
4	are	N	O
5	no	N	O
6	guidelines	N	O
7	available	N	O
8	with	N	O
9	regard	N	O
10	to	N	O
11	the	N	O
12	exercises	N	O
13	that	N	O
14	can	N	O
15	be	N	O
16	recommended	N	O
17	and	N	O
18	difficulties	N	O
19	are	N	O
20	encountered	N	O
21	in	N	O
22	the	N	O
23	clinical	N	O
24	practice	N	O
25	as	N	O
26	to	N	O
27	which	N	O
28	exercise	N	O
29	is	N	O
30	more	N	O
31	suitable	N	O
32	to	N	O
33	the	N	O
34	patients	N	O
35	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	investigate	N	O
9	the	N	O
10	impact	N	O
11	of	N	O
12	pilates	N	O
13	exercises	N	O
14	on	N	O
15	physical	N	O
16	performance	N	O
17	,	N	O
18	flexibility	N	O
19	,	N	O
20	fatigue	N	O
21	,	N	O
22	depression	N	O
23	and	N	O
24	quality	N	O
25	of	N	O
26	life	N	O
27	in	N	O
28	women	N	O
29	who	N	O
30	had	N	O
31	been	N	O
32	treated	N	O
33	for	N	O
34	breast	N	O
35	cancer	N	O
36	.	N	O

1	Randomized	N	O
2	controlled	N	O
3	trial	N	O
4	.	N	O

1	Out	N	O
2	patient	N	O
3	group	N	O
4	,	N	O
5	Department	N	O
6	of	N	O
7	Physical	N	O
8	Medicine	N	O
9	and	N	O
10	Rehabilitation	N	O
11	and	N	O
12	Medical	N	O
13	Oncology	N	O
14	Department	N	O
15	,	N	O
16	University	N	O
17	Hospital	N	O
18	.	N	O

1	Fifty-two	N	O
2	patients	N	O
3	with	N	O
4	breast	N	O
5	cancer	N	O
6	were	N	O
7	divided	N	O
8	into	N	O
9	either	N	O
10	pilates	N	O
11	exercise	N	O
12	(	N	O
13	group	N	O
14	1	N	O
15	)	N	O
16	and	N	O
17	control	N	O
18	group	N	O
19	(	N	O
20	group	N	O
21	2	N	O
22	)	N	O
23	.	N	O

1	Patients	N	O
2	in	N	O
3	Group	N	O
4	1	N	O
5	performed	N	O
6	pilates	N	O
7	and	N	O
8	home	N	O
9	exercises	N	O
10	and	N	O
11	patients	N	O
12	in	N	O
13	group	N	O
14	2	N	O
15	performed	N	O
16	only	N	O
17	home	N	O
18	exercises	N	O
19	.	N	O

1	Pilates	N	O
2	exercise	N	O
3	sessions	N	O
4	were	N	O
5	performed	N	O
6	three	N	O
7	times	N	O
8	a	N	O
9	week	N	O
10	for	N	O
11	a	N	O
12	period	N	O
13	of	N	O
14	eight	N	O
15	weeks	N	O
16	in	N	O
17	the	N	O
18	rehabilitation	N	O
19	unit	N	O
20	.	N	O

1	Subjects	N	O
2	were	N	O
3	assessed	N	O
4	before	N	O
5	and	N	O
6	after	N	O
7	rehabilitation	N	O
8	program	N	O
9	,	N	O
10	with	N	O
11	respect	N	O
12	to	N	O
13	,	N	O
14	6-min	N	O
15	walk	N	O
16	test	N	O
17	(	N	O
18	6MWT	N	O
19	)	N	O
20	,	N	O
21	modified	N	O
22	sit	N	O
23	and	N	O
24	reach	N	O
25	test	N	O
26	,	N	O
27	Brief	N	O
28	Fatigue	N	O
29	Inventory	N	O
30	(	N	O
31	BFI	N	O
32	)	N	O
33	,	N	O
34	Beck	N	O
35	Depression	N	O
36	Index	N	O
37	(	N	O
38	BDI	N	O
39	)	N	O
40	and	N	O
41	the	N	O
42	European	N	O
43	Organisation	N	O
44	for	N	O
45	Research	N	O
46	and	N	O
47	Treatment	N	O
48	of	N	O
49	Cancer	N	O
50	Quality	N	O
51	of	N	O
52	Life	N	O
53	C30	N	O
54	(	N	O
55	EORTC	N	O
56	QLQ-C30	N	O
57	)	N	O
58	and	N	O
59	EORTC	N	O
60	QLQ	N	O
61	BR23	N	O
62	.	N	O

1	After	N	I-Premise
2	the	N	I-Premise
3	exercise	N	I-Premise
4	program	N	I-Premise
5	,	N	I-Premise
6	improvements	N	I-Premise
7	were	N	I-Premise
8	observed	N	I-Premise
9	in	N	I-Premise
10	Group	N	I-Premise
11	1	N	I-Premise
12	in	N	I-Premise
13	6-minute	N	I-Premise
14	walk	N	I-Premise
15	test	N	I-Premise
16	,	N	I-Premise
17	BDI	N	I-Premise
18	,	N	I-Premise
19	EORTC	N	I-Premise
20	QLQ-C30	N	I-Premise
21	functional	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	EORTC	N	I-Premise
25	QLQ-C30	N	I-Premise
26	BR23	N	I-Premise
27	functional	N	I-Premise
28	scores	N	I-Premise
29	(	N	I-Premise
30	P	N	I-Premise
31	<	N	I-Premise
32	0.05	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	In	N	O
2	contrast	N	O
3	,	N	O
4	no	N	I-Premise
5	significant	N	I-Premise
6	improvement	N	I-Premise
7	was	N	I-Premise
8	observed	N	I-Premise
9	in	N	I-Premise
10	Group	N	I-Premise
11	2	N	I-Premise
12	after	N	I-Premise
13	the	N	I-Premise
14	exercise	N	I-Premise
15	program	N	I-Premise
16	in	N	I-Premise
17	any	N	I-Premise
18	of	N	I-Premise
19	parameters	N	I-Premise
20	in	N	I-Premise
21	comparison	N	I-Premise
22	to	N	I-Premise
23	the	N	I-Premise
24	pre-exercise	N	I-Premise
25	period	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	>	N	I-Premise
29	0.05	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	When	N	I-Premise
2	the	N	I-Premise
3	two	N	I-Premise
4	exercise	N	I-Premise
5	groups	N	I-Premise
6	were	N	I-Premise
7	compared	N	I-Premise
8	,	N	I-Premise
9	there	N	I-Premise
10	were	N	I-Premise
11	significant	N	I-Premise
12	differences	N	I-Premise
13	in	N	I-Premise
14	6MWT	N	I-Premise
15	in	N	I-Premise
16	pilates-exercise	N	I-Premise
17	group	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	0.05	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	Pilates	N	I-Claim
2	exercises	N	I-Claim
3	are	N	I-Claim
4	effective	N	I-Claim
5	and	N	I-Claim
6	safe	N	I-Claim
7	in	N	I-Claim
8	female	N	I-Claim
9	breast	N	I-Claim
10	cancer	N	I-Claim
11	patients	N	I-Claim
12	.	N	I-Claim

1	There	N	I-Claim
2	is	N	I-Claim
3	a	N	I-Claim
4	need	N	I-Claim
5	for	N	I-Claim
6	further	N	I-Claim
7	studies	N	I-Claim
8	so	N	I-Claim
9	that	N	I-Claim
10	its	N	I-Claim
11	effect	N	I-Claim
12	can	N	I-Claim
13	be	N	I-Claim
14	confirmed	N	I-Claim
15	.	N	I-Claim

1	This	N	O
2	study	N	O
3	addressed	N	O
4	the	N	O
5	effects	N	O
6	of	N	O
7	pilates	N	O
8	exercise	N	O
9	,	N	O
10	as	N	O
11	a	N	O
12	new	N	O
13	approach	N	O
14	,	N	O
15	on	N	O
16	functional	N	O
17	capacity	N	O
18	,	N	O
19	fatigue	N	O
20	,	N	O
21	depression	N	O
22	and	N	O
23	quality	N	O
24	of	N	O
25	life	N	O
26	in	N	O
27	breast	N	O
28	cancer	N	O
29	patients	N	O
30	in	N	O
31	whom	N	O
32	there	N	O
33	are	N	O
34	doubts	N	O
35	regarding	N	O
36	the	N	O
37	efficacy	N	O
38	and	N	O
39	usefulness	N	O
40	of	N	O
41	the	N	O
42	exercise	N	O
43	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	compare	N	O
9	the	N	O
10	2-year	N	O
11	functional	N	O
12	performance	N	O
13	and	N	O
14	quality	N	O
15	of	N	O
16	life	N	O
17	in	N	O
18	patients	N	O
19	with	N	O
20	operable	N	O
21	squamous	N	O
22	cell	N	O
23	carcinoma	N	O
24	of	N	O
25	the	N	O
26	esophagus	N	O
27	,	N	O
28	who	N	O
29	have	N	O
30	received	N	O
31	either	N	O
32	surgery	N	O
33	or	N	O
34	definitive	N	O
35	chemoradiation	N	O
36	(	N	O
37	CRT	N	O
38	)	N	O
39	.	N	O

1	The	N	O
2	functional	N	O
3	outcomes	N	O
4	and	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	in	N	O
9	patients	N	O
10	receiving	N	O
11	esophagectomy	N	O
12	or	N	O
13	definitive	N	O
14	CRT	N	O
15	is	N	O
16	uncertain	N	O
17	.	N	O

1	Data	N	O
2	were	N	O
3	extracted	N	O
4	from	N	O
5	the	N	O
6	database	N	O
7	of	N	O
8	a	N	O
9	prospective	N	O
10	randomized	N	O
11	controlled	N	O
12	trial	N	O
13	that	N	O
14	included	N	O
15	patients	N	O
16	with	N	O
17	resectable	N	O
18	mid	N	O
19	or	N	O
20	lower	N	O
21	thoracic	N	O
22	esophageal	N	O
23	cancers	N	O
24	.	N	O

1	The	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	to	N	O
6	either	N	O
7	standard	N	O
8	esophagectomy	N	O
9	or	N	O
10	definitive	N	O
11	CRT	N	O
12	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	assessments	N	O
5	were	N	O
6	performed	N	O
7	using	N	O
8	the	N	O
9	EORTC	N	O
10	QLQ-C30	N	O
11	and	N	O
12	QLQ-OES24	N	O
13	modules	N	O
14	.	N	O

1	Other	N	O
2	functional	N	O
3	assessments	N	O
4	included	N	O
5	pulmonary	N	O
6	and	N	O
7	eating	N	O
8	functions	N	O
9	.	N	O

1	From	N	O
2	July	N	O
3	2000	N	O
4	to	N	O
5	December	N	O
6	2004	N	O
7	,	N	O
8	a	N	O
9	total	N	O
10	of	N	O
11	81	N	O
12	patients	N	O
13	were	N	O
14	enrolled	N	O
15	into	N	O
16	the	N	O
17	study	N	O
18	.	N	O

1	No	N	I-Premise
2	significant	N	I-Premise
3	longitudinal	N	I-Premise
4	changes	N	I-Premise
5	were	N	I-Premise
6	detected	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	global	N	I-Premise
10	health	N	I-Premise
11	status	N	I-Premise
12	in	N	I-Premise
13	both	N	I-Premise
14	groups	N	I-Premise
15	upon	N	I-Premise
16	available	N	I-Premise
17	follow-up	N	I-Premise
18	.	N	I-Premise

1	Surgery	N	I-Premise
2	was	N	I-Premise
3	associated	N	I-Premise
4	with	N	I-Premise
5	worsened	N	I-Premise
6	physical	N	I-Premise
7	functioning	N	I-Premise
8	and	N	I-Premise
9	fatigue	N	I-Premise
10	symptoms	N	I-Premise
11	up	N	I-Premise
12	to	N	I-Premise
13	6	N	I-Premise
14	months	N	I-Premise
15	after	N	I-Premise
16	treatment	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	<	N	I-Premise
20	0.001	N	I-Premise
21	and	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	0.021	N	I-Premise
25	,	N	I-Premise
26	respectively	N	I-Premise
27	)	N	I-Premise
28	and	N	I-Premise
29	these	N	I-Premise
30	scales	N	I-Premise
31	improved	N	I-Premise
32	at	N	I-Premise
33	2	N	I-Premise
34	years	N	I-Premise
35	.	N	I-Premise

1	In	N	I-Premise
2	terms	N	I-Premise
3	of	N	I-Premise
4	pulmonary	N	I-Premise
5	function	N	I-Premise
6	,	N	I-Premise
7	dyspnoic	N	I-Premise
8	and	N	I-Premise
9	coughing	N	I-Premise
10	symptoms	N	I-Premise
11	were	N	I-Premise
12	significantly	N	I-Premise
13	worsened	N	I-Premise
14	3	N	I-Premise
15	months	N	I-Premise
16	after	N	I-Premise
17	surgery	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	0.024	N	I-Premise
22	and	N	I-Premise
23	P	N	I-Premise
24	=	N	I-Premise
25	0.036	N	I-Premise
26	,	N	I-Premise
27	respectively	N	I-Premise
28	)	N	I-Premise
29	whereas	N	I-Premise
30	symptoms	N	I-Premise
31	in	N	I-Premise
32	the	N	I-Premise
33	CRT	N	I-Premise
34	group	N	I-Premise
35	progressively	N	I-Premise
36	deteriorated	N	I-Premise
37	over	N	I-Premise
38	time	N	I-Premise
39	.	N	I-Premise

1	Concerning	N	I-Premise
2	the	N	I-Premise
3	eating	N	I-Premise
4	function	N	I-Premise
5	,	N	I-Premise
6	both	N	I-Premise
7	groups	N	I-Premise
8	had	N	I-Premise
9	improvements	N	I-Premise
10	in	N	I-Premise
11	dysphagia	N	I-Premise
12	but	N	I-Premise
13	there	N	I-Premise
14	were	N	I-Premise
15	frequent	N	I-Premise
16	need	N	I-Premise
17	for	N	I-Premise
18	endoscopic	N	I-Premise
19	intervention	N	I-Premise
20	.	N	I-Premise

1	Neither	N	I-Premise
2	surgery	N	I-Premise
3	nor	N	I-Premise
4	definitive	N	I-Premise
5	CRT	N	I-Premise
6	significantly	N	I-Premise
7	impaired	N	I-Premise
8	the	N	I-Premise
9	global	N	I-Premise
10	health	N	I-Premise
11	status	N	I-Premise
12	of	N	I-Premise
13	patients	N	I-Premise
14	.	N	I-Premise

1	Surgery	N	I-Claim
2	was	N	I-Claim
3	associated	N	I-Claim
4	with	N	I-Claim
5	a	N	I-Claim
6	short-term	N	I-Claim
7	negative	N	I-Claim
8	impact	N	I-Claim
9	in	N	I-Claim
10	some	N	I-Claim
11	aspects	N	I-Claim
12	of	N	I-Claim
13	health	N	I-Claim
14	related	N	I-Claim
15	quality	N	I-Claim
16	of	N	I-Claim
17	life	N	I-Claim
18	assessments	N	I-Claim
19	but	N	I-Claim
20	these	N	I-Claim
21	changes	N	I-Claim
22	became	N	I-Claim
23	insignificant	N	I-Claim
24	2	N	I-Claim
25	years	N	I-Claim
26	after	N	I-Claim
27	treatment	N	I-Claim
28	.	N	I-Claim

1	However	N	O
2	,	N	O
3	CRT	N	I-Claim
4	was	N	I-Claim
5	associated	N	I-Claim
6	with	N	I-Claim
7	progressive	N	I-Claim
8	deteriorations	N	I-Claim
9	in	N	I-Claim
10	pulmonary	N	I-Claim
11	function	N	I-Claim
12	in	N	I-Claim
13	the	N	I-Claim
14	longer	N	I-Claim
15	term	N	I-Claim
16	.	N	I-Claim

1	Anti-aromatase	N	I-MajorClaim
2	therapy	N	I-MajorClaim
3	is	N	I-MajorClaim
4	important	N	I-MajorClaim
5	in	N	I-MajorClaim
6	the	N	I-MajorClaim
7	treatment	N	I-MajorClaim
8	of	N	I-MajorClaim
9	breast	N	I-MajorClaim
10	cancer	N	I-MajorClaim
11	in	N	I-MajorClaim
12	postmenopausal	N	I-MajorClaim
13	women	N	I-MajorClaim
14	but	N	O
15	they	N	O
16	have	N	O
17	effects	N	O
18	on	N	O
19	the	N	O
20	bone	N	O
21	mineral	N	O
22	density	N	O
23	(	N	O
24	BMD	N	O
25	)	N	O
26	and	N	O
27	osteoporosis	N	O
28	.	N	O

1	Cyclooxygenase-2	N	I-Claim
2	(	N	I-Claim
3	COX-2	N	I-Claim
4	)	N	I-Claim
5	inhibitors	N	I-Claim
6	have	N	I-Claim
7	been	N	I-Claim
8	shown	N	I-Claim
9	to	N	I-Claim
10	be	N	I-Claim
11	effective	N	I-Claim
12	in	N	I-Claim
13	chemoprevention	N	I-Claim
14	in	N	I-Claim
15	animal	N	I-Claim
16	and	N	I-Claim
17	clinical	N	I-Claim
18	studies	N	I-Claim
19	.	N	I-Claim

1	A	N	O
2	proof	N	O
3	of	N	O
4	principle	N	O
5	study	N	O
6	was	N	O
7	performed	N	O
8	to	N	O
9	investigate	N	O
10	the	N	O
11	efficacy	N	O
12	of	N	O
13	combing	N	O
14	anti-aromatase	N	O
15	therapy	N	O
16	(	N	O
17	exemestane	N	O
18	)	N	O
19	and	N	O
20	COX-2	N	O
21	inhibitors	N	O
22	neoadjuvantly	N	O
23	.	N	O

1	The	N	O
2	changes	N	O
3	in	N	O
4	the	N	O
5	BMD	N	O
6	,	N	O
7	bone	N	O
8	turnover	N	O
9	proteins	N	O
10	and	N	O
11	quality-of-life	N	O
12	(	N	O
13	QoL	N	O
14	)	N	O
15	were	N	O
16	analyzed	N	O
17	and	N	O
18	presented	N	O
19	here	N	O
20	.	N	O

1	82	N	O
2	postmenopausal	N	O
3	patients	N	O
4	with	N	O
5	histologically	N	O
6	confirmed	N	O
7	invasive	N	O
8	hormone-sensitive	N	O
9	breast	N	O
10	cancers	N	O
11	were	N	O
12	included	N	O
13	for	N	O
14	the	N	O
15	neoadjuvant	N	O
16	therapy	N	O
17	(	N	O
18	NHT	N	O
19	)	N	O
20	.	N	O

1	30	N	O
2	patients	N	O
3	received	N	O
4	exemestane	N	O
5	(	N	O
6	EXE	N	O
7	)	N	O
8	25	N	O
9	mg	N	O
10	daily	N	O
11	and	N	O
12	celecoxib	N	O
13	(	N	O
14	CXB	N	O
15	)	N	O
16	400	N	O
17	mg	N	O
18	twice	N	O
19	daily	N	O
20	(	N	O
21	group	N	O
22	A	N	O
23	)	N	O
24	,	N	O
25	24	N	O
26	patients	N	O
27	received	N	O
28	EXE	N	O
29	25	N	O
30	mg	N	O
31	daily	N	O
32	(	N	O
33	group	N	O
34	B	N	O
35	)	N	O
36	and	N	O
37	28	N	O
38	patients	N	O
39	received	N	O
40	letrozole	N	O
41	(	N	O
42	LET	N	O
43	)	N	O
44	2.5	N	O
45	mg	N	O
46	daily	N	O
47	(	N	O
48	group	N	O
49	C	N	O
50	)	N	O
51	.	N	O

1	The	N	O
2	same	N	O
3	assigned	N	O
4	treatment	N	O
5	was	N	O
6	intended	N	O
7	to	N	O
8	continue	N	O
9	for	N	O
10	2	N	O
11	years	N	O
12	to	N	O
13	study	N	O
14	the	N	O
15	changes	N	O
16	in	N	O
17	the	N	O
18	bone	N	O
19	metabolism	N	O
20	.	N	O

1	BMD	N	O
2	of	N	O
3	48	N	O
4	patients	N	O
5	were	N	O
6	analyzed	N	O
7	;	N	O
8	23	N	O
9	belongs	N	O
10	to	N	O
11	group	N	O
12	A	N	O
13	,	N	O
14	10	N	O
15	to	N	O
16	group	N	O
17	B	N	O
18	and	N	O
19	15	N	O
20	to	N	O
21	group	N	O
22	C.	N	O
23	The	N	O
24	serum	N	O
25	bone	N	O
26	turnover	N	O
27	proteins	N	O
28	bone-specific	N	O
29	alkaline	N	O
30	phosphatase	N	O
31	(	N	O
32	BAP	N	O
33	)	N	O
34	and	N	O
35	carboxyterminal	N	O
36	crosslinked	N	O
37	telopeptide	N	O
38	of	N	O
39	type	N	O
40	I	N	O
41	collagen	N	O
42	(	N	O
43	ICTP	N	O
44	)	N	O
45	,	N	O
46	were	N	O
47	measured	N	O
48	with	N	O
49	commercially	N	O
50	available	N	O
51	test	N	O
52	kits	N	O
53	before	N	O
54	treatment	N	O
55	,	N	O
56	3	N	O
57	months	N	O
58	and	N	O
59	15	N	O
60	months	N	O
61	after	N	O
62	treatment	N	O
63	.	N	O

1	Functional	N	O
2	Assessment	N	O
3	of	N	O
4	Cancer	N	O
5	Therapy	N	O
6	core	N	O
7	questionnaire	N	O
8	(	N	O
9	FACT-G	N	O
10	)	N	O
11	with	N	O
12	its	N	O
13	additional	N	O
14	breast	N	O
15	cancer	N	O
16	subscale	N	O
17	were	N	O
18	performed	N	O
19	at	N	O
20	baseline	N	O
21	,	N	O
22	4	N	O
23	,	N	O
24	8	N	O
25	,	N	O
26	and	N	O
27	12	N	O
28	weeks	N	O
29	after	N	O
30	NHT	N	O
31	.	N	O

1	Difference	N	I-Premise
2	between	N	I-Premise
3	groups	N	I-Premise
4	(	N	I-Premise
5	p=0.007	N	I-Premise
6	)	N	I-Premise
7	for	N	I-Premise
8	BMD	N	I-Premise
9	at	N	I-Premise
10	femur	N	I-Premise
11	was	N	I-Premise
12	significant	N	I-Premise
13	.	N	I-Premise

1	The	N	I-Premise
2	changes	N	I-Premise
3	of	N	I-Premise
4	BMD	N	I-Premise
5	in	N	I-Premise
6	group	N	I-Premise
7	B	N	I-Premise
8	patients	N	I-Premise
9	were	N	I-Premise
10	significantly	N	I-Premise
11	greater	N	I-Premise
12	than	N	I-Premise
13	patients	N	I-Premise
14	in	N	I-Premise
15	group	N	I-Premise
16	A	N	I-Premise
17	(	N	I-Premise
18	p=0.011	N	I-Premise
19	,	N	I-Premise
20	CI=0.063-0.437	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	group	N	I-Premise
25	C	N	I-Premise
26	(	N	I-Premise
27	p=0.003	N	I-Premise
28	,	N	I-Premise
29	CI=0.146-0.620	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	The	N	I-Premise
2	mean	N	I-Premise
3	BAP	N	I-Premise
4	increased	N	I-Premise
5	from	N	I-Premise
6	baseline	N	I-Premise
7	in	N	I-Premise
8	group	N	I-Premise
9	B	N	I-Premise
10	patients	N	I-Premise
11	but	N	I-Premise
12	decreased	N	I-Premise
13	from	N	I-Premise
14	baseline	N	I-Premise
15	in	N	I-Premise
16	group	N	I-Premise
17	C	N	I-Premise
18	patients	N	I-Premise
19	at	N	I-Premise
20	3	N	I-Premise
21	months	N	I-Premise
22	and	N	I-Premise
23	15	N	I-Premise
24	months	N	I-Premise
25	.	N	I-Premise

1	No	N	I-Premise
2	statistical	N	I-Premise
3	significance	N	I-Premise
4	was	N	I-Premise
5	found	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	FACT-G	N	I-Premise
9	scores	N	I-Premise
10	and	N	I-Premise
11	FACT-B	N	I-Premise
12	scores	N	I-Premise
13	among	N	I-Premise
14	different	N	I-Premise
15	groups	N	I-Premise
16	at	N	I-Premise
17	baseline	N	I-Premise
18	,	N	I-Premise
19	week	N	I-Premise
20	4	N	I-Premise
21	,	N	I-Premise
22	week	N	I-Premise
23	8	N	I-Premise
24	and	N	I-Premise
25	week	N	I-Premise
26	12	N	I-Premise
27	after	N	I-Premise
28	NHT	N	I-Premise
29	.	N	I-Premise

1	The	N	I-Premise
2	Breast	N	I-Premise
3	Cancer	N	I-Premise
4	Subscale	N	I-Premise
5	scores	N	I-Premise
6	in	N	I-Premise
7	group	N	I-Premise
8	A	N	I-Premise
9	patients	N	I-Premise
10	were	N	I-Premise
11	significantly	N	I-Premise
12	higher	N	I-Premise
13	than	N	I-Premise
14	that	N	I-Premise
15	of	N	I-Premise
16	group	N	I-Premise
17	C	N	I-Premise
18	patients	N	I-Premise
19	(	N	I-Premise
20	p=0.021	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	After	N	I-Premise
2	4	N	I-Premise
3	weeks	N	I-Premise
4	of	N	I-Premise
5	NHT	N	I-Premise
6	,	N	I-Premise
7	negative	N	I-Premise
8	changes	N	I-Premise
9	of	N	I-Premise
10	FACT-B	N	I-Premise
11	and	N	I-Premise
12	FACT-G	N	I-Premise
13	scores	N	I-Premise
14	were	N	I-Premise
15	found	N	I-Premise
16	in	N	I-Premise
17	group	N	I-Premise
18	B	N	I-Premise
19	and	N	I-Premise
20	C	N	I-Premise
21	patients	N	I-Premise
22	,	N	I-Premise
23	but	N	I-Premise
24	there	N	I-Premise
25	were	N	I-Premise
26	positive	N	I-Premise
27	changes	N	I-Premise
28	in	N	I-Premise
29	group	N	I-Premise
30	A	N	I-Premise
31	patients	N	I-Premise
32	.	N	I-Premise

1	Significant	N	I-Premise
2	differences	N	I-Premise
3	of	N	I-Premise
4	FACT-B	N	I-Premise
5	score	N	I-Premise
6	(	N	I-Premise
7	p=0.008	N	I-Premise
8	)	N	I-Premise
9	and	N	I-Premise
10	FACT-G	N	I-Premise
11	score	N	I-Premise
12	(	N	I-Premise
13	p=0.019	N	I-Premise
14	)	N	I-Premise
15	were	N	I-Premise
16	observed	N	I-Premise
17	at	N	I-Premise
18	that	N	I-Premise
19	time	N	I-Premise
20	point	N	I-Premise
21	.	N	I-Premise

1	Article	N	O
2	from	N	O
3	the	N	O
4	Special	N	O
5	issue	N	O
6	on	N	O
7	Targeted	N	O
8	Inhibitors	N	O
9	.	N	O

1	To	N	O
2	investigate	N	O
3	whether	N	O
4	frequent	N	O
5	hospital	N	O
6	follow-up	N	O
7	in	N	O
8	the	N	O
9	first	N	O
10	year	N	O
11	after	N	O
12	breast	N	O
13	cancer	N	O
14	treatment	N	O
15	might	N	O
16	partly	N	O
17	be	N	O
18	replaced	N	O
19	by	N	O
20	nurse-led	N	O
21	telephone	N	O
22	follow-up	N	O
23	without	N	O
24	deteriorating	N	O
25	health-related	N	O
26	quality	N	O
27	of	N	O
28	life	N	O
29	(	N	O
30	HRQoL	N	O
31	)	N	O
32	,	N	O
33	and	N	O
34	whether	N	O
35	a	N	O
36	short	N	O
37	educational	N	O
38	group	N	O
39	programme	N	O
40	(	N	O
41	EGP	N	O
42	)	N	O
43	would	N	O
44	enhance	N	O
45	HRQoL	N	O
46	.	N	O

1	A	N	O
2	multicentre	N	O
3	pragmatic	N	O
4	randomised	N	O
5	controlled	N	O
6	trial	N	O
7	(	N	O
8	RCT	N	O
9	)	N	O
10	with	N	O
11	a	N	O
12	2×2	N	O
13	factorial	N	O
14	design	N	O
15	was	N	O
16	performed	N	O
17	among	N	O
18	320	N	O
19	breast	N	O
20	cancer	N	O
21	patients	N	O
22	who	N	O
23	were	N	O
24	treated	N	O
25	with	N	O
26	curative	N	O
27	intent	N	O
28	.	N	O

1	Participants	N	O
2	were	N	O
3	randomised	N	O
4	to	N	O
5	follow-up	N	O
6	care	N	O
7	as	N	O
8	usual	N	O
9	(	N	O
10	3-monthly	N	O
11	outpatient	N	O
12	clinic	N	O
13	visits	N	O
14	)	N	O
15	,	N	O
16	nurse-led	N	O
17	telephone	N	O
18	follow-up	N	O
19	,	N	O
20	or	N	O
21	the	N	O
22	former	N	O
23	strategies	N	O
24	combined	N	O
25	with	N	O
26	an	N	O
27	educational	N	O
28	group	N	O
29	programme	N	O
30	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	for	N	O
5	both	N	O
6	interventions	N	O
7	was	N	O
8	HRQoL	N	O
9	,	N	O
10	measured	N	O
11	by	N	O
12	EORTC	N	O
13	QLQ-C30	N	O
14	.	N	O

1	Secondary	N	O
2	outcomes	N	O
3	were	N	O
4	role	N	O
5	and	N	O
6	emotional	N	O
7	functioning	N	O
8	and	N	O
9	feelings	N	O
10	of	N	O
11	control	N	O
12	and	N	O
13	anxiety	N	O
14	.	N	O

1	Data	N	O
2	of	N	O
3	299	N	O
4	patients	N	O
5	were	N	O
6	available	N	O
7	for	N	O
8	evaluation	N	O
9	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	HRQoL	N	I-Premise
8	between	N	I-Premise
9	nurse-led	N	I-Premise
10	telephone	N	I-Premise
11	and	N	I-Premise
12	hospital	N	I-Premise
13	follow-up	N	I-Premise
14	at	N	I-Premise
15	12	N	I-Premise
16	months	N	I-Premise
17	after	N	I-Premise
18	treatment	N	I-Premise
19	(	N	I-Premise
20	p	N	I-Premise
21	=	N	I-Premise
22	0.42	N	I-Premise
23	;	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	confidence	N	I-Premise
27	interval	N	I-Premise
28	(	N	I-Premise
29	CI	N	I-Premise
30	)	N	I-Premise
31	for	N	I-Premise
32	difference	N	I-Premise
33	:	N	I-Premise
34	-1.93-4.64	N	I-Premise
35	)	N	I-Premise
36	and	N	I-Premise
37	neither	N	I-Premise
38	between	N	I-Premise
39	follow-up	N	I-Premise
40	with	N	I-Premise
41	or	N	I-Premise
42	without	N	I-Premise
43	EGP	N	I-Premise
44	(	N	I-Premise
45	p	N	I-Premise
46	=	N	I-Premise
47	0.86	N	I-Premise
48	;	N	I-Premise
49	95	N	I-Premise
50	%	N	I-Premise
51	CI	N	I-Premise
52	for	N	I-Premise
53	difference	N	I-Premise
54	:	N	I-Premise
55	-3.59-3.00	N	I-Premise
56	)	N	I-Premise
57	.	N	I-Premise

1	Furthermore	N	O
2	,	N	O
3	no	N	I-Premise
4	differences	N	I-Premise
5	between	N	I-Premise
6	the	N	I-Premise
7	intervention	N	I-Premise
8	groups	N	I-Premise
9	and	N	I-Premise
10	their	N	I-Premise
11	corresponding	N	I-Premise
12	control	N	I-Premise
13	groups	N	I-Premise
14	were	N	I-Premise
15	found	N	I-Premise
16	in	N	I-Premise
17	role	N	I-Premise
18	and	N	I-Premise
19	emotional	N	I-Premise
20	functioning	N	I-Premise
21	,	N	I-Premise
22	and	N	I-Premise
23	feelings	N	I-Premise
24	of	N	I-Premise
25	control	N	I-Premise
26	and	N	I-Premise
27	anxiety	N	I-Premise
28	(	N	I-Premise
29	all	N	I-Premise
30	p-values	N	I-Premise
31	>	N	I-Premise
32	0.05	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	Replacement	N	I-Claim
2	of	N	I-Claim
3	most	N	I-Claim
4	hospital	N	I-Claim
5	follow-up	N	I-Claim
6	visits	N	I-Claim
7	in	N	I-Claim
8	the	N	I-Claim
9	first	N	I-Claim
10	year	N	I-Claim
11	after	N	I-Claim
12	breast	N	I-Claim
13	cancer	N	I-Claim
14	treatment	N	I-Claim
15	by	N	I-Claim
16	nurse-led	N	I-Claim
17	telephone	N	I-Claim
18	follow-up	N	I-Claim
19	does	N	I-Claim
20	not	N	I-Claim
21	impede	N	I-Claim
22	patient	N	I-Claim
23	outcomes	N	I-Claim
24	.	N	I-Claim

1	Hence	N	O
2	,	N	O
3	nurse-led	N	I-MajorClaim
4	telephone	N	I-MajorClaim
5	follow-up	N	I-MajorClaim
6	seems	N	I-MajorClaim
7	an	N	I-MajorClaim
8	appropriate	N	I-MajorClaim
9	way	N	I-MajorClaim
10	to	N	I-MajorClaim
11	reduce	N	I-MajorClaim
12	clinic	N	I-MajorClaim
13	visits	N	I-MajorClaim
14	and	N	I-MajorClaim
15	represents	N	I-MajorClaim
16	an	N	I-MajorClaim
17	accepted	N	I-MajorClaim
18	alternative	N	I-MajorClaim
19	strategy	N	I-MajorClaim
20	.	N	I-MajorClaim

1	An	N	O
2	EGP	N	O
3	does	N	O
4	not	N	O
5	unequivocally	N	O
6	affect	N	O
7	positive	N	O
8	HRQoL	N	O
9	outcomes	N	O
10	.	N	O

1	A	N	O
2	phase	N	O
3	III	N	O
4	trial	N	O
5	(	N	O
6	Cancer	N	O
7	and	N	O
8	Leukemia	N	O
9	Group	N	O
10	B	N	O
11	CALGB-49907	N	O
12	)	N	O
13	was	N	O
14	conducted	N	O
15	to	N	O
16	test	N	O
17	whether	N	O
18	older	N	O
19	patients	N	O
20	with	N	O
21	early-stage	N	O
22	breast	N	O
23	cancer	N	O
24	would	N	O
25	have	N	O
26	equivalent	N	O
27	relapse-free	N	O
28	and	N	O
29	overall	N	O
30	survival	N	O
31	with	N	O
32	capecitabine	N	O
33	compared	N	O
34	with	N	O
35	standard	N	O
36	chemotherapy	N	O
37	.	N	O

1	The	N	O
2	quality	N	O
3	of	N	O
4	life	N	O
5	(	N	O
6	QoL	N	O
7	)	N	O
8	substudy	N	O
9	tested	N	O
10	whether	N	O
11	capecitabine	N	O
12	treatment	N	O
13	would	N	O
14	be	N	O
15	associated	N	O
16	with	N	O
17	a	N	O
18	better	N	O
19	QoL	N	O
20	than	N	O
21	standard	N	O
22	chemotherapy	N	O
23	.	N	O

1	QoL	N	O
2	was	N	O
3	assessed	N	O
4	in	N	O
5	350	N	O
6	patients	N	O
7	randomly	N	O
8	assigned	N	O
9	to	N	O
10	either	N	O
11	standard	N	O
12	chemotherapy	N	O
13	(	N	O
14	cyclophosphamide	N	O
15	,	N	O
16	methotrexate	N	O
17	,	N	O
18	and	N	O
19	fluorouracil	N	O
20	[	N	O
21	CMF	N	O
22	]	N	O
23	or	N	O
24	doxorubicin	N	O
25	and	N	O
26	cyclophosphamide	N	O
27	[	N	O
28	AC	N	O
29	]	N	O
30	;	N	O
31	n	N	O
32	=	N	O
33	182	N	O
34	)	N	O
35	or	N	O
36	capecitabine	N	O
37	(	N	O
38	n	N	O
39	=	N	O
40	168	N	O
41	)	N	O
42	.	N	O

1	Patients	N	O
2	were	N	O
3	interviewed	N	O
4	by	N	O
5	telephone	N	O
6	before	N	O
7	treatment	N	O
8	(	N	O
9	baseline	N	O
10	)	N	O
11	,	N	O
12	midtreatment	N	O
13	,	N	O
14	within	N	O
15	1	N	O
16	month	N	O
17	post-treatment	N	O
18	,	N	O
19	and	N	O
20	at	N	O
21	12	N	O
22	,	N	O
23	18	N	O
24	,	N	O
25	and	N	O
26	24	N	O
27	months	N	O
28	postbaseline	N	O
29	by	N	O
30	using	N	O
31	questionnaires	N	O
32	from	N	O
33	the	N	O
34	European	N	O
35	Organisation	N	O
36	for	N	O
37	Research	N	O
38	and	N	O
39	Treatment	N	O
40	of	N	O
41	Cancer	N	O
42	Quality	N	O
43	of	N	O
44	Life	N	O
45	Questionnaire	N	O
46	C30	N	O
47	(	N	O
48	EORTC	N	O
49	QLQ-C30	N	O
50	)	N	O
51	,	N	O
52	a	N	O
53	breast	N	O
54	systemic	N	O
55	adverse	N	O
56	effects	N	O
57	scale	N	O
58	(	N	O
59	EORTC	N	O
60	BR23	N	O
61	)	N	O
62	,	N	O
63	and	N	O
64	the	N	O
65	Hospital	N	O
66	Anxiety	N	O
67	and	N	O
68	Depression	N	O
69	Scale	N	O
70	(	N	O
71	HADS	N	O
72	)	N	O
73	.	N	O

1	Compared	N	I-Premise
2	with	N	I-Premise
3	patients	N	I-Premise
4	who	N	I-Premise
5	were	N	I-Premise
6	treated	N	I-Premise
7	with	N	I-Premise
8	standard	N	I-Premise
9	chemotherapy	N	I-Premise
10	,	N	I-Premise
11	patients	N	I-Premise
12	who	N	I-Premise
13	were	N	I-Premise
14	treated	N	I-Premise
15	with	N	I-Premise
16	capecitabine	N	I-Premise
17	had	N	I-Premise
18	significantly	N	I-Premise
19	better	N	I-Premise
20	QoL	N	I-Premise
21	,	N	I-Premise
22	role	N	I-Premise
23	function	N	I-Premise
24	,	N	I-Premise
25	and	N	I-Premise
26	social	N	I-Premise
27	function	N	I-Premise
28	,	N	I-Premise
29	fewer	N	I-Premise
30	systemic	N	I-Premise
31	adverse	N	I-Premise
32	effects	N	I-Premise
33	,	N	I-Premise
34	less	N	I-Premise
35	psychological	N	I-Premise
36	distress	N	I-Premise
37	,	N	I-Premise
38	and	N	I-Premise
39	less	N	I-Premise
40	fatigue	N	I-Premise
41	during	N	I-Premise
42	and	N	I-Premise
43	at	N	I-Premise
44	the	N	I-Premise
45	completion	N	I-Premise
46	of	N	I-Premise
47	treatment	N	I-Premise
48	(	N	I-Premise
49	P	N	I-Premise
50	≤	N	I-Premise
51	.005	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	Capecitabine	N	I-Premise
2	treatment	N	I-Premise
3	was	N	I-Premise
4	associated	N	I-Premise
5	with	N	I-Premise
6	less	N	I-Premise
7	nausea	N	I-Premise
8	,	N	I-Premise
9	vomiting	N	I-Premise
10	,	N	I-Premise
11	and	N	I-Premise
12	constipation	N	I-Premise
13	and	N	I-Premise
14	with	N	I-Premise
15	better	N	I-Premise
16	appetite	N	I-Premise
17	than	N	I-Premise
18	standard	N	I-Premise
19	treatment	N	I-Premise
20	(	N	I-Premise
21	P	N	I-Premise
22	≤	N	I-Premise
23	.004	N	I-Premise
24	)	N	I-Premise
25	,	N	I-Premise
26	but	N	I-Premise
27	worse	N	I-Premise
28	hand-foot	N	I-Premise
29	syndrome	N	I-Premise
30	and	N	I-Premise
31	diarrhea	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	<	N	I-Premise
35	.005	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	These	N	O
2	differences	N	O
3	all	N	O
4	resolved	N	O
5	by	N	O
6	12	N	O
7	months	N	O
8	.	N	O

1	Standard	N	I-Claim
2	chemotherapy	N	I-Claim
3	was	N	I-Claim
4	superior	N	I-Claim
5	to	N	I-Claim
6	capecitabine	N	I-Claim
7	in	N	I-Claim
8	improving	N	I-Claim
9	relapse-free	N	I-Claim
10	and	N	I-Claim
11	overall	N	I-Claim
12	survival	N	I-Claim
13	for	N	I-Claim
14	older	N	I-Claim
15	women	N	I-Claim
16	with	N	I-Claim
17	early-stage	N	I-Claim
18	breast	N	I-Claim
19	cancer	N	I-Claim
20	.	N	I-Claim

1	Although	N	O
2	capecitabine	N	I-Claim
3	was	N	I-Claim
4	associated	N	I-Claim
5	with	N	I-Claim
6	better	N	I-Claim
7	QoL	N	I-Claim
8	during	N	I-Claim
9	treatment	N	I-Claim
10	,	N	O
11	QoL	N	I-Premise
12	was	N	I-Premise
13	similar	N	I-Premise
14	for	N	I-Premise
15	both	N	I-Premise
16	groups	N	I-Premise
17	at	N	I-Premise
18	1	N	I-Premise
19	year	N	I-Premise
20	.	N	I-Premise

1	The	N	O
2	brief	N	O
3	period	N	O
4	of	N	O
5	poorer	N	O
6	QoL	N	O
7	with	N	O
8	standard	N	O
9	treatment	N	O
10	is	N	O
11	a	N	O
12	modest	N	O
13	price	N	O
14	to	N	O
15	pay	N	O
16	for	N	O
17	a	N	O
18	chance	N	O
19	at	N	O
20	improved	N	O
21	survival	N	O
22	.	N	O

1	Premenopausal	N	O
2	women	N	O
3	with	N	O
4	breast	N	O
5	cancer	N	O
6	receiving	N	O
7	adjuvant	N	O
8	chemotherapy	N	O
9	are	N	O
10	at	N	O
11	risk	N	O
12	for	N	O
13	amenorrhea	N	O
14	.	N	O

1	The	N	O
2	National	N	O
3	Surgical	N	O
4	Adjuvant	N	O
5	Breast	N	O
6	and	N	O
7	Bowel	N	O
8	Project	N	O
9	B-30	N	O
10	trial	N	O
11	included	N	O
12	menstrual	N	O
13	history	N	O
14	(	N	O
15	MH	N	O
16	)	N	O
17	and	N	O
18	quality-of-life	N	O
19	(	N	O
20	QOL	N	O
21	)	N	O
22	studies	N	O
23	to	N	O
24	compare	N	O
25	treatments	N	O
26	on	N	O
27	these	N	O
28	outcomes	N	O
29	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	sequential	N	O
7	doxorubicin	N	O
8	(	N	O
9	A	N	O
10	)	N	O
11	and	N	O
12	cyclophosphamide	N	O
13	(	N	O
14	C	N	O
15	)	N	O
16	followed	N	O
17	by	N	O
18	docetaxel	N	O
19	(	N	O
20	T	N	O
21	;	N	O
22	AC→T	N	O
23	)	N	O
24	,	N	O
25	concurrent	N	O
26	TAC	N	O
27	,	N	O
28	or	N	O
29	AT	N	O
30	,	N	O
31	which	N	O
32	varied	N	O
33	in	N	O
34	duration	N	O
35	(	N	O
36	24	N	O
37	,	N	O
38	12	N	O
39	,	N	O
40	12	N	O
41	weeks	N	O
42	,	N	O
43	respectively	N	O
44	)	N	O
45	,	N	O
46	and	N	O
47	use	N	O
48	of	N	O
49	C.	N	O
50	Endocrine	N	O
51	therapy	N	O
52	was	N	O
53	prescribed	N	O
54	for	N	O
55	women	N	O
56	with	N	O
57	hormone	N	O
58	receptor-positive	N	O
59	tumors	N	O
60	.	N	O

1	MH	N	O
2	and	N	O
3	QOL	N	O
4	were	N	O
5	assessed	N	O
6	with	N	O
7	standardized	N	O
8	questionnaires	N	O
9	at	N	O
10	baseline	N	O
11	;	N	O
12	cycle	N	O
13	4	N	O
14	,	N	O
15	day	N	O
16	1	N	O
17	;	N	O
18	and	N	O
19	every	N	O
20	6	N	O
21	months	N	O
22	through	N	O
23	24	N	O
24	months	N	O
25	.	N	O

1	Prespecified	N	O
2	analyses	N	O
3	examined	N	O
4	rates	N	O
5	of	N	O
6	amenorrhea	N	O
7	by	N	O
8	treatment	N	O
9	arm	N	O
10	,	N	O
11	the	N	O
12	relationship	N	O
13	between	N	O
14	amenorrhea	N	O
15	and	N	O
16	QOL	N	O
17	,	N	O
18	and	N	O
19	QOL	N	O
20	by	N	O
21	treatment	N	O
22	arm	N	O
23	.	N	O

1	Amenorrhea	N	I-Premise
2	12	N	I-Premise
3	months	N	I-Premise
4	after	N	I-Premise
5	random	N	I-Premise
6	assignment	N	I-Premise
7	was	N	I-Premise
8	significantly	N	I-Premise
9	different	N	I-Premise
10	between	N	I-Premise
11	treatment	N	I-Premise
12	groups	N	I-Premise
13	:	N	I-Premise
14	69.8	N	I-Premise
15	%	N	I-Premise
16	for	N	I-Premise
17	AC→T	N	I-Premise
18	,	N	I-Premise
19	57.7	N	I-Premise
20	%	N	I-Premise
21	for	N	I-Premise
22	TAC	N	I-Premise
23	,	N	I-Premise
24	and	N	I-Premise
25	37.9	N	I-Premise
26	%	N	I-Premise
27	for	N	I-Premise
28	AT	N	I-Premise
29	(	N	I-Premise
30	P	N	I-Premise
31	<	N	I-Premise
32	.001	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	The	N	I-Premise
2	AT	N	I-Premise
3	group	N	I-Premise
4	without	N	I-Premise
5	tamoxifen	N	I-Premise
6	had	N	I-Premise
7	the	N	I-Premise
8	lowest	N	I-Premise
9	rate	N	I-Premise
10	of	N	I-Premise
11	amenorrhea	N	I-Premise
12	.	N	I-Premise

1	QOL	N	I-Premise
2	was	N	I-Premise
3	poorer	N	I-Premise
4	for	N	I-Premise
5	patients	N	I-Premise
6	receiving	N	I-Premise
7	AC→T	N	I-Premise
8	at	N	I-Premise
9	6	N	I-Premise
10	months	N	I-Premise
11	but	N	I-Premise
12	similar	N	I-Premise
13	to	N	I-Premise
14	others	N	I-Premise
15	by	N	I-Premise
16	12	N	I-Premise
17	months	N	I-Premise
18	.	N	I-Premise

1	Post-treatment	N	I-Premise
2	symptoms	N	I-Premise
3	were	N	I-Premise
4	increased	N	I-Premise
5	above	N	I-Premise
6	baseline	N	I-Premise
7	for	N	I-Premise
8	all	N	I-Premise
9	treatments	N	I-Premise
10	.	N	I-Premise

1	Multivariable	N	I-Premise
2	repeated	N	I-Premise
3	measures	N	I-Premise
4	modeling	N	I-Premise
5	demonstrated	N	I-Premise
6	that	N	I-Premise
7	treatment	N	I-Premise
8	arm	N	I-Premise
9	,	N	I-Premise
10	time	N	I-Premise
11	point	N	I-Premise
12	,	N	I-Premise
13	age	N	I-Premise
14	,	N	I-Premise
15	and	N	I-Premise
16	tamoxifen	N	I-Premise
17	use	N	I-Premise
18	were	N	I-Premise
19	significantly	N	I-Premise
20	associated	N	I-Premise
21	with	N	I-Premise
22	symptom	N	I-Premise
23	severity	N	I-Premise
24	(	N	I-Premise
25	all	N	I-Premise
26	P	N	I-Premise
27	values	N	I-Premise
28	<	N	I-Premise
29	.002	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	Amenorrhea	N	I-Claim
2	rates	N	I-Claim
3	differed	N	I-Claim
4	significantly	N	I-Claim
5	by	N	I-Claim
6	treatment	N	I-Claim
7	arm	N	I-Claim
8	,	N	I-Claim
9	with	N	I-Claim
10	the	N	I-Claim
11	AT	N	I-Claim
12	arm	N	I-Claim
13	having	N	I-Claim
14	the	N	I-Claim
15	lowest	N	I-Claim
16	rate	N	I-Claim
17	.	N	I-Claim

1	Patients	N	I-Claim
2	treated	N	I-Claim
3	with	N	I-Claim
4	longer	N	I-Claim
5	duration	N	I-Claim
6	therapy	N	I-Claim
7	(	N	I-Claim
8	AC→T	N	I-Claim
9	)	N	I-Claim
10	had	N	I-Claim
11	greater	N	I-Claim
12	symptom	N	I-Claim
13	severity	N	I-Claim
14	and	N	I-Claim
15	poorer	N	I-Claim
16	QOL	N	I-Claim
17	at	N	I-Claim
18	6	N	I-Claim
19	months	N	I-Claim
20	,	N	I-Claim
21	but	N	I-Claim
22	did	N	I-Claim
23	not	N	I-Claim
24	differ	N	I-Claim
25	from	N	I-Claim
26	shorter	N	I-Claim
27	duration	N	I-Claim
28	treatments	N	I-Claim
29	at	N	I-Claim
30	12	N	I-Claim
31	months	N	I-Claim
32	.	N	I-Claim

1	The	N	O
2	objective	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	is	N	O
7	to	N	O
8	explore	N	O
9	the	N	O
10	inflammatory	N	O
11	modulation	N	O
12	effect	N	O
13	of	N	O
14	glutamine-enriched	N	O
15	total	N	O
16	parenteral	N	O
17	nutrition	N	O
18	(	N	O
19	TPN	N	O
20	)	N	O
21	by	N	O
22	investigating	N	O
23	the	N	O
24	alterations	N	O
25	of	N	O
26	inflammation-related	N	O
27	cytokines	N	O
28	in	N	O
29	gastrointestinal	N	O
30	(	N	O
31	GI	N	O
32	)	N	O
33	cancer	N	O
34	patients	N	O
35	postoperatively	N	O
36	.	N	O

1	Fifty	N	O
2	GI	N	O
3	cancer	N	O
4	patients	N	O
5	received	N	O
6	postoperative	N	O
7	7	N	O
8	days	N	O
9	of	N	O
10	isocaloric	N	O
11	and	N	O
12	isonitrogenous	N	O
13	TPN	N	O
14	after	N	O
15	operation	N	O
16	.	N	O

1	They	N	O
2	were	N	O
3	randomly	N	O
4	divided	N	O
5	to	N	O
6	receive	N	O
7	either	N	O
8	glutamine-enriched	N	O
9	TPN	N	O
10	or	N	O
11	standard	N	O
12	TPN	N	O
13	.	N	O

1	The	N	O
2	inflammation-related	N	O
3	cytokines	N	O
4	including	N	O
5	interleukin-6	N	O
6	,	N	O
7	interleukin-10	N	O
8	,	N	O
9	and	N	O
10	tumor	N	O
11	necrosis	N	O
12	factor-α	N	O
13	were	N	O
14	also	N	O
15	determined	N	O
16	.	N	O

1	Records	N	O
2	of	N	O
3	nutritional	N	O
4	assessments	N	O
5	,	N	O
6	inflammatory	N	O
7	status	N	O
8	,	N	O
9	and	N	O
10	postoperative	N	O
11	complications	N	O
12	were	N	O
13	compared	N	O
14	between	N	O
15	the	N	O
16	two	N	O
17	groups	N	O
18	.	N	O

1	Of	N	O
2	50	N	O
3	enrolled	N	O
4	patients	N	O
5	,	N	O
6	25	N	O
7	patients	N	O
8	were	N	O
9	classified	N	O
10	as	N	O
11	the	N	O
12	intervention	N	O
13	group	N	O
14	,	N	O
15	and	N	O
16	the	N	O
17	control	N	O
18	group	N	O
19	also	N	O
20	comprised	N	O
21	25	N	O
22	patients	N	O
23	.	N	O

1	The	N	O
2	differences	N	O
3	of	N	O
4	gender	N	O
5	,	N	O
6	age	N	O
7	,	N	O
8	primary	N	O
9	GI	N	O
10	malignancies	N	O
11	,	N	O
12	and	N	O
13	hematological	N	O
14	and	N	O
15	biochemical	N	O
16	data	N	O
17	between	N	O
18	the	N	O
19	two	N	O
20	compared	N	O
21	groups	N	O
22	were	N	O
23	not	N	O
24	statistically	N	O
25	significant	N	O
26	(	N	O
27	all	N	O
28	P	N	O
29	>	N	O
30	0.05	N	O
31	)	N	O
32	.	N	O

1	Compared	N	I-Premise
2	with	N	I-Premise
3	standard	N	I-Premise
4	TPN	N	I-Premise
5	,	N	I-Premise
6	a	N	I-Premise
7	higher	N	I-Premise
8	serum	N	I-Premise
9	prealbumin	N	I-Premise
10	level	N	I-Premise
11	and	N	I-Premise
12	better	N	I-Premise
13	nitrogen	N	I-Premise
14	balance	N	I-Premise
15	were	N	I-Premise
16	observed	N	I-Premise
17	in	N	I-Premise
18	glutamine-enriched	N	I-Premise
19	TPN	N	I-Premise
20	(	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	0.039	N	I-Premise
24	and	N	I-Premise
25	0.048	N	I-Premise
26	respectively	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	A	N	I-Premise
2	significantly	N	I-Premise
3	lower	N	I-Premise
4	serum	N	I-Premise
5	interleukin-6	N	I-Premise
6	level	N	I-Premise
7	was	N	I-Premise
8	found	N	I-Premise
9	in	N	I-Premise
10	comparing	N	I-Premise
11	glutamine-enriched	N	I-Premise
12	with	N	I-Premise
13	standard	N	I-Premise
14	TPN	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	=	N	I-Premise
18	0.01	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	but	N	I-Premise
22	not	N	I-Premise
23	in	N	I-Premise
24	interleukin-10	N	I-Premise
25	(	N	I-Premise
26	P	N	I-Premise
27	=	N	I-Premise
28	0.374	N	I-Premise
29	)	N	I-Premise
30	and	N	I-Premise
31	tumor	N	I-Premise
32	necrosis	N	I-Premise
33	factor-α	N	I-Premise
34	levels	N	I-Premise
35	(	N	I-Premise
36	P	N	I-Premise
37	=	N	I-Premise
38	0.653	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	Moreover	N	O
2	,	N	O
3	a	N	I-Premise
4	significant	N	I-Premise
5	lower	N	I-Premise
6	serum	N	I-Premise
7	C-reactive	N	I-Premise
8	protein	N	I-Premise
9	level	N	I-Premise
10	was	N	I-Premise
11	detected	N	I-Premise
12	in	N	I-Premise
13	glutamine-enriched	N	I-Premise
14	TPN	N	I-Premise
15	compared	N	I-Premise
16	with	N	I-Premise
17	standard	N	I-Premise
18	TPN	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	0.013	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Indeed	N	O
2	,	N	O
3	four	N	I-Premise
4	cases	N	I-Premise
5	of	N	I-Premise
6	postoperative	N	I-Premise
7	infectious	N	I-Premise
8	complications	N	I-Premise
9	were	N	I-Premise
10	noted	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	control	N	I-Premise
14	group	N	I-Premise
15	,	N	I-Premise
16	but	N	I-Premise
17	no	N	I-Premise
18	postoperative	N	I-Premise
19	infectious	N	I-Premise
20	complications	N	I-Premise
21	were	N	I-Premise
22	observed	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	interventional	N	I-Premise
26	group	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	0.037	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Our	N	I-Claim
2	present	N	I-Claim
3	study	N	I-Claim
4	shows	N	I-Claim
5	that	N	I-Claim
6	glutamine-enriched	N	I-Claim
7	TPN	N	I-Claim
8	may	N	I-Claim
9	be	N	I-Claim
10	beneficial	N	I-Claim
11	in	N	I-Claim
12	improving	N	I-Claim
13	the	N	I-Claim
14	inflammatory	N	I-Claim
15	status	N	I-Claim
16	and	N	I-Claim
17	decreasing	N	I-Claim
18	the	N	I-Claim
19	infectious	N	I-Claim
20	morbidity	N	I-Claim
21	in	N	I-Claim
22	postoperative	N	I-Claim
23	GI	N	I-Claim
24	cancer	N	I-Claim
25	patients	N	I-Claim
26	.	N	I-Claim

1	We	N	O
2	aimed	N	O
3	to	N	O
4	determine	N	O
5	the	N	O
6	effectiveness	N	O
7	of	N	O
8	a	N	O
9	lay-administered	N	O
10	tailored	N	O
11	education	N	O
12	and	N	O
13	coaching	N	O
14	(	N	O
15	TEC	N	O
16	)	N	O
17	intervention	N	O
18	(	N	O
19	aimed	N	O
20	at	N	O
21	reducing	N	O
22	pain	N	O
23	misconceptions	N	O
24	and	N	O
25	enhancing	N	O
26	self-efficacy	N	O
27	for	N	O
28	communicating	N	O
29	with	N	O
30	physicians	N	O
31	)	N	O
32	on	N	O
33	cancer	N	O
34	pain	N	O
35	severity	N	O
36	,	N	O
37	pain-related	N	O
38	impairment	N	O
39	,	N	O
40	and	N	O
41	quality	N	O
42	of	N	O
43	life	N	O
44	.	N	O

1	Cancer	N	O
2	patients	N	O
3	with	N	O
4	baseline	N	O
5	``	N	O
6	worst	N	O
7	pain	N	O
8	''	N	O
9	of	N	O
10	≥4	N	O
11	on	N	O
12	a	N	O
13	0-10	N	O
14	scale	N	O
15	or	N	O
16	at	N	O
17	least	N	O
18	moderate	N	O
19	functional	N	O
20	impairment	N	O
21	due	N	O
22	to	N	O
23	pain	N	O
24	were	N	O
25	randomly	N	O
26	assigned	N	O
27	to	N	O
28	TEC	N	O
29	or	N	O
30	enhanced	N	O
31	usual	N	O
32	care	N	O
33	(	N	O
34	EUC	N	O
35	)	N	O
36	during	N	O
37	a	N	O
38	telephone	N	O
39	interview	N	O
40	conducted	N	O
41	in	N	O
42	advance	N	O
43	of	N	O
44	a	N	O
45	planned	N	O
46	oncology	N	O
47	office	N	O
48	visit	N	O
49	(	N	O
50	265	N	O
51	patients	N	O
52	randomized	N	O
53	to	N	O
54	TEC	N	O
55	or	N	O
56	EUC	N	O
57	;	N	O
58	258	N	O
59	completed	N	O
60	at	N	O
61	least	N	O
62	one	N	O
63	follow-up	N	O
64	)	N	O
65	.	N	O

1	Patients	N	O
2	completed	N	O
3	questionnaires	N	O
4	before	N	O
5	and	N	O
6	after	N	O
7	the	N	O
8	visit	N	O
9	and	N	O
10	were	N	O
11	interviewed	N	O
12	by	N	O
13	telephone	N	O
14	at	N	O
15	2	N	O
16	,	N	O
17	6	N	O
18	,	N	O
19	and	N	O
20	12	N	O
21	weeks	N	O
22	.	N	O

1	Mixed	N	O
2	effects	N	O
3	regressions	N	O
4	were	N	O
5	used	N	O
6	to	N	O
7	evaluate	N	O
8	the	N	O
9	intervention	N	O
10	adjusting	N	O
11	for	N	O
12	patient	N	O
13	,	N	O
14	practice	N	O
15	,	N	O
16	and	N	O
17	site	N	O
18	characteristics	N	O
19	.	N	O

1	Compared	N	I-Premise
2	to	N	I-Premise
3	EUC	N	I-Premise
4	,	N	I-Premise
5	TEC	N	I-Premise
6	was	N	I-Premise
7	associated	N	I-Premise
8	with	N	I-Premise
9	increased	N	I-Premise
10	pain	N	I-Premise
11	communication	N	I-Premise
12	self-efficacy	N	I-Premise
13	after	N	I-Premise
14	the	N	I-Premise
15	intervention	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	<	N	I-Premise
19	.001	N	I-Premise
20	)	N	I-Premise
21	;	N	I-Premise
22	both	N	I-Premise
23	groups	N	I-Premise
24	showed	N	I-Premise
25	significant	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	<	N	I-Premise
29	.0001	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	similar	N	I-Premise
33	,	N	I-Premise
34	reductions	N	I-Premise
35	in	N	I-Premise
36	pain	N	I-Premise
37	misconceptions	N	I-Premise
38	.	N	I-Premise

1	At	N	I-Premise
2	2	N	I-Premise
3	weeks	N	I-Premise
4	,	N	I-Premise
5	assignment	N	I-Premise
6	to	N	I-Premise
7	TEC	N	I-Premise
8	was	N	I-Premise
9	associated	N	I-Premise
10	with	N	I-Premise
11	improvement	N	I-Premise
12	in	N	I-Premise
13	pain-related	N	I-Premise
14	impairment	N	I-Premise
15	(	N	I-Premise
16	-0.25	N	I-Premise
17	points	N	I-Premise
18	on	N	I-Premise
19	a	N	I-Premise
20	5-point	N	I-Premise
21	scale	N	I-Premise
22	,	N	I-Premise
23	95	N	I-Premise
24	%	N	I-Premise
25	confidence	N	I-Premise
26	interval	N	I-Premise
27	-0.43	N	I-Premise
28	to	N	I-Premise
29	-0.06	N	I-Premise
30	,	N	I-Premise
31	P=.01	N	I-Premise
32	)	N	I-Premise
33	but	N	I-Premise
34	not	N	I-Premise
35	in	N	I-Premise
36	pain	N	I-Premise
37	severity	N	I-Premise
38	(	N	I-Premise
39	-0.21	N	I-Premise
40	points	N	I-Premise
41	on	N	I-Premise
42	an	N	I-Premise
43	11-point	N	I-Premise
44	scale	N	I-Premise
45	,	N	I-Premise
46	-0.60	N	I-Premise
47	to	N	I-Premise
48	0.17	N	I-Premise
49	,	N	I-Premise
50	P=.27	N	I-Premise
51	)	N	I-Premise
52	.	N	I-Premise

1	The	N	I-Premise
2	improvement	N	I-Premise
3	in	N	I-Premise
4	pain-related	N	I-Premise
5	impairment	N	I-Premise
6	was	N	I-Premise
7	not	N	I-Premise
8	sustained	N	I-Premise
9	at	N	I-Premise
10	6	N	I-Premise
11	and	N	I-Premise
12	12	N	I-Premise
13	weeks	N	I-Premise
14	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	intervention	N	I-Premise
6	by	N	I-Premise
7	subgroup	N	I-Premise
8	interactions	N	I-Premise
9	(	N	I-Premise
10	P	N	I-Premise
11	>	N	I-Premise
12	.10	N	I-Premise
13	)	N	I-Premise
14	.	N	I-Premise

1	We	N	I-Claim
2	conclude	N	I-Claim
3	that	N	I-Claim
4	TEC	N	I-Claim
5	,	N	I-Claim
6	compared	N	I-Claim
7	with	N	I-Claim
8	EUC	N	I-Claim
9	,	N	I-Claim
10	resulted	N	I-Claim
11	in	N	I-Claim
12	improved	N	I-Claim
13	pain	N	I-Claim
14	communication	N	I-Claim
15	self-efficacy	N	I-Claim
16	and	N	I-Claim
17	temporary	N	I-Claim
18	improvement	N	I-Claim
19	in	N	I-Claim
20	pain-related	N	I-Claim
21	impairment	N	I-Claim
22	,	N	I-Claim
23	but	N	I-Claim
24	no	N	I-Claim
25	improvement	N	I-Claim
26	in	N	I-Claim
27	pain	N	I-Claim
28	severity	N	I-Claim
29	.	N	I-Claim

1	To	N	O
2	determine	N	O
3	the	N	O
4	long-term	N	O
5	outcome	N	O
6	and	N	O
7	health-related	N	O
8	quality	N	O
9	of	N	O
10	life	N	O
11	(	N	O
12	HRQL	N	O
13	)	N	O
14	of	N	O
15	patients	N	O
16	with	N	O
17	endometrial	N	O
18	carcinoma	N	O
19	(	N	O
20	EC	N	O
21	)	N	O
22	treated	N	O
23	with	N	O
24	or	N	O
25	without	N	O
26	pelvic	N	O
27	radiotherapy	N	O
28	in	N	O
29	the	N	O
30	Post	N	O
31	Operative	N	O
32	Radiation	N	O
33	Therapy	N	O
34	in	N	O
35	Endometrial	N	O
36	Carcinoma	N	O
37	1	N	O
38	(	N	O
39	PORTEC-1	N	O
40	)	N	O
41	trial	N	O
42	.	N	O

1	Between	N	O
2	1990	N	O
3	and	N	O
4	1997	N	O
5	,	N	O
6	714	N	O
7	patients	N	O
8	with	N	O
9	stage	N	O
10	IC	N	O
11	grade	N	O
12	1	N	O
13	to	N	O
14	2	N	O
15	or	N	O
16	IB	N	O
17	grade	N	O
18	2	N	O
19	to	N	O
20	3	N	O
21	EC	N	O
22	were	N	O
23	randomly	N	O
24	allocated	N	O
25	to	N	O
26	pelvic	N	O
27	external-beam	N	O
28	radiotherapy	N	O
29	(	N	O
30	EBRT	N	O
31	)	N	O
32	or	N	O
33	no	N	O
34	additional	N	O
35	treatment	N	O
36	(	N	O
37	NAT	N	O
38	)	N	O
39	.	N	O

1	HRQL	N	O
2	was	N	O
3	evaluated	N	O
4	with	N	O
5	the	N	O
6	Short	N	O
7	Form	N	O
8	36-Item	N	O
9	(	N	O
10	SF-36	N	O
11	)	N	O
12	questionnaire	N	O
13	;	N	O
14	subscales	N	O
15	from	N	O
16	the	N	O
17	European	N	O
18	Organisation	N	O
19	for	N	O
20	Research	N	O
21	and	N	O
22	Treatment	N	O
23	of	N	O
24	Cancer	N	O
25	(	N	O
26	EORTC	N	O
27	)	N	O
28	PR25	N	O
29	module	N	O
30	for	N	O
31	bowel	N	O
32	and	N	O
33	bladder	N	O
34	symptoms	N	O
35	and	N	O
36	the	N	O
37	OV28	N	O
38	and	N	O
39	CX24	N	O
40	modules	N	O
41	for	N	O
42	sexual	N	O
43	symptoms	N	O
44	;	N	O
45	and	N	O
46	demographic	N	O
47	questions	N	O
48	.	N	O

1	Analysis	N	O
2	was	N	O
3	by	N	O
4	intention-to-treat	N	O
5	.	N	O

1	Median	N	O
2	follow-up	N	O
3	was	N	O
4	13.3	N	O
5	years	N	O
6	.	N	O

1	The	N	I-Premise
2	15-year	N	I-Premise
3	actuarial	N	I-Premise
4	locoregional	N	I-Premise
5	recurrence	N	I-Premise
6	rates	N	I-Premise
7	were	N	I-Premise
8	5.8	N	I-Premise
9	%	N	I-Premise
10	for	N	I-Premise
11	EBRT	N	I-Premise
12	versus	N	I-Premise
13	15.5	N	I-Premise
14	%	N	I-Premise
15	for	N	I-Premise
16	NAT	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	<	N	I-Premise
20	.001	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	15-year	N	I-Premise
25	overall	N	I-Premise
26	survival	N	I-Premise
27	was	N	I-Premise
28	52	N	I-Premise
29	%	N	I-Premise
30	versus	N	I-Premise
31	60	N	I-Premise
32	%	N	I-Premise
33	(	N	I-Premise
34	P	N	I-Premise
35	=	N	I-Premise
36	.14	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	Of	N	O
2	the	N	O
3	351	N	O
4	patients	N	O
5	confirmed	N	O
6	to	N	O
7	be	N	O
8	alive	N	O
9	with	N	O
10	correct	N	O
11	address	N	O
12	,	N	O
13	246	N	O
14	(	N	O
15	70	N	O
16	%	N	O
17	)	N	O
18	returned	N	O
19	the	N	O
20	questionnaire	N	O
21	.	N	O

1	Patients	N	I-Premise
2	treated	N	I-Premise
3	with	N	I-Premise
4	EBRT	N	I-Premise
5	reported	N	I-Premise
6	significant	N	I-Premise
7	(	N	I-Premise
8	P	N	I-Premise
9	<	N	I-Premise
10	.01	N	I-Premise
11	)	N	I-Premise
12	and	N	I-Premise
13	clinically	N	I-Premise
14	relevant	N	I-Premise
15	higher	N	I-Premise
16	rates	N	I-Premise
17	of	N	I-Premise
18	urinary	N	I-Premise
19	incontinence	N	I-Premise
20	,	N	I-Premise
21	diarrhea	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	fecal	N	I-Premise
25	leakage	N	I-Premise
26	leading	N	I-Premise
27	to	N	I-Premise
28	more	N	I-Premise
29	limitations	N	I-Premise
30	in	N	I-Premise
31	daily	N	I-Premise
32	activities	N	I-Premise
33	.	N	I-Premise

1	Increased	N	I-Premise
2	symptoms	N	I-Premise
3	were	N	I-Premise
4	reflected	N	I-Premise
5	by	N	I-Premise
6	the	N	I-Premise
7	frequent	N	I-Premise
8	use	N	I-Premise
9	of	N	I-Premise
10	incontinence	N	I-Premise
11	materials	N	I-Premise
12	after	N	I-Premise
13	EBRT	N	I-Premise
14	(	N	I-Premise
15	day	N	I-Premise
16	and	N	I-Premise
17	night	N	I-Premise
18	use	N	I-Premise
19	,	N	I-Premise
20	42.9	N	I-Premise
21	%	N	I-Premise
22	v	N	I-Premise
23	15.2	N	I-Premise
24	%	N	I-Premise
25	for	N	I-Premise
26	NAT	N	I-Premise
27	;	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	.001	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Patients	N	I-Premise
2	treated	N	I-Premise
3	with	N	I-Premise
4	EBRT	N	I-Premise
5	reported	N	I-Premise
6	lower	N	I-Premise
7	scores	N	I-Premise
8	on	N	I-Premise
9	the	N	I-Premise
10	SF-36	N	I-Premise
11	scales	N	I-Premise
12	``	N	I-Premise
13	physical	N	I-Premise
14	functioning	N	I-Premise
15	''	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	=	N	I-Premise
19	.004	N	I-Premise
20	)	N	I-Premise
21	and	N	I-Premise
22	``	N	I-Premise
23	role-physical	N	I-Premise
24	''	N	I-Premise
25	(	N	I-Premise
26	P	N	I-Premise
27	=	N	I-Premise
28	.003	N	I-Premise
29	)	N	I-Claim
30	.	N	I-Claim

1	EBRT	N	I-Claim
2	for	N	I-Claim
3	endometrial	N	I-Claim
4	cancer	N	I-Claim
5	is	N	I-Claim
6	associated	N	I-Claim
7	with	N	I-Claim
8	long-term	N	I-Claim
9	urinary	N	I-Claim
10	and	N	I-Claim
11	bowel	N	I-Claim
12	symptoms	N	I-Claim
13	and	N	I-Claim
14	lower	N	I-Claim
15	physical	N	I-Claim
16	and	N	I-Claim
17	role-physical	N	I-Claim
18	functioning	N	I-Claim
19	,	N	I-Claim
20	even	N	I-Claim
21	15	N	I-Claim
22	years	N	I-Claim
23	after	N	I-Claim
24	treatment	N	I-Claim
25	.	N	I-Claim

1	Despite	N	I-MajorClaim
2	its	N	I-MajorClaim
3	efficacy	N	I-MajorClaim
4	in	N	I-MajorClaim
5	reducing	N	I-MajorClaim
6	locoregional	N	I-MajorClaim
7	recurrence	N	I-MajorClaim
8	,	N	I-MajorClaim
9	EBRT	N	I-MajorClaim
10	should	N	I-MajorClaim
11	be	N	I-MajorClaim
12	avoided	N	I-MajorClaim
13	in	N	I-MajorClaim
14	patients	N	I-MajorClaim
15	with	N	I-MajorClaim
16	low-	N	I-MajorClaim
17	and	N	I-MajorClaim
18	intermediate-risk	N	I-MajorClaim
19	EC	N	I-MajorClaim
20	.	N	I-MajorClaim

1	Postoperative	N	I-Claim
2	outcomes	N	I-Claim
3	of	N	I-Claim
4	patients	N	I-Claim
5	undergoing	N	I-Claim
6	laparoscopic-assisted	N	I-Claim
7	colectomy	N	I-Claim
8	(	N	I-Claim
9	LAC	N	I-Claim
10	)	N	I-Claim
11	have	N	I-Claim
12	shown	N	I-Claim
13	modest	N	I-Claim
14	improvements	N	I-Claim
15	in	N	I-Claim
16	recovery	N	I-Claim
17	but	N	I-Claim
18	only	N	I-Claim
19	minimal	N	I-Claim
20	differences	N	I-Claim
21	in	N	I-Claim
22	quality	N	I-Claim
23	of	N	I-Claim
24	life	N	I-Claim
25	(	N	I-Claim
26	QOL	N	I-Claim
27	)	N	I-Claim
28	compared	N	I-Claim
29	with	N	I-Claim
30	open	N	I-Claim
31	colectomy	N	I-Claim
32	.	N	I-Claim

1	We	N	O
2	therefore	N	O
3	sought	N	O
4	to	N	O
5	assess	N	O
6	the	N	O
7	effect	N	O
8	of	N	O
9	LAC	N	O
10	on	N	O
11	QOL	N	O
12	in	N	O
13	the	N	O
14	short	N	O
15	and	N	O
16	long	N	O
17	term	N	O
18	,	N	O
19	using	N	O
20	individual	N	O
21	item	N	O
22	analysis	N	O
23	of	N	O
24	multi-item	N	O
25	QOL	N	O
26	assessments	N	O
27	.	N	O

1	QOL	N	O
2	variables	N	O
3	were	N	O
4	analyzed	N	O
5	in	N	O
6	449	N	O
7	randomized	N	O
8	patients	N	O
9	from	N	O
10	the	N	O
11	COST	N	O
12	trial	N	O
13	93-46-53	N	O
14	(	N	O
15	INT	N	O
16	0146	N	O
17	)	N	O
18	.	N	O

1	Both	N	O
2	cross-sectional	N	O
3	single-time	N	O
4	and	N	O
5	change	N	O
6	from	N	O
7	baseline	N	O
8	assessments	N	O
9	were	N	O
10	run	N	O
11	at	N	O
12	day	N	O
13	2	N	O
14	,	N	O
15	week	N	O
16	2	N	O
17	,	N	O
18	month	N	O
19	2	N	O
20	,	N	O
21	and	N	O
22	month	N	O
23	18	N	O
24	postoperatively	N	O
25	in	N	O
26	an	N	O
27	intention-to-treat	N	O
28	analysis	N	O
29	using	N	O
30	Wilcoxon	N	O
31	rank-sum	N	O
32	tests	N	O
33	.	N	O

1	Stepwise	N	O
2	regression	N	O
3	models	N	O
4	were	N	O
5	used	N	O
6	to	N	O
7	determine	N	O
8	predictors	N	O
9	of	N	O
10	QOL	N	O
11	.	N	O

1	Of	N	O
2	449	N	O
3	colon	N	O
4	cancer	N	O
5	patients	N	O
6	,	N	O
7	230	N	O
8	underwent	N	O
9	LAC	N	O
10	and	N	O
11	219	N	O
12	underwent	N	O
13	open	N	O
14	colectomy	N	O
15	.	N	O

1	Subdomain	N	I-Premise
2	analysis	N	I-Premise
3	revealed	N	I-Premise
4	a	N	I-Premise
5	clinically	N	I-Premise
6	moderate	N	I-Premise
7	improvement	N	I-Premise
8	from	N	I-Premise
9	baseline	N	I-Premise
10	for	N	I-Premise
11	LAC	N	I-Premise
12	in	N	I-Premise
13	total	N	I-Premise
14	QOL	N	I-Premise
15	index	N	I-Premise
16	at	N	I-Premise
17	18	N	I-Premise
18	months	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	0.02	N	I-Premise
23	)	N	I-Premise
24	as	N	I-Premise
25	well	N	I-Premise
26	as	N	I-Premise
27	other	N	I-Premise
28	small	N	I-Premise
29	symptomatic	N	I-Premise
30	improvements	N	I-Premise
31	.	N	I-Premise

1	Poor	N	O
2	preoperative	N	O
3	QOL	N	O
4	as	N	O
5	indicated	N	O
6	by	N	O
7	a	N	O
8	rating	N	O
9	scale	N	O
10	of	N	O
11	≤	N	O
12	50	N	O
13	was	N	O
14	an	N	O
15	independent	N	O
16	predictor	N	O
17	of	N	O
18	poor	N	O
19	QOL	N	O
20	at	N	O
21	2	N	O
22	months	N	O
23	postoperatively	N	O
24	.	N	O

1	QOL	N	O
2	variables	N	O
3	related	N	O
4	to	N	O
5	survival	N	O
6	were	N	O
7	baseline	N	O
8	support	N	O
9	(	N	O
10	P	N	O
11	=	N	O
12	0.001	N	O
13	)	N	O
14	and	N	O
15	baseline	N	O
16	outlook	N	O
17	(	N	O
18	P	N	O
19	=	N	O
20	0.01	N	O
21	)	N	O
22	.	N	O

1	Eighteen	N	I-Premise
2	months	N	I-Premise
3	after	N	I-Premise
4	surgery	N	I-Premise
5	,	N	I-Premise
6	any	N	I-Premise
7	differences	N	I-Premise
8	in	N	I-Premise
9	quality	N	I-Premise
10	of	N	I-Premise
11	life	N	I-Premise
12	between	N	I-Premise
13	patients	N	I-Premise
14	randomized	N	I-Premise
15	to	N	I-Premise
16	LAC	N	I-Premise
17	or	N	I-Premise
18	open	N	I-Premise
19	colectomy	N	I-Premise
20	favored	N	I-Premise
21	LAC	N	I-Premise
22	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	the	N	I-Premise
4	magnitude	N	I-Premise
5	of	N	I-Premise
6	the	N	I-Premise
7	benefits	N	I-Premise
8	was	N	I-Premise
9	small	N	I-Premise
10	.	N	I-Premise

1	Patients	N	I-Claim
2	with	N	I-Claim
3	poor	N	I-Claim
4	preoperative	N	I-Claim
5	QOL	N	I-Claim
6	appear	N	I-Claim
7	to	N	I-Claim
8	be	N	I-Claim
9	at	N	I-Claim
10	higher	N	I-Claim
11	risk	N	I-Claim
12	for	N	I-Claim
13	difficult	N	I-Claim
14	postoperative	N	I-Claim
15	courses	N	I-Claim
16	,	N	I-Claim
17	and	N	I-Claim
18	may	N	I-Claim
19	be	N	I-Claim
20	candidates	N	I-Claim
21	for	N	I-Claim
22	enhanced	N	I-Claim
23	ancillary	N	I-Claim
24	services	N	I-Claim
25	to	N	I-Claim
26	address	N	I-Claim
27	their	N	I-Claim
28	particular	N	I-Claim
29	needs	N	I-Claim
30	.	N	I-Claim

1	Improvements	N	O
2	can	N	O
3	be	N	O
4	made	N	O
5	in	N	O
6	the	N	O
7	quality	N	O
8	of	N	O
9	cancer	N	O
10	care	N	O
11	if	N	O
12	supportive	N	O
13	care	N	O
14	needs	N	O
15	are	N	O
16	addressed	N	O
17	;	N	O
18	however	N	O
19	,	N	O
20	there	N	O
21	are	N	O
22	few	N	O
23	trials	N	O
24	of	N	O
25	supportive	N	O
26	care	N	O
27	interventions	N	O
28	to	N	O
29	guide	N	O
30	policy	N	O
31	and	N	O
32	practice	N	O
33	.	N	O

1	This	N	O
2	study	N	O
3	aimed	N	O
4	to	N	O
5	determine	N	O
6	the	N	O
7	effectiveness	N	O
8	of	N	O
9	a	N	O
10	nurse-delivered	N	O
11	telephone	N	O
12	supportive	N	O
13	intervention	N	O
14	(	N	O
15	the	N	O
16	``	N	O
17	CONNECT	N	O
18	''	N	O
19	intervention	N	O
20	)	N	O
21	.	N	O

1	This	N	O
2	study	N	O
3	was	N	O
4	a	N	O
5	pilot	N	O
6	randomized	N	O
7	controlled	N	O
8	trial	N	O
9	.	N	O

1	Intervention	N	O
2	group	N	O
3	patients	N	O
4	received	N	O
5	5	N	O
6	calls	N	O
7	from	N	O
8	a	N	O
9	specialist	N	O
10	colorectal	N	O
11	nurse	N	O
12	in	N	O
13	the	N	O
14	6	N	O
15	months	N	O
16	after	N	O
17	hospital	N	O
18	discharge	N	O
19	.	N	O

1	Each	N	O
2	call	N	O
3	was	N	O
4	standardized	N	O
5	,	N	O
6	comprising	N	O
7	the	N	O
8	assessment	N	O
9	of	N	O
10	unmet	N	O
11	need	N	O
12	and	N	O
13	the	N	O
14	provision	N	O
15	of	N	O
16	information	N	O
17	and	N	O
18	emotional	N	O
19	support	N	O
20	.	N	O

1	CONNECT	N	O
2	was	N	O
3	in	N	O
4	addition	N	O
5	to	N	O
6	standard	N	O
7	clinical	N	O
8	follow-up	N	O
9	.	N	O

1	Patients	N	O
2	allocated	N	O
3	to	N	O
4	the	N	O
5	control	N	O
6	group	N	O
7	received	N	O
8	standard	N	O
9	follow-up	N	O
10	only	N	O
11	.	N	O

1	This	N	O
2	study	N	O
3	took	N	O
4	place	N	O
5	at	N	O
6	the	N	O
7	Royal	N	O
8	Prince	N	O
9	Alfred	N	O
10	Hospital	N	O
11	,	N	O
12	Sydney	N	O
13	,	N	O
14	Australia	N	O
15	.	N	O

1	Patients	N	O
2	(	N	O
3	n	N	O
4	=	N	O
5	75	N	O
6	)	N	O
7	were	N	O
8	included	N	O
9	who	N	O
10	had	N	O
11	been	N	O
12	surgically	N	O
13	treated	N	O
14	for	N	O
15	colorectal	N	O
16	cancer	N	O
17	(	N	O
18	any	N	O
19	stage	N	O
20	)	N	O
21	.	N	O

1	The	N	O
2	main	N	O
3	outcome	N	O
4	measures	N	O
5	were	N	O
6	the	N	O
7	unmet	N	O
8	supportive	N	O
9	care	N	O
10	needs	N	O
11	,	N	O
12	health	N	O
13	service	N	O
14	utilization	N	O
15	,	N	O
16	and	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	at	N	O
21	1	N	O
22	,	N	O
23	3	N	O
24	,	N	O
25	and	N	O
26	6	N	O
27	months	N	O
28	postdischarge	N	O
29	.	N	O

1	Of	N	O
2	87	N	O
3	eligible	N	O
4	patients	N	O
5	,	N	O
6	75	N	O
7	consented	N	O
8	(	N	O
9	86	N	O
10	%	N	O
11	consent	N	O
12	rate	N	O
13	)	N	O
14	.	N	O

1	Thirty-nine	N	O
2	patients	N	O
3	were	N	O
4	randomly	N	O
5	assigned	N	O
6	to	N	O
7	CONNECT	N	O
8	and	N	O
9	36	N	O
10	to	N	O
11	usual	N	O
12	care	N	O
13	.	N	O

1	At	N	I-Premise
2	6	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	there	N	I-Premise
6	was	N	I-Premise
7	a	N	I-Premise
8	clinically	N	I-Premise
9	relevant	N	I-Premise
10	,	N	I-Premise
11	but	N	I-Premise
12	nonsignificant	N	I-Premise
13	reduction	N	I-Premise
14	in	N	I-Premise
15	presentations	N	I-Premise
16	to	N	I-Premise
17	emergency	N	I-Premise
18	departments	N	I-Premise
19	(	N	I-Premise
20	21	N	I-Premise
21	%	N	I-Premise
22	vs	N	I-Premise
23	33	N	I-Premise
24	%	N	I-Premise
25	;	N	I-Premise
26	χ1	N	I-Premise
27	=	N	I-Premise
28	1.41	N	I-Premise
29	,	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.23	N	I-Premise
33	)	N	I-Premise
34	and	N	I-Premise
35	readmission	N	I-Premise
36	to	N	I-Premise
37	the	N	I-Premise
38	hospital	N	I-Premise
39	(	N	I-Premise
40	37	N	I-Premise
41	%	N	I-Premise
42	vs	N	I-Premise
43	47	N	I-Premise
44	%	N	I-Premise
45	;	N	I-Premise
46	χ1	N	I-Premise
47	=	N	I-Premise
48	0.82	N	I-Premise
49	,	N	I-Premise
50	P	N	I-Premise
51	=	N	I-Premise
52	.37	N	I-Premise
53	)	N	I-Premise
54	among	N	I-Premise
55	intervention	N	I-Premise
56	compared	N	I-Premise
57	with	N	I-Premise
58	control	N	I-Premise
59	group	N	I-Premise
60	participants	N	I-Premise
61	.	N	I-Premise

1	Nonsignificant	N	I-Premise
2	differences	N	I-Premise
3	between	N	I-Premise
4	groups	N	I-Premise
5	were	N	I-Premise
6	found	N	I-Premise
7	for	N	I-Premise
8	all	N	I-Premise
9	unmet	N	I-Premise
10	supportive	N	I-Premise
11	care	N	I-Premise
12	need	N	I-Premise
13	and	N	I-Premise
14	quality-of-life	N	I-Premise
15	scores	N	I-Premise
16	,	N	I-Premise
17	change	N	I-Premise
18	scores	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	trends	N	I-Premise
22	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	at	N	I-Premise
4	6	N	I-Premise
5	months	N	I-Premise
6	,	N	I-Premise
7	total	N	I-Premise
8	quality-of-life	N	I-Premise
9	scores	N	I-Premise
10	were	N	I-Premise
11	higher	N	I-Premise
12	for	N	I-Premise
13	intervention	N	I-Premise
14	group	N	I-Premise
15	patients	N	I-Premise
16	than	N	I-Premise
17	controls	N	I-Premise
18	(	N	I-Premise
19	106.0	N	I-Premise
20	vs	N	I-Premise
21	98.6	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	This	N	O
2	difference	N	O
3	(	N	O
4	7.4	N	O
5	)	N	O
6	was	N	O
7	clinically	N	O
8	relevant	N	O
9	.	N	O

1	Improvements	N	I-Claim
2	in	N	I-Claim
3	total	N	I-Claim
4	quality-of-life	N	I-Claim
5	change	N	I-Claim
6	scores	N	I-Claim
7	demonstrated	N	I-Claim
8	that	N	I-Claim
9	at	N	I-Claim
10	6	N	I-Claim
11	months	N	I-Claim
12	,	N	I-Claim
13	improvements	N	I-Claim
14	were	N	I-Claim
15	more	N	I-Claim
16	than	N	I-Claim
17	twice	N	I-Claim
18	as	N	I-Claim
19	large	N	I-Claim
20	and	N	I-Claim
21	clinically	N	I-Claim
22	significant	N	I-Claim
23	in	N	I-Claim
24	the	N	I-Claim
25	intervention	N	I-Claim
26	compared	N	I-Claim
27	with	N	I-Claim
28	the	N	I-Claim
29	control	N	I-Claim
30	group	N	I-Claim
31	.	N	I-Claim

1	CONNECT	N	I-Claim
2	has	N	I-Claim
3	shown	N	I-Claim
4	promising	N	I-Claim
5	indications	N	I-Claim
6	on	N	I-Claim
7	health	N	I-Claim
8	system	N	I-Claim
9	and	N	I-Claim
10	patient	N	I-Claim
11	outcomes	N	I-Claim
12	that	N	I-Claim
13	warrant	N	I-Claim
14	a	N	I-Claim
15	larger	N	I-Claim
16	study	N	I-Claim
17	to	N	I-Claim
18	further	N	I-Claim
19	investigate	N	I-Claim
20	the	N	I-Claim
21	potential	N	I-Claim
22	of	N	I-Claim
23	this	N	I-Claim
24	intervention	N	I-Claim
25	.	N	I-Claim

1	Thalidomide	N	O
2	with	N	O
3	melphalan/prednisone	N	O
4	(	N	O
5	MPT	N	O
6	)	N	O
7	was	N	O
8	defined	N	O
9	as	N	O
10	standard	N	O
11	treatment	N	O
12	in	N	O
13	elderly	N	O
14	patients	N	O
15	with	N	O
16	multiple	N	O
17	myeloma	N	O
18	(	N	O
19	MM	N	O
20	)	N	O
21	based	N	O
22	on	N	O
23	five	N	O
24	randomized	N	O
25	trials	N	O
26	.	N	O

1	In	N	O
2	one	N	O
3	of	N	O
4	these	N	O
5	trials	N	O
6	,	N	O
7	HOVON49	N	O
8	,	N	O
9	a	N	O
10	prospective	N	O
11	health-related	N	O
12	quality-of-life	N	O
13	(	N	O
14	HRQoL	N	O
15	)	N	O
16	study	N	O
17	was	N	O
18	initiated	N	O
19	in	N	O
20	order	N	O
21	to	N	O
22	assess	N	O
23	the	N	O
24	impact	N	O
25	of	N	O
26	thalidomide	N	O
27	on	N	O
28	QoL	N	O
29	.	N	O

1	Patients	N	O
2	aged	N	O
3	>	N	O
4	65	N	O
5	years	N	O
6	with	N	O
7	newly	N	O
8	diagnosed	N	O
9	MM	N	O
10	were	N	O
11	randomized	N	O
12	to	N	O
13	receive	N	O
14	melphalan	N	O
15	plus	N	O
16	prednisone	N	O
17	(	N	O
18	MP	N	O
19	)	N	O
20	or	N	O
21	MPT	N	O
22	,	N	O
23	followed	N	O
24	by	N	O
25	thalidomide	N	O
26	maintenance	N	O
27	in	N	O
28	the	N	O
29	MPT	N	O
30	arm	N	O
31	.	N	O

1	Two	N	O
2	hundred	N	O
3	eighty-four	N	O
4	patients	N	O
5	were	N	O
6	included	N	O
7	in	N	O
8	this	N	O
9	side	N	O
10	study	N	O
11	(	N	O
12	MP	N	O
13	,	N	O
14	n=149	N	O
15	;	N	O
16	MPT	N	O
17	n=135	N	O
18	)	N	O
19	.	N	O

1	HRQoL	N	O
2	was	N	O
3	assessed	N	O
4	with	N	O
5	the	N	O
6	EORTC	N	O
7	Core	N	O
8	QoL	N	O
9	Questionnaire	N	O
10	(	N	O
11	QLQ-C30	N	O
12	)	N	O
13	and	N	O
14	the	N	O
15	myeloma-specific	N	O
16	module	N	O
17	(	N	O
18	QLQ-MY24	N	O
19	)	N	O
20	at	N	O
21	baseline	N	O
22	and	N	O
23	at	N	O
24	predetermined	N	O
25	intervals	N	O
26	during	N	O
27	treatment	N	O
28	.	N	O

1	The	N	I-Premise
2	QLQ-C30	N	I-Premise
3	subscales	N	I-Premise
4	physical	N	I-Premise
5	function	N	I-Premise
6	(	N	I-Premise
7	P=0.044	N	I-Premise
8	)	N	I-Premise
9	and	N	I-Premise
10	constipation	N	I-Premise
11	(	N	I-Premise
12	P	N	I-Premise
13	<	N	I-Premise
14	0.001	N	I-Premise
15	)	N	I-Premise
16	showed	N	I-Premise
17	an	N	I-Premise
18	improvement	N	I-Premise
19	during	N	I-Premise
20	induction	N	I-Premise
21	in	N	I-Premise
22	favour	N	I-Premise
23	of	N	I-Premise
24	the	N	I-Premise
25	MP	N	I-Premise
26	arm	N	I-Premise
27	.	N	I-Premise

1	During	N	I-Premise
2	thalidomide	N	I-Premise
3	maintenance	N	I-Premise
4	,	N	I-Premise
5	the	N	I-Premise
6	scores	N	I-Premise
7	for	N	I-Premise
8	the	N	I-Premise
9	QLQ-MY24	N	I-Premise
10	paraesthesia	N	I-Premise
11	became	N	I-Premise
12	significantly	N	I-Premise
13	higher	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	MPT	N	I-Premise
17	arm	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	0.001	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	The	N	I-Premise
2	QLQ-C30	N	I-Premise
3	subscales	N	I-Premise
4	pain	N	I-Premise
5	(	N	I-Premise
6	P=0.12	N	I-Premise
7	)	N	I-Premise
8	,	N	I-Premise
9	insomnia	N	I-Premise
10	(	N	I-Premise
11	P=0.068	N	I-Premise
12	)	N	I-Premise
13	,	N	I-Premise
14	appetite	N	I-Premise
15	loss	N	I-Premise
16	(	N	I-Premise
17	P=0.074	N	I-Premise
18	)	N	I-Premise
19	and	N	I-Premise
20	the	N	I-Premise
21	QLQ-MY24	N	I-Premise
22	item	N	I-Premise
23	sick	N	I-Premise
24	(	N	I-Premise
25	P=0.086	N	I-Premise
26	)	N	I-Premise
27	scored	N	I-Premise
28	marginally	N	I-Premise
29	better	N	I-Premise
30	during	N	I-Premise
31	thalidomide	N	I-Premise
32	maintenance	N	I-Premise
33	.	N	I-Premise

1	The	N	I-Premise
2	overall	N	I-Premise
3	QoL-scale	N	I-Premise
4	QLQ-C30-HRQoL	N	I-Premise
5	showed	N	I-Premise
6	a	N	I-Premise
7	significant	N	I-Premise
8	time	N	I-Premise
9	trend	N	I-Premise
10	towards	N	I-Premise
11	more	N	I-Premise
12	favourable	N	I-Premise
13	mean	N	I-Premise
14	values	N	I-Premise
15	during	N	I-Premise
16	protocol	N	I-Premise
17	treatment	N	I-Premise
18	without	N	I-Premise
19	differences	N	I-Premise
20	between	N	I-Premise
21	MP	N	I-Premise
22	and	N	I-Premise
23	MPT	N	I-Premise
24	.	N	I-Premise

1	For	N	I-Premise
2	the	N	I-Premise
3	QLQ-C30	N	I-Premise
4	subscales	N	I-Premise
5	emotional	N	I-Premise
6	function	N	I-Premise
7	and	N	I-Premise
8	future	N	I-Premise
9	perspectives	N	I-Premise
10	,	N	I-Premise
11	difference	N	I-Premise
12	in	N	I-Premise
13	favour	N	I-Premise
14	of	N	I-Premise
15	the	N	I-Premise
16	MPT	N	I-Premise
17	arm	N	I-Premise
18	from	N	I-Premise
19	the	N	I-Premise
20	start	N	I-Premise
21	of	N	I-Premise
22	treatment	N	I-Premise
23	was	N	I-Premise
24	observed	N	I-Premise
25	(	N	I-Premise
26	P=0.018	N	I-Premise
27	and	N	I-Premise
28	P=0.045	N	I-Premise
29	,	N	I-Premise
30	respectively	N	I-Premise
31	)	N	I-Premise
32	with	N	I-Premise
33	no	N	I-Premise
34	significant	N	I-Premise
35	'time	N	I-Premise
36	×	N	I-Premise
37	arm	N	I-Premise
38	'	N	I-Premise
39	interaction	N	I-Premise
40	,	N	I-Premise
41	indicating	N	I-Premise
42	a	N	I-Premise
43	persistent	N	I-Premise
44	better	N	I-Premise
45	patient	N	I-Premise
46	perspective	N	I-Premise
47	with	N	I-Premise
48	MPT	N	I-Premise
49	treatment	N	I-Premise
50	.	N	I-Premise

1	This	N	I-Claim
2	study	N	I-Claim
3	shows	N	I-Claim
4	that	N	I-Claim
5	the	N	I-Claim
6	higher	N	I-Claim
7	frequency	N	I-Claim
8	of	N	I-Claim
9	toxicity	N	I-Claim
10	associated	N	I-Claim
11	with	N	I-Claim
12	MPT	N	I-Claim
13	does	N	I-Claim
14	not	N	I-Claim
15	translate	N	I-Claim
16	into	N	I-Claim
17	a	N	I-Claim
18	negative	N	I-Claim
19	effect	N	I-Claim
20	on	N	I-Claim
21	HRQoL	N	I-Claim
22	and	N	I-Claim
23	that	N	I-Claim
24	MPT	N	I-Claim
25	holds	N	I-Claim
26	a	N	I-Claim
27	better	N	I-Claim
28	patient	N	I-Claim
29	perspective	N	I-Claim
30	.	N	I-Claim

1	Insomnia	N	I-MajorClaim
2	is	N	I-MajorClaim
3	a	N	I-MajorClaim
4	common	N	I-MajorClaim
5	complaint	N	I-MajorClaim
6	among	N	I-MajorClaim
7	cancer	N	I-MajorClaim
8	survivors	N	I-MajorClaim
9	.	N	I-MajorClaim

1	Fortunately	N	O
2	,	N	O
3	cognitive-behavioral	N	O
4	therapy	N	O
5	for	N	O
6	insomnia	N	O
7	(	N	O
8	CBT-I	N	O
9	)	N	O
10	has	N	O
11	been	N	O
12	shown	N	O
13	to	N	O
14	be	N	O
15	an	N	O
16	effective	N	O
17	treatment	N	O
18	in	N	O
19	this	N	O
20	population	N	O
21	.	N	O

1	However	N	O
2	,	N	O
3	it	N	O
4	is	N	O
5	rarely	N	O
6	implemented	N	O
7	given	N	O
8	its	N	O
9	limited	N	O
10	availability	N	O
11	.	N	O

1	To	N	O
2	address	N	O
3	this	N	O
4	barrier	N	O
5	,	N	O
6	we	N	O
7	examined	N	O
8	the	N	O
9	ability	N	O
10	of	N	O
11	an	N	O
12	easily	N	O
13	accessible	N	O
14	online	N	O
15	CBT-I	N	O
16	program	N	O
17	to	N	O
18	improve	N	O
19	insomnia	N	O
20	symptoms	N	O
21	in	N	O
22	cancer	N	O
23	survivors	N	O
24	.	N	O

1	Twenty-eight	N	O
2	cancer	N	O
3	survivors	N	O
4	with	N	O
5	insomnia	N	O
6	were	N	O
7	randomly	N	O
8	assigned	N	O
9	to	N	O
10	either	N	O
11	an	N	O
12	Internet	N	O
13	insomnia	N	O
14	intervention	N	O
15	(	N	O
16	n	N	O
17	=	N	O
18	14	N	O
19	)	N	O
20	or	N	O
21	to	N	O
22	a	N	O
23	waitlist	N	O
24	control	N	O
25	group	N	O
26	(	N	O
27	n	N	O
28	=	N	O
29	14	N	O
30	)	N	O
31	.	N	O

1	The	N	O
2	online	N	O
3	program	N	O
4	,	N	O
5	Sleep	N	O
6	Healthy	N	O
7	Using	N	O
8	The	N	O
9	Internet	N	O
10	,	N	O
11	delivers	N	O
12	the	N	O
13	primary	N	O
14	components	N	O
15	of	N	O
16	CBT-I	N	O
17	(	N	O
18	sleep	N	O
19	restriction	N	O
20	,	N	O
21	stimulus	N	O
22	control	N	O
23	,	N	O
24	cognitive	N	O
25	restructuring	N	O
26	,	N	O
27	sleep	N	O
28	hygiene	N	O
29	,	N	O
30	and	N	O
31	relapse	N	O
32	prevention	N	O
33	)	N	O
34	.	N	O

1	Pre-	N	O
2	and	N	O
3	post-assessment	N	O
4	data	N	O
5	were	N	O
6	collected	N	O
7	via	N	O
8	online	N	O
9	questionnaires	N	O
10	and	N	O
11	daily	N	O
12	sleep	N	O
13	diaries	N	O
14	.	N	O

1	Participants	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	Internet	N	I-Premise
5	group	N	I-Premise
6	showed	N	I-Premise
7	significant	N	I-Premise
8	improvements	N	I-Premise
9	at	N	I-Premise
10	post-assessment	N	I-Premise
11	compared	N	I-Premise
12	with	N	I-Premise
13	those	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	control	N	I-Premise
17	group	N	I-Premise
18	in	N	I-Premise
19	overall	N	I-Premise
20	insomnia	N	I-Premise
21	severity	N	I-Premise
22	(	N	I-Premise
23	F	N	I-Premise
24	(	N	I-Premise
25	1,26	N	I-Premise
26	)	N	I-Premise
27	=	N	I-Premise
28	22.8	N	I-Premise
29	;	N	I-Premise
30	p	N	I-Premise
31	<	N	I-Premise
32	0.001	N	I-Premise
33	)	N	I-Premise
34	,	N	I-Premise
35	sleep	N	I-Premise
36	efficiency	N	I-Premise
37	(	N	I-Premise
38	F	N	I-Premise
39	(	N	I-Premise
40	1,24	N	I-Premise
41	)	N	I-Premise
42	=	N	I-Premise
43	11.45	N	I-Premise
44	;	N	I-Premise
45	P	N	I-Premise
46	=	N	I-Premise
47	0.002	N	I-Premise
48	)	N	I-Premise
49	,	N	I-Premise
50	sleep	N	I-Premise
51	onset	N	I-Premise
52	latency	N	I-Premise
53	(	N	I-Premise
54	F	N	I-Premise
55	(	N	I-Premise
56	1,24	N	I-Premise
57	)	N	I-Premise
58	=	N	I-Premise
59	5.18	N	I-Premise
60	;	N	I-Premise
61	P	N	I-Premise
62	=	N	I-Premise
63	0.03	N	I-Premise
64	)	N	I-Premise
65	,	N	I-Premise
66	soundness	N	I-Premise
67	of	N	I-Premise
68	sleep	N	I-Premise
69	(	N	I-Premise
70	F	N	I-Premise
71	(	N	I-Premise
72	1,24	N	I-Premise
73	)	N	I-Premise
74	=	N	I-Premise
75	9.34	N	I-Premise
76	;	N	I-Premise
77	P	N	I-Premise
78	=	N	I-Premise
79	0.005	N	I-Premise
80	)	N	I-Premise
81	,	N	I-Premise
82	restored	N	I-Premise
83	feeling	N	I-Premise
84	upon	N	I-Premise
85	awakening	N	I-Premise
86	(	N	I-Premise
87	F	N	I-Premise
88	(	N	I-Premise
89	1,24	N	I-Premise
90	)	N	I-Premise
91	=	N	I-Premise
92	11.95	N	I-Premise
93	;	N	I-Premise
94	P	N	I-Premise
95	=	N	I-Premise
96	0.002	N	I-Premise
97	)	N	I-Premise
98	,	N	I-Premise
99	and	N	I-Premise
100	general	N	I-Premise
101	fatigue	N	I-Premise
102	(	N	I-Premise
103	F	N	I-Premise
104	(	N	I-Premise
105	1,26	N	I-Premise
106	)	N	I-Premise
107	=	N	I-Premise
108	13.88	N	I-Premise
109	;	N	I-Premise
110	P	N	I-Premise
111	=	N	I-Premise
112	0.001	N	I-Premise
113	)	N	I-Premise
114	.	N	I-Premise

1	Although	N	I-Premise
2	other	N	I-Premise
3	group	N	I-Premise
4	×	N	I-Premise
5	time	N	I-Premise
6	interactions	N	I-Premise
7	were	N	I-Premise
8	not	N	I-Premise
9	significant	N	I-Premise
10	,	N	I-Premise
11	overall	N	I-Premise
12	adjusted	N	I-Premise
13	effect	N	I-Premise
14	sizes	N	I-Premise
15	for	N	I-Premise
16	all	N	I-Premise
17	sleep	N	I-Premise
18	variables	N	I-Premise
19	as	N	I-Premise
20	well	N	I-Premise
21	as	N	I-Premise
22	for	N	I-Premise
23	fatigue	N	I-Premise
24	,	N	I-Premise
25	depression	N	I-Premise
26	,	N	I-Premise
27	anxiety	N	I-Premise
28	,	N	I-Premise
29	and	N	I-Premise
30	quality	N	I-Premise
31	of	N	I-Premise
32	life	N	I-Premise
33	ranged	N	I-Premise
34	from	N	I-Premise
35	small	N	I-Premise
36	to	N	I-Premise
37	large	N	I-Premise
38	.	N	I-Premise

1	CBT-I	N	I-Claim
2	delivered	N	I-Claim
3	through	N	I-Claim
4	an	N	I-Claim
5	interactive	N	I-Claim
6	,	N	I-Claim
7	individually	N	I-Claim
8	tailored	N	I-Claim
9	Internet	N	I-Claim
10	intervention	N	I-Claim
11	may	N	I-Claim
12	be	N	I-Claim
13	a	N	I-Claim
14	viable	N	I-Claim
15	treatment	N	I-Claim
16	option	N	I-Claim
17	for	N	I-Claim
18	cancer	N	I-Claim
19	survivors	N	I-Claim
20	experiencing	N	I-Claim
21	insomnia	N	I-Claim
22	.	N	I-Claim

1	A	N	O
2	randomised	N	O
3	controlled	N	O
4	trial	N	O
5	(	N	O
6	RCT	N	O
7	)	N	O
8	demonstrated	N	O
9	that	N	O
10	cognitive	N	O
11	behaviour	N	O
12	therapy	N	O
13	(	N	O
14	CBT	N	O
15	)	N	O
16	for	N	O
17	fatigue	N	O
18	during	N	O
19	curative	N	O
20	cancer	N	O
21	treatment	N	O
22	was	N	O
23	effective	N	O
24	shortly	N	O
25	after	N	O
26	cancer	N	O
27	treatment	N	O
28	.	N	O

1	This	N	O
2	study	N	O
3	aimed	N	O
4	to	N	O
5	identify	N	O
6	which	N	O
7	patient	N	O
8	characteristics	N	O
9	predict	N	O
10	fatigue	N	O
11	improvement	N	O
12	after	N	O
13	CBT	N	O
14	.	N	O

1	In	N	O
2	addition	N	O
3	,	N	O
4	the	N	O
5	long-term	N	O
6	effectiveness	N	O
7	was	N	O
8	investigated	N	O
9	.	N	O

1	Patients	N	O
2	with	N	O
3	various	N	O
4	malignancies	N	O
5	participated	N	O
6	in	N	O
7	the	N	O
8	RCT	N	O
9	(	N	O
10	n	N	O
11	=	N	O
12	210	N	O
13	)	N	O
14	.	N	O

1	Participants	N	O
2	were	N	O
3	assessed	N	O
4	before	N	O
5	cancer	N	O
6	treatment	N	O
7	(	N	O
8	T1	N	O
9	)	N	O
10	,	N	O
11	postintervention	N	O
12	(	N	O
13	T2	N	O
14	)	N	O
15	,	N	O
16	which	N	O
17	was	N	O
18	at	N	O
19	least	N	O
20	2	N	O
21	months	N	O
22	after	N	O
23	cancer	N	O
24	treatment	N	O
25	,	N	O
26	and	N	O
27	after	N	O
28	1-year	N	O
29	follow-up	N	O
30	(	N	O
31	T3	N	O
32	)	N	O
33	.	N	O

1	Monthly	N	O
2	fatigue	N	O
3	assessments	N	O
4	were	N	O
5	completed	N	O
6	between	N	O
7	T2	N	O
8	and	N	O
9	T3	N	O
10	.	N	O

1	A	N	O
2	regression	N	O
3	analysis	N	O
4	with	N	O
5	interactions	N	O
6	was	N	O
7	performed	N	O
8	to	N	O
9	determine	N	O
10	if	N	O
11	domains	N	O
12	of	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	(	N	O
17	EORTC-QLQ-C30	N	O
18	)	N	O
19	functioning	N	O
20	(	N	O
21	Health	N	O
22	Survey	N	O
23	Short	N	O
24	Form-36	N	O
25	)	N	O
26	or	N	O
27	psychological	N	O
28	distress	N	O
29	(	N	O
30	Symptom	N	O
31	Checklist-90	N	O
32	)	N	O
33	moderated	N	O
34	the	N	O
35	effect	N	O
36	of	N	O
37	CBT	N	O
38	on	N	O
39	fatigue	N	O
40	.	N	O

1	Analyses	N	O
2	of	N	O
3	covariance	N	O
4	were	N	O
5	used	N	O
6	to	N	O
7	study	N	O
8	the	N	O
9	long-term	N	O
10	effectiveness	N	O
11	of	N	O
12	CBT	N	O
13	.	N	O

1	Fatigue	N	I-Premise
2	at	N	I-Premise
3	T2	N	I-Premise
4	was	N	I-Premise
5	predicted	N	I-Premise
6	by	N	I-Premise
7	a	N	I-Premise
8	significant	N	I-Premise
9	interaction	N	I-Premise
10	between	N	I-Premise
11	self-reported	N	I-Premise
12	cognitive	N	I-Premise
13	functioning	N	I-Premise
14	and	N	I-Premise
15	CBT	N	I-Premise
16	.	N	I-Premise

1	No	N	I-Premise
2	interactions	N	I-Premise
3	were	N	I-Premise
4	found	N	I-Premise
5	between	N	I-Premise
6	other	N	I-Premise
7	domains	N	I-Premise
8	of	N	I-Premise
9	quality	N	I-Premise
10	of	N	I-Premise
11	life	N	I-Premise
12	,	N	I-Premise
13	functioning	N	I-Premise
14	,	N	I-Premise
15	psychological	N	I-Premise
16	distress	N	I-Premise
17	and	N	I-Premise
18	CBT	N	I-Premise
19	.	N	I-Premise

1	At	N	I-Premise
2	T3	N	I-Premise
3	,	N	I-Premise
4	no	N	I-Premise
5	significant	N	I-Premise
6	difference	N	I-Premise
7	on	N	I-Premise
8	fatigue	N	I-Premise
9	was	N	I-Premise
10	found	N	I-Premise
11	between	N	I-Premise
12	CBT	N	I-Premise
13	and	N	I-Premise
14	usual	N	I-Premise
15	care	N	I-Premise
16	.	N	I-Premise

1	Exploratory	N	I-Premise
2	analyses	N	I-Premise
3	showed	N	I-Premise
4	that	N	I-Premise
5	the	N	I-Premise
6	difference	N	I-Premise
7	nearly	N	I-Premise
8	reached	N	I-Premise
9	significance	N	I-Premise
10	until	N	I-Premise
11	7	N	I-Premise
12	months	N	I-Premise
13	postintervention	N	I-Premise
14	.	N	I-Premise

1	Patients	N	I-Premise
2	who	N	I-Premise
3	experienced	N	I-Premise
4	more	N	I-Premise
5	concentration	N	I-Premise
6	and	N	I-Premise
7	memory	N	I-Premise
8	problems	N	I-Premise
9	at	N	I-Premise
10	T1	N	I-Premise
11	benefited	N	I-Premise
12	more	N	I-Premise
13	from	N	I-Premise
14	CBT	N	I-Premise
15	for	N	I-Premise
16	fatigue	N	I-Premise
17	and	N	I-Premise
18	are	N	I-Premise
19	indicators	N	I-Premise
20	.	N	I-Premise

1	After	N	I-Premise
2	a	N	I-Premise
3	year	N	I-Premise
4	of	N	I-Premise
5	follow-up	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	effect	N	I-Premise
9	of	N	I-Premise
10	CBT	N	I-Premise
11	for	N	I-Premise
12	fatigue	N	I-Premise
13	was	N	I-Premise
14	no	N	I-Premise
15	longer	N	I-Premise
16	observed	N	I-Premise
17	,	N	I-Premise
18	and	N	I-Premise
19	the	N	I-Premise
20	effect	N	I-Premise
21	on	N	I-Premise
22	fatigue	N	I-Premise
23	seemed	N	I-Premise
24	to	N	I-Premise
25	be	N	I-Premise
26	diminished	N	I-Premise
27	7	N	I-Premise
28	months	N	I-Premise
29	postintervention	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Claim
2	implication	N	I-Claim
3	is	N	I-Claim
4	that	N	I-Claim
5	CBT	N	I-Claim
6	for	N	I-Claim
7	fatigue	N	I-Claim
8	should	N	I-Claim
9	be	N	I-Claim
10	offered	N	I-Claim
11	to	N	I-Claim
12	patients	N	I-Claim
13	with	N	I-Claim
14	cancer	N	I-Claim
15	with	N	I-Claim
16	the	N	I-Claim
17	highest	N	I-Claim
18	chance	N	I-Claim
19	to	N	I-Claim
20	benefit	N	I-Claim
21	.	N	I-Claim

1	To	N	O
2	analyze	N	O
3	the	N	O
4	predictive	N	O
5	value	N	O
6	of	N	O
7	PSA	N	O
8	for	N	O
9	progression	N	O
10	and	N	O
11	the	N	O
12	role	N	O
13	of	N	O
14	testosterone	N	O
15	for	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	QOL	N	O
21	)	N	O
22	in	N	O
23	patients	N	O
24	with	N	O
25	androgen	N	O
26	deprivation	N	O
27	therapy	N	O
28	(	N	O
29	ADT	N	O
30	)	N	O
31	for	N	O
32	metastatic	N	O
33	prostate	N	O
34	cancer	N	O
35	.	N	O

1	PSA	N	O
2	and	N	O
3	testosterone	N	O
4	data	N	O
5	were	N	O
6	used	N	O
7	from	N	O
8	a	N	O
9	phase	N	O
10	III	N	O
11	trial	N	O
12	randomizing	N	O
13	patients	N	O
14	without	N	O
15	progression	N	O
16	and	N	O
17	PSA	N	O
18	<	N	O
19	4	N	O
20	ng/ml	N	O
21	(	N	O
22	n	N	O
23	=	N	O
24	193	N	O
25	)	N	O
26	,	N	O
27	after	N	O
28	6	N	O
29	months	N	O
30	induction	N	O
31	course	N	O
32	,	N	O
33	between	N	O
34	continuous	N	O
35	(	N	O
36	CAD	N	O
37	)	N	O
38	(	N	O
39	n	N	O
40	=	N	O
41	96	N	O
42	)	N	O
43	and	N	O
44	intermittent	N	O
45	(	N	O
46	IAD	N	O
47	)	N	O
48	(	N	O
49	n	N	O
50	=	N	O
51	97	N	O
52	)	N	O
53	ADT	N	O
54	.	N	O

1	The	N	O
2	2-year	N	O
3	risk	N	O
4	of	N	O
5	progression	N	O
6	was	N	O
7	calculated	N	O
8	for	N	O
9	baseline	N	O
10	PSA	N	O
11	,	N	O
12	'fast	N	O
13	'	N	O
14	and	N	O
15	'slow	N	O
16	'	N	O
17	PSA	N	O
18	decline	N	O
19	to	N	O
20	<	N	O
21	4	N	O
22	ng/ml	N	O
23	(	N	O
24	60	N	O
25	days	N	O
26	cut-off	N	O
27	)	N	O
28	,	N	O
29	PSA	N	O
30	nadir	N	O
31	,	N	O
32	performance	N	O
33	status	N	O
34	and	N	O
35	pain	N	O
36	.	N	O

1	Testosterone	N	O
2	kinetics	N	O
3	and	N	O
4	QOL	N	O
5	were	N	O
6	also	N	O
7	evaluated	N	O
8	.	N	O

1	Univariate	N	O
2	Kaplan	N	O
3	Meier	N	O
4	survival	N	O
5	analysis	N	O
6	and	N	O
7	log	N	O
8	rank	N	O
9	tests	N	O
10	were	N	O
11	used	N	O
12	to	N	O
13	compare	N	O
14	the	N	O
15	risk	N	O
16	of	N	O
17	progression	N	O
18	.	N	O

1	For	N	O
2	progression	N	O
3	analysis	N	O
4	,	N	O
5	173	N	O
6	patients	N	O
7	'	N	O
8	data	N	O
9	were	N	O
10	available	N	O
11	.	N	O

1	The	N	O
2	2-year	N	O
3	risk	N	O
4	of	N	O
5	progression	N	O
6	for	N	O
7	baseline	N	O
8	PSA	N	O
9	<	N	O
10	50	N	O
11	ng/ml	N	O
12	,	N	O
13	50	N	O
14	to	N	O
15	<	N	O
16	500	N	O
17	ng/ml	N	O
18	,	N	O
19	and	N	O
20	≥	N	O
21	500	N	O
22	ng/ml	N	O
23	was	N	O
24	25	N	O
25	%	N	O
26	,	N	O
27	55	N	O
28	%	N	O
29	,	N	O
30	and	N	O
31	76	N	O
32	%	N	O
33	(	N	O
34	P	N	O
35	=	N	O
36	0.03	N	O
37	)	N	O
38	in	N	O
39	CAD	N	O
40	,	N	O
41	and	N	O
42	38	N	O
43	%	N	O
44	,	N	O
45	64	N	O
46	%	N	O
47	,	N	O
48	and	N	O
49	85	N	O
50	%	N	O
51	(	N	O
52	P	N	O
53	=	N	O
54	0.006	N	O
55	)	N	O
56	in	N	O
57	IAD	N	O
58	,	N	O
59	respectively	N	O
60	.	N	O

1	The	N	I-Premise
2	2-year	N	I-Premise
3	risk	N	I-Premise
4	of	N	I-Premise
5	progression	N	I-Premise
6	for	N	I-Premise
7	PSA	N	I-Premise
8	nadir	N	I-Premise
9	≤	N	I-Premise
10	0.2	N	I-Premise
11	ng/ml	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	>	N	I-Premise
15	0.2	N	I-Premise
16	to	N	I-Premise
17	4	N	I-Premise
18	ng/ml	N	I-Premise
19	in	N	I-Premise
20	CAD	N	I-Premise
21	was	N	I-Premise
22	31	N	I-Premise
23	%	N	I-Premise
24	and	N	I-Premise
25	70	N	I-Premise
26	%	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	0.001	N	I-Premise
31	)	N	I-Premise
32	,	N	I-Premise
33	respectively	N	I-Premise
34	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	IAD	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	a	N	I-Premise
7	similar	N	I-Premise
8	trend	N	I-Premise
9	was	N	I-Premise
10	seen	N	I-Premise
11	.	N	I-Premise

1	Patients	N	I-Premise
2	with	N	I-Premise
3	PSA	N	I-Premise
4	nadir	N	I-Premise
5	≤	N	I-Premise
6	0.2	N	I-Premise
7	ng/ml	N	I-Premise
8	,	N	I-Premise
9	though	N	I-Premise
10	had	N	I-Premise
11	significantly	N	I-Premise
12	higher	N	I-Premise
13	2-year	N	I-Premise
14	risk	N	I-Premise
15	of	N	I-Premise
16	progression	N	I-Premise
17	compared	N	I-Premise
18	to	N	I-Premise
19	CAD	N	I-Premise
20	(	N	I-Premise
21	53	N	I-Premise
22	%	N	I-Premise
23	vs.	N	I-Premise
24	31	N	I-Premise
25	%	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	=	N	I-Premise
29	0.03	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	respectively	N	I-Premise
33	.	N	I-Premise

1	PSA	N	O
2	decline	N	O
3	showed	N	O
4	no	N	O
5	predictive	N	O
6	value	N	O
7	.	N	O

1	Patients	N	I-Premise
2	without	N	I-Premise
3	pain	N	I-Premise
4	had	N	I-Premise
5	a	N	I-Premise
6	significantly	N	I-Premise
7	lower	N	I-Premise
8	2-year	N	I-Premise
9	risk	N	I-Premise
10	of	N	I-Premise
11	progression	N	I-Premise
12	in	N	I-Premise
13	both	N	I-Premise
14	groups	N	I-Premise
15	.	N	I-Premise

1	Without	N	I-Premise
2	ADT	N	I-Premise
3	testosterone	N	I-Premise
4	remained	N	I-Premise
5	at	N	I-Premise
6	castrate	N	I-Premise
7	level	N	I-Premise
8	for	N	I-Premise
9	4	N	I-Premise
10	months	N	I-Premise
11	.	N	I-Premise

1	After	N	O
2	the	N	O
3	first	N	O
4	and	N	O
5	second	N	O
6	IAD	N	O
7	cycle	N	O
8	92	N	O
9	%	N	O
10	and	N	O
11	46	N	O
12	%	N	O
13	,	N	O
14	respectively	N	O
15	,	N	O
16	had	N	O
17	a	N	O
18	normalized	N	O
19	testosterone	N	O
20	.	N	O

1	No	N	I-Premise
2	QOL	N	I-Premise
3	difference	N	I-Premise
4	was	N	I-Premise
5	found	N	I-Premise
6	,	N	I-Premise
7	although	N	I-Premise
8	more	N	I-Premise
9	side	N	I-Premise
10	effects	N	I-Premise
11	occurred	N	I-Premise
12	in	N	I-Premise
13	CAD	N	I-Premise
14	.	N	I-Premise

1	Metastatic	N	I-Claim
2	prostate	N	I-Claim
3	cancer	N	I-Claim
4	patients	N	I-Claim
5	with	N	I-Claim
6	high	N	I-Claim
7	baseline	N	I-Claim
8	PSA	N	I-Claim
9	,	N	I-Claim
10	pain	N	I-Claim
11	,	N	I-Claim
12	and	N	I-Claim
13	high	N	I-Claim
14	PSA	N	I-Claim
15	nadir	N	I-Claim
16	have	N	I-Claim
17	a	N	I-Claim
18	poor	N	I-Claim
19	prognosis	N	I-Claim
20	with	N	I-Claim
21	ADT	N	I-Claim
22	.	N	I-Claim

1	Patients	N	I-Claim
2	with	N	I-Claim
3	low	N	I-Claim
4	PSA	N	I-Claim
5	nadir	N	I-Claim
6	do	N	I-Claim
7	significantly	N	I-Claim
8	worse	N	I-Claim
9	with	N	I-Claim
10	IAD	N	I-Claim
11	compared	N	I-Claim
12	with	N	I-Claim
13	CAD	N	I-Claim
14	.	N	I-Claim

1	Low	N	O
2	testosterone	N	O
3	after	N	O
4	ADT	N	O
5	and	N	O
6	incomplete	N	O
7	testosterone	N	O
8	recovery	N	O
9	may	N	O
10	explain	N	O
11	similar	N	O
12	QOL	N	O
13	.	N	O

1	Therefore	N	O
2	,	N	O
3	IAD	N	I-Claim
4	is	N	I-Claim
5	not	N	I-Claim
6	a	N	I-Claim
7	good	N	I-Claim
8	treatment	N	I-Claim
9	option	N	I-Claim
10	for	N	I-Claim
11	many	N	I-Claim
12	metastatic	N	I-Claim
13	prostate	N	I-Claim
14	cancer	N	I-Claim
15	patients	N	I-Claim
16	.	N	I-Claim

1	This	N	O
2	randomised	N	O
3	non-inferiority	N	O
4	trial	N	O
5	was	N	O
6	designed	N	O
7	to	N	O
8	assess	N	O
9	whether	N	O
10	radiosurgery	N	O
11	plus	N	O
12	adjuvant	N	O
13	whole	N	O
14	brain	N	O
15	radiotherapy	N	O
16	(	N	O
17	RS	N	O
18	+	N	O
19	WBRT	N	O
20	)	N	O
21	is	N	O
22	as	N	O
23	effective	N	O
24	as	N	O
25	surgery	N	O
26	plus	N	O
27	whole	N	O
28	brain	N	O
29	radiotherapy	N	O
30	(	N	O
31	S	N	O
32	+	N	O
33	WBRT	N	O
34	)	N	O
35	for	N	O
36	cancer	N	O
37	patients	N	O
38	with	N	O
39	a	N	O
40	solitary	N	O
41	brain	N	O
42	metastasis	N	O
43	,	N	O
44	with	N	O
45	respect	N	O
46	to	N	O
47	overall	N	O
48	survival	N	O
49	and	N	O
50	quality	N	O
51	of	N	O
52	life	N	O
53	.	N	O

1	Major	N	O
2	inclusion	N	O
3	criteria	N	O
4	were	N	O
5	a	N	O
6	history	N	O
7	of	N	O
8	systemic	N	O
9	cancer	N	O
10	within	N	O
11	5	N	O
12	years	N	O
13	and	N	O
14	enhanced	N	O
15	magnetic	N	O
16	resonance	N	O
17	imaging-confirmed	N	O
18	solitary	N	O
19	brain	N	O
20	metastasis	N	O
21	suitable	N	O
22	for	N	O
23	both	N	O
24	radiosurgery	N	O
25	and	N	O
26	surgery	N	O
27	.	N	O

1	All	N	O
2	patients	N	O
3	were	N	O
4	to	N	O
5	receive	N	O
6	WBRT	N	O
7	(	N	O
8	30	N	O
9	Gy	N	O
10	in	N	O
11	10	N	O
12	fractions	N	O
13	)	N	O
14	.	N	O

1	Between	N	O
2	February	N	O
3	2003	N	O
4	and	N	O
5	April	N	O
6	2009	N	O
7	,	N	O
8	40	N	O
9	patients	N	O
10	were	N	O
11	considered	N	O
12	eligible	N	O
13	,	N	O
14	22	N	O
15	consented	N	O
16	to	N	O
17	randomisation	N	O
18	and	N	O
19	21	N	O
20	were	N	O
21	analysed	N	O
22	(	N	O
23	11	N	O
24	RS	N	O
25	+	N	O
26	WBRT	N	O
27	,	N	O
28	10	N	O
29	S	N	O
30	+	N	O
31	WBRT	N	O
32	)	N	O
33	.	N	O

1	The	N	O
2	trial	N	O
3	was	N	O
4	closed	N	O
5	early	N	O
6	due	N	O
7	to	N	O
8	slow	N	O
9	accrual	N	O
10	.	N	O

1	The	N	I-Premise
2	estimated	N	I-Premise
3	median	N	I-Premise
4	overall	N	I-Premise
5	survival	N	I-Premise
6	times	N	I-Premise
7	for	N	I-Premise
8	RS	N	I-Premise
9	+	N	I-Premise
10	WBRT	N	I-Premise
11	and	N	I-Premise
12	S	N	I-Premise
13	+	N	I-Premise
14	WBRT	N	I-Premise
15	patients	N	I-Premise
16	were	N	I-Premise
17	6.2	N	I-Premise
18	and	N	I-Premise
19	2.8	N	I-Premise
20	months	N	I-Premise
21	,	N	I-Premise
22	respectively	N	I-Premise
23	(	N	I-Premise
24	hazard	N	I-Premise
25	ratio	N	I-Premise
26	0.53	N	I-Premise
27	,	N	I-Premise
28	95	N	I-Premise
29	%	N	I-Premise
30	confidence	N	I-Premise
31	interval	N	I-Premise
32	0.20-1.43	N	I-Premise
33	,	N	I-Premise
34	P	N	I-Premise
35	=	N	I-Premise
36	0.20	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	Corresponding	N	I-Premise
2	median	N	I-Premise
3	failure-free	N	I-Premise
4	survival	N	I-Premise
5	times	N	I-Premise
6	were	N	I-Premise
7	3.1	N	I-Premise
8	and	N	I-Premise
9	1.7	N	I-Premise
10	months	N	I-Premise
11	(	N	I-Premise
12	P	N	I-Premise
13	=	N	I-Premise
14	0.20	N	I-Premise
15	)	N	I-Premise
16	.	N	I-Premise

1	For	N	I-Premise
2	19	N	I-Premise
3	'per	N	I-Premise
4	protocol	N	I-Premise
5	'	N	I-Premise
6	patients	N	I-Premise
7	,	N	I-Premise
8	2/10	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	RS	N	I-Premise
12	+	N	I-Premise
13	WBRT	N	I-Premise
14	arm	N	I-Premise
15	had	N	I-Premise
16	distant	N	I-Premise
17	intracranial	N	I-Premise
18	failure	N	I-Premise
19	(	N	I-Premise
20	one	N	I-Premise
21	also	N	I-Premise
22	had	N	I-Premise
23	local	N	I-Premise
24	failure	N	I-Premise
25	)	N	I-Premise
26	and	N	I-Premise
27	3/9	N	I-Premise
28	S	N	I-Premise
29	+	N	I-Premise
30	WBRT	N	I-Premise
31	patients	N	I-Premise
32	had	N	I-Premise
33	distant	N	I-Premise
34	intracranial	N	I-Premise
35	failure	N	I-Premise
36	(	N	I-Premise
37	no	N	I-Premise
38	local	N	I-Premise
39	failures	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	grade	N	I-Premise
5	3-4	N	I-Premise
6	late	N	I-Premise
7	radiation	N	I-Premise
8	toxicities	N	I-Premise
9	.	N	I-Premise

1	Two	N	I-Claim
2	months	N	I-Claim
3	after	N	I-Claim
4	starting	N	I-Claim
5	treatment	N	I-Claim
6	there	N	I-Claim
7	were	N	I-Claim
8	no	N	I-Claim
9	significant	N	I-Claim
10	differences	N	I-Claim
11	in	N	I-Claim
12	quality	N	I-Claim
13	of	N	I-Claim
14	life	N	I-Claim
15	between	N	I-Claim
16	the	N	I-Claim
17	arms	N	I-Claim
18	.	N	I-Claim

1	This	N	I-Claim
2	randomised	N	I-Claim
3	trial	N	I-Claim
4	encountered	N	I-Claim
5	the	N	I-Claim
6	accrual	N	I-Claim
7	difficulties	N	I-Claim
8	and	N	I-Claim
9	consequent	N	I-Claim
10	low	N	I-Claim
11	statistical	N	I-Claim
12	power	N	I-Claim
13	commonly	N	I-Claim
14	associated	N	I-Claim
15	with	N	I-Claim
16	interdisciplinary	N	I-Claim
17	studies	N	I-Claim
18	drawing	N	I-Claim
19	from	N	I-Claim
20	a	N	I-Claim
21	small	N	I-Claim
22	eligible	N	I-Claim
23	population	N	I-Claim
24	,	N	I-Claim
25	but	N	O
26	can	N	O
27	contribute	N	O
28	to	N	O
29	future	N	O
30	overviews	N	O
31	on	N	O
32	the	N	O
33	management	N	O
34	of	N	O
35	solitary	N	O
36	brain	N	O
37	metastases	N	O
38	.	N	O

1	Regularly	N	O
2	collecting	N	O
3	patient-reported	N	O
4	outcomes	N	O
5	(	N	O
6	PROs	N	O
7	)	N	O
8	of	N	O
9	health-related	N	O
10	quality	N	O
11	of	N	O
12	life	N	O
13	with	N	O
14	feedback	N	O
15	to	N	O
16	oncologists	N	O
17	may	N	O
18	assist	N	O
19	in	N	O
20	eliciting	N	O
21	and	N	O
22	monitoring	N	O
23	patients	N	O
24	'	N	O
25	problems	N	O
26	during	N	O
27	cancer	N	O
28	treatment	N	O
29	.	N	O

1	This	N	O
2	study	N	O
3	examined	N	O
4	how	N	O
5	PRO	N	O
6	feedback	N	O
7	had	N	O
8	an	N	O
9	impact	N	O
10	on	N	O
11	patient-physician	N	O
12	communication	N	O
13	over	N	O
14	time	N	O
15	to	N	O
16	gain	N	O
17	a	N	O
18	better	N	O
19	understanding	N	O
20	of	N	O
21	how	N	O
22	it	N	O
23	may	N	O
24	influence	N	O
25	patient	N	O
26	care	N	O
27	.	N	O

1	Exploratory	N	O
2	analyses	N	O
3	were	N	O
4	performed	N	O
5	on	N	O
6	a	N	O
7	data	N	O
8	set	N	O
9	from	N	O
10	a	N	O
11	previous	N	O
12	study	N	O
13	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	intervention	N	O
7	(	N	O
8	regular	N	O
9	completion	N	O
10	of	N	O
11	European	N	O
12	Organisation	N	O
13	for	N	O
14	Research	N	O
15	and	N	O
16	Treatment	N	O
17	of	N	O
18	Cancer	N	O
19	Quality	N	O
20	of	N	O
21	Life	N	O
22	Questionnaire-Core	N	O
23	30	N	O
24	and	N	O
25	Hospital	N	O
26	Anxiety	N	O
27	and	N	O
28	Depression	N	O
29	Scale	N	O
30	with	N	O
31	feedback	N	O
32	to	N	O
33	oncologists	N	O
34	)	N	O
35	,	N	O
36	attention-control	N	O
37	(	N	O
38	completion	N	O
39	of	N	O
40	same	N	O
41	questionnaires	N	O
42	without	N	O
43	feedback	N	O
44	)	N	O
45	,	N	O
46	and	N	O
47	control	N	O
48	(	N	O
49	standard	N	O
50	care	N	O
51	)	N	O
52	arms	N	O
53	.	N	O

1	The	N	O
2	content	N	O
3	of	N	O
4	consultation	N	O
5	audio	N	O
6	recordings	N	O
7	between	N	O
8	28	N	O
9	oncologists	N	O
10	and	N	O
11	198	N	O
12	patients	N	O
13	over	N	O
14	four	N	O
15	consecutive	N	O
16	visits	N	O
17	(	N	O
18	792	N	O
19	consultations	N	O
20	)	N	O
21	was	N	O
22	analyzed	N	O
23	.	N	O

1	Mixed-effects	N	O
2	models	N	O
3	and	N	O
4	multivariate	N	O
5	regressions	N	O
6	were	N	O
7	used	N	O
8	to	N	O
9	examine	N	O
10	the	N	O
11	longitudinal	N	O
12	impact	N	O
13	of	N	O
14	the	N	O
15	intervention	N	O
16	on	N	O
17	patient-physician	N	O
18	communication	N	O
19	,	N	O
20	dynamics	N	O
21	of	N	O
22	patient-physician	N	O
23	interaction	N	O
24	,	N	O
25	and	N	O
26	the	N	O
27	association	N	O
28	between	N	O
29	PROs	N	O
30	and	N	O
31	the	N	O
32	content	N	O
33	of	N	O
34	clinic	N	O
35	discussion	N	O
36	.	N	O

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	intervention	N	I-Premise
5	arm	N	I-Premise
6	discussed	N	I-Premise
7	more	N	I-Premise
8	symptoms	N	I-Premise
9	over	N	I-Premise
10	time	N	I-Premise
11	compared	N	I-Premise
12	with	N	I-Premise
13	patients	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	attention-control	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	.008	N	I-Premise
21	)	N	I-Premise
22	and	N	I-Premise
23	control	N	I-Premise
24	(	N	I-Premise
25	P	N	I-Premise
26	=	N	I-Premise
27	.04	N	I-Premise
28	)	N	I-Premise
29	arms	N	I-Premise
30	.	N	I-Premise

1	No	N	I-Premise
2	study	N	I-Premise
3	arm	N	I-Premise
4	effect	N	I-Premise
5	was	N	I-Premise
6	observed	N	I-Premise
7	for	N	I-Premise
8	function	N	I-Premise
9	discussions	N	I-Premise
10	.	N	I-Premise

1	Discussion	N	O
2	topics	N	O
3	were	N	O
4	predominantly	N	O
5	raised	N	O
6	by	N	O
7	patients/relatives	N	O
8	,	N	O
9	regardless	N	O
10	of	N	O
11	arm	N	O
12	allocation	N	O
13	.	N	O

1	Clinic	N	I-Premise
2	discussions	N	I-Premise
3	were	N	I-Premise
4	associated	N	I-Premise
5	with	N	I-Premise
6	severity	N	I-Premise
7	of	N	I-Premise
8	patient-reported	N	I-Premise
9	symptoms	N	I-Premise
10	but	N	I-Premise
11	not	N	I-Premise
12	with	N	I-Premise
13	patient-reported	N	I-Premise
14	functional	N	I-Premise
15	concerns	N	I-Premise
16	.	N	I-Premise

1	A	N	I-Premise
2	positive	N	I-Premise
3	longitudinal	N	I-Premise
4	impact	N	I-Premise
5	of	N	I-Premise
6	the	N	I-Premise
7	intervention	N	I-Premise
8	on	N	I-Premise
9	symptom	N	I-Premise
10	discussion	N	I-Premise
11	was	N	I-Premise
12	observed	N	I-Premise
13	,	N	I-Premise
14	but	N	I-Premise
15	not	N	I-Premise
16	for	N	I-Premise
17	function	N	I-Premise
18	discussion	N	I-Premise
19	,	N	I-Premise
20	suggesting	N	I-Premise
21	that	N	I-Premise
22	potentially	N	I-Premise
23	serious	N	I-Premise
24	problems	N	I-Premise
25	may	N	I-Premise
26	remain	N	I-Premise
27	unaddressed	N	I-Premise
28	.	N	I-Premise

1	Training	N	I-Claim
2	oncologists	N	I-Claim
3	in	N	I-Claim
4	responding	N	I-Claim
5	to	N	I-Claim
6	patient-reported	N	I-Claim
7	functional	N	I-Claim
8	concerns	N	I-Claim
9	may	N	I-Claim
10	increase	N	I-Claim
11	the	N	I-Claim
12	impact	N	I-Claim
13	of	N	I-Claim
14	this	N	I-Claim
15	intervention	N	I-Claim
16	.	N	I-Claim

1	This	N	O
2	phase	N	O
3	III	N	O
4	trial	N	O
5	was	N	O
6	conducted	N	O
7	to	N	O
8	test	N	O
9	whether	N	O
10	the	N	O
11	novel	N	O
12	vascular	N	O
13	disrupting	N	O
14	agent	N	O
15	ASA404	N	O
16	(	N	O
17	vadimezan	N	O
18	)	N	O
19	,	N	O
20	when	N	O
21	combined	N	O
22	with	N	O
23	first-line	N	O
24	platinum-based	N	O
25	chemotherapy	N	O
26	,	N	O
27	improves	N	O
28	survival	N	O
29	in	N	O
30	patients	N	O
31	with	N	O
32	advanced	N	O
33	non-small-cell	N	O
34	lung	N	O
35	cancer	N	O
36	(	N	O
37	NSCLC	N	O
38	)	N	O
39	versus	N	O
40	chemotherapy	N	O
41	alone	N	O
42	.	N	O

1	Patients	N	O
2	with	N	O
3	advanced	N	O
4	stage	N	O
5	IIIB	N	O
6	or	N	O
7	IV	N	O
8	NSCLC	N	O
9	,	N	O
10	stratified	N	O
11	by	N	O
12	sex	N	O
13	and	N	O
14	tumor	N	O
15	histology	N	O
16	,	N	O
17	were	N	O
18	randomly	N	O
19	assigned	N	O
20	1:1	N	O
21	to	N	O
22	paclitaxel	N	O
23	(	N	O
24	200	N	O
25	mg/m	N	O
26	(	N	O
27	2	N	O
28	)	N	O
29	)	N	O
30	and	N	O
31	carboplatin	N	O
32	(	N	O
33	area	N	O
34	under	N	O
35	the	N	O
36	curve	N	O
37	,	N	O
38	6.0	N	O
39	)	N	O
40	with	N	O
41	or	N	O
42	without	N	O
43	ASA404	N	O
44	(	N	O
45	1,800	N	O
46	mg	N	O
47	m	N	O
48	(	N	O
49	2	N	O
50	)	N	O
51	)	N	O
52	,	N	O
53	given	N	O
54	intravenously	N	O
55	once	N	O
56	every	N	O
57	3	N	O
58	weeks	N	O
59	for	N	O
60	six	N	O
61	cycles	N	O
62	followed	N	O
63	by	N	O
64	maintenance	N	O
65	ASA404	N	O
66	or	N	O
67	placebo	N	O
68	.	N	O

1	Primary	N	O
2	end	N	O
3	point	N	O
4	was	N	O
5	overall	N	O
6	survival	N	O
7	(	N	O
8	OS	N	O
9	)	N	O
10	;	N	O
11	secondary	N	O
12	end	N	O
13	points	N	O
14	included	N	O
15	overall	N	O
16	response	N	O
17	rate	N	O
18	(	N	O
19	ORR	N	O
20	)	N	O
21	and	N	O
22	progression-free	N	O
23	survival	N	O
24	(	N	O
25	PFS	N	O
26	)	N	O
27	.	N	O

1	One	N	O
2	thousand	N	O
3	two	N	O
4	hundred	N	O
5	ninety-nine	N	O
6	patients	N	O
7	were	N	O
8	randomly	N	O
9	assigned	N	O
10	.	N	O

1	The	N	O
2	trial	N	O
3	was	N	O
4	stopped	N	O
5	for	N	O
6	futility	N	O
7	at	N	O
8	interim	N	O
9	analysis	N	O
10	.	N	O

1	At	N	O
2	final	N	O
3	analysis	N	O
4	,	N	O
5	there	N	I-Premise
6	was	N	I-Premise
7	no	N	I-Premise
8	difference	N	I-Premise
9	in	N	I-Premise
10	OS	N	I-Premise
11	seen	N	I-Premise
12	between	N	I-Premise
13	ASA404	N	I-Premise
14	(	N	I-Premise
15	n	N	I-Premise
16	=	N	I-Premise
17	649	N	I-Premise
18	)	N	I-Premise
19	and	N	I-Premise
20	placebo	N	I-Premise
21	(	N	I-Premise
22	n	N	I-Premise
23	=	N	I-Premise
24	650	N	I-Premise
25	)	N	I-Premise
26	arms	N	I-Premise
27	:	N	I-Premise
28	median	N	I-Premise
29	OS	N	I-Premise
30	was	N	I-Premise
31	13.4	N	I-Premise
32	and	N	I-Premise
33	12.7	N	I-Premise
34	months	N	I-Premise
35	respectively	N	I-Premise
36	(	N	I-Premise
37	hazard	N	I-Premise
38	ratio	N	I-Premise
39	[	N	I-Premise
40	HR	N	I-Premise
41	]	N	I-Premise
42	,	N	I-Premise
43	1.01	N	I-Premise
44	;	N	I-Premise
45	95	N	I-Premise
46	%	N	I-Premise
47	CI	N	I-Premise
48	,	N	I-Premise
49	0.85	N	I-Premise
50	to	N	I-Premise
51	1.19	N	I-Premise
52	;	N	I-Premise
53	P	N	I-Premise
54	=	N	I-Premise
55	.535	N	I-Premise
56	)	N	I-Premise
57	.	N	I-Premise

1	Similarly	N	O
2	,	N	O
3	no	N	I-Premise
4	OS	N	I-Premise
5	difference	N	I-Premise
6	was	N	I-Premise
7	seen	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	histologic	N	I-Premise
11	(	N	I-Premise
12	squamous	N	I-Premise
13	or	N	I-Premise
14	nonsquamous	N	I-Premise
15	)	N	I-Premise
16	and	N	I-Premise
17	sex	N	I-Premise
18	(	N	I-Premise
19	male	N	I-Premise
20	or	N	I-Premise
21	female	N	I-Premise
22	)	N	I-Premise
23	strata	N	I-Premise
24	.	N	I-Premise

1	Median	N	I-Premise
2	PFS	N	I-Premise
3	was	N	I-Premise
4	5.5	N	I-Premise
5	months	N	I-Premise
6	in	N	I-Premise
7	both	N	I-Premise
8	arms	N	I-Premise
9	(	N	I-Premise
10	HR	N	I-Premise
11	,	N	I-Premise
12	1.04	N	I-Premise
13	;	N	I-Premise
14	P	N	I-Premise
15	=	N	I-Premise
16	.727	N	I-Premise
17	)	N	I-Premise
18	,	N	I-Premise
19	while	N	I-Premise
20	ORR	N	I-Premise
21	was	N	I-Premise
22	25	N	I-Premise
23	%	N	I-Premise
24	in	N	I-Premise
25	both	N	I-Premise
26	arms	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	1.0	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	Overall	N	I-Premise
2	rate	N	I-Premise
3	of	N	I-Premise
4	adverse	N	I-Premise
5	events	N	I-Premise
6	(	N	I-Premise
7	AEs	N	I-Premise
8	)	N	I-Premise
9	was	N	I-Premise
10	comparable	N	I-Premise
11	between	N	I-Premise
12	the	N	I-Premise
13	ASA404	N	I-Premise
14	and	N	I-Premise
15	placebo	N	I-Premise
16	arms	N	I-Premise
17	.	N	I-Premise

1	Grade	N	I-Premise
2	4	N	I-Premise
3	neutropenia	N	I-Premise
4	(	N	I-Premise
5	27	N	I-Premise
6	%	N	I-Premise
7	v	N	I-Premise
8	19	N	I-Premise
9	%	N	I-Premise
10	)	N	I-Premise
11	and	N	I-Premise
12	infusion	N	I-Premise
13	site	N	I-Premise
14	pain	N	I-Premise
15	(	N	I-Premise
16	10	N	I-Premise
17	%	N	I-Premise
18	v	N	I-Premise
19	0.5	N	I-Premise
20	%	N	I-Premise
21	)	N	I-Premise
22	were	N	I-Premise
23	reported	N	I-Premise
24	more	N	I-Premise
25	frequently	N	I-Premise
26	in	N	I-Premise
27	the	N	I-Premise
28	ASA404	N	I-Premise
29	arm	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Claim
2	addition	N	I-Claim
3	of	N	I-Claim
4	ASA404	N	I-Claim
5	to	N	I-Claim
6	carboplatin	N	I-Claim
7	and	N	I-Claim
8	paclitaxel	N	I-Claim
9	,	N	I-Claim
10	although	N	I-Claim
11	generally	N	I-Claim
12	well	N	I-Claim
13	tolerated	N	I-Claim
14	,	N	I-Claim
15	failed	N	I-Claim
16	to	N	I-Claim
17	improve	N	I-Claim
18	frontline	N	I-Claim
19	efficacy	N	I-Claim
20	in	N	I-Claim
21	advanced	N	I-Claim
22	NSCLC	N	I-Claim
23	.	N	I-Claim

1	The	N	I-Claim
2	addition	N	I-Claim
3	of	N	I-Claim
4	bevacizumab	N	I-Claim
5	to	N	I-Claim
6	paclitaxel	N	I-Claim
7	improved	N	I-Claim
8	progression-free	N	I-Claim
9	survival	N	I-Claim
10	(	N	I-Claim
11	PFS	N	I-Claim
12	)	N	I-Claim
13	of	N	I-Claim
14	patients	N	I-Claim
15	with	N	I-Claim
16	metastatic	N	I-Claim
17	breast	N	I-Claim
18	cancer	N	I-Claim
19	(	N	I-Claim
20	MBC	N	I-Claim
21	)	N	I-Claim
22	.	N	I-Claim

1	We	N	O
2	examined	N	O
3	the	N	O
4	efficacy	N	O
5	and	N	O
6	safety	N	O
7	of	N	O
8	adding	N	O
9	gemcitabine	N	O
10	to	N	O
11	paclitaxel/bevacizumab	N	O
12	(	N	O
13	PB	N	O
14	)	N	O
15	.	N	O

1	In	N	O
2	this	N	O
3	multicenter	N	O
4	,	N	O
5	open-label	N	O
6	,	N	O
7	randomized	N	O
8	phase	N	O
9	II	N	O
10	trial	N	O
11	,	N	O
12	women	N	O
13	with	N	O
14	locally	N	O
15	advanced	N	O
16	or	N	O
17	MBC	N	O
18	were	N	O
19	randomly	N	O
20	assigned	N	O
21	to	N	O
22	receive	N	O
23	paclitaxel	N	O
24	90	N	O
25	mg/m	N	O
26	(	N	O
27	2	N	O
28	)	N	O
29	(	N	O
30	days	N	O
31	1	N	O
32	,	N	O
33	8	N	O
34	,	N	O
35	15	N	O
36	)	N	O
37	and	N	O
38	bevacizumab	N	O
39	10	N	O
40	mg/kg	N	O
41	(	N	O
42	days	N	O
43	1	N	O
44	,	N	O
45	15	N	O
46	)	N	O
47	with	N	O
48	or	N	O
49	without	N	O
50	gemcitabine	N	O
51	1500	N	O
52	mg/m	N	O
53	(	N	O
54	2	N	O
55	)	N	O
56	(	N	O
57	days	N	O
58	1	N	O
59	,	N	O
60	15	N	O
61	)	N	O
62	in	N	O
63	28-day	N	O
64	cycles	N	O
65	.	N	O

1	Patients	N	O
2	with	N	O
3	prior	N	O
4	cytotoxic	N	O
5	therapy	N	O
6	for	N	O
7	MBC	N	O
8	were	N	O
9	ineligible	N	O
10	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	investigator-assessed	N	O
6	overall	N	O
7	response	N	O
8	rate	N	O
9	(	N	O
10	ORR	N	O
11	)	N	O
12	;	N	O
13	secondary	N	O
14	endpoints	N	O
15	were	N	O
16	PFS	N	O
17	,	N	O
18	overall	N	O
19	survival	N	O
20	(	N	O
21	OS	N	O
22	)	N	O
23	,	N	O
24	safety	N	O
25	,	N	O
26	and	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	.	N	O

1	Ninety-four	N	O
2	patients	N	O
3	received	N	O
4	PB	N	O
5	,	N	O
6	and	N	O
7	93	N	O
8	received	N	O
9	paclitaxel/bevacizumab/gemcitabine	N	O
10	(	N	O
11	PB+G	N	O
12	)	N	O
13	.	N	O

1	The	N	I-Premise
2	ORRs	N	I-Premise
3	were	N	I-Premise
4	48.9	N	I-Premise
5	%	N	I-Premise
6	(	N	I-Premise
7	95	N	I-Premise
8	%	N	I-Premise
9	confidence	N	I-Premise
10	interval	N	I-Premise
11	[	N	I-Premise
12	CI	N	I-Premise
13	]	N	I-Premise
14	,	N	I-Premise
15	38.5	N	I-Premise
16	%	N	I-Premise
17	-59.5	N	I-Premise
18	%	N	I-Premise
19	)	N	I-Premise
20	and	N	I-Premise
21	58.7	N	I-Premise
22	%	N	I-Premise
23	(	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	CI	N	I-Premise
27	,	N	I-Premise
28	47.9	N	I-Premise
29	%	N	I-Premise
30	-68.9	N	I-Premise
31	%	N	I-Premise
32	;	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	.117	N	I-Premise
36	)	N	I-Premise
37	with	N	I-Premise
38	PB	N	I-Premise
39	and	N	I-Premise
40	PB+G	N	I-Premise
41	,	N	I-Premise
42	respectively	N	I-Premise
43	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	PFS	N	I-Premise
4	was	N	I-Premise
5	8.8	N	I-Premise
6	months	N	I-Premise
7	(	N	I-Premise
8	95	N	I-Premise
9	%	N	I-Premise
10	CI	N	I-Premise
11	,	N	I-Premise
12	8.1-10.4	N	I-Premise
13	months	N	I-Premise
14	)	N	I-Premise
15	and	N	I-Premise
16	11.3	N	I-Premise
17	months	N	I-Premise
18	(	N	I-Premise
19	95	N	I-Premise
20	%	N	I-Premise
21	CI	N	I-Premise
22	,	N	I-Premise
23	9.7-12.7	N	I-Premise
24	months	N	I-Premise
25	;	N	I-Premise
26	P	N	I-Premise
27	=	N	I-Premise
28	.247	N	I-Premise
29	;	N	I-Premise
30	hazard	N	I-Premise
31	ratio	N	I-Premise
32	,	N	I-Premise
33	0.82	N	I-Premise
34	)	N	I-Premise
35	;	N	I-Premise
36	the	N	I-Premise
37	median	N	I-Premise
38	OS	N	I-Premise
39	was	N	I-Premise
40	25.0	N	I-Premise
41	months	N	I-Premise
42	(	N	I-Premise
43	95	N	I-Premise
44	%	N	I-Premise
45	CI	N	I-Premise
46	,	N	I-Premise
47	18.8-not	N	I-Premise
48	assessable	N	I-Premise
49	[	N	I-Premise
50	N/A	N	I-Premise
51	]	N	I-Premise
52	months	N	I-Premise
53	)	N	I-Premise
54	and	N	I-Premise
55	24.3	N	I-Premise
56	months	N	I-Premise
57	(	N	I-Premise
58	95	N	I-Premise
59	%	N	I-Premise
60	CI	N	I-Premise
61	,	N	I-Premise
62	20.3-N/A	N	I-Premise
63	months	N	I-Premise
64	;	N	I-Premise
65	P	N	I-Premise
66	=	N	I-Premise
67	.475	N	I-Premise
68	;	N	I-Premise
69	hazard	N	I-Premise
70	ratio	N	I-Premise
71	,	N	I-Premise
72	0.84	N	I-Premise
73	)	N	I-Premise
74	,	N	I-Premise
75	with	N	I-Premise
76	PB	N	I-Premise
77	and	N	I-Premise
78	PB+G	N	I-Premise
79	,	N	I-Premise
80	respectively	N	I-Premise
81	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	significantly	N	I-Premise
4	more	N	I-Premise
5	grade	N	I-Premise
6	3-4	N	I-Premise
7	neutropenia	N	I-Premise
8	(	N	I-Premise
9	P	N	I-Premise
10	=	N	I-Premise
11	.001	N	I-Premise
12	)	N	I-Premise
13	and	N	I-Premise
14	dyspnea	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	=	N	I-Premise
18	.014	N	I-Premise
19	)	N	I-Premise
20	with	N	I-Premise
21	PB+G	N	I-Premise
22	.	N	I-Premise

1	Patients	N	I-Premise
2	treated	N	I-Premise
3	with	N	I-Premise
4	PB	N	I-Premise
5	experienced	N	I-Premise
6	more	N	I-Premise
7	improvement	N	I-Premise
8	in	N	I-Premise
9	total	N	I-Premise
10	FACT-B	N	I-Premise
11	(	N	I-Premise
12	Functional	N	I-Premise
13	Assessment	N	I-Premise
14	of	N	I-Premise
15	Cancer	N	I-Premise
16	Therapy-Breast	N	I-Premise
17	)	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	.021	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	FACT-B	N	I-Premise
25	Social/Family	N	I-Premise
26	Well-being	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	.041	N	I-Premise
31	)	N	I-Premise
32	,	N	I-Premise
33	and	N	I-Premise
34	Breast	N	I-Premise
35	Cancer-Additional	N	I-Premise
36	Concerns	N	I-Premise
37	(	N	I-Premise
38	P	N	I-Premise
39	=	N	I-Premise
40	.008	N	I-Premise
41	)	N	I-Premise
42	scores	N	I-Premise
43	than	N	I-Premise
44	patients	N	I-Premise
45	treated	N	I-Premise
46	with	N	I-Premise
47	PB+G	N	I-Premise
48	.	N	I-Premise

1	The	N	I-Claim
2	addition	N	I-Claim
3	of	N	I-Claim
4	gemcitabine	N	I-Claim
5	to	N	I-Claim
6	PB	N	I-Claim
7	was	N	I-Claim
8	not	N	I-Claim
9	associated	N	I-Claim
10	with	N	I-Claim
11	a	N	I-Claim
12	statistically	N	I-Claim
13	significant	N	I-Claim
14	improvement	N	I-Claim
15	in	N	I-Claim
16	ORR	N	I-Claim
17	.	N	I-Claim

1	Treatment	N	I-Claim
2	with	N	I-Claim
3	PB+G	N	I-Claim
4	increased	N	I-Claim
5	the	N	I-Claim
6	incidence	N	I-Claim
7	of	N	I-Claim
8	severe	N	I-Claim
9	neutropenia	N	I-Claim
10	and	N	I-Claim
11	dyspnea	N	I-Claim
12	,	N	I-Claim
13	although	N	I-Claim
14	the	N	I-Claim
15	regimen	N	I-Claim
16	generally	N	I-Claim
17	was	N	I-Claim
18	well	N	I-Claim
19	tolerated	N	I-Claim
20	.	N	I-Claim

1	Dignity	N	O
2	therapy	N	O
3	is	N	O
4	a	N	O
5	unique	N	O
6	,	N	O
7	individualised	N	O
8	,	N	O
9	short-term	N	O
10	psychotherapy	N	O
11	that	N	O
12	was	N	O
13	developed	N	O
14	for	N	O
15	patients	N	O
16	(	N	O
17	and	N	O
18	their	N	O
19	families	N	O
20	)	N	O
21	living	N	O
22	with	N	O
23	life-threatening	N	O
24	or	N	O
25	life-limiting	N	O
26	illness	N	O
27	.	N	O

1	We	N	O
2	investigated	N	O
3	whether	N	O
4	dignity	N	O
5	therapy	N	O
6	could	N	O
7	mitigate	N	O
8	distress	N	O
9	or	N	O
10	bolster	N	O
11	the	N	O
12	experience	N	O
13	in	N	O
14	patients	N	O
15	nearing	N	O
16	the	N	O
17	end	N	O
18	of	N	O
19	their	N	O
20	lives	N	O
21	.	N	O

1	Patients	N	O
2	(	N	O
3	aged	N	O
4	≥18	N	O
5	years	N	O
6	)	N	O
7	with	N	O
8	a	N	O
9	terminal	N	O
10	prognosis	N	O
11	(	N	O
12	life	N	O
13	expectancy	N	O
14	≤6	N	O
15	months	N	O
16	)	N	O
17	who	N	O
18	were	N	O
19	receiving	N	O
20	palliative	N	O
21	care	N	O
22	in	N	O
23	a	N	O
24	hospital	N	O
25	or	N	O
26	community	N	O
27	setting	N	O
28	(	N	O
29	hospice	N	O
30	or	N	O
31	home	N	O
32	)	N	O
33	in	N	O
34	Canada	N	O
35	,	N	O
36	USA	N	O
37	,	N	O
38	and	N	O
39	Australia	N	O
40	were	N	O
41	randomly	N	O
42	assigned	N	O
43	to	N	O
44	dignity	N	O
45	therapy	N	O
46	,	N	O
47	client-centred	N	O
48	care	N	O
49	,	N	O
50	or	N	O
51	standard	N	O
52	palliative	N	O
53	care	N	O
54	in	N	O
55	a	N	O
56	1:1:1	N	O
57	ratio	N	O
58	.	N	O

1	Randomisation	N	O
2	was	N	O
3	by	N	O
4	use	N	O
5	of	N	O
6	a	N	O
7	computer-generated	N	O
8	table	N	O
9	of	N	O
10	random	N	O
11	numbers	N	O
12	in	N	O
13	blocks	N	O
14	of	N	O
15	30	N	O
16	.	N	O

1	Allocation	N	O
2	concealment	N	O
3	was	N	O
4	by	N	O
5	use	N	O
6	of	N	O
7	opaque	N	O
8	sealed	N	O
9	envelopes	N	O
10	.	N	O

1	The	N	O
2	primary	N	O
3	outcomes	N	O
4	--	N	O
5	reductions	N	O
6	in	N	O
7	various	N	O
8	dimensions	N	O
9	of	N	O
10	distress	N	O
11	before	N	O
12	and	N	O
13	after	N	O
14	completion	N	O
15	of	N	O
16	the	N	O
17	study	N	O
18	--	N	O
19	were	N	O
20	measured	N	O
21	with	N	O
22	the	N	O
23	Functional	N	O
24	Assessment	N	O
25	of	N	O
26	Chronic	N	O
27	Illness	N	O
28	Therapy	N	O
29	Spiritual	N	O
30	Well-Being	N	O
31	Scale	N	O
32	,	N	O
33	Patient	N	O
34	Dignity	N	O
35	Inventory	N	O
36	,	N	O
37	Hospital	N	O
38	Anxiety	N	O
39	and	N	O
40	Depression	N	O
41	Scale	N	O
42	,	N	O
43	items	N	O
44	from	N	O
45	the	N	O
46	Structured	N	O
47	Interview	N	O
48	for	N	O
49	Symptoms	N	O
50	and	N	O
51	Concerns	N	O
52	,	N	O
53	Quality	N	O
54	of	N	O
55	Life	N	O
56	Scale	N	O
57	,	N	O
58	and	N	O
59	modified	N	O
60	Edmonton	N	O
61	Symptom	N	O
62	Assessment	N	O
63	Scale	N	O
64	.	N	O

1	Secondary	N	O
2	outcomes	N	O
3	of	N	O
4	self-reported	N	O
5	end-of-life	N	O
6	experiences	N	O
7	were	N	O
8	assessed	N	O
9	in	N	O
10	a	N	O
11	survey	N	O
12	that	N	O
13	was	N	O
14	undertaken	N	O
15	after	N	O
16	the	N	O
17	completion	N	O
18	of	N	O
19	the	N	O
20	study	N	O
21	.	N	O

1	Outcomes	N	O
2	were	N	O
3	assessed	N	O
4	by	N	O
5	research	N	O
6	staff	N	O
7	with	N	O
8	whom	N	O
9	the	N	O
10	participant	N	O
11	had	N	O
12	no	N	O
13	previous	N	O
14	contact	N	O
15	to	N	O
16	avoid	N	O
17	any	N	O
18	possible	N	O
19	response	N	O
20	bias	N	O
21	or	N	O
22	contamination	N	O
23	.	N	O

1	Analyses	N	O
2	were	N	O
3	done	N	O
4	on	N	O
5	all	N	O
6	patients	N	O
7	with	N	O
8	available	N	O
9	data	N	O
10	at	N	O
11	baseline	N	O
12	and	N	O
13	at	N	O
14	the	N	O
15	end	N	O
16	of	N	O
17	the	N	O
18	study	N	O
19	intervention	N	O
20	.	N	O

1	165	N	O
2	of	N	O
3	441	N	O
4	patients	N	O
5	were	N	O
6	assigned	N	O
7	to	N	O
8	dignity	N	O
9	therapy	N	O
10	,	N	O
11	140	N	O
12	standard	N	O
13	palliative	N	O
14	care	N	O
15	,	N	O
16	and	N	O
17	136	N	O
18	client-centred	N	O
19	care	N	O
20	.	N	O

1	108	N	O
2	,	N	O
3	111	N	O
4	,	N	O
5	and	N	O
6	107	N	O
7	patients	N	O
8	,	N	O
9	respectively	N	O
10	,	N	O
11	were	N	O
12	analysed	N	O
13	.	N	O

1	No	N	I-Premise
2	significant	N	I-Premise
3	differences	N	I-Premise
4	were	N	I-Premise
5	noted	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	distress	N	I-Premise
9	levels	N	I-Premise
10	before	N	I-Premise
11	and	N	I-Premise
12	after	N	I-Premise
13	completion	N	I-Premise
14	of	N	I-Premise
15	the	N	I-Premise
16	study	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	three	N	I-Premise
20	groups	N	I-Premise
21	.	N	I-Premise

1	For	N	I-Premise
2	the	N	I-Premise
3	secondary	N	I-Premise
4	outcomes	N	I-Premise
5	,	N	I-Premise
6	patients	N	I-Premise
7	reported	N	I-Premise
8	that	N	I-Premise
9	dignity	N	I-Premise
10	therapy	N	I-Premise
11	was	N	I-Premise
12	significantly	N	I-Premise
13	more	N	I-Premise
14	likely	N	I-Premise
15	than	N	I-Premise
16	the	N	I-Premise
17	other	N	I-Premise
18	two	N	I-Premise
19	interventions	N	I-Premise
20	to	N	I-Premise
21	have	N	I-Premise
22	been	N	I-Premise
23	helpful	N	I-Premise
24	(	N	I-Premise
25	χ	N	I-Premise
26	(	N	I-Premise
27	2	N	I-Premise
28	)	N	I-Premise
29	=35·50	N	I-Premise
30	,	N	I-Premise
31	df=2	N	I-Premise
32	;	N	I-Premise
33	p	N	I-Premise
34	<	N	I-Premise
35	0·0001	N	I-Premise
36	)	N	I-Premise
37	,	N	I-Premise
38	improve	N	I-Premise
39	quality	N	I-Premise
40	of	N	I-Premise
41	life	N	I-Premise
42	(	N	I-Premise
43	χ	N	I-Premise
44	(	N	I-Premise
45	2	N	I-Premise
46	)	N	I-Premise
47	=14·52	N	I-Premise
48	;	N	I-Premise
49	p=0·001	N	I-Premise
50	)	N	I-Premise
51	,	N	I-Premise
52	increase	N	I-Premise
53	sense	N	I-Premise
54	of	N	I-Premise
55	dignity	N	I-Premise
56	(	N	I-Premise
57	χ	N	I-Premise
58	(	N	I-Premise
59	2	N	I-Premise
60	)	N	I-Premise
61	=12·66	N	I-Premise
62	;	N	I-Premise
63	p=0·002	N	I-Premise
64	)	N	I-Premise
65	,	N	I-Premise
66	change	N	I-Premise
67	how	N	I-Premise
68	their	N	I-Premise
69	family	N	I-Premise
70	saw	N	I-Premise
71	and	N	I-Premise
72	appreciated	N	I-Premise
73	them	N	I-Premise
74	(	N	I-Premise
75	χ	N	I-Premise
76	(	N	I-Premise
77	2	N	I-Premise
78	)	N	I-Premise
79	=33·81	N	I-Premise
80	;	N	I-Premise
81	p	N	I-Premise
82	<	N	I-Premise
83	0·0001	N	I-Premise
84	)	N	I-Premise
85	,	N	I-Premise
86	and	N	I-Premise
87	be	N	I-Premise
88	helpful	N	I-Premise
89	to	N	I-Premise
90	their	N	I-Premise
91	family	N	I-Premise
92	(	N	I-Premise
93	χ	N	I-Premise
94	(	N	I-Premise
95	2	N	I-Premise
96	)	N	I-Premise
97	=33·86	N	I-Premise
98	;	N	I-Premise
99	p	N	I-Premise
100	<	N	I-Premise
101	0·0001	N	I-Premise
102	)	N	I-Premise
103	.	N	I-Premise

1	Dignity	N	I-Premise
2	therapy	N	I-Premise
3	was	N	I-Premise
4	significantly	N	I-Premise
5	better	N	I-Premise
6	than	N	I-Premise
7	client-centred	N	I-Premise
8	care	N	I-Premise
9	in	N	I-Premise
10	improving	N	I-Premise
11	spiritual	N	I-Premise
12	wellbeing	N	I-Premise
13	(	N	I-Premise
14	χ	N	I-Premise
15	(	N	I-Premise
16	2	N	I-Premise
17	)	N	I-Premise
18	=10·35	N	I-Premise
19	;	N	I-Premise
20	p=0·006	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	was	N	I-Premise
25	significantly	N	I-Premise
26	better	N	I-Premise
27	than	N	I-Premise
28	standard	N	I-Premise
29	palliative	N	I-Premise
30	care	N	I-Premise
31	in	N	I-Premise
32	terms	N	I-Premise
33	of	N	I-Premise
34	lessening	N	I-Premise
35	sadness	N	I-Premise
36	or	N	I-Premise
37	depression	N	I-Premise
38	(	N	I-Premise
39	χ	N	I-Premise
40	(	N	I-Premise
41	2	N	I-Premise
42	)	N	I-Premise
43	=9·38	N	I-Premise
44	;	N	I-Premise
45	p=0·009	N	I-Premise
46	)	N	I-Premise
47	;	N	I-Premise
48	significantly	N	I-Premise
49	more	N	I-Premise
50	patients	N	I-Premise
51	who	N	I-Premise
52	had	N	I-Premise
53	received	N	I-Premise
54	dignity	N	I-Premise
55	therapy	N	I-Premise
56	reported	N	I-Premise
57	that	N	I-Premise
58	the	N	I-Premise
59	study	N	I-Premise
60	group	N	I-Premise
61	had	N	I-Premise
62	been	N	I-Premise
63	satisfactory	N	I-Premise
64	,	N	I-Premise
65	compared	N	I-Premise
66	with	N	I-Premise
67	those	N	I-Premise
68	who	N	I-Premise
69	received	N	I-Premise
70	standard	N	I-Premise
71	palliative	N	I-Premise
72	care	N	I-Premise
73	(	N	I-Premise
74	χ	N	I-Premise
75	(	N	I-Premise
76	2	N	I-Premise
77	)	N	I-Premise
78	=29·58	N	I-Premise
79	;	N	I-Premise
80	p	N	I-Premise
81	<	N	I-Premise
82	0·0001	N	I-Premise
83	)	N	I-Premise
84	.	N	I-Premise

1	Although	N	I-Claim
2	the	N	I-Claim
3	ability	N	I-Claim
4	of	N	I-Claim
5	dignity	N	I-Claim
6	therapy	N	I-Claim
7	to	N	I-Claim
8	mitigate	N	I-Claim
9	outright	N	I-Claim
10	distress	N	I-Claim
11	,	N	I-Claim
12	such	N	I-Claim
13	as	N	I-Claim
14	depression	N	I-Claim
15	,	N	I-Claim
16	desire	N	I-Claim
17	for	N	I-Claim
18	death	N	I-Claim
19	or	N	I-Claim
20	suicidality	N	I-Claim
21	,	N	I-Claim
22	has	N	I-Claim
23	yet	N	I-Claim
24	to	N	I-Claim
25	be	N	I-Claim
26	proven	N	I-Claim
27	,	N	I-Claim
28	its	N	I-Claim
29	benefits	N	I-Claim
30	in	N	I-Claim
31	terms	N	I-Claim
32	of	N	I-Claim
33	self-reported	N	I-Claim
34	end-of-life	N	I-Claim
35	experiences	N	I-Claim
36	support	N	I-Claim
37	its	N	I-Claim
38	clinical	N	I-Claim
39	application	N	I-Claim
40	for	N	I-Claim
41	patients	N	I-Claim
42	nearing	N	I-Claim
43	death	N	I-Claim
44	.	N	I-Claim

1	Anemia	N	I-MajorClaim
2	is	N	I-MajorClaim
3	an	N	I-MajorClaim
4	expected	N	I-MajorClaim
5	consequence	N	I-MajorClaim
6	of	N	I-MajorClaim
7	intensive	N	I-MajorClaim
8	chemotherapy	N	I-MajorClaim
9	regimens	N	I-MajorClaim
10	administered	N	I-MajorClaim
11	to	N	I-MajorClaim
12	patients	N	I-MajorClaim
13	with	N	I-MajorClaim
14	acute	N	I-MajorClaim
15	leukemia	N	I-MajorClaim
16	.	N	I-MajorClaim

1	This	N	O
2	study	N	O
3	was	N	O
4	designed	N	O
5	to	N	O
6	determine	N	O
7	whether	N	O
8	epoetin	N	O
9	alpha	N	O
10	would	N	O
11	decrease	N	O
12	the	N	O
13	number	N	O
14	of	N	O
15	transfusion	N	O
16	events	N	O
17	and	N	O
18	units	N	O
19	of	N	O
20	packed	N	O
21	erythrocytes	N	O
22	(	N	O
23	PRBCs	N	O
24	)	N	O
25	transfused	N	O
26	,	N	O
27	and	N	O
28	the	N	O
29	secondary	N	O
30	objective	N	O
31	was	N	O
32	to	N	O
33	study	N	O
34	the	N	O
35	effects	N	O
36	of	N	O
37	epoetin	N	O
38	alpha	N	O
39	on	N	O
40	quality	N	O
41	of	N	O
42	life	N	O
43	(	N	O
44	QOL	N	O
45	)	N	O
46	and	N	O
47	complete	N	O
48	remission	N	O
49	(	N	O
50	CR	N	O
51	)	N	O
52	rates	N	O
53	.	N	O

1	Patients	N	O
2	with	N	O
3	acute	N	O
4	lymphoblastic	N	O
5	leukemia	N	O
6	(	N	O
7	ALL	N	O
8	)	N	O
9	,	N	O
10	lymphoblastic	N	O
11	lymphoma	N	O
12	(	N	O
13	LL	N	O
14	)	N	O
15	,	N	O
16	or	N	O
17	Burkitt	N	O
18	lymphoma	N	O
19	(	N	O
20	BL	N	O
21	)	N	O
22	who	N	O
23	were	N	O
24	receiving	N	O
25	frontline	N	O
26	myelosuppressive	N	O
27	chemotherapy	N	O
28	were	N	O
29	randomized	N	O
30	to	N	O
31	receive	N	O
32	epoetin	N	O
33	alpha	N	O
34	or	N	O
35	no	N	O
36	epoetin	N	O
37	during	N	O
38	the	N	O
39	first	N	O
40	6	N	O
41	cycles	N	O
42	of	N	O
43	their	N	O
44	planned	N	O
45	chemotherapy	N	O
46	.	N	O

1	QOL	N	O
2	was	N	O
3	assessed	N	O
4	by	N	O
5	using	N	O
6	the	N	O
7	Edmonton	N	O
8	Symptom	N	O
9	Assessment	N	O
10	Scale	N	O
11	(	N	O
12	ESAS	N	O
13	)	N	O
14	and	N	O
15	the	N	O
16	Functional	N	O
17	Assessment	N	O
18	of	N	O
19	Cancer	N	O
20	Therapy	N	O
21	(	N	O
22	FACT	N	O
23	)	N	O
24	-Anemia	N	O
25	questionnaires	N	O
26	.	N	O

1	Fifty-five	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	to	N	O
6	receive	N	O
7	epoetin	N	O
8	alpha	N	O
9	,	N	O
10	and	N	O
11	54	N	O
12	patients	N	O
13	received	N	O
14	no	N	O
15	epoetin	N	O
16	.	N	O

1	Transfusion	N	O
2	data	N	O
3	were	N	O
4	available	N	O
5	for	N	O
6	79	N	O
7	of	N	O
8	81	N	O
9	evaluable	N	O
10	patients	N	O
11	(	N	O
12	98	N	O
13	%	N	O
14	)	N	O
15	who	N	O
16	completed	N	O
17	the	N	O
18	treatment/observation	N	O
19	period	N	O
20	.	N	O

1	The	N	I-Premise
2	trial	N	I-Premise
3	was	N	I-Premise
4	stopped	N	I-Premise
5	early	N	I-Premise
6	because	N	I-Premise
7	of	N	I-Premise
8	poor	N	I-Premise
9	accrual	N	I-Premise
10	before	N	I-Premise
11	the	N	I-Premise
12	target	N	I-Premise
13	of	N	I-Premise
14	123	N	I-Premise
15	evaluable	N	I-Premise
16	patients	N	I-Premise
17	was	N	I-Premise
18	met	N	I-Premise
19	.	N	I-Premise

1	A	N	I-Premise
2	mean	N	I-Premise
3	of	N	I-Premise
4	10.6	N	I-Premise
5	units	N	I-Premise
6	of	N	I-Premise
7	PRBCs	N	I-Premise
8	over	N	I-Premise
9	5	N	I-Premise
10	months	N	I-Premise
11	were	N	I-Premise
12	administered	N	I-Premise
13	to	N	I-Premise
14	those	N	I-Premise
15	who	N	I-Premise
16	received	N	I-Premise
17	epoetin	N	I-Premise
18	alpha	N	I-Premise
19	compared	N	I-Premise
20	with	N	I-Premise
21	13	N	I-Premise
22	units	N	I-Premise
23	for	N	I-Premise
24	those	N	I-Premise
25	who	N	I-Premise
26	did	N	I-Premise
27	not	N	I-Premise
28	receive	N	I-Premise
29	epoetin	N	I-Premise
30	(	N	I-Premise
31	P	N	I-Premise
32	=	N	I-Premise
33	.04	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	QOL	N	I-Premise
8	as	N	I-Premise
9	assessed	N	I-Premise
10	by	N	I-Premise
11	the	N	I-Premise
12	FACT-Anemia	N	I-Premise
13	or	N	I-Premise
14	ESAS	N	I-Premise
15	instruments	N	I-Premise
16	.	N	I-Premise

1	The	N	I-Premise
2	CR	N	I-Premise
3	rate	N	I-Premise
4	and	N	I-Premise
5	the	N	I-Premise
6	3-year	N	I-Premise
7	CR	N	I-Premise
8	duration	N	I-Premise
9	were	N	I-Premise
10	not	N	I-Premise
11	affected	N	I-Premise
12	adversely	N	I-Premise
13	by	N	I-Premise
14	use	N	I-Premise
15	of	N	I-Premise
16	epoetin	N	I-Premise
17	alpha	N	I-Premise
18	.	N	I-Premise

1	Epoetin	N	I-Claim
2	alpha	N	I-Claim
3	decreased	N	I-Claim
4	the	N	I-Claim
5	number	N	I-Claim
6	of	N	I-Claim
7	PRBC	N	I-Claim
8	transfusions	N	I-Claim
9	and	N	I-Claim
10	did	N	I-Claim
11	not	N	I-Claim
12	appear	N	I-Claim
13	to	N	I-Claim
14	have	N	I-Claim
15	a	N	I-Claim
16	negative	N	I-Claim
17	impact	N	I-Claim
18	on	N	I-Claim
19	remission	N	I-Claim
20	duration	N	I-Claim
21	.	N	I-Claim

1	No	N	I-Claim
2	difference	N	I-Claim
3	in	N	I-Claim
4	QOL	N	I-Claim
5	was	N	I-Claim
6	observed	N	I-Claim
7	.	N	I-Claim

1	The	N	I-MajorClaim
2	generalizability	N	I-MajorClaim
3	of	N	I-MajorClaim
4	palliative	N	I-MajorClaim
5	care	N	I-MajorClaim
6	intervention	N	I-MajorClaim
7	research	N	I-MajorClaim
8	is	N	I-MajorClaim
9	often	N	I-MajorClaim
10	limited	N	I-MajorClaim
11	by	N	I-MajorClaim
12	high	N	I-MajorClaim
13	rates	N	I-MajorClaim
14	of	N	I-MajorClaim
15	study	N	I-MajorClaim
16	attrition	N	I-MajorClaim
17	.	N	I-MajorClaim

1	This	N	O
2	study	N	O
3	examined	N	O
4	factors	N	O
5	associated	N	O
6	with	N	O
7	attrition	N	O
8	from	N	O
9	a	N	O
10	randomized	N	O
11	controlled	N	O
12	trial	N	O
13	comparing	N	O
14	meaning-centered	N	O
15	group	N	O
16	psychotherapy	N	O
17	(	N	O
18	MCGP	N	O
19	)	N	O
20	,	N	O
21	an	N	O
22	intervention	N	O
23	designed	N	O
24	to	N	O
25	help	N	O
26	advanced	N	O
27	cancer	N	O
28	patients	N	O
29	sustain	N	O
30	or	N	O
31	enhance	N	O
32	their	N	O
33	sense	N	O
34	of	N	O
35	meaning	N	O
36	to	N	O
37	the	N	O
38	supportive	N	O
39	group	N	O
40	psychotherapy	N	O
41	(	N	O
42	SGP	N	O
43	)	N	O
44	,	N	O
45	a	N	O
46	standardized	N	O
47	support	N	O
48	group	N	O
49	.	N	O

1	Patients	N	O
2	with	N	O
3	advanced	N	O
4	solid	N	O
5	tumor	N	O
6	cancers	N	O
7	(	N	O
8	n	N	O
9	=	N	O
10	153	N	O
11	)	N	O
12	were	N	O
13	randomized	N	O
14	to	N	O
15	eight	N	O
16	sessions	N	O
17	of	N	O
18	either	N	O
19	the	N	O
20	MCGP	N	O
21	or	N	O
22	SGP	N	O
23	.	N	O

1	They	N	O
2	completed	N	O
3	assessments	N	O
4	of	N	O
5	psychosocial	N	O
6	,	N	O
7	spiritual	N	O
8	,	N	O
9	and	N	O
10	physical	N	O
11	well-being	N	O
12	pretreatment	N	O
13	,	N	O
14	midtreatment	N	O
15	,	N	O
16	and	N	O
17	2	N	O
18	months	N	O
19	post-treatment	N	O
20	.	N	O

1	Attrition	N	O
2	was	N	O
3	assessed	N	O
4	in	N	O
5	terms	N	O
6	of	N	O
7	the	N	O
8	percent	N	O
9	of	N	O
10	participants	N	O
11	who	N	O
12	failed	N	O
13	to	N	O
14	complete	N	O
15	these	N	O
16	assessments	N	O
17	,	N	O
18	and	N	O
19	demographic	N	O
20	,	N	O
21	psychiatric	N	O
22	,	N	O
23	medical	N	O
24	,	N	O
25	and	N	O
26	study-related	N	O
27	correlates	N	O
28	of	N	O
29	attrition	N	O
30	were	N	O
31	examined	N	O
32	for	N	O
33	the	N	O
34	participants	N	O
35	in	N	O
36	each	N	O
37	of	N	O
38	these	N	O
39	categories	N	O
40	.	N	O

1	The	N	I-Premise
2	rates	N	I-Premise
3	of	N	I-Premise
4	attrition	N	I-Premise
5	at	N	I-Premise
6	these	N	I-Premise
7	time	N	I-Premise
8	points	N	I-Premise
9	were	N	I-Premise
10	28.1	N	I-Premise
11	%	N	I-Premise
12	,	N	I-Premise
13	17.7	N	I-Premise
14	%	N	I-Premise
15	,	N	I-Premise
16	and	N	I-Premise
17	11.1	N	I-Premise
18	%	N	I-Premise
19	,	N	I-Premise
20	respectively	N	I-Premise
21	;	N	I-Premise
22	43.1	N	I-Premise
23	%	N	I-Premise
24	of	N	I-Premise
25	the	N	I-Premise
26	participants	N	I-Premise
27	(	N	I-Premise
28	66	N	I-Premise
29	of	N	I-Premise
30	153	N	I-Premise
31	)	N	I-Premise
32	completed	N	I-Premise
33	the	N	I-Premise
34	entire	N	I-Premise
35	study	N	I-Premise
36	.	N	I-Premise

1	The	N	I-Premise
2	most	N	I-Premise
3	common	N	I-Premise
4	reason	N	I-Premise
5	for	N	I-Premise
6	dropout	N	I-Premise
7	was	N	I-Premise
8	patients	N	I-Premise
9	feeling	N	I-Premise
10	too	N	I-Premise
11	ill	N	I-Premise
12	.	N	I-Premise

1	Attrition	N	I-Premise
2	rates	N	I-Premise
3	did	N	I-Premise
4	not	N	I-Premise
5	vary	N	I-Premise
6	significantly	N	I-Premise
7	between	N	I-Premise
8	study	N	I-Premise
9	arms	N	I-Premise
10	.	N	I-Premise

1	The	N	O
2	participants	N	O
3	who	N	O
4	dropped	N	O
5	out	N	O
6	pretreatment	N	O
7	reported	N	O
8	less	N	O
9	financial	N	O
10	concerns	N	O
11	than	N	O
12	post-treatment	N	O
13	dropouts	N	O
14	,	N	O
15	and	N	O
16	the	N	O
17	participants	N	O
18	who	N	O
19	dropped	N	O
20	out	N	O
21	of	N	O
22	the	N	O
23	study	N	O
24	midtreatment	N	O
25	had	N	O
26	poorer	N	O
27	physical	N	O
28	health	N	O
29	than	N	O
30	treatment	N	O
31	completers	N	O
32	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	other	N	I-Premise
5	significant	N	I-Premise
6	associations	N	I-Premise
7	between	N	I-Premise
8	attrition	N	I-Premise
9	and	N	I-Premise
10	any	N	I-Premise
11	demographic	N	I-Premise
12	,	N	I-Premise
13	medical	N	I-Premise
14	,	N	I-Premise
15	psychiatric	N	I-Premise
16	,	N	I-Premise
17	or	N	I-Premise
18	study-related	N	I-Premise
19	variables	N	I-Premise
20	.	N	I-Premise

1	These	N	I-Claim
2	findings	N	I-Claim
3	highlight	N	I-Claim
4	the	N	I-Claim
5	challenge	N	I-Claim
6	of	N	I-Claim
7	maintaining	N	I-Claim
8	advanced	N	I-Claim
9	cancer	N	I-Claim
10	patients	N	I-Claim
11	in	N	I-Claim
12	longitudinal	N	I-Claim
13	research	N	I-Claim
14	and	N	I-Claim
15	suggest	N	I-Claim
16	the	N	I-Claim
17	need	N	I-Claim
18	to	N	I-Claim
19	consider	N	I-Claim
20	alternative	N	I-Claim
21	approaches	N	I-Claim
22	(	N	I-Claim
23	e.g.	N	I-Claim
24	,	N	I-Claim
25	telemedicine	N	I-Claim
26	)	N	I-Claim
27	for	N	I-Claim
28	patients	N	I-Claim
29	who	N	I-Claim
30	might	N	I-Claim
31	benefit	N	I-Claim
32	from	N	I-Claim
33	group	N	I-Claim
34	interventions	N	I-Claim
35	but	N	I-Claim
36	are	N	I-Claim
37	too	N	I-Claim
38	ill	N	I-Claim
39	to	N	I-Claim
40	travel	N	I-Claim
41	.	N	I-Claim

1	For	N	I-Claim
2	men	N	I-Claim
3	with	N	I-Claim
4	localised	N	I-Claim
5	prostate	N	I-Claim
6	cancer	N	I-Claim
7	,	N	I-Claim
8	surgery	N	I-Claim
9	provides	N	I-Claim
10	a	N	I-Claim
11	survival	N	I-Claim
12	benefit	N	I-Claim
13	compared	N	I-Claim
14	with	N	I-Claim
15	watchful	N	I-Claim
16	waiting	N	I-Claim
17	.	N	I-Claim

1	Treatments	N	O
2	are	N	O
3	associated	N	O
4	with	N	O
5	morbidity	N	O
6	.	N	O

1	Results	N	O
2	for	N	O
3	functional	N	O
4	outcome	N	O
5	and	N	O
6	quality	N	O
7	of	N	O
8	life	N	O
9	are	N	O
10	rarely	N	O
11	reported	N	O
12	beyond	N	O
13	10	N	O
14	years	N	O
15	and	N	O
16	are	N	O
17	lacking	N	O
18	from	N	O
19	randomised	N	O
20	settings	N	O
21	.	N	O

1	We	N	O
2	report	N	O
3	results	N	O
4	for	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	for	N	O
9	men	N	O
10	in	N	O
11	the	N	O
12	Scandinavian	N	O
13	Prostate	N	O
14	Cancer	N	O
15	Group	N	O
16	Study	N	O
17	Number	N	O
18	4	N	O
19	(	N	O
20	SPCG-4	N	O
21	)	N	O
22	after	N	O
23	a	N	O
24	median	N	O
25	follow-up	N	O
26	of	N	O
27	more	N	O
28	than	N	O
29	12	N	O
30	years	N	O
31	.	N	O

1	All	N	O
2	living	N	O
3	Swedish	N	O
4	and	N	O
5	Finnish	N	O
6	men	N	O
7	(	N	O
8	400	N	O
9	of	N	O
10	695	N	O
11	)	N	O
12	randomly	N	O
13	assigned	N	O
14	to	N	O
15	radical	N	O
16	prostatectomy	N	O
17	or	N	O
18	watchful	N	O
19	waiting	N	O
20	in	N	O
21	SPCG-4	N	O
22	from	N	O
23	1989	N	O
24	to	N	O
25	1999	N	O
26	were	N	O
27	included	N	O
28	in	N	O
29	our	N	O
30	analysis	N	O
31	.	N	O

1	An	N	O
2	additional	N	O
3	281	N	O
4	men	N	O
5	were	N	O
6	included	N	O
7	in	N	O
8	a	N	O
9	population-based	N	O
10	control	N	O
11	group	N	O
12	matched	N	O
13	for	N	O
14	region	N	O
15	and	N	O
16	age	N	O
17	.	N	O

1	Physical	N	O
2	symptoms	N	O
3	,	N	O
4	symptom-induced	N	O
5	stress	N	O
6	,	N	O
7	and	N	O
8	self-assessed	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	were	N	O
13	evaluated	N	O
14	with	N	O
15	a	N	O
16	study-specific	N	O
17	questionnaire	N	O
18	.	N	O

1	Longitudinal	N	O
2	data	N	O
3	were	N	O
4	available	N	O
5	for	N	O
6	166	N	O
7	Swedish	N	O
8	men	N	O
9	who	N	O
10	had	N	O
11	answered	N	O
12	quality-of-life	N	O
13	questionnaires	N	O
14	at	N	O
15	an	N	O
16	earlier	N	O
17	timepoint	N	O
18	.	N	O

1	182	N	O
2	(	N	O
3	88	N	O
4	%	N	O
5	)	N	O
6	of	N	O
7	208	N	O
8	men	N	O
9	in	N	O
10	the	N	O
11	radical	N	O
12	prostatectomy	N	O
13	group	N	O
14	,	N	O
15	167	N	O
16	(	N	O
17	87	N	O
18	%	N	O
19	)	N	O
20	of	N	O
21	192	N	O
22	men	N	O
23	in	N	O
24	the	N	O
25	watchful-waiting	N	O
26	group	N	O
27	,	N	O
28	and	N	O
29	214	N	O
30	(	N	O
31	76	N	O
32	%	N	O
33	)	N	O
34	of	N	O
35	281	N	O
36	men	N	O
37	in	N	O
38	the	N	O
39	population-based	N	O
40	control	N	O
41	group	N	O
42	answered	N	O
43	the	N	O
44	questionnaire	N	O
45	.	N	O

1	Men	N	O
2	in	N	O
3	SPCG-4	N	O
4	had	N	O
5	a	N	O
6	median	N	O
7	follow-up	N	O
8	of	N	O
9	12·2	N	O
10	years	N	O
11	(	N	O
12	range	N	O
13	7-17	N	O
14	)	N	O
15	and	N	O
16	a	N	O
17	median	N	O
18	age	N	O
19	of	N	O
20	77·0	N	O
21	years	N	O
22	(	N	O
23	range	N	O
24	61-88	N	O
25	)	N	O
26	.	N	O

1	High	N	I-Premise
2	self-assessed	N	I-Premise
3	quality	N	I-Premise
4	of	N	I-Premise
5	life	N	I-Premise
6	was	N	I-Premise
7	reported	N	I-Premise
8	by	N	I-Premise
9	62	N	I-Premise
10	(	N	I-Premise
11	35	N	I-Premise
12	%	N	I-Premise
13	)	N	I-Premise
14	of	N	I-Premise
15	179	N	I-Premise
16	men	N	I-Premise
17	allocated	N	I-Premise
18	radical	N	I-Premise
19	prostatectomy	N	I-Premise
20	,	N	I-Premise
21	55	N	I-Premise
22	(	N	I-Premise
23	34	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	of	N	I-Premise
27	160	N	I-Premise
28	men	N	I-Premise
29	assigned	N	I-Premise
30	to	N	I-Premise
31	watchful	N	I-Premise
32	waiting	N	I-Premise
33	,	N	I-Premise
34	and	N	I-Premise
35	93	N	I-Premise
36	(	N	I-Premise
37	45	N	I-Premise
38	%	N	I-Premise
39	)	N	I-Premise
40	of	N	I-Premise
41	208	N	I-Premise
42	men	N	I-Premise
43	in	N	I-Premise
44	the	N	I-Premise
45	control	N	I-Premise
46	group	N	I-Premise
47	.	N	I-Premise

1	Anxiety	N	I-Premise
2	was	N	I-Premise
3	higher	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	SPCG-4	N	I-Premise
7	groups	N	I-Premise
8	(	N	I-Premise
9	77	N	I-Premise
10	[	N	I-Premise
11	43	N	I-Premise
12	%	N	I-Premise
13	]	N	I-Premise
14	of	N	I-Premise
15	178	N	I-Premise
16	and	N	I-Premise
17	69	N	I-Premise
18	[	N	I-Premise
19	43	N	I-Premise
20	%	N	I-Premise
21	]	N	I-Premise
22	of	N	I-Premise
23	161	N	I-Premise
24	men	N	I-Premise
25	)	N	I-Premise
26	than	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	control	N	I-Premise
30	group	N	I-Premise
31	(	N	I-Premise
32	68	N	I-Premise
33	[	N	I-Premise
34	33	N	I-Premise
35	%	N	I-Premise
36	]	N	I-Premise
37	of	N	I-Premise
38	208	N	I-Premise
39	men	N	I-Premise
40	;	N	I-Premise
41	relative	N	I-Premise
42	risk	N	I-Premise
43	1·42	N	I-Premise
44	,	N	I-Premise
45	95	N	I-Premise
46	%	N	I-Premise
47	CI	N	I-Premise
48	1·07-1·88	N	I-Premise
49	)	N	I-Premise
50	.	N	I-Premise

1	Prevalence	N	I-Premise
2	of	N	I-Premise
3	erectile	N	I-Premise
4	dysfunction	N	I-Premise
5	was	N	I-Premise
6	84	N	I-Premise
7	%	N	I-Premise
8	(	N	I-Premise
9	146	N	I-Premise
10	of	N	I-Premise
11	173	N	I-Premise
12	men	N	I-Premise
13	)	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	radical	N	I-Premise
17	prostatectomy	N	I-Premise
18	group	N	I-Premise
19	,	N	I-Premise
20	80	N	I-Premise
21	%	N	I-Premise
22	(	N	I-Premise
23	122	N	I-Premise
24	of	N	I-Premise
25	153	N	I-Premise
26	)	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	watchful-waiting	N	I-Premise
30	group	N	I-Premise
31	,	N	I-Premise
32	and	N	I-Premise
33	46	N	I-Premise
34	%	N	I-Premise
35	(	N	I-Premise
36	95	N	I-Premise
37	of	N	I-Premise
38	208	N	I-Premise
39	)	N	I-Premise
40	in	N	I-Premise
41	the	N	I-Premise
42	control	N	I-Premise
43	group	N	I-Premise
44	and	N	I-Premise
45	prevalence	N	I-Premise
46	of	N	I-Premise
47	urinary	N	I-Premise
48	leakage	N	I-Premise
49	was	N	I-Premise
50	41	N	I-Premise
51	%	N	I-Premise
52	(	N	I-Premise
53	71	N	I-Premise
54	of	N	I-Premise
55	173	N	I-Premise
56	)	N	I-Premise
57	,	N	I-Premise
58	11	N	I-Premise
59	%	N	I-Premise
60	(	N	I-Premise
61	18	N	I-Premise
62	of	N	I-Premise
63	164	N	I-Premise
64	)	N	I-Premise
65	,	N	I-Premise
66	and	N	I-Premise
67	3	N	I-Premise
68	%	N	I-Premise
69	(	N	I-Premise
70	six	N	I-Premise
71	of	N	I-Premise
72	209	N	I-Premise
73	)	N	I-Premise
74	,	N	I-Premise
75	respectively	N	I-Premise
76	.	N	I-Premise

1	Distress	N	I-Premise
2	caused	N	I-Premise
3	by	N	I-Premise
4	these	N	I-Premise
5	symptoms	N	I-Premise
6	was	N	I-Premise
7	reported	N	I-Premise
8	significantly	N	I-Premise
9	more	N	I-Premise
10	often	N	I-Premise
11	by	N	I-Premise
12	men	N	I-Premise
13	allocated	N	I-Premise
14	radical	N	I-Premise
15	prostatectomy	N	I-Premise
16	than	N	I-Premise
17	by	N	I-Premise
18	men	N	I-Premise
19	assigned	N	I-Premise
20	to	N	I-Premise
21	watchful	N	I-Premise
22	waiting	N	I-Premise
23	.	N	I-Premise

1	In	N	I-Premise
2	a	N	I-Premise
3	longitudinal	N	I-Premise
4	analysis	N	I-Premise
5	of	N	I-Premise
6	men	N	I-Premise
7	in	N	I-Premise
8	SPCG-4	N	I-Premise
9	who	N	I-Premise
10	provided	N	I-Premise
11	information	N	I-Premise
12	at	N	I-Premise
13	two	N	I-Premise
14	follow-up	N	I-Premise
15	points	N	I-Premise
16	9	N	I-Premise
17	years	N	I-Premise
18	apart	N	I-Premise
19	,	N	I-Premise
20	38	N	I-Premise
21	(	N	I-Premise
22	45	N	I-Premise
23	%	N	I-Premise
24	)	N	I-Premise
25	of	N	I-Premise
26	85	N	I-Premise
27	men	N	I-Premise
28	allocated	N	I-Premise
29	radical	N	I-Premise
30	prostatectomy	N	I-Premise
31	and	N	I-Premise
32	48	N	I-Premise
33	(	N	I-Premise
34	60	N	I-Premise
35	%	N	I-Premise
36	)	N	I-Premise
37	of	N	I-Premise
38	80	N	I-Premise
39	men	N	I-Premise
40	allocated	N	I-Premise
41	watchful	N	I-Premise
42	waiting	N	I-Premise
43	reported	N	I-Premise
44	an	N	I-Premise
45	increase	N	I-Premise
46	in	N	I-Premise
47	number	N	I-Premise
48	of	N	I-Premise
49	physical	N	I-Premise
50	symptoms	N	I-Premise
51	;	N	I-Premise
52	50	N	I-Premise
53	(	N	I-Premise
54	61	N	I-Premise
55	%	N	I-Premise
56	)	N	I-Premise
57	of	N	I-Premise
58	82	N	I-Premise
59	and	N	I-Premise
60	47	N	I-Premise
61	(	N	I-Premise
62	64	N	I-Premise
63	%	N	I-Premise
64	)	N	I-Premise
65	of	N	I-Premise
66	74	N	I-Premise
67	men	N	I-Premise
68	,	N	I-Premise
69	respectively	N	I-Premise
70	,	N	I-Premise
71	reported	N	I-Premise
72	a	N	I-Premise
73	reduction	N	I-Premise
74	in	N	I-Premise
75	quality	N	I-Premise
76	of	N	I-Premise
77	life	N	I-Premise
78	.	N	I-Premise

1	For	N	I-Premise
2	men	N	I-Premise
3	in	N	I-Premise
4	SPCG-4	N	I-Premise
5	,	N	I-Premise
6	negative	N	I-Premise
7	side-effects	N	I-Premise
8	were	N	I-Premise
9	common	N	I-Premise
10	and	N	I-Premise
11	added	N	I-Premise
12	more	N	I-Premise
13	stress	N	I-Premise
14	than	N	I-Premise
15	was	N	I-Premise
16	reported	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	control	N	I-Premise
20	population	N	I-Premise
21	.	N	I-Premise

1	In	N	I-Claim
2	the	N	I-Claim
3	radical	N	I-Claim
4	prostatectomy	N	I-Claim
5	group	N	I-Claim
6	,	N	I-Claim
7	erectile	N	I-Claim
8	dysfunction	N	I-Claim
9	and	N	I-Claim
10	urinary	N	I-Claim
11	leakage	N	I-Claim
12	were	N	I-Claim
13	often	N	I-Claim
14	consequences	N	I-Claim
15	of	N	I-Claim
16	surgery	N	I-Claim
17	.	N	I-Claim

1	In	N	I-Claim
2	the	N	I-Claim
3	watchful-waiting	N	I-Claim
4	group	N	I-Claim
5	,	N	I-Claim
6	side-effects	N	I-Claim
7	can	N	I-Claim
8	be	N	I-Claim
9	caused	N	I-Claim
10	by	N	I-Claim
11	tumour	N	I-Claim
12	progression	N	I-Claim
13	.	N	I-Claim

1	The	N	I-Claim
2	number	N	I-Claim
3	and	N	I-Claim
4	severity	N	I-Claim
5	of	N	I-Claim
6	side-effects	N	I-Claim
7	changes	N	I-Claim
8	over	N	I-Claim
9	time	N	I-Claim
10	at	N	I-Claim
11	a	N	I-Claim
12	higher	N	I-Claim
13	rate	N	I-Claim
14	than	N	I-Claim
15	is	N	I-Claim
16	caused	N	I-Claim
17	by	N	I-Claim
18	normal	N	I-Claim
19	ageing	N	I-Claim
20	and	N	I-Claim
21	a	N	I-Claim
22	loss	N	I-Claim
23	of	N	I-Claim
24	sexual	N	I-Claim
25	ability	N	I-Claim
26	is	N	I-Claim
27	a	N	I-Claim
28	persistent	N	I-Claim
29	psychological	N	I-Claim
30	problem	N	I-Claim
31	for	N	I-Claim
32	both	N	I-Claim
33	interventions	N	I-Claim
34	.	N	I-Claim

1	An	N	O
2	understanding	N	O
3	of	N	O
4	the	N	O
5	patterns	N	O
6	of	N	O
7	side-effects	N	O
8	and	N	O
9	time	N	O
10	dimension	N	O
11	of	N	O
12	their	N	O
13	occurrence	N	O
14	for	N	O
15	each	N	O
16	treatment	N	O
17	is	N	O
18	important	N	O
19	for	N	O
20	full	N	O
21	patient	N	O
22	information	N	O
23	.	N	O

1	This	N	O
2	randomized	N	O
3	controlled	N	O
4	trial	N	O
5	assessed	N	O
6	the	N	O
7	effect	N	O
8	of	N	O
9	a	N	O
10	SMART	N	O
11	(	N	O
12	Stress	N	O
13	Management	N	O
14	and	N	O
15	Resiliency	N	O
16	Training	N	O
17	)	N	O
18	program	N	O
19	among	N	O
20	25	N	O
21	women	N	O
22	diagnosed	N	O
23	with	N	O
24	breast	N	O
25	cancer	N	O
26	.	N	O

1	Resilience	N	O
2	,	N	O
3	perceived	N	O
4	stress	N	O
5	,	N	O
6	anxiety	N	O
7	,	N	O
8	and	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	improved	N	O
13	at	N	O
14	12	N	O
15	weeks	N	O
16	in	N	O
17	the	N	O
18	active	N	O
19	but	N	O
20	not	N	O
21	the	N	O
22	control	N	O
23	arm	N	O
24	.	N	O

1	A	N	O
2	brief	N	O
3	training	N	O
4	in	N	O
5	the	N	O
6	SMART	N	O
7	program	N	O
8	can	N	O
9	enhance	N	O
10	resilience	N	O
11	and	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	and	N	O
16	decrease	N	O
17	stress	N	O
18	and	N	O
19	anxiety	N	O
20	.	N	O

1	Patients	N	O
2	with	N	O
3	breast	N	O
4	cancer	N	O
5	experience	N	O
6	stress	N	O
7	and	N	O
8	anxiety	N	O
9	related	N	O
10	to	N	O
11	their	N	O
12	diagnosis	N	O
13	,	N	O
14	with	N	O
15	resulting	N	O
16	lower	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	the	N	O
10	effect	N	O
11	of	N	O
12	a	N	O
13	SMART	N	O
14	(	N	O
15	Stress	N	O
16	Management	N	O
17	and	N	O
18	Resiliency	N	O
19	Training	N	O
20	)	N	O
21	program	N	O
22	for	N	O
23	increasing	N	O
24	resiliency	N	O
25	and	N	O
26	for	N	O
27	decreasing	N	O
28	stress	N	O
29	and	N	O
30	anxiety	N	O
31	among	N	O
32	mentors	N	O
33	who	N	O
34	themselves	N	O
35	were	N	O
36	previously	N	O
37	diagnosed	N	O
38	with	N	O
39	breast	N	O
40	cancer	N	O
41	.	N	O

1	The	N	O
2	program	N	O
3	consisted	N	O
4	of	N	O
5	two	N	O
6	90-minute	N	O
7	group	N	O
8	training	N	O
9	sessions	N	O
10	,	N	O
11	a	N	O
12	brief	N	O
13	individual	N	O
14	session	N	O
15	,	N	O
16	and	N	O
17	3	N	O
18	follow-up	N	O
19	telephone	N	O
20	calls	N	O
21	.	N	O

1	Twenty-four	N	O
2	mentors	N	O
3	at	N	O
4	Mayo	N	O
5	Clinic	N	O
6	in	N	O
7	Rochester	N	O
8	,	N	O
9	Minnesota	N	O
10	,	N	O
11	were	N	O
12	randomized	N	O
13	in	N	O
14	a	N	O
15	single-blind	N	O
16	,	N	O
17	wait-list	N	O
18	controlled	N	O
19	clinical	N	O
20	trial	N	O
21	to	N	O
22	either	N	O
23	the	N	O
24	SMART	N	O
25	intervention	N	O
26	or	N	O
27	a	N	O
28	control	N	O
29	group	N	O
30	for	N	O
31	12	N	O
32	weeks	N	O
33	.	N	O

1	Primary	N	O
2	outcome	N	O
3	measures	N	O
4	assessed	N	O
5	at	N	O
6	baseline	N	O
7	and	N	O
8	at	N	O
9	week	N	O
10	12	N	O
11	included	N	O
12	the	N	O
13	Connor	N	O
14	Davidson	N	O
15	Resilience	N	O
16	Scale	N	O
17	,	N	O
18	Perceived	N	O
19	Stress	N	O
20	Scale	N	O
21	,	N	O
22	Smith	N	O
23	Anxiety	N	O
24	Scale	N	O
25	,	N	O
26	and	N	O
27	Linear	N	O
28	Analog	N	O
29	Self	N	O
30	Assessment	N	O
31	Scale	N	O
32	.	N	O

1	Twenty	N	O
2	patients	N	O
3	completed	N	O
4	the	N	O
5	study	N	O
6	.	N	O

1	A	N	I-Premise
2	statistically	N	I-Premise
3	significant	N	I-Premise
4	improvement	N	I-Premise
5	in	N	I-Premise
6	resilience	N	I-Premise
7	,	N	I-Premise
8	perceived	N	I-Premise
9	stress	N	I-Premise
10	,	N	I-Premise
11	anxiety	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	overall	N	I-Premise
15	quality	N	I-Premise
16	of	N	I-Premise
17	life	N	I-Premise
18	at	N	I-Premise
19	12	N	I-Premise
20	weeks	N	I-Premise
21	,	N	I-Premise
22	compared	N	I-Premise
23	with	N	I-Premise
24	baseline	N	I-Premise
25	was	N	I-Premise
26	observed	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	study	N	I-Premise
30	arm	N	I-Premise
31	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	difference	N	I-Premise
4	in	N	I-Premise
5	any	N	I-Premise
6	of	N	I-Premise
7	these	N	I-Premise
8	measures	N	I-Premise
9	was	N	I-Premise
10	noted	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	control	N	I-Premise
14	group	N	I-Premise
15	.	N	I-Premise

1	This	N	I-Claim
2	study	N	I-Claim
3	demonstrates	N	I-Claim
4	that	N	I-Claim
5	a	N	I-Claim
6	brief	N	I-Claim
7	,	N	I-Claim
8	predominantly	N	I-Claim
9	group-based	N	I-Claim
10	resilience	N	I-Claim
11	training	N	I-Claim
12	intervention	N	I-Claim
13	is	N	I-Claim
14	feasible	N	I-Claim
15	in	N	I-Claim
16	patients	N	I-Claim
17	with	N	I-Claim
18	previous	N	I-Claim
19	breast	N	I-Claim
20	cancer	N	I-Claim
21	;	N	I-Claim
22	also	N	I-Claim
23	,	N	I-Claim
24	it	N	I-Claim
25	may	N	I-Claim
26	be	N	I-Claim
27	efficacious	N	I-Claim
28	.	N	I-Claim

1	To	N	O
2	examine	N	O
3	health-related	N	O
4	quality	N	O
5	of	N	O
6	life	N	O
7	,	N	O
8	we	N	O
9	investigated	N	O
10	the	N	O
11	effect	N	O
12	of	N	O
13	adjuvant	N	O
14	chemotherapy	N	O
15	regimens	N	O
16	on	N	O
17	utility	N	O
18	scores	N	O
19	assessed	N	O
20	by	N	O
21	the	N	O
22	EuroQoL-5D	N	O
23	(	N	O
24	EQ-5D	N	O
25	)	N	O
26	instrument	N	O
27	in	N	O
28	a	N	O
29	randomized	N	O
30	,	N	O
31	controlled	N	O
32	trial	N	O
33	for	N	O
34	breast	N	O
35	cancer	N	O
36	patients	N	O
37	after	N	O
38	surgery	N	O
39	.	N	O

1	We	N	O
2	also	N	O
3	investigated	N	O
4	the	N	O
5	relationship	N	O
6	between	N	O
7	Functional	N	O
8	Assessment	N	O
9	of	N	O
10	Cancer	N	O
11	Therapy	N	O
12	(	N	O
13	FACT	N	O
14	)	N	O
15	scale	N	O
16	scores	N	O
17	and	N	O
18	EQ-5D	N	O
19	utilities	N	O
20	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	the	N	O
7	following	N	O
8	four	N	O
9	chemotherapy	N	O
10	regimens	N	O
11	:	N	O
12	four	N	O
13	cycles	N	O
14	of	N	O
15	anthracycline	N	O
16	followed	N	O
17	by	N	O
18	paclitaxel	N	O
19	(	N	O
20	ACP	N	O
21	)	N	O
22	,	N	O
23	four	N	O
24	cycles	N	O
25	of	N	O
26	anthracycline-containing	N	O
27	regimens	N	O
28	followed	N	O
29	by	N	O
30	docetaxel	N	O
31	(	N	O
32	ACD	N	O
33	)	N	O
34	,	N	O
35	eight	N	O
36	cycles	N	O
37	of	N	O
38	paclitaxel	N	O
39	(	N	O
40	PTX	N	O
41	)	N	O
42	,	N	O
43	and	N	O
44	eight	N	O
45	cycles	N	O
46	of	N	O
47	docetaxel	N	O
48	(	N	O
49	DTX	N	O
50	)	N	O
51	.	N	O

1	Of	N	O
2	1060	N	O
3	registered	N	O
4	,	N	O
5	the	N	O
6	first	N	O
7	300	N	O
8	consecutive	N	O
9	patients	N	O
10	were	N	O
11	included	N	O
12	in	N	O
13	the	N	O
14	current	N	O
15	utility	N	O
16	study	N	O
17	.	N	O

1	Utility	N	O
2	scores	N	O
3	were	N	O
4	assessed	N	O
5	using	N	O
6	the	N	O
7	EQ-5D	N	O
8	instrument	N	O
9	at	N	O
10	baseline	N	O
11	;	N	O
12	cycles	N	O
13	3	N	O
14	,	N	O
15	5	N	O
16	,	N	O
17	and	N	O
18	7	N	O
19	;	N	O
20	7	N	O
21	months	N	O
22	;	N	O
23	and	N	O
24	1	N	O
25	year	N	O
26	.	N	O

1	We	N	O
2	also	N	O
3	evaluated	N	O
4	the	N	O
5	correlation	N	O
6	between	N	O
7	these	N	O
8	scores	N	O
9	and	N	O
10	FACT-G	N	O
11	,	N	O
12	-B	N	O
13	,	N	O
14	and	N	O
15	-Taxane	N	O
16	scores	N	O
17	at	N	O
18	each	N	O
19	time	N	O
20	point	N	O
21	.	N	O

1	Utility	N	I-Premise
2	scores	N	I-Premise
3	were	N	I-Premise
4	significantly	N	I-Premise
5	lower	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	DTX	N	I-Premise
9	group	N	I-Premise
10	than	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	ACP	N	I-Premise
14	and	N	I-Premise
15	ACD	N	I-Premise
16	groups	N	I-Premise
17	.	N	I-Premise

1	Mean	N	I-Premise
2	utility	N	I-Premise
3	scores	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	DTX	N	I-Premise
7	group	N	I-Premise
8	were	N	I-Premise
9	lowest	N	I-Premise
10	at	N	I-Premise
11	7	N	I-Premise
12	months	N	I-Premise
13	and	N	I-Premise
14	tended	N	I-Premise
15	to	N	I-Premise
16	remain	N	I-Premise
17	low	N	I-Premise
18	for	N	I-Premise
19	a	N	I-Premise
20	long	N	I-Premise
21	time	N	I-Premise
22	.	N	I-Premise

1	The	N	I-Premise
2	combined	N	I-Premise
3	anthracycline	N	I-Premise
4	followed	N	I-Premise
5	by	N	I-Premise
6	taxane	N	I-Premise
7	group	N	I-Premise
8	had	N	I-Premise
9	significantly	N	I-Premise
10	higher	N	I-Premise
11	utility	N	I-Premise
12	scores	N	I-Premise
13	that	N	I-Premise
14	the	N	I-Premise
15	taxane-alone	N	I-Premise
16	group	N	I-Premise
17	,	N	I-Premise
18	with	N	I-Premise
19	no	N	I-Premise
20	significant	N	I-Premise
21	difference	N	I-Premise
22	depending	N	I-Premise
23	on	N	I-Premise
24	the	N	I-Premise
25	type	N	I-Premise
26	of	N	I-Premise
27	taxane	N	I-Premise
28	.	N	I-Premise

1	Only	N	I-Premise
2	the	N	I-Premise
3	FACT-G	N	I-Premise
4	social/family	N	I-Premise
5	well-being	N	I-Premise
6	subscale	N	I-Premise
7	had	N	I-Premise
8	no	N	I-Premise
9	relationship	N	I-Premise
10	with	N	I-Premise
11	EQ-5D	N	I-Premise
12	responses	N	I-Premise
13	and	N	I-Premise
14	utility	N	I-Premise
15	scores	N	I-Premise
16	.	N	I-Premise

1	Although	N	I-Claim
2	the	N	I-Claim
3	regimens	N	I-Claim
4	in	N	I-Claim
5	this	N	I-Claim
6	study	N	I-Claim
7	were	N	I-Claim
8	similar	N	I-Claim
9	in	N	I-Claim
10	that	N	I-Claim
11	they	N	I-Claim
12	included	N	I-Claim
13	taxane	N	I-Claim
14	,	N	I-Claim
15	the	N	I-Claim
16	mean	N	I-Claim
17	utility	N	I-Claim
18	scores	N	I-Claim
19	and	N	I-Claim
20	longitudinal	N	I-Claim
21	patterns	N	I-Claim
22	of	N	I-Claim
23	utility	N	I-Claim
24	scores	N	I-Claim
25	were	N	I-Claim
26	different	N	I-Claim
27	among	N	I-Claim
28	regimens	N	I-Claim
29	.	N	I-Claim

1	The	N	I-MajorClaim
2	postoperative	N	I-MajorClaim
3	clinical	N	I-MajorClaim
4	superiority	N	I-MajorClaim
5	of	N	I-MajorClaim
6	the	N	I-MajorClaim
7	interposition	N	I-MajorClaim
8	of	N	I-MajorClaim
9	jejunum	N	I-MajorClaim
10	reconstruction	N	I-MajorClaim
11	(	N	I-MajorClaim
12	INT	N	I-MajorClaim
13	)	N	I-MajorClaim
14	to	N	I-MajorClaim
15	Roux-en-Y	N	I-MajorClaim
16	reconstruction	N	I-MajorClaim
17	(	N	I-MajorClaim
18	RY	N	I-MajorClaim
19	)	N	I-MajorClaim
20	after	N	I-MajorClaim
21	total	N	I-MajorClaim
22	gastrectomy	N	I-MajorClaim
23	has	N	I-MajorClaim
24	not	N	I-MajorClaim
25	been	N	I-MajorClaim
26	clarified	N	I-MajorClaim
27	.	N	I-MajorClaim

1	Postoperative	N	O
2	quality	N	O
3	of	N	O
4	life	N	O
5	(	N	O
6	QOL	N	O
7	)	N	O
8	was	N	O
9	evaluated	N	O
10	between	N	O
11	the	N	O
12	2	N	O
13	methods	N	O
14	by	N	O
15	a	N	O
16	multi-institutional	N	O
17	prospective	N	O
18	randomized	N	O
19	trial	N	O
20	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	103	N	O
5	patients	N	O
6	with	N	O
7	gastric	N	O
8	cancer	N	O
9	were	N	O
10	prospectively	N	O
11	randomly	N	O
12	divided	N	O
13	into	N	O
14	groups	N	O
15	for	N	O
16	RY	N	O
17	(	N	O
18	n	N	O
19	=	N	O
20	51	N	O
21	)	N	O
22	or	N	O
23	INT	N	O
24	reconstruction	N	O
25	(	N	O
26	n	N	O
27	=	N	O
28	52	N	O
29	)	N	O
30	after	N	O
31	total	N	O
32	gastrectomy	N	O
33	.	N	O

1	They	N	O
2	were	N	O
3	stratified	N	O
4	by	N	O
5	sex	N	O
6	,	N	O
7	age	N	O
8	,	N	O
9	institute	N	O
10	,	N	O
11	histology	N	O
12	,	N	O
13	and	N	O
14	degree	N	O
15	of	N	O
16	lymph	N	O
17	node	N	O
18	dissection	N	O
19	.	N	O

1	Postoperatively	N	O
2	,	N	O
3	body	N	O
4	mass	N	O
5	index	N	O
6	(	N	O
7	BMI	N	O
8	)	N	O
9	and	N	O
10	nutritional	N	O
11	conditions	N	O
12	were	N	O
13	measured	N	O
14	serially	N	O
15	,	N	O
16	and	N	O
17	QOL	N	O
18	and	N	O
19	postoperative	N	O
20	squalor	N	O
21	scores	N	O
22	were	N	O
23	evaluated	N	O
24	at	N	O
25	3	N	O
26	,	N	O
27	12	N	O
28	,	N	O
29	and	N	O
30	60	N	O
31	months	N	O
32	and	N	O
33	compared	N	O
34	between	N	O
35	the	N	O
36	2	N	O
37	groups	N	O
38	.	N	O

1	After	N	O
2	removing	N	O
3	patients	N	O
4	who	N	O
5	did	N	O
6	not	N	O
7	complete	N	O
8	the	N	O
9	follow-up	N	O
10	survey	N	O
11	or	N	O
12	censured	N	O
13	cases	N	O
14	,	N	O
15	24	N	O
16	patients	N	O
17	in	N	O
18	the	N	O
19	RY	N	O
20	group	N	O
21	and	N	O
22	18	N	O
23	patients	N	O
24	in	N	O
25	the	N	O
26	INT	N	O
27	group	N	O
28	were	N	O
29	clinically	N	O
30	available	N	O
31	and	N	O
32	their	N	O
33	postoperative	N	O
34	status	N	O
35	was	N	O
36	assessed	N	O
37	.	N	O

1	QOL	N	I-Premise
2	scores	N	I-Premise
3	were	N	I-Premise
4	increased	N	I-Premise
5	and	N	I-Premise
6	complication	N	I-Premise
7	scores	N	I-Premise
8	were	N	I-Premise
9	improved	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	postoperative	N	I-Premise
13	periods	N	I-Premise
14	(	N	I-Premise
15	P	N	I-Premise
16	<	N	I-Premise
17	.01	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	Postoperative	N	I-Premise
2	BMI	N	I-Premise
3	significantly	N	I-Premise
4	deteriorated	N	I-Premise
5	compared	N	I-Premise
6	with	N	I-Premise
7	preoperative	N	I-Premise
8	BMI	N	I-Premise
9	in	N	I-Premise
10	each	N	I-Premise
11	group	N	I-Premise
12	.	N	I-Premise

1	The	N	I-Premise
2	postoperative	N	I-Premise
3	QOL	N	I-Premise
4	and	N	I-Premise
5	complication	N	I-Premise
6	scores	N	I-Premise
7	at	N	I-Premise
8	60	N	I-Premise
9	months	N	I-Premise
10	after	N	I-Premise
11	surgery	N	I-Premise
12	were	N	I-Premise
13	significantly	N	I-Premise
14	better	N	I-Premise
15	than	N	I-Premise
16	those	N	I-Premise
17	at	N	I-Premise
18	3	N	I-Premise
19	months	N	I-Premise
20	after	N	I-Premise
21	surgery	N	I-Premise
22	in	N	I-Premise
23	each	N	I-Premise
24	group	N	I-Premise
25	(	N	I-Premise
26	P	N	I-Premise
27	<	N	I-Premise
28	.01	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	However	N	O
2	,	N	O
3	there	N	I-Premise
4	was	N	I-Premise
5	no	N	I-Premise
6	significant	N	I-Premise
7	difference	N	I-Premise
8	of	N	I-Premise
9	QOL	N	I-Premise
10	scores	N	I-Premise
11	and	N	I-Premise
12	postoperative	N	I-Premise
13	complication	N	I-Premise
14	scores	N	I-Premise
15	between	N	I-Premise
16	the	N	I-Premise
17	2	N	I-Premise
18	reconstruction	N	I-Premise
19	groups	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	nutritional	N	I-Premise
3	condition	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	INT	N	I-Premise
7	group	N	I-Premise
8	was	N	I-Premise
9	nearly	N	I-Premise
10	the	N	I-Premise
11	same	N	I-Premise
12	as	N	I-Premise
13	that	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	RY	N	I-Premise
17	group	N	I-Premise
18	.	N	I-Premise

1	Although	N	I-Premise
2	our	N	I-Premise
3	patient	N	I-Premise
4	sample	N	I-Premise
5	was	N	I-Premise
6	small	N	I-Premise
7	and	N	I-Premise
8	patients	N	I-Premise
9	who	N	I-Premise
10	did	N	I-Premise
11	not	N	I-Premise
12	complete	N	I-Premise
13	the	N	I-Premise
14	follow-up	N	I-Premise
15	survey	N	I-Premise
16	were	N	I-Premise
17	present	N	I-Premise
18	,	N	I-Premise
19	we	N	I-Claim
20	could	N	I-Claim
21	not	N	I-Claim
22	identify	N	I-Claim
23	any	N	I-Claim
24	clinical	N	I-Claim
25	difference	N	I-Claim
26	between	N	I-Claim
27	INT	N	I-Claim
28	and	N	I-Claim
29	RY	N	I-Claim
30	after	N	I-Claim
31	total	N	I-Claim
32	gastrectomy	N	I-Claim
33	60	N	I-Claim
34	months	N	I-Claim
35	after	N	I-Claim
36	surgery	N	I-Claim
37	.	N	I-Claim

1	The	N	I-MajorClaim
2	safer	N	I-MajorClaim
3	and	N	I-MajorClaim
4	simpler	N	I-MajorClaim
5	RY	N	I-MajorClaim
6	method	N	I-MajorClaim
7	may	N	I-MajorClaim
8	be	N	I-MajorClaim
9	a	N	I-MajorClaim
10	more	N	I-MajorClaim
11	suitable	N	I-MajorClaim
12	reconstruction	N	I-MajorClaim
13	method	N	I-MajorClaim
14	than	N	I-MajorClaim
15	INT	N	I-MajorClaim
16	after	N	I-MajorClaim
17	total	N	I-MajorClaim
18	gastrectomy	N	I-MajorClaim
19	.	N	I-MajorClaim

1	Gemcitabine	N	O
2	for	N	O
3	advanced	N	O
4	pancreatic	N	O
5	cancer	N	O
6	(	N	O
7	APC	N	O
8	)	N	O
9	is	N	O
10	palliative	N	O
11	and	N	O
12	the	N	O
13	prognosis	N	O
14	is	N	O
15	poor	N	O
16	,	N	O
17	making	N	O
18	health-related	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	(	N	O
23	HRQOL	N	O
24	)	N	O
25	particularly	N	O
26	important	N	O
27	.	N	O

1	We	N	O
2	evaluated	N	O
3	HRQOL	N	O
4	with	N	O
5	the	N	O
6	EuroQol	N	O
7	(	N	O
8	EQ-5D™	N	O
9	)	N	O
10	in	N	O
11	patients	N	O
12	with	N	O
13	APC	N	O
14	participating	N	O
15	in	N	O
16	Cancer	N	O
17	and	N	O
18	Leukemia	N	O
19	Group	N	O
20	B	N	O
21	80303	N	O
22	,	N	O
23	a	N	O
24	multicenter	N	O
25	,	N	O
26	double-blind	N	O
27	,	N	O
28	randomized	N	O
29	trial	N	O
30	comparing	N	O
31	overall	N	O
32	survival	N	O
33	(	N	O
34	OS	N	O
35	)	N	O
36	between	N	O
37	two	N	O
38	treatment	N	O
39	arms	N	O
40	:	N	O
41	gemcitabine	N	O
42	with	N	O
43	bevacizumab	N	O
44	or	N	O
45	gemcitabine	N	O
46	with	N	O
47	placebo	N	O
48	.	N	O

1	A	N	O
2	consecutive	N	O
3	subsample	N	O
4	of	N	O
5	patients	N	O
6	was	N	O
7	invited	N	O
8	to	N	O
9	complete	N	O
10	the	N	O
11	EQ-5D	N	O
12	surveys	N	O
13	.	N	O

1	Because	N	O
2	neither	N	O
3	clinical	N	O
4	nor	N	O
5	HRQOL	N	O
6	outcomes	N	O
7	differed	N	O
8	based	N	O
9	on	N	O
10	the	N	O
11	study	N	O
12	arm	N	O
13	,	N	O
14	analyses	N	O
15	were	N	O
16	pooled	N	O
17	.	N	O

1	Changes	N	O
2	in	N	O
3	mean	N	O
4	scores	N	O
5	from	N	O
6	baseline	N	O
7	to	N	O
8	eight	N	O
9	weeks	N	O
10	and	N	O
11	the	N	O
12	prognostic	N	O
13	value	N	O
14	of	N	O
15	the	N	O
16	EQ-5D	N	O
17	were	N	O
18	evaluated	N	O
19	.	N	O

1	Mean	N	I-Premise
2	index	N	I-Premise
3	scores	N	I-Premise
4	remained	N	I-Premise
5	stable	N	I-Premise
6	(	N	I-Premise
7	0.78	N	I-Premise
8	at	N	I-Premise
9	baseline	N	I-Premise
10	[	N	I-Premise
11	n=267	N	I-Premise
12	]	N	I-Premise
13	,	N	I-Premise
14	0.79	N	I-Premise
15	at	N	I-Premise
16	eight	N	I-Premise
17	weeks	N	I-Premise
18	[	N	I-Premise
19	n=186	N	I-Premise
20	]	N	I-Premise
21	,	N	I-Premise
22	P=0.34	N	I-Premise
23	,	N	I-Premise
24	Wilcoxon	N	I-Premise
25	signed	N	I-Premise
26	rank	N	I-Premise
27	test	N	I-Premise
28	)	N	I-Premise
29	,	N	I-Premise
30	attributable	N	I-Premise
31	to	N	I-Premise
32	a	N	I-Premise
33	modest	N	I-Premise
34	deterioration	N	I-Premise
35	of	N	I-Premise
36	physical	N	I-Premise
37	function	N	I-Premise
38	domain	N	I-Premise
39	scores	N	I-Premise
40	coincident	N	I-Premise
41	with	N	I-Premise
42	small	N	I-Premise
43	improvements	N	I-Premise
44	in	N	I-Premise
45	pain	N	I-Premise
46	and	N	I-Premise
47	anxiety/depression	N	I-Premise
48	scores	N	I-Premise
49	.	N	I-Premise

1	A	N	I-Premise
2	small	N	I-Premise
3	decline	N	I-Premise
4	in	N	I-Premise
5	visual	N	I-Premise
6	analogue	N	I-Premise
7	scale	N	I-Premise
8	scores	N	I-Premise
9	was	N	I-Premise
10	observed	N	I-Premise
11	(	N	I-Premise
12	70.7	N	I-Premise
13	vs.	N	I-Premise
14	68.2	N	I-Premise
15	,	N	I-Premise
16	P=0.026	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	HRQOL	N	I-Premise
2	changes	N	I-Premise
3	within	N	I-Premise
4	chemotherapy	N	I-Premise
5	response	N	I-Premise
6	strata	N	I-Premise
7	revealed	N	I-Premise
8	stable	N	I-Premise
9	index	N	I-Premise
10	scores	N	I-Premise
11	but	N	I-Premise
12	a	N	I-Premise
13	trend	N	I-Premise
14	of	N	I-Premise
15	worsened	N	I-Premise
16	physical	N	I-Premise
17	function	N	I-Premise
18	among	N	I-Premise
19	patients	N	I-Premise
20	with	N	I-Premise
21	disease	N	I-Premise
22	progression	N	I-Premise
23	compared	N	I-Premise
24	with	N	I-Premise
25	those	N	I-Premise
26	with	N	I-Premise
27	stable	N	I-Premise
28	or	N	I-Premise
29	improved	N	I-Premise
30	disease	N	I-Premise
31	.	N	I-Premise

1	Visual	N	I-Premise
2	analogue	N	I-Premise
3	scale	N	I-Premise
4	scores	N	I-Premise
5	trended	N	I-Premise
6	downward	N	I-Premise
7	over	N	I-Premise
8	time	N	I-Premise
9	irrespective	N	I-Premise
10	of	N	I-Premise
11	chemotherapy	N	I-Premise
12	response	N	I-Premise
13	status	N	I-Premise
14	,	N	I-Premise
15	with	N	I-Premise
16	a	N	I-Premise
17	statistically	N	I-Premise
18	meaningful	N	I-Premise
19	deterioration	N	I-Premise
20	in	N	I-Premise
21	patients	N	I-Premise
22	who	N	I-Premise
23	progressed	N	I-Premise
24	(	N	I-Premise
25	68.9	N	I-Premise
26	vs.	N	I-Premise
27	64.4	N	I-Premise
28	,	N	I-Premise
29	P=0.029	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	Baseline	N	O
2	scores	N	O
3	from	N	O
4	both	N	O
5	EQ-5D	N	O
6	scales	N	O
7	were	N	O
8	significant	N	O
9	predictors	N	O
10	of	N	O
11	OS	N	O
12	in	N	O
13	Cox	N	O
14	proportional	N	O
15	hazard	N	O
16	models	N	O
17	.	N	O

1	Response	N	I-Claim
2	to	N	I-Claim
3	gemcitabine	N	I-Claim
4	treatment	N	I-Claim
5	in	N	I-Claim
6	APC	N	I-Claim
7	is	N	I-Claim
8	not	N	I-Claim
9	associated	N	I-Claim
10	with	N	I-Claim
11	appreciable	N	I-Claim
12	improvement	N	I-Claim
13	of	N	I-Claim
14	global	N	I-Claim
15	HRQOL	N	I-Claim
16	.	N	I-Claim

1	Small	N	O
2	improvements	N	O
3	in	N	O
4	pain	N	O
5	and	N	O
6	mood	N	O
7	are	N	O
8	observed	N	O
9	despite	N	O
10	progressive	N	O
11	functional	N	O
12	decline	N	O
13	.	N	O

1	Those	N	I-Claim
2	who	N	I-Claim
3	respond	N	I-Claim
4	to	N	I-Claim
5	gemcitabine	N	I-Claim
6	may	N	I-Claim
7	experience	N	I-Claim
8	a	N	I-Claim
9	slight	N	I-Claim
10	slowing	N	I-Claim
11	of	N	I-Claim
12	functional	N	I-Claim
13	deterioration	N	I-Claim
14	.	N	I-Claim

1	Observational	N	O
2	studies	N	O
3	demonstrate	N	O
4	an	N	O
5	association	N	O
6	between	N	O
7	physical	N	O
8	activity	N	O
9	and	N	O
10	improved	N	O
11	outcomes	N	O
12	in	N	O
13	breast	N	O
14	and	N	O
15	colon	N	O
16	cancer	N	O
17	survivors	N	O
18	.	N	O

1	To	N	O
2	test	N	O
3	these	N	O
4	observations	N	O
5	with	N	O
6	a	N	O
7	large	N	O
8	,	N	O
9	randomized	N	O
10	clinical	N	O
11	trial	N	O
12	,	N	O
13	an	N	O
14	intervention	N	O
15	that	N	O
16	significantly	N	O
17	impacts	N	O
18	physical	N	O
19	activity	N	O
20	in	N	O
21	these	N	O
22	patients	N	O
23	is	N	O
24	needed	N	O
25	.	N	O

1	The	N	O
2	Active	N	O
3	After	N	O
4	Cancer	N	O
5	Trial	N	O
6	(	N	O
7	AACT	N	O
8	)	N	O
9	was	N	O
10	a	N	O
11	multicenter	N	O
12	pilot	N	O
13	study	N	O
14	evaluating	N	O
15	the	N	O
16	feasibility	N	O
17	of	N	O
18	a	N	O
19	telephone-based	N	O
20	exercise	N	O
21	intervention	N	O
22	in	N	O
23	a	N	O
24	cooperative	N	O
25	group	N	O
26	setting	N	O
27	.	N	O

1	Sedentary	N	O
2	(	N	O
3	engaging	N	O
4	in	N	O
5	<	N	O
6	60	N	O
7	min	N	O
8	of	N	O
9	recreational	N	O
10	activity/week	N	O
11	)	N	O
12	breast	N	O
13	and	N	O
14	colorectal	N	O
15	cancer	N	O
16	survivors	N	O
17	were	N	O
18	randomized	N	O
19	to	N	O
20	a	N	O
21	telephone-based	N	O
22	exercise	N	O
23	intervention	N	O
24	or	N	O
25	usual	N	O
26	care	N	O
27	control	N	O
28	group	N	O
29	.	N	O

1	The	N	O
2	intervention	N	O
3	was	N	O
4	delivered	N	O
5	through	N	O
6	the	N	O
7	University	N	O
8	of	N	O
9	California	N	O
10	at	N	O
11	San	N	O
12	Diego	N	O
13	;	N	O
14	participants	N	O
15	received	N	O
16	ten	N	O
17	phone	N	O
18	calls	N	O
19	over	N	O
20	the	N	O
21	course	N	O
22	of	N	O
23	the	N	O
24	16-week	N	O
25	intervention	N	O
26	.	N	O

1	All	N	O
2	participants	N	O
3	underwent	N	O
4	assessment	N	O
5	of	N	O
6	physical	N	O
7	activity	N	O
8	,	N	O
9	fitness	N	O
10	,	N	O
11	physical	N	O
12	functioning	N	O
13	,	N	O
14	fatigue	N	O
15	and	N	O
16	exercise	N	O
17	self-efficacy	N	O
18	at	N	O
19	baseline	N	O
20	and	N	O
21	after	N	O
22	the	N	O
23	16-week	N	O
24	intervention	N	O
25	.	N	O

1	One	N	O
2	hundred	N	O
3	and	N	O
4	twenty-one	N	O
5	patients	N	O
6	were	N	O
7	enrolled	N	O
8	through	N	O
9	ten	N	O
10	Cancer	N	O
11	and	N	O
12	Leukemia	N	O
13	Group	N	O
14	B	N	O
15	(	N	O
16	CALGB	N	O
17	)	N	O
18	institutions	N	O
19	;	N	O
20	100	N	O
21	patients	N	O
22	had	N	O
23	breast	N	O
24	cancer	N	O
25	and	N	O
26	21	N	O
27	had	N	O
28	colorectal	N	O
29	cancer	N	O
30	.	N	O

1	Participants	N	I-Premise
2	randomized	N	I-Premise
3	to	N	I-Premise
4	the	N	I-Premise
5	exercise	N	I-Premise
6	group	N	I-Premise
7	increased	N	I-Premise
8	physical	N	I-Premise
9	activity	N	I-Premise
10	by	N	I-Premise
11	more	N	I-Premise
12	than	N	I-Premise
13	100	N	I-Premise
14	versus	N	I-Premise
15	22	N	I-Premise
16	%	N	I-Premise
17	in	N	I-Premise
18	controls	N	I-Premise
19	(	N	I-Premise
20	54.5	N	I-Premise
21	vs.	N	I-Premise
22	14.6	N	I-Premise
23	min	N	I-Premise
24	,	N	I-Premise
25	P	N	I-Premise
26	=	N	I-Premise
27	0.13	N	I-Premise
28	)	N	I-Premise
29	,	N	I-Premise
30	and	N	I-Premise
31	experienced	N	I-Premise
32	significant	N	I-Premise
33	increases	N	I-Premise
34	in	N	I-Premise
35	fitness	N	I-Premise
36	(	N	I-Premise
37	increased	N	I-Premise
38	6-min	N	I-Premise
39	walk	N	I-Premise
40	test	N	I-Premise
41	distance	N	I-Premise
42	by	N	I-Premise
43	186.9	N	I-Premise
44	vs.	N	I-Premise
45	81.9	N	I-Premise
46	feet	N	I-Premise
47	,	N	I-Premise
48	P	N	I-Premise
49	=	N	I-Premise
50	0.006	N	I-Premise
51	)	N	I-Premise
52	and	N	I-Premise
53	physical	N	I-Premise
54	functioning	N	I-Premise
55	(	N	I-Premise
56	7.1	N	I-Premise
57	vs.	N	I-Premise
58	2.6	N	I-Premise
59	,	N	I-Premise
60	P	N	I-Premise
61	=	N	I-Premise
62	0.04	N	I-Premise
63	)	N	I-Premise
64	as	N	I-Premise
65	compared	N	I-Premise
66	to	N	I-Premise
67	the	N	I-Premise
68	control	N	I-Premise
69	group	N	I-Premise
70	.	N	I-Premise

1	Breast	N	I-Claim
2	and	N	I-Claim
3	colorectal	N	I-Claim
4	cancer	N	I-Claim
5	survivors	N	I-Claim
6	enrolled	N	I-Claim
7	in	N	I-Claim
8	a	N	I-Claim
9	multicenter	N	I-Claim
10	,	N	I-Claim
11	telephone-based	N	I-Claim
12	physical	N	I-Claim
13	activity	N	I-Claim
14	intervention	N	I-Claim
15	increased	N	I-Claim
16	physical	N	I-Claim
17	activity	N	I-Claim
18	and	N	I-Claim
19	experienced	N	I-Claim
20	significant	N	I-Claim
21	improvements	N	I-Claim
22	in	N	I-Claim
23	fitness	N	I-Claim
24	and	N	I-Claim
25	physical	N	I-Claim
26	functioning	N	I-Claim
27	.	N	I-Claim

1	Lifestyle	N	I-MajorClaim
2	intervention	N	I-MajorClaim
3	research	N	I-MajorClaim
4	is	N	I-MajorClaim
5	feasible	N	I-MajorClaim
6	in	N	I-MajorClaim
7	a	N	I-MajorClaim
8	cooperative	N	I-MajorClaim
9	group	N	I-MajorClaim
10	setting	N	I-MajorClaim
11	.	N	I-MajorClaim

1	This	N	O
2	study	N	O
3	sought	N	O
4	to	N	O
5	evaluate	N	O
6	effectiveness	N	O
7	of	N	O
8	autologous	N	O
9	dendritic	N	O
10	cell	N	O
11	vaccine	N	O
12	(	N	O
13	immunotherapy	N	O
14	)	N	O
15	for	N	O
16	glioblastoma	N	O
17	multiforme	N	O
18	(	N	O
19	GBM	N	O
20	)	N	O
21	.	N	O

1	Patients	N	O
2	14	N	O
3	to	N	O
4	70	N	O
5	years	N	O
6	of	N	O
7	age	N	O
8	with	N	O
9	newly	N	O
10	diagnosed	N	O
11	GBM	N	O
12	and	N	O
13	Karnofsky	N	O
14	Performance	N	O
15	Scale	N	O
16	(	N	O
17	KPS	N	O
18	)	N	O
19	score	N	O
20	>	N	O
21	70	N	O
22	who	N	O
23	were	N	O
24	receiving	N	O
25	initial	N	O
26	treatment	N	O
27	were	N	O
28	enrolled	N	O
29	and	N	O
30	were	N	O
31	randomized	N	O
32	into	N	O
33	2	N	O
34	groups	N	O
35	during	N	O
36	the	N	O
37	5-year	N	O
38	study	N	O
39	period	N	O
40	.	N	O

1	Eighteen	N	O
2	patients	N	O
3	underwent	N	O
4	conventional	N	O
5	treatment	N	O
6	(	N	O
7	surgery	N	O
8	,	N	O
9	radiotherapy	N	O
10	,	N	O
11	and	N	O
12	chemotherapy	N	O
13	)	N	O
14	and	N	O
15	received	N	O
16	adjuvant	N	O
17	autologous	N	O
18	dendritic	N	O
19	cell	N	O
20	vaccine	N	O
21	,	N	O
22	and	N	O
23	16	N	O
24	patients	N	O
25	(	N	O
26	control	N	O
27	group	N	O
28	)	N	O
29	underwent	N	O
30	conventional	N	O
31	treatment	N	O
32	only	N	O
33	.	N	O

1	Administration	N	O
2	of	N	O
3	the	N	O
4	vaccine	N	O
5	was	N	O
6	begun	N	O
7	within	N	O
8	1	N	O
9	to	N	O
10	2	N	O
11	months	N	O
12	postoperatively	N	O
13	,	N	O
14	with	N	O
15	10	N	O
16	inoculations	N	O
17	given	N	O
18	over	N	O
19	6	N	O
20	months	N	O
21	.	N	O

1	Outcome	N	O
2	measures	N	O
3	were	N	O
4	overall	N	O
5	survival	N	O
6	(	N	O
7	OS	N	O
8	)	N	O
9	;	N	O
10	progression-free	N	O
11	survival	N	O
12	(	N	O
13	PFS	N	O
14	)	N	O
15	;	N	O
16	1-	N	O
17	,	N	O
18	2-	N	O
19	,	N	O
20	and	N	O
21	3-year	N	O
22	survival	N	O
23	rates	N	O
24	,	N	O
25	and	N	O
26	quality	N	O
27	of	N	O
28	life	N	O
29	(	N	O
30	QoL	N	O
31	)	N	O
32	.	N	O

1	Follow-up	N	O
2	time	N	O
3	ranged	N	O
4	from	N	O
5	14	N	O
6	to	N	O
7	56	N	O
8	months	N	O
9	(	N	O
10	median	N	O
11	,	N	O
12	33	N	O
13	months	N	O
14	)	N	O
15	.	N	O

1	The	N	I-Premise
2	1-	N	I-Premise
3	,	N	I-Premise
4	2-	N	I-Premise
5	,	N	I-Premise
6	and	N	I-Premise
7	3-year	N	I-Premise
8	survival	N	I-Premise
9	rates	N	I-Premise
10	were	N	I-Premise
11	88.9	N	I-Premise
12	%	N	I-Premise
13	,	N	I-Premise
14	44.4	N	I-Premise
15	%	N	I-Premise
16	,	N	I-Premise
17	and	N	I-Premise
18	16.7	N	I-Premise
19	%	N	I-Premise
20	for	N	I-Premise
21	the	N	I-Premise
22	vaccine	N	I-Premise
23	group	N	I-Premise
24	,	N	I-Premise
25	respectively	N	I-Premise
26	,	N	I-Premise
27	and	N	I-Premise
28	75.0	N	I-Premise
29	%	N	I-Premise
30	,	N	I-Premise
31	18.8	N	I-Premise
32	%	N	I-Premise
33	,	N	I-Premise
34	and	N	I-Premise
35	0	N	I-Premise
36	%	N	I-Premise
37	,	N	I-Premise
38	respectively	N	I-Premise
39	,	N	I-Premise
40	for	N	I-Premise
41	the	N	I-Premise
42	control	N	I-Premise
43	group	N	I-Premise
44	,	N	I-Premise
45	(	N	I-Premise
46	P	N	I-Premise
47	=	N	I-Premise
48	0.299	N	I-Premise
49	,	N	I-Premise
50	0.0035	N	I-Premise
51	,	N	I-Premise
52	0.0014	N	I-Premise
53	,	N	I-Premise
54	respectively	N	I-Premise
55	)	N	I-Premise
56	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	OS	N	I-Premise
4	for	N	I-Premise
5	the	N	I-Premise
6	vaccine	N	I-Premise
7	group	N	I-Premise
8	was	N	I-Premise
9	31.9	N	I-Premise
10	months	N	I-Premise
11	and	N	I-Premise
12	for	N	I-Premise
13	the	N	I-Premise
14	control	N	I-Premise
15	group	N	I-Premise
16	was	N	I-Premise
17	15.0	N	I-Premise
18	months	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	<	N	I-Premise
22	0.002	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	progression-free	N	I-Premise
4	survival	N	I-Premise
5	(	N	I-Premise
6	PFS	N	I-Premise
7	)	N	I-Premise
8	for	N	I-Premise
9	the	N	I-Premise
10	vaccine	N	I-Premise
11	group	N	I-Premise
12	was	N	I-Premise
13	8.5	N	I-Premise
14	months	N	I-Premise
15	,	N	I-Premise
16	and	N	I-Premise
17	8.0	N	I-Premise
18	months	N	I-Premise
19	for	N	I-Premise
20	the	N	I-Premise
21	control	N	I-Premise
22	group	N	I-Premise
23	(	N	I-Premise
24	P	N	I-Premise
25	=	N	I-Premise
26	0.075	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	The	N	I-Premise
2	surviving	N	I-Premise
3	fraction	N	I-Premise
4	was	N	I-Premise
5	significantly	N	I-Premise
6	higher	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	vaccine	N	I-Premise
10	group	N	I-Premise
11	based	N	I-Premise
12	on	N	I-Premise
13	Kaplan-Meier	N	I-Premise
14	analysis	N	I-Premise
15	.	N	I-Premise

1	Adjuvant	N	I-Claim
2	immunotherapy	N	I-Claim
3	with	N	I-Claim
4	whole-cell	N	I-Claim
5	lysate	N	I-Claim
6	dendritic	N	I-Claim
7	cell	N	I-Claim
8	vaccine	N	I-Claim
9	may	N	I-Claim
10	improve	N	I-Claim
11	short-term	N	I-Claim
12	survival	N	I-Claim
13	.	N	I-Claim

1	It	N	I-Claim
2	seems	N	I-Claim
3	to	N	I-Claim
4	be	N	I-Claim
5	safe	N	I-Claim
6	,	N	I-Claim
7	and	N	I-Claim
8	its	N	I-Claim
9	long-term	N	I-Claim
10	effectiveness	N	I-Claim
11	is	N	I-Claim
12	worthy	N	I-Claim
13	of	N	I-Claim
14	further	N	I-Claim
15	investigation	N	I-Claim
16	.	N	I-Claim

1	Molecular	N	O
2	markers	N	O
3	to	N	O
4	predict	N	O
5	response	N	O
6	to	N	O
7	5-fluorouracil	N	O
8	(	N	O
9	FU	N	O
10	)	N	O
11	-based	N	O
12	treatment	N	O
13	of	N	O
14	recurrent	N	O
15	or	N	O
16	metastasised	N	O
17	colorectal	N	O
18	cancer	N	O
19	(	N	O
20	mCRC	N	O
21	)	N	O
22	are	N	O
23	not	N	O
24	established	N	O
25	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	trial	N	O
6	was	N	O
7	to	N	O
8	determine	N	O
9	the	N	O
10	value	N	O
11	of	N	O
12	thymidylate	N	O
13	synthase	N	O
14	(	N	O
15	TS	N	O
16	)	N	O
17	,	N	O
18	a	N	O
19	key	N	O
20	enzyme	N	O
21	of	N	O
22	DNA	N	O
23	synthesis	N	O
24	and	N	O
25	target	N	O
26	of	N	O
27	5-FU	N	O
28	,	N	O
29	to	N	O
30	predict	N	O
31	response	N	O
32	to	N	O
33	chemotherapy	N	O
34	of	N	O
35	mCRC	N	O
36	.	N	O

1	Tumour	N	O
2	tissue	N	O
3	was	N	O
4	obtained	N	O
5	from	N	O
6	168	N	O
7	patients	N	O
8	with	N	O
9	mCRC	N	O
10	for	N	O
11	relative	N	O
12	thymidylate	N	O
13	synthase	N	O
14	(	N	O
15	TS	N	O
16	)	N	O
17	mRNA	N	O
18	quantitation	N	O
19	.	N	O

1	Patients	N	O
2	were	N	O
3	randomised	N	O
4	to	N	O
5	receive	N	O
6	either	N	O
7	5-FU/folinic	N	O
8	acid	N	O
9	(	N	O
10	FA	N	O
11	,	N	O
12	FUFA	N	O
13	)	N	O
14	alone	N	O
15	or	N	O
16	in	N	O
17	combination	N	O
18	with	N	O
19	irinotecan	N	O
20	5-fluorouracil/folinic	N	O
21	acid	N	O
22	and	N	O
23	irinotecan	N	O
24	(	N	O
25	FOLFIRI	N	O
26	)	N	O
27	stratified	N	O
28	by	N	O
29	TS	N	O
30	(	N	O
31	low	N	O
32	versus	N	O
33	high	N	O
34	)	N	O
35	.	N	O

1	Primary	N	O
2	end-point	N	O
3	was	N	O
4	overall	N	O
5	response	N	O
6	to	N	O
7	first-line	N	O
8	treatment	N	O
9	among	N	O
10	TS	N	O
11	high	N	O
12	patients	N	O
13	.	N	O

1	All	N	O
2	parties	N	O
3	,	N	O
4	except	N	O
5	for	N	O
6	the	N	O
7	randomisation	N	O
8	centre	N	O
9	,	N	O
10	were	N	O
11	blinded	N	O
12	for	N	O
13	TS	N	O
14	status	N	O
15	.	N	O

1	Biopsies	N	O
2	(	N	O
3	n=168	N	O
4	)	N	O
5	were	N	O
6	taken	N	O
7	without	N	O
8	complications	N	O
9	.	N	O

1	TS	N	O
2	levels	N	O
3	were	N	O
4	available	N	O
5	for	N	O
6	147	N	O
7	patients	N	O
8	(	N	O
9	87.5	N	O
10	%	N	O
11	)	N	O
12	.	N	O

1	Analysing	N	I-Premise
2	response	N	I-Premise
3	to	N	I-Premise
4	FUFA	N	I-Premise
5	and	N	I-Premise
6	FOLFIRI	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	per	N	I-Premise
10	protocol	N	I-Premise
11	set	N	I-Premise
12	(	N	I-Premise
13	n=119	N	I-Premise
14	)	N	I-Premise
15	after	N	I-Premise
16	un-blinding	N	I-Premise
17	TS	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	data	N	I-Premise
21	base	N	I-Premise
22	revealed	N	I-Premise
23	a	N	I-Premise
24	trend	N	I-Premise
25	to	N	I-Premise
26	better	N	I-Premise
27	overall	N	I-Premise
28	response	N	I-Premise
29	to	N	I-Premise
30	FOLFIRI	N	I-Premise
31	(	N	I-Premise
32	9/19	N	I-Premise
33	,	N	I-Premise
34	47	N	I-Premise
35	%	N	I-Premise
36	)	N	I-Premise
37	in	N	I-Premise
38	TS	N	I-Premise
39	high	N	I-Premise
40	compared	N	I-Premise
41	to	N	I-Premise
42	FUFA	N	I-Premise
43	(	N	I-Premise
44	5/23	N	I-Premise
45	,	N	I-Premise
46	22	N	I-Premise
47	%	N	I-Premise
48	,	N	I-Premise
49	p=0.077	N	I-Premise
50	)	N	I-Premise
51	.	N	I-Premise

1	In	N	I-Premise
2	patients	N	I-Premise
3	with	N	I-Premise
4	biopsies	N	I-Premise
5	taken	N	I-Premise
6	from	N	I-Premise
7	liver	N	I-Premise
8	lesions	N	I-Premise
9	(	N	I-Premise
10	n=91	N	I-Premise
11	)	N	I-Premise
12	overall	N	I-Premise
13	response	N	I-Premise
14	to	N	I-Premise
15	FOLFIRI	N	I-Premise
16	and	N	I-Premise
17	FUFA	N	I-Premise
18	in	N	I-Premise
19	TS	N	I-Premise
20	high	N	I-Premise
21	was	N	I-Premise
22	53	N	I-Premise
23	%	N	I-Premise
24	(	N	I-Premise
25	9/17	N	I-Premise
26	)	N	I-Premise
27	and	N	I-Premise
28	18	N	I-Premise
29	%	N	I-Premise
30	(	N	I-Premise
31	3/17	N	I-Premise
32	)	N	I-Premise
33	,	N	I-Premise
34	respectively	N	I-Premise
35	(	N	I-Premise
36	p=0.035	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	In	N	I-Premise
2	patients	N	I-Premise
3	with	N	I-Premise
4	low	N	I-Premise
5	TS	N	I-Premise
6	,	N	I-Premise
7	no	N	I-Premise
8	remarkable	N	I-Premise
9	difference	N	I-Premise
10	in	N	I-Premise
11	overall	N	I-Premise
12	response	N	I-Premise
13	to	N	I-Premise
14	FOLFIRI	N	I-Premise
15	and	N	I-Premise
16	FUFA	N	I-Premise
17	was	N	I-Premise
18	observed	N	I-Premise
19	.	N	I-Premise

1	Taking	N	I-Claim
2	a	N	I-Claim
3	pre-treatment	N	I-Claim
4	biopsy	N	I-Claim
5	is	N	I-Claim
6	a	N	I-Claim
7	safe	N	I-Claim
8	and	N	I-Claim
9	feasible	N	I-Claim
10	procedure	N	I-Claim
11	in	N	I-Claim
12	mCRC	N	I-Claim
13	.	N	I-Claim

1	After	N	I-Claim
2	validation	N	I-Claim
3	of	N	I-Claim
4	our	N	I-Claim
5	data	N	I-Claim
6	in	N	I-Claim
7	a	N	I-Claim
8	larger	N	I-Claim
9	group	N	I-Claim
10	TS	N	I-Claim
11	determination	N	I-Claim
12	may	N	I-Claim
13	have	N	I-Claim
14	the	N	I-Claim
15	potential	N	I-Claim
16	to	N	I-Claim
17	better	N	I-Claim
18	help	N	I-Claim
19	direct	N	I-Claim
20	systemic	N	I-Claim
21	treatment	N	I-Claim
22	in	N	I-Claim
23	patients	N	I-Claim
24	with	N	I-Claim
25	primarily	N	I-Claim
26	non-resectable	N	I-Claim
27	mCRC	N	I-Claim
28	.	N	I-Claim

1	The	N	O
2	primary	N	O
3	objective	N	O
4	of	N	O
5	this	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	compare	N	O
10	the	N	O
11	response	N	O
12	rates	N	O
13	of	N	O
14	elderly	N	O
15	,	N	O
16	chemonaive	N	O
17	patients	N	O
18	with	N	O
19	advanced	N	O
20	non-small	N	O
21	cell	N	O
22	lung	N	O
23	cancer	N	O
24	(	N	O
25	NSCLC	N	O
26	)	N	O
27	treated	N	O
28	with	N	O
29	daily	N	O
30	oral	N	O
31	erlotinib	N	O
32	versus	N	O
33	oral	N	O
34	vinorelbine	N	O
35	.	N	O

1	Chemonaive	N	O
2	Taiwanese	N	O
3	patients	N	O
4	aged	N	O
5	70	N	O
6	years	N	O
7	or	N	O
8	older	N	O
9	who	N	O
10	had	N	O
11	advanced	N	O
12	NSCLC	N	O
13	were	N	O
14	randomized	N	O
15	to	N	O
16	receive	N	O
17	either	N	O
18	oral	N	O
19	erlotinib	N	O
20	150	N	O
21	mg	N	O
22	(	N	O
23	E	N	O
24	)	N	O
25	daily	N	O
26	or	N	O
27	oral	N	O
28	vinorelbine	N	O
29	60	N	O
30	mg/m	N	O
31	(	N	O
32	V	N	O
33	)	N	O
34	on	N	O
35	days	N	O
36	1	N	O
37	and	N	O
38	8	N	O
39	every	N	O
40	3	N	O
41	weeks	N	O
42	.	N	O

1	From	N	O
2	February	N	O
3	2007	N	O
4	to	N	O
5	July	N	O
6	2008	N	O
7	,	N	O
8	116	N	O
9	patients	N	O
10	were	N	O
11	enrolled	N	O
12	and	N	O
13	113	N	O
14	were	N	O
15	included	N	O
16	in	N	O
17	the	N	O
18	intent-to-treat	N	O
19	population	N	O
20	:	N	O
21	57	N	O
22	patients	N	O
23	in	N	O
24	the	N	O
25	E	N	O
26	group	N	O
27	and	N	O
28	56	N	O
29	patients	N	O
30	in	N	O
31	the	N	O
32	V	N	O
33	group	N	O
34	.	N	O

1	Objective	N	I-Premise
2	response	N	I-Premise
3	rates	N	I-Premise
4	were	N	I-Premise
5	22.8	N	I-Premise
6	%	N	I-Premise
7	(	N	I-Premise
8	13	N	I-Premise
9	of	N	I-Premise
10	57	N	I-Premise
11	)	N	I-Premise
12	in	N	I-Premise
13	E	N	I-Premise
14	and	N	I-Premise
15	8.9	N	I-Premise
16	%	N	I-Premise
17	(	N	I-Premise
18	5	N	I-Premise
19	of	N	I-Premise
20	56	N	I-Premise
21	)	N	I-Premise
22	in	N	I-Premise
23	V	N	I-Premise
24	(	N	I-Premise
25	p	N	I-Premise
26	=	N	I-Premise
27	0.0388	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	Median	N	I-Premise
2	progression-free	N	I-Premise
3	survival	N	I-Premise
4	(	N	I-Premise
5	PFS	N	I-Premise
6	)	N	I-Premise
7	was	N	I-Premise
8	4.57	N	I-Premise
9	months	N	I-Premise
10	in	N	I-Premise
11	E	N	I-Premise
12	and	N	I-Premise
13	2.53	N	I-Premise
14	months	N	I-Premise
15	in	N	I-Premise
16	V	N	I-Premise
17	(	N	I-Premise
18	p	N	I-Premise
19	=	N	I-Premise
20	0.0287	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	with	N	I-Premise
24	an	N	I-Premise
25	80.6	N	I-Premise
26	%	N	I-Premise
27	increase	N	I-Premise
28	in	N	I-Premise
29	median	N	I-Premise
30	PFS	N	I-Premise
31	for	N	I-Premise
32	E	N	I-Premise
33	compared	N	I-Premise
34	with	N	I-Premise
35	V.	N	I-Premise
36	Median	N	I-Premise
37	survival	N	I-Premise
38	time	N	I-Premise
39	was	N	I-Premise
40	11.67	N	I-Premise
41	months	N	I-Premise
42	in	N	I-Premise
43	E	N	I-Premise
44	and	N	I-Premise
45	9.3	N	I-Premise
46	months	N	I-Premise
47	in	N	I-Premise
48	V	N	I-Premise
49	(	N	I-Premise
50	p	N	I-Premise
51	=	N	I-Premise
52	0.6975	N	I-Premise
53	)	N	I-Premise
54	.	N	I-Premise

1	Toxicities	N	I-Premise
2	were	N	I-Premise
3	generally	N	I-Premise
4	mild	N	I-Premise
5	in	N	I-Premise
6	both	N	I-Premise
7	groups	N	I-Premise
8	.	N	I-Premise

1	Median	N	I-Premise
2	PFS	N	I-Premise
3	was	N	I-Premise
4	longest	N	I-Premise
5	for	N	I-Premise
6	epidermal	N	I-Premise
7	growth	N	I-Premise
8	factor	N	I-Premise
9	receptor	N	I-Premise
10	gene	N	I-Premise
11	(	N	I-Premise
12	EGFR	N	I-Premise
13	)	N	I-Premise
14	-mutated	N	I-Premise
15	patients	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	E	N	I-Premise
19	group	N	I-Premise
20	,	N	I-Premise
21	followed	N	I-Premise
22	by	N	I-Premise
23	EGFR-mutated	N	I-Premise
24	patients	N	I-Premise
25	in	N	I-Premise
26	V	N	I-Premise
27	,	N	I-Premise
28	EGFR	N	I-Premise
29	wild	N	I-Premise
30	type	N	I-Premise
31	in	N	I-Premise
32	E	N	I-Premise
33	,	N	I-Premise
34	and	N	I-Premise
35	EGFR	N	I-Premise
36	wild	N	I-Premise
37	type	N	I-Premise
38	in	N	I-Premise
39	V	N	I-Premise
40	(	N	I-Premise
41	p	N	I-Premise
42	=	N	I-Premise
43	0.0034	N	I-Premise
44	)	N	I-Premise
45	.	N	I-Premise

1	Overall	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	longer	N	I-Premise
5	for	N	I-Premise
6	EGFR-mutated	N	I-Premise
7	patients	N	I-Premise
8	than	N	I-Premise
9	for	N	I-Premise
10	EGFR	N	I-Premise
11	wild-type	N	I-Premise
12	patients	N	I-Premise
13	(	N	I-Premise
14	p	N	I-Premise
15	<	N	I-Premise
16	0.0001	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	Erlotinib	N	I-Claim
2	is	N	I-Claim
3	highly	N	I-Claim
4	effective	N	I-Claim
5	compared	N	I-Claim
6	with	N	I-Claim
7	oral	N	I-Claim
8	vinorelbine	N	I-Claim
9	in	N	I-Claim
10	elderly	N	I-Claim
11	,	N	I-Claim
12	chemonaive	N	I-Claim
13	,	N	I-Claim
14	Taiwanese	N	I-Claim
15	patients	N	I-Claim
16	with	N	I-Claim
17	NSCLC	N	I-Claim
18	.	N	I-Claim

1	EGFR-mutated	N	I-Claim
2	patients	N	I-Claim
3	had	N	I-Claim
4	better	N	I-Claim
5	survival	N	I-Claim
6	than	N	I-Claim
7	those	N	I-Claim
8	with	N	I-Claim
9	EGFR	N	I-Claim
10	wild-type	N	I-Claim
11	disease	N	I-Claim
12	,	N	I-Claim
13	regardless	N	I-Claim
14	of	N	I-Claim
15	the	N	I-Claim
16	treatment	N	I-Claim
17	received	N	I-Claim
18	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	low-frequency	N	O
7	low-intensity	N	O
8	electrotherapy	N	O
9	and	N	O
10	manual	N	O
11	lymphatic	N	O
12	drainage	N	O
13	in	N	O
14	the	N	O
15	treatment	N	O
16	of	N	O
17	chronic	N	O
18	upper	N	O
19	limb	N	O
20	breast	N	O
21	cancer-related	N	O
22	lymphoedema	N	O
23	.	N	O

1	Cross-over	N	O
2	single-blind	N	O
3	random	N	O
4	clinical	N	O
5	trial	N	O
6	.	N	O

1	Rehabilitation	N	O
2	service	N	O
3	.	N	O

1	Thirty-six	N	O
2	women	N	O
3	with	N	O
4	chronic	N	O
5	upper	N	O
6	limb	N	O
7	breast	N	O
8	cancer-related	N	O
9	lymphoedema	N	O
10	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	undergo	N	O
6	10	N	O
7	sessions	N	O
8	of	N	O
9	manual	N	O
10	lymphatic	N	O
11	drainage	N	O
12	followed	N	O
13	by	N	O
14	10	N	O
15	sessions	N	O
16	of	N	O
17	low-frequency	N	O
18	low-intensity	N	O
19	electrotherapy	N	O
20	or	N	O
21	to	N	O
22	undergo	N	O
23	first	N	O
24	low-frequency	N	O
25	low-intensity	N	O
26	electrotherapy	N	O
27	followed	N	O
28	by	N	O
29	manual	N	O
30	lymphatic	N	O
31	drainage	N	O
32	.	N	O

1	There	N	O
2	was	N	O
3	a	N	O
4	month	N	O
5	of	N	O
6	washout	N	O
7	time	N	O
8	between	N	O
9	treatments	N	O
10	.	N	O

1	Each	N	O
2	patient	N	O
3	was	N	O
4	examined	N	O
5	just	N	O
6	before	N	O
7	and	N	O
8	after	N	O
9	each	N	O
10	treatment	N	O
11	.	N	O

1	Researchers	N	O
2	and	N	O
3	outcome	N	O
4	assessors	N	O
5	were	N	O
6	blinded	N	O
7	for	N	O
8	assigned	N	O
9	treatment	N	O
10	.	N	O

1	Outcomes	N	O
2	were	N	O
3	lymphoedema	N	O
4	volume	N	O
5	,	N	O
6	pain	N	O
7	,	N	O
8	heaviness	N	O
9	and	N	O
10	tightness	N	O
11	,	N	O
12	and	N	O
13	health-related	N	O
14	quality	N	O
15	of	N	O
16	life	N	O
17	measured	N	O
18	with	N	O
19	the	N	O
20	Functional	N	O
21	Assessment	N	O
22	of	N	O
23	Cancer	N	O
24	Therapy	N	O
25	Questionnaire	N	O
26	for	N	O
27	Breast	N	O
28	Cancer	N	O
29	version	N	O
30	4	N	O
31	(	N	O
32	FACT-B+4	N	O
33	)	N	O
34	.	N	O

1	Carry-over	N	O
2	,	N	O
3	period	N	O
4	and	N	O
5	treatment	N	O
6	effects	N	O
7	were	N	O
8	analysed	N	O
9	.	N	O

1	Treatment	N	O
2	effect	N	O
3	was	N	O
4	assessed	N	O
5	using	N	O
6	paired	N	O
7	t-test	N	O
8	.	N	O

1	Thirty	N	O
2	patients	N	O
3	finalized	N	O
4	treatment	N	O
5	.	N	O

1	Comparing	N	I-Premise
2	the	N	I-Premise
3	changes	N	I-Premise
4	in	N	I-Premise
5	low-frequency	N	I-Premise
6	low-intensity	N	I-Premise
7	electrotherapy	N	I-Premise
8	with	N	I-Premise
9	manual	N	I-Premise
10	lymphatic	N	I-Premise
11	drainage	N	I-Premise
12	changes	N	I-Premise
13	,	N	I-Premise
14	there	N	I-Premise
15	were	N	I-Premise
16	no	N	I-Premise
17	significant	N	I-Premise
18	differences	N	I-Premise
19	.	N	I-Premise

1	Low-frequency	N	I-Premise
2	low-intensity	N	I-Premise
3	electrotherapy	N	I-Premise
4	did	N	I-Premise
5	not	N	I-Premise
6	reduce	N	I-Premise
7	lymphoedema	N	I-Premise
8	volume	N	I-Premise
9	(	N	I-Premise
10	mean	N	I-Premise
11	of	N	I-Premise
12	change	N	I-Premise
13	=	N	I-Premise
14	19.77	N	I-Premise
15	mL	N	I-Premise
16	,	N	I-Premise
17	P	N	I-Premise
18	=	N	I-Premise
19	0.36	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	but	N	O
23	significant	N	I-Premise
24	reductions	N	I-Premise
25	were	N	I-Premise
26	observed	N	I-Premise
27	in	N	I-Premise
28	pain	N	I-Premise
29	,	N	I-Premise
30	heaviness	N	I-Premise
31	and	N	I-Premise
32	tightness	N	I-Premise
33	(	N	I-Premise
34	mean	N	I-Premise
35	of	N	I-Premise
36	change	N	I-Premise
37	=	N	I-Premise
38	13.1	N	I-Premise
39	,	N	I-Premise
40	16.2	N	I-Premise
41	and	N	I-Premise
42	6.4	N	I-Premise
43	mm	N	I-Premise
44	,	N	I-Premise
45	respectively	N	I-Premise
46	)	N	I-Premise
47	,	N	I-Premise
48	and	N	I-Premise
49	FACT-B+4	N	I-Premise
50	summaries	N	I-Premise
51	improved	N	I-Premise
52	significantly	N	I-Premise
53	(	N	I-Premise
54	Trial	N	I-Premise
55	Outcome	N	I-Premise
56	Index	N	I-Premise
57	mean	N	I-Premise
58	of	N	I-Premise
59	change	N	I-Premise
60	=	N	I-Premise
61	5.4	N	I-Premise
62	,	N	I-Premise
63	P	N	I-Premise
64	=	N	I-Premise
65	0.015	N	I-Premise
66	)	N	I-Premise
67	.	N	I-Premise

1	Manual	N	I-Premise
2	lymphatic	N	I-Premise
3	drainage	N	I-Premise
4	showed	N	I-Premise
5	no	N	I-Premise
6	significant	N	I-Premise
7	changes	N	I-Premise
8	in	N	I-Premise
9	any	N	I-Premise
10	of	N	I-Premise
11	the	N	I-Premise
12	outcomes	N	I-Premise
13	.	N	I-Premise

1	Although	N	I-Claim
2	there	N	I-Claim
3	are	N	I-Claim
4	no	N	I-Claim
5	significant	N	I-Claim
6	differences	N	I-Claim
7	between	N	I-Claim
8	treatment	N	I-Claim
9	changes	N	I-Claim
10	,	N	I-Claim
11	the	N	I-Claim
12	observed	N	I-Claim
13	trend	N	I-Claim
14	towards	N	I-Claim
15	a	N	I-Claim
16	better	N	I-Claim
17	health-related	N	I-Claim
18	quality	N	I-Claim
19	of	N	I-Claim
20	life	N	I-Claim
21	is	N	I-Claim
22	remarkable	N	I-Claim
23	in	N	I-Claim
24	low-frequency	N	I-Claim
25	low-intensity	N	I-Claim
26	electrotherapy	N	I-Claim
27	.	N	I-Claim

1	Gynecological	N	O
2	neoplastic	N	O
3	disease	N	O
4	progression	N	O
5	is	N	O
6	characterized	N	O
7	by	N	O
8	specific	N	O
9	energy	N	O
10	metabolism	N	O
11	alterations	N	O
12	and	N	O
13	by	N	O
14	symptoms	N	O
15	including	N	O
16	fatigue	N	O
17	,	N	O
18	anorexia	N	O
19	,	N	O
20	nausea	N	O
21	,	N	O
22	anemia	N	O
23	,	N	O
24	and	N	O
25	immunodepression	N	O
26	,	N	O
27	which	N	O
28	result	N	O
29	in	N	O
30	a	N	O
31	cachexia	N	O
32	syndrome	N	O
33	and	N	O
34	a	N	O
35	marked	N	O
36	decrease	N	O
37	in	N	O
38	patient	N	O
39	quality	N	O
40	of	N	O
41	life	N	O
42	(	N	O
43	QoL	N	O
44	)	N	O
45	.	N	O

1	Therapeutic	N	O
2	protocols	N	O
3	associated	N	O
4	with	N	O
5	appropriate	N	O
6	and	N	O
7	effective	N	O
8	psychological	N	O
9	and	N	O
10	social	N	O
11	support	N	O
12	systems	N	O
13	are	N	O
14	essential	N	O
15	to	N	O
16	counteract	N	O
17	the	N	O
18	symptoms	N	O
19	of	N	O
20	neoplastic	N	O
21	disease	N	O
22	in	N	O
23	incurable	N	O
24	patients	N	O
25	.	N	O

1	A	N	O
2	phase	N	O
3	III	N	O
4	randomized	N	O
5	study	N	O
6	was	N	O
7	performed	N	O
8	to	N	O
9	establish	N	O
10	the	N	O
11	most	N	O
12	effective	N	O
13	and	N	O
14	safest	N	O
15	treatment	N	O
16	to	N	O
17	improve	N	O
18	the	N	O
19	key	N	O
20	symptoms	N	O
21	in	N	O
22	advanced	N	O
23	gynecological	N	O
24	cancer	N	O
25	patients	N	O
26	,	N	O
27	i.e.	N	O
28	,	N	O
29	lean	N	O
30	body	N	O
31	mass	N	O
32	(	N	O
33	LBM	N	O
34	)	N	O
35	,	N	O
36	resting	N	O
37	energy	N	O
38	expenditure	N	O
39	(	N	O
40	REE	N	O
41	)	N	O
42	,	N	O
43	fatigue	N	O
44	,	N	O
45	and	N	O
46	QoL	N	O
47	.	N	O

1	In	N	O
2	addition	N	O
3	,	N	O
4	the	N	O
5	impact	N	O
6	of	N	O
7	the	N	O
8	treatment	N	O
9	arms	N	O
10	on	N	O
11	the	N	O
12	main	N	O
13	metabolic	N	O
14	and	N	O
15	inflammatory	N	O
16	parameters	N	O
17	,	N	O
18	including	N	O
19	C-reactive	N	O
20	protein	N	O
21	(	N	O
22	CRP	N	O
23	)	N	O
24	,	N	O
25	interleukin	N	O
26	(	N	O
27	IL	N	O
28	)	N	O
29	-6	N	O
30	,	N	O
31	tumor	N	O
32	necrosis	N	O
33	factor	N	O
34	(	N	O
35	TNF	N	O
36	)	N	O
37	-α	N	O
38	,	N	O
39	leptin	N	O
40	,	N	O
41	reactive	N	O
42	oxygen	N	O
43	species	N	O
44	(	N	O
45	ROS	N	O
46	)	N	O
47	,	N	O
48	and	N	O
49	glutathione	N	O
50	peroxidase	N	O
51	,	N	O
52	was	N	O
53	evaluated	N	O
54	.	N	O

1	The	N	O
2	change	N	O
3	in	N	O
4	the	N	O
5	Glasgow	N	O
6	Prognostic	N	O
7	Score	N	O
8	(	N	O
9	GPS	N	O
10	)	N	O
11	during	N	O
12	treatment	N	O
13	was	N	O
14	also	N	O
15	assessed	N	O
16	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	104	N	O
5	advanced-stage	N	O
6	gynecological	N	O
7	cancer	N	O
8	patients	N	O
9	were	N	O
10	enrolled	N	O
11	and	N	O
12	randomly	N	O
13	assigned	N	O
14	to	N	O
15	receive	N	O
16	either	N	O
17	megestrol	N	O
18	acetate	N	O
19	(	N	O
20	MA	N	O
21	)	N	O
22	plus	N	O
23	l-carnitine	N	O
24	,	N	O
25	celecoxib	N	O
26	,	N	O
27	and	N	O
28	antioxidants	N	O
29	(	N	O
30	arm	N	O
31	1	N	O
32	)	N	O
33	or	N	O
34	MA	N	O
35	alone	N	O
36	(	N	O
37	arm	N	O
38	2	N	O
39	)	N	O
40	.	N	O

1	The	N	O
2	treatment	N	O
3	duration	N	O
4	was	N	O
5	4	N	O
6	months	N	O
7	.	N	O

1	The	N	I-Premise
2	combination	N	I-Premise
3	arm	N	I-Premise
4	was	N	I-Premise
5	more	N	I-Premise
6	effective	N	I-Premise
7	than	N	I-Premise
8	arm	N	I-Premise
9	2	N	I-Premise
10	with	N	I-Premise
11	respect	N	I-Premise
12	to	N	I-Premise
13	LBM	N	I-Premise
14	,	N	I-Premise
15	REE	N	I-Premise
16	,	N	I-Premise
17	fatigue	N	I-Premise
18	,	N	I-Premise
19	and	N	I-Premise
20	global	N	I-Premise
21	QoL	N	I-Premise
22	.	N	I-Premise

1	As	N	I-Premise
2	for	N	I-Premise
3	the	N	I-Premise
4	secondary	N	I-Premise
5	efficacy	N	I-Premise
6	endpoints	N	I-Premise
7	,	N	I-Premise
8	patient	N	I-Premise
9	appetite	N	I-Premise
10	increased	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	ECOG	N	I-Premise
14	PS	N	I-Premise
15	decreased	N	I-Premise
16	significantly	N	I-Premise
17	in	N	I-Premise
18	both	N	I-Premise
19	arms	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	inflammation	N	I-Premise
3	and	N	I-Premise
4	oxidative	N	I-Premise
5	stress	N	I-Premise
6	parameters	N	I-Premise
7	IL-6	N	I-Premise
8	,	N	I-Premise
9	TNF-α	N	I-Premise
10	,	N	I-Premise
11	CRP	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	ROS	N	I-Premise
15	decreased	N	I-Premise
16	significantly	N	I-Premise
17	in	N	I-Premise
18	arm	N	I-Premise
19	1	N	I-Premise
20	,	N	I-Premise
21	while	N	I-Premise
22	no	N	I-Premise
23	significant	N	I-Premise
24	change	N	I-Premise
25	was	N	I-Premise
26	observed	N	I-Premise
27	in	N	I-Premise
28	arm	N	I-Premise
29	2	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Claim
2	combined	N	I-Claim
3	treatment	N	I-Claim
4	improved	N	I-Claim
5	both	N	I-Claim
6	immunometabolic	N	I-Claim
7	alterations	N	I-Claim
8	and	N	I-Claim
9	patient	N	I-Claim
10	QoL	N	I-Claim
11	.	N	I-Claim

1	Multimodality	N	I-MajorClaim
2	therapies	N	I-MajorClaim
3	for	N	I-MajorClaim
4	cachexia	N	I-MajorClaim
5	ideally	N	I-MajorClaim
6	should	N	I-MajorClaim
7	be	N	I-MajorClaim
8	introduced	N	I-MajorClaim
9	within	N	I-MajorClaim
10	a	N	I-MajorClaim
11	context	N	I-MajorClaim
12	of	N	I-MajorClaim
13	``	N	I-MajorClaim
14	best	N	I-MajorClaim
15	supportive	N	I-MajorClaim
16	care	N	I-MajorClaim
17	''	N	I-MajorClaim
18	that	N	I-MajorClaim
19	includes	N	I-MajorClaim
20	optimal	N	I-MajorClaim
21	symptom	N	I-MajorClaim
22	management	N	I-MajorClaim
23	and	N	I-MajorClaim
24	careful	N	I-MajorClaim
25	psychosocial	N	I-MajorClaim
26	counseling	N	I-MajorClaim
27	.	N	I-MajorClaim

1	Pain	N	O
2	is	N	O
3	1	N	O
4	of	N	O
5	the	N	O
6	most	N	O
7	common	N	O
8	symptoms	N	O
9	that	N	O
10	a	N	O
11	cancer	N	O
12	patient	N	O
13	would	N	O
14	experience	N	O
15	.	N	O

1	A	N	O
2	significant	N	O
3	barrier	N	O
4	to	N	O
5	positive	N	O
6	pain	N	O
7	management	N	O
8	is	N	O
9	patients	N	O
10	'	N	O
11	misconceptions	N	O
12	regarding	N	O
13	analgesics	N	O
14	and	N	O
15	inadequate	N	O
16	use	N	O
17	of	N	O
18	nonpharmacological	N	O
19	strategies	N	O
20	as	N	O
21	pain	N	O
22	relief	N	O
23	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	investigate	N	O
9	the	N	O
10	effectiveness	N	O
11	of	N	O
12	a	N	O
13	pain	N	O
14	management	N	O
15	program	N	O
16	(	N	O
17	PMP	N	O
18	)	N	O
19	on	N	O
20	pain	N	O
21	intensity	N	O
22	,	N	O
23	use	N	O
24	of	N	O
25	PRN	N	O
26	drugs	N	O
27	and	N	O
28	nonpharmacological	N	O
29	strategies	N	O
30	as	N	O
31	pain	N	O
32	relief	N	O
33	,	N	O
34	and	N	O
35	barriers	N	O
36	to	N	O
37	managing	N	O
38	pain	N	O
39	in	N	O
40	cancer	N	O
41	patients	N	O
42	.	N	O

1	The	N	O
2	study	N	O
3	was	N	O
4	conducted	N	O
5	in	N	O
6	the	N	O
7	palliative	N	O
8	care	N	O
9	and	N	O
10	hospice	N	O
11	ward	N	O
12	of	N	O
13	a	N	O
14	public	N	O
15	hospital	N	O
16	in	N	O
17	Hong	N	O
18	Kong	N	O
19	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	either	N	O
6	an	N	O
7	experimental	N	O
8	group	N	O
9	(	N	O
10	receiving	N	O
11	the	N	O
12	PMP	N	O
13	)	N	O
14	or	N	O
15	a	N	O
16	control	N	O
17	group	N	O
18	(	N	O
19	routine	N	O
20	care	N	O
21	)	N	O
22	.	N	O

1	There	N	O
2	were	N	O
3	38	N	O
4	hospitalized	N	O
5	patients	N	O
6	,	N	O
7	with	N	O
8	20	N	O
9	(	N	O
10	13	N	O
11	males	N	O
12	and	N	O
13	7	N	O
14	females	N	O
15	)	N	O
16	in	N	O
17	the	N	O
18	experimental	N	O
19	group	N	O
20	and	N	O
21	18	N	O
22	(	N	O
23	11	N	O
24	males	N	O
25	and	N	O
26	7	N	O
27	females	N	O
28	)	N	O
29	in	N	O
30	the	N	O
31	control	N	O
32	group	N	O
33	;	N	O
34	mean	N	O
35	age	N	O
36	was	N	O
37	61.95	N	O
38	years	N	O
39	(	N	O
40	experimental	N	O
41	group	N	O
42	)	N	O
43	to	N	O
44	63.94	N	O
45	years	N	O
46	(	N	O
47	control	N	O
48	group	N	O
49	)	N	O
50	.	N	O

1	Upon	N	I-Premise
2	the	N	I-Premise
3	completion	N	I-Premise
4	of	N	I-Premise
5	PMP	N	I-Premise
6	,	N	I-Premise
7	pain	N	I-Premise
8	scores	N	I-Premise
9	were	N	I-Premise
10	significantly	N	I-Premise
11	reduced	N	I-Premise
12	in	N	I-Premise
13	both	N	I-Premise
14	groups	N	I-Premise
15	,	N	I-Premise
16	yet	N	I-Premise
17	patients	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	experimental	N	I-Premise
21	group	N	I-Premise
22	showed	N	I-Premise
23	a	N	I-Premise
24	significant	N	I-Premise
25	increase	N	I-Premise
26	in	N	I-Premise
27	the	N	I-Premise
28	use	N	I-Premise
29	of	N	I-Premise
30	PRN	N	I-Premise
31	analgesics	N	I-Premise
32	and	N	I-Premise
33	nonpharmacological	N	I-Premise
34	strategies	N	I-Premise
35	to	N	I-Premise
36	relieve	N	I-Premise
37	pain	N	I-Premise
38	(	N	I-Premise
39	P	N	I-Premise
40	<	N	I-Premise
41	.05	N	I-Premise
42	)	N	I-Premise
43	and	N	I-Premise
44	significantly	N	I-Premise
45	reduce	N	I-Premise
46	barriers	N	I-Premise
47	to	N	I-Premise
48	managing	N	I-Premise
49	their	N	I-Premise
50	cancer	N	I-Premise
51	pain	N	I-Premise
52	(	N	I-Premise
53	P	N	I-Premise
54	<	N	I-Premise
55	.05	N	I-Premise
56	)	N	I-Premise
57	compared	N	I-Premise
58	with	N	I-Premise
59	the	N	I-Premise
60	control	N	I-Premise
61	group	N	I-Premise
62	.	N	I-Premise

1	Cancer	N	I-Claim
2	patients	N	I-Claim
3	should	N	I-Claim
4	be	N	I-Claim
5	empowered	N	I-Claim
6	with	N	I-Claim
7	pain	N	I-Claim
8	management	N	I-Claim
9	education	N	I-Claim
10	to	N	I-Claim
11	gain	N	I-Claim
12	knowledge	N	I-Claim
13	and	N	I-Claim
14	correct	N	I-Claim
15	misconceptions	N	I-Claim
16	in	N	I-Claim
17	managing	N	I-Claim
18	their	N	I-Claim
19	cancer	N	I-Claim
20	pain	N	I-Claim
21	.	N	I-Claim

1	Integration	N	I-Claim
2	of	N	I-Claim
3	the	N	I-Claim
4	PMP	N	I-Claim
5	into	N	I-Claim
6	routine	N	I-Claim
7	clinical	N	I-Claim
8	work	N	I-Claim
9	may	N	I-Claim
10	help	N	I-Claim
11	to	N	I-Claim
12	improve	N	I-Claim
13	the	N	I-Claim
14	standard	N	I-Claim
15	of	N	I-Claim
16	care	N	I-Claim
17	for	N	I-Claim
18	cancer	N	I-Claim
19	patients	N	I-Claim
20	.	N	I-Claim

1	It	N	O
2	is	N	O
3	recommended	N	O
4	to	N	O
5	provide	N	O
6	pain	N	O
7	management	N	O
8	education	N	O
9	to	N	O
10	all	N	O
11	cancer	N	O
12	patients	N	O
13	.	N	O

1	Health-related	N	O
2	quality	N	O
3	of	N	O
4	life	N	O
5	(	N	O
6	HRQOL	N	O
7	)	N	O
8	,	N	O
9	symptoms	N	O
10	of	N	O
11	depression	N	O
12	,	N	O
13	and	N	O
14	adverse	N	O
15	events	N	O
16	(	N	O
17	AEs	N	O
18	)	N	O
19	were	N	O
20	compared	N	O
21	between	N	O
22	Japanese	N	O
23	postmenopausal	N	O
24	patients	N	O
25	with	N	O
26	hormone-sensitive	N	O
27	breast	N	O
28	cancer	N	O
29	(	N	O
30	BC	N	O
31	)	N	O
32	who	N	O
33	received	N	O
34	adjuvant	N	O
35	tamoxifen	N	O
36	,	N	O
37	exemestane	N	O
38	,	N	O
39	or	N	O
40	anastrozole	N	O
41	in	N	O
42	an	N	O
43	open-labeled	N	O
44	,	N	O
45	randomized	N	O
46	,	N	O
47	multicenter	N	O
48	trial	N	O
49	designated	N	O
50	as	N	O
51	the	N	O
52	National	N	O
53	Surgical	N	O
54	Adjuvant	N	O
55	Study	N	O
56	of	N	O
57	Breast	N	O
58	Cancer	N	O
59	(	N	O
60	N-SAS	N	O
61	BC	N	O
62	)	N	O
63	04	N	O
64	substudy	N	O
65	of	N	O
66	the	N	O
67	Tamoxifen	N	O
68	Exemestane	N	O
69	Adjuvant	N	O
70	Multinational	N	O
71	(	N	O
72	TEAM	N	O
73	)	N	O
74	trial	N	O
75	.	N	O

1	During	N	O
2	the	N	O
3	first	N	O
4	year	N	O
5	of	N	O
6	treatment	N	O
7	,	N	O
8	HRQOL	N	O
9	and	N	O
10	symptoms	N	O
11	of	N	O
12	depression	N	O
13	were	N	O
14	analyzed	N	O
15	using	N	O
16	the	N	O
17	Functional	N	O
18	Assessment	N	O
19	of	N	O
20	Cancer	N	O
21	Therapy-Breast	N	O
22	(	N	O
23	FACT-B	N	O
24	)	N	O
25	and	N	O
26	its	N	O
27	Endocrine	N	O
28	Symptom	N	O
29	Subscale	N	O
30	(	N	O
31	ES	N	O
32	)	N	O
33	,	N	O
34	and	N	O
35	the	N	O
36	Center	N	O
37	for	N	O
38	Epidemiologic	N	O
39	Studies	N	O
40	Depression	N	O
41	Scale	N	O
42	(	N	O
43	CES-D	N	O
44	)	N	O
45	,	N	O
46	respectively	N	O
47	.	N	O

1	In	N	O
2	addition	N	O
3	,	N	O
4	predefined	N	O
5	AEs	N	O
6	were	N	O
7	analyzed	N	O
8	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	166	N	O
5	eligible	N	O
6	patients	N	O
7	were	N	O
8	randomly	N	O
9	assigned	N	O
10	to	N	O
11	receive	N	O
12	adjuvant	N	O
13	tamoxifen	N	O
14	,	N	O
15	exemestane	N	O
16	,	N	O
17	or	N	O
18	anastrozole	N	O
19	.	N	O

1	FACT-B	N	I-Premise
2	scores	N	I-Premise
3	increased	N	I-Premise
4	after	N	I-Premise
5	treatment	N	I-Premise
6	began	N	I-Premise
7	and	N	I-Premise
8	remained	N	I-Premise
9	significantly	N	I-Premise
10	higher	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	tamoxifen	N	I-Premise
14	group	N	I-Premise
15	than	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	exemestane	N	I-Premise
19	group	N	I-Premise
20	or	N	I-Premise
21	anastrozole	N	I-Premise
22	group	N	I-Premise
23	during	N	I-Premise
24	the	N	I-Premise
25	first	N	I-Premise
26	year	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	0.045	N	I-Premise
31	)	N	I-Premise
32	.	N	I-Premise

1	FACT-B	N	I-Premise
2	scores	N	I-Premise
3	were	N	I-Premise
4	similar	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	exemestane	N	I-Premise
8	group	N	I-Premise
9	and	N	I-Premise
10	anastrozole	N	I-Premise
11	group	N	I-Premise
12	.	N	I-Premise

1	ES	N	I-Premise
2	scores	N	I-Premise
3	and	N	I-Premise
4	CES-D	N	I-Premise
5	scores	N	I-Premise
6	were	N	I-Premise
7	similar	N	I-Premise
8	in	N	I-Premise
9	all	N	I-Premise
10	treatment	N	I-Premise
11	groups	N	I-Premise
12	.	N	I-Premise

1	Arthralgia	N	I-Premise
2	and	N	I-Premise
3	fatigue	N	I-Premise
4	were	N	I-Premise
5	less	N	I-Premise
6	frequent	N	I-Premise
7	,	N	I-Premise
8	but	N	I-Premise
9	vaginal	N	I-Premise
10	discharge	N	I-Premise
11	was	N	I-Premise
12	more	N	I-Premise
13	frequent	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	tamoxifen	N	I-Premise
17	group	N	I-Premise
18	than	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	exemestane	N	I-Premise
22	group	N	I-Premise
23	or	N	I-Premise
24	anastrozole	N	I-Premise
25	group	N	I-Premise
26	.	N	I-Premise

1	HRQOL	N	I-Claim
2	was	N	I-Claim
3	better	N	I-Claim
4	in	N	I-Claim
5	Japanese	N	I-Claim
6	postmenopausal	N	I-Claim
7	women	N	I-Claim
8	treated	N	I-Claim
9	with	N	I-Claim
10	tamoxifen	N	I-Claim
11	than	N	I-Claim
12	those	N	I-Claim
13	treated	N	I-Claim
14	with	N	I-Claim
15	exemestane	N	I-Claim
16	or	N	I-Claim
17	anastrozole	N	I-Claim
18	.	N	I-Claim

1	HRQOL	N	I-Claim
2	and	N	I-Claim
3	AEs	N	I-Claim
4	were	N	I-Claim
5	similar	N	I-Claim
6	with	N	I-Claim
7	exemestane	N	I-Claim
8	and	N	I-Claim
9	anastrozole	N	I-Claim
10	.	N	I-Claim

1	Given	N	I-Claim
2	the	N	I-Claim
3	results	N	I-Claim
4	of	N	I-Claim
5	the	N	I-Claim
6	TEAM	N	I-Claim
7	trial	N	I-Claim
8	,	N	I-Claim
9	upfront	N	I-Claim
10	use	N	I-Claim
11	of	N	I-Claim
12	tamoxifen	N	I-Claim
13	followed	N	I-Claim
14	by	N	I-Claim
15	an	N	I-Claim
16	aromatase	N	I-Claim
17	inhibitor	N	I-Claim
18	(	N	I-Claim
19	AI	N	I-Claim
20	)	N	I-Claim
21	may	N	I-Claim
22	be	N	I-Claim
23	an	N	I-Claim
24	important	N	I-Claim
25	option	N	I-Claim
26	for	N	I-Claim
27	adjuvant	N	I-Claim
28	endocrine	N	I-Claim
29	therapy	N	I-Claim
30	in	N	I-Claim
31	Japanese	N	I-Claim
32	postmenopausal	N	I-Claim
33	women	N	I-Claim
34	.	N	I-Claim

1	Cisplatin	N	I-MajorClaim
2	reduces	N	I-MajorClaim
3	plasma	N	I-MajorClaim
4	ghrelin	N	I-MajorClaim
5	levels	N	I-MajorClaim
6	through	N	I-MajorClaim
7	the	N	I-MajorClaim
8	5-hydroxytryptamine	N	I-MajorClaim
9	(	N	I-MajorClaim
10	5-HT	N	I-MajorClaim
11	)	N	I-MajorClaim
12	receptor	N	I-MajorClaim
13	.	N	I-MajorClaim

1	This	N	O
2	may	N	O
3	cause	N	O
4	cisplatin-induced	N	O
5	gastrointestinal	N	O
6	disorders	N	O
7	and	N	O
8	hinders	N	O
9	the	N	O
10	continuation	N	O
11	of	N	O
12	chemotherapy	N	O
13	.	N	O

1	The	N	O
2	authors	N	O
3	of	N	O
4	this	N	O
5	report	N	O
6	conducted	N	O
7	a	N	O
8	prospective	N	O
9	,	N	O
10	randomized	N	O
11	phase	N	O
12	2	N	O
13	trial	N	O
14	to	N	O
15	evaluate	N	O
16	the	N	O
17	effects	N	O
18	of	N	O
19	exogenous	N	O
20	ghrelin	N	O
21	during	N	O
22	cisplatin-based	N	O
23	chemotherapy	N	O
24	.	N	O

1	Forty-two	N	O
2	patients	N	O
3	with	N	O
4	esophageal	N	O
5	cancer	N	O
6	who	N	O
7	were	N	O
8	receiving	N	O
9	cisplatin-based	N	O
10	neoadjuvant	N	O
11	chemotherapy	N	O
12	were	N	O
13	assigned	N	O
14	to	N	O
15	either	N	O
16	a	N	O
17	ghrelin	N	O
18	group	N	O
19	(	N	O
20	n	N	O
21	=	N	O
22	21	N	O
23	)	N	O
24	or	N	O
25	a	N	O
26	placebo	N	O
27	group	N	O
28	(	N	O
29	n	N	O
30	=	N	O
31	21	N	O
32	)	N	O
33	.	N	O

1	They	N	O
2	received	N	O
3	either	N	O
4	intravenous	N	O
5	infusions	N	O
6	of	N	O
7	synthetic	N	O
8	human	N	O
9	ghrelin	N	O
10	(	N	O
11	3	N	O
12	μg/kg	N	O
13	)	N	O
14	or	N	O
15	saline	N	O
16	twice	N	O
17	daily	N	O
18	for	N	O
19	1	N	O
20	week	N	O
21	with	N	O
22	cisplatin	N	O
23	administration	N	O
24	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	changes	N	O
6	in	N	O
7	oral	N	O
8	calorie	N	O
9	intake	N	O
10	,	N	O
11	and	N	O
12	the	N	O
13	secondary	N	O
14	endpoints	N	O
15	were	N	O
16	chemotherapy-related	N	O
17	adverse	N	O
18	events	N	O
19	;	N	O
20	appetite	N	O
21	visual	N	O
22	analog	N	O
23	scale	N	O
24	(	N	O
25	VAS	N	O
26	)	N	O
27	scores	N	O
28	;	N	O
29	changes	N	O
30	in	N	O
31	gastrointestinal	N	O
32	hormones	N	O
33	and	N	O
34	nutritional	N	O
35	status	N	O
36	,	N	O
37	including	N	O
38	rapid	N	O
39	turnover	N	O
40	proteins	N	O
41	,	N	O
42	and	N	O
43	quality	N	O
44	of	N	O
45	life	N	O
46	(	N	O
47	QoL	N	O
48	)	N	O
49	estimated	N	O
50	with	N	O
51	the	N	O
52	European	N	O
53	Organization	N	O
54	for	N	O
55	Research	N	O
56	and	N	O
57	Treatment	N	O
58	of	N	O
59	Cancer	N	O
60	QoL	N	O
61	core	N	O
62	questionnaire	N	O
63	(	N	O
64	QLQ-C30	N	O
65	)	N	O
66	.	N	O

1	Two	N	O
2	patients	N	O
3	were	N	O
4	excluded	N	O
5	from	N	O
6	the	N	O
7	final	N	O
8	analysis	N	O
9	:	N	O
10	One	N	O
11	patient	N	O
12	suspended	N	O
13	ghrelin	N	O
14	administration	N	O
15	because	N	O
16	of	N	O
17	excessive	N	O
18	diaphoresis	N	O
19	,	N	O
20	and	N	O
21	another	N	O
22	patient	N	O
23	in	N	O
24	the	N	O
25	placebo	N	O
26	group	N	O
27	failed	N	O
28	to	N	O
29	monitor	N	O
30	the	N	O
31	self-questionnaire	N	O
32	.	N	O

1	Food	N	I-Premise
2	intake	N	I-Premise
3	and	N	I-Premise
4	appetite	N	I-Premise
5	VAS	N	I-Premise
6	scores	N	I-Premise
7	were	N	I-Premise
8	significantly	N	I-Premise
9	higher	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	ghrelin	N	I-Premise
13	group	N	I-Premise
14	than	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	placebo	N	I-Premise
18	group	N	I-Premise
19	(	N	I-Premise
20	18.2	N	I-Premise
21	±	N	I-Premise
22	5.2	N	I-Premise
23	kcal/kg/day	N	I-Premise
24	vs	N	I-Premise
25	12.7	N	I-Premise
26	±	N	I-Premise
27	3.4	N	I-Premise
28	kcal/kg/day	N	I-Premise
29	[	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.001	N	I-Premise
33	]	N	I-Premise
34	and	N	I-Premise
35	6.2	N	I-Premise
36	±	N	I-Premise
37	0.9	N	I-Premise
38	vs	N	I-Premise
39	4.1	N	I-Premise
40	±	N	I-Premise
41	0.9	N	I-Premise
42	[	N	I-Premise
43	P	N	I-Premise
44	<	N	I-Premise
45	.0001	N	I-Premise
46	]	N	I-Premise
47	,	N	I-Premise
48	respectively	N	I-Premise
49	)	N	I-Premise
50	.	N	I-Premise

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	ghrelin	N	I-Premise
5	group	N	I-Premise
6	had	N	I-Premise
7	fewer	N	I-Premise
8	adverse	N	I-Premise
9	events	N	I-Premise
10	during	N	I-Premise
11	chemotherapy	N	I-Premise
12	related	N	I-Premise
13	to	N	I-Premise
14	anorexia	N	I-Premise
15	and	N	I-Premise
16	nausea	N	I-Premise
17	than	N	I-Premise
18	patients	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	control	N	I-Premise
22	group	N	I-Premise
23	.	N	I-Premise

1	Significant	N	I-Premise
2	deterioration	N	I-Premise
3	was	N	I-Premise
4	noted	N	I-Premise
5	after	N	I-Premise
6	chemotherapy	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	placebo	N	I-Premise
10	group	N	I-Premise
11	in	N	I-Premise
12	QoL	N	I-Premise
13	scores	N	I-Premise
14	,	N	I-Premise
15	appetite	N	I-Premise
16	,	N	I-Premise
17	nausea	N	I-Premise
18	and	N	I-Premise
19	vomiting	N	I-Premise
20	,	N	I-Premise
21	and	N	I-Premise
22	global	N	I-Premise
23	health	N	I-Premise
24	status	N	I-Premise
25	.	N	I-Premise

1	Short-term	N	I-Claim
2	administration	N	I-Claim
3	of	N	I-Claim
4	exogenous	N	I-Claim
5	ghrelin	N	I-Claim
6	at	N	I-Claim
7	the	N	I-Claim
8	start	N	I-Claim
9	of	N	I-Claim
10	cisplatin-based	N	I-Claim
11	chemotherapy	N	I-Claim
12	stimulated	N	I-Claim
13	food	N	I-Claim
14	intake	N	I-Claim
15	and	N	I-Claim
16	minimized	N	I-Claim
17	adverse	N	I-Claim
18	events	N	I-Claim
19	.	N	I-Claim

1	This	N	O
2	study	N	O
3	aims	N	O
4	to	N	O
5	examine	N	O
6	the	N	O
7	effectiveness	N	O
8	of	N	O
9	a	N	O
10	self-management	N	O
11	multimodal	N	O
12	comprehensive	N	O
13	coping	N	O
14	strategy	N	O
15	program	N	O
16	(	N	O
17	CCSP	N	O
18	)	N	O
19	on	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	(	N	O
24	QOL	N	O
25	)	N	O
26	among	N	O
27	breast	N	O
28	cancer	N	O
29	patients	N	O
30	1	N	O
31	year	N	O
32	after	N	O
33	treatment	N	O
34	.	N	O

1	Patients	N	O
2	(	N	O
3	n	N	O
4	=	N	O
5	110	N	O
6	)	N	O
7	with	N	O
8	stage	N	O
9	II	N	O
10	,	N	O
11	III	N	O
12	,	N	O
13	or	N	O
14	IV	N	O
15	breast	N	O
16	cancer	N	O
17	scheduled	N	O
18	to	N	O
19	receive	N	O
20	high	N	O
21	dose	N	O
22	chemotherapy	N	O
23	and	N	O
24	autologous	N	O
25	hematopoietic	N	O
26	stem	N	O
27	cell	N	O
28	transplantation	N	O
29	were	N	O
30	randomized	N	O
31	to	N	O
32	either	N	O
33	CCSP	N	O
34	treatment	N	O
35	or	N	O
36	control	N	O
37	group	N	O
38	.	N	O

1	The	N	O
2	CCSP	N	O
3	intervention	N	O
4	was	N	O
5	taught	N	O
6	2	N	O
7	week	N	O
8	before	N	O
9	hospital	N	O
10	admission	N	O
11	with	N	O
12	reinforcement	N	O
13	at	N	O
14	specified	N	O
15	times	N	O
16	during	N	O
17	treatment	N	O
18	and	N	O
19	3	N	O
20	months	N	O
21	after	N	O
22	discharge	N	O
23	.	N	O

1	The	N	O
2	CCSP	N	O
3	components	N	O
4	included	N	O
5	educational	N	O
6	information	N	O
7	,	N	O
8	cognitive	N	O
9	restructuring	N	O
10	,	N	O
11	coping	N	O
12	skills	N	O
13	enhancement	N	O
14	,	N	O
15	and	N	O
16	relaxation	N	O
17	with	N	O
18	guided	N	O
19	imagery	N	O
20	.	N	O

1	Instruments	N	O
2	administered	N	O
3	at	N	O
4	baseline	N	O
5	included	N	O
6	the	N	O
7	following	N	O
8	:	N	O
9	Quality	N	O
10	of	N	O
11	Life	N	O
12	Index-Cancer	N	O
13	Version	N	O
14	(	N	O
15	QOLI-CV	N	O
16	)	N	O
17	,	N	O
18	State-Trait	N	O
19	Anxiety	N	O
20	Inventory	N	O
21	,	N	O
22	Beck	N	O
23	Depression	N	O
24	Inventory	N	O
25	,	N	O
26	and	N	O
27	Coping	N	O
28	Strategies	N	O
29	Questionnaire	N	O
30	.	N	O

1	At	N	O
2	1-year	N	O
3	follow-up	N	O
4	,	N	O
5	patients	N	O
6	(	N	O
7	n	N	O
8	=	N	O
9	73	N	O
10	)	N	O
11	completed	N	O
12	and	N	O
13	returned	N	O
14	the	N	O
15	follow-up	N	O
16	QOLI-CV	N	O
17	.	N	O

1	Patients	N	O
2	were	N	O
3	mainly	N	O
4	≥	N	O
5	40	N	O
6	years	N	O
7	of	N	O
8	age	N	O
9	,	N	O
10	married	N	O
11	,	N	O
12	Caucasian	N	O
13	,	N	O
14	and	N	O
15	diagnosed	N	O
16	with	N	O
17	advanced	N	O
18	breast	N	O
19	cancer	N	O
20	.	N	O

1	A	N	I-Premise
2	model	N	I-Premise
3	measuring	N	I-Premise
4	effectiveness	N	I-Premise
5	of	N	I-Premise
6	CCSP	N	I-Premise
7	on	N	I-Premise
8	QOL	N	I-Premise
9	(	N	I-Premise
10	total	N	I-Premise
11	and	N	I-Premise
12	subscale	N	I-Premise
13	)	N	I-Premise
14	at	N	I-Premise
15	1-year	N	I-Premise
16	follow-up	N	I-Premise
17	showed	N	I-Premise
18	that	N	I-Premise
19	the	N	I-Premise
20	CCSP	N	I-Premise
21	group	N	I-Premise
22	(	N	I-Premise
23	n	N	I-Premise
24	=	N	I-Premise
25	38	N	I-Premise
26	)	N	I-Premise
27	had	N	I-Premise
28	significant	N	I-Premise
29	improvement	N	I-Premise
30	in	N	I-Premise
31	overall	N	I-Premise
32	QOL	N	I-Premise
33	(	N	I-Premise
34	p	N	I-Premise
35	<	N	I-Premise
36	0.01	N	I-Premise
37	)	N	I-Premise
38	,	N	I-Premise
39	health	N	I-Premise
40	and	N	I-Premise
41	functioning	N	I-Premise
42	(	N	I-Premise
43	p	N	I-Premise
44	<	N	I-Premise
45	0.05	N	I-Premise
46	)	N	I-Premise
47	,	N	I-Premise
48	and	N	I-Premise
49	socioeconomic	N	I-Premise
50	(	N	I-Premise
51	p	N	I-Premise
52	<	N	I-Premise
53	0.05	N	I-Premise
54	)	N	I-Premise
55	and	N	I-Premise
56	psychological/spiritual	N	I-Premise
57	well-being	N	I-Premise
58	(	N	I-Premise
59	p	N	I-Premise
60	<	N	I-Premise
61	0.01	N	I-Premise
62	)	N	I-Premise
63	compared	N	I-Premise
64	with	N	I-Premise
65	the	N	I-Premise
66	control	N	I-Premise
67	group	N	I-Premise
68	(	N	I-Premise
69	n	N	I-Premise
70	=	N	I-Premise
71	35	N	I-Premise
72	)	N	I-Premise
73	.	N	I-Premise

1	The	N	I-Premise
2	CCSP	N	I-Premise
3	patients	N	I-Premise
4	frequently	N	I-Premise
5	used	N	I-Premise
6	the	N	I-Premise
7	CCSP	N	I-Premise
8	to	N	I-Premise
9	manage	N	I-Premise
10	psychological	N	I-Premise
11	(	N	I-Premise
12	51	N	I-Premise
13	%	N	I-Premise
14	)	N	I-Premise
15	and	N	I-Premise
16	sleep	N	I-Premise
17	problems	N	I-Premise
18	(	N	I-Premise
19	60	N	I-Premise
20	%	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	The	N	I-Premise
2	CCSP	N	I-Premise
3	improved	N	I-Premise
4	QOL	N	I-Premise
5	for	N	I-Premise
6	patients	N	I-Premise
7	at	N	I-Premise
8	1-year	N	I-Premise
9	follow-up	N	I-Premise
10	.	N	I-Premise

1	Patients	N	I-Premise
2	overwhelmingly	N	I-Premise
3	reported	N	I-Premise
4	that	N	I-Premise
5	CCSP	N	I-Premise
6	was	N	I-Premise
7	beneficial	N	I-Premise
8	.	N	I-Premise

1	The	N	I-Claim
2	CCSP	N	I-Claim
3	as	N	I-Claim
4	an	N	I-Claim
5	effective	N	I-Claim
6	coping	N	I-Claim
7	intervention	N	I-Claim
8	has	N	I-Claim
9	potential	N	I-Claim
10	as	N	I-Claim
11	a	N	I-Claim
12	self-management	N	I-Claim
13	program	N	I-Claim
14	for	N	I-Claim
15	breast	N	I-Claim
16	cancer	N	I-Claim
17	survivors	N	I-Claim
18	.	N	I-Claim

1	Few	N	O
2	intervention	N	O
3	programs	N	O
4	assist	N	O
5	patients	N	O
6	and	N	O
7	their	N	O
8	family	N	O
9	caregivers	N	O
10	to	N	O
11	manage	N	O
12	advanced	N	O
13	cancer	N	O
14	and	N	O
15	maintain	N	O
16	their	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QOL	N	O
22	)	N	O
23	.	N	O

1	This	N	O
2	study	N	O
3	examined	N	O
4	(	N	O
5	i	N	O
6	)	N	O
7	whether	N	O
8	patient-caregiver	N	O
9	dyads	N	O
10	(	N	O
11	i.e.	N	O
12	,	N	O
13	pairs	N	O
14	)	N	O
15	randomly	N	O
16	assigned	N	O
17	to	N	O
18	a	N	O
19	brief	N	O
20	or	N	O
21	extensive	N	O
22	dyadic	N	O
23	intervention	N	O
24	(	N	O
25	the	N	O
26	FOCUS	N	O
27	Program	N	O
28	)	N	O
29	had	N	O
30	better	N	O
31	outcomes	N	O
32	than	N	O
33	dyads	N	O
34	randomly	N	O
35	assigned	N	O
36	to	N	O
37	usual	N	O
38	care	N	O
39	and	N	O
40	(	N	O
41	ii	N	O
42	)	N	O
43	whether	N	O
44	patients	N	O
45	'	N	O
46	risk	N	O
47	for	N	O
48	distress	N	O
49	and	N	O
50	other	N	O
51	factors	N	O
52	moderated	N	O
53	the	N	O
54	effect	N	O
55	of	N	O
56	the	N	O
57	brief	N	O
58	or	N	O
59	extensive	N	O
60	program	N	O
61	on	N	O
62	outcomes	N	O
63	.	N	O

1	Advanced	N	O
2	cancer	N	O
3	patients	N	O
4	and	N	O
5	their	N	O
6	caregivers	N	O
7	(	N	O
8	N	N	O
9	=	N	O
10	484	N	O
11	dyads	N	O
12	)	N	O
13	were	N	O
14	stratified	N	O
15	by	N	O
16	patients	N	O
17	'	N	O
18	baseline	N	O
19	risk	N	O
20	for	N	O
21	distress	N	O
22	(	N	O
23	high	N	O
24	versus	N	O
25	low	N	O
26	)	N	O
27	,	N	O
28	cancer	N	O
29	type	N	O
30	(	N	O
31	lung	N	O
32	,	N	O
33	colorectal	N	O
34	,	N	O
35	breast	N	O
36	,	N	O
37	or	N	O
38	prostate	N	O
39	)	N	O
40	,	N	O
41	and	N	O
42	research	N	O
43	site	N	O
44	and	N	O
45	then	N	O
46	randomly	N	O
47	assigned	N	O
48	to	N	O
49	a	N	O
50	brief	N	O
51	(	N	O
52	three-session	N	O
53	)	N	O
54	or	N	O
55	extensive	N	O
56	(	N	O
57	six-session	N	O
58	)	N	O
59	intervention	N	O
60	or	N	O
61	control	N	O
62	.	N	O

1	The	N	O
2	interventions	N	O
3	offered	N	O
4	dyads	N	O
5	information	N	O
6	and	N	O
7	support	N	O
8	.	N	O

1	Intermediary	N	O
2	outcomes	N	O
3	were	N	O
4	appraisals	N	O
5	(	N	O
6	i.e.	N	O
7	,	N	O
8	appraisal	N	O
9	of	N	O
10	illness/caregiving	N	O
11	,	N	O
12	uncertainty	N	O
13	,	N	O
14	and	N	O
15	hopelessness	N	O
16	)	N	O
17	and	N	O
18	resources	N	O
19	(	N	O
20	i.e.	N	O
21	,	N	O
22	coping	N	O
23	,	N	O
24	interpersonal	N	O
25	relationships	N	O
26	,	N	O
27	and	N	O
28	self-efficacy	N	O
29	)	N	O
30	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	QOL	N	O
6	.	N	O

1	Data	N	O
2	were	N	O
3	collected	N	O
4	prior	N	O
5	to	N	O
6	intervention	N	O
7	and	N	O
8	post-intervention	N	O
9	(	N	O
10	3	N	O
11	and	N	O
12	6	N	O
13	months	N	O
14	from	N	O
15	baseline	N	O
16	)	N	O
17	.	N	O

1	The	N	O
2	final	N	O
3	sample	N	O
4	was	N	O
5	302	N	O
6	dyads	N	O
7	.	N	O

1	Repeated	N	O
2	measures	N	O
3	MANCOVA	N	O
4	was	N	O
5	used	N	O
6	to	N	O
7	evaluate	N	O
8	outcomes	N	O
9	.	N	O

1	Significant	N	I-Premise
2	group	N	I-Premise
3	by	N	I-Premise
4	time	N	I-Premise
5	interactions	N	I-Premise
6	showed	N	I-Premise
7	that	N	I-Premise
8	there	N	I-Premise
9	was	N	I-Premise
10	an	N	I-Premise
11	improvement	N	I-Premise
12	in	N	I-Premise
13	dyads	N	I-Premise
14	'	N	I-Premise
15	coping	N	I-Premise
16	(	N	I-Premise
17	p	N	I-Premise
18	<	N	I-Premise
19	0.05	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	self-efficacy	N	I-Premise
23	(	N	I-Premise
24	p	N	I-Premise
25	<	N	I-Premise
26	0.05	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	and	N	I-Premise
30	social	N	I-Premise
31	QOL	N	I-Premise
32	(	N	I-Premise
33	p	N	I-Premise
34	<	N	I-Premise
35	0.01	N	I-Premise
36	)	N	I-Premise
37	and	N	I-Premise
38	in	N	I-Premise
39	caregivers	N	I-Premise
40	'	N	I-Premise
41	emotional	N	I-Premise
42	QOL	N	I-Premise
43	(	N	I-Premise
44	p	N	I-Premise
45	<	N	I-Premise
46	0.05	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	Effects	N	O
2	varied	N	O
3	by	N	O
4	intervention	N	O
5	dose	N	O
6	.	N	O

1	Most	N	O
2	effects	N	O
3	were	N	O
4	found	N	O
5	at	N	O
6	3	N	O
7	months	N	O
8	only	N	O
9	.	N	O

1	Risk	N	I-Premise
2	for	N	I-Premise
3	distress	N	I-Premise
4	accounted	N	I-Premise
5	for	N	I-Premise
6	very	N	I-Premise
7	few	N	I-Premise
8	moderation	N	I-Premise
9	effects	N	I-Premise
10	.	N	I-Premise

1	Both	N	I-Premise
2	brief	N	I-Premise
3	and	N	I-Premise
4	extensive	N	I-Premise
5	programs	N	I-Premise
6	had	N	I-Premise
7	positive	N	I-Premise
8	outcomes	N	I-Premise
9	for	N	I-Premise
10	patient-caregiver	N	I-Premise
11	dyads	N	I-Premise
12	,	N	I-Premise
13	but	N	I-Premise
14	few	N	I-Premise
15	sustained	N	I-Premise
16	effects	N	I-Premise
17	.	N	I-Premise

1	Patient-caregiver	N	I-Claim
2	dyads	N	I-Claim
3	benefit	N	I-Claim
4	when	N	I-Claim
5	viewed	N	I-Claim
6	as	N	I-Claim
7	the	N	I-Claim
8	'unit	N	I-Claim
9	of	N	I-Claim
10	care	N	I-Claim
11	'	N	I-Claim
12	.	N	I-Claim

1	As	N	O
2	patients	N	O
3	with	N	O
4	pancreas	N	O
5	and	N	O
6	periampullary	N	O
7	cancer	N	O
8	(	N	O
9	PPC	N	O
10	)	N	O
11	experience	N	O
12	improved	N	O
13	survival	N	O
14	rates	N	O
15	and	N	O
16	longevity	N	O
17	,	N	O
18	the	N	O
19	focus	N	O
20	shifts	N	O
21	toward	N	O
22	living	N	O
23	life	N	O
24	while	N	O
25	surviving	N	O
26	cancer	N	O
27	.	N	O

1	Fatigue	N	O
2	is	N	O
3	the	N	O
4	most	N	O
5	commonly	N	O
6	reported	N	O
7	symptom	N	O
8	in	N	O
9	all	N	O
10	cancer	N	O
11	patients	N	O
12	.	N	O

1	Exercise	N	O
2	has	N	O
3	been	N	O
4	found	N	O
5	to	N	O
6	effectively	N	O
7	decrease	N	O
8	fatigue	N	O
9	levels	N	O
10	and	N	O
11	improve	N	O
12	physical	N	O
13	functioning	N	O
14	in	N	O
15	cancer	N	O
16	patients	N	O
17	.	N	O

1	One	N	O
2	hundred	N	O
3	two	N	O
4	patients	N	O
5	with	N	O
6	resected	N	O
7	PPC	N	O
8	consented	N	O
9	to	N	O
10	participate	N	O
11	in	N	O
12	this	N	O
13	study	N	O
14	and	N	O
15	were	N	O
16	randomized	N	O
17	to	N	O
18	either	N	O
19	an	N	O
20	intervention	N	O
21	group	N	O
22	(	N	O
23	IG	N	O
24	)	N	O
25	or	N	O
26	a	N	O
27	usual	N	O
28	care	N	O
29	group	N	O
30	(	N	O
31	UCG	N	O
32	)	N	O
33	.	N	O

1	Subjects	N	O
2	completed	N	O
3	visual	N	O
4	analog	N	O
5	scales	N	O
6	,	N	O
7	the	N	O
8	FACIT-Fatigue	N	O
9	Scale	N	O
10	and	N	O
11	the	N	O
12	Short	N	O
13	Form-36v2	N	O
14	after	N	O
15	surgery	N	O
16	and	N	O
17	again	N	O
18	3	N	O
19	to	N	O
20	6	N	O
21	months	N	O
22	after	N	O
23	hospital	N	O
24	discharge	N	O
25	.	N	O

1	Patients	N	O
2	in	N	O
3	the	N	O
4	IG	N	O
5	and	N	O
6	UCG	N	O
7	were	N	O
8	comparable	N	O
9	with	N	O
10	regard	N	O
11	to	N	O
12	demographics	N	O
13	,	N	O
14	comorbidities	N	O
15	,	N	O
16	cancer	N	O
17	type	N	O
18	and	N	O
19	staging	N	O
20	,	N	O
21	type	N	O
22	of	N	O
23	resection	N	O
24	,	N	O
25	preoperative	N	O
26	fatigue	N	O
27	and	N	O
28	pain	N	O
29	levels	N	O
30	,	N	O
31	adjuvant	N	O
32	therapy	N	O
33	,	N	O
34	and	N	O
35	baseline	N	O
36	walking	N	O
37	distance	N	O
38	.	N	O

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	IG	N	I-Premise
5	had	N	I-Premise
6	significantly	N	I-Premise
7	improved	N	I-Premise
8	scores	N	I-Premise
9	on	N	I-Premise
10	the	N	I-Premise
11	FACIT-Fatigue	N	I-Premise
12	Scale	N	I-Premise
13	at	N	I-Premise
14	study	N	I-Premise
15	completion	N	I-Premise
16	,	N	I-Premise
17	improved	N	I-Premise
18	fatigue	N	I-Premise
19	and	N	I-Premise
20	pain	N	I-Premise
21	scores	N	I-Premise
22	,	N	I-Premise
23	as	N	I-Premise
24	well	N	I-Premise
25	as	N	I-Premise
26	overall	N	I-Premise
27	physical	N	I-Premise
28	functioning	N	I-Premise
29	and	N	I-Premise
30	mental	N	I-Premise
31	health	N	I-Premise
32	composite	N	I-Premise
33	scores	N	I-Premise
34	.	N	I-Premise

1	At	N	I-Premise
2	study	N	I-Premise
3	completion	N	I-Premise
4	,	N	I-Premise
5	participants	N	I-Premise
6	in	N	I-Premise
7	the	N	I-Premise
8	IG	N	I-Premise
9	were	N	I-Premise
10	walking	N	I-Premise
11	twice	N	I-Premise
12	as	N	I-Premise
13	far	N	I-Premise
14	and	N	I-Premise
15	were	N	I-Premise
16	significantly	N	I-Premise
17	more	N	I-Premise
18	likely	N	I-Premise
19	to	N	I-Premise
20	have	N	I-Premise
21	continued	N	I-Premise
22	walking	N	I-Premise
23	or	N	I-Premise
24	another	N	I-Premise
25	form	N	I-Premise
26	of	N	I-Premise
27	exercise	N	I-Premise
28	as	N	I-Premise
29	compared	N	I-Premise
30	with	N	I-Premise
31	the	N	I-Premise
32	UCG	N	I-Premise
33	.	N	I-Premise

1	Using	N	O
2	hierarchical	N	O
3	cluster	N	O
4	analysis	N	O
5	,	N	O
6	3	N	O
7	mutually	N	O
8	exclusive	N	O
9	symptom	N	O
10	groupings	N	O
11	were	N	O
12	identified	N	O
13	in	N	O
14	the	N	O
15	cohort	N	O
16	.	N	O

1	Kaplan-Meier	N	I-Premise
2	survival	N	I-Premise
3	analysis	N	I-Premise
4	did	N	I-Premise
5	not	N	I-Premise
6	indicate	N	I-Premise
7	an	N	I-Premise
8	overall	N	I-Premise
9	survival	N	I-Premise
10	benefit	N	I-Premise
11	for	N	I-Premise
12	the	N	I-Premise
13	IG	N	I-Premise
14	.	N	I-Premise

1	This	N	I-Claim
2	is	N	I-Claim
3	the	N	I-Claim
4	first	N	I-Claim
5	prospective	N	I-Claim
6	,	N	I-Claim
7	randomized	N	I-Claim
8	controlled	N	I-Claim
9	trial	N	I-Claim
10	to	N	I-Claim
11	report	N	I-Claim
12	that	N	I-Claim
13	participation	N	I-Claim
14	in	N	I-Claim
15	a	N	I-Claim
16	home	N	I-Claim
17	walking	N	I-Claim
18	program	N	I-Claim
19	confers	N	I-Claim
20	a	N	I-Claim
21	significant	N	I-Claim
22	benefit	N	I-Claim
23	in	N	I-Claim
24	resected	N	I-Claim
25	PPC	N	I-Claim
26	patients	N	I-Claim
27	with	N	I-Claim
28	regard	N	I-Claim
29	to	N	I-Claim
30	fatigue	N	I-Claim
31	levels	N	I-Claim
32	,	N	I-Claim
33	physical	N	I-Claim
34	functioning	N	I-Claim
35	,	N	I-Claim
36	and	N	I-Claim
37	health-related	N	I-Claim
38	quality	N	I-Claim
39	of	N	I-Claim
40	life	N	I-Claim
41	.	N	I-Claim

1	Pemetrexed	N	O
2	maintenance	N	O
3	therapy	N	O
4	significantly	N	O
5	improved	N	O
6	overall	N	O
7	survival	N	O
8	and	N	O
9	progression-free	N	O
10	survival	N	O
11	compared	N	O
12	with	N	O
13	placebo	N	O
14	,	N	O
15	and	N	O
16	had	N	O
17	a	N	O
18	good	N	O
19	safety	N	O
20	profile	N	O
21	in	N	O
22	a	N	O
23	phase	N	O
24	3	N	O
25	placebo-controlled	N	O
26	study	N	O
27	in	N	O
28	patients	N	O
29	with	N	O
30	advanced	N	O
31	non-small-cell	N	O
32	lung	N	O
33	cancer	N	O
34	(	N	O
35	NSCLC	N	O
36	)	N	O
37	.	N	O

1	Results	N	O
2	for	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	,	N	O
7	symptom	N	O
8	palliation	N	O
9	,	N	O
10	and	N	O
11	tolerability	N	O
12	are	N	O
13	presented	N	O
14	here	N	O
15	.	N	O

1	After	N	O
2	four	N	O
3	cycles	N	O
4	of	N	O
5	platinum-based	N	O
6	induction	N	O
7	therapy	N	O
8	,	N	O
9	663	N	O
10	patients	N	O
11	with	N	O
12	stage	N	O
13	IIIB	N	O
14	or	N	O
15	stage	N	O
16	IV	N	O
17	NSCLC	N	O
18	and	N	O
19	Eastern	N	O
20	Cooperative	N	O
21	Oncology	N	O
22	Group	N	O
23	performance	N	O
24	status	N	O
25	of	N	O
26	0	N	O
27	or	N	O
28	1	N	O
29	were	N	O
30	randomly	N	O
31	assigned	N	O
32	(	N	O
33	in	N	O
34	a	N	O
35	2:1	N	O
36	ratio	N	O
37	)	N	O
38	from	N	O
39	March	N	O
40	15	N	O
41	,	N	O
42	2005	N	O
43	,	N	O
44	to	N	O
45	July	N	O
46	20	N	O
47	,	N	O
48	2007	N	O
49	,	N	O
50	using	N	O
51	the	N	O
52	Pocock	N	O
53	and	N	O
54	Simon	N	O
55	minimisation	N	O
56	method	N	O
57	to	N	O
58	receive	N	O
59	pemetrexed	N	O
60	(	N	O
61	500	N	O
62	mg/m	N	O
63	(	N	O
64	2	N	O
65	)	N	O
66	every	N	O
67	21	N	O
68	days	N	O
69	;	N	O
70	n=441	N	O
71	)	N	O
72	or	N	O
73	placebo	N	O
74	(	N	O
75	n=222	N	O
76	)	N	O
77	plus	N	O
78	best	N	O
79	supportive	N	O
80	care	N	O
81	until	N	O
82	disease	N	O
83	progression	N	O
84	.	N	O

1	The	N	O
2	primary	N	O
3	efficacy	N	O
4	data	N	O
5	have	N	O
6	been	N	O
7	reported	N	O
8	previously	N	O
9	.	N	O

1	Patients	N	O
2	completed	N	O
3	the	N	O
4	Lung	N	O
5	Cancer	N	O
6	Symptom	N	O
7	Scale	N	O
8	(	N	O
9	LCSS	N	O
10	)	N	O
11	at	N	O
12	baseline	N	O
13	,	N	O
14	after	N	O
15	each	N	O
16	cycle	N	O
17	,	N	O
18	and	N	O
19	post-discontinuation	N	O
20	.	N	O

1	Worsening	N	O
2	of	N	O
3	symptoms	N	O
4	was	N	O
5	defined	N	O
6	as	N	O
7	an	N	O
8	increase	N	O
9	of	N	O
10	15	N	O
11	mm	N	O
12	or	N	O
13	more	N	O
14	from	N	O
15	baseline	N	O
16	on	N	O
17	a	N	O
18	100	N	O
19	mm	N	O
20	scale	N	O
21	for	N	O
22	each	N	O
23	LCSS	N	O
24	item	N	O
25	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	for	N	O
5	these	N	O
6	quality-of-life	N	O
7	analyses	N	O
8	was	N	O
9	time	N	O
10	to	N	O
11	worsening	N	O
12	of	N	O
13	symptoms	N	O
14	,	N	O
15	analysed	N	O
16	for	N	O
17	all	N	O
18	randomised	N	O
19	patients	N	O
20	.	N	O

1	Baseline	N	O
2	characteristics	N	O
3	,	N	O
4	including	N	O
5	LCSS	N	O
6	scores	N	O
7	,	N	O
8	were	N	O
9	well	N	O
10	balanced	N	O
11	between	N	O
12	groups	N	O
13	.	N	O

1	Baseline	N	O
2	LCSS	N	O
3	scores	N	O
4	were	N	O
5	low	N	O
6	,	N	O
7	indicating	N	O
8	low	N	O
9	symptom	N	O
10	burden	N	O
11	for	N	O
12	patients	N	O
13	without	N	O
14	disease	N	O
15	progression	N	O
16	after	N	O
17	completion	N	O
18	of	N	O
19	first-line	N	O
20	treatment	N	O
21	.	N	O

1	Longer	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	worsening	N	I-Premise
5	was	N	I-Premise
6	recorded	N	I-Premise
7	for	N	I-Premise
8	pain	N	I-Premise
9	(	N	I-Premise
10	hazard	N	I-Premise
11	ratio	N	I-Premise
12	[	N	I-Premise
13	HR	N	I-Premise
14	]	N	I-Premise
15	0·76	N	I-Premise
16	,	N	I-Premise
17	95	N	I-Premise
18	%	N	I-Premise
19	CI	N	I-Premise
20	0·59-0·99	N	I-Premise
21	;	N	I-Premise
22	p=0·041	N	I-Premise
23	)	N	I-Premise
24	and	N	I-Premise
25	haemoptysis	N	I-Premise
26	(	N	I-Premise
27	HR	N	I-Premise
28	0·58	N	I-Premise
29	,	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	CI	N	I-Premise
33	0·34-0·97	N	I-Premise
34	;	N	I-Premise
35	p=0·038	N	I-Premise
36	)	N	I-Premise
37	with	N	I-Premise
38	pemetrexed	N	I-Premise
39	than	N	I-Premise
40	with	N	I-Premise
41	placebo	N	I-Premise
42	;	N	I-Premise
43	no	N	I-Premise
44	other	N	I-Premise
45	significant	N	I-Premise
46	differences	N	I-Premise
47	in	N	I-Premise
48	analyses	N	I-Premise
49	of	N	I-Premise
50	time	N	I-Premise
51	to	N	I-Premise
52	worsening	N	I-Premise
53	were	N	I-Premise
54	noted	N	I-Premise
55	.	N	I-Premise

1	Additional	N	I-Premise
2	longitudinal	N	I-Premise
3	analyses	N	I-Premise
4	showed	N	I-Premise
5	a	N	I-Premise
6	greater	N	I-Premise
7	increase	N	I-Premise
8	in	N	I-Premise
9	loss	N	I-Premise
10	of	N	I-Premise
11	appetite	N	I-Premise
12	in	N	I-Premise
13	the	N	I-Premise
14	pemetrexed	N	I-Premise
15	group	N	I-Premise
16	than	N	I-Premise
17	in	N	I-Premise
18	the	N	I-Premise
19	placebo	N	I-Premise
20	group	N	I-Premise
21	(	N	I-Premise
22	4·3	N	I-Premise
23	mm	N	I-Premise
24	vs	N	I-Premise
25	0·2	N	I-Premise
26	mm	N	I-Premise
27	;	N	I-Premise
28	p=0·028	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	Rates	N	I-Premise
2	of	N	I-Premise
3	resource	N	I-Premise
4	use	N	I-Premise
5	were	N	I-Premise
6	statistically	N	I-Premise
7	higher	N	I-Premise
8	for	N	I-Premise
9	pemetrexed	N	I-Premise
10	than	N	I-Premise
11	for	N	I-Premise
12	placebo	N	I-Premise
13	:	N	I-Premise
14	admissions	N	I-Premise
15	to	N	I-Premise
16	hospital	N	I-Premise
17	for	N	I-Premise
18	drug-related	N	I-Premise
19	adverse	N	I-Premise
20	events	N	I-Premise
21	(	N	I-Premise
22	19	N	I-Premise
23	[	N	I-Premise
24	4	N	I-Premise
25	%	N	I-Premise
26	]	N	I-Premise
27	vs	N	I-Premise
28	none	N	I-Premise
29	;	N	I-Premise
30	p=0·001	N	I-Premise
31	)	N	I-Premise
32	,	N	I-Premise
33	transfusions	N	I-Premise
34	(	N	I-Premise
35	42	N	I-Premise
36	[	N	I-Premise
37	10	N	I-Premise
38	%	N	I-Premise
39	]	N	I-Premise
40	vs	N	I-Premise
41	seven	N	I-Premise
42	[	N	I-Premise
43	3	N	I-Premise
44	%	N	I-Premise
45	]	N	I-Premise
46	;	N	I-Premise
47	p=0·003	N	I-Premise
48	)	N	I-Premise
49	,	N	I-Premise
50	and	N	I-Premise
51	erythropoiesis-stimulating	N	I-Premise
52	agents	N	I-Premise
53	(	N	I-Premise
54	26	N	I-Premise
55	[	N	I-Premise
56	6	N	I-Premise
57	%	N	I-Premise
58	]	N	I-Premise
59	vs	N	I-Premise
60	four	N	I-Premise
61	[	N	I-Premise
62	2	N	I-Premise
63	%	N	I-Premise
64	]	N	I-Premise
65	;	N	I-Premise
66	p=0·017	N	I-Premise
67	)	N	I-Premise
68	.	N	I-Premise

1	Quality	N	I-Claim
2	of	N	I-Claim
3	life	N	I-Claim
4	during	N	I-Claim
5	maintenance	N	I-Claim
6	therapy	N	I-Claim
7	with	N	I-Claim
8	pemetrexed	N	I-Claim
9	is	N	I-Claim
10	similar	N	I-Claim
11	to	N	I-Claim
12	placebo	N	I-Claim
13	,	N	I-Claim
14	except	N	I-Claim
15	for	N	I-Claim
16	a	N	I-Claim
17	small	N	I-Claim
18	increase	N	I-Claim
19	in	N	I-Claim
20	loss	N	I-Claim
21	of	N	I-Claim
22	appetite	N	I-Claim
23	,	N	I-Claim
24	and	N	I-Claim
25	significantly	N	I-Claim
26	delayed	N	I-Claim
27	worsening	N	I-Claim
28	of	N	I-Claim
29	pain	N	I-Claim
30	and	N	I-Claim
31	haemoptysis	N	I-Claim
32	.	N	I-Claim

1	In	N	O
2	view	N	O
3	of	N	O
4	the	N	O
5	improvements	N	O
6	in	N	O
7	overall	N	O
8	and	N	O
9	progression-free	N	O
10	survival	N	O
11	noted	N	O
12	with	N	O
13	pemetrexed	N	O
14	maintenance	N	O
15	therapy	N	O
16	,	N	O
17	such	N	I-MajorClaim
18	treatment	N	I-MajorClaim
19	is	N	I-MajorClaim
20	an	N	I-MajorClaim
21	option	N	I-MajorClaim
22	for	N	I-MajorClaim
23	patients	N	I-MajorClaim
24	with	N	I-MajorClaim
25	advanced	N	I-MajorClaim
26	non-squamous	N	I-MajorClaim
27	NSCLC	N	I-MajorClaim
28	who	N	I-MajorClaim
29	have	N	I-MajorClaim
30	not	N	I-MajorClaim
31	progressed	N	I-MajorClaim
32	after	N	I-MajorClaim
33	platinum-based	N	I-MajorClaim
34	induction	N	I-MajorClaim
35	therapy	N	I-MajorClaim
36	.	N	I-MajorClaim

1	Topical	N	O
2	photodynamic	N	O
3	therapy	N	O
4	(	N	O
5	PDT	N	O
6	)	N	O
7	with	N	O
8	aminolevulinic	N	O
9	acid	N	O
10	(	N	O
11	ALA	N	O
12	)	N	O
13	and	N	O
14	5	N	O
15	%	N	O
16	imiquimod	N	O
17	cream	N	O
18	are	N	O
19	effective	N	O
20	therapies	N	O
21	for	N	O
22	the	N	O
23	treatment	N	O
24	of	N	O
25	actinic	N	O
26	keratoses	N	O
27	(	N	O
28	AKs	N	O
29	)	N	O
30	,	N	O
31	but	N	O
32	no	N	O
33	split-face	N	O
34	studies	N	O
35	directly	N	O
36	comparing	N	O
37	these	N	O
38	treatment	N	O
39	options	N	O
40	are	N	O
41	available	N	O
42	in	N	O
43	the	N	O
44	literature	N	O
45	.	N	O

1	To	N	O
2	compare	N	O
3	the	N	O
4	efficacy	N	O
5	and	N	O
6	tolerability	N	O
7	of	N	O
8	ALA-PDT	N	O
9	and	N	O
10	imiquimod	N	O
11	5	N	O
12	%	N	O
13	cream	N	O
14	for	N	O
15	the	N	O
16	treatment	N	O
17	of	N	O
18	AKs	N	O
19	.	N	O

1	Sixty-one	N	O
2	patients	N	O
3	were	N	O
4	enrolled	N	O
5	from	N	O
6	the	N	O
7	Salt	N	O
8	Lake	N	O
9	City	N	O
10	Veterans	N	O
11	Affairs	N	O
12	Hospital	N	O
13	;	N	O
14	51	N	O
15	completed	N	O
16	the	N	O
17	study	N	O
18	and	N	O
19	were	N	O
20	included	N	O
21	in	N	O
22	the	N	O
23	analysis	N	O
24	.	N	O

1	All	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	to	N	O
6	receive	N	O
7	half	N	O
8	of	N	O
9	a	N	O
10	sachet	N	O
11	of	N	O
12	imiquimod	N	O
13	5	N	O
14	%	N	O
15	cream	N	O
16	twice	N	O
17	weekly	N	O
18	on	N	O
19	half	N	O
20	of	N	O
21	their	N	O
22	face	N	O
23	and	N	O
24	two	N	O
25	sessions	N	O
26	of	N	O
27	PDT	N	O
28	with	N	O
29	20	N	O
30	%	N	O
31	solution	N	O
32	of	N	O
33	ALA	N	O
34	applied	N	O
35	for	N	O
36	1	N	O
37	hour	N	O
38	to	N	O
39	the	N	O
40	other	N	O
41	side	N	O
42	of	N	O
43	the	N	O
44	face	N	O
45	.	N	O

1	The	N	I-Premise
2	75	N	I-Premise
3	%	N	I-Premise
4	AK	N	I-Premise
5	clearance	N	I-Premise
6	rate	N	I-Premise
7	was	N	I-Premise
8	34.6	N	I-Premise
9	%	N	I-Premise
10	for	N	I-Premise
11	ALA-PDT	N	I-Premise
12	and	N	I-Premise
13	25	N	I-Premise
14	%	N	I-Premise
15	for	N	I-Premise
16	imiquimod	N	I-Premise
17	5	N	I-Premise
18	%	N	I-Premise
19	cream	N	I-Premise
20	(	N	I-Premise
21	p	N	I-Premise
22	=	N	I-Premise
23	.30	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	The	N	I-Premise
2	mean	N	I-Premise
3	reduction	N	I-Premise
4	in	N	I-Premise
5	AK	N	I-Premise
6	count	N	I-Premise
7	was	N	I-Premise
8	59.2	N	I-Premise
9	%	N	I-Premise
10	for	N	I-Premise
11	ALA-PDT	N	I-Premise
12	and	N	I-Premise
13	41.4	N	I-Premise
14	%	N	I-Premise
15	for	N	I-Premise
16	imiquimod	N	I-Premise
17	5	N	I-Premise
18	%	N	I-Premise
19	cream	N	I-Premise
20	(	N	I-Premise
21	p	N	I-Premise
22	=	N	I-Premise
23	.002	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	Dermatology	N	I-Premise
2	Life	N	I-Premise
3	Quality	N	I-Premise
4	Index	N	I-Premise
5	(	N	I-Premise
6	DLQI	N	I-Premise
7	)	N	I-Premise
8	scores	N	I-Premise
9	were	N	I-Premise
10	assessed	N	I-Premise
11	for	N	I-Premise
12	each	N	I-Premise
13	treatment	N	I-Premise
14	modality	N	I-Premise
15	at	N	I-Premise
16	week	N	I-Premise
17	4	N	I-Premise
18	and	N	I-Premise
19	were	N	I-Premise
20	1.95	N	I-Premise
21	and	N	I-Premise
22	1.38	N	I-Premise
23	,	N	I-Premise
24	respectively	N	I-Premise
25	(	N	I-Premise
26	p	N	I-Premise
27	=	N	I-Premise
28	.20	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Premise
2	sample	N	I-Premise
3	size	N	I-Premise
4	was	N	I-Premise
5	small	N	I-Premise
6	,	N	I-Premise
7	and	N	I-Premise
8	patients	N	I-Premise
9	applied	N	I-Premise
10	a	N	I-Premise
11	small	N	I-Premise
12	amount	N	I-Premise
13	of	N	I-Premise
14	imiquimod	N	I-Premise
15	5	N	I-Premise
16	%	N	I-Premise
17	cream	N	I-Premise
18	(	N	I-Premise
19	half	N	I-Premise
20	a	N	I-Premise
21	sachet	N	I-Premise
22	)	N	I-Premise
23	to	N	I-Premise
24	a	N	I-Premise
25	large	N	I-Premise
26	surface	N	I-Premise
27	area	N	I-Premise
28	.	N	I-Premise

1	There	N	I-Claim
2	was	N	I-Claim
3	no	N	I-Claim
4	statistically	N	I-Claim
5	significant	N	I-Claim
6	difference	N	I-Claim
7	in	N	I-Claim
8	treatment	N	I-Claim
9	response	N	I-Claim
10	when	N	I-Claim
11	the	N	I-Claim
12	100	N	I-Claim
13	%	N	I-Claim
14	or	N	I-Claim
15	75	N	I-Claim
16	%	N	I-Claim
17	clearance	N	I-Claim
18	rate	N	I-Claim
19	cutoff	N	I-Claim
20	was	N	I-Claim
21	used	N	I-Claim
22	,	N	I-Claim
23	but	N	I-Claim
24	our	N	I-Claim
25	secondary	N	I-Claim
26	outcome	N	I-Claim
27	suggests	N	I-Claim
28	that	N	I-Claim
29	two	N	I-Claim
30	sessions	N	I-Claim
31	of	N	I-Claim
32	ALA-PDT	N	I-Claim
33	is	N	I-Claim
34	superior	N	I-Claim
35	to	N	I-Claim
36	imiquimod	N	I-Claim
37	5	N	I-Claim
38	%	N	I-Claim
39	cream	N	I-Claim
40	for	N	I-Claim
41	the	N	I-Claim
42	treatment	N	I-Claim
43	of	N	I-Claim
44	AKs	N	I-Claim
45	.	N	I-Claim

1	There	N	I-Claim
2	was	N	I-Claim
3	no	N	I-Claim
4	statistically	N	I-Claim
5	significant	N	I-Claim
6	difference	N	I-Claim
7	in	N	I-Claim
8	effect	N	I-Claim
9	on	N	I-Claim
10	quality	N	I-Claim
11	of	N	I-Claim
12	life	N	I-Claim
13	as	N	I-Claim
14	assessed	N	I-Claim
15	using	N	I-Claim
16	the	N	I-Claim
17	DLQI	N	I-Claim
18	.	N	I-Claim

1	Hot	N	O
2	flushes	N	O
3	and	N	O
4	night	N	O
5	sweats	N	O
6	(	N	O
7	HFNS	N	O
8	)	N	O
9	affect	N	O
10	65-85	N	O
11	%	N	O
12	of	N	O
13	women	N	O
14	after	N	O
15	breast	N	O
16	cancer	N	O
17	treatment	N	O
18	;	N	O
19	they	N	O
20	are	N	O
21	distressing	N	O
22	,	N	O
23	causing	N	O
24	sleep	N	O
25	problems	N	O
26	and	N	O
27	decreased	N	O
28	quality	N	O
29	of	N	O
30	life	N	O
31	.	N	O

1	Hormone	N	I-MajorClaim
2	replacement	N	I-MajorClaim
3	therapy	N	I-MajorClaim
4	is	N	I-MajorClaim
5	often	N	I-MajorClaim
6	either	N	I-MajorClaim
7	undesirable	N	I-MajorClaim
8	or	N	I-MajorClaim
9	contraindicated	N	I-MajorClaim
10	.	N	I-MajorClaim

1	Safe	N	I-MajorClaim
2	,	N	I-MajorClaim
3	effective	N	I-MajorClaim
4	non-hormonal	N	I-MajorClaim
5	treatments	N	I-MajorClaim
6	are	N	I-MajorClaim
7	needed	N	I-MajorClaim
8	.	N	I-MajorClaim

1	We	N	O
2	investigated	N	O
3	whether	N	O
4	cognitive	N	O
5	behavioural	N	O
6	therapy	N	O
7	(	N	O
8	CBT	N	O
9	)	N	O
10	can	N	O
11	help	N	O
12	breast	N	O
13	cancer	N	O
14	survivors	N	O
15	to	N	O
16	effectively	N	O
17	manage	N	O
18	HFNS	N	O
19	.	N	O

1	In	N	O
2	this	N	O
3	randomised	N	O
4	controlled	N	O
5	trial	N	O
6	,	N	O
7	we	N	O
8	recruited	N	O
9	women	N	O
10	from	N	O
11	breast	N	O
12	clinics	N	O
13	in	N	O
14	London	N	O
15	,	N	O
16	UK	N	O
17	,	N	O
18	who	N	O
19	had	N	O
20	problematic	N	O
21	HFNS	N	O
22	(	N	O
23	minimum	N	O
24	ten	N	O
25	problematic	N	O
26	episodes	N	O
27	a	N	O
28	week	N	O
29	)	N	O
30	after	N	O
31	breast-cancer	N	O
32	treatment	N	O
33	.	N	O

1	Participants	N	O
2	were	N	O
3	randomly	N	O
4	allocated	N	O
5	to	N	O
6	receive	N	O
7	either	N	O
8	usual	N	O
9	care	N	O
10	or	N	O
11	usual	N	O
12	care	N	O
13	plus	N	O
14	group	N	O
15	CBT	N	O
16	(	N	O
17	1:1	N	O
18	)	N	O
19	.	N	O

1	Randomisation	N	O
2	was	N	O
3	done	N	O
4	in	N	O
5	blocks	N	O
6	of	N	O
7	12-20	N	O
8	participants	N	O
9	,	N	O
10	stratifying	N	O
11	by	N	O
12	age	N	O
13	(	N	O
14	younger	N	O
15	than	N	O
16	50	N	O
17	years	N	O
18	,	N	O
19	50	N	O
20	years	N	O
21	or	N	O
22	older	N	O
23	)	N	O
24	,	N	O
25	and	N	O
26	was	N	O
27	done	N	O
28	with	N	O
29	a	N	O
30	computer-generated	N	O
31	sequence	N	O
32	.	N	O

1	The	N	O
2	trial	N	O
3	statistician	N	O
4	and	N	O
5	researchers	N	O
6	collecting	N	O
7	outcome	N	O
8	measures	N	O
9	were	N	O
10	masked	N	O
11	to	N	O
12	group	N	O
13	allocation	N	O
14	.	N	O

1	Group	N	O
2	CBT	N	O
3	comprised	N	O
4	one	N	O
5	90	N	O
6	min	N	O
7	session	N	O
8	a	N	O
9	week	N	O
10	for	N	O
11	6	N	O
12	weeks	N	O
13	,	N	O
14	and	N	O
15	included	N	O
16	psycho-education	N	O
17	,	N	O
18	paced	N	O
19	breathing	N	O
20	,	N	O
21	and	N	O
22	cognitive	N	O
23	and	N	O
24	behavioural	N	O
25	strategies	N	O
26	to	N	O
27	manage	N	O
28	HFNS	N	O
29	.	N	O

1	Assessments	N	O
2	were	N	O
3	done	N	O
4	at	N	O
5	baseline	N	O
6	,	N	O
7	9	N	O
8	weeks	N	O
9	,	N	O
10	and	N	O
11	26	N	O
12	weeks	N	O
13	after	N	O
14	randomisation	N	O
15	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	the	N	O
6	adjusted	N	O
7	mean	N	O
8	difference	N	O
9	in	N	O
10	HFNS	N	O
11	problem	N	O
12	rating	N	O
13	(	N	O
14	1-10	N	O
15	)	N	O
16	between	N	O
17	CBT	N	O
18	and	N	O
19	usual	N	O
20	care	N	O
21	groups	N	O
22	at	N	O
23	9	N	O
24	weeks	N	O
25	after	N	O
26	randomisation	N	O
27	.	N	O

1	Analysis	N	O
2	of	N	O
3	the	N	O
4	primary	N	O
5	endpoint	N	O
6	was	N	O
7	done	N	O
8	by	N	O
9	modified	N	O
10	intention	N	O
11	to	N	O
12	treat	N	O
13	.	N	O

1	The	N	O
2	trial	N	O
3	is	N	O
4	registered	N	O
5	,	N	O
6	ISRCTN13771934	N	O
7	,	N	O
8	and	N	O
9	was	N	O
10	closed	N	O
11	March	N	O
12	15	N	O
13	,	N	O
14	2011	N	O
15	.	N	O

1	Between	N	O
2	May	N	O
3	5	N	O
4	,	N	O
5	2009	N	O
6	,	N	O
7	and	N	O
8	Aug	N	O
9	27	N	O
10	,	N	O
11	2010	N	O
12	,	N	O
13	96	N	O
14	women	N	O
15	were	N	O
16	randomly	N	O
17	allocated	N	O
18	to	N	O
19	group	N	O
20	CBT	N	O
21	(	N	O
22	n=47	N	O
23	)	N	O
24	or	N	O
25	usual	N	O
26	care	N	O
27	(	N	O
28	n=49	N	O
29	)	N	O
30	.	N	O

1	Group	N	I-Premise
2	CBT	N	I-Premise
3	significantly	N	I-Premise
4	reduced	N	I-Premise
5	HFNS	N	I-Premise
6	problem	N	I-Premise
7	rating	N	I-Premise
8	at	N	I-Premise
9	9	N	I-Premise
10	weeks	N	I-Premise
11	after	N	I-Premise
12	randomisation	N	I-Premise
13	compared	N	I-Premise
14	with	N	I-Premise
15	usual	N	I-Premise
16	care	N	I-Premise
17	(	N	I-Premise
18	mean	N	I-Premise
19	difference	N	I-Premise
20	-1·67	N	I-Premise
21	,	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	-2·43	N	I-Premise
26	to	N	I-Premise
27	-0·91	N	I-Premise
28	;	N	I-Premise
29	p	N	I-Premise
30	<	N	I-Premise
31	0·0001	N	I-Premise
32	)	N	I-Premise
33	and	N	I-Premise
34	improvements	N	I-Premise
35	were	N	I-Premise
36	maintained	N	I-Premise
37	at	N	I-Premise
38	26	N	I-Premise
39	weeks	N	I-Premise
40	(	N	I-Premise
41	mean	N	I-Premise
42	difference	N	I-Premise
43	-1·76	N	I-Premise
44	,	N	I-Premise
45	-2·54	N	I-Premise
46	to	N	I-Premise
47	-0·99	N	I-Premise
48	;	N	I-Premise
49	p	N	I-Premise
50	<	N	I-Premise
51	0·0001	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	We	N	I-Premise
2	recorded	N	I-Premise
3	no	N	I-Premise
4	CBT-related	N	I-Premise
5	adverse	N	I-Premise
6	events	N	I-Premise
7	.	N	I-Premise

1	Group	N	I-Claim
2	CBT	N	I-Claim
3	seems	N	I-Claim
4	to	N	I-Claim
5	be	N	I-Claim
6	a	N	I-Claim
7	safe	N	I-Claim
8	and	N	I-Claim
9	effective	N	I-Claim
10	treatment	N	I-Claim
11	for	N	I-Claim
12	women	N	I-Claim
13	who	N	I-Claim
14	have	N	I-Claim
15	problematic	N	I-Claim
16	HFNS	N	I-Claim
17	after	N	I-Claim
18	breast	N	I-Claim
19	cancer	N	I-Claim
20	treatment	N	I-Claim
21	with	N	I-Claim
22	additional	N	I-Claim
23	benefits	N	I-Claim
24	to	N	I-Claim
25	mood	N	I-Claim
26	,	N	I-Claim
27	sleep	N	I-Claim
28	,	N	I-Claim
29	and	N	I-Claim
30	quality	N	I-Claim
31	of	N	I-Claim
32	life	N	I-Claim
33	.	N	I-Claim

1	The	N	O
2	treatment	N	O
3	could	N	O
4	be	N	O
5	incorporated	N	O
6	into	N	O
7	breast	N	O
8	cancer	N	O
9	survivorship	N	O
10	programmes	N	O
11	and	N	O
12	delivered	N	O
13	by	N	O
14	trained	N	O
15	breast	N	O
16	cancer	N	O
17	nurses	N	O
18	.	N	O

1	To	N	O
2	evaluate	N	O
3	the	N	O
4	analgesic	N	O
5	effect	N	O
6	,	N	O
7	safety	N	O
8	,	N	O
9	and	N	O
10	cost-effectiveness	N	O
11	of	N	O
12	controlled-release	N	O
13	oxycodone	N	O
14	(	N	O
15	CRO	N	O
16	)	N	O
17	to	N	O
18	control	N	O
19	postoperative	N	O
20	pain	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	liver	N	O
25	cancer	N	O
26	who	N	O
27	are	N	O
28	undergoing	N	O
29	transarterial	N	O
30	chemoembolization	N	O
31	.	N	O

1	This	N	O
2	randomized	N	O
3	,	N	O
4	double-blind	N	O
5	,	N	O
6	placebo-controlled	N	O
7	,	N	O
8	prospective	N	O
9	clinical	N	O
10	study	N	O
11	received	N	O
12	institutional	N	O
13	review	N	O
14	board	N	O
15	approval	N	O
16	.	N	O

1	After	N	O
2	written	N	O
3	informed	N	O
4	consent	N	O
5	was	N	O
6	obtained	N	O
7	,	N	O
8	210	N	O
9	patients	N	O
10	with	N	O
11	liver	N	O
12	cancer	N	O
13	were	N	O
14	randomized	N	O
15	into	N	O
16	three	N	O
17	groups	N	O
18	of	N	O
19	70	N	O
20	patients	N	O
21	.	N	O

1	Group	N	O
2	1	N	O
3	received	N	O
4	20	N	O
5	mg	N	O
6	of	N	O
7	CRO	N	O
8	,	N	O
9	group	N	O
10	2	N	O
11	received	N	O
12	10	N	O
13	mg	N	O
14	of	N	O
15	CRO	N	O
16	,	N	O
17	and	N	O
18	group	N	O
19	3	N	O
20	received	N	O
21	a	N	O
22	placebo	N	O
23	at	N	O
24	1	N	O
25	hour	N	O
26	before	N	O
27	transarterial	N	O
28	chemoembolization	N	O
29	(	N	O
30	T	N	O
31	(	N	O
32	0	N	O
33	)	N	O
34	)	N	O
35	and	N	O
36	12	N	O
37	(	N	O
38	T	N	O
39	(	N	O
40	12	N	O
41	)	N	O
42	)	N	O
43	and	N	O
44	24	N	O
45	(	N	O
46	T	N	O
47	(	N	O
48	24	N	O
49	)	N	O
50	)	N	O
51	hours	N	O
52	after	N	O
53	T	N	O
54	(	N	O
55	0	N	O
56	)	N	O
57	.	N	O

1	Pain	N	O
2	intensity	N	O
3	on	N	O
4	a	N	O
5	numeric	N	O
6	rating	N	O
7	scale	N	O
8	,	N	O
9	percentage	N	O
10	of	N	O
11	patients	N	O
12	with	N	O
13	each	N	O
14	degree	N	O
15	of	N	O
16	pain	N	O
17	,	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	,	N	O
22	adverse	N	O
23	reactions	N	O
24	,	N	O
25	analgesic	N	O
26	costs	N	O
27	,	N	O
28	and	N	O
29	hospital	N	O
30	stays	N	O
31	were	N	O
32	evaluated	N	O
33	and	N	O
34	compared	N	O
35	among	N	O
36	the	N	O
37	three	N	O
38	groups	N	O
39	.	N	O

1	Numeric	N	I-Premise
2	rating	N	I-Premise
3	scale	N	I-Premise
4	scores	N	I-Premise
5	for	N	I-Premise
6	pain	N	I-Premise
7	intensity	N	I-Premise
8	in	N	I-Premise
9	group	N	I-Premise
10	1	N	I-Premise
11	and	N	I-Premise
12	group	N	I-Premise
13	2	N	I-Premise
14	were	N	I-Premise
15	significantly	N	I-Premise
16	lower	N	I-Premise
17	than	N	I-Premise
18	those	N	I-Premise
19	in	N	I-Premise
20	group	N	I-Premise
21	3	N	I-Premise
22	at	N	I-Premise
23	T	N	I-Premise
24	(	N	I-Premise
25	0-12	N	I-Premise
26	)	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	.001	N	I-Premise
31	)	N	I-Premise
32	;	N	I-Premise
33	T	N	I-Premise
34	(	N	I-Premise
35	12-24	N	I-Premise
36	)	N	I-Premise
37	(	N	I-Premise
38	P	N	I-Premise
39	<	N	I-Premise
40	.001	N	I-Premise
41	)	N	I-Premise
42	;	N	I-Premise
43	and	N	I-Premise
44	T	N	I-Premise
45	(	N	I-Premise
46	24-48	N	I-Premise
47	)	N	I-Premise
48	(	N	I-Premise
49	P	N	I-Premise
50	<	N	I-Premise
51	.001	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	When	N	I-Premise
2	group	N	I-Premise
3	1	N	I-Premise
4	with	N	I-Premise
5	group	N	I-Premise
6	2	N	I-Premise
7	were	N	I-Premise
8	compared	N	I-Premise
9	,	N	I-Premise
10	numeric	N	I-Premise
11	rating	N	I-Premise
12	scale	N	I-Premise
13	scores	N	I-Premise
14	were	N	I-Premise
15	significantly	N	I-Premise
16	lower	N	I-Premise
17	in	N	I-Premise
18	group	N	I-Premise
19	1	N	I-Premise
20	than	N	I-Premise
21	in	N	I-Premise
22	group	N	I-Premise
23	2	N	I-Premise
24	during	N	I-Premise
25	the	N	I-Premise
26	period	N	I-Premise
27	of	N	I-Premise
28	T	N	I-Premise
29	(	N	I-Premise
30	0-12	N	I-Premise
31	)	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	<	N	I-Premise
35	.001	N	I-Premise
36	)	N	I-Premise
37	but	N	I-Premise
38	were	N	I-Premise
39	not	N	I-Premise
40	significantly	N	I-Premise
41	different	N	I-Premise
42	at	N	I-Premise
43	T	N	I-Premise
44	(	N	I-Premise
45	12-24	N	I-Premise
46	)	N	I-Premise
47	(	N	I-Premise
48	P	N	I-Premise
49	=	N	I-Premise
50	.68	N	I-Premise
51	)	N	I-Premise
52	and	N	I-Premise
53	T	N	I-Premise
54	(	N	I-Premise
55	24-48	N	I-Premise
56	)	N	I-Premise
57	(	N	I-Premise
58	P	N	I-Premise
59	=	N	I-Premise
60	.10	N	I-Premise
61	)	N	I-Premise
62	.	N	I-Premise

1	Analgesic	N	I-Premise
2	cost	N	I-Premise
3	and	N	I-Premise
4	hospital	N	I-Premise
5	stay	N	I-Premise
6	were	N	I-Premise
7	significantly	N	I-Premise
8	lower	N	I-Premise
9	in	N	I-Premise
10	treated	N	I-Premise
11	groups	N	I-Premise
12	than	N	I-Premise
13	in	N	I-Premise
14	the	N	I-Premise
15	placebo	N	I-Premise
16	group	N	I-Premise
17	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	difference	N	I-Premise
4	was	N	I-Premise
5	observed	N	I-Premise
6	in	N	I-Premise
7	quality	N	I-Premise
8	of	N	I-Premise
9	life	N	I-Premise
10	and	N	I-Premise
11	adverse	N	I-Premise
12	events	N	I-Premise
13	between	N	I-Premise
14	the	N	I-Premise
15	treated	N	I-Premise
16	groups	N	I-Premise
17	and	N	I-Premise
18	the	N	I-Premise
19	placebo	N	I-Premise
20	group	N	I-Premise
21	.	N	I-Premise

1	CRO	N	I-Claim
2	is	N	I-Claim
3	effective	N	I-Claim
4	,	N	I-Claim
5	safe	N	I-Claim
6	,	N	I-Claim
7	and	N	I-Claim
8	cost-effective	N	I-Claim
9	in	N	I-Claim
10	the	N	I-Claim
11	control	N	I-Claim
12	of	N	I-Claim
13	postoperative	N	I-Claim
14	pain	N	I-Claim
15	after	N	I-Claim
16	transarterial	N	I-Claim
17	chemoembolization	N	I-Claim
18	for	N	I-Claim
19	patients	N	I-Claim
20	with	N	I-Claim
21	inoperable	N	I-Claim
22	liver	N	I-Claim
23	cancer	N	I-Claim
24	.	N	I-Claim

1	Gefitinib	N	O
2	has	N	O
3	shown	N	O
4	high	N	O
5	response	N	O
6	rate	N	O
7	and	N	O
8	improved	N	O
9	progression-free	N	O
10	survival	N	O
11	(	N	O
12	PFS	N	O
13	)	N	O
14	in	N	O
15	never-smokers	N	O
16	with	N	O
17	lung	N	O
18	adenocarcinoma	N	O
19	(	N	O
20	NSLAs	N	O
21	)	N	O
22	.	N	O

1	We	N	O
2	compared	N	O
3	efficacy	N	O
4	of	N	O
5	gefitinib	N	O
6	with	N	O
7	gemcitabine	N	O
8	and	N	O
9	cisplatin	N	O
10	(	N	O
11	GP	N	O
12	)	N	O
13	chemotherapy	N	O
14	in	N	O
15	this	N	O
16	group	N	O
17	of	N	O
18	patients	N	O
19	as	N	O
20	first-line	N	O
21	therapy	N	O
22	.	N	O

1	In	N	O
2	this	N	O
3	randomized	N	O
4	phase	N	O
5	III	N	O
6	trial	N	O
7	,	N	O
8	a	N	O
9	total	N	O
10	of	N	O
11	313	N	O
12	Korean	N	O
13	never-smokers	N	O
14	with	N	O
15	stage	N	O
16	IIIB	N	O
17	or	N	O
18	IV	N	O
19	lung	N	O
20	adenocarcinoma	N	O
21	,	N	O
22	Eastern	N	O
23	Cooperative	N	O
24	Oncology	N	O
25	Group	N	O
26	performance	N	O
27	status	N	O
28	0	N	O
29	to	N	O
30	2	N	O
31	,	N	O
32	and	N	O
33	adequate	N	O
34	organ	N	O
35	function	N	O
36	were	N	O
37	randomly	N	O
38	assigned	N	O
39	to	N	O
40	receive	N	O
41	either	N	O
42	gefitinib	N	O
43	(	N	O
44	250	N	O
45	mg	N	O
46	daily	N	O
47	)	N	O
48	or	N	O
49	GP	N	O
50	chemotherapy	N	O
51	(	N	O
52	gemcitabine	N	O
53	1,250	N	O
54	mg/m	N	O
55	(	N	O
56	2	N	O
57	)	N	O
58	on	N	O
59	days	N	O
60	1	N	O
61	and	N	O
62	8	N	O
63	;	N	O
64	cisplatin	N	O
65	80	N	O
66	mg/m	N	O
67	(	N	O
68	2	N	O
69	)	N	O
70	on	N	O
71	day	N	O
72	1	N	O
73	every	N	O
74	3	N	O
75	weeks	N	O
76	,	N	O
77	for	N	O
78	up	N	O
79	to	N	O
80	nine	N	O
81	courses	N	O
82	)	N	O
83	.	N	O

1	The	N	O
2	primary	N	O
3	objective	N	O
4	was	N	O
5	to	N	O
6	demonstrate	N	O
7	better	N	O
8	overall	N	O
9	survival	N	O
10	(	N	O
11	OS	N	O
12	)	N	O
13	for	N	O
14	gefitinib	N	O
15	compared	N	O
16	with	N	O
17	GP	N	O
18	in	N	O
19	chemotherapy-naive	N	O
20	NSLAs	N	O
21	.	N	O

1	Three	N	O
2	hundred	N	O
3	nine	N	O
4	patients	N	O
5	were	N	O
6	analyzed	N	O
7	per	N	O
8	protocol	N	O
9	(	N	O
10	gefitinib	N	O
11	arm	N	O
12	,	N	O
13	n	N	O
14	=	N	O
15	159	N	O
16	;	N	O
17	GP	N	O
18	arm	N	O
19	,	N	O
20	n	N	O
21	=	N	O
22	150	N	O
23	)	N	O
24	.	N	O

1	Gefitinib	N	I-Premise
2	did	N	I-Premise
3	not	N	I-Premise
4	show	N	I-Premise
5	better	N	I-Premise
6	OS	N	I-Premise
7	compared	N	I-Premise
8	with	N	I-Premise
9	GP	N	I-Premise
10	(	N	I-Premise
11	hazard	N	I-Premise
12	ratio	N	I-Premise
13	[	N	I-Premise
14	HR	N	I-Premise
15	]	N	I-Premise
16	,	N	I-Premise
17	0.932	N	I-Premise
18	;	N	I-Premise
19	95	N	I-Premise
20	%	N	I-Premise
21	CI	N	I-Premise
22	,	N	I-Premise
23	0.716	N	I-Premise
24	to	N	I-Premise
25	1.213	N	I-Premise
26	;	N	I-Premise
27	P	N	I-Premise
28	=	N	I-Premise
29	.604	N	I-Premise
30	;	N	I-Premise
31	median	N	I-Premise
32	OS	N	I-Premise
33	,	N	I-Premise
34	22.3	N	I-Premise
35	v	N	I-Premise
36	22.9	N	I-Premise
37	months	N	I-Premise
38	,	N	I-Premise
39	respectively	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	The	N	I-Premise
2	1-year	N	I-Premise
3	PFS	N	I-Premise
4	rates	N	I-Premise
5	were	N	I-Premise
6	16.7	N	I-Premise
7	%	N	I-Premise
8	with	N	I-Premise
9	gefitinib	N	I-Premise
10	and	N	I-Premise
11	2.8	N	I-Premise
12	%	N	I-Premise
13	with	N	I-Premise
14	GP	N	I-Premise
15	(	N	I-Premise
16	HR	N	I-Premise
17	,	N	I-Premise
18	1.198	N	I-Premise
19	;	N	I-Premise
20	95	N	I-Premise
21	%	N	I-Premise
22	CI	N	I-Premise
23	,	N	I-Premise
24	0.944	N	I-Premise
25	to	N	I-Premise
26	1.520	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	Response	N	I-Premise
2	rates	N	I-Premise
3	were	N	I-Premise
4	55	N	I-Premise
5	%	N	I-Premise
6	with	N	I-Premise
7	gefitinib	N	I-Premise
8	and	N	I-Premise
9	46	N	I-Premise
10	%	N	I-Premise
11	with	N	I-Premise
12	GP	N	I-Premise
13	(	N	I-Premise
14	P	N	I-Premise
15	=	N	I-Premise
16	.101	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	Myelosuppression	N	I-Premise
2	,	N	I-Premise
3	renal	N	I-Premise
4	insufficiency	N	I-Premise
5	,	N	I-Premise
6	and	N	I-Premise
7	fatigue	N	I-Premise
8	were	N	I-Premise
9	more	N	I-Premise
10	common	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	GP	N	I-Premise
14	arm	N	I-Premise
15	,	N	I-Premise
16	but	N	O
17	skin	N	I-Premise
18	toxicities	N	I-Premise
19	and	N	I-Premise
20	liver	N	I-Premise
21	dysfunction	N	I-Premise
22	were	N	I-Premise
23	more	N	I-Premise
24	common	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	gefitinib	N	I-Premise
28	arm	N	I-Premise
29	.	N	I-Premise

1	Two	N	I-Premise
2	patients	N	I-Premise
3	(	N	I-Premise
4	1.3	N	I-Premise
5	%	N	I-Premise
6	)	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	gefitinib	N	I-Premise
10	arm	N	I-Premise
11	developed	N	I-Premise
12	interstitial	N	I-Premise
13	lung	N	I-Premise
14	disease	N	I-Premise
15	and	N	I-Premise
16	died	N	I-Premise
17	.	N	I-Premise

1	Gefitinib	N	I-Claim
2	failed	N	I-Claim
3	to	N	I-Claim
4	demonstrate	N	I-Claim
5	superior	N	I-Claim
6	OS	N	I-Claim
7	compared	N	I-Claim
8	with	N	I-Claim
9	GP	N	I-Claim
10	as	N	I-Claim
11	first-line	N	I-Claim
12	therapy	N	I-Claim
13	for	N	I-Claim
14	NSLAs	N	I-Claim
15	.	N	I-Claim

1	Spiritual	N	O
2	well-being	N	O
3	and	N	O
4	sense	N	O
5	of	N	O
6	meaning	N	O
7	are	N	O
8	important	N	O
9	concerns	N	O
10	for	N	O
11	clinicians	N	O
12	who	N	O
13	care	N	O
14	for	N	O
15	patients	N	O
16	with	N	O
17	cancer	N	O
18	.	N	O

1	We	N	O
2	developed	N	O
3	Individual	N	O
4	Meaning-Centered	N	O
5	Psychotherapy	N	O
6	(	N	O
7	IMCP	N	O
8	)	N	O
9	to	N	O
10	address	N	O
11	the	N	O
12	need	N	O
13	for	N	O
14	brief	N	O
15	interventions	N	O
16	targeting	N	O
17	spiritual	N	O
18	well-being	N	O
19	and	N	O
20	meaning	N	O
21	for	N	O
22	patients	N	O
23	with	N	O
24	advanced	N	O
25	cancer	N	O
26	.	N	O

1	Patients	N	O
2	with	N	O
3	stage	N	O
4	III	N	O
5	or	N	O
6	IV	N	O
7	cancer	N	O
8	(	N	O
9	N	N	O
10	=	N	O
11	120	N	O
12	)	N	O
13	were	N	O
14	randomly	N	O
15	assigned	N	O
16	to	N	O
17	seven	N	O
18	sessions	N	O
19	of	N	O
20	either	N	O
21	IMCP	N	O
22	or	N	O
23	therapeutic	N	O
24	massage	N	O
25	(	N	O
26	TM	N	O
27	)	N	O
28	.	N	O

1	Patients	N	O
2	were	N	O
3	assessed	N	O
4	before	N	O
5	and	N	O
6	after	N	O
7	completing	N	O
8	the	N	O
9	intervention	N	O
10	and	N	O
11	2	N	O
12	months	N	O
13	postintervention	N	O
14	.	N	O

1	Primary	N	O
2	outcome	N	O
3	measures	N	O
4	assessed	N	O
5	spiritual	N	O
6	well-being	N	O
7	and	N	O
8	quality	N	O
9	of	N	O
10	life	N	O
11	;	N	O
12	secondary	N	O
13	outcomes	N	O
14	included	N	O
15	anxiety	N	O
16	,	N	O
17	depression	N	O
18	,	N	O
19	hopelessness	N	O
20	,	N	O
21	symptom	N	O
22	burden	N	O
23	,	N	O
24	and	N	O
25	symptom-related	N	O
26	distress	N	O
27	.	N	O

1	Of	N	O
2	the	N	O
3	120	N	O
4	participants	N	O
5	randomly	N	O
6	assigned	N	O
7	,	N	O
8	78	N	O
9	(	N	O
10	65	N	O
11	%	N	O
12	)	N	O
13	completed	N	O
14	the	N	O
15	post-treatment	N	O
16	assessment	N	O
17	and	N	O
18	67	N	O
19	(	N	O
20	56	N	O
21	%	N	O
22	)	N	O
23	completed	N	O
24	the	N	O
25	2-month	N	O
26	follow-up	N	O
27	.	N	O

1	At	N	I-Premise
2	the	N	I-Premise
3	post-treatment	N	I-Premise
4	assessment	N	I-Premise
5	,	N	I-Premise
6	IMCP	N	I-Premise
7	participants	N	I-Premise
8	demonstrated	N	I-Premise
9	significantly	N	I-Premise
10	greater	N	I-Premise
11	improvement	N	I-Premise
12	than	N	I-Premise
13	the	N	I-Premise
14	control	N	I-Premise
15	condition	N	I-Premise
16	for	N	I-Premise
17	the	N	I-Premise
18	primary	N	I-Premise
19	outcomes	N	I-Premise
20	of	N	I-Premise
21	spiritual	N	I-Premise
22	well-being	N	I-Premise
23	(	N	I-Premise
24	b	N	I-Premise
25	=	N	I-Premise
26	0.39	N	I-Premise
27	;	N	I-Premise
28	P	N	I-Premise
29	<	N	I-Premise
30	.001	N	I-Premise
31	,	N	I-Premise
32	including	N	I-Premise
33	both	N	I-Premise
34	components	N	I-Premise
35	of	N	I-Premise
36	spiritual	N	I-Premise
37	well-being	N	I-Premise
38	(	N	I-Premise
39	sense	N	I-Premise
40	of	N	I-Premise
41	meaning	N	I-Premise
42	:	N	I-Premise
43	b	N	I-Premise
44	=	N	I-Premise
45	0.34	N	I-Premise
46	;	N	I-Premise
47	P	N	I-Premise
48	=	N	I-Premise
49	.003	N	I-Premise
50	and	N	I-Premise
51	faith	N	I-Premise
52	:	N	I-Premise
53	b	N	I-Premise
54	=	N	I-Premise
55	0.42	N	I-Premise
56	;	N	I-Premise
57	P	N	I-Premise
58	=	N	I-Premise
59	.03	N	I-Premise
60	)	N	I-Premise
61	,	N	I-Premise
62	and	N	I-Premise
63	quality	N	I-Premise
64	of	N	I-Premise
65	life	N	I-Premise
66	(	N	I-Premise
67	b	N	I-Premise
68	=	N	I-Premise
69	0.76	N	I-Premise
70	;	N	I-Premise
71	P	N	I-Premise
72	=	N	I-Premise
73	.013	N	I-Premise
74	)	N	I-Premise
75	.	N	I-Premise

1	Significantly	N	I-Premise
2	greater	N	I-Premise
3	improvements	N	I-Premise
4	for	N	I-Premise
5	IMCP	N	I-Premise
6	patients	N	I-Premise
7	were	N	I-Premise
8	also	N	I-Premise
9	observed	N	I-Premise
10	for	N	I-Premise
11	the	N	I-Premise
12	secondary	N	I-Premise
13	outcomes	N	I-Premise
14	of	N	I-Premise
15	symptom	N	I-Premise
16	burden	N	I-Premise
17	(	N	I-Premise
18	b	N	I-Premise
19	=	N	I-Premise
20	-6.56	N	I-Premise
21	;	N	I-Premise
22	P	N	I-Premise
23	<	N	I-Premise
24	.001	N	I-Premise
25	)	N	I-Premise
26	and	N	I-Premise
27	symptom-related	N	I-Premise
28	distress	N	I-Premise
29	(	N	I-Premise
30	b	N	I-Premise
31	=	N	I-Premise
32	-0.47	N	I-Premise
33	;	N	I-Premise
34	P	N	I-Premise
35	<	N	I-Premise
36	.001	N	I-Premise
37	)	N	I-Premise
38	but	N	I-Premise
39	not	N	I-Premise
40	for	N	I-Premise
41	anxiety	N	I-Premise
42	,	N	I-Premise
43	depression	N	I-Premise
44	,	N	I-Premise
45	or	N	I-Premise
46	hopelessness	N	I-Premise
47	.	N	I-Premise

1	At	N	I-Premise
2	the	N	I-Premise
3	2-month	N	I-Premise
4	follow-up	N	I-Premise
5	assessment	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	improvements	N	I-Premise
9	observed	N	I-Premise
10	for	N	I-Premise
11	the	N	I-Premise
12	IMCP	N	I-Premise
13	group	N	I-Premise
14	were	N	I-Premise
15	no	N	I-Premise
16	longer	N	I-Premise
17	significantly	N	I-Premise
18	greater	N	I-Premise
19	than	N	I-Premise
20	those	N	I-Premise
21	observed	N	I-Premise
22	for	N	I-Premise
23	the	N	I-Premise
24	TM	N	I-Premise
25	group	N	I-Premise
26	.	N	I-Premise

1	IMCP	N	I-Claim
2	has	N	I-Claim
3	clear	N	I-Claim
4	short-term	N	I-Claim
5	benefits	N	I-Claim
6	for	N	I-Claim
7	spiritual	N	I-Claim
8	suffering	N	I-Claim
9	and	N	I-Claim
10	quality	N	I-Claim
11	of	N	I-Claim
12	life	N	I-Claim
13	in	N	I-Claim
14	patients	N	I-Claim
15	with	N	I-Claim
16	advanced	N	I-Claim
17	cancer	N	I-Claim
18	.	N	I-Claim

1	Clinicians	N	O
2	working	N	O
3	with	N	O
4	patients	N	O
5	who	N	O
6	have	N	O
7	advanced	N	O
8	cancer	N	O
9	should	N	O
10	consider	N	O
11	IMCP	N	O
12	as	N	O
13	an	N	O
14	approach	N	O
15	to	N	O
16	enhance	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	and	N	O
21	spiritual	N	O
22	well-being	N	O
23	.	N	O

1	To	N	O
2	determine	N	O
3	whether	N	O
4	an	N	O
5	Internet-based	N	I-Claim
6	tailored	N	I-Claim
7	education	N	I-Claim
8	program	N	I-Claim
9	is	N	I-Claim
10	effective	N	I-Claim
11	for	N	I-Claim
12	disease-free	N	I-Claim
13	cancer	N	I-Claim
14	survivors	N	I-Claim
15	with	N	I-Claim
16	cancer-related	N	I-Claim
17	fatigue	N	I-Claim
18	(	N	I-Claim
19	CRF	N	I-Claim
20	)	N	I-Claim
21	.	N	I-Claim

1	We	N	O
2	randomly	N	O
3	assigned	N	O
4	patients	N	O
5	who	N	O
6	had	N	O
7	completed	N	O
8	primary	N	O
9	cancer	N	O
10	treatment	N	O
11	within	N	O
12	the	N	O
13	past	N	O
14	24	N	O
15	months	N	O
16	in	N	O
17	any	N	O
18	of	N	O
19	four	N	O
20	Korean	N	O
21	hospitals	N	O
22	and	N	O
23	had	N	O
24	reported	N	O
25	moderate	N	O
26	to	N	O
27	severe	N	O
28	fatigue	N	O
29	for	N	O
30	at	N	O
31	least	N	O
32	1	N	O
33	week	N	O
34	to	N	O
35	participate	N	O
36	in	N	O
37	a	N	O
38	12-week	N	O
39	,	N	O
40	Internet-based	N	O
41	,	N	O
42	individually	N	O
43	tailored	N	O
44	CRF	N	O
45	education	N	O
46	program	N	O
47	or	N	O
48	to	N	O
49	receive	N	O
50	routine	N	O
51	care	N	O
52	.	N	O

1	We	N	O
2	based	N	O
3	the	N	O
4	program	N	O
5	on	N	O
6	the	N	O
7	CRF	N	O
8	guidelines	N	O
9	of	N	O
10	the	N	O
11	National	N	O
12	Comprehensive	N	O
13	Cancer	N	O
14	Network	N	O
15	(	N	O
16	NCCN	N	O
17	)	N	O
18	and	N	O
19	incorporated	N	O
20	the	N	O
21	transtheoretic	N	O
22	model	N	O
23	(	N	O
24	TTM	N	O
25	)	N	O
26	.	N	O

1	At	N	O
2	baseline	N	O
3	and	N	O
4	12	N	O
5	weeks	N	O
6	,	N	O
7	we	N	O
8	used	N	O
9	the	N	O
10	Brief	N	O
11	Fatigue	N	O
12	Inventory	N	O
13	(	N	O
14	BFI	N	O
15	)	N	O
16	and	N	O
17	Fatigue	N	O
18	Severity	N	O
19	Scale	N	O
20	(	N	O
21	FSS	N	O
22	)	N	O
23	as	N	O
24	primary	N	O
25	outcomes	N	O
26	and	N	O
27	the	N	O
28	Hospital	N	O
29	Anxiety	N	O
30	and	N	O
31	Depression	N	O
32	Scale	N	O
33	(	N	O
34	HADS	N	O
35	)	N	O
36	and	N	O
37	European	N	O
38	Organisation	N	O
39	for	N	O
40	Research	N	O
41	and	N	O
42	Treatment	N	O
43	of	N	O
44	Cancer	N	O
45	Quality	N	O
46	of	N	O
47	Life	N	O
48	Questionnaire	N	O
49	C30	N	O
50	(	N	O
51	EORTC	N	O
52	QLQ-C30	N	O
53	)	N	O
54	for	N	O
55	secondary	N	O
56	outcomes	N	O
57	.	N	O

1	We	N	O
2	recruited	N	O
3	273	N	O
4	participants	N	O
5	and	N	O
6	randomly	N	O
7	assigned	N	O
8	136	N	O
9	to	N	O
10	the	N	O
11	intervention	N	O
12	group	N	O
13	.	N	O

1	Compared	N	I-Premise
2	with	N	I-Premise
3	the	N	I-Premise
4	control	N	I-Premise
5	group	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	intervention	N	I-Premise
9	group	N	I-Premise
10	had	N	I-Premise
11	an	N	I-Premise
12	improvement	N	I-Premise
13	in	N	I-Premise
14	fatigue	N	I-Premise
15	as	N	I-Premise
16	shown	N	I-Premise
17	by	N	I-Premise
18	a	N	I-Premise
19	significantly	N	I-Premise
20	greater	N	I-Premise
21	decrease	N	I-Premise
22	in	N	I-Premise
23	BFI	N	I-Premise
24	global	N	I-Premise
25	score	N	I-Premise
26	(	N	I-Premise
27	-0.66	N	I-Premise
28	points	N	I-Premise
29	;	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	CI	N	I-Premise
33	-1.04	N	I-Premise
34	to	N	I-Premise
35	-0.27	N	I-Premise
36	)	N	I-Premise
37	and	N	I-Premise
38	FSS	N	I-Premise
39	total	N	I-Premise
40	score	N	I-Premise
41	(	N	I-Premise
42	-0.49	N	I-Premise
43	;	N	I-Premise
44	95	N	I-Premise
45	%	N	I-Premise
46	CI	N	I-Premise
47	,	N	I-Premise
48	-0.78	N	I-Premise
49	to	N	I-Premise
50	-0.21	N	I-Premise
51	)	N	I-Premise
52	.	N	I-Premise

1	In	N	I-Premise
2	secondary	N	I-Premise
3	outcomes	N	I-Premise
4	,	N	I-Premise
5	the	N	I-Premise
6	intervention	N	I-Premise
7	group	N	I-Premise
8	experienced	N	I-Premise
9	a	N	I-Premise
10	significantly	N	I-Premise
11	greater	N	I-Premise
12	decrease	N	I-Premise
13	in	N	I-Premise
14	HADS	N	I-Premise
15	anxiety	N	I-Premise
16	score	N	I-Premise
17	(	N	I-Premise
18	-0.90	N	I-Premise
19	;	N	I-Premise
20	95	N	I-Premise
21	%	N	I-Premise
22	CI	N	I-Premise
23	,	N	I-Premise
24	-1.51	N	I-Premise
25	to	N	I-Premise
26	-0.29	N	I-Premise
27	)	N	I-Premise
28	as	N	I-Premise
29	well	N	I-Premise
30	as	N	I-Premise
31	global	N	I-Premise
32	quality	N	I-Premise
33	of	N	I-Premise
34	life	N	I-Premise
35	(	N	I-Premise
36	5.22	N	I-Premise
37	;	N	I-Premise
38	95	N	I-Premise
39	%	N	I-Premise
40	CI	N	I-Premise
41	,	N	I-Premise
42	0.93	N	I-Premise
43	to	N	I-Premise
44	9.50	N	I-Premise
45	)	N	I-Premise
46	and	N	I-Premise
47	several	N	I-Premise
48	functioning	N	I-Premise
49	scores	N	I-Premise
50	of	N	I-Premise
51	the	N	I-Premise
52	EORTC	N	I-Premise
53	QLQ-C30	N	I-Premise
54	.	N	I-Premise

1	An	N	I-Claim
2	Internet-based	N	I-Claim
3	education	N	I-Claim
4	program	N	I-Claim
5	based	N	I-Claim
6	on	N	I-Claim
7	NCCN	N	I-Claim
8	guidelines	N	I-Claim
9	and	N	I-Claim
10	TTM	N	I-Claim
11	may	N	I-Claim
12	help	N	I-Claim
13	patients	N	I-Claim
14	manage	N	I-Claim
15	CRF	N	I-Claim
16	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	effectiveness	N	O
5	of	N	O
6	mindfulness-based	N	O
7	stress	N	O
8	reduction	N	O
9	(	N	O
10	MBSR	N	O
11	)	N	O
12	for	N	O
13	mood	N	O
14	,	N	O
15	breast-	N	O
16	and	N	O
17	endocrine-specific	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	,	N	O
22	and	N	O
23	well-being	N	O
24	after	N	O
25	hospital	N	O
26	treatment	N	O
27	in	N	O
28	women	N	O
29	with	N	O
30	stage	N	O
31	0	N	O
32	to	N	O
33	III	N	O
34	breast	N	O
35	cancer	N	O
36	.	N	O

1	A	N	O
2	randomized	N	O
3	,	N	O
4	wait-listed	N	O
5	,	N	O
6	controlled	N	O
7	trial	N	O
8	was	N	O
9	carried	N	O
10	out	N	O
11	in	N	O
12	229	N	O
13	women	N	O
14	after	N	O
15	surgery	N	O
16	,	N	O
17	chemotherapy	N	O
18	,	N	O
19	and	N	O
20	radiotherapy	N	O
21	for	N	O
22	breast	N	O
23	cancer	N	O
24	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	the	N	O
7	8-week	N	O
8	MBSR	N	O
9	program	N	O
10	or	N	O
11	standard	N	O
12	care	N	O
13	.	N	O

1	Profile	N	O
2	of	N	O
3	Mood	N	O
4	States	N	O
5	(	N	O
6	POMS	N	O
7	;	N	O
8	primary	N	O
9	outcome	N	O
10	)	N	O
11	,	N	O
12	Functional	N	O
13	Assessment	N	O
14	of	N	O
15	Cancer	N	O
16	Therapy-Breast	N	O
17	(	N	O
18	FACT-B	N	O
19	)	N	O
20	,	N	O
21	Functional	N	O
22	Assessment	N	O
23	of	N	O
24	Cancer	N	O
25	Therapy-Endocrine	N	O
26	Symptoms	N	O
27	(	N	O
28	FACT-ES	N	O
29	)	N	O
30	scales	N	O
31	and	N	O
32	the	N	O
33	WHO	N	O
34	five-item	N	O
35	well-being	N	O
36	questionnaire	N	O
37	(	N	O
38	WHO-5	N	O
39	)	N	O
40	evaluated	N	O
41	mood	N	O
42	,	N	O
43	quality	N	O
44	of	N	O
45	life	N	O
46	,	N	O
47	and	N	O
48	well-being	N	O
49	at	N	O
50	weeks	N	O
51	0	N	O
52	,	N	O
53	8	N	O
54	,	N	O
55	and	N	O
56	12	N	O
57	.	N	O

1	For	N	O
2	each	N	O
3	outcome	N	O
4	measure	N	O
5	,	N	O
6	a	N	O
7	repeated-measures	N	O
8	analysis	N	O
9	of	N	O
10	variance	N	O
11	model	N	O
12	,	N	O
13	which	N	O
14	incorporated	N	O
15	week	N	O
16	0	N	O
17	measurements	N	O
18	as	N	O
19	a	N	O
20	covariate	N	O
21	,	N	O
22	was	N	O
23	used	N	O
24	to	N	O
25	compare	N	O
26	treatment	N	O
27	groups	N	O
28	at	N	O
29	8	N	O
30	and	N	O
31	12	N	O
32	weeks	N	O
33	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	statistically	N	I-Premise
4	significant	N	I-Premise
5	improvements	N	I-Premise
6	in	N	I-Premise
7	outcome	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	experimental	N	I-Premise
11	group	N	I-Premise
12	compared	N	I-Premise
13	with	N	I-Premise
14	control	N	I-Premise
15	group	N	I-Premise
16	at	N	I-Premise
17	both	N	I-Premise
18	8	N	I-Premise
19	and	N	I-Premise
20	12	N	I-Premise
21	weeks	N	I-Premise
22	(	N	I-Premise
23	except	N	I-Premise
24	as	N	I-Premise
25	indicated	N	I-Premise
26	)	N	I-Premise
27	for	N	I-Premise
28	POMS	N	I-Premise
29	total	N	I-Premise
30	mood	N	I-Premise
31	disturbance	N	I-Premise
32	(	N	I-Premise
33	and	N	I-Premise
34	its	N	I-Premise
35	subscales	N	I-Premise
36	of	N	I-Premise
37	anxiety	N	I-Premise
38	,	N	I-Premise
39	depression	N	I-Premise
40	[	N	I-Premise
41	8	N	I-Premise
42	weeks	N	I-Premise
43	only	N	I-Premise
44	]	N	I-Premise
45	,	N	I-Premise
46	anger	N	I-Premise
47	[	N	I-Premise
48	12	N	I-Premise
49	weeks	N	I-Premise
50	only	N	I-Premise
51	]	N	I-Premise
52	,	N	I-Premise
53	vigor	N	I-Premise
54	,	N	I-Premise
55	fatigue	N	I-Premise
56	,	N	I-Premise
57	and	N	I-Premise
58	confusion	N	I-Premise
59	[	N	I-Premise
60	8	N	I-Premise
61	weeks	N	I-Premise
62	only	N	I-Premise
63	]	N	I-Premise
64	)	N	I-Premise
65	,	N	I-Premise
66	FACT-B	N	I-Premise
67	,	N	I-Premise
68	FACT-ES	N	I-Premise
69	,	N	I-Premise
70	(	N	I-Premise
71	and	N	I-Premise
72	Functional	N	I-Premise
73	Assessment	N	I-Premise
74	of	N	I-Premise
75	Cancer	N	I-Premise
76	Therapy	N	I-Premise
77	subscales	N	I-Premise
78	of	N	I-Premise
79	physical	N	I-Premise
80	,	N	I-Premise
81	social	N	I-Premise
82	[	N	I-Premise
83	8	N	I-Premise
84	weeks	N	I-Premise
85	only	N	I-Premise
86	]	N	I-Premise
87	,	N	I-Premise
88	emotional	N	I-Premise
89	,	N	I-Premise
90	and	N	I-Premise
91	functional	N	I-Premise
92	well-being	N	I-Premise
93	)	N	I-Premise
94	,	N	I-Premise
95	and	N	I-Premise
96	WHO-5	N	I-Premise
97	.	N	I-Premise

1	MSBR	N	I-Premise
2	improved	N	I-Premise
3	mood	N	I-Premise
4	,	N	I-Premise
5	breast-	N	I-Premise
6	and	N	I-Premise
7	endocrine-related	N	I-Premise
8	quality	N	I-Premise
9	of	N	I-Premise
10	life	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	well-being	N	I-Premise
14	more	N	I-Premise
15	effectively	N	I-Premise
16	than	N	I-Premise
17	standard	N	I-Premise
18	care	N	I-Premise
19	in	N	I-Premise
20	women	N	I-Premise
21	with	N	I-Premise
22	stage	N	I-Premise
23	0	N	I-Premise
24	to	N	I-Premise
25	III	N	I-Premise
26	breast	N	I-Premise
27	cancer	N	I-Premise
28	,	N	I-Premise
29	and	N	I-Premise
30	these	N	I-Premise
31	results	N	I-Premise
32	persisted	N	I-Premise
33	at	N	I-Premise
34	three	N	I-Premise
35	months	N	I-Premise
36	.	N	I-Premise

1	To	N	I-Claim
2	our	N	I-Claim
3	knowledge	N	I-Claim
4	,	N	I-Claim
5	this	N	I-Claim
6	study	N	I-Claim
7	provided	N	I-Claim
8	novel	N	I-Claim
9	evidence	N	I-Claim
10	that	N	I-Claim
11	MBSR	N	I-Claim
12	can	N	I-Claim
13	help	N	I-Claim
14	alleviate	N	I-Claim
15	long-term	N	I-Claim
16	emotional	N	I-Claim
17	and	N	I-Claim
18	physical	N	I-Claim
19	adverse	N	I-Claim
20	effects	N	I-Claim
21	of	N	I-Claim
22	medical	N	I-Claim
23	treatments	N	I-Claim
24	,	N	I-Claim
25	including	N	I-Claim
26	endocrine	N	I-Claim
27	treatments	N	I-Claim
28	.	N	I-Claim

1	MBSR	N	I-MajorClaim
2	is	N	I-MajorClaim
3	recommended	N	I-MajorClaim
4	to	N	I-MajorClaim
5	support	N	I-MajorClaim
6	survivors	N	I-MajorClaim
7	of	N	I-MajorClaim
8	breast	N	I-MajorClaim
9	cancer	N	I-MajorClaim
10	.	N	I-MajorClaim

1	This	N	O
2	study	N	O
3	examined	N	O
4	the	N	O
5	feasibility	N	O
6	and	N	O
7	acceptability	N	O
8	of	N	O
9	an	N	O
10	Individual	N	O
11	Internet	N	O
12	Intervention	N	O
13	(	N	O
14	III	N	O
15	)	N	O
16	embedded	N	O
17	and	N	O
18	integrated	N	O
19	into	N	O
20	an	N	O
21	Internet	N	O
22	Support	N	O
23	Group	N	O
24	(	N	O
25	ISG	N	O
26	)	N	O
27	with	N	O
28	the	N	O
29	ultimate	N	O
30	goal	N	O
31	of	N	O
32	enhancing	N	O
33	adherence	N	O
34	and	N	O
35	learning	N	O
36	,	N	O
37	compared	N	O
38	with	N	O
39	an	N	O
40	individual	N	O
41	internet	N	O
42	invention	N	O
43	alone	N	O
44	.	N	O

1	Thirty-one	N	O
2	posttreatment	N	O
3	cancer	N	O
4	survivors	N	O
5	were	N	O
6	randomized	N	O
7	in	N	O
8	groups	N	O
9	of	N	O
10	seven	N	O
11	to	N	O
12	nine	N	O
13	to	N	O
14	either	N	O
15	the	N	O
16	8-week	N	O
17	III	N	O
18	+	N	O
19	ISG	N	O
20	intervention	N	O
21	or	N	O
22	the	N	O
23	8-week	N	O
24	III	N	O
25	condition	N	O
26	.	N	O

1	Seventeen	N	O
2	participants	N	O
3	met	N	O
4	the	N	O
5	Hospital	N	O
6	Anxiety	N	O
7	and	N	O
8	Depression	N	O
9	Scale	N	O
10	(	N	O
11	HADS	N	O
12	)	N	O
13	criteria	N	O
14	for	N	O
15	depressive	N	O
16	symptoms	N	O
17	(	N	O
18	HADS	N	O
19	≥	N	O
20	8	N	O
21	)	N	O
22	.	N	O

1	Among	N	O
2	all	N	O
3	participants	N	O
4	,	N	O
5	the	N	O
6	mean	N	O
7	number	N	O
8	of	N	O
9	logins	N	O
10	over	N	O
11	8	N	O
12	weeks	N	O
13	was	N	O
14	20.8	N	O
15	±	N	O
16	17.7	N	O
17	logins	N	O
18	for	N	O
19	the	N	O
20	III	N	O
21	+	N	O
22	ISG	N	O
23	compared	N	O
24	with	N	O
25	12.5	N	O
26	±	N	O
27	12.5	N	O
28	in	N	O
29	III-only	N	O
30	(	N	O
31	p	N	O
32	=	N	O
33	0.15	N	O
34	)	N	O
35	.	N	O

1	Two	N	O
2	participants	N	O
3	in	N	O
4	the	N	O
5	III	N	O
6	+	N	O
7	ISG	N	O
8	dropped	N	O
9	out	N	O
10	,	N	O
11	compared	N	O
12	with	N	O
13	five	N	O
14	in	N	O
15	III	N	O
16	(	N	O
17	p	N	O
18	=	N	O
19	0.39	N	O
20	)	N	O
21	.	N	O

1	Among	N	I-Premise
2	the	N	I-Premise
3	17	N	I-Premise
4	participants	N	I-Premise
5	with	N	I-Premise
6	depressive	N	I-Premise
7	symptoms	N	I-Premise
8	at	N	I-Premise
9	baseline	N	I-Premise
10	,	N	I-Premise
11	both	N	I-Premise
12	the	N	I-Premise
13	Onward	N	I-Premise
14	and	N	I-Premise
15	the	N	I-Premise
16	III-only	N	I-Premise
17	condition	N	I-Premise
18	showed	N	I-Premise
19	large	N	I-Premise
20	reductions	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	depression	N	I-Premise
24	scale	N	I-Premise
25	of	N	I-Premise
26	HADS	N	I-Premise
27	(	N	I-Premise
28	d	N	I-Premise
29	=	N	I-Premise
30	1.27	N	I-Premise
31	and	N	I-Premise
32	0.89	N	I-Premise
33	,	N	I-Premise
34	respectively	N	I-Premise
35	)	N	I-Premise
36	.	N	I-Premise

1	Improvement	N	I-Premise
2	over	N	I-Premise
3	time	N	I-Premise
4	and	N	I-Premise
5	time	N	I-Premise
6	x	N	I-Premise
7	treatment	N	I-Premise
8	effects	N	I-Premise
9	only	N	I-Premise
10	reached	N	I-Premise
11	trend	N	I-Premise
12	significance	N	I-Premise
13	levels	N	I-Premise
14	(	N	I-Premise
15	ps	N	I-Premise
16	=	N	I-Premise
17	0.07	N	I-Premise
18	&	N	I-Premise
19	amp	N	I-Premise
20	;	N	I-Premise
21	0.12	N	I-Premise
22	)	N	I-Premise
23	as	N	I-Premise
24	this	N	I-Premise
25	pilot	N	I-Premise
26	was	N	I-Premise
27	not	N	I-Premise
28	powered	N	I-Premise
29	to	N	I-Premise
30	detect	N	I-Premise
31	these	N	I-Premise
32	differences	N	I-Premise
33	.	N	I-Premise

1	Both	N	I-Claim
2	the	N	I-Claim
3	III	N	I-Claim
4	+	N	I-Claim
5	ISG	N	I-Claim
6	and	N	I-Claim
7	III-only	N	I-Claim
8	demonstrated	N	I-Claim
9	pre-post	N	I-Claim
10	reductions	N	I-Claim
11	in	N	I-Claim
12	depressive	N	I-Claim
13	symptoms	N	I-Claim
14	and	N	I-Claim
15	high	N	I-Claim
16	rates	N	I-Claim
17	of	N	I-Claim
18	utilization	N	I-Claim
19	compared	N	I-Claim
20	with	N	I-Claim
21	other	N	I-Claim
22	web-based	N	I-Claim
23	treatments	N	I-Claim
24	for	N	I-Claim
25	depression	N	I-Claim
26	.	N	I-Claim

1	Although	N	I-Claim
2	it	N	I-Claim
3	is	N	I-Claim
4	premature	N	I-Claim
5	to	N	I-Claim
6	make	N	I-Claim
7	any	N	I-Claim
8	determination	N	I-Claim
9	as	N	I-Claim
10	to	N	I-Claim
11	the	N	I-Claim
12	efficacy	N	I-Claim
13	of	N	I-Claim
14	the	N	I-Claim
15	interventions	N	I-Claim
16	tested	N	I-Claim
17	in	N	I-Claim
18	this	N	I-Claim
19	feasibility	N	I-Claim
20	study	N	I-Claim
21	,	N	I-Claim
22	these	N	I-Claim
23	results	N	I-Claim
24	indicate	N	I-Claim
25	that	N	I-Claim
26	pursuing	N	I-Claim
27	the	N	I-Claim
28	III	N	I-Claim
29	+	N	I-Claim
30	ISG	N	I-Claim
31	model	N	I-Claim
32	,	N	I-Claim
33	as	N	I-Claim
34	well	N	I-Claim
35	as	N	I-Claim
36	standard	N	I-Claim
37	IIIs	N	I-Claim
38	,	N	I-Claim
39	may	N	I-Claim
40	be	N	I-Claim
41	fruitful	N	I-Claim
42	areas	N	I-Claim
43	of	N	I-Claim
44	future	N	I-Claim
45	research	N	I-Claim
46	.	N	I-Claim

1	The	N	O
2	phase	N	O
3	3	N	O
4	VISTA	N	O
5	study	N	O
6	in	N	O
7	transplant-ineligible	N	O
8	myeloma	N	O
9	patients	N	O
10	demonstrated	N	O
11	superior	N	O
12	efficacy	N	O
13	with	N	O
14	bortezomib-melphalan-prednisone	N	O
15	(	N	O
16	VMP	N	O
17	;	N	O
18	nine	N	O
19	6-wk	N	O
20	cycles	N	O
21	)	N	O
22	vs.	N	O
23	melphalan-prednisone	N	O
24	(	N	O
25	MP	N	O
26	)	N	O
27	but	N	O
28	also	N	O
29	increased	N	O
30	toxicity	N	O
31	.	N	O

1	Health-related	N	O
2	quality	N	O
3	of	N	O
4	life	N	O
5	(	N	O
6	HRQoL	N	O
7	;	N	O
8	exploratory	N	O
9	endpoint	N	O
10	)	N	O
11	was	N	O
12	evaluated	N	O
13	using	N	O
14	the	N	O
15	European	N	O
16	Organization	N	O
17	for	N	O
18	Research	N	O
19	and	N	O
20	Treatment	N	O
21	of	N	O
22	Cancer	N	O
23	(	N	O
24	EORTC	N	O
25	)	N	O
26	Quality	N	O
27	of	N	O
28	Life	N	O
29	Questionnaire	N	O
30	(	N	O
31	QLQ-C30	N	O
32	)	N	O
33	.	N	O

1	The	N	O
2	phase	N	O
3	3	N	O
4	VISTA	N	O
5	study	N	O
6	in	N	O
7	transplant-ineligible	N	O
8	myeloma	N	O
9	patients	N	O
10	demonstrated	N	O
11	superior	N	O
12	efficacy	N	O
13	with	N	O
14	bortezomib-melphalan-prednisone	N	O
15	(	N	O
16	VMP	N	O
17	;	N	O
18	nine	N	O
19	6-wk	N	O
20	cycles	N	O
21	)	N	O
22	vs.	N	O
23	melphalan-prednisone	N	O
24	(	N	O
25	MP	N	O
26	)	N	O
27	but	N	O
28	also	N	O
29	increased	N	O
30	toxicity	N	O
31	.	N	O

1	Health-related	N	O
2	quality	N	O
3	of	N	O
4	life	N	O
5	(	N	O
6	HRQoL	N	O
7	;	N	O
8	exploratory	N	O
9	endpoint	N	O
10	)	N	O
11	was	N	O
12	evaluated	N	O
13	using	N	O
14	the	N	O
15	European	N	O
16	Organization	N	O
17	for	N	O
18	Research	N	O
19	and	N	O
20	Treatment	N	O
21	of	N	O
22	Cancer	N	O
23	(	N	O
24	EORTC	N	O
25	)	N	O
26	Quality	N	O
27	of	N	O
28	Life	N	O
29	Questionnaire	N	O
30	(	N	O
31	QLQ-C30	N	O
32	)	N	O
33	.	N	O

1	EORTC	N	O
2	QLQ-C30	N	O
3	was	N	O
4	administered	N	O
5	at	N	O
6	screening	N	O
7	,	N	O
8	on	N	O
9	day	N	O
10	1	N	O
11	of	N	O
12	each	N	O
13	cycle	N	O
14	,	N	O
15	at	N	O
16	the	N	O
17	end-of-treatment	N	O
18	visit	N	O
19	,	N	O
20	and	N	O
21	every	N	O
22	8	N	O
23	wk	N	O
24	until	N	O
25	progression	N	O
26	.	N	O

1	EORTC	N	O
2	QLQ-C30	N	O
3	scores	N	O
4	were	N	O
5	evaluated	N	O
6	among	N	O
7	patients	N	O
8	with	N	O
9	a	N	O
10	valid	N	O
11	baseline	N	O
12	and	N	O
13	at	N	O
14	least	N	O
15	one	N	O
16	post-baseline	N	O
17	HRQoL	N	O
18	assessment	N	O
19	.	N	O

1	At	N	O
2	baseline	N	O
3	,	N	O
4	domain	N	O
5	scores	N	O
6	were	N	O
7	similar	N	O
8	between	N	O
9	arms	N	O
10	.	N	O

1	By	N	I-Premise
2	cycle	N	I-Premise
3	4	N	I-Premise
4	,	N	I-Premise
5	mean	N	I-Premise
6	differences	N	I-Premise
7	were	N	I-Premise
8	clinically	N	I-Premise
9	meaningful	N	I-Premise
10	for	N	I-Premise
11	most	N	I-Premise
12	domains	N	I-Premise
13	,	N	I-Premise
14	indicating	N	I-Premise
15	poorer	N	I-Premise
16	health	N	I-Premise
17	status	N	I-Premise
18	with	N	I-Premise
19	VMP	N	I-Premise
20	.	N	I-Premise

1	From	N	I-Premise
2	cycle	N	I-Premise
3	5	N	I-Premise
4	onwards	N	I-Premise
5	,	N	I-Premise
6	improvements	N	I-Premise
7	relative	N	I-Premise
8	to	N	I-Premise
9	baseline/MP	N	I-Premise
10	were	N	I-Premise
11	observed	N	I-Premise
12	for	N	I-Premise
13	all	N	I-Premise
14	domains	N	I-Premise
15	with	N	I-Premise
16	VMP	N	I-Premise
17	.	N	I-Premise

1	Mean	N	I-Premise
2	scores	N	I-Premise
3	were	N	I-Premise
4	generally	N	I-Premise
5	improved	N	I-Premise
6	by	N	I-Premise
7	the	N	I-Premise
8	end-of-treatment	N	I-Premise
9	assessment	N	I-Premise
10	vs.	N	I-Premise
11	baseline	N	I-Premise
12	in	N	I-Premise
13	both	N	I-Premise
14	arms	N	I-Premise
15	.	N	I-Premise

1	Among	N	I-Premise
2	responding	N	I-Premise
3	patients	N	I-Premise
4	,	N	I-Premise
5	mean	N	I-Premise
6	scores	N	I-Premise
7	generally	N	I-Premise
8	improved	N	I-Premise
9	from	N	I-Premise
10	time	N	I-Premise
11	of	N	I-Premise
12	response	N	I-Premise
13	to	N	I-Premise
14	end-of-treatment	N	I-Premise
15	assessment	N	I-Premise
16	,	N	I-Premise
17	substantially	N	I-Premise
18	driven	N	I-Premise
19	by	N	I-Premise
20	patients	N	I-Premise
21	achieving	N	I-Premise
22	complete	N	I-Premise
23	response	N	I-Premise
24	(	N	I-Premise
25	CR	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	Multivariate	N	I-Premise
2	analysis	N	I-Premise
3	showed	N	I-Premise
4	a	N	I-Premise
5	significant	N	I-Premise
6	impact	N	I-Premise
7	of	N	I-Premise
8	duration	N	I-Premise
9	of	N	I-Premise
10	response/CR	N	I-Premise
11	on	N	I-Premise
12	improving	N	I-Premise
13	global	N	I-Premise
14	health	N	I-Premise
15	status	N	I-Premise
16	,	N	I-Premise
17	pain	N	I-Premise
18	,	N	I-Premise
19	and	N	I-Premise
20	appetite	N	I-Premise
21	loss	N	I-Premise
22	scores	N	I-Premise
23	.	N	I-Premise

1	Analyses	N	I-Claim
2	by	N	I-Claim
3	bortezomib	N	I-Claim
4	dose	N	I-Claim
5	intensity	N	I-Claim
6	indicated	N	I-Claim
7	better	N	I-Claim
8	HRQoL	N	I-Claim
9	in	N	I-Claim
10	patients	N	I-Claim
11	receiving	N	I-Claim
12	lower	N	I-Claim
13	dose	N	I-Claim
14	intensity	N	I-Claim
15	.	N	I-Claim

1	These	N	I-Claim
2	findings	N	I-Claim
3	demonstrate	N	I-Claim
4	clinically	N	I-Claim
5	meaningful	N	I-Claim
6	,	N	I-Claim
7	transitory	N	I-Claim
8	HRQoL	N	I-Claim
9	decrements	N	I-Claim
10	with	N	I-Claim
11	VMP	N	I-Claim
12	and	N	I-Claim
13	relatively	N	I-Claim
14	lower	N	I-Claim
15	HRQoL	N	I-Claim
16	vs.	N	I-Claim
17	MP	N	I-Claim
18	during	N	I-Claim
19	early	N	I-Claim
20	treatment	N	I-Claim
21	cycles	N	I-Claim
22	,	N	I-Claim
23	associated	N	I-Claim
24	with	N	I-Claim
25	the	N	I-Claim
26	expected	N	I-Claim
27	additional	N	I-Claim
28	toxicities	N	I-Claim
29	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	HRQoL	N	I-Claim
4	is	N	I-Claim
5	not	N	I-Claim
6	compromised	N	I-Claim
7	in	N	I-Claim
8	the	N	I-Claim
9	long	N	I-Claim
10	term	N	I-Claim
11	,	N	I-Claim
12	recovering	N	I-Claim
13	by	N	I-Claim
14	the	N	I-Claim
15	end-of-treatment	N	I-Claim
16	visit	N	I-Claim
17	to	N	I-Claim
18	be	N	I-Claim
19	comparable	N	I-Claim
20	vs.	N	I-Claim
21	MP	N	I-Claim
22	.	N	I-Claim

1	Maintenance	N	O
2	therapy	N	O
3	,	N	O
4	commenced	N	O
5	immediately	N	O
6	after	N	O
7	the	N	O
8	completion	N	O
9	of	N	O
10	first-line	N	O
11	chemotherapy	N	O
12	,	N	O
13	is	N	O
14	a	N	O
15	promising	N	O
16	strategy	N	O
17	for	N	O
18	improving	N	O
19	treatment	N	O
20	outcomes	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	non-small-cell	N	O
25	lung	N	O
26	cancer	N	O
27	(	N	O
28	NSCLC	N	O
29	)	N	O
30	.	N	O

1	The	N	O
2	global	N	O
3	phase	N	O
4	III	N	O
5	SequentiAl	N	O
6	Tarceva	N	O
7	in	N	O
8	UnResectable	N	O
9	NSCLC	N	O
10	(	N	O
11	SATURN	N	O
12	)	N	O
13	study	N	O
14	evaluated	N	O
15	the	N	O
16	efficacy	N	O
17	and	N	O
18	safety	N	O
19	of	N	O
20	the	N	O
21	epidermal	N	O
22	growth	N	O
23	factor	N	O
24	receptor	N	O
25	(	N	O
26	EGFR	N	O
27	)	N	O
28	tyrosine-kinase	N	O
29	inhibitor	N	O
30	erlotinib	N	O
31	as	N	O
32	maintenance	N	O
33	treatment	N	O
34	in	N	O
35	NSCLC	N	O
36	patients	N	O
37	without	N	O
38	progression	N	O
39	after	N	O
40	first-line	N	O
41	chemotherapy	N	O
42	.	N	O

1	We	N	O
2	report	N	O
3	a	N	O
4	retrospective	N	O
5	subanalysis	N	O
6	of	N	O
7	Asian	N	O
8	patients	N	O
9	enrolled	N	O
10	in	N	O
11	SATURN	N	O
12	.	N	O

1	Patients	N	O
2	with	N	O
3	advanced	N	O
4	NSCLC	N	O
5	with	N	O
6	no	N	O
7	evidence	N	O
8	of	N	O
9	progression	N	O
10	after	N	O
11	four	N	O
12	cycles	N	O
13	of	N	O
14	chemotherapy	N	O
15	were	N	O
16	randomized	N	O
17	to	N	O
18	receive	N	O
19	erlotinib	N	O
20	150	N	O
21	mg/day	N	O
22	or	N	O
23	placebo	N	O
24	,	N	O
25	until	N	O
26	progressive	N	O
27	disease	N	O
28	or	N	O
29	limiting	N	O
30	toxicity	N	O
31	.	N	O

1	The	N	O
2	co-primary	N	O
3	endpoints	N	O
4	of	N	O
5	SATURN	N	O
6	were	N	O
7	progression-free	N	O
8	survival	N	O
9	(	N	O
10	PFS	N	O
11	)	N	O
12	in	N	O
13	all	N	O
14	patients	N	O
15	and	N	O
16	in	N	O
17	those	N	O
18	with	N	O
19	positive	N	O
20	EGFR	N	O
21	immunohistochemistry	N	O
22	(	N	O
23	IHC	N	O
24	)	N	O
25	status	N	O
26	.	N	O

1	Secondary	N	O
2	endpoints	N	O
3	included	N	O
4	overall	N	O
5	survival	N	O
6	(	N	O
7	OS	N	O
8	)	N	O
9	,	N	O
10	disease	N	O
11	control	N	O
12	rate	N	O
13	,	N	O
14	safety	N	O
15	,	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	QoL	N	O
21	)	N	O
22	and	N	O
23	biomarker	N	O
24	analyses	N	O
25	.	N	O

1	In	N	O
2	total	N	O
3	,	N	O
4	126	N	O
5	patients	N	O
6	from	N	O
7	East	N	O
8	and	N	O
9	South-East	N	O
10	Asian	N	O
11	centers	N	O
12	were	N	O
13	randomized	N	O
14	(	N	O
15	14	N	O
16	%	N	O
17	of	N	O
18	the	N	O
19	intent-to-treat	N	O
20	population	N	O
21	)	N	O
22	:	N	O
23	88	N	O
24	from	N	O
25	Korea	N	O
26	,	N	O
27	28	N	O
28	from	N	O
29	China	N	O
30	and	N	O
31	10	N	O
32	from	N	O
33	Malaysia	N	O
34	;	N	O
35	one	N	O
36	patient	N	O
37	was	N	O
38	excluded	N	O
39	from	N	O
40	this	N	O
41	analysis	N	O
42	due	N	O
43	to	N	O
44	Indian	N	O
45	ethnicity	N	O
46	.	N	O

1	PFS	N	I-Premise
2	was	N	I-Premise
3	significantly	N	I-Premise
4	prolonged	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	erlotinib	N	I-Premise
8	treatment	N	I-Premise
9	arm	N	I-Premise
10	,	N	I-Premise
11	both	N	I-Premise
12	overall	N	I-Premise
13	(	N	I-Premise
14	hazard	N	I-Premise
15	ratio	N	I-Premise
16	[	N	I-Premise
17	HR	N	I-Premise
18	]	N	I-Premise
19	:	N	I-Premise
20	0.57	N	I-Premise
21	;	N	I-Premise
22	p=0.0067	N	I-Premise
23	)	N	I-Premise
24	and	N	I-Premise
25	in	N	I-Premise
26	patients	N	I-Premise
27	with	N	I-Premise
28	EGFR	N	I-Premise
29	IHC-positive	N	I-Premise
30	disease	N	I-Premise
31	(	N	I-Premise
32	HR=0.50	N	I-Premise
33	;	N	I-Premise
34	p=0.0057	N	I-Premise
35	)	N	I-Premise
36	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	trend	N	I-Premise
5	towards	N	I-Premise
6	an	N	I-Premise
7	increase	N	I-Premise
8	in	N	I-Premise
9	OS	N	I-Premise
10	,	N	I-Premise
11	which	N	I-Premise
12	reached	N	I-Premise
13	statistical	N	I-Premise
14	significance	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	EGFR	N	I-Premise
18	IHC-positive	N	I-Premise
19	subgroup	N	I-Premise
20	(	N	I-Premise
21	p=0.0233	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	The	N	I-Premise
2	overall	N	I-Premise
3	response	N	I-Premise
4	rate	N	I-Premise
5	was	N	I-Premise
6	significantly	N	I-Premise
7	higher	N	I-Premise
8	with	N	I-Premise
9	erlotinib	N	I-Premise
10	compared	N	I-Premise
11	with	N	I-Premise
12	placebo	N	I-Premise
13	(	N	I-Premise
14	24	N	I-Premise
15	%	N	I-Premise
16	versus	N	I-Premise
17	5	N	I-Premise
18	%	N	I-Premise
19	;	N	I-Premise
20	p=0.0025	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	Erlotinib	N	I-Claim
2	was	N	I-Claim
3	generally	N	I-Claim
4	well	N	I-Claim
5	tolerated	N	I-Claim
6	and	N	I-Claim
7	had	N	I-Claim
8	no	N	I-Claim
9	negative	N	I-Claim
10	impact	N	I-Claim
11	on	N	I-Claim
12	QoL	N	I-Claim
13	in	N	I-Claim
14	this	N	I-Claim
15	subpopulation	N	I-Claim
16	.	N	I-Claim

1	The	N	I-Premise
2	most	N	I-Premise
3	common	N	I-Premise
4	treatment-related	N	I-Premise
5	adverse	N	I-Premise
6	events	N	I-Premise
7	were	N	I-Premise
8	rash	N	I-Premise
9	,	N	I-Premise
10	diarrhea	N	I-Premise
11	and	N	I-Premise
12	pruritus	N	I-Premise
13	.	N	I-Premise

1	Erlotinib	N	I-Claim
2	was	N	I-Claim
3	effective	N	I-Claim
4	and	N	I-Claim
5	well	N	I-Claim
6	tolerated	N	I-Claim
7	in	N	I-Claim
8	Asian	N	I-Claim
9	patients	N	I-Claim
10	,	N	I-Claim
11	producing	N	I-Claim
12	benefits	N	I-Claim
13	consistent	N	I-Claim
14	with	N	I-Claim
15	those	N	I-Claim
16	observed	N	I-Claim
17	in	N	I-Claim
18	the	N	I-Claim
19	overall	N	I-Claim
20	SATURN	N	I-Claim
21	population	N	I-Claim
22	.	N	I-Claim

1	Maintenance	N	I-MajorClaim
2	treatment	N	I-MajorClaim
3	with	N	I-MajorClaim
4	erlotinib	N	I-MajorClaim
5	appears	N	I-MajorClaim
6	to	N	I-MajorClaim
7	be	N	I-MajorClaim
8	a	N	I-MajorClaim
9	useful	N	I-MajorClaim
10	option	N	I-MajorClaim
11	for	N	I-MajorClaim
12	the	N	I-MajorClaim
13	management	N	I-MajorClaim
14	of	N	I-MajorClaim
15	Asian	N	I-MajorClaim
16	patients	N	I-MajorClaim
17	with	N	I-MajorClaim
18	advanced	N	I-MajorClaim
19	NSCLC	N	I-MajorClaim
20	without	N	I-MajorClaim
21	progression	N	I-MajorClaim
22	after	N	I-MajorClaim
23	first-line	N	I-MajorClaim
24	chemotherapy	N	I-MajorClaim
25	.	N	I-MajorClaim

1	Study	N	O
2	Type	N	O
3	--	N	O
4	Therapy	N	O
5	(	N	O
6	RCT	N	O
7	)	N	O
8	Level	N	O
9	of	N	O
10	Evidence	N	O
11	1b	N	O
12	.	N	O

1	What	N	O
2	's	N	O
3	known	N	O
4	on	N	O
5	the	N	O
6	subject	N	O
7	?	N	O
1	and	N	O
2	What	N	O
3	does	N	O
4	the	N	O
5	study	N	O
6	add	N	O
7	?	N	O
1	Androgen	N	O
2	deprivation	N	O
3	therapy	N	O
4	(	N	O
5	ADT	N	O
6	)	N	O
7	is	N	O
8	commonly	N	O
9	used	N	O
10	as	N	O
11	a	N	O
12	primary	N	O
13	treatment	N	O
14	for	N	O
15	patients	N	O
16	with	N	O
17	prostate	N	O
18	cancer	N	O
19	(	N	O
20	PCa	N	O
21	)	N	O
22	who	N	O
23	are	N	O
24	not	N	O
25	eligible	N	O
26	for	N	O
27	radical	N	O
28	treatment	N	O
29	options	N	O
30	.	N	O

1	ADT	N	O
2	is	N	O
3	also	N	O
4	used	N	O
5	in	N	O
6	patients	N	O
7	with	N	O
8	PCa	N	O
9	as	N	O
10	neo-adjuvant	N	O
11	hormone	N	O
12	therapy	N	O
13	to	N	O
14	reduce	N	O
15	prostate	N	O
16	volume	N	O
17	and	N	O
18	down-stage	N	O
19	the	N	O
20	disease	N	O
21	before	N	O
22	radiotherapy	N	O
23	with	N	O
24	curative	N	O
25	intent	N	O
26	.	N	O

1	The	N	O
2	present	N	O
3	study	N	O
4	showed	N	O
5	that	N	O
6	ADT	N	O
7	with	N	O
8	the	N	O
9	gonadotropin	N	O
10	hormone-releasing	N	O
11	hormone	N	O
12	(	N	O
13	GhRH	N	O
14	)	N	O
15	antagonist	N	O
16	degarelix	N	O
17	is	N	O
18	non-inferior	N	O
19	to	N	O
20	combined	N	O
21	treatment	N	O
22	with	N	O
23	the	N	O
24	LHRH	N	O
25	agonist	N	O
26	goserelin	N	O
27	and	N	O
28	bicalutamide	N	O
29	in	N	O
30	terms	N	O
31	of	N	O
32	reducing	N	O
33	prostate	N	O
34	volume	N	O
35	during	N	O
36	the	N	O
37	treatment	N	O
38	period	N	O
39	of	N	O
40	3	N	O
41	months	N	O
42	.	N	O

1	Degarelix	N	O
2	treatment	N	O
3	evokes	N	O
4	,	N	O
5	however	N	O
6	,	N	O
7	significantly	N	O
8	better	N	O
9	relief	N	O
10	of	N	O
11	lower	N	O
12	urinary	N	O
13	tract	N	O
14	symptoms	N	O
15	in	N	O
16	patients	N	O
17	having	N	O
18	moderate	N	O
19	and	N	O
20	severe	N	O
21	voiding	N	O
22	problems	N	O
23	.	N	O

1	To	N	O
2	assess	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	monthly	N	O
7	degarelix	N	O
8	treatment	N	O
9	for	N	O
10	reduction	N	O
11	of	N	O
12	total	N	O
13	prostate	N	O
14	volume	N	O
15	(	N	O
16	TPV	N	O
17	)	N	O
18	,	N	O
19	relief	N	O
20	of	N	O
21	lower	N	O
22	urinary	N	O
23	tract	N	O
24	symptoms	N	O
25	(	N	O
26	LUTS	N	O
27	)	N	O
28	and	N	O
29	improvement	N	O
30	of	N	O
31	quality	N	O
32	of	N	O
33	life	N	O
34	(	N	O
35	QoL	N	O
36	)	N	O
37	in	N	O
38	patients	N	O
39	with	N	O
40	prostate	N	O
41	cancer	N	O
42	(	N	O
43	PCa	N	O
44	)	N	O
45	using	N	O
46	monthly	N	O
47	goserelin	N	O
48	as	N	O
49	active	N	O
50	control	N	O
51	.	N	O

1	This	N	O
2	was	N	O
3	a	N	O
4	randomized	N	O
5	,	N	O
6	parallel-arm	N	O
7	,	N	O
8	active-controlled	N	O
9	,	N	O
10	open-label	N	O
11	,	N	O
12	multicentre	N	O
13	trial	N	O
14	on	N	O
15	182	N	O
16	patients	N	O
17	treated	N	O
18	with	N	O
19	either	N	O
20	monthly	N	O
21	degarelix	N	O
22	(	N	O
23	240/80	N	O
24	mg	N	O
25	)	N	O
26	or	N	O
27	goserelin	N	O
28	(	N	O
29	3.6	N	O
30	mg	N	O
31	)	N	O
32	for	N	O
33	12	N	O
34	weeks	N	O
35	.	N	O

1	For	N	O
2	flare	N	O
3	protection	N	O
4	,	N	O
5	goserelin-treated	N	O
6	patients	N	O
7	also	N	O
8	received	N	O
9	daily	N	O
10	bicalutamide	N	O
11	(	N	O
12	50	N	O
13	mg	N	O
14	)	N	O
15	during	N	O
16	the	N	O
17	initial	N	O
18	28	N	O
19	days	N	O
20	.	N	O

1	Key	N	O
2	trial	N	O
3	variables	N	O
4	monitored	N	O
5	monthly	N	O
6	were	N	O
7	TPV	N	O
8	(	N	O
9	primary	N	O
10	endpoint	N	O
11	)	N	O
12	,	N	O
13	serum	N	O
14	testosterone	N	O
15	,	N	O
16	prostate-specific	N	O
17	antigen	N	O
18	(	N	O
19	PSA	N	O
20	)	N	O
21	,	N	O
22	the	N	O
23	International	N	O
24	Prostate	N	O
25	Symptom	N	O
26	Score	N	O
27	(	N	O
28	IPSS	N	O
29	)	N	O
30	and	N	O
31	the	N	O
32	Benign	N	O
33	Prostate	N	O
34	Hyperplasia	N	O
35	Impact	N	O
36	Index	N	O
37	.	N	O

1	In	N	O
2	all	N	O
3	,	N	O
4	175	N	O
5	patients	N	O
6	completed	N	O
7	the	N	O
8	trial	N	O
9	(	N	O
10	96.1	N	O
11	%	N	O
12	)	N	O
13	.	N	O

1	At	N	I-Premise
2	week	N	I-Premise
3	12	N	I-Premise
4	,	N	I-Premise
5	changes	N	I-Premise
6	in	N	I-Premise
7	TPV	N	I-Premise
8	for	N	I-Premise
9	degarelix	N	I-Premise
10	and	N	I-Premise
11	goserelin	N	I-Premise
12	were	N	I-Premise
13	similar	N	I-Premise
14	(	N	I-Premise
15	-37.2	N	I-Premise
16	%	N	I-Premise
17	vs	N	I-Premise
18	-39.0	N	I-Premise
19	%	N	I-Premise
20	)	N	I-Premise
21	and	N	I-Premise
22	met	N	I-Premise
23	the	N	I-Premise
24	predefined	N	I-Premise
25	non-inferiority	N	I-Premise
26	criterion	N	I-Premise
27	.	N	I-Premise

1	Decreases	N	I-Premise
2	in	N	I-Premise
3	IPSS	N	I-Premise
4	were	N	I-Premise
5	greater	N	I-Premise
6	in	N	I-Premise
7	degarelix	N	I-Premise
8	than	N	I-Premise
9	in	N	I-Premise
10	goserelin-treated	N	I-Premise
11	patients	N	I-Premise
12	,	N	I-Premise
13	differences	N	I-Premise
14	being	N	I-Premise
15	statistically	N	I-Premise
16	significant	N	I-Premise
17	in	N	I-Premise
18	patients	N	I-Premise
19	with	N	I-Premise
20	baseline	N	I-Premise
21	IPSS	N	I-Premise
22	>	N	I-Premise
23	13	N	I-Premise
24	(	N	I-Premise
25	-6.7	N	I-Premise
26	±	N	I-Premise
27	1.8	N	I-Premise
28	vs	N	I-Premise
29	-4.0	N	I-Premise
30	±	N	I-Premise
31	1.0	N	I-Premise
32	;	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	0.02	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	The	N	I-Premise
2	number	N	I-Premise
3	of	N	I-Premise
4	patients	N	I-Premise
5	with	N	I-Premise
6	an	N	I-Premise
7	IPSS	N	I-Premise
8	change	N	I-Premise
9	of	N	I-Premise
10	≥	N	I-Premise
11	3	N	I-Premise
12	over	N	I-Premise
13	baseline	N	I-Premise
14	was	N	I-Premise
15	also	N	I-Premise
16	significantly	N	I-Premise
17	higher	N	I-Premise
18	in	N	I-Premise
19	patients	N	I-Premise
20	treated	N	I-Premise
21	with	N	I-Premise
22	degarelix	N	I-Premise
23	(	N	I-Premise
24	61.0	N	I-Premise
25	vs	N	I-Premise
26	44.3	N	I-Premise
27	%	N	I-Premise
28	,	N	I-Premise
29	P	N	I-Premise
30	=	N	I-Premise
31	0.02	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	Both	N	I-Claim
2	treatments	N	I-Claim
3	were	N	I-Claim
4	safe	N	I-Claim
5	and	N	I-Claim
6	well	N	I-Claim
7	tolerated	N	I-Claim
8	.	N	I-Claim

1	Medical	N	I-Claim
2	castration	N	I-Claim
3	reduces	N	I-Claim
4	TPV	N	I-Claim
5	and	N	I-Claim
6	could	N	I-Claim
7	also	N	I-Claim
8	improve	N	I-Claim
9	LUTS	N	I-Claim
10	in	N	I-Claim
11	patients	N	I-Claim
12	with	N	I-Claim
13	PCa	N	I-Claim
14	.	N	I-Claim

1	While	N	O
2	the	N	I-Claim
3	short-term	N	I-Claim
4	efficacy	N	I-Claim
5	of	N	I-Claim
6	degarelix	N	I-Claim
7	and	N	I-Claim
8	goserelin	N	I-Claim
9	+	N	I-Claim
10	bicalutamide	N	I-Claim
11	was	N	I-Claim
12	the	N	I-Claim
13	same	N	I-Claim
14	in	N	I-Claim
15	terms	N	I-Claim
16	of	N	I-Claim
17	TPV	N	I-Claim
18	reduction	N	I-Claim
19	,	N	I-Claim
20	degarelix	N	I-Claim
21	showed	N	I-Claim
22	superiority	N	I-Claim
23	in	N	I-Claim
24	LUTS	N	I-Claim
25	relief	N	I-Claim
26	in	N	I-Claim
27	symptomatic	N	I-Claim
28	patients	N	I-Claim
29	,	N	I-Claim
30	which	N	I-Claim
31	could	N	I-Claim
32	highlight	N	I-Claim
33	the	N	I-Claim
34	different	N	I-Claim
35	actions	N	I-Claim
36	of	N	I-Claim
37	these	N	I-Claim
38	drugs	N	I-Claim
39	on	N	I-Claim
40	extrapituitary	N	I-Claim
41	gonadotrophin-releasing	N	I-Claim
42	hormone	N	I-Claim
43	(	N	I-Claim
44	GnRH	N	I-Claim
45	)	N	I-Claim
46	receptors	N	I-Claim
47	in	N	I-Claim
48	the	N	I-Claim
49	bladder	N	I-Claim
50	and/or	N	I-Claim
51	the	N	I-Claim
52	prostate	N	I-Claim
53	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	the	N	O
4	efficacy	N	O
5	of	N	O
6	prophylactic	N	O
7	swallowing	N	O
8	exercises	N	O
9	on	N	O
10	swallowing	N	O
11	function	N	O
12	in	N	O
13	patients	N	O
14	undergoing	N	O
15	chemoradiation	N	O
16	therapy	N	O
17	(	N	O
18	CRT	N	O
19	)	N	O
20	for	N	O
21	head	N	O
22	and	N	O
23	neck	N	O
24	cancer	N	O
25	.	N	O

1	Randomized	N	O
2	controlled	N	O
3	trial	N	O
4	.	N	O

1	Tertiary	N	O
2	care	N	O
3	,	N	O
4	academic	N	O
5	medical	N	O
6	center	N	O
7	.	N	O

1	Twenty-six	N	O
2	patients	N	O
3	with	N	O
4	head	N	O
5	and	N	O
6	neck	N	O
7	cancer	N	O
8	receiving	N	O
9	CRT	N	O
10	.	N	O

1	Patients	N	O
2	performed	N	O
3	5	N	O
4	targeted	N	O
5	swallowing	N	O
6	exercises	N	O
7	throughout	N	O
8	their	N	O
9	CRT	N	O
10	and	N	O
11	participated	N	O
12	in	N	O
13	weekly	N	O
14	swallowing	N	O
15	therapy	N	O
16	sessions	N	O
17	to	N	O
18	promote	N	O
19	adherence	N	O
20	and	N	O
21	accurate	N	O
22	technique	N	O
23	.	N	O

1	Controls	N	O
2	had	N	O
3	no	N	O
4	prophylactic	N	O
5	exercises	N	O
6	and	N	O
7	were	N	O
8	referred	N	O
9	for	N	O
10	swallowing	N	O
11	treatment	N	O
12	after	N	O
13	completion	N	O
14	of	N	O
15	CRT	N	O
16	if	N	O
17	indicated	N	O
18	.	N	O

1	Swallowing	N	O
2	function	N	O
3	was	N	O
4	assessed	N	O
5	with	N	O
6	the	N	O
7	Functional	N	O
8	Oral	N	O
9	Intake	N	O
10	Scale	N	O
11	(	N	O
12	FOIS	N	O
13	)	N	O
14	and	N	O
15	the	N	O
16	Performance	N	O
17	Status	N	O
18	Scale	N	O
19	for	N	O
20	Head	N	O
21	and	N	O
22	Neck	N	O
23	Cancer	N	O
24	Patients	N	O
25	(	N	O
26	PSS-H	N	O
27	&	N	O
28	N	N	O
29	)	N	O
30	at	N	O
31	baseline	N	O
32	,	N	O
33	immediately	N	O
34	after	N	O
35	CRT	N	O
36	,	N	O
37	and	N	O
38	at	N	O
39	3	N	O
40	,	N	O
41	6	N	O
42	,	N	O
43	9	N	O
44	,	N	O
45	and	N	O
46	12	N	O
47	months	N	O
48	after	N	O
49	CRT	N	O
50	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	differences	N	I-Premise
7	in	N	I-Premise
8	FOIS	N	I-Premise
9	scores	N	I-Premise
10	between	N	I-Premise
11	intervention	N	I-Premise
12	and	N	I-Premise
13	control	N	I-Premise
14	patients	N	I-Premise
15	immediately	N	I-Premise
16	after	N	I-Premise
17	CRT	N	I-Premise
18	(	N	I-Premise
19	immediately	N	I-Premise
20	after	N	I-Premise
21	CRT	N	I-Premise
22	:	N	I-Premise
23	intervention	N	I-Premise
24	group	N	I-Premise
25	median	N	I-Premise
26	score	N	I-Premise
27	,	N	I-Premise
28	3	N	I-Premise
29	[	N	I-Premise
30	range	N	I-Premise
31	,	N	I-Premise
32	1-7	N	I-Premise
33	]	N	I-Premise
34	,	N	I-Premise
35	vs	N	I-Premise
36	median	N	I-Premise
37	control	N	I-Premise
38	score	N	I-Premise
39	,	N	I-Premise
40	4	N	I-Premise
41	[	N	I-Premise
42	range	N	I-Premise
43	,	N	I-Premise
44	1-6	N	I-Premise
45	]	N	I-Premise
46	(	N	I-Premise
47	P	N	I-Premise
48	=	N	I-Premise
49	.88	N	I-Premise
50	)	N	I-Premise
51	.	N	I-Premise

1	However	N	O
2	,	N	O
3	intervention	N	I-Premise
4	patients	N	I-Premise
5	had	N	I-Premise
6	significantly	N	I-Premise
7	better	N	I-Premise
8	scores	N	I-Premise
9	at	N	I-Premise
10	months	N	I-Premise
11	3	N	I-Premise
12	and	N	I-Premise
13	6	N	I-Premise
14	(	N	I-Premise
15	median	N	I-Premise
16	3-month	N	I-Premise
17	intervention	N	I-Premise
18	score	N	I-Premise
19	,	N	I-Premise
20	7	N	I-Premise
21	[	N	I-Premise
22	range	N	I-Premise
23	,	N	I-Premise
24	5-7	N	I-Premise
25	]	N	I-Premise
26	,	N	I-Premise
27	vs	N	I-Premise
28	median	N	I-Premise
29	control	N	I-Premise
30	score	N	I-Premise
31	,	N	I-Premise
32	5	N	I-Premise
33	[	N	I-Premise
34	range	N	I-Premise
35	,	N	I-Premise
36	3-7	N	I-Premise
37	]	N	I-Premise
38	[	N	I-Premise
39	P	N	I-Premise
40	=	N	I-Premise
41	.03	N	I-Premise
42	]	N	I-Premise
43	;	N	I-Premise
44	median	N	I-Premise
45	6-month	N	I-Premise
46	intervention	N	I-Premise
47	score	N	I-Premise
48	,	N	I-Premise
49	7	N	I-Premise
50	[	N	I-Premise
51	range	N	I-Premise
52	,	N	I-Premise
53	6-7	N	I-Premise
54	]	N	I-Premise
55	,	N	I-Premise
56	vs	N	I-Premise
57	median	N	I-Premise
58	control	N	I-Premise
59	score	N	I-Premise
60	,	N	I-Premise
61	6	N	I-Premise
62	[	N	I-Premise
63	range	N	I-Premise
64	,	N	I-Premise
65	3-7	N	I-Premise
66	]	N	I-Premise
67	[	N	I-Premise
68	P	N	I-Premise
69	=	N	I-Premise
70	.009	N	I-Premise
71	]	N	I-Premise
72	)	N	I-Premise
73	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	scores	N	I-Premise
8	at	N	I-Premise
9	months	N	I-Premise
10	9	N	I-Premise
11	and	N	I-Premise
12	12	N	I-Premise
13	(	N	I-Premise
14	P	N	I-Premise
15	=	N	I-Premise
16	.24	N	I-Premise
17	and	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	.93	N	I-Premise
21	,	N	I-Premise
22	respectively	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	The	N	I-Premise
2	same	N	I-Premise
3	pattern	N	I-Premise
4	between	N	I-Premise
5	intervention	N	I-Premise
6	and	N	I-Premise
7	control	N	I-Premise
8	patients	N	I-Premise
9	was	N	I-Premise
10	observed	N	I-Premise
11	for	N	I-Premise
12	scores	N	I-Premise
13	on	N	I-Premise
14	the	N	I-Premise
15	PSS-H	N	I-Premise
16	&	N	I-Premise
17	N	N	I-Premise
18	.	N	I-Premise

1	Patients	N	I-Claim
2	who	N	I-Claim
3	performed	N	I-Claim
4	prophylactic	N	I-Claim
5	swallowing	N	I-Claim
6	exercises	N	I-Claim
7	had	N	I-Claim
8	improved	N	I-Claim
9	swallowing	N	I-Claim
10	function	N	I-Claim
11	at	N	I-Claim
12	3	N	I-Claim
13	and	N	I-Claim
14	6	N	I-Claim
15	months	N	I-Claim
16	after	N	I-Claim
17	CRT	N	I-Claim
18	but	N	I-Claim
19	not	N	I-Claim
20	immediately	N	I-Claim
21	after	N	I-Claim
22	CRT	N	I-Claim
23	or	N	I-Claim
24	at	N	I-Claim
25	9	N	I-Claim
26	and	N	I-Claim
27	12	N	I-Claim
28	months	N	I-Claim
29	after	N	I-Claim
30	CRT	N	I-Claim
31	.	N	I-Claim

1	The	N	I-Claim
2	small	N	I-Claim
3	sample	N	I-Claim
4	size	N	I-Claim
5	may	N	I-Claim
6	have	N	I-Claim
7	limited	N	I-Claim
8	our	N	I-Claim
9	ability	N	I-Claim
10	to	N	I-Claim
11	detect	N	I-Claim
12	significant	N	I-Claim
13	differences	N	I-Claim
14	beyond	N	I-Claim
15	6	N	I-Claim
16	months	N	I-Claim
17	of	N	I-Claim
18	observation	N	I-Claim
19	as	N	I-Claim
20	well	N	I-Claim
21	as	N	I-Claim
22	additional	N	I-Claim
23	significant	N	I-Claim
24	differences	N	I-Claim
25	in	N	I-Claim
26	our	N	I-Claim
27	study	N	I-Claim
28	.	N	I-Claim

1	Patients	N	O
2	with	N	O
3	lymphoma	N	O
4	experience	N	O
5	sleep	N	O
6	problems	N	O
7	that	N	O
8	may	N	O
9	be	N	O
10	managed	N	O
11	with	N	O
12	aerobic	N	O
13	exercise	N	O
14	but	N	O
15	no	N	O
16	previous	N	O
17	study	N	O
18	has	N	O
19	examined	N	O
20	this	N	O
21	issue	N	O
22	.	N	O

1	We	N	O
2	randomized	N	O
3	122	N	O
4	patients	N	O
5	with	N	O
6	lymphoma	N	O
7	to	N	O
8	usual	N	O
9	care	N	O
10	(	N	O
11	n	N	O
12	=	N	O
13	62	N	O
14	)	N	O
15	or	N	O
16	12	N	O
17	weeks	N	O
18	of	N	O
19	supervised	N	O
20	aerobic	N	O
21	exercise	N	O
22	training	N	O
23	(	N	O
24	AET	N	O
25	;	N	O
26	n	N	O
27	=	N	O
28	60	N	O
29	)	N	O
30	.	N	O

1	Our	N	O
2	primary	N	O
3	sleep	N	O
4	endpoint	N	O
5	was	N	O
6	global	N	O
7	sleep	N	O
8	quality	N	O
9	assessed	N	O
10	by	N	O
11	the	N	O
12	Pittsburgh	N	O
13	Sleep	N	O
14	Quality	N	O
15	Index	N	O
16	(	N	O
17	PSQI	N	O
18	)	N	O
19	.	N	O

1	Secondary	N	O
2	endpoints	N	O
3	were	N	O
4	the	N	O
5	PSQI	N	O
6	component	N	O
7	scores	N	O
8	.	N	O

1	Planned	N	O
2	subgroup	N	O
3	analyses	N	O
4	were	N	O
5	also	N	O
6	conducted	N	O
7	.	N	O

1	Intention-to-treat	N	I-Premise
2	analyses	N	I-Premise
3	indicated	N	I-Premise
4	that	N	I-Premise
5	AET	N	I-Premise
6	resulted	N	I-Premise
7	in	N	I-Premise
8	a	N	I-Premise
9	nonsignificant	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	=	N	I-Premise
13	0.16	N	I-Premise
14	)	N	I-Premise
15	improvement	N	I-Premise
16	in	N	I-Premise
17	global	N	I-Premise
18	sleep	N	I-Premise
19	quality	N	I-Premise
20	compared	N	I-Premise
21	with	N	I-Premise
22	usual	N	I-Premise
23	care	N	I-Premise
24	[	N	I-Premise
25	mean	N	I-Premise
26	group	N	I-Premise
27	difference	N	I-Premise
28	=	N	I-Premise
29	-0.64	N	I-Premise
30	;	N	I-Premise
31	95	N	I-Premise
32	%	N	I-Premise
33	confidence	N	I-Premise
34	interval	N	I-Premise
35	(	N	I-Premise
36	CI	N	I-Premise
37	)	N	I-Premise
38	,	N	I-Premise
39	-1.56	N	I-Premise
40	to	N	I-Premise
41	+0.27	N	I-Premise
42	]	N	I-Premise
43	.	N	I-Premise

1	In	N	I-Premise
2	planned	N	I-Premise
3	subgroup	N	I-Premise
4	analyses	N	I-Premise
5	,	N	I-Premise
6	statistically	N	I-Premise
7	significant	N	I-Premise
8	or	N	I-Premise
9	borderline	N	I-Premise
10	significant	N	I-Premise
11	interactions	N	I-Premise
12	were	N	I-Premise
13	identified	N	I-Premise
14	for	N	I-Premise
15	type	N	I-Premise
16	of	N	I-Premise
17	lymphoma	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	(	N	I-Premise
21	interaction	N	I-Premise
22	)	N	I-Premise
23	=	N	I-Premise
24	0.006	N	I-Premise
25	)	N	I-Premise
26	,	N	I-Premise
27	current	N	I-Premise
28	treatment	N	I-Premise
29	status	N	I-Premise
30	(	N	I-Premise
31	P	N	I-Premise
32	(	N	I-Premise
33	interaction	N	I-Premise
34	)	N	I-Premise
35	=	N	I-Premise
36	0.036	N	I-Premise
37	)	N	I-Premise
38	,	N	I-Premise
39	time	N	I-Premise
40	since	N	I-Premise
41	diagnosis	N	I-Premise
42	(	N	I-Premise
43	P	N	I-Premise
44	(	N	I-Premise
45	interaction	N	I-Premise
46	)	N	I-Premise
47	=	N	I-Premise
48	0.010	N	I-Premise
49	)	N	I-Premise
50	,	N	I-Premise
51	body	N	I-Premise
52	mass	N	I-Premise
53	index	N	I-Premise
54	(	N	I-Premise
55	P	N	I-Premise
56	(	N	I-Premise
57	interaction	N	I-Premise
58	)	N	I-Premise
59	=	N	I-Premise
60	0.075	N	I-Premise
61	)	N	I-Premise
62	,	N	I-Premise
63	and	N	I-Premise
64	baseline	N	I-Premise
65	sleep	N	I-Premise
66	quality	N	I-Premise
67	(	N	I-Premise
68	P	N	I-Premise
69	(	N	I-Premise
70	interaction	N	I-Premise
71	)	N	I-Premise
72	=	N	I-Premise
73	0.041	N	I-Premise
74	)	N	I-Premise
75	.	N	I-Premise

1	Specifically	N	O
2	,	N	O
3	AET	N	I-Premise
4	improved	N	I-Premise
5	global	N	I-Premise
6	sleep	N	I-Premise
7	quality	N	I-Premise
8	in	N	I-Premise
9	patients	N	I-Premise
10	with	N	I-Premise
11	lymphoma	N	I-Premise
12	who	N	I-Premise
13	had	N	I-Premise
14	indolent	N	I-Premise
15	non-Hodgkin	N	I-Premise
16	lymphoma	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	0.001	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	were	N	I-Premise
24	receiving	N	I-Premise
25	chemotherapy	N	I-Premise
26	(	N	I-Premise
27	P	N	I-Premise
28	=	N	I-Premise
29	0.013	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	were	N	I-Premise
33	<	N	I-Premise
34	2	N	I-Premise
35	years	N	I-Premise
36	post-diagnosis	N	I-Premise
37	(	N	I-Premise
38	P	N	I-Premise
39	=	N	I-Premise
40	0.005	N	I-Premise
41	)	N	I-Premise
42	,	N	I-Premise
43	were	N	I-Premise
44	obese	N	I-Premise
45	(	N	I-Premise
46	P	N	I-Premise
47	=	N	I-Premise
48	0.025	N	I-Premise
49	)	N	I-Premise
50	,	N	I-Premise
51	and	N	I-Premise
52	were	N	I-Premise
53	poor	N	I-Premise
54	sleepers	N	I-Premise
55	at	N	I-Premise
56	baseline	N	I-Premise
57	(	N	I-Premise
58	P	N	I-Premise
59	=	N	I-Premise
60	0.007	N	I-Premise
61	)	N	I-Premise
62	.	N	I-Premise

1	AET	N	I-Claim
2	did	N	I-Claim
3	not	N	I-Claim
4	significantly	N	I-Claim
5	improve	N	I-Claim
6	sleep	N	I-Claim
7	quality	N	I-Claim
8	in	N	I-Claim
9	this	N	I-Claim
10	heterogeneous	N	I-Claim
11	sample	N	I-Claim
12	of	N	I-Claim
13	patients	N	I-Claim
14	with	N	I-Claim
15	lymphoma	N	I-Claim
16	;	N	I-Claim
17	however	N	I-Claim
18	,	N	I-Claim
19	clinically	N	I-Claim
20	identifiable	N	I-Claim
21	subgroups	N	I-Claim
22	appeared	N	I-Claim
23	to	N	I-Claim
24	benefit	N	I-Claim
25	.	N	I-Claim

1	Future	N	O
2	exercise	N	O
3	trials	N	O
4	targeting	N	O
5	these	N	O
6	responsive	N	O
7	subgroups	N	O
8	are	N	O
9	needed	N	O
10	to	N	O
11	confirm	N	O
12	these	N	O
13	findings	N	O
14	.	N	O

1	If	N	O
2	replicated	N	O
3	in	N	O
4	larger	N	O
5	and	N	O
6	more	N	O
7	focused	N	O
8	trials	N	O
9	,	N	O
10	aerobic	N	O
11	exercise	N	O
12	may	N	O
13	be	N	O
14	an	N	O
15	attractive	N	O
16	option	N	O
17	to	N	O
18	manage	N	O
19	sleep	N	O
20	dysfunction	N	O
21	in	N	O
22	patients	N	O
23	with	N	O
24	cancer	N	O
25	because	N	O
26	of	N	O
27	its	N	O
28	favorable	N	O
29	safety	N	O
30	profile	N	O
31	and	N	O
32	other	N	O
33	documented	N	O
34	health	N	O
35	benefits	N	O
36	.	N	O

1	Treosulfan	N	O
2	,	N	O
3	an	N	O
4	alkylating	N	O
5	agent	N	O
6	,	N	O
7	has	N	O
8	demonstrated	N	O
9	activity	N	O
10	in	N	O
11	recurrent	N	O
12	ovarian	N	O
13	carcinoma	N	O
14	.	N	O

1	It	N	O
2	is	N	O
3	equieffective	N	O
4	as	N	O
5	oral	N	O
6	(	N	O
7	p.o	N	O
8	.	N	O

1	)	N	O
2	and	N	O
3	intravenous	N	O
4	(	N	O
5	i.v	N	O
6	.	N	O

1	)	N	O
2	formulation	N	O
3	.	N	O

1	To	N	O
2	explore	N	O
3	the	N	O
4	preference	N	O
5	and	N	O
6	compliance	N	O
7	of	N	O
8	elderly	N	O
9	patients	N	O
10	regarding	N	O
11	p.o	N	O
12	.	N	O

1	or	N	O
2	i.v	N	O
3	.	N	O

1	treosulfan	N	O
2	for	N	O
3	the	N	O
4	treatment	N	O
5	of	N	O
6	relapsed	N	O
7	ovarian	N	O
8	carcinoma	N	O
9	,	N	O
10	women	N	O
11	aged	N	O
12	65	N	O
13	years	N	O
14	or	N	O
15	older	N	O
16	were	N	O
17	included	N	O
18	in	N	O
19	this	N	O
20	prospective	N	O
21	multicenter	N	O
22	study	N	O
23	.	N	O

1	Since	N	O
2	elderly	N	O
3	patients	N	O
4	usually	N	O
5	have	N	O
6	several	N	O
7	concomitant	N	O
8	diseases	N	O
9	and	N	O
10	experience	N	O
11	more	N	O
12	treatment	N	O
13	toxicity	N	O
14	,	N	O
15	an	N	O
16	interim	N	O
17	safety	N	O
18	analysis	N	O
19	was	N	O
20	planned	N	O
21	and	N	O
22	performed	N	O
23	after	N	O
24	25	N	O
25	patients	N	O
26	finished	N	O
27	therapy	N	O
28	to	N	O
29	assess	N	O
30	the	N	O
31	tolerability	N	O
32	of	N	O
33	the	N	O
34	treatment	N	O
35	regimens	N	O
36	.	N	O

1	Patients	N	O
2	had	N	O
3	a	N	O
4	free	N	O
5	choice	N	O
6	of	N	O
7	treosulfan	N	O
8	i.v	N	O
9	.	N	O

1	(	N	O
2	7,000	N	O
3	mg/m	N	O
4	(	N	O
5	2	N	O
6	)	N	O
7	day	N	O
8	1	N	O
9	of	N	O
10	a	N	O
11	28-day	N	O
12	cycle	N	O
13	)	N	O
14	or	N	O
15	p.o	N	O
16	.	N	O

1	(	N	O
2	600	N	O
3	mg/m	N	O
4	(	N	O
5	2	N	O
6	)	N	O
7	day	N	O
8	1-28	N	O
9	of	N	O
10	a	N	O
11	56-day	N	O
12	cycle	N	O
13	)	N	O
14	for	N	O
15	a	N	O
16	maximum	N	O
17	of	N	O
18	12	N	O
19	cycles	N	O
20	(	N	O
21	i.v	N	O
22	.	N	O

1	)	N	O
2	or	N	O
3	12	N	O
4	months	N	O
5	(	N	O
6	p.o.	N	O
7	)	N	O
8	.	N	O

1	Indecisive	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	.	N	O

1	Toxicity	N	O
2	was	N	O
3	evaluated	N	O
4	according	N	O
5	to	N	O
6	the	N	O
7	NCI-CTC	N	O
8	version	N	O
9	2.0	N	O
10	.	N	O

1	Twenty-five	N	O
2	of	N	O
3	51	N	O
4	recruited	N	O
5	patients	N	O
6	completed	N	O
7	therapy	N	O
8	at	N	O
9	the	N	O
10	time	N	O
11	of	N	O
12	the	N	O
13	planned	N	O
14	interim	N	O
15	analysis	N	O
16	(	N	O
17	median	N	O
18	age	N	O
19	,	N	O
20	75	N	O
21	years	N	O
22	;	N	O
23	range	N	O
24	,	N	O
25	70-82	N	O
26	)	N	O
27	.	N	O

1	Median	N	O
2	ECOG	N	O
3	was	N	O
4	1	N	O
5	,	N	O
6	and	N	O
7	median	N	O
8	number	N	O
9	of	N	O
10	prior	N	O
11	chemotherapy	N	O
12	regimens	N	O
13	was	N	O
14	2	N	O
15	.	N	O

1	A	N	O
2	median	N	O
3	number	N	O
4	of	N	O
5	4	N	O
6	cycles	N	O
7	(	N	O
8	range	N	O
9	,	N	O
10	1-12	N	O
11	)	N	O
12	were	N	O
13	administered	N	O
14	per	N	O
15	patient	N	O
16	.	N	O

1	Anemia	N	I-Premise
2	was	N	I-Premise
3	the	N	I-Premise
4	most	N	I-Premise
5	common	N	I-Premise
6	hematological	N	I-Premise
7	toxicity	N	I-Premise
8	(	N	I-Premise
9	88	N	I-Premise
10	%	N	I-Premise
11	of	N	I-Premise
12	patients	N	I-Premise
13	)	N	I-Premise
14	.	N	I-Premise

1	Most	N	I-Premise
2	frequent	N	I-Premise
3	non-hematological	N	I-Premise
4	toxicities	N	I-Premise
5	were	N	I-Premise
6	nausea	N	I-Premise
7	(	N	I-Premise
8	76	N	I-Premise
9	%	N	I-Premise
10	)	N	I-Premise
11	,	N	I-Premise
12	constipation	N	I-Premise
13	(	N	I-Premise
14	68	N	I-Premise
15	%	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	and	N	I-Premise
19	fatigue	N	I-Premise
20	(	N	I-Premise
21	64	N	I-Premise
22	%	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Treatment	N	I-Claim
2	was	N	I-Claim
3	generally	N	I-Claim
4	well	N	I-Claim
5	tolerated	N	I-Claim
6	despite	N	I-Claim
7	the	N	I-Claim
8	fact	N	I-Claim
9	that	N	I-Claim
10	most	N	I-Claim
11	patients	N	I-Claim
12	suffered	N	I-Claim
13	from	N	I-Claim
14	multiple	N	I-Claim
15	comorbidities	N	I-Claim
16	and	N	I-Claim
17	were	N	I-Claim
18	heavily	N	I-Claim
19	pretreated	N	I-Claim
20	.	N	I-Claim

1	There	N	I-Claim
2	were	N	I-Claim
3	no	N	I-Claim
4	unexpected	N	I-Claim
5	hematological	N	I-Claim
6	or	N	I-Claim
7	non-hematological	N	I-Claim
8	toxicities	N	I-Claim
9	.	N	I-Claim

1	Based	N	O
2	on	N	O
3	this	N	O
4	safety	N	O
5	analysis	N	O
6	,	N	O
7	the	N	O
8	next	N	O
9	step	N	O
10	of	N	O
11	study	N	O
12	recruitment	N	O
13	was	N	O
14	continued	N	O
15	.	N	O

1	This	N	O
2	study	N	O
3	examined	N	O
4	whether	N	O
5	changes	N	O
6	in	N	O
7	self-efficacy	N	O
8	explain	N	O
9	the	N	O
10	effects	N	O
11	of	N	O
12	a	N	O
13	mailed	N	O
14	print	N	O
15	intervention	N	O
16	on	N	O
17	long-term	N	O
18	dietary	N	O
19	practices	N	O
20	of	N	O
21	breast	N	O
22	and	N	O
23	prostate	N	O
24	cancer	N	O
25	survivors	N	O
26	.	N	O

1	The	N	O
2	relationship	N	O
3	between	N	O
4	change	N	O
5	in	N	O
6	self-efficacy	N	O
7	and	N	O
8	long-term	N	O
9	physical	N	O
10	activity	N	O
11	(	N	O
12	PA	N	O
13	)	N	O
14	also	N	O
15	was	N	O
16	examined	N	O
17	.	N	O

1	Breast	N	O
2	and	N	O
3	prostate	N	O
4	cancer	N	O
5	survivors	N	O
6	(	N	O
7	N	N	O
8	=	N	O
9	543	N	O
10	)	N	O
11	from	N	O
12	39	N	O
13	US	N	O
14	states	N	O
15	and	N	O
16	two	N	O
17	Canadian	N	O
18	provinces	N	O
19	participated	N	O
20	in	N	O
21	the	N	O
22	FRESH	N	O
23	START	N	O
24	intervention	N	O
25	trial	N	O
26	.	N	O

1	Participants	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	receive	N	O
7	a	N	O
8	10-month	N	O
9	program	N	O
10	of	N	O
11	mailed	N	O
12	print	N	O
13	materials	N	O
14	on	N	O
15	diet	N	O
16	and	N	O
17	PA	N	O
18	available	N	O
19	in	N	O
20	the	N	O
21	public	N	O
22	domain	N	O
23	or	N	O
24	a	N	O
25	10-month	N	O
26	program	N	O
27	of	N	O
28	tailored	N	O
29	materials	N	O
30	designed	N	O
31	to	N	O
32	increase	N	O
33	fruit	N	O
34	and	N	O
35	vegetable	N	O
36	(	N	O
37	F	N	O
38	&	N	O
39	V	N	O
40	)	N	O
41	intake	N	O
42	,	N	O
43	decrease	N	O
44	fat	N	O
45	intake	N	O
46	,	N	O
47	and/or	N	O
48	increase	N	O
49	PA.	N	O
50	Changes	N	O
51	in	N	O
52	self-efficacy	N	O
53	for	N	O
54	F	N	O
55	&	N	O
56	V	N	O
57	intake	N	O
58	and	N	O
59	fat	N	O
60	restriction	N	O
61	were	N	O
62	analyzed	N	O
63	as	N	O
64	potential	N	O
65	mediators	N	O
66	of	N	O
67	the	N	O
68	intervention	N	O
69	's	N	O
70	effects	N	O
71	on	N	O
72	diet	N	O
73	at	N	O
74	2-year	N	O
75	follow-up	N	O
76	.	N	O

1	Because	N	O
2	we	N	O
3	previously	N	O
4	found	N	O
5	that	N	O
6	change	N	O
7	in	N	O
8	self-efficacy	N	O
9	for	N	O
10	PA	N	O
11	did	N	O
12	not	N	O
13	vary	N	O
14	by	N	O
15	group	N	O
16	assignment	N	O
17	,	N	O
18	the	N	O
19	relationship	N	O
20	between	N	O
21	change	N	O
22	in	N	O
23	self-efficacy	N	O
24	and	N	O
25	PA	N	O
26	at	N	O
27	2-year	N	O
28	follow-up	N	O
29	was	N	O
30	examined	N	O
31	across	N	O
32	study	N	O
33	conditions	N	O
34	.	N	O

1	Results	N	I-Claim
2	suggest	N	I-Claim
3	that	N	I-Claim
4	change	N	I-Claim
5	in	N	I-Claim
6	self-efficacy	N	I-Claim
7	for	N	I-Claim
8	fat	N	I-Claim
9	restriction	N	I-Claim
10	partially	N	I-Claim
11	explained	N	I-Claim
12	the	N	I-Claim
13	intervention	N	I-Claim
14	's	N	I-Claim
15	effect	N	I-Claim
16	on	N	I-Claim
17	fat	N	I-Claim
18	intake	N	I-Claim
19	(	N	I-Claim
20	mean	N	I-Claim
21	indirect	N	I-Claim
22	effect	N	I-Claim
23	=	N	I-Claim
24	-0.28	N	I-Claim
25	)	N	I-Claim
26	,	N	I-Claim
27	and	N	I-Claim
28	change	N	I-Claim
29	in	N	I-Claim
30	self-efficacy	N	I-Claim
31	for	N	I-Claim
32	F	N	I-Claim
33	&	N	I-Claim
34	V	N	I-Claim
35	consumption	N	I-Claim
36	partially	N	I-Claim
37	explained	N	I-Claim
38	the	N	I-Claim
39	intervention	N	I-Claim
40	's	N	I-Claim
41	effect	N	I-Claim
42	on	N	I-Claim
43	daily	N	I-Claim
44	F	N	I-Claim
45	&	N	I-Claim
46	V	N	I-Claim
47	intake	N	I-Claim
48	(	N	I-Claim
49	mean	N	I-Claim
50	indirect	N	I-Claim
51	effect	N	I-Claim
52	=	N	I-Claim
53	.11	N	I-Claim
54	)	N	I-Claim
55	.	N	I-Claim

1	Change	N	I-Premise
2	in	N	I-Premise
3	self-efficacy	N	I-Premise
4	for	N	I-Premise
5	fat	N	I-Premise
6	restriction	N	I-Premise
7	partially	N	I-Premise
8	accounted	N	I-Premise
9	for	N	I-Premise
10	the	N	I-Premise
11	intervention	N	I-Premise
12	's	N	I-Premise
13	impact	N	I-Premise
14	on	N	I-Premise
15	overall	N	I-Premise
16	diet	N	I-Premise
17	quality	N	I-Premise
18	among	N	I-Premise
19	men	N	I-Premise
20	only	N	I-Premise
21	(	N	I-Premise
22	mean	N	I-Premise
23	indirect	N	I-Premise
24	effect	N	I-Premise
25	=	N	I-Premise
26	0.60	N	I-Premise
27	)	N	I-Premise
28	.	N	I-Premise

1	Finally	N	O
2	,	N	O
3	change	N	O
4	in	N	O
5	self-efficacy	N	O
6	for	N	O
7	PA	N	O
8	predicted	N	O
9	PA	N	O
10	at	N	O
11	2-year	N	O
12	follow-up	N	O
13	.	N	O

1	Findings	N	I-Claim
2	suggest	N	I-Claim
3	that	N	I-Claim
4	self-efficacy	N	I-Claim
5	may	N	I-Claim
6	influence	N	I-Claim
7	long-term	N	I-Claim
8	maintenance	N	I-Claim
9	of	N	I-Claim
10	healthy	N	I-Claim
11	lifestyle	N	I-Claim
12	practices	N	I-Claim
13	among	N	I-Claim
14	cancer	N	I-Claim
15	survivors	N	I-Claim
16	.	N	I-Claim

1	It	N	O
2	is	N	O
3	not	N	O
4	clear	N	O
5	whether	N	O
6	the	N	O
7	administration	N	O
8	of	N	O
9	radioiodine	N	O
10	provides	N	O
11	any	N	O
12	benefit	N	O
13	to	N	O
14	patients	N	O
15	with	N	O
16	low-risk	N	O
17	thyroid	N	O
18	cancer	N	O
19	after	N	O
20	a	N	O
21	complete	N	O
22	surgical	N	O
23	resection	N	O
24	.	N	O

1	The	N	O
2	administration	N	O
3	of	N	O
4	the	N	O
5	smallest	N	O
6	possible	N	O
7	amount	N	O
8	of	N	O
9	radioiodine	N	O
10	would	N	O
11	improve	N	O
12	care	N	O
13	.	N	O

1	In	N	O
2	our	N	O
3	randomized	N	O
4	,	N	O
5	phase	N	O
6	3	N	O
7	trial	N	O
8	,	N	O
9	we	N	O
10	compared	N	O
11	two	N	O
12	thyrotropin-stimulation	N	O
13	methods	N	O
14	(	N	O
15	thyroid	N	O
16	hormone	N	O
17	withdrawal	N	O
18	and	N	O
19	use	N	O
20	of	N	O
21	recombinant	N	O
22	human	N	O
23	thyrotropin	N	O
24	)	N	O
25	and	N	O
26	two	N	O
27	radioiodine	N	O
28	(	N	O
29	(	N	O
30	131	N	O
31	)	N	O
32	I	N	O
33	)	N	O
34	doses	N	O
35	(	N	O
36	i.e.	N	O
37	,	N	O
38	administered	N	O
39	activities	N	O
40	)	N	O
41	(	N	O
42	1.1	N	O
43	GBq	N	O
44	and	N	O
45	3.7	N	O
46	GBq	N	O
47	)	N	O
48	in	N	O
49	a	N	O
50	2-by-2	N	O
51	design	N	O
52	.	N	O

1	Inclusion	N	O
2	criteria	N	O
3	were	N	O
4	an	N	O
5	age	N	O
6	of	N	O
7	18	N	O
8	years	N	O
9	or	N	O
10	older	N	O
11	;	N	O
12	total	N	O
13	thyroidectomy	N	O
14	for	N	O
15	differentiated	N	O
16	thyroid	N	O
17	carcinoma	N	O
18	;	N	O
19	tumor-node-metastasis	N	O
20	(	N	O
21	TNM	N	O
22	)	N	O
23	stage	N	O
24	,	N	O
25	ascertained	N	O
26	on	N	O
27	pathological	N	O
28	examination	N	O
29	(	N	O
30	p	N	O
31	)	N	O
32	of	N	O
33	a	N	O
34	surgical	N	O
35	specimen	N	O
36	,	N	O
37	of	N	O
38	pT1	N	O
39	(	N	O
40	with	N	O
41	tumor	N	O
42	diameter	N	O
43	≤1	N	O
44	cm	N	O
45	)	N	O
46	and	N	O
47	N1	N	O
48	or	N	O
49	Nx	N	O
50	,	N	O
51	pT1	N	O
52	(	N	O
53	with	N	O
54	tumor	N	O
55	diameter	N	O
56	>	N	O
57	1	N	O
58	to	N	O
59	2	N	O
60	cm	N	O
61	)	N	O
62	and	N	O
63	any	N	O
64	N	N	O
65	stage	N	O
66	,	N	O
67	or	N	O
68	pT2N0	N	O
69	;	N	O
70	absence	N	O
71	of	N	O
72	distant	N	O
73	metastasis	N	O
74	;	N	O
75	and	N	O
76	no	N	O
77	iodine	N	O
78	contamination	N	O
79	.	N	O

1	Thyroid	N	O
2	ablation	N	O
3	was	N	O
4	assessed	N	O
5	8	N	O
6	months	N	O
7	after	N	O
8	radioiodine	N	O
9	administration	N	O
10	by	N	O
11	neck	N	O
12	ultrasonography	N	O
13	and	N	O
14	measurement	N	O
15	of	N	O
16	recombinant	N	O
17	human	N	O
18	thyrotropin-stimulated	N	O
19	thyroglobulin	N	O
20	.	N	O

1	Comparisons	N	O
2	were	N	O
3	based	N	O
4	on	N	O
5	an	N	O
6	equivalence	N	O
7	framework	N	O
8	.	N	O

1	There	N	O
2	were	N	O
3	752	N	O
4	patients	N	O
5	enrolled	N	O
6	between	N	O
7	2007	N	O
8	and	N	O
9	2010	N	O
10	;	N	O
11	92	N	O
12	%	N	O
13	had	N	O
14	papillary	N	O
15	cancer	N	O
16	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	unexpected	N	I-Premise
5	serious	N	I-Premise
6	adverse	N	I-Premise
7	events	N	I-Premise
8	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	684	N	I-Premise
4	patients	N	I-Premise
5	with	N	I-Premise
6	data	N	I-Premise
7	that	N	I-Premise
8	could	N	I-Premise
9	be	N	I-Premise
10	evaluated	N	I-Premise
11	,	N	I-Premise
12	ultrasonography	N	I-Premise
13	of	N	I-Premise
14	the	N	I-Premise
15	neck	N	I-Premise
16	was	N	I-Premise
17	normal	N	I-Premise
18	in	N	I-Premise
19	652	N	I-Premise
20	(	N	I-Premise
21	95	N	I-Premise
22	%	N	I-Premise
23	)	N	I-Premise
24	,	N	I-Premise
25	and	N	I-Premise
26	the	N	I-Premise
27	stimulated	N	I-Premise
28	thyroglobulin	N	I-Premise
29	level	N	I-Premise
30	was	N	I-Premise
31	1.0	N	I-Premise
32	ng	N	I-Premise
33	per	N	I-Premise
34	milliliter	N	I-Premise
35	or	N	I-Premise
36	less	N	I-Premise
37	in	N	I-Premise
38	621	N	I-Premise
39	of	N	I-Premise
40	the	N	I-Premise
41	652	N	I-Premise
42	patients	N	I-Premise
43	(	N	I-Premise
44	95	N	I-Premise
45	%	N	I-Premise
46	)	N	I-Premise
47	without	N	I-Premise
48	detectable	N	I-Premise
49	thyroglobulin	N	I-Premise
50	antibodies	N	I-Premise
51	.	N	I-Premise

1	Thyroid	N	I-Premise
2	ablation	N	I-Premise
3	was	N	I-Premise
4	complete	N	I-Premise
5	in	N	I-Premise
6	631	N	I-Premise
7	of	N	I-Premise
8	the	N	I-Premise
9	684	N	I-Premise
10	patients	N	I-Premise
11	(	N	I-Premise
12	92	N	I-Premise
13	%	N	I-Premise
14	)	N	I-Premise
15	.	N	I-Premise

1	The	N	I-Premise
2	ablation	N	I-Premise
3	rate	N	I-Premise
4	was	N	I-Premise
5	equivalent	N	I-Premise
6	between	N	I-Premise
7	the	N	I-Premise
8	(	N	I-Premise
9	131	N	I-Premise
10	)	N	I-Premise
11	I	N	I-Premise
12	doses	N	I-Premise
13	and	N	I-Premise
14	between	N	I-Premise
15	the	N	I-Premise
16	thyrotropin-stimulation	N	I-Premise
17	methods	N	I-Premise
18	.	N	I-Premise

1	The	N	I-Claim
2	use	N	I-Claim
3	of	N	I-Claim
4	recombinant	N	I-Claim
5	human	N	I-Claim
6	thyrotropin	N	I-Claim
7	and	N	I-Claim
8	low-dose	N	I-Claim
9	(	N	I-Claim
10	1.1	N	I-Claim
11	GBq	N	I-Claim
12	)	N	I-Claim
13	postoperative	N	I-Claim
14	radioiodine	N	I-Claim
15	ablation	N	I-Claim
16	may	N	I-Claim
17	be	N	I-Claim
18	sufficient	N	I-Claim
19	for	N	I-Claim
20	the	N	I-Claim
21	management	N	I-Claim
22	of	N	I-Claim
23	low-risk	N	I-Claim
24	thyroid	N	I-Claim
25	cancer	N	I-Claim
26	.	N	I-Claim

1	It	N	O
2	is	N	O
3	not	N	O
4	known	N	O
5	whether	N	O
6	low-dose	N	O
7	radioiodine	N	O
8	(	N	O
9	1.1	N	O
10	GBq	N	O
11	[	N	O
12	30	N	O
13	mCi	N	O
14	]	N	O
15	)	N	O
16	is	N	O
17	as	N	O
18	effective	N	O
19	as	N	O
20	high-dose	N	O
21	radioiodine	N	O
22	(	N	O
23	3.7	N	O
24	GBq	N	O
25	[	N	O
26	100	N	O
27	mCi	N	O
28	]	N	O
29	)	N	O
30	for	N	O
31	treating	N	O
32	patients	N	O
33	with	N	O
34	differentiated	N	O
35	thyroid	N	O
36	cancer	N	O
37	or	N	O
38	whether	N	O
39	the	N	O
40	effects	N	O
41	of	N	O
42	radioiodine	N	O
43	(	N	O
44	especially	N	O
45	at	N	O
46	a	N	O
47	low	N	O
48	dose	N	O
49	)	N	O
50	are	N	O
51	influenced	N	O
52	by	N	O
53	using	N	O
54	either	N	O
55	recombinant	N	O
56	human	N	O
57	thyrotropin	N	O
58	(	N	O
59	thyrotropin	N	O
60	alfa	N	O
61	)	N	O
62	or	N	O
63	thyroid	N	O
64	hormone	N	O
65	withdrawal	N	O
66	.	N	O

1	At	N	O
2	29	N	O
3	centers	N	O
4	in	N	O
5	the	N	O
6	United	N	O
7	Kingdom	N	O
8	,	N	O
9	we	N	O
10	conducted	N	O
11	a	N	O
12	randomized	N	O
13	noninferiority	N	O
14	trial	N	O
15	comparing	N	O
16	low-dose	N	O
17	and	N	O
18	high-dose	N	O
19	radioiodine	N	O
20	,	N	O
21	each	N	O
22	in	N	O
23	combination	N	O
24	with	N	O
25	either	N	O
26	thyrotropin	N	O
27	alfa	N	O
28	or	N	O
29	thyroid	N	O
30	hormone	N	O
31	withdrawal	N	O
32	before	N	O
33	ablation	N	O
34	.	N	O

1	Patients	N	O
2	(	N	O
3	age	N	O
4	range	N	O
5	,	N	O
6	16	N	O
7	to	N	O
8	80	N	O
9	years	N	O
10	)	N	O
11	had	N	O
12	tumor	N	O
13	stage	N	O
14	T1	N	O
15	to	N	O
16	T3	N	O
17	,	N	O
18	with	N	O
19	possible	N	O
20	spread	N	O
21	to	N	O
22	nearby	N	O
23	lymph	N	O
24	nodes	N	O
25	but	N	O
26	without	N	O
27	metastasis	N	O
28	.	N	O

1	End	N	O
2	points	N	O
3	were	N	O
4	the	N	O
5	rate	N	O
6	of	N	O
7	success	N	O
8	of	N	O
9	ablation	N	O
10	at	N	O
11	6	N	O
12	to	N	O
13	9	N	O
14	months	N	O
15	,	N	O
16	adverse	N	O
17	events	N	O
18	,	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	,	N	O
23	and	N	O
24	length	N	O
25	of	N	O
26	hospital	N	O
27	stay	N	O
28	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	438	N	O
5	patients	N	O
6	underwent	N	O
7	randomization	N	O
8	;	N	O
9	data	N	O
10	could	N	O
11	be	N	O
12	analyzed	N	O
13	for	N	O
14	421	N	O
15	.	N	O

1	Ablation	N	I-Premise
2	success	N	I-Premise
3	rates	N	I-Premise
4	were	N	I-Premise
5	85.0	N	I-Premise
6	%	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	group	N	I-Premise
10	receiving	N	I-Premise
11	low-dose	N	I-Premise
12	radioiodine	N	I-Premise
13	versus	N	I-Premise
14	88.9	N	I-Premise
15	%	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	group	N	I-Premise
19	receiving	N	I-Premise
20	the	N	I-Premise
21	high	N	I-Premise
22	dose	N	I-Premise
23	and	N	I-Premise
24	87.1	N	I-Premise
25	%	N	I-Premise
26	in	N	I-Premise
27	the	N	I-Premise
28	thyrotropin	N	I-Premise
29	alfa	N	I-Premise
30	group	N	I-Premise
31	versus	N	I-Premise
32	86.7	N	I-Premise
33	%	N	I-Premise
34	in	N	I-Premise
35	the	N	I-Premise
36	group	N	I-Premise
37	undergoing	N	I-Premise
38	thyroid	N	I-Premise
39	hormone	N	I-Premise
40	withdrawal	N	I-Premise
41	.	N	I-Premise

1	All	N	I-Premise
2	95	N	I-Premise
3	%	N	I-Premise
4	confidence	N	I-Premise
5	intervals	N	I-Premise
6	for	N	I-Premise
7	the	N	I-Premise
8	differences	N	I-Premise
9	were	N	I-Premise
10	within	N	I-Premise
11	±10	N	I-Premise
12	percentage	N	I-Premise
13	points	N	I-Premise
14	,	N	I-Premise
15	indicating	N	I-Premise
16	noninferiority	N	I-Premise
17	.	N	I-Premise

1	Similar	N	I-Premise
2	results	N	I-Premise
3	were	N	I-Premise
4	found	N	I-Premise
5	for	N	I-Premise
6	low-dose	N	I-Premise
7	radioiodine	N	I-Premise
8	plus	N	I-Premise
9	thyrotropin	N	I-Premise
10	alfa	N	I-Premise
11	(	N	I-Premise
12	84.3	N	I-Premise
13	%	N	I-Premise
14	)	N	I-Premise
15	versus	N	I-Premise
16	high-dose	N	I-Premise
17	radioiodine	N	I-Premise
18	plus	N	I-Premise
19	thyroid	N	I-Premise
20	hormone	N	I-Premise
21	withdrawal	N	I-Premise
22	(	N	I-Premise
23	87.6	N	I-Premise
24	%	N	I-Premise
25	)	N	I-Premise
26	or	N	I-Premise
27	high-dose	N	I-Premise
28	radioiodine	N	I-Premise
29	plus	N	I-Premise
30	thyrotropin	N	I-Premise
31	alfa	N	I-Premise
32	(	N	I-Premise
33	90.2	N	I-Premise
34	%	N	I-Premise
35	)	N	I-Premise
36	.	N	I-Premise

1	More	N	I-Premise
2	patients	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	high-dose	N	I-Premise
6	group	N	I-Premise
7	than	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	low-dose	N	I-Premise
11	group	N	I-Premise
12	were	N	I-Premise
13	hospitalized	N	I-Premise
14	for	N	I-Premise
15	at	N	I-Premise
16	least	N	I-Premise
17	3	N	I-Premise
18	days	N	I-Premise
19	(	N	I-Premise
20	36.3	N	I-Premise
21	%	N	I-Premise
22	vs.	N	I-Premise
23	13.0	N	I-Premise
24	%	N	I-Premise
25	,	N	I-Premise
26	P	N	I-Premise
27	<	N	I-Premise
28	0.001	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Premise
2	proportions	N	I-Premise
3	of	N	I-Premise
4	patients	N	I-Premise
5	with	N	I-Premise
6	adverse	N	I-Premise
7	events	N	I-Premise
8	were	N	I-Premise
9	21	N	I-Premise
10	%	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	low-dose	N	I-Premise
14	group	N	I-Premise
15	versus	N	I-Premise
16	33	N	I-Premise
17	%	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	high-dose	N	I-Premise
21	group	N	I-Premise
22	(	N	I-Premise
23	P=0.007	N	I-Premise
24	)	N	I-Premise
25	and	N	I-Premise
26	23	N	I-Premise
27	%	N	I-Premise
28	in	N	I-Premise
29	the	N	I-Premise
30	thyrotropin	N	I-Premise
31	alfa	N	I-Premise
32	group	N	I-Premise
33	versus	N	I-Premise
34	30	N	I-Premise
35	%	N	I-Premise
36	in	N	I-Premise
37	the	N	I-Premise
38	group	N	I-Premise
39	undergoing	N	I-Premise
40	thyroid	N	I-Premise
41	hormone	N	I-Premise
42	withdrawal	N	I-Premise
43	(	N	I-Premise
44	P=0.11	N	I-Premise
45	)	N	I-Premise
46	.	N	I-Premise

1	Low-dose	N	I-Claim
2	radioiodine	N	I-Claim
3	plus	N	I-Claim
4	thyrotropin	N	I-Claim
5	alfa	N	I-Claim
6	was	N	I-Claim
7	as	N	I-Claim
8	effective	N	I-Claim
9	as	N	I-Claim
10	high-dose	N	I-Claim
11	radioiodine	N	I-Claim
12	,	N	I-Claim
13	with	N	I-Claim
14	a	N	I-Claim
15	lower	N	I-Claim
16	rate	N	I-Claim
17	of	N	I-Claim
18	adverse	N	I-Claim
19	events	N	I-Claim
20	.	N	I-Claim

1	Surgical	N	O
2	resection	N	O
3	is	N	O
4	regarded	N	O
5	as	N	O
6	the	N	O
7	only	N	O
8	curative	N	O
9	option	N	O
10	for	N	O
11	resectable	N	O
12	oesophageal	N	O
13	cancer	N	O
14	,	N	O
15	but	N	O
16	pulmonary	N	O
17	complications	N	O
18	occurring	N	O
19	in	N	O
20	more	N	O
21	than	N	O
22	half	N	O
23	of	N	O
24	patients	N	O
25	after	N	O
26	open	N	O
27	oesophagectomy	N	O
28	are	N	O
29	a	N	O
30	great	N	O
31	concern	N	O
32	.	N	O

1	We	N	O
2	assessed	N	O
3	whether	N	O
4	minimally	N	O
5	invasive	N	O
6	oesophagectomy	N	O
7	reduces	N	O
8	morbidity	N	O
9	compared	N	O
10	with	N	O
11	open	N	O
12	oesophagectomy	N	O
13	.	N	O

1	We	N	O
2	did	N	O
3	a	N	O
4	multicentre	N	O
5	,	N	O
6	open-label	N	O
7	,	N	O
8	randomised	N	O
9	controlled	N	O
10	trial	N	O
11	at	N	O
12	five	N	O
13	study	N	O
14	centres	N	O
15	in	N	O
16	three	N	O
17	countries	N	O
18	between	N	O
19	June	N	O
20	1	N	O
21	,	N	O
22	2009	N	O
23	,	N	O
24	and	N	O
25	March	N	O
26	31	N	O
27	,	N	O
28	2011	N	O
29	.	N	O

1	Patients	N	O
2	aged	N	O
3	18-75	N	O
4	years	N	O
5	with	N	O
6	resectable	N	O
7	cancer	N	O
8	of	N	O
9	the	N	O
10	oesophagus	N	O
11	or	N	O
12	gastro-oesophageal	N	O
13	junction	N	O
14	were	N	O
15	randomly	N	O
16	assigned	N	O
17	via	N	O
18	a	N	O
19	computer-generated	N	O
20	randomisation	N	O
21	sequence	N	O
22	to	N	O
23	receive	N	O
24	either	N	O
25	open	N	O
26	transthoracic	N	O
27	or	N	O
28	minimally	N	O
29	invasive	N	O
30	transthoracic	N	O
31	oesophagectomy	N	O
32	.	N	O

1	Randomisation	N	O
2	was	N	O
3	stratified	N	O
4	by	N	O
5	centre	N	O
6	.	N	O

1	Patients	N	O
2	,	N	O
3	and	N	O
4	investigators	N	O
5	undertaking	N	O
6	interventions	N	O
7	,	N	O
8	assessing	N	O
9	outcomes	N	O
10	,	N	O
11	and	N	O
12	analysing	N	O
13	data	N	O
14	,	N	O
15	were	N	O
16	not	N	O
17	masked	N	O
18	to	N	O
19	group	N	O
20	assignment	N	O
21	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	pulmonary	N	O
6	infection	N	O
7	within	N	O
8	the	N	O
9	first	N	O
10	2	N	O
11	weeks	N	O
12	after	N	O
13	surgery	N	O
14	and	N	O
15	during	N	O
16	the	N	O
17	whole	N	O
18	stay	N	O
19	in	N	O
20	hospital	N	O
21	.	N	O

1	Analysis	N	O
2	was	N	O
3	by	N	O
4	intention	N	O
5	to	N	O
6	treat	N	O
7	.	N	O

1	This	N	O
2	trial	N	O
3	is	N	O
4	registered	N	O
5	with	N	O
6	the	N	O
7	Netherlands	N	O
8	Trial	N	O
9	Register	N	O
10	,	N	O
11	NTR	N	O
12	TC	N	O
13	2452	N	O
14	.	N	O

1	We	N	O
2	randomly	N	O
3	assigned	N	O
4	56	N	O
5	patients	N	O
6	to	N	O
7	the	N	O
8	open	N	O
9	oesophagectomy	N	O
10	group	N	O
11	and	N	O
12	59	N	O
13	to	N	O
14	the	N	O
15	minimally	N	O
16	invasive	N	O
17	oesophagectomy	N	O
18	group	N	O
19	.	N	O

1	16	N	I-Premise
2	(	N	I-Premise
3	29	N	I-Premise
4	%	N	I-Premise
5	)	N	I-Premise
6	patients	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	open	N	I-Premise
10	oesophagectomy	N	I-Premise
11	group	N	I-Premise
12	had	N	I-Premise
13	pulmonary	N	I-Premise
14	infection	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	first	N	I-Premise
18	2	N	I-Premise
19	weeks	N	I-Premise
20	compared	N	I-Premise
21	with	N	I-Premise
22	five	N	I-Premise
23	(	N	I-Premise
24	9	N	I-Premise
25	%	N	I-Premise
26	)	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	minimally	N	I-Premise
30	invasive	N	I-Premise
31	group	N	I-Premise
32	(	N	I-Premise
33	relative	N	I-Premise
34	risk	N	I-Premise
35	[	N	I-Premise
36	RR	N	I-Premise
37	]	N	I-Premise
38	0·30	N	I-Premise
39	,	N	I-Premise
40	95	N	I-Premise
41	%	N	I-Premise
42	CI	N	I-Premise
43	0·12-0·76	N	I-Premise
44	;	N	I-Premise
45	p=0·005	N	I-Premise
46	)	N	I-Premise
47	.	N	I-Premise

1	19	N	I-Premise
2	(	N	I-Premise
3	34	N	I-Premise
4	%	N	I-Premise
5	)	N	I-Premise
6	patients	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	open	N	I-Premise
10	oesophagectomy	N	I-Premise
11	group	N	I-Premise
12	had	N	I-Premise
13	pulmonary	N	I-Premise
14	infection	N	I-Premise
15	in-hospital	N	I-Premise
16	compared	N	I-Premise
17	with	N	I-Premise
18	seven	N	I-Premise
19	(	N	I-Premise
20	12	N	I-Premise
21	%	N	I-Premise
22	)	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	minimally	N	I-Premise
26	invasive	N	I-Premise
27	group	N	I-Premise
28	(	N	I-Premise
29	0·35	N	I-Premise
30	,	N	I-Premise
31	0·16-0·78	N	I-Premise
32	;	N	I-Premise
33	p=0·005	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	For	N	I-Premise
2	in-hospital	N	I-Premise
3	mortality	N	I-Premise
4	,	N	I-Premise
5	one	N	I-Premise
6	patient	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	open	N	I-Premise
10	oesophagectomy	N	I-Premise
11	group	N	I-Premise
12	died	N	I-Premise
13	from	N	I-Premise
14	anastomotic	N	I-Premise
15	leakage	N	I-Premise
16	and	N	I-Premise
17	two	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	minimally	N	I-Premise
21	invasive	N	I-Premise
22	group	N	I-Premise
23	from	N	I-Premise
24	aspiration	N	I-Premise
25	and	N	I-Premise
26	mediastinitis	N	I-Premise
27	after	N	I-Premise
28	anastomotic	N	I-Premise
29	leakage	N	I-Premise
30	.	N	I-Premise

1	These	N	I-Claim
2	findings	N	I-Claim
3	provide	N	I-Claim
4	evidence	N	I-Claim
5	for	N	I-Claim
6	the	N	I-Claim
7	short-term	N	I-Claim
8	benefits	N	I-Claim
9	of	N	I-Claim
10	minimally	N	I-Claim
11	invasive	N	I-Claim
12	oesophagectomy	N	I-Claim
13	for	N	I-Claim
14	patients	N	I-Claim
15	with	N	I-Claim
16	resectable	N	I-Claim
17	oesophageal	N	I-Claim
18	cancer	N	I-Claim
19	.	N	I-Claim

1	Phase	N	O
2	III	N	O
3	EGF104900	N	O
4	data	N	O
5	demonstrated	N	O
6	that	N	O
7	lapatinib	N	O
8	plus	N	O
9	trastuzumab	N	O
10	significantly	N	O
11	improved	N	O
12	progression-free	N	O
13	survival	N	O
14	(	N	O
15	PFS	N	O
16	)	N	O
17	and	N	O
18	clinical	N	O
19	benefit	N	O
20	rate	N	O
21	versus	N	O
22	lapatinib	N	O
23	monotherapy	N	O
24	,	N	O
25	offering	N	O
26	a	N	O
27	chemotherapy-free	N	O
28	option	N	O
29	for	N	O
30	patients	N	O
31	with	N	O
32	heavily	N	O
33	pretreated	N	O
34	human	N	O
35	epidermal	N	O
36	growth	N	O
37	factor	N	O
38	receptor	N	O
39	2	N	O
40	(	N	O
41	HER2	N	O
42	)	N	O
43	-positive	N	O
44	metastatic	N	O
45	breast	N	O
46	cancer	N	O
47	(	N	O
48	MBC	N	O
49	)	N	O
50	.	N	O

1	Final	N	O
2	planned	N	O
3	overall	N	O
4	survival	N	O
5	(	N	O
6	OS	N	O
7	)	N	O
8	analysis	N	O
9	from	N	O
10	EGF104900	N	O
11	is	N	O
12	reported	N	O
13	here	N	O
14	.	N	O

1	Patients	N	O
2	with	N	O
3	HER2-positive	N	O
4	MBC	N	O
5	whose	N	O
6	disease	N	O
7	progressed	N	O
8	during	N	O
9	prior	N	O
10	trastuzumab-based	N	O
11	therapies	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	to	N	O
16	receive	N	O
17	lapatinib	N	O
18	monotherapy	N	O
19	or	N	O
20	lapatinib	N	O
21	in	N	O
22	combination	N	O
23	with	N	O
24	trastuzumab	N	O
25	.	N	O

1	OS	N	O
2	and	N	O
3	updated	N	O
4	PFS	N	O
5	data	N	O
6	are	N	O
7	presented	N	O
8	using	N	O
9	Kaplan-Meier	N	O
10	curves	N	O
11	and	N	O
12	log-rank	N	O
13	tests	N	O
14	stratified	N	O
15	for	N	O
16	hormone	N	O
17	receptor	N	O
18	and	N	O
19	visceral	N	O
20	disease	N	O
21	status	N	O
22	.	N	O

1	Subgroup	N	O
2	analyses	N	O
3	were	N	O
4	conducted	N	O
5	to	N	O
6	identify	N	O
7	characteristics	N	O
8	of	N	O
9	patients	N	O
10	deriving	N	O
11	the	N	O
12	greatest	N	O
13	clinical	N	O
14	benefit	N	O
15	.	N	O

1	In	N	I-Premise
2	this	N	I-Premise
3	updated	N	I-Premise
4	final	N	I-Premise
5	analysis	N	I-Premise
6	of	N	I-Premise
7	all	N	I-Premise
8	patients	N	I-Premise
9	randomly	N	I-Premise
10	assigned	N	I-Premise
11	with	N	I-Premise
12	strata	N	I-Premise
13	(	N	I-Premise
14	n	N	I-Premise
15	=	N	I-Premise
16	291	N	I-Premise
17	)	N	I-Premise
18	,	N	I-Premise
19	lapatinib	N	I-Premise
20	plus	N	I-Premise
21	trastuzumab	N	I-Premise
22	continued	N	I-Premise
23	to	N	I-Premise
24	show	N	I-Premise
25	superiority	N	I-Premise
26	to	N	I-Premise
27	lapatinib	N	I-Premise
28	monotherapy	N	I-Premise
29	in	N	I-Premise
30	PFS	N	I-Premise
31	(	N	I-Premise
32	hazard	N	I-Premise
33	ratio	N	I-Premise
34	[	N	I-Premise
35	HR	N	I-Premise
36	]	N	I-Premise
37	,	N	I-Premise
38	0.74	N	I-Premise
39	;	N	I-Premise
40	95	N	I-Premise
41	%	N	I-Premise
42	CI	N	I-Premise
43	,	N	I-Premise
44	0.58	N	I-Premise
45	to	N	I-Premise
46	0.94	N	I-Premise
47	;	N	I-Premise
48	P	N	I-Premise
49	=	N	I-Premise
50	.011	N	I-Premise
51	)	N	I-Premise
52	and	N	I-Premise
53	offered	N	I-Premise
54	significant	N	I-Premise
55	OS	N	I-Premise
56	benefit	N	I-Premise
57	(	N	I-Premise
58	HR	N	I-Premise
59	,	N	I-Premise
60	0.74	N	I-Premise
61	;	N	I-Premise
62	95	N	I-Premise
63	%	N	I-Premise
64	CI	N	I-Premise
65	,	N	I-Premise
66	0.57	N	I-Premise
67	to	N	I-Premise
68	0.97	N	I-Premise
69	;	N	I-Premise
70	P	N	I-Premise
71	=	N	I-Premise
72	.026	N	I-Premise
73	)	N	I-Premise
74	.	N	I-Premise

1	Improvements	N	I-Premise
2	in	N	I-Premise
3	absolute	N	I-Premise
4	OS	N	I-Premise
5	rates	N	I-Premise
6	were	N	I-Premise
7	10	N	I-Premise
8	%	N	I-Premise
9	at	N	I-Premise
10	6	N	I-Premise
11	months	N	I-Premise
12	and	N	I-Premise
13	15	N	I-Premise
14	%	N	I-Premise
15	at	N	I-Premise
16	12	N	I-Premise
17	months	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	combination	N	I-Premise
21	arm	N	I-Premise
22	compared	N	I-Premise
23	with	N	I-Premise
24	the	N	I-Premise
25	monotherapy	N	I-Premise
26	arm	N	I-Premise
27	.	N	I-Premise

1	Multiple	N	I-Premise
2	baseline	N	I-Premise
3	factors	N	I-Premise
4	,	N	I-Premise
5	including	N	I-Premise
6	Eastern	N	I-Premise
7	Cooperative	N	I-Premise
8	Oncology	N	I-Premise
9	Group	N	I-Premise
10	performance	N	I-Premise
11	status	N	I-Premise
12	of	N	I-Premise
13	0	N	I-Premise
14	,	N	I-Premise
15	nonvisceral	N	I-Premise
16	disease	N	I-Premise
17	,	N	I-Premise
18	<	N	I-Premise
19	three	N	I-Premise
20	metastatic	N	I-Premise
21	sites	N	I-Premise
22	,	N	I-Premise
23	and	N	I-Premise
24	less	N	I-Premise
25	time	N	I-Premise
26	from	N	I-Premise
27	initial	N	I-Premise
28	diagnosis	N	I-Premise
29	until	N	I-Premise
30	random	N	I-Premise
31	assignment	N	I-Premise
32	,	N	I-Premise
33	were	N	I-Premise
34	associated	N	I-Premise
35	with	N	I-Premise
36	improved	N	I-Premise
37	OS	N	I-Premise
38	.	N	I-Premise

1	Incidence	N	I-Premise
2	of	N	I-Premise
3	adverse	N	I-Premise
4	events	N	I-Premise
5	was	N	I-Premise
6	consistent	N	I-Premise
7	with	N	I-Premise
8	previously	N	I-Premise
9	reported	N	I-Premise
10	rates	N	I-Premise
11	.	N	I-Premise

1	These	N	I-Claim
2	data	N	I-Claim
3	demonstrated	N	I-Claim
4	a	N	I-Claim
5	significant	N	I-Claim
6	4.5-month	N	I-Claim
7	median	N	I-Claim
8	OS	N	I-Claim
9	advantage	N	I-Claim
10	with	N	I-Claim
11	the	N	I-Claim
12	lapatinib	N	I-Claim
13	and	N	I-Claim
14	trastuzumab	N	I-Claim
15	combination	N	I-Claim
16	and	N	I-Claim
17	support	N	I-Claim
18	dual	N	I-Claim
19	HER2	N	I-Claim
20	blockade	N	I-Claim
21	in	N	I-Claim
22	patients	N	I-Claim
23	with	N	I-Claim
24	heavily	N	I-Claim
25	pretreated	N	I-Claim
26	HER2-positive	N	I-Claim
27	MBC	N	I-Claim
28	.	N	I-Claim

1	This	N	O
2	study	N	O
3	tested	N	O
4	hyperbaric	N	O
5	oxygen	N	O
6	(	N	O
7	HBO	N	O
8	)	N	O
9	as	N	O
10	an	N	O
11	adjunct	N	O
12	to	N	O
13	surgery	N	O
14	and	N	O
15	antibiotics	N	O
16	in	N	O
17	the	N	O
18	treatment	N	O
19	of	N	O
20	bisphosphonate-related	N	O
21	osteonecrosis	N	O
22	of	N	O
23	the	N	O
24	jaw	N	O
25	(	N	O
26	ONJ	N	O
27	)	N	O
28	and	N	O
29	evaluated	N	O
30	its	N	O
31	effects	N	O
32	on	N	O
33	gingival	N	O
34	healing	N	O
35	,	N	O
36	pain	N	O
37	,	N	O
38	and	N	O
39	quality	N	O
40	of	N	O
41	life	N	O
42	.	N	O

1	The	N	O
2	investigators	N	O
3	implemented	N	O
4	a	N	O
5	randomized	N	O
6	controlled	N	O
7	trial	N	O
8	and	N	O
9	enrolled	N	O
10	a	N	O
11	sample	N	O
12	composed	N	O
13	of	N	O
14	patients	N	O
15	with	N	O
16	ONJ	N	O
17	,	N	O
18	where	N	O
19	the	N	O
20	predictor	N	O
21	variable	N	O
22	was	N	O
23	HBO	N	O
24	administered	N	O
25	at	N	O
26	2	N	O
27	atm	N	O
28	twice	N	O
29	a	N	O
30	day	N	O
31	for	N	O
32	40	N	O
33	treatments	N	O
34	as	N	O
35	an	N	O
36	adjunct	N	O
37	to	N	O
38	conventional	N	O
39	therapy	N	O
40	of	N	O
41	surgery	N	O
42	and	N	O
43	antibiotics	N	O
44	versus	N	O
45	conventional	N	O
46	therapy	N	O
47	alone	N	O
48	.	N	O

1	Over	N	O
2	the	N	O
3	next	N	O
4	24	N	O
5	months	N	O
6	,	N	O
7	oral	N	O
8	lesion	N	O
9	size	N	O
10	and	N	O
11	number	N	O
12	,	N	O
13	pain	N	O
14	,	N	O
15	and	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	were	N	O
20	assessed	N	O
21	.	N	O

1	Forty-six	N	O
2	patients	N	O
3	(	N	O
4	mean	N	O
5	age	N	O
6	,	N	O
7	66	N	O
8	yrs	N	O
9	;	N	O
10	57	N	O
11	%	N	O
12	women	N	O
13	)	N	O
14	contributed	N	O
15	data	N	O
16	to	N	O
17	the	N	O
18	trial	N	O
19	.	N	O

1	There	N	O
2	were	N	O
3	no	N	O
4	statistically	N	O
5	significant	N	O
6	differences	N	O
7	in	N	O
8	the	N	O
9	distribution	N	O
10	of	N	O
11	variables	N	O
12	used	N	O
13	to	N	O
14	assess	N	O
15	randomization	N	O
16	success	N	O
17	between	N	O
18	the	N	O
19	HBO	N	O
20	and	N	O
21	standard	N	O
22	treatment	N	O
23	groups	N	O
24	.	N	O

1	Seventeen	N	I-Premise
2	of	N	I-Premise
3	25	N	I-Premise
4	HBO-treated	N	I-Premise
5	patients	N	I-Premise
6	(	N	I-Premise
7	68	N	I-Premise
8	%	N	I-Premise
9	)	N	I-Premise
10	improved	N	I-Premise
11	versus	N	I-Premise
12	8	N	I-Premise
13	of	N	I-Premise
14	21	N	I-Premise
15	controls	N	I-Premise
16	(	N	I-Premise
17	38.1	N	I-Premise
18	%	N	I-Premise
19	;	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	.043	N	I-Premise
23	,	N	I-Premise
24	χ	N	I-Premise
25	(	N	I-Premise
26	2	N	I-Premise
27	)	N	I-Premise
28	test	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	Mean	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	improvement	N	I-Premise
5	was	N	I-Premise
6	39.7	N	I-Premise
7	weeks	N	I-Premise
8	(	N	I-Premise
9	95	N	I-Premise
10	%	N	I-Premise
11	confidence	N	I-Premise
12	interval	N	I-Premise
13	[	N	I-Premise
14	CI	N	I-Premise
15	]	N	I-Premise
16	,	N	I-Premise
17	22.4	N	I-Premise
18	to	N	I-Premise
19	57.0	N	I-Premise
20	weeks	N	I-Premise
21	)	N	I-Premise
22	for	N	I-Premise
23	HBO-treated	N	I-Premise
24	patients	N	I-Premise
25	versus	N	I-Premise
26	67.9	N	I-Premise
27	weeks	N	I-Premise
28	(	N	I-Premise
29	95	N	I-Premise
30	CI	N	I-Premise
31	,	N	I-Premise
32	48.4	N	I-Premise
33	to	N	I-Premise
34	87.5	N	I-Premise
35	weeks	N	I-Premise
36	)	N	I-Premise
37	for	N	I-Premise
38	controls	N	I-Premise
39	(	N	I-Premise
40	P	N	I-Premise
41	=	N	I-Premise
42	.03	N	I-Premise
43	,	N	I-Premise
44	log-rank	N	I-Premise
45	test	N	I-Premise
46	)	N	I-Premise
47	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	complete	N	I-Premise
4	gingival	N	I-Premise
5	healing	N	I-Premise
6	occurred	N	I-Premise
7	in	N	I-Premise
8	only	N	I-Premise
9	14	N	I-Premise
10	of	N	I-Premise
11	25	N	I-Premise
12	HBO-treated	N	I-Premise
13	patients	N	I-Premise
14	(	N	I-Premise
15	52	N	I-Premise
16	%	N	I-Premise
17	)	N	I-Premise
18	versus	N	I-Premise
19	7	N	I-Premise
20	of	N	I-Premise
21	21	N	I-Premise
22	controls	N	I-Premise
23	(	N	I-Premise
24	33.3	N	I-Premise
25	%	N	I-Premise
26	;	N	I-Premise
27	P	N	I-Premise
28	=	N	I-Premise
29	.203	N	I-Premise
30	,	N	I-Premise
31	χ	N	I-Premise
32	(	N	I-Premise
33	2	N	I-Premise
34	)	N	I-Premise
35	test	N	I-Premise
36	)	N	I-Premise
37	,	N	I-Premise
38	and	N	I-Premise
39	time	N	I-Premise
40	to	N	I-Premise
41	healing	N	I-Premise
42	was	N	I-Premise
43	59	N	I-Premise
44	weeks	N	I-Premise
45	(	N	I-Premise
46	95	N	I-Premise
47	%	N	I-Premise
48	CI	N	I-Premise
49	,	N	I-Premise
50	42.8	N	I-Premise
51	%	N	I-Premise
52	to	N	I-Premise
53	75.8	N	I-Premise
54	%	N	I-Premise
55	)	N	I-Premise
56	for	N	I-Premise
57	HBO-treated	N	I-Premise
58	patients	N	I-Premise
59	versus	N	I-Premise
60	70	N	I-Premise
61	weeks	N	I-Premise
62	(	N	I-Premise
63	95	N	I-Premise
64	CI	N	I-Premise
65	,	N	I-Premise
66	52.2	N	I-Premise
67	%	N	I-Premise
68	to	N	I-Premise
69	88.36	N	I-Premise
70	%	N	I-Premise
71	)	N	I-Premise
72	for	N	I-Premise
73	controls	N	I-Premise
74	(	N	I-Premise
75	P	N	I-Premise
76	=	N	I-Premise
77	.32	N	I-Premise
78	,	N	I-Premise
79	log-rank	N	I-Premise
80	test	N	I-Premise
81	)	N	I-Premise
82	.	N	I-Premise

1	Pain	N	I-Premise
2	decreased	N	I-Premise
3	faster	N	I-Premise
4	for	N	I-Premise
5	HBO-treated	N	I-Premise
6	subjects	N	I-Premise
7	(	N	I-Premise
8	P	N	I-Premise
9	<	N	I-Premise
10	.01	N	I-Premise
11	,	N	I-Premise
12	linear	N	I-Premise
13	regression	N	I-Premise
14	)	N	I-Premise
15	.	N	I-Premise

1	Quality-of-life	N	I-Premise
2	scores	N	I-Premise
3	for	N	I-Premise
4	physical	N	I-Premise
5	health	N	I-Premise
6	(	N	I-Premise
7	P	N	I-Premise
8	=	N	I-Premise
9	.002	N	I-Premise
10	)	N	I-Premise
11	and	N	I-Premise
12	perceived	N	I-Premise
13	health	N	I-Premise
14	(	N	I-Premise
15	P	N	I-Premise
16	=	N	I-Premise
17	.043	N	I-Premise
18	)	N	I-Premise
19	decreased	N	I-Premise
20	at	N	I-Premise
21	6	N	I-Premise
22	months	N	I-Premise
23	for	N	I-Premise
24	control	N	I-Premise
25	group	N	I-Premise
26	but	N	I-Premise
27	for	N	I-Premise
28	not	N	I-Premise
29	the	N	I-Premise
30	HBO	N	I-Premise
31	group	N	I-Premise
32	.	N	I-Premise

1	ONJ	N	I-Claim
2	is	N	I-Claim
3	multifactorial	N	I-Claim
4	and	N	I-Claim
5	no	N	I-Claim
6	single	N	I-Claim
7	treatment	N	I-Claim
8	modality	N	I-Claim
9	is	N	I-Claim
10	likely	N	I-Claim
11	to	N	I-Claim
12	reverse	N	I-Claim
13	it	N	I-Claim
14	;	N	I-Claim
15	however	N	I-Claim
16	,	N	I-Claim
17	it	N	I-Claim
18	is	N	I-Claim
19	treatable	N	I-Claim
20	and	N	I-Claim
21	even	N	I-Claim
22	advanced	N	I-Claim
23	presentations	N	I-Claim
24	can	N	I-Claim
25	improve	N	I-Claim
26	with	N	I-Claim
27	intensive	N	I-Claim
28	multimodal	N	I-Claim
29	therapy	N	I-Claim
30	.	N	I-Claim

1	Clinically	N	I-Claim
2	,	N	I-Claim
3	HBO	N	I-Claim
4	appears	N	I-Claim
5	to	N	I-Claim
6	be	N	I-Claim
7	a	N	I-Claim
8	useful	N	I-Claim
9	adjunct	N	I-Claim
10	to	N	I-Claim
11	ONJ	N	I-Claim
12	treatment	N	I-Claim
13	,	N	I-Claim
14	particularly	N	I-Claim
15	for	N	I-Claim
16	more	N	I-Claim
17	severe	N	I-Claim
18	cases	N	I-Claim
19	,	N	I-Claim
20	although	N	I-Claim
21	this	N	I-Claim
22	study	N	I-Claim
23	was	N	I-Claim
24	underpowered	N	I-Claim
25	to	N	I-Claim
26	fully	N	I-Claim
27	support	N	I-Claim
28	this	N	I-Claim
29	claim	N	I-Claim
30	.	N	I-Claim

1	Older	N	O
2	breast	N	O
3	cancer	N	O
4	survivors	N	O
5	(	N	O
6	BCSs	N	O
7	)	N	O
8	are	N	O
9	at	N	O
10	risk	N	O
11	for	N	O
12	late	N	O
13	and	N	O
14	long-term	N	O
15	treatment	N	O
16	effects	N	O
17	on	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	(	N	O
22	QOL	N	O
23	)	N	O
24	,	N	O
25	including	N	O
26	lower	N	O
27	physical	N	O
28	functioning	N	O
29	and	N	O
30	fear	N	O
31	of	N	O
32	recurrence	N	O
33	.	N	O

1	Two	N	O
2	promising	N	O
3	approaches	N	O
4	to	N	O
5	address	N	O
6	this	N	O
7	include	N	O
8	dance/movement	N	O
9	therapy	N	O
10	and	N	O
11	mindfulness	N	O
12	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	2-group	N	O
6	randomized	N	O
7	controlled	N	O
8	pilot	N	O
9	feasibility	N	O
10	study	N	O
11	was	N	O
12	to	N	O
13	test	N	O
14	short-term	N	O
15	effects	N	O
16	of	N	O
17	a	N	O
18	12-week	N	O
19	Mindful	N	O
20	Movement	N	O
21	Program	N	O
22	(	N	O
23	MMP	N	O
24	)	N	O
25	intervention	N	O
26	combining	N	O
27	mindfulness	N	O
28	with	N	O
29	self-directed	N	O
30	movement	N	O
31	on	N	O
32	QOL	N	O
33	and	N	O
34	mindfulness	N	O
35	in	N	O
36	female	N	O
37	BCSs	N	O
38	50	N	O
39	years	N	O
40	or	N	O
41	older	N	O
42	and	N	O
43	at	N	O
44	12	N	O
45	months	N	O
46	or	N	O
47	more	N	O
48	following	N	O
49	treatment	N	O
50	.	N	O

1	Consented	N	O
2	participants	N	O
3	were	N	O
4	randomized	N	O
5	to	N	O
6	an	N	O
7	experimental	N	O
8	group	N	O
9	(	N	O
10	EG	N	O
11	)	N	O
12	(	N	O
13	12	N	O
14	weekly	N	O
15	MMP	N	O
16	sessions	N	O
17	)	N	O
18	or	N	O
19	a	N	O
20	control	N	O
21	group	N	O
22	(	N	O
23	no	N	O
24	sessions	N	O
25	)	N	O
26	.	N	O

1	All	N	O
2	completed	N	O
3	questionnaires	N	O
4	3	N	O
5	times	N	O
6	.	N	O

1	The	N	O
2	EG	N	O
3	participants	N	O
4	kept	N	O
5	home	N	O
6	practice	N	O
7	diaries	N	O
8	.	N	O

1	Analysis	N	O
2	was	N	O
3	conducted	N	O
4	after	N	O
5	intervention	N	O
6	for	N	O
7	immediate	N	O
8	effects	N	O
9	on	N	O
10	outcome	N	O
11	variables	N	O
12	and	N	O
13	6	N	O
14	weeks	N	O
15	later	N	O
16	for	N	O
17	maintenance	N	O
18	of	N	O
19	effects	N	O
20	.	N	O

1	Participants	N	O
2	(	N	O
3	n	N	O
4	=	N	O
5	49	N	O
6	)	N	O
7	ranged	N	O
8	in	N	O
9	age	N	O
10	from	N	O
11	50	N	O
12	to	N	O
13	90	N	O
14	years	N	O
15	(	N	O
16	average	N	O
17	,	N	O
18	65.6	N	O
19	years	N	O
20	)	N	O
21	and	N	O
22	were	N	O
23	at	N	O
24	9.8	N	O
25	years	N	O
26	since	N	O
27	diagnosis	N	O
28	(	N	O
29	range	N	O
30	,	N	O
31	1-32	N	O
32	years	N	O
33	)	N	O
34	,	N	O
35	and	N	O
36	the	N	O
37	majority	N	O
38	were	N	O
39	white	N	O
40	,	N	O
41	unpartnered	N	O
42	,	N	O
43	and	N	O
44	retired	N	O
45	.	N	O

1	After	N	I-Premise
2	intervention	N	I-Premise
3	,	N	I-Premise
4	EG	N	I-Premise
5	participants	N	I-Premise
6	showed	N	I-Premise
7	improved	N	I-Premise
8	QOL	N	I-Premise
9	via	N	I-Premise
10	decreased	N	I-Premise
11	fear	N	I-Premise
12	of	N	I-Premise
13	recurrence	N	I-Premise
14	and	N	I-Premise
15	increased	N	I-Premise
16	mindfulness	N	I-Premise
17	attitude	N	I-Premise
18	.	N	I-Premise

1	At	N	I-Premise
2	6	N	I-Premise
3	weeks	N	I-Premise
4	,	N	I-Premise
5	initial	N	I-Premise
6	effects	N	I-Premise
7	were	N	I-Premise
8	retained	N	I-Premise
9	.	N	I-Premise

1	The	N	I-Premise
2	MMP	N	I-Premise
3	appears	N	I-Premise
4	to	N	I-Premise
5	benefit	N	I-Premise
6	older	N	I-Premise
7	BCSs	N	I-Premise
8	by	N	I-Premise
9	reducing	N	I-Premise
10	fear	N	I-Premise
11	of	N	I-Premise
12	recurrence	N	I-Premise
13	and	N	I-Premise
14	improving	N	I-Premise
15	mindfulness	N	I-Premise
16	attitude	N	I-Premise
17	.	N	I-Premise

1	Although	N	I-Claim
2	these	N	I-Claim
3	findings	N	I-Claim
4	are	N	I-Claim
5	promising	N	I-Claim
6	,	N	I-Claim
7	a	N	I-Claim
8	larger	N	I-Claim
9	study	N	I-Claim
10	is	N	I-Claim
11	needed	N	I-Claim
12	to	N	I-Claim
13	determine	N	I-Claim
14	more	N	I-Claim
15	specifically	N	I-Claim
16	what	N	I-Claim
17	short-	N	I-Claim
18	and	N	I-Claim
19	long-term	N	I-Claim
20	effects	N	I-Claim
21	are	N	I-Claim
22	possible	N	I-Claim
23	.	N	I-Claim

1	The	N	I-Claim
2	combination	N	I-Claim
3	of	N	I-Claim
4	self-directed	N	I-Claim
5	movement	N	I-Claim
6	and	N	I-Claim
7	mindfulness	N	I-Claim
8	,	N	I-Claim
9	as	N	I-Claim
10	tested	N	I-Claim
11	here	N	I-Claim
12	,	N	I-Claim
13	may	N	I-Claim
14	be	N	I-Claim
15	a	N	I-Claim
16	valuable	N	I-Claim
17	tool	N	I-Claim
18	for	N	I-Claim
19	promoting	N	I-Claim
20	health	N	I-Claim
21	and	N	I-Claim
22	well-being	N	I-Claim
23	in	N	I-Claim
24	older	N	I-Claim
25	long-term	N	I-Claim
26	survivors	N	I-Claim
27	of	N	I-Claim
28	breast	N	I-Claim
29	cancer	N	I-Claim
30	.	N	I-Claim

1	Research	N	O
2	has	N	O
3	shown	N	O
4	that	N	O
5	self-directed	N	O
6	stress	N	O
7	management	N	O
8	training	N	O
9	improves	N	O
10	mental	N	O
11	well-being	N	O
12	in	N	O
13	patients	N	O
14	undergoing	N	O
15	chemotherapy	N	O
16	.	N	O

1	The	N	O
2	present	N	O
3	study	N	O
4	extends	N	O
5	this	N	O
6	work	N	O
7	by	N	O
8	evaluating	N	O
9	separate	N	O
10	and	N	O
11	combined	N	O
12	effects	N	O
13	of	N	O
14	stress	N	O
15	management	N	O
16	training	N	O
17	and	N	O
18	home-based	N	O
19	exercise	N	O
20	.	N	O

1	Following	N	O
2	assessment	N	O
3	of	N	O
4	mental	N	O
5	and	N	O
6	physical	N	O
7	well-being	N	O
8	,	N	O
9	depression	N	O
10	,	N	O
11	anxiety	N	O
12	,	N	O
13	exercise	N	O
14	,	N	O
15	and	N	O
16	stress	N	O
17	reduction	N	O
18	activity	N	O
19	before	N	O
20	chemotherapy	N	O
21	started	N	O
22	,	N	O
23	patients	N	O
24	were	N	O
25	randomized	N	O
26	to	N	O
27	stress	N	O
28	management	N	O
29	training	N	O
30	(	N	O
31	SM	N	O
32	)	N	O
33	,	N	O
34	exercise	N	O
35	(	N	O
36	EX	N	O
37	)	N	O
38	,	N	O
39	combined	N	O
40	stress	N	O
41	management	N	O
42	and	N	O
43	exercise	N	O
44	(	N	O
45	SMEX	N	O
46	)	N	O
47	,	N	O
48	or	N	O
49	usual	N	O
50	care	N	O
51	only	N	O
52	(	N	O
53	UCO	N	O
54	)	N	O
55	.	N	O

1	Outcomes	N	O
2	were	N	O
3	reassessed	N	O
4	6	N	O
5	and	N	O
6	12	N	O
7	weeks	N	O
8	after	N	O
9	chemotherapy	N	O
10	started	N	O
11	.	N	O

1	Significance	N	O
2	testing	N	O
3	of	N	O
4	group-by-time	N	O
5	interactions	N	O
6	in	N	O
7	286	N	O
8	patients	N	O
9	who	N	O
10	completed	N	O
11	all	N	O
12	assessments	N	O
13	was	N	O
14	used	N	O
15	to	N	O
16	evaluate	N	O
17	intervention	N	O
18	efficacy	N	O
19	.	N	O

1	Interaction	N	I-Premise
2	effects	N	I-Premise
3	for	N	I-Premise
4	mental	N	I-Premise
5	and	N	I-Premise
6	physical	N	I-Premise
7	well-being	N	I-Premise
8	scores	N	I-Premise
9	were	N	I-Premise
10	not	N	I-Premise
11	significant	N	I-Premise
12	.	N	I-Premise

1	Depression	N	I-Premise
2	scores	N	I-Premise
3	yielded	N	I-Premise
4	a	N	I-Premise
5	linear	N	I-Premise
6	interaction	N	I-Premise
7	comparing	N	I-Premise
8	UCO	N	I-Premise
9	and	N	I-Premise
10	SMEX	N	I-Premise
11	(	N	I-Premise
12	p	N	I-Premise
13	=	N	I-Premise
14	0.019	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	with	N	I-Premise
18	decreases	N	I-Premise
19	in	N	I-Premise
20	SMEX	N	I-Premise
21	but	N	I-Premise
22	not	N	I-Premise
23	UCO	N	I-Premise
24	.	N	I-Premise

1	Anxiety	N	I-Premise
2	scores	N	I-Premise
3	yielded	N	I-Premise
4	a	N	I-Premise
5	quadratic	N	I-Premise
6	interaction	N	I-Premise
7	comparing	N	I-Premise
8	UCO	N	I-Premise
9	and	N	I-Premise
10	SMEX	N	I-Premise
11	(	N	I-Premise
12	p	N	I-Premise
13	=	N	I-Premise
14	0.049	N	I-Premise
15	)	N	I-Premise
16	,	N	I-Premise
17	with	N	I-Premise
18	trends	N	I-Premise
19	for	N	I-Premise
20	changes	N	I-Premise
21	in	N	I-Premise
22	SMEX	N	I-Premise
23	but	N	I-Premise
24	not	N	I-Premise
25	UCO	N	I-Premise
26	.	N	I-Premise

1	Additional	N	I-Premise
2	analyses	N	I-Premise
3	yielded	N	I-Premise
4	quadratic	N	I-Premise
5	interactions	N	I-Premise
6	for	N	I-Premise
7	exercise	N	I-Premise
8	activity	N	I-Premise
9	comparing	N	I-Premise
10	UCO	N	I-Premise
11	and	N	I-Premise
12	SMEX	N	I-Premise
13	(	N	I-Premise
14	p	N	I-Premise
15	=	N	I-Premise
16	0.022	N	I-Premise
17	)	N	I-Premise
18	,	N	I-Premise
19	with	N	I-Premise
20	positive	N	I-Premise
21	changes	N	I-Premise
22	in	N	I-Premise
23	SMEX	N	I-Premise
24	but	N	I-Premise
25	not	N	I-Premise
26	UCO	N	I-Premise
27	,	N	I-Premise
28	and	N	I-Premise
29	for	N	I-Premise
30	stress	N	I-Premise
31	management	N	I-Premise
32	activity	N	I-Premise
33	comparing	N	I-Premise
34	UCO	N	I-Premise
35	and	N	I-Premise
36	SM	N	I-Premise
37	(	N	I-Premise
38	p	N	I-Premise
39	<	N	I-Premise
40	0.001	N	I-Premise
41	)	N	I-Premise
42	and	N	I-Premise
43	UCO	N	I-Premise
44	and	N	I-Premise
45	SMEX	N	I-Premise
46	(	N	I-Premise
47	p	N	I-Premise
48	=	N	I-Premise
49	0.013	N	I-Premise
50	)	N	I-Premise
51	,	N	I-Premise
52	with	N	I-Premise
53	positive	N	I-Premise
54	changes	N	I-Premise
55	in	N	I-Premise
56	SM	N	I-Premise
57	and	N	I-Premise
58	SMEX	N	I-Premise
59	but	N	I-Premise
60	not	N	I-Premise
61	UCO	N	I-Premise
62	.	N	I-Premise

1	Only	N	I-Claim
2	the	N	I-Claim
3	combined	N	I-Claim
4	intervention	N	I-Claim
5	yielded	N	I-Claim
6	effects	N	I-Claim
7	on	N	I-Claim
8	quality	N	I-Claim
9	of	N	I-Claim
10	life	N	I-Claim
11	outcomes	N	I-Claim
12	,	N	I-Claim
13	and	N	I-Claim
14	these	N	I-Claim
15	were	N	I-Claim
16	limited	N	I-Claim
17	to	N	I-Claim
18	anxiety	N	I-Claim
19	and	N	I-Claim
20	depression	N	I-Claim
21	.	N	I-Claim

1	These	N	I-Premise
2	findings	N	I-Premise
3	are	N	I-Premise
4	consistent	N	I-Premise
5	with	N	I-Premise
6	evidence	N	I-Premise
7	that	N	I-Premise
8	only	N	I-Premise
9	the	N	I-Premise
10	combined	N	I-Premise
11	intervention	N	I-Premise
12	yielded	N	I-Premise
13	increases	N	I-Premise
14	in	N	I-Premise
15	both	N	I-Premise
16	exercise	N	I-Premise
17	and	N	I-Premise
18	stress	N	I-Premise
19	management	N	I-Premise
20	activity	N	I-Premise
21	.	N	I-Premise

1	Future	N	O
2	research	N	O
3	should	N	O
4	investigate	N	O
5	ways	N	O
6	to	N	O
7	augment	N	O
8	this	N	O
9	intervention	N	O
10	to	N	O
11	enhance	N	O
12	its	N	O
13	benefits	N	O
14	.	N	O

1	The	N	I-MajorClaim
2	incidence	N	I-MajorClaim
3	and	N	I-MajorClaim
4	development	N	I-MajorClaim
5	of	N	I-MajorClaim
6	cancer	N	I-MajorClaim
7	are	N	I-MajorClaim
8	closely	N	I-MajorClaim
9	related	N	I-MajorClaim
10	to	N	I-MajorClaim
11	dysfunction	N	I-MajorClaim
12	of	N	I-MajorClaim
13	immune	N	I-MajorClaim
14	function	N	I-MajorClaim
15	.	N	I-MajorClaim

1	The	N	O
2	immune	N	O
3	system	N	O
4	can	N	O
5	not	N	O
6	identify	N	O
7	and	N	O
8	remove	N	O
9	malignant	N	O
10	and	N	O
11	mutant	N	O
12	cells	N	O
13	,	N	O
14	which	N	O
15	cause	N	O
16	tumor	N	O
17	cells	N	O
18	to	N	O
19	escape	N	O
20	from	N	O
21	surveillance	N	O
22	and	N	O
23	clearance	N	O
24	of	N	O
25	the	N	O
26	immune	N	O
27	system	N	O
28	.	N	O

1	Immunobiological	N	O
2	cancer	N	O
3	therapy	N	O
4	plays	N	O
5	an	N	O
6	important	N	O
7	role	N	O
8	in	N	O
9	strengthening	N	O
10	body	N	O
11	immunological	N	O
12	surveillance	N	O
13	function	N	O
14	and	N	O
15	killing	N	O
16	remaining	N	O
17	tumor	N	O
18	cells	N	O
19	in	N	O
20	the	N	O
21	body	N	O
22	.	N	O

1	We	N	O
2	investigated	N	O
3	the	N	O
4	role	N	O
5	of	N	O
6	DC/CIK	N	O
7	(	N	O
8	dendritic	N	O
9	cell/cytokine-induced	N	O
10	killer	N	O
11	cells	N	O
12	)	N	O
13	immunobiological	N	O
14	cancer	N	O
15	therapy	N	O
16	in	N	O
17	maintenance	N	O
18	therapy	N	O
19	of	N	O
20	advanced	N	O
21	non-small	N	O
22	cell	N	O
23	lung	N	O
24	cancer	N	O
25	.	N	O

1	When	N	O
2	60	N	O
3	cases	N	O
4	of	N	O
5	non-small	N	O
6	cell	N	O
7	lung	N	O
8	cancer	N	O
9	patients	N	O
10	in	N	O
11	stage	N	O
12	IIIb	N	O
13	and	N	O
14	IV	N	O
15	reached	N	O
16	stable	N	O
17	disease	N	O
18	after	N	O
19	treatment	N	O
20	with	N	O
21	4	N	O
22	cycles	N	O
23	of	N	O
24	a	N	O
25	two-drug	N	O
26	regimen	N	O
27	with	N	O
28	platinum	N	O
29	,	N	O
30	they	N	O
31	were	N	O
32	randomly	N	O
33	divided	N	O
34	into	N	O
35	two	N	O
36	groups	N	O
37	.	N	O

1	One	N	O
2	group	N	O
3	was	N	O
4	treated	N	O
5	with	N	O
6	DC/CIK	N	O
7	immunobiological	N	O
8	cancer	N	O
9	therapy	N	O
10	,	N	O
11	and	N	O
12	the	N	O
13	other	N	O
14	was	N	O
15	taken	N	O
16	as	N	O
17	a	N	O
18	control	N	O
19	group	N	O
20	.	N	O

1	Finally	N	O
2	,	N	O
3	cancer	N	O
4	progression	N	O
5	time	N	O
6	and	N	O
7	toxicity	N	O
8	reaction	N	O
9	of	N	O
10	the	N	O
11	two	N	O
12	groups	N	O
13	were	N	O
14	evaluated	N	O
15	.	N	O

1	DC/CIK	N	I-Premise
2	treatment	N	I-Premise
3	prolongs	N	I-Premise
4	progression-free	N	I-Premise
5	survival	N	I-Premise
6	(	N	I-Premise
7	3.20	N	I-Premise
8	months	N	I-Premise
9	[	N	I-Premise
10	95	N	I-Premise
11	%	N	I-Premise
12	CI	N	I-Premise
13	,	N	I-Premise
14	2.94-3.50	N	I-Premise
15	]	N	I-Premise
16	vs	N	I-Premise
17	2.56	N	I-Premise
18	months	N	I-Premise
19	[	N	I-Premise
20	95	N	I-Premise
21	%	N	I-Premise
22	CI	N	I-Premise
23	,	N	I-Premise
24	2.39-2.73	N	I-Premise
25	]	N	I-Premise
26	;	N	I-Premise
27	P	N	I-Premise
28	<	N	I-Premise
29	0.05	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	treatment	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	proportion	N	I-Premise
8	of	N	I-Premise
9	NK	N	I-Premise
10	cells	N	I-Premise
11	,	N	I-Premise
12	T-cell	N	I-Premise
13	subgroups	N	I-Premise
14	CD3+	N	I-Premise
15	,	N	I-Premise
16	CD4+	N	I-Premise
17	and	N	I-Premise
18	CD8+	N	I-Premise
19	had	N	I-Premise
20	a	N	I-Premise
21	significant	N	I-Premise
22	change	N	I-Premise
23	before	N	I-Premise
24	and	N	I-Premise
25	after	N	I-Premise
26	treatment	N	I-Premise
27	.	N	I-Premise

1	Liver	N	I-Premise
2	and	N	I-Premise
3	kidney	N	I-Premise
4	function	N	I-Premise
5	and	N	I-Premise
6	blood	N	I-Premise
7	tests	N	I-Premise
8	of	N	I-Premise
9	the	N	I-Premise
10	treatment	N	I-Premise
11	group	N	I-Premise
12	were	N	I-Premise
13	within	N	I-Premise
14	the	N	I-Premise
15	normal	N	I-Premise
16	range	N	I-Premise
17	before	N	I-Premise
18	and	N	I-Premise
19	after	N	I-Premise
20	treatment	N	I-Premise
21	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	treatment	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	1	N	I-Premise
7	case	N	I-Premise
8	suffered	N	I-Premise
9	from	N	I-Premise
10	chest	N	I-Premise
11	distress	N	I-Premise
12	,	N	I-Premise
13	3	N	I-Premise
14	cases	N	I-Premise
15	suffered	N	I-Premise
16	from	N	I-Premise
17	acratia	N	I-Premise
18	,	N	I-Premise
19	and	N	I-Premise
20	4	N	I-Premise
21	cases	N	I-Premise
22	suffered	N	I-Premise
23	from	N	I-Premise
24	pyrexia	N	I-Premise
25	.	N	I-Premise

1	DC/CIK	N	I-Claim
2	treatment	N	I-Claim
3	had	N	I-Claim
4	potential	N	I-Claim
5	benefit	N	I-Claim
6	for	N	I-Claim
7	patients	N	I-Claim
8	with	N	I-Claim
9	advanced	N	I-Claim
10	non-small	N	I-Claim
11	cell	N	I-Claim
12	lung	N	I-Claim
13	cancer	N	I-Claim
14	compared	N	I-Claim
15	with	N	I-Claim
16	the	N	I-Claim
17	control	N	I-Claim
18	group	N	I-Claim
19	and	N	I-Claim
20	had	N	I-Claim
21	no	N	I-Claim
22	obvious	N	I-Claim
23	side	N	I-Claim
24	effects	N	I-Claim
25	.	N	I-Claim

1	DC/CIK	N	I-Claim
2	treatment	N	I-Claim
3	is	N	I-Claim
4	a	N	I-Claim
5	safe	N	I-Claim
6	and	N	I-Claim
7	effective	N	I-Claim
8	method	N	I-Claim
9	for	N	I-Claim
10	maintenance	N	I-Claim
11	therapy	N	I-Claim
12	of	N	I-Claim
13	advanced	N	I-Claim
14	non-small	N	I-Claim
15	cell	N	I-Claim
16	lung	N	I-Claim
17	cancer	N	I-Claim
18	.	N	I-Claim

1	Nocturnal	N	O
2	administration	N	O
3	of	N	O
4	branched-chain	N	O
5	amino	N	O
6	acid	N	O
7	(	N	O
8	BCAA	N	O
9	)	N	O
10	granules	N	O
11	improves	N	O
12	serum	N	O
13	albumin	N	O
14	levels	N	O
15	in	N	O
16	patients	N	O
17	with	N	O
18	cirrhosis	N	O
19	.	N	O

1	However	N	O
2	,	N	O
3	it	N	O
4	is	N	O
5	unclear	N	O
6	whether	N	O
7	or	N	O
8	not	N	O
9	this	N	O
10	administration	N	O
11	method	N	O
12	can	N	O
13	improve	N	O
14	the	N	O
15	patients	N	O
16	'	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	(	N	O
21	QOL	N	O
22	)	N	O
23	.	N	O

1	In	N	O
2	this	N	O
3	study	N	O
4	,	N	O
5	we	N	O
6	aimed	N	O
7	to	N	O
8	investigate	N	O
9	the	N	O
10	efficacy	N	O
11	of	N	O
12	BCAA	N	O
13	granules	N	O
14	,	N	O
15	given	N	O
16	nocturnally	N	O
17	,	N	O
18	in	N	O
19	improving	N	O
20	QOL	N	O
21	in	N	O
22	these	N	O
23	patients	N	O
24	.	N	O

1	We	N	O
2	performed	N	O
3	a	N	O
4	multicenter	N	O
5	,	N	O
6	randomized	N	O
7	controlled	N	O
8	trial	N	O
9	examining	N	O
10	the	N	O
11	comparative	N	O
12	effects	N	O
13	of	N	O
14	BCAA	N	O
15	granules	N	O
16	given	N	O
17	orally	N	O
18	for	N	O
19	3	N	O
20	months	N	O
21	with	N	O
22	daytime	N	O
23	or	N	O
24	nocturnal	N	O
25	administration	N	O
26	in	N	O
27	patients	N	O
28	with	N	O
29	compensated	N	O
30	cirrhosis	N	O
31	.	N	O

1	Health-related	N	O
2	QOL	N	O
3	was	N	O
4	measured	N	O
5	by	N	O
6	a	N	O
7	Japanese	N	O
8	version	N	O
9	of	N	O
10	the	N	O
11	questionnaire	N	O
12	on	N	O
13	subjective	N	O
14	and	N	O
15	objective	N	O
16	symptoms	N	O
17	,	N	O
18	and	N	O
19	the	N	O
20	Short	N	O
21	Form-8	N	O
22	(	N	O
23	SF-8	N	O
24	)	N	O
25	questionnaire	N	O
26	.	N	O

1	Twenty-one	N	O
2	patients	N	O
3	received	N	O
4	BCAA	N	O
5	granules	N	O
6	three	N	O
7	times	N	O
8	a	N	O
9	day	N	O
10	(	N	O
11	one	N	O
12	sachet	N	O
13	after	N	O
14	each	N	O
15	meal	N	O
16	:	N	O
17	the	N	O
18	daytime	N	O
19	group	N	O
20	)	N	O
21	,	N	O
22	and	N	O
23	16	N	O
24	patients	N	O
25	received	N	O
26	the	N	O
27	granules	N	O
28	twice	N	O
29	a	N	O
30	day	N	O
31	(	N	O
32	one	N	O
33	sachet	N	O
34	after	N	O
35	breakfast	N	O
36	,	N	O
37	and	N	O
38	two	N	O
39	sachets	N	O
40	before	N	O
41	bedtime	N	O
42	:	N	O
43	the	N	O
44	nocturnal	N	O
45	group	N	O
46	)	N	O
47	.	N	O

1	Baseline	N	O
2	characteristics	N	O
3	did	N	O
4	not	N	O
5	differ	N	O
6	between	N	O
7	the	N	O
8	groups	N	O
9	(	N	O
10	whole	N	O
11	cohort	N	O
12	:	N	O
13	Child-Pugh	N	O
14	grade	N	O
15	A/B	N	O
16	,	N	O
17	21/16	N	O
18	;	N	O
19	mean	N	O
20	age	N	O
21	,	N	O
22	68.2	N	O
23	years	N	O
24	)	N	O
25	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	any	N	I-Premise
8	of	N	I-Premise
9	the	N	I-Premise
10	subjects	N	I-Premise
11	revealed	N	I-Premise
12	by	N	I-Premise
13	the	N	I-Premise
14	questionnaire	N	I-Premise
15	regarding	N	I-Premise
16	subjective	N	I-Premise
17	or	N	I-Premise
18	objective	N	I-Premise
19	symptoms	N	I-Premise
20	,	N	I-Premise
21	or	N	I-Premise
22	by	N	I-Premise
23	the	N	I-Premise
24	SF-8	N	I-Premise
25	between	N	I-Premise
26	the	N	I-Premise
27	daytime	N	I-Premise
28	group	N	I-Premise
29	and	N	I-Premise
30	the	N	I-Premise
31	nocturnal	N	I-Premise
32	group	N	I-Premise
33	after	N	I-Premise
34	3	N	I-Premise
35	months	N	I-Premise
36	of	N	I-Premise
37	treatment	N	I-Premise
38	.	N	I-Premise

1	The	N	I-Premise
2	daytime	N	I-Premise
3	group	N	I-Premise
4	showed	N	I-Premise
5	a	N	I-Premise
6	significant	N	I-Premise
7	effect	N	I-Premise
8	on	N	I-Premise
9	general	N	I-Premise
10	health	N	I-Premise
11	,	N	I-Premise
12	vitality	N	I-Premise
13	,	N	I-Premise
14	social	N	I-Premise
15	functioning	N	I-Premise
16	,	N	I-Premise
17	mental	N	I-Premise
18	health	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	role	N	I-Premise
22	emotional	N	I-Premise
23	as	N	I-Premise
24	revealed	N	I-Premise
25	on	N	I-Premise
26	the	N	I-Premise
27	SF-8	N	I-Premise
28	.	N	I-Premise

1	Conversely	N	I-Premise
2	,	N	I-Premise
3	the	N	I-Premise
4	nocturnal	N	I-Premise
5	group	N	I-Premise
6	exhibited	N	I-Premise
7	a	N	I-Premise
8	significant	N	I-Premise
9	decrease	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	occurrence	N	I-Premise
13	of	N	I-Premise
14	muscle	N	I-Premise
15	cramps	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	legs	N	I-Premise
19	(	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	0.014	N	I-Premise
23	)	N	I-Premise
24	and	N	I-Premise
25	significantly	N	I-Premise
26	improved	N	I-Premise
27	Fisher	N	I-Premise
28	's	N	I-Premise
29	ratio	N	I-Premise
30	after	N	I-Premise
31	3	N	I-Premise
32	months	N	I-Premise
33	(	N	I-Premise
34	P	N	I-Premise
35	=	N	I-Premise
36	0.04	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	Nocturnal	N	I-Claim
2	administration	N	I-Claim
3	of	N	I-Claim
4	BCAA	N	I-Claim
5	granules	N	I-Claim
6	in	N	I-Claim
7	patients	N	I-Claim
8	with	N	I-Claim
9	cirrhosis	N	I-Claim
10	reduced	N	I-Claim
11	the	N	I-Claim
12	occurrence	N	I-Claim
13	of	N	I-Claim
14	muscle	N	I-Claim
15	cramps	N	I-Claim
16	in	N	I-Claim
17	the	N	I-Claim
18	leg	N	I-Claim
19	but	N	I-Claim
20	did	N	I-Claim
21	not	N	I-Claim
22	improve	N	I-Claim
23	the	N	I-Claim
24	patients	N	I-Claim
25	'	N	I-Claim
26	QOL	N	I-Claim
27	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	prospective	N	O
6	controlled	N	O
7	study	N	O
8	was	N	O
9	to	N	O
10	assess	N	O
11	the	N	O
12	efficacy	N	O
13	of	N	O
14	two	N	O
15	different	N	O
16	combination	N	O
17	treatment	N	O
18	modalities	N	O
19	of	N	O
20	lymphedema	N	O
21	(	N	O
22	LE	N	O
23	)	N	O
24	.	N	O

1	Manual	N	O
2	lymphatic	N	O
3	drainage	N	O
4	(	N	O
5	MLD	N	O
6	)	N	O
7	and	N	O
8	compression	N	O
9	bandage	N	O
10	combination	N	O
11	(	N	O
12	complex	N	O
13	decongestive	N	O
14	therapy	N	O
15	)	N	O
16	have	N	O
17	been	N	O
18	compared	N	O
19	with	N	O
20	intermittent	N	O
21	pneumatic	N	O
22	compression	N	O
23	(	N	O
24	IPC	N	O
25	)	N	O
26	plus	N	O
27	self-lymphatic	N	O
28	drainage	N	O
29	(	N	O
30	SLD	N	O
31	)	N	O
32	.	N	O

1	Both	N	O
2	MLD	N	O
3	with	N	O
4	compression	N	O
5	bandage	N	O
6	(	N	O
7	complex	N	O
8	decongestive	N	O
9	therapy	N	O
10	)	N	O
11	group	N	O
12	(	N	O
13	Group	N	O
14	I	N	O
15	,	N	O
16	n=15	N	O
17	)	N	O
18	and	N	O
19	IPC	N	O
20	with	N	O
21	SLD	N	O
22	group	N	O
23	(	N	O
24	Group	N	O
25	II	N	O
26	,	N	O
27	n=15	N	O
28	)	N	O
29	received	N	O
30	treatment	N	O
31	for	N	O
32	LE	N	O
33	3	N	O
34	days	N	O
35	in	N	O
36	a	N	O
37	week	N	O
38	and	N	O
39	every	N	O
40	other	N	O
41	day	N	O
42	for	N	O
43	6	N	O
44	weeks	N	O
45	.	N	O

1	Arm	N	O
2	circumferences	N	O
3	were	N	O
4	measured	N	O
5	before	N	O
6	and	N	O
7	the	N	O
8	1st	N	O
9	,	N	O
10	3rd	N	O
11	,	N	O
12	and	N	O
13	6th	N	O
14	weeks	N	O
15	of	N	O
16	the	N	O
17	treatment	N	O
18	.	N	O

1	EORTC-QLQ	N	O
2	and	N	O
3	ASES-tests	N	O
4	were	N	O
5	performed	N	O
6	to	N	O
7	assess	N	O
8	the	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	before	N	O
13	and	N	O
14	after	N	O
15	6	N	O
16	week-treatment	N	O
17	.	N	O

1	Patients	N	O
2	in	N	O
3	both	N	O
4	groups	N	O
5	had	N	O
6	similar	N	O
7	demographic	N	O
8	and	N	O
9	clinical	N	O
10	characteristics	N	O
11	.	N	O

1	Even	N	O
2	though	N	O
3	both	N	I-Premise
4	treatment	N	I-Premise
5	modalities	N	I-Premise
6	resulted	N	I-Premise
7	in	N	I-Premise
8	significant	N	I-Premise
9	decrease	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	total	N	I-Premise
13	arm	N	I-Premise
14	volume	N	I-Premise
15	(	N	I-Premise
16	12.2	N	I-Premise
17	%	N	I-Premise
18	decrease	N	I-Premise
19	in	N	I-Premise
20	Group	N	I-Premise
21	II	N	I-Premise
22	and	N	I-Premise
23	14.9	N	I-Premise
24	%	N	I-Premise
25	decrease	N	I-Premise
26	in	N	I-Premise
27	Group	N	I-Premise
28	I	N	I-Premise
29	)	N	I-Premise
30	(	N	I-Premise
31	p	N	I-Premise
32	<	N	I-Premise
33	0.001	N	I-Premise
34	)	N	I-Premise
35	,	N	I-Premise
36	no	N	I-Premise
37	significant	N	I-Premise
38	difference	N	I-Premise
39	(	N	I-Premise
40	p=0.582	N	I-Premise
41	)	N	I-Premise
42	was	N	I-Premise
43	found	N	I-Premise
44	between	N	I-Premise
45	those	N	I-Premise
46	two	N	I-Premise
47	groups	N	I-Premise
48	.	N	I-Premise

1	Similarly	N	I-Premise
2	,	N	I-Premise
3	ASES	N	I-Premise
4	scores	N	I-Premise
5	were	N	I-Premise
6	significantly	N	I-Premise
7	(	N	I-Premise
8	p=0.001	N	I-Premise
9	)	N	I-Premise
10	improved	N	I-Premise
11	in	N	I-Premise
12	both	N	I-Premise
13	Group	N	I-Premise
14	I	N	I-Premise
15	and	N	I-Premise
16	II	N	I-Premise
17	without	N	I-Premise
18	any	N	I-Premise
19	significant	N	I-Premise
20	difference	N	I-Premise
21	between	N	I-Premise
22	the	N	I-Premise
23	groups	N	I-Premise
24	.	N	I-Premise

1	While	N	I-Premise
2	emotional	N	I-Premise
3	functioning	N	I-Premise
4	,	N	I-Premise
5	fatigue	N	I-Premise
6	,	N	I-Premise
7	and	N	I-Premise
8	pain	N	I-Premise
9	scores	N	I-Premise
10	were	N	I-Premise
11	significantly	N	I-Premise
12	improved	N	I-Premise
13	in	N	I-Premise
14	both	N	I-Premise
15	groups	N	I-Premise
16	,	N	I-Premise
17	global	N	I-Premise
18	health	N	I-Premise
19	status	N	I-Premise
20	,	N	I-Premise
21	functional	N	I-Premise
22	and	N	I-Premise
23	cognitive	N	I-Premise
24	functioning	N	I-Premise
25	scores	N	I-Premise
26	appeared	N	I-Premise
27	to	N	I-Premise
28	be	N	I-Premise
29	improved	N	I-Premise
30	only	N	I-Premise
31	in	N	I-Premise
32	patients	N	I-Premise
33	of	N	I-Premise
34	group	N	I-Premise
35	I	N	I-Premise
36	.	N	I-Premise

1	Different	N	I-Claim
2	treatment	N	I-Claim
3	modalities	N	I-Claim
4	consisting	N	I-Claim
5	of	N	I-Claim
6	MLD	N	I-Claim
7	and	N	I-Claim
8	compression	N	I-Claim
9	bandage	N	I-Claim
10	(	N	I-Claim
11	complex	N	I-Claim
12	decongestive	N	I-Claim
13	therapy	N	I-Claim
14	)	N	I-Claim
15	or	N	I-Claim
16	IPC	N	I-Claim
17	and	N	I-Claim
18	SLD	N	I-Claim
19	appear	N	I-Claim
20	to	N	I-Claim
21	be	N	I-Claim
22	effective	N	I-Claim
23	in	N	I-Claim
24	the	N	I-Claim
25	treatment	N	I-Claim
26	of	N	I-Claim
27	LE	N	I-Claim
28	with	N	I-Claim
29	similar	N	I-Claim
30	therapeutic	N	I-Claim
31	efficacy	N	I-Claim
32	in	N	I-Claim
33	patients	N	I-Claim
34	with	N	I-Claim
35	breast	N	I-Claim
36	cancer	N	I-Claim
37	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	combination	N	I-Claim
4	modalities	N	I-Claim
5	including	N	I-Claim
6	IPC	N	I-Claim
7	and	N	I-Claim
8	SLD	N	I-Claim
9	may	N	I-Claim
10	be	N	I-Claim
11	the	N	I-Claim
12	preferred	N	I-Claim
13	choices	N	I-Claim
14	for	N	I-Claim
15	their	N	I-Claim
16	applicability	N	I-Claim
17	at	N	I-Claim
18	home	N	I-Claim
19	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	study	N	O
6	is	N	O
7	to	N	O
8	demonstrate	N	O
9	that	N	O
10	intrapatient	N	O
11	dose	N	O
12	escalation	N	O
13	of	N	O
14	carboplatin	N	O
15	would	N	O
16	improve	N	O
17	the	N	O
18	outcome	N	O
19	in	N	O
20	ovarian	N	O
21	cancer	N	O
22	compared	N	O
23	with	N	O
24	flat	N	O
25	dosing	N	O
26	.	N	O

1	Patients	N	O
2	with	N	O
3	untreated	N	O
4	stage	N	O
5	IC-IV	N	O
6	ovarian	N	O
7	cancer	N	O
8	received	N	O
9	six	N	O
10	cycles	N	O
11	of	N	O
12	carboplatin	N	O
13	area	N	O
14	under	N	O
15	the	N	O
16	curve	N	O
17	6	N	O
18	(	N	O
19	AUC	N	O
20	6	N	O
21	)	N	O
22	3	N	O
23	weekly	N	O
24	either	N	O
25	with	N	O
26	no	N	O
27	dose	N	O
28	modification	N	O
29	except	N	O
30	for	N	O
31	toxicity	N	O
32	(	N	O
33	Arm	N	O
34	A	N	O
35	)	N	O
36	or	N	O
37	with	N	O
38	dose	N	O
39	escalations	N	O
40	in	N	O
41	cycles	N	O
42	2-6	N	O
43	based	N	O
44	on	N	O
45	nadir	N	O
46	neutrophil	N	O
47	and	N	O
48	platelet	N	O
49	counts	N	O
50	(	N	O
51	Arm	N	O
52	B	N	O
53	)	N	O
54	.	N	O

1	The	N	O
2	primary	N	O
3	end-point	N	O
4	was	N	O
5	progression-free	N	O
6	survival	N	O
7	(	N	O
8	PFS	N	O
9	)	N	O
10	.	N	O

1	Nine	N	O
2	hundred	N	O
3	and	N	O
4	sixty-four	N	O
5	patients	N	O
6	were	N	O
7	recruited	N	O
8	from	N	O
9	71	N	O
10	centers	N	O
11	.	N	O

1	Dose	N	O
2	escalation	N	O
3	was	N	O
4	achieved	N	O
5	in	N	O
6	77	N	O
7	%	N	O
8	of	N	O
9	patients	N	O
10	who	N	O
11	had	N	O
12	≥1	N	O
13	cycle	N	O
14	.	N	O

1	The	N	I-Premise
2	median	N	I-Premise
3	AUCs	N	I-Premise
4	(	N	I-Premise
5	cycle	N	I-Premise
6	2-6	N	I-Premise
7	)	N	I-Premise
8	received	N	I-Premise
9	were	N	I-Premise
10	6.0	N	I-Premise
11	(	N	I-Premise
12	Arm	N	I-Premise
13	A	N	I-Premise
14	)	N	I-Premise
15	and	N	I-Premise
16	7.2	N	I-Premise
17	(	N	I-Premise
18	Arm	N	I-Premise
19	B	N	I-Premise
20	)	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	<	N	I-Premise
24	0.001	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	Grade	N	I-Premise
2	3/4	N	I-Premise
3	non-hematological	N	I-Premise
4	toxicity	N	I-Premise
5	was	N	I-Premise
6	higher	N	I-Premise
7	in	N	I-Premise
8	Arm	N	I-Premise
9	B	N	I-Premise
10	(	N	I-Premise
11	31	N	I-Premise
12	%	N	I-Premise
13	versus	N	I-Premise
14	22	N	I-Premise
15	%	N	I-Premise
16	P	N	I-Premise
17	=	N	I-Premise
18	0.001	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	PFS	N	I-Premise
4	was	N	I-Premise
5	12.1	N	I-Premise
6	months	N	I-Premise
7	in	N	I-Premise
8	Arm	N	I-Premise
9	A	N	I-Premise
10	and	N	I-Premise
11	B	N	I-Premise
12	[	N	I-Premise
13	hazard	N	I-Premise
14	ratio	N	I-Premise
15	(	N	I-Premise
16	HR	N	I-Premise
17	)	N	I-Premise
18	0.99	N	I-Premise
19	;	N	I-Premise
20	95	N	I-Premise
21	%	N	I-Premise
22	confidence	N	I-Premise
23	interval	N	I-Premise
24	(	N	I-Premise
25	CI	N	I-Premise
26	)	N	I-Premise
27	0.85-1.15	N	I-Premise
28	;	N	I-Premise
29	P	N	I-Premise
30	=	N	I-Premise
31	0.93	N	I-Premise
32	]	N	I-Premise
33	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	overall	N	I-Premise
4	survival	N	I-Premise
5	(	N	I-Premise
6	OS	N	I-Premise
7	)	N	I-Premise
8	was	N	I-Premise
9	34.1	N	I-Premise
10	and	N	I-Premise
11	30.7	N	I-Premise
12	months	N	I-Premise
13	in	N	I-Premise
14	Arms	N	I-Premise
15	A	N	I-Premise
16	and	N	I-Premise
17	B	N	I-Premise
18	,	N	I-Premise
19	respectively	N	I-Premise
20	(	N	I-Premise
21	HR	N	I-Premise
22	0.98	N	I-Premise
23	;	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	CI	N	I-Premise
27	0.81-1.18	N	I-Premise
28	,	N	I-Premise
29	P	N	I-Premise
30	=	N	I-Premise
31	0.82	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	In	N	I-Premise
2	multivariate	N	I-Premise
3	analysis	N	I-Premise
4	,	N	I-Premise
5	baseline	N	I-Premise
6	neutrophil	N	I-Premise
7	(	N	I-Premise
8	P	N	I-Premise
9	<	N	I-Premise
10	0.001	N	I-Premise
11	)	N	I-Premise
12	,	N	I-Premise
13	baseline	N	I-Premise
14	platelet	N	I-Premise
15	counts	N	I-Premise
16	(	N	I-Premise
17	P	N	I-Premise
18	<	N	I-Premise
19	0.001	N	I-Premise
20	)	N	I-Premise
21	and	N	I-Premise
22	the	N	I-Premise
23	difference	N	I-Premise
24	between	N	I-Premise
25	white	N	I-Premise
26	blood	N	I-Premise
27	cell	N	I-Premise
28	(	N	I-Premise
29	WBC	N	I-Premise
30	)	N	I-Premise
31	and	N	I-Premise
32	neutrophil	N	I-Premise
33	count	N	I-Premise
34	(	N	I-Premise
35	P	N	I-Premise
36	=	N	I-Premise
37	0.009	N	I-Premise
38	)	N	I-Premise
39	had	N	I-Premise
40	a	N	I-Premise
41	significant	N	I-Premise
42	adverse	N	I-Premise
43	prognostic	N	I-Premise
44	value	N	I-Premise
45	.	N	I-Premise

1	Intrapatient	N	I-Claim
2	dose	N	I-Claim
3	escalation	N	I-Claim
4	of	N	I-Claim
5	carboplatin	N	I-Claim
6	based	N	I-Claim
7	on	N	I-Claim
8	nadir	N	I-Claim
9	blood	N	I-Claim
10	counts	N	I-Claim
11	is	N	I-Claim
12	feasible	N	I-Claim
13	and	N	I-Claim
14	safe	N	I-Claim
15	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	it	N	I-Claim
4	provided	N	I-Claim
5	no	N	I-Claim
6	improvement	N	I-Claim
7	in	N	I-Claim
8	PFS	N	I-Claim
9	or	N	I-Claim
10	OS	N	I-Claim
11	compared	N	I-Claim
12	with	N	I-Claim
13	flat	N	I-Claim
14	dosing	N	I-Claim
15	.	N	I-Claim

1	Baseline	N	O
2	neutrophils	N	O
3	over-ride	N	O
4	nadir	N	O
5	counts	N	O
6	in	N	O
7	prognostic	N	O
8	significance	N	O
9	.	N	O

1	These	N	O
2	data	N	O
3	may	N	O
4	have	N	O
5	wider	N	O
6	implications	N	O
7	particularly	N	O
8	in	N	O
9	respect	N	O
10	of	N	O
11	the	N	O
12	management	N	O
13	of	N	O
14	chemotherapy-induced	N	O
15	neutropenia	N	O
16	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	our	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	evaluate	N	O
9	the	N	O
10	effect	N	O
11	of	N	O
12	cognitive	N	O
13	behavioral	N	O
14	therapy	N	O
15	(	N	O
16	CBT	N	O
17	)	N	O
18	,	N	O
19	physical	N	O
20	exercise	N	O
21	(	N	O
22	PE	N	O
23	)	N	O
24	,	N	O
25	and	N	O
26	of	N	O
27	these	N	O
28	two	N	O
29	interventions	N	O
30	combined	N	O
31	(	N	O
32	CBT/PE	N	O
33	)	N	O
34	on	N	O
35	menopausal	N	O
36	symptoms	N	O
37	(	N	O
38	primary	N	O
39	outcome	N	O
40	)	N	O
41	,	N	O
42	body	N	O
43	image	N	O
44	,	N	O
45	sexual	N	O
46	functioning	N	O
47	,	N	O
48	psychological	N	O
49	well-being	N	O
50	,	N	O
51	and	N	O
52	health-related	N	O
53	quality	N	O
54	of	N	O
55	life	N	O
56	(	N	O
57	secondary	N	O
58	outcomes	N	O
59	)	N	O
60	in	N	O
61	patients	N	O
62	with	N	O
63	breast	N	O
64	cancer	N	O
65	experiencing	N	O
66	treatment-induced	N	O
67	menopause	N	O
68	.	N	O

1	Patients	N	O
2	with	N	O
3	breast	N	O
4	cancer	N	O
5	reporting	N	O
6	treatment-induced	N	O
7	menopausal	N	O
8	symptoms	N	O
9	(	N	O
10	N=422	N	O
11	)	N	O
12	were	N	O
13	randomly	N	O
14	assigned	N	O
15	to	N	O
16	CBT	N	O
17	(	N	O
18	n=109	N	O
19	)	N	O
20	,	N	O
21	PE	N	O
22	(	N	O
23	n=104	N	O
24	)	N	O
25	,	N	O
26	CBT/PE	N	O
27	(	N	O
28	n=106	N	O
29	)	N	O
30	,	N	O
31	or	N	O
32	to	N	O
33	a	N	O
34	waiting	N	O
35	list	N	O
36	control	N	O
37	group	N	O
38	(	N	O
39	n=103	N	O
40	)	N	O
41	.	N	O

1	Self-report	N	O
2	questionnaires	N	O
3	were	N	O
4	completed	N	O
5	at	N	O
6	baseline	N	O
7	,	N	O
8	12	N	O
9	weeks	N	O
10	,	N	O
11	and	N	O
12	6	N	O
13	months	N	O
14	.	N	O

1	Multilevel	N	O
2	procedures	N	O
3	were	N	O
4	used	N	O
5	to	N	O
6	compare	N	O
7	the	N	O
8	intervention	N	O
9	groups	N	O
10	with	N	O
11	the	N	O
12	control	N	O
13	group	N	O
14	over	N	O
15	time	N	O
16	.	N	O

1	Compared	N	I-Premise
2	with	N	I-Premise
3	the	N	I-Premise
4	control	N	I-Premise
5	group	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	intervention	N	I-Premise
9	groups	N	I-Premise
10	had	N	I-Premise
11	a	N	I-Premise
12	significant	N	I-Premise
13	decrease	N	I-Premise
14	in	N	I-Premise
15	levels	N	I-Premise
16	of	N	I-Premise
17	endocrine	N	I-Premise
18	symptoms	N	I-Premise
19	(	N	I-Premise
20	Functional	N	I-Premise
21	Assessment	N	I-Premise
22	of	N	I-Premise
23	Cancer	N	I-Premise
24	Therapy-Endocrine	N	I-Premise
25	Symptoms	N	I-Premise
26	;	N	I-Premise
27	P	N	I-Premise
28	<	N	I-Premise
29	.001	N	I-Premise
30	;	N	I-Premise
31	effect	N	I-Premise
32	size	N	I-Premise
33	,	N	I-Premise
34	0.31-0.52	N	I-Premise
35	)	N	I-Premise
36	and	N	I-Premise
37	urinary	N	I-Premise
38	symptoms	N	I-Premise
39	(	N	I-Premise
40	Bristol	N	I-Premise
41	Female	N	I-Premise
42	Lower	N	I-Premise
43	Urinary	N	I-Premise
44	Tract	N	I-Premise
45	Symptoms	N	I-Premise
46	Questionnaire	N	I-Premise
47	;	N	I-Premise
48	P=.002	N	I-Premise
49	;	N	I-Premise
50	effect	N	I-Premise
51	size	N	I-Premise
52	,	N	I-Premise
53	0.29-0.33	N	I-Premise
54	)	N	I-Premise
55	,	N	I-Premise
56	and	N	I-Premise
57	they	N	I-Premise
58	showed	N	I-Premise
59	an	N	I-Premise
60	improvement	N	I-Premise
61	in	N	I-Premise
62	physical	N	I-Premise
63	functioning	N	I-Premise
64	(	N	I-Premise
65	36-Item	N	I-Premise
66	Short	N	I-Premise
67	Form	N	I-Premise
68	Health	N	I-Premise
69	Survey	N	I-Premise
70	physical	N	I-Premise
71	functioning	N	I-Premise
72	subscale	N	I-Premise
73	;	N	I-Premise
74	P=.002	N	I-Premise
75	;	N	I-Premise
76	effect	N	I-Premise
77	size	N	I-Premise
78	,	N	I-Premise
79	0.37-0.46	N	I-Premise
80	)	N	I-Premise
81	.	N	I-Premise

1	The	N	I-Premise
2	groups	N	I-Premise
3	that	N	I-Premise
4	included	N	I-Premise
5	CBT	N	I-Premise
6	also	N	I-Premise
7	showed	N	I-Premise
8	a	N	I-Premise
9	significant	N	I-Premise
10	decrease	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	perceived	N	I-Premise
14	burden	N	I-Premise
15	of	N	I-Premise
16	hot	N	I-Premise
17	flashes	N	I-Premise
18	and	N	I-Premise
19	night	N	I-Premise
20	sweats	N	I-Premise
21	(	N	I-Premise
22	problem	N	I-Premise
23	rating	N	I-Premise
24	scale	N	I-Premise
25	of	N	I-Premise
26	the	N	I-Premise
27	Hot	N	I-Premise
28	Flush	N	I-Premise
29	Rating	N	I-Premise
30	Scale	N	I-Premise
31	;	N	I-Premise
32	P	N	I-Premise
33	<	N	I-Premise
34	.001	N	I-Premise
35	;	N	I-Premise
36	effect	N	I-Premise
37	size	N	I-Premise
38	,	N	I-Premise
39	0.39-0.56	N	I-Premise
40	)	N	I-Premise
41	and	N	I-Premise
42	an	N	I-Premise
43	increase	N	I-Premise
44	in	N	I-Premise
45	sexual	N	I-Premise
46	activity	N	I-Premise
47	(	N	I-Premise
48	Sexual	N	I-Premise
49	Activity	N	I-Premise
50	Questionnaire	N	I-Premise
51	habit	N	I-Premise
52	subscale	N	I-Premise
53	;	N	I-Premise
54	P=.027	N	I-Premise
55	;	N	I-Premise
56	effect	N	I-Premise
57	size	N	I-Premise
58	,	N	I-Premise
59	0.65	N	I-Premise
60	)	N	I-Premise
61	.	N	I-Premise

1	Most	N	O
2	of	N	O
3	these	N	O
4	effects	N	O
5	were	N	O
6	observed	N	O
7	at	N	O
8	both	N	O
9	the	N	O
10	12-week	N	O
11	and	N	O
12	6-month	N	O
13	follow-ups	N	O
14	.	N	O

1	CBT	N	I-Claim
2	and	N	I-Claim
3	PE	N	I-Claim
4	can	N	I-Claim
5	have	N	I-Claim
6	salutary	N	I-Claim
7	effects	N	I-Claim
8	on	N	I-Claim
9	endocrine	N	I-Claim
10	symptoms	N	I-Claim
11	and	N	I-Claim
12	,	N	I-Claim
13	to	N	I-Claim
14	a	N	I-Claim
15	lesser	N	I-Claim
16	degree	N	I-Claim
17	,	N	I-Claim
18	on	N	I-Claim
19	sexuality	N	I-Claim
20	and	N	I-Claim
21	physical	N	I-Claim
22	functioning	N	I-Claim
23	of	N	I-Claim
24	patients	N	I-Claim
25	with	N	I-Claim
26	breast	N	I-Claim
27	cancer	N	I-Claim
28	experiencing	N	I-Claim
29	treatment-induced	N	I-Claim
30	menopause	N	I-Claim
31	.	N	I-Claim

1	Future	N	I-Claim
2	work	N	I-Claim
3	is	N	I-Claim
4	needed	N	I-Claim
5	to	N	I-Claim
6	improve	N	I-Claim
7	the	N	I-Claim
8	design	N	I-Claim
9	and	N	I-Claim
10	the	N	I-Claim
11	planning	N	I-Claim
12	of	N	I-Claim
13	these	N	I-Claim
14	interventions	N	I-Claim
15	to	N	I-Claim
16	improve	N	I-Claim
17	program	N	I-Claim
18	adherence	N	I-Claim
19	.	N	I-Claim

1	To	N	O
2	report	N	O
3	5-year	N	O
4	contrast-enhanced	N	O
5	magnetic	N	O
6	resonance	N	O
7	imaging	N	O
8	findings	N	O
9	of	N	O
10	the	N	O
11	REST	N	O
12	trial	N	O
13	recruits	N	O
14	who	N	O
15	underwent	N	O
16	either	N	O
17	uterine	N	O
18	artery	N	O
19	embolization	N	O
20	(	N	O
21	UAE	N	O
22	)	N	O
23	or	N	O
24	myomectomy	N	O
25	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	157	N	O
5	patients	N	O
6	were	N	O
7	randomized	N	O
8	to	N	O
9	UAE	N	O
10	or	N	O
11	surgery	N	O
12	(	N	O
13	hysterectomy	N	O
14	or	N	O
15	myomectomy	N	O
16	)	N	O
17	.	N	O

1	Ninety-nine	N	O
2	patients	N	O
3	who	N	O
4	had	N	O
5	UAE	N	O
6	and	N	O
7	eight	N	O
8	patients	N	O
9	who	N	O
10	had	N	O
11	myomectomy	N	O
12	were	N	O
13	analyzed	N	O
14	.	N	O

1	MRI	N	O
2	scans	N	O
3	at	N	O
4	baseline	N	O
5	,	N	O
6	6	N	O
7	months	N	O
8	,	N	O
9	and	N	O
10	5	N	O
11	years	N	O
12	were	N	O
13	independently	N	O
14	interpreted	N	O
15	by	N	O
16	two	N	O
17	radiologists	N	O
18	.	N	O

1	Dominant	N	O
2	fibroid	N	O
3	diameter	N	O
4	,	N	O
5	uterine	N	O
6	volume	N	O
7	,	N	O
8	total	N	O
9	fibroid	N	O
10	infarction	N	O
11	(	N	O
12	complete	N	O
13	100	N	O
14	%	N	O
15	,	N	O
16	almost	N	O
17	complete	N	O
18	90-99	N	O
19	%	N	O
20	,	N	O
21	partial	N	O
22	<	N	O
23	90	N	O
24	%	N	O
25	)	N	O
26	,	N	O
27	and	N	O
28	new	N	O
29	fibroid	N	O
30	formation	N	O
31	were	N	O
32	the	N	O
33	main	N	O
34	parameters	N	O
35	assessed	N	O
36	and	N	O
37	related	N	O
38	to	N	O
39	the	N	O
40	need	N	O
41	for	N	O
42	reintervention	N	O
43	.	N	O

1	In	N	I-Premise
2	the	N	I-Premise
3	UAE	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	mean	N	I-Premise
7	±	N	I-Premise
8	standard	N	I-Premise
9	deviation	N	I-Premise
10	uterine	N	I-Premise
11	volume	N	I-Premise
12	was	N	I-Premise
13	670	N	I-Premise
14	±	N	I-Premise
15	503	N	I-Premise
16	,	N	I-Premise
17	422	N	I-Premise
18	±	N	I-Premise
19	353	N	I-Premise
20	,	N	I-Premise
21	and	N	I-Premise
22	292	N	I-Premise
23	±	N	I-Premise
24	287	N	I-Premise
25	mL	N	I-Premise
26	at	N	I-Premise
27	baseline	N	I-Premise
28	,	N	I-Premise
29	6	N	I-Premise
30	months	N	I-Premise
31	,	N	I-Premise
32	and	N	I-Premise
33	5	N	I-Premise
34	years	N	I-Premise
35	,	N	I-Premise
36	respectively	N	I-Premise
37	.	N	I-Premise

1	Mean	N	I-Premise
2	dominant	N	I-Premise
3	fibroid	N	I-Premise
4	diameter	N	I-Premise
5	was	N	I-Premise
6	7.6	N	I-Premise
7	±	N	I-Premise
8	3.0	N	I-Premise
9	,	N	I-Premise
10	5.8	N	I-Premise
11	±	N	I-Premise
12	2.9	N	I-Premise
13	,	N	I-Premise
14	and	N	I-Premise
15	5	N	I-Premise
16	±	N	I-Premise
17	2.9	N	I-Premise
18	cm	N	I-Premise
19	at	N	I-Premise
20	baseline	N	I-Premise
21	,	N	I-Premise
22	6	N	I-Premise
23	months	N	I-Premise
24	,	N	I-Premise
25	and	N	I-Premise
26	5	N	I-Premise
27	years	N	I-Premise
28	.	N	I-Premise

1	Fibroid	N	I-Premise
2	infarction	N	I-Premise
3	at	N	I-Premise
4	6	N	I-Premise
5	months	N	I-Premise
6	was	N	I-Premise
7	complete	N	I-Premise
8	in	N	I-Premise
9	35	N	I-Premise
10	%	N	I-Premise
11	of	N	I-Premise
12	women	N	I-Premise
13	,	N	I-Premise
14	almost	N	I-Premise
15	complete	N	I-Premise
16	in	N	I-Premise
17	29	N	I-Premise
18	%	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	partial	N	I-Premise
22	in	N	I-Premise
23	36	N	I-Premise
24	%	N	I-Premise
25	.	N	I-Premise

1	Need	N	I-Premise
2	for	N	I-Premise
3	reintervention	N	I-Premise
4	was	N	I-Premise
5	19	N	I-Premise
6	,	N	I-Premise
7	10	N	I-Premise
8	,	N	I-Premise
9	and	N	I-Premise
10	33	N	I-Premise
11	%	N	I-Premise
12	in	N	I-Premise
13	these	N	I-Premise
14	groups	N	I-Premise
15	,	N	I-Premise
16	respectively	N	I-Premise
17	(	N	I-Premise
18	p	N	I-Premise
19	=	N	I-Premise
20	0.123	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	No	N	I-Premise
2	myomectomy	N	I-Premise
3	cases	N	I-Premise
4	had	N	I-Premise
5	further	N	I-Premise
6	intervention	N	I-Premise
7	.	N	I-Premise

1	At	N	I-Premise
2	5	N	I-Premise
3	years	N	I-Premise
4	,	N	I-Premise
5	the	N	I-Premise
6	prevalence	N	I-Premise
7	of	N	I-Premise
8	new	N	I-Premise
9	fibroid	N	I-Premise
10	was	N	I-Premise
11	60	N	I-Premise
12	%	N	I-Premise
13	in	N	I-Premise
14	the	N	I-Premise
15	myomectomy	N	I-Premise
16	group	N	I-Premise
17	and	N	I-Premise
18	7	N	I-Premise
19	%	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	UAE	N	I-Premise
23	group	N	I-Premise
24	(	N	I-Premise
25	p	N	I-Premise
26	=	N	I-Premise
27	0.008	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	There	N	I-Premise
2	is	N	I-Premise
3	a	N	I-Premise
4	further	N	I-Premise
5	significant	N	I-Premise
6	reduction	N	I-Premise
7	in	N	I-Premise
8	both	N	I-Premise
9	uterine	N	I-Premise
10	volume	N	I-Premise
11	and	N	I-Premise
12	dominant	N	I-Premise
13	fibroid	N	I-Premise
14	diameter	N	I-Premise
15	between	N	I-Premise
16	6	N	I-Premise
17	months	N	I-Premise
18	and	N	I-Premise
19	5	N	I-Premise
20	years	N	I-Premise
21	after	N	I-Premise
22	UAE	N	I-Premise
23	.	N	I-Premise

1	Complete	N	I-Claim
2	fibroid	N	I-Claim
3	infarction	N	I-Claim
4	does	N	I-Claim
5	not	N	I-Claim
6	translate	N	I-Claim
7	into	N	I-Claim
8	total	N	I-Claim
9	freedom	N	I-Claim
10	from	N	I-Claim
11	a	N	I-Claim
12	subsequent	N	I-Claim
13	reintervention	N	I-Claim
14	.	N	I-Claim

1	New	N	I-Claim
2	fibroid	N	I-Claim
3	formation	N	I-Claim
4	is	N	I-Claim
5	significantly	N	I-Claim
6	higher	N	I-Claim
7	after	N	I-Claim
8	myomectomy	N	I-Claim
9	.	N	I-Claim

1	Due	N	O
2	to	N	O
3	the	N	O
4	various	N	O
5	inter-individual	N	O
6	differences	N	O
7	in	N	O
8	the	N	O
9	biological	N	O
10	characteristics	N	O
11	of	N	O
12	tumor	N	O
13	cells	N	O
14	,	N	O
15	as	N	O
16	well	N	O
17	as	N	O
18	issues	N	O
19	on	N	O
20	the	N	O
21	efficacy	N	O
22	,	N	O
23	adverse	N	O
24	reactions	N	O
25	,	N	O
26	and	N	O
27	defects	N	O
28	of	N	O
29	existing	N	O
30	drugs	N	O
31	,	N	O
32	we	N	O
33	compared	N	O
34	the	N	O
35	clinical	N	O
36	efficacy	N	O
37	and	N	O
38	toxicity	N	O
39	of	N	O
40	pemetrexed	N	O
41	and	N	O
42	gemcitabine	N	O
43	combined	N	O
44	with	N	O
45	cisplatin	N	O
46	for	N	O
47	the	N	O
48	treatment	N	O
49	of	N	O
50	previously	N	O
51	untreated	N	O
52	advanced	N	O
53	non-small	N	O
54	cell	N	O
55	lung	N	O
56	cancer	N	O
57	(	N	O
58	NSCLC	N	O
59	)	N	O
60	.	N	O

1	251	N	O
2	patients	N	O
3	were	N	O
4	randomly	N	O
5	divided	N	O
6	into	N	O
7	pemetrexed	N	O
8	combined	N	O
9	with	N	O
10	cisplatin	N	O
11	group	N	O
12	(	N	O
13	PP	N	O
14	group	N	O
15	)	N	O
16	with	N	O
17	127	N	O
18	cases	N	O
19	and	N	O
20	gemcitabine	N	O
21	combined	N	O
22	with	N	O
23	cisplatin	N	O
24	group	N	O
25	(	N	O
26	GP	N	O
27	group	N	O
28	)	N	O
29	with	N	O
30	124	N	O
31	cases	N	O
32	.	N	O

1	PP	N	O
2	group	N	O
3	received	N	O
4	pemetrexed	N	O
5	500	N	O
6	mg/m²	N	O
7	iv	N	O
8	infusion	N	O
9	d1	N	O
10	and	N	O
11	cisplatin	N	O
12	75	N	O
13	mg/m²	N	O
14	iv	N	O
15	infusion	N	O
16	d1	N	O
17	,	N	O
18	whereas	N	O
19	GP	N	O
20	group	N	O
21	received	N	O
22	gemcitabine	N	O
23	1,000	N	O
24	mg/m²	N	O
25	iv	N	O
26	infusion	N	O
27	d1,8	N	O
28	and	N	O
29	cisplatin	N	O
30	75	N	O
31	mg/m²	N	O
32	iv	N	O
33	infusion	N	O
34	d1	N	O
35	.	N	O

1	The	N	O
2	treatment	N	O
3	cycle	N	O
4	was	N	O
5	once	N	O
6	every	N	O
7	three	N	O
8	weeks	N	O
9	.	N	O

1	In	N	O
2	addition	N	O
3	,	N	O
4	folic	N	O
5	acid	N	O
6	,	N	O
7	vitamin	N	O
8	B12	N	O
9	,	N	O
10	and	N	O
11	dexamethasone	N	O
12	were	N	O
13	administered	N	O
14	in	N	O
15	both	N	O
16	groups	N	O
17	.	N	O

1	The	N	I-Premise
2	total	N	I-Premise
3	clinical	N	I-Premise
4	effective	N	I-Premise
5	rates	N	I-Premise
6	in	N	I-Premise
7	PP	N	I-Premise
8	group	N	I-Premise
9	and	N	I-Premise
10	GP	N	I-Premise
11	group	N	I-Premise
12	were	N	I-Premise
13	25.20	N	I-Premise
14	%	N	I-Premise
15	and	N	I-Premise
16	17.74	N	I-Premise
17	%	N	I-Premise
18	,	N	I-Premise
19	respectively	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	total	N	I-Premise
3	efficiencies	N	I-Premise
4	of	N	I-Premise
5	non-squamous	N	I-Premise
6	cell	N	I-Premise
7	carcinoma	N	I-Premise
8	were	N	I-Premise
9	27.62	N	I-Premise
10	%	N	I-Premise
11	and	N	I-Premise
12	16.00	N	I-Premise
13	%	N	I-Premise
14	.	N	I-Premise

1	The	N	I-Premise
2	tumor	N	I-Premise
3	progression	N	I-Premise
4	duration	N	I-Premise
5	in	N	I-Premise
6	these	N	I-Premise
7	two	N	I-Premise
8	groups	N	I-Premise
9	was	N	I-Premise
10	6.5	N	I-Premise
11	and	N	I-Premise
12	5.6	N	I-Premise
13	months	N	I-Premise
14	,	N	I-Premise
15	respectively	N	I-Premise
16	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	time	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	two	N	I-Premise
8	groups	N	I-Premise
9	was	N	I-Premise
10	16.9	N	I-Premise
11	and	N	I-Premise
12	17.0	N	I-Premise
13	months	N	I-Premise
14	,	N	I-Premise
15	respectively	N	I-Premise
16	,	N	I-Premise
17	with	N	I-Premise
18	59.62	N	I-Premise
19	%	N	I-Premise
20	and	N	I-Premise
21	65.87	N	I-Premise
22	%	N	I-Premise
23	survival	N	I-Premise
24	rates	N	I-Premise
25	of	N	I-Premise
26	1	N	I-Premise
27	year	N	I-Premise
28	and	N	I-Premise
29	27.28	N	I-Premise
30	%	N	I-Premise
31	and	N	I-Premise
32	27.93	N	I-Premise
33	%	N	I-Premise
34	survival	N	I-Premise
35	rates	N	I-Premise
36	of	N	I-Premise
37	2	N	I-Premise
38	years	N	I-Premise
39	,	N	I-Premise
40	respectively	N	I-Premise
41	.	N	I-Premise

1	The	N	I-Premise
2	total	N	I-Premise
3	efficacy	N	I-Premise
4	of	N	I-Premise
5	non-squamous	N	I-Premise
6	cell	N	I-Premise
7	carcinoma	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	PP	N	I-Premise
11	group	N	I-Premise
12	was	N	I-Premise
13	significantly	N	I-Premise
14	higher	N	I-Premise
15	than	N	I-Premise
16	that	N	I-Premise
17	in	N	I-Premise
18	GP	N	I-Premise
19	group	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	results	N	I-Premise
3	were	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	.	N	I-Premise

1	However	N	O
2	,	N	O
3	there	N	O
4	were	N	O
5	no	N	O
6	significant	N	O
7	differences	N	O
8	in	N	O
9	total	N	O
10	response	N	O
11	rates	N	O
12	,	N	O
13	tumor	N	O
14	progression	N	O
15	duration	N	O
16	,	N	O
17	and	N	O
18	median	N	O
19	survival	N	O
20	rates	N	O
21	of	N	O
22	1	N	O
23	and	N	O
24	2	N	O
25	years	N	O
26	.	N	O

1	The	N	I-Premise
2	rate	N	I-Premise
3	of	N	I-Premise
4	adverse	N	I-Premise
5	reactions	N	I-Premise
6	,	N	I-Premise
7	including	N	I-Premise
8	white	N	I-Premise
9	blood	N	I-Premise
10	cell	N	I-Premise
11	reduction	N	I-Premise
12	,	N	I-Premise
13	lower	N	I-Premise
14	platelet	N	I-Premise
15	count	N	I-Premise
16	,	N	I-Premise
17	lower	N	I-Premise
18	hemoglobin	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	hair	N	I-Premise
22	loss	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	PP	N	I-Premise
26	group	N	I-Premise
27	was	N	I-Premise
28	significantly	N	I-Premise
29	lower	N	I-Premise
30	than	N	I-Premise
31	that	N	I-Premise
32	in	N	I-Premise
33	the	N	I-Premise
34	GP	N	I-Premise
35	group	N	I-Premise
36	.	N	I-Premise

1	The	N	I-Premise
2	results	N	I-Premise
3	were	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	.	N	I-Premise

1	The	N	I-Claim
2	clinical	N	I-Claim
3	efficacy	N	I-Claim
4	of	N	I-Claim
5	pemetrexed	N	I-Claim
6	and	N	I-Claim
7	gemcitabine	N	I-Claim
8	combined	N	I-Claim
9	with	N	I-Claim
10	cisplatin	N	I-Claim
11	for	N	I-Claim
12	the	N	I-Claim
13	treatment	N	I-Claim
14	of	N	I-Claim
15	previously	N	I-Claim
16	untreated	N	I-Claim
17	advanced	N	I-Claim
18	NSCLC	N	I-Claim
19	was	N	I-Claim
20	roughly	N	I-Claim
21	the	N	I-Claim
22	same	N	I-Claim
23	,	N	I-Claim
24	but	N	I-Claim
25	the	N	I-Claim
26	adverse	N	I-Claim
27	reactions	N	I-Claim
28	decreased	N	I-Claim
29	significantly	N	I-Claim
30	in	N	I-Claim
31	the	N	I-Claim
32	PP	N	I-Claim
33	group	N	I-Claim
34	compared	N	I-Claim
35	with	N	I-Claim
36	those	N	I-Claim
37	in	N	I-Claim
38	the	N	I-Claim
39	GP	N	I-Claim
40	group	N	I-Claim
41	.	N	I-Claim

1	Therefore	N	I-MajorClaim
2	,	N	I-MajorClaim
3	pemetrexed	N	I-MajorClaim
4	combined	N	I-MajorClaim
5	with	N	I-MajorClaim
6	cisplatin	N	I-MajorClaim
7	can	N	I-MajorClaim
8	be	N	I-MajorClaim
9	used	N	I-MajorClaim
10	as	N	I-MajorClaim
11	a	N	I-MajorClaim
12	safe	N	I-MajorClaim
13	and	N	I-MajorClaim
14	effective	N	I-MajorClaim
15	drug	N	I-MajorClaim
16	for	N	I-MajorClaim
17	clinical	N	I-MajorClaim
18	first-line	N	I-MajorClaim
19	treatment	N	I-MajorClaim
20	for	N	I-MajorClaim
21	previously	N	I-MajorClaim
22	untreated	N	I-MajorClaim
23	NSCLC	N	I-MajorClaim
24	.	N	I-MajorClaim

1	Cancer	N	O
2	related	N	O
3	fatigue	N	O
4	(	N	O
5	CRF	N	O
6	)	N	O
7	is	N	O
8	a	N	O
9	common	N	O
10	problem	N	O
11	for	N	O
12	cancer	N	O
13	patients	N	O
14	across	N	O
15	diagnoses	N	O
16	during	N	O
17	chemotherapy	N	O
18	and	N	O
19	is	N	O
20	associated	N	O
21	with	N	O
22	physical	N	O
23	inactivity	N	O
24	,	N	O
25	lower	N	O
26	functional	N	O
27	level	N	O
28	and	N	O
29	lack	N	O
30	of	N	O
31	energy	N	O
32	.	N	O

1	Few	N	O
2	RCT	N	O
3	exercise	N	O
4	intervention	N	O
5	studies	N	O
6	have	N	O
7	included	N	O
8	cancer	N	O
9	patients	N	O
10	undergoing	N	O
11	chemotherapy	N	O
12	.	N	O

1	The	N	O
2	objective	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	is	N	O
7	to	N	O
8	evaluate	N	O
9	whether	N	O
10	a	N	O
11	six-week	N	O
12	supervised	N	O
13	multimodal	N	O
14	exercise	N	O
15	intervention	N	O
16	,	N	O
17	adjunct	N	O
18	to	N	O
19	chemotherapy	N	O
20	and	N	O
21	standard	N	O
22	care	N	O
23	,	N	O
24	can	N	O
25	reduce	N	O
26	the	N	O
27	patient	N	O
28	's	N	O
29	CRF	N	O
30	level	N	O
31	.	N	O

1	Data	N	O
2	is	N	O
3	based	N	O
4	on	N	O
5	analyses	N	O
6	of	N	O
7	a	N	O
8	prospective	N	O
9	randomised	N	O
10	controlled	N	O
11	trial	N	O
12	'The	N	O
13	Body	N	O
14	Cancer	N	O
15	Trial	N	O
16	'	N	O
17	.	N	O

1	213	N	O
2	cancer	N	O
3	patients	N	O
4	with	N	O
5	different	N	O
6	diagnoses	N	O
7	were	N	O
8	randomised	N	O
9	into	N	O
10	an	N	O
11	intervention	N	O
12	group	N	O
13	or	N	O
14	wait-list	N	O
15	control	N	O
16	group	N	O
17	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	,	N	O
5	Fatigue	N	O
6	score	N	O
7	(	N	O
8	CRF	N	O
9	)	N	O
10	,	N	O
11	was	N	O
12	evaluated	N	O
13	by	N	O
14	the	N	O
15	Functional	N	O
16	Assessment	N	O
17	of	N	O
18	Cancer	N	O
19	Therapy-Anaemia	N	O
20	Questionnaire	N	O
21	(	N	O
22	FACT-An-	N	O
23	)	N	O
24	(	N	O
25	FACT-G	N	O
26	score	N	O
27	&	N	O
28	FACT-An	N	O
29	Anemia	N	O
30	subscale	N	O
31	)	N	O
32	.	N	O

1	Supervised	N	O
2	exercise	N	O
3	,	N	O
4	comprising	N	O
5	high-intensity	N	O
6	cardiovascular	N	O
7	and	N	O
8	heavy	N	O
9	resistance	N	O
10	training	N	O
11	,	N	O
12	relaxation-	N	O
13	and	N	O
14	body	N	O
15	awareness	N	O
16	training	N	O
17	and	N	O
18	massage	N	O
19	,	N	O
20	9	N	O
21	h	N	O
22	weekly	N	O
23	for	N	O
24	6	N	O
25	weeks	N	O
26	.	N	O

1	CRF	N	I-Premise
2	was	N	I-Premise
3	significantly	N	I-Premise
4	reduced	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	intervention	N	I-Premise
8	group	N	I-Premise
9	,	N	I-Premise
10	corresponding	N	I-Premise
11	to	N	I-Premise
12	a	N	I-Premise
13	Fatigue	N	I-Premise
14	score	N	I-Premise
15	reduction	N	I-Premise
16	of	N	I-Premise
17	3.04	N	I-Premise
18	(	N	I-Premise
19	effect	N	I-Premise
20	size	N	I-Premise
21	of	N	I-Premise
22	0.44	N	I-Premise
23	,	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	CI	N	I-Premise
27	0.17-0.72	N	I-Premise
28	)	N	I-Premise
29	(	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	.002	N	I-Premise
33	)	N	I-Premise
34	,	N	I-Premise
35	the	N	I-Premise
36	FACT-An	N	I-Premise
37	score	N	I-Premise
38	by	N	I-Premise
39	5.40	N	I-Premise
40	(	N	I-Premise
41	P	N	I-Premise
42	=	N	I-Premise
43	.015	N	I-Premise
44	)	N	I-Premise
45	,	N	I-Premise
46	the	N	I-Premise
47	FACT-An	N	I-Premise
48	Toi	N	I-Premise
49	score	N	I-Premise
50	by	N	I-Premise
51	5.22	N	I-Premise
52	(	N	I-Premise
53	P	N	I-Premise
54	=	N	I-Premise
55	.009	N	I-Premise
56	)	N	I-Premise
57	and	N	I-Premise
58	the	N	I-Premise
59	Anaemia-ANS	N	I-Premise
60	by	N	I-Premise
61	3.76	N	I-Premise
62	(	N	I-Premise
63	P	N	I-Premise
64	=	N	I-Premise
65	.002	N	I-Premise
66	)	N	I-Premise
67	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	effect	N	I-Premise
7	on	N	I-Premise
8	the	N	I-Premise
9	General	N	I-Premise
10	Quality	N	I-Premise
11	of	N	I-Premise
12	Life	N	I-Premise
13	score	N	I-Premise
14	(	N	I-Premise
15	FACT-G	N	I-Premise
16	)	N	I-Premise
17	or	N	I-Premise
18	on	N	I-Premise
19	any	N	I-Premise
20	of	N	I-Premise
21	the	N	I-Premise
22	individual	N	I-Premise
23	wellbeing	N	I-Premise
24	scores	N	I-Premise
25	;	N	I-Premise
26	Physical	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	.13	N	I-Premise
31	)	N	I-Premise
32	,	N	I-Premise
33	Emotional	N	I-Premise
34	(	N	I-Premise
35	P	N	I-Premise
36	=	N	I-Premise
37	.87	N	I-Premise
38	)	N	I-Premise
39	,	N	I-Premise
40	Social	N	I-Premise
41	(	N	I-Premise
42	P	N	I-Premise
43	=	N	I-Premise
44	.83	N	I-Premise
45	)	N	I-Premise
46	and	N	I-Premise
47	Functional	N	I-Premise
48	(	N	I-Premise
49	P	N	I-Premise
50	=	N	I-Premise
51	.26	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	In	N	I-Claim
2	summary	N	I-Claim
3	,	N	I-Claim
4	this	N	I-Claim
5	six-week	N	I-Claim
6	supervised	N	I-Claim
7	multimodal	N	I-Claim
8	exercise	N	I-Claim
9	intervention	N	I-Claim
10	can	N	I-Claim
11	lead	N	I-Claim
12	to	N	I-Claim
13	significant	N	I-Claim
14	reduction	N	I-Claim
15	in	N	I-Claim
16	self-reported	N	I-Claim
17	CRF	N	I-Claim
18	in	N	I-Claim
19	cancer	N	I-Claim
20	patients	N	I-Claim
21	undergoing	N	I-Claim
22	chemotherapy	N	I-Claim
23	.	N	I-Claim

1	We	N	O
2	aimed	N	O
3	to	N	O
4	assess	N	O
5	the	N	O
6	effectiveness	N	O
7	of	N	O
8	acupuncture	N	O
9	for	N	O
10	cancer-related	N	O
11	fatigue	N	O
12	(	N	O
13	CRF	N	O
14	)	N	O
15	in	N	O
16	patients	N	O
17	with	N	O
18	breast	N	O
19	cancer	N	O
20	.	N	O

1	We	N	O
2	conducted	N	O
3	a	N	O
4	pragmatic	N	O
5	,	N	O
6	randomized	N	O
7	controlled	N	O
8	trial	N	O
9	comparing	N	O
10	acupuncture	N	O
11	with	N	O
12	enhanced	N	O
13	usual	N	O
14	care	N	O
15	.	N	O

1	Three	N	O
2	hundred	N	O
3	two	N	O
4	outpatients	N	O
5	with	N	O
6	breast	N	O
7	cancer	N	O
8	participated	N	O
9	.	N	O

1	We	N	O
2	randomly	N	O
3	assigned	N	O
4	75	N	O
5	patients	N	O
6	to	N	O
7	usual	N	O
8	care	N	O
9	and	N	O
10	227	N	O
11	patients	N	O
12	to	N	O
13	acupuncture	N	O
14	plus	N	O
15	usual	N	O
16	care	N	O
17	(	N	O
18	random	N	O
19	assignment	N	O
20	of	N	O
21	1:3	N	O
22	respectively	N	O
23	)	N	O
24	with	N	O
25	minimization	N	O
26	controlling	N	O
27	for	N	O
28	baseline	N	O
29	general	N	O
30	fatigue	N	O
31	and	N	O
32	maintenance	N	O
33	treatment	N	O
34	.	N	O

1	Treatment	N	O
2	was	N	O
3	delivered	N	O
4	by	N	O
5	acupuncturists	N	O
6	once	N	O
7	a	N	O
8	week	N	O
9	for	N	O
10	6	N	O
11	weeks	N	O
12	through	N	O
13	needling	N	O
14	three	N	O
15	pairs	N	O
16	of	N	O
17	acupoints	N	O
18	.	N	O

1	The	N	O
2	usual	N	O
3	care	N	O
4	group	N	O
5	received	N	O
6	a	N	O
7	booklet	N	O
8	with	N	O
9	information	N	O
10	about	N	O
11	fatigue	N	O
12	and	N	O
13	its	N	O
14	management	N	O
15	.	N	O

1	Primary	N	O
2	outcome	N	O
3	was	N	O
4	general	N	O
5	fatigue	N	O
6	at	N	O
7	6	N	O
8	weeks	N	O
9	,	N	O
10	measured	N	O
11	with	N	O
12	the	N	O
13	Multidimensional	N	O
14	Fatigue	N	O
15	Inventory	N	O
16	(	N	O
17	MFI	N	O
18	)	N	O
19	.	N	O

1	Other	N	O
2	measurements	N	O
3	included	N	O
4	the	N	O
5	Hospital	N	O
6	Anxiety	N	O
7	and	N	O
8	Depression	N	O
9	Scale	N	O
10	,	N	O
11	Functional	N	O
12	Assessment	N	O
13	of	N	O
14	Cancer	N	O
15	Therapy-General	N	O
16	quality-of-life	N	O
17	scale	N	O
18	,	N	O
19	and	N	O
20	expectation	N	O
21	of	N	O
22	acupuncture	N	O
23	effect	N	O
24	.	N	O

1	Analyses	N	O
2	were	N	O
3	by	N	O
4	intention	N	O
5	to	N	O
6	treat	N	O
7	.	N	O

1	Two	N	O
2	hundred	N	O
3	forty-six	N	O
4	of	N	O
5	302	N	O
6	patients	N	O
7	randomly	N	O
8	assigned	N	O
9	provided	N	O
10	complete	N	O
11	data	N	O
12	at	N	O
13	6	N	O
14	weeks	N	O
15	.	N	O

1	The	N	I-Premise
2	difference	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	mean	N	I-Premise
6	General	N	I-Premise
7	Fatigue	N	I-Premise
8	score	N	I-Premise
9	,	N	I-Premise
10	between	N	I-Premise
11	those	N	I-Premise
12	who	N	I-Premise
13	received	N	I-Premise
14	the	N	I-Premise
15	intervention	N	I-Premise
16	and	N	I-Premise
17	those	N	I-Premise
18	who	N	I-Premise
19	did	N	I-Premise
20	not	N	I-Premise
21	,	N	I-Premise
22	was	N	I-Premise
23	-3.11	N	I-Premise
24	(	N	I-Premise
25	95	N	I-Premise
26	%	N	I-Premise
27	CI	N	I-Premise
28	,	N	I-Premise
29	-3.97	N	I-Premise
30	to	N	I-Premise
31	-2.25	N	I-Premise
32	;	N	I-Premise
33	P	N	I-Premise
34	<	N	I-Premise
35	.001	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	The	N	I-Premise
2	intervention	N	I-Premise
3	also	N	I-Premise
4	improved	N	I-Premise
5	all	N	I-Premise
6	other	N	I-Premise
7	fatigue	N	I-Premise
8	aspects	N	I-Premise
9	measured	N	I-Premise
10	by	N	I-Premise
11	MFI	N	I-Premise
12	,	N	I-Premise
13	including	N	I-Premise
14	Physical	N	I-Premise
15	Fatigue	N	I-Premise
16	and	N	I-Premise
17	Mental	N	I-Premise
18	Fatigue	N	I-Premise
19	(	N	I-Premise
20	acupuncture	N	I-Premise
21	effect	N	I-Premise
22	,	N	I-Premise
23	-2.36	N	I-Premise
24	and	N	I-Premise
25	-1.94	N	I-Premise
26	,	N	I-Premise
27	respectively	N	I-Premise
28	;	N	I-Premise
29	both	N	I-Premise
30	at	N	I-Premise
31	P	N	I-Premise
32	<	N	I-Premise
33	.001	N	I-Premise
34	)	N	I-Premise
35	,	N	I-Premise
36	anxiety	N	I-Premise
37	and	N	I-Premise
38	depression	N	I-Premise
39	(	N	I-Premise
40	acupuncture	N	I-Premise
41	effect	N	I-Premise
42	,	N	I-Premise
43	-1.83	N	I-Premise
44	and	N	I-Premise
45	-2.13	N	I-Premise
46	,	N	I-Premise
47	respectively	N	I-Premise
48	;	N	I-Premise
49	both	N	I-Premise
50	at	N	I-Premise
51	P	N	I-Premise
52	<	N	I-Premise
53	.001	N	I-Premise
54	)	N	I-Premise
55	,	N	I-Premise
56	and	N	I-Premise
57	quality	N	I-Premise
58	of	N	I-Premise
59	life	N	I-Premise
60	(	N	I-Premise
61	Physical	N	I-Premise
62	Well-Being	N	I-Premise
63	effect	N	I-Premise
64	,	N	I-Premise
65	3.30	N	I-Premise
66	;	N	I-Premise
67	Functional	N	I-Premise
68	Well-Being	N	I-Premise
69	effect	N	I-Premise
70	,	N	I-Premise
71	3.57	N	I-Premise
72	;	N	I-Premise
73	both	N	I-Premise
74	at	N	I-Premise
75	P	N	I-Premise
76	<	N	I-Premise
77	.001	N	I-Premise
78	;	N	I-Premise
79	Emotional	N	I-Premise
80	Well-Being	N	I-Premise
81	effect	N	I-Premise
82	,	N	I-Premise
83	1.93	N	I-Premise
84	;	N	I-Premise
85	P	N	I-Premise
86	=	N	I-Premise
87	.001	N	I-Premise
88	;	N	I-Premise
89	and	N	I-Premise
90	Social	N	I-Premise
91	Functioning	N	I-Premise
92	Well-Being	N	I-Premise
93	effect	N	I-Premise
94	,	N	I-Premise
95	1.05	N	I-Premise
96	;	N	I-Premise
97	P	N	I-Premise
98	<	N	I-Premise
99	.05	N	I-Premise
100	)	N	I-Premise
101	.	N	I-Premise

1	Acupuncture	N	I-Claim
2	is	N	I-Claim
3	an	N	I-Claim
4	effective	N	I-Claim
5	intervention	N	I-Claim
6	for	N	I-Claim
7	managing	N	I-Claim
8	the	N	I-Claim
9	symptom	N	I-Claim
10	of	N	I-Claim
11	CRF	N	I-Claim
12	and	N	I-Claim
13	improving	N	I-Claim
14	patients	N	I-Claim
15	'	N	I-Claim
16	quality	N	I-Claim
17	of	N	I-Claim
18	life	N	I-Claim
19	.	N	I-Claim

1	Exercise	N	O
2	for	N	O
3	Health	N	O
4	was	N	O
5	a	N	O
6	randomized	N	O
7	,	N	O
8	controlled	N	O
9	trial	N	O
10	designed	N	O
11	to	N	O
12	evaluate	N	O
13	two	N	O
14	modes	N	O
15	of	N	O
16	delivering	N	O
17	(	N	O
18	face-to-face	N	O
19	[	N	O
20	FtF	N	O
21	]	N	O
22	and	N	O
23	over-the-telephone	N	O
24	[	N	O
25	Tel	N	O
26	]	N	O
27	)	N	O
28	an	N	O
29	8-month	N	O
30	translational	N	O
31	exercise	N	O
32	intervention	N	O
33	,	N	O
34	commencing	N	O
35	6-weeks	N	O
36	post-breast	N	O
37	cancer	N	O
38	surgery	N	O
39	(	N	O
40	PS	N	O
41	)	N	O
42	.	N	O

1	Outcomes	N	O
2	included	N	O
3	quality	N	O
4	of	N	O
5	life	N	O
6	(	N	O
7	QoL	N	O
8	)	N	O
9	,	N	O
10	function	N	O
11	(	N	O
12	fitness	N	O
13	and	N	O
14	upper	N	O
15	body	N	O
16	)	N	O
17	and	N	O
18	treatment-related	N	O
19	side	N	O
20	effects	N	O
21	(	N	O
22	fatigue	N	O
23	,	N	O
24	lymphoedema	N	O
25	,	N	O
26	body	N	O
27	mass	N	O
28	index	N	O
29	,	N	O
30	menopausal	N	O
31	symptoms	N	O
32	,	N	O
33	anxiety	N	O
34	,	N	O
35	depression	N	O
36	and	N	O
37	pain	N	O
38	)	N	O
39	.	N	O

1	Generalised	N	O
2	estimating	N	O
3	equation	N	O
4	modelling	N	O
5	determined	N	O
6	time	N	O
7	(	N	O
8	baseline	N	O
9	[	N	O
10	5	N	O
11	weeks	N	O
12	PS	N	O
13	]	N	O
14	,	N	O
15	mid-intervention	N	O
16	[	N	O
17	6	N	O
18	months	N	O
19	PS	N	O
20	]	N	O
21	,	N	O
22	post-intervention	N	O
23	[	N	O
24	12	N	O
25	months	N	O
26	PS	N	O
27	]	N	O
28	)	N	O
29	,	N	O
30	group	N	O
31	(	N	O
32	FtF	N	O
33	,	N	O
34	Tel	N	O
35	,	N	O
36	Usual	N	O
37	Care	N	O
38	[	N	O
39	UC	N	O
40	]	N	O
41	)	N	O
42	and	N	O
43	time-by-group	N	O
44	effects	N	O
45	.	N	O

1	194	N	O
2	women	N	O
3	representative	N	O
4	of	N	O
5	the	N	O
6	breast	N	O
7	cancer	N	O
8	population	N	O
9	were	N	O
10	randomised	N	O
11	to	N	O
12	the	N	O
13	FtF	N	O
14	(	N	O
15	n	N	O
16	=	N	O
17	67	N	O
18	)	N	O
19	,	N	O
20	Tel	N	O
21	(	N	O
22	n	N	O
23	=	N	O
24	67	N	O
25	)	N	O
26	and	N	O
27	UC	N	O
28	(	N	O
29	n	N	O
30	=	N	O
31	60	N	O
32	)	N	O
33	groups	N	O
34	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	significant	N	I-Premise
4	(	N	I-Premise
5	p	N	I-Premise
6	<	N	I-Premise
7	0.05	N	I-Premise
8	)	N	I-Premise
9	interaction	N	I-Premise
10	effects	N	I-Premise
11	on	N	I-Premise
12	QoL	N	I-Premise
13	,	N	I-Premise
14	fitness	N	I-Premise
15	and	N	I-Premise
16	fatigue	N	I-Premise
17	with	N	I-Premise
18	differences	N	I-Premise
19	being	N	I-Premise
20	observed	N	I-Premise
21	between	N	I-Premise
22	the	N	I-Premise
23	treatment	N	I-Premise
24	groups	N	I-Premise
25	and	N	I-Premise
26	the	N	I-Premise
27	UC	N	I-Premise
28	group	N	I-Premise
29	.	N	I-Premise

1	Trends	N	I-Premise
2	observed	N	I-Premise
3	for	N	I-Premise
4	the	N	I-Premise
5	treatment	N	I-Premise
6	groups	N	I-Premise
7	were	N	I-Premise
8	similar	N	I-Premise
9	.	N	I-Premise

1	The	N	I-Premise
2	treatment	N	I-Premise
3	groups	N	I-Premise
4	reported	N	I-Premise
5	improved	N	I-Premise
6	QoL	N	I-Premise
7	,	N	I-Premise
8	fitness	N	I-Premise
9	and	N	I-Premise
10	fatigue	N	I-Premise
11	over	N	I-Premise
12	time	N	I-Premise
13	and	N	I-Premise
14	changes	N	I-Premise
15	observed	N	I-Premise
16	between	N	I-Premise
17	baseline	N	I-Premise
18	and	N	I-Premise
19	post-intervention	N	I-Premise
20	were	N	I-Premise
21	clinically	N	I-Premise
22	relevant	N	I-Premise
23	.	N	I-Premise

1	In	N	I-Premise
2	contrast	N	I-Premise
3	,	N	I-Premise
4	the	N	I-Premise
5	UC	N	I-Premise
6	group	N	I-Premise
7	experienced	N	I-Premise
8	no	N	I-Premise
9	change	N	I-Premise
10	,	N	I-Premise
11	or	N	I-Premise
12	worsening	N	I-Premise
13	QoL	N	I-Premise
14	,	N	I-Premise
15	fitness	N	I-Premise
16	and	N	I-Premise
17	fatigue	N	I-Premise
18	,	N	I-Premise
19	mid-intervention	N	I-Premise
20	.	N	I-Premise

1	Although	N	I-Premise
2	improvements	N	I-Premise
3	in	N	I-Premise
4	the	N	I-Premise
5	UC	N	I-Premise
6	group	N	I-Premise
7	occurred	N	I-Premise
8	by	N	I-Premise
9	12-months	N	I-Premise
10	post-surgery	N	I-Premise
11	,	N	I-Premise
12	the	N	I-Premise
13	change	N	I-Premise
14	did	N	I-Premise
15	not	N	I-Premise
16	meet	N	I-Premise
17	the	N	I-Premise
18	clinically	N	I-Premise
19	relevant	N	I-Premise
20	threshold	N	I-Premise
21	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	differences	N	I-Premise
5	in	N	I-Premise
6	other	N	I-Premise
7	treatment-related	N	I-Premise
8	side	N	I-Premise
9	effects	N	I-Premise
10	between	N	I-Premise
11	groups	N	I-Premise
12	.	N	I-Premise

1	This	N	I-Claim
2	translational	N	I-Claim
3	intervention	N	I-Claim
4	trial	N	I-Claim
5	,	N	I-Claim
6	delivered	N	I-Claim
7	either	N	I-Claim
8	FtF	N	I-Claim
9	or	N	I-Claim
10	Tel	N	I-Claim
11	,	N	I-Claim
12	supports	N	I-Claim
13	exercise	N	I-Claim
14	as	N	I-Claim
15	a	N	I-Claim
16	form	N	I-Claim
17	of	N	I-Claim
18	adjuvant	N	I-Claim
19	breast	N	I-Claim
20	cancer	N	I-Claim
21	therapy	N	I-Claim
22	that	N	I-Claim
23	can	N	I-Claim
24	prevent	N	I-Claim
25	declines	N	I-Claim
26	in	N	I-Claim
27	fitness	N	I-Claim
28	and	N	I-Claim
29	function	N	I-Claim
30	during	N	I-Claim
31	treatment	N	I-Claim
32	and	N	I-Claim
33	optimise	N	I-Claim
34	recovery	N	I-Claim
35	post-treatment	N	I-Claim
36	.	N	I-Claim

1	Two	N	O
2	million	N	O
3	people	N	O
4	across	N	O
5	the	N	O
6	U.K.	N	O
7	are	N	O
8	living	N	O
9	with	N	O
10	cancer	N	O
11	,	N	O
12	often	N	O
13	experienced	N	O
14	as	N	O
15	a	N	O
16	long-term	N	O
17	condition	N	O
18	.	N	O

1	They	N	O
2	may	N	O
3	have	N	O
4	unmet	N	O
5	needs	N	O
6	after	N	O
7	active	N	O
8	treatment	N	O
9	.	N	O

1	Rehabilitation	N	O
2	aims	N	O
3	to	N	O
4	address	N	O
5	these	N	O
6	needs	N	O
7	,	N	O
8	maximize	N	O
9	psychological	N	O
10	and	N	O
11	physical	N	O
12	function	N	O
13	,	N	O
14	and	N	O
15	enable	N	O
16	minimum	N	O
17	dependency	N	O
18	regardless	N	O
19	of	N	O
20	life	N	O
21	expectancy	N	O
22	.	N	O

1	We	N	O
2	aimed	N	O
3	to	N	O
4	test	N	O
5	,	N	O
6	in	N	O
7	a	N	O
8	randomized	N	O
9	controlled	N	O
10	trial	N	O
11	,	N	O
12	the	N	O
13	clinical	N	O
14	and	N	O
15	cost	N	O
16	effectiveness	N	O
17	of	N	O
18	a	N	O
19	rehabilitation	N	O
20	intervention	N	O
21	for	N	O
22	patients	N	O
23	with	N	O
24	advanced	N	O
25	,	N	O
26	recurrent	N	O
27	cancer	N	O
28	.	N	O

1	We	N	O
2	conducted	N	O
3	a	N	O
4	two-arm	N	O
5	,	N	O
6	wait-list	N	O
7	control	N	O
8	,	N	O
9	randomized	N	O
10	trial	N	O
11	of	N	O
12	a	N	O
13	complex	N	O
14	rehabilitation	N	O
15	intervention	N	O
16	delivered	N	O
17	by	N	O
18	a	N	O
19	hospice-based	N	O
20	multidisciplinary	N	O
21	team	N	O
22	vs.	N	O
23	usual	N	O
24	care	N	O
25	for	N	O
26	active	N	O
27	,	N	O
28	progressive	N	O
29	,	N	O
30	recurrent	N	O
31	hematological	N	O
32	and	N	O
33	breast	N	O
34	malignancies	N	O
35	,	N	O
36	with	N	O
37	a	N	O
38	follow-up	N	O
39	at	N	O
40	three	N	O
41	months	N	O
42	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	the	N	O
6	psychological	N	O
7	subscale	N	O
8	of	N	O
9	the	N	O
10	Supportive	N	O
11	Care	N	O
12	Needs	N	O
13	Survey	N	O
14	(	N	O
15	SCNS	N	O
16	)	N	O
17	.	N	O

1	Secondary	N	O
2	outcomes	N	O
3	were	N	O
4	other	N	O
5	domains	N	O
6	of	N	O
7	the	N	O
8	SCNS	N	O
9	,	N	O
10	psychological	N	O
11	status	N	O
12	,	N	O
13	continuity	N	O
14	of	N	O
15	care	N	O
16	,	N	O
17	quality	N	O
18	of	N	O
19	life	N	O
20	,	N	O
21	and	N	O
22	resource	N	O
23	use	N	O
24	.	N	O

1	Forty-one	N	O
2	participants	N	O
3	were	N	O
4	enrolled	N	O
5	and	N	O
6	36	N	O
7	completed	N	O
8	the	N	O
9	trial	N	O
10	.	N	O

1	The	N	I-Premise
2	primary	N	I-Premise
3	outcome	N	I-Premise
4	was	N	I-Premise
5	significantly	N	I-Premise
6	lower	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	intervention	N	I-Premise
10	arm	N	I-Premise
11	(	N	I-Premise
12	adjusted	N	I-Premise
13	difference	N	I-Premise
14	-16.8	N	I-Premise
15	,	N	I-Premise
16	95	N	I-Premise
17	%	N	I-Premise
18	CI	N	I-Premise
19	-28.34	N	I-Premise
20	to	N	I-Premise
21	-5.3	N	I-Premise
22	;	N	I-Premise
23	P	N	I-Premise
24	=	N	I-Premise
25	0.006	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	The	N	I-Premise
2	SCNS	N	I-Premise
3	physical	N	I-Premise
4	and	N	I-Premise
5	patient	N	I-Premise
6	care	N	I-Premise
7	subscales	N	I-Premise
8	(	N	I-Premise
9	-14.2	N	I-Premise
10	,	N	I-Premise
11	95	N	I-Premise
12	%	N	I-Premise
13	CI	N	I-Premise
14	-26.2	N	I-Premise
15	to	N	I-Premise
16	-2.2	N	I-Premise
17	;	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	0.02	N	I-Premise
21	and	N	I-Premise
22	-7.4	N	I-Premise
23	,	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	CI	N	I-Premise
27	-13.7	N	I-Premise
28	to	N	I-Premise
29	-1.1	N	I-Premise
30	;	N	I-Premise
31	P	N	I-Premise
32	=	N	I-Premise
33	0.02	N	I-Premise
34	,	N	I-Premise
35	respectively	N	I-Premise
36	)	N	I-Premise
37	and	N	I-Premise
38	self-reported	N	I-Premise
39	health	N	I-Premise
40	state	N	I-Premise
41	(	N	I-Premise
42	12.8	N	I-Premise
43	,	N	I-Premise
44	95	N	I-Premise
45	%	N	I-Premise
46	CI	N	I-Premise
47	3.2	N	I-Premise
48	to	N	I-Premise
49	22.4	N	I-Premise
50	;	N	I-Premise
51	P	N	I-Premise
52	=	N	I-Premise
53	0.01	N	I-Premise
54	)	N	I-Premise
55	also	N	I-Premise
56	differed	N	I-Premise
57	significantly	N	I-Premise
58	.	N	I-Premise

1	The	N	I-Premise
2	incremental	N	I-Premise
3	cost-effectiveness	N	I-Premise
4	ratio	N	I-Premise
5	was	N	I-Premise
6	£19,390	N	I-Premise
7	per	N	I-Premise
8	quality-adjusted	N	I-Premise
9	life	N	I-Premise
10	year	N	I-Premise
11	.	N	I-Premise

1	This	N	I-Claim
2	intervention	N	I-Claim
3	significantly	N	I-Claim
4	reduced	N	I-Claim
5	the	N	I-Claim
6	unmet	N	I-Claim
7	needs	N	I-Claim
8	of	N	I-Claim
9	cancer	N	I-Claim
10	survivors	N	I-Claim
11	and	N	I-Claim
12	it	N	I-Claim
13	is	N	I-Claim
14	likely	N	I-Claim
15	that	N	I-Claim
16	it	N	I-Claim
17	is	N	I-Claim
18	cost-effective	N	I-Claim
19	.	N	I-Claim

1	Despite	N	I-Claim
2	small	N	I-Claim
3	numbers	N	I-Claim
4	,	N	I-Claim
5	the	N	I-Claim
6	main	N	I-Claim
7	effect	N	I-Claim
8	size	N	I-Claim
9	was	N	I-Claim
10	robust	N	I-Claim
11	.	N	I-Claim

1	We	N	I-Claim
2	recommend	N	I-Claim
3	implementation	N	I-Claim
4	alongside	N	I-Claim
5	evaluation	N	I-Claim
6	in	N	I-Claim
7	wider	N	I-Claim
8	clinical	N	I-Claim
9	settings	N	I-Claim
10	and	N	I-Claim
11	patient	N	I-Claim
12	populations	N	I-Claim
13	.	N	I-Claim

1	To	N	O
2	study	N	O
3	the	N	O
4	effects	N	O
5	of	N	O
6	Fuzheng	N	O
7	Jianpi	N	O
8	Decoction	N	O
9	(	N	O
10	FJD	N	O
11	)	N	O
12	combined	N	O
13	chemotherapy	N	O
14	on	N	O
15	the	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	QOL	N	O
21	)	N	O
22	and	N	O
23	the	N	O
24	survival	N	O
25	time	N	O
26	of	N	O
27	children	N	O
28	with	N	O
29	solid	N	O
30	tumor	N	O
31	.	N	O

1	Recruited	N	O
2	were	N	O
3	167	N	O
4	solid	N	O
5	tumor	N	O
6	children	N	O
7	patients	N	O
8	at	N	O
9	Department	N	O
10	of	N	O
11	Tumor	N	O
12	,	N	O
13	Beijing	N	O
14	Children	N	O
15	's	N	O
16	Hospital	N	O
17	.	N	O

1	They	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	to	N	O
6	the	N	O
7	treatment	N	O
8	group	N	O
9	(	N	O
10	83	N	O
11	cases	N	O
12	)	N	O
13	and	N	O
14	the	N	O
15	control	N	O
16	group	N	O
17	(	N	O
18	84	N	O
19	cases	N	O
20	)	N	O
21	according	N	O
22	to	N	O
23	the	N	O
24	random	N	O
25	digit	N	O
26	table	N	O
27	.	N	O

1	All	N	O
2	had	N	O
3	chemotherapy	N	O
4	.	N	O

1	Those	N	O
2	in	N	O
3	the	N	O
4	treatment	N	O
5	group	N	O
6	additionally	N	O
7	took	N	O
8	FJD	N	O
9	,	N	O
10	50	N	O
11	-100	N	O
12	mL	N	O
13	each	N	O
14	time	N	O
15	,	N	O
16	twice	N	O
17	daily	N	O
18	.	N	O

1	After	N	O
2	chemotherapy	N	O
3	those	N	O
4	in	N	O
5	the	N	O
6	treatment	N	O
7	group	N	O
8	took	N	O
9	modified	N	O
10	FJD	N	O
11	.	N	O

1	The	N	O
2	WBC	N	O
3	,	N	O
4	Hb	N	O
5	,	N	O
6	and	N	O
7	PLT	N	O
8	were	N	O
9	detected	N	O
10	in	N	O
11	all	N	O
12	patients	N	O
13	before	N	O
14	treatment	N	O
15	,	N	O
16	6	N	O
17	months	N	O
18	after	N	O
19	treatment	N	O
20	,	N	O
21	and	N	O
22	1	N	O
23	year	N	O
24	after	N	O
25	treatment	N	O
26	.	N	O

1	The	N	O
2	1-	N	O
3	,	N	O
4	2-	N	O
5	,	N	O
6	and	N	O
7	3-year	N	O
8	QOL	N	O
9	,	N	O
10	3-year	N	O
11	survival	N	O
12	rate	N	O
13	,	N	O
14	and	N	O
15	the	N	O
16	survival	N	O
17	life	N	O
18	of	N	O
19	dead	N	O
20	children	N	O
21	patients	N	O
22	were	N	O
23	observed	N	O
24	.	N	O

1	Compared	N	I-Premise
2	with	N	I-Premise
3	the	N	I-Premise
4	control	N	I-Premise
5	group	N	I-Premise
6	of	N	I-Premise
7	the	N	I-Premise
8	same	N	I-Premise
9	period	N	I-Premise
10	,	N	I-Premise
11	the	N	I-Premise
12	6-month	N	I-Premise
13	and	N	I-Premise
14	1-year	N	I-Premise
15	WBC	N	I-Premise
16	and	N	I-Premise
17	Hb	N	I-Premise
18	increased	N	I-Premise
19	,	N	I-Premise
20	the	N	I-Premise
21	1-year	N	I-Premise
22	PLT	N	I-Premise
23	increased	N	I-Premise
24	in	N	I-Premise
25	the	N	I-Premise
26	treatment	N	I-Premise
27	group	N	I-Premise
28	,	N	I-Premise
29	showing	N	I-Premise
30	statistical	N	I-Premise
31	difference	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	<	N	I-Premise
35	0.05	N	I-Premise
36	,	N	I-Premise
37	P	N	I-Premise
38	<	N	I-Premise
39	0.01	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	Compared	N	I-Premise
2	with	N	I-Premise
3	1-year	N	I-Premise
4	treatment	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	treatment	N	I-Premise
8	group	N	I-Premise
9	,	N	I-Premise
10	the	N	I-Premise
11	2-and	N	I-Premise
12	3-year	N	I-Premise
13	psychological	N	I-Premise
14	functions	N	I-Premise
15	and	N	I-Premise
16	the	N	I-Premise
17	general	N	I-Premise
18	symptoms	N	I-Premise
19	scores	N	I-Premise
20	decreased	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	<	N	I-Premise
24	0.05	N	I-Premise
25	,	N	I-Premise
26	P	N	I-Premise
27	<	N	I-Premise
28	0.01	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	Compared	N	I-Premise
2	with	N	I-Premise
3	the	N	I-Premise
4	control	N	I-Premise
5	group	N	I-Premise
6	of	N	I-Premise
7	the	N	I-Premise
8	same	N	I-Premise
9	period	N	I-Premise
10	,	N	I-Premise
11	the	N	I-Premise
12	2-and	N	I-Premise
13	3-year	N	I-Premise
14	somatic	N	I-Premise
15	functions	N	I-Premise
16	,	N	I-Premise
17	psychological	N	I-Premise
18	functions	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	the	N	I-Premise
22	general	N	I-Premise
23	symptoms	N	I-Premise
24	scores	N	I-Premise
25	decreased	N	I-Premise
26	in	N	I-Premise
27	the	N	I-Premise
28	treatment	N	I-Premise
29	group	N	I-Premise
30	;	N	I-Premise
31	the	N	I-Premise
32	2-year	N	I-Premise
33	somatic	N	I-Premise
34	functions	N	I-Premise
35	and	N	I-Premise
36	psychological	N	I-Premise
37	functions	N	I-Premise
38	decreased	N	I-Premise
39	in	N	I-Premise
40	the	N	I-Premise
41	treatment	N	I-Premise
42	group	N	I-Premise
43	;	N	I-Premise
44	the	N	I-Premise
45	3-year	N	I-Premise
46	psychological	N	I-Premise
47	functions	N	I-Premise
48	and	N	I-Premise
49	the	N	I-Premise
50	general	N	I-Premise
51	symptoms	N	I-Premise
52	scores	N	I-Premise
53	decreased	N	I-Premise
54	in	N	I-Premise
55	the	N	I-Premise
56	treatment	N	I-Premise
57	group	N	I-Premise
58	,	N	I-Premise
59	all	N	I-Premise
60	with	N	I-Premise
61	statistical	N	I-Premise
62	difference	N	I-Premise
63	(	N	I-Premise
64	all	N	I-Premise
65	P	N	I-Premise
66	<	N	I-Premise
67	0.05	N	I-Premise
68	)	N	I-Premise
69	.	N	I-Premise

1	Compared	N	I-Premise
2	with	N	I-Premise
3	the	N	I-Premise
4	control	N	I-Premise
5	group	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	death	N	I-Premise
9	number	N	I-Premise
10	decreased	N	I-Premise
11	,	N	I-Premise
12	the	N	I-Premise
13	survival	N	I-Premise
14	rate	N	I-Premise
15	increased	N	I-Premise
16	,	N	I-Premise
17	the	N	I-Premise
18	life	N	I-Premise
19	span	N	I-Premise
20	of	N	I-Premise
21	dead	N	I-Premise
22	children	N	I-Premise
23	was	N	I-Premise
24	prolonged	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	treatment	N	I-Premise
28	group	N	I-Premise
29	,	N	I-Premise
30	showing	N	I-Premise
31	statistical	N	I-Premise
32	difference	N	I-Premise
33	(	N	I-Premise
34	P	N	I-Premise
35	<	N	I-Premise
36	0.05	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	FJD	N	I-Claim
2	combined	N	I-Claim
3	chemotherapy	N	I-Claim
4	could	N	I-Claim
5	effectively	N	I-Claim
6	improve	N	I-Claim
7	the	N	I-Claim
8	QOL	N	I-Claim
9	of	N	I-Claim
10	solid	N	I-Claim
11	tumor	N	I-Claim
12	children	N	I-Claim
13	patients	N	I-Claim
14	,	N	I-Claim
15	elevate	N	I-Claim
16	their	N	I-Claim
17	survival	N	I-Claim
18	rate	N	I-Claim
19	,	N	I-Claim
20	and	N	I-Claim
21	prolong	N	I-Claim
22	their	N	I-Claim
23	life	N	I-Claim
24	spans	N	I-Claim
25	.	N	I-Claim

1	Over	N	O
2	30	N	O
3	%	N	O
4	of	N	O
5	patients	N	O
6	with	N	O
7	non-small	N	O
8	cell	N	O
9	lung	N	O
10	cancer	N	O
11	(	N	O
12	NSCLC	N	O
13	)	N	O
14	develop	N	O
15	brain	N	O
16	metastases	N	O
17	.	N	O

1	If	N	O
2	inoperable	N	O
3	,	N	O
4	optimal	N	O
5	supportive	N	O
6	care	N	O
7	(	N	O
8	OSC	N	O
9	)	N	O
10	,	N	O
11	including	N	O
12	steroids	N	O
13	,	N	O
14	and	N	O
15	whole	N	O
16	brain	N	O
17	radiotherapy	N	O
18	(	N	O
19	WBRT	N	O
20	)	N	O
21	are	N	O
22	generally	N	O
23	considered	N	O
24	to	N	O
25	be	N	O
26	standard	N	O
27	care	N	O
28	,	N	O
29	although	N	O
30	there	N	O
31	is	N	O
32	no	N	O
33	randomised	N	O
34	evidence	N	O
35	demonstrating	N	O
36	that	N	O
37	the	N	O
38	addition	N	O
39	of	N	O
40	WBRT	N	O
41	to	N	O
42	OSC	N	O
43	improves	N	O
44	survival	N	O
45	or	N	O
46	quality	N	O
47	of	N	O
48	life	N	O
49	.	N	O

1	QUARTZ	N	O
2	is	N	O
3	a	N	O
4	randomised	N	O
5	,	N	O
6	non-inferiority	N	O
7	,	N	O
8	phase	N	O
9	III	N	O
10	trial	N	O
11	comparing	N	O
12	OSC	N	O
13	+	N	O
14	WBRT	N	O
15	versus	N	O
16	OSC	N	O
17	in	N	O
18	patients	N	O
19	with	N	O
20	inoperable	N	O
21	brain	N	O
22	metastases	N	O
23	from	N	O
24	NSCLC	N	O
25	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	measure	N	O
5	is	N	O
6	quality-adjusted	N	O
7	life	N	O
8	years	N	O
9	(	N	O
10	QALYs	N	O
11	)	N	O
12	.	N	O

1	QUARTZ	N	O
2	was	N	O
3	threatened	N	O
4	with	N	O
5	both	N	O
6	loss	N	O
7	of	N	O
8	funding	N	O
9	and	N	O
10	early	N	O
11	closure	N	O
12	due	N	O
13	to	N	O
14	poor	N	O
15	accrual	N	O
16	.	N	O

1	A	N	O
2	lack	N	O
3	of	N	O
4	preliminary	N	O
5	randomised	N	O
6	data	N	O
7	supporting	N	O
8	the	N	O
9	trial	N	O
10	's	N	O
11	hypotheses	N	O
12	was	N	O
13	thought	N	O
14	to	N	O
15	underlie	N	O
16	the	N	O
17	poor	N	O
18	accrual	N	O
19	,	N	O
20	so	N	O
21	,	N	O
22	with	N	O
23	no	N	O
24	knowledge	N	O
25	of	N	O
26	the	N	O
27	data	N	O
28	,	N	O
29	the	N	O
30	independent	N	O
31	trial	N	O
32	steering	N	O
33	committee	N	O
34	agreed	N	O
35	to	N	O
36	the	N	O
37	unusual	N	O
38	step	N	O
39	of	N	O
40	releasing	N	O
41	interim	N	O
42	data	N	O
43	.	N	O

1	Between	N	O
2	March	N	O
3	2007	N	O
4	and	N	O
5	April	N	O
6	2010	N	O
7	,	N	O
8	151	N	O
9	(	N	O
10	of	N	O
11	the	N	O
12	planned	N	O
13	534	N	O
14	)	N	O
15	patients	N	O
16	were	N	O
17	randomised	N	O
18	(	N	O
19	75	N	O
20	OSC	N	O
21	+	N	O
22	WBRT	N	O
23	,	N	O
24	76	N	O
25	OSC	N	O
26	)	N	O
27	.	N	O

1	Participants	N	O
2	'	N	O
3	baseline	N	O
4	demographics	N	O
5	included	N	O
6	median	N	O
7	age	N	O
8	67	N	O
9	years	N	O
10	(	N	O
11	interquartile	N	O
12	range	N	O
13	62-73	N	O
14	)	N	O
15	,	N	O
16	60	N	O
17	%	N	O
18	male	N	O
19	,	N	O
20	50	N	O
21	%	N	O
22	with	N	O
23	a	N	O
24	Karnofsky	N	O
25	performance	N	O
26	status	N	O
27	<	N	O
28	70	N	O
29	;	N	O
30	steroid	N	O
31	usage	N	O
32	was	N	O
33	similar	N	O
34	in	N	O
35	the	N	O
36	two	N	O
37	groups	N	O
38	;	N	O
39	64/75	N	O
40	(	N	O
41	85	N	O
42	%	N	O
43	)	N	O
44	received	N	O
45	WBRT	N	O
46	(	N	O
47	20	N	O
48	Gy	N	O
49	in	N	O
50	five	N	O
51	fractions	N	O
52	)	N	O
53	.	N	O

1	Median	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	:	N	I-Premise
5	OSC	N	I-Premise
6	+	N	I-Premise
7	WBRT	N	I-Premise
8	49	N	I-Premise
9	days	N	I-Premise
10	(	N	I-Premise
11	95	N	I-Premise
12	%	N	I-Premise
13	confidence	N	I-Premise
14	interval	N	I-Premise
15	39-61	N	I-Premise
16	)	N	I-Premise
17	,	N	I-Premise
18	OSC	N	I-Premise
19	51	N	I-Premise
20	days	N	I-Premise
21	(	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	confidence	N	I-Premise
25	interval	N	I-Premise
26	27-57	N	I-Premise
27	)	N	I-Premise
28	-	N	I-Premise
29	hazard	N	I-Premise
30	ratio	N	I-Premise
31	1.11	N	I-Premise
32	(	N	I-Premise
33	95	N	I-Premise
34	%	N	I-Premise
35	confidence	N	I-Premise
36	interval	N	I-Premise
37	0.80-1.53	N	I-Premise
38	)	N	I-Premise
39	in	N	I-Premise
40	favour	N	I-Premise
41	of	N	I-Premise
42	WBRT	N	I-Premise
43	.	N	I-Premise

1	Quality	N	I-Premise
2	of	N	I-Premise
3	life	N	I-Premise
4	assessed	N	I-Premise
5	using	N	I-Premise
6	EQ-5D	N	I-Premise
7	showed	N	I-Premise
8	no	N	I-Premise
9	evidence	N	I-Premise
10	of	N	I-Premise
11	a	N	I-Premise
12	difference	N	I-Premise
13	.	N	I-Premise

1	The	N	I-Premise
2	estimated	N	I-Premise
3	mean	N	I-Premise
4	QALYs	N	I-Premise
5	was	N	I-Premise
6	:	N	I-Premise
7	OSC	N	I-Premise
8	+	N	I-Premise
9	WBRT	N	I-Premise
10	31	N	I-Premise
11	days	N	I-Premise
12	and	N	I-Premise
13	OSC	N	I-Premise
14	30	N	I-Premise
15	days	N	I-Premise
16	,	N	I-Premise
17	difference	N	I-Premise
18	-1	N	I-Premise
19	day	N	I-Premise
20	(	N	I-Premise
21	95	N	I-Premise
22	%	N	I-Premise
23	confidence	N	I-Premise
24	interval	N	I-Premise
25	-12.0	N	I-Premise
26	to	N	I-Premise
27	+13.2	N	I-Premise
28	days	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	These	N	I-Claim
2	interim	N	I-Claim
3	data	N	I-Claim
4	indicate	N	I-Claim
5	no	N	I-Claim
6	early	N	I-Claim
7	evidence	N	I-Claim
8	of	N	I-Claim
9	detriment	N	I-Claim
10	to	N	I-Claim
11	quality	N	I-Claim
12	of	N	I-Claim
13	life	N	I-Claim
14	,	N	I-Claim
15	overall	N	I-Claim
16	survival	N	I-Claim
17	or	N	I-Claim
18	QALYs	N	I-Claim
19	for	N	I-Claim
20	patients	N	I-Claim
21	allocated	N	I-Claim
22	to	N	I-Claim
23	OSC	N	I-Claim
24	alone	N	I-Claim
25	.	N	I-Claim

1	They	N	O
2	provide	N	O
3	key	N	O
4	information	N	O
5	for	N	O
6	discussing	N	O
7	the	N	O
8	trial	N	O
9	with	N	O
10	patients	N	O
11	and	N	O
12	strengthen	N	O
13	the	N	O
14	argument	N	O
15	for	N	O
16	continuing	N	O
17	QUARTZ	N	O
18	to	N	O
19	definitively	N	O
20	answer	N	O
21	this	N	O
22	important	N	O
23	clinical	N	O
24	question	N	O
25	.	N	O

1	Chemoradiotherapy	N	O
2	(	N	O
3	CRT	N	O
4	)	N	O
5	-induced	N	O
6	oral	N	O
7	mucositis	N	O
8	(	N	O
9	OM	N	O
10	)	N	O
11	adversely	N	O
12	affects	N	O
13	a	N	O
14	patient	N	O
15	's	N	O
16	oral	N	O
17	functions	N	O
18	and	N	O
19	quality	N	O
20	of	N	O
21	life	N	O
22	(	N	O
23	QOL	N	O
24	)	N	O
25	.	N	O

1	Low-level	N	O
2	laser	N	O
3	therapy	N	O
4	(	N	O
5	LLLT	N	O
6	)	N	O
7	showed	N	O
8	some	N	O
9	preventive	N	O
10	and	N	O
11	curative	N	O
12	effects	N	O
13	against	N	O
14	clinically	N	O
15	reported	N	O
16	objective	N	O
17	measures	N	O
18	of	N	O
19	OM	N	O
20	in	N	O
21	few	N	O
22	trials	N	O
23	including	N	O
24	our	N	O
25	recently	N	O
26	published	N	O
27	study	N	O
28	.	N	O

1	There	N	O
2	is	N	O
3	dearth	N	O
4	of	N	O
5	evidence	N	O
6	regarding	N	O
7	the	N	O
8	effects	N	O
9	of	N	O
10	LLLT	N	O
11	on	N	O
12	patient	N	O
13	's	N	O
14	subjective	N	O
15	experience	N	O
16	of	N	O
17	OM	N	O
18	and	N	O
19	QOL	N	O
20	.	N	O

1	Hence	N	O
2	,	N	O
3	we	N	O
4	did	N	O
5	this	N	O
6	study	N	O
7	to	N	O
8	evaluate	N	O
9	the	N	O
10	effects	N	O
11	of	N	O
12	LLLT	N	O
13	on	N	O
14	a	N	O
15	patient	N	O
16	's	N	O
17	reported	N	O
18	measures	N	O
19	of	N	O
20	OM	N	O
21	and	N	O
22	QOL	N	O
23	in	N	O
24	head	N	O
25	and	N	O
26	neck	N	O
27	cancer	N	O
28	(	N	O
29	HNC	N	O
30	)	N	O
31	patients	N	O
32	receiving	N	O
33	CRT	N	O
34	.	N	O

1	This	N	O
2	triple	N	O
3	blinded	N	O
4	study	N	O
5	randomized	N	O
6	220	N	O
7	HNC	N	O
8	patients	N	O
9	scheduled	N	O
10	for	N	O
11	CRT	N	O
12	(	N	O
13	three	N	O
14	weekly	N	O
15	Cisplatin	N	O
16	+	N	O
17	RT	N	O
18	=	N	O
19	66	N	O
20	Gray	N	O
21	(	N	O
22	2	N	O
23	Gy/session	N	O
24	)	N	O
25	,	N	O
26	five	N	O
27	fractions/week	N	O
28	for	N	O
29	6.5	N	O
30	weeks	N	O
31	,	N	O
32	total	N	O
33	33	N	O
34	fractions	N	O
35	)	N	O
36	into	N	O
37	laser	N	O
38	(	N	O
39	110	N	O
40	)	N	O
41	and	N	O
42	placebo	N	O
43	(	N	O
44	110	N	O
45	)	N	O
46	groups	N	O
47	.	N	O

1	The	N	O
2	laser	N	O
3	group	N	O
4	received	N	O
5	LLLT	N	O
6	(	N	O
7	Technomed	N	O
8	Electronics	N	O
9	Advanced	N	O
10	Laser	N	O
11	Therapy	N	O
12	1000	N	O
13	,	N	O
14	He-Ne	N	O
15	,	N	O
16	λ	N	O
17	=	N	O
18	632.8	N	O
19	nm	N	O
20	,	N	O
21	power	N	O
22	density	N	O
23	=	N	O
24	24	N	O
25	mW/cm	N	O
26	(	N	O
27	2	N	O
28	)	N	O
29	,	N	O
30	dosage	N	O
31	=	N	O
32	3.0	N	O
33	J	N	O
34	at	N	O
35	each	N	O
36	point	N	O
37	,	N	O
38	total	N	O
39	dose/session	N	O
40	=	N	O
41	36-40	N	O
42	J	N	O
43	,	N	O
44	spot	N	O
45	size	N	O
46	1	N	O
47	cm	N	O
48	(	N	O
49	2	N	O
50	)	N	O
51	,	N	O
52	irradiation	N	O
53	time/point	N	O
54	125	N	O
55	s	N	O
56	)	N	O
57	before	N	O
58	each	N	O
59	radiation	N	O
60	session	N	O
61	,	N	O
62	while	N	O
63	the	N	O
64	placebo	N	O
65	group	N	O
66	did	N	O
67	not	N	O
68	receive	N	O
69	laser	N	O
70	therapy	N	O
71	.	N	O

1	Methodology	N	O
2	was	N	O
3	similar	N	O
4	to	N	O
5	our	N	O
6	recently	N	O
7	published	N	O
8	study	N	O
9	(	N	O
10	Gautam	N	O
11	et	N	O
12	al	N	O
13	.	N	O

1	Radiother	N	O
2	Oncol	N	O
3	104:349-354	N	O
4	,	N	O
5	2012	N	O
6	)	N	O
7	.	N	O

1	In	N	O
2	this	N	O
3	part	N	O
4	of	N	O
5	our	N	O
6	study	N	O
7	,	N	O
8	a	N	O
9	blinded	N	O
10	assessor	N	O
11	collected	N	O
12	subjective	N	O
13	outcomes	N	O
14	of	N	O
15	the	N	O
16	patient	N	O
17	's	N	O
18	reported	N	O
19	measures	N	O
20	of	N	O
21	OM	N	O
22	using	N	O
23	Oral	N	O
24	Mucositis	N	O
25	Weekly	N	O
26	Questionnaire-Head	N	O
27	and	N	O
28	Neck	N	O
29	(	N	O
30	OMWQ-HN	N	O
31	)	N	O
32	and	N	O
33	QOL	N	O
34	using	N	O
35	Functional	N	O
36	Assessment	N	O
37	of	N	O
38	Cancer	N	O
39	Treatment-Head	N	O
40	and	N	O
41	Neck	N	O
42	(	N	O
43	FACT-HN	N	O
44	)	N	O
45	Questionnaire	N	O
46	.	N	O

1	Data	N	O
2	were	N	O
3	analyzed	N	O
4	using	N	O
5	repeated	N	O
6	measure	N	O
7	ANOVA	N	O
8	through	N	O
9	general	N	O
10	linear	N	O
11	model	N	O
12	.	N	O

1	Statistical	N	O
2	significance	N	O
3	was	N	O
4	kept	N	O
5	at	N	O
6	p	N	O
7	<	N	O
8	0.05	N	O
9	.	N	O

1	Results	N	I-Premise
2	analysis	N	I-Premise
3	revealed	N	I-Premise
4	that	N	I-Premise
5	OMWQ-HN	N	I-Premise
6	(	N	I-Premise
7	F	N	I-Premise
8	=	N	I-Premise
9	12.199	N	I-Premise
10	,	N	I-Premise
11	df	N	I-Premise
12	=	N	I-Premise
13	6,1314	N	I-Premise
14	,	N	I-Premise
15	p	N	I-Premise
16	<	N	I-Premise
17	0.001	N	I-Premise
18	)	N	I-Premise
19	and	N	I-Premise
20	FACT-HN	N	I-Premise
21	(	N	I-Premise
22	p	N	I-Premise
23	<	N	I-Premise
24	0.05	N	I-Premise
25	)	N	I-Premise
26	scores	N	I-Premise
27	were	N	I-Premise
28	significantly	N	I-Premise
29	lower	N	I-Premise
30	in	N	I-Premise
31	LLLT	N	I-Premise
32	than	N	I-Premise
33	placebo	N	I-Premise
34	group	N	I-Premise
35	patients	N	I-Premise
36	.	N	I-Premise

1	Also	N	O
2	,	N	O
3	a	N	I-Premise
4	significant	N	I-Premise
5	reduction	N	I-Premise
6	(	N	I-Premise
7	p	N	I-Premise
8	<	N	I-Premise
9	0.001	N	I-Premise
10	)	N	I-Premise
11	in	N	I-Premise
12	incidence	N	I-Premise
13	of	N	I-Premise
14	severe	N	I-Premise
15	OM	N	I-Premise
16	,	N	I-Premise
17	need	N	I-Premise
18	for	N	I-Premise
19	opioid	N	I-Premise
20	analgesics	N	I-Premise
21	,	N	I-Premise
22	and	N	I-Premise
23	total	N	I-Premise
24	parenteral	N	I-Premise
25	nutrition	N	I-Premise
26	was	N	I-Premise
27	observed	N	I-Premise
28	.	N	I-Premise

1	LLLT	N	I-Claim
2	was	N	I-Claim
3	effective	N	I-Claim
4	in	N	I-Claim
5	improving	N	I-Claim
6	the	N	I-Claim
7	patient	N	I-Claim
8	's	N	I-Claim
9	subjective	N	I-Claim
10	experience	N	I-Claim
11	of	N	I-Claim
12	OM	N	I-Claim
13	and	N	I-Claim
14	QOL	N	I-Claim
15	in	N	I-Claim
16	HNC	N	I-Claim
17	patients	N	I-Claim
18	receiving	N	I-Claim
19	CRT	N	I-Claim
20	.	N	I-Claim

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	blinded	N	O
6	,	N	O
7	randomized	N	O
8	clinical	N	O
9	trial	N	O
10	was	N	O
11	to	N	O
12	compare	N	O
13	two	N	O
14	topical	N	O
15	agents	N	O
16	(	N	O
17	Calendula	N	O
18	Weleda	N	O
19	cream	N	O
20	vs.	N	O
21	Essex	N	O
22	cream	N	O
23	)	N	O
24	in	N	O
25	reducing	N	O
26	the	N	O
27	risk	N	O
28	of	N	O
29	severe	N	O
30	acute	N	O
31	radiation	N	O
32	skin	N	O
33	reactions	N	O
34	(	N	O
35	ARSR	N	O
36	)	N	O
37	in	N	O
38	relation	N	O
39	to	N	O
40	adjuvant	N	O
41	radiotherapy	N	O
42	(	N	O
43	RT	N	O
44	)	N	O
45	for	N	O
46	breast	N	O
47	cancer	N	O
48	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	the	N	O
6	difference	N	O
7	in	N	O
8	proportion	N	O
9	of	N	O
10	patients	N	O
11	with	N	O
12	ARSR	N	O
13	,	N	O
14	assessed	N	O
15	with	N	O
16	the	N	O
17	Radiation	N	O
18	Therapy	N	O
19	Oncology	N	O
20	Group/The	N	O
21	Organization	N	O
22	for	N	O
23	Research	N	O
24	and	N	O
25	Treatment	N	O
26	of	N	O
27	Cancer	N	O
28	Acute	N	O
29	Radiation	N	O
30	Morbidity	N	O
31	Scoring	N	O
32	Criteria	N	O
33	(	N	O
34	RTOG/EORTC	N	O
35	scale	N	O
36	)	N	O
37	at	N	O
38	follow-up	N	O
39	.	N	O

1	The	N	O
2	secondary	N	O
3	endpoints	N	O
4	included	N	O
5	patient	N	O
6	reported	N	O
7	outcome	N	O
8	measures	N	O
9	;	N	O
10	Quality	N	O
11	of	N	O
12	Life	N	O
13	Questionnaire	N	O
14	(	N	O
15	QLQ-C30	N	O
16	)	N	O
17	,	N	O
18	Sleep	N	O
19	disturbances	N	O
20	(	N	O
21	MOS-sleep	N	O
22	questionnaire	N	O
23	)	N	O
24	and	N	O
25	symptoms	N	O
26	from	N	O
27	the	N	O
28	irradiated	N	O
29	area	N	O
30	(	N	O
31	visual	N	O
32	analogue	N	O
33	scale	N	O
34	)	N	O
35	.	N	O

1	Patients	N	O
2	'	N	O
3	experiences	N	O
4	and	N	O
5	adherence	N	O
6	to	N	O
7	the	N	O
8	topical	N	O
9	agents	N	O
10	were	N	O
11	also	N	O
12	evaluated	N	O
13	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	420	N	O
5	patients	N	O
6	were	N	O
7	randomised	N	O
8	and	N	O
9	411	N	O
10	were	N	O
11	analysed	N	O
12	.	N	O

1	With	N	O
2	the	N	O
3	exception	N	O
4	of	N	O
5	previous	N	O
6	chemotherapy	N	O
7	,	N	O
8	the	N	O
9	treatment	N	O
10	groups	N	O
11	were	N	O
12	well	N	O
13	balanced	N	O
14	,	N	O
15	both	N	O
16	regarding	N	O
17	treatment-	N	O
18	and	N	O
19	patient-related	N	O
20	factors	N	O
21	.	N	O

1	The	N	I-Premise
2	incidence	N	I-Premise
3	of	N	I-Premise
4	severe	N	I-Premise
5	ARSR	N	I-Premise
6	(	N	I-Premise
7	RTOG/EORTC	N	I-Premise
8	grade	N	I-Premise
9	≤2	N	I-Premise
10	)	N	I-Premise
11	at	N	I-Premise
12	the	N	I-Premise
13	follow-up	N	I-Premise
14	visit	N	I-Premise
15	was	N	I-Premise
16	23	N	I-Premise
17	%	N	I-Premise
18	(	N	I-Premise
19	n	N	I-Premise
20	=	N	I-Premise
21	45	N	I-Premise
22	)	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	Calendula	N	I-Premise
26	group	N	I-Premise
27	and	N	I-Premise
28	19	N	I-Premise
29	%	N	I-Premise
30	(	N	I-Premise
31	n	N	I-Premise
32	=	N	I-Premise
33	38	N	I-Premise
34	)	N	I-Premise
35	in	N	I-Premise
36	the	N	I-Premise
37	Essex	N	I-Premise
38	group	N	I-Premise
39	.	N	I-Premise

1	We	N	I-Premise
2	found	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	severe	N	I-Premise
7	ARSR	N	I-Premise
8	between	N	I-Premise
9	the	N	I-Premise
10	groups	N	I-Premise
11	at	N	I-Premise
12	any	N	I-Premise
13	point	N	I-Premise
14	of	N	I-Premise
15	assessment	N	I-Premise
16	.	N	I-Premise

1	The	N	I-Premise
2	patients	N	I-Premise
3	reported	N	I-Premise
4	low	N	I-Premise
5	levels	N	I-Premise
6	of	N	I-Premise
7	skin	N	I-Premise
8	related	N	I-Premise
9	symptoms	N	I-Premise
10	and	N	I-Premise
11	no	N	I-Premise
12	statistically	N	I-Premise
13	significant	N	I-Premise
14	differences	N	I-Premise
15	between	N	I-Premise
16	the	N	I-Premise
17	groups	N	I-Premise
18	were	N	I-Premise
19	found	N	I-Premise
20	.	N	I-Premise

1	No	N	I-Claim
2	differences	N	I-Claim
3	in	N	I-Claim
4	ARSR	N	I-Claim
5	between	N	I-Claim
6	patients	N	I-Claim
7	randomised	N	I-Claim
8	to	N	I-Claim
9	Calendula	N	I-Claim
10	or	N	I-Claim
11	Essex	N	I-Claim
12	cream	N	I-Claim
13	was	N	I-Claim
14	found	N	I-Claim
15	.	N	I-Claim

1	ARSR	N	I-Claim
2	seem	N	I-Claim
3	to	N	I-Claim
4	be	N	I-Claim
5	a	N	I-Claim
6	relatively	N	I-Claim
7	limited	N	I-Claim
8	problem	N	I-Claim
9	,	N	I-Claim
10	probably	N	I-Claim
11	more	N	I-Claim
12	influenced	N	I-Claim
13	by	N	I-Claim
14	treatment	N	I-Claim
15	related	N	I-Claim
16	factors	N	I-Claim
17	than	N	I-Claim
18	by	N	I-Claim
19	choice	N	I-Claim
20	of	N	I-Claim
21	skin	N	I-Claim
22	care	N	I-Claim
23	products	N	I-Claim
24	in	N	I-Claim
25	this	N	I-Claim
26	patient	N	I-Claim
27	group	N	I-Claim
28	.	N	I-Claim

1	With	N	O
2	the	N	O
3	adoption	N	O
4	of	N	O
5	enhanced	N	O
6	recovery	N	O
7	and	N	O
8	emerging	N	O
9	new	N	O
10	modalities	N	O
11	of	N	O
12	analgesia	N	O
13	after	N	O
14	laparoscopic	N	O
15	colorectal	N	O
16	resection	N	O
17	(	N	O
18	LCR	N	O
19	)	N	O
20	,	N	O
21	the	N	O
22	role	N	O
23	of	N	O
24	epidural	N	O
25	analgesia	N	O
26	has	N	O
27	been	N	O
28	questioned	N	O
29	.	N	O

1	This	N	O
2	pilot	N	O
3	trial	N	O
4	assessed	N	O
5	the	N	O
6	feasibility	N	O
7	of	N	O
8	a	N	O
9	randomized	N	O
10	controlled	N	O
11	trial	N	O
12	(	N	O
13	RCT	N	O
14	)	N	O
15	comparing	N	O
16	epidural	N	O
17	analgesia	N	O
18	and	N	O
19	use	N	O
20	of	N	O
21	a	N	O
22	local	N	O
23	anaesthetic	N	O
24	wound	N	O
25	infusion	N	O
26	catheter	N	O
27	(	N	O
28	WIC	N	O
29	)	N	O
30	following	N	O
31	LCR	N	O
32	.	N	O

1	Between	N	O
2	April	N	O
3	2010	N	O
4	and	N	O
5	May	N	O
6	2011	N	O
7	,	N	O
8	patients	N	O
9	undergoing	N	O
10	elective	N	O
11	LCR	N	O
12	in	N	O
13	two	N	O
14	centres	N	O
15	were	N	O
16	randomized	N	O
17	to	N	O
18	analgesia	N	O
19	via	N	O
20	epidural	N	O
21	or	N	O
22	WIC	N	O
23	.	N	O

1	Sham	N	O
2	procedures	N	O
3	were	N	O
4	used	N	O
5	to	N	O
6	blind	N	O
7	surgeons	N	O
8	,	N	O
9	patients	N	O
10	and	N	O
11	outcome	N	O
12	assessors	N	O
13	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	the	N	O
6	feasibility	N	O
7	of	N	O
8	a	N	O
9	large	N	O
10	RCT	N	O
11	,	N	O
12	and	N	O
13	all	N	O
14	outcomes	N	O
15	for	N	O
16	a	N	O
17	definitive	N	O
18	trial	N	O
19	were	N	O
20	tested	N	O
21	.	N	O

1	The	N	O
2	success	N	O
3	of	N	O
4	blinding	N	O
5	was	N	O
6	assessed	N	O
7	using	N	O
8	a	N	O
9	mixed-methods	N	O
10	approach	N	O
11	.	N	O

1	Forty-five	N	O
2	patients	N	O
3	were	N	O
4	eligible	N	O
5	,	N	O
6	of	N	O
7	whom	N	O
8	34	N	O
9	were	N	O
10	randomized	N	O
11	(	N	O
12	mean	N	O
13	(	N	O
14	s.d	N	O
15	.	N	O

1	)	N	O
2	age	N	O
3	70	N	O
4	(	N	O
5	11·8	N	O
6	)	N	O
7	years	N	O
8	)	N	O
9	.	N	O

1	Patients	N	O
2	were	N	O
3	followed	N	O
4	up	N	O
5	per-protocol	N	O
6	;	N	O
7	there	N	O
8	were	N	O
9	no	N	O
10	deaths	N	O
11	,	N	O
12	and	N	O
13	five	N	O
14	patients	N	O
15	had	N	O
16	a	N	O
17	total	N	O
18	of	N	O
19	six	N	O
20	complications	N	O
21	.	N	O

1	Challenges	N	O
2	with	N	O
3	capturing	N	O
4	pain	N	O
5	data	N	O
6	were	N	O
7	identified	N	O
8	and	N	O
9	resolved	N	O
10	.	N	O

1	Mean	N	I-Premise
2	(	N	I-Premise
3	s.d	N	I-Premise
4	.	N	I-Premise

1	)	N	I-Premise
2	pain	N	I-Premise
3	scores	N	I-Premise
4	on	N	I-Premise
5	the	N	I-Premise
6	day	N	I-Premise
7	of	N	I-Premise
8	discharge	N	I-Premise
9	were	N	I-Premise
10	1·9	N	I-Premise
11	(	N	I-Premise
12	3·1	N	I-Premise
13	)	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	epidural	N	I-Premise
17	group	N	I-Premise
18	and	N	I-Premise
19	0·7	N	I-Premise
20	(	N	I-Premise
21	0·7	N	I-Premise
22	)	N	I-Premise
23	in	N	I-Premise
24	the	N	I-Premise
25	WIC	N	I-Premise
26	group	N	I-Premise
27	.	N	I-Premise

1	Median	N	I-Premise
2	length	N	I-Premise
3	of	N	I-Premise
4	stay	N	I-Premise
5	was	N	I-Premise
6	4	N	I-Premise
7	(	N	I-Premise
8	range	N	I-Premise
9	2-35	N	I-Premise
10	,	N	I-Premise
11	interquartile	N	I-Premise
12	range	N	I-Premise
13	3-5	N	I-Premise
14	)	N	I-Premise
15	days	N	I-Premise
16	.	N	I-Premise

1	Mean	N	I-Premise
2	use	N	I-Premise
3	of	N	I-Premise
4	additional	N	I-Premise
5	analgesia	N	I-Premise
6	(	N	I-Premise
7	intravenous	N	I-Premise
8	morphine	N	I-Premise
9	equivalents	N	I-Premise
10	)	N	I-Premise
11	was	N	I-Premise
12	12	N	I-Premise
13	mg	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	WIC	N	I-Premise
17	arm	N	I-Premise
18	and	N	I-Premise
19	9	N	I-Premise
20	mg	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	epidural	N	I-Premise
24	arm	N	I-Premise
25	.	N	I-Premise

1	Patient	N	O
2	blinding	N	O
3	was	N	O
4	successful	N	O
5	in	N	O
6	both	N	O
7	arms	N	O
8	.	N	O

1	Qualitative	N	I-Claim
2	interviews	N	I-Claim
3	suggested	N	I-Claim
4	that	N	I-Claim
5	patients	N	I-Claim
6	found	N	I-Claim
7	participation	N	I-Claim
8	in	N	I-Claim
9	the	N	I-Claim
10	trial	N	I-Claim
11	acceptable	N	I-Claim
12	and	N	I-Claim
13	that	N	I-Claim
14	they	N	I-Claim
15	would	N	I-Claim
16	consider	N	I-Claim
17	participating	N	I-Claim
18	in	N	I-Claim
19	a	N	I-Claim
20	future	N	I-Claim
21	trial	N	I-Claim
22	.	N	I-Claim

1	A	N	I-Claim
2	blinded	N	I-Claim
3	RCT	N	I-Claim
4	investigating	N	I-Claim
5	the	N	I-Claim
6	role	N	I-Claim
7	of	N	I-Claim
8	epidural	N	I-Claim
9	and	N	I-Claim
10	WIC	N	I-Claim
11	administration	N	I-Claim
12	for	N	I-Claim
13	postoperative	N	I-Claim
14	analgesia	N	I-Claim
15	following	N	I-Claim
16	LCR	N	I-Claim
17	is	N	I-Claim
18	feasible	N	I-Claim
19	.	N	I-Claim

1	Rigorous	N	I-MajorClaim
2	standard	N	I-MajorClaim
3	operating	N	I-MajorClaim
4	procedures	N	I-MajorClaim
5	for	N	I-MajorClaim
6	data	N	I-MajorClaim
7	collection	N	I-MajorClaim
8	are	N	I-MajorClaim
9	required	N	I-MajorClaim
10	.	N	I-MajorClaim

1	Several	N	O
2	guidelines	N	O
3	on	N	O
4	the	N	O
5	treatment	N	O
6	of	N	O
7	cancer-related	N	O
8	fatigue	N	O
9	recommend	N	O
10	optimizing	N	O
11	treatment	N	O
12	of	N	O
13	accompanying	N	O
14	symptoms	N	O
15	.	N	O

1	However	N	O
2	,	N	O
3	evidence	N	O
4	for	N	O
5	this	N	O
6	recommendation	N	O
7	from	N	O
8	randomized	N	O
9	clinical	N	O
10	trials	N	O
11	is	N	O
12	lacking	N	O
13	.	N	O

1	We	N	O
2	investigated	N	O
3	whether	N	O
4	monitoring	N	O
5	and	N	O
6	protocolized	N	O
7	treatment	N	O
8	of	N	O
9	physical	N	O
10	symptoms	N	O
11	alleviates	N	O
12	fatigue	N	O
13	.	N	O

1	In	N	O
2	all	N	O
3	,	N	O
4	152	N	O
5	fatigued	N	O
6	patients	N	O
7	with	N	O
8	advanced	N	O
9	cancer	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	to	N	O
14	protocolized	N	O
15	patient-tailored	N	O
16	treatment	N	O
17	(	N	O
18	PPT	N	O
19	)	N	O
20	of	N	O
21	symptoms	N	O
22	or	N	O
23	care	N	O
24	as	N	O
25	usual	N	O
26	.	N	O

1	The	N	O
2	PPT	N	O
3	group	N	O
4	had	N	O
5	four	N	O
6	appointments	N	O
7	with	N	O
8	a	N	O
9	nurse	N	O
10	who	N	O
11	assessed	N	O
12	nine	N	O
13	symptoms	N	O
14	on	N	O
15	a	N	O
16	0	N	O
17	to	N	O
18	10	N	O
19	numeric	N	O
20	rating	N	O
21	scale	N	O
22	(	N	O
23	NRS	N	O
24	)	N	O
25	.	N	O

1	Patients	N	O
2	received	N	O
3	a	N	O
4	nonpharmacologic	N	O
5	intervention	N	O
6	for	N	O
7	symptoms	N	O
8	with	N	O
9	a	N	O
10	score	N	O
11	≥	N	O
12	1	N	O
13	and	N	O
14	a	N	O
15	medical	N	O
16	intervention	N	O
17	for	N	O
18	symptoms	N	O
19	with	N	O
20	a	N	O
21	score	N	O
22	≥	N	O
23	4	N	O
24	.	N	O

1	Fatigue	N	O
2	dimensions	N	O
3	,	N	O
4	fatigue	N	O
5	NRS	N	O
6	score	N	O
7	,	N	O
8	interference	N	O
9	of	N	O
10	fatigue	N	O
11	with	N	O
12	daily	N	O
13	life	N	O
14	,	N	O
15	symptom	N	O
16	burden	N	O
17	,	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	,	N	O
22	anxiety	N	O
23	,	N	O
24	and	N	O
25	depression	N	O
26	were	N	O
27	measured	N	O
28	at	N	O
29	baseline	N	O
30	and	N	O
31	after	N	O
32	1	N	O
33	,	N	O
34	2	N	O
35	,	N	O
36	and	N	O
37	3	N	O
38	months	N	O
39	.	N	O

1	Differences	N	O
2	between	N	O
3	the	N	O
4	groups	N	O
5	over	N	O
6	time	N	O
7	were	N	O
8	assessed	N	O
9	by	N	O
10	using	N	O
11	mixed	N	O
12	modeling	N	O
13	.	N	O

1	Seventy-six	N	O
2	patients	N	O
3	were	N	O
4	randomly	N	O
5	assigned	N	O
6	to	N	O
7	each	N	O
8	study	N	O
9	arm	N	O
10	.	N	O

1	Mean	N	O
2	age	N	O
3	was	N	O
4	58	N	O
5	±	N	O
6	10	N	O
7	years	N	O
8	,	N	O
9	57	N	O
10	%	N	O
11	were	N	O
12	female	N	O
13	,	N	O
14	and	N	O
15	65	N	O
16	%	N	O
17	were	N	O
18	given	N	O
19	palliative	N	O
20	chemotherapy	N	O
21	.	N	O

1	We	N	I-Premise
2	found	N	I-Premise
3	significant	N	I-Premise
4	improvements	N	I-Premise
5	over	N	I-Premise
6	time	N	I-Premise
7	in	N	I-Premise
8	favor	N	I-Premise
9	of	N	I-Premise
10	PPT	N	I-Premise
11	for	N	I-Premise
12	the	N	I-Premise
13	primary	N	I-Premise
14	outcome	N	I-Premise
15	general	N	I-Premise
16	fatigue	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	.01	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	with	N	I-Premise
24	significant	N	I-Premise
25	group	N	I-Premise
26	differences	N	I-Premise
27	at	N	I-Premise
28	month	N	I-Premise
29	1	N	I-Premise
30	(	N	I-Premise
31	effect	N	I-Premise
32	size	N	I-Premise
33	,	N	I-Premise
34	0.26	N	I-Premise
35	;	N	I-Premise
36	P	N	I-Premise
37	=	N	I-Premise
38	.007	N	I-Premise
39	)	N	I-Premise
40	and	N	I-Premise
41	month	N	I-Premise
42	2	N	I-Premise
43	(	N	I-Premise
44	effect	N	I-Premise
45	size	N	I-Premise
46	,	N	I-Premise
47	0.35	N	I-Premise
48	;	N	I-Premise
49	P	N	I-Premise
50	=	N	I-Premise
51	.005	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	Improvements	N	I-Premise
2	in	N	I-Premise
3	favor	N	I-Premise
4	of	N	I-Premise
5	PPT	N	I-Premise
6	were	N	I-Premise
7	also	N	I-Premise
8	found	N	I-Premise
9	for	N	I-Premise
10	the	N	I-Premise
11	following	N	I-Premise
12	secondary	N	I-Premise
13	outcomes	N	I-Premise
14	:	N	I-Premise
15	fatigue	N	I-Premise
16	dimensions	N	I-Premise
17	``	N	I-Premise
18	reduced	N	I-Premise
19	activity	N	I-Premise
20	''	N	I-Premise
21	and	N	I-Premise
22	``	N	I-Premise
23	reduced	N	I-Premise
24	motivation	N	I-Premise
25	,	N	I-Premise
26	''	N	I-Premise
27	fatigue	N	I-Premise
28	NRS	N	I-Premise
29	,	N	I-Premise
30	symptom	N	I-Premise
31	burden	N	I-Premise
32	,	N	I-Premise
33	interference	N	I-Premise
34	of	N	I-Premise
35	fatigue	N	I-Premise
36	with	N	I-Premise
37	daily	N	I-Premise
38	life	N	I-Premise
39	,	N	I-Premise
40	and	N	I-Premise
41	anxiety	N	I-Premise
42	(	N	I-Premise
43	all	N	I-Premise
44	P	N	I-Premise
45	≤	N	I-Premise
46	.03	N	I-Premise
47	)	N	I-Premise
48	.	N	I-Premise

1	In	N	I-Claim
2	fatigued	N	I-Claim
3	patients	N	I-Claim
4	with	N	I-Claim
5	advanced	N	I-Claim
6	cancer	N	I-Claim
7	,	N	I-Claim
8	nurse-led	N	I-Claim
9	monitoring	N	I-Claim
10	and	N	I-Claim
11	protocolized	N	I-Claim
12	treatment	N	I-Claim
13	of	N	I-Claim
14	physical	N	I-Claim
15	symptoms	N	I-Claim
16	is	N	I-Claim
17	effective	N	I-Claim
18	in	N	I-Claim
19	alleviating	N	I-Claim
20	fatigue	N	I-Claim
21	.	N	I-Claim

1	Behavioral	N	O
2	symptoms	N	O
3	are	N	O
4	common	N	O
5	in	N	O
6	breast	N	O
7	cancer	N	O
8	survivors	N	O
9	,	N	O
10	including	N	O
11	disturbances	N	O
12	in	N	O
13	energy	N	O
14	,	N	O
15	sleep	N	O
16	,	N	O
17	and	N	O
18	mood	N	O
19	,	N	O
20	though	N	O
21	few	N	O
22	risk	N	O
23	factors	N	O
24	for	N	O
25	these	N	O
26	negative	N	O
27	outcomes	N	O
28	have	N	O
29	been	N	O
30	identified	N	O
31	.	N	O

1	Our	N	O
2	study	N	O
3	examined	N	O
4	intrusive	N	O
5	thoughts	N	O
6	as	N	O
7	a	N	O
8	predictor	N	O
9	of	N	O
10	lingering	N	O
11	symptoms	N	O
12	in	N	O
13	breast	N	O
14	cancer	N	O
15	survivors	N	O
16	in	N	O
17	the	N	O
18	year	N	O
19	following	N	O
20	treatment	N	O
21	.	N	O

1	Data	N	O
2	come	N	O
3	from	N	O
4	the	N	O
5	Moving	N	O
6	Beyond	N	O
7	Cancer	N	O
8	psychoeducational	N	O
9	intervention	N	O
10	trial	N	O
11	,	N	O
12	aimed	N	O
13	at	N	O
14	easing	N	O
15	the	N	O
16	transition	N	O
17	from	N	O
18	patient	N	O
19	to	N	O
20	survivor	N	O
21	.	N	O

1	Women	N	O
2	(	N	O
3	n	N	O
4	=	N	O
5	558	N	O
6	)	N	O
7	completed	N	O
8	psychosocial	N	O
9	questionnaires	N	O
10	within	N	O
11	4	N	O
12	weeks	N	O
13	posttreatment	N	O
14	and	N	O
15	again	N	O
16	2	N	O
17	,	N	O
18	6	N	O
19	,	N	O
20	and	N	O
21	12	N	O
22	months	N	O
23	later	N	O
24	.	N	O

1	We	N	O
2	examined	N	O
3	intrusive	N	O
4	thoughts	N	O
5	about	N	O
6	cancer	N	O
7	at	N	O
8	the	N	O
9	baseline	N	O
10	assessment	N	O
11	as	N	O
12	a	N	O
13	predictor	N	O
14	of	N	O
15	fatigue	N	O
16	,	N	O
17	sleep	N	O
18	problems	N	O
19	,	N	O
20	pain	N	O
21	,	N	O
22	breast	N	O
23	cancer-specific	N	O
24	symptoms	N	O
25	,	N	O
26	depressive	N	O
27	symptoms	N	O
28	,	N	O
29	negative	N	O
30	affect	N	O
31	,	N	O
32	and	N	O
33	quality	N	O
34	of	N	O
35	life	N	O
36	using	N	O
37	growth	N	O
38	curve	N	O
39	modeling	N	O
40	,	N	O
41	controlling	N	O
42	for	N	O
43	study	N	O
44	condition	N	O
45	and	N	O
46	other	N	O
47	covariates	N	O
48	.	N	O

1	Intrusive	N	I-Premise
2	thoughts	N	I-Premise
3	were	N	I-Premise
4	associated	N	I-Premise
5	with	N	I-Premise
6	higher	N	I-Premise
7	levels	N	I-Premise
8	of	N	I-Premise
9	all	N	I-Premise
10	symptoms	N	I-Premise
11	at	N	I-Premise
12	baseline	N	I-Premise
13	and	N	I-Premise
14	at	N	I-Premise
15	the	N	I-Premise
16	12-month	N	I-Premise
17	assessment	N	I-Premise
18	.	N	I-Premise

1	Intrusive	N	I-Premise
2	thoughts	N	I-Premise
3	also	N	I-Premise
4	influenced	N	I-Premise
5	the	N	I-Premise
6	trajectory	N	I-Premise
7	of	N	I-Premise
8	pain	N	I-Premise
9	,	N	I-Premise
10	depressive	N	I-Premise
11	symptoms	N	I-Premise
12	,	N	I-Premise
13	negative	N	I-Premise
14	affect	N	I-Premise
15	,	N	I-Premise
16	and	N	I-Premise
17	physical	N	I-Premise
18	functioning	N	I-Premise
19	over	N	I-Premise
20	time	N	I-Premise
21	;	N	I-Premise
22	women	N	I-Premise
23	with	N	I-Premise
24	higher	N	I-Premise
25	intrusions	N	I-Premise
26	at	N	I-Premise
27	baseline	N	I-Premise
28	started	N	I-Premise
29	worse	N	I-Premise
30	and	N	I-Premise
31	improved	N	I-Premise
32	over	N	I-Premise
33	time	N	I-Premise
34	,	N	I-Premise
35	whereas	N	I-Premise
36	those	N	I-Premise
37	with	N	I-Premise
38	lower	N	I-Premise
39	intrusions	N	I-Premise
40	remained	N	I-Premise
41	at	N	I-Premise
42	a	N	I-Premise
43	constant	N	I-Premise
44	,	N	I-Premise
45	lower	N	I-Premise
46	level	N	I-Premise
47	over	N	I-Premise
48	time	N	I-Premise
49	.	N	I-Premise

1	Intrusions	N	I-Premise
2	were	N	I-Premise
3	not	N	I-Premise
4	associated	N	I-Premise
5	with	N	I-Premise
6	the	N	I-Premise
7	trajectory	N	I-Premise
8	of	N	I-Premise
9	fatigue	N	I-Premise
10	,	N	I-Premise
11	sleep	N	I-Premise
12	,	N	I-Premise
13	breast	N	I-Premise
14	cancer-specific	N	I-Premise
15	symptoms	N	I-Premise
16	,	N	I-Premise
17	or	N	I-Premise
18	mental	N	I-Premise
19	functioning	N	I-Premise
20	;	N	I-Premise
21	women	N	I-Premise
22	with	N	I-Premise
23	higher	N	I-Premise
24	intrusions	N	I-Premise
25	at	N	I-Premise
26	baseline	N	I-Premise
27	started	N	I-Premise
28	worse	N	I-Premise
29	and	N	I-Premise
30	remained	N	I-Premise
31	worse	N	I-Premise
32	over	N	I-Premise
33	time	N	I-Premise
34	.	N	I-Premise

1	Intrusive	N	I-Claim
2	thoughts	N	I-Claim
3	are	N	I-Claim
4	associated	N	I-Claim
5	with	N	I-Claim
6	enduring	N	I-Claim
7	elevations	N	I-Claim
8	in	N	I-Claim
9	behavioral	N	I-Claim
10	symptoms	N	I-Claim
11	and	N	I-Claim
12	impaired	N	I-Claim
13	quality	N	I-Claim
14	of	N	I-Claim
15	life	N	I-Claim
16	in	N	I-Claim
17	the	N	I-Claim
18	year	N	I-Claim
19	after	N	I-Claim
20	breast	N	I-Claim
21	cancer	N	I-Claim
22	treatment	N	I-Claim
23	and	N	I-Claim
24	may	N	I-Claim
25	be	N	I-Claim
26	a	N	I-Claim
27	risk	N	I-Claim
28	factor	N	I-Claim
29	for	N	I-Claim
30	poor	N	I-Claim
31	outcomes	N	I-Claim
32	.	N	I-Claim

1	The	N	O
2	management	N	O
3	of	N	O
4	cancer-related	N	O
5	anorexia/cachexia	N	O
6	syndrome	N	O
7	(	N	O
8	CACS	N	O
9	)	N	O
10	is	N	O
11	a	N	O
12	great	N	O
13	challenge	N	O
14	in	N	O
15	clinical	N	O
16	practice	N	O
17	.	N	O

1	To	N	O
2	date	N	O
3	,	N	O
4	practice	N	O
5	guidelines	N	O
6	for	N	O
7	the	N	O
8	prevention	N	O
9	and	N	O
10	treatment	N	O
11	of	N	O
12	CACS	N	O
13	are	N	O
14	lacking	N	O
15	.	N	O

1	The	N	O
2	authors	N	O
3	conducted	N	O
4	a	N	O
5	randomized	N	O
6	study	N	O
7	to	N	O
8	confirm	N	O
9	the	N	O
10	effectiveness	N	O
11	and	N	O
12	safety	N	O
13	of	N	O
14	treatment	N	O
15	of	N	O
16	CACS	N	O
17	utilizing	N	O
18	megestrol	N	O
19	acetate	N	O
20	(	N	O
21	MA	N	O
22	)	N	O
23	plus	N	O
24	thalidomide	N	O
25	.	N	O

1	One	N	O
2	hundred	N	O
3	and	N	O
4	two	N	O
5	candidates	N	O
6	with	N	O
7	CACS	N	O
8	were	N	O
9	randomly	N	O
10	assigned	N	O
11	to	N	O
12	two	N	O
13	treatment	N	O
14	groups	N	O
15	(	N	O
16	trial	N	O
17	group	N	O
18	and	N	O
19	control	N	O
20	group	N	O
21	)	N	O
22	:	N	O
23	the	N	O
24	trial	N	O
25	group	N	O
26	received	N	O
27	MA	N	O
28	(	N	O
29	160	N	O
30	mg	N	O
31	po	N	O
32	,	N	O
33	bid	N	O
34	)	N	O
35	plus	N	O
36	thalidomide	N	O
37	(	N	O
38	50	N	O
39	mg	N	O
40	po	N	O
41	,	N	O
42	bid	N	O
43	)	N	O
44	,	N	O
45	while	N	O
46	the	N	O
47	control	N	O
48	group	N	O
49	received	N	O
50	MA	N	O
51	(	N	O
52	160	N	O
53	mg	N	O
54	po	N	O
55	,	N	O
56	bid	N	O
57	)	N	O
58	alone	N	O
59	.	N	O

1	Treatment	N	O
2	duration	N	O
3	was	N	O
4	8	N	O
5	weeks	N	O
6	.	N	O

1	Analysis	N	I-Premise
2	of	N	I-Premise
3	the	N	I-Premise
4	trial	N	I-Premise
5	group	N	I-Premise
6	demonstrated	N	I-Premise
7	a	N	I-Premise
8	significant	N	I-Premise
9	increase	N	I-Premise
10	from	N	I-Premise
11	baseline	N	I-Premise
12	in	N	I-Premise
13	body	N	I-Premise
14	weight	N	I-Premise
15	(	N	I-Premise
16	<	N	I-Premise
17	0.01	N	I-Premise
18	)	N	I-Premise
19	,	N	I-Premise
20	quality	N	I-Premise
21	of	N	I-Premise
22	life	N	I-Premise
23	(	N	I-Premise
24	p	N	I-Premise
25	=	N	I-Premise
26	0.02	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	appetite	N	I-Premise
30	(	N	I-Premise
31	p	N	I-Premise
32	=	N	I-Premise
33	0.01	N	I-Premise
34	)	N	I-Premise
35	,	N	I-Premise
36	and	N	I-Premise
37	grip	N	I-Premise
38	strength	N	I-Premise
39	(	N	I-Premise
40	p	N	I-Premise
41	=	N	I-Premise
42	0.01	N	I-Premise
43	)	N	I-Premise
44	,	N	I-Premise
45	and	N	I-Premise
46	a	N	I-Premise
47	significant	N	I-Premise
48	decrease	N	I-Premise
49	in	N	I-Premise
50	fatigue	N	I-Premise
51	,	N	I-Premise
52	Glasgow	N	I-Premise
53	Prognostic	N	I-Premise
54	Score	N	I-Premise
55	(	N	I-Premise
56	p	N	I-Premise
57	=	N	I-Premise
58	0.05	N	I-Premise
59	)	N	I-Premise
60	,	N	I-Premise
61	Eastern	N	I-Premise
62	Cooperative	N	I-Premise
63	Oncology	N	I-Premise
64	Group	N	I-Premise
65	performance	N	I-Premise
66	status	N	I-Premise
67	(	N	I-Premise
68	p	N	I-Premise
69	=	N	I-Premise
70	0.03	N	I-Premise
71	)	N	I-Premise
72	,	N	I-Premise
73	IL-6	N	I-Premise
74	(	N	I-Premise
75	p	N	I-Premise
76	<	N	I-Premise
77	0.01	N	I-Premise
78	)	N	I-Premise
79	,	N	I-Premise
80	and	N	I-Premise
81	tumor	N	I-Premise
82	necrosis	N	I-Premise
83	factor-α	N	I-Premise
84	(	N	I-Premise
85	p	N	I-Premise
86	=	N	I-Premise
87	0.02	N	I-Premise
88	)	N	I-Premise
89	.	N	I-Premise

1	In	N	I-Premise
2	contrast	N	I-Premise
3	,	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	control	N	I-Premise
7	group	N	I-Premise
8	,	N	I-Premise
9	endpoints	N	I-Premise
10	with	N	I-Premise
11	a	N	I-Premise
12	significant	N	I-Premise
13	improvement	N	I-Premise
14	from	N	I-Premise
15	baseline	N	I-Premise
16	included	N	I-Premise
17	body	N	I-Premise
18	weight	N	I-Premise
19	(	N	I-Premise
20	p	N	I-Premise
21	<	N	I-Premise
22	0.02	N	I-Premise
23	)	N	I-Premise
24	and	N	I-Premise
25	appetite	N	I-Premise
26	(	N	I-Premise
27	p	N	I-Premise
28	=	N	I-Premise
29	0.02	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	The	N	I-Premise
2	mean	N	I-Premise
3	changes	N	I-Premise
4	in	N	I-Premise
5	the	N	I-Premise
6	endpoints	N	I-Premise
7	from	N	I-Premise
8	baseline	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	trial	N	I-Premise
12	group	N	I-Premise
13	were	N	I-Premise
14	significantly	N	I-Premise
15	greater	N	I-Premise
16	compared	N	I-Premise
17	with	N	I-Premise
18	the	N	I-Premise
19	control	N	I-Premise
20	group	N	I-Premise
21	:	N	I-Premise
22	in	N	I-Premise
23	the	N	I-Premise
24	primary	N	I-Premise
25	endpoints	N	I-Premise
26	,	N	I-Premise
27	body	N	I-Premise
28	weight	N	I-Premise
29	(	N	I-Premise
30	p	N	I-Premise
31	=	N	I-Premise
32	0.05	N	I-Premise
33	)	N	I-Premise
34	,	N	I-Premise
35	fatigue	N	I-Premise
36	(	N	I-Premise
37	p	N	I-Premise
38	<	N	I-Premise
39	0.01	N	I-Premise
40	)	N	I-Premise
41	and	N	I-Premise
42	quality	N	I-Premise
43	of	N	I-Premise
44	life	N	I-Premise
45	(	N	I-Premise
46	p	N	I-Premise
47	=	N	I-Premise
48	0.01	N	I-Premise
49	)	N	I-Premise
50	,	N	I-Premise
51	and	N	I-Premise
52	in	N	I-Premise
53	the	N	I-Premise
54	secondary	N	I-Premise
55	endpoints	N	I-Premise
56	,	N	I-Premise
57	grip	N	I-Premise
58	strength	N	I-Premise
59	(	N	I-Premise
60	p	N	I-Premise
61	=	N	I-Premise
62	0.05	N	I-Premise
63	)	N	I-Premise
64	,	N	I-Premise
65	Glasgow	N	I-Premise
66	Prognostic	N	I-Premise
67	Score	N	I-Premise
68	(	N	I-Premise
69	p	N	I-Premise
70	=	N	I-Premise
71	0.02	N	I-Premise
72	)	N	I-Premise
73	,	N	I-Premise
74	Eastern	N	I-Premise
75	Cooperative	N	I-Premise
76	Oncology	N	I-Premise
77	Group	N	I-Premise
78	performance	N	I-Premise
79	status	N	I-Premise
80	(	N	I-Premise
81	p	N	I-Premise
82	=	N	I-Premise
83	0.02	N	I-Premise
84	)	N	I-Premise
85	,	N	I-Premise
86	IL-6	N	I-Premise
87	(	N	I-Premise
88	p	N	I-Premise
89	<	N	I-Premise
90	0.01	N	I-Premise
91	)	N	I-Premise
92	and	N	I-Premise
93	tumor	N	I-Premise
94	necrosis	N	I-Premise
95	factor-α	N	I-Premise
96	(	N	I-Premise
97	p	N	I-Premise
98	=	N	I-Premise
99	0.01	N	I-Premise
100	)	N	I-Premise
101	.	N	I-Premise

1	Toxicity	N	I-Premise
2	was	N	I-Premise
3	found	N	I-Premise
4	to	N	I-Premise
5	be	N	I-Premise
6	relatively	N	I-Premise
7	negligible	N	I-Premise
8	in	N	I-Premise
9	both	N	I-Premise
10	groups	N	I-Premise
11	.	N	I-Premise

1	A	N	I-Claim
2	combination	N	I-Claim
3	regimen	N	I-Claim
4	of	N	I-Claim
5	MA	N	I-Claim
6	and	N	I-Claim
7	thalidomide	N	I-Claim
8	is	N	I-Claim
9	more	N	I-Claim
10	effective	N	I-Claim
11	than	N	I-Claim
12	MA	N	I-Claim
13	alone	N	I-Claim
14	in	N	I-Claim
15	the	N	I-Claim
16	treatment	N	I-Claim
17	of	N	I-Claim
18	CACS	N	I-Claim
19	.	N	I-Claim

1	Prior	N	O
2	studies	N	O
3	have	N	O
4	suggested	N	O
5	that	N	O
6	melatonin	N	O
7	,	N	O
8	a	N	O
9	frequently	N	O
10	used	N	O
11	integrative	N	O
12	medicine	N	O
13	,	N	O
14	can	N	O
15	attenuate	N	O
16	weight	N	O
17	loss	N	O
18	,	N	O
19	anorexia	N	O
20	,	N	O
21	and	N	O
22	fatigue	N	O
23	in	N	O
24	patients	N	O
25	with	N	O
26	cancer	N	O
27	.	N	O

1	These	N	O
2	studies	N	O
3	were	N	O
4	limited	N	O
5	by	N	O
6	a	N	O
7	lack	N	O
8	of	N	O
9	blinding	N	O
10	and	N	O
11	absence	N	O
12	of	N	O
13	placebo	N	O
14	controls	N	O
15	.	N	O

1	The	N	O
2	primary	N	O
3	purpose	N	O
4	of	N	O
5	this	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	compare	N	O
10	melatonin	N	O
11	with	N	O
12	placebo	N	O
13	for	N	O
14	appetite	N	O
15	improvement	N	O
16	in	N	O
17	patients	N	O
18	with	N	O
19	cancer	N	O
20	cachexia	N	O
21	.	N	O

1	We	N	O
2	performed	N	O
3	a	N	O
4	randomized	N	O
5	,	N	O
6	double-blind	N	O
7	,	N	O
8	28-day	N	O
9	trial	N	O
10	of	N	O
11	melatonin	N	O
12	20	N	O
13	mg	N	O
14	versus	N	O
15	placebo	N	O
16	in	N	O
17	patients	N	O
18	with	N	O
19	advanced	N	O
20	lung	N	O
21	or	N	O
22	GI	N	O
23	cancer	N	O
24	,	N	O
25	appetite	N	O
26	scores	N	O
27	≥	N	O
28	4	N	O
29	on	N	O
30	a	N	O
31	0	N	O
32	to	N	O
33	10	N	O
34	scale	N	O
35	(	N	O
36	10	N	O
37	=	N	O
38	worst	N	O
39	appetite	N	O
40	)	N	O
41	,	N	O
42	and	N	O
43	history	N	O
44	of	N	O
45	weight	N	O
46	loss	N	O
47	≥	N	O
48	5	N	O
49	%	N	O
50	.	N	O

1	Assessments	N	O
2	included	N	O
3	weight	N	O
4	,	N	O
5	symptoms	N	O
6	by	N	O
7	the	N	O
8	Edmonton	N	O
9	Symptom	N	O
10	Assessment	N	O
11	Scale	N	O
12	,	N	O
13	and	N	O
14	quality	N	O
15	of	N	O
16	life	N	O
17	by	N	O
18	the	N	O
19	Functional	N	O
20	Assessment	N	O
21	of	N	O
22	Anorexia/Cachexia	N	O
23	Therapy	N	O
24	(	N	O
25	FAACT	N	O
26	)	N	O
27	questionnaire	N	O
28	.	N	O

1	Differences	N	O
2	between	N	O
3	groups	N	O
4	from	N	O
5	baseline	N	O
6	to	N	O
7	day	N	O
8	28	N	O
9	were	N	O
10	analyzed	N	O
11	using	N	O
12	one-sided	N	O
13	,	N	O
14	two-sample	N	O
15	t	N	O
16	tests	N	O
17	or	N	O
18	Wilcoxon	N	O
19	two-sample	N	O
20	tests	N	O
21	.	N	O

1	Interim	N	O
2	analysis	N	O
3	halfway	N	O
4	through	N	O
5	the	N	O
6	trial	N	O
7	had	N	O
8	a	N	O
9	Lan-DeMets	N	O
10	monitoring	N	O
11	boundary	N	O
12	with	N	O
13	an	N	O
14	O'Brien-Fleming	N	O
15	stopping	N	O
16	rule	N	O
17	.	N	O

1	Decision	N	O
2	boundaries	N	O
3	were	N	O
4	to	N	O
5	accept	N	O
6	the	N	O
7	null	N	O
8	hypothesis	N	O
9	of	N	O
10	futility	N	O
11	if	N	O
12	the	N	O
13	test	N	O
14	statistic	N	O
15	z	N	O
16	<	N	O
17	0.39	N	O
18	(	N	O
19	P	N	O
20	≥	N	O
21	.348	N	O
22	)	N	O
23	and	N	O
24	reject	N	O
25	the	N	O
26	null	N	O
27	hypothesis	N	O
28	if	N	O
29	z	N	O
30	>	N	O
31	2.54	N	O
32	(	N	O
33	P	N	O
34	≤	N	O
35	.0056	N	O
36	)	N	O
37	.	N	O

1	After	N	O
2	interim	N	O
3	analysis	N	O
4	of	N	O
5	48	N	O
6	patients	N	O
7	,	N	O
8	the	N	O
9	study	N	O
10	was	N	O
11	closed	N	O
12	for	N	O
13	futility	N	O
14	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	between	N	I-Premise
7	groups	N	I-Premise
8	for	N	I-Premise
9	appetite	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	=	N	I-Premise
13	.78	N	I-Premise
14	)	N	I-Premise
15	or	N	I-Premise
16	other	N	I-Premise
17	symptoms	N	I-Premise
18	,	N	I-Premise
19	weight	N	I-Premise
20	(	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	.17	N	I-Premise
24	)	N	I-Premise
25	,	N	I-Premise
26	FAACT	N	I-Premise
27	score	N	I-Premise
28	(	N	I-Premise
29	P	N	I-Premise
30	=	N	I-Premise
31	.95	N	I-Premise
32	)	N	I-Premise
33	,	N	I-Premise
34	toxicity	N	I-Premise
35	,	N	I-Premise
36	or	N	I-Premise
37	survival	N	I-Premise
38	from	N	I-Premise
39	baseline	N	I-Premise
40	to	N	I-Premise
41	day	N	I-Premise
42	28	N	I-Premise
43	.	N	I-Premise

1	In	N	I-Claim
2	cachectic	N	I-Claim
3	patients	N	I-Claim
4	with	N	I-Claim
5	advanced	N	I-Claim
6	cancer	N	I-Claim
7	,	N	I-Claim
8	oral	N	I-Claim
9	melatonin	N	I-Claim
10	20	N	I-Claim
11	mg	N	I-Claim
12	at	N	I-Claim
13	night	N	I-Claim
14	did	N	I-Claim
15	not	N	I-Claim
16	improve	N	I-Claim
17	appetite	N	I-Claim
18	,	N	I-Claim
19	weight	N	I-Claim
20	,	N	I-Claim
21	or	N	I-Claim
22	quality	N	I-Claim
23	of	N	I-Claim
24	life	N	I-Claim
25	compared	N	I-Claim
26	with	N	I-Claim
27	placebo	N	I-Claim
28	.	N	I-Claim

1	Treatment	N	O
2	of	N	O
3	patients	N	O
4	with	N	O
5	advanced	N	O
6	or	N	O
7	metastatic	N	O
8	esophagogastric	N	O
9	adenocarcinoma	N	O
10	should	N	O
11	not	N	O
12	only	N	O
13	prolong	N	O
14	life	N	O
15	but	N	O
16	also	N	O
17	provide	N	O
18	relief	N	O
19	of	N	O
20	symptoms	N	O
21	and	N	O
22	improve	N	O
23	quality	N	O
24	of	N	O
25	life	N	O
26	(	N	O
27	QOL	N	O
28	)	N	O
29	.	N	O

1	Esophagogastric	N	O
2	adenocarcinoma	N	O
3	mainly	N	O
4	occurs	N	O
5	in	N	O
6	elderly	N	O
7	patients	N	O
8	,	N	O
9	but	N	O
10	they	N	O
11	are	N	O
12	underrepresented	N	O
13	in	N	O
14	most	N	O
15	clinical	N	O
16	trials	N	O
17	and	N	O
18	often	N	O
19	do	N	O
20	not	N	O
21	receive	N	O
22	effective	N	O
23	combination	N	O
24	chemotherapy	N	O
25	,	N	O
26	most	N	O
27	probably	N	O
28	for	N	O
29	fear	N	O
30	of	N	O
31	intolerance	N	O
32	.	N	O

1	Using	N	O
2	validated	N	O
3	instruments	N	O
4	,	N	O
5	we	N	O
6	prospectively	N	O
7	assessed	N	O
8	QOL	N	O
9	within	N	O
10	the	N	O
11	randomized	N	O
12	FLOT65+	N	O
13	phase	N	O
14	II	N	O
15	trial	N	O
16	.	N	O

1	Within	N	O
2	the	N	O
3	FLOT65+	N	O
4	trial	N	O
5	,	N	O
6	a	N	O
7	total	N	O
8	of	N	O
9	143	N	O
10	patients	N	O
11	aged	N	O
12	≥65	N	O
13	years	N	O
14	were	N	O
15	randomly	N	O
16	allocated	N	O
17	to	N	O
18	receive	N	O
19	biweekly	N	O
20	oxaliplatin	N	O
21	plus	N	O
22	5-fluorouracil	N	O
23	(	N	O
24	5-FU	N	O
25	)	N	O
26	continuous	N	O
27	infusion	N	O
28	and	N	O
29	folinic	N	O
30	acid	N	O
31	(	N	O
32	FLO	N	O
33	)	N	O
34	or	N	O
35	the	N	O
36	same	N	O
37	regimen	N	O
38	in	N	O
39	combination	N	O
40	with	N	O
41	docetaxel	N	O
42	50	N	O
43	mg/m	N	O
44	(	N	O
45	2	N	O
46	)	N	O
47	(	N	O
48	FLOT	N	O
49	)	N	O
50	.	N	O

1	The	N	O
2	European	N	O
3	Organisation	N	O
4	for	N	O
5	Research	N	O
6	and	N	O
7	Treatment	N	O
8	of	N	O
9	Cancer	N	O
10	Quality	N	O
11	of	N	O
12	Life	N	O
13	Questionnaire	N	O
14	C30	N	O
15	(	N	O
16	EORTC	N	O
17	QLQ-C30	N	O
18	)	N	O
19	and	N	O
20	the	N	O
21	gastric	N	O
22	module	N	O
23	STO22	N	O
24	were	N	O
25	administered	N	O
26	every	N	O
27	8	N	O
28	weeks	N	O
29	until	N	O
30	progression	N	O
31	.	N	O

1	Time	N	O
2	to	N	O
3	definitive	N	O
4	deterioration	N	O
5	of	N	O
6	QOL	N	O
7	parameters	N	O
8	was	N	O
9	analyzed	N	O
10	and	N	O
11	compared	N	O
12	within	N	O
13	the	N	O
14	treatment	N	O
15	arms	N	O
16	.	N	O

1	The	N	O
2	median	N	O
3	age	N	O
4	of	N	O
5	patients	N	O
6	was	N	O
7	70	N	O
8	years	N	O
9	.	N	O

1	Patients	N	I-Premise
2	receiving	N	I-Premise
3	FLOT	N	I-Premise
4	exhibited	N	I-Premise
5	higher	N	I-Premise
6	response	N	I-Premise
7	rates	N	I-Premise
8	and	N	I-Premise
9	had	N	I-Premise
10	improved	N	I-Premise
11	disease-free	N	I-Premise
12	and	N	I-Premise
13	progression-free	N	I-Premise
14	survival	N	I-Premise
15	(	N	I-Premise
16	PFS	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	The	N	O
2	proportions	N	O
3	of	N	O
4	patients	N	O
5	with	N	O
6	evaluable	N	O
7	baseline	N	O
8	EORTC	N	O
9	QLQ-C30	N	O
10	and	N	O
11	STO22	N	O
12	questionnaires	N	O
13	were	N	O
14	balanced	N	O
15	(	N	O
16	83	N	O
17	%	N	O
18	in	N	O
19	FLOT	N	O
20	and	N	O
21	89	N	O
22	%	N	O
23	in	N	O
24	FLO	N	O
25	)	N	O
26	.	N	O

1	Considering	N	O
2	evaluable	N	O
3	patients	N	O
4	with	N	O
5	assessable	N	O
6	questionnaires	N	O
7	(	N	O
8	n	N	O
9	=	N	O
10	123	N	O
11	)	N	O
12	,	N	O
13	neither	N	O
14	functioning	N	O
15	nor	N	O
16	symptom	N	O
17	parameters	N	O
18	differed	N	O
19	significantly	N	O
20	in	N	O
21	favor	N	O
22	of	N	O
23	one	N	O
24	of	N	O
25	the	N	O
26	two	N	O
27	treatment	N	O
28	groups	N	O
29	.	N	O

1	Particularly	N	O
2	,	N	O
3	there	N	I-Premise
4	was	N	I-Premise
5	no	N	I-Premise
6	significant	N	I-Premise
7	difference	N	I-Premise
8	regarding	N	I-Premise
9	time	N	I-Premise
10	to	N	I-Premise
11	definitive	N	I-Premise
12	deterioration	N	I-Premise
13	of	N	I-Premise
14	global	N	I-Premise
15	health	N	I-Premise
16	status/quality	N	I-Premise
17	of	N	I-Premise
18	life	N	I-Premise
19	from	N	I-Premise
20	baseline	N	I-Premise
21	(	N	I-Premise
22	primary	N	I-Premise
23	endpoint	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	Notably	N	O
2	,	N	O
3	patients	N	I-Premise
4	receiving	N	I-Premise
5	FLO	N	I-Premise
6	or	N	I-Premise
7	FLOT	N	I-Premise
8	as	N	I-Premise
9	palliative	N	I-Premise
10	treatment	N	I-Premise
11	(	N	I-Premise
12	n	N	I-Premise
13	=	N	I-Premise
14	98	N	I-Premise
15	)	N	I-Premise
16	achieved	N	I-Premise
17	comparable	N	I-Premise
18	QOL	N	I-Premise
19	results	N	I-Premise
20	.	N	I-Premise

1	Although	N	I-Premise
2	toxicity	N	I-Premise
3	was	N	I-Premise
4	higher	N	I-Premise
5	in	N	I-Premise
6	patients	N	I-Premise
7	receiving	N	I-Premise
8	FLOT	N	I-Premise
9	,	N	I-Premise
10	no	N	I-Premise
11	negative	N	I-Premise
12	impact	N	I-Premise
13	of	N	I-Premise
14	the	N	I-Premise
15	addition	N	I-Premise
16	of	N	I-Premise
17	docetaxel	N	I-Premise
18	on	N	I-Premise
19	QOL	N	I-Premise
20	parameters	N	I-Premise
21	could	N	I-Premise
22	be	N	I-Premise
23	demonstrated	N	I-Premise
24	.	N	I-Premise

1	Thus	N	O
2	,	N	O
3	elderly	N	I-Claim
4	patients	N	I-Claim
5	in	N	I-Claim
6	need	N	I-Claim
7	of	N	I-Claim
8	intensified	N	I-Claim
9	chemotherapy	N	I-Claim
10	may	N	I-Claim
11	receive	N	I-Claim
12	FLOT	N	I-Claim
13	without	N	I-Claim
14	compromising	N	I-Claim
15	patient-reported	N	I-Claim
16	outcome	N	I-Claim
17	parameters	N	I-Claim
18	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	dose-volume	N	O
4	histogram	N	O
5	variables	N	O
6	for	N	O
7	the	N	O
8	internal	N	O
9	and	N	O
10	external	N	O
11	urinary	N	O
12	sphincters	N	O
13	(	N	O
14	IUS/EUS	N	O
15	)	N	O
16	with	N	O
17	urinary	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	after	N	O
22	prostate	N	O
23	brachytherapy	N	O
24	.	N	O

1	Subjects	N	O
2	were	N	O
3	42	N	O
4	consecutive	N	O
5	men	N	O
6	from	N	O
7	a	N	O
8	prospective	N	O
9	study	N	O
10	of	N	O
11	brachytherapy	N	O
12	as	N	O
13	monotherapy	N	O
14	with	N	O
15	(	N	O
16	125	N	O
17	)	N	O
18	I	N	O
19	for	N	O
20	intermediate-risk	N	O
21	localized	N	O
22	prostate	N	O
23	cancer	N	O
24	.	N	O

1	No	N	O
2	patient	N	O
3	received	N	O
4	hormonal	N	O
5	therapy	N	O
6	.	N	O

1	Preplanning	N	O
2	constraints	N	O
3	included	N	O
4	prostate	N	O
5	V100	N	O
6	higher	N	O
7	than	N	O
8	95	N	O
9	%	N	O
10	,	N	O
11	V150	N	O
12	lower	N	O
13	than	N	O
14	60	N	O
15	%	N	O
16	,	N	O
17	and	N	O
18	V200	N	O
19	lower	N	O
20	than	N	O
21	20	N	O
22	%	N	O
23	and	N	O
24	rectal	N	O
25	R100	N	O
26	less	N	O
27	than	N	O
28	1cm	N	O
29	(	N	O
30	3	N	O
31	)	N	O
32	.	N	O

1	Patients	N	O
2	completed	N	O
3	the	N	O
4	Expanded	N	O
5	Prostate	N	O
6	Cancer	N	O
7	Index	N	O
8	Composite	N	O
9	quality-of-life	N	O
10	questionnaire	N	O
11	before	N	O
12	and	N	O
13	at	N	O
14	1	N	O
15	,	N	O
16	4	N	O
17	,	N	O
18	8	N	O
19	,	N	O
20	and	N	O
21	12	N	O
22	months	N	O
23	after	N	O
24	implantation	N	O
25	,	N	O
26	and	N	O
27	urinary	N	O
28	domain	N	O
29	scores	N	O
30	were	N	O
31	analyzed	N	O
32	.	N	O

1	All	N	O
2	structures	N	O
3	including	N	O
4	the	N	O
5	IUS	N	O
6	and	N	O
7	EUS	N	O
8	were	N	O
9	contoured	N	O
10	on	N	O
11	T2-weighted	N	O
12	MRI	N	O
13	at	N	O
14	day	N	O
15	30	N	O
16	,	N	O
17	and	N	O
18	doses	N	O
19	received	N	O
20	were	N	O
21	calculated	N	O
22	from	N	O
23	identification	N	O
24	of	N	O
25	seeds	N	O
26	on	N	O
27	CT.	N	O
28	Spearman	N	O
29	's	N	O
30	(	N	O
31	nonparametric	N	O
32	)	N	O
33	rank	N	O
34	correlation	N	O
35	coefficient	N	O
36	(	N	O
37	ρ	N	O
38	)	N	O
39	was	N	O
40	used	N	O
41	for	N	O
42	statistical	N	O
43	analyses	N	O
44	.	N	O

1	Overall	N	O
2	urinary	N	O
3	morbidity	N	O
4	was	N	O
5	worst	N	O
6	at	N	O
7	1	N	O
8	month	N	O
9	after	N	O
10	the	N	O
11	implant	N	O
12	.	N	O

1	Urinary	N	I-Premise
2	function	N	I-Premise
3	declined	N	I-Premise
4	when	N	I-Premise
5	the	N	I-Premise
6	IUS	N	I-Premise
7	V285	N	I-Premise
8	was	N	I-Premise
9	0.4	N	I-Premise
10	%	N	I-Premise
11	(	N	I-Premise
12	ρ=-0.32	N	I-Premise
13	,	N	I-Premise
14	p=0.04	N	I-Premise
15	)	N	I-Premise
16	;	N	I-Premise
17	bother	N	I-Premise
18	worsened	N	I-Premise
19	when	N	I-Premise
20	the	N	I-Premise
21	IUS	N	I-Premise
22	V35	N	I-Premise
23	was	N	I-Premise
24	99	N	I-Premise
25	%	N	I-Premise
26	(	N	I-Premise
27	ρ=-0.31	N	I-Premise
28	,	N	I-Premise
29	p=0.05	N	I-Premise
30	)	N	I-Premise
31	or	N	I-Premise
32	the	N	I-Premise
33	EUS	N	I-Premise
34	V240	N	I-Premise
35	was	N	I-Premise
36	63	N	I-Premise
37	%	N	I-Premise
38	(	N	I-Premise
39	ρ=-0.31	N	I-Premise
40	,	N	I-Premise
41	p=0.05	N	I-Premise
42	)	N	I-Premise
43	;	N	I-Premise
44	irritation	N	I-Premise
45	increased	N	I-Premise
46	when	N	I-Premise
47	the	N	I-Premise
48	IUS	N	I-Premise
49	V35	N	I-Premise
50	was	N	I-Premise
51	95	N	I-Premise
52	%	N	I-Premise
53	(	N	I-Premise
54	ρ=-0.37	N	I-Premise
55	,	N	I-Premise
56	p=0.02	N	I-Premise
57	)	N	I-Premise
58	and	N	I-Premise
59	the	N	I-Premise
60	EUS	N	I-Premise
61	V265	N	I-Premise
62	was	N	I-Premise
63	24	N	I-Premise
64	%	N	I-Premise
65	(	N	I-Premise
66	ρ=-0.32	N	I-Premise
67	,	N	I-Premise
68	p=0.04	N	I-Premise
69	)	N	I-Premise
70	;	N	I-Premise
71	and	N	O
72	urgency	N	I-Premise
73	worsened	N	I-Premise
74	when	N	I-Premise
75	the	N	I-Premise
76	IUS	N	I-Premise
77	V35	N	I-Premise
78	was	N	I-Premise
79	99.5	N	I-Premise
80	%	N	I-Premise
81	(	N	I-Premise
82	ρ=-0.38	N	I-Premise
83	,	N	I-Premise
84	p=0.02	N	I-Premise
85	)	N	I-Premise
86	.	N	I-Premise

1	Incontinence	N	I-Premise
2	did	N	I-Premise
3	not	N	I-Premise
4	correlate	N	I-Premise
5	with	N	I-Premise
6	EUS	N	I-Premise
7	or	N	I-Premise
8	IUS	N	I-Premise
9	dose	N	I-Premise
10	.	N	I-Premise

1	Doses	N	I-Claim
2	to	N	I-Claim
3	the	N	I-Claim
4	IUS	N	I-Claim
5	and	N	I-Claim
6	EUS	N	I-Claim
7	on	N	I-Claim
8	MRI/CT	N	I-Claim
9	predicted	N	I-Claim
10	worse	N	I-Claim
11	urinary	N	I-Claim
12	function	N	I-Claim
13	,	N	I-Claim
14	with	N	I-Claim
15	greater	N	I-Claim
16	bother	N	I-Claim
17	,	N	I-Claim
18	irritative	N	I-Claim
19	symptoms	N	I-Claim
20	,	N	I-Claim
21	and	N	I-Claim
22	urgency	N	I-Claim
23	.	N	I-Claim

1	Incorporating	N	I-MajorClaim
2	MRI-based	N	I-MajorClaim
3	dose-volume	N	I-MajorClaim
4	histogram	N	I-MajorClaim
5	analysis	N	I-MajorClaim
6	into	N	I-MajorClaim
7	the	N	I-MajorClaim
8	treatment	N	I-MajorClaim
9	planning	N	I-MajorClaim
10	process	N	I-MajorClaim
11	may	N	I-MajorClaim
12	reduce	N	I-MajorClaim
13	acute	N	I-MajorClaim
14	urinary	N	I-MajorClaim
15	morbidity	N	I-MajorClaim
16	after	N	I-MajorClaim
17	brachytherapy	N	I-MajorClaim
18	.	N	I-MajorClaim

1	Maintenance	N	O
2	therapy	N	O
3	can	N	O
4	delay	N	O
5	progression	N	O
6	and	N	O
7	prolong	N	O
8	survival	N	O
9	in	N	O
10	metastatic	N	O
11	non-small-cell	N	O
12	lung	N	O
13	cancer	N	O
14	(	N	O
15	mNSCLC	N	O
16	)	N	O
17	.	N	O

1	As	N	O
2	treatment	N	O
3	for	N	O
4	mNSCLC	N	O
5	is	N	O
6	non-curative	N	O
7	,	N	O
8	its	N	O
9	impact	N	O
10	on	N	O
11	patient	N	O
12	health-related	N	O
13	quality	N	O
14	of	N	O
15	life	N	O
16	(	N	O
17	HRQoL	N	O
18	)	N	O
19	is	N	O
20	an	N	O
21	important	N	O
22	consideration	N	O
23	.	N	O

1	SATURN	N	O
2	(	N	O
3	Sequential	N	O
4	Tarceva	N	O
5	in	N	O
6	Unresectable	N	O
7	NSCLC	N	O
8	)	N	O
9	was	N	O
10	a	N	O
11	randomised	N	O
12	,	N	O
13	double-blind	N	O
14	,	N	O
15	placebo-controlled	N	O
16	,	N	O
17	multicentre	N	O
18	study	N	O
19	investigating	N	O
20	the	N	O
21	impact	N	O
22	of	N	O
23	erlotinib	N	O
24	maintenance	N	O
25	therapy	N	O
26	on	N	O
27	HRQoL	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	locally	N	O
32	advanced	N	O
33	or	N	O
34	recurrent	N	O
35	NSCLC	N	O
36	.	N	O

1	Eligible	N	O
2	patients	N	O
3	who	N	O
4	had	N	O
5	previously	N	O
6	completed	N	O
7	four	N	O
8	cycles	N	O
9	of	N	O
10	platinum-based	N	O
11	chemotherapy	N	O
12	were	N	O
13	randomised	N	O
14	1:1	N	O
15	to	N	O
16	receive	N	O
17	erlotinib	N	O
18	150	N	O
19	mg/day	N	O
20	or	N	O
21	placebo	N	O
22	until	N	O
23	disease	N	O
24	progression	N	O
25	,	N	O
26	unacceptable	N	O
27	toxicity	N	O
28	or	N	O
29	death	N	O
30	.	N	O

1	Patient	N	O
2	HRQoL	N	O
3	was	N	O
4	assessed	N	O
5	using	N	O
6	the	N	O
7	Functional	N	O
8	Assessment	N	O
9	of	N	O
10	Cancer	N	O
11	Therapy-Lung	N	O
12	questionnaire	N	O
13	,	N	O
14	in	N	O
15	terms	N	O
16	of	N	O
17	time	N	O
18	to	N	O
19	symptom	N	O
20	progression	N	O
21	(	N	O
22	TSP	N	O
23	)	N	O
24	,	N	O
25	time	N	O
26	to	N	O
27	deterioration	N	O
28	(	N	O
29	TTD	N	O
30	)	N	O
31	in	N	O
32	Trial	N	O
33	Outcome	N	O
34	Index	N	O
35	(	N	O
36	TOI	N	O
37	)	N	O
38	and	N	O
39	TTD	N	O
40	.	N	O

1	Exploratory	N	O
2	analysis	N	O
3	was	N	O
4	based	N	O
5	on	N	O
6	time	N	O
7	to	N	O
8	analgesia	N	O
9	and	N	O
10	appearance	N	O
11	of	N	O
12	key	N	O
13	symptoms	N	O
14	(	N	O
15	pain	N	O
16	,	N	O
17	cough	N	O
18	and	N	O
19	dyspnoea	N	O
20	)	N	O
21	.	N	O

1	Compared	N	I-Premise
2	with	N	I-Premise
3	placebo	N	I-Premise
4	,	N	I-Premise
5	erlotinib	N	I-Premise
6	maintenance	N	I-Premise
7	therapy	N	I-Premise
8	prolonged	N	I-Premise
9	progression-free	N	I-Premise
10	and	N	I-Premise
11	overall	N	I-Premise
12	survival	N	I-Premise
13	by	N	I-Premise
14	41	N	I-Premise
15	%	N	I-Premise
16	and	N	I-Premise
17	23	N	I-Premise
18	%	N	I-Premise
19	,	N	I-Premise
20	respectively	N	I-Premise
21	.	N	I-Premise

1	At	N	O
2	baseline	N	O
3	,	N	O
4	HRQoL	N	O
5	measures	N	O
6	were	N	O
7	comparable	N	O
8	between	N	O
9	the	N	O
10	two	N	O
11	treatment	N	O
12	groups	N	O
13	.	N	O

1	Maintenance	N	I-Premise
2	therapy	N	I-Premise
3	with	N	I-Premise
4	erlotinib	N	I-Premise
5	did	N	I-Premise
6	not	N	I-Premise
7	impact	N	I-Premise
8	on	N	I-Premise
9	deterioration	N	I-Premise
10	in	N	I-Premise
11	HRQoL	N	I-Premise
12	:	N	I-Premise
13	TSP	N	I-Premise
14	(	N	I-Premise
15	hazard	N	I-Premise
16	ratio	N	I-Premise
17	[	N	I-Premise
18	HR	N	I-Premise
19	]	N	I-Premise
20	=0.91	N	I-Premise
21	[	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	confidence	N	I-Premise
25	interval	N	I-Premise
26	(	N	I-Premise
27	CI	N	I-Premise
28	)	N	I-Premise
29	0.74-1.12	N	I-Premise
30	]	N	I-Premise
31	;	N	I-Premise
32	n=785	N	I-Premise
33	)	N	I-Premise
34	,	N	I-Premise
35	TTD	N	I-Premise
36	in	N	I-Premise
37	TOI	N	I-Premise
38	(	N	I-Premise
39	HR=1.06	N	I-Premise
40	[	N	I-Premise
41	95	N	I-Premise
42	%	N	I-Premise
43	CI	N	I-Premise
44	0.87-1.31	N	I-Premise
45	]	N	I-Premise
46	;	N	I-Premise
47	n=781	N	I-Premise
48	)	N	I-Premise
49	and	N	I-Premise
50	TTD	N	I-Premise
51	in	N	I-Premise
52	HRQoL	N	I-Premise
53	(	N	I-Premise
54	HR=0.96	N	I-Premise
55	[	N	I-Premise
56	95	N	I-Premise
57	%	N	I-Premise
58	CI	N	I-Premise
59	0.79-1.16	N	I-Premise
60	]	N	I-Premise
61	;	N	I-Premise
62	n=776	N	I-Premise
63	)	N	I-Premise
64	.	N	I-Premise

1	Time	N	I-Premise
2	to	N	I-Premise
3	pain	N	I-Premise
4	and	N	I-Premise
5	time	N	I-Premise
6	to	N	I-Premise
7	analgesic	N	I-Premise
8	use	N	I-Premise
9	were	N	I-Premise
10	significantly	N	I-Premise
11	delayed	N	I-Premise
12	in	N	I-Premise
13	patients	N	I-Premise
14	receiving	N	I-Premise
15	erlotinib	N	I-Premise
16	compared	N	I-Premise
17	with	N	I-Premise
18	placebo	N	I-Premise
19	(	N	I-Premise
20	HR=0.61	N	I-Premise
21	[	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	0.42-0.88	N	I-Premise
26	]	N	I-Premise
27	;	N	I-Premise
28	p=0.0080	N	I-Premise
29	and	N	I-Premise
30	HR=0.66	N	I-Premise
31	[	N	I-Premise
32	95	N	I-Premise
33	%	N	I-Premise
34	CI	N	I-Premise
35	0.46-0.94	N	I-Premise
36	]	N	I-Premise
37	;	N	I-Premise
38	p=0.0199	N	I-Premise
39	,	N	I-Premise
40	respectively	N	I-Premise
41	)	N	I-Premise
42	.	N	I-Premise

1	A	N	I-Premise
2	non-significant	N	I-Premise
3	trend	N	I-Premise
4	towards	N	I-Premise
5	delayed	N	I-Premise
6	time	N	I-Premise
7	to	N	I-Premise
8	cough	N	I-Premise
9	and	N	I-Premise
10	time	N	I-Premise
11	to	N	I-Premise
12	dyspnoea	N	I-Premise
13	(	N	I-Premise
14	HR=0.77	N	I-Premise
15	[	N	I-Premise
16	95	N	I-Premise
17	%	N	I-Premise
18	CI	N	I-Premise
19	0.49-1.21	N	I-Premise
20	]	N	I-Premise
21	and	N	I-Premise
22	HR=0.75	N	I-Premise
23	[	N	I-Premise
24	95	N	I-Premise
25	%	N	I-Premise
26	CI	N	I-Premise
27	0.48-1.17	N	I-Premise
28	]	N	I-Premise
29	,	N	I-Premise
30	respectively	N	I-Premise
31	)	N	I-Premise
32	was	N	I-Premise
33	also	N	I-Premise
34	observed	N	I-Premise
35	.	N	I-Premise

1	Erlotinib	N	I-Claim
2	maintenance	N	I-Claim
3	therapy	N	I-Claim
4	significantly	N	I-Claim
5	extends	N	I-Claim
6	progression-free	N	I-Claim
7	survival	N	I-Claim
8	without	N	I-Claim
9	compromising	N	I-Claim
10	patient	N	I-Claim
11	HRQoL	N	I-Claim
12	in	N	I-Claim
13	comparison	N	I-Claim
14	with	N	I-Claim
15	placebo	N	I-Claim
16	,	N	I-Claim
17	with	N	I-Claim
18	some	N	I-Claim
19	improvement	N	I-Claim
20	in	N	I-Claim
21	symptoms	N	I-Claim
22	.	N	I-Claim

1	The	N	O
2	randomized	N	O
3	,	N	O
4	controlled	N	O
5	BOLERO-2	N	O
6	(	N	O
7	Breast	N	O
8	Cancer	N	O
9	Trials	N	O
10	of	N	O
11	Oral	N	O
12	Everolimus	N	O
13	)	N	O
14	trial	N	O
15	demonstrated	N	O
16	significantly	N	O
17	improved	N	O
18	progression-free	N	O
19	survival	N	O
20	with	N	O
21	the	N	O
22	use	N	O
23	of	N	O
24	everolimus	N	O
25	plus	N	O
26	exemestane	N	O
27	(	N	O
28	EVE	N	O
29	+	N	O
30	EXE	N	O
31	)	N	O
32	versus	N	O
33	placebo	N	O
34	plus	N	O
35	exemestane	N	O
36	(	N	O
37	PBO	N	O
38	+	N	O
39	EXE	N	O
40	)	N	O
41	in	N	O
42	patients	N	O
43	with	N	O
44	advanced	N	O
45	breast	N	O
46	cancer	N	O
47	who	N	O
48	developed	N	O
49	disease	N	O
50	progression	N	O
51	after	N	O
52	treatment	N	O
53	with	N	O
54	nonsteroidal	N	O
55	aromatase	N	O
56	inhibitors	N	O
57	.	N	O

1	This	N	O
2	analysis	N	O
3	investigated	N	O
4	the	N	O
5	treatment	N	O
6	effects	N	O
7	on	N	O
8	health-related	N	O
9	quality	N	O
10	of	N	O
11	life	N	O
12	(	N	O
13	HRQOL	N	O
14	)	N	O
15	.	N	O

1	Using	N	O
2	the	N	O
3	European	N	O
4	Organisation	N	O
5	for	N	O
6	Research	N	O
7	and	N	O
8	Treatment	N	O
9	of	N	O
10	Cancer	N	O
11	Quality	N	O
12	of	N	O
13	Life	N	O
14	Questionnaire-Core	N	O
15	30	N	O
16	(	N	O
17	EORTC	N	O
18	QLQ-C30	N	O
19	)	N	O
20	questionnaire	N	O
21	,	N	O
22	HRQOL	N	O
23	was	N	O
24	assessed	N	O
25	at	N	O
26	baseline	N	O
27	and	N	O
28	every	N	O
29	6	N	O
30	weeks	N	O
31	thereafter	N	O
32	until	N	O
33	disease	N	O
34	progression	N	O
35	and/or	N	O
36	treatment	N	O
37	discontinuation	N	O
38	.	N	O

1	The	N	O
2	30	N	O
3	items	N	O
4	in	N	O
5	15	N	O
6	subscales	N	O
7	of	N	O
8	the	N	O
9	QLQ-C30	N	O
10	include	N	O
11	global	N	O
12	health	N	O
13	status	N	O
14	wherein	N	O
15	higher	N	O
16	scores	N	O
17	(	N	O
18	range	N	O
19	,	N	O
20	0-100	N	O
21	)	N	O
22	indicate	N	O
23	better	N	O
24	HRQOL	N	O
25	.	N	O

1	This	N	O
2	analysis	N	O
3	included	N	O
4	a	N	O
5	protocol-specified	N	O
6	time	N	O
7	to	N	O
8	definitive	N	O
9	deterioration	N	O
10	(	N	O
11	TDD	N	O
12	)	N	O
13	analysis	N	O
14	at	N	O
15	a	N	O
16	5	N	O
17	%	N	O
18	decrease	N	O
19	in	N	O
20	HRQOL	N	O
21	versus	N	O
22	baseline	N	O
23	,	N	O
24	with	N	O
25	no	N	O
26	subsequent	N	O
27	increase	N	O
28	above	N	O
29	this	N	O
30	threshold	N	O
31	.	N	O

1	The	N	O
2	authors	N	O
3	report	N	O
4	additional	N	O
5	sensitivity	N	O
6	analyses	N	O
7	using	N	O
8	10-point	N	O
9	minimal	N	O
10	important	N	O
11	difference	N	O
12	decreases	N	O
13	in	N	O
14	the	N	O
15	global	N	O
16	health	N	O
17	status	N	O
18	score	N	O
19	versus	N	O
20	baseline	N	O
21	.	N	O

1	Treatment	N	O
2	arms	N	O
3	were	N	O
4	compared	N	O
5	using	N	O
6	the	N	O
7	stratified	N	O
8	log-rank	N	O
9	test	N	O
10	and	N	O
11	Cox	N	O
12	proportional	N	O
13	hazards	N	O
14	model	N	O
15	adjusted	N	O
16	for	N	O
17	trial	N	O
18	stratum	N	O
19	(	N	O
20	visceral	N	O
21	metastases	N	O
22	,	N	O
23	previous	N	O
24	hormone	N	O
25	sensitivity	N	O
26	)	N	O
27	,	N	O
28	age	N	O
29	,	N	O
30	sex	N	O
31	,	N	O
32	race	N	O
33	,	N	O
34	baseline	N	O
35	global	N	O
36	health	N	O
37	status	N	O
38	score	N	O
39	and	N	O
40	Eastern	N	O
41	Cooperative	N	O
42	Oncology	N	O
43	Group	N	O
44	performance	N	O
45	status	N	O
46	,	N	O
47	prognostic	N	O
48	risk	N	O
49	factors	N	O
50	,	N	O
51	and	N	O
52	treatment	N	O
53	history	N	O
54	.	N	O

1	Baseline	N	O
2	global	N	O
3	health	N	O
4	status	N	O
5	scores	N	O
6	were	N	O
7	found	N	O
8	to	N	O
9	be	N	O
10	similar	N	O
11	between	N	O
12	treatment	N	O
13	groups	N	O
14	(	N	O
15	64.7	N	O
16	vs	N	O
17	65.3	N	O
18	)	N	O
19	.	N	O

1	The	N	I-Premise
2	median	N	I-Premise
3	TDD	N	I-Premise
4	in	N	I-Premise
5	HRQOL	N	I-Premise
6	was	N	I-Premise
7	8.3	N	I-Premise
8	months	N	I-Premise
9	with	N	I-Premise
10	EVE	N	I-Premise
11	+	N	I-Premise
12	EXE	N	I-Premise
13	versus	N	I-Premise
14	5.8	N	I-Premise
15	months	N	I-Premise
16	with	N	I-Premise
17	PBO	N	I-Premise
18	+	N	I-Premise
19	EXE	N	I-Premise
20	(	N	I-Premise
21	hazard	N	I-Premise
22	ratio	N	I-Premise
23	,	N	I-Premise
24	0.74	N	I-Premise
25	;	N	I-Premise
26	P	N	I-Premise
27	=	N	I-Premise
28	.0084	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	At	N	I-Premise
2	the	N	I-Premise
3	10-point	N	I-Premise
4	minimal	N	I-Premise
5	important	N	I-Premise
6	difference	N	I-Premise
7	,	N	I-Premise
8	the	N	I-Premise
9	median	N	I-Premise
10	TDD	N	I-Premise
11	with	N	I-Premise
12	EVE	N	I-Premise
13	+	N	I-Premise
14	EXE	N	I-Premise
15	was	N	I-Premise
16	11.7	N	I-Premise
17	months	N	I-Premise
18	versus	N	I-Premise
19	8.4	N	I-Premise
20	months	N	I-Premise
21	with	N	I-Premise
22	PBO	N	I-Premise
23	+	N	I-Premise
24	EXE	N	I-Premise
25	(	N	I-Premise
26	hazard	N	I-Premise
27	ratio	N	I-Premise
28	,	N	I-Premise
29	0.80	N	I-Premise
30	;	N	I-Premise
31	P	N	I-Premise
32	=	N	I-Premise
33	.1017	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	In	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	advanced	N	I-Claim
5	breast	N	I-Claim
6	cancer	N	I-Claim
7	who	N	I-Claim
8	develop	N	I-Claim
9	disease	N	I-Claim
10	progression	N	I-Claim
11	after	N	I-Claim
12	treatment	N	I-Claim
13	with	N	I-Claim
14	nonsteroidal	N	I-Claim
15	aromatase	N	I-Claim
16	inhibitors	N	I-Claim
17	,	N	I-Claim
18	EVE	N	I-Claim
19	+	N	I-Claim
20	EXE	N	I-Claim
21	was	N	I-Claim
22	associated	N	I-Claim
23	with	N	I-Claim
24	a	N	I-Claim
25	longer	N	I-Claim
26	TDD	N	I-Claim
27	in	N	I-Claim
28	global	N	I-Claim
29	HRQOL	N	I-Claim
30	versus	N	I-Claim
31	PBO	N	I-Claim
32	+	N	I-Claim
33	EXE	N	I-Claim
34	.	N	I-Claim

1	Malignant	N	I-MajorClaim
2	pleural	N	I-MajorClaim
3	effusion	N	I-MajorClaim
4	(	N	I-MajorClaim
5	MPE	N	I-MajorClaim
6	)	N	I-MajorClaim
7	is	N	I-MajorClaim
8	a	N	I-MajorClaim
9	common	N	I-MajorClaim
10	complication	N	I-MajorClaim
11	of	N	I-MajorClaim
12	advanced	N	I-MajorClaim
13	non-small	N	I-MajorClaim
14	cell	N	I-MajorClaim
15	lung	N	I-MajorClaim
16	cancer	N	I-MajorClaim
17	(	N	I-MajorClaim
18	NSCLC	N	I-MajorClaim
19	)	N	I-MajorClaim
20	.	N	I-MajorClaim

1	Bevacizumab	N	I-MajorClaim
2	,	N	I-MajorClaim
3	a	N	I-MajorClaim
4	humanized	N	I-MajorClaim
5	monoclonal	N	I-MajorClaim
6	antibody	N	I-MajorClaim
7	against	N	I-MajorClaim
8	vascular	N	I-MajorClaim
9	endothelial	N	I-MajorClaim
10	growth	N	I-MajorClaim
11	factor	N	I-MajorClaim
12	(	N	I-MajorClaim
13	VEGF	N	I-MajorClaim
14	)	N	I-MajorClaim
15	,	N	I-MajorClaim
16	has	N	I-MajorClaim
17	been	N	I-MajorClaim
18	shown	N	I-MajorClaim
19	to	N	I-MajorClaim
20	be	N	I-MajorClaim
21	efficient	N	I-MajorClaim
22	in	N	I-MajorClaim
23	suppressing	N	I-MajorClaim
24	the	N	I-MajorClaim
25	accumulation	N	I-MajorClaim
26	of	N	I-MajorClaim
27	pleural	N	I-MajorClaim
28	fluid	N	I-MajorClaim
29	.	N	I-MajorClaim

1	However	N	O
2	,	N	O
3	whether	N	O
4	intrapleural	N	O
5	delivery	N	O
6	of	N	O
7	bevacizumab	N	O
8	can	N	O
9	be	N	O
10	used	N	O
11	to	N	O
12	treat	N	O
13	MPE	N	O
14	remains	N	O
15	unknown	N	O
16	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	present	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	evaluate	N	O
10	the	N	O
11	efficacy	N	O
12	and	N	O
13	safety	N	O
14	of	N	O
15	combined	N	O
16	intrapleural	N	O
17	therapy	N	O
18	with	N	O
19	bevacizumab	N	O
20	and	N	O
21	cisplatin	N	O
22	,	N	O
23	an	N	O
24	antineoplastic	N	O
25	agent	N	O
26	,	N	O
27	in	N	O
28	controlling	N	O
29	MPE	N	O
30	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	72	N	O
5	NSCLC	N	O
6	study	N	O
7	subjects	N	O
8	with	N	O
9	MPE	N	O
10	were	N	O
11	randomly	N	O
12	assigned	N	O
13	to	N	O
14	one	N	O
15	of	N	O
16	two	N	O
17	groups	N	O
18	.	N	O

1	The	N	O
2	first	N	O
3	group	N	O
4	received	N	O
5	intrapleural	N	O
6	bevacizumab	N	O
7	(	N	O
8	300	N	O
9	mg	N	O
10	)	N	O
11	with	N	O
12	cisplatin	N	O
13	(	N	O
14	30	N	O
15	mg	N	O
16	)	N	O
17	therapy	N	O
18	and	N	O
19	the	N	O
20	second	N	O
21	group	N	O
22	received	N	O
23	intrapleural	N	O
24	cisplatin	N	O
25	(	N	O
26	30	N	O
27	mg	N	O
28	)	N	O
29	therapy	N	O
30	alone	N	O
31	.	N	O

1	Pleural	N	O
2	fluid	N	O
3	was	N	O
4	collected	N	O
5	from	N	O
6	both	N	O
7	groups	N	O
8	prior	N	O
9	to	N	O
10	and	N	O
11	following	N	O
12	treatment	N	O
13	.	N	O

1	The	N	O
2	levels	N	O
3	of	N	O
4	VEGF	N	O
5	and	N	O
6	carcinoembryonic	N	O
7	antigen	N	O
8	(	N	O
9	CEA	N	O
10	)	N	O
11	in	N	O
12	the	N	O
13	pleural	N	O
14	fluid	N	O
15	were	N	O
16	determined	N	O
17	by	N	O
18	ELISA	N	O
19	.	N	O

1	In	N	I-Premise
2	70	N	I-Premise
3	evaluable	N	I-Premise
4	study	N	I-Premise
5	subjects	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	curative	N	I-Premise
9	efficacy	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	bevacizumab	N	I-Premise
13	group	N	I-Premise
14	was	N	I-Premise
15	significantly	N	I-Premise
16	higher	N	I-Premise
17	than	N	I-Premise
18	that	N	I-Premise
19	found	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	cisplatin	N	I-Premise
23	group	N	I-Premise
24	(	N	I-Premise
25	83.33	N	I-Premise
26	vs.	N	I-Premise
27	50.00	N	I-Premise
28	%	N	I-Premise
29	,	N	I-Premise
30	respectively	N	I-Premise
31	;	N	I-Premise
32	p	N	I-Premise
33	<	N	I-Premise
34	0.05	N	I-Premise
35	)	N	I-Premise
36	.	N	I-Premise

1	Therapy	N	I-Premise
2	with	N	I-Premise
3	combined	N	I-Premise
4	bevacizumab	N	I-Premise
5	plus	N	I-Premise
6	cisplatin	N	I-Premise
7	significantly	N	I-Premise
8	reduced	N	I-Premise
9	VEGF	N	I-Premise
10	levels	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	pleural	N	I-Premise
14	fluid	N	I-Premise
15	(	N	I-Premise
16	p	N	I-Premise
17	<	N	I-Premise
18	0.01	N	I-Premise
19	)	N	I-Premise
20	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	bevacizumab	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	levels	N	I-Premise
8	of	N	I-Premise
9	VEGF	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	pleural	N	I-Premise
13	fluid	N	I-Premise
14	were	N	I-Premise
15	significantly	N	I-Premise
16	lower	N	I-Premise
17	compared	N	I-Premise
18	to	N	I-Premise
19	those	N	I-Premise
20	of	N	I-Premise
21	the	N	I-Premise
22	cisplatin	N	I-Premise
23	group	N	I-Premise
24	after	N	I-Premise
25	treatment	N	I-Premise
26	,	N	I-Premise
27	which	N	I-Premise
28	showed	N	I-Premise
29	greater	N	I-Premise
30	efficacy	N	I-Premise
31	(	N	I-Premise
32	p	N	I-Premise
33	<	N	I-Premise
34	0.01	N	I-Premise
35	)	N	I-Premise
36	.	N	I-Premise

1	In	N	I-Premise
2	addition	N	I-Premise
3	,	N	I-Premise
4	combination	N	I-Premise
5	therapy	N	I-Premise
6	showed	N	I-Premise
7	greater	N	I-Premise
8	efficacy	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	patients	N	I-Premise
12	with	N	I-Premise
13	high	N	I-Premise
14	levels	N	I-Premise
15	of	N	I-Premise
16	VEGF	N	I-Premise
17	expression	N	I-Premise
18	(	N	I-Premise
19	p	N	I-Premise
20	<	N	I-Premise
21	0.01	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	in	N	I-Premise
7	grade	N	I-Premise
8	III/IV	N	I-Premise
9	adverse	N	I-Premise
10	events	N	I-Premise
11	between	N	I-Premise
12	the	N	I-Premise
13	two	N	I-Premise
14	groups	N	I-Premise
15	.	N	I-Premise

1	All	N	I-Premise
2	procedures	N	I-Premise
3	were	N	I-Premise
4	well	N	I-Premise
5	tolerated	N	I-Premise
6	by	N	I-Premise
7	the	N	I-Premise
8	patients	N	I-Premise
9	.	N	I-Premise

1	Combined	N	I-Claim
2	intrapleural	N	I-Claim
3	therapy	N	I-Claim
4	with	N	I-Claim
5	bevacizumab	N	I-Claim
6	and	N	I-Claim
7	cisplatin	N	I-Claim
8	was	N	I-Claim
9	effective	N	I-Claim
10	and	N	I-Claim
11	safe	N	I-Claim
12	in	N	I-Claim
13	managing	N	I-Claim
14	NSCLC-mediated	N	I-Claim
15	MPE	N	I-Claim
16	.	N	I-Claim

1	We	N	I-MajorClaim
2	propose	N	I-MajorClaim
3	that	N	I-MajorClaim
4	VEGF	N	I-MajorClaim
5	expression	N	I-MajorClaim
6	levels	N	I-MajorClaim
7	in	N	I-MajorClaim
8	MPE	N	I-MajorClaim
9	could	N	I-MajorClaim
10	serve	N	I-MajorClaim
11	as	N	I-MajorClaim
12	a	N	I-MajorClaim
13	prognostic	N	I-MajorClaim
14	marker	N	I-MajorClaim
15	for	N	I-MajorClaim
16	bevacizumab	N	I-MajorClaim
17	therapy	N	I-MajorClaim
18	.	N	I-MajorClaim

1	There	N	O
2	are	N	O
3	no	N	O
4	known	N	O
5	effective	N	O
6	treatments	N	O
7	for	N	O
8	painful	N	O
9	chemotherapy-induced	N	O
10	peripheral	N	O
11	neuropathy	N	O
12	.	N	O

1	To	N	O
2	determine	N	O
3	the	N	O
4	effect	N	O
5	of	N	O
6	duloxetine	N	O
7	,	N	O
8	60	N	O
9	mg	N	O
10	daily	N	O
11	,	N	O
12	on	N	O
13	average	N	O
14	pain	N	O
15	severity	N	O
16	.	N	O

1	Randomized	N	O
2	,	N	O
3	double-blind	N	O
4	,	N	O
5	placebo-controlled	N	O
6	crossover	N	O
7	trial	N	O
8	at	N	O
9	8	N	O
10	National	N	O
11	Cancer	N	O
12	Institute	N	O
13	(	N	O
14	NCI	N	O
15	)	N	O
16	-funded	N	O
17	cooperative	N	O
18	research	N	O
19	networks	N	O
20	that	N	O
21	enrolled	N	O
22	231	N	O
23	patients	N	O
24	who	N	O
25	were	N	O
26	25	N	O
27	years	N	O
28	or	N	O
29	older	N	O
30	being	N	O
31	treated	N	O
32	at	N	O
33	community	N	O
34	and	N	O
35	academic	N	O
36	settings	N	O
37	between	N	O
38	April	N	O
39	2008	N	O
40	and	N	O
41	March	N	O
42	2011	N	O
43	.	N	O

1	Study	N	O
2	follow-up	N	O
3	was	N	O
4	completed	N	O
5	July	N	O
6	2012	N	O
7	.	N	O

1	Stratified	N	O
2	by	N	O
3	chemotherapeutic	N	O
4	drug	N	O
5	and	N	O
6	comorbid	N	O
7	pain	N	O
8	risk	N	O
9	,	N	O
10	patients	N	O
11	were	N	O
12	randomized	N	O
13	to	N	O
14	receive	N	O
15	either	N	O
16	duloxetine	N	O
17	followed	N	O
18	by	N	O
19	placebo	N	O
20	or	N	O
21	placebo	N	O
22	followed	N	O
23	by	N	O
24	duloxetine	N	O
25	.	N	O

1	Eligibility	N	O
2	required	N	O
3	that	N	O
4	patients	N	O
5	have	N	O
6	grade	N	O
7	1	N	O
8	or	N	O
9	higher	N	O
10	sensory	N	O
11	neuropathy	N	O
12	according	N	O
13	to	N	O
14	the	N	O
15	NCI	N	O
16	Common	N	O
17	Terminology	N	O
18	Criteria	N	O
19	for	N	O
20	Adverse	N	O
21	Events	N	O
22	and	N	O
23	at	N	O
24	least	N	O
25	4	N	O
26	on	N	O
27	a	N	O
28	scale	N	O
29	of	N	O
30	0	N	O
31	to	N	O
32	10	N	O
33	,	N	O
34	representing	N	O
35	average	N	O
36	chemotherapy-induced	N	O
37	pain	N	O
38	,	N	O
39	after	N	O
40	paclitaxel	N	O
41	,	N	O
42	other	N	O
43	taxane	N	O
44	,	N	O
45	or	N	O
46	oxaliplatin	N	O
47	treatment	N	O
48	.	N	O

1	The	N	O
2	initial	N	O
3	treatment	N	O
4	consisted	N	O
5	of	N	O
6	taking	N	O
7	1	N	O
8	capsule	N	O
9	daily	N	O
10	of	N	O
11	either	N	O
12	30	N	O
13	mg	N	O
14	of	N	O
15	duloxetine	N	O
16	or	N	O
17	placebo	N	O
18	for	N	O
19	the	N	O
20	first	N	O
21	week	N	O
22	and	N	O
23	2	N	O
24	capsules	N	O
25	of	N	O
26	either	N	O
27	30	N	O
28	mg	N	O
29	of	N	O
30	duloxetine	N	O
31	or	N	O
32	placebo	N	O
33	daily	N	O
34	for	N	O
35	4	N	O
36	additional	N	O
37	weeks	N	O
38	.	N	O

1	The	N	O
2	primary	N	O
3	hypothesis	N	O
4	was	N	O
5	that	N	O
6	duloxetine	N	O
7	would	N	O
8	be	N	O
9	more	N	O
10	effective	N	O
11	than	N	O
12	placebo	N	O
13	in	N	O
14	decreasing	N	O
15	chemotherapy-induced	N	O
16	peripheral	N	O
17	neuropathic	N	O
18	pain	N	O
19	.	N	O

1	Pain	N	O
2	severity	N	O
3	was	N	O
4	assessed	N	O
5	using	N	O
6	the	N	O
7	Brief	N	O
8	Pain	N	O
9	Inventory-Short	N	O
10	Form	N	O
11	``	N	O
12	average	N	O
13	pain	N	O
14	''	N	O
15	item	N	O
16	with	N	O
17	0	N	O
18	representing	N	O
19	no	N	O
20	pain	N	O
21	and	N	O
22	10	N	O
23	representing	N	O
24	as	N	O
25	bad	N	O
26	as	N	O
27	can	N	O
28	be	N	O
29	imagined	N	O
30	.	N	O

1	Individuals	N	I-Premise
2	receiving	N	I-Premise
3	duloxetine	N	I-Premise
4	as	N	I-Premise
5	their	N	I-Premise
6	initial	N	I-Premise
7	5-week	N	I-Premise
8	treatment	N	I-Premise
9	reported	N	I-Premise
10	a	N	I-Premise
11	mean	N	I-Premise
12	decrease	N	I-Premise
13	in	N	I-Premise
14	average	N	I-Premise
15	pain	N	I-Premise
16	of	N	I-Premise
17	1.06	N	I-Premise
18	(	N	I-Premise
19	95	N	I-Premise
20	%	N	I-Premise
21	CI	N	I-Premise
22	,	N	I-Premise
23	0.72-1.40	N	I-Premise
24	)	N	I-Premise
25	vs	N	I-Premise
26	0.34	N	I-Premise
27	(	N	I-Premise
28	95	N	I-Premise
29	%	N	I-Premise
30	CI	N	I-Premise
31	,	N	I-Premise
32	0.01-0.66	N	I-Premise
33	)	N	I-Premise
34	among	N	I-Premise
35	those	N	I-Premise
36	who	N	I-Premise
37	received	N	I-Premise
38	placebo	N	I-Premise
39	(	N	I-Premise
40	P	N	I-Premise
41	=	N	I-Premise
42	.003	N	I-Premise
43	;	N	I-Premise
44	effect	N	I-Premise
45	size	N	I-Premise
46	,	N	I-Premise
47	0.513	N	I-Premise
48	)	N	I-Premise
49	.	N	I-Premise

1	The	N	I-Premise
2	observed	N	I-Premise
3	mean	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	average	N	I-Premise
8	pain	N	I-Premise
9	score	N	I-Premise
10	between	N	I-Premise
11	duloxetine	N	I-Premise
12	and	N	I-Premise
13	placebo	N	I-Premise
14	was	N	I-Premise
15	0.73	N	I-Premise
16	(	N	I-Premise
17	95	N	I-Premise
18	%	N	I-Premise
19	CI	N	I-Premise
20	,	N	I-Premise
21	0.26-1.20	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	Fifty-nine	N	I-Premise
2	percent	N	I-Premise
3	of	N	I-Premise
4	those	N	I-Premise
5	initially	N	I-Premise
6	receiving	N	I-Premise
7	duloxetine	N	I-Premise
8	vs	N	I-Premise
9	38	N	I-Premise
10	%	N	I-Premise
11	of	N	I-Premise
12	those	N	I-Premise
13	initially	N	I-Premise
14	receiving	N	I-Premise
15	placebo	N	I-Premise
16	reported	N	I-Premise
17	decreased	N	I-Premise
18	pain	N	I-Premise
19	of	N	I-Premise
20	any	N	I-Premise
21	amount	N	I-Premise
22	.	N	I-Premise

1	Among	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	painful	N	I-Claim
5	chemotherapy-induced	N	I-Claim
6	peripheral	N	I-Claim
7	neuropathy	N	I-Claim
8	,	N	I-Claim
9	the	N	I-Claim
10	use	N	I-Claim
11	of	N	I-Claim
12	duloxetine	N	I-Claim
13	compared	N	I-Claim
14	with	N	I-Claim
15	placebo	N	I-Claim
16	for	N	I-Claim
17	5	N	I-Claim
18	weeks	N	I-Claim
19	resulted	N	I-Claim
20	in	N	I-Claim
21	a	N	I-Claim
22	greater	N	I-Claim
23	reduction	N	I-Claim
24	in	N	I-Claim
25	pain	N	I-Claim
26	.	N	I-Claim

1	Sexual	N	O
2	dysfunction	N	O
3	represents	N	O
4	a	N	O
5	complex	N	O
6	and	N	O
7	multifactorial	N	O
8	construct	N	O
9	that	N	O
10	can	N	O
11	affect	N	O
12	both	N	O
13	men	N	O
14	and	N	O
15	women	N	O
16	and	N	O
17	has	N	O
18	been	N	O
19	noted	N	O
20	to	N	O
21	often	N	O
22	deteriorate	N	O
23	significantly	N	O
24	after	N	O
25	treatment	N	O
26	for	N	O
27	rectal	N	O
28	and	N	O
29	anal	N	O
30	cancer	N	O
31	.	N	O

1	Despite	N	O
2	this	N	O
3	,	N	O
4	it	N	O
5	remains	N	O
6	an	N	O
7	understudied	N	O
8	,	N	O
9	underreported	N	O
10	,	N	O
11	and	N	O
12	undertreated	N	O
13	issue	N	O
14	in	N	O
15	the	N	O
16	field	N	O
17	of	N	O
18	cancer	N	O
19	survivorship	N	O
20	.	N	O

1	This	N	O
2	study	N	O
3	examined	N	O
4	the	N	O
5	characteristics	N	O
6	of	N	O
7	women	N	O
8	enrolled	N	O
9	in	N	O
10	an	N	O
11	intervention	N	O
12	trial	N	O
13	to	N	O
14	treat	N	O
15	sexual	N	O
16	dysfunction	N	O
17	,	N	O
18	and	N	O
19	explored	N	O
20	the	N	O
21	relationship	N	O
22	between	N	O
23	sexual	N	O
24	functioning	N	O
25	and	N	O
26	psychological	N	O
27	well-being	N	O
28	.	N	O

1	There	N	O
2	were	N	O
3	70	N	O
4	female	N	O
5	posttreatment	N	O
6	anal	N	O
7	or	N	O
8	rectal	N	O
9	cancer	N	O
10	survivors	N	O
11	assessed	N	O
12	as	N	O
13	part	N	O
14	of	N	O
15	the	N	O
16	current	N	O
17	study	N	O
18	.	N	O

1	Participants	N	O
2	were	N	O
3	enrolled	N	O
4	in	N	O
5	a	N	O
6	randomized	N	O
7	intervention	N	O
8	trial	N	O
9	to	N	O
10	treat	N	O
11	sexual	N	O
12	dysfunction	N	O
13	and	N	O
14	completed	N	O
15	outcome	N	O
16	measures	N	O
17	prior	N	O
18	to	N	O
19	randomization	N	O
20	.	N	O

1	The	N	O
2	main	N	O
3	outcome	N	O
4	measures	N	O
5	are	N	O
6	quality	N	O
7	of	N	O
8	life	N	O
9	(	N	O
10	QOL	N	O
11	)	N	O
12	(	N	O
13	European	N	O
14	Organization	N	O
15	for	N	O
16	Research	N	O
17	and	N	O
18	Treatment	N	O
19	of	N	O
20	Cancer	N	O
21	Core	N	O
22	Quality	N	O
23	of	N	O
24	Life	N	O
25	Questionnaire	N	O
26	[	N	O
27	EORTC-QLQ-C30	N	O
28	]	N	O
29	and	N	O
30	Colorectal	N	O
31	Cancer-Specific	N	O
32	Module	N	O
33	[	N	O
34	QLQ-CR38	N	O
35	]	N	O
36	)	N	O
37	,	N	O
38	sexual	N	O
39	functioning	N	O
40	(	N	O
41	Female	N	O
42	Sexual	N	O
43	Functioning	N	O
44	Index	N	O
45	)	N	O
46	,	N	O
47	and	N	O
48	psychological	N	O
49	well-being	N	O
50	(	N	O
51	Brief	N	O
52	Symptom	N	O
53	Inventory	N	O
54	Depression/Anxiety	N	O
55	,	N	O
56	Impact	N	O
57	of	N	O
58	Events	N	O
59	Scale-Revised	N	O
60	,	N	O
61	CR-38	N	O
62	Body	N	O
63	Image	N	O
64	)	N	O
65	.	N	O

1	Women	N	O
2	enrolled	N	O
3	in	N	O
4	the	N	O
5	study	N	O
6	intervention	N	O
7	were	N	O
8	on	N	O
9	average	N	O
10	55	N	O
11	years	N	O
12	old	N	O
13	,	N	O
14	predominantly	N	O
15	Caucasian	N	O
16	(	N	O
17	79	N	O
18	%	N	O
19	)	N	O
20	,	N	O
21	married	N	O
22	(	N	O
23	57	N	O
24	%	N	O
25	)	N	O
26	,	N	O
27	and	N	O
28	a	N	O
29	median	N	O
30	of	N	O
31	4	N	O
32	years	N	O
33	postprimary	N	O
34	treatment	N	O
35	.	N	O

1	For	N	O
2	those	N	O
3	reporting	N	O
4	sexual	N	O
5	activity	N	O
6	at	N	O
7	baseline	N	O
8	(	N	O
9	N=41	N	O
10	)	N	O
11	,	N	O
12	sexual	N	O
13	dysfunction	N	O
14	was	N	O
15	associated	N	O
16	with	N	O
17	a	N	O
18	range	N	O
19	of	N	O
20	specific	N	O
21	measures	N	O
22	of	N	O
23	psychological	N	O
24	well-being	N	O
25	,	N	O
26	all	N	O
27	in	N	O
28	the	N	O
29	hypothesized	N	O
30	direction	N	O
31	.	N	O

1	The	N	I-Premise
2	Sexual/Relationship	N	I-Premise
3	Satisfaction	N	I-Premise
4	subscale	N	I-Premise
5	was	N	I-Premise
6	associated	N	I-Premise
7	with	N	I-Premise
8	all	N	I-Premise
9	measures	N	I-Premise
10	of	N	I-Premise
11	psychological	N	I-Premise
12	well-being	N	I-Premise
13	(	N	I-Premise
14	r=-0.45	N	I-Premise
15	to	N	I-Premise
16	-0.70	N	I-Premise
17	,	N	I-Premise
18	all	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	0.01	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	Body	N	I-Premise
2	image	N	I-Premise
3	,	N	I-Premise
4	anxiety	N	I-Premise
5	,	N	I-Premise
6	and	N	I-Premise
7	cancer-specific	N	I-Premise
8	posttraumatic	N	I-Premise
9	distress	N	I-Premise
10	were	N	I-Premise
11	notable	N	I-Premise
12	in	N	I-Premise
13	their	N	I-Premise
14	association	N	I-Premise
15	with	N	I-Premise
16	subscales	N	I-Premise
17	of	N	I-Premise
18	sexual	N	I-Premise
19	functioning	N	I-Premise
20	,	N	I-Premise
21	while	N	I-Premise
22	a	N	I-Premise
23	global	N	I-Premise
24	QOL	N	I-Premise
25	measure	N	I-Premise
26	was	N	I-Premise
27	largely	N	I-Premise
28	unrelated	N	I-Premise
29	.	N	I-Premise

1	For	N	I-Premise
2	sexually	N	I-Premise
3	active	N	I-Premise
4	female	N	I-Premise
5	rectal	N	I-Premise
6	and	N	I-Premise
7	anal	N	I-Premise
8	cancer	N	I-Premise
9	survivors	N	I-Premise
10	enrolled	N	I-Premise
11	in	N	I-Premise
12	a	N	I-Premise
13	sexual	N	I-Premise
14	health	N	I-Premise
15	intervention	N	I-Premise
16	,	N	I-Premise
17	sexual	N	I-Premise
18	dysfunction	N	I-Premise
19	was	N	I-Premise
20	significantly	N	I-Premise
21	and	N	I-Premise
22	consistently	N	I-Premise
23	associated	N	I-Premise
24	with	N	I-Premise
25	specific	N	I-Premise
26	measures	N	I-Premise
27	of	N	I-Premise
28	psychological	N	I-Premise
29	well-being	N	I-Premise
30	,	N	I-Premise
31	most	N	I-Premise
32	notably	N	I-Premise
33	Sexual/Relationship	N	I-Premise
34	Satisfaction	N	I-Premise
35	.	N	I-Premise

1	These	N	I-Claim
2	results	N	I-Claim
3	suggest	N	I-Claim
4	that	N	I-Claim
5	sexual	N	I-Claim
6	functioning	N	I-Claim
7	may	N	I-Claim
8	require	N	I-Claim
9	focused	N	I-Claim
10	assessment	N	I-Claim
11	by	N	I-Claim
12	providers	N	I-Claim
13	,	N	I-Claim
14	beyond	N	I-Claim
15	broad	N	I-Claim
16	QOL	N	I-Claim
17	assessments	N	I-Claim
18	,	N	I-Claim
19	and	N	O
20	that	N	O
21	attention	N	I-Claim
22	to	N	I-Claim
23	Sexual/Relationship	N	I-Claim
24	Satisfaction	N	I-Claim
25	may	N	I-Claim
26	be	N	I-Claim
27	critical	N	I-Claim
28	in	N	I-Claim
29	the	N	I-Claim
30	development	N	I-Claim
31	and	N	I-Claim
32	implementation	N	I-Claim
33	of	N	I-Claim
34	interventions	N	I-Claim
35	for	N	I-Claim
36	this	N	I-Claim
37	cohort	N	I-Claim
38	of	N	I-Claim
39	patients	N	I-Claim
40	.	N	I-Claim

1	To	N	O
2	prospectively	N	O
3	evaluate	N	O
4	and	N	O
5	compare	N	O
6	health-related	N	O
7	quality-of-life	N	O
8	(	N	O
9	QOL	N	O
10	)	N	O
11	outcomes	N	O
12	in	N	O
13	patients	N	O
14	with	N	O
15	head-neck	N	O
16	squamous	N	O
17	cell	N	O
18	carcinoma	N	O
19	randomized	N	O
20	to	N	O
21	either	N	O
22	intensity-modulated	N	O
23	radiation	N	O
24	therapy	N	O
25	(	N	O
26	IMRT	N	O
27	)	N	O
28	or	N	O
29	three-dimensional	N	O
30	conformal	N	O
31	radiotherapy	N	O
32	(	N	O
33	3D-CRT	N	O
34	)	N	O
35	and	N	O
36	assess	N	O
37	serial	N	O
38	longitudinal	N	O
39	change	N	O
40	in	N	O
41	QOL	N	O
42	over	N	O
43	time	N	O
44	.	N	O

1	QOL	N	O
2	outcomes	N	O
3	were	N	O
4	assessed	N	O
5	using	N	O
6	the	N	O
7	European	N	O
8	Organization	N	O
9	for	N	O
10	Research	N	O
11	and	N	O
12	Treatment	N	O
13	of	N	O
14	Cancer	N	O
15	(	N	O
16	EORTC	N	O
17	)	N	O
18	QOL	N	O
19	questionnaire	N	O
20	(	N	O
21	QLQ-C30	N	O
22	)	N	O
23	and	N	O
24	Head-Neck	N	O
25	module	N	O
26	(	N	O
27	HN-35	N	O
28	)	N	O
29	at	N	O
30	baseline	N	O
31	(	N	O
32	pre-treatment	N	O
33	)	N	O
34	and	N	O
35	subsequently	N	O
36	periodically	N	O
37	on	N	O
38	follow-up	N	O
39	.	N	O

1	Mean	N	O
2	scores	N	O
3	of	N	O
4	individual	N	O
5	domains/scales	N	O
6	of	N	O
7	3D-CRT	N	O
8	and	N	O
9	IMRT	N	O
10	were	N	O
11	compared	N	O
12	using	N	O
13	't	N	O
14	'	N	O
15	test	N	O
16	at	N	O
17	each	N	O
18	time	N	O
19	point	N	O
20	;	N	O
21	while	N	O
22	longitudinal	N	O
23	change	N	O
24	in	N	O
25	mean	N	O
26	scores	N	O
27	of	N	O
28	both	N	O
29	groups	N	O
30	over	N	O
31	time	N	O
32	was	N	O
33	evaluated	N	O
34	by	N	O
35	repeated	N	O
36	measurement	N	O
37	analysis	N	O
38	of	N	O
39	variance	N	O
40	.	N	O

1	Fifty	N	O
2	eight	N	O
3	of	N	O
4	the	N	O
5	60	N	O
6	randomized	N	O
7	patients	N	O
8	who	N	O
9	filled	N	O
10	the	N	O
11	QOL	N	O
12	questionnaire	N	O
13	at	N	O
14	least	N	O
15	at	N	O
16	one	N	O
17	time	N	O
18	point	N	O
19	were	N	O
20	included	N	O
21	in	N	O
22	the	N	O
23	analysis	N	O
24	.	N	O

1	Several	N	O
2	general	N	O
3	(	N	O
4	emotional	N	O
5	functioning	N	O
6	,	N	O
7	role	N	O
8	functioning	N	O
9	,	N	O
10	social	N	O
11	contact	N	O
12	)	N	O
13	as	N	O
14	well	N	O
15	as	N	O
16	head	N	O
17	and	N	O
18	neck	N	O
19	cancer-specific	N	O
20	(	N	O
21	dry	N	O
22	mouth	N	O
23	,	N	O
24	opening	N	O
25	mouth	N	O
26	,	N	O
27	sticky	N	O
28	saliva	N	O
29	,	N	O
30	pain	N	O
31	,	N	O
32	senses	N	O
33	)	N	O
34	QOL	N	O
35	domains	N	O
36	were	N	O
37	better	N	O
38	preserved	N	O
39	with	N	O
40	IMRT	N	O
41	compared	N	O
42	to	N	O
43	3D-CRT	N	O
44	at	N	O
45	different	N	O
46	time	N	O
47	points	N	O
48	.	N	O

1	Importantly	N	O
2	,	N	O
3	none	N	O
4	of	N	O
5	the	N	O
6	QOL	N	O
7	domains	N	O
8	were	N	O
9	worse	N	O
10	with	N	O
11	IMRT	N	O
12	at	N	O
13	any	N	O
14	time	N	O
15	point	N	O
16	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	substantial	N	I-Premise
4	deterioration	N	I-Premise
5	in	N	I-Premise
6	QOL	N	I-Premise
7	scores	N	I-Premise
8	immediate	N	I-Premise
9	post-treatment	N	I-Premise
10	(	N	I-Premise
11	3-months	N	I-Premise
12	)	N	I-Premise
13	in	N	I-Premise
14	both	N	I-Premise
15	arms	N	I-Premise
16	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	QOL	N	I-Premise
4	scores	N	I-Premise
5	gradually	N	I-Premise
6	but	N	I-Premise
7	definitely	N	I-Premise
8	improved	N	I-Premise
9	over	N	I-Premise
10	time	N	I-Premise
11	for	N	I-Premise
12	most	N	I-Premise
13	domains	N	I-Premise
14	.	N	I-Premise

1	Global	N	I-Premise
2	QOL	N	I-Premise
3	,	N	I-Premise
4	emotional/role	N	I-Premise
5	functioning	N	I-Premise
6	,	N	I-Premise
7	nausea/vomiting	N	I-Premise
8	,	N	I-Premise
9	pain	N	I-Premise
10	,	N	I-Premise
11	swallowing	N	I-Premise
12	,	N	I-Premise
13	speech	N	I-Premise
14	,	N	I-Premise
15	social	N	I-Premise
16	contact/eating	N	I-Premise
17	,	N	I-Premise
18	insomnia	N	I-Premise
19	showed	N	I-Premise
20	rapid	N	I-Premise
21	recovery	N	I-Premise
22	(	N	I-Premise
23	<	N	I-Premise
24	6months	N	I-Premise
25	)	N	I-Premise
26	while	N	I-Premise
27	physical/cognitive	N	I-Premise
28	functioning	N	I-Premise
29	,	N	I-Premise
30	dry	N	I-Premise
31	mouth	N	I-Premise
32	,	N	I-Premise
33	sticky	N	I-Premise
34	saliva	N	I-Premise
35	,	N	I-Premise
36	fatigue	N	I-Premise
37	,	N	I-Premise
38	senses	N	I-Premise
39	showed	N	I-Premise
40	delayed	N	I-Premise
41	recovery	N	I-Premise
42	(	N	I-Premise
43	>	N	I-Premise
44	6months	N	I-Premise
45	)	N	I-Premise
46	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	differences	N	I-Premise
6	in	N	I-Premise
7	loco-regional	N	I-Premise
8	or	N	I-Premise
9	survival	N	I-Premise
10	between	N	I-Premise
11	the	N	I-Premise
12	two	N	I-Premise
13	arms	N	I-Premise
14	.	N	I-Premise

1	There	N	I-Claim
2	is	N	I-Claim
3	substantial	N	I-Claim
4	deterioration	N	I-Claim
5	in	N	I-Claim
6	QOL	N	I-Claim
7	after	N	I-Claim
8	curative-intent	N	I-Claim
9	head-neck	N	I-Claim
10	irradiation	N	I-Claim
11	that	N	I-Claim
12	gradually	N	I-Claim
13	improves	N	I-Claim
14	over	N	I-Claim
15	time	N	I-Claim
16	.	N	I-Claim

1	IMRT	N	I-Claim
2	results	N	I-Claim
3	in	N	I-Claim
4	clinically	N	I-Claim
5	meaningful	N	I-Claim
6	and	N	I-Claim
7	statistically	N	I-Claim
8	better	N	I-Claim
9	QOL	N	I-Claim
10	scores	N	I-Claim
11	for	N	I-Claim
12	some	N	I-Claim
13	domains	N	I-Claim
14	compared	N	I-Claim
15	to	N	I-Claim
16	3D-CRT	N	I-Claim
17	at	N	I-Claim
18	several	N	I-Claim
19	time	N	I-Claim
20	points	N	I-Claim
21	with	N	I-Claim
22	comparable	N	I-Claim
23	disease	N	I-Claim
24	outcomes	N	I-Claim
25	that	N	I-Claim
26	could	N	I-Claim
27	support	N	I-Claim
28	its	N	I-Claim
29	widespread	N	I-Claim
30	adoption	N	I-Claim
31	in	N	I-Claim
32	routine	N	I-Claim
33	clinical	N	I-Claim
34	practice	N	I-Claim
35	.	N	I-Claim

1	The	N	O
2	AVEREL	N	O
3	trial	N	O
4	[	N	O
5	A	N	O
6	Study	N	O
7	of	N	O
8	Avastin	N	O
9	(	N	O
10	Bevacizumab	N	O
11	)	N	O
12	in	N	O
13	Combination	N	O
14	With	N	O
15	Herceptin	N	O
16	(	N	O
17	Trastuzumab	N	O
18	)	N	O
19	/Docetaxel	N	O
20	in	N	O
21	Patients	N	O
22	With	N	O
23	HER2-Positive	N	O
24	Metastatic	N	O
25	Breast	N	O
26	Cancer	N	O
27	]	N	O
28	evaluated	N	O
29	first-line	N	O
30	bevacizumab-containing	N	O
31	therapy	N	O
32	for	N	O
33	human	N	O
34	epidermal	N	O
35	growth	N	O
36	factor	N	O
37	receptor	N	O
38	2	N	O
39	(	N	O
40	HER2	N	O
41	)	N	O
42	-positive	N	O
43	locally	N	O
44	recurrent/metastatic	N	O
45	breast	N	O
46	cancer	N	O
47	(	N	O
48	LR/MBC	N	O
49	)	N	O
50	.	N	O

1	Patients	N	O
2	with	N	O
3	measurable/evaluable	N	O
4	HER2-positive	N	O
5	LR/MBC	N	O
6	who	N	O
7	had	N	O
8	not	N	O
9	received	N	O
10	trastuzumab	N	O
11	or	N	O
12	chemotherapy	N	O
13	for	N	O
14	LR/MBC	N	O
15	were	N	O
16	stratified	N	O
17	by	N	O
18	prior	N	O
19	adjuvant	N	O
20	trastuzumab	N	O
21	,	N	O
22	prior	N	O
23	(	N	O
24	neo	N	O
25	)	N	O
26	adjuvant	N	O
27	taxane	N	O
28	,	N	O
29	hormone	N	O
30	receptor	N	O
31	status	N	O
32	,	N	O
33	and	N	O
34	measurable	N	O
35	disease	N	O
36	and	N	O
37	were	N	O
38	randomly	N	O
39	assigned	N	O
40	to	N	O
41	receive	N	O
42	docetaxel	N	O
43	100	N	O
44	mg/m	N	O
45	(	N	O
46	2	N	O
47	)	N	O
48	plus	N	O
49	trastuzumab	N	O
50	8	N	O
51	mg/kg	N	O
52	loading	N	O
53	dose	N	O
54	followed	N	O
55	by	N	O
56	6	N	O
57	mg/kg	N	O
58	either	N	O
59	with	N	O
60	bevacizumab	N	O
61	15	N	O
62	mg/kg	N	O
63	or	N	O
64	without	N	O
65	bevacizumab	N	O
66	,	N	O
67	all	N	O
68	administered	N	O
69	every	N	O
70	3	N	O
71	weeks	N	O
72	.	N	O

1	The	N	O
2	primary	N	O
3	end	N	O
4	point	N	O
5	was	N	O
6	progression-free	N	O
7	survival	N	O
8	(	N	O
9	PFS	N	O
10	)	N	O
11	.	N	O

1	Additional	N	O
2	end	N	O
3	points	N	O
4	included	N	O
5	overall	N	O
6	survival	N	O
7	,	N	O
8	response	N	O
9	rate	N	O
10	(	N	O
11	RR	N	O
12	)	N	O
13	,	N	O
14	safety	N	O
15	,	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	,	N	O
20	and	N	O
21	translational	N	O
22	research	N	O
23	.	N	O

1	Results	N	O
2	Baseline	N	O
3	characteristics	N	O
4	of	N	O
5	the	N	O
6	424	N	O
7	patients	N	O
8	were	N	O
9	balanced	N	O
10	between	N	O
11	treatment	N	O
12	arms	N	O
13	.	N	O

1	Most	N	O
2	patients	N	O
3	had	N	O
4	visceral	N	O
5	metastases	N	O
6	,	N	O
7	43	N	O
8	%	N	O
9	had	N	O
10	a	N	O
11	disease-free	N	O
12	interval	N	O
13	less	N	O
14	than	N	O
15	12	N	O
16	months	N	O
17	,	N	O
18	and	N	O
19	85	N	O
20	%	N	O
21	had	N	O
22	measurable	N	O
23	disease	N	O
24	.	N	O

1	Median	N	O
2	follow-up	N	O
3	was	N	O
4	26	N	O
5	months	N	O
6	.	N	O

1	The	N	I-Premise
2	hazard	N	I-Premise
3	ratio	N	I-Premise
4	for	N	I-Premise
5	investigator-assessed	N	I-Premise
6	PFS	N	I-Premise
7	was	N	I-Premise
8	0.82	N	I-Premise
9	(	N	I-Premise
10	95	N	I-Premise
11	%	N	I-Premise
12	CI	N	I-Premise
13	,	N	I-Premise
14	0.65	N	I-Premise
15	to	N	I-Premise
16	1.02	N	I-Premise
17	;	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	.0775	N	I-Premise
21	;	N	I-Premise
22	median	N	I-Premise
23	PFS	N	I-Premise
24	,	N	I-Premise
25	13.7	N	I-Premise
26	v	N	I-Premise
27	16.5	N	I-Premise
28	months	N	I-Premise
29	in	N	I-Premise
30	the	N	I-Premise
31	non-bevacizumab	N	I-Premise
32	and	N	I-Premise
33	bevacizumab	N	I-Premise
34	arms	N	I-Premise
35	,	N	I-Premise
36	respectively	N	I-Premise
37	;	N	I-Premise
38	PFS	N	I-Premise
39	events	N	I-Premise
40	in	N	I-Premise
41	72	N	I-Premise
42	%	N	I-Premise
43	)	N	I-Premise
44	.	N	I-Premise

1	The	N	I-Premise
2	Independent	N	I-Premise
3	Review	N	I-Premise
4	Committee-assessed	N	I-Premise
5	PFS	N	I-Premise
6	hazard	N	I-Premise
7	ratio	N	I-Premise
8	was	N	I-Premise
9	0.72	N	I-Premise
10	(	N	I-Premise
11	95	N	I-Premise
12	%	N	I-Premise
13	CI	N	I-Premise
14	,	N	I-Premise
15	0.54	N	I-Premise
16	to	N	I-Premise
17	0.94	N	I-Premise
18	;	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	.0162	N	I-Premise
22	;	N	I-Premise
23	median	N	I-Premise
24	PFS	N	I-Premise
25	,	N	I-Premise
26	13.9	N	I-Premise
27	v	N	I-Premise
28	16.8	N	I-Premise
29	months	N	I-Premise
30	,	N	I-Premise
31	respectively	N	I-Premise
32	;	N	I-Premise
33	PFS	N	I-Premise
34	events	N	I-Premise
35	in	N	I-Premise
36	53	N	I-Premise
37	%	N	I-Premise
38	)	N	I-Premise
39	.	N	I-Premise

1	The	N	I-Premise
2	RR	N	I-Premise
3	was	N	I-Premise
4	70	N	I-Premise
5	%	N	I-Premise
6	versus	N	I-Premise
7	74	N	I-Premise
8	%	N	I-Premise
9	,	N	I-Premise
10	respectively	N	I-Premise
11	(	N	I-Premise
12	P	N	I-Premise
13	=	N	I-Premise
14	.3492	N	I-Premise
15	)	N	I-Premise
16	.	N	I-Premise

1	Grade	N	I-Claim
2	≥	N	I-Claim
3	3	N	I-Claim
4	febrile	N	I-Claim
5	neutropenia	N	I-Claim
6	and	N	I-Claim
7	hypertension	N	I-Claim
8	were	N	I-Claim
9	more	N	I-Claim
10	common	N	I-Claim
11	with	N	I-Claim
12	bevacizumab-containing	N	I-Claim
13	therapy	N	I-Claim
14	.	N	I-Claim

1	High	N	I-Premise
2	baseline	N	I-Premise
3	plasma	N	I-Premise
4	vascular	N	I-Premise
5	endothelial	N	I-Premise
6	growth	N	I-Premise
7	factor	N	I-Premise
8	A	N	I-Premise
9	(	N	I-Premise
10	VEGF-A	N	I-Premise
11	)	N	I-Premise
12	concentrations	N	I-Premise
13	were	N	I-Premise
14	associated	N	I-Premise
15	with	N	I-Premise
16	greater	N	I-Premise
17	bevacizumab	N	I-Premise
18	benefit	N	I-Premise
19	(	N	I-Premise
20	not	N	I-Premise
21	statistically	N	I-Premise
22	significant	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Combining	N	I-Claim
2	bevacizumab	N	I-Claim
3	with	N	I-Claim
4	docetaxel	N	I-Claim
5	and	N	I-Claim
6	trastuzumab	N	I-Claim
7	did	N	I-Claim
8	not	N	I-Claim
9	significantly	N	I-Claim
10	improve	N	I-Claim
11	investigator-assessed	N	I-Claim
12	PFS	N	I-Claim
13	.	N	I-Claim

1	The	N	O
2	potential	N	O
3	predictive	N	O
4	value	N	O
5	of	N	O
6	plasma	N	O
7	VEGF-A	N	O
8	is	N	O
9	consistent	N	O
10	with	N	O
11	findings	N	O
12	in	N	O
13	HER2-negative	N	O
14	LR/MBC	N	O
15	,	N	O
16	warranting	N	O
17	prospective	N	O
18	evaluation	N	O
19	.	N	O

1	This	N	O
2	study	N	O
3	was	N	O
4	designed	N	O
5	to	N	O
6	evaluate	N	O
7	efficacy	N	O
8	,	N	O
9	toxicity	N	O
10	,	N	O
11	and	N	O
12	adverse	N	O
13	effects	N	O
14	of	N	O
15	combination	N	O
16	of	N	O
17	chemotherapy	N	O
18	drugs	N	O
19	and	N	O
20	intraperitoneal	N	O
21	perfusion	N	O
22	of	N	O
23	verapamil	N	O
24	in	N	O
25	the	N	O
26	treatment	N	O
27	of	N	O
28	malignant	N	O
29	ascites	N	O
30	.	N	O

1	Seventy-two	N	O
2	patients	N	O
3	with	N	O
4	malignant	N	O
5	ascites	N	O
6	were	N	O
7	divided	N	O
8	into	N	O
9	two	N	O
10	study	N	O
11	groups	N	O
12	.	N	O

1	Patients	N	O
2	in	N	O
3	control	N	O
4	group	N	O
5	(	N	O
6	31	N	O
7	cases	N	O
8	)	N	O
9	received	N	O
10	conventional	N	O
11	chemotherapy	N	O
12	,	N	O
13	whereas	N	O
14	patients	N	O
15	in	N	O
16	the	N	O
17	combined	N	O
18	treatment	N	O
19	group	N	O
20	(	N	O
21	41	N	O
22	cases	N	O
23	)	N	O
24	were	N	O
25	given	N	O
26	verapamil	N	O
27	intraperitoneally	N	O
28	in	N	O
29	addition	N	O
30	to	N	O
31	chemotherapy	N	O
32	drugs	N	O
33	.	N	O

1	Thirty	N	O
2	days	N	O
3	after	N	O
4	the	N	O
5	treatment	N	O
6	,	N	O
7	efficacy	N	O
8	,	N	O
9	toxicity	N	O
10	,	N	O
11	and	N	O
12	adverse	N	O
13	effects	N	O
14	were	N	O
15	assessed	N	O
16	in	N	O
17	both	N	O
18	study	N	O
19	groups	N	O
20	.	N	O

1	The	N	I-Premise
2	treatment	N	I-Premise
3	of	N	I-Premise
4	control	N	I-Premise
5	group	N	I-Premise
6	led	N	I-Premise
7	to	N	I-Premise
8	1	N	I-Premise
9	case	N	I-Premise
10	of	N	I-Premise
11	complete	N	I-Premise
12	remission	N	I-Premise
13	and	N	I-Premise
14	2	N	I-Premise
15	cases	N	I-Premise
16	of	N	I-Premise
17	partial	N	I-Premise
18	remission	N	I-Premise
19	,	N	I-Premise
20	making	N	I-Premise
21	the	N	I-Premise
22	rate	N	I-Premise
23	of	N	I-Premise
24	efficacy	N	I-Premise
25	(	N	I-Premise
26	complete	N	I-Premise
27	+	N	I-Premise
28	partial	N	I-Premise
29	remission	N	I-Premise
30	)	N	I-Premise
31	of	N	I-Premise
32	9.7	N	I-Premise
33	%	N	I-Premise
34	.	N	I-Premise

1	The	N	I-Premise
2	combined	N	I-Premise
3	treatment	N	I-Premise
4	group	N	I-Premise
5	demonstrated	N	I-Premise
6	13	N	I-Premise
7	cases	N	I-Premise
8	of	N	I-Premise
9	complete	N	I-Premise
10	remission	N	I-Premise
11	and	N	I-Premise
12	22	N	I-Premise
13	cases	N	I-Premise
14	of	N	I-Premise
15	partial	N	I-Premise
16	remission	N	I-Premise
17	.	N	I-Premise

1	Thus	N	O
2	,	N	O
3	the	N	I-Premise
4	rate	N	I-Premise
5	of	N	I-Premise
6	efficacy	N	I-Premise
7	was	N	I-Premise
8	significantly	N	I-Premise
9	higher	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	combined	N	I-Premise
13	treatment	N	I-Premise
14	group	N	I-Premise
15	(	N	I-Premise
16	85.36	N	I-Premise
17	%	N	I-Premise
18	;	N	I-Premise
19	p	N	I-Premise
20	<	N	I-Premise
21	0.05	N	I-Premise
22	vs.	N	I-Premise
23	control	N	I-Premise
24	group	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	Using	N	O
2	KPS	N	O
3	scores	N	O
4	,	N	O
5	changes	N	O
6	in	N	O
7	quality	N	O
8	of	N	O
9	life	N	O
10	were	N	O
11	compared	N	O
12	before	N	O
13	and	N	O
14	after	N	O
15	the	N	O
16	treatment	N	O
17	.	N	O

1	The	N	I-Premise
2	quality	N	I-Premise
3	of	N	I-Premise
4	life	N	I-Premise
5	improved	N	I-Premise
6	in	N	I-Premise
7	control	N	I-Premise
8	group	N	I-Premise
9	by	N	I-Premise
10	13.7	N	I-Premise
11	%	N	I-Premise
12	,	N	I-Premise
13	while	N	I-Premise
14	combined	N	I-Premise
15	treatment	N	I-Premise
16	group	N	I-Premise
17	showed	N	I-Premise
18	improvement	N	I-Premise
19	of	N	I-Premise
20	83.5	N	I-Premise
21	%	N	I-Premise
22	(	N	I-Premise
23	p	N	I-Premise
24	<	N	I-Premise
25	0.05	N	I-Premise
26	vs.	N	I-Premise
27	control	N	I-Premise
28	group	N	I-Premise
29	)	N	I-Premise
30	.	N	I-Premise

1	Further	N	O
2	,	N	O
3	cumulative	N	I-Premise
4	survival	N	I-Premise
5	rate	N	I-Premise
6	was	N	I-Premise
7	also	N	I-Premise
8	significantly	N	I-Premise
9	higher	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	combined	N	I-Premise
13	treatment	N	I-Premise
14	group	N	I-Premise
15	.	N	I-Premise

1	Treatment	N	I-Premise
2	toxicity	N	I-Premise
3	and	N	I-Premise
4	the	N	I-Premise
5	rate	N	I-Premise
6	of	N	I-Premise
7	adverse	N	I-Premise
8	effects	N	I-Premise
9	and	N	I-Premise
10	intestinal	N	I-Premise
11	adhesion	N	I-Premise
12	were	N	I-Premise
13	not	N	I-Premise
14	significantly	N	I-Premise
15	different	N	I-Premise
16	between	N	I-Premise
17	study	N	I-Premise
18	groups	N	I-Premise
19	.	N	I-Premise

1	Intraperitoneal	N	I-Claim
2	perfusion	N	I-Claim
3	of	N	I-Claim
4	verapamil	N	I-Claim
5	enhances	N	I-Claim
6	the	N	I-Claim
7	efficacy	N	I-Claim
8	of	N	I-Claim
9	chemotherapy	N	I-Claim
10	drugs	N	I-Claim
11	,	N	I-Claim
12	prolongs	N	I-Claim
13	survival	N	I-Claim
14	,	N	I-Claim
15	and	N	I-Claim
16	improves	N	I-Claim
17	the	N	I-Claim
18	quality	N	I-Claim
19	of	N	I-Claim
20	life	N	I-Claim
21	.	N	I-Claim

1	Intraperitoneal	N	I-Claim
2	administration	N	I-Claim
3	limits	N	I-Claim
4	cardiotoxicity	N	I-Claim
5	of	N	I-Claim
6	verapamil	N	I-Claim
7	.	N	I-Claim

1	Many	N	O
2	patients	N	O
3	with	N	O
4	cancer	N	O
5	experience	N	O
6	depression	N	O
7	and	N	O
8	anxiety	N	O
9	,	N	O
10	and	N	O
11	an	N	O
12	associated	N	O
13	decrease	N	O
14	in	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	(	N	O
19	QOL	N	O
20	)	N	O
21	during	N	O
22	radiation	N	O
23	therapy	N	O
24	(	N	O
25	RT	N	O
26	)	N	O
27	.	N	O

1	The	N	O
2	main	N	O
3	objective	N	O
4	of	N	O
5	the	N	O
6	study	N	O
7	was	N	O
8	to	N	O
9	determine	N	O
10	the	N	O
11	benefits	N	O
12	of	N	O
13	psychosocial	N	O
14	interventions	N	O
15	for	N	O
16	cancer	N	O
17	patients	N	O
18	who	N	O
19	received	N	O
20	RT	N	O
21	.	N	O

1	Patients	N	O
2	with	N	O
3	cancer	N	O
4	(	N	O
5	n	N	O
6	=	N	O
7	178	N	O
8	)	N	O
9	who	N	O
10	agreed	N	O
11	to	N	O
12	participate	N	O
13	in	N	O
14	the	N	O
15	study	N	O
16	were	N	O
17	randomized	N	O
18	to	N	O
19	the	N	O
20	intervention	N	O
21	arm	N	O
22	(	N	O
23	n	N	O
24	=	N	O
25	89	N	O
26	)	N	O
27	or	N	O
28	the	N	O
29	control	N	O
30	arm	N	O
31	(	N	O
32	n	N	O
33	=	N	O
34	89	N	O
35	)	N	O
36	.	N	O

1	Patients	N	O
2	in	N	O
3	the	N	O
4	intervention	N	O
5	group	N	O
6	received	N	O
7	psychosocial	N	O
8	care	N	O
9	during	N	O
10	RT	N	O
11	,	N	O
12	whereas	N	O
13	the	N	O
14	control	N	O
15	group	N	O
16	received	N	O
17	RT	N	O
18	only	N	O
19	.	N	O

1	The	N	O
2	benefits	N	O
3	of	N	O
4	the	N	O
5	intervention	N	O
6	were	N	O
7	evaluated	N	O
8	using	N	O
9	the	N	O
10	Zung	N	O
11	Self-rating	N	O
12	Depression	N	O
13	Scale	N	O
14	(	N	O
15	SDS	N	O
16	)	N	O
17	to	N	O
18	measure	N	O
19	depression	N	O
20	,	N	O
21	the	N	O
22	Self-rating	N	O
23	Anxiety	N	O
24	Scale	N	O
25	(	N	O
26	SAS	N	O
27	)	N	O
28	to	N	O
29	assess	N	O
30	anxiety	N	O
31	,	N	O
32	and	N	O
33	the	N	O
34	European	N	O
35	Organization	N	O
36	for	N	O
37	Research	N	O
38	and	N	O
39	Treatment	N	O
40	of	N	O
41	Cancer	N	O
42	Quality	N	O
43	of	N	O
44	Life	N	O
45	Questionnaire-Core	N	O
46	30	N	O
47	(	N	O
48	EORTC	N	O
49	QLQ-C30	N	O
50	)	N	O
51	to	N	O
52	survey	N	O
53	health-related	N	O
54	QOL	N	O
55	.	N	O

1	The	N	O
2	association	N	O
3	between	N	O
4	intervention	N	O
5	and	N	O
6	survival	N	O
7	was	N	O
8	also	N	O
9	assessed	N	O
10	.	N	O

1	Patients	N	I-Premise
2	randomly	N	I-Premise
3	assigned	N	I-Premise
4	to	N	I-Premise
5	the	N	I-Premise
6	intervention	N	I-Premise
7	arm	N	I-Premise
8	showed	N	I-Premise
9	significant	N	I-Premise
10	improvements	N	I-Premise
11	on	N	I-Premise
12	symptoms	N	I-Premise
13	of	N	I-Premise
14	depression	N	I-Premise
15	(	N	I-Premise
16	p	N	I-Premise
17	<	N	I-Premise
18	0.05	N	I-Premise
19	)	N	I-Premise
20	and	N	I-Premise
21	anxiety	N	I-Premise
22	(	N	I-Premise
23	p	N	I-Premise
24	<	N	I-Premise
25	0.05	N	I-Premise
26	)	N	I-Premise
27	,	N	I-Premise
28	health-related	N	I-Premise
29	QOL	N	I-Premise
30	(	N	I-Premise
31	p	N	I-Premise
32	<	N	I-Premise
33	0.05	N	I-Premise
34	)	N	I-Premise
35	(	N	I-Premise
36	i.e	N	I-Premise
37	.	N	I-Premise

1	better	N	I-Premise
2	global	N	I-Premise
3	health	N	I-Premise
4	status	N	I-Premise
5	,	N	I-Premise
6	and	N	I-Premise
7	physical	N	I-Premise
8	and	N	I-Premise
9	emotional	N	I-Premise
10	functioning	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	less	N	I-Premise
14	insomnia	N	I-Premise
15	)	N	I-Premise
16	when	N	I-Premise
17	compared	N	I-Premise
18	with	N	I-Premise
19	controls	N	I-Premise
20	.	N	I-Premise

1	In	N	I-Claim
2	the	N	I-Claim
3	subset	N	I-Claim
4	analysis	N	I-Claim
5	,	N	I-Claim
6	female	N	I-Claim
7	patients	N	I-Claim
8	,	N	I-Claim
9	those	N	I-Claim
10	that	N	I-Claim
11	received	N	I-Claim
12	high	N	I-Claim
13	dose	N	I-Claim
14	irradiation	N	I-Claim
15	,	N	I-Claim
16	and	N	I-Claim
17	those	N	I-Claim
18	that	N	I-Claim
19	underwent	N	I-Claim
20	adjuvant	N	I-Claim
21	chemotherapy	N	I-Claim
22	could	N	I-Claim
23	benefit	N	I-Claim
24	more	N	I-Claim
25	from	N	I-Claim
26	psychosocial	N	I-Claim
27	intervention	N	I-Claim
28	.	N	I-Claim

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	between	N	I-Premise
6	the	N	I-Premise
7	two	N	I-Premise
8	groups	N	I-Premise
9	in	N	I-Premise
10	disease-free	N	I-Premise
11	survival	N	I-Premise
12	(	N	I-Premise
13	DFS	N	I-Premise
14	)	N	I-Premise
15	(	N	I-Premise
16	2-year	N	I-Premise
17	DFS	N	I-Premise
18	79.8	N	I-Premise
19	%	N	I-Premise
20	in	N	I-Premise
21	the	N	I-Premise
22	intervention	N	I-Premise
23	arm	N	I-Premise
24	and	N	I-Premise
25	76.4	N	I-Premise
26	%	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	control	N	I-Premise
30	arm	N	I-Premise
31	;	N	I-Premise
32	p	N	I-Premise
33	=	N	I-Premise
34	0.527	N	I-Premise
35	)	N	I-Premise
36	and	N	I-Premise
37	overall	N	I-Premise
38	survival	N	I-Premise
39	(	N	I-Premise
40	OS	N	I-Premise
41	)	N	I-Premise
42	(	N	I-Premise
43	2-year	N	I-Premise
44	OS	N	I-Premise
45	83.1	N	I-Premise
46	%	N	I-Premise
47	in	N	I-Premise
48	the	N	I-Premise
49	intervention	N	I-Premise
50	arm	N	I-Premise
51	and	N	I-Premise
52	84.3	N	I-Premise
53	%	N	I-Premise
54	in	N	I-Premise
55	the	N	I-Premise
56	control	N	I-Premise
57	arm	N	I-Premise
58	;	N	I-Premise
59	p	N	I-Premise
60	=	N	I-Premise
61	0.925	N	I-Premise
62	)	N	I-Premise
63	.	N	I-Premise

1	Psychosocial	N	I-Claim
2	intervention	N	I-Claim
3	is	N	I-Claim
4	a	N	I-Claim
5	cost-effective	N	I-Claim
6	approach	N	I-Claim
7	that	N	I-Claim
8	can	N	I-Claim
9	improve	N	I-Claim
10	a	N	I-Claim
11	patient	N	I-Claim
12	's	N	I-Claim
13	mood	N	I-Claim
14	and	N	I-Claim
15	QOL	N	I-Claim
16	both	N	I-Claim
17	during	N	I-Claim
18	and	N	I-Claim
19	after	N	I-Claim
20	RT	N	I-Claim
21	.	N	I-Claim

1	However	N	I-Claim
2	,	N	I-Claim
3	the	N	I-Claim
4	intervention	N	I-Claim
5	was	N	I-Claim
6	not	N	I-Claim
7	found	N	I-Claim
8	to	N	I-Claim
9	reduce	N	I-Claim
10	the	N	I-Claim
11	risk	N	I-Claim
12	of	N	I-Claim
13	cancer	N	I-Claim
14	recurrence	N	I-Claim
15	and	N	I-Claim
16	death	N	I-Claim
17	.	N	I-Claim

1	It	N	O
2	is	N	O
3	well	N	O
4	documented	N	O
5	that	N	O
6	stress	N	O
7	is	N	O
8	associated	N	O
9	with	N	O
10	negative	N	O
11	health	N	O
12	outcomes	N	O
13	in	N	O
14	cancer	N	O
15	patients	N	O
16	.	N	O

1	The	N	O
2	purpose	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	assess	N	O
9	the	N	O
10	effects	N	O
11	of	N	O
12	a	N	O
13	novel	N	O
14	mindfulness	N	O
15	intervention	N	O
16	called	N	O
17	mindfulness-based	N	O
18	art	N	O
19	therapy	N	O
20	(	N	O
21	MBAT	N	O
22	)	N	O
23	versus	N	O
24	standard	N	O
25	educational	N	O
26	support	N	O
27	,	N	O
28	on	N	O
29	indices	N	O
30	of	N	O
31	stress	N	O
32	and	N	O
33	quality	N	O
34	of	N	O
35	life	N	O
36	in	N	O
37	breast	N	O
38	cancer	N	O
39	patients	N	O
40	with	N	O
41	high	N	O
42	stress	N	O
43	levels	N	O
44	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	191	N	O
5	women	N	O
6	were	N	O
7	enrolled	N	O
8	,	N	O
9	stratified	N	O
10	by	N	O
11	age	N	O
12	and	N	O
13	stress	N	O
14	level	N	O
15	,	N	O
16	and	N	O
17	randomized	N	O
18	to	N	O
19	receive	N	O
20	either	N	O
21	an	N	O
22	8-week	N	O
23	MBAT	N	O
24	intervention	N	O
25	or	N	O
26	a	N	O
27	breast	N	O
28	cancer	N	O
29	educational	N	O
30	support	N	O
31	program	N	O
32	of	N	O
33	equal	N	O
34	time	N	O
35	and	N	O
36	duration	N	O
37	.	N	O

1	Psychosocial	N	O
2	stress	N	O
3	was	N	O
4	measured	N	O
5	using	N	O
6	the	N	O
7	Symptoms	N	O
8	Checklist-90-Revised	N	O
9	,	N	O
10	and	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	was	N	O
15	measured	N	O
16	using	N	O
17	the	N	O
18	Medical	N	O
19	Outcomes	N	O
20	Study	N	O
21	Short-Form	N	O
22	Health	N	O
23	Survey	N	O
24	at	N	O
25	baseline	N	O
26	,	N	O
27	immediately	N	O
28	post-intervention	N	O
29	,	N	O
30	and	N	O
31	at	N	O
32	6	N	O
33	months	N	O
34	.	N	O

1	Results	N	I-Premise
2	showed	N	I-Premise
3	overall	N	I-Premise
4	significant	N	I-Premise
5	improvements	N	I-Premise
6	in	N	I-Premise
7	psychosocial	N	I-Premise
8	stress	N	I-Premise
9	and	N	I-Premise
10	quality	N	I-Premise
11	of	N	I-Premise
12	life	N	I-Premise
13	in	N	I-Premise
14	both	N	I-Premise
15	the	N	I-Premise
16	MBAT	N	I-Premise
17	and	N	I-Premise
18	educational	N	I-Premise
19	support	N	I-Premise
20	groups	N	I-Premise
21	immediately	N	I-Premise
22	post-intervention	N	I-Premise
23	;	N	I-Premise
24	however	N	I-Premise
25	,	N	I-Premise
26	participants	N	I-Premise
27	with	N	I-Premise
28	high	N	I-Premise
29	stress	N	I-Premise
30	levels	N	I-Premise
31	at	N	I-Premise
32	baseline	N	I-Premise
33	had	N	I-Premise
34	significantly	N	I-Premise
35	improved	N	I-Premise
36	overall	N	I-Premise
37	outcomes	N	I-Premise
38	only	N	I-Premise
39	in	N	I-Premise
40	the	N	I-Premise
41	MBAT	N	I-Premise
42	group	N	I-Premise
43	,	N	I-Premise
44	both	N	I-Premise
45	immediately	N	I-Premise
46	post-intervention	N	I-Premise
47	and	N	I-Premise
48	at	N	I-Premise
49	6	N	I-Premise
50	months	N	I-Premise
51	.	N	I-Premise

1	In	N	O
2	addition	N	O
3	,	N	O
4	at	N	I-Premise
5	6	N	I-Premise
6	months	N	I-Premise
7	follow-up	N	I-Premise
8	,	N	I-Premise
9	participants	N	I-Premise
10	attending	N	I-Premise
11	five	N	I-Premise
12	or	N	I-Premise
13	more	N	I-Premise
14	sessions	N	I-Premise
15	trended	N	I-Premise
16	toward	N	I-Premise
17	retaining	N	I-Premise
18	treatment	N	I-Premise
19	effects	N	I-Premise
20	better	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	MBAT	N	I-Premise
24	than	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	control	N	I-Premise
28	group	N	I-Premise
29	.	N	I-Premise

1	Finally	N	O
2	,	N	O
3	black	N	I-Premise
4	women	N	I-Premise
5	and	N	I-Premise
6	white	N	I-Premise
7	women	N	I-Premise
8	were	N	I-Premise
9	similar	N	I-Premise
10	in	N	I-Premise
11	terms	N	I-Premise
12	of	N	I-Premise
13	how	N	I-Premise
14	they	N	I-Premise
15	benefited	N	I-Premise
16	from	N	I-Premise
17	the	N	I-Premise
18	MBAT	N	I-Premise
19	intervention	N	I-Premise
20	,	N	I-Premise
21	even	N	I-Premise
22	though	N	I-Premise
23	white	N	I-Premise
24	participants	N	I-Premise
25	tended	N	I-Premise
26	to	N	I-Premise
27	have	N	I-Premise
28	higher	N	I-Premise
29	educational	N	I-Premise
30	level	N	I-Premise
31	and	N	I-Premise
32	marital	N	I-Premise
33	status	N	I-Premise
34	.	N	I-Premise

1	In	N	I-Claim
2	conclusion	N	I-Claim
3	,	N	I-Claim
4	MBAT	N	I-Claim
5	is	N	I-Claim
6	associated	N	I-Claim
7	with	N	I-Claim
8	significant	N	I-Claim
9	,	N	I-Claim
10	sustained	N	I-Claim
11	benefits	N	I-Claim
12	across	N	I-Claim
13	a	N	I-Claim
14	diverse	N	I-Claim
15	range	N	I-Claim
16	of	N	I-Claim
17	breast	N	I-Claim
18	cancer	N	I-Claim
19	patients	N	I-Claim
20	,	N	I-Claim
21	particularly	N	I-Claim
22	those	N	I-Claim
23	with	N	I-Claim
24	high	N	I-Claim
25	stress	N	I-Claim
26	levels	N	I-Claim
27	.	N	I-Claim

1	The	N	O
2	current	N	O
3	study	N	O
4	examined	N	O
5	the	N	O
6	effect	N	O
7	of	N	O
8	recombinant	N	O
9	human	N	O
10	deoxyribonuclease	N	O
11	(	N	O
12	rhDNase	N	O
13	)	N	O
14	on	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	(	N	O
19	QOL	N	O
20	)	N	O
21	measures	N	O
22	,	N	O
23	clinical	N	O
24	improvement	N	O
25	,	N	O
26	and	N	O
27	DNA	N	O
28	content	N	O
29	of	N	O
30	thick	N	O
31	oropharyngeal	N	O
32	secretions	N	O
33	(	N	O
34	OPS	N	O
35	)	N	O
36	in	N	O
37	patients	N	O
38	with	N	O
39	head-and-neck	N	O
40	(	N	O
41	H	N	O
42	&	N	O
43	N	N	O
44	)	N	O
45	cancers	N	O
46	.	N	O

1	Thirty-six	N	O
2	patients	N	O
3	with	N	O
4	local-regional	N	O
5	advanced	N	O
6	H	N	O
7	&	N	O
8	amp	N	O
9	;	N	O
10	N	N	O
11	cancer	N	O
12	receiving	N	O
13	chemoradiationtherapy	N	O
14	(	N	O
15	CRT	N	O
16	)	N	O
17	were	N	O
18	randomized	N	O
19	to	N	O
20	receive	N	O
21	either	N	O
22	placebo	N	O
23	or	N	O
24	rhDNase	N	O
25	.	N	O

1	Endpoints	N	O
2	included	N	O
3	MD	N	O
4	Anderson	N	O
5	Symptom	N	O
6	Inventory-Head	N	O
7	and	N	O
8	Neck	N	O
9	(	N	O
10	MDASI-HN	N	O
11	)	N	O
12	and	N	O
13	Functional	N	O
14	Assessment	N	O
15	of	N	O
16	Cancer	N	O
17	Therapy-Head	N	O
18	and	N	O
19	Neck	N	O
20	(	N	O
21	FACT-NH	N	O
22	)	N	O
23	scores	N	O
24	,	N	O
25	along	N	O
26	with	N	O
27	clinical	N	O
28	assessment	N	O
29	and	N	O
30	DNA	N	O
31	concentration	N	O
32	of	N	O
33	OPS	N	O
34	.	N	O

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	differences	N	I-Premise
7	in	N	I-Premise
8	patients	N	I-Premise
9	'	N	I-Premise
10	QOL	N	I-Premise
11	outcomes	N	I-Premise
12	over	N	I-Premise
13	the	N	I-Premise
14	study	N	I-Premise
15	period	N	I-Premise
16	.	N	I-Premise

1	Both	N	I-Premise
2	groups	N	I-Premise
3	showed	N	I-Premise
4	an	N	I-Premise
5	increase	N	I-Premise
6	in	N	I-Premise
7	symptom	N	I-Premise
8	and	N	I-Premise
9	interference	N	I-Premise
10	scores	N	I-Premise
11	,	N	I-Premise
12	although	N	O
13	patients	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	rhDNase	N	I-Premise
17	group	N	I-Premise
18	showed	N	I-Premise
19	a	N	I-Premise
20	greater	N	I-Premise
21	decline	N	I-Premise
22	in	N	I-Premise
23	both	N	I-Premise
24	scores	N	I-Premise
25	during	N	I-Premise
26	the	N	I-Premise
27	3	N	I-Premise
28	months	N	I-Premise
29	posttreatment	N	I-Premise
30	.	N	I-Premise

1	Similarly	N	I-Premise
2	,	N	I-Premise
3	both	N	I-Premise
4	groups	N	I-Premise
5	showed	N	I-Premise
6	a	N	I-Premise
7	decline	N	I-Premise
8	in	N	I-Premise
9	physical	N	I-Premise
10	and	N	I-Premise
11	functional	N	I-Premise
12	well	N	I-Premise
13	being	N	I-Premise
14	but	N	I-Premise
15	recovered	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	3	N	I-Premise
19	months	N	I-Premise
20	posttreatment	N	I-Premise
21	follow-up	N	I-Premise
22	,	N	I-Premise
23	with	N	I-Premise
24	the	N	I-Premise
25	rhDNase	N	I-Premise
26	group	N	I-Premise
27	exhibiting	N	I-Premise
28	speedier	N	I-Premise
29	recovery	N	I-Premise
30	.	N	I-Premise

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	rhDNase	N	I-Premise
5	group	N	I-Premise
6	exhibited	N	I-Premise
7	significant	N	I-Premise
8	clinical	N	I-Premise
9	improvement	N	I-Premise
10	in	N	I-Premise
11	OPS	N	I-Premise
12	,	N	I-Premise
13	blindly	N	I-Premise
14	assessed	N	I-Premise
15	by	N	I-Premise
16	a	N	I-Premise
17	physician	N	I-Premise
18	,	N	I-Premise
19	compared	N	I-Premise
20	with	N	I-Premise
21	the	N	I-Premise
22	placebo	N	I-Premise
23	group	N	I-Premise
24	(	N	I-Premise
25	67	N	I-Premise
26	%	N	I-Premise
27	vs	N	I-Premise
28	27	N	I-Premise
29	%	N	I-Premise
30	,	N	I-Premise
31	respectively	N	I-Premise
32	;	N	I-Premise
33	P=.046	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	The	N	I-Premise
2	rhDNase	N	I-Premise
3	group	N	I-Premise
4	showed	N	I-Premise
5	no	N	I-Premise
6	change	N	I-Premise
7	in	N	I-Premise
8	OPS-DNA	N	I-Premise
9	concentration	N	I-Premise
10	,	N	I-Premise
11	although	N	O
12	the	N	I-Premise
13	placebo	N	I-Premise
14	group	N	I-Premise
15	showed	N	I-Premise
16	a	N	I-Premise
17	significant	N	I-Premise
18	increase	N	I-Premise
19	in	N	I-Premise
20	DNA	N	I-Premise
21	concentration	N	I-Premise
22	during	N	I-Premise
23	the	N	I-Premise
24	drug	N	I-Premise
25	trial	N	I-Premise
26	(	N	I-Premise
27	P=.045	N	I-Premise
28	)	N	I-Premise
29	.	N	I-Premise

1	There	N	I-Claim
2	was	N	I-Claim
3	no	N	I-Claim
4	differences	N	I-Claim
5	in	N	I-Claim
6	acute	N	I-Claim
7	toxicities	N	I-Claim
8	between	N	I-Claim
9	the	N	I-Claim
10	2	N	I-Claim
11	groups	N	I-Claim
12	.	N	I-Claim

1	Our	N	I-Claim
2	preliminary	N	I-Claim
3	data	N	I-Claim
4	suggest	N	I-Claim
5	that	N	I-Claim
6	rhDNase	N	I-Claim
7	did	N	I-Claim
8	not	N	I-Claim
9	significantly	N	I-Claim
10	improve	N	I-Claim
11	study	N	I-Claim
12	primary	N	I-Claim
13	endpoints	N	I-Claim
14	of	N	I-Claim
15	QOL	N	I-Claim
16	measures	N	I-Claim
17	compared	N	I-Claim
18	with	N	I-Claim
19	the	N	I-Claim
20	placebo	N	I-Claim
21	group	N	I-Claim
22	.	N	I-Claim

1	However	N	O
2	,	N	O
3	there	N	I-Claim
4	was	N	I-Claim
5	a	N	I-Claim
6	significant	N	I-Claim
7	improvement	N	I-Claim
8	in	N	I-Claim
9	secondary	N	I-Claim
10	endpoints	N	I-Claim
11	of	N	I-Claim
12	clinically	N	I-Claim
13	assessed	N	I-Claim
14	OPS	N	I-Claim
15	and	N	I-Claim
16	DNA	N	I-Claim
17	concentration	N	I-Claim
18	compared	N	I-Claim
19	with	N	I-Claim
20	placebo	N	I-Claim
21	in	N	I-Claim
22	H	N	I-Claim
23	&	N	I-Claim
24	N	N	I-Claim
25	cancer	N	I-Claim
26	patients	N	I-Claim
27	treated	N	I-Claim
28	with	N	I-Claim
29	CRT	N	I-Claim
30	.	N	I-Claim

1	Further	N	O
2	investigation	N	O
3	in	N	O
4	larger	N	O
5	numbers	N	O
6	of	N	O
7	patients	N	O
8	is	N	O
9	warranted	N	O
10	.	N	O

1	Due	N	O
2	to	N	O
3	concerns	N	O
4	of	N	O
5	fragility	N	O
6	fracture	N	O
7	,	N	O
8	exercise	N	O
9	is	N	O
10	a	N	O
11	perceived	N	O
12	contraindication	N	O
13	for	N	O
14	prostate	N	O
15	cancer	N	O
16	patients	N	O
17	with	N	O
18	bone	N	O
19	metastases	N	O
20	.	N	O

1	These	N	O
2	patients	N	O
3	experience	N	O
4	significant	N	O
5	functional	N	O
6	impairment	N	O
7	and	N	O
8	muscle	N	O
9	atrophy	N	O
10	,	N	O
11	which	N	O
12	may	N	O
13	lead	N	O
14	to	N	O
15	an	N	O
16	increased	N	O
17	likelihood	N	O
18	of	N	O
19	skeletal	N	O
20	complicaTIOns	N	O
21	(	N	O
22	i.e.	N	O
23	,	N	O
24	pathological	N	O
25	fracture	N	O
26	,	N	O
27	bone	N	O
28	pain	N	O
29	)	N	O
30	and/or	N	O
31	falls	N	O
32	.	N	O

1	Safe	N	O
2	resistance	N	O
3	exercise	N	O
4	prescription	N	O
5	may	N	O
6	counteract	N	O
7	this	N	O
8	effect	N	O
9	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	feasibility	N	O
6	trial	N	O
7	was	N	O
8	to	N	O
9	determine	N	O
10	the	N	O
11	safety	N	O
12	and	N	O
13	efficacy	N	O
14	of	N	O
15	resistance	N	O
16	exercise	N	O
17	by	N	O
18	prostate	N	O
19	cancer	N	O
20	survivors	N	O
21	with	N	O
22	bone	N	O
23	metastatic	N	O
24	disease	N	O
25	.	N	O

1	Twenty	N	O
2	men	N	O
3	with	N	O
4	established	N	O
5	bone	N	O
6	metastases	N	O
7	secondary	N	O
8	to	N	O
9	prostate	N	O
10	cancer	N	O
11	were	N	O
12	randomly	N	O
13	assigned	N	O
14	to	N	O
15	a	N	O
16	12-week	N	O
17	resistance	N	O
18	exercise	N	O
19	program	N	O
20	in	N	O
21	which	N	O
22	exercise	N	O
23	prescription	N	O
24	was	N	O
25	based	N	O
26	on	N	O
27	the	N	O
28	location	N	O
29	of	N	O
30	bone	N	O
31	lesions	N	O
32	(	N	O
33	n=10	N	O
34	)	N	O
35	or	N	O
36	usual	N	O
37	care	N	O
38	(	N	O
39	n=10	N	O
40	)	N	O
41	.	N	O

1	Outcomes	N	O
2	included	N	O
3	safety	N	O
4	and	N	O
5	tolerance	N	O
6	of	N	O
7	the	N	O
8	exercise	N	O
9	program	N	O
10	,	N	O
11	physical	N	O
12	function	N	O
13	,	N	O
14	physical	N	O
15	activity	N	O
16	level	N	O
17	,	N	O
18	body	N	O
19	composition	N	O
20	,	N	O
21	fatigue	N	O
22	,	N	O
23	quality	N	O
24	of	N	O
25	life	N	O
26	and	N	O
27	psychological	N	O
28	distress	N	O
29	.	N	O

1	Outcomes	N	O
2	were	N	O
3	compared	N	O
4	between	N	O
5	groups	N	O
6	using	N	O
7	analysis	N	O
8	of	N	O
9	covariance	N	O
10	adjusted	N	O
11	for	N	O
12	baseline	N	O
13	values	N	O
14	.	N	O

1	Participants	N	O
2	had	N	O
3	significant	N	O
4	disease	N	O
5	load	N	O
6	with	N	O
7	65	N	O
8	%	N	O
9	of	N	O
10	participants	N	O
11	presenting	N	O
12	with	N	O
13	two	N	O
14	or	N	O
15	more	N	O
16	regions	N	O
17	affected	N	O
18	by	N	O
19	bone	N	O
20	metastases	N	O
21	and	N	O
22	an	N	O
23	average	N	O
24	Gleason	N	O
25	score	N	O
26	of	N	O
27	8.2±0.9	N	O
28	.	N	O

1	Five	N	O
2	participants	N	O
3	(	N	O
4	exercise=2	N	O
5	;	N	O
6	usual	N	O
7	care=3	N	O
8	)	N	O
9	did	N	O
10	not	N	O
11	complete	N	O
12	the	N	O
13	intervention	N	O
14	,	N	O
15	three	N	O
16	of	N	O
17	which	N	O
18	were	N	O
19	due	N	O
20	to	N	O
21	advancing	N	O
22	disease	N	O
23	(	N	O
24	exercise=2	N	O
25	;	N	O
26	usual	N	O
27	care=1	N	O
28	)	N	O
29	.	N	O

1	No	N	I-Premise
2	adverse	N	I-Premise
3	events	N	I-Premise
4	or	N	I-Premise
5	skeletal	N	I-Premise
6	complications	N	I-Premise
7	occurred	N	I-Premise
8	during	N	I-Premise
9	the	N	I-Premise
10	supervised	N	I-Premise
11	exercise	N	I-Premise
12	sessions	N	I-Premise
13	.	N	I-Premise

1	The	N	I-Premise
2	exercise	N	I-Premise
3	program	N	I-Premise
4	was	N	I-Premise
5	well	N	I-Premise
6	tolerated	N	I-Premise
7	as	N	I-Premise
8	evidenced	N	I-Premise
9	by	N	I-Premise
10	high	N	I-Premise
11	attendance	N	I-Premise
12	(	N	I-Premise
13	83	N	I-Premise
14	%	N	I-Premise
15	)	N	I-Premise
16	and	N	I-Premise
17	compliance	N	I-Premise
18	rates	N	I-Premise
19	(	N	I-Premise
20	93	N	I-Premise
21	%	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	and	N	I-Premise
25	the	N	I-Premise
26	ability	N	I-Premise
27	of	N	I-Premise
28	the	N	I-Premise
29	participants	N	I-Premise
30	to	N	I-Premise
31	exercise	N	I-Premise
32	at	N	I-Premise
33	an	N	I-Premise
34	intensity	N	I-Premise
35	within	N	I-Premise
36	the	N	I-Premise
37	target	N	I-Premise
38	range	N	I-Premise
39	for	N	I-Premise
40	cancer	N	I-Premise
41	survivors	N	I-Premise
42	(	N	I-Premise
43	rating	N	I-Premise
44	of	N	I-Premise
45	perceived	N	I-Premise
46	exertion	N	I-Premise
47	=13.8±1.5	N	I-Premise
48	)	N	I-Premise
49	.	N	I-Premise

1	The	N	I-Premise
2	change	N	I-Premise
3	in	N	I-Premise
4	physical	N	I-Premise
5	function	N	I-Premise
6	(	N	I-Premise
7	muscle	N	I-Premise
8	strength	N	I-Premise
9	∼11	N	I-Premise
10	%	N	I-Premise
11	;	N	I-Premise
12	submaximal	N	I-Premise
13	aerobic	N	I-Premise
14	exercise	N	I-Premise
15	capacity	N	I-Premise
16	∼5	N	I-Premise
17	%	N	I-Premise
18	and	N	I-Premise
19	ambulation	N	I-Premise
20	∼12	N	I-Premise
21	%	N	I-Premise
22	)	N	I-Premise
23	,	N	I-Premise
24	physical	N	I-Premise
25	activity	N	I-Premise
26	level	N	I-Premise
27	(	N	I-Premise
28	∼24	N	I-Premise
29	%	N	I-Premise
30	)	N	I-Premise
31	and	N	I-Premise
32	lean	N	I-Premise
33	mass	N	I-Premise
34	(	N	I-Premise
35	∼3	N	I-Premise
36	%	N	I-Premise
37	)	N	I-Premise
38	differed	N	I-Premise
39	significantly	N	I-Premise
40	between	N	I-Premise
41	groups	N	I-Premise
42	following	N	I-Premise
43	the	N	I-Premise
44	intervention	N	I-Premise
45	,	N	I-Premise
46	with	N	I-Premise
47	favorable	N	I-Premise
48	changes	N	I-Premise
49	in	N	I-Premise
50	the	N	I-Premise
51	exercise	N	I-Premise
52	group	N	I-Premise
53	compared	N	I-Premise
54	with	N	I-Premise
55	the	N	I-Premise
56	usual	N	I-Premise
57	care	N	I-Premise
58	group	N	I-Premise
59	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	between-group	N	I-Premise
4	differences	N	I-Premise
5	were	N	I-Premise
6	observed	N	I-Premise
7	for	N	I-Premise
8	fatigue	N	I-Premise
9	,	N	I-Premise
10	quality	N	I-Premise
11	of	N	I-Premise
12	life	N	I-Premise
13	or	N	I-Premise
14	psychological	N	I-Premise
15	distress	N	I-Premise
16	.	N	I-Premise

1	This	N	I-Claim
2	initial	N	I-Claim
3	evidence	N	I-Claim
4	involving	N	I-Claim
5	a	N	I-Claim
6	small	N	I-Claim
7	sample	N	I-Claim
8	size	N	I-Claim
9	suggests	N	I-Claim
10	that	N	I-Claim
11	appropriately	N	I-Claim
12	designed	N	I-Claim
13	and	N	I-Claim
14	supervised	N	I-Claim
15	resistance	N	I-Claim
16	exercise	N	I-Claim
17	may	N	I-Claim
18	be	N	I-Claim
19	safe	N	I-Claim
20	and	N	I-Claim
21	well	N	I-Claim
22	tolerated	N	I-Claim
23	by	N	I-Claim
24	prostate	N	I-Claim
25	cancer	N	I-Claim
26	patients	N	I-Claim
27	with	N	I-Claim
28	bone	N	I-Claim
29	metastatic	N	I-Claim
30	disease	N	I-Claim
31	and	N	I-Claim
32	can	N	I-Claim
33	lead	N	I-Claim
34	to	N	I-Claim
35	improvements	N	I-Claim
36	in	N	I-Claim
37	physical	N	I-Claim
38	function	N	I-Claim
39	,	N	I-Claim
40	physical	N	I-Claim
41	activity	N	I-Claim
42	levels	N	I-Claim
43	and	N	I-Claim
44	lean	N	I-Claim
45	mass	N	I-Claim
46	.	N	I-Claim

1	Future	N	I-Claim
2	trials	N	I-Claim
3	involving	N	I-Claim
4	larger	N	I-Claim
5	sample	N	I-Claim
6	sizes	N	I-Claim
7	are	N	I-Claim
8	required	N	I-Claim
9	to	N	I-Claim
10	expand	N	I-Claim
11	these	N	I-Claim
12	preliminary	N	I-Claim
13	findings	N	I-Claim
14	.	N	I-Claim

1	Gefitinib	N	O
2	and	N	O
3	Pemetrexed	N	O
4	are	N	O
5	drugs	N	O
6	used	N	O
7	as	N	O
8	second-line	N	O
9	therapy	N	O
10	for	N	O
11	advanced	N	O
12	non-small	N	O
13	cell	N	O
14	lung	N	O
15	cancer	N	O
16	(	N	O
17	NSCLC	N	O
18	)	N	O
19	,	N	O
20	although	N	O
21	studies	N	O
22	comparing	N	O
23	the	N	O
24	two	N	O
25	drugs	N	O
26	are	N	O
27	limited	N	O
28	.	N	O

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	is	N	O
7	to	N	O
8	explore	N	O
9	the	N	O
10	effects	N	O
11	,	N	O
12	safety	N	O
13	,	N	O
14	and	N	O
15	quality	N	O
16	of	N	O
17	life	N	O
18	(	N	O
19	QoL	N	O
20	)	N	O
21	of	N	O
22	Gefitinib	N	O
23	and	N	O
24	Pemetrexed	N	O
25	on	N	O
26	patients	N	O
27	with	N	O
28	advanced	N	O
29	non-squamous	N	O
30	NSCLC	N	O
31	.	N	O

1	Forty-six	N	O
2	advanced	N	O
3	non-squamous	N	O
4	NSCLC	N	O
5	patients	N	O
6	who	N	O
7	failed	N	O
8	to	N	O
9	first-line	N	O
10	therapy	N	O
11	were	N	O
12	randomly	N	O
13	divided	N	O
14	into	N	O
15	two	N	O
16	groups	N	O
17	with	N	O
18	23	N	O
19	patients	N	O
20	each	N	O
21	,	N	O
22	one	N	O
23	using	N	O
24	oral	N	O
25	Gefitinib	N	O
26	(	N	O
27	Gefitinib	N	O
28	group	N	O
29	)	N	O
30	and	N	O
31	the	N	O
32	other	N	O
33	using	N	O
34	intravenous	N	O
35	injection	N	O
36	Pemetrexed	N	O
37	(	N	O
38	Pemetrexed	N	O
39	group	N	O
40	)	N	O
41	.	N	O

1	The	N	O
2	effects	N	O
3	,	N	O
4	safety	N	O
5	,	N	O
6	and	N	O
7	QoL	N	O
8	were	N	O
9	determined	N	O
10	and	N	O
11	analyzed	N	O
12	.	N	O

1	For	N	I-Premise
2	the	N	I-Premise
3	Pemetrexed	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	objective	N	I-Premise
7	response	N	I-Premise
8	rate	N	I-Premise
9	(	N	I-Premise
10	ORR	N	I-Premise
11	)	N	I-Premise
12	was	N	I-Premise
13	13.0	N	I-Premise
14	%	N	I-Premise
15	(	N	I-Premise
16	3/23	N	I-Premise
17	)	N	I-Premise
18	,	N	I-Premise
19	disease	N	I-Premise
20	control	N	I-Premise
21	rate	N	I-Premise
22	(	N	I-Premise
23	DCR	N	I-Premise
24	)	N	I-Premise
25	was	N	I-Premise
26	30.4	N	I-Premise
27	%	N	I-Premise
28	(	N	I-Premise
29	7/23	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	and	N	I-Premise
33	median	N	I-Premise
34	progression-free	N	I-Premise
35	survival	N	I-Premise
36	(	N	I-Premise
37	mPFS	N	I-Premise
38	)	N	I-Premise
39	was	N	I-Premise
40	3.1	N	I-Premise
41	months	N	I-Premise
42	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	Gefitinib	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	ORR	N	I-Premise
7	was	N	I-Premise
8	17.3	N	I-Premise
9	%	N	I-Premise
10	(	N	I-Premise
11	4/23	N	I-Premise
12	)	N	I-Premise
13	,	N	I-Premise
14	DCR	N	I-Premise
15	was	N	I-Premise
16	39.1	N	I-Premise
17	%	N	I-Premise
18	(	N	I-Premise
19	9/23	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	and	N	I-Premise
23	mPFS	N	I-Premise
24	was	N	I-Premise
25	4.4	N	I-Premise
26	months	N	I-Premise
27	.	N	I-Premise

1	Compared	N	I-Premise
2	with	N	I-Premise
3	the	N	I-Premise
4	Pemetrexed	N	I-Premise
5	group	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	ORR	N	I-Premise
9	,	N	I-Premise
10	DCR	N	I-Premise
11	,	N	I-Premise
12	and	N	I-Premise
13	mPFS	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	Gefitinib	N	I-Premise
17	group	N	I-Premise
18	exhibited	N	I-Premise
19	no	N	I-Premise
20	statistical	N	I-Premise
21	significance	N	I-Premise
22	(	N	I-Premise
23	P	N	I-Premise
24	>	N	I-Premise
25	0.05	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	Furthermore	N	O
2	,	N	O
3	the	N	I-Premise
4	most	N	I-Premise
5	common	N	I-Premise
6	toxicities	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	Pemetrexed	N	I-Premise
10	group	N	I-Premise
11	were	N	I-Premise
12	neutropenia	N	I-Premise
13	(	N	I-Premise
14	n=9	N	I-Premise
15	,	N	I-Premise
16	39.13	N	I-Premise
17	%	N	I-Premise
18	)	N	I-Premise
19	and	N	I-Premise
20	fatigue	N	I-Premise
21	(	N	I-Premise
22	n=8	N	I-Premise
23	,	N	I-Premise
24	34.78	N	I-Premise
25	%	N	I-Premise
26	)	N	I-Premise
27	,	N	I-Premise
28	whereas	N	I-Premise
29	those	N	I-Premise
30	in	N	I-Premise
31	the	N	I-Premise
32	in	N	I-Premise
33	Gefitinib	N	I-Premise
34	group	N	I-Premise
35	were	N	I-Premise
36	skin	N	I-Premise
37	rash	N	I-Premise
38	(	N	I-Premise
39	n=8	N	I-Premise
40	,	N	I-Premise
41	34.78	N	I-Premise
42	%	N	I-Premise
43	)	N	I-Premise
44	and	N	I-Premise
45	diarrhea	N	I-Premise
46	(	N	I-Premise
47	n=4	N	I-Premise
48	,	N	I-Premise
49	17.39	N	I-Premise
50	%	N	I-Premise
51	)	N	I-Premise
52	.	N	I-Premise

1	Compared	N	I-Premise
2	with	N	I-Premise
3	baseline	N	I-Premise
4	,	N	I-Premise
5	the	N	I-Premise
6	QoL	N	I-Premise
7	improved	N	I-Premise
8	in	N	I-Premise
9	both	N	I-Premise
10	groups	N	I-Premise
11	but	N	I-Premise
12	to	N	I-Premise
13	different	N	I-Premise
14	degrees	N	I-Premise
15	.	N	I-Premise

1	Likewise	N	O
2	,	N	O
3	emotional	N	I-Premise
4	,	N	I-Premise
5	functional	N	I-Premise
6	well-being	N	I-Premise
7	,	N	I-Premise
8	and	N	I-Premise
9	QoL	N	I-Premise
10	aspects	N	I-Premise
11	specifically	N	I-Premise
12	related	N	I-Premise
13	to	N	I-Premise
14	lung	N	I-Premise
15	cancer	N	I-Premise
16	were	N	I-Premise
17	better	N	I-Premise
18	improved	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	Gefitinib	N	I-Premise
22	group	N	I-Premise
23	than	N	I-Premise
24	in	N	I-Premise
25	the	N	I-Premise
26	Pemetrexed	N	I-Premise
27	group	N	I-Premise
28	(	N	I-Premise
29	P	N	I-Premise
30	<	N	I-Premise
31	0.05	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	The	N	I-Claim
2	effects	N	I-Claim
3	of	N	I-Claim
4	Pemetrexed	N	I-Claim
5	and	N	I-Claim
6	Gefitinib	N	I-Claim
7	as	N	I-Claim
8	second	N	I-Claim
9	line	N	I-Claim
10	therapy	N	I-Claim
11	were	N	I-Claim
12	similar	N	I-Claim
13	,	N	I-Claim
14	although	N	I-Premise
15	with	N	I-Premise
16	different	N	I-Premise
17	AEs	N	I-Premise
18	.	N	I-Premise

1	Both	N	I-Claim
2	drugs	N	I-Claim
3	could	N	I-Claim
4	improve	N	I-Claim
5	the	N	I-Claim
6	QoL	N	I-Claim
7	,	N	I-Claim
8	but	N	O
9	Gefitinib	N	I-Claim
10	showed	N	I-Claim
11	better	N	I-Claim
12	overall	N	I-Claim
13	results	N	I-Claim
14	than	N	I-Claim
15	Pemetrexed	N	I-Claim
16	.	N	I-Claim

1	Everolimus	N	O
2	(	N	O
3	EVE	N	O
4	)	N	O
5	+exemestane	N	O
6	(	N	O
7	EXE	N	O
8	;	N	O
9	n	N	O
10	=	N	O
11	485	N	O
12	)	N	O
13	more	N	O
14	than	N	O
15	doubled	N	O
16	median	N	O
17	progression-free	N	O
18	survival	N	O
19	versus	N	O
20	placebo	N	O
21	(	N	O
22	PBO	N	O
23	)	N	O
24	+	N	O
25	EXE	N	O
26	(	N	O
27	n	N	O
28	=	N	O
29	239	N	O
30	)	N	O
31	,	N	O
32	with	N	O
33	a	N	O
34	manageable	N	O
35	safety	N	O
36	profile	N	O
37	and	N	O
38	no	N	O
39	deterioration	N	O
40	in	N	O
41	health-related	N	O
42	quality-of-life	N	O
43	(	N	O
44	HRQOL	N	O
45	)	N	O
46	in	N	O
47	patients	N	O
48	with	N	O
49	hormone-receptor-positive	N	O
50	(	N	O
51	HR	N	O
52	(	N	O
53	+	N	O
54	)	N	O
55	)	N	O
56	advanced	N	O
57	breast	N	O
58	cancer	N	O
59	(	N	O
60	ABC	N	O
61	)	N	O
62	who	N	O
63	recurred	N	O
64	or	N	O
65	progressed	N	O
66	on/after	N	O
67	nonsteroidal	N	O
68	aromatase	N	O
69	inhibitor	N	O
70	(	N	O
71	NSAI	N	O
72	)	N	O
73	therapy	N	O
74	.	N	O

1	To	N	O
2	further	N	O
3	evaluate	N	O
4	EVE	N	O
5	+	N	O
6	EXE	N	O
7	impact	N	O
8	on	N	O
9	disease	N	O
10	burden	N	O
11	,	N	O
12	we	N	O
13	conducted	N	O
14	additional	N	O
15	post-hoc	N	O
16	analyses	N	O
17	of	N	O
18	patient-reported	N	O
19	HRQOL	N	O
20	.	N	O

1	HRQOL	N	O
2	was	N	O
3	assessed	N	O
4	using	N	O
5	EORTC	N	O
6	QLQ-C30	N	O
7	and	N	O
8	QLQ-BR23	N	O
9	questionnaires	N	O
10	at	N	O
11	baseline	N	O
12	and	N	O
13	every	N	O
14	6	N	O
15	weeks	N	O
16	thereafter	N	O
17	until	N	O
18	treatment	N	O
19	discontinuation	N	O
20	because	N	O
21	of	N	O
22	disease	N	O
23	progression	N	O
24	,	N	O
25	toxicity	N	O
26	,	N	O
27	or	N	O
28	consent	N	O
29	withdrawal	N	O
30	.	N	O

1	Endpoints	N	O
2	included	N	O
3	the	N	O
4	QLQ-C30	N	O
5	Global	N	O
6	Health	N	O
7	Status	N	O
8	(	N	O
9	QL2	N	O
10	)	N	O
11	scale	N	O
12	,	N	O
13	the	N	O
14	QLQ-BR23	N	O
15	breast	N	O
16	symptom	N	O
17	(	N	O
18	BRBS	N	O
19	)	N	O
20	,	N	O
21	and	N	O
22	arm	N	O
23	symptom	N	O
24	(	N	O
25	BRAS	N	O
26	)	N	O
27	scales	N	O
28	.	N	O

1	Between-group	N	O
2	differences	N	O
3	in	N	O
4	change	N	O
5	from	N	O
6	baseline	N	O
7	were	N	O
8	assessed	N	O
9	using	N	O
10	linear	N	O
11	mixed	N	O
12	models	N	O
13	with	N	O
14	selected	N	O
15	covariates	N	O
16	.	N	O

1	Sensitivity	N	O
2	analysis	N	O
3	using	N	O
4	pattern-mixture	N	O
5	models	N	O
6	determined	N	O
7	the	N	O
8	effect	N	O
9	of	N	O
10	study	N	O
11	discontinuation	N	O
12	on/before	N	O
13	week	N	O
14	24	N	O
15	.	N	O

1	Treatment	N	O
2	arms	N	O
3	were	N	O
4	compared	N	O
5	using	N	O
6	differences	N	O
7	of	N	O
8	least	N	O
9	squares	N	O
10	mean	N	O
11	(	N	O
12	LSM	N	O
13	)	N	O
14	changes	N	O
15	from	N	O
16	baseline	N	O
17	and	N	O
18	95	N	O
19	%	N	O
20	confidence	N	O
21	intervals	N	O
22	(	N	O
23	CIs	N	O
24	)	N	O
25	at	N	O
26	each	N	O
27	timepoint	N	O
28	and	N	O
29	overall	N	O
30	.	N	O

1	Progression-free	N	O
2	survival	N	O
3	,	N	O
4	survival	N	O
5	,	N	O
6	response	N	O
7	rate	N	O
8	,	N	O
9	safety	N	O
10	,	N	O
11	and	N	O
12	HRQOL	N	O
13	.	N	O

1	Linear	N	I-Premise
2	mixed	N	I-Premise
3	models	N	I-Premise
4	(	N	I-Premise
5	primary	N	I-Premise
6	model	N	I-Premise
7	)	N	I-Premise
8	demonstrated	N	I-Premise
9	no	N	I-Premise
10	statistically	N	I-Premise
11	significant	N	I-Premise
12	overall	N	I-Premise
13	difference	N	I-Premise
14	between	N	I-Premise
15	EVE	N	I-Premise
16	+	N	I-Premise
17	EXE	N	I-Premise
18	and	N	I-Premise
19	PBO	N	I-Premise
20	+	N	I-Premise
21	EXE	N	I-Premise
22	for	N	I-Premise
23	QL2	N	I-Premise
24	(	N	I-Premise
25	LSM	N	I-Premise
26	difference	N	I-Premise
27	=	N	I-Premise
28	-1.91	N	I-Premise
29	;	N	I-Premise
30	95	N	I-Premise
31	%	N	I-Premise
32	CI	N	I-Premise
33	=	N	I-Premise
34	-4.61	N	I-Premise
35	,	N	I-Premise
36	0.78	N	I-Premise
37	)	N	I-Premise
38	,	N	I-Premise
39	BRBS	N	I-Premise
40	(	N	I-Premise
41	LSM	N	I-Premise
42	difference	N	I-Premise
43	=	N	I-Premise
44	-0.18	N	I-Premise
45	;	N	I-Premise
46	95	N	I-Premise
47	%	N	I-Premise
48	CI	N	I-Premise
49	=	N	I-Premise
50	-1.98	N	I-Premise
51	,	N	I-Premise
52	1.62	N	I-Premise
53	)	N	I-Premise
54	,	N	I-Premise
55	or	N	I-Premise
56	BRAS	N	I-Premise
57	(	N	I-Premise
58	LSM	N	I-Premise
59	difference	N	I-Premise
60	=	N	I-Premise
61	-0.42	N	I-Premise
62	;	N	I-Premise
63	95	N	I-Premise
64	%	N	I-Premise
65	CI	N	I-Premise
66	=	N	I-Premise
67	-2.94	N	I-Premise
68	,	N	I-Premise
69	2.10	N	I-Premise
70	)	N	I-Premise
71	.	N	I-Premise

1	Based	N	O
2	on	N	O
3	pattern-mixture	N	O
4	models	N	O
5	,	N	O
6	patients	N	O
7	who	N	O
8	dropped	N	O
9	out	N	O
10	early	N	O
11	had	N	O
12	worse	N	O
13	QL2	N	O
14	decline	N	O
15	on	N	O
16	both	N	O
17	treatments	N	O
18	.	N	O

1	In	N	I-Premise
2	the	N	I-Premise
3	expanded	N	I-Premise
4	pattern-mixture	N	I-Premise
5	model	N	I-Premise
6	,	N	I-Premise
7	EVE	N	I-Premise
8	+	N	I-Premise
9	EXE-treated	N	I-Premise
10	patients	N	I-Premise
11	who	N	I-Premise
12	did	N	I-Premise
13	not	N	I-Premise
14	drop	N	I-Premise
15	out	N	I-Premise
16	early	N	I-Premise
17	had	N	I-Premise
18	stable	N	I-Premise
19	BRBS	N	I-Premise
20	and	N	I-Premise
21	BRAS	N	I-Premise
22	relative	N	I-Premise
23	to	N	I-Premise
24	PBO	N	I-Premise
25	+	N	I-Premise
26	EXE	N	I-Premise
27	.	N	I-Premise

1	HRQOL	N	O
2	data	N	O
3	were	N	O
4	not	N	O
5	collected	N	O
6	after	N	O
7	disease	N	O
8	progression	N	O
9	.	N	O

1	These	N	I-Claim
2	analyses	N	I-Claim
3	confirm	N	I-Claim
4	that	N	I-Claim
5	EVE	N	I-Claim
6	+	N	I-Claim
7	EXE	N	I-Claim
8	provides	N	I-Claim
9	clinical	N	I-Claim
10	benefit	N	I-Claim
11	without	N	I-Claim
12	adversely	N	I-Claim
13	impacting	N	I-Claim
14	HRQOL	N	I-Claim
15	in	N	I-Claim
16	patients	N	I-Claim
17	with	N	I-Claim
18	HR	N	I-Claim
19	(	N	I-Claim
20	+	N	I-Claim
21	)	N	I-Claim
22	ABC	N	I-Claim
23	who	N	I-Claim
24	recurred/progressed	N	I-Claim
25	on	N	I-Claim
26	prior	N	I-Claim
27	NSAIs	N	I-Claim
28	versus	N	I-Claim
29	endocrine	N	I-Claim
30	therapy	N	I-Claim
31	alone	N	I-Claim
32	.	N	I-Claim

1	Care	N	O
2	closer	N	O
3	to	N	O
4	home	N	O
5	is	N	O
6	being	N	O
7	explored	N	O
8	as	N	O
9	a	N	O
10	means	N	O
11	of	N	O
12	improving	N	O
13	patient	N	O
14	experience	N	O
15	as	N	O
16	well	N	O
17	as	N	O
18	efficiency	N	O
19	in	N	O
20	terms	N	O
21	of	N	O
22	cost	N	O
23	savings	N	O
24	.	N	O

1	Evidence	N	O
2	that	N	O
3	community	N	O
4	cancer	N	O
5	services	N	O
6	improve	N	O
7	care	N	O
8	quality	N	O
9	and/or	N	O
10	generate	N	O
11	cost	N	O
12	savings	N	O
13	is	N	O
14	currently	N	O
15	limited	N	O
16	.	N	O

1	A	N	O
2	randomised	N	O
3	study	N	O
4	was	N	O
5	undertaken	N	O
6	to	N	O
7	compare	N	O
8	delivery	N	O
9	of	N	O
10	cancer	N	O
11	treatment	N	O
12	in	N	O
13	the	N	O
14	hospital	N	O
15	with	N	O
16	two	N	O
17	different	N	O
18	community	N	O
19	settings	N	O
20	.	N	O

1	Ninety-seven	N	O
2	patients	N	O
3	being	N	O
4	offered	N	O
5	outpatient-based	N	O
6	cancer	N	O
7	treatment	N	O
8	were	N	O
9	randomised	N	O
10	to	N	O
11	treatment	N	O
12	delivered	N	O
13	in	N	O
14	a	N	O
15	hospital	N	O
16	day	N	O
17	unit	N	O
18	,	N	O
19	at	N	O
20	the	N	O
21	patient	N	O
22	's	N	O
23	home	N	O
24	or	N	O
25	in	N	O
26	local	N	O
27	general	N	O
28	practice	N	O
29	(	N	O
30	GP	N	O
31	)	N	O
32	surgeries	N	O
33	.	N	O

1	The	N	O
2	primary	N	O
3	outcome	N	O
4	was	N	O
5	patient-perceived	N	O
6	benefits	N	O
7	,	N	O
8	using	N	O
9	the	N	O
10	emotional	N	O
11	function	N	O
12	domain	N	O
13	of	N	O
14	the	N	O
15	EORTC	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	(	N	O
20	QOL	N	O
21	)	N	O
22	QLQC30	N	O
23	questionnaire	N	O
24	evaluated	N	O
25	after	N	O
26	12	N	O
27	weeks	N	O
28	.	N	O

1	Secondary	N	O
2	outcomes	N	O
3	included	N	O
4	additional	N	O
5	QOL	N	O
6	measures	N	O
7	,	N	O
8	patient	N	O
9	satisfaction	N	O
10	,	N	O
11	safety	N	O
12	and	N	O
13	health	N	O
14	economics	N	O
15	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	QOL	N	I-Premise
7	difference	N	I-Premise
8	between	N	I-Premise
9	treatment	N	I-Premise
10	in	N	I-Premise
11	the	N	I-Premise
12	combined	N	I-Premise
13	community	N	I-Premise
14	locations	N	I-Premise
15	relative	N	I-Premise
16	to	N	I-Premise
17	hospital	N	I-Premise
18	(	N	I-Premise
19	difference	N	I-Premise
20	of	N	I-Premise
21	-7.2	N	I-Premise
22	,	N	I-Premise
23	95	N	I-Premise
24	%	N	I-Premise
25	confidence	N	I-Premise
26	interval	N	I-Premise
27	:	N	I-Premise
28	-19·5	N	I-Premise
29	to	N	I-Premise
30	+5·2	N	I-Premise
31	,	N	I-Premise
32	P=0.25	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	difference	N	I-Premise
6	between	N	I-Premise
7	the	N	I-Premise
8	two	N	I-Premise
9	community	N	I-Premise
10	locations	N	I-Premise
11	in	N	I-Premise
12	favour	N	I-Premise
13	of	N	I-Premise
14	home	N	I-Premise
15	(	N	I-Premise
16	+15·2	N	I-Premise
17	,	N	I-Premise
18	1·3	N	I-Premise
19	to	N	I-Premise
20	29·1	N	I-Premise
21	,	N	I-Premise
22	P=0.033	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	Hospital	N	O
2	anxiety	N	O
3	and	N	O
4	depression	N	O
5	scale	N	O
6	scores	N	O
7	were	N	O
8	consistent	N	O
9	with	N	O
10	the	N	O
11	primary	N	O
12	outcome	N	O
13	measure	N	O
14	.	N	O

1	There	N	I-Premise
2	was	N	I-Premise
3	no	N	I-Premise
4	evidence	N	I-Premise
5	that	N	I-Premise
6	community	N	I-Premise
7	treatment	N	I-Premise
8	compromised	N	I-Premise
9	patient	N	I-Premise
10	safety	N	I-Premise
11	and	N	O
12	no	N	I-Premise
13	significant	N	I-Premise
14	difference	N	I-Premise
15	between	N	I-Premise
16	treatment	N	I-Premise
17	arms	N	I-Premise
18	in	N	I-Premise
19	terms	N	I-Premise
20	of	N	I-Premise
21	overall	N	I-Premise
22	costs	N	I-Premise
23	or	N	I-Premise
24	Quality	N	I-Premise
25	Adjusted	N	I-Premise
26	Life	N	I-Premise
27	Year	N	I-Premise
28	.	N	I-Premise

1	Seventy-eight	N	I-Premise
2	percent	N	I-Premise
3	of	N	I-Premise
4	patients	N	I-Premise
5	expressed	N	I-Premise
6	satisfaction	N	I-Premise
7	with	N	I-Premise
8	their	N	I-Premise
9	treatment	N	I-Premise
10	whatever	N	I-Premise
11	their	N	I-Premise
12	location	N	I-Premise
13	,	N	I-Premise
14	whereas	N	I-Premise
15	57	N	I-Premise
16	%	N	I-Premise
17	of	N	I-Premise
18	patients	N	I-Premise
19	preferred	N	I-Premise
20	future	N	I-Premise
21	treatment	N	I-Premise
22	to	N	I-Premise
23	continue	N	I-Premise
24	at	N	I-Premise
25	the	N	I-Premise
26	hospital	N	I-Premise
27	,	N	I-Premise
28	81	N	I-Premise
29	%	N	I-Premise
30	at	N	I-Premise
31	GP	N	I-Premise
32	surgeries	N	I-Premise
33	and	N	I-Premise
34	90	N	I-Premise
35	%	N	I-Premise
36	at	N	I-Premise
37	home	N	I-Premise
38	.	N	I-Premise

1	Although	N	O
2	initial	N	O
3	pre-trial	N	O
4	interviews	N	O
5	revealed	N	O
6	concerns	N	O
7	among	N	O
8	health-care	N	O
9	professionals	N	O
10	and	N	O
11	some	N	O
12	patients	N	O
13	regarding	N	O
14	community	N	O
15	treatment	N	O
16	,	N	O
17	opinions	N	O
18	were	N	O
19	largely	N	O
20	more	N	O
21	favourable	N	O
22	in	N	O
23	post-trial	N	O
24	interviews	N	O
25	.	N	O

1	Patient	N	I-Claim
2	QOL	N	I-Claim
3	favours	N	I-Claim
4	delivering	N	I-Claim
5	cancer	N	I-Claim
6	treatment	N	I-Claim
7	in	N	I-Claim
8	the	N	I-Claim
9	home	N	I-Claim
10	rather	N	I-Claim
11	than	N	I-Claim
12	GP	N	I-Claim
13	surgeries	N	I-Claim
14	.	N	I-Claim

1	Nevertheless	N	I-Claim
2	,	N	I-Claim
3	both	N	I-Claim
4	community	N	I-Claim
5	settings	N	I-Claim
6	were	N	I-Claim
7	acceptable	N	I-Claim
8	to	N	I-Claim
9	and	N	I-Claim
10	preferred	N	I-Claim
11	by	N	I-Claim
12	patients	N	I-Claim
13	compared	N	I-Claim
14	with	N	I-Claim
15	hospital	N	I-Claim
16	,	N	I-Claim
17	were	N	I-Claim
18	safe	N	I-Claim
19	,	N	I-Claim
20	with	N	I-Claim
21	no	N	I-Claim
22	detrimental	N	I-Claim
23	impact	N	I-Claim
24	on	N	I-Claim
25	overall	N	I-Claim
26	health-care	N	I-Claim
27	costs	N	I-Claim
28	.	N	I-Claim

1	The	N	O
2	optimal	N	O
3	duration	N	O
4	over	N	O
5	which	N	O
6	lung	N	O
7	SBRT	N	O
8	should	N	O
9	be	N	O
10	delivered	N	O
11	is	N	O
12	unknown	N	O
13	.	N	O

1	We	N	O
2	conducted	N	O
3	a	N	O
4	randomized	N	O
5	pilot	N	O
6	study	N	O
7	in	N	O
8	patients	N	O
9	treated	N	O
10	with	N	O
11	four	N	O
12	fractions	N	O
13	of	N	O
14	lung	N	O
15	SBRT	N	O
16	delivered	N	O
17	over	N	O
18	4	N	O
19	or	N	O
20	over	N	O
21	11	N	O
22	days	N	O
23	.	N	O

1	Patients	N	O
2	with	N	O
3	a	N	O
4	peripheral	N	O
5	solitary	N	O
6	lung	N	O
7	tumor	N	O
8	(	N	O
9	NSCLC	N	O
10	or	N	O
11	pulmonary	N	O
12	metastasis	N	O
13	)	N	O
14	≤	N	O
15	5	N	O
16	cm	N	O
17	were	N	O
18	eligible	N	O
19	.	N	O

1	For	N	O
2	NSCLC	N	O
3	lung	N	O
4	tumors	N	O
5	≤	N	O
6	3	N	O
7	cm	N	O
8	,	N	O
9	a	N	O
10	dose	N	O
11	of	N	O
12	48	N	O
13	Gy	N	O
14	in	N	O
15	4	N	O
16	fractions	N	O
17	was	N	O
18	used	N	O
19	,	N	O
20	otherwise	N	O
21	52	N	O
22	Gy	N	O
23	in	N	O
24	4	N	O
25	fractions	N	O
26	was	N	O
27	delivered	N	O
28	.	N	O

1	Patients	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	receive	N	O
6	treatment	N	O
7	over	N	O
8	4	N	O
9	consecutive	N	O
10	days	N	O
11	or	N	O
12	over	N	O
13	11	N	O
14	days	N	O
15	.	N	O

1	The	N	O
2	primary	N	O
3	end-point	N	O
4	was	N	O
5	acute	N	O
6	grade	N	O
7	≥	N	O
8	2	N	O
9	toxicity	N	O
10	.	N	O

1	Secondary	N	O
2	end-points	N	O
3	included	N	O
4	quality	N	O
5	of	N	O
6	life	N	O
7	(	N	O
8	QOL	N	O
9	)	N	O
10	assessed	N	O
11	using	N	O
12	the	N	O
13	EORTC	N	O
14	QLQ-C30	N	O
15	and	N	O
16	QLQ-LC13	N	O
17	questionnaires	N	O
18	.	N	O

1	Fifty	N	O
2	four	N	O
3	patients	N	O
4	were	N	O
5	enrolled	N	O
6	.	N	O

1	More	N	O
2	patients	N	O
3	in	N	O
4	the	N	O
5	11	N	O
6	day	N	O
7	group	N	O
8	had	N	O
9	respiratory	N	O
10	symptoms	N	O
11	at	N	O
12	baseline	N	O
13	.	N	O

1	55.6	N	I-Premise
2	%	N	I-Premise
3	patients	N	I-Premise
4	treated	N	I-Premise
5	over	N	I-Premise
6	4	N	I-Premise
7	days	N	I-Premise
8	and	N	I-Premise
9	33.3	N	I-Premise
10	%	N	I-Premise
11	of	N	I-Premise
12	patients	N	I-Premise
13	treated	N	I-Premise
14	over	N	I-Premise
15	11	N	I-Premise
16	days	N	I-Premise
17	experienced	N	I-Premise
18	acute	N	I-Premise
19	grade	N	I-Premise
20	≥	N	I-Premise
21	2	N	I-Premise
22	toxicity	N	I-Premise
23	(	N	I-Premise
24	p=0.085	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	Dyspnea	N	I-Premise
2	,	N	I-Premise
3	fatigue	N	I-Premise
4	and	N	I-Premise
5	coughing	N	I-Premise
6	domains	N	I-Premise
7	were	N	I-Premise
8	worse	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	11	N	I-Premise
12	day	N	I-Premise
13	group	N	I-Premise
14	at	N	I-Premise
15	baseline	N	I-Premise
16	.	N	I-Premise

1	At	N	I-Premise
2	1	N	I-Premise
3	and	N	I-Premise
4	4	N	I-Premise
5	months	N	I-Premise
6	,	N	I-Premise
7	more	N	I-Premise
8	patients	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	4	N	I-Premise
12	day	N	I-Premise
13	group	N	I-Premise
14	experienced	N	I-Premise
15	a	N	I-Premise
16	clinically	N	I-Premise
17	meaningful	N	I-Premise
18	worsening	N	I-Premise
19	in	N	I-Premise
20	the	N	I-Premise
21	dyspnea	N	I-Premise
22	QOL	N	I-Premise
23	domain	N	I-Premise
24	compared	N	I-Premise
25	to	N	I-Premise
26	the	N	I-Premise
27	11	N	I-Premise
28	day	N	I-Premise
29	group	N	I-Premise
30	(	N	I-Premise
31	44.5	N	I-Premise
32	%	N	I-Premise
33	vs	N	I-Premise
34	15.4	N	I-Premise
35	%	N	I-Premise
36	,	N	I-Premise
37	p=0.02	N	I-Premise
38	;	N	I-Premise
39	38.5	N	I-Premise
40	%	N	I-Premise
41	vs	N	I-Premise
42	12.0	N	I-Premise
43	%	N	I-Premise
44	,	N	I-Premise
45	p=0.03	N	I-Premise
46	,	N	I-Premise
47	respectively	N	I-Premise
48	)	N	I-Premise
49	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	raw	N	I-Premise
4	QOL	N	I-Premise
5	scores	N	I-Premise
6	were	N	I-Premise
7	not	N	I-Premise
8	different	N	I-Premise
9	at	N	I-Premise
10	these	N	I-Premise
11	time-points	N	I-Premise
12	between	N	I-Premise
13	treatment	N	I-Premise
14	groups	N	I-Premise
15	.	N	I-Premise

1	Grade	N	I-Claim
2	2	N	I-Claim
3	or	N	I-Claim
4	higher	N	I-Claim
5	acute	N	I-Claim
6	toxicity	N	I-Claim
7	was	N	I-Claim
8	more	N	I-Claim
9	common	N	I-Claim
10	in	N	I-Claim
11	the	N	I-Claim
12	4	N	I-Claim
13	day	N	I-Claim
14	group	N	I-Claim
15	,	N	I-Claim
16	approaching	N	I-Claim
17	statistical	N	I-Claim
18	significance	N	I-Claim
19	.	N	I-Claim

1	More	N	I-Claim
2	patients	N	I-Claim
3	treated	N	I-Claim
4	on	N	I-Claim
5	4	N	I-Claim
6	consecutive	N	I-Claim
7	days	N	I-Claim
8	reported	N	I-Claim
9	a	N	I-Claim
10	clinically	N	I-Claim
11	meaningful	N	I-Claim
12	increase	N	I-Claim
13	in	N	I-Claim
14	dyspnea	N	I-Claim
15	,	N	I-Claim
16	although	N	I-Claim
17	interpretation	N	I-Claim
18	of	N	I-Claim
19	these	N	I-Claim
20	results	N	I-Claim
21	is	N	I-Claim
22	challenging	N	I-Claim
23	due	N	I-Claim
24	to	N	I-Claim
25	baseline	N	I-Claim
26	imbalance	N	I-Claim
27	between	N	I-Claim
28	treatment	N	I-Claim
29	groups	N	I-Claim
30	.	N	I-Claim

1	Larger	N	I-Claim
2	studies	N	I-Claim
3	are	N	I-Claim
4	required	N	I-Claim
5	to	N	I-Claim
6	validate	N	I-Claim
7	these	N	I-Claim
8	results	N	I-Claim
9	.	N	I-Claim

1	Patients	N	O
2	experience	N	O
3	reductions	N	O
4	in	N	O
5	quality	N	O
6	of	N	O
7	life	N	O
8	(	N	O
9	QOL	N	O
10	)	N	O
11	while	N	O
12	receiving	N	O
13	cancer	N	O
14	treatment	N	O
15	and	N	O
16	several	N	O
17	approaches	N	O
18	have	N	O
19	been	N	O
20	proposed	N	O
21	to	N	O
22	address	N	O
23	QOL	N	O
24	issues	N	O
25	.	N	O

1	In	N	O
2	this	N	O
3	project	N	O
4	,	N	O
5	the	N	O
6	QOL	N	O
7	differences	N	O
8	between	N	O
9	older	N	O
10	adult	N	O
11	(	N	O
12	age	N	O
13	65+	N	O
14	)	N	O
15	and	N	O
16	younger	N	O
17	adult	N	O
18	(	N	O
19	age	N	O
20	18-64	N	O
21	)	N	O
22	advanced	N	O
23	cancer	N	O
24	patients	N	O
25	in	N	O
26	response	N	O
27	to	N	O
28	a	N	O
29	multidisciplinary	N	O
30	intervention	N	O
31	designed	N	O
32	to	N	O
33	improve	N	O
34	QOL	N	O
35	were	N	O
36	examined	N	O
37	.	N	O

1	This	N	O
2	study	N	O
3	was	N	O
4	registered	N	O
5	on	N	O
6	ClinicalTrials.gov	N	O
7	.	N	O

1	Newly	N	O
2	diagnosed	N	O
3	advanced	N	O
4	cancer	N	O
5	patients	N	O
6	undergoing	N	O
7	radiation	N	O
8	therapy	N	O
9	were	N	O
10	randomized	N	O
11	to	N	O
12	active	N	O
13	QOL	N	O
14	intervention	N	O
15	or	N	O
16	control	N	O
17	groups	N	O
18	.	N	O

1	Those	N	O
2	in	N	O
3	the	N	O
4	intervention	N	O
5	group	N	O
6	received	N	O
7	six	N	O
8	multidisciplinary	N	O
9	90-minute	N	O
10	sessions	N	O
11	designed	N	O
12	to	N	O
13	address	N	O
14	the	N	O
15	five	N	O
16	major	N	O
17	domains	N	O
18	of	N	O
19	QOL	N	O
20	.	N	O

1	Outcomes	N	O
2	measured	N	O
3	at	N	O
4	baseline	N	O
5	and	N	O
6	weeks	N	O
7	4	N	O
8	,	N	O
9	27	N	O
10	,	N	O
11	and	N	O
12	52	N	O
13	included	N	O
14	QOL	N	O
15	(	N	O
16	Linear	N	O
17	Analogue	N	O
18	Self-Assessment	N	O
19	(	N	O
20	LASA	N	O
21	)	N	O
22	,	N	O
23	Functional	N	O
24	Assessment	N	O
25	of	N	O
26	Cancer	N	O
27	Therapy-General	N	O
28	(	N	O
29	FACT-G	N	O
30	)	N	O
31	)	N	O
32	and	N	O
33	mood	N	O
34	(	N	O
35	Profile	N	O
36	of	N	O
37	Mood	N	O
38	States	N	O
39	(	N	O
40	POMS	N	O
41	)	N	O
42	)	N	O
43	.	N	O

1	Kruskall-Wallis	N	O
2	methodology	N	O
3	was	N	O
4	used	N	O
5	to	N	O
6	compare	N	O
7	scores	N	O
8	between	N	O
9	older	N	O
10	and	N	O
11	younger	N	O
12	adult	N	O
13	patients	N	O
14	randomized	N	O
15	to	N	O
16	the	N	O
17	intervention	N	O
18	.	N	O

1	Of	N	O
2	131	N	O
3	patients	N	O
4	in	N	O
5	the	N	O
6	larger	N	O
7	randomized	N	O
8	controlled	N	O
9	study	N	O
10	,	N	O
11	we	N	O
12	report	N	O
13	data	N	O
14	on	N	O
15	54	N	O
16	evaluable	N	O
17	patients	N	O
18	(	N	O
19	16	N	O
20	older	N	O
21	adults	N	O
22	and	N	O
23	38	N	O
24	younger	N	O
25	adults	N	O
26	)	N	O
27	randomized	N	O
28	to	N	O
29	the	N	O
30	intervention	N	O
31	.	N	O

1	Older	N	I-Premise
2	adult	N	I-Premise
3	patients	N	I-Premise
4	reported	N	I-Premise
5	better	N	I-Premise
6	overall	N	I-Premise
7	QOL	N	I-Premise
8	(	N	I-Premise
9	LASA	N	I-Premise
10	74.4	N	I-Premise
11	vs.	N	I-Premise
12	62.9	N	I-Premise
13	,	N	I-Premise
14	p	N	I-Premise
15	=	N	I-Premise
16	0.040	N	I-Premise
17	)	N	I-Premise
18	,	N	I-Premise
19	higher	N	I-Premise
20	social	N	I-Premise
21	well-being	N	I-Premise
22	(	N	I-Premise
23	FACT-G	N	I-Premise
24	91.1	N	I-Premise
25	vs.	N	I-Premise
26	83.3	N	I-Premise
27	,	N	I-Premise
28	p	N	I-Premise
29	=	N	I-Premise
30	0.045	N	I-Premise
31	)	N	I-Premise
32	,	N	I-Premise
33	and	N	I-Premise
34	fewer	N	I-Premise
35	problems	N	I-Premise
36	with	N	I-Premise
37	anger	N	I-Premise
38	(	N	I-Premise
39	POMS	N	I-Premise
40	anger-hostility	N	I-Premise
41	95.0	N	I-Premise
42	vs.	N	I-Premise
43	86.4	N	I-Premise
44	,	N	I-Premise
45	p	N	I-Premise
46	=	N	I-Premise
47	0.028	N	I-Premise
48	)	N	I-Premise
49	.	N	I-Premise

1	Long-term	N	I-Premise
2	benefits	N	I-Premise
3	for	N	I-Premise
4	older	N	I-Premise
5	patients	N	I-Premise
6	were	N	I-Premise
7	seen	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	anger-hostility	N	I-Premise
11	scale	N	I-Premise
12	at	N	I-Premise
13	week	N	I-Premise
14	27	N	I-Premise
15	(	N	I-Premise
16	92.2	N	I-Premise
17	vs.	N	I-Premise
18	84.2	N	I-Premise
19	,	N	I-Premise
20	p	N	I-Premise
21	=	N	I-Premise
22	0.027	N	I-Premise
23	)	N	I-Premise
24	and	N	I-Premise
25	week	N	I-Premise
26	52	N	I-Premise
27	(	N	I-Premise
28	96.3	N	I-Premise
29	vs.	N	I-Premise
30	85.9	N	I-Premise
31	,	N	I-Premise
32	p	N	I-Premise
33	=	N	I-Premise
34	0.005	N	I-Premise
35	)	N	I-Premise
36	.	N	I-Premise

1	Older	N	I-Claim
2	adult	N	I-Claim
3	patients	N	I-Claim
4	who	N	I-Claim
5	received	N	I-Claim
6	a	N	I-Claim
7	multidisciplinary	N	I-Claim
8	intervention	N	I-Claim
9	to	N	I-Claim
10	improve	N	I-Claim
11	QOL	N	I-Claim
12	while	N	I-Claim
13	undergoing	N	I-Claim
14	advanced	N	I-Claim
15	cancer	N	I-Claim
16	treatments	N	I-Claim
17	benefited	N	I-Claim
18	differently	N	I-Claim
19	in	N	I-Claim
20	some	N	I-Claim
21	QOL	N	I-Claim
22	domains	N	I-Claim
23	,	N	I-Claim
24	compared	N	I-Claim
25	to	N	I-Claim
26	younger	N	I-Claim
27	adult	N	I-Claim
28	patients	N	I-Claim
29	.	N	I-Claim

1	Future	N	O
2	studies	N	O
3	can	N	O
4	provide	N	O
5	further	N	O
6	insight	N	O
7	on	N	O
8	how	N	O
9	to	N	O
10	tailor	N	O
11	QOL	N	O
12	interventions	N	O
13	for	N	O
14	these	N	O
15	age	N	O
16	groups	N	O
17	.	N	O

1	Chronic	N	O
2	gastrointestinal	N	O
3	symptoms	N	O
4	after	N	O
5	pelvic	N	O
6	radiotherapy	N	O
7	are	N	O
8	common	N	O
9	,	N	O
10	multifactorial	N	O
11	in	N	O
12	cause	N	O
13	,	N	O
14	and	N	O
15	affect	N	O
16	patients	N	O
17	'	N	O
18	quality	N	O
19	of	N	O
20	life	N	O
21	.	N	O

1	We	N	O
2	assessed	N	O
3	whether	N	O
4	such	N	O
5	patients	N	O
6	could	N	O
7	be	N	O
8	helped	N	O
9	if	N	O
10	a	N	O
11	practitioner	N	O
12	followed	N	O
13	an	N	O
14	investigative	N	O
15	and	N	O
16	management	N	O
17	algorithm	N	O
18	,	N	O
19	and	N	O
20	whether	N	O
21	outcomes	N	O
22	differed	N	O
23	by	N	O
24	whether	N	O
25	a	N	O
26	nurse	N	O
27	or	N	O
28	a	N	O
29	gastroenterologist	N	O
30	led	N	O
31	this	N	O
32	algorithm-based	N	O
33	care	N	O
34	.	N	O

1	For	N	O
2	this	N	O
3	three-arm	N	O
4	randomised	N	O
5	controlled	N	O
6	trial	N	O
7	we	N	O
8	recruited	N	O
9	patients	N	O
10	(	N	O
11	aged	N	O
12	≥18	N	O
13	years	N	O
14	)	N	O
15	from	N	O
16	clinics	N	O
17	in	N	O
18	London	N	O
19	,	N	O
20	UK	N	O
21	,	N	O
22	with	N	O
23	new-onset	N	O
24	gastrointestinal	N	O
25	symptoms	N	O
26	persisting	N	O
27	6	N	O
28	months	N	O
29	after	N	O
30	pelvic	N	O
31	radiotherapy	N	O
32	.	N	O

1	Using	N	O
2	a	N	O
3	computer-generated	N	O
4	randomisation	N	O
5	sequence	N	O
6	,	N	O
7	we	N	O
8	randomly	N	O
9	allocated	N	O
10	patients	N	O
11	to	N	O
12	one	N	O
13	of	N	O
14	three	N	O
15	groups	N	O
16	(	N	O
17	1:1:1	N	O
18	;	N	O
19	stratified	N	O
20	by	N	O
21	tumour	N	O
22	site	N	O
23	[	N	O
24	urological	N	O
25	,	N	O
26	gynaecological	N	O
27	,	N	O
28	or	N	O
29	gastrointestinal	N	O
30	]	N	O
31	,	N	O
32	and	N	O
33	degree	N	O
34	of	N	O
35	bowel	N	O
36	dysfunction	N	O
37	[	N	O
38	IBDQ-B	N	O
39	score	N	O
40	<	N	O
41	60	N	O
42	vs	N	O
43	60-70	N	O
44	]	N	O
45	)	N	O
46	:	N	O
47	usual	N	O
48	care	N	O
49	(	N	O
50	a	N	O
51	detailed	N	O
52	self-help	N	O
53	booklet	N	O
54	)	N	O
55	,	N	O
56	gastroenterologist-led	N	O
57	algorithm-based	N	O
58	treatment	N	O
59	,	N	O
60	or	N	O
61	nurse-led	N	O
62	algorithm-based	N	O
63	treatment	N	O
64	.	N	O

1	The	N	O
2	primary	N	O
3	endpoint	N	O
4	was	N	O
5	change	N	O
6	in	N	O
7	Inflammatory	N	O
8	Bowel	N	O
9	Disease	N	O
10	Questionnaire-Bowel	N	O
11	subset	N	O
12	score	N	O
13	(	N	O
14	IBDQ-B	N	O
15	)	N	O
16	at	N	O
17	6	N	O
18	months	N	O
19	,	N	O
20	analysed	N	O
21	by	N	O
22	intention	N	O
23	to	N	O
24	treat	N	O
25	.	N	O

1	Between	N	O
2	Nov	N	O
3	26	N	O
4	,	N	O
5	2007	N	O
6	,	N	O
7	and	N	O
8	Dec	N	O
9	12	N	O
10	,	N	O
11	2011	N	O
12	,	N	O
13	we	N	O
14	enrolled	N	O
15	and	N	O
16	randomly	N	O
17	allocated	N	O
18	218	N	O
19	patients	N	O
20	to	N	O
21	treatment	N	O
22	:	N	O
23	80	N	O
24	to	N	O
25	the	N	O
26	nurse	N	O
27	group	N	O
28	,	N	O
29	70	N	O
30	to	N	O
31	the	N	O
32	gastroenterologist	N	O
33	group	N	O
34	,	N	O
35	and	N	O
36	68	N	O
37	to	N	O
38	the	N	O
39	booklet	N	O
40	group	N	O
41	(	N	O
42	figure	N	O
43	)	N	O
44	.	N	O

1	Most	N	O
2	had	N	O
3	a	N	O
4	baseline	N	O
5	IBDQ-B	N	O
6	score	N	O
7	indicating	N	O
8	moderate-to-severe	N	O
9	symptoms	N	O
10	.	N	O

1	We	N	I-Premise
2	recorded	N	I-Premise
3	the	N	I-Premise
4	following	N	I-Premise
5	pair-wise	N	I-Premise
6	mean	N	I-Premise
7	difference	N	I-Premise
8	in	N	I-Premise
9	change	N	I-Premise
10	in	N	I-Premise
11	IBDQ-B	N	I-Premise
12	score	N	I-Premise
13	between	N	I-Premise
14	groups	N	I-Premise
15	:	N	I-Premise
16	nurse	N	I-Premise
17	versus	N	I-Premise
18	booklet	N	I-Premise
19	4·12	N	I-Premise
20	(	N	I-Premise
21	95	N	I-Premise
22	%	N	I-Premise
23	CI	N	I-Premise
24	0·04-8·19	N	I-Premise
25	;	N	I-Premise
26	p=0·04	N	I-Premise
27	)	N	I-Premise
28	,	N	I-Premise
29	gastroenterologist	N	I-Premise
30	versus	N	I-Premise
31	booklet	N	I-Premise
32	5·47	N	I-Premise
33	(	N	I-Premise
34	1·14-9·81	N	I-Premise
35	;	N	I-Premise
36	p=0·01	N	I-Premise
37	)	N	I-Premise
38	.	N	I-Premise

1	Outcomes	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	nurse	N	I-Premise
5	group	N	I-Premise
6	were	N	I-Premise
7	not	N	I-Premise
8	inferior	N	I-Premise
9	to	N	I-Premise
10	outcomes	N	I-Premise
11	in	N	I-Premise
12	the	N	I-Premise
13	gastroenterologist	N	I-Premise
14	group	N	I-Premise
15	(	N	I-Premise
16	mean	N	I-Premise
17	difference	N	I-Premise
18	1·36	N	I-Premise
19	,	N	I-Premise
20	one	N	I-Premise
21	sided	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	-1·48	N	I-Premise
26	)	N	I-Premise
27	.	N	I-Premise

1	Patients	N	I-Claim
2	given	N	I-Claim
3	targeted	N	I-Claim
4	intervention	N	I-Claim
5	following	N	I-Claim
6	a	N	I-Claim
7	detailed	N	I-Claim
8	clinical	N	I-Claim
9	algorithm	N	I-Claim
10	had	N	I-Claim
11	better	N	I-Claim
12	improvements	N	I-Claim
13	in	N	I-Claim
14	radiotherapy-induced	N	I-Claim
15	gastrointestinal	N	I-Claim
16	symptoms	N	I-Claim
17	than	N	I-Claim
18	did	N	I-Claim
19	patients	N	I-Claim
20	given	N	I-Claim
21	usual	N	I-Claim
22	care	N	I-Claim
23	.	N	I-Claim

1	Our	N	I-Claim
2	findings	N	I-Claim
3	suggest	N	I-Claim
4	that	N	I-Claim
5	,	N	I-Claim
6	for	N	I-Claim
7	most	N	I-Claim
8	patients	N	I-Claim
9	,	N	I-Claim
10	this	N	I-Claim
11	algorithm-based	N	I-Claim
12	care	N	I-Claim
13	can	N	I-Claim
14	be	N	I-Claim
15	given	N	I-Claim
16	by	N	I-Claim
17	a	N	I-Claim
18	trained	N	I-Claim
19	nurse	N	I-Claim
20	.	N	I-Claim

1	Abiraterone	N	I-Claim
2	acetate	N	I-Claim
3	plus	N	I-Claim
4	prednisone	N	I-Claim
5	significantly	N	I-Claim
6	improves	N	I-Claim
7	radiographic	N	I-Claim
8	progression-free	N	I-Claim
9	survival	N	I-Claim
10	in	N	I-Claim
11	asymptomatic	N	I-Claim
12	or	N	I-Claim
13	mildly	N	I-Claim
14	symptomatic	N	I-Claim
15	,	N	I-Claim
16	chemotherapy-naive	N	I-Claim
17	patients	N	I-Claim
18	with	N	I-Claim
19	metastatic	N	I-Claim
20	castration-resistant	N	I-Claim
21	prostate	N	I-Claim
22	cancer	N	I-Claim
23	compared	N	I-Claim
24	with	N	I-Claim
25	prednisone	N	I-Claim
26	alone	N	I-Claim
27	.	N	I-Claim

1	We	N	O
2	describe	N	O
3	analyses	N	O
4	of	N	O
5	data	N	O
6	for	N	O
7	patient-reported	N	O
8	pain	N	O
9	and	N	O
10	functional	N	O
11	status	N	O
12	in	N	O
13	a	N	O
14	preplanned	N	O
15	interim	N	O
16	analysis	N	O
17	of	N	O
18	a	N	O
19	phase	N	O
20	3	N	O
21	trial	N	O
22	.	N	O

1	Between	N	O
2	April	N	O
3	28	N	O
4	,	N	O
5	2009	N	O
6	,	N	O
7	and	N	O
8	June	N	O
9	23	N	O
10	,	N	O
11	2010	N	O
12	,	N	O
13	patients	N	O
14	with	N	O
15	progressive	N	O
16	,	N	O
17	metastatic	N	O
18	castration-resistant	N	O
19	prostate	N	O
20	cancer	N	O
21	were	N	O
22	enrolled	N	O
23	into	N	O
24	a	N	O
25	multinational	N	O
26	,	N	O
27	double-blind	N	O
28	,	N	O
29	placebo-controlled	N	O
30	trial	N	O
31	.	N	O

1	Patients	N	O
2	were	N	O
3	eligible	N	O
4	if	N	O
5	they	N	O
6	were	N	O
7	asymptomatic	N	O
8	(	N	O
9	score	N	O
10	of	N	O
11	0	N	O
12	or	N	O
13	1	N	O
14	on	N	O
15	item	N	O
16	three	N	O
17	of	N	O
18	the	N	O
19	Brief	N	O
20	Pain	N	O
21	Inventory	N	O
22	Short	N	O
23	Form	N	O
24	[	N	O
25	BPI-SF	N	O
26	]	N	O
27	questionnaire	N	O
28	)	N	O
29	or	N	O
30	mildly	N	O
31	symptomatic	N	O
32	(	N	O
33	score	N	O
34	of	N	O
35	2	N	O
36	or	N	O
37	3	N	O
38	)	N	O
39	and	N	O
40	had	N	O
41	not	N	O
42	previously	N	O
43	received	N	O
44	chemotherapy	N	O
45	.	N	O

1	Patients	N	O
2	were	N	O
3	randomly	N	O
4	assigned	N	O
5	(	N	O
6	1:1	N	O
7	)	N	O
8	to	N	O
9	receive	N	O
10	oral	N	O
11	abiraterone	N	O
12	(	N	O
13	1	N	O
14	g	N	O
15	daily	N	O
16	)	N	O
17	plus	N	O
18	prednisone	N	O
19	(	N	O
20	5	N	O
21	mg	N	O
22	twice	N	O
23	daily	N	O
24	)	N	O
25	or	N	O
26	placebo	N	O
27	plus	N	O
28	prednisone	N	O
29	in	N	O
30	continuous	N	O
31	4-week	N	O
32	cycles	N	O
33	.	N	O

1	Pain	N	O
2	was	N	O
3	assessed	N	O
4	with	N	O
5	the	N	O
6	BPI-SF	N	O
7	questionnaire	N	O
8	,	N	O
9	and	N	O
10	health-related	N	O
11	quality	N	O
12	of	N	O
13	life	N	O
14	(	N	O
15	HRQoL	N	O
16	)	N	O
17	with	N	O
18	the	N	O
19	Functional	N	O
20	Assessment	N	O
21	of	N	O
22	Cancer	N	O
23	Therapy-Prostate	N	O
24	(	N	O
25	FACT-P	N	O
26	)	N	O
27	questionnaire	N	O
28	.	N	O

1	We	N	O
2	analysed	N	O
3	data	N	O
4	with	N	O
5	prespecified	N	O
6	criteria	N	O
7	for	N	O
8	clinically	N	O
9	meaningful	N	O
10	pain	N	O
11	progression	N	O
12	and	N	O
13	deterioration	N	O
14	in	N	O
15	HRQoL	N	O
16	.	N	O

1	All	N	O
2	patients	N	O
3	who	N	O
4	underwent	N	O
5	randomisation	N	O
6	were	N	O
7	included	N	O
8	in	N	O
9	analyses	N	O
10	.	N	O

1	1088	N	O
2	patients	N	O
3	underwent	N	O
4	randomisation	N	O
5	:	N	O
6	546	N	O
7	were	N	O
8	assigned	N	O
9	to	N	O
10	abiraterone	N	O
11	plus	N	O
12	prednisone	N	O
13	and	N	O
14	542	N	O
15	to	N	O
16	placebo	N	O
17	plus	N	O
18	prednisone	N	O
19	.	N	O

1	At	N	O
2	the	N	O
3	time	N	O
4	of	N	O
5	the	N	O
6	second	N	O
7	prespecified	N	O
8	interim	N	O
9	analysis	N	O
10	,	N	O
11	median	N	O
12	follow-up	N	O
13	was	N	O
14	22·2	N	O
15	months	N	O
16	(	N	O
17	IQR	N	O
18	20·2-24·8	N	O
19	)	N	O
20	.	N	O

1	Median	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	progression	N	I-Premise
5	of	N	I-Premise
6	mean	N	I-Premise
7	pain	N	I-Premise
8	intensity	N	I-Premise
9	was	N	I-Premise
10	longer	N	I-Premise
11	in	N	I-Premise
12	patients	N	I-Premise
13	assigned	N	I-Premise
14	to	N	I-Premise
15	abiraterone	N	I-Premise
16	plus	N	I-Premise
17	prednisone	N	I-Premise
18	(	N	I-Premise
19	26·7	N	I-Premise
20	months	N	I-Premise
21	[	N	I-Premise
22	95	N	I-Premise
23	%	N	I-Premise
24	CI	N	I-Premise
25	19·3-not	N	I-Premise
26	estimable	N	I-Premise
27	]	N	I-Premise
28	)	N	I-Premise
29	than	N	I-Premise
30	in	N	I-Premise
31	those	N	I-Premise
32	assigned	N	I-Premise
33	to	N	I-Premise
34	placebo	N	I-Premise
35	plus	N	I-Premise
36	prednisone	N	I-Premise
37	(	N	I-Premise
38	18·4	N	I-Premise
39	months	N	I-Premise
40	[	N	I-Premise
41	14·9-not	N	I-Premise
42	estimable	N	I-Premise
43	]	N	I-Premise
44	;	N	I-Premise
45	hazard	N	I-Premise
46	ratio	N	I-Premise
47	[	N	I-Premise
48	HR	N	I-Premise
49	]	N	I-Premise
50	0·82	N	I-Premise
51	,	N	I-Premise
52	95	N	I-Premise
53	%	N	I-Premise
54	CI	N	I-Premise
55	0·67-1·00	N	I-Premise
56	;	N	I-Premise
57	p=0·0490	N	I-Premise
58	)	N	I-Premise
59	,	N	I-Premise
60	as	N	I-Premise
61	was	N	I-Premise
62	median	N	I-Premise
63	time	N	I-Premise
64	to	N	I-Premise
65	progression	N	I-Premise
66	of	N	I-Premise
67	pain	N	I-Premise
68	interference	N	I-Premise
69	with	N	I-Premise
70	daily	N	I-Premise
71	activities	N	I-Premise
72	(	N	I-Premise
73	10·3	N	I-Premise
74	months	N	I-Premise
75	[	N	I-Premise
76	95	N	I-Premise
77	%	N	I-Premise
78	CI	N	I-Premise
79	9·3-13·0	N	I-Premise
80	]	N	I-Premise
81	vs	N	I-Premise
82	7·4	N	I-Premise
83	months	N	I-Premise
84	[	N	I-Premise
85	6·4-8·6	N	I-Premise
86	]	N	I-Premise
87	;	N	I-Premise
88	HR	N	I-Premise
89	0·79	N	I-Premise
90	,	N	I-Premise
91	95	N	I-Premise
92	%	N	I-Premise
93	CI	N	I-Premise
94	0·67-0·93	N	I-Premise
95	;	N	I-Premise
96	p=0·005	N	I-Premise
97	)	N	I-Premise
98	.	N	I-Premise

1	Median	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	progression	N	I-Premise
5	of	N	I-Premise
6	worst	N	I-Premise
7	pain	N	I-Premise
8	was	N	I-Premise
9	also	N	I-Premise
10	longer	N	I-Premise
11	with	N	I-Premise
12	abiraterone	N	I-Premise
13	plus	N	I-Premise
14	prednisone	N	I-Premise
15	(	N	I-Premise
16	26·7	N	I-Premise
17	months	N	I-Premise
18	[	N	I-Premise
19	95	N	I-Premise
20	%	N	I-Premise
21	CI	N	I-Premise
22	19·4-not	N	I-Premise
23	estimable	N	I-Premise
24	]	N	I-Premise
25	)	N	I-Premise
26	than	N	I-Premise
27	with	N	I-Premise
28	placebo	N	I-Premise
29	plus	N	I-Premise
30	prednisone	N	I-Premise
31	(	N	I-Premise
32	19·4	N	I-Premise
33	months	N	I-Premise
34	[	N	I-Premise
35	16·6-not	N	I-Premise
36	estimable	N	I-Premise
37	]	N	I-Premise
38	)	N	I-Premise
39	,	N	I-Premise
40	but	N	I-Premise
41	the	N	I-Premise
42	difference	N	I-Premise
43	was	N	I-Premise
44	not	N	I-Premise
45	significant	N	I-Premise
46	(	N	I-Premise
47	HR	N	I-Premise
48	0·85	N	I-Premise
49	,	N	I-Premise
50	95	N	I-Premise
51	%	N	I-Premise
52	CI	N	I-Premise
53	0·69-1·04	N	I-Premise
54	;	N	I-Premise
55	p=0·109	N	I-Premise
56	)	N	I-Premise
57	.	N	I-Premise

1	Median	N	I-Premise
2	time	N	I-Premise
3	to	N	I-Premise
4	HRQoL	N	I-Premise
5	deterioration	N	I-Premise
6	was	N	I-Premise
7	longer	N	I-Premise
8	in	N	I-Premise
9	patients	N	I-Premise
10	assigned	N	I-Premise
11	to	N	I-Premise
12	abiraterone	N	I-Premise
13	plus	N	I-Premise
14	prednisone	N	I-Premise
15	than	N	I-Premise
16	in	N	I-Premise
17	those	N	I-Premise
18	assigned	N	I-Premise
19	to	N	I-Premise
20	placebo	N	I-Premise
21	plus	N	I-Premise
22	prednisone	N	I-Premise
23	as	N	I-Premise
24	assessed	N	I-Premise
25	by	N	I-Premise
26	the	N	I-Premise
27	FACT-P	N	I-Premise
28	total	N	I-Premise
29	score	N	I-Premise
30	(	N	I-Premise
31	12·7	N	I-Premise
32	months	N	I-Premise
33	[	N	I-Premise
34	95	N	I-Premise
35	%	N	I-Premise
36	CI	N	I-Premise
37	11·1-14·0	N	I-Premise
38	]	N	I-Premise
39	vs	N	I-Premise
40	8·3	N	I-Premise
41	months	N	I-Premise
42	[	N	I-Premise
43	7·4-10·6	N	I-Premise
44	]	N	I-Premise
45	;	N	I-Premise
46	HR	N	I-Premise
47	0·78	N	I-Premise
48	,	N	I-Premise
49	95	N	I-Premise
50	%	N	I-Premise
51	CI	N	I-Premise
52	0·66-0·92	N	I-Premise
53	;	N	I-Premise
54	p=0·003	N	I-Premise
55	)	N	I-Premise
56	and	N	I-Premise
57	by	N	I-Premise
58	the	N	I-Premise
59	score	N	I-Premise
60	on	N	I-Premise
61	its	N	I-Premise
62	prostate-cancer-specific	N	I-Premise
63	subscale	N	I-Premise
64	(	N	I-Premise
65	11·1	N	I-Premise
66	months	N	I-Premise
67	[	N	I-Premise
68	8·6-13·8	N	I-Premise
69	]	N	I-Premise
70	vs	N	I-Premise
71	5·8	N	I-Premise
72	months	N	I-Premise
73	[	N	I-Premise
74	5·5-8·3	N	I-Premise
75	]	N	I-Premise
76	;	N	I-Premise
77	HR	N	I-Premise
78	0·70	N	I-Premise
79	,	N	I-Premise
80	95	N	I-Premise
81	%	N	I-Premise
82	CI	N	I-Premise
83	0·60-0·83	N	I-Premise
84	;	N	I-Premise
85	p	N	I-Premise
86	<	N	I-Premise
87	0·0001	N	I-Premise
88	)	N	I-Premise
89	.	N	I-Premise

1	Abiraterone	N	I-Claim
2	plus	N	I-Claim
3	prednisone	N	I-Claim
4	delays	N	I-Claim
5	patient-reported	N	I-Claim
6	pain	N	I-Claim
7	progression	N	I-Claim
8	and	N	I-Claim
9	HRQoL	N	I-Claim
10	deterioration	N	I-Claim
11	in	N	I-Claim
12	chemotherapy-naive	N	I-Claim
13	patients	N	I-Claim
14	with	N	I-Claim
15	metastatic	N	I-Claim
16	castration-resistant	N	I-Claim
17	prostate	N	I-Claim
18	cancer	N	I-Claim
19	.	N	I-Claim

1	These	N	I-Claim
2	results	N	I-Claim
3	provide	N	I-Claim
4	further	N	I-Claim
5	support	N	I-Claim
6	for	N	I-Claim
7	the	N	I-Claim
8	efficacy	N	I-Claim
9	of	N	I-Claim
10	abiraterone	N	I-Claim
11	in	N	I-Claim
12	this	N	I-Claim
13	population	N	I-Claim
14	.	N	I-Claim

1	Single-agent	N	O
2	therapy	N	O
3	with	N	O
4	bicalutamide	N	O
5	,	N	O
6	a	N	O
7	nonsteroidal	N	O
8	antiandrogen	N	O
9	,	N	O
10	was	N	O
11	compared	N	O
12	with	N	O
13	castration	N	O
14	,	N	O
15	either	N	O
16	surgical	N	O
17	or	N	O
18	medical	N	O
19	,	N	O
20	in	N	O
21	patients	N	O
22	with	N	O
23	untreated	N	O
24	Stage	N	O
25	D2	N	O
26	prostate	N	O
27	cancer	N	O
28	.	N	O

1	In	N	O
2	an	N	O
3	open	N	O
4	,	N	O
5	randomized	N	O
6	,	N	O
7	multicenter	N	O
8	trial	N	O
9	,	N	O
10	patients	N	O
11	were	N	O
12	randomized	N	O
13	to	N	O
14	treatment	N	O
15	with	N	O
16	50	N	O
17	mg	N	O
18	bicalutamide	N	O
19	(	N	O
20	n	N	O
21	=	N	O
22	243	N	O
23	)	N	O
24	once	N	O
25	daily	N	O
26	or	N	O
27	to	N	O
28	castration	N	O
29	(	N	O
30	n	N	O
31	=	N	O
32	243	N	O
33	)	N	O
34	,	N	O
35	either	N	O
36	orchiectomy	N	O
37	or	N	O
38	depot	N	O
39	injection	N	O
40	of	N	O
41	goserelin	N	O
42	acetate	N	O
43	every	N	O
44	28	N	O
45	days	N	O
46	.	N	O

1	Primary	N	O
2	efficacy	N	O
3	endpoints	N	O
4	were	N	O
5	times	N	O
6	to	N	O
7	treatment	N	O
8	failure	N	O
9	and	N	O
10	objective	N	O
11	disease	N	O
12	progression	N	O
13	and	N	O
14	survival	N	O
15	.	N	O

1	Assessments	N	O
2	included	N	O
3	review	N	O
4	of	N	O
5	measurable	N	O
6	metastases	N	O
7	,	N	O
8	prostate	N	O
9	dimensions	N	O
10	,	N	O
11	Eastern	N	O
12	Cooperative	N	O
13	Oncology	N	O
14	Group	N	O
15	performance	N	O
16	status	N	O
17	,	N	O
18	pain	N	O
19	,	N	O
20	analgesic	N	O
21	requirements	N	O
22	,	N	O
23	and	N	O
24	quality	N	O
25	of	N	O
26	life	N	O
27	responses	N	O
28	.	N	O

1	The	N	O
2	median	N	O
3	duration	N	O
4	of	N	O
5	therapy	N	O
6	was	N	O
7	39	N	O
8	weeks	N	O
9	for	N	O
10	bicalutamide-treated	N	O
11	patients	N	O
12	and	N	O
13	42	N	O
14	weeks	N	O
15	for	N	O
16	castrated	N	O
17	patients	N	O
18	;	N	O
19	treatment	N	O
20	failure	N	O
21	occurred	N	O
22	in	N	O
23	53	N	O
24	%	N	O
25	and	N	O
26	42	N	O
27	%	N	O
28	and	N	O
29	disease	N	O
30	progression	N	O
31	in	N	O
32	43	N	O
33	%	N	O
34	and	N	O
35	33	N	O
36	%	N	O
37	,	N	O
38	respectively	N	O
39	.	N	O

1	Treatment	N	I-Premise
2	effects	N	I-Premise
3	favored	N	I-Premise
4	castration	N	I-Premise
5	for	N	I-Premise
6	both	N	I-Premise
7	endpoints	N	I-Premise
8	(	N	I-Premise
9	P	N	I-Premise
10	<	N	I-Premise
11	or	N	I-Premise
12	=	N	I-Premise
13	0.002	N	I-Premise
14	)	N	I-Premise
15	,	N	I-Premise
16	with	N	I-Premise
17	hazard	N	I-Premise
18	ratios	N	I-Premise
19	(	N	I-Premise
20	bicalutamide	N	I-Premise
21	:	N	I-Premise
22	castration	N	I-Premise
23	)	N	I-Premise
24	of	N	I-Premise
25	1.54	N	I-Premise
26	(	N	I-Premise
27	95	N	I-Premise
28	%	N	I-Premise
29	confidence	N	I-Premise
30	interval	N	I-Premise
31	[	N	I-Premise
32	CI	N	I-Premise
33	]	N	I-Premise
34	,	N	I-Premise
35	1.18	N	I-Premise
36	to	N	I-Premise
37	2.00	N	I-Premise
38	)	N	I-Premise
39	for	N	I-Premise
40	time	N	I-Premise
41	to	N	I-Premise
42	treatment	N	I-Premise
43	failure	N	I-Premise
44	and	N	I-Premise
45	1.6	N	I-Premise
46	(	N	I-Premise
47	95	N	I-Premise
48	%	N	I-Premise
49	CI	N	I-Premise
50	,	N	I-Premise
51	1.19	N	I-Premise
52	to	N	I-Premise
53	2.15	N	I-Premise
54	)	N	I-Premise
55	for	N	I-Premise
56	time	N	I-Premise
57	to	N	I-Premise
58	disease	N	I-Premise
59	progression	N	I-Premise
60	.	N	I-Premise

1	From	N	I-Premise
2	the	N	I-Premise
3	1-year	N	I-Premise
4	survival	N	I-Premise
5	analysis	N	I-Premise
6	,	N	I-Premise
7	the	N	I-Premise
8	hazard	N	I-Premise
9	ratio	N	I-Premise
10	for	N	I-Premise
11	probability	N	I-Premise
12	of	N	I-Premise
13	death	N	I-Premise
14	was	N	I-Premise
15	1.29	N	I-Premise
16	(	N	I-Premise
17	95	N	I-Premise
18	%	N	I-Premise
19	CI	N	I-Premise
20	,	N	I-Premise
21	0.96	N	I-Premise
22	to	N	I-Premise
23	1.72	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	Thus	N	I-Premise
2	far	N	I-Premise
3	,	N	I-Premise
4	with	N	I-Premise
5	a	N	I-Premise
6	median	N	I-Premise
7	follow-up	N	I-Premise
8	of	N	I-Premise
9	86	N	I-Premise
10	weeks	N	I-Premise
11	,	N	I-Premise
12	median	N	I-Premise
13	survival	N	I-Premise
14	has	N	I-Premise
15	not	N	I-Premise
16	been	N	I-Premise
17	reached	N	I-Premise
18	in	N	I-Premise
19	either	N	I-Premise
20	group	N	I-Premise
21	.	N	I-Premise

1	Changes	N	I-Premise
2	from	N	I-Premise
3	baseline	N	I-Premise
4	in	N	I-Premise
5	several	N	I-Premise
6	quality	N	I-Premise
7	of	N	I-Premise
8	life	N	I-Premise
9	variables	N	I-Premise
10	were	N	I-Premise
11	significantly	N	I-Premise
12	different	N	I-Premise
13	(	N	I-Premise
14	P	N	I-Premise
15	<	N	I-Premise
16	or	N	I-Premise
17	=	N	I-Premise
18	0.01	N	I-Premise
19	)	N	I-Premise
20	between	N	I-Premise
21	treatment	N	I-Premise
22	groups	N	I-Premise
23	periodically	N	I-Premise
24	from	N	I-Premise
25	months	N	I-Premise
26	1	N	I-Premise
27	to	N	I-Premise
28	6	N	I-Premise
29	,	N	I-Premise
30	and	N	I-Premise
31	all	N	I-Premise
32	favored	N	I-Premise
33	bicalutamide	N	I-Premise
34	.	N	I-Premise

1	Overall	N	I-Premise
2	,	N	I-Premise
3	the	N	I-Premise
4	antiandrogen	N	I-Premise
5	was	N	I-Premise
6	well	N	I-Premise
7	tolerated	N	I-Premise
8	compared	N	I-Premise
9	with	N	I-Premise
10	castration	N	I-Premise
11	;	N	I-Premise
12	with	N	I-Premise
13	bicalutamide	N	I-Premise
14	,	N	I-Premise
15	hot	N	I-Premise
16	flushes	N	I-Premise
17	occurred	N	I-Premise
18	less	N	I-Premise
19	often	N	I-Premise
20	and	N	I-Premise
21	breast	N	I-Premise
22	tenderness	N	I-Premise
23	and	N	I-Premise
24	gynecomastia	N	I-Premise
25	more	N	I-Premise
26	often	N	I-Premise
27	.	N	I-Premise

1	Although	N	I-Premise
2	a	N	I-Premise
3	dosage	N	I-Premise
4	of	N	I-Premise
5	50	N	I-Premise
6	mg	N	I-Premise
7	of	N	I-Premise
8	bicalutamide	N	I-Premise
9	once	N	I-Premise
10	daily	N	I-Premise
11	was	N	I-Premise
12	not	N	I-Premise
13	as	N	I-Premise
14	effective	N	I-Premise
15	as	N	I-Premise
16	castration	N	I-Premise
17	,	N	I-Premise
18	the	N	I-Claim
19	favorable	N	I-Claim
20	quality	N	I-Claim
21	of	N	I-Claim
22	life	N	I-Claim
23	outcomes	N	I-Claim
24	and	N	I-Claim
25	the	N	I-Claim
26	low	N	I-Claim
27	incidence	N	I-Claim
28	of	N	I-Claim
29	nonhormonal	N	I-Claim
30	adverse	N	I-Claim
31	events	N	I-Claim
32	provide	N	I-Claim
33	reasons	N	I-Claim
34	to	N	I-Claim
35	evaluate	N	I-Claim
36	bicalutamide	N	I-Claim
37	,	N	I-Claim
38	as	N	I-Claim
39	a	N	I-Claim
40	single	N	I-Claim
41	therapeutic	N	I-Claim
42	agent	N	I-Claim
43	,	N	I-Claim
44	at	N	I-Claim
45	higher	N	I-Claim
46	doses	N	I-Claim
47	.	N	I-Claim

1	An	N	O
2	open	N	O
3	,	N	O
4	randomized	N	O
5	study	N	O
6	was	N	O
7	performed	N	O
8	to	N	O
9	assess	N	O
10	the	N	O
11	effects	N	O
12	of	N	O
13	supportive	N	O
14	pamidronate	N	O
15	treatment	N	O
16	on	N	O
17	morbidity	N	O
18	from	N	O
19	bone	N	O
20	metastases	N	O
21	in	N	O
22	breast	N	O
23	cancer	N	O
24	patients	N	O
25	.	N	O

1	Eighty-one	N	O
2	pamidronate	N	O
3	patients	N	O
4	and	N	O
5	80	N	O
6	control	N	O
7	patients	N	O
8	were	N	O
9	monitored	N	O
10	for	N	O
11	a	N	O
12	median	N	O
13	of	N	O
14	18	N	O
15	and	N	O
16	21	N	O
17	months	N	O
18	,	N	O
19	respectively	N	O
20	,	N	O
21	for	N	O
22	events	N	O
23	of	N	O
24	skeletal	N	O
25	morbidity	N	O
26	and	N	O
27	the	N	O
28	radiologic	N	O
29	course	N	O
30	of	N	O
31	metastatic	N	O
32	bone	N	O
33	disease	N	O
34	.	N	O

1	The	N	O
2	oral	N	O
3	pamidronate	N	O
4	dose	N	O
5	was	N	O
6	600	N	O
7	mg/d	N	O
8	(	N	O
9	high	N	O
10	dose	N	O
11	[	N	O
12	HD	N	O
13	]	N	O
14	)	N	O
15	during	N	O
16	the	N	O
17	earliest	N	O
18	study	N	O
19	years	N	O
20	,	N	O
21	then	N	O
22	changed	N	O
23	to	N	O
24	300	N	O
25	mg/d	N	O
26	(	N	O
27	low	N	O
28	dose	N	O
29	[	N	O
30	LD	N	O
31	]	N	O
32	)	N	O
33	because	N	O
34	of	N	O
35	gastrointestinal	N	O
36	toxicity	N	O
37	.	N	O

1	Twenty-nine	N	O
2	of	N	O
3	81	N	O
4	pamidronate	N	O
5	(	N	O
6	HD/LD	N	O
7	)	N	O
8	patients	N	O
9	first	N	O
10	received	N	O
11	600	N	O
12	mg/d	N	O
13	and	N	O
14	were	N	O
15	then	N	O
16	changed	N	O
17	to	N	O
18	300	N	O
19	mg/d	N	O
20	;	N	O
21	52	N	O
22	of	N	O
23	81	N	O
24	pamidronate	N	O
25	LD	N	O
26	patients	N	O
27	received	N	O
28	300	N	O
29	mg/d	N	O
30	throughout	N	O
31	the	N	O
32	study	N	O
33	.	N	O

1	Tumor	N	O
2	treatment	N	O
3	was	N	O
4	unrestricted	N	O
5	.	N	O

1	An	N	O
2	overall	N	O
3	intent-to-treat	N	O
4	analysis	N	O
5	was	N	O
6	performed	N	O
7	.	N	O

1	In	N	I-Premise
2	the	N	I-Premise
3	pamidronate	N	I-Premise
4	group	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	occurrence	N	I-Premise
8	of	N	I-Premise
9	hypercalcemia	N	I-Premise
10	,	N	I-Premise
11	severe	N	I-Premise
12	bone	N	I-Premise
13	pain	N	I-Premise
14	,	N	I-Premise
15	and	N	I-Premise
16	symptomatic	N	I-Premise
17	impending	N	I-Premise
18	fractures	N	I-Premise
19	decreased	N	I-Premise
20	by	N	I-Premise
21	65	N	I-Premise
22	%	N	I-Premise
23	,	N	I-Premise
24	30	N	I-Premise
25	%	N	I-Premise
26	,	N	I-Premise
27	and	N	I-Premise
28	50	N	I-Premise
29	%	N	I-Premise
30	,	N	I-Premise
31	respectively	N	I-Premise
32	;	N	I-Premise
33	event-rates	N	I-Premise
34	of	N	I-Premise
35	systemic	N	I-Premise
36	treatment	N	I-Premise
37	and	N	I-Premise
38	radiotherapy	N	I-Premise
39	decreased	N	I-Premise
40	by	N	I-Premise
41	35	N	I-Premise
42	%	N	I-Premise
43	(	N	I-Premise
44	P	N	I-Premise
45	<	N	I-Premise
46	or	N	I-Premise
47	=	N	I-Premise
48	.02	N	I-Premise
49	)	N	I-Premise
50	.	N	I-Premise

1	The	N	I-Premise
2	event-free	N	I-Premise
3	period	N	I-Premise
4	(	N	I-Premise
5	EFP	N	I-Premise
6	)	N	I-Premise
7	,	N	I-Premise
8	radiologic	N	I-Premise
9	course	N	I-Premise
10	of	N	I-Premise
11	disease	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	survival	N	I-Premise
15	did	N	I-Premise
16	not	N	I-Premise
17	improve	N	I-Premise
18	.	N	I-Premise

1	Subgroup	N	I-Claim
2	analyses	N	I-Claim
3	suggested	N	I-Claim
4	a	N	I-Claim
5	dose-dependent	N	I-Claim
6	treatment	N	I-Claim
7	effect	N	I-Claim
8	.	N	I-Claim

1	Compared	N	I-Premise
2	with	N	I-Premise
3	their	N	I-Premise
4	controls	N	I-Premise
5	,	N	I-Premise
6	in	N	I-Premise
7	pamidronate	N	I-Premise
8	HD/LD	N	I-Premise
9	patients	N	I-Premise
10	,	N	I-Premise
11	events	N	I-Premise
12	occurred	N	I-Premise
13	60	N	I-Premise
14	%	N	I-Premise
15	to	N	I-Premise
16	90	N	I-Premise
17	%	N	I-Premise
18	less	N	I-Premise
19	frequently	N	I-Premise
20	(	N	I-Premise
21	P	N	I-Premise
22	<	N	I-Premise
23	or	N	I-Premise
24	=	N	I-Premise
25	.03	N	I-Premise
26	)	N	I-Premise
27	and	N	I-Premise
28	the	N	I-Premise
29	EFP	N	I-Premise
30	was	N	I-Premise
31	prolonged	N	I-Premise
32	(	N	I-Premise
33	P	N	I-Premise
34	=	N	I-Premise
35	.002	N	I-Premise
36	)	N	I-Premise
37	.	N	I-Premise

1	In	N	I-Premise
2	pamidronate	N	I-Premise
3	LD	N	I-Premise
4	patients	N	I-Premise
5	,	N	I-Premise
6	event-rates	N	I-Premise
7	decreased	N	I-Premise
8	by	N	I-Premise
9	15	N	I-Premise
10	%	N	I-Premise
11	to	N	I-Premise
12	45	N	I-Premise
13	%	N	I-Premise
14	(	N	I-Premise
15	P	N	I-Premise
16	<	N	I-Premise
17	or	N	I-Premise
18	=	N	I-Premise
19	.04	N	I-Premise
20	)	N	I-Premise
21	.	N	I-Premise

1	Gastrointestinal	N	I-Premise
2	toxicity	N	I-Premise
3	of	N	I-Premise
4	pamidronate	N	I-Premise
5	caused	N	I-Premise
6	a	N	I-Premise
7	23	N	I-Premise
8	%	N	I-Premise
9	drop-out	N	I-Premise
10	rate	N	I-Premise
11	,	N	I-Premise
12	but	N	I-Claim
13	other	N	I-Claim
14	cancer-associated	N	I-Claim
15	factors	N	I-Claim
16	seemed	N	I-Claim
17	to	N	I-Claim
18	contribute	N	I-Claim
19	to	N	I-Claim
20	this	N	I-Claim
21	toxicity	N	I-Claim
22	.	N	I-Claim

1	Pamidronate	N	I-Claim
2	treatment	N	I-Claim
3	of	N	I-Claim
4	breast	N	I-Claim
5	cancer	N	I-Claim
6	patients	N	I-Claim
7	efficaciously	N	I-Claim
8	reduced	N	I-Claim
9	skeletal	N	I-Claim
10	morbidity	N	I-Claim
11	.	N	I-Claim

1	The	N	I-Claim
2	effect	N	I-Claim
3	appeared	N	I-Claim
4	to	N	I-Claim
5	be	N	I-Claim
6	dose-dependent	N	I-Claim
7	.	N	I-Claim

1	Further	N	I-Claim
2	research	N	I-Claim
3	on	N	I-Claim
4	dose	N	I-Claim
5	and	N	I-Claim
6	mode	N	I-Claim
7	of	N	I-Claim
8	treatment	N	I-Claim
9	is	N	I-Claim
10	mandatory	N	I-Claim
11	.	N	I-Claim

1	From	N	O
2	1984	N	O
3	to	N	O
4	1989	N	O
5	,	N	O
6	the	N	O
7	Swiss	N	O
8	Group	N	O
9	for	N	O
10	Clinical	N	O
11	Cancer	N	O
12	Research	N	O
13	(	N	O
14	SAKK	N	O
15	)	N	O
16	performed	N	O
17	a	N	O
18	randomized	N	O
19	phase	N	O
20	III	N	O
21	trial	N	O
22	comparing	N	O
23	early	N	O
24	versus	N	O
25	late	N	O
26	alternating	N	O
27	chemotherapy	N	O
28	in	N	O
29	patients	N	O
30	with	N	O
31	small-cell	N	O
32	lung	N	O
33	cancer	N	O
34	.	N	O

1	406	N	O
2	eligible	N	O
3	patients	N	O
4	were	N	O
5	entered	N	O
6	into	N	O
7	the	N	O
8	trial	N	O
9	.	N	O

1	Regimen	N	O
2	A	N	O
3	consisted	N	O
4	of	N	O
5	PAV	N	O
6	(	N	O
7	cisPlatin	N	O
8	,	N	O
9	Adriamycin	N	O
10	,	N	O
11	VP	N	O
12	16-213	N	O
13	,	N	O
14	and	N	O
15	Regimen	N	O
16	B	N	O
17	of	N	O
18	CyMOC	N	O
19	(	N	O
20	Cyclophosphamide	N	O
21	,	N	O
22	Methotrexate	N	O
23	,	N	O
24	Oncovin	N	O
25	,	N	O
26	CCNU	N	O
27	)	N	O
28	.	N	O

1	Cycles	N	O
2	were	N	O
3	repeated	N	O
4	as	N	O
5	rapidly	N	O
6	as	N	O
7	possible	N	O
8	.	N	O

1	patients	N	O
2	were	N	O
3	randomized	N	O
4	to	N	O
5	receive	N	O
6	either	N	O
7	ABABAB	N	O
8	(	N	O
9	early	N	O
10	alternating	N	O
11	chemotherapy	N	O
12	)	N	O
13	or	N	O
14	AAABBB	N	O
15	(	N	O
16	late	N	O
17	alternating	N	O
18	chemotherapy	N	O
19	)	N	O
20	.	N	O

1	After	N	O
2	six	N	O
3	cycles	N	O
4	patients	N	O
5	with	N	O
6	limited	N	O
7	disease	N	O
8	in	N	O
9	complete	N	O
10	or	N	O
11	partial	N	O
12	remission	N	O
13	and	N	O
14	those	N	O
15	with	N	O
16	extensive	N	O
17	disease	N	O
18	in	N	O
19	complete	N	O
20	remission	N	O
21	received	N	O
22	irradiation	N	O
23	to	N	O
24	the	N	O
25	primary	N	O
26	(	N	O
27	45	N	O
28	Gy	N	O
29	)	N	O
30	and	N	O
31	the	N	O
32	CNS	N	O
33	(	N	O
34	36	N	O
35	Gy	N	O
36	)	N	O
37	.	N	O

1	The	N	I-Premise
2	overall	N	I-Premise
3	remission	N	I-Premise
4	rate	N	I-Premise
5	was	N	I-Premise
6	87	N	I-Premise
7	%	N	I-Premise
8	with	N	I-Premise
9	31	N	I-Premise
10	%	N	I-Premise
11	complete	N	I-Premise
12	remissions	N	I-Premise
13	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	of	N	I-Premise
5	all	N	I-Premise
6	406	N	I-Premise
7	eligible	N	I-Premise
8	patients	N	I-Premise
9	was	N	I-Premise
10	346	N	I-Premise
11	days	N	I-Premise
12	with	N	I-Premise
13	15	N	I-Premise
14	%	N	I-Premise
15	of	N	I-Premise
16	the	N	I-Premise
17	patients	N	I-Premise
18	alive	N	I-Premise
19	at	N	I-Premise
20	two	N	I-Premise
21	years	N	I-Premise
22	.	N	I-Premise

1	The	N	I-Premise
2	overall	N	I-Premise
3	remission	N	I-Premise
4	rate	N	I-Premise
5	,	N	I-Premise
6	the	N	I-Premise
7	rate	N	I-Premise
8	of	N	I-Premise
9	complete	N	I-Premise
10	remission	N	I-Premise
11	,	N	I-Premise
12	the	N	I-Premise
13	median	N	I-Premise
14	survival	N	I-Premise
15	and	N	I-Premise
16	the	N	I-Premise
17	rate	N	I-Premise
18	of	N	I-Premise
19	long-term	N	I-Premise
20	survival	N	I-Premise
21	were	N	I-Premise
22	not	N	I-Premise
23	significantly	N	I-Premise
24	different	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	two	N	I-Premise
28	treatment	N	I-Premise
29	arms	N	I-Premise
30	.	N	I-Premise

1	In	N	I-Premise
2	limited	N	I-Premise
3	disease	N	I-Premise
4	the	N	I-Premise
5	estimated	N	I-Premise
6	percentages	N	I-Premise
7	of	N	I-Premise
8	survival	N	I-Premise
9	at	N	I-Premise
10	2	N	I-Premise
11	years	N	I-Premise
12	were	N	I-Premise
13	33	N	I-Premise
14	%	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	early	N	I-Premise
18	and	N	I-Premise
19	24	N	I-Premise
20	%	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	late	N	I-Premise
24	alternating	N	I-Premise
25	chemotherapy	N	I-Premise
26	arms	N	I-Premise
27	.	N	I-Premise

1	Patients	N	I-Premise
2	with	N	I-Premise
3	extensive	N	I-Premise
4	disease	N	I-Premise
5	survived	N	I-Premise
6	significantly	N	I-Premise
7	longer	N	I-Premise
8	with	N	I-Premise
9	late	N	I-Premise
10	alternating	N	I-Premise
11	chemotherapy	N	I-Premise
12	than	N	I-Premise
13	on	N	I-Premise
14	the	N	I-Premise
15	early	N	I-Premise
16	alternation	N	I-Premise
17	regimen	N	I-Premise
18	(	N	I-Premise
19	median	N	I-Premise
20	survival	N	I-Premise
21	336	N	I-Premise
22	days	N	I-Premise
23	versus	N	I-Premise
24	301	N	I-Premise
25	days	N	I-Premise
26	,	N	I-Premise
27	p	N	I-Premise
28	=	N	I-Premise
29	0.01	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	latter	N	I-Premise
4	patients	N	I-Premise
5	the	N	I-Premise
6	received	N	I-Premise
7	dose	N	I-Premise
8	intensities	N	I-Premise
9	(	N	I-Premise
10	RDI	N	I-Premise
11	)	N	I-Premise
12	of	N	I-Premise
13	cisplatin	N	I-Premise
14	,	N	I-Premise
15	adriamycin	N	I-Premise
16	and	N	I-Premise
17	etoposide	N	I-Premise
18	were	N	I-Premise
19	significantly	N	I-Premise
20	higher	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	late-alternation	N	I-Premise
24	arm	N	I-Premise
25	.	N	I-Premise

1	Patients	N	I-Premise
2	treated	N	I-Premise
3	with	N	I-Premise
4	early	N	I-Premise
5	alternating	N	I-Premise
6	chemotherapy	N	I-Premise
7	rated	N	I-Premise
8	their	N	I-Premise
9	tumor	N	I-Premise
10	symptoms	N	I-Premise
11	,	N	I-Premise
12	functional	N	I-Premise
13	states	N	I-Premise
14	,	N	I-Premise
15	fatigue/malaise	N	I-Premise
16	and	N	I-Premise
17	restriction	N	I-Premise
18	of	N	I-Premise
19	social	N	I-Premise
20	activity	N	I-Premise
21	significantly	N	I-Premise
22	better	N	I-Premise
23	,	N	I-Premise
24	reflecting	N	I-Premise
25	an	N	I-Premise
26	improved	N	I-Premise
27	subjective	N	I-Premise
28	adjustment	N	I-Premise
29	.	N	I-Premise

1	Alternating	N	I-Claim
2	chemotherapy	N	I-Claim
3	with	N	I-Claim
4	PAV-CyMOC	N	I-Claim
5	plus	N	I-Claim
6	consolidating	N	I-Claim
7	radiotherapy	N	I-Claim
8	is	N	I-Claim
9	a	N	I-Claim
10	feasible	N	I-Claim
11	and	N	I-Claim
12	effective	N	I-Claim
13	treatment	N	I-Claim
14	for	N	I-Claim
15	small-cell	N	I-Claim
16	lung	N	I-Claim
17	cancer	N	I-Claim
18	,	N	I-Claim
19	with	N	I-Claim
20	acceptable	N	I-Claim
21	toxicity	N	I-Claim
22	.	N	I-Claim

1	Whereas	N	O
2	patients	N	I-Claim
3	with	N	I-Claim
4	early	N	I-Claim
5	alternating	N	I-Claim
6	chemotherapy	N	I-Claim
7	achieve	N	I-Claim
8	a	N	I-Claim
9	better	N	I-Claim
10	subjective	N	I-Claim
11	adjustment	N	I-Claim
12	,	N	I-Claim
13	late	N	I-Claim
14	alternating	N	I-Claim
15	chemotherapy	N	I-Claim
16	allows	N	I-Claim
17	for	N	I-Claim
18	a	N	I-Claim
19	higher	N	I-Claim
20	RDI	N	I-Claim
21	of	N	I-Claim
22	cisplatin	N	I-Claim
23	,	N	I-Claim
24	adriamycin	N	I-Claim
25	and	N	I-Claim
26	etoposide	N	I-Claim
27	,	N	I-Claim
28	which	N	I-Claim
29	results	N	I-Claim
30	in	N	I-Claim
31	a	N	I-Claim
32	significantly	N	I-Claim
33	longer	N	I-Claim
34	median	N	I-Claim
35	survival	N	I-Claim
36	of	N	I-Claim
37	patients	N	I-Claim
38	with	N	I-Claim
39	extensive	N	I-Claim
40	disease	N	I-Claim
41	.	N	I-Claim

1	Taxol	N	I-Premise
2	(	N	I-Premise
3	paclitaxel	N	I-Premise
4	;	N	I-Premise
5	Bristol-Myers	N	I-Premise
6	Squibb	N	I-Premise
7	,	N	I-Premise
8	Wallingford	N	I-Premise
9	,	N	I-Premise
10	CT	N	I-Premise
11	)	N	I-Premise
12	is	N	I-Premise
13	a	N	I-Premise
14	new	N	I-Premise
15	anticancer	N	I-Premise
16	agent	N	I-Premise
17	with	N	I-Premise
18	activity	N	I-Premise
19	in	N	I-Premise
20	a	N	I-Premise
21	number	N	I-Premise
22	of	N	I-Premise
23	human	N	I-Premise
24	tumors	N	I-Premise
25	,	N	I-Premise
26	including	N	I-Premise
27	epithelial	N	I-Premise
28	ovarian	N	I-Premise
29	cancer	N	I-Premise
30	.	N	I-Premise

1	In	N	O
2	nonrandomized	N	O
3	trials	N	O
4	,	N	O
5	doses	N	O
6	studied	N	O
7	have	N	O
8	ranged	N	O
9	from	N	O
10	135	N	O
11	mg/m2	N	O
12	to	N	O
13	250	N	O
14	mg/m2	N	O
15	administered	N	O
16	over	N	O
17	24	N	O
18	hours	N	O
19	with	N	O
20	premedication	N	O
21	to	N	O
22	avoid	N	O
23	hypersensitivity	N	O
24	reactions	N	O
25	(	N	O
26	HSRs	N	O
27	)	N	O
28	.	N	O

1	This	N	O
2	study	N	O
3	addressed	N	O
4	two	N	O
5	questions	N	O
6	:	N	O
7	the	N	O
8	dose-response	N	O
9	relationship	N	O
10	of	N	O
11	Taxol	N	O
12	in	N	O
13	relapsed	N	O
14	ovarian	N	O
15	cancer	N	O
16	and	N	O
17	the	N	O
18	safety	N	O
19	of	N	O
20	a	N	O
21	short	N	O
22	infusion	N	O
23	given	N	O
24	with	N	O
25	premedication	N	O
26	.	N	O

1	Women	N	O
2	with	N	O
3	platinum-pretreated	N	O
4	epithelial	N	O
5	ovarian	N	O
6	cancer	N	O
7	and	N	O
8	measurable	N	O
9	recurrent	N	O
10	disease	N	O
11	were	N	O
12	randomized	N	O
13	in	N	O
14	a	N	O
15	bifactorial	N	O
16	design	N	O
17	to	N	O
18	receive	N	O
19	either	N	O
20	175	N	O
21	or	N	O
22	135	N	O
23	mg/m2	N	O
24	of	N	O
25	Taxol	N	O
26	over	N	O
27	either	N	O
28	24	N	O
29	or	N	O
30	3	N	O
31	hours	N	O
32	.	N	O

1	Major	N	O
2	end	N	O
3	points	N	O
4	were	N	O
5	the	N	O
6	frequency	N	O
7	of	N	O
8	significant	N	O
9	HSRs	N	O
10	and	N	O
11	objective	N	O
12	response	N	O
13	rate	N	O
14	.	N	O

1	Secondary	N	O
2	end	N	O
3	points	N	O
4	were	N	O
5	progression-free	N	O
6	and	N	O
7	overall	N	O
8	survival	N	O
9	.	N	O

1	Of	N	O
2	407	N	O
3	patients	N	O
4	randomized	N	O
5	,	N	O
6	391	N	O
7	were	N	O
8	eligible	N	O
9	and	N	O
10	382	N	O
11	assessable	N	O
12	for	N	O
13	response	N	O
14	.	N	O

1	Analysis	N	O
2	was	N	O
3	performed	N	O
4	according	N	O
5	to	N	O
6	the	N	O
7	bifactorial	N	O
8	design	N	O
9	.	N	O

1	Severe	N	I-Premise
2	HSRs	N	I-Premise
3	were	N	I-Premise
4	rare	N	I-Premise
5	(	N	I-Premise
6	1.5	N	I-Premise
7	%	N	I-Premise
8	patients	N	I-Premise
9	)	N	I-Premise
10	and	N	I-Premise
11	were	N	I-Premise
12	not	N	I-Premise
13	affected	N	I-Premise
14	by	N	I-Premise
15	either	N	I-Premise
16	dose	N	I-Premise
17	or	N	I-Premise
18	schedule	N	I-Premise
19	.	N	I-Premise

1	Response	N	I-Premise
2	was	N	I-Premise
3	slightly	N	I-Premise
4	higher	N	I-Premise
5	at	N	I-Premise
6	the	N	I-Premise
7	175-mg/m2	N	I-Premise
8	dose	N	I-Premise
9	(	N	I-Premise
10	20	N	I-Premise
11	%	N	I-Premise
12	)	N	I-Premise
13	than	N	I-Premise
14	at	N	I-Premise
15	135	N	I-Premise
16	mg/m2	N	I-Premise
17	(	N	I-Premise
18	15	N	I-Premise
19	%	N	I-Premise
20	)	N	I-Premise
21	,	N	I-Premise
22	but	N	I-Premise
23	this	N	I-Premise
24	was	N	I-Premise
25	not	N	I-Premise
26	statistically	N	I-Premise
27	significant	N	I-Premise
28	(	N	I-Premise
29	P	N	I-Premise
30	=	N	I-Premise
31	.2	N	I-Premise
32	)	N	I-Premise
33	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	progression-free	N	I-Premise
4	survival	N	I-Premise
5	was	N	I-Premise
6	significantly	N	I-Premise
7	longer	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	high-dose	N	I-Premise
11	group	N	I-Premise
12	(	N	I-Premise
13	19	N	I-Premise
14	v	N	I-Premise
15	14	N	I-Premise
16	weeks	N	I-Premise
17	;	N	I-Premise
18	P	N	I-Premise
19	=	N	I-Premise
20	.02	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	Significantly	N	I-Premise
2	more	N	I-Premise
3	neutropenia	N	I-Premise
4	was	N	I-Premise
5	seen	N	I-Premise
6	when	N	I-Premise
7	Taxol	N	I-Premise
8	was	N	I-Premise
9	administered	N	I-Premise
10	as	N	I-Premise
11	a	N	I-Premise
12	24-hour	N	I-Premise
13	infusion	N	I-Premise
14	.	N	I-Premise

1	Response	N	I-Premise
2	rates	N	I-Premise
3	were	N	I-Premise
4	similar	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	24-	N	I-Premise
8	and	N	I-Premise
9	3-hour	N	I-Premise
10	groups	N	I-Premise
11	(	N	I-Premise
12	19	N	I-Premise
13	%	N	I-Premise
14	and	N	I-Premise
15	16	N	I-Premise
16	%	N	I-Premise
17	,	N	I-Premise
18	respectively	N	I-Premise
19	;	N	I-Premise
20	P	N	I-Premise
21	=	N	I-Premise
22	.6	N	I-Premise
23	)	N	I-Premise
24	.	N	I-Premise

1	No	N	I-Premise
2	survival	N	I-Premise
3	differences	N	I-Premise
4	were	N	I-Premise
5	noted	N	I-Premise
6	.	N	I-Premise

1	The	N	I-Claim
2	3-hour	N	I-Claim
3	infusion	N	I-Claim
4	of	N	I-Claim
5	Taxol	N	I-Claim
6	is	N	I-Claim
7	safe	N	I-Claim
8	when	N	I-Claim
9	given	N	I-Claim
10	with	N	I-Claim
11	premedication	N	I-Claim
12	and	N	I-Claim
13	is	N	I-Claim
14	associated	N	I-Claim
15	with	N	I-Claim
16	less	N	I-Claim
17	neutropenia	N	I-Claim
18	.	N	I-Claim

1	There	N	O
2	is	N	O
3	a	N	O
4	modest	N	O
5	dose	N	O
6	effect	N	O
7	with	N	O
8	longer	N	O
9	time	N	O
10	to	N	O
11	progression	N	O
12	at	N	O
13	175	N	O
14	mg/m2	N	O
15	.	N	O

1	The	N	I-Claim
2	observation	N	I-Claim
3	that	N	I-Claim
4	longer	N	I-Claim
5	infusion	N	I-Claim
6	produces	N	I-Claim
7	more	N	I-Claim
8	myelosuppression	N	I-Claim
9	but	N	I-Claim
10	does	N	I-Claim
11	not	N	I-Claim
12	yield	N	I-Claim
13	higher	N	I-Claim
14	response	N	I-Claim
15	rates	N	I-Claim
16	should	N	I-Claim
17	lead	N	I-Claim
18	to	N	I-Claim
19	further	N	I-Claim
20	studies	N	I-Claim
21	to	N	I-Claim
22	determine	N	I-Claim
23	the	N	I-Claim
24	optimal	N	I-Claim
25	dose	N	I-Claim
26	and	N	I-Claim
27	schedule	N	I-Claim
28	of	N	I-Claim
29	this	N	I-Claim
30	interesting	N	I-Claim
31	new	N	I-Claim
32	agent	N	I-Claim
33	.	N	I-Claim

1	The	N	O
2	impact	N	O
3	of	N	O
4	the	N	O
5	side	N	O
6	effects	N	O
7	of	N	O
8	megestrol	N	O
9	acetate	N	O
10	on	N	O
11	the	N	O
12	quality	N	O
13	of	N	O
14	life	N	O
15	of	N	O
16	noncachectic	N	O
17	women	N	O
18	with	N	O
19	advanced	N	O
20	breast	N	O
21	cancer	N	O
22	was	N	O
23	studied	N	O
24	in	N	O
25	a	N	O
26	dose-response	N	O
27	clinical	N	O
28	trial	N	O
29	of	N	O
30	the	N	O
31	Cancer	N	O
32	and	N	O
33	Leukemia	N	O
34	Group	N	O
35	B	N	O
36	(	N	O
37	CALGB	N	O
38	8741	N	O
39	)	N	O
40	.	N	O

1	Side	N	O
2	effects	N	O
3	of	N	O
4	appetite	N	O
5	increase	N	O
6	and	N	O
7	weight	N	O
8	gain	N	O
9	at	N	O
10	higher	N	O
11	doses	N	O
12	were	N	O
13	predicted	N	O
14	to	N	O
15	have	N	O
16	a	N	O
17	negative	N	O
18	effect	N	O
19	on	N	O
20	quality	N	O
21	of	N	O
22	life	N	O
23	.	N	O

1	Stage	N	O
2	IV	N	O
3	breast	N	O
4	cancer	N	O
5	patients	N	O
6	were	N	O
7	randomized	N	O
8	to	N	O
9	receive	N	O
10	either	N	O
11	160	N	O
12	,	N	O
13	800	N	O
14	,	N	O
15	or	N	O
16	1,600	N	O
17	mg/d	N	O
18	of	N	O
19	megestrol	N	O
20	acetate	N	O
21	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	assessed	N	O
6	in	N	O
7	131	N	O
8	patients	N	O
9	at	N	O
10	trial	N	O
11	entry	N	O
12	and	N	O
13	at	N	O
14	1	N	O
15	and	N	O
16	3	N	O
17	months	N	O
18	while	N	O
19	on	N	O
20	treatment	N	O
21	,	N	O
22	by	N	O
23	telephone	N	O
24	interview	N	O
25	,	N	O
26	using	N	O
27	the	N	O
28	following	N	O
29	measures	N	O
30	:	N	O
31	the	N	O
32	Functional	N	O
33	Living	N	O
34	Index-Cancer	N	O
35	(	N	O
36	FLIC	N	O
37	)	N	O
38	,	N	O
39	Rand	N	O
40	Functional	N	O
41	Limitations	N	O
42	Scale	N	O
43	,	N	O
44	Rand	N	O
45	Mental	N	O
46	Health	N	O
47	Inventory	N	O
48	(	N	O
49	MHI	N	O
50	)	N	O
51	,	N	O
52	the	N	O
53	Body	N	O
54	Image	N	O
55	Subscale	N	O
56	,	N	O
57	and	N	O
58	linear	N	O
59	analog	N	O
60	scales	N	O
61	of	N	O
62	drug	N	O
63	side	N	O
64	effects	N	O
65	.	N	O

1	At	N	I-Premise
2	3	N	I-Premise
3	months	N	I-Premise
4	,	N	I-Premise
5	women	N	I-Premise
6	treated	N	I-Premise
7	with	N	I-Premise
8	160	N	I-Premise
9	mg/d	N	I-Premise
10	reported	N	I-Premise
11	less	N	I-Premise
12	severe	N	I-Premise
13	side	N	I-Premise
14	effects	N	I-Premise
15	(	N	I-Premise
16	P	N	I-Premise
17	<	N	I-Premise
18	.0005	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	better	N	I-Premise
22	physical	N	I-Premise
23	functioning	N	I-Premise
24	(	N	I-Premise
25	FLS	N	I-Premise
26	,	N	I-Premise
27	P	N	I-Premise
28	<	N	I-Premise
29	.0005	N	I-Premise
30	)	N	I-Premise
31	,	N	I-Premise
32	less	N	I-Premise
33	psychologic	N	I-Premise
34	distress	N	I-Premise
35	(	N	I-Premise
36	MHI	N	I-Premise
37	,	N	I-Premise
38	P	N	I-Premise
39	=	N	I-Premise
40	.008	N	I-Premise
41	)	N	I-Premise
42	,	N	I-Premise
43	and	N	I-Premise
44	an	N	I-Premise
45	improvement	N	I-Premise
46	in	N	I-Premise
47	overall	N	I-Premise
48	quality	N	I-Premise
49	of	N	I-Premise
50	life	N	I-Premise
51	(	N	I-Premise
52	FLIC	N	I-Premise
53	,	N	I-Premise
54	P	N	I-Premise
55	=	N	I-Premise
56	.003	N	I-Premise
57	)	N	I-Premise
58	from	N	I-Premise
59	the	N	I-Premise
60	time	N	I-Premise
61	of	N	I-Premise
62	study	N	I-Premise
63	entry	N	I-Premise
64	as	N	I-Premise
65	compared	N	I-Premise
66	with	N	I-Premise
67	those	N	I-Premise
68	treated	N	I-Premise
69	with	N	I-Premise
70	1,600	N	I-Premise
71	mg/d	N	I-Premise
72	.	N	I-Premise

1	Patients	N	I-Premise
2	who	N	I-Premise
3	received	N	I-Premise
4	the	N	I-Premise
5	800-mg/d	N	I-Premise
6	dose	N	I-Premise
7	fell	N	I-Premise
8	between	N	I-Premise
9	the	N	I-Premise
10	low-	N	I-Premise
11	and	N	I-Premise
12	high-dose	N	I-Premise
13	arms	N	I-Premise
14	in	N	I-Premise
15	reported	N	I-Premise
16	intensity	N	I-Premise
17	of	N	I-Premise
18	drug	N	I-Premise
19	side	N	I-Premise
20	effects	N	I-Premise
21	,	N	I-Premise
22	but	N	I-Premise
23	responded	N	I-Premise
24	similarly	N	I-Premise
25	to	N	I-Premise
26	those	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	160-mg/d	N	I-Premise
30	group	N	I-Premise
31	in	N	I-Premise
32	terms	N	I-Premise
33	of	N	I-Premise
34	physical	N	I-Premise
35	functioning	N	I-Premise
36	,	N	I-Premise
37	psychologic	N	I-Premise
38	distress	N	I-Premise
39	,	N	I-Premise
40	and	N	I-Premise
41	overall	N	I-Premise
42	quality	N	I-Premise
43	of	N	I-Premise
44	life	N	I-Premise
45	.	N	I-Premise

1	Unless	N	I-Claim
2	additional	N	I-Claim
3	follow-up	N	I-Claim
4	data	N	I-Claim
5	demonstrate	N	I-Claim
6	a	N	I-Claim
7	survival	N	I-Claim
8	advantage	N	I-Claim
9	at	N	I-Claim
10	higher	N	I-Claim
11	doses	N	I-Claim
12	,	N	I-Claim
13	the	N	I-Claim
14	160-mg/d	N	I-Claim
15	dose	N	I-Claim
16	is	N	I-Claim
17	optimal	N	I-Claim
18	,	N	I-Claim
19	achieving	N	I-Claim
20	maximal	N	I-Claim
21	treatment	N	I-Claim
22	effect	N	I-Claim
23	with	N	I-Claim
24	the	N	I-Claim
25	fewest	N	I-Claim
26	side	N	I-Claim
27	effects	N	I-Claim
28	and	N	I-Claim
29	better	N	I-Claim
30	quality	N	I-Claim
31	of	N	I-Claim
32	life	N	I-Claim
33	.	N	I-Claim

1	A	N	O
2	single-item	N	O
3	linear	N	O
4	analogue	N	O
5	self-assessment	N	O
6	scale	N	O
7	for	N	O
8	mood	N	O
9	was	N	O
10	compared	N	O
11	with	N	O
12	a	N	O
13	28-item	N	O
14	adjective	N	O
15	checklist	N	O
16	for	N	O
17	emotional	N	O
18	well-being	N	O
19	.	N	O

1	To	N	O
2	confirm	N	O
3	its	N	O
4	concurrent	N	O
5	validity	N	O
6	and	N	O
7	responsiveness	N	O
8	to	N	O
9	treatment	N	O
10	and	N	O
11	recurrence	N	O
12	in	N	O
13	patients	N	O
14	with	N	O
15	breast	N	O
16	cancer	N	O
17	,	N	O
18	emotional	N	O
19	well-being	N	O
20	was	N	O
21	assessed	N	O
22	every	N	O
23	3	N	O
24	months	N	O
25	for	N	O
26	2	N	O
27	years	N	O
28	and	N	O
29	at	N	O
30	1	N	O
31	and	N	O
32	6	N	O
33	months	N	O
34	after	N	O
35	recurrence	N	O
36	in	N	O
37	1,169	N	O
38	patients	N	O
39	who	N	O
40	were	N	O
41	premenopausal	N	O
42	and	N	O
43	960	N	O
44	patients	N	O
45	who	N	O
46	were	N	O
47	postmenopausal	N	O
48	.	N	O

1	These	N	O
2	patients	N	O
3	were	N	O
4	enrolled	N	O
5	in	N	O
6	two	N	O
7	International	N	O
8	Breast	N	O
9	Cancer	N	O
10	Study	N	O
11	Group	N	O
12	randomized	N	O
13	clinical	N	O
14	trials	N	O
15	in	N	O
16	operable	N	O
17	breast	N	O
18	cancer	N	O
19	conducted	N	O
20	from	N	O
21	1986	N	O
22	to	N	O
23	1993	N	O
24	.	N	O

1	To	N	O
2	assess	N	O
3	concurrent	N	O
4	validity	N	O
5	,	N	O
6	Pearson	N	O
7	's	N	O
8	correlation	N	O
9	between	N	O
10	the	N	O
11	linear	N	O
12	analogue	N	O
13	self-assessment	N	O
14	scale	N	O
15	and	N	O
16	the	N	O
17	adjective	N	O
18	checklist	N	O
19	were	N	O
20	calculated	N	O
21	for	N	O
22	each	N	O
23	time-point	N	O
24	within	N	O
25	each	N	O
26	treatment	N	O
27	group	N	O
28	and	N	O
29	for	N	O
30	the	N	O
31	two	N	O
32	assessments	N	O
33	after	N	O
34	recurrence	N	O
35	.	N	O

1	Responsiveness	N	O
2	to	N	O
3	treatment	N	O
4	and	N	O
5	recurrence	N	O
6	were	N	O
7	analyzed	N	O
8	using	N	O
9	paired	N	O
10	t	N	O
11	tests	N	O
12	and	N	O
13	the	N	O
14	squared	N	O
15	ratio	N	O
16	of	N	O
17	these	N	O
18	t	N	O
19	tests	N	O
20	,	N	O
21	an	N	O
22	estimate	N	O
23	of	N	O
24	relative	N	O
25	efficiency	N	O
26	.	N	O

1	Concurrent	N	O
2	validity	N	O
3	of	N	O
4	the	N	O
5	mood	N	O
6	linear	N	O
7	analogue	N	O
8	self-assessment	N	O
9	was	N	O
10	consistently	N	O
11	confirmed	N	O
12	across	N	O
13	four	N	O
14	language	N	O
15	groups	N	O
16	.	N	O

1	Both	N	I-Claim
2	measures	N	I-Claim
3	were	N	I-Claim
4	responsive	N	I-Claim
5	;	N	I-Claim
6	out	N	I-Premise
7	of	N	I-Premise
8	24	N	I-Premise
9	changes	N	I-Premise
10	over	N	I-Premise
11	time	N	I-Premise
12	,	N	I-Premise
13	19	N	I-Premise
14	were	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	expected	N	I-Premise
18	direction	N	I-Premise
19	for	N	I-Premise
20	the	N	I-Premise
21	linear	N	I-Premise
22	analogue	N	I-Premise
23	self-assessment	N	I-Premise
24	scale	N	I-Premise
25	(	N	I-Premise
26	p	N	I-Premise
27	<	N	I-Premise
28	or	N	I-Premise
29	=	N	I-Premise
30	0.05	N	I-Premise
31	for	N	I-Premise
32	9	N	I-Premise
33	of	N	I-Premise
34	19	N	I-Premise
35	)	N	I-Premise
36	and	N	I-Premise
37	17	N	I-Premise
38	for	N	I-Premise
39	the	N	I-Premise
40	adjective	N	I-Premise
41	checklist	N	I-Premise
42	(	N	I-Premise
43	p	N	I-Premise
44	<	N	I-Premise
45	or	N	I-Premise
46	=	N	I-Premise
47	0.05	N	I-Premise
48	for	N	I-Premise
49	10	N	I-Premise
50	of	N	I-Premise
51	17	N	I-Premise
52	)	N	I-Premise
53	.	N	I-Premise

1	The	N	I-Premise
2	linear	N	I-Premise
3	analogue	N	I-Premise
4	self-assessment	N	I-Premise
5	scale	N	I-Premise
6	was	N	I-Premise
7	less	N	I-Premise
8	but	N	I-Premise
9	significantly	N	I-Premise
10	efficient	N	I-Premise
11	for	N	I-Premise
12	detection	N	I-Premise
13	of	N	I-Premise
14	treatment	N	I-Premise
15	effects	N	I-Premise
16	,	N	I-Premise
17	with	N	I-Premise
18	relative	N	I-Premise
19	efficiency	N	I-Premise
20	estimates	N	I-Premise
21	ranging	N	I-Premise
22	from	N	I-Premise
23	0.16	N	I-Premise
24	to	N	I-Premise
25	2.45	N	I-Premise
26	and	N	I-Premise
27	a	N	I-Premise
28	median	N	I-Premise
29	of	N	I-Premise
30	0.66	N	I-Premise
31	among	N	I-Premise
32	the	N	I-Premise
33	comparisons	N	I-Premise
34	with	N	I-Premise
35	relatively	N	I-Premise
36	stable	N	I-Premise
37	estimates	N	I-Premise
38	(	N	I-Premise
39	/t/	N	I-Premise
40	>	N	I-Premise
41	or	N	I-Premise
42	=	N	I-Premise
43	1.0	N	I-Premise
44	)	N	I-Premise
45	and	N	I-Premise
46	more	N	I-Premise
47	efficient	N	I-Premise
48	for	N	I-Premise
49	recurrence	N	I-Premise
50	than	N	I-Premise
51	the	N	I-Premise
52	adjective	N	I-Premise
53	checklist	N	I-Premise
54	.	N	I-Premise

1	The	N	I-Claim
2	mood	N	I-Claim
3	linear	N	I-Claim
4	analogue	N	I-Claim
5	self-assessment	N	I-Claim
6	scale	N	I-Claim
7	is	N	I-Claim
8	a	N	I-Claim
9	valid	N	I-Claim
10	indicator	N	I-Claim
11	of	N	I-Claim
12	emotional	N	I-Claim
13	well-being	N	I-Claim
14	in	N	I-Claim
15	patients	N	I-Claim
16	with	N	I-Claim
17	breast	N	I-Claim
18	cancer	N	I-Claim
19	in	N	I-Claim
20	large	N	I-Claim
21	multicenter	N	I-Claim
22	,	N	I-Claim
23	multicultural	N	I-Claim
24	trials	N	I-Claim
25	in	N	I-Claim
26	which	N	I-Claim
27	comprehensive	N	I-Claim
28	scales	N	I-Claim
29	are	N	I-Claim
30	less	N	I-Claim
31	feasible	N	I-Claim
32	.	N	I-Claim

1	This	N	I-Claim
2	investigation	N	I-Claim
3	supports	N	I-Claim
4	the	N	I-Claim
5	clinical	N	I-Claim
6	relevance	N	I-Claim
7	of	N	I-Claim
8	linear	N	I-Claim
9	analogue	N	I-Claim
10	self-assessment	N	I-Claim
11	scales	N	I-Claim
12	as	N	I-Claim
13	indicators	N	I-Claim
14	of	N	I-Claim
15	components	N	I-Claim
16	of	N	I-Claim
17	quality	N	I-Claim
18	of	N	I-Claim
19	life	N	I-Claim
20	in	N	I-Claim
21	cancer	N	I-Claim
22	clinical	N	I-Claim
23	trials	N	I-Claim
24	.	N	I-Claim

1	To	N	O
2	assess	N	O
3	whether	N	O
4	the	N	O
5	administration	N	O
6	of	N	O
7	recombinant	N	O
8	human	N	O
9	erythropoietin	N	O
10	(	N	O
11	r-HuEPO	N	O
12	)	N	O
13	would	N	O
14	increase	N	O
15	the	N	O
16	hematocrit	N	O
17	,	N	O
18	reduce	N	O
19	the	N	O
20	requirement	N	O
21	for	N	O
22	transfusion	N	O
23	,	N	O
24	and	N	O
25	improve	N	O
26	the	N	O
27	quality	N	O
28	of	N	O
29	life	N	O
30	in	N	O
31	anemic	N	O
32	cancer	N	O
33	patients	N	O
34	receiving	N	O
35	myelosuppressive	N	O
36	,	N	O
37	cisplatin-based	N	O
38	chemotherapy	N	O
39	.	N	O

1	One	N	O
2	hundred	N	O
3	thirty-two	N	O
4	anemic	N	O
5	cancer	N	O
6	patients	N	O
7	receiving	N	O
8	cyclic	N	O
9	,	N	O
10	cisplatin-containing	N	O
11	,	N	O
12	myelosuppressive	N	O
13	chemotherapy	N	O
14	were	N	O
15	evaluated	N	O
16	.	N	O

1	Patients	N	O
2	received	N	O
3	either	N	O
4	r-HuEPO	N	O
5	(	N	O
6	150	N	O
7	U/kg	N	O
8	)	N	O
9	or	N	O
10	placebo	N	O
11	,	N	O
12	subcutaneously	N	O
13	,	N	O
14	three	N	O
15	times	N	O
16	a	N	O
17	week	N	O
18	for	N	O
19	3	N	O
20	months	N	O
21	.	N	O

1	Responses	N	O
2	were	N	O
3	assessed	N	O
4	by	N	O
5	measuring	N	O
6	changes	N	O
7	in	N	O
8	hemoglobin/hematocrit	N	O
9	,	N	O
10	transfusion	N	O
11	requirement	N	O
12	,	N	O
13	and	N	O
14	quality	N	O
15	of	N	O
16	life	N	O
17	.	N	O

1	The	N	I-Premise
2	mean	N	I-Premise
3	hematocrit	N	I-Premise
4	increased	N	I-Premise
5	by	N	I-Premise
6	6.0	N	I-Premise
7	percentage	N	I-Premise
8	points	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	r-HuEPO	N	I-Premise
12	group	N	I-Premise
13	versus	N	I-Premise
14	1.3	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	placebo	N	I-Premise
18	group	N	I-Premise
19	.	N	I-Premise

1	A	N	I-Premise
2	decrease	N	I-Premise
3	in	N	I-Premise
4	transfusion	N	I-Premise
5	requirement	N	I-Premise
6	did	N	I-Premise
7	not	N	I-Premise
8	reach	N	I-Premise
9	significance	N	I-Premise
10	over	N	I-Premise
11	all	N	I-Premise
12	3	N	I-Premise
13	months	N	I-Premise
14	,	N	I-Premise
15	but	N	I-Premise
16	there	N	I-Premise
17	was	N	I-Premise
18	a	N	I-Premise
19	significant	N	I-Premise
20	reduction	N	I-Premise
21	in	N	I-Premise
22	the	N	I-Premise
23	percentage	N	I-Premise
24	of	N	I-Premise
25	patients	N	I-Premise
26	transfused	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	second	N	I-Premise
30	and	N	I-Premise
31	third	N	I-Premise
32	months	N	I-Premise
33	(	N	I-Premise
34	27	N	I-Premise
35	%	N	I-Premise
36	r-HuEPO	N	I-Premise
37	vs.	N	I-Premise
38	56	N	I-Premise
39	%	N	I-Premise
40	placebo	N	I-Premise
41	)	N	I-Premise
42	and	N	I-Premise
43	a	N	I-Premise
44	trend	N	I-Premise
45	toward	N	I-Premise
46	reduction	N	I-Premise
47	in	N	I-Premise
48	the	N	I-Premise
49	mean	N	I-Premise
50	total	N	I-Premise
51	number	N	I-Premise
52	of	N	I-Premise
53	units	N	I-Premise
54	transfused	N	I-Premise
55	(	N	I-Premise
56	1.20	N	I-Premise
57	units	N	I-Premise
58	r-HuEPO	N	I-Premise
59	vs.	N	I-Premise
60	2.02	N	I-Premise
61	units	N	I-Premise
62	placebo	N	I-Premise
63	)	N	I-Premise
64	,	N	I-Premise
65	suggesting	N	I-Premise
66	a	N	I-Premise
67	lag	N	I-Premise
68	of	N	I-Premise
69	1	N	I-Premise
70	month	N	I-Premise
71	before	N	I-Premise
72	r-HuEPO	N	I-Premise
73	can	N	I-Premise
74	affect	N	I-Premise
75	the	N	I-Premise
76	transfusion	N	I-Premise
77	requirement	N	I-Premise
78	.	N	I-Premise

1	Pretreatment	N	I-Premise
2	serum	N	I-Premise
3	erythropoietin	N	I-Premise
4	levels	N	I-Premise
5	were	N	I-Premise
6	lower	N	I-Premise
7	in	N	I-Premise
8	responders	N	I-Premise
9	than	N	I-Premise
10	in	N	I-Premise
11	nonresponders	N	I-Premise
12	(	N	I-Premise
13	73.5	N	I-Premise
14	IU/L	N	I-Premise
15	and	N	I-Premise
16	86.3	N	I-Premise
17	IU/L	N	I-Premise
18	means	N	I-Premise
19	,	N	I-Premise
20	respectively	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	However	N	I-Premise
2	,	N	I-Premise
3	the	N	I-Premise
4	magnitude	N	I-Premise
5	of	N	I-Premise
6	this	N	I-Premise
7	difference	N	I-Premise
8	was	N	I-Premise
9	not	N	I-Premise
10	helpful	N	I-Premise
11	in	N	I-Premise
12	defining	N	I-Premise
13	which	N	I-Premise
14	patients	N	I-Premise
15	were	N	I-Premise
16	likely	N	I-Premise
17	to	N	I-Premise
18	respond	N	I-Premise
19	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	significant	N	I-Premise
5	improvement	N	I-Premise
6	in	N	I-Premise
7	overall	N	I-Premise
8	quality	N	I-Premise
9	of	N	I-Premise
10	life	N	I-Premise
11	between	N	I-Premise
12	the	N	I-Premise
13	two	N	I-Premise
14	treatment	N	I-Premise
15	arms	N	I-Premise
16	in	N	I-Premise
17	favor	N	I-Premise
18	of	N	I-Premise
19	the	N	I-Premise
20	r-HuEPO-treated	N	I-Premise
21	group	N	I-Premise
22	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	no	N	I-Premise
4	significant	N	I-Premise
5	adverse	N	I-Premise
6	effects	N	I-Premise
7	associated	N	I-Premise
8	with	N	I-Premise
9	r-HuEPO	N	I-Premise
10	.	N	I-Premise

1	r-HuEPO	N	I-Claim
2	is	N	I-Claim
3	safe	N	I-Claim
4	and	N	I-Claim
5	can	N	I-Claim
6	cause	N	I-Claim
7	a	N	I-Claim
8	significant	N	I-Claim
9	improvement	N	I-Claim
10	in	N	I-Claim
11	the	N	I-Claim
12	hematocrit	N	I-Claim
13	and	N	I-Claim
14	quality	N	I-Claim
15	of	N	I-Claim
16	life	N	I-Claim
17	of	N	I-Claim
18	anemic	N	I-Claim
19	cancer	N	I-Claim
20	patients	N	I-Claim
21	receiving	N	I-Claim
22	myelosuppressive	N	I-Claim
23	,	N	I-Claim
24	cisplatin-based	N	I-Claim
25	chemotherapy	N	I-Claim
26	.	N	I-Claim

1	After	N	I-Claim
2	1	N	I-Claim
3	month	N	I-Claim
4	of	N	I-Claim
5	r-HuEPO	N	I-Claim
6	,	N	I-Claim
7	there	N	I-Claim
8	is	N	I-Claim
9	also	N	I-Claim
10	a	N	I-Claim
11	reduction	N	I-Claim
12	in	N	I-Claim
13	transfusion	N	I-Claim
14	requirement	N	I-Claim
15	.	N	I-Claim

1	To	N	O
2	compare	N	O
3	protracted	N	O
4	venous	N	O
5	infusion	N	O
6	(	N	O
7	PVI	N	O
8	)	N	O
9	5-fluorouracil	N	O
10	(	N	O
11	5-FU	N	O
12	)	N	O
13	with	N	O
14	and	N	O
15	without	N	O
16	mitomycin	N	O
17	C	N	O
18	(	N	O
19	MMC	N	O
20	)	N	O
21	in	N	O
22	a	N	O
23	prospectively	N	O
24	randomised	N	O
25	study	N	O
26	and	N	O
27	analyse	N	O
28	for	N	O
29	tumour	N	O
30	response	N	O
31	,	N	O
32	survival	N	O
33	,	N	O
34	toxicity	N	O
35	and	N	O
36	quality	N	O
37	of	N	O
38	life	N	O
39	(	N	O
40	QL	N	O
41	)	N	O
42	.	N	O

1	Two	N	O
2	hundred	N	O
3	patients	N	O
4	with	N	O
5	advanced	N	O
6	colorectal	N	O
7	cancer	N	O
8	received	N	O
9	PVI	N	O
10	5-FU	N	O
11	300	N	O
12	mg/m2/day	N	O
13	for	N	O
14	a	N	O
15	maximum	N	O
16	of	N	O
17	24	N	O
18	weeks	N	O
19	and	N	O
20	were	N	O
21	randomised	N	O
22	to	N	O
23	PVI	N	O
24	5-FU	N	O
25	alone	N	O
26	or	N	O
27	PVI	N	O
28	5-FU	N	O
29	+	N	O
30	MMC	N	O
31	10	N	O
32	mg/m2	N	O
33	(	N	O
34	7	N	O
35	mg/m2	N	O
36	from	N	O
37	June	N	O
38	1995	N	O
39	)	N	O
40	6	N	O
41	weekly	N	O
42	for	N	O
43	4	N	O
44	courses	N	O
45	.	N	O

1	Overall	N	I-Premise
2	response	N	I-Premise
3	was	N	I-Premise
4	54	N	I-Premise
5	%	N	I-Premise
6	(	N	I-Premise
7	95	N	I-Premise
8	%	N	I-Premise
9	confidence	N	I-Premise
10	interval	N	I-Premise
11	[	N	I-Premise
12	CI	N	I-Premise
13	]	N	I-Premise
14	44.1	N	I-Premise
15	%	N	I-Premise
16	-63.9	N	I-Premise
17	%	N	I-Premise
18	)	N	I-Premise
19	with	N	I-Premise
20	PVI	N	I-Premise
21	5-FU	N	I-Premise
22	+	N	I-Premise
23	MMC	N	I-Premise
24	compared	N	I-Premise
25	to	N	I-Premise
26	38	N	I-Premise
27	%	N	I-Premise
28	(	N	I-Premise
29	95	N	I-Premise
30	%	N	I-Premise
31	CI	N	I-Premise
32	:	N	I-Premise
33	28.3	N	I-Premise
34	%	N	I-Premise
35	-47.7	N	I-Premise
36	%	N	I-Premise
37	)	N	I-Premise
38	for	N	I-Premise
39	PVI	N	I-Premise
40	5-FU	N	I-Premise
41	alone	N	I-Premise
42	(	N	I-Premise
43	P	N	I-Premise
44	=	N	I-Premise
45	0.024	N	I-Premise
46	)	N	I-Premise
47	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	failure	N	I-Premise
4	free	N	I-Premise
5	survival	N	I-Premise
6	was	N	I-Premise
7	7.9	N	I-Premise
8	months	N	I-Premise
9	in	N	I-Premise
10	PVI	N	I-Premise
11	5-FU	N	I-Premise
12	plus	N	I-Premise
13	MMC	N	I-Premise
14	and	N	I-Premise
15	5.4	N	I-Premise
16	months	N	I-Premise
17	with	N	I-Premise
18	PVI	N	I-Premise
19	5-FU	N	I-Premise
20	alone	N	I-Premise
21	(	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	0.033	N	I-Premise
25	)	N	I-Premise
26	and	N	I-Premise
27	at	N	I-Premise
28	one	N	I-Premise
29	year	N	I-Premise
30	31.9	N	I-Premise
31	%	N	I-Premise
32	for	N	I-Premise
33	the	N	I-Premise
34	combination	N	I-Premise
35	compared	N	I-Premise
36	to	N	I-Premise
37	17.7	N	I-Premise
38	%	N	I-Premise
39	for	N	I-Premise
40	PVI	N	I-Premise
41	5-FU	N	I-Premise
42	alone	N	I-Premise
43	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	was	N	I-Premise
4	14	N	I-Premise
5	months	N	I-Premise
6	with	N	I-Premise
7	MMC	N	I-Premise
8	and	N	I-Premise
9	15	N	I-Premise
10	months	N	I-Premise
11	in	N	I-Premise
12	5-FU	N	I-Premise
13	alone	N	I-Premise
14	;	N	I-Premise
15	one-year	N	I-Premise
16	survival	N	I-Premise
17	51.7	N	I-Premise
18	%	N	I-Premise
19	vs.	N	I-Premise
20	57.2	N	I-Premise
21	%	N	I-Premise
22	.	N	I-Premise

1	PVI	N	I-Premise
2	5-FU	N	I-Premise
3	+	N	I-Premise
4	MMC	N	I-Premise
5	caused	N	I-Premise
6	more	N	I-Premise
7	overall	N	I-Premise
8	haematological	N	I-Premise
9	toxicity	N	I-Premise
10	but	N	I-Premise
11	CTC	N	I-Premise
12	grades	N	I-Premise
13	3/4	N	I-Premise
14	was	N	I-Premise
15	increased	N	I-Premise
16	only	N	I-Premise
17	for	N	I-Premise
18	thrombocytopaenia	N	I-Premise
19	.	N	I-Premise

1	Two	N	I-Premise
2	patients	N	I-Premise
3	treated	N	I-Premise
4	with	N	I-Premise
5	a	N	I-Premise
6	cumulative	N	I-Premise
7	dose	N	I-Premise
8	of	N	I-Premise
9	MMC	N	I-Premise
10	of	N	I-Premise
11	40	N	I-Premise
12	mg/m2	N	I-Premise
13	developed	N	I-Premise
14	haemolytic	N	I-Premise
15	uraemic	N	I-Premise
16	syndrome	N	I-Premise
17	warranting	N	I-Premise
18	the	N	I-Premise
19	reduction	N	I-Premise
20	in	N	I-Premise
21	cumulative	N	I-Premise
22	MMC	N	I-Premise
23	dose	N	I-Premise
24	to	N	I-Premise
25	28	N	I-Premise
26	mg/m2	N	I-Premise
27	.	N	I-Premise

1	The	N	I-Premise
2	global	N	I-Premise
3	QL	N	I-Premise
4	scores	N	I-Premise
5	were	N	I-Premise
6	better	N	I-Premise
7	for	N	I-Premise
8	PVI	N	I-Premise
9	5-FU	N	I-Premise
10	+	N	I-Premise
11	MMC	N	I-Premise
12	arm	N	I-Premise
13	at	N	I-Premise
14	24	N	I-Premise
15	weeks	N	I-Premise
16	,	N	I-Premise
17	but	N	I-Premise
18	the	N	I-Premise
19	remaining	N	I-Premise
20	QL	N	I-Premise
21	data	N	I-Premise
22	showed	N	I-Premise
23	no	N	I-Premise
24	differences	N	I-Premise
25	.	N	I-Premise

1	PVI	N	I-Claim
2	5-FU	N	I-Claim
3	+	N	I-Claim
4	MMC	N	I-Claim
5	results	N	I-Claim
6	in	N	I-Claim
7	failure-free	N	I-Claim
8	survival	N	I-Claim
9	and	N	I-Claim
10	response	N	I-Claim
11	advantage	N	I-Claim
12	,	N	I-Claim
13	tolerable	N	I-Claim
14	toxicity	N	I-Claim
15	and	N	I-Claim
16	better	N	I-Claim
17	QL	N	I-Claim
18	when	N	I-Claim
19	compared	N	I-Claim
20	to	N	I-Claim
21	PVI	N	I-Claim
22	5-FU	N	I-Claim
23	alone	N	I-Claim
24	but	N	I-Claim
25	no	N	I-Claim
26	overall	N	I-Claim
27	survival	N	I-Claim
28	advantage	N	I-Claim
29	.	N	I-Claim

1	There	N	I-Premise
2	is	N	I-Premise
3	no	N	I-Premise
4	irreversible	N	I-Premise
5	toxicity	N	I-Premise
6	with	N	I-Premise
7	MMC	N	I-Premise
8	at	N	I-Premise
9	a	N	I-Premise
10	cumulative	N	I-Premise
11	dose	N	I-Premise
12	of	N	I-Premise
13	28	N	I-Premise
14	mg/m2	N	I-Premise
15	.	N	I-Premise

1	The	N	O
2	effectiveness	N	O
3	of	N	O
4	a	N	O
5	Pain	N	O
6	Education	N	O
7	Program	N	O
8	in	N	O
9	cancer	N	O
10	patients	N	O
11	with	N	O
12	chronic	N	O
13	pain	N	O
14	offered	N	O
15	by	N	O
16	nurses	N	O
17	was	N	O
18	investigated	N	O
19	in	N	O
20	a	N	O
21	randomized	N	O
22	controlled	N	O
23	clinical	N	O
24	trial	N	O
25	.	N	O

1	A	N	O
2	multi-method	N	O
3	approach	N	O
4	was	N	O
5	used	N	O
6	in	N	O
7	which	N	O
8	verbal	N	O
9	instruction	N	O
10	,	N	O
11	written	N	O
12	material	N	O
13	,	N	O
14	an	N	O
15	audio	N	O
16	cassette	N	O
17	tape	N	O
18	,	N	O
19	and	N	O
20	the	N	O
21	use	N	O
22	of	N	O
23	a	N	O
24	pain	N	O
25	diary	N	O
26	were	N	O
27	combined	N	O
28	to	N	O
29	inform	N	O
30	and	N	O
31	instruct	N	O
32	patients	N	O
33	about	N	O
34	pain	N	O
35	and	N	O
36	pain	N	O
37	management	N	O
38	.	N	O

1	The	N	O
2	Pain	N	O
3	Education	N	O
4	Program	N	O
5	was	N	O
6	tailored	N	O
7	to	N	O
8	the	N	O
9	needs	N	O
10	of	N	O
11	the	N	O
12	individual	N	O
13	patient	N	O
14	and	N	O
15	consisted	N	O
16	of	N	O
17	three	N	O
18	elements	N	O
19	:	N	O
20	(	N	O
21	1	N	O
22	)	N	O
23	educating	N	O
24	patients	N	O
25	about	N	O
26	the	N	O
27	basic	N	O
28	principles	N	O
29	regarding	N	O
30	pain	N	O
31	and	N	O
32	pain	N	O
33	management	N	O
34	;	N	O
35	(	N	O
36	2	N	O
37	)	N	O
38	instructing	N	O
39	patients	N	O
40	how	N	O
41	to	N	O
42	report	N	O
43	their	N	O
44	pain	N	O
45	in	N	O
46	a	N	O
47	pain	N	O
48	diary	N	O
49	;	N	O
50	and	N	O
51	(	N	O
52	3	N	O
53	)	N	O
54	instructing	N	O
55	patients	N	O
56	how	N	O
57	to	N	O
58	communicate	N	O
59	about	N	O
60	pain	N	O
61	and	N	O
62	how	N	O
63	to	N	O
64	contact	N	O
65	health	N	O
66	care	N	O
67	providers	N	O
68	.	N	O

1	Following	N	O
2	pretesting	N	O
3	in	N	O
4	313	N	O
5	patients	N	O
6	,	N	O
7	patients	N	O
8	who	N	O
9	needed	N	O
10	district	N	O
11	nursing	N	O
12	and	N	O
13	who	N	O
14	did	N	O
15	not	N	O
16	need	N	O
17	district	N	O
18	nursing	N	O
19	at	N	O
20	home	N	O
21	were	N	O
22	randomly	N	O
23	assigned	N	O
24	to	N	O
25	a	N	O
26	control	N	O
27	or	N	O
28	intervention	N	O
29	group	N	O
30	.	N	O

1	Intervention	N	O
2	group	N	O
3	patients	N	O
4	received	N	O
5	the	N	O
6	Pain	N	O
7	Education	N	O
8	Program	N	O
9	in	N	O
10	the	N	O
11	hospital	N	O
12	,	N	O
13	and	N	O
14	3	N	O
15	and	N	O
16	7	N	O
17	days	N	O
18	postdischarge	N	O
19	by	N	O
20	telephone	N	O
21	;	N	O
22	this	N	O
23	was	N	O
24	done	N	O
25	by	N	O
26	nurses	N	O
27	who	N	O
28	were	N	O
29	specially	N	O
30	trained	N	O
31	as	N	O
32	pain	N	O
33	counselors	N	O
34	.	N	O

1	Follow-up	N	O
2	assessments	N	O
3	were	N	O
4	at	N	O
5	2	N	O
6	,	N	O
7	4	N	O
8	and	N	O
9	8	N	O
10	weeks	N	O
11	postdischarge	N	O
12	.	N	O

1	Results	N	O
2	of	N	O
3	the	N	O
4	pretest	N	O
5	showed	N	O
6	that	N	O
7	many	N	O
8	patients	N	O
9	lacked	N	O
10	knowledge	N	O
11	about	N	O
12	pain	N	O
13	and	N	O
14	pain	N	O
15	management	N	O
16	.	N	O

1	The	N	O
2	majority	N	O
3	of	N	O
4	pain	N	O
5	topics	N	O
6	had	N	O
7	to	N	O
8	be	N	O
9	discussed	N	O
10	.	N	O

1	The	N	I-Claim
2	Pain	N	I-Claim
3	Education	N	I-Claim
4	Program	N	I-Claim
5	proved	N	I-Claim
6	to	N	I-Claim
7	be	N	I-Claim
8	feasible	N	I-Claim
9	:	N	I-Claim
10	75.0	N	I-Premise
11	%	N	I-Premise
12	of	N	I-Premise
13	the	N	I-Premise
14	patients	N	I-Premise
15	had	N	I-Premise
16	read	N	I-Premise
17	the	N	I-Premise
18	entire	N	I-Premise
19	pain	N	I-Premise
20	brochure	N	I-Premise
21	,	N	I-Premise
22	55.7	N	I-Premise
23	%	N	I-Premise
24	had	N	I-Premise
25	listened	N	I-Premise
26	to	N	I-Premise
27	the	N	I-Premise
28	audio	N	I-Premise
29	cassette	N	I-Premise
30	,	N	I-Premise
31	and	N	I-Premise
32	85.6	N	I-Premise
33	%	N	I-Premise
34	of	N	I-Premise
35	pain	N	I-Premise
36	scores	N	I-Premise
37	were	N	I-Premise
38	completed	N	I-Premise
39	in	N	I-Premise
40	the	N	I-Premise
41	pain	N	I-Premise
42	diary	N	I-Premise
43	.	N	I-Premise

1	Results	N	I-Claim
2	showed	N	I-Claim
3	a	N	I-Claim
4	significant	N	I-Claim
5	increase	N	I-Claim
6	in	N	I-Claim
7	pain	N	I-Claim
8	knowledge	N	I-Claim
9	in	N	I-Claim
10	patients	N	I-Claim
11	who	N	I-Claim
12	received	N	I-Claim
13	the	N	I-Claim
14	Pain	N	I-Claim
15	Education	N	I-Claim
16	Program	N	I-Claim
17	and	N	I-Claim
18	a	N	I-Claim
19	significant	N	I-Claim
20	decrease	N	I-Claim
21	in	N	I-Claim
22	pain	N	I-Claim
23	intensity	N	I-Claim
24	.	N	I-Claim

1	However	N	I-Premise
2	,	N	I-Premise
3	pain	N	I-Premise
4	relief	N	I-Premise
5	was	N	I-Premise
6	mainly	N	I-Premise
7	found	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	intervention	N	I-Premise
11	group	N	I-Premise
12	patients	N	I-Premise
13	without	N	I-Premise
14	district	N	I-Premise
15	nursing	N	I-Premise
16	.	N	I-Premise

1	It	N	I-Claim
2	can	N	I-Claim
3	be	N	I-Claim
4	concluded	N	I-Claim
5	that	N	I-Claim
6	the	N	I-Claim
7	tailored	N	I-Claim
8	Pain	N	I-Claim
9	Education	N	I-Claim
10	Program	N	I-Claim
11	is	N	I-Claim
12	effective	N	I-Claim
13	for	N	I-Claim
14	cancer	N	I-Claim
15	patients	N	I-Claim
16	in	N	I-Claim
17	chronic	N	I-Claim
18	pain	N	I-Claim
19	.	N	I-Claim

1	The	N	I-MajorClaim
2	use	N	I-MajorClaim
3	of	N	I-MajorClaim
4	the	N	I-MajorClaim
5	Pain	N	I-MajorClaim
6	Education	N	I-MajorClaim
7	Program	N	I-MajorClaim
8	by	N	I-MajorClaim
9	nurses	N	I-MajorClaim
10	should	N	I-MajorClaim
11	be	N	I-MajorClaim
12	seriously	N	I-MajorClaim
13	considered	N	I-MajorClaim
14	on	N	I-MajorClaim
15	oncology	N	I-MajorClaim
16	units	N	I-MajorClaim
17	.	N	I-MajorClaim

1	The	N	O
2	aim	N	O
3	of	N	O
4	this	N	O
5	study	N	O
6	was	N	O
7	to	N	O
8	evaluate	N	O
9	pamidronate	N	O
10	for	N	O
11	bone	N	O
12	pain	N	O
13	in	N	O
14	a	N	O
15	randomised	N	O
16	double-blind	N	O
17	trial	N	O
18	and	N	O
19	to	N	O
20	evaluate	N	O
21	the	N	O
22	contribution	N	O
23	of	N	O
24	new	N	O
25	markers	N	O
26	of	N	O
27	bone	N	O
28	resorption	N	O
29	in	N	O
30	patients	N	O
31	with	N	O
32	bone	N	O
33	metastases	N	O
34	.	N	O

1	Fifty-two	N	O
2	patients	N	O
3	with	N	O
4	painful	N	O
5	bone	N	O
6	metastases	N	O
7	were	N	O
8	randomised	N	O
9	to	N	O
10	receive	N	O
11	a	N	O
12	two-hour	N	O
13	infusion	N	O
14	of	N	O
15	pamidronate	N	O
16	120	N	O
17	mg	N	O
18	or	N	O
19	an	N	O
20	identical	N	O
21	infusion	N	O
22	of	N	O
23	saline	N	O
24	.	N	O

1	Four	N	O
2	weeks	N	O
3	later	N	O
4	,	N	O
5	all	N	O
6	patients	N	O
7	received	N	O
8	pamidronate	N	O
9	120	N	O
10	mg	N	O
11	.	N	O

1	Bone	N	O
2	resorption	N	O
3	markers	N	O
4	measured	N	O
5	included	N	O
6	urinary	N	O
7	calcium	N	O
8	(	N	O
9	uCa	N	O
10	)	N	O
11	,	N	O
12	hydroxyproline	N	O
13	(	N	O
14	Hyp	N	O
15	)	N	O
16	,	N	O
17	and	N	O
18	the	N	O
19	collagen	N	O
20	breakdown	N	O
21	products	N	O
22	:	N	O
23	NTx	N	O
24	,	N	O
25	Crosslaps	N	O
26	and	N	O
27	Free	N	O
28	Dpd	N	O
29	.	N	O

1	Symptomatic	N	I-Premise
2	response	N	I-Premise
3	during	N	I-Premise
4	the	N	I-Premise
5	first	N	I-Premise
6	four	N	I-Premise
7	weeks	N	I-Premise
8	was	N	I-Premise
9	seen	N	I-Premise
10	after	N	I-Premise
11	pamidronate	N	I-Premise
12	,	N	I-Premise
13	but	N	I-Premise
14	not	N	I-Premise
15	with	N	I-Premise
16	placebo	N	I-Premise
17	(	N	I-Premise
18	P	N	I-Premise
19	<	N	I-Premise
20	0.05	N	I-Premise
21	)	N	I-Premise
22	.	N	I-Premise

1	Quality	N	I-Premise
2	of	N	I-Premise
3	life	N	I-Premise
4	was	N	I-Premise
5	maintained	N	I-Premise
6	with	N	I-Premise
7	pamidronate	N	I-Premise
8	and	N	I-Premise
9	deteriorated	N	I-Premise
10	after	N	I-Premise
11	placebo	N	I-Premise
12	(	N	I-Premise
13	P	N	I-Premise
14	<	N	I-Premise
15	0.05	N	I-Premise
16	)	N	I-Premise
17	.	N	I-Premise

1	Resorption	N	I-Premise
2	markers	N	I-Premise
3	did	N	I-Premise
4	not	N	I-Premise
5	decrease	N	I-Premise
6	after	N	I-Premise
7	placebo	N	I-Premise
8	,	N	I-Premise
9	but	N	I-Premise
10	NTx	N	I-Premise
11	and	N	I-Premise
12	Crosslaps	N	I-Premise
13	both	N	I-Premise
14	decreased	N	I-Premise
15	by	N	I-Premise
16	70	N	I-Premise
17	%	N	I-Premise
18	after	N	I-Premise
19	pamidronate	N	I-Premise
20	(	N	I-Premise
21	P	N	I-Premise
22	=	N	I-Premise
23	0.001	N	I-Premise
24	)	N	I-Premise
25	.	N	I-Premise

1	A	N	I-Premise
2	second	N	I-Premise
3	infusion	N	I-Premise
4	of	N	I-Premise
5	pamidronate	N	I-Premise
6	did	N	I-Premise
7	not	N	I-Premise
8	decrease	N	I-Premise
9	resorption	N	I-Premise
10	further	N	I-Premise
11	,	N	I-Premise
12	but	N	I-Premise
13	maintained	N	I-Premise
14	the	N	I-Premise
15	suppression	N	I-Premise
16	of	N	I-Premise
17	resorption	N	I-Premise
18	at	N	I-Premise
19	similar	N	I-Premise
20	levels	N	I-Premise
21	for	N	I-Premise
22	a	N	I-Premise
23	further	N	I-Premise
24	four	N	I-Premise
25	weeks	N	I-Premise
26	.	N	I-Premise

1	Symptomatic	N	I-Premise
2	response	N	I-Premise
3	to	N	I-Premise
4	pamidronate	N	I-Premise
5	correlated	N	I-Premise
6	closely	N	I-Premise
7	with	N	I-Premise
8	the	N	I-Premise
9	rate	N	I-Premise
10	of	N	I-Premise
11	bone	N	I-Premise
12	resorption	N	I-Premise
13	;	N	I-Premise
14	it	N	I-Premise
15	was	N	I-Premise
16	more	N	I-Premise
17	frequent	N	I-Premise
18	in	N	I-Premise
19	those	N	I-Premise
20	patients	N	I-Premise
21	with	N	I-Premise
22	an	N	I-Premise
23	initial	N	I-Premise
24	NTx	N	I-Premise
25	value	N	I-Premise
26	of	N	I-Premise
27	<	N	I-Premise
28	2	N	I-Premise
29	times	N	I-Premise
30	the	N	I-Premise
31	upper	N	I-Premise
32	limit	N	I-Premise
33	of	N	I-Premise
34	normal	N	I-Premise
35	(	N	I-Premise
36	17	N	I-Premise
37	of	N	I-Premise
38	27	N	I-Premise
39	,	N	I-Premise
40	62	N	I-Premise
41	%	N	I-Premise
42	)	N	I-Premise
43	and	N	I-Premise
44	in	N	I-Premise
45	those	N	I-Premise
46	where	N	I-Premise
47	the	N	I-Premise
48	level	N	I-Premise
49	of	N	I-Premise
50	Ntx	N	I-Premise
51	returned	N	I-Premise
52	to	N	I-Premise
53	normal	N	I-Premise
54	(	N	I-Premise
55	19	N	I-Premise
56	of	N	I-Premise
57	32	N	I-Premise
58	,	N	I-Premise
59	59	N	I-Premise
60	%	N	I-Premise
61	)	N	I-Premise
62	,	N	I-Premise
63	than	N	I-Premise
64	in	N	I-Premise
65	the	N	I-Premise
66	patients	N	I-Premise
67	with	N	I-Premise
68	either	N	I-Premise
69	high	N	I-Premise
70	baseline	N	I-Premise
71	values	N	I-Premise
72	of	N	I-Premise
73	NTx	N	I-Premise
74	(	N	I-Premise
75	>	N	I-Premise
76	2	N	I-Premise
77	times	N	I-Premise
78	the	N	I-Premise
79	upper	N	I-Premise
80	limit	N	I-Premise
81	of	N	I-Premise
82	normal	N	I-Premise
83	)	N	I-Premise
84	or	N	I-Premise
85	Ntx	N	I-Premise
86	levels	N	I-Premise
87	which	N	I-Premise
88	failed	N	I-Premise
89	to	N	I-Premise
90	normalise	N	I-Premise
91	for	N	I-Premise
92	whom	N	I-Premise
93	the	N	I-Premise
94	response	N	I-Premise
95	frequencies	N	I-Premise
96	were	N	I-Premise
97	2	N	I-Premise
98	of	N	I-Premise
99	16	N	I-Premise
100	(	N	I-Premise
101	13	N	I-Premise
102	%	N	I-Premise
103	)	N	I-Premise
104	and	N	I-Premise
105	0	N	I-Premise
106	of	N	I-Premise
107	11	N	I-Premise
108	(	N	I-Premise
109	0	N	I-Premise
110	%	N	I-Premise
111	)	N	I-Premise
112	,	N	I-Premise
113	respectively	N	I-Premise
114	.	N	I-Premise

1	Subjective	N	I-Claim
2	benefit	N	I-Claim
3	after	N	I-Claim
4	intravenous	N	I-Claim
5	pamidronate	N	I-Claim
6	is	N	I-Claim
7	confirmed	N	I-Claim
8	in	N	I-Claim
9	this	N	I-Claim
10	placebo-controlled	N	I-Claim
11	study	N	I-Claim
12	.	N	I-Claim

1	The	N	I-Claim
2	new	N	I-Claim
3	bone	N	I-Claim
4	resorption	N	I-Claim
5	markers	N	I-Claim
6	of	N	I-Claim
7	collagen	N	I-Claim
8	breakdown	N	I-Claim
9	were	N	I-Claim
10	able	N	I-Claim
11	to	N	I-Claim
12	predict	N	I-Claim
13	clinical	N	I-Claim
14	response	N	I-Claim
15	to	N	I-Claim
16	pamidronate	N	I-Claim
17	.	N	I-Claim

1	We	N	O
2	conducted	N	O
3	a	N	O
4	prospective	N	O
5	,	N	O
6	randomized	N	O
7	,	N	O
8	multicentre	N	O
9	clinical	N	O
10	trial	N	O
11	comparing	N	O
12	the	N	O
13	effects	N	O
14	and	N	O
15	costs	N	O
16	of	N	O
17	GM-CSF	N	O
18	as	N	O
19	an	N	O
20	adjunct	N	O
21	to	N	O
22	intensive	N	O
23	chemotherapy	N	O
24	in	N	O
25	elderly	N	O
26	patients	N	O
27	with	N	O
28	acute	N	O
29	myeloid	N	O
30	leukaemia	N	O
31	(	N	O
32	AML	N	O
33	)	N	O
34	.	N	O

1	The	N	O
2	patients	N	O
3	were	N	O
4	randomized	N	O
5	to	N	O
6	either	N	O
7	daunomycin-cytosine	N	O
8	arabinoside	N	O
9	(	N	O
10	control	N	O
11	arm	N	O
12	:	N	O
13	n	N	O
14	=	N	O
15	161	N	O
16	)	N	O
17	or	N	O
18	daunomycin-cytosine	N	O
19	arabinoside	N	O
20	with	N	O
21	GM-CSF	N	O
22	(	N	O
23	GM-CSF	N	O
24	arm	N	O
25	:	N	O
26	n	N	O
27	=	N	O
28	157	N	O
29	)	N	O
30	.	N	O

1	The	N	O
2	primary	N	O
3	end-point	N	O
4	was	N	O
5	the	N	O
6	effect	N	O
7	of	N	O
8	GM-CSF	N	O
9	on	N	O
10	the	N	O
11	percentage	N	O
12	of	N	O
13	complete	N	O
14	remissions	N	O
15	(	N	O
16	CR	N	O
17	)	N	O
18	.	N	O

1	Survival	N	O
2	duration	N	O
3	,	N	O
4	disease-free	N	O
5	survival	N	O
6	,	N	O
7	quality	N	O
8	of	N	O
9	life	N	O
10	and	N	O
11	costs	N	O
12	were	N	O
13	evaluated	N	O
14	separately	N	O
15	.	N	O

1	CR	N	I-Premise
2	after	N	I-Premise
3	remission	N	I-Premise
4	induction	N	I-Premise
5	treatment	N	I-Premise
6	was	N	I-Premise
7	achieved	N	I-Premise
8	in	N	I-Premise
9	55	N	I-Premise
10	%	N	I-Premise
11	of	N	I-Premise
12	the	N	I-Premise
13	patients	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	control	N	I-Premise
17	group	N	I-Premise
18	and	N	I-Premise
19	in	N	I-Premise
20	56	N	I-Premise
21	%	N	I-Premise
22	of	N	I-Premise
23	the	N	I-Premise
24	patients	N	I-Premise
25	in	N	I-Premise
26	the	N	I-Premise
27	GM-CSF	N	I-Premise
28	group	N	I-Premise
29	(	N	I-Premise
30	P	N	I-Premise
31	=	N	I-Premise
32	NS	N	I-Premise
33	)	N	I-Premise
34	.	N	I-Premise

1	The	N	I-Premise
2	duration	N	I-Premise
3	of	N	I-Premise
4	survival	N	I-Premise
5	and	N	I-Premise
6	disease-free	N	I-Premise
7	survival	N	I-Premise
8	at	N	I-Premise
9	2	N	I-Premise
10	years	N	I-Premise
11	after	N	I-Premise
12	randomization	N	I-Premise
13	were	N	I-Premise
14	estimated	N	I-Premise
15	at	N	I-Premise
16	22	N	I-Premise
17	%	N	I-Premise
18	and	N	I-Premise
19	19	N	I-Premise
20	%	N	I-Premise
21	for	N	I-Premise
22	the	N	I-Premise
23	control	N	I-Premise
24	group	N	I-Premise
25	and	N	I-Premise
26	22	N	I-Premise
27	%	N	I-Premise
28	and	N	I-Premise
29	14	N	I-Premise
30	%	N	I-Premise
31	for	N	I-Premise
32	the	N	I-Premise
33	GM-CSF	N	I-Premise
34	group	N	I-Premise
35	(	N	I-Premise
36	P	N	I-Premise
37	=	N	I-Premise
38	NS	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	Considering	N	I-Premise
2	the	N	I-Premise
3	short-term	N	I-Premise
4	quality	N	I-Premise
5	of	N	I-Premise
6	life	N	I-Premise
7	,	N	I-Premise
8	the	N	I-Premise
9	administration	N	I-Premise
10	of	N	I-Premise
11	GM-CSF	N	I-Premise
12	resulted	N	I-Premise
13	in	N	I-Premise
14	more	N	I-Premise
15	problems	N	I-Premise
16	with	N	I-Premise
17	regard	N	I-Premise
18	to	N	I-Premise
19	depressed	N	I-Premise
20	mood	N	I-Premise
21	,	N	I-Premise
22	diarrhoea	N	I-Premise
23	and	N	I-Premise
24	rash/eczema	N	I-Premise
25	.	N	I-Premise

1	With	N	I-Premise
2	regard	N	I-Premise
3	to	N	I-Premise
4	the	N	I-Premise
5	long-term	N	I-Premise
6	quality	N	I-Premise
7	of	N	I-Premise
8	life	N	I-Premise
9	there	N	I-Premise
10	were	N	I-Premise
11	no	N	I-Premise
12	significant	N	I-Premise
13	differences	N	I-Premise
14	between	N	I-Premise
15	the	N	I-Premise
16	two	N	I-Premise
17	groups	N	I-Premise
18	.	N	I-Premise

1	The	N	I-Premise
2	average	N	I-Premise
3	costs	N	I-Premise
4	of	N	I-Premise
5	the	N	I-Premise
6	primary	N	I-Premise
7	treatment	N	I-Premise
8	were	N	I-Premise
9	higher	N	I-Premise
10	in	N	I-Premise
11	GM-CSF-treated	N	I-Premise
12	patients	N	I-Premise
13	than	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	control	N	I-Premise
17	group	N	I-Premise
18	,	N	I-Premise
19	i.e	N	I-Premise
20	.	N	I-Premise

1	US	N	I-Premise
2	$	N	I-Premise
3	40782	N	I-Premise
4	and	N	I-Premise
5	US	N	I-Premise
6	$	N	I-Premise
7	34465	N	I-Premise
8	,	N	I-Premise
9	respectively	N	I-Premise
10	(	N	I-Premise
11	P	N	I-Premise
12	<	N	I-Premise
13	0.01	N	I-Premise
14	)	N	I-Premise
15	.	N	I-Premise

1	The	N	I-Premise
2	costs	N	I-Premise
3	during	N	I-Premise
4	the	N	I-Premise
5	follow-up	N	I-Premise
6	period	N	I-Premise
7	did	N	I-Premise
8	not	N	I-Premise
9	differ	N	I-Premise
10	between	N	I-Premise
11	the	N	I-Premise
12	two	N	I-Premise
13	groups	N	I-Premise
14	.	N	I-Premise

1	The	N	I-Claim
2	results	N	I-Claim
3	of	N	I-Claim
4	this	N	I-Claim
5	randomized	N	I-Claim
6	clinical	N	I-Claim
7	trial	N	I-Claim
8	indicate	N	I-Claim
9	that	N	I-Claim
10	daunomycin-cytosine	N	I-Claim
11	arabinoside	N	I-Claim
12	plus	N	I-Claim
13	GM-CSF	N	I-Claim
14	is	N	I-Claim
15	not	N	I-Claim
16	a	N	I-Claim
17	cost-effective	N	I-Claim
18	treatment	N	I-Claim
19	strategy	N	I-Claim
20	when	N	I-Claim
21	compared	N	I-Claim
22	with	N	I-Claim
23	daunomycin-cytosine	N	I-Claim
24	arabinoside	N	I-Claim
25	alone	N	I-Claim
26	.	N	I-Claim

1	Although	N	O
2	many	N	O
3	drug	N	O
4	combination	N	O
5	therapies	N	O
6	have	N	O
7	been	N	O
8	proposed	N	O
9	,	N	O
10	there	N	I-MajorClaim
11	is	N	I-MajorClaim
12	no	N	I-MajorClaim
13	standard	N	I-MajorClaim
14	therapy	N	I-MajorClaim
15	for	N	I-MajorClaim
16	patients	N	I-MajorClaim
17	with	N	I-MajorClaim
18	advanced	N	I-MajorClaim
19	gastric	N	I-MajorClaim
20	carcinoma	N	I-MajorClaim
21	.	N	I-MajorClaim

1	The	N	I-Claim
2	superiority	N	I-Claim
3	of	N	I-Claim
4	combination	N	I-Claim
5	therapy	N	I-Claim
6	over	N	I-Claim
7	monochemotherapy	N	I-Claim
8	has	N	I-Claim
9	not	N	I-Claim
10	been	N	I-Claim
11	demonstrated	N	I-Claim
12	convincingly	N	I-Claim
13	.	N	I-Claim

1	To	N	O
2	explore	N	O
3	the	N	O
4	role	N	O
5	of	N	O
6	monochemotherapy	N	O
7	,	N	O
8	the	N	O
9	authors	N	O
10	evaluated	N	O
11	5-fluorouracil	N	O
12	(	N	O
13	5-FU	N	O
14	)	N	O
15	,	N	O
16	modulated	N	O
17	by	N	O
18	6S-leucovorin	N	O
19	(	N	O
20	6S-LV	N	O
21	)	N	O
22	and	N	O
23	a	N	O
24	cisplatin-containing	N	O
25	regimen	N	O
26	,	N	O
27	which	N	O
28	was	N	O
29	comprised	N	O
30	of	N	O
31	epirubicin	N	O
32	,	N	O
33	etoposide	N	O
34	,	N	O
35	and	N	O
36	cisplatin	N	O
37	with	N	O
38	the	N	O
39	addition	N	O
40	of	N	O
41	the	N	O
42	reversal	N	O
43	agent	N	O
44	lonidamine	N	O
45	(	N	O
46	EEP-L	N	O
47	)	N	O
48	.	N	O

1	After	N	O
2	stratification	N	O
3	according	N	O
4	to	N	O
5	performance	N	O
6	status	N	O
7	(	N	O
8	PS	N	O
9	)	N	O
10	and	N	O
11	resection	N	O
12	of	N	O
13	the	N	O
14	primary	N	O
15	tumor	N	O
16	,	N	O
17	72	N	O
18	patients	N	O
19	with	N	O
20	advanced	N	O
21	gastric	N	O
22	carcinoma	N	O
23	were	N	O
24	randomized	N	O
25	to	N	O
26	2	N	O
27	parallel	N	O
28	Phase	N	O
29	II	N	O
30	trials	N	O
31	with	N	O
32	5-FU/6S-LV	N	O
33	and	N	O
34	EEP-L	N	O
35	,	N	O
36	respectively	N	O
37	.	N	O

1	Thirty-six	N	O
2	patients	N	O
3	in	N	O
4	Study	N	O
5	A	N	O
6	received	N	O
7	bolus	N	O
8	6S-LV	N	O
9	,	N	O
10	100	N	O
11	mg/m2	N	O
12	,	N	O
13	followed	N	O
14	by	N	O
15	bolus	N	O
16	5-FU	N	O
17	,	N	O
18	370	N	O
19	mg/m2	N	O
20	,	N	O
21	on	N	O
22	Days	N	O
23	1-5	N	O
24	and	N	O
25	36	N	O
26	others	N	O
27	in	N	O
28	Study	N	O
29	B	N	O
30	received	N	O
31	epirubicin	N	O
32	,	N	O
33	30	N	O
34	mg/m2	N	O
35	,	N	O
36	on	N	O
37	Days	N	O
38	1	N	O
39	and	N	O
40	5	N	O
41	;	N	O
42	etoposide	N	O
43	,	N	O
44	100	N	O
45	mg/m2	N	O
46	,	N	O
47	on	N	O
48	Days	N	O
49	1	N	O
50	,	N	O
51	3	N	O
52	,	N	O
53	and	N	O
54	5	N	O
55	;	N	O
56	cisplatin	N	O
57	,	N	O
58	30	N	O
59	mg/m2	N	O
60	,	N	O
61	on	N	O
62	Days	N	O
63	2	N	O
64	and	N	O
65	4	N	O
66	;	N	O
67	and	N	O
68	lonidamine	N	O
69	,	N	O
70	150	N	O
71	mg/day	N	O
72	.	N	O

1	There	N	O
2	were	N	O
3	6	N	O
4	partial	N	O
5	responses	N	O
6	(	N	O
7	18.2	N	O
8	%	N	O
9	)	N	O
10	(	N	O
11	95	N	O
12	%	N	O
13	confidence	N	O
14	interval	N	O
15	[	N	O
16	CI	N	O
17	]	N	O
18	+/-	N	O
19	13.2	N	O
20	)	N	O
21	in	N	O
22	Study	N	O
23	A	N	O
24	and	N	O
25	7	N	O
26	partial	N	O
27	responses	N	O
28	(	N	O
29	21.9	N	O
30	%	N	O
31	)	N	O
32	(	N	O
33	95	N	O
34	%	N	O
35	CI	N	O
36	+/-	N	O
37	14.3	N	O
38	)	N	O
39	in	N	O
40	Study	N	O
41	B	N	O
42	.	N	O

1	Partial	N	O
2	responses	N	O
3	were	N	O
4	more	N	O
5	frequent	N	O
6	in	N	O
7	patients	N	O
8	with	N	O
9	resected	N	O
10	tumors	N	O
11	or	N	O
12	with	N	O
13	an	N	O
14	Eastern	N	O
15	Cooperative	N	O
16	Oncology	N	O
17	Group	N	O
18	PS	N	O
19	of	N	O
20	0-1	N	O
21	.	N	O

1	The	N	I-Premise
2	median	N	I-Premise
3	duration	N	I-Premise
4	of	N	I-Premise
5	response	N	I-Premise
6	was	N	I-Premise
7	8.8	N	I-Premise
8	and	N	I-Premise
9	8.3	N	I-Premise
10	months	N	I-Premise
11	,	N	I-Premise
12	respectively	N	I-Premise
13	,	N	I-Premise
14	in	N	I-Premise
15	Study	N	I-Premise
16	A	N	I-Premise
17	and	N	I-Premise
18	Study	N	I-Premise
19	B	N	I-Premise
20	.	N	I-Premise

1	The	N	I-Premise
2	median	N	I-Premise
3	survival	N	I-Premise
4	reached	N	I-Premise
5	8	N	I-Premise
6	months	N	I-Premise
7	in	N	I-Premise
8	Study	N	I-Premise
9	A	N	I-Premise
10	and	N	I-Premise
11	9	N	I-Premise
12	months	N	I-Premise
13	in	N	I-Premise
14	Study	N	I-Premise
15	B	N	I-Premise
16	.	N	I-Premise

1	In	N	I-Premise
2	the	N	I-Premise
3	whole	N	I-Premise
4	population	N	I-Premise
5	of	N	I-Premise
6	patients	N	I-Premise
7	survival	N	I-Premise
8	was	N	I-Premise
9	significantly	N	I-Premise
10	higher	N	I-Premise
11	in	N	I-Premise
12	patients	N	I-Premise
13	with	N	I-Premise
14	a	N	I-Premise
15	PS	N	I-Premise
16	of	N	I-Premise
17	0-1	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	<	N	I-Premise
21	0.05	N	I-Premise
22	)	N	I-Premise
23	.	N	I-Premise

1	Patients	N	I-Premise
2	with	N	I-Premise
3	a	N	I-Premise
4	PS	N	I-Premise
5	of	N	I-Premise
6	0-1	N	I-Premise
7	and	N	I-Premise
8	a	N	I-Premise
9	resected	N	I-Premise
10	tumor	N	I-Premise
11	had	N	I-Premise
12	the	N	I-Premise
13	significantly	N	I-Premise
14	longest	N	I-Premise
15	survival	N	I-Premise
16	both	N	I-Premise
17	in	N	I-Premise
18	EEP-L	N	I-Premise
19	treated	N	I-Premise
20	patients	N	I-Premise
21	and	N	I-Premise
22	in	N	I-Premise
23	all	N	I-Premise
24	evaluable	N	I-Premise
25	patients	N	I-Premise
26	in	N	I-Premise
27	the	N	I-Premise
28	two	N	I-Premise
29	studies	N	I-Premise
30	.	N	I-Premise

1	The	N	I-Premise
2	most	N	I-Premise
3	frequent	N	I-Premise
4	World	N	I-Premise
5	Health	N	I-Premise
6	Organization	N	I-Premise
7	Grade	N	I-Premise
8	3-4	N	I-Premise
9	toxic	N	I-Premise
10	effects	N	I-Premise
11	were	N	I-Premise
12	gastrointestinal	N	I-Premise
13	in	N	I-Premise
14	Study	N	I-Premise
15	A	N	I-Premise
16	and	N	I-Premise
17	hematologic	N	I-Premise
18	in	N	I-Premise
19	Study	N	I-Premise
20	B	N	I-Premise
21	.	N	I-Premise

1	No	N	I-Premise
2	treatment-related	N	I-Premise
3	death	N	I-Premise
4	was	N	I-Premise
5	observed	N	I-Premise
6	.	N	I-Premise

1	The	N	I-Claim
2	efficacy	N	I-Claim
3	of	N	I-Claim
4	5-FU	N	I-Claim
5	,	N	I-Claim
6	modulated	N	I-Claim
7	with	N	I-Claim
8	6S-LV	N	I-Claim
9	,	N	I-Claim
10	is	N	I-Claim
11	moderate	N	I-Claim
12	in	N	I-Claim
13	patients	N	I-Claim
14	with	N	I-Claim
15	advanced	N	I-Claim
16	gastric	N	I-Claim
17	carcinoma	N	I-Claim
18	,	N	I-Claim
19	similar	N	I-Claim
20	to	N	I-Claim
21	cisplatin-containing	N	I-Claim
22	regimens	N	I-Claim
23	.	N	I-Claim

1	PS	N	I-Claim
2	and	N	I-Claim
3	other	N	I-Claim
4	prognostic	N	I-Claim
5	factors	N	I-Claim
6	could	N	I-Claim
7	influence	N	I-Claim
8	the	N	I-Claim
9	response	N	I-Claim
10	rate	N	I-Claim
11	,	N	I-Claim
12	which	N	I-Claim
13	does	N	I-Claim
14	not	N	I-Claim
15	appear	N	I-Claim
16	to	N	I-Claim
17	be	N	I-Claim
18	a	N	I-Claim
19	reliable	N	I-Claim
20	parameter	N	I-Claim
21	for	N	I-Claim
22	evaluating	N	I-Claim
23	the	N	I-Claim
24	outcome	N	I-Claim
25	of	N	I-Claim
26	chemotherapy	N	I-Claim
27	trials	N	I-Claim
28	.	N	I-Claim

1	The	N	O
2	Intergroup	N	O
3	conducted	N	O
4	this	N	O
5	breast	N	O
6	cancer	N	O
7	adjuvant	N	O
8	trial	N	O
9	to	N	O
10	compare	N	O
11	an	N	O
12	investigational	N	O
13	16-week	N	O
14	regimen	N	O
15	with	N	O
16	cyclophosphamide	N	O
17	,	N	O
18	doxorubicin	N	O
19	,	N	O
20	and	N	O
21	fluorouracil	N	O
22	(	N	O
23	5-FU	N	O
24	;	N	O
25	CAF	N	O
26	)	N	O
27	.	N	O

1	The	N	O
2	16-week	N	O
3	regimen	N	O
4	features	N	O
5	greater	N	O
6	doxorubicin	N	O
7	and	N	O
8	5-FU	N	O
9	dose-intensity	N	O
10	than	N	O
11	CAF	N	O
12	and	N	O
13	improved	N	O
14	scheduling	N	O
15	of	N	O
16	antimetabolites	N	O
17	with	N	O
18	sequential	N	O
19	methotrexate	N	O
20	and	N	O
21	5-FU	N	O
22	,	N	O
23	as	N	O
24	well	N	O
25	as	N	O
26	infusion	N	O
27	5-FU	N	O
28	.	N	O

1	A	N	O
2	total	N	O
3	of	N	O
4	646	N	O
5	node-positive	N	O
6	,	N	O
7	receptor-negative	N	O
8	patients	N	O
9	were	N	O
10	randomly	N	O
11	assigned	N	O
12	to	N	O
13	receive	N	O
14	either	N	O
15	the	N	O
16	1	N	O
17	6-week	N	O
18	regimen	N	O
19	or	N	O
20	six	N	O
21	cycles	N	O
22	of	N	O
23	CAF	N	O
24	.	N	O

1	Breast	N	O
2	cancer	N	O
3	outcomes	N	O
4	included	N	O
5	recurrence	N	O
6	as	N	O
7	well	N	O
8	as	N	O
9	disease-free	N	O
10	and	N	O
11	overall	N	O
12	survival	N	O
13	.	N	O

1	Toxicity	N	O
2	was	N	O
3	evaluated	N	O
4	by	N	O
5	the	N	O
6	Common	N	O
7	Toxicity	N	O
8	Criteria	N	O
9	(	N	O
10	CTC	N	O
11	)	N	O
12	.	N	O

1	Treatment-related	N	O
2	quality	N	O
3	of	N	O
4	life	N	O
5	was	N	O
6	assessed	N	O
7	by	N	O
8	the	N	O
9	Breast	N	O
10	Chemotherapy	N	O
11	Questionnaire	N	O
12	(	N	O
13	BCQ	N	O
14	)	N	O
15	before	N	O
16	,	N	O
17	during	N	O
18	,	N	O
19	and	N	O
20	4	N	O
21	months	N	O
22	after	N	O
23	treatment	N	O
24	in	N	O
25	163	N	O
26	patients	N	O
27	.	N	O

1	The	N	O
2	trial	N	O
3	was	N	O
4	designed	N	O
5	to	N	O
6	use	N	O
7	one-sided	N	O
8	tests	N	O
9	of	N	O
10	significance	N	O
11	for	N	O
12	power	N	O
13	calculations	N	O
14	,	N	O
15	but	N	O
16	is	N	O
17	now	N	O
18	reported	N	O
19	with	N	O
20	both	N	O
21	one-sided	N	O
22	and	N	O
23	the	N	O
24	traditional	N	O
25	two-sided	N	O
26	tests	N	O
27	of	N	O
28	significance	N	O
29	.	N	O

1	At	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	3.9	N	I-Premise
7	years	N	I-Premise
8	,	N	I-Premise
9	the	N	I-Premise
10	estimated	N	I-Premise
11	4-year	N	I-Premise
12	recurrence-free	N	I-Premise
13	survival	N	I-Premise
14	rate	N	I-Premise
15	was	N	I-Premise
16	67.5	N	I-Premise
17	%	N	I-Premise
18	with	N	I-Premise
19	the	N	I-Premise
20	16-week	N	I-Premise
21	regimen	N	I-Premise
22	versus	N	I-Premise
23	62.7	N	I-Premise
24	%	N	I-Premise
25	with	N	I-Premise
26	CAF	N	I-Premise
27	(	N	I-Premise
28	P	N	I-Premise
29	=	N	I-Premise
30	.19	N	I-Premise
31	,	N	I-Premise
32	two-sided	N	I-Premise
33	;	N	I-Premise
34	P	N	I-Premise
35	=	N	I-Premise
36	.095	N	I-Premise
37	,	N	I-Premise
38	one-sided	N	I-Premise
39	)	N	I-Premise
40	.	N	I-Premise

1	The	N	I-Premise
2	estimated	N	I-Premise
3	4-year	N	I-Premise
4	survival	N	I-Premise
5	rate	N	I-Premise
6	was	N	I-Premise
7	78.1	N	I-Premise
8	%	N	I-Premise
9	with	N	I-Premise
10	the	N	I-Premise
11	16-week	N	I-Premise
12	regimen	N	I-Premise
13	versus	N	I-Premise
14	71.4	N	I-Premise
15	%	N	I-Premise
16	with	N	I-Premise
17	CAF	N	I-Premise
18	(	N	I-Premise
19	P	N	I-Premise
20	=	N	I-Premise
21	.10	N	I-Premise
22	,	N	I-Premise
23	two-sided	N	I-Premise
24	;	N	I-Premise
25	P	N	I-Premise
26	=	N	I-Premise
27	.05	N	I-Premise
28	,	N	I-Premise
29	one-sided	N	I-Premise
30	)	N	I-Premise
31	.	N	I-Premise

1	CAF	N	I-Premise
2	produced	N	I-Premise
3	significantly	N	I-Premise
4	higher	N	I-Premise
5	grades	N	I-Premise
6	of	N	I-Premise
7	leukopenia	N	I-Premise
8	,	N	I-Premise
9	granulocytopenia	N	I-Premise
10	,	N	I-Premise
11	and	N	I-Premise
12	thrombocytopenia	N	I-Premise
13	,	N	I-Premise
14	as	N	I-Premise
15	well	N	I-Premise
16	as	N	I-Premise
17	liver	N	I-Premise
18	and	N	I-Premise
19	cardiac	N	I-Premise
20	toxicity	N	I-Premise
21	,	N	I-Premise
22	whereas	N	O
23	the	N	I-Premise
24	16-week	N	I-Premise
25	regimen	N	I-Premise
26	produced	N	I-Premise
27	significantly	N	I-Premise
28	higher	N	I-Premise
29	grades	N	I-Premise
30	of	N	I-Premise
31	anemia	N	I-Premise
32	,	N	I-Premise
33	nausea	N	I-Premise
34	,	N	I-Premise
35	stomatitis	N	I-Premise
36	,	N	I-Premise
37	and	N	I-Premise
38	weight	N	I-Premise
39	loss	N	I-Premise
40	,	N	I-Premise
41	as	N	I-Premise
42	well	N	I-Premise
43	as	N	I-Premise
44	skin	N	I-Premise
45	and	N	I-Premise
46	neurotoxicity	N	I-Premise
47	.	N	I-Premise

1	There	N	I-Premise
2	were	N	I-Premise
3	three	N	I-Premise
4	treatment-related	N	I-Premise
5	deaths	N	I-Premise
6	with	N	I-Premise
7	CAF	N	I-Premise
8	but	N	I-Premise
9	none	N	I-Premise
10	with	N	I-Premise
11	the	N	I-Premise
12	16-week	N	I-Premise
13	regimen	N	I-Premise
14	.	N	I-Premise

1	During	N	I-Premise
2	treatment	N	I-Premise
3	,	N	I-Premise
4	quality	N	I-Premise
5	of	N	I-Premise
6	life	N	I-Premise
7	declined	N	I-Premise
8	significantly	N	I-Premise
9	more	N	I-Premise
10	with	N	I-Premise
11	the	N	I-Premise
12	16-week	N	I-Premise
13	regimen	N	I-Premise
14	than	N	I-Premise
15	CAF	N	I-Premise
16	,	N	I-Premise
17	but	N	I-Premise
18	by	N	I-Premise
19	4	N	I-Premise
20	months	N	I-Premise
21	posttreatment	N	I-Premise
22	,	N	I-Premise
23	there	N	I-Premise
24	was	N	I-Premise
25	no	N	I-Premise
26	difference	N	I-Premise
27	.	N	I-Premise

1	The	N	I-Premise
2	16-week	N	I-Premise
3	regimen	N	I-Premise
4	produced	N	I-Premise
5	marginally	N	I-Premise
6	better	N	I-Premise
7	breast	N	I-Premise
8	cancer	N	I-Premise
9	outcomes	N	I-Premise
10	than	N	I-Premise
11	CAF	N	I-Premise
12	with	N	I-Premise
13	similar	N	I-Premise
14	toxicity	N	I-Premise
15	but	N	I-Premise
16	a	N	I-Premise
17	greater	N	I-Premise
18	reduction	N	I-Premise
19	in	N	I-Premise
20	during-treatment	N	I-Premise
21	quality	N	I-Premise
22	of	N	I-Premise
23	life	N	I-Premise
24	.	N	I-Premise

1	The	N	I-Claim
2	16-week	N	I-Claim
3	regimen	N	I-Claim
4	should	N	I-Claim
5	not	N	I-Claim
6	be	N	I-Claim
7	used	N	I-Claim
8	instead	N	I-Claim
9	of	N	I-Claim
10	a	N	I-Claim
11	standard-dose	N	I-Claim
12	regimen	N	I-Claim
13	without	N	I-Claim
14	careful	N	I-Claim
15	consideration	N	I-Claim
16	of	N	I-Claim
17	the	N	I-Claim
18	16-week	N	I-Claim
19	regimen	N	I-Claim
20	's	N	I-Claim
21	pros	N	I-Claim
22	and	N	I-Claim
23	cons	N	I-Claim
24	,	N	I-Claim
25	which	N	I-Claim
26	include	N	I-Claim
27	its	N	I-Claim
28	complicated	N	I-Claim
29	schedule	N	I-Claim
30	.	N	I-Claim

1	It	N	I-Claim
2	should	N	I-Claim
3	probably	N	I-Claim
4	not	N	I-Claim
5	be	N	I-Claim
6	tested	N	I-Claim
7	further	N	I-Claim
8	,	N	I-Claim
9	but	N	I-Claim
10	its	N	I-Claim
11	antimetabolite	N	I-Claim
12	schedules	N	I-Claim
13	and	N	I-Claim
14	frequent	N	I-Claim
15	drug	N	I-Claim
16	administration	N	I-Claim
17	(	N	I-Claim
18	ie	N	I-Claim
19	,	N	I-Claim
20	dose	N	I-Claim
21	density	N	I-Claim
22	)	N	I-Claim
23	should	N	I-Claim
24	be	N	I-Claim
25	considered	N	I-Claim
26	in	N	I-Claim
27	the	N	I-Claim
28	development	N	I-Claim
29	of	N	I-Claim
30	new	N	I-Claim
31	regimens	N	I-Claim
32	.	N	I-Claim

1	The	N	O
2	finding	N	O
3	of	N	O
4	a	N	O
5	decrease	N	O
6	in	N	O
7	contralateral	N	O
8	breast	N	O
9	cancer	N	O
10	incidence	N	O
11	following	N	O
12	tamoxifen	N	O
13	administration	N	O
14	for	N	O
15	adjuvant	N	O
16	therapy	N	O
17	led	N	O
18	to	N	O
19	the	N	O
20	concept	N	O
21	that	N	O
22	the	N	O
23	drug	N	O
24	might	N	O
25	play	N	O
26	a	N	O
27	role	N	O
28	in	N	O
29	breast	N	O
30	cancer	N	O
31	prevention	N	O
32	.	N	O

1	To	N	O
2	test	N	O
3	this	N	O
4	hypothesis	N	O
5	,	N	O
6	the	N	O
7	National	N	O
8	Surgical	N	O
9	Adjuvant	N	O
10	Breast	N	O
11	and	N	O
12	Bowel	N	O
13	Project	N	O
14	initiated	N	O
15	the	N	O
16	Breast	N	O
17	Cancer	N	O
18	Prevention	N	O
19	Trial	N	O
20	(	N	O
21	P-1	N	O
22	)	N	O
23	in	N	O
24	1992	N	O
25	.	N	O

1	Women	N	O
2	(	N	O
3	N=13388	N	O
4	)	N	O
5	at	N	O
6	increased	N	O
7	risk	N	O
8	for	N	O
9	breast	N	O
10	cancer	N	O
11	because	N	O
12	they	N	O
13	1	N	O
14	)	N	O
15	were	N	O
16	60	N	O
17	years	N	O
18	of	N	O
19	age	N	O
20	or	N	O
21	older	N	O
22	,	N	O
23	2	N	O
24	)	N	O
25	were	N	O
26	35-59	N	O
27	years	N	O
28	of	N	O
29	age	N	O
30	with	N	O
31	a	N	O
32	5-year	N	O
33	predicted	N	O
34	risk	N	O
35	for	N	O
36	breast	N	O
37	cancer	N	O
38	of	N	O
39	at	N	O
40	least	N	O
41	1.66	N	O
42	%	N	O
43	,	N	O
44	or	N	O
45	3	N	O
46	)	N	O
47	had	N	O
48	a	N	O
49	history	N	O
50	of	N	O
51	lobular	N	O
52	carcinoma	N	O
53	in	N	O
54	situ	N	O
55	were	N	O
56	randomly	N	O
57	assigned	N	O
58	to	N	O
59	receive	N	O
60	placebo	N	O
61	(	N	O
62	n=6707	N	O
63	)	N	O
64	or	N	O
65	20	N	O
66	mg/day	N	O
67	tamoxifen	N	O
68	(	N	O
69	n=6681	N	O
70	)	N	O
71	for	N	O
72	5	N	O
73	years	N	O
74	.	N	O

1	Gail	N	O
2	's	N	O
3	algorithm	N	O
4	,	N	O
5	based	N	O
6	on	N	O
7	a	N	O
8	multivariate	N	O
9	logistic	N	O
10	regression	N	O
11	model	N	O
12	using	N	O
13	combinations	N	O
14	of	N	O
15	risk	N	O
16	factors	N	O
17	,	N	O
18	was	N	O
19	used	N	O
20	to	N	O
21	estimate	N	O
22	the	N	O
23	probability	N	O
24	(	N	O
25	risk	N	O
26	)	N	O
27	of	N	O
28	occurrence	N	O
29	of	N	O
30	breast	N	O
31	cancer	N	O
32	over	N	O
33	time	N	O
34	.	N	O

1	Tamoxifen	N	I-Premise
2	reduced	N	I-Premise
3	the	N	I-Premise
4	risk	N	I-Premise
5	of	N	I-Premise
6	invasive	N	I-Premise
7	breast	N	I-Premise
8	cancer	N	I-Premise
9	by	N	I-Premise
10	49	N	I-Premise
11	%	N	I-Premise
12	(	N	I-Premise
13	two-sided	N	I-Premise
14	P	N	I-Premise
15	<	N	I-Premise
16	.00001	N	I-Premise
17	)	N	I-Premise
18	,	N	I-Premise
19	with	N	I-Premise
20	cumulative	N	I-Premise
21	incidence	N	I-Premise
22	through	N	I-Premise
23	69	N	I-Premise
24	months	N	I-Premise
25	of	N	I-Premise
26	follow-up	N	I-Premise
27	of	N	I-Premise
28	43.4	N	I-Premise
29	versus	N	I-Premise
30	22.0	N	I-Premise
31	per	N	I-Premise
32	1000	N	I-Premise
33	women	N	I-Premise
34	in	N	I-Premise
35	the	N	I-Premise
36	placebo	N	I-Premise
37	and	N	I-Premise
38	tamoxifen	N	I-Premise
39	groups	N	I-Premise
40	,	N	I-Premise
41	respectively	N	I-Premise
42	.	N	I-Premise

1	The	N	O
2	decreased	N	O
3	risk	N	O
4	occurred	N	O
5	in	N	O
6	women	N	O
7	aged	N	O
8	49	N	O
9	years	N	O
10	or	N	O
11	younger	N	O
12	(	N	O
13	44	N	O
14	%	N	O
15	)	N	O
16	,	N	O
17	50-59	N	O
18	years	N	O
19	(	N	O
20	51	N	O
21	%	N	O
22	)	N	O
23	,	N	O
24	and	N	O
25	60	N	O
26	years	N	O
27	or	N	O
28	older	N	O
29	(	N	O
30	55	N	O
31	%	N	O
32	)	N	O
33	;	N	O
34	risk	N	I-Premise
35	was	N	I-Premise
36	also	N	I-Premise
37	reduced	N	I-Premise
38	in	N	I-Premise
39	women	N	I-Premise
40	with	N	I-Premise
41	a	N	I-Premise
42	history	N	I-Premise
43	of	N	I-Premise
44	lobular	N	I-Premise
45	carcinoma	N	I-Premise
46	in	N	I-Premise
47	situ	N	I-Premise
48	(	N	I-Premise
49	56	N	I-Premise
50	%	N	I-Premise
51	)	N	I-Premise
52	or	N	I-Premise
53	atypical	N	I-Premise
54	hyperplasia	N	I-Premise
55	(	N	I-Premise
56	86	N	I-Premise
57	%	N	I-Premise
58	)	N	I-Premise
59	and	N	I-Premise
60	in	N	I-Premise
61	those	N	I-Premise
62	with	N	I-Premise
63	any	N	I-Premise
64	category	N	I-Premise
65	of	N	I-Premise
66	predicted	N	I-Premise
67	5-year	N	I-Premise
68	risk	N	I-Premise
69	.	N	I-Premise

1	Tamoxifen	N	I-Premise
2	reduced	N	I-Premise
3	the	N	I-Premise
4	risk	N	I-Premise
5	of	N	I-Premise
6	noninvasive	N	I-Premise
7	breast	N	I-Premise
8	cancer	N	I-Premise
9	by	N	I-Premise
10	50	N	I-Premise
11	%	N	I-Premise
12	(	N	I-Premise
13	two-sided	N	I-Premise
14	P	N	I-Premise
15	<	N	I-Premise
16	.002	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	Tamoxifen	N	I-Premise
2	reduced	N	I-Premise
3	the	N	I-Premise
4	occurrence	N	I-Premise
5	of	N	I-Premise
6	estrogen	N	I-Premise
7	receptor-positive	N	I-Premise
8	tumors	N	I-Premise
9	by	N	I-Premise
10	69	N	I-Premise
11	%	N	I-Premise
12	,	N	I-Premise
13	but	N	I-Premise
14	no	N	I-Premise
15	difference	N	I-Premise
16	in	N	I-Premise
17	the	N	I-Premise
18	occurrence	N	I-Premise
19	of	N	I-Premise
20	estrogen	N	I-Premise
21	receptor-negative	N	I-Premise
22	tumors	N	I-Premise
23	was	N	I-Premise
24	seen	N	I-Premise
25	.	N	I-Premise

1	Tamoxifen	N	I-Premise
2	administration	N	I-Premise
3	did	N	I-Premise
4	not	N	I-Premise
5	alter	N	I-Premise
6	the	N	I-Premise
7	average	N	I-Premise
8	annual	N	I-Premise
9	rate	N	I-Premise
10	of	N	I-Premise
11	ischemic	N	I-Premise
12	heart	N	I-Premise
13	disease	N	I-Premise
14	;	N	I-Premise
15	however	N	I-Premise
16	,	N	I-Premise
17	a	N	I-Premise
18	reduction	N	I-Premise
19	in	N	I-Premise
20	hip	N	I-Premise
21	,	N	I-Premise
22	radius	N	I-Premise
23	(	N	I-Premise
24	Colles	N	I-Premise
25	'	N	I-Premise
26	)	N	I-Premise
27	,	N	I-Premise
28	and	N	I-Premise
29	spine	N	I-Premise
30	fractures	N	I-Premise
31	was	N	I-Premise
32	observed	N	I-Premise
33	.	N	I-Premise

1	The	N	I-Premise
2	rate	N	I-Premise
3	of	N	I-Premise
4	endometrial	N	I-Premise
5	cancer	N	I-Premise
6	was	N	I-Premise
7	increased	N	I-Premise
8	in	N	I-Premise
9	the	N	I-Premise
10	tamoxifen	N	I-Premise
11	group	N	I-Premise
12	(	N	I-Premise
13	risk	N	I-Premise
14	ratio	N	I-Premise
15	=	N	I-Premise
16	2.53	N	I-Premise
17	;	N	I-Premise
18	95	N	I-Premise
19	%	N	I-Premise
20	confidence	N	I-Premise
21	interval	N	I-Premise
22	=	N	I-Premise
23	1.35-4.97	N	I-Premise
24	)	N	I-Premise
25	;	N	I-Premise
26	this	N	I-Premise
27	increased	N	I-Premise
28	risk	N	I-Premise
29	occurred	N	I-Premise
30	predominantly	N	I-Premise
31	in	N	I-Premise
32	women	N	I-Premise
33	aged	N	I-Premise
34	50	N	I-Premise
35	years	N	I-Premise
36	or	N	I-Premise
37	older	N	I-Premise
38	.	N	I-Premise

1	All	N	O
2	endometrial	N	O
3	cancers	N	O
4	in	N	O
5	the	N	O
6	tamoxifen	N	O
7	group	N	O
8	were	N	O
9	stage	N	O
10	I	N	O
11	(	N	O
12	localized	N	O
13	disease	N	O
14	)	N	O
15	;	N	O
16	no	N	I-Premise
17	endometrial	N	I-Premise
18	cancer	N	I-Premise
19	deaths	N	I-Premise
20	have	N	I-Premise
21	occurred	N	I-Premise
22	in	N	I-Premise
23	this	N	I-Premise
24	group	N	I-Premise
25	.	N	I-Premise

1	No	N	I-Premise
2	liver	N	I-Premise
3	cancers	N	I-Premise
4	or	N	I-Premise
5	increase	N	I-Premise
6	in	N	I-Premise
7	colon	N	I-Premise
8	,	N	I-Premise
9	rectal	N	I-Premise
10	,	N	I-Premise
11	ovarian	N	I-Premise
12	,	N	I-Premise
13	or	N	I-Premise
14	other	N	I-Premise
15	tumors	N	I-Premise
16	was	N	I-Premise
17	observed	N	I-Premise
18	in	N	I-Premise
19	the	N	I-Premise
20	tamoxifen	N	I-Premise
21	group	N	I-Premise
22	.	N	I-Premise

1	The	N	I-Premise
2	rates	N	I-Premise
3	of	N	I-Premise
4	stroke	N	I-Premise
5	,	N	I-Premise
6	pulmonary	N	I-Premise
7	embolism	N	I-Premise
8	,	N	I-Premise
9	and	N	I-Premise
10	deep-vein	N	I-Premise
11	thrombosis	N	I-Premise
12	were	N	I-Premise
13	elevated	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	tamoxifen	N	I-Premise
17	group	N	I-Premise
18	;	N	I-Premise
19	these	N	I-Premise
20	events	N	I-Premise
21	occurred	N	I-Premise
22	more	N	I-Premise
23	frequently	N	I-Premise
24	in	N	I-Premise
25	women	N	I-Premise
26	aged	N	I-Premise
27	50	N	I-Premise
28	years	N	I-Premise
29	or	N	I-Premise
30	older	N	I-Premise
31	.	N	I-Premise

1	Tamoxifen	N	I-Claim
2	decreases	N	I-Claim
3	the	N	I-Claim
4	incidence	N	I-Claim
5	of	N	I-Claim
6	invasive	N	I-Claim
7	and	N	I-Claim
8	noninvasive	N	I-Claim
9	breast	N	I-Claim
10	cancer	N	I-Claim
11	.	N	I-Claim

1	Despite	N	I-Claim
2	side	N	I-Claim
3	effects	N	I-Claim
4	resulting	N	I-Claim
5	from	N	I-Claim
6	administration	N	I-Claim
7	of	N	I-Claim
8	tamoxifen	N	I-Claim
9	,	N	I-Claim
10	its	N	I-Claim
11	use	N	I-Claim
12	as	N	I-Claim
13	a	N	I-Claim
14	breast	N	I-Claim
15	cancer	N	I-Claim
16	preventive	N	I-Claim
17	agent	N	I-Claim
18	is	N	I-Claim
19	appropriate	N	I-Claim
20	in	N	I-Claim
21	many	N	I-Claim
22	women	N	I-Claim
23	at	N	I-Claim
24	increased	N	I-Claim
25	risk	N	I-Claim
26	for	N	I-Claim
27	the	N	I-Claim
28	disease	N	I-Claim
29	.	N	I-Claim

1	For	N	I-Claim
2	patients	N	I-Claim
3	with	N	I-Claim
4	metastatic	N	I-Claim
5	prostate	N	I-Claim
6	cancer	N	I-Claim
7	,	N	I-Claim
8	treatment	N	I-Claim
9	is	N	I-Claim
10	primarily	N	I-Claim
11	palliative	N	I-Claim
12	,	N	I-Claim
13	relying	N	I-Claim
14	mainly	N	I-Claim
15	on	N	I-Claim
16	the	N	I-Claim
17	suppression	N	I-Claim
18	of	N	I-Claim
19	systemic	N	I-Claim
20	androgen	N	I-Claim
21	hormone	N	I-Claim
22	levels	N	I-Claim
23	.	N	I-Claim

1	To	N	O
2	help	N	O
3	document	N	O
4	the	N	O
5	achievement	N	O
6	of	N	O
7	palliation	N	O
8	and	N	O
9	to	N	O
10	characterize	N	O
11	positive	N	O
12	and	N	O
13	negative	N	O
14	effects	N	O
15	of	N	O
16	treatment	N	O
17	,	N	O
18	we	N	O
19	evaluated	N	O
20	quality-of-life	N	O
21	(	N	O
22	QOL	N	O
23	)	N	O
24	parameters	N	O
25	in	N	O
26	patients	N	O
27	with	N	O
28	metastatic	N	O
29	prostate	N	O
30	cancer	N	O
31	who	N	O
32	were	N	O
33	randomly	N	O
34	assigned	N	O
35	to	N	O
36	two	N	O
37	methods	N	O
38	of	N	O
39	androgen	N	O
40	deprivation	N	O
41	.	N	O

1	Patients	N	O
2	(	N	O
3	n	N	O
4	=	N	O
5	739	N	O
6	)	N	O
7	with	N	O
8	stage	N	O
9	M1	N	O
10	(	N	O
11	bone	N	O
12	or	N	O
13	soft	N	O
14	tissue	N	O
15	metastasis	N	O
16	)	N	O
17	prostate	N	O
18	cancer	N	O
19	were	N	O
20	enrolled	N	O
21	in	N	O
22	a	N	O
23	QOL	N	O
24	protocol	N	O
25	that	N	O
26	was	N	O
27	a	N	O
28	companion	N	O
29	to	N	O
30	Southwest	N	O
31	Oncology	N	O
32	Group	N	O
33	INT-0105	N	O
34	,	N	O
35	a	N	O
36	randomized	N	O
37	double-blind	N	O
38	trial	N	O
39	comparing	N	O
40	treatment	N	O
41	with	N	O
42	bilateral	N	O
43	orchiectomy	N	O
44	(	N	O
45	surgical	N	O
46	castration	N	O
47	)	N	O
48	plus	N	O
49	either	N	O
50	flutamide	N	O
51	or	N	O
52	placebo	N	O
53	.	N	O

1	Patients	N	O
2	completed	N	O
3	a	N	O
4	comprehensive	N	O
5	battery	N	O
6	of	N	O
7	QOL	N	O
8	questionnaires	N	O
9	at	N	O
10	random	N	O
11	assignment	N	O
12	to	N	O
13	treatment	N	O
14	and	N	O
15	at	N	O
16	1	N	O
17	,	N	O
18	3	N	O
19	,	N	O
20	and	N	O
21	6	N	O
22	months	N	O
23	later	N	O
24	.	N	O

1	Data	N	O
2	were	N	O
3	collected	N	O
4	on	N	O
5	three	N	O
6	treatment-specific	N	O
7	symptoms	N	O
8	(	N	O
9	diarrhea	N	O
10	,	N	O
11	gas	N	O
12	pain	N	O
13	,	N	O
14	and	N	O
15	body	N	O
16	image	N	O
17	)	N	O
18	,	N	O
19	on	N	O
20	physical	N	O
21	functioning	N	O
22	,	N	O
23	and	N	O
24	on	N	O
25	emotional	N	O
26	functioning	N	O
27	.	N	O

1	All	N	O
2	P	N	O
3	values	N	O
4	are	N	O
5	two-sided	N	O
6	.	N	O

1	Questionnaire	N	O
2	return	N	O
3	rates	N	O
4	for	N	O
5	this	N	O
6	study	N	O
7	never	N	O
8	dropped	N	O
9	below	N	O
10	80	N	O
11	%	N	O
12	;	N	O
13	only	N	O
14	2	N	O
15	%	N	O
16	of	N	O
17	the	N	O
18	patients	N	O
19	did	N	O
20	not	N	O
21	submit	N	O
22	baseline	N	O
23	QOL	N	O
24	assessments	N	O
25	.	N	O

1	Cross-sectional	N	I-Premise
2	analyses	N	I-Premise
3	(	N	I-Premise
4	corrected	N	I-Premise
5	for	N	I-Premise
6	multiple	N	I-Premise
7	testing	N	I-Premise
8	)	N	I-Premise
9	identified	N	I-Premise
10	statistically	N	I-Premise
11	significant	N	I-Premise
12	differences	N	I-Premise
13	that	N	I-Premise
14	favored	N	I-Premise
15	orchiectomy	N	I-Premise
16	plus	N	I-Premise
17	placebo	N	I-Premise
18	for	N	I-Premise
19	two	N	I-Premise
20	of	N	I-Premise
21	the	N	I-Premise
22	five	N	I-Premise
23	primary	N	I-Premise
24	QOL	N	I-Premise
25	parameters	N	I-Premise
26	as	N	I-Premise
27	follows	N	I-Premise
28	:	N	I-Premise
29	patients	N	I-Premise
30	receiving	N	I-Premise
31	flutamide	N	I-Premise
32	reported	N	I-Premise
33	more	N	I-Premise
34	diarrhea	N	I-Premise
35	at	N	I-Premise
36	3	N	I-Premise
37	months	N	I-Premise
38	(	N	I-Premise
39	P	N	I-Premise
40	=	N	I-Premise
41	.001	N	I-Premise
42	)	N	I-Premise
43	and	N	I-Premise
44	worse	N	I-Premise
45	emotional	N	I-Premise
46	functioning	N	I-Premise
47	at	N	I-Premise
48	3	N	I-Premise
49	and	N	I-Premise
50	6	N	I-Premise
51	months	N	I-Premise
52	(	N	I-Premise
53	both	N	I-Premise
54	P	N	I-Premise
55	<	N	I-Premise
56	.003	N	I-Premise
57	)	N	I-Premise
58	.	N	I-Premise

1	Longitudinal	N	I-Premise
2	analyses	N	I-Premise
3	replicated	N	I-Premise
4	these	N	I-Premise
5	findings	N	I-Premise
6	.	N	I-Premise

1	Other	N	I-Premise
2	analyzed	N	I-Premise
3	QOL	N	I-Premise
4	parameters	N	I-Premise
5	favored	N	I-Premise
6	the	N	I-Premise
7	group	N	I-Premise
8	receiving	N	I-Premise
9	placebo	N	I-Premise
10	but	N	I-Premise
11	were	N	I-Premise
12	not	N	I-Premise
13	statistically	N	I-Premise
14	significant	N	I-Premise
15	after	N	I-Premise
16	adjustment	N	I-Premise
17	for	N	I-Premise
18	multiple	N	I-Premise
19	testing	N	I-Premise
20	.	N	I-Premise

1	We	N	I-Claim
2	found	N	I-Claim
3	a	N	I-Claim
4	consistent	N	I-Claim
5	pattern	N	I-Claim
6	of	N	I-Claim
7	better	N	I-Claim
8	QOL	N	I-Claim
9	outcomes	N	I-Claim
10	at	N	I-Claim
11	each	N	I-Claim
12	follow-up	N	I-Claim
13	assessment	N	I-Claim
14	during	N	I-Claim
15	the	N	I-Claim
16	first	N	I-Claim
17	6	N	I-Claim
18	months	N	I-Claim
19	of	N	I-Claim
20	treatment	N	I-Claim
21	for	N	I-Claim
22	orchiectomized	N	I-Claim
23	patients	N	I-Claim
24	with	N	I-Claim
25	metastatic	N	I-Claim
26	prostate	N	I-Claim
27	cancer	N	I-Claim
28	who	N	I-Claim
29	received	N	I-Claim
30	placebo	N	I-Claim
31	versus	N	I-Claim
32	flutamide	N	I-Claim
33	.	N	I-Claim

1	Improvement	N	I-Claim
2	over	N	I-Claim
3	time	N	I-Claim
4	was	N	I-Claim
5	evident	N	I-Claim
6	in	N	I-Claim
7	both	N	I-Claim
8	treatment	N	I-Claim
9	groups	N	I-Claim
10	but	N	I-Claim
11	more	N	I-Claim
12	so	N	I-Claim
13	for	N	I-Claim
14	patients	N	I-Claim
15	receiving	N	I-Claim
16	placebo	N	I-Claim
17	.	N	I-Claim

1	In	N	O
2	phase	N	O
3	II	N	O
4	studies	N	O
5	,	N	O
6	irinotecan	N	O
7	is	N	O
8	active	N	O
9	in	N	O
10	metastatic	N	O
11	colorectal	N	O
12	cancer	N	O
13	,	N	O
14	but	N	O
15	the	N	O
16	overall	N	O
17	benefit	N	O
18	has	N	O
19	not	N	O
20	been	N	O
21	assessed	N	O
22	in	N	O
23	a	N	O
24	randomised	N	O
25	clinical	N	O
26	trial	N	O
27	.	N	O

1	Patients	N	O
2	with	N	O
3	proven	N	O
4	metastatic	N	O
5	colorectal	N	O
6	cancer	N	O
7	,	N	O
8	which	N	O
9	had	N	O
10	progressed	N	O
11	within	N	O
12	6	N	O
13	months	N	O
14	of	N	O
15	treatment	N	O
16	with	N	O
17	fluorouracil	N	O
18	,	N	O
19	were	N	O
20	randomly	N	O
21	assigned	N	O
22	either	N	O
23	300-350	N	O
24	mg/m2	N	O
25	irinotecan	N	O
26	every	N	O
27	3	N	O
28	weeks	N	O
29	with	N	O
30	supportive	N	O
31	care	N	O
32	or	N	O
33	supportive	N	O
34	care	N	O
35	alone	N	O
36	,	N	O
37	in	N	O
38	a	N	O
39	2:1	N	O
40	ratio	N	O
41	.	N	O

1	189	N	O
2	patients	N	O
3	were	N	O
4	allocated	N	O
5	irinotecan	N	O
6	and	N	O
7	supportive	N	O
8	care	N	O
9	and	N	O
10	90	N	O
11	supportive	N	O
12	care	N	O
13	alone	N	O
14	.	N	O

1	The	N	O
2	mean	N	O
3	age	N	O
4	of	N	O
5	the	N	O
6	participants	N	O
7	was	N	O
8	58.8	N	O
9	years	N	O
10	;	N	O
11	181	N	O
12	(	N	O
13	65	N	O
14	%	N	O
15	)	N	O
16	were	N	O
17	men	N	O
18	and	N	O
19	98	N	O
20	(	N	O
21	35	N	O
22	%	N	O
23	)	N	O
24	were	N	O
25	women	N	O
26	.	N	O

1	WHO	N	O
2	performance	N	O
3	status	N	O
4	was	N	O
5	0	N	O
6	in	N	O
7	79	N	O
8	(	N	O
9	42	N	O
10	%	N	O
11	)	N	O
12	patients	N	O
13	,	N	O
14	1	N	O
15	in	N	O
16	77	N	O
17	(	N	O
18	41	N	O
19	%	N	O
20	)	N	O
21	patients	N	O
22	,	N	O
23	and	N	O
24	2	N	O
25	in	N	O
26	32	N	O
27	(	N	O
28	17	N	O
29	%	N	O
30	)	N	O
31	patients	N	O
32	.	N	O

1	Tumour-related	N	O
2	symptoms	N	O
3	were	N	O
4	present	N	O
5	in	N	O
6	134	N	O
7	(	N	O
8	71	N	O
9	%	N	O
10	)	N	O
11	patients	N	O
12	and	N	O
13	weight	N	O
14	loss	N	O
15	of	N	O
16	more	N	O
17	than	N	O
18	5	N	O
19	%	N	O
20	was	N	O
21	seen	N	O
22	in	N	O
23	15	N	O
24	(	N	O
25	8	N	O
26	%	N	O
27	)	N	O
28	patients	N	O
29	.	N	O

1	With	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	13	N	I-Premise
7	months	N	I-Premise
8	,	N	I-Premise
9	the	N	I-Premise
10	overall	N	I-Premise
11	survival	N	I-Premise
12	was	N	I-Premise
13	significantly	N	I-Premise
14	better	N	I-Premise
15	in	N	I-Premise
16	the	N	I-Premise
17	irinotecan	N	I-Premise
18	group	N	I-Premise
19	(	N	I-Premise
20	p=0.0001	N	I-Premise
21	)	N	I-Premise
22	,	N	I-Premise
23	with	N	I-Premise
24	36.2	N	I-Premise
25	%	N	I-Premise
26	1-year	N	I-Premise
27	survival	N	I-Premise
28	in	N	I-Premise
29	the	N	I-Premise
30	irinotecan	N	I-Premise
31	group	N	I-Premise
32	versus	N	I-Premise
33	13.8	N	I-Premise
34	%	N	I-Premise
35	in	N	I-Premise
36	the	N	I-Premise
37	supportive-care	N	I-Premise
38	group	N	I-Premise
39	.	N	I-Premise

1	The	N	I-Premise
2	survival	N	I-Premise
3	benefit	N	I-Premise
4	,	N	I-Premise
5	adjusted	N	I-Premise
6	for	N	I-Premise
7	prognostic	N	I-Premise
8	factors	N	I-Premise
9	in	N	I-Premise
10	a	N	I-Premise
11	multivariate	N	I-Premise
12	analysis	N	I-Premise
13	,	N	I-Premise
14	remained	N	I-Premise
15	significant	N	I-Premise
16	(	N	I-Premise
17	p=0.001	N	I-Premise
18	)	N	I-Premise
19	.	N	I-Premise

1	Survival	N	I-Premise
2	without	N	I-Premise
3	performance-status	N	I-Premise
4	deterioration	N	I-Premise
5	(	N	I-Premise
6	p=0.0001	N	I-Premise
7	)	N	I-Premise
8	,	N	I-Premise
9	without	N	I-Premise
10	weight	N	I-Premise
11	loss	N	I-Premise
12	of	N	I-Premise
13	more	N	I-Premise
14	than	N	I-Premise
15	5	N	I-Premise
16	%	N	I-Premise
17	(	N	I-Premise
18	p=0.018	N	I-Premise
19	)	N	I-Premise
20	,	N	I-Premise
21	and	N	I-Premise
22	pain-free	N	I-Premise
23	survival	N	I-Premise
24	(	N	I-Premise
25	p=0.003	N	I-Premise
26	)	N	I-Premise
27	were	N	I-Premise
28	significantly	N	I-Premise
29	better	N	I-Premise
30	in	N	I-Premise
31	the	N	I-Premise
32	patients	N	I-Premise
33	given	N	I-Premise
34	irinotecan	N	I-Premise
35	.	N	I-Premise

1	In	N	I-Premise
2	a	N	I-Premise
3	quality-of-life	N	I-Premise
4	analysis	N	I-Premise
5	,	N	I-Premise
6	all	N	I-Premise
7	significant	N	I-Premise
8	differences	N	I-Premise
9	,	N	I-Premise
10	except	N	I-Premise
11	on	N	I-Premise
12	diarrhoea	N	I-Premise
13	score	N	I-Premise
14	,	N	I-Premise
15	were	N	I-Premise
16	in	N	I-Premise
17	favour	N	I-Premise
18	of	N	I-Premise
19	the	N	I-Premise
20	irinotecan	N	I-Premise
21	group	N	I-Premise
22	.	N	I-Premise

1	Our	N	I-Claim
2	study	N	I-Claim
3	shows	N	I-Claim
4	that	N	I-Claim
5	despite	N	I-Claim
6	the	N	I-Claim
7	side-effects	N	I-Claim
8	of	N	I-Claim
9	treatment	N	I-Claim
10	,	N	I-Claim
11	patients	N	I-Claim
12	who	N	I-Claim
13	have	N	I-Claim
14	metastatic	N	I-Claim
15	colorectal	N	I-Claim
16	cancer	N	I-Claim
17	,	N	I-Claim
18	and	N	I-Claim
19	for	N	I-Claim
20	whom	N	I-Claim
21	fluorouracil	N	I-Claim
22	has	N	I-Claim
23	failed	N	I-Claim
24	,	N	I-Claim
25	have	N	I-Claim
26	a	N	I-Claim
27	longer	N	I-Claim
28	survival	N	I-Claim
29	,	N	I-Claim
30	fewer	N	I-Claim
31	tumour-related	N	I-Claim
32	symptoms	N	I-Claim
33	,	N	I-Claim
34	and	N	I-Claim
35	a	N	I-Claim
36	better	N	I-Claim
37	quality	N	I-Claim
38	of	N	I-Claim
39	life	N	I-Claim
40	when	N	I-Claim
41	treated	N	I-Claim
42	with	N	I-Claim
43	irinotecan	N	I-Claim
44	than	N	I-Claim
45	with	N	I-Claim
46	supportive	N	I-Claim
47	care	N	I-Claim
48	alone	N	I-Claim
49	.	N	I-Claim

1	The	N	O
2	aim	N	O
3	of	N	O
4	the	N	O
5	present	N	O
6	trial	N	O
7	was	N	O
8	to	N	O
9	evaluate	N	O
10	the	N	O
11	effects	N	O
12	of	N	O
13	chemotherapy	N	O
14	on	N	O
15	the	N	O
16	quality	N	O
17	of	N	O
18	life	N	O
19	and	N	O
20	survival	N	O
21	of	N	O
22	patients	N	O
23	with	N	O
24	advanced	N	O
25	non-small	N	O
26	cell	N	O
27	lung	N	O
28	cancer	N	O
29	(	N	O
30	NSCLC	N	O
31	)	N	O
32	(	N	O
33	stage	N	O
34	IIIB	N	O
35	or	N	O
36	IV	N	O
37	)	N	O
38	.	N	O

1	In	N	O
2	a	N	O
3	controlled	N	O
4	multicentre	N	O
5	trial	N	O
6	,	N	O
7	patients	N	O
8	were	N	O
9	randomised	N	O
10	to	N	O
11	receive	N	O
12	supportive	N	O
13	care	N	O
14	only	N	O
15	or	N	O
16	supportive	N	O
17	care	N	O
18	plus	N	O
19	chemotherapy	N	O
20	.	N	O

1	Chemotherapy	N	O
2	consisted	N	O
3	of	N	O
4	intravenous	N	O
5	(	N	O
6	i.v	N	O
7	.	N	O

1	)	N	O
2	carboplatin	N	O
3	300	N	O
4	mg/m2	N	O
5	on	N	O
6	day	N	O
7	1	N	O
8	and	N	O
9	etoposide	N	O
10	120	N	O
11	mg/m2	N	O
12	orally	N	O
13	on	N	O
14	days	N	O
15	1-5	N	O
16	every	N	O
17	4	N	O
18	weeks	N	O
19	for	N	O
20	a	N	O
21	maximum	N	O
22	of	N	O
23	eight	N	O
24	courses	N	O
25	.	N	O

1	Quality	N	O
2	of	N	O
3	life	N	O
4	was	N	O
5	measured	N	O
6	at	N	O
7	randomisation	N	O
8	and	N	O
9	prior	N	O
10	to	N	O
11	each	N	O
12	treatment	N	O
13	course	N	O
14	and	N	O
15	at	N	O
16	corresponding	N	O
17	4-week	N	O
18	intervals	N	O
19	in	N	O
20	the	N	O
21	control	N	O
22	arm	N	O
23	,	N	O
24	using	N	O
25	the	N	O
26	EORTC	N	O
27	QLQ-C30	N	O
28	+	N	O
29	LC13	N	O
30	questionnaire	N	O
31	.	N	O

1	48	N	O
2	patients	N	O
3	were	N	O
4	randomised	N	O
5	(	N	O
6	supportive	N	O
7	care	N	O
8	26	N	O
9	,	N	O
10	chemotherapy	N	O
11	22	N	O
12	)	N	O
13	,	N	O
14	being	N	O
15	eligible	N	O
16	for	N	O
17	comparative	N	O
18	analyses	N	O
19	.	N	O

1	Another	N	O
2	102	N	O
3	patients	N	O
4	,	N	O
5	97	N	O
6	of	N	O
7	which	N	O
8	received	N	O
9	chemotherapy	N	O
10	,	N	O
11	were	N	O
12	subsequently	N	O
13	included	N	O
14	in	N	O
15	the	N	O
16	study	N	O
17	on	N	O
18	an	N	O
19	individual	N	O
20	treatment	N	O
21	preference	N	O
22	basis	N	O
23	.	N	O

1	Data	N	O
2	from	N	O
3	these	N	O
4	patients	N	O
5	were	N	O
6	used	N	O
7	for	N	O
8	confirmative	N	O
9	purposes	N	O
10	.	N	O

1	Patients	N	I-Premise
2	in	N	I-Premise
3	the	N	I-Premise
4	chemotherapy	N	I-Premise
5	group	N	I-Premise
6	reported	N	I-Premise
7	better	N	I-Premise
8	overall	N	I-Premise
9	physical	N	I-Premise
10	functioning	N	I-Premise
11	and	N	I-Premise
12	symptom	N	I-Premise
13	control	N	I-Premise
14	compared	N	I-Premise
15	with	N	I-Premise
16	the	N	I-Premise
17	supportive	N	I-Premise
18	care	N	I-Premise
19	group	N	I-Premise
20	.	N	I-Premise

1	Group	N	I-Premise
2	differences	N	I-Premise
3	were	N	I-Premise
4	smaller	N	I-Premise
5	within	N	I-Premise
6	the	N	I-Premise
7	psychosocial	N	I-Premise
8	domain	N	I-Premise
9	,	N	I-Premise
10	although	N	I-Premise
11	trends	N	I-Premise
12	were	N	I-Premise
13	seen	N	I-Premise
14	in	N	I-Premise
15	favour	N	I-Premise
16	of	N	I-Premise
17	the	N	I-Premise
18	chemotherapy	N	I-Premise
19	group	N	I-Premise
20	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	differences	N	I-Premise
4	were	N	I-Premise
5	seen	N	I-Premise
6	in	N	I-Premise
7	favour	N	I-Premise
8	of	N	I-Premise
9	the	N	I-Premise
10	supportive	N	I-Premise
11	care	N	I-Premise
12	group	N	I-Premise
13	,	N	I-Premise
14	except	N	I-Premise
15	for	N	I-Premise
16	hair	N	I-Premise
17	loss	N	I-Premise
18	.	N	I-Premise

1	Median	N	I-Premise
2	survival	N	I-Premise
3	times	N	I-Premise
4	were	N	I-Premise
5	29	N	I-Premise
6	weeks	N	I-Premise
7	in	N	I-Premise
8	the	N	I-Premise
9	chemotherapy	N	I-Premise
10	group	N	I-Premise
11	versus	N	I-Premise
12	11	N	I-Premise
13	weeks	N	I-Premise
14	in	N	I-Premise
15	the	N	I-Premise
16	supportive	N	I-Premise
17	care	N	I-Premise
18	group	N	I-Premise
19	,	N	I-Premise
20	and	N	I-Premise
21	1-year	N	I-Premise
22	survival	N	I-Premise
23	rates	N	I-Premise
24	were	N	I-Premise
25	28	N	I-Premise
26	%	N	I-Premise
27	versus	N	I-Premise
28	8	N	I-Premise
29	%	N	I-Premise
30	.	N	I-Premise

1	Quality	N	I-Premise
2	of	N	I-Premise
3	life	N	I-Premise
4	and	N	I-Premise
5	survival	N	I-Premise
6	outcomes	N	I-Premise
7	were	N	I-Premise
8	similar	N	I-Premise
9	in	N	I-Premise
10	the	N	I-Premise
11	randomised	N	I-Premise
12	and	N	I-Premise
13	non-randomised	N	I-Premise
14	patients	N	I-Premise
15	receiving	N	I-Premise
16	chemotherapy	N	I-Premise
17	.	N	I-Premise

1	No	N	I-Premise
2	treatment-related	N	I-Premise
3	deaths	N	I-Premise
4	occurred	N	I-Premise
5	.	N	I-Premise

1	In	N	I-Claim
2	conclusion	N	I-Claim
3	,	N	I-Claim
4	treatment	N	I-Claim
5	with	N	I-Claim
6	carboplatin	N	I-Claim
7	and	N	I-Claim
8	etoposide	N	I-Claim
9	can	N	I-Claim
10	improve	N	I-Claim
11	both	N	I-Claim
12	the	N	I-Claim
13	quality	N	I-Claim
14	of	N	I-Claim
15	life	N	I-Claim
16	and	N	I-Claim
17	the	N	I-Claim
18	survival	N	I-Claim
19	of	N	I-Claim
20	patients	N	I-Claim
21	with	N	I-Claim
22	advanced	N	I-Claim
23	NSCLC	N	I-Claim
24	.	N	I-Claim

1	The	N	O
2	second	N	O
3	International	N	O
4	Society	N	O
5	of	N	O
6	Paediatric	N	O
7	Oncology	N	O
8	(	N	O
9	SIOP	N	O
10	)	N	O
11	study	N	O
12	for	N	O
13	rhabdomyosarcoma	N	O
14	(	N	O
15	MMT84	N	O
16	)	N	O
17	had	N	O
18	several	N	O
19	goals	N	O
20	.	N	O

1	The	N	O
2	two	N	O
3	principal	N	O
4	aims	N	O
5	were	N	O
6	:	N	O
7	(	N	O
8	1	N	O
9	)	N	O
10	to	N	O
11	improve	N	O
12	the	N	O
13	survival	N	O
14	of	N	O
15	children	N	O
16	with	N	O
17	rhabdomyosarcoma	N	O
18	;	N	O
19	and	N	O
20	(	N	O
21	2	N	O
22	)	N	O
23	to	N	O
24	reduce	N	O
25	the	N	O
26	late	N	O
27	effects	N	O
28	from	N	O
29	therapy	N	O
30	by	N	O
31	restricting	N	O
32	the	N	O
33	indications	N	O
34	for	N	O
35	surgery	N	O
36	and/or	N	O
37	radiotherapy	N	O
38	after	N	O
39	good	N	O
40	response	N	O
41	to	N	O
42	initial	N	O
43	chemotherapy	N	O
44	.	N	O

1	A	N	O
2	further	N	O
3	aim	N	O
4	was	N	O
5	to	N	O
6	investigate	N	O
7	the	N	O
8	role	N	O
9	of	N	O
10	high-dose	N	O
11	chemotherapy	N	O
12	in	N	O
13	young	N	O
14	patients	N	O
15	with	N	O
16	parameningeal	N	O
17	primary	N	O
18	tumours	N	O
19	.	N	O

1	186	N	O
2	previously	N	O
3	untreated	N	O
4	eligible	N	O
5	patients	N	O
6	entered	N	O
7	the	N	O
8	study	N	O
9	.	N	O

1	Patients	N	O
2	with	N	O
3	completely	N	O
4	resected	N	O
5	primary	N	O
6	tumour	N	O
7	received	N	O
8	three	N	O
9	courses	N	O
10	of	N	O
11	IVA	N	O
12	(	N	O
13	ifosfamide	N	O
14	,	N	O
15	vincristine	N	O
16	and	N	O
17	actinomycin	N	O
18	D	N	O
19	)	N	O
20	.	N	O

1	Patients	N	O
2	with	N	O
3	incompletely	N	O
4	resected	N	O
5	tumour	N	O
6	received	N	O
7	six	N	O
8	to	N	O
9	10	N	O
10	courses	N	O
11	of	N	O
12	IVA	N	O
13	according	N	O
14	to	N	O
15	stage	N	O
16	.	N	O

1	Patients	N	O
2	achieving	N	O
3	complete	N	O
4	remission	N	O
5	with	N	O
6	chemotherapy	N	O
7	alone	N	O
8	did	N	O
9	not	N	O
10	usually	N	O
11	receive	N	O
12	radiotherapy	N	O
13	or	N	O
14	undergo	N	O
15	extensive	N	O
16	surgery	N	O
17	,	N	O
18	but	N	O
19	patients	N	O
20	remaining	N	O
21	in	N	O
22	partial	N	O
23	remission	N	O
24	received	N	O
25	local	N	O
26	therapy	N	O
27	with	N	O
28	surgery	N	O
29	and/or	N	O
30	radiotherapy	N	O
31	.	N	O

1	Only	N	O
2	patients	N	O
3	over	N	O
4	5	N	O
5	years	N	O
6	of	N	O
7	age	N	O
8	with	N	O
9	parameningeal	N	O
10	disease	N	O
11	and	N	O
12	patients	N	O
13	over	N	O
14	12	N	O
15	years	N	O
16	with	N	O
17	tumours	N	O
18	at	N	O
19	any	N	O
20	site	N	O
21	were	N	O
22	given	N	O
23	systematic	N	O
24	irradiation	N	O
25	.	N	O

1	Complete	N	I-Premise
2	remission	N	I-Premise
3	was	N	I-Premise
4	achieved	N	I-Premise
5	in	N	I-Premise
6	91	N	I-Premise
7	%	N	I-Premise
8	(	N	I-Premise
9	170/186	N	I-Premise
10	)	N	I-Premise
11	of	N	I-Premise
12	all	N	I-Premise
13	patients	N	I-Premise
14	.	N	I-Premise

1	With	N	I-Premise
2	a	N	I-Premise
3	median	N	I-Premise
4	follow-up	N	I-Premise
5	of	N	I-Premise
6	8	N	I-Premise
7	years	N	I-Premise
8	,	N	I-Premise
9	the	N	I-Premise
10	5-year	N	I-Premise
11	overall	N	I-Premise
12	survival	N	I-Premise
13	was	N	I-Premise
14	68	N	I-Premise
15	%	N	I-Premise
16	(	N	I-Premise
17	+/-	N	I-Premise
18	3	N	I-Premise
19	%	N	I-Premise
20	standard	N	I-Premise
21	error	N	I-Premise
22	of	N	I-Premise
23	the	N	I-Premise
24	mean	N	I-Premise
25	(	N	I-Premise
26	SEM	N	I-Premise
27	)	N	I-Premise
28	and	N	I-Premise
29	the	N	I-Premise
30	5-year	N	I-Premise
31	event-free	N	I-Premise
32	survival	N	I-Premise
33	53	N	I-Premise
34	%	N	I-Premise
35	(	N	I-Premise
36	+/-	N	I-Premise
37	4	N	I-Premise
38	%	N	I-Premise
39	SEM	N	I-Premise
40	)	N	I-Premise
41	.	N	I-Premise

1	These	N	I-Premise
2	results	N	I-Premise
3	show	N	I-Premise
4	an	N	I-Premise
5	improvement	N	I-Premise
6	over	N	I-Premise
7	previous	N	I-Premise
8	SIOP	N	I-Premise
9	study	N	I-Premise
10	(	N	I-Premise
11	RMS75	N	I-Premise
12	)	N	I-Premise
13	in	N	I-Premise
14	which	N	I-Premise
15	survival	N	I-Premise
16	was	N	I-Premise
17	52	N	I-Premise
18	%	N	I-Premise
19	and	N	I-Premise
20	event-free	N	I-Premise
21	survival	N	I-Premise
22	was	N	I-Premise
23	47	N	I-Premise
24	%	N	I-Premise
25	.	N	I-Premise

1	Among	N	I-Premise
2	the	N	I-Premise
3	54	N	I-Premise
4	patients	N	I-Premise
5	who	N	I-Premise
6	exhibited	N	I-Premise
7	isolated	N	I-Premise
8	local	N	I-Premise
9	relapse	N	I-Premise
10	,	N	I-Premise
11	35	N	I-Premise
12	%	N	I-Premise
13	(	N	I-Premise
14	19/54	N	I-Premise
15	)	N	I-Premise
16	survived	N	I-Premise
17	in	N	I-Premise
18	further	N	I-Premise
19	remission	N	I-Premise
20	longer	N	I-Premise
21	than	N	I-Premise
22	2	N	I-Premise
23	years	N	I-Premise
24	after	N	I-Premise
25	retreatment	N	I-Premise
26	,	N	I-Premise
27	including	N	I-Premise
28	local	N	I-Premise
29	therapy	N	I-Premise
30	(	N	I-Premise
31	surgery	N	I-Premise
32	+/-	N	I-Premise
33	radiotherapy	N	I-Premise
34	)	N	I-Premise
35	.	N	I-Premise

1	Analysis	N	O
2	of	N	O
3	the	N	O
4	overall	N	O
5	burden	N	O
6	of	N	O
7	therapy	N	O
8	received	N	O
9	by	N	O
10	all	N	O
11	surviving	N	O
12	children	N	O
13	(	N	O
14	including	N	O
15	primary	N	O
16	treatment	N	O
17	and	N	O
18	treatment	N	O
19	for	N	O
20	relapse	N	O
21	if	N	O
22	required	N	O
23	)	N	O
24	showed	N	O
25	that	N	O
26	24	N	O
27	%	N	O
28	(	N	O
29	28/116	N	O
30	)	N	O
31	were	N	O
32	treated	N	O
33	by	N	O
34	limited	N	O
35	surgery	N	O
36	followed	N	O
37	by	N	O
38	three	N	O
39	courses	N	O
40	of	N	O
41	IVA	N	O
42	,	N	O
43	29	N	O
44	%	N	O
45	(	N	O
46	34/116	N	O
47	)	N	O
48	were	N	O
49	treated	N	O
50	by	N	O
51	chemotherapy	N	O
52	alone	N	O
53	(	N	O
54	after	N	O
55	initial	N	O
56	biopsy	N	O
57	)	N	O
58	and	N	O
59	13	N	O
60	%	N	O
61	(	N	O
62	15/116	N	O
63	)	N	O
64	received	N	O
65	chemotherapy	N	O
66	plus	N	O
67	conservative	N	O
68	local	N	O
69	treatment	N	O
70	(	N	O
71	limited	N	O
72	surgery	N	O
73	or	N	O
74	radiotherapy	N	O
75	for	N	O
76	residual	N	O
77	disease	N	O
78	)	N	O
79	.	N	O

1	Only	N	O
2	34	N	O
3	%	N	O
4	(	N	O
5	39/116	N	O
6	)	N	O
7	received	N	O
8	intensive	N	O
9	local	N	O
10	therapy	N	O
11	defined	N	O
12	as	N	O
13	radical	N	O
14	wide	N	O
15	field	N	O
16	radiotherapy	N	O
17	or	N	O
18	radical	N	O
19	surgery	N	O
20	or	N	O
21	both	N	O
22	.	N	O

1	Compared	N	I-Claim
2	with	N	I-Claim
3	the	N	I-Claim
4	results	N	I-Claim
5	obtained	N	I-Claim
6	in	N	I-Claim
7	the	N	I-Claim
8	previous	N	I-Claim
9	SIOP	N	I-Claim
10	study	N	I-Claim
11	,	N	I-Claim
12	treatment	N	I-Claim
13	in	N	I-Claim
14	MMT84	N	I-Claim
15	was	N	I-Claim
16	based	N	I-Claim
17	on	N	I-Claim
18	response	N	I-Claim
19	to	N	I-Claim
20	initial	N	I-Claim
21	chemotherapy	N	I-Claim
22	and	N	I-Claim
23	,	N	I-Claim
24	despite	N	I-Claim
25	an	N	I-Claim
26	overall	N	I-Claim
27	reduction	N	I-Claim
28	of	N	I-Claim
29	the	N	I-Claim
30	use	N	I-Claim
31	of	N	I-Claim
32	local	N	I-Claim
33	therapy	N	I-Claim
34	,	N	I-Claim
35	significantly	N	I-Claim
36	improved	N	I-Claim
37	survival	N	I-Claim
38	for	N	I-Claim
39	patients	N	I-Claim
40	with	N	I-Claim
41	non-metastatic	N	I-Claim
42	disease	N	I-Claim
43	.	N	I-Claim

1	This	N	I-Claim
2	trial	N	I-Claim
3	,	N	I-Claim
4	also	N	I-Claim
5	for	N	I-Claim
6	the	N	I-Claim
7	first	N	I-Claim
8	time	N	I-Claim
9	,	N	I-Claim
10	provides	N	I-Claim
11	evidence	N	I-Claim
12	that	N	I-Claim
13	retreatment	N	I-Claim
14	after	N	I-Claim
15	local	N	I-Claim
16	relapse	N	I-Claim
17	can	N	I-Claim
18	achieve	N	I-Claim
19	long-term	N	I-Claim
20	second	N	I-Claim
21	remissions	N	I-Claim
22	.	N	I-Claim

1	We	N	O
2	report	N	O
3	results	N	O
4	of	N	O
5	a	N	O
6	randomized	N	O
7	prospective	N	O
8	study	N	O
9	that	N	O
10	compared	N	O
11	single	N	O
12	agents	N	O
13	of	N	O
14	low	N	O
15	toxicity	N	O
16	given	N	O
17	both	N	O
18	as	N	O
19	the	N	O
20	first-line	N	O
21	and	N	O
22	second-line	N	O
23	chemotherapy	N	O
24	with	N	O
25	combination	N	O
26	chemotherapy	N	O
27	in	N	O
28	advanced	N	O
29	breast	N	O
30	cancer	N	O
31	with	N	O
32	distant	N	O
33	metastases	N	O
34	.	N	O

1	Patients	N	O
2	in	N	O
3	the	N	O
4	single-agent	N	O
5	arm	N	O
6	(	N	O
7	n	N	O
8	=	N	O
9	153	N	O
10	)	N	O
11	received	N	O
12	weekly	N	O
13	epirubicin	N	O
14	(	N	O
15	E	N	O
16	)	N	O
17	20	N	O
18	mg/m2	N	O
19	until	N	O
20	progression	N	O
21	or	N	O
22	until	N	O
23	the	N	O
24	cumulative	N	O
25	dose	N	O
26	of	N	O
27	1,000	N	O
28	mg/m2	N	O
29	,	N	O
30	followed	N	O
31	by	N	O
32	mitomycin	N	O
33	(	N	O
34	M	N	O
35	)	N	O
36	8	N	O
37	mg/m2	N	O
38	every	N	O
39	4	N	O
40	weeks	N	O
41	,	N	O
42	and	N	O
43	those	N	O
44	in	N	O
45	the	N	O
46	combination	N	O
47	chemotherapy	N	O
48	arm	N	O
49	(	N	O
50	n	N	O
51	=	N	O
52	150	N	O
53	)	N	O
54	were	N	O
55	first	N	O
56	given	N	O
57	cyclophosphamide	N	O
58	500	N	O
59	mg/m2	N	O
60	,	N	O
61	E	N	O
62	60	N	O
63	mg/m2	N	O
64	,	N	O
65	and	N	O
66	fluorouracil	N	O
67	500	N	O
68	mg/m2	N	O
69	three	N	O
70	times	N	O
71	per	N	O
72	week	N	O
73	(	N	O
74	CEF	N	O
75	)	N	O
76	followed	N	O
77	by	N	O
78	M	N	O
79	8	N	O
80	mg/m2	N	O
81	plus	N	O
82	vinblastine	N	O
83	(	N	O
84	V	N	O
85	)	N	O
86	6	N	O
87	mg/m2	N	O
88	every	N	O
89	4	N	O
90	weeks	N	O
91	.	N	O

1	Exclusion	N	O
2	criteria	N	O
3	included	N	O
4	age	N	O
5	greater	N	O
6	than	N	O
7	70	N	O
8	years	N	O
9	,	N	O
10	World	N	O
11	Health	N	O
12	Organization	N	O
13	(	N	O
14	WHO	N	O
15	)	N	O
16	performance	N	O
17	status	N	O
18	greater	N	O
19	than	N	O
20	2	N	O
21	,	N	O
22	prior	N	O
23	chemotherapy	N	O
24	for	N	O
25	metastatic	N	O
26	disease	N	O
27	,	N	O
28	and	N	O
29	presence	N	O
30	of	N	O
31	liver	N	O
32	metastases	N	O
33	in	N	O
34	patients	N	O
35	younger	N	O
36	than	N	O
37	50	N	O
38	.	N	O

1	An	N	I-Premise
2	objective	N	I-Premise
3	response	N	I-Premise
4	(	N	I-Premise
5	complete	N	I-Premise
6	[	N	I-Premise
7	CR	N	I-Premise
8	]	N	I-Premise
9	or	N	I-Premise
10	partial	N	I-Premise
11	[	N	I-Premise
12	PR	N	I-Premise
13	]	N	I-Premise
14	)	N	I-Premise
15	was	N	I-Premise
16	obtained	N	I-Premise
17	in	N	I-Premise
18	55	N	I-Premise
19	%	N	I-Premise
20	,	N	I-Premise
21	48	N	I-Premise
22	%	N	I-Premise
23	,	N	I-Premise
24	16	N	I-Premise
25	%	N	I-Premise
26	,	N	I-Premise
27	and	N	I-Premise
28	7	N	I-Premise
29	%	N	I-Premise
30	of	N	I-Premise
31	patients	N	I-Premise
32	treated	N	I-Premise
33	with	N	I-Premise
34	CEF	N	I-Premise
35	,	N	I-Premise
36	E	N	I-Premise
37	,	N	I-Premise
38	M	N	I-Premise
39	,	N	I-Premise
40	and	N	I-Premise
41	MV	N	I-Premise
42	,	N	I-Premise
43	respectively	N	I-Premise
44	.	N	I-Premise

1	A	N	I-Premise
2	response	N	I-Premise
3	to	N	I-Premise
4	CEF	N	I-Premise
5	tended	N	I-Premise
6	to	N	I-Premise
7	last	N	I-Premise
8	longer	N	I-Premise
9	than	N	I-Premise
10	a	N	I-Premise
11	response	N	I-Premise
12	to	N	I-Premise
13	E	N	I-Premise
14	(	N	I-Premise
15	median	N	I-Premise
16	,	N	I-Premise
17	12	N	I-Premise
18	v	N	I-Premise
19	10.5	N	I-Premise
20	months	N	I-Premise
21	;	N	I-Premise
22	P	N	I-Premise
23	=	N	I-Premise
24	.07	N	I-Premise
25	)	N	I-Premise
26	.	N	I-Premise

1	Treatment-related	N	I-Premise
2	toxicity	N	I-Premise
3	was	N	I-Premise
4	less	N	I-Premise
5	in	N	I-Premise
6	the	N	I-Premise
7	single-agent	N	I-Premise
8	arm	N	I-Premise
9	and	N	I-Premise
10	quality-of-life	N	I-Premise
11	(	N	I-Premise
12	QOL	N	I-Premise
13	)	N	I-Premise
14	analysis	N	I-Premise
15	favored	N	I-Premise
16	the	N	I-Premise
17	single-agent	N	I-Premise
18	arm	N	I-Premise
19	.	N	I-Premise

1	No	N	I-Premise
2	significant	N	I-Premise
3	difference	N	I-Premise
4	in	N	I-Premise
5	time	N	I-Premise
6	to	N	I-Premise
7	progression	N	I-Premise
8	or	N	I-Premise
9	survival	N	I-Premise
10	was	N	I-Premise
11	found	N	I-Premise
12	between	N	I-Premise
13	the	N	I-Premise
14	two	N	I-Premise
15	arms	N	I-Premise
16	.	N	I-Premise

1	Similarly	N	I-Premise
2	,	N	I-Premise
3	no	N	I-Premise
4	difference	N	I-Premise
5	in	N	I-Premise
6	survival	N	I-Premise
7	was	N	I-Premise
8	found	N	I-Premise
9	when	N	I-Premise
10	the	N	I-Premise
11	patients	N	I-Premise
12	who	N	I-Premise
13	received	N	I-Premise
14	both	N	I-Premise
15	the	N	I-Premise
16	planned	N	I-Premise
17	first-and	N	I-Premise
18	second-line	N	I-Premise
19	treatments	N	I-Premise
20	were	N	I-Premise
21	compared	N	I-Premise
22	or	N	I-Premise
23	when	N	I-Premise
24	survival	N	I-Premise
25	was	N	I-Premise
26	calculated	N	I-Premise
27	from	N	I-Premise
28	the	N	I-Premise
29	beginning	N	I-Premise
30	of	N	I-Premise
31	the	N	I-Premise
32	second-line	N	I-Premise
33	therapy	N	I-Premise
34	.	N	I-Premise

1	Patients	N	I-Claim
2	treated	N	I-Claim
3	with	N	I-Claim
4	single-agent	N	I-Claim
5	E	N	I-Claim
6	followed	N	I-Claim
7	by	N	I-Claim
8	single-agent	N	I-Claim
9	M	N	I-Claim
10	had	N	I-Claim
11	similar	N	I-Claim
12	survival	N	I-Claim
13	,	N	I-Claim
14	but	N	I-Claim
15	less	N	I-Claim
16	treatment-related	N	I-Claim
17	toxicity	N	I-Claim
18	and	N	I-Claim
19	better	N	I-Claim
20	QOL	N	I-Claim
21	as	N	I-Claim
22	compared	N	I-Claim
23	with	N	I-Claim
24	those	N	I-Claim
25	treated	N	I-Claim
26	with	N	I-Claim
27	CEF	N	I-Claim
28	followed	N	I-Claim
29	by	N	I-Claim
30	MV	N	I-Claim
31	.	N	I-Claim

1	Vinorelbine	N	I-Claim
2	,	N	I-Claim
3	a	N	I-Claim
4	semisynthetic	N	I-Claim
5	vinca	N	I-Claim
6	alkaloid	N	I-Claim
7	,	N	I-Claim
8	represents	N	I-Claim
9	a	N	I-Claim
10	well-tolerated	N	I-Claim
11	treatment	N	I-Claim
12	for	N	I-Claim
13	elderly	N	I-Claim
14	patients	N	I-Claim
15	with	N	I-Claim
16	advanced	N	I-Claim
17	non-small-cell	N	I-Claim
18	lung	N	I-Claim
19	cancer	N	I-Claim
20	(	N	I-Claim
21	NSCLC	N	I-Claim
22	)	N	I-Claim
23	.	N	I-Claim

1	We	N	O
2	explored	N	O
3	the	N	O
4	quality	N	O
5	of	N	O
6	life	N	O
7	(	N	O
8	QoL	N	O
9	)	N	O
10	of	N	O
11	such	N	O
12	patients	N	O
13	in	N	O
14	a	N	O
15	multicenter	N	O
16	randomized	N	O
17	trial	N	O
18	that	N	O
19	compared	N	O
20	vinorelbine	N	O
21	treatment	N	O
22	with	N	O
23	supportive	N	O
24	care	N	O
25	alone	N	O
26	.	N	O

1	Eligible	N	O
2	patients	N	O
3	were	N	O
4	70	N	O
5	years	N	O
6	of	N	O
7	age	N	O
8	or	N	O
9	older	N	O
10	,	N	O
11	had	N	O
12	stage	N	O
13	IV	N	O
14	or	N	O
15	IIIB	N	O
16	NSCLC	N	O
17	that	N	O
18	was	N	O
19	ineligible	N	O
20	for	N	O
21	radiotherapy	N	O
22	,	N	O
23	and	N	O
24	had	N	O
25	a	N	O
26	performance	N	O
27	status	N	O
28	of	N	O
29	0-2	N	O
30	(	N	O
31	a	N	O
32	status	N	O
33	of	N	O
34	fully	N	O
35	active	N	O
36	to	N	O
37	a	N	O
38	status	N	O
39	of	N	O
40	capable	N	O
41	of	N	O
42	all	N	O
43	self-care	N	O
44	but	N	O
45	unable	N	O
46	to	N	O
47	work	N	O
48	)	N	O
49	.	N	O

1	Vinorelbine	N	O
2	was	N	O
3	given	N	O
4	intravenously	N	O
5	on	N	O
6	days	N	O
7	1	N	O
8	and	N	O
9	8	N	O
10	of	N	O
11	a	N	O
12	21-day	N	O
13	treatment	N	O
14	cycle	N	O
15	,	N	O
16	for	N	O
17	a	N	O
18	total	N	O
19	of	N	O
20	six	N	O
21	cycles	N	O
22	.	N	O

1	QoL	N	O
2	was	N	O
3	evaluated	N	O
4	with	N	O
5	European	N	O
6	Organization	N	O
7	for	N	O
8	Research	N	O
9	and	N	O
10	Treatment	N	O
11	of	N	O
12	Cancer	N	O
13	questionnaires	N	O
14	QLQ-C30	N	O
15	and	N	O
16	QLQ-LC13	N	O
17	,	N	O
18	and	N	O
19	the	N	O
20	QoL	N	O
21	data	N	O
22	were	N	O
23	analyzed	N	O
24	by	N	O
25	fitting	N	O
26	a	N	O
27	linear	N	O
28	mixed	N	O
29	model	N	O
30	for	N	O
31	each	N	O
32	QoL	N	O
33	scale	N	O
34	.	N	O

1	Survival	N	O
2	curves	N	O
3	were	N	O
4	plotted	N	O
5	and	N	O
6	were	N	O
7	compared	N	O
8	with	N	O
9	the	N	O
10	Mantel-Haenszel	N	O
11	test	N	O
12	.	N	O

1	Relative	N	O
2	hazards	N	O
3	of	N	O
4	death	N	O
5	and	N	O
6	95	N	O
7	%	N	O
8	confidence	N	O
9	intervals	N	O
10	(	N	O
11	CIs	N	O
12	)	N	O
13	were	N	O
14	estimated	N	O
15	by	N	O
16	the	N	O
17	Cox	N	O
18	model	N	O
19	.	N	O

1	Investigators	N	O
2	,	N	O
3	blinded	N	O
4	to	N	O
5	the	N	O
6	results	N	O
7	,	N	O
8	stopped	N	O
9	the	N	O
10	trial	N	O
11	early	N	O
12	because	N	O
13	of	N	O
14	a	N	O
15	low	N	O
16	enrollment	N	O
17	rate	N	O
18	.	N	O

1	(	N	O
2	From	N	O
3	April	N	O
4	1996	N	O
5	to	N	O
6	November	N	O
7	1997	N	O
8	,	N	O
9	191	N	O
10	of	N	O
11	the	N	O
12	350	N	O
13	targeted	N	O
14	patients	N	O
15	were	N	O
16	randomly	N	O
17	assigned	N	O
18	.	N	O

1	)	N	O
2	Data	N	O
3	from	N	O
4	161	N	O
5	patients	N	O
6	have	N	O
7	been	N	O
8	analyzed	N	O
9	.	N	O

1	Vinorelbine-treated	N	I-Premise
2	patients	N	I-Premise
3	scored	N	I-Premise
4	better	N	I-Premise
5	than	N	I-Premise
6	control	N	I-Premise
7	patients	N	I-Premise
8	on	N	I-Premise
9	QoL	N	I-Premise
10	functioning	N	I-Premise
11	scales	N	I-Premise
12	,	N	I-Premise
13	and	N	I-Premise
14	they	N	I-Premise
15	reported	N	I-Premise
16	fewer	N	I-Premise
17	lung	N	I-Premise
18	cancer-related	N	I-Premise
19	symptoms	N	I-Premise
20	but	N	I-Premise
21	reported	N	I-Premise
22	worse	N	I-Premise
23	toxicity-related	N	I-Premise
24	symptoms	N	I-Premise
25	.	N	I-Premise

1	There	N	I-Premise
2	was	N	I-Premise
3	a	N	I-Premise
4	statistically	N	I-Premise
5	significant	N	I-Premise
6	(	N	I-Premise
7	two-sided	N	I-Premise
8	P	N	I-Premise
9	=	N	I-Premise
10	.03	N	I-Premise
11	)	N	I-Premise
12	survival	N	I-Premise
13	advantage	N	I-Premise
14	for	N	I-Premise
15	patients	N	I-Premise
16	receiving	N	I-Premise
17	vinorelbine	N	I-Premise
18	;	N	I-Premise
19	median	N	I-Premise
20	survival	N	I-Premise
21	increased	N	I-Premise
22	from	N	I-Premise
23	21	N	I-Premise
24	to	N	I-Premise
25	28	N	I-Premise
26	weeks	N	I-Premise
27	in	N	I-Premise
28	the	N	I-Premise
29	vinorelbine-treated	N	I-Premise
30	group	N	I-Premise
31	.	N	I-Premise

1	The	N	I-Premise
2	relative	N	I-Premise
3	hazard	N	I-Premise
4	of	N	I-Premise
5	death	N	I-Premise
6	for	N	I-Premise
7	vinorelbine-treated	N	I-Premise
8	patients	N	I-Premise
9	was	N	I-Premise
10	0.65	N	I-Premise
11	(	N	I-Premise
12	95	N	I-Premise
13	%	N	I-Premise
14	CI	N	I-Premise
15	=	N	I-Premise
16	0.45-0.93	N	I-Premise
17	)	N	I-Premise
18	.	N	I-Premise

1	Vinorelbine	N	I-Claim
2	improves	N	I-Claim
3	survival	N	I-Claim
4	of	N	I-Claim
5	elderly	N	I-Claim
6	patients	N	I-Claim
7	with	N	I-Claim
8	advanced	N	I-Claim
9	NSCLC	N	I-Claim
10	and	N	I-Claim
11	possibly	N	I-Claim
12	improves	N	I-Claim
13	overall	N	I-Claim
14	QoL	N	I-Claim
15	.	N	I-Claim

